data_2g0k_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2g0k _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.622 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.633 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.32 -178.76 3.49 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.298 3.332 . . . . 0.0 109.635 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.95 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.08 113.64 26.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 1.02 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.96 136.11 51.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.55 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.54 115.41 29.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.756 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -113.71 147.39 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.762 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.32 167.43 21.82 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.762 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.38 118.52 5.64 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.294 3.329 . . . . 0.0 109.631 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.698 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.59 13.86 7.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 111' ' ' SER . 47.3 p -89.86 115.08 26.92 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.99 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 90.11 20.59 41.89 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.698 HD12 ' HA ' ' A' ' 10' ' ' SER . 1.0 OUTLIER -106.98 134.12 50.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.52 173.21 9.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -45.05 152.2 0.27 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.19 -23.6 32.69 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.673 HG23 ' N ' ' A' ' 18' ' ' VAL . 3.0 m -66.5 150.41 49.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.673 ' N ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -120.91 122.59 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.785 HG13 ' O ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -105.35 119.35 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.756 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -79.78 149.85 30.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.69 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -142.37 109.7 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 1.02 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.62 116.96 26.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.712 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.32 144.93 21.0 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.95 ' O ' HG23 ' A' ' 4' ' ' THR . . . -144.81 110.07 5.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.39 15.07 24.22 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.884 HD22 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.22 166.09 13.56 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.461 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.5 mt-30 -50.2 121.64 5.81 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.518 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.57 131.35 41.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 7.67 85.21 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.6 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.85 146.21 23.81 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.623 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.25 151.39 22.16 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.65 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.2 m-85 -138.39 147.48 43.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -114.02 113.21 24.47 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.269 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -96.88 147.71 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.78 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.03 163.23 36.61 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.906 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.3 tt0 -106.25 112.4 25.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.199 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.4 m -113.53 146.51 39.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.144 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.42 128.97 50.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.593 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.51 120.94 13.79 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.383 HG22 ' CD1' ' A' ' 83' ' ' TRP . 2.7 m -101.2 -43.45 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.97 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -139.23 179.21 6.66 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 47.1 m -62.38 112.75 2.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.33 7.43 63.71 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.59 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 81.2 t -122.33 109.19 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.554 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 1.0 OUTLIER -125.0 137.26 54.25 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.137 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -87.61 156.21 19.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.199 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.9 m -121.72 151.27 40.7 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.662 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 32.9 t30 -119.2 111.63 36.69 Favored Pre-proline 0 N--CA 1.448 -0.542 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -72.44 -0.65 9.05 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.289 3.326 . . . . 0.0 109.578 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.471 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -87.04 -13.67 43.74 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.516 ' HB3' ' CG2' ' A' ' 68' ' ' THR . 3.8 m-20 -130.37 27.56 5.04 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.684 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -96.7 115.82 28.08 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.4 t -109.23 -177.76 3.38 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.3 p -147.37 153.91 40.24 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.456 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.59 162.85 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.456 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 16.6 m -128.11 138.8 52.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.91 36.22 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 42.2 p30 -80.61 -173.26 4.04 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.94 -24.92 68.1 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -74.93 -8.49 56.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.721 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 73.9 31.61 59.86 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -128.26 139.33 52.5 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.85 167.75 16.9 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 84.1 p -150.49 127.01 10.8 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.611 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.71 163.31 38.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.864 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.611 ' N ' HG21 ' A' ' 65' ' ' THR . 0.1 OUTLIER -112.7 130.73 55.95 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.994 ' HG ' HG23 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.54 125.43 51.81 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.568 ' N ' HD12 ' A' ' 67' ' ' LEU . 5.2 t -81.52 129.45 34.67 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.516 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -90.69 128.22 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.516 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.4 OUTLIER -119.42 141.81 48.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.987 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -69.88 -34.19 73.22 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 51.5 p -164.63 159.85 19.44 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.906 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -178.03 172.24 1.64 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -62.72 119.37 9.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.137 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -78.86 91.63 1.21 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.912 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.5 99.65 10.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.741 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.8 tp -57.4 132.27 52.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 3.7 m-85 -46.95 -37.05 8.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.741 ' HB3' HD23 ' A' ' 77' ' ' LEU . 5.7 t0 -57.6 -16.89 11.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.72 27.97 9.25 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -113.81 147.48 38.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -86.34 94.37 9.34 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.59 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -64.06 -57.93 8.17 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.4 164.33 11.36 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 108.97 0.66 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.144 HG11 ' CB ' ' A' ' 38' ' ' ALA . 5.7 t -85.55 152.0 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -115.19 93.74 4.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.964 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 4.9 m -53.9 -24.86 17.5 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.7 p -81.73 2.26 30.66 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -115.92 -27.18 7.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.12 -178.91 5.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.658 ' HA ' ' HG ' ' A' ' 111' ' ' SER . . . -98.3 126.3 43.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.278 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 28.9 m -105.2 171.54 7.27 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.184 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.1 OUTLIER -154.05 147.39 24.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.994 HG23 ' HG ' ' A' ' 67' ' ' LEU . 8.8 t -103.87 165.28 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.269 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.79 166.32 35.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.149 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.14 133.04 43.81 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 13.5 m -116.11 145.2 43.23 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.623 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -99.93 -158.04 0.65 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.62 -48.66 76.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.49 -25.46 62.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 43.34 2.89 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.447 HD22 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -114.05 161.49 17.65 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.65 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -168.75 170.46 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.633 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.37 166.04 30.94 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.373 3.382 . . . . 0.0 109.577 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.622 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 5.2 mt-10 -36.62 118.1 0.54 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.92 156.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.184 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 5.6 t -106.15 102.16 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.15 116.99 20.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.278 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.3 pt -129.95 -177.5 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.658 ' HG ' ' HA ' ' A' ' 92' ' ' ALA . 0.4 OUTLIER -169.55 173.95 6.15 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.964 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 8.2 m-85 -129.42 110.32 11.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.99 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.9 p30 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.524 ' HB2' ' CG ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.457 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.614 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.0 Cg_endo -72.4 -177.78 2.93 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.292 3.328 . . . . 0.0 109.566 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.844 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.1 110.34 22.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.897 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.13 135.77 50.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -97.95 113.02 24.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.826 HG13 HG21 ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.58 154.57 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.916 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.11 174.4 2.44 Favored Pre-proline 0 N--CA 1.45 -0.463 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.941 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.916 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.8 Cg_endo -72.39 119.44 6.13 Favored 'Trans proline' 0 N--CA 1.447 -1.233 0 C-N-CA 124.334 3.356 . . . . 0.0 109.569 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.782 ' HB2' HG22 ' A' ' 110' ' ' ILE . 96.1 p -111.4 48.34 0.95 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -129.39 106.01 8.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.715 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.17 31.37 9.81 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.715 HD22 ' C ' ' A' ' 12' ' ' GLY . 0.8 OUTLIER -104.44 131.48 51.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -108.79 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -48.66 142.08 6.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.435 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 101.34 -22.58 38.48 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.6 m -77.69 151.21 34.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 18' ' ' VAL . 11.7 p -119.67 132.37 69.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.509 HG13 HG21 ' A' ' 8' ' ' THR . 20.9 t -95.66 155.38 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.775 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.02 144.49 42.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.7 110.9 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.897 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.54 116.5 25.51 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.499 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -83.08 146.6 24.1 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.844 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.85 110.8 4.34 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 101.57 14.63 29.38 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.85 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.87 179.32 6.01 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.898 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 25.1 mt-30 -60.87 121.38 12.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.513 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 132.24 42.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.31 8.12 79.16 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.647 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.96 143.33 26.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.677 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.69 151.19 23.62 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.041 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 42.2 m-85 -137.97 140.35 40.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.24 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.7 m-20 -104.47 115.12 29.81 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.385 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -101.02 139.84 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.928 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -160.67 169.78 36.46 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.858 HE22 ' H ' ' A' ' 70' ' ' ARG . 25.9 tt0 -120.31 114.06 21.3 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.5 m -106.13 171.16 7.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.194 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -156.82 133.08 9.82 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.506 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.83 129.58 40.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.945 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.543 HG22 ' CD1' ' A' ' 83' ' ' TRP . 3.7 m -110.81 -37.47 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.683 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -147.95 165.69 29.93 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.942 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -53.13 113.82 1.25 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.1 4.66 60.1 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.094 HG23 ' CH2' ' A' ' 83' ' ' TRP . 98.8 t -121.58 120.53 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.492 HD11 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.65 163.57 21.73 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.3 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -127.03 143.74 51.21 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.7 m -110.35 150.47 28.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.687 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.5 t30 -110.26 106.56 58.12 Favored Pre-proline 0 N--CA 1.449 -0.495 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.39 7.46 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.319 3.346 . . . . 0.0 109.591 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.428 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -87.98 -12.5 44.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 11.2 p30 -127.58 27.56 5.78 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.417 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.92 104.8 11.68 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.1 t -99.29 170.54 8.58 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.49 152.6 40.03 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.401 HG23 ' N ' ' A' ' 56' ' ' THR . 6.4 p -165.94 159.7 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.401 ' N ' HG23 ' A' ' 55' ' ' VAL . 18.2 m -128.23 137.11 51.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.68 146.98 39.79 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.6 p30 -83.93 -175.02 5.61 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -24.6 67.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.36 -7.57 55.28 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.685 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.14 32.04 58.88 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.1 p -127.94 135.78 50.43 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.76 167.9 12.45 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.1 121.91 9.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.483 ' O ' HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -162.33 148.04 12.84 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.931 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.422 ' N ' HG22 ' A' ' 65' ' ' THR . 0.4 OUTLIER -110.5 137.37 48.29 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.883 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.054 ' HG ' HG21 ' A' ' 95' ' ' VAL . 0.6 OUTLIER -106.04 119.1 38.34 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.909 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.62 ' HG1' ' NE ' ' A' ' 70' ' ' ARG . 5.2 t -60.84 127.2 30.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.524 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.7 OUTLIER -87.58 124.33 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.858 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.7 OUTLIER -115.74 143.68 45.04 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -86.73 -16.45 36.4 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.5 t -171.47 145.11 2.03 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.758 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.0 p90 -169.62 163.93 10.18 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.37 124.78 20.68 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.3 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -81.04 91.54 1.43 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.915 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.22 100.67 10.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.709 HD11 ' N ' ' A' ' 78' ' ' PHE . 3.6 tp -57.3 136.69 56.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.709 ' N ' HD11 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.54 -39.98 17.71 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.559 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -56.74 -17.14 7.97 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.955 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.94 28.1 9.69 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.407 ' HB ' HD21 ' A' ' 77' ' ' LEU . 15.7 m -112.38 147.36 36.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.69 93.82 6.85 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.543 ' CD1' HG22 ' A' ' 40' ' ' VAL . 11.5 t-105 -65.42 -48.29 73.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.57 165.08 10.16 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.79 133.66 54.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.194 HG22 ' CB ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -111.67 143.8 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.41 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.1 m-20 -109.84 104.07 12.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.481 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 26.3 m -51.81 -26.85 10.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.9 p -80.51 -2.26 45.27 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -116.71 -27.45 6.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.05 179.94 5.59 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.97 125.68 43.01 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.016 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 87.1 m -104.34 152.56 22.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.024 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.7 pt20 -150.57 152.72 34.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.054 HG21 ' HG ' ' A' ' 67' ' ' LEU . 10.3 t -117.51 159.78 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.278 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.46 166.51 37.52 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.385 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.74 131.19 51.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.24 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 3.2 m -111.73 153.09 27.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.677 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.5 -163.33 0.85 Allowed 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.43 -48.18 65.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.26 -24.45 66.58 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.6 53.77 1.77 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.898 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.26 170.92 14.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.041 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.4 46.72 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.614 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.42 162.8 40.47 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.328 3.352 . . . . 0.0 109.573 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.524 ' CG ' ' HB2' ' A' ' 2' ' ' ALA . 7.4 mt-10 -37.68 120.19 0.8 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.02 158.27 0.01 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.911 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.6 t -121.58 104.13 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.89 120.28 28.01 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.024 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.2 mt -98.61 159.09 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.0 OUTLIER -145.27 116.97 8.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.902 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -93.81 127.56 39.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.383 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.552 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.8 Cg_endo -72.47 -178.45 3.36 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.285 3.323 . . . . 0.0 109.592 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.859 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.92 111.04 23.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.705 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.09 157.84 36.98 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.6 p -121.86 119.59 32.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.799 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 22.5 t -114.82 146.34 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.713 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.1 165.78 35.12 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.713 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.0 Cg_endo -72.41 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.347 3.365 . . . . 0.0 109.546 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.712 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.88 12.35 7.26 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.709 ' HA ' ' O ' ' A' ' 111' ' ' SER . 42.2 m -87.78 110.58 20.58 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 1.069 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.33 14.31 42.07 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.712 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -105.56 132.79 51.28 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m -91.83 -179.97 5.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -44.54 152.68 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.84 -23.29 33.56 Favored Glycine 0 C--N 1.335 0.528 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.613 HG21 ' N ' ' A' ' 18' ' ' VAL . 26.1 m -69.38 148.76 49.2 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.613 ' N ' HG21 ' A' ' 17' ' ' THR . 7.4 p -125.47 115.86 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.686 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 2.4 p -91.86 153.77 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.799 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.27 147.93 31.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.7 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.37 106.4 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.705 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.56 116.96 23.29 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.691 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -84.72 150.32 25.28 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.859 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -147.73 109.62 4.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.43 15.94 33.48 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.8 HD22 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.19 172.89 8.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.509 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -53.27 120.65 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.498 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.7 131.16 42.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.68 82.69 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.583 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.19 143.48 26.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.449 ' N ' HG23 ' A' ' 30' ' ' THR . . . -87.59 147.18 25.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.667 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 34.0 m-85 -134.48 134.05 41.07 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.095 ' HB2' ' O ' ' A' ' 98' ' ' SER . 1.7 m-20 -98.66 114.12 26.47 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.253 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.71 145.19 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.955 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.2 166.47 39.25 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.76 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.19 108.83 18.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.009 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.41 146.93 38.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.58 143.51 50.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.564 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.35 124.39 21.62 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.787 HG23 ' HB3' ' A' ' 83' ' ' TRP . 1.2 t -104.04 -49.26 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.269 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -135.43 169.65 17.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.956 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 112.23 0.71 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.35 8.62 66.48 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.977 HG11 ' HE1' ' A' ' 83' ' ' TRP . 2.4 t -121.98 123.19 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.663 HD23 ' HD2' ' A' ' 78' ' ' PHE . 0.5 OUTLIER -132.08 133.79 44.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.281 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -91.81 147.77 22.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.009 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.3 m -105.62 152.12 23.51 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.764 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -111.07 110.15 56.75 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.43 -0.07 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 124.311 3.341 . . . . 0.0 109.616 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.478 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -88.29 -9.45 52.83 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -133.83 26.8 3.97 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.448 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.07 107.24 12.7 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.1 m -101.48 176.21 5.31 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.0 p -144.93 153.97 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.49 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.69 155.18 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.49 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.1 m -128.0 141.72 51.44 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.99 141.28 33.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 p30 -82.66 -173.18 4.48 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.71 -26.45 68.05 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -76.09 -9.17 58.41 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.733 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 76.23 32.28 52.57 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 80.9 p -127.79 135.83 50.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.95 164.38 18.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -145.64 136.19 24.19 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.59 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.88 174.62 10.39 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.59 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.3 OUTLIER -138.95 122.96 17.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.891 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.995 HD21 HG23 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.04 156.43 16.33 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -103.78 133.37 48.89 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.954 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.456 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -93.47 127.18 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.628 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.4 OUTLIER -117.66 141.99 47.75 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -32.58 73.24 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 78.2 p -157.9 158.97 36.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.764 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 2.1 p90 -177.14 161.8 1.91 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.17 112.35 2.62 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.281 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -71.72 96.75 0.68 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.789 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.23 99.41 9.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.781 HD21 ' HB3' ' A' ' 79' ' ' ASP . 3.9 tp -57.18 131.68 50.7 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.663 ' HD2' HD23 ' A' ' 45' ' ' LEU . 38.0 p90 -47.52 -36.11 9.88 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.781 ' HB3' HD21 ' A' ' 77' ' ' LEU . 3.3 t0 -57.67 -16.25 10.17 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.78 9.5 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.557 HG21 ' N ' ' A' ' 82' ' ' ARG . 2.6 m -115.55 147.97 40.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.557 ' N ' HG21 ' A' ' 81' ' ' THR . 0.3 OUTLIER -87.64 96.43 10.42 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.269 ' HZ2' ' CG ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.63 -55.16 25.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.63 170.89 16.15 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -66.12 103.83 1.04 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.459 HG12 HG22 ' A' ' 40' ' ' VAL . 35.5 m -80.18 154.15 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -112.7 92.62 4.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.942 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.7 m -53.07 -24.63 10.41 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -82.32 2.07 33.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.38 -27.28 6.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.71 178.98 6.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.2 126.23 43.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.376 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 7.2 m -104.82 173.68 6.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.078 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 1.1 pt20 -153.61 147.12 24.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.995 HG23 HD21 ' A' ' 67' ' ' LEU . 3.7 t -104.97 165.32 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.253 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.29 166.38 36.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.915 ' HB3' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.83 132.9 46.63 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.095 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 3.7 t -113.48 150.89 32.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.455 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -110.48 -163.63 0.87 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.74 -48.43 71.92 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.65 -24.37 65.44 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.9 53.75 1.74 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.46 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -133.41 169.53 16.81 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.992 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.516 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.03 171.42 43.43 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.552 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.34 170.71 18.57 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.322 3.348 . . . . 0.0 109.597 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.383 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.67 121.6 0.9 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.98 163.87 0.01 OUTLIER Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.078 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 23.2 t -120.53 103.18 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.2 120.39 26.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.376 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -129.1 -178.76 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.709 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -168.33 171.14 9.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.942 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.0 m-85 -122.4 115.11 21.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 1.069 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.196 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.571 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.4 -178.3 3.24 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 124.339 3.36 . . . . 0.0 109.633 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.305 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 5.1 t -99.69 116.12 31.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.665 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.78 153.76 48.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -110.66 112.16 23.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.811 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 95.2 t -107.47 145.93 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.953 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -66.79 176.42 1.11 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.953 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.9 Cg_endo -72.41 117.46 5.14 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.293 3.329 . . . . 0.0 109.612 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.705 ' HB2' HG23 ' A' ' 110' ' ' ILE . 32.4 p -112.58 47.07 1.12 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 51.4 p -126.36 106.73 9.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.698 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.9 28.72 14.72 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.7 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -101.73 131.77 47.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.983 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -111.41 174.57 5.8 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -48.05 140.3 7.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.08 -22.79 35.54 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.6 m -79.81 151.42 30.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.412 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 8.8 p -128.26 123.43 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.618 HG11 HG23 ' A' ' 69' ' ' VAL . 29.4 m -88.28 171.45 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.811 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.49 146.86 47.0 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.51 HG11 HG23 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -144.44 106.25 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.665 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.67 116.66 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -82.92 148.32 25.67 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.305 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -148.15 118.61 7.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.86 16.1 46.4 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.667 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -88.68 -174.15 4.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.517 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -70.3 120.7 16.36 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.931 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.02 136.02 53.21 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.02 7.82 60.21 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.721 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -82.95 146.71 28.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.868 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -96.07 134.96 38.48 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.822 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 38.6 m-85 -126.42 149.17 49.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.016 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -116.79 113.95 23.27 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.233 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -97.05 143.92 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.696 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.21 161.66 34.8 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.833 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 37.6 tt0 -110.85 118.44 36.13 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.212 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.1 m -115.95 148.37 40.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.045 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.27 140.39 52.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.517 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.26 127.42 31.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.94 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.711 HG13 ' CG1' ' A' ' 44' ' ' VAL . 1.1 t -108.7 -39.34 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.422 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 1.5 t0 -151.84 -178.53 6.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.1 m -70.41 111.47 6.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.51 10.01 86.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.316 HG13 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -136.99 124.52 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.573 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -133.1 137.23 46.27 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.159 ' HB2' ' C ' ' A' ' 75' ' ' GLY . . . -85.53 155.77 21.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.212 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 67.7 m -120.77 156.91 30.85 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.669 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t30 -121.5 109.21 34.82 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.43 0.64 7.17 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.313 3.342 . . . . 0.0 109.592 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.455 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -88.63 -16.37 32.61 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 14.6 p30 -127.26 28.15 5.77 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.92 118.3 35.37 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.5 t -113.41 -177.77 3.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 94.9 p -146.49 157.36 43.74 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 56' ' ' THR . 4.9 p -167.68 159.4 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.8 m -128.06 137.45 52.17 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.419 ' N ' HG21 ' A' ' 56' ' ' THR . . . -74.9 136.02 41.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 17.1 p30 -73.62 -175.28 1.97 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -24.74 68.02 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -75.17 -7.25 53.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.667 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.15 32.09 58.78 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.3 p -129.89 135.83 48.82 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.92 164.06 18.22 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -147.73 127.96 13.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.593 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.86 170.0 23.08 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.936 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.593 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -126.86 136.76 52.78 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.034 ' HG ' HG22 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -111.71 120.37 41.81 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.968 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.622 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -70.88 117.67 12.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.618 HG23 HG11 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -75.14 128.43 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.622 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -116.77 147.14 42.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.978 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.435 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.3 OUTLIER -90.21 -15.68 30.92 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 52.2 p -178.81 154.89 0.75 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.833 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -177.94 179.75 0.83 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -66.89 123.11 19.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.159 ' C ' ' HB2' ' A' ' 46' ' ' ALA . . . -79.7 91.93 1.31 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.89 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.75 100.62 11.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.744 HD21 ' HB3' ' A' ' 79' ' ' ASP . 2.4 tp -55.38 140.27 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.725 ' N ' HD13 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.58 -41.49 21.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.744 ' HB3' HD21 ' A' ' 77' ' ' LEU . 0.8 OUTLIER -57.19 -17.44 11.26 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.54 28.36 9.71 Favored Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.645 HG22 ' N ' ' A' ' 82' ' ' ARG . 2.1 m -110.89 145.23 38.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.645 ' N ' HG22 ' A' ' 81' ' ' THR . 0.1 OUTLIER -77.0 93.21 3.79 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.949 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.422 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 54.7 t-105 -64.18 -58.12 7.53 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.87 155.86 7.3 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -54.95 109.99 0.6 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.045 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.9 t -86.43 151.65 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.77 96.16 6.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.069 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.5 OUTLIER -54.07 -23.91 15.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.5 p -84.6 0.5 49.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -113.72 -27.38 7.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.82 177.94 7.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.54 128.33 44.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.241 ' O ' HG13 ' A' ' 110' ' ' ILE . 58.0 m -104.84 157.17 17.39 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.039 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -141.21 145.8 36.1 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.034 HG22 ' HG ' ' A' ' 67' ' ' LEU . 20.4 t -108.94 157.47 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.233 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.74 172.41 45.36 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.051 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.57 130.96 46.36 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.016 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 40.2 m -111.04 145.02 39.24 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.868 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -106.86 -163.58 0.92 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.73 -49.13 69.56 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.18 -24.11 65.83 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.26 53.34 1.88 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.8 174.81 9.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.822 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -177.82 179.34 48.37 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.571 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.37 165.78 31.66 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.347 3.364 . . . . 0.0 109.577 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.196 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 8.8 pt-20 -37.0 133.88 0.58 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.77 149.63 5.36 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.98 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -121.85 110.54 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -93.17 139.46 30.57 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.241 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.6 OUTLIER -109.93 160.09 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -143.22 112.53 6.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.069 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 23.1 m-85 -93.68 124.4 37.65 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.943 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.031 ' HB2' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.5 Cg_endo -72.42 -178.19 3.18 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.293 3.328 . . . . 0.0 109.635 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.367 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 5.2 t -102.31 115.74 31.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.742 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.4 146.96 52.05 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.546 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.65 115.72 31.02 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.93 HG21 HG23 ' A' ' 108' ' ' VAL . 35.9 t -111.92 148.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.949 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.41 176.2 1.31 Allowed Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.949 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.1 Cg_endo -72.34 117.28 5.06 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.325 3.35 . . . . 0.0 109.626 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.914 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 96.3 p -110.17 49.23 0.86 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 111' ' ' SER . 94.3 p -127.37 106.09 8.97 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.705 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.47 27.26 18.2 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.716 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -103.34 131.38 50.46 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.982 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -118.97 -179.35 3.79 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -46.19 138.89 5.0 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.58 -23.17 33.61 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.1 m -87.51 150.95 23.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.496 HG11 ' O ' ' A' ' 18' ' ' VAL . 13.0 p -131.63 121.54 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.534 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 23.7 m -80.74 167.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.813 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.37 145.54 43.14 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.688 HG11 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.87 112.82 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.08 114.8 20.18 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.547 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -81.93 147.9 26.72 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.315 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.8 115.49 5.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.22 15.39 51.49 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.04 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.35 -179.79 5.92 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.977 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 37.1 mt-30 -59.01 120.8 9.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.565 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.92 132.05 42.07 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.87 7.64 75.94 Favored Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.51 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -92.86 139.46 30.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.578 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.06 150.45 24.86 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.878 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 26.7 m-85 -135.58 143.81 45.84 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.258 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -105.83 114.59 28.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.309 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -100.18 139.6 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.897 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.7 164.59 37.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.87 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 20.9 tt0 -109.75 105.33 14.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.165 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 61.5 m -106.32 142.79 35.42 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB1' HG22 ' A' ' 86' ' ' VAL . . . -122.72 130.09 52.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.624 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.69 121.33 14.73 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.56 HG13 ' CD1' ' A' ' 83' ' ' TRP . 6.0 m -101.78 -43.05 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.48 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -138.17 169.95 16.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.0 m -55.03 112.56 1.08 Allowed 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.72 9.05 64.84 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.565 ' O ' HG22 ' A' ' 40' ' ' VAL . 77.0 t -123.49 105.42 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.829 HD21 ' CD2' ' A' ' 78' ' ' PHE . 0.8 OUTLIER -121.3 138.35 54.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.335 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -92.42 158.13 16.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.165 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 52.2 m -118.59 148.13 43.0 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.927 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.3 t30 -110.61 106.19 57.64 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.459 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.8 Cg_endo -72.42 -1.27 9.96 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.356 3.37 . . . . 0.0 109.567 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.527 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.17 -11.09 42.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.527 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 6.1 m-20 -133.35 27.41 4.11 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.663 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.6 118.87 36.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -112.07 -176.1 2.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -144.84 153.02 41.17 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.64 156.27 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.3 m -126.45 141.0 52.04 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.426 ' N ' HG21 ' A' ' 56' ' ' THR . . . -79.26 138.33 37.74 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.0 p30 -73.57 -174.34 1.69 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.45 -25.04 68.09 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -75.23 -8.06 55.57 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.721 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.73 31.34 58.5 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 71.5 p -127.08 133.23 50.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.79 166.47 14.29 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.89 131.76 15.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.642 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.0 166.19 17.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.642 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -122.33 132.63 54.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.131 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.24 118.23 36.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.496 HG21 ' HB3' ' A' ' 51' ' ' ASP . 2.0 t -68.94 143.19 54.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.504 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -107.0 131.4 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.562 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -118.98 152.04 37.1 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.52 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -87.15 -10.63 52.25 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -174.04 149.43 1.47 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.927 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 5.7 p90 -176.72 158.91 1.75 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -58.75 112.53 1.66 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.335 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.66 94.54 0.67 Allowed Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.83 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -82.71 98.81 9.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.979 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.776 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.8 tp -54.93 132.68 47.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.829 ' CD2' HD21 ' A' ' 45' ' ' LEU . 19.0 p90 -46.81 -37.43 8.66 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.776 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.3 t0 -56.69 -17.13 7.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.45 28.04 8.76 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.5 HG22 ' N ' ' A' ' 82' ' ' ARG . 1.3 m -114.97 143.12 45.66 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.5 ' N ' HG22 ' A' ' 81' ' ' THR . 0.5 OUTLIER -85.38 96.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.56 ' CD1' HG13 ' A' ' 40' ' ' VAL . 3.3 t-105 -63.35 -58.95 5.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.29 171.31 21.1 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -64.78 104.39 0.83 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -79.75 149.99 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -110.56 97.44 6.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.841 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 9.0 m -52.82 -25.4 11.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 53.0 p -82.57 -0.17 45.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -119.04 -28.41 5.51 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.1 179.72 5.28 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 125.23 44.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.099 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 61.3 m -104.17 152.95 21.52 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.024 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -144.47 147.36 33.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.131 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -110.64 159.9 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.221 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.85 167.74 39.29 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.309 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.04 125.25 43.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.258 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 15.8 m -112.8 143.98 43.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.578 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -101.85 -160.23 0.78 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.983 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.71 -47.94 61.32 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.73 -20.08 65.89 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.5 53.51 2.59 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.296 -1.121 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.977 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.64 167.75 19.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.878 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.97 176.53 46.44 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.34 170.2 19.8 Favored 'Trans proline' 0 N--CA 1.448 -1.2 0 C-N-CA 124.294 3.33 . . . . 0.0 109.618 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.367 ' OE2' ' CA ' ' A' ' 4' ' ' THR . 3.3 pm0 -40.96 120.02 1.25 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.46 162.81 0.01 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.93 HG23 HG21 ' A' ' 7' ' ' VAL . 34.8 t -128.57 104.44 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.74 30.18 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.099 ' HB ' ' O ' ' A' ' 93' ' ' CYS . 5.2 mt -99.5 153.58 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.664 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -138.31 123.05 18.73 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.841 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 6.1 m-85 -92.69 127.44 38.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.917 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.588 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.34 -177.78 2.91 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.312 3.341 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.9 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.46 109.59 22.32 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.753 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 146.63 50.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.2 p -110.22 121.01 44.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.866 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 41.2 t -113.88 143.64 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.679 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.74 166.11 30.18 Favored Pre-proline 0 N--CA 1.449 -0.475 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.679 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.2 Cg_endo -72.41 117.16 5.0 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.29 3.327 . . . . 0.0 109.629 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.6 OUTLIER -129.29 11.78 5.94 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.689 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.6 m -92.34 108.72 20.17 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.85 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.17 24.08 13.45 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.69 HD22 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.24 133.78 51.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 t -67.36 154.39 41.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 1.3 p-10 -46.07 147.58 1.01 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.02 -18.69 51.55 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.563 HG23 ' N ' ' A' ' 18' ' ' VAL . 30.6 m -61.91 145.36 53.09 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.563 ' N ' HG23 ' A' ' 17' ' ' THR . 15.0 p -110.26 134.69 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.522 HG11 ' CG1' ' A' ' 7' ' ' VAL . 10.5 t -107.03 152.72 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.866 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.03 109.84 15.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.592 HG13 HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -103.18 121.12 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.753 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -128.41 117.01 20.64 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.654 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.55 147.41 23.1 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.9 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.46 111.11 5.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.56 16.53 31.37 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.099 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.27 173.43 8.4 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.582 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.9 mt-30 -53.66 121.38 7.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.31 129.55 38.66 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.98 8.67 85.07 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.692 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.1 141.7 28.24 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 1.196 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.88 150.78 23.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.237 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 52.6 m-85 -136.19 143.35 44.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.23 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.73 114.7 29.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.533 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.03 141.87 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.029 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.52 161.99 35.79 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.95 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 54.9 tt0 -94.69 117.96 30.97 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.5 m -107.25 158.12 17.37 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.002 ' HB3' HG13 ' A' ' 86' ' ' VAL . . . -147.22 134.6 20.73 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.535 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -68.36 125.32 26.06 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.482 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.4 m -114.64 -36.05 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.536 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -150.17 -179.96 7.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -64.12 110.37 2.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 69.76 8.84 61.32 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.606 ' O ' HG23 ' A' ' 40' ' ' VAL . 61.0 t -110.19 105.2 18.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.687 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.5 mt -105.82 156.61 18.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.372 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -135.11 129.35 33.78 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.914 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.52 156.01 19.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.624 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.6 p-10 -116.23 121.76 33.14 Favored Pre-proline 0 N--CA 1.449 -0.523 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.415 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.8 Cg_endo -72.37 1.98 5.56 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.26 3.307 . . . . 0.0 109.608 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.63 -20.87 28.82 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.428 ' OD1' HG21 ' A' ' 68' ' ' THR . 85.2 m-20 -128.47 28.78 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.59 117.1 29.6 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.3 t -109.99 -176.86 3.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.37 153.8 41.61 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.49 HG22 ' N ' ' A' ' 56' ' ' THR . 7.5 p -166.47 153.71 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.49 ' N ' HG22 ' A' ' 55' ' ' VAL . 32.8 m -126.59 132.89 51.19 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.61 149.79 48.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -88.98 -168.38 2.17 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.29 -27.94 68.98 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -75.16 -9.32 58.44 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.551 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 77.2 31.51 51.9 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.0 p -127.97 141.24 51.58 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.15 164.68 24.98 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -143.35 139.62 30.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.57 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -167.56 172.1 9.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.57 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.4 OUTLIER -124.88 129.03 49.58 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.942 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.287 HD13 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -112.56 119.57 38.62 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.428 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -79.59 141.45 36.56 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.581 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -112.02 132.81 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.917 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -119.11 155.68 31.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 ptt180 -74.67 -34.58 62.72 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -151.15 149.34 29.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.95 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.5 p90 -177.13 163.66 2.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.474 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.4 OUTLIER -61.25 125.1 22.55 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.372 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.93 95.56 2.11 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.914 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -84.46 103.71 13.84 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.723 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.5 tp -53.91 135.01 42.94 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.568 ' N ' HD11 ' A' ' 77' ' ' LEU . 8.3 m-85 -45.71 -38.68 7.16 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.723 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.6 t0 -57.26 -17.02 9.89 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.92 28.91 8.97 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.476 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.6 m -114.41 112.43 23.02 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 96.44 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.482 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 50.6 t-105 -62.41 -53.63 52.03 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 143.45 -179.66 20.74 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.17 140.79 43.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.005 HG22 HG11 ' A' ' 40' ' ' VAL . 4.8 t -127.7 152.6 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.26 90.4 3.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.204 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 30.6 m -54.15 -25.57 23.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.8 p -76.9 -0.64 24.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.597 ' O ' HG22 ' A' ' 90' ' ' THR . 0.9 OUTLIER -114.48 -27.21 7.62 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.68 -164.2 1.28 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.4 125.49 43.58 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.228 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.1 OUTLIER -103.89 152.5 21.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.03 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -159.42 147.56 17.56 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.287 ' CG2' HD13 ' A' ' 67' ' ' LEU . 6.8 t -105.62 165.32 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.251 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.29 164.68 34.67 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.533 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.6 133.16 47.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.23 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 67.7 m -112.1 150.31 30.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 1.196 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -109.92 -161.31 0.75 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.08 -48.68 70.15 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.09 -24.13 64.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.74 52.47 1.8 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.618 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.57 171.87 12.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.237 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.37 175.24 44.34 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.588 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.34 169.55 21.37 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.377 3.385 . . . . 0.0 109.59 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.022 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -38.49 126.09 1.4 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.959 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.84 160.31 0.01 OUTLIER Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.03 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 89.1 t -123.08 102.69 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.97 134.54 33.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.228 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -140.53 -173.73 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.689 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.7 t -176.48 178.51 1.3 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.204 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.8 m-85 -130.75 113.15 13.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.85 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 42.5 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.578 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.501 ' HB2' ' CD2' ' A' ' 26' ' ' LEU . 84.4 Cg_endo -72.35 -175.28 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.355 3.37 . . . . 0.0 109.626 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.963 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.32 109.37 21.89 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.97 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.2 146.02 50.85 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -110.18 114.35 27.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.819 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.03 152.39 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.649 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -75.5 163.96 64.03 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.649 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.36 118.16 5.47 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.337 3.358 . . . . 0.0 109.621 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.708 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -128.59 14.29 6.5 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 1.075 ' HA ' ' O ' ' A' ' 111' ' ' SER . 68.9 p -95.73 109.2 21.53 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 1.111 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 95.59 26.07 12.53 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.728 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.48 140.94 41.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 t -71.45 156.31 39.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.512 ' HB3' ' HD2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.73 151.96 0.79 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.63 -16.1 59.96 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.53 HG22 ' N ' ' A' ' 18' ' ' VAL . 15.2 m -62.34 138.56 58.46 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' N ' HG22 ' A' ' 17' ' ' THR . 9.7 p -99.69 146.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.614 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.5 t -125.32 156.64 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.819 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.79 150.21 40.19 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.77 105.67 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.97 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.17 117.07 30.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.759 ' HA2' ' HB3' ' A' ' 5' ' ' ALA . . . -83.63 143.47 21.63 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.963 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.49 106.76 5.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.534 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 22.96 8.56 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.501 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.66 -167.03 1.75 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.522 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 29.7 mt-30 -85.57 125.56 33.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.488 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.29 134.4 44.19 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.37 8.16 83.39 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.65 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -96.3 139.44 32.43 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -90.65 150.96 21.47 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.963 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 54.0 m-85 -136.95 147.33 46.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.103 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.7 m-20 -110.97 112.85 24.98 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.274 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -102.26 151.03 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.948 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -178.1 176.67 48.14 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 1.058 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 9.2 tt0 -117.25 121.6 41.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.6 m -120.42 144.81 47.74 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.92 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -123.1 142.31 51.02 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.608 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.02 124.29 21.7 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.937 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.515 ' CB ' ' CD1' ' A' ' 83' ' ' TRP . 3.3 m -106.68 -38.37 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.095 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.49 -178.35 5.07 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.5 m -70.98 112.08 6.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.12 10.21 81.07 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.307 HG23 ' CZ2' ' A' ' 83' ' ' TRP . 1.8 m -130.94 124.92 57.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.537 HD13 ' HB2' ' A' ' 37' ' ' CYS . 1.6 pt? -127.76 147.04 50.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.396 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -102.22 150.65 23.08 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.7 m -106.27 160.33 15.44 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.737 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 26.8 t30 -119.24 109.96 38.29 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.35 0.01 8.03 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.33 3.353 . . . . 0.0 109.627 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.488 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.44 -13.08 38.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.517 ' HB3' HG23 ' A' ' 68' ' ' THR . 19.0 m-20 -134.73 27.71 3.62 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.628 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.43 115.17 27.0 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.4 t -106.53 178.34 4.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 p -147.18 156.32 42.87 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.473 ' CG2' ' N ' ' A' ' 56' ' ' THR . 2.3 p -167.35 161.93 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.473 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 24.4 m -128.28 131.87 48.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 152.4 44.28 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -91.44 -170.8 2.73 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.43 -26.14 68.34 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -76.38 -6.06 49.95 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.488 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 75.27 9.42 84.25 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 85.9 p -101.64 140.16 36.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.43 164.11 17.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -150.38 121.86 7.94 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.615 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.38 172.19 15.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.615 ' N ' HG23 ' A' ' 65' ' ' THR . 1.1 m -128.24 120.23 26.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.305 HD11 ' CG2' ' A' ' 95' ' ' VAL . 0.2 OUTLIER -105.64 133.43 50.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.517 HG23 ' HB3' ' A' ' 51' ' ' ASP . 5.5 t -97.62 149.13 22.58 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.588 ' CG2' ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -114.67 131.48 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.879 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.58 159.04 20.89 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.512 ' HD2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -80.3 -23.32 40.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.949 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.494 ' N ' ' HG2' ' A' ' 71' ' ' ARG . 53.9 p -160.72 156.72 25.81 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 1.058 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.5 p90 -178.12 158.82 1.24 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -60.58 109.43 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.396 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -64.27 98.77 0.28 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.802 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 98.78 10.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.771 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.2 tp -54.66 132.46 45.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.672 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.9 m-85 -47.0 -37.24 8.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.771 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.8 t0 -57.57 -16.65 10.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.84 28.99 8.94 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.59 HG22 ' N ' ' A' ' 82' ' ' ARG . 1.3 m -117.3 152.2 35.38 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.59 ' N ' HG22 ' A' ' 81' ' ' THR . 0.0 OUTLIER -80.94 99.54 8.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.515 ' CD1' ' CB ' ' A' ' 40' ' ' VAL . 15.0 t-105 -68.74 -50.49 50.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.5 163.72 9.62 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.99 104.7 0.21 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.92 HG23 ' CB ' ' A' ' 38' ' ' ALA . 14.4 p -85.83 149.71 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.509 ' N ' HG21 ' A' ' 86' ' ' VAL . 0.7 OUTLIER -100.77 97.24 7.9 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.854 ' SG ' ' HZ ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.8 -20.63 9.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.7 p -92.76 2.4 56.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.7 m -106.1 -24.35 12.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.52 179.01 6.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -90.97 125.5 35.8 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.246 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.3 m -104.48 162.98 12.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.045 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.3 OUTLIER -153.56 147.92 25.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.305 ' CG2' HD11 ' A' ' 67' ' ' LEU . 15.8 t -101.71 161.21 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.264 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.96 166.0 35.33 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.274 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.41 128.92 43.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 180.0 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.103 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 26.8 m -108.74 151.65 25.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.488 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -113.19 -162.41 0.8 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.58 -48.49 77.19 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.17 -24.37 62.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.22 53.77 1.69 Allowed Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.522 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.88 172.26 11.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.963 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.58 -179.21 46.89 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.417 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 81.7 Cg_endo -72.42 160.29 47.19 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.357 3.372 . . . . 0.0 109.549 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.121 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 2.8 tt0 -35.45 123.7 0.64 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -34.67 151.14 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.023 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 90.1 t -117.28 102.31 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 137.15 34.8 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.246 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 2.8 pt -143.0 179.71 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 1.075 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -177.99 178.54 0.93 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.964 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 1.2 m-85 -126.21 116.1 20.78 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 1.111 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 6.3 p30 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.291 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.475 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.37 -178.24 3.2 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.356 3.371 . . . . 0.0 109.609 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.257 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 6.8 t -100.17 116.95 33.38 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.767 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.37 135.36 47.15 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.95 113.11 24.69 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.612 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.96 155.03 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.969 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.936 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.09 175.42 1.79 Allowed Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.936 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.2 Cg_endo -72.39 118.94 5.84 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 124.299 3.333 . . . . 0.0 109.602 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.975 ' HB2' HG22 ' A' ' 110' ' ' ILE . 20.6 p -110.74 48.48 0.91 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 55.5 p -127.06 105.99 8.97 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.712 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 91.12 31.93 9.36 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.289 -1.125 . . . . 0.0 110.289 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.719 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -110.18 129.19 55.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.89 175.84 5.27 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -44.92 139.74 2.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.93 -22.47 35.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.465 HG22 ' N ' ' A' ' 18' ' ' VAL . 17.3 m -81.19 150.64 28.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.465 ' N ' HG22 ' A' ' 17' ' ' THR . 10.7 p -121.03 120.45 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.515 HG22 ' N ' ' A' ' 20' ' ' LYS . 1.7 p -87.62 154.87 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.612 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.7 147.14 31.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.712 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.23 110.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.99 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.767 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.24 115.83 23.06 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.55 ' HA3' HD23 ' A' ' 26' ' ' LEU . . . -83.21 148.86 25.76 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.257 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.35 114.83 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.36 13.62 44.42 Favored Glycine 0 C--N 1.335 0.485 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.711 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.46 172.6 8.6 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.494 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -52.95 119.84 5.12 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.522 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.51 132.84 43.33 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.77 7.84 75.88 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.494 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.56 141.56 28.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.413 ' N ' HG21 ' A' ' 30' ' ' THR . . . -84.42 150.16 25.5 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.488 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 30.1 m-85 -135.73 141.79 44.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.266 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.77 118.07 35.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.25 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -104.83 145.32 13.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.853 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.99 169.2 41.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.769 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 40.6 tt0 -112.01 108.96 18.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.185 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.2 m -111.74 144.63 40.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.915 ' HB1' HG11 ' A' ' 86' ' ' VAL . . . -123.83 130.41 52.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.583 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.18 122.83 17.98 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.444 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 9.7 m -102.94 -42.87 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.7 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -139.0 179.64 6.38 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.4 m -63.63 112.35 2.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.44 8.38 66.37 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.557 ' O ' HG22 ' A' ' 40' ' ' VAL . 59.3 t -123.83 106.44 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -121.42 137.84 54.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.15 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -89.4 153.34 20.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.185 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m -115.04 151.86 33.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.665 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.4 t30 -117.72 109.54 41.44 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.33 -1.07 9.61 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.315 3.343 . . . . 0.0 109.602 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.589 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -84.68 -11.1 56.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.589 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.5 OUTLIER -131.79 26.25 4.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.71 104.38 13.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.7 t -101.33 176.32 5.28 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.51 150.04 35.73 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -166.96 153.63 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 67.9 m -123.49 132.7 54.0 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 141.63 53.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -77.53 -174.65 3.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.91 -24.83 68.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -76.29 -6.9 53.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.711 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.73 31.17 58.72 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.2 p -127.09 137.78 53.07 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.26 165.21 16.56 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 p -147.91 120.22 8.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.476 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -157.42 148.08 21.2 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.476 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -111.32 129.81 55.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.344 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -98.47 157.27 16.32 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.589 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.7 t -101.01 119.29 38.53 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.517 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -80.31 127.18 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.654 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.6 OUTLIER -118.7 152.47 36.07 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.49 ' HD3' ' N ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -91.59 -12.68 33.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.941 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 5.1 t -169.2 151.35 4.63 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.769 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.1 p90 -177.16 155.43 1.15 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.25 115.92 2.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.15 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -72.83 91.63 0.6 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.803 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -82.79 99.23 9.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.731 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.1 tp -55.54 134.55 50.9 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.76 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.4 m-85 -46.36 -38.68 9.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.731 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.5 t0 -56.99 -17.48 9.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.77 28.37 8.9 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.645 HG23 ' N ' ' A' ' 82' ' ' ARG . 1.2 m -113.62 142.86 45.48 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.645 ' N ' HG23 ' A' ' 81' ' ' THR . 4.7 mtm180 -80.88 94.97 6.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.444 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 71.4 t-105 -64.28 -58.61 6.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.67 167.54 16.66 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.81 108.6 1.22 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.915 HG11 ' HB1' ' A' ' 38' ' ' ALA . 38.7 t -81.76 143.96 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.17 93.6 4.62 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.471 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 58.4 m -52.04 -26.07 10.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.489 HG21 ' HB2' ' A' ' 71' ' ' ARG . 77.9 p -79.85 -2.43 43.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.591 ' O ' HG22 ' A' ' 90' ' ' THR . 1.3 m -116.48 -27.76 6.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.07 -176.63 3.93 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.92 125.74 45.95 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.914 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 69.8 m -103.5 152.98 21.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.087 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -143.17 148.53 36.68 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.344 ' CG1' HD12 ' A' ' 67' ' ' LEU . 4.9 t -112.01 161.4 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.07 171.46 43.92 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.957 ' HB3' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.57 135.56 48.03 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.266 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 72.6 p -115.71 154.95 28.63 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.426 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -115.12 -167.07 1.18 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.974 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.03 -48.75 75.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.87 66.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.59 1.93 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.481 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.62 169.16 17.04 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.82 176.82 46.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 81.8 Cg_endo -72.41 161.84 43.16 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.332 3.355 . . . . 0.0 109.555 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.291 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 10.9 pt-20 -38.37 122.82 1.12 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -37.49 157.52 0.01 OUTLIER Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.843 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.8 t -124.66 104.59 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.01 138.29 32.55 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.087 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.8 mt -116.68 156.09 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -138.22 112.67 8.78 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.595 ' CE1' ' HB2' ' A' ' 93' ' ' CYS . 5.7 m-85 -87.3 101.11 13.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.588 ' CG ' ' C ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.545 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.64 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.3 Cg_endo -72.42 -175.39 1.77 Allowed 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.302 3.335 . . . . 0.0 109.615 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.22 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.82 22.51 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.44 148.95 49.56 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.4 p -113.23 117.75 32.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.799 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 48.3 t -113.58 145.92 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.723 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.56 166.67 28.6 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.723 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.39 117.55 5.18 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.332 3.355 . . . . 0.0 109.58 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.736 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.8 OUTLIER -127.55 13.08 6.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.863 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.6 p -92.56 106.51 18.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.964 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 100.57 22.66 11.0 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.736 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -109.81 140.49 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.68 173.19 8.74 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 19.4 p-10 -44.78 152.39 0.23 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.35 -22.09 40.67 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.652 HG22 ' N ' ' A' ' 18' ' ' VAL . 22.9 m -63.46 150.46 43.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.652 ' N ' HG22 ' A' ' 17' ' ' THR . 0.0 OUTLIER -130.28 114.1 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.663 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -97.56 119.08 45.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.799 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.57 146.07 36.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.502 ' CG1' HG23 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -131.51 102.88 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -113.17 116.23 29.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.716 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -87.76 144.08 18.69 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.895 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.93 107.92 6.71 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 99.31 25.88 9.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.397 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.15 -175.77 5.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.917 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 24.7 mt-30 -74.32 122.28 22.65 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.445 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.96 130.87 42.04 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.48 9.23 81.71 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.724 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -97.43 139.95 32.6 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 1.143 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.69 151.99 22.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.304 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 33.3 m-85 -137.44 149.69 47.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.111 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.5 m-20 -111.84 113.82 26.39 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.42 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -101.01 142.48 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.961 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.69 164.36 37.98 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.958 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 11.8 tt0 -106.65 111.54 24.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.195 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 81.2 m -111.16 151.31 28.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.466 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -129.72 126.16 37.6 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.19 119.06 10.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.378 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 7.0 m -100.97 -42.71 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.502 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -139.47 165.53 26.98 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.36 112.78 0.8 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.27 8.24 65.26 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.547 ' O ' HG22 ' A' ' 40' ' ' VAL . 71.7 t -123.28 105.04 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.561 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -122.85 137.41 54.94 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.431 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -89.28 157.32 18.26 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.195 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 41.7 m -121.22 151.83 39.53 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.782 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -114.67 105.74 53.06 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -72.42 -0.91 9.42 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.296 3.331 . . . . 0.0 109.584 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -89.99 -11.77 40.63 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.501 ' OD1' HG21 ' A' ' 68' ' ' THR . 65.0 m-20 -132.69 26.42 4.36 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.668 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.86 120.83 37.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.3 t -113.4 -174.68 2.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.35 157.2 43.76 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.408 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.83 156.95 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.408 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.5 m -127.63 127.24 43.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.95 146.31 42.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -87.35 -171.98 3.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.16 -28.38 69.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -76.49 -11.0 59.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.445 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 83.03 1.22 90.63 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.2 p -94.19 136.73 34.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.59 163.62 18.62 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.91 130.04 13.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.57 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -156.24 174.64 15.1 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.57 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.1 OUTLIER -124.76 126.68 46.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.954 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.155 ' CG ' HG23 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.16 119.45 38.99 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.653 ' N ' HD11 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -80.7 137.52 36.3 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.508 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -107.74 128.31 63.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.536 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -117.41 141.7 48.02 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -42.79 87.01 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.586 ' OG ' HG21 ' A' ' 85' ' ' THR . 11.5 t -147.01 156.74 43.28 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.958 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.0 p90 -177.02 157.93 1.48 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.03 111.54 0.86 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.431 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -76.5 99.05 1.3 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.758 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -84.46 99.51 10.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.804 HD21 ' HB3' ' A' ' 79' ' ' ASP . 3.7 tp -54.4 131.34 42.04 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.515 ' N ' HD13 ' A' ' 77' ' ' LEU . 3.3 p90 -47.55 -36.29 10.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.804 ' HB3' HD21 ' A' ' 77' ' ' LEU . 2.0 t0 -57.3 -17.24 11.18 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.91 28.5 8.23 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.638 HG22 ' N ' ' A' ' 82' ' ' ARG . 1.0 OUTLIER -115.61 145.07 43.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.638 ' N ' HG22 ' A' ' 81' ' ' THR . 2.0 ttp180 -85.16 95.53 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.378 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 0.8 OUTLIER -64.87 -56.92 10.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.914 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.52 168.78 12.8 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.586 HG21 ' OG ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -58.28 104.7 0.22 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.558 HG13 HG11 ' A' ' 40' ' ' VAL . 33.7 m -83.09 154.12 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 90' ' ' THR . 0.2 OUTLIER -117.81 93.32 4.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.503 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 75.9 m -50.3 -29.32 9.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.753 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 5.5 t -73.5 -1.67 19.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.633 ' O ' HG22 ' A' ' 90' ' ' THR . 2.2 m -115.47 -27.48 7.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.36 -164.21 1.33 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.62 123.35 47.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.187 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -103.89 160.15 15.04 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.056 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -160.45 147.7 15.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.155 HG23 ' CG ' ' A' ' 67' ' ' LEU . 3.0 t -106.51 165.42 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.274 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.24 164.05 33.11 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.42 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.79 131.11 42.65 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.111 ' N ' ' H ' ' A' ' 33' ' ' ASP . 23.9 m -113.83 151.29 32.31 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 1.143 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -108.67 -158.09 0.64 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.436 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.54 -47.92 65.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.12 -25.05 64.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.3 53.99 1.65 Allowed Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.917 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.45 166.86 20.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.304 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.1 174.67 43.59 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.64 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.37 167.49 26.81 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.333 3.356 . . . . 0.0 109.603 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.545 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 1.4 pm0 -38.37 124.83 1.29 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.96 156.79 0.01 OUTLIER Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.983 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.1 t -118.38 103.29 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.62 135.99 34.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.187 HG13 ' C ' ' A' ' 93' ' ' CYS . 2.9 pt -145.03 -176.55 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.863 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -176.7 177.88 1.31 Allowed 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.503 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.8 m-85 -127.73 113.75 16.41 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.964 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 6.6 p30 . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.215 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.547 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.39 -178.6 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.339 3.359 . . . . 0.0 109.591 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.905 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.66 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.687 ' CB ' ' HA2' ' A' ' 23' ' ' GLY . . . -124.14 157.92 33.54 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.579 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -126.31 129.41 48.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.939 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -119.41 148.59 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.717 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.64 165.76 33.01 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.717 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.35 117.2 5.02 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.286 3.324 . . . . 0.0 109.63 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.758 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -129.7 14.1 5.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 111' ' ' SER . 71.0 m -86.56 105.94 17.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.925 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 99.27 17.72 26.16 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.758 HD13 ' HA ' ' A' ' 10' ' ' SER . 1.1 mt -106.79 133.17 51.86 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -87.28 -179.74 6.47 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.778 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 4.2 t0 -45.05 152.39 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.92 38.24 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.579 HG22 ' N ' ' A' ' 18' ' ' VAL . 51.6 m -64.73 150.97 46.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.579 ' N ' HG22 ' A' ' 17' ' ' THR . 1.2 t -125.58 119.31 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.691 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 2.4 m -95.5 116.31 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.939 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -86.27 115.24 23.69 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.408 ' CG1' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -102.47 119.37 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.619 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -130.66 118.4 20.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.687 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -90.1 148.68 19.88 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.905 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.03 110.87 5.42 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.11 16.48 27.75 Favored Glycine 0 C--N 1.335 0.497 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.066 HD21 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.73 170.55 10.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.985 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 1.6 mp0 -52.08 118.92 3.82 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.494 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.78 130.62 41.55 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.05 7.64 86.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.638 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.94 145.74 24.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.479 ' N ' HG23 ' A' ' 30' ' ' THR . . . -89.0 151.4 22.31 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.985 ' HH ' ' NE2' ' A' ' 27' ' ' GLN . 39.1 m-85 -138.76 140.57 38.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.257 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.2 m-20 -104.41 114.19 28.25 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.277 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.7 146.45 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.047 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.45 166.88 40.05 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.894 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.2 tt0 -111.73 118.91 36.9 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.941 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -123.84 147.91 47.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.901 ' HB2' HG12 ' A' ' 86' ' ' VAL . . . -123.27 135.5 54.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.588 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.9 121.32 14.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.525 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 10.6 m -102.15 -43.42 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.793 ' CG ' ' HH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.58 165.52 25.34 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.664 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.2 t -51.7 111.96 0.68 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.87 9.18 70.19 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.556 HG13 HD11 ' A' ' 77' ' ' LEU . 21.3 t -123.96 113.69 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.58 HD11 ' HB2' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.54 139.14 53.44 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.243 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -96.92 144.34 26.94 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.941 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 66.3 m -107.0 158.3 17.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.597 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -115.65 111.46 43.69 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.52 7.28 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.326 3.351 . . . . 0.0 109.603 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.466 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.37 -10.81 45.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 7.1 p30 -131.54 28.23 4.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.415 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.86 104.63 12.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.96 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.6 t -100.88 174.35 6.07 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.1 p -145.95 156.13 43.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 56' ' ' THR . 4.4 p -166.49 159.43 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.428 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.8 m -127.25 139.54 52.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.95 141.02 36.41 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.0 p30 -82.3 -172.24 3.88 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.2 -27.88 69.29 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -75.1 -7.27 53.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.738 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.89 30.9 58.75 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 77.9 p -125.29 136.12 53.19 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.26 157.44 33.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.71 126.46 23.87 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.499 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -150.21 161.67 41.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.499 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -125.57 108.53 11.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.905 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.185 HD23 ' CG2' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -95.6 157.88 15.7 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.415 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.1 OUTLIER -107.49 140.17 40.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.512 HG22 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -109.88 123.28 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.778 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -109.91 157.94 18.72 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.532 ' HG2' HG21 ' A' ' 89' ' ' THR . 5.8 mtm180 -87.63 -13.06 43.7 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -163.41 145.47 9.76 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.894 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.5 p90 -177.42 150.69 0.71 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -53.4 113.48 1.17 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.243 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -75.7 101.47 1.42 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.82 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.33 100.67 10.8 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.735 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.0 tp -54.53 131.23 42.35 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.565 ' N ' HD13 ' A' ' 77' ' ' LEU . 4.5 p90 -47.49 -36.04 9.64 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.735 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.2 t0 -57.77 -16.56 11.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.49 27.39 9.89 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.445 HG21 ' N ' ' A' ' 82' ' ' ARG . 1.5 m -115.62 152.85 32.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.445 ' N ' HG21 ' A' ' 81' ' ' THR . 0.3 OUTLIER -85.15 98.68 10.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 75.0 t-105 -65.61 -43.53 89.31 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.41 175.54 14.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.46 107.75 0.62 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.901 HG12 ' HB2' ' A' ' 38' ' ' ALA . 2.4 t -80.02 152.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -120.36 95.84 4.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.941 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.3 m -54.11 -22.93 12.23 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.532 HG21 ' HG2' ' A' ' 71' ' ' ARG . 70.2 p -84.75 2.13 43.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -112.41 -23.36 10.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.05 179.29 7.3 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.32 130.94 40.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.368 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 11.1 m -104.47 164.89 11.43 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.07 ' HA ' HG12 ' A' ' 110' ' ' ILE . 1.1 tt0 -156.91 151.41 25.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.185 ' CG2' HD23 ' A' ' 67' ' ' LEU . 2.7 t -106.09 165.61 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.277 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.79 162.08 30.28 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.993 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -124.68 128.94 49.59 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.257 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 27.6 m -112.73 141.56 46.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -103.15 -162.03 0.88 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.996 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.83 -48.16 67.0 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.51 -24.67 66.43 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.61 53.69 1.92 Allowed Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.81 173.43 11.18 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.7 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -175.64 169.12 41.79 Favored Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.547 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.39 171.85 16.16 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.314 3.342 . . . . 0.0 109.595 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.215 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.8 OUTLIER -36.45 133.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.21 160.73 2.44 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.884 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 6.6 t -116.25 103.58 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.09 127.9 35.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.368 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -138.2 179.21 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -163.68 175.52 10.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.031 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.0 m-85 -131.01 114.85 15.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.925 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 10.7 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.654 ' HB1' ' CD ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.405 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.4 -174.51 1.45 Allowed 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 124.295 3.33 . . . . 0.0 109.619 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.73 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.28 108.83 21.38 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.834 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 140.42 52.39 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -102.06 112.45 25.11 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.719 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.74 154.86 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.939 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 174.41 2.52 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.939 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.3 Cg_endo -72.36 118.4 5.58 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.679 ' HA ' HD11 ' A' ' 13' ' ' LEU . 30.3 p -112.36 46.9 1.12 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.8 p -127.4 106.19 9.03 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.654 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.81 27.67 16.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.686 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -99.65 131.99 45.28 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -107.54 168.4 9.27 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -44.67 141.17 2.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.85 -22.32 37.41 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.4 m -76.86 150.35 36.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.442 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 8.8 p -126.53 117.27 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.964 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 13.3 m -83.73 164.12 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.75 152.25 36.51 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -147.1 111.51 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.834 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.49 116.37 26.54 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.573 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -81.84 143.25 23.16 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.73 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.0 105.54 4.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.522 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 104.22 23.05 8.28 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.077 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.81 -164.98 1.22 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.93 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -85.6 123.77 31.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.635 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.12 134.57 45.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.86 7.57 75.73 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.638 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -94.82 138.97 31.92 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.956 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.504 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.4 150.76 22.38 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.242 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -137.17 146.42 44.93 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.211 ' CB ' ' H ' ' A' ' 98' ' ' SER . 1.2 m-20 -107.47 112.15 24.79 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.345 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -101.84 150.19 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.916 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -179.38 174.54 46.36 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 1.097 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 31.0 tt0 -114.96 113.25 23.89 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.106 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.1 m -118.02 145.62 44.65 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.255 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -122.73 135.98 54.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.582 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.45 124.8 22.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.537 HG22 ' CD1' ' A' ' 83' ' ' TRP . 11.1 m -107.15 -42.25 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.336 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -138.29 129.91 27.9 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.427 ' C ' ' O ' ' A' ' 41' ' ' ASP . 9.5 t -38.04 112.01 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.434 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 93.03 8.98 61.22 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.455 ' CG2' ' HE1' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -151.8 130.44 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.576 HD13 ' HB2' ' A' ' 37' ' ' CYS . 1.7 pt? -133.02 142.88 49.05 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.538 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.4 144.65 25.14 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.106 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 6.1 m -106.69 156.55 18.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.935 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.4 t-20 -112.97 109.1 52.71 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.4 8.65 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.31 3.34 . . . . 0.0 109.628 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.542 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -94.09 -9.32 37.0 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.68 ' HB3' HG23 ' A' ' 68' ' ' THR . 7.9 m-20 -133.58 15.17 4.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.648 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -85.09 117.11 23.86 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.7 t -112.13 -178.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -145.72 156.14 43.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.513 HG22 ' N ' ' A' ' 56' ' ' THR . 5.1 p -166.99 157.74 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.513 ' N ' HG22 ' A' ' 55' ' ' VAL . 35.0 m -127.66 132.89 49.65 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.7 153.39 39.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -92.98 -172.04 2.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.82 -29.15 69.3 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -75.22 -9.11 58.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.635 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.88 7.19 88.72 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 99.3 p -99.22 138.94 35.61 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.27 163.91 17.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.1 p -149.38 127.77 12.21 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.466 ' O ' HG21 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -164.51 152.9 12.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -109.24 125.0 51.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.384 HD13 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.44 122.15 45.39 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.68 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.1 t -77.94 142.36 38.41 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.795 HG11 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -114.95 131.16 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.991 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 1.033 ' H ' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -113.74 156.84 23.08 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.981 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.26 -13.49 49.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 92.1 p -168.98 144.3 3.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 1.097 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 14.2 p90 -176.53 158.11 1.73 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -59.22 122.35 13.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.538 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.48 104.32 2.61 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.597 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.4 m-85 -84.82 101.31 12.17 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.822 HD23 ' HB2' ' A' ' 79' ' ' ASP . 6.0 tp -54.33 138.78 38.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.752 ' N ' HD13 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.46 -41.85 21.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.822 ' HB2' HD23 ' A' ' 77' ' ' LEU . 44.1 m-20 -56.85 -17.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.42 26.08 12.73 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.426 ' HB ' HD22 ' A' ' 77' ' ' LEU . 1.2 m -108.63 149.17 29.31 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.7 mtt180 -78.7 95.21 5.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.537 ' CD1' HG22 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -62.85 -39.49 94.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 126.5 170.26 12.91 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.226 -1.149 . . . . 0.0 110.226 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.92 130.95 43.31 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.255 HG12 ' CB ' ' A' ' 38' ' ' ALA . 2.0 t -109.13 154.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -125.53 98.0 5.41 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.726 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 9.9 m -53.13 -27.2 19.64 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.5 p -80.12 0.99 29.78 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.624 ' O ' HG22 ' A' ' 90' ' ' THR . 1.3 m -116.97 -27.59 6.51 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.2 -177.72 4.58 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.34 124.37 45.74 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.85 ' O ' HG13 ' A' ' 110' ' ' ILE . 60.2 m -103.92 153.27 20.99 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.056 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -146.52 146.98 30.7 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.921 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.384 ' CG2' HD13 ' A' ' 67' ' ' LEU . 4.0 t -107.48 159.58 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.345 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.25 171.96 44.78 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.224 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.97 122.12 25.05 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.211 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 6.7 m -102.95 154.79 18.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.504 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -114.75 -160.93 0.75 Allowed 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.467 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.8 -49.04 79.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.14 -26.02 60.08 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 98.6 49.21 1.7 Allowed Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.442 HD22 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -120.5 167.48 12.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.242 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.66 -176.85 45.16 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.405 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.41 159.6 48.89 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.32 3.347 . . . . 0.0 109.577 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.371 ' H ' ' CD ' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -37.32 125.44 1.01 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.94 147.64 0.09 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.056 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -115.89 104.51 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.65 138.09 32.38 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.026 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.4 mt -113.61 159.09 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -143.52 119.12 10.4 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.726 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 40.1 m-85 -95.14 123.42 38.63 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.939 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.671 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.525 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.466 ' HB2' ' CD2' ' A' ' 26' ' ' LEU . 83.1 Cg_endo -72.41 -175.48 1.81 Allowed 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 124.336 3.357 . . . . 0.0 109.628 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.322 HG23 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -100.03 117.92 35.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -133.52 150.63 51.68 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.1 114.24 25.81 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.707 ' HB ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -111.08 149.75 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.745 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.9 167.36 24.76 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.745 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.3 Cg_endo -72.38 119.31 6.06 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.295 3.33 . . . . 0.0 109.586 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.726 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -125.38 13.71 8.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.1 p -92.33 114.95 27.63 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.709 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.03 22.58 32.34 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.726 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -108.39 139.16 43.5 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 179.963 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 59.1 m -97.27 169.57 9.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -44.71 151.2 0.3 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.81 -24.35 31.4 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 18' ' ' VAL . 2.4 m -78.51 144.23 35.86 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.614 ' N ' HG23 ' A' ' 17' ' ' THR . 7.3 p -112.99 146.05 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.668 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.7 OUTLIER -117.2 157.61 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.707 ' O ' ' HB ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -113.1 151.1 31.2 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.753 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -146.16 105.37 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.21 115.46 26.03 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.799 ' HA2' ' HB3' ' A' ' 5' ' ' ALA . . . -84.26 143.34 21.03 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.322 ' O ' HG23 ' A' ' 4' ' ' THR . . . -139.56 110.66 6.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.455 ' C ' HD21 ' A' ' 26' ' ' LEU . . . 98.81 23.83 11.4 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.466 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.75 -169.77 2.73 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.665 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -81.83 122.78 28.15 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.31 131.74 43.88 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.95 7.83 81.92 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.659 HG21 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.31 140.48 30.14 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.905 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -90.59 151.61 21.24 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.497 ' CB ' ' CD1' ' A' ' 97' ' ' LEU . 43.2 m-85 -138.0 154.58 49.32 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.512 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 11.1 m-20 -118.5 112.46 19.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.484 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -97.62 149.61 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.994 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.99 167.01 38.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.837 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 15.5 tt0 -107.72 129.34 55.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.251 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.0 m -125.88 165.5 18.6 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.035 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -142.51 123.93 14.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.634 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.97 117.63 7.9 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.814 HG21 ' CD1' ' A' ' 83' ' ' TRP . 5.5 m -99.53 -42.52 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.432 ' N ' HG23 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -138.23 -179.49 5.82 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.973 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.4 m -63.38 111.52 2.33 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.18 8.46 65.32 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.582 HG11 ' CH2' ' A' ' 83' ' ' TRP . 62.4 t -121.97 106.96 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.61 HD13 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.84 136.47 54.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.216 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -85.45 157.79 20.37 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.251 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.3 m -126.24 156.63 39.97 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.572 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.5 t30 -123.91 111.94 28.9 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -72.4 -0.68 9.07 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.308 3.339 . . . . 0.0 109.604 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.493 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -87.55 -13.32 43.25 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.0 p30 -130.09 27.9 5.08 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.56 117.72 33.63 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.8 t -111.36 -178.24 3.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.0 p -147.78 155.42 41.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.423 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.0 p -167.52 160.42 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.423 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 37.6 m -127.15 129.91 48.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.83 150.86 40.57 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -90.5 -171.08 2.94 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.62 -28.85 69.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -75.53 -7.94 55.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.5 10.05 86.48 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.2 p -102.03 137.68 39.99 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.35 165.04 15.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 p -150.1 125.18 9.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.576 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.96 164.4 38.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.949 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.576 ' N ' HG21 ' A' ' 65' ' ' THR . 0.6 OUTLIER -120.39 126.17 49.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.899 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -103.74 118.69 37.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.68 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -68.44 116.78 9.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.546 HG21 ' HB3' ' A' ' 10' ' ' SER . 0.5 OUTLIER -73.32 122.83 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.68 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -118.02 133.01 56.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -67.85 -40.8 83.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.469 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 19.5 m -155.96 159.37 39.17 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.837 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -177.35 177.78 1.15 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -64.9 121.89 15.69 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.216 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -80.6 87.21 1.32 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.783 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.29 100.18 10.46 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.958 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.6 tp -54.15 144.13 20.62 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.415 ' N ' ' CD1' ' A' ' 77' ' ' LEU . 1.8 m-85 -47.16 -43.67 21.27 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.724 ' HB3' HD23 ' A' ' 77' ' ' LEU . 10.3 t0 -57.76 -17.16 13.88 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.24 29.09 9.89 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.2 m -108.61 121.18 44.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.432 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.1 ptt180 -62.81 91.07 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.582 ' CH2' HG11 ' A' ' 44' ' ' VAL . 4.9 t-105 -63.13 -58.37 7.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.15 157.0 8.15 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -54.52 110.13 0.59 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.035 HG11 ' CB ' ' A' ' 38' ' ' ALA . 16.8 t -88.49 154.54 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.469 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 27.4 m-20 -118.85 94.55 4.49 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.186 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 93.5 m -52.0 -28.82 18.26 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.841 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 2.1 t -76.18 -1.24 25.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.49 ' O ' HG22 ' A' ' 90' ' ' THR . 1.8 m -115.24 -27.16 7.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.74 -166.2 1.6 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.52 123.39 46.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.14 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 0.8 OUTLIER -104.47 156.29 18.07 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.04 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.12 154.87 42.29 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.899 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 6.4 t -122.11 160.79 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.229 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.28 171.83 42.81 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.512 ' HA ' ' C ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -127.66 124.79 38.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.302 ' N ' ' O ' ' A' ' 33' ' ' ASP . 59.6 p -99.47 152.62 19.79 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.905 ' HB2' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -115.14 -164.24 0.93 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.9 -48.89 77.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -70.73 -24.86 62.71 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 95.6 53.81 1.51 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.831 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.13 175.9 8.71 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.669 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 179.31 -173.91 45.86 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.19 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.33 157.58 53.13 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.357 3.371 . . . . 0.0 109.611 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.671 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.01 124.71 1.18 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.64 140.13 0.3 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.0 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.3 t -101.47 113.99 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.837 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -87.27 126.08 34.61 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.072 HD11 ' HB3' ' A' ' 93' ' ' CYS . 13.1 pt -135.07 -172.94 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.54 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -175.74 178.27 1.57 Allowed 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.186 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.1 m-85 -140.75 109.35 5.94 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.516 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 8.2 p30 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.518 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.7 Cg_endo -72.34 -177.73 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.263 0 C-N-CA 124.353 3.369 . . . . 0.0 109.619 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.88 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.4 m -98.51 109.51 22.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.858 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.27 163.67 22.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.469 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.1 p -129.55 115.63 17.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.771 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.3 t -111.07 149.53 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.867 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.66 171.17 7.6 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.867 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.33 117.18 5.01 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.366 3.377 . . . . 0.0 109.589 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.777 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.32 13.21 7.12 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.528 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.8 p -91.08 108.39 19.84 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.915 ' HA2' HD21 ' A' ' 113' ' ' ASN . . . 99.81 16.04 29.69 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.777 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -103.81 140.46 37.62 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 p -95.67 173.28 7.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -47.04 153.77 0.41 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.38 -24.28 28.1 Favored Glycine 0 C--N 1.335 0.493 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.601 HG22 ' N ' ' A' ' 18' ' ' VAL . 3.6 m -71.36 149.66 45.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.601 ' N ' HG22 ' A' ' 17' ' ' THR . 8.4 p -120.49 132.74 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.569 ' HA ' HG23 ' A' ' 8' ' ' THR . 0.6 OUTLIER -111.51 153.51 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.771 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.32 152.87 23.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.75 ' HA ' HG21 ' A' ' 7' ' ' VAL . 1.1 p -145.04 109.42 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.858 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.23 114.44 21.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.667 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.65 146.39 22.37 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.88 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.94 113.25 7.26 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.49 14.97 31.03 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.817 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.99 165.89 13.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.598 ' CD ' ' OH ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -49.61 119.83 3.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.525 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.25 134.81 44.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.89 8.06 67.63 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.498 HG22 ' N ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -95.6 145.74 25.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.498 ' N ' HG22 ' A' ' 30' ' ' THR . . . -88.04 151.03 23.06 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.431 ' CB ' HD21 ' A' ' 97' ' ' LEU . 35.3 m-85 -137.96 159.16 42.77 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.249 ' HB3' ' CA ' ' A' ' 98' ' ' SER . 3.3 t0 -124.0 115.04 20.57 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.209 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -96.56 142.26 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.856 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.42 164.67 34.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.716 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.2 tt0 -116.19 111.34 20.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 59.4 m -107.82 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.105 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -149.63 123.86 9.53 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.64 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.95 117.45 7.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.597 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 5.6 m -98.2 -43.26 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 40' ' ' VAL . 0.2 OUTLIER -135.46 177.83 7.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.8 m -61.34 112.01 1.99 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.3 8.54 66.05 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 59.1 t -121.53 111.14 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.453 HD11 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -126.26 139.61 53.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.989 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.247 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -94.57 144.36 25.66 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.5 m -110.19 146.9 34.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.709 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 29.2 t30 -107.47 107.74 60.77 Favored Pre-proline 0 N--CA 1.449 -0.488 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.2 Cg_endo -72.34 0.61 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 124.368 3.378 . . . . 0.0 109.599 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.497 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.05 -14.1 39.82 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.492 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.7 p30 -126.04 28.24 6.13 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.43 105.49 14.42 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.1 t -103.14 178.27 4.6 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.8 p -147.06 156.86 43.36 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.642 ' CG1' HD22 ' A' ' 97' ' ' LEU . 7.1 p -167.88 160.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.478 ' N ' HG22 ' A' ' 55' ' ' VAL . 26.9 m -126.96 138.32 53.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.8 143.6 34.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.4 p30 -80.25 -171.05 2.8 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.13 -26.11 68.39 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -10.07 59.13 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.817 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 77.11 31.18 53.6 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -127.61 137.27 52.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.46 168.32 13.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.6 128.51 11.75 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.578 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -154.09 162.32 41.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.578 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -115.82 119.73 36.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.074 HD13 HG12 ' A' ' 95' ' ' VAL . 1.0 OUTLIER -97.57 133.94 41.45 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.73 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -79.75 134.56 36.38 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.497 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 1.1 t -94.29 124.1 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.73 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.7 OUTLIER -117.2 142.95 46.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.428 ' HG2' HG22 ' A' ' 89' ' ' THR . 0.1 OUTLIER -80.92 -26.74 36.54 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -155.42 149.85 26.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.949 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.716 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -173.77 157.88 3.16 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.28 117.51 4.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.247 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.26 93.3 1.09 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.786 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -84.14 99.86 10.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.757 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.8 tp -57.02 130.39 45.87 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.627 ' N ' HD11 ' A' ' 77' ' ' LEU . 4.5 p90 -47.16 -35.63 7.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.757 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.78 -16.57 11.73 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.68 28.38 8.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.632 HG23 ' N ' ' A' ' 82' ' ' ARG . 1.3 m -116.23 147.78 41.1 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.632 ' N ' HG23 ' A' ' 81' ' ' THR . 1.5 ttp180 -84.73 96.02 9.12 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.597 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 68.7 t90 -64.97 -58.82 5.13 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.75 163.87 10.93 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.17 106.42 0.23 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.105 HG12 ' HB3' ' A' ' 38' ' ' ALA . 20.2 t -80.77 152.46 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.68 93.99 4.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.277 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 12.1 m -53.13 -26.57 17.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.717 ' HA ' ' HB3' ' A' ' 112' ' ' PHE . 7.3 t -82.37 0.1 43.46 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.447 ' O ' HG22 ' A' ' 90' ' ' THR . 8.0 m -114.3 -27.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.93 3.63 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.897 ' HB3' ' HG ' ' A' ' 111' ' ' SER . . . -99.57 126.0 45.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.264 ' CB ' HD11 ' A' ' 110' ' ' ILE . 92.4 m -104.2 172.01 7.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.041 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 1.2 tt0 -160.93 151.5 18.14 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.074 HG12 HD13 ' A' ' 67' ' ' LEU . 3.0 t -108.65 167.1 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.209 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.36 166.65 37.29 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.431 HD21 ' CB ' ' A' ' 32' ' ' TYR . 6.0 mp -102.16 161.82 13.39 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.249 ' CA ' ' HB3' ' A' ' 33' ' ' ASP . 46.7 t -150.86 121.07 7.25 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.645 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.8 OUTLIER -115.86 -170.9 1.88 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -46.0 -39.65 9.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.96 -25.33 26.12 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 91.16 22.61 31.94 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 1.35 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.11 -150.27 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.996 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.2 150.62 5.49 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 166.0 31.03 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.307 3.338 . . . . 0.0 109.578 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.518 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 6.6 pt-20 -34.34 124.3 0.5 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.21 135.32 1.48 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.041 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 3.4 t -90.05 107.43 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.91 127.83 34.12 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.264 HD11 ' CB ' ' A' ' 93' ' ' CYS . 4.0 pt -141.5 -173.77 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.897 ' HG ' ' HB3' ' A' ' 92' ' ' ALA . 0.6 OUTLIER -174.75 163.4 3.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.277 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 6.6 m-85 -125.88 112.16 15.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.915 HD21 ' HA2' ' A' ' 12' ' ' GLY . 0.8 OUTLIER . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.579 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.542 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.39 -177.2 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.317 3.344 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.756 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.78 109.59 22.33 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.721 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.08 140.3 52.03 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -100.5 111.48 23.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.742 ' CG2' HG22 ' A' ' 108' ' ' VAL . 21.8 t -105.84 150.29 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.5 175.7 1.51 Allowed Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.956 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.4 118.59 5.67 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.318 3.346 . . . . 0.0 109.586 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.908 ' HB2' HG23 ' A' ' 110' ' ' ILE . 54.5 p -113.0 47.52 1.11 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.0 p -126.56 107.38 10.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.698 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.9 27.0 20.62 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.701 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -102.01 132.49 47.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 82.0 p -109.88 169.28 8.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -45.04 140.72 2.57 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.67 38.31 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.6 m -77.05 141.87 40.11 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 18' ' ' VAL . 10.9 p -113.78 108.95 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.729 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 4.4 m -77.13 164.07 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.56 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.1 149.72 38.52 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.653 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -146.56 115.41 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.86 116.96 23.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.602 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -84.18 147.94 23.9 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.756 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.61 111.81 4.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.66 14.44 34.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.776 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.64 173.64 8.19 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.489 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 33.5 mt-30 -56.37 119.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.08 131.23 41.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.13 7.82 84.75 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.489 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.83 141.37 28.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.679 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.46 150.35 25.35 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.28 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 25.4 m-85 -136.38 140.81 43.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.489 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.5 m-20 -103.11 116.91 33.4 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.628 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -107.12 145.63 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.886 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.54 161.73 31.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.953 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 18.9 tt0 -101.97 120.61 40.69 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.482 ' SG ' HD13 ' A' ' 45' ' ' LEU . 1.5 m -109.99 169.0 9.01 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.114 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.73 124.91 8.71 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.611 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.64 124.03 20.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.792 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 15.4 m -103.73 -44.07 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.847 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -138.52 165.23 27.39 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.5 m -51.88 112.6 0.81 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.24 8.21 65.05 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 97.3 t -122.32 107.47 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.482 HD13 ' SG ' ' A' ' 37' ' ' CYS . 1.4 pp -117.71 162.38 18.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.357 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -127.11 156.59 41.5 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.863 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -118.47 155.49 30.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.666 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 19.8 t30 -112.86 113.58 49.79 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -72.38 0.03 8.02 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.343 3.362 . . . . 0.0 109.612 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.98 -9.51 45.73 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.2 p30 -134.16 27.72 3.82 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.42 107.29 17.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -103.49 171.38 7.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.2 p -145.27 153.54 41.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.7 p -166.6 158.23 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 85.7 m -127.52 135.53 50.49 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.45 139.97 48.02 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.2 p30 -77.6 -174.75 3.54 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.8 -25.08 68.06 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -75.99 -8.04 56.04 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.633 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 75.3 32.18 55.96 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -129.87 137.62 50.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.6 167.39 14.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -150.56 125.43 9.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.497 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -159.84 158.26 30.68 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.497 ' N ' HG21 ' A' ' 65' ' ' THR . 0.8 OUTLIER -111.17 133.46 53.51 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.225 ' CG ' HG22 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -110.3 120.16 41.54 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.623 ' OG1' ' NH1' ' A' ' 70' ' ' ARG . 3.5 t -79.26 129.86 34.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.565 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -107.88 137.02 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.868 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -120.31 165.62 14.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.5 -14.12 33.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.601 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.2 m -164.51 144.49 7.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.953 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.4 p90 -176.3 154.24 1.32 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.494 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.9 OUTLIER -57.3 124.26 18.26 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.357 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -84.75 98.08 2.18 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.863 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.2 101.75 12.1 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.618 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.0 tp -57.81 131.62 50.88 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.512 ' N ' HD12 ' A' ' 77' ' ' LEU . 29.6 p90 -47.64 -35.76 9.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.618 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -58.01 -16.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.22 28.46 9.18 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 ' N ' ' A' ' 82' ' ' ARG . 22.0 m -115.66 146.69 41.6 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.587 ' N ' HG22 ' A' ' 81' ' ' THR . 0.0 OUTLIER -84.0 96.58 8.91 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.95 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.847 ' HZ2' ' HB2' ' A' ' 41' ' ' ASP . 5.2 t-105 -63.45 -42.69 98.66 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 128.43 176.55 14.49 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.53 135.55 54.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.114 HG11 ' CB ' ' A' ' 38' ' ' ALA . 1.6 t -114.82 154.93 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -127.81 101.34 6.31 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.904 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 48.9 m -53.35 -28.04 26.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -79.04 -2.45 40.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.617 HG21 ' O ' ' A' ' 90' ' ' THR . 1.3 m -116.19 -27.59 6.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.92 -176.12 3.76 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.0 123.38 45.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.703 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 72.3 m -104.35 152.24 22.5 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.02 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -145.05 148.81 34.12 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.225 HG22 ' CG ' ' A' ' 67' ' ' LEU . 2.5 t -114.31 148.2 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.405 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.74 173.87 46.41 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.628 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -125.66 159.88 31.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.489 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 2.9 m -139.64 156.95 46.55 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.679 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.11 -165.45 1.0 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -55.79 -49.18 73.89 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.435 ' HB1' ' OD1' ' A' ' 103' ' ' ASN . . . -71.0 -25.37 62.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.69 39.55 3.37 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.589 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -113.57 154.32 27.34 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.28 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -161.86 -173.1 30.11 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.542 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.41 158.41 51.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.332 3.354 . . . . 0.0 109.557 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.579 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 2.4 mt-10 -38.64 117.26 0.63 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.09 153.2 0.01 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.742 HG22 ' CG2' ' A' ' 7' ' ' VAL . 11.0 t -127.05 106.71 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.433 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -82.69 133.89 35.15 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.02 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.5 mt -102.76 163.87 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.722 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -145.73 123.34 11.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.904 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.7 m-85 -95.32 127.36 41.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.968 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.58 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.63 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.37 -174.1 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.327 3.351 . . . . 0.0 109.591 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.49 110.75 23.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.864 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.72 139.16 52.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.544 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.71 112.48 24.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.88 HG13 HG22 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -110.51 152.89 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.926 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.48 174.06 2.87 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.926 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.9 Cg_endo -72.38 118.74 5.74 Favored 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 124.321 3.348 . . . . 0.0 109.618 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.757 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 92.0 p -111.94 49.08 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -127.54 106.41 9.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.672 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.44 27.5 20.0 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.691 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -100.67 132.22 46.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.6 m -109.22 172.27 6.95 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 1.023 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 7.6 t70 -46.6 141.53 3.71 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.2 -22.5 36.3 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.1 m -76.58 149.75 36.58 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.471 HG12 ' O ' ' A' ' 18' ' ' VAL . 11.7 p -121.5 114.66 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.695 HG21 HG11 ' A' ' 69' ' ' VAL . 11.6 t -81.03 153.19 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.768 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.82 147.18 33.76 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.614 HG11 ' CG1' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.3 111.15 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.864 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.87 117.13 27.32 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -82.08 144.77 24.0 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.9 102.29 3.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.571 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 109.04 17.64 10.01 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.127 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -90.23 171.36 9.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.988 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.982 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 26.7 mt-30 -56.9 121.82 10.8 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.649 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.59 131.75 42.04 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.0 7.77 86.72 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.53 HG23 ' CZ ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.12 136.59 36.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.964 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -82.64 152.25 25.96 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.871 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.4 m-85 -136.57 146.05 45.68 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.239 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -107.47 113.55 26.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.984 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.462 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.09 144.53 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.987 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.57 169.7 42.53 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.957 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 38.5 tt0 -106.4 105.31 15.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.142 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -105.71 141.14 37.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.979 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -122.78 138.57 54.59 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.563 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.93 124.44 22.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.918 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.141 HG23 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -103.66 -51.32 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.953 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -132.72 168.29 18.58 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.94 112.49 0.72 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.47 7.96 65.52 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.938 HG11 ' HE1' ' A' ' 83' ' ' TRP . 86.3 t -121.8 120.97 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.566 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -130.26 134.5 47.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.979 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.39 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -93.42 153.53 18.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.142 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 98.6 m -112.64 145.51 40.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.902 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -108.88 114.18 58.72 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.36 -0.24 8.41 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 124.332 3.355 . . . . 0.0 109.584 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.33 -12.67 58.96 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.635 ' OD1' HG21 ' A' ' 68' ' ' THR . 96.2 m-20 -136.66 29.78 2.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -84.36 108.36 17.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.8 t -107.0 173.41 6.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 p -145.59 154.45 42.17 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG21 ' N ' ' A' ' 56' ' ' THR . 6.8 p -167.06 156.82 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.512 ' N ' HG21 ' A' ' 55' ' ' VAL . 36.3 m -126.84 135.62 51.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.14 154.1 42.62 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -92.86 -169.42 2.17 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.57 -28.34 69.81 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.72 -7.56 54.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.649 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.11 14.96 81.76 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -107.83 137.68 45.41 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.92 165.45 15.19 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 p -149.94 128.12 12.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.524 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.67 160.85 20.39 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.899 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.524 ' N ' HG21 ' A' ' 65' ' ' THR . 0.5 OUTLIER -117.65 127.41 53.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.104 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.2 120.19 40.93 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.905 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.635 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.42 134.99 39.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.695 HG11 HG21 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.9 135.28 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 1.023 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -116.71 162.47 17.62 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -87.98 -19.51 27.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.492 ' HB2' ' OD1' ' A' ' 87' ' ' ASP . 28.5 t -163.05 146.73 10.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.957 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.7 p90 -177.04 152.75 0.93 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -57.66 118.96 5.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.39 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -80.64 98.98 1.83 Allowed Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.793 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.13 100.96 10.86 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.769 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.5 tp -54.78 131.79 44.62 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.536 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 4.8 m-85 -47.43 -36.48 9.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.769 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.7 t0 -57.13 -16.66 8.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.27 27.72 9.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.435 ' HB ' HD22 ' A' ' 77' ' ' LEU . 1.6 m -115.89 149.93 37.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.56 98.04 11.54 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.141 ' CE3' HG23 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -63.94 -43.71 95.06 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.946 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 135.69 -179.65 17.55 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.44 126.16 26.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.979 HG12 ' CB ' ' A' ' 38' ' ' ALA . 2.1 t -101.45 154.02 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.492 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 11.7 m-20 -127.45 96.79 4.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.78 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 54.4 m -53.23 -27.81 24.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -78.32 1.28 22.34 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.14 -27.53 6.06 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.16 -173.28 3.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.8 124.72 48.86 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.869 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 97.6 m -104.36 152.52 22.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.071 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -146.39 148.43 32.31 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.104 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.7 t -110.3 160.06 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.397 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 168.8 41.07 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.462 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.12 128.38 44.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.239 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 22.2 m -114.72 148.3 38.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.964 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -107.13 -157.97 0.64 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.49 -47.26 64.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.02 -23.97 64.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.01 53.88 1.98 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.982 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.21 165.96 20.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.871 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.62 46.71 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.63 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.38 162.44 41.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.346 3.364 . . . . 0.0 109.59 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.58 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 1.5 tt0 -37.59 120.83 0.84 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.535 ' N ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.66 153.54 0.02 OUTLIER Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.952 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.8 t -118.3 104.18 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.62 124.05 32.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.071 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.9 mt -101.31 157.0 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.65 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -141.94 125.36 16.64 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.78 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 9.5 m-85 -96.6 124.28 40.54 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.405 ' HB3' ' N ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.465 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.377 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.4 Cg_endo -72.4 -174.31 1.39 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.268 3.312 . . . . 0.0 109.616 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.805 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.66 108.27 19.75 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.867 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.57 146.24 47.17 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.501 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -113.24 118.17 33.92 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.82 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -114.13 155.15 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.993 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.639 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -71.54 162.19 74.32 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.635 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 121.98 7.93 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.322 3.348 . . . . 0.0 109.606 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.736 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.2 OUTLIER -126.93 15.84 7.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.6 111.73 22.23 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.978 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 91.3 22.58 31.7 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.736 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -109.11 144.12 37.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 75.5 m -94.29 166.03 12.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 1.128 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 11.5 t0 -46.15 153.34 0.33 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 100.02 -24.27 32.78 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.489 ' HG1' ' HB3' ' A' ' 13' ' ' LEU . 24.5 m -69.17 132.62 46.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 8.3 p -106.43 111.33 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.639 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 6.4 m -90.37 166.08 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.82 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.04 149.1 44.82 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' CG1' HG13 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -136.41 104.88 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.867 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.8 117.83 31.84 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.644 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -88.03 143.82 18.37 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.805 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -135.01 108.09 7.65 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.509 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 101.69 25.69 7.98 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.34 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.89 179.69 6.14 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 180.0 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -76.83 123.74 26.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.484 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.11 137.46 54.96 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.78 7.28 65.25 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.644 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.16 145.12 24.65 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.2 149.11 22.01 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.531 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 39.8 m-85 -138.05 136.83 37.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.065 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -99.61 114.75 27.99 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.197 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.99 143.19 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.897 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.66 162.14 35.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.936 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -101.01 117.78 35.7 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 m -108.65 164.57 12.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.789 ' HB1' HG12 ' A' ' 86' ' ' VAL . . . -150.47 139.44 20.98 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.527 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -64.67 124.55 22.21 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.228 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -106.4 -53.93 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.625 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -138.1 167.03 22.66 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -51.02 111.58 0.58 Allowed 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.59 8.15 66.51 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.602 ' CG1' ' CZ3' ' A' ' 83' ' ' TRP . 13.8 t -124.21 118.91 55.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.426 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 2.0 pp -121.93 163.3 19.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.204 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -127.51 146.19 50.59 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.769 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.15 159.13 17.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.985 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.906 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.2 t30 -113.04 112.74 49.81 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.39 -0.82 9.28 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.339 3.36 . . . . 0.0 109.592 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.449 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.95 -7.92 50.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.449 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 32.9 m-20 -133.82 26.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.25 106.12 15.62 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.8 t -104.73 176.38 5.18 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.7 p -146.09 158.45 43.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -166.98 158.3 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.5 m -128.37 127.35 42.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.61 141.57 58.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.5 p30 -85.22 -171.57 3.7 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.53 -23.52 67.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -83.67 1.0 44.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 70.44 2.35 41.83 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 t -95.12 136.08 35.88 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.45 161.99 21.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -147.51 129.59 15.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.592 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -151.7 174.24 13.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.888 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.592 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -130.96 114.64 15.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.315 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -98.38 156.89 16.52 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.601 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -116.64 134.67 54.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.634 HG13 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -101.03 131.06 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 1.128 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -115.74 147.92 40.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 ptt180 -74.48 -25.15 59.2 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.5 t -159.94 150.01 18.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.936 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.6 p90 -177.34 156.03 1.17 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.23 119.83 7.58 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.204 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -76.32 100.39 1.39 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.769 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.35 100.04 10.41 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.824 HD21 ' HB2' ' A' ' 79' ' ' ASP . 4.3 tp -55.05 137.12 47.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -46.62 -40.99 13.93 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.824 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.5 m-20 -57.09 -17.0 8.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.98 26.87 10.84 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 m -109.51 148.63 30.89 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.76 95.73 8.52 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.625 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 33.3 t-105 -62.8 -56.43 17.55 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.04 170.72 19.0 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.53 107.44 0.8 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.789 HG12 ' HB1' ' A' ' 38' ' ' ALA . 2.8 t -83.41 152.33 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.77 93.71 4.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.268 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -55.03 -22.27 15.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.517 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 25.7 p -85.93 2.24 46.86 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -110.98 -26.57 9.2 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.54 179.22 6.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.7 ' HB3' ' OG ' ' A' ' 111' ' ' SER . . . -94.06 129.45 40.59 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.066 ' CB ' HD13 ' A' ' 110' ' ' ILE . 59.1 m -104.86 173.07 6.46 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.371 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -158.67 142.55 15.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.951 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.315 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.4 t -98.21 164.13 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.112 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.93 161.25 26.87 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.197 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -126.55 135.71 51.63 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.065 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 52.4 p -106.99 158.79 16.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.466 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.0 OUTLIER -112.46 -167.53 1.2 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.466 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -53.8 -49.83 67.45 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.52 -25.4 59.31 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.4 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 104.67 39.44 2.37 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.44 ' ND2' ' CG ' ' A' ' 99' ' ' ASP . 0.5 OUTLIER -122.92 -175.34 3.14 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.531 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 162.14 -161.88 33.79 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.377 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.91 52.44 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.382 3.388 . . . . 0.0 109.553 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.405 ' N ' ' HB3' ' A' ' 2' ' ' ALA . 9.0 pt-20 -42.84 145.23 0.48 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.76 164.5 1.75 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.371 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 37.3 t -116.84 102.69 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.436 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -75.88 132.48 40.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.066 HD13 ' CB ' ' A' ' 93' ' ' CYS . 6.2 pt -142.41 -174.36 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.7 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 0.1 OUTLIER -171.02 176.1 4.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.268 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 4.6 m-85 -132.55 114.29 14.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.978 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.4 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.652 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.601 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.38 -177.7 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 124.314 3.343 . . . . 0.0 109.635 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.785 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.77 109.69 22.41 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.769 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.46 133.52 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.632 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -96.51 115.85 28.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.29 155.95 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.947 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 175.61 1.77 Allowed Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.947 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.37 117.4 5.11 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.32 3.346 . . . . 0.0 109.58 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.852 ' HB2' HG23 ' A' ' 110' ' ' ILE . 1.6 p -110.73 48.57 0.91 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 79.9 p -126.97 105.88 8.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.696 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 92.32 29.27 11.43 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.712 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -108.43 130.29 55.24 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.951 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.19 177.36 4.67 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -45.83 139.39 4.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.07 -22.77 34.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.408 HG21 ' N ' ' A' ' 18' ' ' VAL . 17.2 m -83.13 150.56 26.19 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.408 ' N ' HG21 ' A' ' 17' ' ' THR . 13.9 p -121.49 123.96 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.843 HG13 HG22 ' A' ' 69' ' ' VAL . 6.8 m -90.44 158.44 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.38 149.08 30.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.709 HG11 ' O ' ' A' ' 65' ' ' THR . 0.3 OUTLIER -145.09 113.38 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.769 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.65 117.19 22.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.623 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -84.06 147.75 23.89 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.785 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.36 111.32 4.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.17 15.61 30.04 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.623 HD22 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.6 177.05 6.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.52 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 29.7 mt-30 -59.61 121.5 11.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.532 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.22 129.8 39.3 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.08 7.04 86.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.659 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.23 141.5 28.51 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.92 149.85 23.83 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.786 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.6 m-85 -136.43 138.09 41.14 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.987 ' HB3' ' O ' ' A' ' 98' ' ' SER . 1.5 t0 -99.99 113.84 26.7 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.245 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.04 144.72 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.73 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.84 171.05 42.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.929 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 33.8 tt0 -117.64 108.77 15.84 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.077 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.76 147.66 37.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.028 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -122.33 142.87 50.04 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.503 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.98 124.97 23.45 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.898 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.443 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -104.89 -44.25 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.334 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -149.05 134.8 18.81 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 41' ' ' ASP . 1.5 m -38.18 110.92 0.14 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.459 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 94.46 8.3 59.87 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.172 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.7 OUTLIER -151.59 129.26 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.635 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -133.96 132.95 40.78 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.283 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -84.27 144.69 28.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.077 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 2.6 m -106.44 152.92 23.0 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.851 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 41.4 t-20 -111.64 107.4 56.64 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 82.1 Cg_endo -72.4 -0.05 8.16 Favored 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 124.308 3.338 . . . . 0.0 109.599 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.17 -10.44 49.89 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.697 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.3 OUTLIER -131.71 27.56 4.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.501 ' HD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -80.5 104.6 11.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -100.11 175.35 5.77 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.3 p -143.94 153.39 42.22 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.545 HG22 ' N ' ' A' ' 56' ' ' THR . 8.6 p -167.98 152.24 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.545 ' N ' HG22 ' A' ' 55' ' ' VAL . 39.7 m -127.47 134.71 49.81 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.4 141.63 50.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 45.2 p30 -81.57 -173.33 4.34 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -27.21 68.71 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -8.61 57.13 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.595 ' O ' HD13 ' A' ' 26' ' ' LEU . . . 76.81 31.87 52.05 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.1 p -127.93 139.67 52.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.503 ' HB1' HG21 ' A' ' 55' ' ' VAL . . . -123.35 165.81 16.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.71 122.89 8.91 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.709 ' O ' HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -158.73 152.22 22.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.541 ' N ' HG21 ' A' ' 65' ' ' THR . 0.3 OUTLIER -113.75 127.95 56.23 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.939 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.205 HD11 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -97.78 156.4 16.59 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.956 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 51' ' ' ASP . 4.8 t -102.67 120.96 41.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.843 HG22 HG13 ' A' ' 19' ' ' VAL . 1.0 OUTLIER -83.22 127.79 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.924 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.8 OUTLIER -117.14 155.81 28.7 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -94.21 -18.26 21.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 3.6 m -164.19 144.75 8.22 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.929 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.7 p90 -172.24 153.64 3.09 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -57.98 111.67 1.25 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.283 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.67 101.76 0.89 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.757 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.37 99.68 10.2 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.719 HD13 ' N ' ' A' ' 78' ' ' PHE . 2.3 tp -55.44 141.14 37.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.719 ' N ' HD13 ' A' ' 77' ' ' LEU . 1.3 m-85 -46.54 -42.9 16.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.572 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.33 -16.89 9.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.82 27.69 12.27 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.641 HG21 ' N ' ' A' ' 82' ' ' ARG . 3.3 m -109.23 144.72 36.97 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.641 ' N ' HG21 ' A' ' 81' ' ' THR . 1.6 ptt180 -76.89 94.77 3.97 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.443 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 31.5 t-105 -63.19 -57.2 11.3 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.52 163.79 12.51 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.1 104.67 0.33 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.028 HG11 ' HB3' ' A' ' 38' ' ' ALA . 67.9 t -76.64 150.45 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.5 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 4.2 m-20 -117.19 93.91 4.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.999 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 30.8 m -52.16 -27.22 13.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.6 p -80.01 0.36 32.01 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.607 ' O ' HG23 ' A' ' 90' ' ' THR . 1.6 m -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.73 -175.1 3.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.65 126.48 47.15 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.903 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.2 m -104.55 154.37 20.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.016 ' HA ' HG13 ' A' ' 110' ' ' ILE . 2.1 pt20 -142.55 150.05 39.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.205 ' CG1' HD11 ' A' ' 67' ' ' LEU . 4.4 t -110.62 164.04 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.245 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.66 166.31 36.01 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.961 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.96 121.03 27.15 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.987 ' O ' ' HB3' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -103.52 150.96 23.41 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -109.81 -159.93 0.7 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.973 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.27 -48.87 79.07 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.53 -25.71 57.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.86 42.24 2.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.449 HD22 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -111.68 166.27 11.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.99 -177.64 44.24 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.601 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.06 54.0 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.3 3.333 . . . . 0.0 109.6 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.13 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 1.9 mt-10 -35.39 125.89 0.62 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.06 151.88 0.02 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.913 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -124.39 104.68 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.483 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -84.63 146.06 27.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.016 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.8 mt -121.05 157.37 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.54 115.76 11.77 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.999 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 11.6 m-85 -86.56 114.27 23.15 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 2.8 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.443 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.468 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.6 Cg_endo -72.4 -178.26 3.22 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 124.303 3.336 . . . . 0.0 109.581 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.839 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.62 111.33 23.68 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.835 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.69 159.58 33.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.434 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.5 p -124.29 121.28 34.57 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.821 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 55.5 t -116.87 146.39 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.769 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.96 167.75 18.72 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.769 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 118.65 5.7 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.357 3.372 . . . . 0.0 109.576 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.729 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.7 OUTLIER -129.71 9.93 5.51 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.965 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 1.043 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.2 p -85.66 106.44 16.94 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 1.386 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 102.25 14.52 28.1 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.729 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -106.04 136.07 46.38 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.969 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -92.31 176.63 6.41 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.64 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 11.0 t70 -44.79 153.12 0.19 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.82 -23.34 34.68 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.592 HG21 ' N ' ' A' ' 18' ' ' VAL . 10.4 m -72.58 142.97 48.42 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.592 ' N ' HG21 ' A' ' 17' ' ' THR . 10.6 p -118.9 121.04 65.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.666 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.8 OUTLIER -100.59 154.31 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.821 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.2 151.0 26.51 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.724 ' HA ' HG21 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -141.95 109.19 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.835 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.46 115.43 22.21 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.662 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -86.62 146.36 20.7 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.839 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.2 112.12 6.86 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.49 17.75 25.56 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.896 HD21 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.48 167.61 12.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.786 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 18.2 mt-30 -52.22 121.21 6.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.522 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.23 130.69 40.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.35 7.12 86.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.531 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -94.95 139.12 31.78 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.503 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.42 152.55 23.95 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.701 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 33.5 m-85 -136.71 139.82 42.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.245 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.72 113.8 27.59 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.268 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -102.68 149.66 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.835 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.4 172.32 43.99 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.847 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 36.8 tt0 -113.5 110.91 21.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.7 m -108.94 147.12 32.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.919 ' HB2' HG23 ' A' ' 86' ' ' VAL . . . -125.95 131.58 52.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.61 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.25 120.52 12.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.919 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.975 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.7 m -100.35 -43.23 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.508 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -136.85 166.1 24.41 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.951 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.511 ' O ' HG23 ' A' ' 42' ' ' THR . 15.3 t -51.14 111.74 0.61 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.12 8.52 65.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.567 ' O ' HG21 ' A' ' 40' ' ' VAL . 21.0 t -122.09 109.41 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -123.89 141.17 52.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.184 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -100.28 155.13 17.95 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.9 m -111.04 149.61 30.5 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.542 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -117.1 115.66 38.22 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.37 1.02 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.345 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.28 -14.25 57.6 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.456 ' OD1' HG23 ' A' ' 68' ' ' THR . 95.1 m-20 -132.86 29.58 4.11 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.53 109.77 18.18 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.5 t -105.7 174.1 6.03 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -146.35 149.78 34.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.1 p -166.22 155.51 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 97.1 m -126.05 133.02 51.84 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.17 138.73 47.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.7 p30 -77.44 -174.06 3.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -17.39 58.58 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -85.16 5.66 29.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 59.12 32.37 71.2 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.6 t -130.44 137.09 49.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.52 167.49 17.03 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 53.1 p -150.83 128.04 11.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.576 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.52 172.91 13.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.853 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.576 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.4 OUTLIER -126.09 122.78 36.75 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.905 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -100.43 143.45 30.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.926 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.549 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -100.45 143.99 29.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.606 ' CG2' ' HG ' ' A' ' 10' ' ' SER . 2.0 t -103.35 129.33 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.64 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -119.42 143.91 47.22 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.02 -32.05 68.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 33.2 t -158.09 158.96 35.71 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.847 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -177.0 163.93 2.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.26 120.93 13.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.184 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.11 93.2 0.96 Allowed Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 1.003 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 100.07 10.48 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.773 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.1 tp -54.5 137.47 42.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.816 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 3.0 m-85 -46.6 -40.77 13.49 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.773 ' HB3' HD23 ' A' ' 77' ' ' LEU . 7.7 t0 -56.89 -17.39 9.31 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 96.56 27.94 9.39 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.418 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.2 m -110.33 139.87 45.08 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -78.25 92.5 4.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.975 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 13.6 t90 -62.49 -57.92 9.48 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.07 166.06 13.41 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.95 128.83 38.83 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.919 HG23 ' HB2' ' A' ' 38' ' ' ALA . 13.7 p -113.15 147.51 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.528 ' N ' HG21 ' A' ' 86' ' ' VAL . 5.5 m-20 -99.3 95.19 6.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.745 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -54.88 -20.71 9.39 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.9 p -91.24 1.78 56.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.422 ' O ' HG22 ' A' ' 90' ' ' THR . 6.8 m -108.71 -27.01 10.04 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.4 176.64 8.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 1.075 ' HB1' ' HG ' ' A' ' 111' ' ' SER . . . -89.59 126.72 35.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.24 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -104.98 172.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.964 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.68 147.81 22.1 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.905 ' CG2' HD12 ' A' ' 67' ' ' LEU . 29.6 t -104.86 163.49 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.268 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.55 167.98 37.72 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.241 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -133.02 138.75 46.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.245 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 22.8 m -121.73 145.55 47.91 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.503 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -103.19 -158.56 0.67 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -70.55 -47.75 58.83 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.95 -24.39 66.06 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.2 53.62 1.85 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.786 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.04 165.26 23.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.52 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.01 171.46 42.96 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.468 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 166.2 30.46 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.344 3.363 . . . . 0.0 109.604 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.443 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 11.2 pt-20 -37.87 120.24 0.82 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.83 158.78 0.01 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.918 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.6 t -115.03 103.56 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.08 124.03 30.67 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.24 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.6 pt -134.49 -174.87 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 1.075 ' HG ' ' HB1' ' A' ' 92' ' ' ALA . 1.0 OUTLIER -170.83 175.94 4.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.2 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.8 m-85 -124.46 115.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 1.386 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 36.1 m-80 . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.602 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.479 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.37 -174.46 1.43 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.29 3.327 . . . . 0.0 109.642 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.279 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 5.8 t -100.94 115.24 29.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.736 ' CB ' ' HA2' ' A' ' 23' ' ' GLY . . . -129.73 165.18 22.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.429 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.3 p -125.99 122.2 35.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.846 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -118.7 145.78 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.641 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.29 163.03 65.88 Favored Pre-proline 0 N--CA 1.448 -0.538 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.641 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.2 Cg_endo -72.42 119.27 6.03 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.284 3.323 . . . . 0.0 109.595 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.757 ' HA ' HD13 ' A' ' 13' ' ' LEU . 2.2 t -126.95 14.03 7.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.818 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.0 p -88.95 105.83 18.02 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.691 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.17 21.59 13.22 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.757 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -109.87 139.51 44.87 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -85.96 169.2 13.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -44.42 152.29 0.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.53 -22.54 40.38 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.524 HG23 ' N ' ' A' ' 18' ' ' VAL . 35.9 m -64.17 140.63 58.89 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.524 ' N ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -116.82 110.95 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -180.0 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.662 HG21 ' O ' ' A' ' 67' ' ' LEU . 0.9 OUTLIER -93.29 118.61 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.846 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.6 146.38 36.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.69 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -135.19 110.5 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.663 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.56 115.01 22.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.736 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.21 143.35 20.25 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.205 ' O ' HG22 ' A' ' 4' ' ' THR . . . -136.8 110.38 8.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 100.18 24.15 9.9 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.384 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.6 -175.04 4.8 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.995 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.522 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 25.3 mt-30 -74.2 124.5 26.49 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.514 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.48 128.01 34.28 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.65 87.02 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.833 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.84 134.3 40.33 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.48 152.15 23.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.945 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 66.6 m-85 -137.05 156.15 48.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.037 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -114.62 115.26 26.87 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.942 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.131 HG23 ' CB ' ' A' ' 97' ' ' LEU . 1.4 t -98.77 143.11 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.775 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.7 163.58 37.3 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.922 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -106.38 115.55 30.4 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 93.9 m -107.45 168.23 9.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.994 ' HB1' HG13 ' A' ' 86' ' ' VAL . . . -153.71 126.7 8.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.604 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.39 122.82 18.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.619 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 11.6 m -103.92 -43.44 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.621 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -142.48 171.94 13.37 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.1 m -56.75 112.55 1.33 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 5.11 56.59 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.127 HG13 ' CD1' ' A' ' 83' ' ' TRP . 24.0 t -118.63 107.05 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.573 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.2 pp -117.08 162.85 17.15 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.527 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -125.26 146.12 49.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 51.1 m -115.53 152.36 33.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.692 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -112.64 107.15 55.17 Favored Pre-proline 0 N--CA 1.449 -0.5 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 81.7 Cg_endo -72.46 -0.31 8.57 Favored 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.317 3.345 . . . . 0.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.449 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.65 -12.04 40.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.499 ' OD1' HG22 ' A' ' 68' ' ' THR . 69.8 m-20 -131.82 24.88 4.67 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.664 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -95.51 117.86 31.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.9 t -110.77 -171.76 1.9 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.78 156.45 43.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 p -166.4 152.79 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 54.6 m -126.19 132.06 51.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.47 150.8 48.41 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.4 p30 -90.93 -169.11 2.25 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.25 -27.84 68.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -76.27 -10.57 59.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.58 9.33 86.97 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -100.64 137.61 38.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.11 161.67 21.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.88 130.38 13.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.591 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.23 173.26 15.31 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.591 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -121.36 133.35 55.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.903 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.071 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -117.59 119.4 34.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.499 HG22 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -78.72 141.08 38.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.948 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.678 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -113.78 130.24 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.986 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.701 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -114.78 154.75 27.99 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -76.25 -22.1 55.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 87.7 p -161.42 151.84 17.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.922 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -176.98 160.4 1.8 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.49 113.11 2.49 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.527 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -74.63 95.97 0.91 Allowed Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.699 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 99.9 10.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.816 HD23 ' HB2' ' A' ' 79' ' ' ASP . 3.6 tp -53.56 144.51 17.18 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.73 ' N ' HD11 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.61 -43.93 26.2 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.816 ' HB2' HD23 ' A' ' 77' ' ' LEU . 12.0 m-20 -58.08 -16.5 13.25 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.45 27.51 13.05 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.2 m -105.18 125.99 51.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -64.53 91.69 0.08 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.619 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 87.2 t90 -62.02 -39.29 91.76 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 132.15 174.73 13.72 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.16 105.05 1.29 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.245 HG23 ' CG1' ' A' ' 40' ' ' VAL . 42.8 t -80.73 146.42 7.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -105.08 92.96 4.44 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.055 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -53.49 -21.26 5.96 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.2 p -89.18 3.14 52.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.537 ' O ' HG22 ' A' ' 90' ' ' THR . 2.9 m -112.92 -27.64 8.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.84 174.63 10.4 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.762 ' HB1' ' HG ' ' A' ' 111' ' ' SER . . . -91.4 127.66 36.92 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.4 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 33.2 m -105.41 167.23 9.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.069 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -155.29 140.58 17.63 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.071 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -92.7 164.93 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.075 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.46 160.93 27.24 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.131 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.03 127.09 42.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.037 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 26.4 m -106.44 151.02 25.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.41 -161.45 0.75 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.998 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.86 -48.65 65.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.23 -24.17 65.8 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.12 53.82 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 172.17 13.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.945 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.02 178.45 45.0 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.479 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.39 164.06 36.75 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.265 3.31 . . . . 0.0 109.577 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.602 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 13.2 pt-20 -38.12 124.05 1.16 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.434 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.29 152.6 0.01 OUTLIER Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.045 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.8 t -111.8 103.26 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.33 130.59 35.6 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.4 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.0 pt -143.84 177.31 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.818 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -173.49 176.31 2.83 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.055 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 1.7 m-85 -128.09 120.0 26.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.674 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 27.5 m-80 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.258 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.458 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.453 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.44 -177.53 2.8 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.296 3.33 . . . . 0.0 109.595 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.21 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.17 109.06 21.88 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.87 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 139.66 53.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.65 117.75 34.87 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.842 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -113.17 155.27 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.83 176.65 1.22 Allowed Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.952 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.1 Cg_endo -72.39 117.71 5.26 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.305 3.337 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.73 ' HA ' HD12 ' A' ' 13' ' ' LEU . 24.0 p -113.29 43.56 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 60.7 p -123.58 106.79 10.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.682 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 91.75 28.39 14.24 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.73 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -101.08 133.5 45.51 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 m -104.61 165.0 11.35 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.689 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -44.75 139.13 3.11 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.28 -22.33 34.96 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -76.07 141.89 41.9 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.4 p -113.28 128.86 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.571 ' CG1' ' N ' ' A' ' 20' ' ' LYS . 2.7 t -96.23 164.36 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.842 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.21 144.85 41.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.662 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -139.58 113.21 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.87 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.46 114.62 19.06 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.568 ' HA3' HD23 ' A' ' 26' ' ' LEU . . . -88.74 140.96 16.22 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.21 ' O ' HG23 ' A' ' 4' ' ' THR . . . -140.31 116.76 10.73 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.18 19.35 21.55 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.568 HD23 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -88.35 173.76 8.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.478 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 27.0 mt-30 -64.35 120.74 12.78 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.13 136.95 56.67 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.09 8.19 61.14 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.722 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -86.1 146.58 26.55 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.872 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.97 138.22 33.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.046 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 32.7 m-85 -131.32 146.75 52.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.217 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -117.12 116.49 27.4 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.376 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.45 153.67 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.001 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.72 163.66 30.8 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.946 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 21.0 tt0 -103.1 120.33 40.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.1 m -108.25 164.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.74 -0.466 . . . . 0.0 109.74 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.834 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -152.0 131.08 12.65 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.496 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -66.29 128.75 37.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.923 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.53 ' CB ' ' NE1' ' A' ' 83' ' ' TRP . 3.3 m -117.07 -38.1 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.256 ' OD1' ' HH2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -146.68 178.78 8.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.7 t -64.48 110.95 2.47 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 8.3 63.51 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.016 HG13 ' CE3' ' A' ' 83' ' ' TRP . 84.9 t -111.7 104.88 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.643 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.0 OUTLIER -104.33 154.81 19.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.934 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.163 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -129.16 129.01 44.56 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.831 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.72 157.43 18.12 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.747 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.1 t30 -115.67 114.56 42.13 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -72.46 -1.26 9.96 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.318 3.345 . . . . 0.0 109.611 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -91.19 -11.39 38.46 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 21.0 p30 -133.84 25.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.642 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -97.84 116.17 29.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 t -103.53 178.57 4.52 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.2 p -146.38 153.11 40.12 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -166.91 157.37 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 60.3 m -125.32 127.48 46.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.55 124.72 20.97 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.3 p30 -69.95 -170.3 0.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -23.73 66.46 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.25 2.12 29.33 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.566 ' O ' HD11 ' A' ' 26' ' ' LEU . . . 65.54 32.45 83.35 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 32.7 t -127.65 145.03 51.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.85 124.66 14.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -108.72 133.68 52.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.613 HG21 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -148.94 155.65 41.15 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.613 ' N ' HG21 ' A' ' 65' ' ' THR . 0.1 OUTLIER -111.24 120.43 42.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.637 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.79 159.36 15.85 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.803 -0.444 . . . . 0.0 109.803 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.413 ' H ' HG21 ' A' ' 68' ' ' THR . 0.1 OUTLIER -124.91 133.05 53.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.26 130.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.73 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -110.78 168.37 9.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 29.7 ptt180 -96.53 -8.34 32.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.8 t -176.54 146.15 0.59 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.946 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.3 p90 -176.77 166.72 2.58 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -62.13 127.29 30.68 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.163 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -83.15 93.41 1.7 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.831 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.58 100.59 11.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.786 HD21 ' HB3' ' A' ' 79' ' ' ASP . 4.2 tp -57.19 130.67 47.18 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.655 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m-85 -47.67 -35.76 10.05 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.786 ' HB3' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.81 -16.88 12.88 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.55 27.5 9.08 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.48 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.26 150.18 36.6 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.45 97.19 10.93 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.53 ' NE1' ' CB ' ' A' ' 40' ' ' VAL . 15.2 t-105 -66.64 -56.88 8.63 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.5 168.25 13.41 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.45 142.88 31.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.834 HG23 ' CB ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -127.13 154.64 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.981 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.418 ' N ' ' CG2' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -113.81 100.97 8.85 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.574 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.9 OUTLIER -53.78 -26.33 23.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -83.71 0.69 46.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 m -117.74 -27.85 6.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.23 175.64 7.28 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.95 123.04 40.56 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.207 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.9 m -104.47 152.62 22.12 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.998 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -143.77 143.39 31.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.637 ' CG1' HD12 ' A' ' 67' ' ' LEU . 3.4 t -101.95 151.57 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.373 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.72 171.57 43.78 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.376 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -128.27 146.05 50.87 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.217 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 5.9 m -123.18 153.25 40.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.872 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.59 -163.98 0.89 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.29 -49.28 78.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.37 -25.76 62.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 97.75 46.52 2.27 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.453 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -119.27 166.82 12.52 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.046 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.84 -176.53 41.5 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.453 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.47 162.45 41.41 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.306 3.337 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.258 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.85 127.45 1.58 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -43.75 144.54 1.72 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.998 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -120.87 110.94 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.507 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.85 142.84 27.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.207 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.9 OUTLIER -108.13 168.59 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.73 120.44 7.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.574 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 39.5 m-85 -97.99 121.89 40.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.948 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.048 ' HB2' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.485 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.1 Cg_endo -72.42 -177.53 2.79 Favored 'Trans proline' 0 N--CA 1.448 -1.205 0 C-N-CA 124.328 3.352 . . . . 0.0 109.537 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.83 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -97.47 109.83 22.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.78 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.8 133.59 50.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.561 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.35 114.64 26.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.709 HG11 HG22 ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.3 155.87 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.993 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.92 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.79 174.61 2.15 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.92 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.7 Cg_endo -72.43 118.12 5.45 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.346 3.364 . . . . 0.0 109.538 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 1.026 ' HB3' HG22 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -117.05 46.79 1.6 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.635 ' HA ' ' O ' ' A' ' 111' ' ' SER . 96.6 p -124.85 105.33 9.17 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.866 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.634 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.9 28.5 15.48 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.724 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -97.06 133.43 41.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.996 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.6 p -99.83 163.26 12.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.494 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.01 140.96 4.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.24 36.43 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.9 m -71.38 150.22 45.24 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.474 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 9.9 p -121.13 118.29 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.535 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.8 OUTLIER -86.8 169.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.997 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.74 153.05 37.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -146.58 113.17 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.78 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.05 115.9 22.62 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.585 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.99 143.89 21.57 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.719 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.08 112.98 6.38 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.87 19.09 23.09 Favored Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.696 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.81 -176.55 4.72 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.938 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.456 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 22.7 mt-30 -70.91 124.83 25.26 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.451 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.69 127.59 33.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.32 7.26 88.71 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.629 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -88.65 143.67 26.78 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.843 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -91.3 141.93 28.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.98 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 33.5 m-85 -131.53 146.22 52.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.217 ' CB ' ' H ' ' A' ' 98' ' ' SER . 13.8 m-20 -111.97 113.13 25.25 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.384 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -95.8 144.36 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.925 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.17 163.77 36.1 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.981 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 19.3 tt0 -107.41 108.04 19.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -107.83 142.19 38.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.871 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -122.48 139.18 54.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.558 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.11 124.86 22.73 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.341 HG21 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -105.26 -49.67 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.569 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.64 167.67 20.68 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -50.28 112.45 0.68 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.0 63.01 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.678 HG13 ' HE1' ' A' ' 83' ' ' TRP . 93.5 t -122.22 116.46 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.522 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -125.97 135.47 51.88 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.144 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -90.14 159.39 16.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 28.8 m -116.12 151.92 34.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.78 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.5 t30 -112.03 106.12 56.32 Favored Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.3 Cg_endo -72.44 -1.12 9.75 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 124.3 3.333 . . . . 0.0 109.599 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.511 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -90.41 -10.43 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 79.3 m-20 -135.61 27.04 3.38 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.51 121.22 38.1 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.8 t -115.4 -173.37 2.32 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.3 p -145.95 156.99 43.88 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.861 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.2 p -167.19 157.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 m -128.61 136.59 50.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.24 130.63 38.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p30 -72.13 -177.84 2.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.31 -16.22 43.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -86.12 7.56 24.35 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.696 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 57.01 32.64 62.84 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.1 t -131.89 135.38 46.61 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.91 166.64 16.53 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.7 m -151.15 128.0 10.97 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.574 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -155.46 169.85 23.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.89 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.574 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -118.69 133.28 55.97 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.203 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -115.69 118.99 34.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.936 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.423 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -77.64 137.04 38.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.973 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.502 HG13 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.09 125.85 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.41 ' N ' ' HD3' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -109.76 168.48 9.38 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.98 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.494 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -97.04 -15.73 20.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.993 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.526 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 47.8 t -167.37 146.45 5.04 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.981 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.7 p90 -176.92 151.8 0.88 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.7 OUTLIER -53.12 116.43 2.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.921 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.144 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -77.08 102.99 1.74 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.986 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -84.01 100.6 11.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.768 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.9 tp -54.24 132.89 44.41 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.987 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.966 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.5 m-85 -46.94 -37.16 8.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.768 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -57.51 -16.93 11.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.8 27.63 9.46 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.655 HG23 ' N ' ' A' ' 82' ' ' ARG . 1.5 m -115.29 151.3 34.81 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.655 ' N ' HG23 ' A' ' 81' ' ' THR . 7.7 ptp180 -85.9 98.5 10.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.341 ' CE3' HG21 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -64.52 -58.03 7.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.883 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 174.42 23.29 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.13 110.73 1.94 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.871 HG12 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -85.93 154.39 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 11.4 m-20 -122.02 95.14 4.54 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.731 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 35.9 m -53.61 -26.69 22.98 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -80.0 -1.51 40.01 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.602 ' O ' HG22 ' A' ' 90' ' ' THR . 1.8 m -114.65 -27.67 7.4 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.53 -173.94 3.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.883 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.55 125.48 48.21 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.854 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 93.1 m -104.2 152.66 21.9 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.021 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -143.94 150.52 38.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.944 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.203 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 2.4 t -112.41 160.29 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.379 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.28 169.96 42.36 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.384 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.88 128.03 44.44 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.217 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 56.8 m -107.23 151.22 25.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.843 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.29 -163.24 0.84 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.985 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.426 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -64.97 -48.85 72.55 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.22 -24.12 63.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.88 53.37 1.79 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.511 ' OD1' ' HE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -130.49 172.62 11.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.98 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -177.85 -179.16 47.85 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.485 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.4 157.99 52.2 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.324 3.349 . . . . 0.0 109.573 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.094 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.8 pt-20 -36.02 123.13 0.72 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.72 149.86 0.03 OUTLIER Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.993 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.1 t -117.6 104.97 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.73 135.42 33.76 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.026 HG22 ' HB3' ' A' ' 10' ' ' SER . 3.2 mt -111.79 167.12 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.635 ' O ' ' HA ' ' A' ' 11' ' ' SER . 4.7 t -153.11 128.48 9.89 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.731 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 26.6 m-85 -102.02 125.4 48.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.467 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 m-80 . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.227 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.451 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.38 -177.79 2.93 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.328 3.352 . . . . 0.0 109.592 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.237 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.83 111.93 24.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.742 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.12 160.58 30.75 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.521 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -120.37 113.46 20.39 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.742 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -105.16 148.27 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.975 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.97 177.81 0.93 Allowed Pre-proline 0 N--CA 1.448 -0.533 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.959 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.975 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.8 Cg_endo -72.4 115.99 4.54 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.342 3.361 . . . . 0.0 109.61 179.888 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.811 ' OG ' HG22 ' A' ' 110' ' ' ILE . 27.9 p -113.4 40.9 2.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.505 ' HA ' ' O ' ' A' ' 111' ' ' SER . 30.9 p -120.31 106.22 11.67 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.689 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.29 30.4 10.95 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.723 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -101.33 132.21 47.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -104.69 169.54 8.4 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -48.54 140.06 8.52 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.01 -22.54 36.5 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 46.2 m -75.14 147.04 40.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.5 p -120.62 124.96 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.617 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 2.6 m -90.68 168.06 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.742 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -117.32 152.48 34.82 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.966 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.656 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -150.1 114.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.989 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.77 114.59 18.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.609 ' HA3' HD23 ' A' ' 26' ' ' LEU . . . -83.86 148.5 24.7 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.237 ' O ' HG23 ' A' ' 4' ' ' THR . . . -145.6 112.64 6.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.51 14.74 31.64 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.746 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.94 169.01 11.58 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.934 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 28.1 mt-30 -50.39 120.09 4.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.6 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.71 131.63 41.82 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.32 8.28 83.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.555 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.82 139.94 30.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.977 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.888 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.22 151.73 25.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.769 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.0 m-85 -137.47 144.61 42.36 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.344 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.0 m-20 -106.0 115.22 29.86 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.526 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.16 143.16 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.955 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.86 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.94 172.5 43.28 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.909 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.8 tt0 -116.61 117.41 29.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.236 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 94.1 m -109.44 167.84 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.153 ' CB ' HG13 ' A' ' 86' ' ' VAL . . . -151.6 126.11 9.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.595 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -66.35 124.97 24.17 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.699 HG21 ' CD1' ' A' ' 83' ' ' TRP . 12.2 m -105.12 -44.05 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.519 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -143.3 163.56 32.64 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.9 t -51.91 113.48 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.21 8.35 69.81 Favored Glycine 0 C--N 1.336 0.553 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.637 ' O ' HG23 ' A' ' 40' ' ' VAL . 17.0 t -126.27 106.11 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.592 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 1.0 OUTLIER -116.17 162.91 16.75 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.41 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.37 138.66 53.58 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.236 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.8 m -109.33 150.28 28.24 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.631 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 24.5 t30 -108.77 109.06 61.2 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.39 -0.13 8.26 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.296 3.33 . . . . 0.0 109.563 179.899 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.49 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.09 -13.44 41.39 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.474 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.4 p30 -127.73 27.06 5.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.6 105.19 14.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.9 t -100.94 173.21 6.59 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.58 153.03 40.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.455 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.27 156.44 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.455 ' N ' HG22 ' A' ' 55' ' ' VAL . 58.2 m -126.6 138.35 53.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.99 149.02 37.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.0 p30 -85.37 -173.47 4.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.64 -22.86 66.75 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -77.53 -7.69 56.67 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.653 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 73.79 31.86 59.81 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.8 p -127.36 139.0 53.15 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.04 166.0 17.77 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 14.8 p -150.48 127.8 11.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.479 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -162.97 156.93 20.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.861 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.479 ' N ' HG22 ' A' ' 65' ' ' THR . 0.9 OUTLIER -109.35 134.74 51.45 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.943 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.53 119.21 37.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 t -74.87 128.33 35.32 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.943 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.698 HG23 ' HZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.91 128.14 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.998 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.77 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.57 149.94 35.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 ppt_? -78.33 -16.55 57.6 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.538 ' HB3' ' OD1' ' A' ' 87' ' ' ASP . 7.9 p -161.71 148.66 14.27 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.909 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.8 p90 -178.09 148.73 0.52 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.11 115.04 1.67 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.41 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.34 94.99 0.94 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.896 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.54 10.57 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.735 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.7 tp -54.22 139.29 36.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.733 ' N ' HD13 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.51 -41.58 21.26 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.735 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.0 t70 -56.33 -17.0 6.45 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.76 27.93 9.96 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.1 m -110.1 141.61 42.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.7 94.2 5.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.699 ' CD1' HG21 ' A' ' 40' ' ' VAL . 7.6 t-105 -62.43 -57.11 12.44 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 168.82 17.39 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.63 108.59 0.75 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.153 HG13 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -79.07 153.96 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.538 ' OD1' ' HB3' ' A' ' 72' ' ' SER . 14.8 m-20 -129.97 97.4 4.46 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.534 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 96.6 m -53.0 -28.04 22.04 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 50.5 p -78.12 -0.53 28.54 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -118.88 -28.04 5.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.68 -173.18 3.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.42 125.28 49.09 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.911 ' O ' HG13 ' A' ' 110' ' ' ILE . 56.6 m -103.93 159.81 15.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.051 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -155.36 144.79 21.1 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -109.9 157.83 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.31 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.51 168.56 40.24 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.526 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.47 139.73 53.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.344 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 85.8 p -122.57 149.03 44.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.888 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -107.6 -161.6 0.79 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -68.56 -47.98 65.43 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.72 -23.71 66.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.68 52.42 2.13 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.934 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.67 165.79 21.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.95 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.07 177.59 44.7 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.933 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.451 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 161.15 45.13 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.372 3.381 . . . . 0.0 109.568 179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.227 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 4.6 pt-20 -36.63 128.92 0.81 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -46.98 150.38 2.08 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.883 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.4 t -126.03 115.05 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.15 143.91 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.051 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.1 mt -109.18 168.51 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.3 t -155.0 121.23 5.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.698 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 10.7 m-85 -94.8 129.76 41.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.972 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.529 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.512 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.463 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.37 -174.7 1.5 Allowed 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.291 3.327 . . . . 0.0 109.595 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.15 108.55 21.27 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.952 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.724 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.2 144.65 49.81 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.524 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -105.81 112.7 25.87 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.999 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.84 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.31 152.84 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.982 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.902 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.34 175.02 2.04 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.92 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.902 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.3 Cg_endo -72.39 118.01 5.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.298 3.332 . . . . 0.0 109.562 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 1.0 ' HB2' HG22 ' A' ' 110' ' ' ILE . 81.1 p -111.49 46.26 1.13 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.665 ' HA ' ' O ' ' A' ' 111' ' ' SER . 4.3 m -127.98 105.05 8.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.874 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.645 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.39 28.31 11.76 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.703 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -100.37 132.1 45.93 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -106.79 170.81 7.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -46.4 142.45 3.02 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.75 -23.41 33.96 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 52.0 m -77.86 151.8 33.7 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.407 HG12 ' O ' ' A' ' 18' ' ' VAL . 7.6 p -128.26 116.26 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.774 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 3.1 p -78.7 152.14 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.84 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.03 143.48 36.68 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.997 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -140.76 106.99 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.724 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.7 117.12 28.93 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.53 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -81.79 139.77 20.32 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.43 108.33 7.12 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.497 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 100.45 25.95 8.45 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.107 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.7 -171.9 3.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 19.5 mt-30 -82.54 124.91 30.55 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.43 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.38 139.7 49.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.92 8.29 68.34 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.703 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.62 146.22 23.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.987 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.901 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.54 149.05 23.15 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.201 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 56.4 m-85 -136.95 145.06 43.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.867 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.082 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -110.54 113.76 26.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.995 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.345 HG23 ' CB ' ' A' ' 97' ' ' LEU . 1.5 t -99.07 140.07 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.944 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -162.37 164.44 35.58 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.566 HE22 ' H ' ' A' ' 70' ' ' ARG . 29.5 tt0 -114.58 108.16 16.46 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.987 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.0 OUTLIER -110.83 146.32 36.65 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.987 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.94 ' HB1' HG23 ' A' ' 86' ' ' VAL . . . -122.81 138.28 54.69 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.605 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.52 123.2 19.04 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.959 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.912 HG23 ' CD1' ' A' ' 83' ' ' TRP . 0.0 OUTLIER -103.05 -44.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.395 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 1.1 m-20 -133.44 -179.28 5.42 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 m -69.03 111.12 4.82 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.66 85.97 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG23 ' HE1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -130.78 125.52 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.954 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.538 HD13 ' HB2' ' A' ' 37' ' ' CYS . 1.2 pt? -134.09 141.48 47.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.39 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.07 147.22 24.25 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.987 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.9 m -107.11 150.3 26.71 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.584 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 8.3 t30 -111.46 109.02 56.36 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -72.45 -0.65 9.06 Favored 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.315 3.343 . . . . 0.0 109.608 179.909 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.457 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -88.75 -11.87 43.79 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -132.71 28.64 4.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.666 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.92 119.3 38.01 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.994 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 t -113.4 -179.17 3.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.96 158.13 43.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.51 HG21 ' N ' ' A' ' 56' ' ' THR . 3.4 p -166.45 161.91 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.51 ' N ' HG21 ' A' ' 55' ' ' VAL . 22.8 m -127.98 126.21 40.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.31 146.32 40.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.927 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 47.3 p30 -87.43 -173.44 4.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.52 -25.43 67.28 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -82.21 4.37 23.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 66.3 6.12 31.84 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.5 t -96.9 134.25 40.48 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.0 164.96 15.94 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -148.48 127.9 13.1 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.577 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -160.02 155.27 25.07 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.88 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.577 ' N ' HG22 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.56 125.4 52.93 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.938 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.095 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -105.35 123.33 47.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.975 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.464 ' N ' HD11 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -78.06 136.08 37.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.939 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.408 ' O ' HG21 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -112.6 124.99 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.979 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.566 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.97 173.46 6.32 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.445 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 27.5 ptt180 -99.41 -9.67 23.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 97.2 p -168.05 145.69 4.29 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.584 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.9 p90 -176.6 156.16 1.44 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -55.46 114.5 1.86 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.39 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -79.25 100.68 1.8 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.817 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.68 101.5 12.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.582 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.6 tp -53.64 136.07 39.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.578 ' HE1' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m-85 -46.59 -39.95 12.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.582 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -56.31 -17.67 8.42 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.913 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 97.13 27.7 9.18 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.486 HG21 ' N ' ' A' ' 82' ' ' ARG . 1.7 m -111.77 142.42 44.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' N ' HG21 ' A' ' 81' ' ' THR . 4.1 ttm180 -79.93 94.33 5.85 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.955 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.395 ' CZ2' ' OD2' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.51 -58.34 7.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.886 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 173.14 20.41 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 104.38 0.52 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.94 HG23 ' HB1' ' A' ' 38' ' ' ALA . 9.9 p -79.44 150.92 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' HG21 ' A' ' 86' ' ' VAL . 4.3 m-20 -107.21 98.09 7.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.445 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -53.24 -23.84 9.77 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.2 p -85.44 1.41 48.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.532 HG21 ' O ' ' A' ' 90' ' ' THR . 1.4 m -112.7 -26.93 8.37 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.03 179.69 6.1 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.0 128.44 41.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.884 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 36.7 m -104.41 153.29 21.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.079 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -147.25 147.05 30.03 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.981 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.095 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.9 t -110.92 160.04 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.27 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.24 166.37 37.39 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.345 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.01 123.82 35.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.978 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.082 ' N ' ' H ' ' A' ' 33' ' ' ASP . 14.2 m -107.65 144.18 35.08 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.901 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.6 OUTLIER -102.56 -160.75 0.8 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.979 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.63 -47.78 65.76 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.98 -24.42 66.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.72 53.78 1.76 Allowed Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.555 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.57 169.81 16.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.989 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.201 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.41 179.16 45.92 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.463 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.32 164.19 36.37 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.318 3.345 . . . . 0.0 109.601 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.529 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.61 126.92 1.14 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.976 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -42.93 154.69 0.17 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.906 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.9 t -120.84 103.79 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.64 126.54 35.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.079 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.6 mt -103.24 159.07 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.735 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -146.95 123.22 10.91 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.522 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 39.7 m-85 -95.36 125.57 40.07 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.98 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.175 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.685 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.3 Cg_endo -72.34 -178.13 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.288 3.325 . . . . 0.0 109.6 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.905 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.97 108.95 21.76 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 1.278 ' N ' ' OE2' ' A' ' 106' ' ' GLU . . . -124.29 146.78 48.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.587 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.85 114.62 28.89 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.98 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.951 HG23 HG21 ' A' ' 108' ' ' VAL . 41.4 t -109.82 147.74 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.942 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.43 176.01 1.38 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.913 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.942 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.1 Cg_endo -72.39 117.36 5.1 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.323 3.349 . . . . 0.0 109.615 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 1.044 ' HB2' HG22 ' A' ' 110' ' ' ILE . 14.5 p -113.38 48.52 1.04 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.981 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.717 ' HA ' ' O ' ' A' ' 111' ' ' SER . 5.9 m -128.99 105.83 8.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.872 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.705 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 93.49 28.04 12.12 Favored Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.73 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -105.01 129.25 53.5 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -104.45 170.39 7.92 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.564 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 7.4 p-10 -44.59 141.29 2.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.65 -22.87 32.84 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.6 m -79.39 149.6 31.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.423 HG12 ' O ' ' A' ' 18' ' ' VAL . 13.8 p -122.34 121.72 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.662 ' CG2' ' CG1' ' A' ' 69' ' ' VAL . 12.2 t -85.44 153.15 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.744 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.89 143.2 34.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.952 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.745 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -140.58 111.5 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.2 117.71 25.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.672 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -83.59 145.5 22.89 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.793 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -144.36 113.38 6.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 95.63 17.97 34.24 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.672 ' CD2' ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.87 170.78 9.8 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.772 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.6 mt-30 -51.78 119.58 4.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.521 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.33 130.28 39.83 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.64 7.34 87.23 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.517 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.83 137.27 34.13 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.703 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -81.47 152.41 27.36 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.741 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 36.8 m-85 -138.08 141.08 40.27 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.913 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.144 ' CB ' ' O ' ' A' ' 98' ' ' SER . 7.8 m-20 -106.01 113.45 26.99 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.309 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.0 147.46 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.919 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.1 168.16 41.1 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.742 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 22.7 tt0 -112.13 113.2 25.33 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.163 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 25.9 m -114.2 141.99 46.82 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.579 ' HB1' HG23 ' A' ' 86' ' ' VAL . . . -121.96 129.08 52.21 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.56 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.19 128.58 36.43 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.906 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.342 HG22 ' CD1' ' A' ' 83' ' ' TRP . 11.7 m -109.78 -43.91 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.664 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -141.08 160.12 40.76 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.5 m -55.55 113.49 1.46 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.94 8.06 87.98 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.308 HG13 ' NE1' ' A' ' 83' ' ' TRP . 58.8 t -130.34 108.99 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.973 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.796 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -118.22 144.23 45.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.102 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.64 143.63 33.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.163 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 15.5 m -110.24 152.71 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.688 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 42.6 t30 -111.86 108.02 55.94 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.73 9.12 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.355 3.37 . . . . 0.0 109.573 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.48 -11.23 35.2 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.852 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -129.82 19.62 5.56 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.77 107.76 16.39 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.0 t -101.46 173.36 6.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.9 p -146.06 149.39 33.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.89 159.72 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 63.6 m -127.74 136.68 51.86 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.38 142.44 46.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 40.6 p30 -80.86 -172.45 3.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -22.02 66.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -80.87 4.05 20.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.636 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 60.44 31.29 73.83 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 t -128.13 133.76 49.02 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.68 164.65 18.68 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.27 129.96 17.05 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.602 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -156.57 164.61 37.99 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.861 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.602 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -125.25 118.23 25.56 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.973 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.679 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.68 156.2 16.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -112.36 132.73 54.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.662 ' CG1' ' CG2' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.34 128.06 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.99 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.692 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.07 164.04 13.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.999 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.467 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 ptt180 -91.88 -9.47 43.13 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 12.8 t -174.8 144.37 0.81 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.742 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 13.3 p90 -175.83 157.63 1.99 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 117.06 3.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.102 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.32 100.56 1.92 Allowed Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.989 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.26 100.28 10.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.796 ' HA ' ' O ' ' A' ' 45' ' ' LEU . 1.7 tp -54.42 136.7 43.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.859 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.1 m-85 -46.25 -39.93 10.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.793 ' HB3' HD23 ' A' ' 77' ' ' LEU . 7.6 t0 -56.84 -17.36 9.07 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 96.38 28.2 9.3 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.427 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.2 m -112.31 140.08 47.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.6 ptt-85 -79.72 94.53 5.76 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.342 ' CD1' HG22 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.25 -55.78 24.99 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.59 172.86 19.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.35 107.09 1.01 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.579 HG23 ' HB1' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -83.7 152.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.962 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -109.5 99.6 8.79 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.58 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.2 m -53.27 -25.06 13.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 30.4 p -84.04 1.25 44.79 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -118.32 -27.98 5.88 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.911 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.55 177.4 6.24 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.07 125.3 41.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.284 ' O ' HG13 ' A' ' 110' ' ' ILE . 38.7 m -104.53 153.05 21.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.023 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.4 OUTLIER -151.17 146.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.929 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.679 ' CG1' HD13 ' A' ' 67' ' ' LEU . 21.5 t -105.84 153.48 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.943 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.232 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -170.2 165.97 39.22 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.309 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.32 131.76 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.144 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 7.6 t -112.29 150.91 30.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.703 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -112.6 -164.25 0.9 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.948 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.41 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.92 -48.51 68.44 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.8 -23.76 66.1 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.7 53.2 1.99 Allowed Glycine 0 C--N 1.336 0.55 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.772 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.94 171.89 13.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.977 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.741 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.27 176.43 46.64 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.685 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.1 Cg_endo -72.38 165.17 33.43 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.349 3.366 . . . . 0.0 109.622 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.278 ' OE2' ' N ' ' A' ' 5' ' ' ALA . 0.2 OUTLIER -38.08 136.51 0.6 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.988 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.98 149.0 6.06 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.951 HG21 HG23 ' A' ' 7' ' ' VAL . 11.9 t -123.84 105.93 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.471 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.57 147.96 23.0 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.284 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.09 159.76 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.717 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -142.28 111.98 6.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.953 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 66.2 m-85 -87.15 110.71 20.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.408 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.517 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.34 -178.29 3.22 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 124.357 3.371 . . . . 0.0 109.616 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.081 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -97.46 110.26 22.85 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.963 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.5 156.53 40.6 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -114.96 117.15 29.83 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.822 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 58.5 t -114.5 144.21 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.695 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.2 165.82 40.02 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.921 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.695 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.34 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 124.318 3.345 . . . . 0.0 109.617 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.812 ' OG ' HG13 ' A' ' 69' ' ' VAL . 47.7 t -127.84 17.57 6.79 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 1.026 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.1 p -92.2 111.78 23.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.967 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 89.43 25.6 27.79 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.731 HD12 ' HA ' ' A' ' 10' ' ' SER . 1.0 OUTLIER -108.52 139.48 43.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.989 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.6 m -67.47 144.69 55.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB3' ' H ' ' A' ' 71' ' ' ARG . 17.9 p-10 -48.1 147.49 2.14 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -18.97 45.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.6 m -60.99 130.53 46.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.46 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 9.3 p -92.87 115.05 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.651 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 3.6 m -100.58 159.33 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.943 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.822 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.6 146.1 39.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.82 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -138.5 114.52 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.8 116.31 23.47 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.944 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.639 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.21 145.96 22.57 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.081 ' O ' HG23 ' A' ' 4' ' ' THR . . . -142.23 115.83 9.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.73 16.02 29.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.661 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.92 168.6 11.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.468 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.7 mt-30 -52.03 119.24 4.11 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.469 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.37 132.06 44.29 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.89 7.78 84.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.706 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 141.89 30.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.543 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.46 150.86 24.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.024 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 40.3 m-85 -138.29 141.73 39.82 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.18 ' OD2' ' HB2' ' A' ' 98' ' ' SER . 0.9 OUTLIER -105.85 115.54 30.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.413 ' CG2' ' HG ' ' A' ' 97' ' ' LEU . 1.8 t -96.64 136.46 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.874 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.66 153.51 24.53 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.856 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 17.2 tt0 -94.46 119.68 33.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.844 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.724 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.3 m -107.04 159.26 16.43 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.738 ' HB2' HG21 ' A' ' 86' ' ' VAL . . . -147.16 130.08 16.25 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.543 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -69.96 125.92 28.16 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.185 ' CG1' HG11 ' A' ' 86' ' ' VAL . 4.0 m -113.74 -39.56 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.609 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -146.65 -179.59 6.88 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.95 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.8 m -64.69 111.58 2.82 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.56 8.52 63.26 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.686 HG22 ' CH2' ' A' ' 83' ' ' TRP . 40.1 t -110.02 104.0 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.807 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 mt -106.86 155.94 19.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.372 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -134.27 126.7 30.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.141 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -107.84 158.83 16.99 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.482 ' OD1' ' HB1' ' A' ' 50' ' ' ALA . 8.5 t30 -118.83 113.96 35.78 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -72.43 -1.45 10.23 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.317 3.345 . . . . 0.0 109.577 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -11.48 40.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -131.63 26.58 4.71 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.667 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.34 122.07 41.97 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.983 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -104.65 -175.32 2.76 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.0 p -146.72 154.37 41.34 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.527 HG23 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.89 156.18 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.527 ' N ' HG23 ' A' ' 55' ' ' VAL . 41.7 m -125.97 121.68 33.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.76 150.18 20.45 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 p30 -97.02 -168.02 1.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.13 -25.37 68.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.983 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -83.37 3.75 30.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.661 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 62.25 31.23 78.4 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.3 t -126.22 142.85 51.36 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.402 ' HB2' HG22 ' A' ' 55' ' ' VAL . . . -133.98 159.81 39.61 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.21 124.96 22.42 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.618 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -144.62 178.43 7.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.866 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.618 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.3 OUTLIER -129.46 122.32 29.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.949 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.116 ' CD1' HG22 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.09 149.19 28.79 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.925 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.531 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -111.37 143.0 42.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.812 HG13 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -109.55 125.93 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.967 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.796 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -115.08 153.08 31.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.986 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.467 ' H ' ' HB3' ' A' ' 15' ' ' ASP . 10.0 ttp180 -74.03 -37.79 64.22 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 t -151.06 153.25 34.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.856 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.4 p90 -177.09 159.44 1.65 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.931 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.98 114.43 1.59 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.372 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -71.71 93.77 0.57 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 1.141 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.34 99.94 10.34 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.807 ' HA ' ' O ' ' A' ' 45' ' ' LEU . 3.4 tp -58.76 131.79 51.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.724 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 8.4 m-85 -47.06 -36.46 8.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.729 ' HB3' HD23 ' A' ' 77' ' ' LEU . 3.4 t0 -56.99 -17.51 10.08 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.15 27.29 8.87 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.3 m -114.0 143.05 45.37 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.77 94.71 9.83 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.609 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 34.8 t-105 -63.41 -58.46 6.99 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.893 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 171.11 18.48 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.6 109.0 0.71 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.185 HG11 ' CG1' ' A' ' 40' ' ' VAL . 18.1 m -89.93 150.83 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -108.88 89.14 2.9 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.115 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 2.0 m -52.92 -24.48 9.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -79.27 -1.75 38.06 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.18 -28.36 6.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -118.64 -165.63 1.14 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 124.62 40.9 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.273 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -104.27 152.36 22.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.044 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 0.7 OUTLIER -168.12 147.67 4.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.944 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.116 HG22 ' CD1' ' A' ' 67' ' ' LEU . 4.9 t -99.4 164.92 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.941 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -171.67 160.01 31.73 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.413 ' HG ' ' CG2' ' A' ' 34' ' ' VAL . 4.5 mp -100.2 163.57 12.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.18 ' HB2' ' OD2' ' A' ' 33' ' ' ASP . 14.8 m -155.83 121.68 5.01 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.635 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 4.8 p-10 -113.88 -168.93 1.42 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -47.64 -26.76 1.61 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.7 -25.94 14.52 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.912 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 92.01 21.15 33.98 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 1.024 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.64 -149.42 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' HD2' ' A' ' 3' ' ' PRO . . . 141.4 151.82 5.62 Favored Glycine 0 C--N 1.336 0.556 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.517 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.6 Cg_endo -72.37 161.69 43.63 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.302 3.335 . . . . 0.0 109.609 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.408 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 10.3 mt-10 -32.06 120.26 0.28 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -32.94 149.8 0.01 OUTLIER Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.044 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 2.6 t -108.26 103.33 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.52 126.72 31.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.273 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 7.0 pt -141.81 177.82 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 1.026 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -171.65 177.82 3.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.115 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -130.3 115.21 16.62 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.967 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.3 p30 . . . . . 0 N--CA 1.45 -0.469 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.097 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.601 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.5 Cg_endo -72.46 -178.59 3.44 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.301 3.334 . . . . 0.0 109.57 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.218 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.0 21.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.83 ' H ' ' CD ' ' A' ' 106' ' ' GLU . . . -122.53 151.05 41.75 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.952 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.7 p -116.49 116.27 27.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.77 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -106.82 148.92 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 1.026 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -65.69 179.39 0.45 Allowed Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.917 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 1.026 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.8 Cg_endo -72.36 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.315 3.343 . . . . 0.0 109.648 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.792 ' HB2' HG23 ' A' ' 110' ' ' ILE . 3.8 p -112.42 35.87 3.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -119.8 106.75 12.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.836 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.714 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.58 30.89 8.66 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.754 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -101.42 131.52 47.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.97 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -99.75 163.84 12.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -46.95 140.07 5.08 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.35 -22.22 36.91 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 37.0 m -72.05 149.53 44.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.459 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 7.6 p -126.7 117.12 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.636 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.0 m -84.33 165.27 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.77 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.6 135.18 54.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.456 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 9.8 p -124.3 120.46 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.29 117.5 23.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.533 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -93.49 140.14 14.92 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.724 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.5 116.38 10.92 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.99 20.53 18.26 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.968 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.52 -177.28 5.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.98 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.492 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 25.9 mt-30 -69.29 122.23 18.46 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.43 130.04 39.75 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.1 8.09 86.85 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.668 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.48 137.13 34.96 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.975 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 1.005 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.56 150.62 25.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.121 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.9 m-85 -136.81 146.84 46.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.891 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.113 ' H ' ' N ' ' A' ' 98' ' ' SER . 4.4 m-20 -111.96 113.85 26.41 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.535 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.5 t -99.98 143.23 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.871 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.33 165.34 38.73 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.782 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.28 113.07 25.29 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 62.6 m -111.13 145.76 38.03 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.921 ' HB2' HG22 ' A' ' 86' ' ' VAL . . . -123.23 128.29 49.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.75 120.63 13.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.951 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.307 HG12 ' NE1' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -99.35 -44.14 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.53 ' OD1' ' C ' ' A' ' 40' ' ' VAL . 0.2 OUTLIER -136.83 175.5 9.56 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.948 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.1 t -60.8 112.67 2.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.03 8.14 72.96 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.613 ' O ' HG21 ' A' ' 40' ' ' VAL . 3.2 t -124.17 110.89 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.506 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -126.01 138.69 53.75 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.971 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.157 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -93.09 156.04 17.12 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 37.1 m -117.12 150.63 38.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.683 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -114.11 107.11 52.39 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.31 -0.84 9.25 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.327 3.351 . . . . 0.0 109.627 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.456 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -12.11 41.38 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.521 ' OD1' HG21 ' A' ' 68' ' ' THR . 92.9 m-20 -131.46 26.14 4.78 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -97.23 120.03 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 32.2 t -113.84 -177.38 3.12 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.0 p -147.08 156.61 43.14 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.94 157.59 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 55' ' ' VAL . 48.3 m -125.35 134.08 52.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.57 140.73 48.26 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -83.82 -170.88 3.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.75 -26.14 68.55 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.2 -4.91 44.37 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.67 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.93 31.61 69.83 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.964 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.3 p -124.11 133.77 53.52 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.38 10.02 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -123.0 144.28 49.37 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.553 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -141.0 178.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.553 ' N ' HG21 ' A' ' 65' ' ' THR . 0.3 OUTLIER -108.32 116.56 32.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.301 ' CG ' HG22 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -108.46 123.6 49.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.95 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.521 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -91.4 137.48 32.33 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.516 HG22 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -112.31 126.54 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.497 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -114.36 173.38 6.48 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.962 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.499 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 10.6 ptt85 -100.99 -7.97 22.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.539 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.4 p -169.73 147.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.782 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.6 p90 -177.65 160.58 1.58 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.13 115.58 2.52 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.157 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -78.32 94.03 1.24 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.744 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.2 m-85 -83.85 99.58 10.42 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.805 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.4 tp -53.73 134.66 41.96 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.494 ' N ' HD11 ' A' ' 77' ' ' LEU . 3.6 p90 -46.26 -38.84 9.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.805 ' HB3' HD23 ' A' ' 77' ' ' LEU . 4.4 t70 -56.77 -17.26 8.47 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.29 27.99 8.88 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.412 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.2 m -112.59 139.73 47.93 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -82.12 93.28 7.0 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.307 ' NE1' HG12 ' A' ' 40' ' ' VAL . 6.8 t-105 -63.38 -57.57 9.9 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.77 169.91 17.86 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -60.92 104.68 0.38 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.977 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.921 HG22 ' HB2' ' A' ' 38' ' ' ALA . 6.2 p -81.61 149.27 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.497 ' N ' HG23 ' A' ' 86' ' ' VAL . 68.8 m-20 -105.93 98.33 8.03 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.514 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.6 m -51.76 -25.41 7.46 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 21.1 p -80.55 2.55 25.01 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.961 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.424 ' O ' HG22 ' A' ' 90' ' ' THR . 21.8 m -112.93 -27.2 8.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.59 -178.49 5.09 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.64 127.21 42.41 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.317 ' O ' HG13 ' A' ' 110' ' ' ILE . 82.4 m -103.17 153.0 20.79 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.097 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -147.34 146.18 29.59 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.301 HG22 ' CG ' ' A' ' 67' ' ' LEU . 3.3 t -100.6 163.15 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.329 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.13 158.61 24.36 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.535 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.66 127.56 37.22 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.996 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.113 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.0 m -117.03 158.27 24.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 1.005 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 1.0 OUTLIER -110.79 -157.36 0.61 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.986 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.91 -48.15 77.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.56 -25.93 61.54 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.78 47.3 2.31 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.62 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.34 154.7 29.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.121 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -165.09 171.98 40.61 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.601 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.36 171.88 16.09 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.294 3.329 . . . . 0.0 109.647 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.218 ' OE1' ' HA ' ' A' ' 4' ' ' THR . 6.5 pt-20 -36.49 153.44 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.72 153.97 52.96 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.991 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.972 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.5 t -128.07 109.92 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.992 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.706 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.7 151.33 19.72 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.923 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.317 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -120.63 164.87 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 t -154.82 120.39 5.09 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.516 ' HE2' HG22 ' A' ' 69' ' ' VAL . 46.4 m-85 -97.01 127.06 42.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.947 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.043 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.361 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.38 -174.19 1.35 Allowed 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.316 3.344 . . . . 0.0 109.545 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.795 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.5 m -93.95 108.51 20.31 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.746 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.65 143.59 51.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.63 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -98.29 111.98 24.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.795 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 24.2 t -109.51 143.98 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.932 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.0 175.19 1.86 Allowed Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.921 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.932 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.33 118.41 5.59 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.34 3.36 . . . . 0.0 109.598 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.718 ' HA ' HD11 ' A' ' 13' ' ' LEU . 25.0 p -116.77 46.04 1.72 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.3 p -124.8 106.04 9.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.9 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.701 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 92.72 28.08 13.16 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.718 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -103.99 129.75 51.61 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.967 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -103.8 170.99 7.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.762 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -45.91 142.32 2.67 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.984 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.13 -22.97 34.88 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.5 m -77.36 148.2 35.7 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.4 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 7.5 p -124.19 123.08 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 m -91.05 166.88 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.795 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.4 138.49 54.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.994 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.574 HG12 HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -132.73 117.81 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.746 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.86 116.22 21.21 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.56 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -82.0 144.41 23.83 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.795 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.79 106.26 4.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.505 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 104.19 22.09 8.98 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.066 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.64 -165.0 1.22 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -80.43 124.19 28.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.503 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 129.74 38.64 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.57 7.94 85.79 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.657 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.74 143.89 25.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.876 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -91.44 150.11 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.997 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.5 m-85 -138.29 146.41 42.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.27 ' CB ' ' HG ' ' A' ' 98' ' ' SER . 12.2 m-20 -112.48 113.86 26.25 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.519 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.27 152.58 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.792 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . 179.95 173.63 45.11 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.324 -1.111 . . . . 0.0 110.324 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.908 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 47.8 tt0 -106.23 119.68 39.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.0 m -109.14 162.58 14.13 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.305 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -148.73 136.26 20.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.892 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.03 123.69 19.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.89 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.022 HG23 ' HB3' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -102.2 -41.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.634 ' HB2' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -150.45 179.21 8.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.944 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -65.85 109.36 2.46 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.29 10.34 86.1 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.543 HG22 ' CE2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -130.87 131.7 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.405 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 1.8 pp -133.71 162.35 32.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.329 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -129.02 144.96 51.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.678 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.44 158.86 17.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.848 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -120.18 118.58 31.3 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.424 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.7 Cg_endo -72.37 1.64 5.92 Favored 'Trans proline' 0 N--CA 1.446 -1.278 0 C-N-CA 124.326 3.351 . . . . 0.0 109.606 179.884 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.29 -20.65 31.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.868 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.412 ' HB3' HG23 ' A' ' 68' ' ' THR . 91.7 m-20 -129.78 30.56 4.86 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.66 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -94.88 117.96 30.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.993 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.5 t -114.01 176.99 4.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.4 p -147.13 155.56 42.26 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' N ' ' A' ' 56' ' ' THR . 3.2 p -167.1 162.36 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.508 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.8 m -127.9 128.69 45.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.94 152.05 28.67 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.41 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.1 p30 -94.13 -170.75 2.37 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.52 69.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -76.02 -7.57 54.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.503 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.91 8.69 87.28 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.0 p -99.06 139.79 34.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.66 156.01 32.62 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -136.76 121.92 19.12 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.56 HG22 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -158.57 153.57 25.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.56 ' N ' HG22 ' A' ' 65' ' ' THR . 1.5 m -114.48 130.61 56.74 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.315 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -107.72 154.25 21.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.507 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -113.76 140.5 48.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.96 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.549 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.25 129.78 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.99 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.854 ' H ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.18 164.88 13.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -88.06 -25.01 23.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.572 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -162.11 147.58 13.0 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.932 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.908 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.2 p90 -176.57 156.01 1.44 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -55.86 121.18 8.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.329 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -82.46 96.86 1.88 Allowed Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.678 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.99 99.96 10.74 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.779 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.1 tp -57.46 129.3 41.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.995 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.622 ' N ' HD11 ' A' ' 77' ' ' LEU . 17.9 p90 -47.67 -34.51 8.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.779 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.7 t0 -57.68 -16.36 10.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.14 8.49 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.464 ' HB ' HD22 ' A' ' 77' ' ' LEU . 1.3 m -118.16 150.62 39.08 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.97 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.4 mtp180 -93.85 97.53 10.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.543 ' CE2' HG22 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.9 -55.6 21.44 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.947 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.81 176.47 22.19 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.9 113.42 4.37 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.986 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.305 HG12 ' CB ' ' A' ' 38' ' ' ALA . 3.6 t -89.15 152.96 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -117.65 93.13 4.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.161 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 57.6 m -52.92 -26.59 15.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 36.7 p -78.33 -0.23 28.1 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.589 ' O ' HG23 ' A' ' 90' ' ' THR . 1.1 m -117.63 -28.04 6.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.984 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.47 -173.56 2.94 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.13 124.21 47.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.812 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 65.9 m -105.25 152.52 22.78 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.103 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -144.21 145.5 32.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.315 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.2 t -107.82 156.04 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.303 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.46 174.34 46.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.519 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -128.08 142.61 51.16 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.27 ' HG ' ' CB ' ' A' ' 33' ' ' ASP . 97.3 p -118.77 152.63 35.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.876 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -114.06 -165.6 1.02 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.974 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -54.32 -49.34 69.92 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.13 -25.24 58.26 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 98.71 45.29 2.31 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.708 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.63 167.64 10.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.959 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.997 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.03 -171.3 39.71 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.361 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.34 152.51 55.37 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.322 3.348 . . . . 0.0 109.599 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.124 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -35.26 121.13 0.56 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.55 143.91 0.09 OUTLIER Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.971 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.103 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -114.3 105.49 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.05 130.48 34.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.096 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.8 mt -103.79 164.08 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.907 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.99 121.52 10.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.161 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 18.0 m-85 -90.56 113.15 25.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.51 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.637 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.391 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.0 Cg_endo -72.42 -174.7 1.51 Allowed 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 124.319 3.346 . . . . 0.0 109.623 179.927 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.771 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.8 108.97 21.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.695 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.22 140.1 52.81 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.939 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.599 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -98.7 114.11 26.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.742 HG21 HG22 ' A' ' 108' ' ' VAL . 38.2 t -111.25 149.17 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.938 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.19 175.7 1.43 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.909 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.938 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.9 Cg_endo -72.35 119.2 5.99 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.312 3.341 . . . . 0.0 109.635 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.928 ' CB ' HG22 ' A' ' 110' ' ' ILE . 51.7 p -113.17 47.9 1.08 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.541 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.2 p -125.21 106.85 10.19 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.87 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.672 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.63 26.15 23.51 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.947 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.707 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -100.95 131.58 46.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.415 ' OG ' ' OD1' ' A' ' 15' ' ' ASP . 17.7 t -118.04 177.06 4.93 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.645 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 5.2 p-10 -45.41 139.26 3.76 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.66 34.73 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.9 m -85.98 150.58 24.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -126.26 123.79 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.686 HG12 HG23 ' A' ' 69' ' ' VAL . 18.5 m -87.19 162.31 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.95 143.87 44.47 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.7 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -138.84 112.06 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.981 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.695 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.9 115.66 22.33 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.531 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -83.31 140.78 20.12 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.771 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -138.72 106.68 5.69 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.445 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 100.03 26.16 8.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.111 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.12 -169.27 2.5 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.521 HE21 ' HH ' ' A' ' 32' ' ' TYR . 33.4 mt-30 -80.14 123.47 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.685 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.39 130.12 40.53 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.68 8.74 84.6 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.678 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.8 134.4 38.8 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.795 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.84 151.76 23.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.506 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 40.9 m-85 -137.26 148.65 46.58 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.145 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -112.11 116.27 30.23 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.923 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.481 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.78 140.47 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.948 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.852 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -163.3 157.82 30.05 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.833 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.6 tt0 -106.53 116.38 31.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.441 ' SG ' HD12 ' A' ' 45' ' ' LEU . 1.6 m -102.96 165.21 11.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.906 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -151.91 142.94 23.15 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.95 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 0.5 OUTLIER -64.98 122.13 16.28 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.76 HG13 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -101.68 -55.23 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.939 ' OD2' ' CH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -131.86 168.62 17.53 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -50.07 110.88 0.44 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.87 8.31 63.8 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.517 HG12 ' CE2' ' A' ' 83' ' ' TRP . 62.1 t -119.62 125.14 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.442 HD11 ' N ' ' A' ' 46' ' ' ALA . 1.6 pp -125.85 162.05 26.03 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.379 ' HB3' ' C ' ' A' ' 75' ' ' GLY . . . -130.96 161.49 31.81 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.898 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.892 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -115.65 156.07 26.53 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.745 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 23.0 t30 -116.71 110.79 41.87 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -72.43 -0.89 9.4 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.356 3.371 . . . . 0.0 109.546 179.956 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.601 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.97 -11.58 43.93 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.601 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 3.5 m-20 -133.39 28.87 4.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.884 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.643 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -101.9 118.17 36.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 40.9 t -107.86 -176.39 3.05 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 96.9 p -146.25 152.65 39.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.892 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -166.59 155.57 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 74.0 m -126.41 126.94 44.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.924 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -56.43 146.68 23.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.3 p30 -88.16 -170.25 2.89 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.91 -25.85 67.82 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -84.58 5.23 28.63 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.685 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 65.27 8.78 38.99 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -98.35 134.42 41.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.39 166.23 14.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.5 p -150.03 124.5 9.64 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.574 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -159.36 151.87 21.39 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.901 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.574 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -111.16 132.79 54.01 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.952 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.126 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -109.8 119.17 38.52 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.895 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.574 ' N ' HD11 ' A' ' 67' ' ' LEU . 1.8 t -70.04 143.55 52.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.686 HG23 HG12 ' A' ' 19' ' ' VAL . 1.3 t -104.23 131.51 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.833 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -119.84 153.07 36.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.97 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 ptt85 -85.66 -22.77 27.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 t -166.79 152.96 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.745 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.5 p90 -175.4 167.24 3.33 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.921 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.38 125.02 22.46 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.915 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.379 ' C ' ' HB3' ' A' ' 46' ' ' ALA . . . -77.79 90.92 1.07 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.55 10.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.999 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.714 HD11 ' N ' ' A' ' 78' ' ' PHE . 1.6 tp -54.47 141.64 30.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.714 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.05 -42.13 18.05 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.63 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -57.52 -17.1 12.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.978 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.55 29.1 9.65 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.2 m -110.17 122.08 46.79 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.38 92.27 0.08 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.517 ' CE2' HG12 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.56 -58.34 7.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.93 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.03 170.28 21.15 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.63 139.36 53.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.906 HG22 ' CB ' ' A' ' 38' ' ' ALA . 2.7 p -126.34 140.55 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.52 ' N ' HG23 ' A' ' 86' ' ' VAL . 0.5 OUTLIER -93.48 94.97 8.97 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.964 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.98 -21.07 10.62 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.5 p -89.27 1.98 54.96 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.48 HG21 ' O ' ' A' ' 90' ' ' THR . 7.3 m -114.09 -27.38 7.7 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.95 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -123.26 -177.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.61 128.45 37.44 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.937 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.078 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 1.5 m -105.0 152.62 22.49 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.054 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.2 pt20 -152.89 147.32 25.85 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.126 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.6 t -114.17 158.16 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.957 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.262 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 163.71 33.06 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.481 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.07 124.16 36.36 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.988 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.145 ' N ' ' H ' ' A' ' 33' ' ' ASP . 11.5 m -113.52 156.68 23.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.795 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.19 -161.17 0.74 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.31 -48.62 69.74 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.68 -26.07 66.85 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.889 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.12 42.53 3.24 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.523 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.68 157.98 24.54 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.506 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.4 177.53 45.74 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.391 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.0 Cg_endo -72.41 154.86 55.88 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.317 3.345 . . . . 0.0 109.581 179.96 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.637 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -36.96 119.34 0.65 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.941 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.13 155.92 0.01 OUTLIER Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.855 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.1 t -119.23 107.59 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 118.19 25.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.054 HG13 ' HA ' ' A' ' 94' ' ' GLN . 8.5 mt -98.25 159.12 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.75 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -144.1 123.48 13.09 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.078 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 5.4 m-85 -92.02 127.26 37.42 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.892 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.7 p30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.96 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.345 ' HB3' ' CB ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.565 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.39 -178.25 3.21 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.297 3.331 . . . . 0.0 109.584 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.121 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -100.23 111.87 24.16 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.936 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.741 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.5 160.53 29.29 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.8 p -124.75 119.08 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.806 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -116.73 154.84 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.933 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.22 174.9 1.74 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.954 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.933 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.4 Cg_endo -72.4 118.58 5.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.305 3.337 . . . . 0.0 109.593 179.889 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 1.231 ' OG ' HG22 ' A' ' 110' ' ' ILE . 11.9 p -116.02 48.76 1.19 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.651 ' HA ' ' O ' ' A' ' 111' ' ' SER . 18.8 p -126.43 104.71 8.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.606 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 89.79 29.05 16.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.726 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -94.85 133.41 38.6 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.986 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.4 t -96.61 158.32 15.49 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.998 ' OD1' ' HG3' ' A' ' 70' ' ' ARG . 25.5 t70 -45.1 142.51 1.9 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.26 -23.13 34.21 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.7 m -71.59 150.94 44.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.404 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 7.5 p -125.27 122.78 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.89 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 32.7 m -91.07 167.3 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.806 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -116.56 152.92 33.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.63 115.52 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.741 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -127.77 114.36 17.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.621 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -84.48 144.7 21.6 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.121 ' O ' HG23 ' A' ' 4' ' ' THR . . . -140.48 114.58 9.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.69 19.04 25.98 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.701 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.28 175.67 7.03 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -180.0 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 1.11 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 34.4 mt-30 -59.6 121.93 12.81 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.13 130.81 40.5 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.68 7.83 85.99 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.536 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -93.67 141.21 28.74 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.972 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 1.191 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.88 151.24 23.5 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.867 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.0 m-85 -135.77 146.81 48.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.437 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -109.79 114.89 28.84 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.951 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.522 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.9 140.24 22.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.772 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.78 168.98 39.91 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.219 -1.152 . . . . 0.0 110.219 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.96 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 45.3 tt0 -114.31 128.74 56.5 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 28.3 m -130.19 143.1 50.59 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.937 ' HB2' HG23 ' A' ' 86' ' ' VAL . . . -121.78 130.62 53.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.894 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.491 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.48 129.05 38.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.947 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.779 ' CG1' HG12 ' A' ' 86' ' ' VAL . 0.0 OUTLIER -111.12 -41.84 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.92 163.26 35.68 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 95.1 m -54.74 120.08 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.25 6.81 62.05 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.918 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 1.5 t -125.91 115.45 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.978 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.776 HD21 ' HE2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -125.08 143.62 50.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.97 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.152 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.39 142.93 34.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.0 m -112.14 163.71 14.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.513 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.2 t30 -126.82 110.73 22.3 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.43 0.58 7.25 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.299 3.332 . . . . 0.0 109.571 179.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.465 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.12 -12.67 43.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.7 p30 -129.24 28.85 5.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.41 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 0.1 OUTLIER -86.39 105.62 16.85 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.2 t -104.31 173.26 6.38 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.0 p -145.52 155.56 43.16 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 56' ' ' THR . 7.0 p -167.26 157.35 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 179.963 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.461 ' N ' HG23 ' A' ' 55' ' ' VAL . 89.8 m -128.1 137.0 51.95 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.16 137.29 41.23 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -76.82 -174.71 3.16 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.69 -19.11 61.99 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -84.6 7.51 19.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.987 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.649 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 56.87 32.06 61.77 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 t -129.31 133.52 47.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.25 164.37 19.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.67 126.35 11.02 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.504 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -158.64 154.19 26.07 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.87 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.504 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -105.39 133.35 50.29 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.951 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.438 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -115.25 119.84 37.68 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.893 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.645 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -72.07 133.82 45.47 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.882 HG21 ' HZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -108.17 123.9 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.998 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.998 ' HG3' ' OD1' ' A' ' 15' ' ' ASP . 0.5 OUTLIER -113.25 140.7 47.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.956 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.6 ptt180 -76.49 -7.71 55.68 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 77.3 p -167.29 146.6 5.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.96 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 7.2 p90 -177.19 164.98 2.26 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.02 115.07 3.45 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.956 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.152 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.47 98.31 1.25 Allowed Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.887 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 101.49 11.41 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.981 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.725 HD12 ' N ' ' A' ' 78' ' ' PHE . 2.2 tp -57.32 137.3 56.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.776 ' HE2' HD21 ' A' ' 45' ' ' LEU . 13.4 m-85 -47.23 -40.14 15.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.713 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.3 t0 -56.45 -17.06 6.96 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.65 28.11 9.88 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.4 ' HB ' HD22 ' A' ' 77' ' ' LEU . 28.3 m -112.3 143.44 43.39 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -81.17 94.48 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.918 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.7 t-105 -63.08 -48.97 76.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.13 173.56 13.68 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.39 106.91 1.49 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.937 HG23 ' HB2' ' A' ' 38' ' ' ALA . 26.8 m -87.66 151.86 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -101.97 92.33 4.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -53.55 -24.66 14.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 8.3 t -84.26 1.73 43.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.5 m -115.14 -27.49 7.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.45 -171.53 2.24 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.6 131.22 42.04 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.613 ' HB2' ' HB ' ' A' ' 110' ' ' ILE . 1.9 m -102.81 167.77 9.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.177 ' HG3' ' O ' ' A' ' 108' ' ' VAL . 11.2 tt0 -169.78 126.29 0.86 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.438 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 67.3 t -112.91 159.23 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.989 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.998 ' C ' HG13 ' A' ' 34' ' ' VAL . . . -179.17 -179.79 48.77 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.942 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.522 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.64 144.37 51.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.281 ' OG ' ' HB3' ' A' ' 33' ' ' ASP . 94.0 p -129.62 147.08 51.38 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 1.191 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -105.27 -163.41 0.95 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.987 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.86 -48.21 69.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.937 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.23 -21.04 66.29 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.76 53.2 2.62 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.909 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 1.11 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.14 162.53 27.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.98 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.867 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -171.94 -179.52 42.94 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.565 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 156.85 54.3 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.357 3.371 . . . . 0.0 109.593 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.345 ' CB ' ' HB3' ' A' ' 2' ' ' ALA . 10.8 pt-20 -35.69 120.84 0.6 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.9 148.2 0.04 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.177 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 72.0 t -124.4 118.95 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -98.14 150.47 21.43 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.231 HG22 ' OG ' ' A' ' 10' ' ' SER . 16.9 mt -126.09 163.49 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.651 ' O ' ' HA ' ' A' ' 11' ' ' SER . 13.5 t -152.75 134.61 14.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.882 ' HZ ' HG21 ' A' ' 69' ' ' VAL . 9.6 m-85 -102.5 125.52 49.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 31.0 m-80 . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.991 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.63 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.354 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.7 Cg_endo -72.35 -174.12 1.33 Allowed 'Trans proline' 0 N--CA 1.448 -1.201 0 C-N-CA 124.323 3.349 . . . . 0.0 109.609 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.792 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -96.47 107.12 19.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.66 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.39 147.53 48.18 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.987 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.528 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -102.26 111.57 23.9 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.924 ' CG2' HG22 ' A' ' 108' ' ' VAL . 38.6 t -107.28 148.04 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.89 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -73.24 176.74 2.39 Favored Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.93 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.89 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.6 Cg_endo -72.43 116.28 4.65 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.332 3.354 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 1.009 ' HB2' HG21 ' A' ' 110' ' ' ILE . 91.6 p -111.51 47.38 1.03 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.518 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.1 p -127.1 107.06 9.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.63 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.72 26.12 23.39 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.921 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.696 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -97.96 131.64 44.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.995 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.1 m -111.21 173.98 6.08 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 1.5 t0 -47.87 144.0 3.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.489 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 99.41 -23.6 35.57 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.953 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.7 m -74.33 151.17 39.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 7.8 p -125.31 117.41 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.949 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.62 ' HA ' HG23 ' A' ' 8' ' ' THR . 55.1 t -83.99 163.46 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.82 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tppt? -124.01 133.4 53.68 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.649 ' CG1' HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -135.53 110.39 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.973 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.66 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.6 119.24 33.2 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.569 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -82.76 140.68 20.44 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.751 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.4 108.8 6.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.93 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.489 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 101.99 24.37 8.6 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.053 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.66 -163.59 1.03 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.819 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -85.5 126.56 33.94 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.536 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.25 131.57 41.32 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.936 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.89 84.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.627 HG21 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.52 138.2 31.71 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.666 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -88.49 145.17 25.9 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.934 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -133.61 146.03 50.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.237 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -110.72 117.37 33.28 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.906 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.356 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.32 145.56 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.99 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.95 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.25 171.57 41.99 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.817 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -118.14 112.01 19.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.969 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.6 m -105.05 172.4 6.81 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.029 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -155.09 138.17 15.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.905 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.509 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.93 127.18 30.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.912 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.905 HG23 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -108.27 -51.85 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.027 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -143.01 165.14 28.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.946 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.1 t -51.46 112.15 0.7 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.08 9.15 75.87 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.966 HG12 ' CD1' ' A' ' 83' ' ' TRP . 4.5 t -129.06 114.37 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.647 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -118.22 162.84 17.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.352 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -123.64 138.63 54.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.983 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 58.3 m -109.49 148.46 31.16 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.71 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.8 t-20 -107.04 107.17 60.08 Favored Pre-proline 0 N--CA 1.45 -0.469 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.456 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.7 Cg_endo -72.47 0.35 7.61 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.344 . . . . 0.0 109.564 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.445 ' N ' ' OD1' ' A' ' 48' ' ' ASN . . . -89.02 -9.54 50.92 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.9 p30 -131.72 27.16 4.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 104.98 13.9 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.991 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 29.8 t -98.32 172.29 7.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.34 154.68 41.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.504 HG22 ' N ' ' A' ' 56' ' ' THR . 6.0 p -166.7 158.31 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.954 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.504 ' N ' HG22 ' A' ' 55' ' ' VAL . 13.7 m -127.05 130.16 49.42 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.967 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.38 43.74 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.2 p30 -92.24 -171.59 2.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.27 -23.92 66.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.421 ' N ' ' OD1' ' A' ' 60' ' ' ASN . 1.8 m-20 -85.19 9.74 14.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 58.58 14.28 20.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -104.51 133.91 48.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.934 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.45 162.21 19.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -146.09 127.45 14.92 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.498 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -163.9 150.03 11.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.877 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.498 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -109.25 142.5 40.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.945 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.105 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -113.85 123.27 49.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.702 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.4 t -70.08 124.54 24.35 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.546 HG21 HG21 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -85.09 125.2 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.802 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.0 OUTLIER -117.08 144.76 44.3 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.412 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -87.16 -13.43 44.08 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 51.9 p -166.99 149.7 6.35 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.952 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.817 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.1 p90 -177.03 152.42 0.9 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.5 121.68 8.21 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.352 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -78.7 93.13 1.25 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.887 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 99.85 10.84 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.981 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.766 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.1 tp -57.1 130.8 47.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.532 ' N ' HD13 ' A' ' 77' ' ' LEU . 24.1 p90 -47.35 -35.75 8.55 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.766 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.68 -16.62 11.35 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.47 26.35 10.09 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 29.9 m -112.9 145.77 40.13 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -86.56 95.6 9.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.027 ' HZ2' ' CB ' ' A' ' 41' ' ' ASP . 1.0 OUTLIER -62.98 -53.84 47.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.939 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.7 173.21 14.32 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.13 125.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.029 HG11 ' HB3' ' A' ' 38' ' ' ALA . 54.5 t -100.05 148.63 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.47 93.25 4.14 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.412 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.5 m -52.86 -26.01 13.38 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.0 p -81.75 1.4 34.66 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.433 ' O ' HG23 ' A' ' 90' ' ' THR . 2.0 m -116.89 -27.18 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.98 -176.92 4.16 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.915 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.79 124.73 45.37 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.001 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 73.2 m -104.62 154.88 19.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.029 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -143.39 149.75 38.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.92 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.105 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 5.4 t -117.85 154.25 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.238 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.95 173.54 46.08 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.356 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.45 146.32 50.14 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.988 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.237 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 4.7 m -127.09 151.49 48.56 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.666 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -109.53 -165.62 1.03 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.984 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.48 -49.33 77.98 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.964 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.476 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . . . -68.64 -25.33 64.78 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.41 41.82 3.34 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.476 ' OD1' ' HB2' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -115.94 164.04 15.0 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.934 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.57 -177.49 42.01 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.354 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.44 156.25 54.54 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.251 3.301 . . . . 0.0 109.57 179.903 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.63 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 3.3 pt-20 -37.36 119.87 0.74 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.49 151.93 0.02 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.924 HG22 ' CG2' ' A' ' 7' ' ' VAL . 3.6 t -124.01 104.44 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.42 128.83 34.83 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.029 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.4 mt -102.03 160.77 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.931 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.744 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -144.52 120.89 10.95 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.946 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.46 123.43 40.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.458 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 . . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.534 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.34 -178.64 3.42 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 124.356 3.371 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.191 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.2 m -101.91 109.52 21.28 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.961 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.91 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.71 141.9 51.58 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -104.75 117.76 34.87 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.992 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.777 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -115.92 151.73 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.951 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.642 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.4 OUTLIER -74.48 163.54 67.54 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.937 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.612 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.0 Cg_endo -72.41 120.09 6.53 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.267 3.312 . . . . 0.0 109.595 179.918 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.983 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -120.07 16.7 12.46 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.975 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 1.101 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.2 p -98.91 115.15 28.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.94 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.644 ' N ' ' H ' ' A' ' 113' ' ' ASN . . . 104.24 -0.13 44.0 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.983 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 1.3 pp -114.09 142.48 46.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.996 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.8 p -107.54 -167.76 1.3 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.669 ' CG ' HH11 ' A' ' 70' ' ' ARG . 7.2 t70 -42.15 153.67 0.06 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.98 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.75 -23.1 34.23 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.978 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.557 HG22 HD22 ' A' ' 13' ' ' LEU . 26.1 m -80.26 141.42 35.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.485 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 11.2 p -119.46 109.84 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.696 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 1.8 p -83.67 161.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.987 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.777 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.73 150.79 39.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.449 ' CG1' HG12 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -143.62 109.35 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.978 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.91 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.14 116.95 25.11 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.678 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -83.64 144.74 22.38 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.984 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.717 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.04 109.55 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.45 17.82 23.05 Favored Glycine 0 C--N 1.336 0.56 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.99 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.717 HD22 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.01 175.15 7.29 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.991 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.489 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 37.6 mt-30 -58.35 121.37 10.65 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.468 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.65 129.16 37.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.99 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.35 8.22 87.61 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.933 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.651 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.5 143.49 26.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.961 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.665 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.35 151.45 23.09 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.96 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.795 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.3 m-85 -138.9 139.35 38.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.911 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.141 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 6.3 m-20 -105.47 113.73 27.48 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.312 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.98 147.57 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.938 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.863 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.72 166.13 38.26 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 1.01 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 2.2 tt0 -108.26 123.56 48.96 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.963 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.2 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.7 m -117.57 143.86 45.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.959 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.549 ' HB3' HG23 ' A' ' 86' ' ' VAL . . . -124.07 137.61 54.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.52 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -65.61 127.94 33.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.607 HG12 ' CZ3' ' A' ' 83' ' ' TRP . 1.2 t -107.43 -55.14 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.473 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.62 167.62 17.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.962 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -50.81 112.11 0.65 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.72 8.09 66.96 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.999 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.537 HG11 ' NE1' ' A' ' 83' ' ' TRP . 11.6 t -122.74 112.89 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.988 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.639 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -121.97 131.98 54.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.984 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.047 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -89.31 153.77 20.62 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.942 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.2 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.8 m -110.81 156.87 20.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.825 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.6 t30 -114.9 106.24 52.03 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.37 -0.09 8.2 Favored 'Trans proline' 0 N--CA 1.448 -1.178 0 C-N-CA 124.319 3.346 . . . . 0.0 109.603 179.91 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.487 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -89.15 -11.61 43.36 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.7 p30 -130.25 27.26 5.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.23 106.76 15.28 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 t -101.09 171.79 7.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.896 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 p -146.88 154.26 41.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.437 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.77 161.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.928 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.437 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 19.9 m -128.03 135.8 50.37 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.63 135.19 39.16 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.917 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.0 p30 -76.02 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.914 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.5 -19.75 62.42 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -83.28 6.8 18.42 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.689 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 57.94 32.11 65.89 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.9 t -130.92 134.53 46.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.966 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.35 165.5 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -144.94 130.25 18.67 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.988 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.61 HG22 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.61 169.79 20.73 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.88 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.61 ' N ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -128.87 117.52 21.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.092 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.36 157.95 15.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.959 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.534 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -118.67 136.93 53.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.947 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.603 HG13 ' OG ' ' A' ' 10' ' ' SER . 0.5 OUTLIER -103.23 126.69 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.669 HH11 ' CG ' ' A' ' 15' ' ' ASP . 0.1 OUTLIER -113.73 142.68 45.74 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.959 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -62.81 -35.13 78.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 83.7 p -154.55 157.05 37.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.876 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 1.01 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.2 p90 -177.17 155.83 1.19 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' CG ' ' A' ' 74' ' ' GLU . 0.5 OUTLIER -53.49 109.93 0.5 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.935 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.047 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -70.1 103.0 1.07 Allowed Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.96 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.992 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.19 100.21 10.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.987 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.723 HD12 ' N ' ' A' ' 78' ' ' PHE . 3.3 tp -57.87 137.98 56.15 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.723 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.34 -40.36 17.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.566 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -57.32 -17.13 10.78 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.978 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.53 28.56 9.52 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.993 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.4 m -112.45 148.43 34.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.985 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -83.94 94.21 8.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.607 ' CZ3' HG12 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -64.24 -40.18 95.48 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.92 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.33 169.7 12.47 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.31 106.12 0.49 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.942 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.624 ' CG1' HG22 ' A' ' 40' ' ' VAL . 27.6 m -85.35 154.34 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.64 91.72 4.32 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.775 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.28 -20.65 7.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.977 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.518 ' HA ' ' CB ' ' A' ' 112' ' ' PHE . 76.0 p -90.59 2.82 55.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.971 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.552 ' O ' HG22 ' A' ' 90' ' ' THR . 15.6 m -112.61 -27.26 8.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.95 -178.77 4.28 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.28 129.19 35.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.434 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 3.8 m -105.04 155.24 19.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.313 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.6 tt0 -154.02 131.75 11.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 -179.939 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.092 ' CG1' HD12 ' A' ' 67' ' ' LEU . 6.5 t -94.09 163.67 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.989 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.244 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.69 165.0 33.84 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.312 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.41 132.2 45.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.986 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.141 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 32.9 m -111.66 153.01 27.01 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.904 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.665 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.03 -162.47 0.8 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.995 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.9 -48.45 65.98 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.24 -24.15 65.78 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.78 54.09 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -133.97 171.47 14.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.795 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.51 173.77 45.45 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.534 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.42 168.23 24.86 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 124.258 3.306 . . . . 0.0 109.571 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.458 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 9.1 pt-20 -39.54 125.63 1.77 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.945 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.3 161.22 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.914 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.313 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 50.0 t -119.13 102.4 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.91 132.35 36.04 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.232 ' CD1' ' HB2' ' A' ' 93' ' ' CYS . 16.1 pt -136.85 -175.3 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 1.101 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -177.27 153.17 0.92 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.968 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.434 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.1 m-85 -107.17 119.28 38.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.945 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.644 ' H ' ' N ' ' A' ' 12' ' ' GLY . 7.3 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.074 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.594 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 85.0 Cg_endo -72.37 -178.73 3.49 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.36 3.373 . . . . 0.0 109.608 179.925 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.973 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.2 m -100.9 108.74 20.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.644 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -120.16 145.2 47.18 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.957 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -108.66 115.29 29.82 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.976 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.715 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.33 153.57 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.993 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.851 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.18 175.09 1.95 Allowed Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.958 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.851 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.5 Cg_endo -72.43 117.45 5.14 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.292 3.328 . . . . 0.0 109.607 179.869 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 1.033 ' HB3' HG22 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -115.16 47.35 1.3 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.943 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.491 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -123.71 105.81 10.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.676 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.45 28.51 16.66 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.742 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -99.43 134.79 41.8 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.83 163.77 12.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 15' ' ' ASP . 3.5 t0 -45.94 142.91 2.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 103.44 -22.75 35.1 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.6 m -73.3 144.81 46.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 11.0 p -111.74 115.08 48.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.978 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.69 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.6 m -84.21 158.51 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.715 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.53 144.39 42.93 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.979 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.42 HG21 ' C ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -145.36 110.74 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.985 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.644 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.78 122.41 37.37 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.956 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.683 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -84.51 146.79 22.73 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.947 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.1 109.37 4.69 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.72 16.83 27.67 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.952 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.683 ' CD2' ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.43 176.06 6.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.945 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.504 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 31.7 mt-30 -56.5 120.82 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -180.0 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.446 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.73 130.66 41.02 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.28 7.34 84.78 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.558 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.26 140.39 29.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.964 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 1.227 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.8 147.86 27.34 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.112 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 27.4 m-85 -135.75 131.92 36.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.932 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.351 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.45 112.58 24.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.962 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.501 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.77 144.31 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.987 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.983 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.68 161.09 33.92 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.903 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 34.2 tt0 -104.03 119.18 38.39 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.208 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 85.7 m -117.08 143.54 45.67 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.731 ' HB1' HG12 ' A' ' 86' ' ' VAL . . . -123.29 139.25 54.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.544 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.98 125.29 24.43 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.407 ' CG1' ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -105.03 -44.09 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.991 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.543 ' OD1' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -142.36 169.41 17.63 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.4 m -50.99 112.41 0.71 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.997 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.63 7.47 61.33 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.411 HG11 HG13 ' A' ' 40' ' ' VAL . 2.3 t -120.8 118.7 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -128.99 134.91 48.34 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.986 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.148 ' HB2' ' C ' ' A' ' 75' ' ' GLY . . . -91.55 157.61 16.91 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.208 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 69.1 m -117.61 156.04 28.82 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.519 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.0 t30 -122.07 109.28 33.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.442 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.44 0.26 7.73 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.278 3.319 . . . . 0.0 109.576 179.936 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.475 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -85.44 -14.96 44.55 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.878 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 5.9 p30 -129.09 19.53 5.93 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.951 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.689 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -82.07 117.94 22.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.983 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 m -107.11 178.1 4.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.973 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 p -145.23 152.69 40.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.851 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.468 HG21 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.02 156.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.468 ' N ' HG21 ' A' ' 55' ' ' VAL . 22.0 m -127.92 133.05 49.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.959 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.75 134.49 46.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.936 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 37.5 p30 -75.05 -174.46 2.27 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.909 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.54 -25.23 67.93 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.975 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.32 -4.6 42.99 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 72.07 31.08 64.52 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.997 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.1 p -129.2 139.62 51.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.957 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.37 163.43 26.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.69 127.06 15.85 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.543 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -150.62 159.43 44.51 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.855 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.543 ' N ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -119.5 115.08 23.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.932 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.317 ' CD1' HG12 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.78 157.55 16.01 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.925 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.667 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -111.93 136.22 51.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.975 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.67 ' CG1' ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.95 129.16 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.99 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.769 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.38 164.3 15.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.994 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.2 -15.37 29.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.983 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -164.49 143.28 7.12 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.903 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -170.7 159.52 6.6 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -54.59 120.3 6.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.901 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.148 ' C ' ' HB2' ' A' ' 46' ' ' ALA . . . -79.94 92.28 1.35 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 179.986 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.19 100.14 10.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.966 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.747 HD21 ' HB3' ' A' ' 79' ' ' ASP . 1.6 tp -55.14 144.25 24.66 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.991 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.738 ' N ' HD11 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.35 -43.43 23.05 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.747 ' HB3' HD21 ' A' ' 77' ' ' LEU . 8.7 t0 -58.05 -17.02 14.97 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.958 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.2 28.56 10.6 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.999 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.2 m -107.66 119.22 38.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.83 91.43 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.407 ' CE2' ' CG1' ' A' ' 40' ' ' VAL . 29.0 t90 -62.7 -58.55 7.08 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.901 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.48 166.91 17.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.992 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.06 108.82 0.73 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.955 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.84 HG21 HG23 ' A' ' 40' ' ' VAL . 15.7 t -81.95 147.35 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.998 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -105.28 94.44 5.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.988 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -52.56 -24.99 9.23 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.6 p -79.3 -3.64 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 -26.87 7.36 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.4 -178.11 3.9 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.13 138.6 33.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.959 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.656 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -102.47 161.23 13.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.974 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.206 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.4 tt0 -168.39 127.19 1.16 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.317 HG12 ' CD1' ' A' ' 67' ' ' LEU . 2.5 t -97.04 164.56 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.967 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -175.75 167.99 40.09 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.501 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.82 128.5 38.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.981 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.351 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 19.8 m -116.84 142.19 47.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.913 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 1.227 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -98.33 -157.8 0.62 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.87 -48.22 69.45 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.903 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.77 -25.89 64.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.955 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.8 48.46 2.11 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.602 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -120.62 162.94 18.8 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.999 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.112 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.58 176.71 44.04 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.984 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.594 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.46 165.12 33.6 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.319 3.346 . . . . 0.0 109.601 179.935 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.074 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 5.2 pt-20 -38.24 135.91 0.69 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.961 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.61 147.56 3.93 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.967 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.206 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 13.0 t -127.42 104.15 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.985 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.641 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -88.71 157.16 18.62 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.033 HG22 ' HB3' ' A' ' 10' ' ' SER . 22.4 mt -127.97 168.31 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.491 ' O ' ' HA ' ' A' ' 11' ' ' SER . 21.1 t -153.97 137.26 15.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.954 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.656 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -102.09 124.94 48.56 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.51 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 30.3 m-80 . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.97 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.656 ' HB3' ' CG ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.424 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -175.23 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.306 3.337 . . . . 0.0 109.61 179.924 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.912 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.72 108.21 20.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.722 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 146.52 49.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.43 110.33 22.31 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.973 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.682 ' CG2' HG23 ' A' ' 108' ' ' VAL . 14.3 t -105.62 146.1 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.927 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.17 175.24 2.2 Favored Pre-proline 0 N--CA 1.448 -0.528 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.945 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.927 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.42 116.54 4.75 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 124.323 3.349 . . . . 0.0 109.593 179.918 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.908 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 56.6 p -113.33 46.66 1.23 Allowed 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.957 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 111' ' ' SER . 61.9 p -126.34 105.2 8.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.907 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.624 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 92.79 26.84 15.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.723 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -98.13 132.34 43.74 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.965 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -104.15 169.41 8.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 15' ' ' ASP . 15.9 p30 -46.02 141.43 3.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.993 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.19 -22.95 34.84 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.991 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.407 HG22 HD13 ' A' ' 13' ' ' LEU . 24.6 m -79.63 152.32 30.08 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.991 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 t -124.92 125.66 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.998 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.678 HG21 ' O ' ' A' ' 67' ' ' LEU . 4.6 m -89.37 118.22 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -69.24 148.37 49.91 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.605 HG11 HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.81 105.27 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.997 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.722 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.25 117.1 28.2 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.963 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.657 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.29 141.2 19.69 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.912 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.27 108.64 6.88 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.928 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.48 ' C ' HD22 ' A' ' 26' ' ' LEU . . . 101.67 23.88 9.1 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.976 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.295 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.34 -171.79 3.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.983 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.494 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 29.1 mt-30 -76.31 124.29 27.28 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.989 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.54 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.66 130.33 40.31 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.48 8.22 83.7 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.958 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.692 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -95.04 136.48 35.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.96 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.771 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.88 151.31 23.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.999 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.916 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 48.4 m-85 -138.12 144.17 40.71 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.052 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.0 m-20 -104.64 116.63 32.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.956 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.445 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.05 142.29 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.874 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.5 170.78 42.87 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.968 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.6 tt0 -114.42 116.3 28.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.934 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.169 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 64.2 m -114.6 143.2 45.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.664 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -122.9 131.45 53.74 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.914 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.84 123.72 20.53 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.935 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.059 ' HB ' ' CE3' ' A' ' 83' ' ' TRP . 14.2 m -103.58 -43.98 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.578 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -136.8 176.18 8.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.991 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.16 112.08 1.77 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.982 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.98 8.29 64.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.182 HG12 ' CE2' ' A' ' 83' ' ' TRP . 61.6 t -122.79 108.0 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 180.0 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.52 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -121.47 139.52 53.37 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.978 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.349 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -93.83 157.93 15.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.169 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.3 m -118.74 152.26 36.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.843 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.3 t-20 -110.93 107.47 57.79 Favored Pre-proline 0 N--CA 1.449 -0.492 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.37 -0.02 8.09 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.322 3.348 . . . . 0.0 109.591 179.891 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.436 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.78 -11.11 43.13 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.783 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.477 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.6 p30 -131.1 27.05 4.87 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.901 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.97 106.18 15.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.977 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.6 t -104.19 173.23 6.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.943 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 p -145.51 156.75 43.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.7 p -166.29 157.83 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.915 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.7 m -127.76 126.98 42.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.49 153.0 24.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.5 p30 -93.78 -171.63 2.64 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.885 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.22 67.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -83.17 5.24 23.4 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.54 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 64.59 9.24 37.03 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.975 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.5 t -101.22 134.41 44.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.985 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.56 163.48 17.91 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.4 p -147.78 130.72 16.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.972 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.555 HG22 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.49 164.19 17.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.968 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.555 ' N ' HG22 ' A' ' 65' ' ' THR . 0.8 OUTLIER -120.46 132.09 55.06 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.921 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.161 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.61 122.44 47.46 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.912 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.404 ' H ' HG23 ' A' ' 68' ' ' THR . 3.7 t -77.96 130.95 37.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.899 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.553 HG23 ' HZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -106.45 129.87 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.967 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.751 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.43 155.26 23.45 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.932 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -83.02 -13.67 55.45 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.978 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.544 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 13.9 m -167.24 147.4 5.41 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.968 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.6 p90 -177.31 157.36 1.32 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.949 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -56.56 117.61 4.03 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.942 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.349 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -78.14 97.26 1.39 Allowed Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.996 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.806 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.36 10.64 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.986 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.742 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.2 tp -54.5 141.74 30.04 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.74 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.22 -42.85 20.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.742 ' HB3' HD23 ' A' ' 77' ' ' LEU . 5.9 t0 -56.78 -16.8 7.21 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.69 27.98 10.82 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.931 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.405 ' HB ' HD22 ' A' ' 77' ' ' LEU . 2.6 m -108.19 130.82 55.12 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 6.9 ptt180 -72.24 92.95 1.42 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.578 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 0.6 OUTLIER -61.67 -54.96 35.73 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.893 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.5 174.19 21.37 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.07 113.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.664 HG23 ' CB ' ' A' ' 38' ' ' ALA . 1.1 m -91.36 152.4 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 1.5 m-20 -115.7 102.97 10.22 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.975 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.537 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 23.0 m -52.82 -27.46 18.27 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.3 p -79.56 -3.51 47.28 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.994 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.69 -27.78 6.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.27 -178.4 4.2 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.56 122.97 44.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.879 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.573 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 89.7 m -104.03 151.73 22.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.984 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.4 OUTLIER -152.24 146.81 25.71 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.951 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.161 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -110.21 159.05 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.983 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.243 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.07 169.6 41.49 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.445 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.8 129.42 46.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.958 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.052 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 5.8 m -110.26 152.35 26.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.961 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.771 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -114.37 -169.35 1.51 Allowed 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.943 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.65 -48.91 77.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.24 -24.29 66.57 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.928 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.02 53.5 1.89 Allowed Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.955 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.727 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -132.79 172.69 12.24 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.982 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.916 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.24 179.27 48.59 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.966 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.424 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 160.01 47.92 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.313 3.342 . . . . 0.0 109.586 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.656 ' CG ' ' HB3' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -36.82 122.2 0.8 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.38 155.38 0.03 OUTLIER Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.974 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.894 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.6 t -127.51 111.59 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.981 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.98 129.8 38.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.984 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.5 mt -103.74 156.16 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.609 ' O ' ' HA ' ' A' ' 11' ' ' SER . 11.7 t -145.25 129.7 17.86 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.91 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.553 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -96.23 126.59 41.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.947 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.49 ' CB ' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.517 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 . . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.574 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.41 -177.19 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.349 3.366 . . . . 0.0 109.584 179.949 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.833 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -95.42 108.63 20.85 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.926 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.826 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.91 145.26 51.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.577 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.49 111.98 24.86 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.836 HG22 HG23 ' A' ' 108' ' ' VAL . 26.2 t -106.96 149.21 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.993 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.53 178.32 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.938 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.993 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.37 117.75 5.28 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 C-N-CA 124.279 3.32 . . . . 0.0 109.569 179.942 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.687 ' HA ' HD12 ' A' ' 13' ' ' LEU . 17.2 p -114.13 45.16 1.54 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 111' ' ' SER . 92.5 p -127.78 106.38 9.09 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.873 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.589 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.59 24.5 20.86 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.76 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -94.1 130.11 40.39 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 45.8 t -98.49 168.27 10.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.93 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.63 141.15 17.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.4 -23.72 34.23 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 21.1 m -72.27 152.69 42.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.987 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.9 p -126.77 131.19 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.724 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 3.0 m -97.95 169.7 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.73 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.83 150.34 38.53 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.975 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.714 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -144.32 109.4 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.978 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.826 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.53 114.86 23.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.48 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -82.55 146.8 24.91 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.833 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.01 110.92 4.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.864 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.39 13.46 30.58 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.99 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.691 HD13 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.59 165.98 13.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.979 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.52 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.5 mt-30 -46.41 119.71 2.51 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.984 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.735 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.26 131.08 41.54 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.47 8.46 80.55 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.592 HG23 ' N ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -93.78 148.32 22.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.951 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.592 ' N ' HG23 ' A' ' 30' ' ' THR . . . -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.01 ' CB ' HD22 ' A' ' 97' ' ' LEU . 35.1 m-85 -138.26 151.75 47.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.907 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.419 ' CA ' ' H ' ' A' ' 98' ' ' SER . 35.0 m-20 -120.23 117.4 27.77 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -98.58 141.39 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.793 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -161.99 155.44 26.71 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.894 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 40.7 tt0 -105.65 115.7 30.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' SG ' HD12 ' A' ' 45' ' ' LEU . 1.3 m -102.96 166.66 10.32 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.097 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -153.33 134.0 13.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.956 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.592 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.2 122.55 17.36 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.91 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.514 ' HB ' ' CD1' ' A' ' 83' ' ' TRP . 2.5 m -102.9 -42.82 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.992 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.448 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -138.47 166.16 25.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m -50.79 111.77 0.6 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.35 8.92 63.35 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.97 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.413 HG13 ' CE2' ' A' ' 83' ' ' TRP . 75.0 t -120.3 119.35 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.46 HD12 ' SG ' ' A' ' 37' ' ' CYS . 1.9 pp -124.5 162.75 23.32 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.301 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -132.54 155.42 48.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.92 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.1 m -113.46 155.23 25.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.485 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 16.3 t30 -116.11 112.41 42.11 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.38 0.13 7.88 Favored 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 124.31 3.34 . . . . 0.0 109.65 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.478 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -90.03 -16.52 29.61 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.915 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.473 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.0 p30 -127.16 28.33 5.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.93 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -102.1 118.67 37.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.7 t -107.41 -177.27 3.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.932 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -147.65 154.58 40.81 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.412 ' CG2' ' N ' ' A' ' 56' ' ' THR . 6.7 p -167.31 161.9 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.977 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.412 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 20.7 m -126.34 130.19 50.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.58 145.55 55.48 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.977 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 51.6 p30 -83.7 -172.29 4.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.934 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.09 -27.57 69.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.66 -10.06 59.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.735 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.62 31.79 48.77 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.969 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.3 p -127.36 136.32 51.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.991 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.95 170.2 10.86 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.53 123.97 9.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.598 HG22 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -151.94 160.26 43.55 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.907 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.598 ' N ' HG22 ' A' ' 65' ' ' THR . 0.2 OUTLIER -114.43 129.68 56.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.913 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.069 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -107.26 118.01 35.58 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.901 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.656 ' N ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -67.66 120.46 14.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.987 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.491 HG22 HG11 ' A' ' 19' ' ' VAL . 0.6 OUTLIER -76.47 123.94 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.975 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.628 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 26.9 mmt180 -115.57 157.03 24.71 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.475 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 4.1 ptt180 -107.08 -10.73 15.82 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.99 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -177.05 146.93 0.53 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.927 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.894 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -176.69 171.52 2.25 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.878 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 118.36 7.28 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.301 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 94.07 1.35 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -84.44 100.63 11.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.74 HD12 ' N ' ' A' ' 78' ' ' PHE . 2.2 tp -54.45 145.41 18.42 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.74 ' N ' HD12 ' A' ' 77' ' ' LEU . 10.8 m-85 -47.2 -43.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.565 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -58.73 -16.52 17.03 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.965 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.12 28.25 12.15 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.43 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.2 m -106.38 122.67 46.74 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 ttm180 -61.71 90.96 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.956 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.514 ' CD1' ' HB ' ' A' ' 40' ' ' VAL . 42.8 t-105 -62.35 -58.4 7.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.53 163.2 12.09 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.994 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.56 105.73 0.47 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.951 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.097 HG22 ' CB ' ' A' ' 38' ' ' ALA . 3.4 p -80.21 148.89 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.488 ' N ' HG23 ' A' ' 86' ' ' VAL . 11.4 m-20 -110.47 98.74 7.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 17.8 m -51.91 -27.53 13.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.2 p -79.57 1.21 26.85 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.982 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.564 HG21 ' O ' ' A' ' 90' ' ' THR . 2.4 m -116.99 -26.68 6.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.81 -175.31 3.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.58 125.65 48.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.252 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.2 m -103.83 152.69 21.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.992 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.129 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -150.89 144.17 24.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.967 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.069 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 7.1 t -103.96 163.56 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.33 168.41 40.52 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.991 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.193 ' HG ' ' CG2' ' A' ' 34' ' ' VAL . 5.6 mp -99.5 162.16 13.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.419 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 13.0 m -154.16 118.48 4.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.451 ' OD1' ' N ' ' A' ' 102' ' ' GLY . 42.7 p-10 -113.54 -167.9 1.27 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.998 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.16 -19.89 2.23 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.946 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.45 -23.51 13.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.888 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.451 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 85.34 22.0 52.79 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.773 ' ND2' ' HD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -60.11 -151.83 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.974 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 143.47 153.38 5.86 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.953 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.574 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.41 165.4 32.79 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.247 3.298 . . . . 0.0 109.607 179.964 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.49 ' CA ' ' CB ' ' A' ' 2' ' ' ALA . 8.2 pt-20 -33.55 124.45 0.42 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.762 ' N ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.34 133.99 0.98 Allowed Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.129 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.6 104.03 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.952 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.456 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.58 144.97 26.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.252 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.11 159.47 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.917 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -144.2 115.05 7.79 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.587 ' CZ ' ' HB2' ' A' ' 93' ' ' CYS . 30.5 m-85 -100.06 126.21 46.25 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.934 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.947 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.577 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.484 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.39 -175.37 1.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.328 3.352 . . . . 0.0 109.605 179.907 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.21 HG23 ' O ' ' A' ' 24' ' ' ALA . 6.4 t -99.67 116.15 31.11 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.771 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.9 154.64 49.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.48 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -115.76 117.09 29.27 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -114.03 143.77 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.731 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.63 166.68 24.3 Favored Pre-proline 0 N--CA 1.448 -0.539 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.938 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.731 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.37 118.13 5.46 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.331 3.354 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.747 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.45 9.43 7.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.961 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.742 ' HA ' ' O ' ' A' ' 111' ' ' SER . 50.0 p -88.51 106.72 18.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.882 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 1.005 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 101.94 17.98 19.15 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.888 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.747 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -108.12 133.24 52.67 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -87.77 174.54 8.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.913 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 27.8 t70 -46.71 153.33 0.4 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.53 -22.62 36.37 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.965 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.61 HG22 ' N ' ' A' ' 18' ' ' VAL . 18.9 m -71.94 148.0 46.43 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.61 ' N ' HG22 ' A' ' 17' ' ' THR . 7.7 p -118.76 129.6 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.979 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.614 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.8 OUTLIER -104.51 150.54 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.969 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.779 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.1 147.86 28.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.976 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.737 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -142.71 108.63 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.771 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.36 114.75 20.58 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.706 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.17 143.13 20.16 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.954 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.21 ' O ' HG23 ' A' ' 4' ' ' THR . . . -139.29 109.52 6.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.463 ' C ' HD22 ' A' ' 26' ' ' LEU . . . 101.15 24.22 9.14 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.364 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.47 -169.35 2.52 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.671 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -81.03 125.25 29.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.3 131.29 43.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.992 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.94 8.15 77.43 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.763 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.63 132.14 42.56 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.972 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.402 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -86.25 150.67 24.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.856 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 51.6 m-85 -135.03 141.73 46.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.074 ' HB2' ' O ' ' A' ' 98' ' ' SER . 2.2 m-20 -100.69 113.96 27.27 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.958 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.258 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -101.26 151.55 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.977 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.726 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -175.89 172.77 45.76 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.957 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.849 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 41.4 tt0 -108.18 107.12 17.61 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.942 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 60.7 m -106.73 142.43 36.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.646 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -122.49 137.38 54.9 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.875 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.569 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.41 124.73 22.55 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.889 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.562 HG11 ' N ' ' A' ' 41' ' ' ASP . 1.2 t -105.27 -46.76 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.525 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.82 167.09 21.82 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.417 ' O ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -51.14 112.19 0.69 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.954 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.57 7.94 65.94 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.99 HG13 ' CZ3' ' A' ' 83' ' ' TRP . 2.0 t -122.38 117.58 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.983 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.533 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -127.35 136.3 51.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.979 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.291 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -92.34 151.76 20.11 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.97 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.6 m -110.77 146.75 35.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.974 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.751 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.1 p-10 -116.73 115.38 39.24 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.531 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.3 Cg_endo -72.4 -0.54 8.87 Favored 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.317 3.345 . . . . 0.0 109.6 179.868 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.03 -25.4 55.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.89 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -124.8 27.74 6.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -83.33 117.32 22.92 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.966 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 m -110.92 -178.24 3.42 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.8 p -144.86 155.07 43.27 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.875 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 56' ' ' THR . 7.6 p -166.91 151.66 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.472 ' N ' HG22 ' A' ' 55' ' ' VAL . 9.1 m -127.57 133.17 49.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.958 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 143.83 53.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.966 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 43.7 p30 -86.27 -172.03 3.85 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.36 -25.98 68.2 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.925 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -80.16 -7.77 59.1 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.05 30.59 57.13 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.927 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.3 p -122.57 133.01 54.56 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.4 162.66 18.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.981 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.2 p -149.5 129.03 13.07 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.971 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.585 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.91 157.57 31.67 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.868 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.585 ' N ' HG21 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.61 125.04 52.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.211 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -98.83 157.39 16.33 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.916 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -106.41 140.29 39.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.965 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.508 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -99.01 125.37 52.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.913 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -118.99 136.23 54.21 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.954 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.441 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -61.51 -34.49 75.6 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.441 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 62.5 p -156.58 162.4 39.9 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.849 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.9 p90 -177.71 165.62 2.08 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.961 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.8 116.55 8.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.911 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.291 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -76.66 94.73 1.08 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.95 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.868 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.69 99.76 10.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.979 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.747 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.1 tp -56.8 131.13 48.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.677 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 9.5 m-85 -47.83 -35.63 10.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.989 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.747 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.54 -16.91 11.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.948 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.96 27.51 8.84 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.988 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.582 HG22 ' N ' ' A' ' 82' ' ' ARG . 21.7 m -115.79 148.81 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.978 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.582 ' N ' HG22 ' A' ' 81' ' ' THR . 4.5 tmm_? -90.75 96.89 10.86 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 32.9 t-105 -63.44 -58.05 8.31 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 172.93 21.64 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.991 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.75 104.81 2.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.646 HG21 ' CB ' ' A' ' 38' ' ' ALA . 7.1 m -78.76 152.34 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.999 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.422 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.0 OUTLIER -115.75 92.91 4.05 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.971 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.141 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 32.7 m -51.6 -27.06 10.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.964 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -79.61 0.81 28.56 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.994 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.422 ' N ' ' O ' ' A' ' 87' ' ' ASP . 1.3 m -118.63 -27.97 5.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.899 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.46 180.0 5.7 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.827 ' HB3' ' OG ' ' A' ' 111' ' ' SER . . . -97.43 125.32 42.0 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.434 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 82.2 m -104.52 168.88 8.8 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.984 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.141 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -154.66 146.45 23.39 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.957 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.211 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.8 t -101.19 164.77 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.258 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.84 168.62 39.07 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.107 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.16 125.24 30.75 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.821 -0.436 . . . . 0.0 109.821 -179.95 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.074 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 56.6 m -100.75 154.07 18.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.895 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.44 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.1 OUTLIER -116.48 -164.29 0.96 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.44 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -61.77 -49.04 77.96 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.14 -24.4 61.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.922 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.22 53.58 1.46 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.995 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.52 178.28 6.86 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.856 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -179.7 -178.04 48.22 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.41 165.59 32.24 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.295 3.33 . . . . 0.0 109.61 179.928 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.577 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 3.8 pt-20 -38.3 121.84 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.82 153.87 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.141 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.9 t -114.1 102.33 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.51 128.51 34.35 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.434 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -139.28 -177.36 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.827 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 0.5 OUTLIER -172.21 174.66 3.91 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.915 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.141 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.3 m-85 -123.28 114.47 20.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.967 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 1.005 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 21.2 m-80 . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.973 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.076 ' HB2' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 . . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.524 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.44 -178.57 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.306 3.337 . . . . 0.0 109.59 179.945 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.999 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.18 109.11 21.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.942 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.808 ' CB ' ' HA2' ' A' ' 23' ' ' GLY . . . -122.92 150.73 42.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.661 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -113.82 119.64 38.02 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.999 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.897 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -114.79 143.87 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.961 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.776 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.12 167.36 17.98 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.985 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.776 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.34 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.349 3.366 . . . . 0.0 109.579 179.89 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.964 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.9 OUTLIER -122.06 13.96 10.58 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.99 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.864 ' HA ' ' O ' ' A' ' 111' ' ' SER . 53.3 p -98.95 114.61 27.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.877 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.668 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.03 1.59 41.95 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.964 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -114.39 142.01 46.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.972 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.9 m -104.98 -170.26 1.73 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.952 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.772 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 2.3 t0 -42.88 153.54 0.08 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.73 -24.63 31.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.568 HG22 ' CD2' ' A' ' 13' ' ' LEU . 3.7 m -96.21 148.81 22.33 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.413 ' N ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -123.05 146.32 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.996 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.578 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.3 OUTLIER -110.87 119.94 60.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.96 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.897 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -78.55 127.43 32.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.587 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.2 OUTLIER -113.17 114.63 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.983 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' CA ' ' A' ' 5' ' ' ALA . . . -127.17 123.49 36.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.98 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.808 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -90.59 153.48 22.63 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.957 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.999 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.6 108.18 3.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.14 17.35 27.54 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.991 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.844 ' HG ' ' HB2' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -89.47 176.45 6.9 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.969 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.492 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 23.2 mt-30 -58.54 121.71 11.61 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.3 131.21 42.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.995 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.86 7.58 83.9 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.569 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -93.13 141.04 28.85 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.475 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.69 151.16 24.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.971 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.64 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 29.8 m-85 -138.54 134.86 34.43 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.884 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.169 ' CB ' ' O ' ' A' ' 98' ' ' SER . 8.3 m-20 -100.29 113.54 26.32 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.94 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.293 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.19 143.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.723 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -164.96 164.45 37.06 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.96 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.902 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 10.9 tt0 -110.87 117.08 32.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.931 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 98.5 m -108.01 166.31 10.82 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.978 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.747 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -151.98 135.14 15.83 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.933 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.471 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.75 129.94 41.65 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.955 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -108.93 -39.01 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -150.4 155.8 40.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.986 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -51.51 112.9 0.83 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.99 9.86 84.74 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.98 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.622 HG23 ' CH2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -139.04 130.05 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.417 ' HA ' HG21 ' A' ' 40' ' ' VAL . 1.9 pp -132.18 163.85 27.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.103 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -125.48 153.8 43.01 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.973 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.857 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 15.1 m -115.92 153.2 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.834 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 39.6 t30 -111.02 107.05 57.74 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 85.3 Cg_endo -72.3 -1.21 9.8 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.34 3.36 . . . . 0.0 109.631 179.849 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.15 -8.8 50.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.854 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -130.06 27.78 5.1 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.455 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.07 110.94 17.07 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.982 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.28 174.06 6.04 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.924 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 72.7 p -145.14 154.67 42.69 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG22 ' N ' ' A' ' 56' ' ' THR . 4.8 p -166.53 155.62 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.512 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.4 m -128.05 136.67 51.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.38 135.4 38.33 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.993 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.1 p30 -77.8 -173.18 2.94 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.893 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.17 -27.93 69.31 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.871 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -74.53 -6.94 51.3 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.992 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.701 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.99 32.23 56.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 93.4 p -128.48 141.11 51.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.982 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.45 ' HB3' HG21 ' A' ' 55' ' ' VAL . . . -130.11 164.8 23.62 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.997 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.06 134.29 19.44 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.587 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -155.13 176.99 11.84 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.587 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.3 OUTLIER -133.41 117.66 17.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.95 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.081 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.48 156.1 16.48 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.508 ' HG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -111.53 128.38 56.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.457 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -97.13 123.11 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.772 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -115.05 144.48 43.57 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.44 ' HG3' ' N ' ' A' ' 72' ' ' SER . 15.4 ptt85 -65.85 -32.18 73.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.44 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 16.4 p -155.65 158.06 37.7 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.902 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.7 p90 -176.79 155.24 1.25 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -53.71 108.87 0.39 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.103 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -67.05 94.54 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.99 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.857 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -82.53 98.89 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.751 HD12 ' N ' ' A' ' 78' ' ' PHE . 1.4 tp -54.66 144.81 20.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.751 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.2 -43.53 21.59 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.97 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.682 ' HB3' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -58.46 -16.7 16.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.7 28.1 11.78 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.3 m -106.97 120.68 42.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.414 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -64.25 91.42 0.07 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.622 ' CH2' HG23 ' A' ' 44' ' ' VAL . 3.9 t-105 -62.68 -58.52 7.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.915 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.78 163.39 12.92 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.36 104.59 0.18 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.747 HG21 ' CB ' ' A' ' 38' ' ' ALA . 12.6 p -79.2 151.67 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.515 ' N ' HG22 ' A' ' 86' ' ' VAL . 4.0 m-20 -105.71 95.01 5.51 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.153 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.94 -22.14 14.03 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.942 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 49.1 p -88.97 2.1 54.45 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.962 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.6 m -110.11 -24.92 10.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -137.93 174.9 10.08 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.979 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.79 127.27 35.61 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.951 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.393 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -104.56 163.86 12.17 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.984 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.041 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -151.42 142.27 22.91 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.917 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.081 ' CG1' HD12 ' A' ' 67' ' ' LEU . 16.5 t -97.92 164.6 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 180.0 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.293 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.33 163.84 32.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.976 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.006 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.62 131.63 49.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.993 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.169 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 42.5 m -112.28 141.02 46.49 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.52 -164.14 1.02 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.04 -49.03 71.75 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.946 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.2 65.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.937 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.28 1.98 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.941 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.4 177.08 7.76 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.19 174.25 46.59 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.989 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.524 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.4 170.44 19.27 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.304 3.336 . . . . 0.0 109.623 179.944 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.076 ' HA ' ' HB2' ' A' ' 2' ' ' ALA . 9.7 pt-20 -41.2 126.69 2.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.963 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.6 160.82 0.01 OUTLIER Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.032 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.3 t -120.9 103.11 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.969 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.98 133.81 34.67 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.955 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.041 HG12 ' HA ' ' A' ' 94' ' ' GLN . 31.8 pt -136.93 -169.93 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.916 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.864 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -178.28 158.74 1.18 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.393 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.3 m-85 -111.37 119.19 38.0 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.932 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.668 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.8 p30 . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.955 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.576 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.413 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.4 -178.15 3.15 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.331 3.354 . . . . 0.0 109.603 179.904 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.861 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.2 m -101.14 110.7 22.75 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.816 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.65 142.11 51.67 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.914 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.538 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.98 116.07 31.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.96 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.795 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.7 OUTLIER -114.69 149.76 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.963 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.672 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.24 165.35 40.04 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.672 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.42 119.62 6.24 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.333 3.356 . . . . 0.0 109.579 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.963 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -123.87 16.16 9.36 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 1.263 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.6 p -105.3 113.79 27.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.885 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.975 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.86 6.78 37.08 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.963 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -114.52 136.72 52.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.5 m -81.12 171.21 15.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.925 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.444 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 3.3 p-10 -45.24 154.31 0.17 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.979 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.87 -24.01 33.84 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.985 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.603 ' OG1' ' HB2' ' A' ' 13' ' ' LEU . 94.3 m -68.37 131.88 46.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.981 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.422 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 10.4 p -102.08 119.32 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.668 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -99.17 161.14 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.795 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -119.74 148.7 43.09 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.997 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.7 107.18 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.994 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.816 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -117.21 116.42 27.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.633 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -83.66 146.73 23.58 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.992 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.861 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.83 110.01 4.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.938 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.5 15.75 31.27 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.974 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.628 ' H ' ' CD1' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -90.19 172.16 9.0 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.993 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.485 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.0 mt-30 -54.34 120.36 6.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.964 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.526 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.11 131.27 41.87 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.967 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 6.88 84.59 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.999 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.485 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -93.02 144.2 25.49 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -86.1 151.38 23.73 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.52 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.8 m-85 -138.66 144.4 39.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.199 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -112.51 113.11 25.12 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.935 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.214 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -98.96 152.04 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.927 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -178.57 159.71 25.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.979 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 1.028 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 12.4 tt0 -98.77 118.55 35.76 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.942 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.483 ' SG ' HD12 ' A' ' 45' ' ' LEU . 1.8 m -108.28 165.55 11.42 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.982 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.86 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.71 122.66 7.58 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.632 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.68 122.09 16.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.839 HG23 ' CD1' ' A' ' 83' ' ' TRP . 16.7 m -101.32 -44.58 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.973 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.521 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -135.64 168.06 19.97 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.966 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.595 ' O ' ' CG2' ' A' ' 42' ' ' THR . 3.9 t -54.04 112.97 1.06 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.986 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.66 8.56 63.62 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.984 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.471 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.7 t -120.86 109.07 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.483 HD12 ' SG ' ' A' ' 37' ' ' CYS . 1.5 pp -119.83 162.36 19.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.131 ' HB3' ' C ' ' A' ' 75' ' ' GLY . . . -129.4 151.91 49.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.936 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.006 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -117.38 157.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.499 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 17.6 t30 -116.24 112.95 41.49 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -72.35 -0.51 8.79 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.31 3.34 . . . . 0.0 109.61 179.884 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.497 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -12.72 36.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.849 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.466 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 16.5 p30 -132.94 27.01 4.27 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.928 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.11 117.35 32.29 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.993 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.9 t -106.61 177.91 4.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.962 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.4 p -146.5 151.49 37.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.447 ' CG2' ' N ' ' A' ' 56' ' ' THR . 4.6 p -166.77 162.58 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.943 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 97.5 m -127.8 134.82 49.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.951 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.99 143.4 50.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.949 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 42.9 p30 -81.74 -172.73 4.04 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.95 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.1 -25.54 68.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.904 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.68 -7.26 53.88 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.624 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.13 31.07 60.04 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.0 p -127.13 143.8 51.18 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.971 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.01 166.36 21.18 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.983 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -147.5 125.78 12.27 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.95 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.58 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.24 173.04 12.92 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.938 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.58 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.4 OUTLIER -131.13 111.22 11.78 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.944 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.242 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.12 156.55 16.33 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.685 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -119.2 139.97 50.97 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.924 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.627 ' C ' ' CD ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -109.57 133.37 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.796 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -119.83 162.19 19.54 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.444 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 5.8 ptt180 -82.56 -18.14 42.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 p -165.12 151.22 9.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.922 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 1.028 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.1 p90 -175.99 154.94 1.53 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.897 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.45 124.81 14.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.989 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.131 ' C ' ' HB3' ' A' ' 46' ' ' ALA . . . -83.03 92.11 1.62 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 1.006 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.52 100.51 11.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.974 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.742 HD11 ' N ' ' A' ' 78' ' ' PHE . 2.6 tp -58.15 140.96 51.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.967 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.742 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.28 -42.01 19.95 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.935 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.564 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -57.41 -16.66 9.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.965 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.55 28.43 10.43 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.99 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.425 ' HB ' HD22 ' A' ' 77' ' ' LEU . 2.0 m -108.73 128.09 54.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.67 91.59 1.12 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.471 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.14 -58.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.869 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.06 167.59 16.39 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.975 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -59.36 115.16 3.06 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.86 HG11 ' CB ' ' A' ' 38' ' ' ALA . 59.9 t -88.29 146.57 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 180.0 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.82 91.67 4.26 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.949 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.759 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -52.52 -22.63 5.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.997 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.91 2.6 48.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.981 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.566 ' O ' HG23 ' A' ' 90' ' ' THR . 3.3 m -115.82 -27.81 6.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.47 169.39 16.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.91 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.92 126.02 35.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.938 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.598 ' HB2' HD12 ' A' ' 110' ' ' ILE . 12.4 m -104.14 159.77 15.41 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 -179.923 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.055 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -145.45 143.1 29.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.969 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.242 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.7 t -97.34 157.73 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.214 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.55 171.05 43.27 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.997 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.214 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.33 151.31 51.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.199 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 82.8 p -127.96 151.41 49.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.5 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -112.77 -163.46 0.85 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.96 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.43 -48.6 69.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.935 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.24 65.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.952 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.8 53.39 1.8 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.998 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.424 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.11 168.36 18.11 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 179.971 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.52 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.85 178.95 42.51 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.933 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.413 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.36 161.98 42.82 Favored 'Trans proline' 0 N--CA 1.447 -1.24 0 C-N-CA 124.34 3.36 . . . . 0.0 109.627 179.966 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.576 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -40.61 123.72 1.9 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.972 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.54 151.82 0.02 OUTLIER Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.01 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.2 t -119.21 104.24 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.66 138.71 36.4 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.982 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.055 HG12 ' HA ' ' A' ' 94' ' ' GLN . 25.8 pt -137.75 -172.34 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 1.263 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -179.23 163.69 1.31 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.942 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.759 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 2.3 m-85 -117.76 116.81 27.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.937 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.975 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 46.4 m-80 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.973 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.449 ' HB3' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.477 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.39 -174.61 1.48 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.322 3.348 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.174 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.1 t -97.99 110.68 23.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.952 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.84 146.92 50.46 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.953 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.473 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -109.26 112.44 24.59 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.784 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -109.07 145.38 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.993 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.777 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.28 168.65 12.85 Favored Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.777 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.39 117.14 4.99 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.296 3.331 . . . . 0.0 109.571 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.704 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -127.05 17.18 7.25 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.975 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.461 ' HA ' ' O ' ' A' ' 111' ' ' SER . 39.2 p -94.6 112.72 24.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.9 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 1.029 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 87.98 28.75 22.49 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.942 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.741 HD21 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.18 137.33 46.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.976 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.4 t -76.2 150.24 37.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.964 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 2.3 p30 -44.43 153.02 0.17 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.5 -24.72 30.85 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 17.7 m -63.69 150.29 44.71 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.982 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.512 HG11 ' O ' ' A' ' 18' ' ' VAL . 14.7 p -112.46 121.8 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.612 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 2.2 p -97.42 153.52 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.996 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.784 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -107.28 150.45 26.66 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.973 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.741 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -148.63 107.64 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.998 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.952 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.05 114.96 23.33 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.988 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.644 ' HA2' ' HB3' ' A' ' 5' ' ' ALA . . . -85.2 139.95 17.98 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.952 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.174 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -135.89 110.22 8.44 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.922 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.513 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 103.29 21.19 10.17 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.966 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.308 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.4 -168.39 2.19 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.838 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -79.59 121.66 25.54 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.962 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.511 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.61 135.9 47.15 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.97 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.38 6.71 58.78 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.958 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.845 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.92 138.87 33.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.968 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.473 ' N ' HG23 ' A' ' 30' ' ' THR . . . -86.29 150.72 24.15 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.508 ' HB3' ' CD2' ' A' ' 97' ' ' LEU . 39.2 m-85 -136.44 155.79 49.52 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.409 ' O ' ' CA ' ' A' ' 97' ' ' LEU . 2.6 m-20 -121.89 114.18 20.67 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.244 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -95.02 144.7 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.983 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.01 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.07 166.92 34.76 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.954 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.696 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -121.63 106.98 11.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.929 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.3 m -105.21 172.78 6.61 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.961 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.915 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -146.37 127.34 14.55 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.932 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.77 117.83 8.07 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.92 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.59 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 3.6 m -98.22 -42.92 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.972 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -135.67 177.31 7.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.995 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 t -60.36 111.76 1.68 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.99 8.17 63.85 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.763 HG12 ' CD1' ' A' ' 83' ' ' TRP . 22.0 t -120.73 113.31 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.468 HD23 ' CD2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -128.51 140.61 51.72 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.991 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.187 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 138.65 34.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.956 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.929 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 82.1 m -106.37 140.62 39.0 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.971 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.613 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.8 t30 -100.31 111.49 62.58 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.1 Cg_endo -72.39 0.28 7.67 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.524 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -86.56 -14.94 41.45 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.854 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.52 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.9 p30 -123.21 29.69 6.61 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.447 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -82.66 106.02 14.17 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.987 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.6 m -100.32 179.02 4.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.5 p -145.71 158.52 43.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.915 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.662 ' CG1' HD21 ' A' ' 97' ' ' LEU . 7.2 p -169.11 156.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.973 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.509 ' N ' HG22 ' A' ' 55' ' ' VAL . 7.0 m -127.97 137.63 52.32 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.69 139.73 35.99 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.984 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.2 p30 -82.86 -165.85 1.17 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.927 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.89 -28.67 69.07 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.3 m-20 -83.1 6.35 19.4 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.986 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.93 22.04 59.63 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -109.21 130.92 55.48 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.446 ' HB1' HG21 ' A' ' 55' ' ' VAL . . . -121.41 167.31 12.94 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.84 131.61 16.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.905 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.638 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.79 157.71 32.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.638 ' N ' HG22 ' A' ' 65' ' ' THR . 0.2 OUTLIER -116.5 125.66 52.25 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.048 ' CD1' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -97.53 155.95 16.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.919 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.523 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -97.36 123.11 41.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.961 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.536 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -77.49 129.36 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.999 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.707 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -123.58 147.26 47.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.931 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -92.71 -20.2 21.04 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.994 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 53.4 p -172.99 153.18 2.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.922 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.707 ' CE2' ' HB2' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -178.02 179.08 0.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.949 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -68.56 117.83 10.8 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.187 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -79.6 89.13 1.23 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.956 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.781 ' HB3' ' O ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -83.47 103.33 12.73 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.796 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.8 tp -58.34 130.99 49.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.579 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.86 -35.36 10.23 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.796 ' HB3' HD23 ' A' ' 77' ' ' LEU . 5.4 t0 -57.26 -17.28 11.02 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.24 28.39 8.14 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.939 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.432 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.1 m -117.74 145.86 44.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.31 97.21 8.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.59 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 21.9 t90 -64.25 -57.65 8.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.879 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.98 160.27 8.6 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.61 105.18 0.14 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.977 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.915 HG12 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -82.35 154.03 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -120.13 96.78 5.3 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.998 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.11 ' HB3' ' CD1' ' A' ' 112' ' ' PHE . 24.9 m -52.76 -25.6 11.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.9 p -79.68 1.45 26.34 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.32 -177.08 4.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.77 126.67 47.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.239 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 18.6 m -104.43 164.14 11.95 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.964 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.231 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -154.79 149.57 26.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.973 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.048 ' CG1' ' CD1' ' A' ' 67' ' ' LEU . 6.8 t -104.05 165.85 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.244 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 170.63 43.78 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.94 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.508 ' CD2' ' HB3' ' A' ' 32' ' ' TYR . 4.8 mp -99.81 162.87 12.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.168 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -152.48 109.99 3.59 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.896 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.594 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 1.7 p-10 -104.75 -157.96 0.64 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.28 -43.94 64.71 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.981 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.45 -26.01 26.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.937 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.95 52.86 2.33 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.959 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.594 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -109.17 -174.32 2.48 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -179.99 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 172.57 179.24 43.24 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.993 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.477 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.36 160.29 47.32 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.366 3.377 . . . . 0.0 109.567 179.91 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -32.96 128.51 0.26 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.479 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.0 130.94 0.29 Allowed Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.231 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 41.6 t -99.29 101.55 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.482 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -80.04 140.47 36.52 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.938 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.1 pt -147.06 -172.23 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.569 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.4 OUTLIER -173.82 176.17 2.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.948 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.11 ' CD1' ' HB3' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -150.64 105.77 3.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 1.029 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.7 p30 . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.565 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.48 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.8 Cg_endo -72.39 -175.63 1.87 Allowed 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.275 3.317 . . . . 0.0 109.637 179.934 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.976 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.47 109.15 21.95 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.77 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.58 137.75 54.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.685 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -106.11 112.57 25.66 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.981 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.598 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -106.39 155.98 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.988 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.984 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.08 177.29 0.91 Allowed Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.923 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.984 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.5 Cg_endo -72.4 117.22 5.03 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.311 3.34 . . . . 0.0 109.573 179.909 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.868 ' HB2' HG22 ' A' ' 110' ' ' ILE . 13.4 p -112.73 44.69 1.44 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -124.73 106.3 9.97 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.885 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.653 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 88.39 31.9 12.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.969 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.733 ' N ' ' CD2' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -97.58 133.0 42.72 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 55.7 m -96.71 162.87 13.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -49.83 146.37 4.58 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.994 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.92 -22.51 35.81 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.965 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.9 m -63.3 147.62 50.56 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -112.2 122.7 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.495 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 3.6 m -96.93 161.24 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.598 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 151.16 32.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.975 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.719 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -150.11 109.96 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.959 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.77 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.14 116.49 22.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.999 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.682 ' HA2' ' HA ' ' A' ' 5' ' ' ALA . . . -94.29 141.1 15.37 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.959 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.976 ' O ' HG23 ' A' ' 4' ' ' THR . . . -133.12 118.0 18.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.887 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.445 ' C ' HD21 ' A' ' 26' ' ' LEU . . . 100.31 24.37 9.61 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.209 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.32 -173.67 4.49 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.972 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.869 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -80.67 120.76 25.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.993 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.78 136.74 57.24 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.955 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.25 7.95 58.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.991 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.692 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -85.6 148.22 26.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 1.009 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -100.81 134.68 43.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.061 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 37.4 m-85 -127.29 147.59 50.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.048 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.8 m-20 -116.86 114.05 23.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.997 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.268 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -96.61 152.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.965 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.099 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -177.66 164.98 34.37 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.963 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.804 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 1.7 tt0 -112.34 118.38 35.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.937 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 93' ' ' CYS . 90.8 m -108.23 173.5 6.29 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.983 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.064 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -152.62 123.97 7.67 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.917 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.617 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.57 124.0 21.18 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.907 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.056 HG23 ' CD2' ' A' ' 83' ' ' TRP . 15.2 m -103.93 -43.85 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.538 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -142.93 169.61 17.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 19.5 m -56.74 113.43 1.64 Allowed 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.952 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.78 4.83 62.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.997 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.49 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 15.5 t -122.19 105.07 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.975 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.541 HD11 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -117.3 162.73 17.43 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.136 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -122.54 140.7 52.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.68 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 23.4 m -109.3 150.8 27.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 1.059 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -108.41 105.75 57.32 Favored Pre-proline 0 N--CA 1.45 -0.453 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.988 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.456 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.0 Cg_endo -72.4 -1.23 9.89 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.309 3.339 . . . . 0.0 109.638 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.469 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -91.41 -12.97 33.22 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.888 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD2' ' HB3' ' A' ' 36' ' ' GLN . 29.6 p30 -127.27 18.77 6.99 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.46 ' CD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -83.5 103.51 12.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.981 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.1 t -93.43 177.57 5.99 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.905 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.3 p -147.04 155.24 42.06 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -167.36 155.97 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.971 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 73.5 m -122.87 130.32 52.72 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.948 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 125.28 24.52 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.915 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -71.39 -170.37 0.5 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 -23.67 66.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -85.38 6.97 24.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.985 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 61.15 14.08 38.04 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.99 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.3 t -102.52 131.83 48.98 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.942 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.81 124.0 38.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.97 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.7 p -110.78 134.05 52.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.988 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.564 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -158.39 152.6 24.13 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.897 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.564 ' N ' HG21 ' A' ' 65' ' ' THR . 0.3 OUTLIER -113.17 131.29 55.92 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.956 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.311 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.93 157.46 17.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.447 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 4.6 t -105.18 127.51 52.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.647 ' C ' ' HD2' ' A' ' 70' ' ' ARG . 1.7 t -84.34 126.23 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.664 ' HB2' ' OE1' ' A' ' 36' ' ' GLN . 1.2 mpt_? -119.76 145.9 46.15 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.55 ' HB2' HG21 ' A' ' 89' ' ' THR . 0.0 OUTLIER -89.83 -8.07 52.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.938 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.569 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 90.3 p -178.02 149.96 0.59 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 1.059 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 3.8 p90 -176.77 154.58 1.19 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.921 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -49.55 114.37 1.03 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.136 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -71.89 92.76 0.55 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.68 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -83.81 99.34 10.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.953 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.753 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.6 tp -59.09 129.03 40.17 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.628 ' N ' HD11 ' A' ' 77' ' ' LEU . 32.4 p90 -47.56 -34.7 8.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.939 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.753 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.7 -16.72 11.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.982 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.08 28.11 8.91 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.42 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 3.4 m -116.93 150.88 37.79 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.933 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -87.04 97.67 10.85 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.902 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.538 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 76.7 t-105 -65.28 -56.41 12.88 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.76 166.46 11.6 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.991 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.19 108.14 0.38 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.944 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.064 HG11 ' HB3' ' A' ' 38' ' ' ALA . 69.3 t -82.25 147.85 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.971 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -114.46 93.7 4.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.949 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.485 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.0 m -52.74 -26.04 12.94 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.55 HG21 ' HB2' ' A' ' 71' ' ' ARG . 78.7 p -80.19 0.14 33.7 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.54 -27.48 6.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.77 -177.98 4.6 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.967 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.21 124.45 46.92 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.908 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.932 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 60.5 m -103.6 153.61 20.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.999 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -142.85 145.12 32.84 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.964 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.311 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.2 t -102.73 160.33 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.268 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.63 166.72 37.25 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.132 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.64 128.59 37.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.974 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.048 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.8 m -115.36 160.97 19.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.936 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 1.009 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -115.45 -157.44 0.64 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.982 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.11 -47.84 81.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.39 -25.78 59.7 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.874 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.64 50.11 1.87 Allowed Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.976 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.52 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -119.46 158.32 26.48 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 1.061 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.48 176.35 43.46 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.988 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.48 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 171.04 17.79 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.317 3.345 . . . . 0.0 109.616 179.922 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.565 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 2.0 mt-10 -40.71 133.68 1.99 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.06 155.97 0.74 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.964 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 93.1 t -122.74 105.18 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.981 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.484 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -87.16 138.4 31.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.962 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.999 ' CG1' ' HA ' ' A' ' 94' ' ' GLN . 2.3 mt -117.68 157.94 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.984 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 10' ' ' SER . 3.1 t -149.34 127.82 12.29 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.894 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 -100.64 127.92 46.87 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.937 . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.481 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.638 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.42 -174.48 1.45 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.304 3.336 . . . . 0.0 109.614 179.949 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.351 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.5 t -98.72 111.7 23.99 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.987 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.63 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.42 152.31 47.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.972 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -109.8 113.32 25.98 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.83 HG22 HG21 ' A' ' 108' ' ' VAL . 40.3 t -110.47 147.28 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.942 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.945 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.77 175.47 1.68 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.952 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.945 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.36 116.59 4.77 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 124.346 3.364 . . . . 0.0 109.617 179.902 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.811 ' HB2' HG23 ' A' ' 110' ' ' ILE . 6.5 p -111.12 43.71 1.42 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.937 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.0 p -124.28 105.16 9.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.892 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.758 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 95.02 30.51 8.27 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.758 HD21 ' C ' ' A' ' 12' ' ' GLY . 0.4 OUTLIER -110.93 129.72 55.8 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -112.88 177.01 4.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -44.67 138.66 3.28 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.984 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.01 -23.1 31.7 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.938 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.5 m -88.67 152.15 22.0 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 p -129.33 134.22 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.994 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.491 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 17.9 m -95.27 166.13 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.989 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.806 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.57 143.64 44.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.679 HG12 ' CG2' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -139.32 104.52 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.919 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.63 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.1 115.29 23.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.934 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -83.03 143.93 22.42 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.949 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.351 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -139.83 107.21 5.53 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.853 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.481 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 103.72 20.02 11.33 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.945 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.269 ' CD1' ' HB3' ' A' ' 105' ' ' PRO . 0.2 OUTLIER -88.87 -172.29 3.64 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.975 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.577 HE22 ' CG ' ' A' ' 103' ' ' ASN . 31.0 mt-30 -71.87 121.47 19.08 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.932 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.977 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.14 133.67 44.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.0 8.48 73.78 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.989 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.643 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.11 138.25 33.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.955 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.791 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.58 151.58 24.43 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.972 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.7 m-85 -137.63 149.68 46.81 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.927 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.155 ' CB ' ' H ' ' A' ' 98' ' ' SER . 3.7 m-20 -113.25 114.18 26.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.991 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.296 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -100.42 145.32 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.124 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.01 169.37 41.34 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.925 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.716 HE22 ' H ' ' A' ' 70' ' ' ARG . 40.8 tt0 -113.74 106.07 14.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.974 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -108.4 146.27 33.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.95 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.964 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -125.97 137.87 53.71 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.629 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.4 119.67 11.42 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.965 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.351 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.6 m -100.56 -42.81 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.046 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -132.65 165.07 25.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.985 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 32.4 m -51.2 111.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.907 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.03 69.06 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.953 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.52 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 10.7 t -122.01 117.96 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.57 HD11 ' HB2' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -129.15 138.24 51.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.984 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.588 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -101.44 152.11 21.13 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.951 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.974 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.0 m -106.79 148.57 28.32 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.994 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.933 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -111.37 117.13 49.95 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.974 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.462 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.6 Cg_endo -72.44 1.06 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.287 3.325 . . . . 0.0 109.621 179.908 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.51 -20.51 36.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.898 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.745 ' OD1' HG21 ' A' ' 68' ' ' THR . 98.3 m-20 -129.72 30.97 4.82 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.913 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.703 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.58 117.52 30.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.1 t -116.26 -178.96 3.53 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.946 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.6 p -146.46 154.52 41.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.874 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.504 HG22 ' N ' ' A' ' 56' ' ' THR . 5.3 p -166.18 158.9 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.998 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.504 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.6 m -127.11 133.16 50.44 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.952 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.26 153.59 42.14 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.975 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -89.63 -171.84 3.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.926 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.0 67.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.911 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.05 -16.83 61.03 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.961 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 88.24 6.35 74.84 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.975 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.01 140.03 32.95 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.941 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.61 163.32 17.52 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.976 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.15 122.92 9.27 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.542 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -157.8 162.73 38.46 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.542 ' N ' HG21 ' A' ' 65' ' ' THR . 0.9 OUTLIER -118.37 129.85 55.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.912 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -106.77 124.45 49.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.913 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.745 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.6 141.43 41.08 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.962 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.471 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -102.67 131.65 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.994 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.716 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -119.13 157.3 28.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 -87.08 -20.66 26.81 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.8 t -168.77 151.71 5.18 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.9 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.933 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 1.7 p90 -173.7 159.54 3.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.94 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -61.01 114.96 3.37 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.943 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.588 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -73.43 94.6 0.74 Allowed Glycine 0 C--N 1.336 0.558 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 180.0 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -82.12 99.37 9.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.779 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.8 tp -54.61 132.58 45.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.982 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD13 ' A' ' 77' ' ' LEU . 5.9 m-85 -46.59 -37.29 7.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.953 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.779 ' HB3' HD23 ' A' ' 77' ' ' LEU . 6.8 t0 -56.98 -16.96 7.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.99 27.59 9.34 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.431 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 2.0 m -113.55 140.9 47.77 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.37 95.9 7.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.351 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 38.1 t-105 -63.0 -57.8 9.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.912 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.04 172.9 19.24 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.959 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.47 109.69 2.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.958 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.964 HG23 ' CB ' ' A' ' 38' ' ' ALA . 3.3 p -90.72 142.13 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.516 ' N ' HG21 ' A' ' 86' ' ' VAL . 3.2 m-20 -98.21 99.48 10.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.36 -22.32 7.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.0 p -87.31 1.58 52.83 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.922 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -112.83 -26.37 8.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.01 -178.94 5.26 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.954 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.04 128.35 42.86 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.301 ' O ' HG13 ' A' ' 110' ' ' ILE . 34.0 m -104.74 155.06 19.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.956 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -147.58 145.61 29.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.984 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.3 t -109.2 156.76 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.981 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.296 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -174.5 172.38 45.35 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.093 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -129.62 128.72 43.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.155 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 36.5 m -118.26 140.07 50.36 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.917 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.791 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 4.4 p-10 -111.81 -162.71 0.81 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.996 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.08 79.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.459 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -66.48 -24.37 66.41 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.926 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 83.02 35.29 18.86 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.957 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.577 ' CG ' HE22 ' A' ' 27' ' ' GLN . 0.3 OUTLIER -108.45 -173.7 2.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.943 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.819 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 167.84 164.75 24.07 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.638 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.39 162.81 40.46 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.242 3.295 . . . . 0.0 109.576 179.954 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.481 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.9 OUTLIER -36.05 126.58 0.74 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.479 ' N ' ' HB1' ' A' ' 2' ' ' ALA . . . -41.78 147.97 0.44 Allowed Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.83 HG21 HG22 ' A' ' 7' ' ' VAL . 9.0 t -122.15 106.74 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -91.36 150.48 21.26 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.954 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.301 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -118.45 161.87 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.944 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.534 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -145.22 111.78 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.954 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 113' ' ' ASN . 6.9 m-85 -87.93 101.91 14.2 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.924 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.584 ' CG ' ' O ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.938 -0.394 . . . . 0.0 109.938 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.383 ' CB ' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.503 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 . . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.054 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.1 Cg_endo -72.38 -175.21 1.69 Allowed 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 124.272 3.314 . . . . 0.0 109.632 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.92 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.71 109.89 21.96 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.946 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.846 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.5 137.64 54.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.995 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.557 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -99.08 114.07 26.6 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.97 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.828 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.2 m -108.09 153.72 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.997 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.965 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.59 176.56 1.21 Allowed Pre-proline 0 N--CA 1.449 -0.476 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.965 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.3 Cg_endo -72.38 117.79 5.3 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 124.352 3.368 . . . . 0.0 109.553 179.925 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.722 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.9 p -114.69 45.7 1.52 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.7 p -123.75 105.39 9.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.87 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.68 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.63 29.84 11.45 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.948 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.722 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -101.43 132.22 47.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.948 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 51.1 m -104.7 166.56 10.31 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.9 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -44.98 140.04 2.84 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.998 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.47 35.71 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.976 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.3 m -76.53 148.83 36.86 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.986 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.8 p -122.38 127.22 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.595 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 16.1 m -93.76 170.31 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.62 148.3 41.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.999 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.724 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -143.75 108.18 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.997 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.846 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.83 115.13 21.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.445 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.81 143.13 19.67 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.958 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.92 ' O ' HG22 ' A' ' 4' ' ' THR . . . -137.6 111.97 8.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.949 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.535 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 102.77 24.59 8.06 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.027 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -91.12 -163.96 1.11 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.993 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.417 ' O ' ' HB ' ' A' ' 30' ' ' THR . 34.4 mt-30 -88.27 127.12 35.46 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.428 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.18 133.77 42.75 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.78 8.68 82.33 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.973 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.733 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -96.89 137.64 35.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.939 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.643 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.94 152.33 22.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.03 ' CD1' ' HD2' ' A' ' 105' ' ' PRO . 45.3 m-85 -139.29 149.34 44.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.91 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.077 ' CB ' ' H ' ' A' ' 98' ' ' SER . 14.7 m-20 -112.21 115.03 28.15 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.187 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.34 146.06 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.999 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.881 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.56 170.79 42.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.92 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.1 tt0 -117.46 122.99 45.27 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.92 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m -125.85 148.31 49.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.048 ' HB2' HG11 ' A' ' 86' ' ' VAL . . . -123.1 134.88 54.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.89 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.659 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.0 OUTLIER -65.31 123.5 19.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.909 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.098 ' CG2' ' CE2' ' A' ' 83' ' ' TRP . 32.3 m -103.84 -42.0 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.976 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.18 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -132.01 -178.67 5.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.963 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 33.1 m -69.67 113.45 6.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.948 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.91 10.01 80.17 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.638 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.23 125.48 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.964 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.618 HD11 ' HB2' ' A' ' 37' ' ' CYS . 1.5 pt? -133.62 140.92 47.39 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.959 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.445 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -94.72 144.15 25.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 23.2 m -105.51 159.89 15.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.739 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 21.8 t30 -118.67 111.57 37.64 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.989 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.44 0.55 7.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.307 3.338 . . . . 0.0 109.591 179.881 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.431 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -11.98 41.77 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.911 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.504 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.2 p30 -129.49 27.59 5.27 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.34 107.09 16.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.4 t -105.02 174.96 5.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.91 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.5 p -146.67 158.36 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.881 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -167.82 158.52 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.935 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 28.0 m -128.13 125.06 38.4 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.93 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.51 152.89 13.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -180.0 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.7 p30 -95.28 -169.47 1.98 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.951 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.65 -24.87 67.84 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.913 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -81.04 -7.26 59.52 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.973 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.428 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.43 13.28 83.55 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.978 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.8 p -105.02 139.69 39.32 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.867 -0.419 . . . . 0.0 109.867 179.951 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.54 162.27 20.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.972 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 p -150.14 122.19 8.26 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.921 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.537 HG23 ' CG1' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -151.24 153.25 34.52 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.903 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.532 ' N ' HG21 ' A' ' 65' ' ' THR . 0.5 OUTLIER -107.95 120.69 43.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.946 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.324 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -99.69 156.02 17.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.547 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -111.71 128.16 56.0 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.658 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -100.23 129.64 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.966 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.92 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -113.68 155.52 25.4 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.961 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? -89.72 -12.77 38.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.992 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -166.06 142.39 5.06 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.92 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.739 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 10.8 p90 -178.0 158.05 1.2 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.895 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.19 124.9 21.69 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.911 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.445 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -83.18 103.97 2.54 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.915 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.732 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.57 102.03 12.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.761 HD21 ' HB3' ' A' ' 79' ' ' ASP . 3.9 tp -56.61 131.6 49.34 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.968 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.526 ' HD2' HD22 ' A' ' 45' ' ' LEU . 26.2 p90 -47.44 -36.6 10.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.761 ' HB3' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.39 -16.48 9.24 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.953 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.41 27.57 9.8 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.523 HG21 ' N ' ' A' ' 82' ' ' ARG . 1.4 m -115.11 150.3 36.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.971 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.523 ' N ' HG21 ' A' ' 81' ' ' THR . 5.4 mtm180 -85.36 98.0 10.3 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.956 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.638 ' CH2' HG21 ' A' ' 44' ' ' VAL . 22.8 t-105 -63.92 -51.33 64.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 179.896 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 139.03 179.73 17.69 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.969 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.86 134.26 56.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.927 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.048 HG11 ' HB2' ' A' ' 38' ' ' ALA . 6.5 t -114.62 150.08 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.2 94.43 4.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.926 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -53.37 -25.31 14.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 180.0 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.4 p -83.92 2.14 40.09 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.95 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.621 ' O ' HG23 ' A' ' 90' ' ' THR . 2.9 m -114.44 -27.85 7.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.942 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.33 179.88 5.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.937 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 126.32 41.93 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.907 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.339 ' C ' HG13 ' A' ' 110' ' ' ILE . 9.0 m -104.39 153.98 20.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.961 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.069 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -149.62 148.23 29.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.95 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.324 ' CG1' HD12 ' A' ' 67' ' ' LEU . 17.9 t -96.76 163.55 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.96 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.187 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.41 158.34 27.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.064 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -141.53 137.61 32.14 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.972 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.077 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -129.13 153.48 47.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.912 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.643 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -98.11 -166.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.996 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -59.28 -49.99 75.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.978 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.29 -24.82 64.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.926 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.415 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 100.65 41.71 2.65 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.417 ' ND2' ' CG ' ' A' ' 99' ' ' ASP . 0.5 OUTLIER -121.4 178.03 4.96 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.27 -176.0 20.81 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.98 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.054 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.46 134.03 21.8 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.298 3.332 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.383 ' O ' ' CB ' ' A' ' 2' ' ' ALA . 0.5 OUTLIER -136.04 144.3 45.17 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.992 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.39 59.46 0.19 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.979 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.001 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 36.4 t -133.54 100.74 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.37 153.75 18.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.969 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.339 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -121.91 161.36 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -148.65 117.05 6.51 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.961 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.039 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 45.3 m-85 -94.72 128.12 41.19 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.931 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.964 . . . . . . . . 0 0 . 1 . 042 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.97 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.38 -177.35 2.67 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.331 3.354 . . . . 0.0 109.59 179.906 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.812 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.31 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.96 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.733 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.28 144.57 49.33 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.988 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.773 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -111.33 108.41 18.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.974 HG21 HG22 ' A' ' 108' ' ' VAL . 1.7 t -99.64 151.05 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.978 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -66.7 177.82 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.979 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.978 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 115.82 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.304 3.336 . . . . 0.0 109.628 179.89 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.789 ' HA ' HD12 ' A' ' 13' ' ' LEU . 30.0 p -118.32 38.84 3.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.968 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 111' ' ' SER . 11.5 p -117.86 104.78 11.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.901 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.937 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 95.22 26.58 12.07 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.961 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.789 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -98.2 129.76 44.95 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.958 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -91.87 161.9 14.65 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -45.33 142.03 2.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.957 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.24 33.14 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.988 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.4 m -76.48 150.71 36.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.99 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.8 124.41 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.995 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.541 ' HA ' HG22 ' A' ' 8' ' ' THR . 18.5 m -96.15 133.95 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.991 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.497 ' H ' ' HB ' ' A' ' 8' ' ' THR . 0.0 OUTLIER -79.2 154.47 29.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.69 ' HA ' HG23 ' A' ' 7' ' ' VAL . 4.2 p -140.95 103.13 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.773 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -109.51 121.33 44.96 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.94 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.624 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -101.7 139.62 14.49 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.812 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -134.37 127.07 30.91 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.992 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.03 24.18 23.24 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.883 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -91.29 -167.24 1.75 Allowed 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.488 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.0 mt-30 -84.93 125.18 32.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.991 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.76 130.74 41.18 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.54 8.22 83.81 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.954 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.731 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -95.4 132.16 40.75 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.899 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -79.64 150.63 30.91 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.934 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.599 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 31.5 m-85 -137.9 148.77 45.63 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.909 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.157 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.9 m-20 -113.89 116.29 29.06 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.917 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.349 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.12 145.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.995 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.038 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.69 169.57 41.3 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.978 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.883 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 29.1 tt0 -111.22 120.72 43.22 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.945 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -110.33 162.7 14.38 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.953 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.172 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -150.81 125.16 9.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.959 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.9 125.86 26.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.988 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.976 HG23 ' CG ' ' A' ' 83' ' ' TRP . 2.6 m -111.69 -35.62 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.154 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.2 -178.55 5.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.967 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 79.0 m -77.19 111.83 13.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.28 10.51 85.94 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.683 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -128.78 114.84 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -108.14 162.85 13.68 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.986 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.227 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -129.39 127.38 40.89 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.944 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.725 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.95 154.25 21.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.719 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.9 t30 -116.29 113.96 40.95 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.972 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.34 -0.11 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.33 3.353 . . . . 0.0 109.598 179.891 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.507 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.55 -16.1 29.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.836 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.3 p30 -125.96 25.63 6.75 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.915 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -91.22 106.25 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.967 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.2 t -99.66 -179.88 4.33 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.916 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.4 p -146.84 157.34 43.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.901 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -166.69 160.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.914 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 55' ' ' VAL . 12.0 m -127.52 141.08 51.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.36 134.51 36.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.4 p30 -78.6 -171.84 2.68 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.933 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.26 -26.14 68.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.947 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -77.77 -3.97 44.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.678 ' O ' HD13 ' A' ' 26' ' ' LEU . . . 69.53 31.26 70.87 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.999 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.6 p -123.14 133.7 54.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.963 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.22 124.57 19.17 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.983 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.97 143.04 46.72 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.949 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.487 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.48 166.23 33.35 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.487 ' N ' HG21 ' A' ' 65' ' ' THR . 0.6 OUTLIER -105.79 124.61 49.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.201 ' CG ' HG21 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.82 118.59 35.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.981 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.581 ' OG1' ' CZ ' ' A' ' 70' ' ' ARG . 3.1 t -80.88 132.34 35.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.938 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.567 HG22 ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -107.78 130.52 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.656 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.5 mpt_? -115.78 146.25 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.98 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.724 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.7 OUTLIER -70.86 -4.39 24.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.957 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 31.7 p -178.79 153.25 0.65 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.9 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.883 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 6.4 p90 -176.87 162.31 2.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.955 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -56.15 126.45 26.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.227 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -83.07 88.64 1.5 Allowed Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.933 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.725 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.87 100.85 11.25 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.996 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.779 HD21 ' HB3' ' A' ' 79' ' ' ASP . 4.3 tp -63.46 130.55 44.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.541 ' N ' HD11 ' A' ' 77' ' ' LEU . 26.9 p90 -47.48 -36.04 9.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.986 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.779 ' HB3' HD21 ' A' ' 77' ' ' LEU . 1.4 t70 -57.37 -16.63 9.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.994 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.0 27.36 9.51 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.994 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.641 HG22 ' N ' ' A' ' 82' ' ' ARG . 2.6 m -113.61 144.99 41.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.641 ' N ' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -88.87 94.24 9.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.683 ' CZ2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.41 -57.75 9.29 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.78 164.28 10.5 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.992 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -56.0 127.5 30.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.934 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.172 HG22 ' CB ' ' A' ' 38' ' ' ALA . 0.8 OUTLIER -107.79 154.95 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.993 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.56 108.7 16.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.957 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.831 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 35.1 m -54.25 -26.48 29.07 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.976 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.6 p -82.02 -0.97 46.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.965 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.613 HG21 ' O ' ' A' ' 90' ' ' THR . 1.1 m -116.4 -27.36 6.81 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.932 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.88 -178.31 4.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.69 124.24 40.62 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.16 ' C ' HG13 ' A' ' 110' ' ' ILE . 94.9 m -104.47 152.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.956 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.052 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -156.42 146.04 20.86 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.949 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.201 HG21 ' CG ' ' A' ' 67' ' ' LEU . 9.2 t -96.53 162.57 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.236 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 160.49 31.33 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.599 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -138.84 141.8 38.65 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.972 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.157 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -134.02 157.8 45.17 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.929 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.899 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.89 -164.16 1.02 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.448 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.13 -49.68 76.13 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.8 -24.78 61.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.902 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.85 41.13 2.95 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.57 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -117.68 176.69 5.06 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.948 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.4 -175.75 20.76 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 179.975 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.97 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.39 133.89 21.67 Favored 'Trans proline' 0 N--CA 1.447 -1.247 0 C-N-CA 124.338 3.359 . . . . 0.0 109.568 179.908 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.803 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 3.7 tt0 -137.26 147.49 45.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.96 58.11 0.23 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.946 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.037 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.4 t -130.88 101.38 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.41 143.36 28.94 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.16 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -110.79 169.27 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.92 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -161.4 127.64 3.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.943 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.831 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 11.2 m-85 -99.1 116.84 32.25 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.893 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.937 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 3.4 p30 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.15 ' HB3' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.162 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.41 -175.3 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.297 3.331 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.723 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -100.55 108.68 20.68 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.92 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.868 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.98 136.87 54.38 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.932 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.625 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -98.53 112.27 24.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.969 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.823 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -106.2 153.42 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.997 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.95 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.73 176.93 1.1 Allowed Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.92 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.95 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.9 Cg_endo -72.35 115.9 4.5 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.323 3.349 . . . . 0.0 109.59 179.881 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.969 ' HB2' HG21 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -112.95 41.23 2.12 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.956 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.532 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -119.04 105.43 11.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.876 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 1.081 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 93.2 28.24 12.08 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.99 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.745 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -103.24 130.16 50.4 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.976 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -106.16 174.52 5.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.944 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -48.65 139.97 8.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.935 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.66 -23.59 32.26 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.999 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.3 m -80.17 151.92 29.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.973 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.1 p -127.11 130.2 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.979 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.783 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 15.4 m -95.87 170.66 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.995 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.823 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.59 148.8 40.58 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.735 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -143.3 106.09 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.971 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.868 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.04 115.76 24.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.482 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.35 142.12 19.42 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.723 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.91 112.53 9.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.964 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.523 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 101.53 25.7 8.04 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -180.0 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.068 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -91.26 -163.8 1.09 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -89.25 125.21 34.99 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.423 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.97 133.86 44.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.66 8.57 84.4 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.691 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -98.83 134.57 41.52 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.995 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.931 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.47 152.24 25.05 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.535 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 38.0 m-85 -138.51 145.25 40.53 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.928 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -110.15 122.45 47.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.924 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.228 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.2 t -102.19 150.17 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.997 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.98 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.88 146.66 9.2 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.943 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.806 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 14.4 tt0 -92.58 115.86 28.48 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -103.13 163.78 12.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.951 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 1.17 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -149.16 131.42 15.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.96 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.542 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.0 OUTLIER -67.32 124.57 23.51 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.987 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.715 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.3 m -111.39 -41.64 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.974 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.532 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -146.1 -178.8 6.32 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.964 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.647 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.3 t -65.1 111.6 2.98 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.986 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 7.92 62.73 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.988 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.625 ' O ' HG23 ' A' ' 40' ' ' VAL . 45.9 t -111.02 105.2 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.694 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.3 mt -107.98 153.29 23.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.483 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -128.15 128.63 45.18 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.966 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -106.87 154.81 20.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.479 ' OD1' ' HB1' ' A' ' 50' ' ' ALA . 13.7 t30 -116.15 112.53 41.94 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -179.982 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -72.33 -0.35 8.55 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.308 3.338 . . . . 0.0 109.616 179.839 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.479 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -91.83 -12.26 34.2 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.832 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.455 ' HB2' ' CG2' ' A' ' 68' ' ' THR . 23.6 p30 -130.82 27.34 4.93 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.63 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -103.35 116.14 31.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.977 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 54' ' ' SER . 30.2 t -100.56 -173.22 2.35 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.984 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.442 ' N ' ' OG ' ' A' ' 53' ' ' SER . 4.7 p -147.14 154.08 40.67 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.85 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -167.06 154.44 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 58.7 m -123.8 122.73 38.8 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.954 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -52.79 149.75 5.95 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -92.27 -171.44 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.955 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.27 -25.06 67.64 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -81.35 -5.0 57.39 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 72.58 23.66 77.53 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 82.4 p -114.42 138.06 51.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.996 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.61 163.02 19.63 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.997 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -150.94 120.0 6.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.86 158.08 43.9 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.892 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.614 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -110.4 126.35 54.19 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.985 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.119 ' CG ' HG22 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -107.58 118.24 36.2 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.965 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.637 ' N ' HD11 ' A' ' 67' ' ' LEU . 4.7 t -69.0 149.73 48.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.922 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.522 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -106.46 123.93 61.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.967 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.522 ' HD2' ' O ' ' A' ' 69' ' ' VAL . 1.5 mpt_? -116.58 137.09 52.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.971 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.477 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 26.0 ptt180 -75.26 -18.34 60.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HB2' ' OD1' ' A' ' 87' ' ' ASP . 9.7 t -163.82 151.57 12.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.911 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.806 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -177.8 155.7 1.04 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.885 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -55.93 122.63 12.01 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.931 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.483 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.54 89.46 1.03 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.966 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.45 10.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.989 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.745 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.6 tp -54.25 141.74 28.56 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.728 ' N ' HD13 ' A' ' 77' ' ' LEU . 4.0 m-85 -47.1 -42.37 18.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.978 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.745 ' HB3' HD23 ' A' ' 77' ' ' LEU . 12.2 t0 -57.05 -17.06 8.71 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.959 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.82 28.16 9.71 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.934 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 3.0 m -108.78 131.16 55.23 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttt180 -72.94 91.62 1.56 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.944 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.532 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 0.5 OUTLIER -61.96 -57.0 13.37 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.884 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.41 170.2 21.31 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 179.982 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.47 142.22 33.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 1.17 HG12 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -117.91 154.11 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.973 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.512 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 10.0 m-20 -128.73 95.0 3.99 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.965 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 1.219 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 99.1 m -54.31 -25.63 24.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.977 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -80.45 1.87 27.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.978 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -113.83 -27.39 7.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.969 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.07 -170.55 2.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.983 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.89 126.52 42.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.92 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.354 ' C ' HG13 ' A' ' 110' ' ' ILE . 11.9 m -104.68 152.84 22.01 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.084 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.8 148.09 31.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.92 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.119 HG22 ' CG ' ' A' ' 67' ' ' LEU . 24.1 t -99.72 164.86 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.952 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.013 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.81 158.03 24.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.535 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -134.9 152.9 52.14 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.974 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER -141.32 158.47 43.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.903 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.931 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -105.28 -163.13 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.967 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.51 -49.34 77.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.941 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.79 -25.44 61.16 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.947 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.07 42.38 2.43 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.95 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.634 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -119.51 176.12 5.51 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.963 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.19 -173.22 22.81 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.994 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.162 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.38 133.35 20.72 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.345 3.363 . . . . 0.0 109.641 179.92 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.15 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 2.3 tt0 -136.1 145.74 46.24 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 57.36 0.23 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.964 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.02 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 25.5 t -131.58 100.94 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.978 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.646 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -97.57 155.22 17.06 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.996 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.354 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -124.29 163.49 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.949 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.532 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -153.61 122.47 6.41 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.959 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.219 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 10.0 m-85 -87.6 116.32 25.65 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 179.902 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 1.081 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 4.4 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.966 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.874 ' HA ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.084 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -174.05 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.347 3.365 . . . . 0.0 109.579 179.964 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.648 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.03 109.48 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.939 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.781 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.73 141.74 49.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.937 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.576 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -96.72 111.44 23.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 1.048 HG21 HG22 ' A' ' 108' ' ' VAL . 21.9 t -107.66 148.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.973 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -68.48 177.63 1.04 Allowed Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.973 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.38 117.97 5.38 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 124.32 3.346 . . . . 0.0 109.607 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.983 ' HB2' HG22 ' A' ' 110' ' ' ILE . 9.3 p -115.11 44.58 1.78 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.957 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.4 m -122.91 105.11 9.71 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.88 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.637 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 91.88 28.1 14.8 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.716 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -97.69 132.69 43.1 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.8 m -107.19 172.93 6.55 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.956 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.65 140.05 15.15 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.39 -22.99 35.67 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.3 m -74.59 153.11 39.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.408 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 7.1 p -129.96 126.1 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.606 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 26.3 m -94.57 176.65 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.98 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.823 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.35 149.28 45.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.944 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.628 HG12 HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -145.11 108.03 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.781 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.27 116.78 23.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.456 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -84.39 144.34 21.48 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.648 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -140.67 112.6 7.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.933 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.574 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 105.22 21.75 8.69 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.957 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -91.29 -163.91 1.1 Allowed 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -89.94 126.43 35.73 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.496 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -69.61 141.59 53.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.978 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.69 7.72 59.03 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.96 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.753 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.57 143.05 26.73 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.548 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.22 148.84 21.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.984 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.007 ' OH ' ' NE2' ' A' ' 27' ' ' GLN . 49.4 m-85 -137.85 148.55 45.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.175 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.7 m-20 -112.38 114.57 27.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.964 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.044 HG23 ' HB3' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -96.18 146.43 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.978 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.887 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.5 167.88 40.97 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.953 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.813 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 8.2 tt0 -115.97 113.38 23.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 1.047 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -114.3 149.05 36.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.971 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.497 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -124.66 134.91 52.72 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.928 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.663 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 120.56 13.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.95 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.507 HG22 ' CD1' ' A' ' 83' ' ' TRP . 24.8 m -101.07 -44.95 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.982 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.865 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.6 OUTLIER -133.36 172.36 12.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 t -56.47 111.44 0.99 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.92 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.88 7.53 62.21 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.003 HG11 ' NE1' ' A' ' 83' ' ' TRP . 21.6 t -120.68 111.08 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.951 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.6 HD11 ' HB2' ' A' ' 37' ' ' CYS . 1.1 pt? -123.43 140.97 52.47 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.297 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.33 146.03 26.09 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.047 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 12.1 m -106.48 153.97 21.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.752 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.0 t30 -114.52 109.82 47.92 Favored Pre-proline 0 N--CA 1.45 -0.468 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.4 -0.35 8.58 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.293 3.328 . . . . 0.0 109.585 179.914 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.458 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.65 -16.57 32.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.876 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 13.7 p30 -128.24 28.44 5.49 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.878 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.47 118.95 36.29 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.97 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -111.43 -172.84 2.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.965 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -146.7 157.66 43.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.888 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' N ' ' A' ' 56' ' ' THR . 4.5 p -166.75 159.53 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.436 ' N ' HG22 ' A' ' 55' ' ' VAL . 14.0 m -127.1 137.5 53.02 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.985 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.83 131.44 39.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -73.75 -173.43 1.51 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.26 -20.42 62.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -85.98 10.09 15.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 56.79 26.78 54.77 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.946 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 t -121.21 133.54 55.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.44 156.75 32.06 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.989 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -139.02 133.69 32.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.597 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.93 170.34 19.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.942 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.597 ' N ' HG21 ' A' ' 65' ' ' THR . 0.7 OUTLIER -121.01 138.39 54.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.939 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.074 ' HG ' HG23 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -115.77 118.81 34.07 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.943 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.719 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -71.1 135.89 47.93 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.552 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -92.67 125.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.971 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.719 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 1.1 mpt_? -117.8 140.63 49.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.416 ' O ' ' OG ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -82.72 -15.84 50.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 58.4 m -167.33 152.13 7.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.979 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.813 ' HE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -176.55 161.86 2.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.929 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.54 110.58 1.74 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.94 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.297 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -69.97 94.21 0.44 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.958 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.867 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.5 m-85 -82.88 98.78 9.36 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.956 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.79 HD23 ' HB2' ' A' ' 79' ' ' ASP . 3.6 tp -55.49 142.28 33.62 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.982 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.735 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.67 -42.91 25.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.79 ' HB2' HD23 ' A' ' 77' ' ' LEU . 4.0 m-20 -57.75 -16.76 12.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.78 27.73 12.25 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.985 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.9 m -106.08 134.07 49.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.97 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.48 91.64 0.78 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.507 ' CD1' HG22 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.76 -48.82 77.51 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.878 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.63 167.13 10.94 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -65.43 103.59 0.85 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.963 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.575 HG13 HG12 ' A' ' 40' ' ' VAL . 3.4 m -78.61 151.81 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.981 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 90' ' ' THR . 5.8 m-20 -110.48 93.85 4.71 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.78 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 13.7 m -51.29 -26.26 7.09 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.7 p -81.06 0.79 34.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 -179.999 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.453 ' N ' ' O ' ' A' ' 87' ' ' ASP . 1.3 m -117.3 -27.62 6.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.51 -179.9 5.43 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.34 123.77 40.1 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.308 ' C ' HG13 ' A' ' 110' ' ' ILE . 89.1 m -104.59 155.66 18.65 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -180.0 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.043 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 1.2 pt20 -144.56 147.49 33.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.944 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.074 HG23 ' HG ' ' A' ' 67' ' ' LEU . 14.2 t -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.944 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.08 160.05 28.71 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.044 ' HB3' HG23 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -128.35 155.29 44.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.954 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.175 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -143.45 144.23 31.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.898 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.548 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -90.97 -161.78 0.85 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.457 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.69 -49.29 78.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.13 -24.79 62.34 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.93 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.83 42.5 2.45 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.994 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.438 ' ND2' ' CG ' ' A' ' 99' ' ' ASP . 0.5 OUTLIER -121.07 177.16 5.24 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.99 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.92 -173.65 22.28 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.084 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.35 133.85 21.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.364 3.376 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.874 ' HG3' ' HA ' ' A' ' 2' ' ' ALA . 1.8 pt-20 -139.8 161.53 37.34 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.79 51.71 0.6 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.925 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.048 HG22 HG21 ' A' ' 7' ' ' VAL . 4.0 t -126.44 101.82 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.996 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.09 146.83 24.32 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.955 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.308 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -115.78 159.71 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.907 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -151.0 126.73 10.25 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.909 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.78 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 8.3 m-85 -101.48 124.93 47.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.932 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.566 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 49.2 m-80 . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.961 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.651 ' C ' ' HB3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.386 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.38 -174.13 1.34 Allowed 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.286 3.324 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.162 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.4 t -95.93 109.73 22.05 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.827 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.99 145.7 50.89 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.444 ' OG1' ' HB1' ' A' ' 22' ' ' ALA . 1.3 p -103.9 113.37 26.85 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 38.5 t -110.66 148.53 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.996 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.15 175.94 1.59 Allowed Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.945 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.952 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 120.95 7.07 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.351 3.367 . . . . 0.0 109.63 179.851 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.772 ' OG ' HG21 ' A' ' 110' ' ' ILE . 30.8 p -120.83 52.48 1.18 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.599 ' HA ' ' O ' ' A' ' 111' ' ' SER . 62.0 p -137.81 106.14 5.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.9 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.68 8.47 40.01 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.9 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.759 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 3.5 pp -114.68 143.08 45.61 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -122.47 -166.99 1.49 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.936 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.943 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 42.7 t0 -43.32 151.73 0.15 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.969 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 92.02 -23.38 26.86 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.998 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.628 HG21 ' N ' ' A' ' 18' ' ' VAL . 3.7 m -85.08 146.05 27.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.628 ' N ' HG21 ' A' ' 17' ' ' THR . 14.8 p -116.21 129.52 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.688 HG11 HG23 ' A' ' 69' ' ' VAL . 6.0 m -99.75 159.4 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.751 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 145.42 41.37 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.969 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.659 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -142.06 110.16 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.989 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.827 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.89 112.91 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.979 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.517 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -84.92 144.77 21.25 Favored Glycine 0 C--N 1.334 0.468 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.162 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -142.86 110.13 5.68 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.955 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.575 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 107.89 14.92 15.95 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.044 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -91.04 165.94 13.26 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.549 ' N ' ' HH ' ' A' ' 32' ' ' TYR . 34.9 mt-30 -48.99 121.26 4.58 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.96 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.608 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.69 134.93 45.28 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.945 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 8.2 76.32 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.981 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.837 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -97.7 137.41 36.63 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.995 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.12 151.97 24.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.998 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.546 ' CB ' HD23 ' A' ' 97' ' ' LEU . 73.0 m-85 -135.77 158.2 44.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.925 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.451 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 17.1 m-20 -119.71 117.93 29.55 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.948 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.212 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.42 138.13 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.958 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 1.165 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -158.91 162.88 32.91 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.839 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 1.8 tt0 -115.13 121.62 43.59 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.915 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 93' ' ' CYS . 66.9 m -108.59 172.7 6.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.976 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.842 ' CB ' HG13 ' A' ' 86' ' ' VAL . . . -152.84 124.34 7.71 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.943 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.598 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 124.25 21.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.947 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.677 ' CG1' HG23 ' A' ' 86' ' ' VAL . 12.1 m -104.43 -43.7 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.952 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.702 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.88 164.13 30.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.6 m -53.33 114.06 1.36 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.944 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.6 7.92 70.4 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.5 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 15.0 t -126.44 105.76 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.953 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.84 162.65 17.76 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.197 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.18 146.96 49.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.822 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.4 m -108.35 155.95 19.96 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.828 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 33.6 t30 -114.59 105.64 53.3 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.443 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.287 3.325 . . . . 0.0 109.609 179.885 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.5 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -88.44 -12.94 41.67 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.878 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.9 p30 -126.71 28.51 5.87 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.72 104.57 13.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.997 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.1 t -101.65 177.26 4.96 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.923 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 p -146.44 153.08 40.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.852 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.532 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -167.37 153.04 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.532 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.1 m -122.58 139.62 53.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.947 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.0 142.86 32.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.917 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -80.02 -170.73 2.59 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -22.08 66.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.961 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.92 4.75 21.36 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.608 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.32 31.01 72.44 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.921 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.8 t -125.05 132.28 53.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.94 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.12 164.07 17.43 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.979 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -146.74 135.64 22.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.627 HG22 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.05 165.35 17.93 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.913 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.627 ' N ' HG22 ' A' ' 65' ' ' THR . 0.4 OUTLIER -122.34 126.06 47.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.939 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.125 HD11 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.83 155.34 16.82 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.441 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 5.0 t -103.7 119.29 38.62 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.946 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.688 HG23 HG11 ' A' ' 19' ' ' VAL . 2.1 t -84.35 128.4 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.943 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.6 OUTLIER -119.1 156.82 29.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HB2' HG23 ' A' ' 89' ' ' THR . 0.2 OUTLIER -90.93 -24.98 20.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.923 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.408 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -156.47 148.35 22.94 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.946 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.839 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.8 p90 -174.41 153.42 1.91 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.935 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -54.29 115.13 1.92 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.197 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.49 100.64 0.83 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.986 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.822 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -83.41 99.95 10.39 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.988 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.776 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.2 tp -58.61 130.94 49.25 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.539 ' N ' HD12 ' A' ' 77' ' ' LEU . 14.1 p90 -47.65 -35.75 9.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.776 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.96 -16.35 12.06 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.19 27.68 9.88 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.986 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.511 HG22 ' N ' ' A' ' 82' ' ' ARG . 2.3 m -115.36 151.65 34.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.511 ' N ' HG22 ' A' ' 81' ' ' THR . 0.0 OUTLIER -89.45 97.86 11.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.5 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.43 -55.9 20.57 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.883 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.56 172.67 17.09 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.26 108.25 0.45 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.978 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.842 HG13 ' CB ' ' A' ' 38' ' ' ALA . 86.4 t -86.05 147.43 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.485 ' N ' HG11 ' A' ' 86' ' ' VAL . 48.1 m-20 -108.09 90.87 3.43 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.963 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.428 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -53.06 -25.24 12.03 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.443 HG23 ' HB2' ' A' ' 71' ' ' ARG . 61.0 p -78.01 -3.33 41.5 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.78 -26.07 7.54 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.46 -179.89 4.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.962 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.26 136.97 36.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.899 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.463 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.69 166.05 10.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.998 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.335 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -169.52 127.9 0.96 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.911 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.165 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.9 t -92.41 164.28 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.212 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -170.22 164.83 38.16 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.546 HD23 ' CB ' ' A' ' 32' ' ' TYR . 4.3 mp -100.33 160.93 13.94 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.451 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 14.6 m -155.0 117.44 4.26 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.591 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 3.2 p-10 -112.11 -158.15 0.64 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.958 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.13 -39.49 59.99 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -26.89 19.6 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.77 53.52 2.23 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.591 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -106.68 -174.7 2.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.994 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.431 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 171.01 175.58 39.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.386 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.9 Cg_endo -72.33 160.63 46.54 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.32 3.347 . . . . 0.0 109.581 179.948 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.281 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -33.84 126.63 0.42 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.991 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.462 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.76 135.75 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.335 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 25.3 t -119.05 102.88 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.956 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.93 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.7 158.22 19.48 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.969 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.887 HG13 ' HA ' ' A' ' 94' ' ' GLN . 35.2 mt -125.98 162.49 29.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.986 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.599 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -141.07 121.39 13.95 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.903 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.463 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 2.9 m-85 -97.72 122.21 40.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.943 . . . . . . . . 0 0 . 1 . 046 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 1.231 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.561 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.4 Cg_endo -72.38 -174.3 1.39 Allowed 'Trans proline' 0 N--CA 1.446 -1.272 0 C-N-CA 124.337 3.358 . . . . 0.0 109.634 179.886 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.282 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.6 t -95.97 111.42 23.43 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.957 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.789 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.57 140.13 50.45 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.508 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -102.25 111.27 23.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.985 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.22 155.05 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.981 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.969 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.43 177.02 1.02 Allowed Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.929 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.969 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.2 Cg_endo -72.39 117.86 5.33 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.316 3.344 . . . . 0.0 109.605 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.711 ' OG ' HG22 ' A' ' 110' ' ' ILE . 22.6 p -114.31 41.39 2.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.963 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 111' ' ' SER . 60.4 p -123.41 105.97 10.26 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.928 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.639 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.68 26.38 15.29 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.976 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.744 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -97.93 132.49 43.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.958 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.2 m -90.79 151.8 21.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.938 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -44.09 137.84 3.19 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.93 -20.9 37.43 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.984 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.9 m -64.78 147.46 53.13 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.995 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 9.7 p -110.58 117.78 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.972 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 67' ' ' LEU . 14.8 m -95.48 164.75 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.615 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.16 153.33 29.75 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.947 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.681 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -149.39 113.48 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.982 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.789 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.25 114.5 21.47 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.555 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.28 147.69 23.61 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.282 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -147.48 109.85 4.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.933 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.562 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 107.67 14.0 18.86 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.025 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -90.49 165.8 13.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' N ' ' HH ' ' A' ' 32' ' ' TYR . 35.5 mt-30 -50.91 118.99 3.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.852 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.05 134.99 46.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.971 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.25 8.73 80.05 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.916 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.739 HG21 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 142.69 29.41 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.975 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.574 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.03 153.21 22.3 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.055 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 59.2 m-85 -138.29 150.88 47.07 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.919 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.509 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.2 m-20 -116.87 114.86 24.47 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.492 ' CG2' ' HG ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.52 139.94 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.956 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.76 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.92 156.92 28.17 Favored Glycine 0 C--N 1.335 0.489 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.702 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 52.8 tt0 -96.33 113.54 25.14 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -102.17 159.5 15.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 -179.977 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.781 ' HB1' HG22 ' A' ' 86' ' ' VAL . . . -149.2 141.45 24.07 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.905 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.549 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.2 t90 -63.6 121.65 14.42 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -109.53 -36.37 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 1.016 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -155.24 -175.81 5.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 7.2 t -73.56 110.55 7.93 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.88 12.75 83.71 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 1.636 HG21 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -128.9 121.15 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.985 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -113.78 162.2 16.59 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.989 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.463 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -132.14 130.91 41.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.758 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.65 155.23 20.39 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.751 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.2 p-10 -118.69 120.1 31.98 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.955 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.34 1.66 5.88 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.298 3.332 . . . . 0.0 109.627 179.879 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.33 -24.79 29.63 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.874 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -123.39 30.98 6.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.932 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.14 117.71 34.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 -179.973 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.2 t -110.86 -177.95 3.35 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.7 p -148.46 153.79 38.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.437 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.1 p -167.63 161.65 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.901 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.437 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 52.4 m -126.53 131.76 51.51 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 153.19 44.25 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 -179.999 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.3 p-10 -90.38 -166.42 1.58 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.937 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -30.23 71.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.885 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.39 -9.55 58.7 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.852 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.48 15.99 80.82 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.983 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.5 p -104.57 138.3 41.13 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.951 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.96 166.65 13.54 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 m -150.92 117.34 5.7 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.568 HG22 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -146.83 157.9 43.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.948 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.568 ' N ' HG22 ' A' ' 65' ' ' THR . 0.2 OUTLIER -110.76 125.22 53.31 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.899 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.298 ' CD1' HG22 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -104.65 155.3 18.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.967 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.431 ' H ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -116.74 142.81 46.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -110.48 125.13 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.623 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -110.14 159.91 16.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.976 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.67 -29.39 59.05 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 69.6 p -165.28 156.96 14.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.751 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 3.1 p90 -175.28 167.35 3.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -63.97 118.82 9.0 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.947 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.463 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -75.01 85.3 0.79 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.758 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.05 98.63 9.39 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.8 tp -54.71 134.7 47.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.546 ' N ' HD13 ' A' ' 77' ' ' LEU . 27.2 p90 -45.63 -38.43 6.65 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.999 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.744 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.3 t70 -57.66 -17.14 13.12 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.943 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.88 28.7 9.18 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.988 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 2.9 m -112.65 115.91 29.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.948 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -66.03 93.36 0.2 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.636 ' CE2' HG21 ' A' ' 44' ' ' VAL . 2.3 t-105 -63.44 -57.98 8.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.925 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.35 171.38 19.88 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.967 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.48 140.67 56.02 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.781 HG22 ' HB1' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.61 151.6 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.524 ' N ' HG21 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -110.56 100.78 9.53 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.977 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.899 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 23.8 m -53.5 -26.0 18.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.979 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -82.5 -1.7 51.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.979 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.579 ' O ' HG23 ' A' ' 90' ' ' THR . 2.2 m -115.48 -27.99 6.98 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.919 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.515 ' HB3' ' HB3' ' A' ' 39' ' ' TRP . . . -125.4 -175.15 3.24 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.39 124.57 41.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.899 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.194 ' O ' HG13 ' A' ' 110' ' ' ILE . 1.7 m -104.66 153.65 20.97 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.141 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -158.5 144.92 17.22 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.959 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.298 HG22 ' CD1' ' A' ' 67' ' ' LEU . 25.4 t -101.41 162.38 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.257 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.81 164.25 35.63 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.492 ' HG ' ' CG2' ' A' ' 34' ' ' VAL . 4.5 mp -101.72 160.95 14.02 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -180.0 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.509 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 3.3 p -153.47 119.48 5.39 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.574 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 13.4 p-10 -115.11 -167.11 1.19 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -50.74 -21.15 1.49 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.875 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.18 -24.59 13.14 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.931 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 85.69 22.52 49.92 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 1.055 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.8 -151.17 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.987 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.06 153.73 6.11 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.975 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.561 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.4 Cg_endo -72.44 161.49 44.1 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.316 3.344 . . . . 0.0 109.6 179.985 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 1.231 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -32.75 123.91 0.35 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.936 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.896 ' H ' ' HB3' ' A' ' 2' ' ' ALA . . . -36.03 134.93 0.6 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.141 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.77 102.45 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.471 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -85.58 141.1 30.08 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.194 HG13 ' O ' ' A' ' 93' ' ' CYS . 1.0 OUTLIER -109.48 167.39 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.949 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -150.52 123.49 8.74 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.962 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 19.7 m-85 -99.6 126.19 45.55 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.903 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.993 . . . . . . . . 0 0 . 1 . 047 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.879 ' HB3' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 . . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 1.21 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.4 -177.83 2.96 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.266 3.311 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 1.142 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.8 114.45 28.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.98 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.892 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.37 131.85 50.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.712 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.03 112.07 23.81 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.975 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.827 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -113.08 149.69 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.926 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.995 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.14 179.87 0.65 Allowed Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.923 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.995 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.6 Cg_endo -72.42 121.0 7.09 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.321 3.348 . . . . 0.0 109.538 179.947 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.743 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -110.48 3.73 19.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.986 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 1.398 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 66.1 m -110.36 126.11 53.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.901 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.445 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 103.71 5.29 45.13 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.937 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.835 HD13 HG23 ' A' ' 69' ' ' VAL . 2.1 pp -114.32 146.58 40.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 88.4 p -99.0 171.5 8.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -45.37 151.82 0.34 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 179.969 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.79 -22.36 34.2 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.968 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.437 HG22 HD23 ' A' ' 13' ' ' LEU . 59.0 m -69.31 138.53 53.88 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.993 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -104.11 132.42 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.634 ' HA ' HG23 ' A' ' 8' ' ' THR . 21.5 t -104.12 168.41 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.979 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.827 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.78 134.87 53.57 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.945 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 2.2 p -128.08 104.86 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.892 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -111.39 115.23 28.91 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.692 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.61 145.62 21.99 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 1.142 ' O ' HG22 ' A' ' 4' ' ' THR . . . -146.2 112.27 5.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.15 26.18 8.48 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.961 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 1.152 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.83 -165.81 1.44 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.953 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.924 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 2.7 mp0 -94.35 124.83 38.61 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.1 137.45 57.98 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.4 8.66 63.01 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.304 -1.119 . . . . 0.0 110.304 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.789 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -91.69 142.71 27.31 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.993 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.761 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.13 150.5 21.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.983 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 1.102 ' CG ' ' HD2' ' A' ' 105' ' ' PRO . 56.9 m-85 -139.3 144.51 38.35 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.908 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 1.341 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.2 m-20 -105.57 114.76 29.13 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 1.29 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.47 150.88 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.983 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.755 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.87 168.4 38.56 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.98 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.884 ' CD ' ' HE2' ' A' ' 73' ' ' PHE . 11.6 tt0 -111.29 120.96 43.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 88.9 m -109.95 169.1 8.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.974 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.974 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -153.68 125.13 7.56 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.481 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.57 129.85 41.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.903 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 1.639 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.4 m -109.33 -37.81 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.408 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -146.82 163.69 35.23 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.958 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -53.19 114.89 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.56 1.93 62.63 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.582 ' O ' HG22 ' A' ' 40' ' ' VAL . 15.9 t -121.02 119.64 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.631 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 pp -126.75 162.22 26.32 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 1.261 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -124.24 139.67 53.7 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 1.031 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 24.1 m -109.18 151.83 25.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.523 ' ND2' ' OD2' ' A' ' 51' ' ' ASP . 16.9 t30 -112.77 110.74 51.9 Favored Pre-proline 0 N--CA 1.448 -0.552 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.977 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 124.341 3.361 . . . . 0.0 109.596 179.936 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.421 ' N ' ' OD1' ' A' ' 48' ' ' ASN . . . -90.05 -20.54 23.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.909 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.581 ' HB3' ' NH1' ' A' ' 70' ' ' ARG . 8.5 p30 -119.38 19.93 12.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.671 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -92.35 113.57 25.87 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.7 t -108.0 -174.28 2.48 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -146.28 155.9 42.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.915 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 p -166.88 158.13 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.941 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 86.5 m -127.78 129.42 46.99 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 135.57 55.62 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 p30 -76.66 -175.19 3.27 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.941 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.66 -19.96 64.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -87.34 10.3 17.73 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.813 ' O ' HD11 ' A' ' 26' ' ' LEU . . . 56.87 30.35 59.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.6 t -124.82 135.98 53.42 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.964 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.35 164.63 19.97 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.0 m -152.41 119.48 5.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.983 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.569 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.17 164.14 34.07 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.865 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.569 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -106.68 133.74 50.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.943 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 1.401 ' CG ' HG21 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -119.59 120.2 36.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.916 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.97 145.04 28.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.989 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.835 HG23 HD13 ' A' ' 13' ' ' LEU . 0.2 OUTLIER -121.51 134.56 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.659 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.92 174.94 5.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.988 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.62 ' HG2' ' CG2' ' A' ' 89' ' ' THR . 6.5 mtt180 -98.68 -12.19 21.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.948 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 20.3 p -173.68 145.95 1.24 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.884 ' HE2' ' CD ' ' A' ' 36' ' ' GLN . 1.2 p90 -171.6 163.25 6.61 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.922 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.14 118.02 3.99 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.943 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 1.261 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -78.74 96.08 1.4 Allowed Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 1.031 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.14 100.64 11.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.772 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.6 tp -56.21 130.64 45.19 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.972 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.624 ' N ' HD13 ' A' ' 77' ' ' LEU . 3.1 p90 -47.42 -35.36 8.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.998 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.772 ' HB3' HD23 ' A' ' 77' ' ' LEU . 6.1 t0 -57.49 -17.55 14.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.4 27.92 8.34 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.638 HG21 ' N ' ' A' ' 82' ' ' ARG . 18.5 m -116.88 148.09 41.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.96 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.638 ' N ' HG21 ' A' ' 81' ' ' THR . 2.3 mtm180 -85.46 96.34 9.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.97 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 1.639 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 72.6 t90 -64.35 -58.05 7.6 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.859 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.42 170.79 16.65 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.987 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.52 0.4 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.974 HG22 ' CB ' ' A' ' 38' ' ' ALA . 2.5 p -86.3 143.1 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.981 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.72 96.43 8.6 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.954 ' O ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -55.35 -20.01 10.52 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.947 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.62 ' CG2' ' HG2' ' A' ' 71' ' ' ARG . 33.5 p -88.94 1.4 55.5 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 m -114.16 -27.44 7.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.978 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.31 179.42 4.91 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.975 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.45 123.14 41.2 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.907 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 1.559 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -104.71 157.71 17.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 1.121 ' N ' HG13 ' A' ' 110' ' ' ILE . 1.3 pt20 -156.19 144.67 20.02 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.975 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.401 HG21 ' CG ' ' A' ' 67' ' ' LEU . 11.9 t -93.58 156.98 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 1.23 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -172.54 165.91 38.51 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.294 -1.123 . . . . 0.0 110.294 179.997 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 1.29 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -136.52 143.44 43.74 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 1.341 ' N ' ' H ' ' A' ' 33' ' ' ASP . 3.5 m -133.52 147.59 51.62 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.95 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . 0.761 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -93.49 -167.01 1.62 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.974 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.08 -50.13 74.53 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -68.76 -24.66 64.47 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.928 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.98 40.53 2.84 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.98 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.414 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -121.89 -178.62 3.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.985 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.64 -174.95 20.8 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.958 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 1.21 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.8 Cg_endo -72.43 134.55 22.77 Favored 'Trans proline' 0 N--CA 1.446 -1.271 0 C-N-CA 124.318 3.345 . . . . 0.0 109.612 179.935 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.879 ' HG3' ' HB3' ' A' ' 2' ' ' ALA . 3.1 pt-20 -137.99 141.54 40.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.904 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 136.27 57.67 0.06 OUTLIER Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.967 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 1.093 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.0 t -134.27 102.73 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.992 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.596 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -96.94 153.6 17.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.944 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 1.559 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.0 OUTLIER -117.94 163.76 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.89 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 1.398 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -162.24 131.0 4.21 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.973 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 1.032 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -108.35 120.07 41.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . 0.445 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.1 t-20 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.463 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.622 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . -99.31 129.64 28.81 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.633 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.32 -178.76 3.49 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.298 3.332 . . . . 0.0 109.635 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.95 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.08 113.64 26.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 1.02 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.96 136.11 51.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.55 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.54 115.41 29.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.756 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -113.71 147.39 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.762 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.32 167.43 21.82 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.762 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.38 118.52 5.64 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.294 3.329 . . . . 0.0 109.631 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.698 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.59 13.86 7.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 111' ' ' SER . 47.3 p -89.86 115.08 26.92 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.99 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 90.11 20.59 41.89 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.698 HD12 ' HA ' ' A' ' 10' ' ' SER . 1.0 OUTLIER -106.98 134.12 50.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.52 173.21 9.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -45.05 152.2 0.27 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.19 -23.6 32.69 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.673 HG23 ' N ' ' A' ' 18' ' ' VAL . 3.0 m -66.5 150.41 49.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.673 ' N ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -120.91 122.59 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.785 HG13 ' O ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -105.35 119.35 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.756 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -79.78 149.85 30.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.69 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -142.37 109.7 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 1.02 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.62 116.96 26.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.712 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.32 144.93 21.0 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.95 ' O ' HG23 ' A' ' 4' ' ' THR . . . -144.81 110.07 5.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.39 15.07 24.22 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.884 HD22 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.22 166.09 13.56 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.461 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.5 mt-30 -50.2 121.64 5.81 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.518 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.57 131.35 41.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 7.67 85.21 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.6 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.85 146.21 23.81 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.623 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.25 151.39 22.16 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.65 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.2 m-85 -138.39 147.48 43.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -114.02 113.21 24.47 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.269 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -96.88 147.71 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.78 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.03 163.23 36.61 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.906 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.3 tt0 -106.25 112.4 25.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.199 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.4 m -113.53 146.51 39.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.144 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.42 128.97 50.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.593 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.51 120.94 13.79 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.383 HG22 ' CD1' ' A' ' 83' ' ' TRP . 2.7 m -101.2 -43.45 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.97 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -139.23 179.21 6.66 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 47.1 m -62.38 112.75 2.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.33 7.43 63.71 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.59 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 81.2 t -122.33 109.19 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.554 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 1.0 OUTLIER -125.0 137.26 54.25 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.137 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -87.61 156.21 19.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.199 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.9 m -121.72 151.27 40.7 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.662 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 32.9 t30 -119.2 111.63 36.69 Favored Pre-proline 0 N--CA 1.448 -0.542 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -72.44 -0.65 9.05 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.289 3.326 . . . . 0.0 109.578 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.471 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -87.04 -13.67 43.74 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.516 ' HB3' ' CG2' ' A' ' 68' ' ' THR . 3.8 m-20 -130.37 27.56 5.04 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.684 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -96.7 115.82 28.08 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.4 t -109.23 -177.76 3.38 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.3 p -147.37 153.91 40.24 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.456 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.59 162.85 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.456 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 16.6 m -128.11 138.8 52.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.91 36.22 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 42.2 p30 -80.61 -173.26 4.04 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.94 -24.92 68.1 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -74.93 -8.49 56.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.721 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 73.9 31.61 59.86 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -128.26 139.33 52.5 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.85 167.75 16.9 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 84.1 p -150.49 127.01 10.8 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.611 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.71 163.31 38.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.864 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.611 ' N ' HG21 ' A' ' 65' ' ' THR . 0.1 OUTLIER -112.7 130.73 55.95 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.994 ' HG ' HG23 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.54 125.43 51.81 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.568 ' N ' HD12 ' A' ' 67' ' ' LEU . 5.2 t -81.52 129.45 34.67 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.516 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -90.69 128.22 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.516 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.4 OUTLIER -119.42 141.81 48.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.987 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -69.88 -34.19 73.22 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 51.5 p -164.63 159.85 19.44 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.906 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -178.03 172.24 1.64 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -62.72 119.37 9.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.137 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -78.86 91.63 1.21 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.912 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.5 99.65 10.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.741 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.8 tp -57.4 132.27 52.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 3.7 m-85 -46.95 -37.05 8.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.741 ' HB3' HD23 ' A' ' 77' ' ' LEU . 5.7 t0 -57.6 -16.89 11.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.72 27.97 9.25 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 22.1 m -113.81 147.48 38.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -86.34 94.37 9.34 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.59 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -64.06 -57.93 8.17 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.4 164.33 11.36 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 108.97 0.66 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.144 HG11 ' CB ' ' A' ' 38' ' ' ALA . 5.7 t -85.55 152.0 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -115.19 93.74 4.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.964 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 4.9 m -53.9 -24.86 17.5 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.7 p -81.73 2.26 30.66 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -115.92 -27.18 7.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.12 -178.91 5.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.658 ' HA ' ' HG ' ' A' ' 111' ' ' SER . . . -98.3 126.3 43.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.278 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 28.9 m -105.2 171.54 7.27 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.184 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.1 OUTLIER -154.05 147.39 24.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.994 HG23 ' HG ' ' A' ' 67' ' ' LEU . 8.8 t -103.87 165.28 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.269 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.79 166.32 35.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.149 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.14 133.04 43.81 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 13.5 m -116.11 145.2 43.23 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.623 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -99.93 -158.04 0.65 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.62 -48.66 76.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.49 -25.46 62.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 43.34 2.89 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.447 HD22 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -114.05 161.49 17.65 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.65 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -168.75 170.46 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.633 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.37 166.04 30.94 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.373 3.382 . . . . 0.0 109.577 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.622 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 5.2 mt-10 -36.62 118.1 0.54 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.92 156.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.184 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 5.6 t -106.15 102.16 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.15 116.99 20.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.278 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.3 pt -129.95 -177.5 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.658 ' HG ' ' HA ' ' A' ' 92' ' ' ALA . 0.4 OUTLIER -169.55 173.95 6.15 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.964 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 8.2 m-85 -129.42 110.32 11.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.99 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.9 p30 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.524 ' HB2' ' CG ' ' A' ' 106' ' ' GLU . . . -145.89 119.07 5.23 Favored Pre-proline 0 N--CA 1.45 -0.457 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.614 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.0 Cg_endo -72.4 -177.78 2.93 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.292 3.328 . . . . 0.0 109.566 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.844 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.1 110.34 22.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.897 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.13 135.77 50.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -97.95 113.02 24.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.826 HG13 HG21 ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.58 154.57 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.916 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.11 174.4 2.44 Favored Pre-proline 0 N--CA 1.45 -0.463 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.941 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.916 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.8 Cg_endo -72.39 119.44 6.13 Favored 'Trans proline' 0 N--CA 1.447 -1.233 0 C-N-CA 124.334 3.356 . . . . 0.0 109.569 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.782 ' HB2' HG22 ' A' ' 110' ' ' ILE . 96.1 p -111.4 48.34 0.95 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -129.39 106.01 8.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.715 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.17 31.37 9.81 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.715 HD22 ' C ' ' A' ' 12' ' ' GLY . 0.8 OUTLIER -104.44 131.48 51.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -108.79 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -48.66 142.08 6.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.435 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 101.34 -22.58 38.48 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.6 m -77.69 151.21 34.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 18' ' ' VAL . 11.7 p -119.67 132.37 69.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.509 HG13 HG21 ' A' ' 8' ' ' THR . 20.9 t -95.66 155.38 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.775 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.02 144.49 42.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.7 110.9 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.897 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.54 116.5 25.51 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.499 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -83.08 146.6 24.1 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.844 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.85 110.8 4.34 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 101.57 14.63 29.38 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.85 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.87 179.32 6.01 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.898 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 25.1 mt-30 -60.87 121.38 12.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.513 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 132.24 42.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.31 8.12 79.16 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.647 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.96 143.33 26.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.677 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.69 151.19 23.62 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.041 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 42.2 m-85 -137.97 140.35 40.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.24 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.7 m-20 -104.47 115.12 29.81 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.385 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -101.02 139.84 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.928 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -160.67 169.78 36.46 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.858 HE22 ' H ' ' A' ' 70' ' ' ARG . 25.9 tt0 -120.31 114.06 21.3 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.5 m -106.13 171.16 7.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.194 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -156.82 133.08 9.82 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.506 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.83 129.58 40.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.945 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.543 HG22 ' CD1' ' A' ' 83' ' ' TRP . 3.7 m -110.81 -37.47 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.683 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -147.95 165.69 29.93 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.942 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -53.13 113.82 1.25 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.1 4.66 60.1 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.094 HG23 ' CH2' ' A' ' 83' ' ' TRP . 98.8 t -121.58 120.53 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.492 HD11 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.65 163.57 21.73 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.3 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -127.03 143.74 51.21 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.7 m -110.35 150.47 28.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.687 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.5 t30 -110.26 106.56 58.12 Favored Pre-proline 0 N--CA 1.449 -0.495 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.39 7.46 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.319 3.346 . . . . 0.0 109.591 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.428 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -87.98 -12.5 44.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 11.2 p30 -127.58 27.56 5.78 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.417 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.92 104.8 11.68 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.1 t -99.29 170.54 8.58 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.49 152.6 40.03 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.401 HG23 ' N ' ' A' ' 56' ' ' THR . 6.4 p -165.94 159.7 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.401 ' N ' HG23 ' A' ' 55' ' ' VAL . 18.2 m -128.23 137.11 51.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.68 146.98 39.79 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.6 p30 -83.93 -175.02 5.61 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -24.6 67.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.36 -7.57 55.28 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.685 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.14 32.04 58.88 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.1 p -127.94 135.78 50.43 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.76 167.9 12.45 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.1 121.91 9.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.483 ' O ' HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -162.33 148.04 12.84 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.931 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.422 ' N ' HG22 ' A' ' 65' ' ' THR . 0.4 OUTLIER -110.5 137.37 48.29 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.883 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.054 ' HG ' HG21 ' A' ' 95' ' ' VAL . 0.6 OUTLIER -106.04 119.1 38.34 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.909 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.62 ' HG1' ' NE ' ' A' ' 70' ' ' ARG . 5.2 t -60.84 127.2 30.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.524 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.7 OUTLIER -87.58 124.33 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.858 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.7 OUTLIER -115.74 143.68 45.04 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -86.73 -16.45 36.4 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.5 t -171.47 145.11 2.03 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.758 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.0 p90 -169.62 163.93 10.18 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.37 124.78 20.68 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.3 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -81.04 91.54 1.43 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.915 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.22 100.67 10.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.709 HD11 ' N ' ' A' ' 78' ' ' PHE . 3.6 tp -57.3 136.69 56.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.709 ' N ' HD11 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.54 -39.98 17.71 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.559 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -56.74 -17.14 7.97 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.955 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.94 28.1 9.69 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.407 ' HB ' HD21 ' A' ' 77' ' ' LEU . 15.7 m -112.38 147.36 36.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.69 93.82 6.85 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.543 ' CD1' HG22 ' A' ' 40' ' ' VAL . 11.5 t-105 -65.42 -48.29 73.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.57 165.08 10.16 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.79 133.66 54.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.194 HG22 ' CB ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -111.67 143.8 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.41 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.1 m-20 -109.84 104.07 12.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.481 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 26.3 m -51.81 -26.85 10.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.9 p -80.51 -2.26 45.27 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -116.71 -27.45 6.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.968 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.05 179.94 5.59 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.97 125.68 43.01 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.016 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 87.1 m -104.34 152.56 22.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.024 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.7 pt20 -150.57 152.72 34.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.054 HG21 ' HG ' ' A' ' 67' ' ' LEU . 10.3 t -117.51 159.78 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.278 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.46 166.51 37.52 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.385 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.74 131.19 51.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.24 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 3.2 m -111.73 153.09 27.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.677 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.5 -163.33 0.85 Allowed 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.43 -48.18 65.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.26 -24.45 66.58 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.6 53.77 1.77 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.898 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.26 170.92 14.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.041 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.4 46.72 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.614 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.42 162.8 40.47 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.328 3.352 . . . . 0.0 109.573 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.524 ' CG ' ' HB2' ' A' ' 2' ' ' ALA . 7.4 mt-10 -37.68 120.19 0.8 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.02 158.27 0.01 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.911 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.6 t -121.58 104.13 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.89 120.28 28.01 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.024 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.2 mt -98.61 159.09 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.0 OUTLIER -145.27 116.97 8.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.902 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -93.81 127.56 39.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.383 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . -59.63 117.24 21.0 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.552 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.8 Cg_endo -72.47 -178.45 3.36 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.285 3.323 . . . . 0.0 109.592 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.859 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.92 111.04 23.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.705 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.09 157.84 36.98 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.6 p -121.86 119.59 32.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.799 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 22.5 t -114.82 146.34 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.713 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.1 165.78 35.12 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.713 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.0 Cg_endo -72.41 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.347 3.365 . . . . 0.0 109.546 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.712 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.88 12.35 7.26 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.709 ' HA ' ' O ' ' A' ' 111' ' ' SER . 42.2 m -87.78 110.58 20.58 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 1.069 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.33 14.31 42.07 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.712 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -105.56 132.79 51.28 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m -91.83 -179.97 5.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -44.54 152.68 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.84 -23.29 33.56 Favored Glycine 0 C--N 1.335 0.528 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.613 HG21 ' N ' ' A' ' 18' ' ' VAL . 26.1 m -69.38 148.76 49.2 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.613 ' N ' HG21 ' A' ' 17' ' ' THR . 7.4 p -125.47 115.86 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.686 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 2.4 p -91.86 153.77 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.799 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.27 147.93 31.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.7 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.37 106.4 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.705 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.56 116.96 23.29 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.691 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -84.72 150.32 25.28 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.859 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -147.73 109.62 4.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.43 15.94 33.48 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.8 HD22 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.19 172.89 8.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.509 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -53.27 120.65 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.498 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.7 131.16 42.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.68 82.69 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.583 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.19 143.48 26.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.449 ' N ' HG23 ' A' ' 30' ' ' THR . . . -87.59 147.18 25.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.667 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 34.0 m-85 -134.48 134.05 41.07 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.095 ' HB2' ' O ' ' A' ' 98' ' ' SER . 1.7 m-20 -98.66 114.12 26.47 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.253 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.71 145.19 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.955 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.2 166.47 39.25 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.76 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.19 108.83 18.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.009 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.41 146.93 38.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.58 143.51 50.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.564 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.35 124.39 21.62 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.787 HG23 ' HB3' ' A' ' 83' ' ' TRP . 1.2 t -104.04 -49.26 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.269 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -135.43 169.65 17.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.956 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 112.23 0.71 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.35 8.62 66.48 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.977 HG11 ' HE1' ' A' ' 83' ' ' TRP . 2.4 t -121.98 123.19 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.663 HD23 ' HD2' ' A' ' 78' ' ' PHE . 0.5 OUTLIER -132.08 133.79 44.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.281 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -91.81 147.77 22.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.009 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.3 m -105.62 152.12 23.51 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.764 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -111.07 110.15 56.75 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.43 -0.07 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 124.311 3.341 . . . . 0.0 109.616 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.478 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -88.29 -9.45 52.83 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -133.83 26.8 3.97 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.448 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.07 107.24 12.7 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.1 m -101.48 176.21 5.31 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.0 p -144.93 153.97 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.49 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.69 155.18 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.49 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.1 m -128.0 141.72 51.44 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.99 141.28 33.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 p30 -82.66 -173.18 4.48 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.71 -26.45 68.05 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -76.09 -9.17 58.41 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.733 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 76.23 32.28 52.57 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 80.9 p -127.79 135.83 50.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.95 164.38 18.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -145.64 136.19 24.19 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.59 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.88 174.62 10.39 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.59 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.3 OUTLIER -138.95 122.96 17.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.891 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.995 HD21 HG23 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.04 156.43 16.33 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -103.78 133.37 48.89 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.954 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.456 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -93.47 127.18 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.628 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.4 OUTLIER -117.66 141.99 47.75 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -32.58 73.24 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 78.2 p -157.9 158.97 36.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.764 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 2.1 p90 -177.14 161.8 1.91 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.17 112.35 2.62 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.281 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -71.72 96.75 0.68 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.789 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.23 99.41 9.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.781 HD21 ' HB3' ' A' ' 79' ' ' ASP . 3.9 tp -57.18 131.68 50.7 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.663 ' HD2' HD23 ' A' ' 45' ' ' LEU . 38.0 p90 -47.52 -36.11 9.88 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.781 ' HB3' HD21 ' A' ' 77' ' ' LEU . 3.3 t0 -57.67 -16.25 10.17 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.78 9.5 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.557 HG21 ' N ' ' A' ' 82' ' ' ARG . 2.6 m -115.55 147.97 40.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.557 ' N ' HG21 ' A' ' 81' ' ' THR . 0.3 OUTLIER -87.64 96.43 10.42 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.269 ' HZ2' ' CG ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.63 -55.16 25.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.63 170.89 16.15 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -66.12 103.83 1.04 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.459 HG12 HG22 ' A' ' 40' ' ' VAL . 35.5 m -80.18 154.15 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -112.7 92.62 4.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.942 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.7 m -53.07 -24.63 10.41 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -82.32 2.07 33.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.38 -27.28 6.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.71 178.98 6.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.2 126.23 43.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.376 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 7.2 m -104.82 173.68 6.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.078 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 1.1 pt20 -153.61 147.12 24.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.995 HG23 HD21 ' A' ' 67' ' ' LEU . 3.7 t -104.97 165.32 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.253 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.29 166.38 36.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.915 ' HB3' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.83 132.9 46.63 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.095 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 3.7 t -113.48 150.89 32.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.455 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -110.48 -163.63 0.87 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.74 -48.43 71.92 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.65 -24.37 65.44 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.9 53.75 1.74 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.46 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -133.41 169.53 16.81 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.992 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.516 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.03 171.42 43.43 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.552 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.34 170.71 18.57 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.322 3.348 . . . . 0.0 109.597 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.383 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.67 121.6 0.9 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.98 163.87 0.01 OUTLIER Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.078 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 23.2 t -120.53 103.18 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.2 120.39 26.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.376 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -129.1 -178.76 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.709 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -168.33 171.14 9.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.942 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.0 m-85 -122.4 115.11 21.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 1.069 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.196 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . -117.98 115.32 36.75 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.571 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.4 -178.3 3.24 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 124.339 3.36 . . . . 0.0 109.633 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.305 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 5.1 t -99.69 116.12 31.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.665 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.78 153.76 48.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -110.66 112.16 23.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.811 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 95.2 t -107.47 145.93 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.953 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -66.79 176.42 1.11 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.953 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.9 Cg_endo -72.41 117.46 5.14 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.293 3.329 . . . . 0.0 109.612 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.705 ' HB2' HG23 ' A' ' 110' ' ' ILE . 32.4 p -112.58 47.07 1.12 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 51.4 p -126.36 106.73 9.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.698 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.9 28.72 14.72 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.7 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -101.73 131.77 47.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.983 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -111.41 174.57 5.8 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -48.05 140.3 7.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.08 -22.79 35.54 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.6 m -79.81 151.42 30.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.412 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 8.8 p -128.26 123.43 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.618 HG11 HG23 ' A' ' 69' ' ' VAL . 29.4 m -88.28 171.45 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.811 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.49 146.86 47.0 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.51 HG11 HG23 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -144.44 106.25 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.665 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.67 116.66 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -82.92 148.32 25.67 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.305 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -148.15 118.61 7.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.86 16.1 46.4 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.667 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -88.68 -174.15 4.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.517 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -70.3 120.7 16.36 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.931 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.02 136.02 53.21 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.02 7.82 60.21 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.721 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -82.95 146.71 28.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.868 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -96.07 134.96 38.48 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.822 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 38.6 m-85 -126.42 149.17 49.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.016 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -116.79 113.95 23.27 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.233 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -97.05 143.92 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.696 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.21 161.66 34.8 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.833 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 37.6 tt0 -110.85 118.44 36.13 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.212 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.1 m -115.95 148.37 40.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.045 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.27 140.39 52.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.517 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.26 127.42 31.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.94 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.711 HG13 ' CG1' ' A' ' 44' ' ' VAL . 1.1 t -108.7 -39.34 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.422 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 1.5 t0 -151.84 -178.53 6.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.1 m -70.41 111.47 6.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.51 10.01 86.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.316 HG13 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -136.99 124.52 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.573 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -133.1 137.23 46.27 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.159 ' HB2' ' C ' ' A' ' 75' ' ' GLY . . . -85.53 155.77 21.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.212 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 67.7 m -120.77 156.91 30.85 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.669 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t30 -121.5 109.21 34.82 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.43 0.64 7.17 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.313 3.342 . . . . 0.0 109.592 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.455 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -88.63 -16.37 32.61 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 14.6 p30 -127.26 28.15 5.77 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.92 118.3 35.37 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.5 t -113.41 -177.77 3.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 94.9 p -146.49 157.36 43.74 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 56' ' ' THR . 4.9 p -167.68 159.4 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.8 m -128.06 137.45 52.17 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.419 ' N ' HG21 ' A' ' 56' ' ' THR . . . -74.9 136.02 41.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 17.1 p30 -73.62 -175.28 1.97 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -24.74 68.02 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -75.17 -7.25 53.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.667 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.15 32.09 58.78 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.3 p -129.89 135.83 48.82 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.92 164.06 18.22 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -147.73 127.96 13.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.593 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.86 170.0 23.08 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.936 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.593 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -126.86 136.76 52.78 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.034 ' HG ' HG22 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -111.71 120.37 41.81 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.968 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.622 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -70.88 117.67 12.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.618 HG23 HG11 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -75.14 128.43 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.622 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -116.77 147.14 42.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.978 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.435 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.3 OUTLIER -90.21 -15.68 30.92 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 52.2 p -178.81 154.89 0.75 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.833 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -177.94 179.75 0.83 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -66.89 123.11 19.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.159 ' C ' ' HB2' ' A' ' 46' ' ' ALA . . . -79.7 91.93 1.31 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.89 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.75 100.62 11.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.744 HD21 ' HB3' ' A' ' 79' ' ' ASP . 2.4 tp -55.38 140.27 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.725 ' N ' HD13 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.58 -41.49 21.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.744 ' HB3' HD21 ' A' ' 77' ' ' LEU . 0.8 OUTLIER -57.19 -17.44 11.26 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.54 28.36 9.71 Favored Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.645 HG22 ' N ' ' A' ' 82' ' ' ARG . 2.1 m -110.89 145.23 38.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.645 ' N ' HG22 ' A' ' 81' ' ' THR . 0.1 OUTLIER -77.0 93.21 3.79 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.949 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.422 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 54.7 t-105 -64.18 -58.12 7.53 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.87 155.86 7.3 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -54.95 109.99 0.6 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.045 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.9 t -86.43 151.65 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.77 96.16 6.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.069 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.5 OUTLIER -54.07 -23.91 15.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.5 p -84.6 0.5 49.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -113.72 -27.38 7.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.82 177.94 7.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.54 128.33 44.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.241 ' O ' HG13 ' A' ' 110' ' ' ILE . 58.0 m -104.84 157.17 17.39 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.039 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -141.21 145.8 36.1 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.034 HG22 ' HG ' ' A' ' 67' ' ' LEU . 20.4 t -108.94 157.47 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.233 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.74 172.41 45.36 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.051 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.57 130.96 46.36 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.016 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 40.2 m -111.04 145.02 39.24 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.868 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -106.86 -163.58 0.92 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.73 -49.13 69.56 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.18 -24.11 65.83 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.26 53.34 1.88 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.8 174.81 9.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.822 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -177.82 179.34 48.37 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.571 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.37 165.78 31.66 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.347 3.364 . . . . 0.0 109.577 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.196 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 8.8 pt-20 -37.0 133.88 0.58 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.77 149.63 5.36 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.98 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -121.85 110.54 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -93.17 139.46 30.57 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.241 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.6 OUTLIER -109.93 160.09 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -143.22 112.53 6.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.069 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 23.1 m-85 -93.68 124.4 37.65 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.943 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.493 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.031 ' HB2' ' HA ' ' A' ' 106' ' ' GLU . . . -65.37 115.68 24.01 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.5 Cg_endo -72.42 -178.19 3.18 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.293 3.328 . . . . 0.0 109.635 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.367 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 5.2 t -102.31 115.74 31.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.742 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.4 146.96 52.05 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.546 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.65 115.72 31.02 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.93 HG21 HG23 ' A' ' 108' ' ' VAL . 35.9 t -111.92 148.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.949 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.41 176.2 1.31 Allowed Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.949 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.1 Cg_endo -72.34 117.28 5.06 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.325 3.35 . . . . 0.0 109.626 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.914 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 96.3 p -110.17 49.23 0.86 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 111' ' ' SER . 94.3 p -127.37 106.09 8.97 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.705 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.47 27.26 18.2 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.716 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -103.34 131.38 50.46 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.982 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -118.97 -179.35 3.79 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -46.19 138.89 5.0 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.58 -23.17 33.61 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.1 m -87.51 150.95 23.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.496 HG11 ' O ' ' A' ' 18' ' ' VAL . 13.0 p -131.63 121.54 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.534 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 23.7 m -80.74 167.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.813 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.37 145.54 43.14 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.688 HG11 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.87 112.82 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.08 114.8 20.18 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.547 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -81.93 147.9 26.72 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.315 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.8 115.49 5.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.22 15.39 51.49 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.04 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.35 -179.79 5.92 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.977 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 37.1 mt-30 -59.01 120.8 9.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.565 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.92 132.05 42.07 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.87 7.64 75.94 Favored Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.51 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -92.86 139.46 30.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.578 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.06 150.45 24.86 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.878 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 26.7 m-85 -135.58 143.81 45.84 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.258 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -105.83 114.59 28.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.309 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.8 OUTLIER -100.18 139.6 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.897 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.7 164.59 37.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.87 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 20.9 tt0 -109.75 105.33 14.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.165 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 61.5 m -106.32 142.79 35.42 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB1' HG22 ' A' ' 86' ' ' VAL . . . -122.72 130.09 52.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.624 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.69 121.33 14.73 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.56 HG13 ' CD1' ' A' ' 83' ' ' TRP . 6.0 m -101.78 -43.05 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.48 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -138.17 169.95 16.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.0 m -55.03 112.56 1.08 Allowed 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.72 9.05 64.84 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.565 ' O ' HG22 ' A' ' 40' ' ' VAL . 77.0 t -123.49 105.42 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.829 HD21 ' CD2' ' A' ' 78' ' ' PHE . 0.8 OUTLIER -121.3 138.35 54.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.335 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -92.42 158.13 16.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.165 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 52.2 m -118.59 148.13 43.0 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.927 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.3 t30 -110.61 106.19 57.64 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.459 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.8 Cg_endo -72.42 -1.27 9.96 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.356 3.37 . . . . 0.0 109.567 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.527 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.17 -11.09 42.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.527 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 6.1 m-20 -133.35 27.41 4.11 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.663 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.6 118.87 36.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -112.07 -176.1 2.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -144.84 153.02 41.17 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.64 156.27 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.3 m -126.45 141.0 52.04 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.426 ' N ' HG21 ' A' ' 56' ' ' THR . . . -79.26 138.33 37.74 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.0 p30 -73.57 -174.34 1.69 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.45 -25.04 68.09 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -75.23 -8.06 55.57 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.721 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.73 31.34 58.5 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 71.5 p -127.08 133.23 50.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.79 166.47 14.29 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.89 131.76 15.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.642 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.0 166.19 17.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.642 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -122.33 132.63 54.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.131 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.24 118.23 36.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.496 HG21 ' HB3' ' A' ' 51' ' ' ASP . 2.0 t -68.94 143.19 54.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.504 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -107.0 131.4 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.562 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -118.98 152.04 37.1 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.52 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -87.15 -10.63 52.25 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -174.04 149.43 1.47 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.927 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 5.7 p90 -176.72 158.91 1.75 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -58.75 112.53 1.66 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.335 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.66 94.54 0.67 Allowed Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.83 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -82.71 98.81 9.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.979 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.776 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.8 tp -54.93 132.68 47.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.829 ' CD2' HD21 ' A' ' 45' ' ' LEU . 19.0 p90 -46.81 -37.43 8.66 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.776 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.3 t0 -56.69 -17.13 7.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.45 28.04 8.76 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.5 HG22 ' N ' ' A' ' 82' ' ' ARG . 1.3 m -114.97 143.12 45.66 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.5 ' N ' HG22 ' A' ' 81' ' ' THR . 0.5 OUTLIER -85.38 96.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.56 ' CD1' HG13 ' A' ' 40' ' ' VAL . 3.3 t-105 -63.35 -58.95 5.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.29 171.31 21.1 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -64.78 104.39 0.83 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -79.75 149.99 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -110.56 97.44 6.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.841 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 9.0 m -52.82 -25.4 11.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 53.0 p -82.57 -0.17 45.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -119.04 -28.41 5.51 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.1 179.72 5.28 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 125.23 44.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.099 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 61.3 m -104.17 152.95 21.52 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.024 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -144.47 147.36 33.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.131 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -110.64 159.9 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.221 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.85 167.74 39.29 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.309 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.04 125.25 43.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.258 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 15.8 m -112.8 143.98 43.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.578 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -101.85 -160.23 0.78 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.983 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.71 -47.94 61.32 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.73 -20.08 65.89 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.5 53.51 2.59 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.296 -1.121 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.977 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.64 167.75 19.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.878 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.97 176.53 46.44 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.34 170.2 19.8 Favored 'Trans proline' 0 N--CA 1.448 -1.2 0 C-N-CA 124.294 3.33 . . . . 0.0 109.618 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.367 ' OE2' ' CA ' ' A' ' 4' ' ' THR . 3.3 pm0 -40.96 120.02 1.25 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.46 162.81 0.01 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.93 HG23 HG21 ' A' ' 7' ' ' VAL . 34.8 t -128.57 104.44 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.74 30.18 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.099 ' HB ' ' O ' ' A' ' 93' ' ' CYS . 5.2 mt -99.5 153.58 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.664 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -138.31 123.05 18.73 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.841 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 6.1 m-85 -92.69 127.44 38.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.917 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -100.26 118.38 61.39 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.588 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.34 -177.78 2.91 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.312 3.341 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.9 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.46 109.59 22.32 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.753 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 146.63 50.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.2 p -110.22 121.01 44.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.866 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 41.2 t -113.88 143.64 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.679 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.74 166.11 30.18 Favored Pre-proline 0 N--CA 1.449 -0.475 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.679 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.2 Cg_endo -72.41 117.16 5.0 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.29 3.327 . . . . 0.0 109.629 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.6 OUTLIER -129.29 11.78 5.94 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.689 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.6 m -92.34 108.72 20.17 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.85 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.17 24.08 13.45 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.69 HD22 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.24 133.78 51.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 t -67.36 154.39 41.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 1.3 p-10 -46.07 147.58 1.01 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.02 -18.69 51.55 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.563 HG23 ' N ' ' A' ' 18' ' ' VAL . 30.6 m -61.91 145.36 53.09 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.563 ' N ' HG23 ' A' ' 17' ' ' THR . 15.0 p -110.26 134.69 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.522 HG11 ' CG1' ' A' ' 7' ' ' VAL . 10.5 t -107.03 152.72 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.866 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.03 109.84 15.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.592 HG13 HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -103.18 121.12 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.753 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -128.41 117.01 20.64 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.654 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.55 147.41 23.1 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.9 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.46 111.11 5.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.56 16.53 31.37 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.099 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.27 173.43 8.4 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.582 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.9 mt-30 -53.66 121.38 7.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.31 129.55 38.66 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.98 8.67 85.07 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.692 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.1 141.7 28.24 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 1.196 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.88 150.78 23.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.237 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 52.6 m-85 -136.19 143.35 44.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.23 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.73 114.7 29.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.533 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.03 141.87 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.029 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.52 161.99 35.79 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.95 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 54.9 tt0 -94.69 117.96 30.97 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.5 m -107.25 158.12 17.37 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.002 ' HB3' HG13 ' A' ' 86' ' ' VAL . . . -147.22 134.6 20.73 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.535 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -68.36 125.32 26.06 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.482 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.4 m -114.64 -36.05 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.536 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -150.17 -179.96 7.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -64.12 110.37 2.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 69.76 8.84 61.32 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.606 ' O ' HG23 ' A' ' 40' ' ' VAL . 61.0 t -110.19 105.2 18.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.687 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.5 mt -105.82 156.61 18.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.372 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -135.11 129.35 33.78 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.914 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.52 156.01 19.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.624 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.6 p-10 -116.23 121.76 33.14 Favored Pre-proline 0 N--CA 1.449 -0.523 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.415 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.8 Cg_endo -72.37 1.98 5.56 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.26 3.307 . . . . 0.0 109.608 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.63 -20.87 28.82 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.428 ' OD1' HG21 ' A' ' 68' ' ' THR . 85.2 m-20 -128.47 28.78 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.59 117.1 29.6 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.3 t -109.99 -176.86 3.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.37 153.8 41.61 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.49 HG22 ' N ' ' A' ' 56' ' ' THR . 7.5 p -166.47 153.71 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.49 ' N ' HG22 ' A' ' 55' ' ' VAL . 32.8 m -126.59 132.89 51.19 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.61 149.79 48.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -88.98 -168.38 2.17 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.29 -27.94 68.98 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -75.16 -9.32 58.44 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.551 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 77.2 31.51 51.9 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.0 p -127.97 141.24 51.58 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.15 164.68 24.98 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -143.35 139.62 30.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.57 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -167.56 172.1 9.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.57 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.4 OUTLIER -124.88 129.03 49.58 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.942 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.287 HD13 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -112.56 119.57 38.62 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.428 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -79.59 141.45 36.56 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.581 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -112.02 132.81 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.917 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -119.11 155.68 31.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 ptt180 -74.67 -34.58 62.72 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -151.15 149.34 29.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.95 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.5 p90 -177.13 163.66 2.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.474 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.4 OUTLIER -61.25 125.1 22.55 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.372 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.93 95.56 2.11 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.914 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -84.46 103.71 13.84 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.723 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.5 tp -53.91 135.01 42.94 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.568 ' N ' HD11 ' A' ' 77' ' ' LEU . 8.3 m-85 -45.71 -38.68 7.16 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.723 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.6 t0 -57.26 -17.02 9.89 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.92 28.91 8.97 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.476 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.6 m -114.41 112.43 23.02 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 96.44 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.482 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 50.6 t-105 -62.41 -53.63 52.03 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 143.45 -179.66 20.74 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.17 140.79 43.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.005 HG22 HG11 ' A' ' 40' ' ' VAL . 4.8 t -127.7 152.6 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.26 90.4 3.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.204 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 30.6 m -54.15 -25.57 23.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.8 p -76.9 -0.64 24.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.597 ' O ' HG22 ' A' ' 90' ' ' THR . 0.9 OUTLIER -114.48 -27.21 7.62 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.98 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.68 -164.2 1.28 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.4 125.49 43.58 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.228 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.1 OUTLIER -103.89 152.5 21.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.03 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -159.42 147.56 17.56 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.287 ' CG2' HD13 ' A' ' 67' ' ' LEU . 6.8 t -105.62 165.32 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.251 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.29 164.68 34.67 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.533 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.6 133.16 47.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.23 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 67.7 m -112.1 150.31 30.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 1.196 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -109.92 -161.31 0.75 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.08 -48.68 70.15 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.09 -24.13 64.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.74 52.47 1.8 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.618 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.57 171.87 12.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.237 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.37 175.24 44.34 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.588 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.34 169.55 21.37 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.377 3.385 . . . . 0.0 109.59 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.022 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -38.49 126.09 1.4 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.959 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.84 160.31 0.01 OUTLIER Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.03 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 89.1 t -123.08 102.69 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.97 134.54 33.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.228 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -140.53 -173.73 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.689 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.7 t -176.48 178.51 1.3 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.204 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.8 m-85 -130.75 113.15 13.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.85 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 42.5 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.578 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -141.25 122.07 8.79 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.501 ' HB2' ' CD2' ' A' ' 26' ' ' LEU . 84.4 Cg_endo -72.35 -175.28 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.355 3.37 . . . . 0.0 109.626 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.963 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.32 109.37 21.89 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.97 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.2 146.02 50.85 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -110.18 114.35 27.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.819 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.03 152.39 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.649 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -75.5 163.96 64.03 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.649 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.36 118.16 5.47 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.337 3.358 . . . . 0.0 109.621 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.708 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -128.59 14.29 6.5 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 1.075 ' HA ' ' O ' ' A' ' 111' ' ' SER . 68.9 p -95.73 109.2 21.53 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 1.111 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 95.59 26.07 12.53 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.728 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.48 140.94 41.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 t -71.45 156.31 39.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.512 ' HB3' ' HD2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.73 151.96 0.79 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.63 -16.1 59.96 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.53 HG22 ' N ' ' A' ' 18' ' ' VAL . 15.2 m -62.34 138.56 58.46 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' N ' HG22 ' A' ' 17' ' ' THR . 9.7 p -99.69 146.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.614 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.5 t -125.32 156.64 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.819 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.79 150.21 40.19 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.77 105.67 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.97 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.17 117.07 30.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.759 ' HA2' ' HB3' ' A' ' 5' ' ' ALA . . . -83.63 143.47 21.63 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.963 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.49 106.76 5.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.534 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 22.96 8.56 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.501 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.66 -167.03 1.75 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.522 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 29.7 mt-30 -85.57 125.56 33.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.488 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.29 134.4 44.19 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.37 8.16 83.39 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.65 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -96.3 139.44 32.43 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -90.65 150.96 21.47 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.963 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 54.0 m-85 -136.95 147.33 46.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.103 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.7 m-20 -110.97 112.85 24.98 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.274 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -102.26 151.03 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.948 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -178.1 176.67 48.14 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 1.058 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 9.2 tt0 -117.25 121.6 41.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.6 m -120.42 144.81 47.74 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.92 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -123.1 142.31 51.02 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.608 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.02 124.29 21.7 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.937 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.515 ' CB ' ' CD1' ' A' ' 83' ' ' TRP . 3.3 m -106.68 -38.37 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.095 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.49 -178.35 5.07 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.5 m -70.98 112.08 6.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.12 10.21 81.07 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.307 HG23 ' CZ2' ' A' ' 83' ' ' TRP . 1.8 m -130.94 124.92 57.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.537 HD13 ' HB2' ' A' ' 37' ' ' CYS . 1.6 pt? -127.76 147.04 50.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.396 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -102.22 150.65 23.08 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.7 m -106.27 160.33 15.44 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.737 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 26.8 t30 -119.24 109.96 38.29 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.35 0.01 8.03 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.33 3.353 . . . . 0.0 109.627 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.488 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.44 -13.08 38.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.517 ' HB3' HG23 ' A' ' 68' ' ' THR . 19.0 m-20 -134.73 27.71 3.62 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.628 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.43 115.17 27.0 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.4 t -106.53 178.34 4.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 p -147.18 156.32 42.87 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.473 ' CG2' ' N ' ' A' ' 56' ' ' THR . 2.3 p -167.35 161.93 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.473 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 24.4 m -128.28 131.87 48.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 152.4 44.28 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -91.44 -170.8 2.73 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.43 -26.14 68.34 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -76.38 -6.06 49.95 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.488 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 75.27 9.42 84.25 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 85.9 p -101.64 140.16 36.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.43 164.11 17.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -150.38 121.86 7.94 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.615 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.38 172.19 15.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.615 ' N ' HG23 ' A' ' 65' ' ' THR . 1.1 m -128.24 120.23 26.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.305 HD11 ' CG2' ' A' ' 95' ' ' VAL . 0.2 OUTLIER -105.64 133.43 50.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.517 HG23 ' HB3' ' A' ' 51' ' ' ASP . 5.5 t -97.62 149.13 22.58 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.588 ' CG2' ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -114.67 131.48 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.879 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.58 159.04 20.89 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.512 ' HD2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -80.3 -23.32 40.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.949 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.494 ' N ' ' HG2' ' A' ' 71' ' ' ARG . 53.9 p -160.72 156.72 25.81 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 1.058 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.5 p90 -178.12 158.82 1.24 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -60.58 109.43 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.396 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -64.27 98.77 0.28 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.802 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 98.78 10.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.771 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.2 tp -54.66 132.46 45.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.672 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.9 m-85 -47.0 -37.24 8.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.771 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.8 t0 -57.57 -16.65 10.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.84 28.99 8.94 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.59 HG22 ' N ' ' A' ' 82' ' ' ARG . 1.3 m -117.3 152.2 35.38 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.59 ' N ' HG22 ' A' ' 81' ' ' THR . 0.0 OUTLIER -80.94 99.54 8.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.515 ' CD1' ' CB ' ' A' ' 40' ' ' VAL . 15.0 t-105 -68.74 -50.49 50.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.5 163.72 9.62 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.99 104.7 0.21 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.92 HG23 ' CB ' ' A' ' 38' ' ' ALA . 14.4 p -85.83 149.71 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.509 ' N ' HG21 ' A' ' 86' ' ' VAL . 0.7 OUTLIER -100.77 97.24 7.9 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.854 ' SG ' ' HZ ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.8 -20.63 9.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.7 p -92.76 2.4 56.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.7 m -106.1 -24.35 12.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.52 179.01 6.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -90.97 125.5 35.8 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.246 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.3 m -104.48 162.98 12.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.045 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.3 OUTLIER -153.56 147.92 25.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.305 ' CG2' HD11 ' A' ' 67' ' ' LEU . 15.8 t -101.71 161.21 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.264 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.96 166.0 35.33 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.274 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.41 128.92 43.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 180.0 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.103 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 26.8 m -108.74 151.65 25.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.488 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -113.19 -162.41 0.8 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.58 -48.49 77.19 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.17 -24.37 62.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.22 53.77 1.69 Allowed Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.522 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.88 172.26 11.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.963 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.58 -179.21 46.89 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.417 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 81.7 Cg_endo -72.42 160.29 47.19 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.357 3.372 . . . . 0.0 109.549 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.121 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 2.8 tt0 -35.45 123.7 0.64 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -34.67 151.14 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.023 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 90.1 t -117.28 102.31 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 137.15 34.8 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.246 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 2.8 pt -143.0 179.71 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 1.075 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -177.99 178.54 0.93 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.964 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 1.2 m-85 -126.21 116.1 20.78 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 1.111 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 6.3 p30 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.291 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -132.64 117.96 15.49 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.37 -178.24 3.2 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.356 3.371 . . . . 0.0 109.609 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.257 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 6.8 t -100.17 116.95 33.38 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.767 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.37 135.36 47.15 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.95 113.11 24.69 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.612 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.96 155.03 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.969 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.936 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.09 175.42 1.79 Allowed Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.936 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.2 Cg_endo -72.39 118.94 5.84 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 124.299 3.333 . . . . 0.0 109.602 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.975 ' HB2' HG22 ' A' ' 110' ' ' ILE . 20.6 p -110.74 48.48 0.91 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 55.5 p -127.06 105.99 8.97 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.712 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 91.12 31.93 9.36 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.289 -1.125 . . . . 0.0 110.289 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.719 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -110.18 129.19 55.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.89 175.84 5.27 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -44.92 139.74 2.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.93 -22.47 35.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.465 HG22 ' N ' ' A' ' 18' ' ' VAL . 17.3 m -81.19 150.64 28.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.465 ' N ' HG22 ' A' ' 17' ' ' THR . 10.7 p -121.03 120.45 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.515 HG22 ' N ' ' A' ' 20' ' ' LYS . 1.7 p -87.62 154.87 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.612 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.7 147.14 31.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.712 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.23 110.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.99 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.767 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.24 115.83 23.06 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.55 ' HA3' HD23 ' A' ' 26' ' ' LEU . . . -83.21 148.86 25.76 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.257 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.35 114.83 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.36 13.62 44.42 Favored Glycine 0 C--N 1.335 0.485 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.711 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.46 172.6 8.6 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.494 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -52.95 119.84 5.12 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.522 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.51 132.84 43.33 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.77 7.84 75.88 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.494 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.56 141.56 28.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.413 ' N ' HG21 ' A' ' 30' ' ' THR . . . -84.42 150.16 25.5 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.488 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 30.1 m-85 -135.73 141.79 44.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.266 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.77 118.07 35.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.25 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -104.83 145.32 13.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.853 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.99 169.2 41.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.769 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 40.6 tt0 -112.01 108.96 18.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.185 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.2 m -111.74 144.63 40.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.915 ' HB1' HG11 ' A' ' 86' ' ' VAL . . . -123.83 130.41 52.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.583 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.18 122.83 17.98 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.444 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 9.7 m -102.94 -42.87 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.7 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -139.0 179.64 6.38 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.4 m -63.63 112.35 2.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.44 8.38 66.37 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.557 ' O ' HG22 ' A' ' 40' ' ' VAL . 59.3 t -123.83 106.44 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -121.42 137.84 54.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.15 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -89.4 153.34 20.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.185 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m -115.04 151.86 33.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.665 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.4 t30 -117.72 109.54 41.44 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.33 -1.07 9.61 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.315 3.343 . . . . 0.0 109.602 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.589 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -84.68 -11.1 56.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.589 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.5 OUTLIER -131.79 26.25 4.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.71 104.38 13.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.7 t -101.33 176.32 5.28 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.51 150.04 35.73 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -166.96 153.63 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 67.9 m -123.49 132.7 54.0 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 141.63 53.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -77.53 -174.65 3.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.91 -24.83 68.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -76.29 -6.9 53.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.711 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.73 31.17 58.72 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.2 p -127.09 137.78 53.07 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.26 165.21 16.56 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 p -147.91 120.22 8.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.476 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -157.42 148.08 21.2 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.476 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -111.32 129.81 55.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.344 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -98.47 157.27 16.32 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.589 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.7 t -101.01 119.29 38.53 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.517 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -80.31 127.18 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.654 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.6 OUTLIER -118.7 152.47 36.07 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.49 ' HD3' ' N ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -91.59 -12.68 33.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.941 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 5.1 t -169.2 151.35 4.63 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.769 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.1 p90 -177.16 155.43 1.15 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.25 115.92 2.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.15 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -72.83 91.63 0.6 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.803 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -82.79 99.23 9.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.731 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.1 tp -55.54 134.55 50.9 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.76 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.4 m-85 -46.36 -38.68 9.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.731 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.5 t0 -56.99 -17.48 9.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.77 28.37 8.9 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.645 HG23 ' N ' ' A' ' 82' ' ' ARG . 1.2 m -113.62 142.86 45.48 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.645 ' N ' HG23 ' A' ' 81' ' ' THR . 4.7 mtm180 -80.88 94.97 6.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.444 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 71.4 t-105 -64.28 -58.61 6.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.67 167.54 16.66 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.81 108.6 1.22 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.915 HG11 ' HB1' ' A' ' 38' ' ' ALA . 38.7 t -81.76 143.96 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.17 93.6 4.62 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.471 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 58.4 m -52.04 -26.07 10.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.489 HG21 ' HB2' ' A' ' 71' ' ' ARG . 77.9 p -79.85 -2.43 43.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.591 ' O ' HG22 ' A' ' 90' ' ' THR . 1.3 m -116.48 -27.76 6.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.07 -176.63 3.93 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.92 125.74 45.95 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.914 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 69.8 m -103.5 152.98 21.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.087 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -143.17 148.53 36.68 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.344 ' CG1' HD12 ' A' ' 67' ' ' LEU . 4.9 t -112.01 161.4 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.07 171.46 43.92 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.957 ' HB3' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.57 135.56 48.03 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.266 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 72.6 p -115.71 154.95 28.63 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.426 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -115.12 -167.07 1.18 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.974 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.03 -48.75 75.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.87 66.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.59 1.93 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.481 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.62 169.16 17.04 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.82 176.82 46.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 81.8 Cg_endo -72.41 161.84 43.16 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.332 3.355 . . . . 0.0 109.555 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.291 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 10.9 pt-20 -38.37 122.82 1.12 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -37.49 157.52 0.01 OUTLIER Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.843 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.8 t -124.66 104.59 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.01 138.29 32.55 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.087 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.8 mt -116.68 156.09 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -138.22 112.67 8.78 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.595 ' CE1' ' HB2' ' A' ' 93' ' ' CYS . 5.7 m-85 -87.3 101.11 13.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.588 ' CG ' ' C ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.545 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . -48.12 120.0 7.8 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.64 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.3 Cg_endo -72.42 -175.39 1.77 Allowed 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.302 3.335 . . . . 0.0 109.615 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.22 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.82 22.51 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.44 148.95 49.56 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.4 p -113.23 117.75 32.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.799 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 48.3 t -113.58 145.92 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.723 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.56 166.67 28.6 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.723 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.39 117.55 5.18 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.332 3.355 . . . . 0.0 109.58 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.736 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.8 OUTLIER -127.55 13.08 6.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.863 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.6 p -92.56 106.51 18.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.964 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 100.57 22.66 11.0 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.736 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -109.81 140.49 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.68 173.19 8.74 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 19.4 p-10 -44.78 152.39 0.23 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.35 -22.09 40.67 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.652 HG22 ' N ' ' A' ' 18' ' ' VAL . 22.9 m -63.46 150.46 43.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.652 ' N ' HG22 ' A' ' 17' ' ' THR . 0.0 OUTLIER -130.28 114.1 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.663 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -97.56 119.08 45.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.799 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.57 146.07 36.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.502 ' CG1' HG23 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -131.51 102.88 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -113.17 116.23 29.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.716 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -87.76 144.08 18.69 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.895 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.93 107.92 6.71 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 99.31 25.88 9.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.397 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.15 -175.77 5.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.917 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 24.7 mt-30 -74.32 122.28 22.65 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.445 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.96 130.87 42.04 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.48 9.23 81.71 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.724 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -97.43 139.95 32.6 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 1.143 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.69 151.99 22.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.304 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 33.3 m-85 -137.44 149.69 47.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.111 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.5 m-20 -111.84 113.82 26.39 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.42 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -101.01 142.48 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.961 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.69 164.36 37.98 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.958 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 11.8 tt0 -106.65 111.54 24.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.195 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 81.2 m -111.16 151.31 28.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.466 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -129.72 126.16 37.6 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.19 119.06 10.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.378 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 7.0 m -100.97 -42.71 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.502 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -139.47 165.53 26.98 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.36 112.78 0.8 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.27 8.24 65.26 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.547 ' O ' HG22 ' A' ' 40' ' ' VAL . 71.7 t -123.28 105.04 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.561 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -122.85 137.41 54.94 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.431 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -89.28 157.32 18.26 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.195 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 41.7 m -121.22 151.83 39.53 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.782 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -114.67 105.74 53.06 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -72.42 -0.91 9.42 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.296 3.331 . . . . 0.0 109.584 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -89.99 -11.77 40.63 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.501 ' OD1' HG21 ' A' ' 68' ' ' THR . 65.0 m-20 -132.69 26.42 4.36 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.668 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.86 120.83 37.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.3 t -113.4 -174.68 2.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.35 157.2 43.76 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.408 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.83 156.95 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.408 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.5 m -127.63 127.24 43.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.95 146.31 42.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -87.35 -171.98 3.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.16 -28.38 69.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -76.49 -11.0 59.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.445 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 83.03 1.22 90.63 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.2 p -94.19 136.73 34.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.59 163.62 18.62 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.91 130.04 13.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.57 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -156.24 174.64 15.1 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.57 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.1 OUTLIER -124.76 126.68 46.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.954 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.155 ' CG ' HG23 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.16 119.45 38.99 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.653 ' N ' HD11 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -80.7 137.52 36.3 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.508 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -107.74 128.31 63.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.536 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -117.41 141.7 48.02 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -42.79 87.01 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.586 ' OG ' HG21 ' A' ' 85' ' ' THR . 11.5 t -147.01 156.74 43.28 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.958 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.0 p90 -177.02 157.93 1.48 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.03 111.54 0.86 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.431 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -76.5 99.05 1.3 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.758 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -84.46 99.51 10.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.804 HD21 ' HB3' ' A' ' 79' ' ' ASP . 3.7 tp -54.4 131.34 42.04 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.515 ' N ' HD13 ' A' ' 77' ' ' LEU . 3.3 p90 -47.55 -36.29 10.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.804 ' HB3' HD21 ' A' ' 77' ' ' LEU . 2.0 t0 -57.3 -17.24 11.18 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.91 28.5 8.23 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.638 HG22 ' N ' ' A' ' 82' ' ' ARG . 1.0 OUTLIER -115.61 145.07 43.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.638 ' N ' HG22 ' A' ' 81' ' ' THR . 2.0 ttp180 -85.16 95.53 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.378 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 0.8 OUTLIER -64.87 -56.92 10.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.914 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.52 168.78 12.8 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.586 HG21 ' OG ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -58.28 104.7 0.22 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.558 HG13 HG11 ' A' ' 40' ' ' VAL . 33.7 m -83.09 154.12 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.445 ' O ' ' N ' ' A' ' 90' ' ' THR . 0.2 OUTLIER -117.81 93.32 4.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.503 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 75.9 m -50.3 -29.32 9.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.753 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 5.5 t -73.5 -1.67 19.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.633 ' O ' HG22 ' A' ' 90' ' ' THR . 2.2 m -115.47 -27.48 7.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.36 -164.21 1.33 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.62 123.35 47.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.187 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -103.89 160.15 15.04 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.056 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -160.45 147.7 15.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.155 HG23 ' CG ' ' A' ' 67' ' ' LEU . 3.0 t -106.51 165.42 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.274 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.24 164.05 33.11 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.42 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.79 131.11 42.65 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.111 ' N ' ' H ' ' A' ' 33' ' ' ASP . 23.9 m -113.83 151.29 32.31 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 1.143 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -108.67 -158.09 0.64 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.436 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.54 -47.92 65.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.12 -25.05 64.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.3 53.99 1.65 Allowed Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.917 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.45 166.86 20.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.304 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.1 174.67 43.59 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.64 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.37 167.49 26.81 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.333 3.356 . . . . 0.0 109.603 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.545 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 1.4 pm0 -38.37 124.83 1.29 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.96 156.79 0.01 OUTLIER Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.983 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.1 t -118.38 103.29 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.62 135.99 34.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.187 HG13 ' C ' ' A' ' 93' ' ' CYS . 2.9 pt -145.03 -176.55 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.863 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -176.7 177.88 1.31 Allowed 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.503 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.8 m-85 -127.73 113.75 16.41 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.964 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 6.6 p30 . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.495 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.215 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -108.17 109.7 61.88 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.547 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.39 -178.6 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.339 3.359 . . . . 0.0 109.591 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.905 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.66 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.687 ' CB ' ' HA2' ' A' ' 23' ' ' GLY . . . -124.14 157.92 33.54 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.579 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -126.31 129.41 48.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.939 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -119.41 148.59 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.717 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.64 165.76 33.01 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.717 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.35 117.2 5.02 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.286 3.324 . . . . 0.0 109.63 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.758 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -129.7 14.1 5.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 111' ' ' SER . 71.0 m -86.56 105.94 17.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.925 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 99.27 17.72 26.16 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.758 HD13 ' HA ' ' A' ' 10' ' ' SER . 1.1 mt -106.79 133.17 51.86 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -87.28 -179.74 6.47 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.778 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 4.2 t0 -45.05 152.39 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.92 38.24 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.579 HG22 ' N ' ' A' ' 18' ' ' VAL . 51.6 m -64.73 150.97 46.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.579 ' N ' HG22 ' A' ' 17' ' ' THR . 1.2 t -125.58 119.31 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.691 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 2.4 m -95.5 116.31 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.939 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -86.27 115.24 23.69 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.408 ' CG1' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -102.47 119.37 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.619 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -130.66 118.4 20.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.687 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -90.1 148.68 19.88 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.905 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.03 110.87 5.42 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.11 16.48 27.75 Favored Glycine 0 C--N 1.335 0.497 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.066 HD21 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.73 170.55 10.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.985 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 1.6 mp0 -52.08 118.92 3.82 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.494 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.78 130.62 41.55 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.05 7.64 86.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.638 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.94 145.74 24.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.479 ' N ' HG23 ' A' ' 30' ' ' THR . . . -89.0 151.4 22.31 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.985 ' HH ' ' NE2' ' A' ' 27' ' ' GLN . 39.1 m-85 -138.76 140.57 38.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.257 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.2 m-20 -104.41 114.19 28.25 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.277 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.7 146.45 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.047 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.45 166.88 40.05 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.894 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.2 tt0 -111.73 118.91 36.9 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.941 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -123.84 147.91 47.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.901 ' HB2' HG12 ' A' ' 86' ' ' VAL . . . -123.27 135.5 54.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.588 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.9 121.32 14.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.525 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 10.6 m -102.15 -43.42 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.793 ' CG ' ' HH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.58 165.52 25.34 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.664 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.2 t -51.7 111.96 0.68 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.87 9.18 70.19 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.556 HG13 HD11 ' A' ' 77' ' ' LEU . 21.3 t -123.96 113.69 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.58 HD11 ' HB2' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.54 139.14 53.44 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.243 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -96.92 144.34 26.94 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.941 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 66.3 m -107.0 158.3 17.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.597 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -115.65 111.46 43.69 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.52 7.28 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.326 3.351 . . . . 0.0 109.603 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.466 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.37 -10.81 45.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 7.1 p30 -131.54 28.23 4.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.415 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.86 104.63 12.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.96 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.6 t -100.88 174.35 6.07 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.1 p -145.95 156.13 43.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 56' ' ' THR . 4.4 p -166.49 159.43 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.428 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.8 m -127.25 139.54 52.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.95 141.02 36.41 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.0 p30 -82.3 -172.24 3.88 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.2 -27.88 69.29 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -75.1 -7.27 53.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.738 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.89 30.9 58.75 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 77.9 p -125.29 136.12 53.19 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.26 157.44 33.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.71 126.46 23.87 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.499 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -150.21 161.67 41.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.499 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -125.57 108.53 11.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.905 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.185 HD23 ' CG2' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -95.6 157.88 15.7 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.415 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.1 OUTLIER -107.49 140.17 40.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.512 HG22 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -109.88 123.28 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.778 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -109.91 157.94 18.72 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.532 ' HG2' HG21 ' A' ' 89' ' ' THR . 5.8 mtm180 -87.63 -13.06 43.7 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.5 m -163.41 145.47 9.76 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.894 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.5 p90 -177.42 150.69 0.71 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -53.4 113.48 1.17 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.243 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -75.7 101.47 1.42 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.82 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.33 100.67 10.8 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.735 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.0 tp -54.53 131.23 42.35 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.565 ' N ' HD13 ' A' ' 77' ' ' LEU . 4.5 p90 -47.49 -36.04 9.64 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.735 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.2 t0 -57.77 -16.56 11.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.49 27.39 9.89 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.445 HG21 ' N ' ' A' ' 82' ' ' ARG . 1.5 m -115.62 152.85 32.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.445 ' N ' HG21 ' A' ' 81' ' ' THR . 0.3 OUTLIER -85.15 98.68 10.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 75.0 t-105 -65.61 -43.53 89.31 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.41 175.54 14.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.46 107.75 0.62 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.901 HG12 ' HB2' ' A' ' 38' ' ' ALA . 2.4 t -80.02 152.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -120.36 95.84 4.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.941 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.3 m -54.11 -22.93 12.23 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.532 HG21 ' HG2' ' A' ' 71' ' ' ARG . 70.2 p -84.75 2.13 43.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -112.41 -23.36 10.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.05 179.29 7.3 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.32 130.94 40.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.368 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 11.1 m -104.47 164.89 11.43 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.07 ' HA ' HG12 ' A' ' 110' ' ' ILE . 1.1 tt0 -156.91 151.41 25.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.185 ' CG2' HD23 ' A' ' 67' ' ' LEU . 2.7 t -106.09 165.61 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.277 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.79 162.08 30.28 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.993 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -124.68 128.94 49.59 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.257 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 27.6 m -112.73 141.56 46.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -103.15 -162.03 0.88 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.996 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.83 -48.16 67.0 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.51 -24.67 66.43 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.61 53.69 1.92 Allowed Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.81 173.43 11.18 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.7 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -175.64 169.12 41.79 Favored Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.547 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.39 171.85 16.16 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.314 3.342 . . . . 0.0 109.595 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.215 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.8 OUTLIER -36.45 133.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.21 160.73 2.44 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.884 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 6.6 t -116.25 103.58 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.09 127.9 35.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.368 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -138.2 179.21 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -163.68 175.52 10.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.031 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.0 m-85 -131.01 114.85 15.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.925 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 10.7 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.654 ' HB1' ' CD ' ' A' ' 106' ' ' GLU . . . -45.14 133.18 5.52 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.405 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.4 -174.51 1.45 Allowed 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 124.295 3.33 . . . . 0.0 109.619 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.73 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.28 108.83 21.38 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.834 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 140.42 52.39 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -102.06 112.45 25.11 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.719 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.74 154.86 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.939 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 174.41 2.52 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.939 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.3 Cg_endo -72.36 118.4 5.58 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.679 ' HA ' HD11 ' A' ' 13' ' ' LEU . 30.3 p -112.36 46.9 1.12 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.8 p -127.4 106.19 9.03 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.654 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.81 27.67 16.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.686 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -99.65 131.99 45.28 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -107.54 168.4 9.27 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -44.67 141.17 2.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.85 -22.32 37.41 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.4 m -76.86 150.35 36.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.442 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 8.8 p -126.53 117.27 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.964 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 13.3 m -83.73 164.12 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.75 152.25 36.51 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 65' ' ' THR . 0.1 OUTLIER -147.1 111.51 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.834 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.49 116.37 26.54 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.573 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -81.84 143.25 23.16 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.73 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.0 105.54 4.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.522 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 104.22 23.05 8.28 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.077 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.81 -164.98 1.22 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.93 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -85.6 123.77 31.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.635 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.12 134.57 45.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.86 7.57 75.73 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.638 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -94.82 138.97 31.92 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.956 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.504 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.4 150.76 22.38 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.242 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -137.17 146.42 44.93 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.211 ' CB ' ' H ' ' A' ' 98' ' ' SER . 1.2 m-20 -107.47 112.15 24.79 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.345 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -101.84 150.19 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.916 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -179.38 174.54 46.36 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 1.097 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 31.0 tt0 -114.96 113.25 23.89 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.106 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.1 m -118.02 145.62 44.65 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.255 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -122.73 135.98 54.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.582 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.45 124.8 22.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.537 HG22 ' CD1' ' A' ' 83' ' ' TRP . 11.1 m -107.15 -42.25 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.336 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -138.29 129.91 27.9 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.427 ' C ' ' O ' ' A' ' 41' ' ' ASP . 9.5 t -38.04 112.01 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.434 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 93.03 8.98 61.22 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.455 ' CG2' ' HE1' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -151.8 130.44 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.576 HD13 ' HB2' ' A' ' 37' ' ' CYS . 1.7 pt? -133.02 142.88 49.05 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.538 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.4 144.65 25.14 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.106 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 6.1 m -106.69 156.55 18.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.935 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.4 t-20 -112.97 109.1 52.71 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.4 8.65 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.31 3.34 . . . . 0.0 109.628 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.542 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -94.09 -9.32 37.0 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.68 ' HB3' HG23 ' A' ' 68' ' ' THR . 7.9 m-20 -133.58 15.17 4.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.648 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -85.09 117.11 23.86 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.7 t -112.13 -178.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -145.72 156.14 43.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.513 HG22 ' N ' ' A' ' 56' ' ' THR . 5.1 p -166.99 157.74 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.513 ' N ' HG22 ' A' ' 55' ' ' VAL . 35.0 m -127.66 132.89 49.65 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.7 153.39 39.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -92.98 -172.04 2.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.82 -29.15 69.3 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -75.22 -9.11 58.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.635 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.88 7.19 88.72 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 99.3 p -99.22 138.94 35.61 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.27 163.91 17.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.1 p -149.38 127.77 12.21 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.466 ' O ' HG21 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -164.51 152.9 12.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -109.24 125.0 51.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.384 HD13 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.44 122.15 45.39 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.68 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.1 t -77.94 142.36 38.41 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.795 HG11 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -114.95 131.16 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.991 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 1.033 ' H ' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -113.74 156.84 23.08 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.981 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.26 -13.49 49.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 92.1 p -168.98 144.3 3.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 1.097 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 14.2 p90 -176.53 158.11 1.73 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -59.22 122.35 13.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.538 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.48 104.32 2.61 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.597 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.4 m-85 -84.82 101.31 12.17 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.822 HD23 ' HB2' ' A' ' 79' ' ' ASP . 6.0 tp -54.33 138.78 38.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.752 ' N ' HD13 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.46 -41.85 21.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.822 ' HB2' HD23 ' A' ' 77' ' ' LEU . 44.1 m-20 -56.85 -17.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.42 26.08 12.73 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.426 ' HB ' HD22 ' A' ' 77' ' ' LEU . 1.2 m -108.63 149.17 29.31 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.7 mtt180 -78.7 95.21 5.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.537 ' CD1' HG22 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -62.85 -39.49 94.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 126.5 170.26 12.91 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.226 -1.149 . . . . 0.0 110.226 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.92 130.95 43.31 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.255 HG12 ' CB ' ' A' ' 38' ' ' ALA . 2.0 t -109.13 154.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -125.53 98.0 5.41 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.726 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 9.9 m -53.13 -27.2 19.64 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.5 p -80.12 0.99 29.78 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.624 ' O ' HG22 ' A' ' 90' ' ' THR . 1.3 m -116.97 -27.59 6.51 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.2 -177.72 4.58 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.34 124.37 45.74 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.85 ' O ' HG13 ' A' ' 110' ' ' ILE . 60.2 m -103.92 153.27 20.99 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.056 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -146.52 146.98 30.7 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.921 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.384 ' CG2' HD13 ' A' ' 67' ' ' LEU . 4.0 t -107.48 159.58 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.345 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.25 171.96 44.78 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.224 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.97 122.12 25.05 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.211 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 6.7 m -102.95 154.79 18.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.504 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -114.75 -160.93 0.75 Allowed 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.467 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.8 -49.04 79.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.14 -26.02 60.08 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 98.6 49.21 1.7 Allowed Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.442 HD22 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -120.5 167.48 12.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.242 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.66 -176.85 45.16 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.405 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.41 159.6 48.89 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.32 3.347 . . . . 0.0 109.577 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.371 ' H ' ' CD ' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -37.32 125.44 1.01 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.94 147.64 0.09 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.056 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -115.89 104.51 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.65 138.09 32.38 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.026 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.4 mt -113.61 159.09 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -143.52 119.12 10.4 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.726 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 40.1 m-85 -95.14 123.42 38.63 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.939 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.671 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . -148.1 121.99 4.84 Favored Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.466 ' HB2' ' CD2' ' A' ' 26' ' ' LEU . 83.1 Cg_endo -72.41 -175.48 1.81 Allowed 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 124.336 3.357 . . . . 0.0 109.628 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.322 HG23 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -100.03 117.92 35.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -133.52 150.63 51.68 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.1 114.24 25.81 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.707 ' HB ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -111.08 149.75 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.745 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.9 167.36 24.76 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.745 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.3 Cg_endo -72.38 119.31 6.06 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.295 3.33 . . . . 0.0 109.586 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.726 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -125.38 13.71 8.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.1 p -92.33 114.95 27.63 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.709 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.03 22.58 32.34 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.726 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -108.39 139.16 43.5 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 179.963 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 59.1 m -97.27 169.57 9.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -44.71 151.2 0.3 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.81 -24.35 31.4 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 18' ' ' VAL . 2.4 m -78.51 144.23 35.86 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.614 ' N ' HG23 ' A' ' 17' ' ' THR . 7.3 p -112.99 146.05 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.668 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.7 OUTLIER -117.2 157.61 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.707 ' O ' ' HB ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -113.1 151.1 31.2 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.753 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -146.16 105.37 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.21 115.46 26.03 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.799 ' HA2' ' HB3' ' A' ' 5' ' ' ALA . . . -84.26 143.34 21.03 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.322 ' O ' HG23 ' A' ' 4' ' ' THR . . . -139.56 110.66 6.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.455 ' C ' HD21 ' A' ' 26' ' ' LEU . . . 98.81 23.83 11.4 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.466 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.75 -169.77 2.73 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.665 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -81.83 122.78 28.15 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.31 131.74 43.88 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.95 7.83 81.92 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.659 HG21 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.31 140.48 30.14 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.905 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -90.59 151.61 21.24 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.497 ' CB ' ' CD1' ' A' ' 97' ' ' LEU . 43.2 m-85 -138.0 154.58 49.32 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.512 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 11.1 m-20 -118.5 112.46 19.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.484 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -97.62 149.61 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.994 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.99 167.01 38.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.837 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 15.5 tt0 -107.72 129.34 55.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.251 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.0 m -125.88 165.5 18.6 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.035 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -142.51 123.93 14.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.634 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.97 117.63 7.9 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.814 HG21 ' CD1' ' A' ' 83' ' ' TRP . 5.5 m -99.53 -42.52 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.432 ' N ' HG23 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -138.23 -179.49 5.82 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.973 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.4 m -63.38 111.52 2.33 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.18 8.46 65.32 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.582 HG11 ' CH2' ' A' ' 83' ' ' TRP . 62.4 t -121.97 106.96 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.61 HD13 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.84 136.47 54.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.216 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -85.45 157.79 20.37 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.251 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.3 m -126.24 156.63 39.97 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.572 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.5 t30 -123.91 111.94 28.9 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -72.4 -0.68 9.07 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.308 3.339 . . . . 0.0 109.604 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.493 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -87.55 -13.32 43.25 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.0 p30 -130.09 27.9 5.08 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.56 117.72 33.63 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.8 t -111.36 -178.24 3.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.0 p -147.78 155.42 41.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.423 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.0 p -167.52 160.42 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.423 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 37.6 m -127.15 129.91 48.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.83 150.86 40.57 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -90.5 -171.08 2.94 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.62 -28.85 69.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -75.53 -7.94 55.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.5 10.05 86.48 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.2 p -102.03 137.68 39.99 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.35 165.04 15.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 p -150.1 125.18 9.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.576 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.96 164.4 38.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.949 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.576 ' N ' HG21 ' A' ' 65' ' ' THR . 0.6 OUTLIER -120.39 126.17 49.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.899 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -103.74 118.69 37.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.68 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -68.44 116.78 9.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.546 HG21 ' HB3' ' A' ' 10' ' ' SER . 0.5 OUTLIER -73.32 122.83 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.68 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -118.02 133.01 56.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -67.85 -40.8 83.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.469 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 19.5 m -155.96 159.37 39.17 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.837 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -177.35 177.78 1.15 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -64.9 121.89 15.69 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.216 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -80.6 87.21 1.32 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.783 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.29 100.18 10.46 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.958 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.6 tp -54.15 144.13 20.62 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.415 ' N ' ' CD1' ' A' ' 77' ' ' LEU . 1.8 m-85 -47.16 -43.67 21.27 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.724 ' HB3' HD23 ' A' ' 77' ' ' LEU . 10.3 t0 -57.76 -17.16 13.88 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.24 29.09 9.89 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.2 m -108.61 121.18 44.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.432 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.1 ptt180 -62.81 91.07 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.582 ' CH2' HG11 ' A' ' 44' ' ' VAL . 4.9 t-105 -63.13 -58.37 7.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.15 157.0 8.15 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -54.52 110.13 0.59 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.035 HG11 ' CB ' ' A' ' 38' ' ' ALA . 16.8 t -88.49 154.54 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.469 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 27.4 m-20 -118.85 94.55 4.49 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.186 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 93.5 m -52.0 -28.82 18.26 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.841 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 2.1 t -76.18 -1.24 25.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.49 ' O ' HG22 ' A' ' 90' ' ' THR . 1.8 m -115.24 -27.16 7.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.74 -166.2 1.6 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.52 123.39 46.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.14 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 0.8 OUTLIER -104.47 156.29 18.07 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.04 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.12 154.87 42.29 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.899 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 6.4 t -122.11 160.79 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.229 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.28 171.83 42.81 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.512 ' HA ' ' C ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -127.66 124.79 38.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.302 ' N ' ' O ' ' A' ' 33' ' ' ASP . 59.6 p -99.47 152.62 19.79 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.905 ' HB2' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -115.14 -164.24 0.93 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.9 -48.89 77.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -70.73 -24.86 62.71 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 95.6 53.81 1.51 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.831 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.13 175.9 8.71 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.669 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 179.31 -173.91 45.86 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.19 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.33 157.58 53.13 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.357 3.371 . . . . 0.0 109.611 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.671 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.01 124.71 1.18 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.64 140.13 0.3 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.0 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.3 t -101.47 113.99 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.837 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -87.27 126.08 34.61 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.072 HD11 ' HB3' ' A' ' 93' ' ' CYS . 13.1 pt -135.07 -172.94 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.54 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -175.74 178.27 1.57 Allowed 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.186 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.1 m-85 -140.75 109.35 5.94 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.516 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 8.2 p30 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.518 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . -79.04 119.15 76.19 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.7 Cg_endo -72.34 -177.73 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.263 0 C-N-CA 124.353 3.369 . . . . 0.0 109.619 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.88 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.4 m -98.51 109.51 22.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.858 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.27 163.67 22.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.469 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.1 p -129.55 115.63 17.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.771 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.3 t -111.07 149.53 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.867 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.66 171.17 7.6 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.867 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.33 117.18 5.01 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.366 3.377 . . . . 0.0 109.589 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.777 ' HA ' HD13 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.32 13.21 7.12 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.528 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.8 p -91.08 108.39 19.84 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.915 ' HA2' HD21 ' A' ' 113' ' ' ASN . . . 99.81 16.04 29.69 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.777 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -103.81 140.46 37.62 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 p -95.67 173.28 7.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -47.04 153.77 0.41 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.38 -24.28 28.1 Favored Glycine 0 C--N 1.335 0.493 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.601 HG22 ' N ' ' A' ' 18' ' ' VAL . 3.6 m -71.36 149.66 45.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.601 ' N ' HG22 ' A' ' 17' ' ' THR . 8.4 p -120.49 132.74 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.569 ' HA ' HG23 ' A' ' 8' ' ' THR . 0.6 OUTLIER -111.51 153.51 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.771 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.32 152.87 23.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.75 ' HA ' HG21 ' A' ' 7' ' ' VAL . 1.1 p -145.04 109.42 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.858 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.23 114.44 21.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.667 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.65 146.39 22.37 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.88 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.94 113.25 7.26 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.49 14.97 31.03 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.817 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.99 165.89 13.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.598 ' CD ' ' OH ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -49.61 119.83 3.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.525 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.25 134.81 44.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.89 8.06 67.63 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.498 HG22 ' N ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -95.6 145.74 25.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.498 ' N ' HG22 ' A' ' 30' ' ' THR . . . -88.04 151.03 23.06 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.431 ' CB ' HD21 ' A' ' 97' ' ' LEU . 35.3 m-85 -137.96 159.16 42.77 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.249 ' HB3' ' CA ' ' A' ' 98' ' ' SER . 3.3 t0 -124.0 115.04 20.57 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.209 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -96.56 142.26 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.856 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.42 164.67 34.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.716 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.2 tt0 -116.19 111.34 20.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 59.4 m -107.82 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.105 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -149.63 123.86 9.53 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.64 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.95 117.45 7.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.597 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 5.6 m -98.2 -43.26 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 40' ' ' VAL . 0.2 OUTLIER -135.46 177.83 7.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.8 m -61.34 112.01 1.99 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.3 8.54 66.05 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 59.1 t -121.53 111.14 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.453 HD11 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -126.26 139.61 53.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.989 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.247 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -94.57 144.36 25.66 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.5 m -110.19 146.9 34.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.709 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 29.2 t30 -107.47 107.74 60.77 Favored Pre-proline 0 N--CA 1.449 -0.488 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.2 Cg_endo -72.34 0.61 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 124.368 3.378 . . . . 0.0 109.599 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.497 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.05 -14.1 39.82 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.492 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.7 p30 -126.04 28.24 6.13 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.43 105.49 14.42 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.1 t -103.14 178.27 4.6 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.8 p -147.06 156.86 43.36 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.642 ' CG1' HD22 ' A' ' 97' ' ' LEU . 7.1 p -167.88 160.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.478 ' N ' HG22 ' A' ' 55' ' ' VAL . 26.9 m -126.96 138.32 53.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.8 143.6 34.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.4 p30 -80.25 -171.05 2.8 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.13 -26.11 68.39 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -10.07 59.13 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.817 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 77.11 31.18 53.6 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -127.61 137.27 52.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.46 168.32 13.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.6 128.51 11.75 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.578 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -154.09 162.32 41.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.578 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -115.82 119.73 36.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.074 HD13 HG12 ' A' ' 95' ' ' VAL . 1.0 OUTLIER -97.57 133.94 41.45 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.73 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -79.75 134.56 36.38 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.497 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 1.1 t -94.29 124.1 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.73 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.7 OUTLIER -117.2 142.95 46.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.428 ' HG2' HG22 ' A' ' 89' ' ' THR . 0.1 OUTLIER -80.92 -26.74 36.54 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -155.42 149.85 26.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.949 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.716 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -173.77 157.88 3.16 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.28 117.51 4.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.247 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.26 93.3 1.09 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.786 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -84.14 99.86 10.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.757 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.8 tp -57.02 130.39 45.87 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.627 ' N ' HD11 ' A' ' 77' ' ' LEU . 4.5 p90 -47.16 -35.63 7.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.757 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.78 -16.57 11.73 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.68 28.38 8.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.632 HG23 ' N ' ' A' ' 82' ' ' ARG . 1.3 m -116.23 147.78 41.1 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.632 ' N ' HG23 ' A' ' 81' ' ' THR . 1.5 ttp180 -84.73 96.02 9.12 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.597 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 68.7 t90 -64.97 -58.82 5.13 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.75 163.87 10.93 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.17 106.42 0.23 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.105 HG12 ' HB3' ' A' ' 38' ' ' ALA . 20.2 t -80.77 152.46 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.68 93.99 4.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.277 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 12.1 m -53.13 -26.57 17.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.717 ' HA ' ' HB3' ' A' ' 112' ' ' PHE . 7.3 t -82.37 0.1 43.46 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.447 ' O ' HG22 ' A' ' 90' ' ' THR . 8.0 m -114.3 -27.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.93 3.63 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.897 ' HB3' ' HG ' ' A' ' 111' ' ' SER . . . -99.57 126.0 45.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.264 ' CB ' HD11 ' A' ' 110' ' ' ILE . 92.4 m -104.2 172.01 7.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.041 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 1.2 tt0 -160.93 151.5 18.14 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.074 HG12 HD13 ' A' ' 67' ' ' LEU . 3.0 t -108.65 167.1 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.209 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.36 166.65 37.29 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.431 HD21 ' CB ' ' A' ' 32' ' ' TYR . 6.0 mp -102.16 161.82 13.39 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.249 ' CA ' ' HB3' ' A' ' 33' ' ' ASP . 46.7 t -150.86 121.07 7.25 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.645 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.8 OUTLIER -115.86 -170.9 1.88 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -46.0 -39.65 9.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.96 -25.33 26.12 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 91.16 22.61 31.94 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 1.35 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.11 -150.27 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.996 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.2 150.62 5.49 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 166.0 31.03 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.307 3.338 . . . . 0.0 109.578 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.518 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 6.6 pt-20 -34.34 124.3 0.5 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.21 135.32 1.48 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.041 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 3.4 t -90.05 107.43 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.91 127.83 34.12 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.264 HD11 ' CB ' ' A' ' 93' ' ' CYS . 4.0 pt -141.5 -173.77 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.897 ' HG ' ' HB3' ' A' ' 92' ' ' ALA . 0.6 OUTLIER -174.75 163.4 3.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.277 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 6.6 m-85 -125.88 112.16 15.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.915 HD21 ' HA2' ' A' ' 12' ' ' GLY . 0.8 OUTLIER . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.579 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -128.38 144.37 51.7 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.542 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.39 -177.2 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.317 3.344 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.756 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.78 109.59 22.33 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.721 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.08 140.3 52.03 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -100.5 111.48 23.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.742 ' CG2' HG22 ' A' ' 108' ' ' VAL . 21.8 t -105.84 150.29 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.5 175.7 1.51 Allowed Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.956 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.4 118.59 5.67 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.318 3.346 . . . . 0.0 109.586 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.908 ' HB2' HG23 ' A' ' 110' ' ' ILE . 54.5 p -113.0 47.52 1.11 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.0 p -126.56 107.38 10.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.698 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.9 27.0 20.62 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.701 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -102.01 132.49 47.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 82.0 p -109.88 169.28 8.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -45.04 140.72 2.57 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.67 38.31 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.6 m -77.05 141.87 40.11 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 18' ' ' VAL . 10.9 p -113.78 108.95 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.729 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 4.4 m -77.13 164.07 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.56 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.1 149.72 38.52 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.653 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -146.56 115.41 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.721 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.86 116.96 23.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.602 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -84.18 147.94 23.9 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.756 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.61 111.81 4.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.66 14.44 34.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.776 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.64 173.64 8.19 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.489 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 33.5 mt-30 -56.37 119.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.08 131.23 41.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.13 7.82 84.75 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.489 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.83 141.37 28.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.679 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.46 150.35 25.35 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.28 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 25.4 m-85 -136.38 140.81 43.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.489 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.5 m-20 -103.11 116.91 33.4 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.628 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -107.12 145.63 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.886 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.54 161.73 31.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.953 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 18.9 tt0 -101.97 120.61 40.69 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.482 ' SG ' HD13 ' A' ' 45' ' ' LEU . 1.5 m -109.99 169.0 9.01 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.114 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.73 124.91 8.71 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.611 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.64 124.03 20.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.792 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 15.4 m -103.73 -44.07 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.847 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -138.52 165.23 27.39 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.5 m -51.88 112.6 0.81 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.24 8.21 65.05 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 97.3 t -122.32 107.47 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.482 HD13 ' SG ' ' A' ' 37' ' ' CYS . 1.4 pp -117.71 162.38 18.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.357 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -127.11 156.59 41.5 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.863 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -118.47 155.49 30.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.666 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 19.8 t30 -112.86 113.58 49.79 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -72.38 0.03 8.02 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.343 3.362 . . . . 0.0 109.612 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.98 -9.51 45.73 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.2 p30 -134.16 27.72 3.82 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.42 107.29 17.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -103.49 171.38 7.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.2 p -145.27 153.54 41.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.7 p -166.6 158.23 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 85.7 m -127.52 135.53 50.49 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.45 139.97 48.02 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.2 p30 -77.6 -174.75 3.54 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.8 -25.08 68.06 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -75.99 -8.04 56.04 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.633 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 75.3 32.18 55.96 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -129.87 137.62 50.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.6 167.39 14.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -150.56 125.43 9.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.497 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -159.84 158.26 30.68 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.497 ' N ' HG21 ' A' ' 65' ' ' THR . 0.8 OUTLIER -111.17 133.46 53.51 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.225 ' CG ' HG22 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -110.3 120.16 41.54 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.623 ' OG1' ' NH1' ' A' ' 70' ' ' ARG . 3.5 t -79.26 129.86 34.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.565 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -107.88 137.02 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.868 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -120.31 165.62 14.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.5 -14.12 33.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.601 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.2 m -164.51 144.49 7.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.953 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.4 p90 -176.3 154.24 1.32 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.494 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.9 OUTLIER -57.3 124.26 18.26 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.357 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -84.75 98.08 2.18 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.863 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.2 101.75 12.1 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.618 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.0 tp -57.81 131.62 50.88 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.512 ' N ' HD12 ' A' ' 77' ' ' LEU . 29.6 p90 -47.64 -35.76 9.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.618 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -58.01 -16.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.22 28.46 9.18 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 ' N ' ' A' ' 82' ' ' ARG . 22.0 m -115.66 146.69 41.6 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.587 ' N ' HG22 ' A' ' 81' ' ' THR . 0.0 OUTLIER -84.0 96.58 8.91 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.95 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.847 ' HZ2' ' HB2' ' A' ' 41' ' ' ASP . 5.2 t-105 -63.45 -42.69 98.66 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 128.43 176.55 14.49 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.53 135.55 54.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.114 HG11 ' CB ' ' A' ' 38' ' ' ALA . 1.6 t -114.82 154.93 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -127.81 101.34 6.31 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.904 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 48.9 m -53.35 -28.04 26.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -79.04 -2.45 40.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.617 HG21 ' O ' ' A' ' 90' ' ' THR . 1.3 m -116.19 -27.59 6.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.92 -176.12 3.76 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.0 123.38 45.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.703 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 72.3 m -104.35 152.24 22.5 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.02 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -145.05 148.81 34.12 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.225 HG22 ' CG ' ' A' ' 67' ' ' LEU . 2.5 t -114.31 148.2 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.405 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.74 173.87 46.41 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.628 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -125.66 159.88 31.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.489 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 2.9 m -139.64 156.95 46.55 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.679 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.11 -165.45 1.0 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -55.79 -49.18 73.89 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.435 ' HB1' ' OD1' ' A' ' 103' ' ' ASN . . . -71.0 -25.37 62.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.69 39.55 3.37 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.589 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -113.57 154.32 27.34 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.28 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -161.86 -173.1 30.11 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.542 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.41 158.41 51.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.332 3.354 . . . . 0.0 109.557 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.579 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 2.4 mt-10 -38.64 117.26 0.63 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.09 153.2 0.01 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.742 HG22 ' CG2' ' A' ' 7' ' ' VAL . 11.0 t -127.05 106.71 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.433 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -82.69 133.89 35.15 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.02 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.5 mt -102.76 163.87 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.722 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -145.73 123.34 11.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.904 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.7 m-85 -95.32 127.36 41.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.968 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.58 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -98.86 125.57 41.69 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.63 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.37 -174.1 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.327 3.351 . . . . 0.0 109.591 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.49 110.75 23.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.864 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.72 139.16 52.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.544 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.71 112.48 24.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.88 HG13 HG22 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -110.51 152.89 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.926 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.48 174.06 2.87 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.926 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.9 Cg_endo -72.38 118.74 5.74 Favored 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 124.321 3.348 . . . . 0.0 109.618 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.757 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 92.0 p -111.94 49.08 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -127.54 106.41 9.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.672 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.44 27.5 20.0 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.691 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -100.67 132.22 46.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.6 m -109.22 172.27 6.95 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 1.023 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 7.6 t70 -46.6 141.53 3.71 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.2 -22.5 36.3 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.1 m -76.58 149.75 36.58 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.471 HG12 ' O ' ' A' ' 18' ' ' VAL . 11.7 p -121.5 114.66 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.695 HG21 HG11 ' A' ' 69' ' ' VAL . 11.6 t -81.03 153.19 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.768 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.82 147.18 33.76 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.614 HG11 ' CG1' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.3 111.15 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.864 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.87 117.13 27.32 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -82.08 144.77 24.0 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.9 102.29 3.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.571 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 109.04 17.64 10.01 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.127 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -90.23 171.36 9.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.988 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.982 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 26.7 mt-30 -56.9 121.82 10.8 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.649 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.59 131.75 42.04 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.0 7.77 86.72 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.53 HG23 ' CZ ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.12 136.59 36.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.964 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -82.64 152.25 25.96 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.871 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.4 m-85 -136.57 146.05 45.68 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.239 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -107.47 113.55 26.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.984 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.462 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.09 144.53 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.987 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.57 169.7 42.53 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.957 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 38.5 tt0 -106.4 105.31 15.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.142 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -105.71 141.14 37.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.979 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -122.78 138.57 54.59 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.563 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.93 124.44 22.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.918 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.141 HG23 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -103.66 -51.32 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.953 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -132.72 168.29 18.58 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.94 112.49 0.72 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.47 7.96 65.52 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.938 HG11 ' HE1' ' A' ' 83' ' ' TRP . 86.3 t -121.8 120.97 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.566 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -130.26 134.5 47.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.979 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.39 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -93.42 153.53 18.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.142 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 98.6 m -112.64 145.51 40.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.902 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -108.88 114.18 58.72 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.36 -0.24 8.41 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 124.332 3.355 . . . . 0.0 109.584 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.33 -12.67 58.96 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.635 ' OD1' HG21 ' A' ' 68' ' ' THR . 96.2 m-20 -136.66 29.78 2.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -84.36 108.36 17.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.8 t -107.0 173.41 6.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 p -145.59 154.45 42.17 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG21 ' N ' ' A' ' 56' ' ' THR . 6.8 p -167.06 156.82 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.512 ' N ' HG21 ' A' ' 55' ' ' VAL . 36.3 m -126.84 135.62 51.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.14 154.1 42.62 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -92.86 -169.42 2.17 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.57 -28.34 69.81 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.72 -7.56 54.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.649 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.11 14.96 81.76 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -107.83 137.68 45.41 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.92 165.45 15.19 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 p -149.94 128.12 12.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.524 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.67 160.85 20.39 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.899 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.524 ' N ' HG21 ' A' ' 65' ' ' THR . 0.5 OUTLIER -117.65 127.41 53.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.104 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.2 120.19 40.93 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.905 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.635 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.42 134.99 39.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.695 HG11 HG21 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.9 135.28 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 1.023 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -116.71 162.47 17.62 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -87.98 -19.51 27.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.492 ' HB2' ' OD1' ' A' ' 87' ' ' ASP . 28.5 t -163.05 146.73 10.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.957 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.7 p90 -177.04 152.75 0.93 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -57.66 118.96 5.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.39 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -80.64 98.98 1.83 Allowed Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.793 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.13 100.96 10.86 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.769 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.5 tp -54.78 131.79 44.62 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.536 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 4.8 m-85 -47.43 -36.48 9.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.769 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.7 t0 -57.13 -16.66 8.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.27 27.72 9.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.435 ' HB ' HD22 ' A' ' 77' ' ' LEU . 1.6 m -115.89 149.93 37.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.56 98.04 11.54 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.141 ' CE3' HG23 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -63.94 -43.71 95.06 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.946 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 135.69 -179.65 17.55 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.44 126.16 26.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.979 HG12 ' CB ' ' A' ' 38' ' ' ALA . 2.1 t -101.45 154.02 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.492 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 11.7 m-20 -127.45 96.79 4.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.78 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 54.4 m -53.23 -27.81 24.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -78.32 1.28 22.34 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.14 -27.53 6.06 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.16 -173.28 3.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.8 124.72 48.86 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.869 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 97.6 m -104.36 152.52 22.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.071 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -146.39 148.43 32.31 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.104 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.7 t -110.3 160.06 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.397 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 168.8 41.07 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.462 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.12 128.38 44.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.239 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 22.2 m -114.72 148.3 38.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.964 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -107.13 -157.97 0.64 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.49 -47.26 64.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.02 -23.97 64.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.01 53.88 1.98 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.982 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.21 165.96 20.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.871 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.62 46.71 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.63 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.38 162.44 41.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.346 3.364 . . . . 0.0 109.59 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.58 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 1.5 tt0 -37.59 120.83 0.84 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.535 ' N ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.66 153.54 0.02 OUTLIER Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.952 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.8 t -118.3 104.18 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.62 124.05 32.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.071 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.9 mt -101.31 157.0 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.65 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -141.94 125.36 16.64 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.78 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 9.5 m-85 -96.6 124.28 40.54 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.405 ' HB3' ' N ' ' A' ' 106' ' ' GLU . . . -61.48 131.64 92.61 Favored Pre-proline 0 N--CA 1.45 -0.465 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.377 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.4 Cg_endo -72.4 -174.31 1.39 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.268 3.312 . . . . 0.0 109.616 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.805 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.66 108.27 19.75 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.867 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.57 146.24 47.17 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.501 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -113.24 118.17 33.92 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.82 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -114.13 155.15 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.993 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.639 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -71.54 162.19 74.32 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.635 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 121.98 7.93 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.322 3.348 . . . . 0.0 109.606 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.736 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.2 OUTLIER -126.93 15.84 7.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.6 111.73 22.23 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.978 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 91.3 22.58 31.7 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.736 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -109.11 144.12 37.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 75.5 m -94.29 166.03 12.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 1.128 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 11.5 t0 -46.15 153.34 0.33 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 100.02 -24.27 32.78 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.489 ' HG1' ' HB3' ' A' ' 13' ' ' LEU . 24.5 m -69.17 132.62 46.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 8.3 p -106.43 111.33 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.639 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 6.4 m -90.37 166.08 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.82 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.04 149.1 44.82 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' CG1' HG13 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -136.41 104.88 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.867 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.8 117.83 31.84 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.644 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -88.03 143.82 18.37 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.805 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -135.01 108.09 7.65 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.509 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 101.69 25.69 7.98 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.34 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.89 179.69 6.14 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 180.0 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -76.83 123.74 26.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.484 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.11 137.46 54.96 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.78 7.28 65.25 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.644 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.16 145.12 24.65 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.2 149.11 22.01 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.531 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 39.8 m-85 -138.05 136.83 37.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.065 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -99.61 114.75 27.99 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.197 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.99 143.19 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.897 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.66 162.14 35.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.936 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -101.01 117.78 35.7 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 m -108.65 164.57 12.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.789 ' HB1' HG12 ' A' ' 86' ' ' VAL . . . -150.47 139.44 20.98 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.527 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -64.67 124.55 22.21 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.228 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -106.4 -53.93 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.625 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -138.1 167.03 22.66 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -51.02 111.58 0.58 Allowed 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.59 8.15 66.51 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.602 ' CG1' ' CZ3' ' A' ' 83' ' ' TRP . 13.8 t -124.21 118.91 55.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.426 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 2.0 pp -121.93 163.3 19.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.204 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -127.51 146.19 50.59 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.769 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.15 159.13 17.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.985 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.906 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.2 t30 -113.04 112.74 49.81 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.39 -0.82 9.28 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.339 3.36 . . . . 0.0 109.592 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.449 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.95 -7.92 50.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.449 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 32.9 m-20 -133.82 26.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.25 106.12 15.62 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.8 t -104.73 176.38 5.18 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.7 p -146.09 158.45 43.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.5 p -166.98 158.3 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.5 m -128.37 127.35 42.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.61 141.57 58.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.5 p30 -85.22 -171.57 3.7 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.53 -23.52 67.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -83.67 1.0 44.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 70.44 2.35 41.83 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 t -95.12 136.08 35.88 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.45 161.99 21.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -147.51 129.59 15.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.592 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -151.7 174.24 13.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.888 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.592 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -130.96 114.64 15.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.315 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -98.38 156.89 16.52 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.601 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -116.64 134.67 54.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.634 HG13 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -101.03 131.06 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 1.128 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -115.74 147.92 40.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 ptt180 -74.48 -25.15 59.2 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.5 t -159.94 150.01 18.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.936 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.6 p90 -177.34 156.03 1.17 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.23 119.83 7.58 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.204 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -76.32 100.39 1.39 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.769 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.35 100.04 10.41 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.824 HD21 ' HB2' ' A' ' 79' ' ' ASP . 4.3 tp -55.05 137.12 47.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -46.62 -40.99 13.93 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.824 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.5 m-20 -57.09 -17.0 8.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.98 26.87 10.84 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 m -109.51 148.63 30.89 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.76 95.73 8.52 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.625 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 33.3 t-105 -62.8 -56.43 17.55 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.04 170.72 19.0 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.53 107.44 0.8 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.789 HG12 ' HB1' ' A' ' 38' ' ' ALA . 2.8 t -83.41 152.33 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.77 93.71 4.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.268 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -55.03 -22.27 15.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.517 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 25.7 p -85.93 2.24 46.86 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -110.98 -26.57 9.2 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.54 179.22 6.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.7 ' HB3' ' OG ' ' A' ' 111' ' ' SER . . . -94.06 129.45 40.59 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.066 ' CB ' HD13 ' A' ' 110' ' ' ILE . 59.1 m -104.86 173.07 6.46 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.371 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -158.67 142.55 15.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.951 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.315 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.4 t -98.21 164.13 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.112 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.93 161.25 26.87 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.197 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -126.55 135.71 51.63 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.065 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 52.4 p -106.99 158.79 16.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.466 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.0 OUTLIER -112.46 -167.53 1.2 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.466 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -53.8 -49.83 67.45 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.52 -25.4 59.31 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.4 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 104.67 39.44 2.37 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.44 ' ND2' ' CG ' ' A' ' 99' ' ' ASP . 0.5 OUTLIER -122.92 -175.34 3.14 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.531 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 162.14 -161.88 33.79 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.377 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.91 52.44 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.382 3.388 . . . . 0.0 109.553 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.405 ' N ' ' HB3' ' A' ' 2' ' ' ALA . 9.0 pt-20 -42.84 145.23 0.48 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.76 164.5 1.75 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.371 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 37.3 t -116.84 102.69 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.436 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -75.88 132.48 40.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.066 HD13 ' CB ' ' A' ' 93' ' ' CYS . 6.2 pt -142.41 -174.36 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.7 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 0.1 OUTLIER -171.02 176.1 4.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.268 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 4.6 m-85 -132.55 114.29 14.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.978 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.4 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.652 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -126.28 131.31 23.9 Favored Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.601 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.38 -177.7 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 124.314 3.343 . . . . 0.0 109.635 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.785 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.77 109.69 22.41 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.769 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.46 133.52 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.632 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -96.51 115.85 28.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.29 155.95 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.947 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 175.61 1.77 Allowed Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.947 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.37 117.4 5.11 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.32 3.346 . . . . 0.0 109.58 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.852 ' HB2' HG23 ' A' ' 110' ' ' ILE . 1.6 p -110.73 48.57 0.91 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 79.9 p -126.97 105.88 8.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.696 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 92.32 29.27 11.43 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.712 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -108.43 130.29 55.24 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.951 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.19 177.36 4.67 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -45.83 139.39 4.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.07 -22.77 34.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.408 HG21 ' N ' ' A' ' 18' ' ' VAL . 17.2 m -83.13 150.56 26.19 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.408 ' N ' HG21 ' A' ' 17' ' ' THR . 13.9 p -121.49 123.96 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.843 HG13 HG22 ' A' ' 69' ' ' VAL . 6.8 m -90.44 158.44 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.38 149.08 30.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.709 HG11 ' O ' ' A' ' 65' ' ' THR . 0.3 OUTLIER -145.09 113.38 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.769 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.65 117.19 22.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.623 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -84.06 147.75 23.89 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.785 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.36 111.32 4.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.17 15.61 30.04 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.623 HD22 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.6 177.05 6.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.52 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 29.7 mt-30 -59.61 121.5 11.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.532 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.22 129.8 39.3 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.08 7.04 86.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.659 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.23 141.5 28.51 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.92 149.85 23.83 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.786 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.6 m-85 -136.43 138.09 41.14 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.987 ' HB3' ' O ' ' A' ' 98' ' ' SER . 1.5 t0 -99.99 113.84 26.7 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.245 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.04 144.72 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.73 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.84 171.05 42.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.929 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 33.8 tt0 -117.64 108.77 15.84 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.077 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.76 147.66 37.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.028 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -122.33 142.87 50.04 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.503 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.98 124.97 23.45 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.898 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.443 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -104.89 -44.25 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.334 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -149.05 134.8 18.81 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 41' ' ' ASP . 1.5 m -38.18 110.92 0.14 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.459 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 94.46 8.3 59.87 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.172 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.7 OUTLIER -151.59 129.26 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.635 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -133.96 132.95 40.78 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.283 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -84.27 144.69 28.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.077 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 2.6 m -106.44 152.92 23.0 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.851 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 41.4 t-20 -111.64 107.4 56.64 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 82.1 Cg_endo -72.4 -0.05 8.16 Favored 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 124.308 3.338 . . . . 0.0 109.599 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.17 -10.44 49.89 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.697 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.3 OUTLIER -131.71 27.56 4.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.501 ' HD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -80.5 104.6 11.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -100.11 175.35 5.77 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.3 p -143.94 153.39 42.22 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.545 HG22 ' N ' ' A' ' 56' ' ' THR . 8.6 p -167.98 152.24 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.545 ' N ' HG22 ' A' ' 55' ' ' VAL . 39.7 m -127.47 134.71 49.81 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.4 141.63 50.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 45.2 p30 -81.57 -173.33 4.34 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -27.21 68.71 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -8.61 57.13 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.595 ' O ' HD13 ' A' ' 26' ' ' LEU . . . 76.81 31.87 52.05 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.1 p -127.93 139.67 52.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.503 ' HB1' HG21 ' A' ' 55' ' ' VAL . . . -123.35 165.81 16.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.71 122.89 8.91 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.709 ' O ' HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -158.73 152.22 22.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.541 ' N ' HG21 ' A' ' 65' ' ' THR . 0.3 OUTLIER -113.75 127.95 56.23 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.939 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.205 HD11 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -97.78 156.4 16.59 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.956 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 51' ' ' ASP . 4.8 t -102.67 120.96 41.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.843 HG22 HG13 ' A' ' 19' ' ' VAL . 1.0 OUTLIER -83.22 127.79 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.924 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.8 OUTLIER -117.14 155.81 28.7 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -94.21 -18.26 21.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 3.6 m -164.19 144.75 8.22 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.929 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.7 p90 -172.24 153.64 3.09 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -57.98 111.67 1.25 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.283 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.67 101.76 0.89 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.757 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.37 99.68 10.2 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.719 HD13 ' N ' ' A' ' 78' ' ' PHE . 2.3 tp -55.44 141.14 37.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.719 ' N ' HD13 ' A' ' 77' ' ' LEU . 1.3 m-85 -46.54 -42.9 16.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.572 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.33 -16.89 9.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.82 27.69 12.27 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.641 HG21 ' N ' ' A' ' 82' ' ' ARG . 3.3 m -109.23 144.72 36.97 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.641 ' N ' HG21 ' A' ' 81' ' ' THR . 1.6 ptt180 -76.89 94.77 3.97 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.443 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 31.5 t-105 -63.19 -57.2 11.3 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.52 163.79 12.51 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.1 104.67 0.33 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.028 HG11 ' HB3' ' A' ' 38' ' ' ALA . 67.9 t -76.64 150.45 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.5 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 4.2 m-20 -117.19 93.91 4.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.999 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 30.8 m -52.16 -27.22 13.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.6 p -80.01 0.36 32.01 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.607 ' O ' HG23 ' A' ' 90' ' ' THR . 1.6 m -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.73 -175.1 3.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.65 126.48 47.15 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.903 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.2 m -104.55 154.37 20.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.016 ' HA ' HG13 ' A' ' 110' ' ' ILE . 2.1 pt20 -142.55 150.05 39.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.205 ' CG1' HD11 ' A' ' 67' ' ' LEU . 4.4 t -110.62 164.04 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.245 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.66 166.31 36.01 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.961 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.96 121.03 27.15 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.987 ' O ' ' HB3' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -103.52 150.96 23.41 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -109.81 -159.93 0.7 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.973 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.27 -48.87 79.07 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.53 -25.71 57.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.86 42.24 2.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.449 HD22 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -111.68 166.27 11.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.99 -177.64 44.24 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.601 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.06 54.0 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.3 3.333 . . . . 0.0 109.6 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.13 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 1.9 mt-10 -35.39 125.89 0.62 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.06 151.88 0.02 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.913 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -124.39 104.68 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.483 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -84.63 146.06 27.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.016 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.8 mt -121.05 157.37 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.54 115.76 11.77 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.999 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 11.6 m-85 -86.56 114.27 23.15 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 2.8 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.443 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . -87.1 122.94 70.85 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.468 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.6 Cg_endo -72.4 -178.26 3.22 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 124.303 3.336 . . . . 0.0 109.581 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.839 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.62 111.33 23.68 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.835 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.69 159.58 33.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.434 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.5 p -124.29 121.28 34.57 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.821 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 55.5 t -116.87 146.39 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.769 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.96 167.75 18.72 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.769 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 118.65 5.7 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.357 3.372 . . . . 0.0 109.576 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.729 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.7 OUTLIER -129.71 9.93 5.51 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.965 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 1.043 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.2 p -85.66 106.44 16.94 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 1.386 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 102.25 14.52 28.1 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.729 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -106.04 136.07 46.38 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.969 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -92.31 176.63 6.41 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.64 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 11.0 t70 -44.79 153.12 0.19 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.82 -23.34 34.68 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.592 HG21 ' N ' ' A' ' 18' ' ' VAL . 10.4 m -72.58 142.97 48.42 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.592 ' N ' HG21 ' A' ' 17' ' ' THR . 10.6 p -118.9 121.04 65.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.666 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.8 OUTLIER -100.59 154.31 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.821 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.2 151.0 26.51 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.724 ' HA ' HG21 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -141.95 109.19 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.835 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.46 115.43 22.21 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.662 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -86.62 146.36 20.7 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.839 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.2 112.12 6.86 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.49 17.75 25.56 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.896 HD21 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.48 167.61 12.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.786 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 18.2 mt-30 -52.22 121.21 6.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.522 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.23 130.69 40.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.35 7.12 86.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.531 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -94.95 139.12 31.78 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.503 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.42 152.55 23.95 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.701 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 33.5 m-85 -136.71 139.82 42.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.245 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.72 113.8 27.59 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.268 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -102.68 149.66 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.835 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.4 172.32 43.99 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.847 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 36.8 tt0 -113.5 110.91 21.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.7 m -108.94 147.12 32.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.919 ' HB2' HG23 ' A' ' 86' ' ' VAL . . . -125.95 131.58 52.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.61 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.25 120.52 12.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.919 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.975 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.7 m -100.35 -43.23 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.508 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -136.85 166.1 24.41 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.951 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.511 ' O ' HG23 ' A' ' 42' ' ' THR . 15.3 t -51.14 111.74 0.61 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.12 8.52 65.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.567 ' O ' HG21 ' A' ' 40' ' ' VAL . 21.0 t -122.09 109.41 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -123.89 141.17 52.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.184 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -100.28 155.13 17.95 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.9 m -111.04 149.61 30.5 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.542 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -117.1 115.66 38.22 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.37 1.02 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.345 . . . . 0.0 109.629 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.28 -14.25 57.6 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.456 ' OD1' HG23 ' A' ' 68' ' ' THR . 95.1 m-20 -132.86 29.58 4.11 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.53 109.77 18.18 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.5 t -105.7 174.1 6.03 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -146.35 149.78 34.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.1 p -166.22 155.51 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 97.1 m -126.05 133.02 51.84 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.17 138.73 47.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.7 p30 -77.44 -174.06 3.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -17.39 58.58 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -85.16 5.66 29.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 59.12 32.37 71.2 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.6 t -130.44 137.09 49.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.52 167.49 17.03 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 53.1 p -150.83 128.04 11.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.576 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.52 172.91 13.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.853 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.576 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.4 OUTLIER -126.09 122.78 36.75 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.905 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -100.43 143.45 30.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.926 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.549 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -100.45 143.99 29.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.606 ' CG2' ' HG ' ' A' ' 10' ' ' SER . 2.0 t -103.35 129.33 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.64 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -119.42 143.91 47.22 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.02 -32.05 68.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 33.2 t -158.09 158.96 35.71 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.847 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -177.0 163.93 2.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.26 120.93 13.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.184 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.11 93.2 0.96 Allowed Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 1.003 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 100.07 10.48 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.773 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.1 tp -54.5 137.47 42.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.816 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 3.0 m-85 -46.6 -40.77 13.49 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.773 ' HB3' HD23 ' A' ' 77' ' ' LEU . 7.7 t0 -56.89 -17.39 9.31 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 96.56 27.94 9.39 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.418 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.2 m -110.33 139.87 45.08 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -78.25 92.5 4.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.975 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 13.6 t90 -62.49 -57.92 9.48 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.07 166.06 13.41 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.95 128.83 38.83 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.919 HG23 ' HB2' ' A' ' 38' ' ' ALA . 13.7 p -113.15 147.51 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.528 ' N ' HG21 ' A' ' 86' ' ' VAL . 5.5 m-20 -99.3 95.19 6.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.745 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -54.88 -20.71 9.39 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.9 p -91.24 1.78 56.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.422 ' O ' HG22 ' A' ' 90' ' ' THR . 6.8 m -108.71 -27.01 10.04 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.4 176.64 8.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 1.075 ' HB1' ' HG ' ' A' ' 111' ' ' SER . . . -89.59 126.72 35.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.24 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -104.98 172.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.964 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.68 147.81 22.1 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.905 ' CG2' HD12 ' A' ' 67' ' ' LEU . 29.6 t -104.86 163.49 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.268 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.55 167.98 37.72 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.241 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -133.02 138.75 46.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.245 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 22.8 m -121.73 145.55 47.91 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.503 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -103.19 -158.56 0.67 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -70.55 -47.75 58.83 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.95 -24.39 66.06 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.2 53.62 1.85 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.786 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.04 165.26 23.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.52 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.01 171.46 42.96 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.468 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 166.2 30.46 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.344 3.363 . . . . 0.0 109.604 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.443 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 11.2 pt-20 -37.87 120.24 0.82 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.83 158.78 0.01 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.918 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.6 t -115.03 103.56 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.08 124.03 30.67 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.24 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.6 pt -134.49 -174.87 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 1.075 ' HG ' ' HB1' ' A' ' 92' ' ' ALA . 1.0 OUTLIER -170.83 175.94 4.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.2 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.8 m-85 -124.46 115.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 1.386 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 36.1 m-80 . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.602 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -143.99 119.9 6.3 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.479 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.37 -174.46 1.43 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.29 3.327 . . . . 0.0 109.642 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.279 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 5.8 t -100.94 115.24 29.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.736 ' CB ' ' HA2' ' A' ' 23' ' ' GLY . . . -129.73 165.18 22.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.429 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.3 p -125.99 122.2 35.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.846 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -118.7 145.78 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.641 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.29 163.03 65.88 Favored Pre-proline 0 N--CA 1.448 -0.538 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.641 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.2 Cg_endo -72.42 119.27 6.03 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.284 3.323 . . . . 0.0 109.595 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.757 ' HA ' HD13 ' A' ' 13' ' ' LEU . 2.2 t -126.95 14.03 7.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.818 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.0 p -88.95 105.83 18.02 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.691 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.17 21.59 13.22 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.757 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -109.87 139.51 44.87 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -85.96 169.2 13.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -44.42 152.29 0.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.53 -22.54 40.38 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.524 HG23 ' N ' ' A' ' 18' ' ' VAL . 35.9 m -64.17 140.63 58.89 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.524 ' N ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -116.82 110.95 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -180.0 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.662 HG21 ' O ' ' A' ' 67' ' ' LEU . 0.9 OUTLIER -93.29 118.61 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.846 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.6 146.38 36.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.69 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -135.19 110.5 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.663 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.56 115.01 22.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.736 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.21 143.35 20.25 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.205 ' O ' HG22 ' A' ' 4' ' ' THR . . . -136.8 110.38 8.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 100.18 24.15 9.9 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.384 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.6 -175.04 4.8 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.995 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.522 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 25.3 mt-30 -74.2 124.5 26.49 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.514 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.48 128.01 34.28 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.65 87.02 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.833 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.84 134.3 40.33 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.48 152.15 23.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.945 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 66.6 m-85 -137.05 156.15 48.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.037 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -114.62 115.26 26.87 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.942 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.131 HG23 ' CB ' ' A' ' 97' ' ' LEU . 1.4 t -98.77 143.11 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.775 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.7 163.58 37.3 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.922 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -106.38 115.55 30.4 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 93.9 m -107.45 168.23 9.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.994 ' HB1' HG13 ' A' ' 86' ' ' VAL . . . -153.71 126.7 8.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.604 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.39 122.82 18.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.619 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 11.6 m -103.92 -43.44 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.621 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -142.48 171.94 13.37 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.1 m -56.75 112.55 1.33 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 5.11 56.59 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.127 HG13 ' CD1' ' A' ' 83' ' ' TRP . 24.0 t -118.63 107.05 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.573 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.2 pp -117.08 162.85 17.15 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.527 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -125.26 146.12 49.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 51.1 m -115.53 152.36 33.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.692 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -112.64 107.15 55.17 Favored Pre-proline 0 N--CA 1.449 -0.5 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 81.7 Cg_endo -72.46 -0.31 8.57 Favored 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.317 3.345 . . . . 0.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.449 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.65 -12.04 40.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.499 ' OD1' HG22 ' A' ' 68' ' ' THR . 69.8 m-20 -131.82 24.88 4.67 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.664 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -95.51 117.86 31.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.9 t -110.77 -171.76 1.9 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.78 156.45 43.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 p -166.4 152.79 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 54.6 m -126.19 132.06 51.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.47 150.8 48.41 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.4 p30 -90.93 -169.11 2.25 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.25 -27.84 68.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -76.27 -10.57 59.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.58 9.33 86.97 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -100.64 137.61 38.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.11 161.67 21.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.88 130.38 13.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.591 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.23 173.26 15.31 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.591 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -121.36 133.35 55.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.903 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.071 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -117.59 119.4 34.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.499 HG22 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -78.72 141.08 38.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.948 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.678 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -113.78 130.24 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.986 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.701 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -114.78 154.75 27.99 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -76.25 -22.1 55.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 87.7 p -161.42 151.84 17.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.922 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -176.98 160.4 1.8 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.49 113.11 2.49 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.527 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -74.63 95.97 0.91 Allowed Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.699 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 99.9 10.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.816 HD23 ' HB2' ' A' ' 79' ' ' ASP . 3.6 tp -53.56 144.51 17.18 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.73 ' N ' HD11 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.61 -43.93 26.2 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.816 ' HB2' HD23 ' A' ' 77' ' ' LEU . 12.0 m-20 -58.08 -16.5 13.25 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.45 27.51 13.05 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.2 m -105.18 125.99 51.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -64.53 91.69 0.08 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.619 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 87.2 t90 -62.02 -39.29 91.76 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 132.15 174.73 13.72 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.16 105.05 1.29 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.245 HG23 ' CG1' ' A' ' 40' ' ' VAL . 42.8 t -80.73 146.42 7.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -105.08 92.96 4.44 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.055 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -53.49 -21.26 5.96 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.2 p -89.18 3.14 52.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.537 ' O ' HG22 ' A' ' 90' ' ' THR . 2.9 m -112.92 -27.64 8.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.84 174.63 10.4 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.762 ' HB1' ' HG ' ' A' ' 111' ' ' SER . . . -91.4 127.66 36.92 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.4 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 33.2 m -105.41 167.23 9.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.069 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -155.29 140.58 17.63 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.071 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -92.7 164.93 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.075 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.46 160.93 27.24 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.131 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.03 127.09 42.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.037 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 26.4 m -106.44 151.02 25.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.41 -161.45 0.75 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.998 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.86 -48.65 65.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.23 -24.17 65.8 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.12 53.82 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 172.17 13.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.945 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.02 178.45 45.0 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.479 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.39 164.06 36.75 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.265 3.31 . . . . 0.0 109.577 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.602 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 13.2 pt-20 -38.12 124.05 1.16 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.434 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.29 152.6 0.01 OUTLIER Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.045 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.8 t -111.8 103.26 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.33 130.59 35.6 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.4 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.0 pt -143.84 177.31 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.818 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -173.49 176.31 2.83 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.055 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 1.7 m-85 -128.09 120.0 26.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.674 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 27.5 m-80 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.258 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -141.41 124.57 9.77 Favored Pre-proline 0 N--CA 1.45 -0.458 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.453 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.44 -177.53 2.8 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.296 3.33 . . . . 0.0 109.595 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.21 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.17 109.06 21.88 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.87 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 139.66 53.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.65 117.75 34.87 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.842 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -113.17 155.27 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.83 176.65 1.22 Allowed Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.952 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.1 Cg_endo -72.39 117.71 5.26 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.305 3.337 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.73 ' HA ' HD12 ' A' ' 13' ' ' LEU . 24.0 p -113.29 43.56 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 60.7 p -123.58 106.79 10.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.682 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 91.75 28.39 14.24 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.73 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -101.08 133.5 45.51 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 m -104.61 165.0 11.35 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.689 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -44.75 139.13 3.11 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.28 -22.33 34.96 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.8 m -76.07 141.89 41.9 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.4 p -113.28 128.86 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.571 ' CG1' ' N ' ' A' ' 20' ' ' LYS . 2.7 t -96.23 164.36 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.842 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.21 144.85 41.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.662 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -139.58 113.21 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.87 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.46 114.62 19.06 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.568 ' HA3' HD23 ' A' ' 26' ' ' LEU . . . -88.74 140.96 16.22 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.21 ' O ' HG23 ' A' ' 4' ' ' THR . . . -140.31 116.76 10.73 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.18 19.35 21.55 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.568 HD23 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -88.35 173.76 8.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.478 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 27.0 mt-30 -64.35 120.74 12.78 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.13 136.95 56.67 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.09 8.19 61.14 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.722 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -86.1 146.58 26.55 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.872 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.97 138.22 33.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.046 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 32.7 m-85 -131.32 146.75 52.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.217 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -117.12 116.49 27.4 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.376 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.45 153.67 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.001 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.72 163.66 30.8 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.946 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 21.0 tt0 -103.1 120.33 40.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.1 m -108.25 164.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.74 -0.466 . . . . 0.0 109.74 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.834 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -152.0 131.08 12.65 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.496 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -66.29 128.75 37.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.923 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.53 ' CB ' ' NE1' ' A' ' 83' ' ' TRP . 3.3 m -117.07 -38.1 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.256 ' OD1' ' HH2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -146.68 178.78 8.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.7 t -64.48 110.95 2.47 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 8.3 63.51 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.016 HG13 ' CE3' ' A' ' 83' ' ' TRP . 84.9 t -111.7 104.88 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.643 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.0 OUTLIER -104.33 154.81 19.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.934 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.163 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -129.16 129.01 44.56 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.831 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.72 157.43 18.12 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.747 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.1 t30 -115.67 114.56 42.13 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -72.46 -1.26 9.96 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.318 3.345 . . . . 0.0 109.611 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -91.19 -11.39 38.46 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 21.0 p30 -133.84 25.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.642 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -97.84 116.17 29.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 t -103.53 178.57 4.52 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.2 p -146.38 153.11 40.12 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -166.91 157.37 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 60.3 m -125.32 127.48 46.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.55 124.72 20.97 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.3 p30 -69.95 -170.3 0.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -23.73 66.46 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.25 2.12 29.33 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.566 ' O ' HD11 ' A' ' 26' ' ' LEU . . . 65.54 32.45 83.35 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 32.7 t -127.65 145.03 51.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -143.85 124.66 14.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -108.72 133.68 52.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.613 HG21 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -148.94 155.65 41.15 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.613 ' N ' HG21 ' A' ' 65' ' ' THR . 0.1 OUTLIER -111.24 120.43 42.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.637 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.79 159.36 15.85 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.803 -0.444 . . . . 0.0 109.803 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.413 ' H ' HG21 ' A' ' 68' ' ' THR . 0.1 OUTLIER -124.91 133.05 53.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.26 130.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.73 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -110.78 168.37 9.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 29.7 ptt180 -96.53 -8.34 32.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.8 t -176.54 146.15 0.59 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.946 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.3 p90 -176.77 166.72 2.58 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -62.13 127.29 30.68 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.163 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -83.15 93.41 1.7 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.831 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.58 100.59 11.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.786 HD21 ' HB3' ' A' ' 79' ' ' ASP . 4.2 tp -57.19 130.67 47.18 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.655 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m-85 -47.67 -35.76 10.05 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.786 ' HB3' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.81 -16.88 12.88 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.55 27.5 9.08 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.48 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.26 150.18 36.6 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.45 97.19 10.93 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.53 ' NE1' ' CB ' ' A' ' 40' ' ' VAL . 15.2 t-105 -66.64 -56.88 8.63 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.5 168.25 13.41 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.45 142.88 31.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.834 HG23 ' CB ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -127.13 154.64 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.981 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.418 ' N ' ' CG2' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -113.81 100.97 8.85 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.574 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.9 OUTLIER -53.78 -26.33 23.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -83.71 0.69 46.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 m -117.74 -27.85 6.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.23 175.64 7.28 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.95 123.04 40.56 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.207 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.9 m -104.47 152.62 22.12 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.998 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.0 OUTLIER -143.77 143.39 31.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.637 ' CG1' HD12 ' A' ' 67' ' ' LEU . 3.4 t -101.95 151.57 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.373 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.72 171.57 43.78 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.376 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -128.27 146.05 50.87 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.217 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 5.9 m -123.18 153.25 40.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.872 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.59 -163.98 0.89 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.29 -49.28 78.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.37 -25.76 62.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 97.75 46.52 2.27 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.453 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -119.27 166.82 12.52 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.046 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.84 -176.53 41.5 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.453 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.47 162.45 41.41 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.306 3.337 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.258 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.85 127.45 1.58 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -43.75 144.54 1.72 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.998 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -120.87 110.94 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.507 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.85 142.84 27.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.207 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.9 OUTLIER -108.13 168.59 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.73 120.44 7.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.574 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 39.5 m-85 -97.99 121.89 40.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.948 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.048 ' HB2' ' HA ' ' A' ' 106' ' ' GLU . . . -136.57 109.33 9.42 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.485 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.1 Cg_endo -72.42 -177.53 2.79 Favored 'Trans proline' 0 N--CA 1.448 -1.205 0 C-N-CA 124.328 3.352 . . . . 0.0 109.537 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.83 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -97.47 109.83 22.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.78 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.8 133.59 50.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.561 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.35 114.64 26.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.709 HG11 HG22 ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.3 155.87 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.993 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.92 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.79 174.61 2.15 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.92 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.7 Cg_endo -72.43 118.12 5.45 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.346 3.364 . . . . 0.0 109.538 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 1.026 ' HB3' HG22 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -117.05 46.79 1.6 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.635 ' HA ' ' O ' ' A' ' 111' ' ' SER . 96.6 p -124.85 105.33 9.17 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.866 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.634 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.9 28.5 15.48 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.724 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -97.06 133.43 41.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.996 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.6 p -99.83 163.26 12.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.494 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.01 140.96 4.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.24 36.43 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.9 m -71.38 150.22 45.24 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.474 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 9.9 p -121.13 118.29 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.535 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.8 OUTLIER -86.8 169.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.997 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.74 153.05 37.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -146.58 113.17 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.78 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.05 115.9 22.62 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.585 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.99 143.89 21.57 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.719 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.08 112.98 6.38 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.87 19.09 23.09 Favored Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.696 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.81 -176.55 4.72 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.938 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.456 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 22.7 mt-30 -70.91 124.83 25.26 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.451 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.69 127.59 33.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.32 7.26 88.71 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.629 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -88.65 143.67 26.78 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.843 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -91.3 141.93 28.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.98 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 33.5 m-85 -131.53 146.22 52.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.217 ' CB ' ' H ' ' A' ' 98' ' ' SER . 13.8 m-20 -111.97 113.13 25.25 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.384 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -95.8 144.36 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.925 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.17 163.77 36.1 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.981 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 19.3 tt0 -107.41 108.04 19.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -107.83 142.19 38.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.871 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -122.48 139.18 54.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.558 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.11 124.86 22.73 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.341 HG21 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -105.26 -49.67 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.569 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.64 167.67 20.68 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -50.28 112.45 0.68 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.0 63.01 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.678 HG13 ' HE1' ' A' ' 83' ' ' TRP . 93.5 t -122.22 116.46 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.522 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -125.97 135.47 51.88 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.144 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -90.14 159.39 16.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 28.8 m -116.12 151.92 34.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.78 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.5 t30 -112.03 106.12 56.32 Favored Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.3 Cg_endo -72.44 -1.12 9.75 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 124.3 3.333 . . . . 0.0 109.599 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.511 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -90.41 -10.43 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 79.3 m-20 -135.61 27.04 3.38 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.51 121.22 38.1 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.8 t -115.4 -173.37 2.32 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.3 p -145.95 156.99 43.88 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.861 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.2 p -167.19 157.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 m -128.61 136.59 50.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.24 130.63 38.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p30 -72.13 -177.84 2.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.31 -16.22 43.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -86.12 7.56 24.35 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.696 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 57.01 32.64 62.84 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.1 t -131.89 135.38 46.61 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.91 166.64 16.53 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.7 m -151.15 128.0 10.97 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.574 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -155.46 169.85 23.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.89 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.574 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -118.69 133.28 55.97 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.203 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -115.69 118.99 34.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.936 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.423 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -77.64 137.04 38.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.973 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.502 HG13 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.09 125.85 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.41 ' N ' ' HD3' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -109.76 168.48 9.38 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.98 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.494 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -97.04 -15.73 20.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.993 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.526 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 47.8 t -167.37 146.45 5.04 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.981 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.7 p90 -176.92 151.8 0.88 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.7 OUTLIER -53.12 116.43 2.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.921 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.144 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -77.08 102.99 1.74 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.986 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -84.01 100.6 11.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.768 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.9 tp -54.24 132.89 44.41 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.987 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.966 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.5 m-85 -46.94 -37.16 8.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.768 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -57.51 -16.93 11.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.8 27.63 9.46 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.655 HG23 ' N ' ' A' ' 82' ' ' ARG . 1.5 m -115.29 151.3 34.81 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.655 ' N ' HG23 ' A' ' 81' ' ' THR . 7.7 ptp180 -85.9 98.5 10.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.341 ' CE3' HG21 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -64.52 -58.03 7.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.883 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 174.42 23.29 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.13 110.73 1.94 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.871 HG12 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -85.93 154.39 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 11.4 m-20 -122.02 95.14 4.54 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.731 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 35.9 m -53.61 -26.69 22.98 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -80.0 -1.51 40.01 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.602 ' O ' HG22 ' A' ' 90' ' ' THR . 1.8 m -114.65 -27.67 7.4 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.53 -173.94 3.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.883 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.55 125.48 48.21 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.854 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 93.1 m -104.2 152.66 21.9 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.021 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -143.94 150.52 38.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.944 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.203 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 2.4 t -112.41 160.29 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.379 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.28 169.96 42.36 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.384 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.88 128.03 44.44 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.217 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 56.8 m -107.23 151.22 25.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.843 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.29 -163.24 0.84 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.985 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.426 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -64.97 -48.85 72.55 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.22 -24.12 63.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.88 53.37 1.79 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.511 ' OD1' ' HE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -130.49 172.62 11.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.98 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -177.85 -179.16 47.85 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.485 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.4 157.99 52.2 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.324 3.349 . . . . 0.0 109.573 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.094 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.8 pt-20 -36.02 123.13 0.72 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.72 149.86 0.03 OUTLIER Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.993 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.1 t -117.6 104.97 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.73 135.42 33.76 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.026 HG22 ' HB3' ' A' ' 10' ' ' SER . 3.2 mt -111.79 167.12 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.635 ' O ' ' HA ' ' A' ' 11' ' ' SER . 4.7 t -153.11 128.48 9.89 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.731 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 26.6 m-85 -102.02 125.4 48.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.467 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 m-80 . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.227 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -122.36 125.13 26.62 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.451 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.38 -177.79 2.93 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.328 3.352 . . . . 0.0 109.592 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.237 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.83 111.93 24.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.742 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.12 160.58 30.75 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.521 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -120.37 113.46 20.39 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.742 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -105.16 148.27 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.975 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.97 177.81 0.93 Allowed Pre-proline 0 N--CA 1.448 -0.533 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.959 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.975 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.8 Cg_endo -72.4 115.99 4.54 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.342 3.361 . . . . 0.0 109.61 179.888 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.811 ' OG ' HG22 ' A' ' 110' ' ' ILE . 27.9 p -113.4 40.9 2.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.505 ' HA ' ' O ' ' A' ' 111' ' ' SER . 30.9 p -120.31 106.22 11.67 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.689 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.29 30.4 10.95 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.723 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -101.33 132.21 47.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -104.69 169.54 8.4 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -48.54 140.06 8.52 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.01 -22.54 36.5 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 46.2 m -75.14 147.04 40.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.5 p -120.62 124.96 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.617 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 2.6 m -90.68 168.06 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.742 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -117.32 152.48 34.82 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.966 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.656 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -150.1 114.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.989 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.77 114.59 18.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.609 ' HA3' HD23 ' A' ' 26' ' ' LEU . . . -83.86 148.5 24.7 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.237 ' O ' HG23 ' A' ' 4' ' ' THR . . . -145.6 112.64 6.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.51 14.74 31.64 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.746 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.94 169.01 11.58 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.934 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 28.1 mt-30 -50.39 120.09 4.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.6 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.71 131.63 41.82 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.32 8.28 83.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.555 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.82 139.94 30.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.977 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.888 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.22 151.73 25.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.769 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.0 m-85 -137.47 144.61 42.36 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.344 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.0 m-20 -106.0 115.22 29.86 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.526 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.16 143.16 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.955 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.86 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.94 172.5 43.28 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.909 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.8 tt0 -116.61 117.41 29.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.236 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 94.1 m -109.44 167.84 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.153 ' CB ' HG13 ' A' ' 86' ' ' VAL . . . -151.6 126.11 9.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.595 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -66.35 124.97 24.17 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.699 HG21 ' CD1' ' A' ' 83' ' ' TRP . 12.2 m -105.12 -44.05 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.519 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -143.3 163.56 32.64 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.9 t -51.91 113.48 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.21 8.35 69.81 Favored Glycine 0 C--N 1.336 0.553 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.637 ' O ' HG23 ' A' ' 40' ' ' VAL . 17.0 t -126.27 106.11 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.592 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 1.0 OUTLIER -116.17 162.91 16.75 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.41 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.37 138.66 53.58 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.236 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.8 m -109.33 150.28 28.24 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.631 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 24.5 t30 -108.77 109.06 61.2 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.39 -0.13 8.26 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.296 3.33 . . . . 0.0 109.563 179.899 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.49 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.09 -13.44 41.39 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.474 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.4 p30 -127.73 27.06 5.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.6 105.19 14.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.9 t -100.94 173.21 6.59 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.58 153.03 40.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.455 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.27 156.44 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.455 ' N ' HG22 ' A' ' 55' ' ' VAL . 58.2 m -126.6 138.35 53.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.99 149.02 37.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.0 p30 -85.37 -173.47 4.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.64 -22.86 66.75 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -77.53 -7.69 56.67 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.653 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 73.79 31.86 59.81 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.8 p -127.36 139.0 53.15 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.04 166.0 17.77 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 14.8 p -150.48 127.8 11.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.479 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -162.97 156.93 20.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.861 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.479 ' N ' HG22 ' A' ' 65' ' ' THR . 0.9 OUTLIER -109.35 134.74 51.45 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.943 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.53 119.21 37.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.5 t -74.87 128.33 35.32 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.943 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.698 HG23 ' HZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.91 128.14 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.998 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.77 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.57 149.94 35.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 ppt_? -78.33 -16.55 57.6 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.538 ' HB3' ' OD1' ' A' ' 87' ' ' ASP . 7.9 p -161.71 148.66 14.27 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.909 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.8 p90 -178.09 148.73 0.52 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.11 115.04 1.67 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.41 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.34 94.99 0.94 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.896 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.54 10.57 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.735 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.7 tp -54.22 139.29 36.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.733 ' N ' HD13 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.51 -41.58 21.26 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.735 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.0 t70 -56.33 -17.0 6.45 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.76 27.93 9.96 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.1 m -110.1 141.61 42.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.7 94.2 5.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.699 ' CD1' HG21 ' A' ' 40' ' ' VAL . 7.6 t-105 -62.43 -57.11 12.44 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 168.82 17.39 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.63 108.59 0.75 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.153 HG13 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -79.07 153.96 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.538 ' OD1' ' HB3' ' A' ' 72' ' ' SER . 14.8 m-20 -129.97 97.4 4.46 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.534 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 96.6 m -53.0 -28.04 22.04 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 50.5 p -78.12 -0.53 28.54 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -118.88 -28.04 5.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.68 -173.18 3.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.42 125.28 49.09 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.911 ' O ' HG13 ' A' ' 110' ' ' ILE . 56.6 m -103.93 159.81 15.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.051 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -155.36 144.79 21.1 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -109.9 157.83 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.31 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.51 168.56 40.24 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.526 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.47 139.73 53.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.344 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 85.8 p -122.57 149.03 44.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.888 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -107.6 -161.6 0.79 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -68.56 -47.98 65.43 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.72 -23.71 66.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.68 52.42 2.13 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.934 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.67 165.79 21.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.95 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.07 177.59 44.7 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.933 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.451 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 161.15 45.13 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.372 3.381 . . . . 0.0 109.568 179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.227 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 4.6 pt-20 -36.63 128.92 0.81 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -46.98 150.38 2.08 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.883 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.4 t -126.03 115.05 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.15 143.91 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.051 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.1 mt -109.18 168.51 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.3 t -155.0 121.23 5.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.698 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 10.7 m-85 -94.8 129.76 41.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.972 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.529 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -92.04 127.22 50.35 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.463 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.37 -174.7 1.5 Allowed 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.291 3.327 . . . . 0.0 109.595 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.15 108.55 21.27 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.952 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.724 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.2 144.65 49.81 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.524 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -105.81 112.7 25.87 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.999 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.84 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.31 152.84 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.982 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.902 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.34 175.02 2.04 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.92 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.902 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.3 Cg_endo -72.39 118.01 5.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.298 3.332 . . . . 0.0 109.562 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 1.0 ' HB2' HG22 ' A' ' 110' ' ' ILE . 81.1 p -111.49 46.26 1.13 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.665 ' HA ' ' O ' ' A' ' 111' ' ' SER . 4.3 m -127.98 105.05 8.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.874 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.645 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.39 28.31 11.76 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.703 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -100.37 132.1 45.93 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -106.79 170.81 7.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -46.4 142.45 3.02 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.75 -23.41 33.96 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 52.0 m -77.86 151.8 33.7 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.407 HG12 ' O ' ' A' ' 18' ' ' VAL . 7.6 p -128.26 116.26 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.774 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 3.1 p -78.7 152.14 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.84 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.03 143.48 36.68 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.997 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -140.76 106.99 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.724 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.7 117.12 28.93 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.53 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -81.79 139.77 20.32 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.43 108.33 7.12 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.497 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 100.45 25.95 8.45 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.107 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.7 -171.9 3.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 19.5 mt-30 -82.54 124.91 30.55 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.43 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.38 139.7 49.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.92 8.29 68.34 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.703 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.62 146.22 23.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.987 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.901 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.54 149.05 23.15 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.201 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 56.4 m-85 -136.95 145.06 43.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.867 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.082 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -110.54 113.76 26.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.995 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.345 HG23 ' CB ' ' A' ' 97' ' ' LEU . 1.5 t -99.07 140.07 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.944 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -162.37 164.44 35.58 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.566 HE22 ' H ' ' A' ' 70' ' ' ARG . 29.5 tt0 -114.58 108.16 16.46 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.987 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.0 OUTLIER -110.83 146.32 36.65 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.987 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.94 ' HB1' HG23 ' A' ' 86' ' ' VAL . . . -122.81 138.28 54.69 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.605 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.52 123.2 19.04 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.959 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.912 HG23 ' CD1' ' A' ' 83' ' ' TRP . 0.0 OUTLIER -103.05 -44.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.395 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 1.1 m-20 -133.44 -179.28 5.42 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 m -69.03 111.12 4.82 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.66 85.97 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG23 ' HE1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -130.78 125.52 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.954 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.538 HD13 ' HB2' ' A' ' 37' ' ' CYS . 1.2 pt? -134.09 141.48 47.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.39 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.07 147.22 24.25 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.987 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.9 m -107.11 150.3 26.71 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.584 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 8.3 t30 -111.46 109.02 56.36 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -72.45 -0.65 9.06 Favored 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.315 3.343 . . . . 0.0 109.608 179.909 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.457 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -88.75 -11.87 43.79 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -132.71 28.64 4.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.666 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.92 119.3 38.01 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.994 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 t -113.4 -179.17 3.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.96 158.13 43.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.51 HG21 ' N ' ' A' ' 56' ' ' THR . 3.4 p -166.45 161.91 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.51 ' N ' HG21 ' A' ' 55' ' ' VAL . 22.8 m -127.98 126.21 40.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.31 146.32 40.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.927 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 47.3 p30 -87.43 -173.44 4.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.52 -25.43 67.28 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -82.21 4.37 23.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 66.3 6.12 31.84 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.5 t -96.9 134.25 40.48 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.0 164.96 15.94 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -148.48 127.9 13.1 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.577 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -160.02 155.27 25.07 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.88 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.577 ' N ' HG22 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.56 125.4 52.93 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.938 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.095 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -105.35 123.33 47.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.975 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.464 ' N ' HD11 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -78.06 136.08 37.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.939 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.408 ' O ' HG21 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -112.6 124.99 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.979 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.566 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.97 173.46 6.32 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.445 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 27.5 ptt180 -99.41 -9.67 23.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 97.2 p -168.05 145.69 4.29 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.584 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.9 p90 -176.6 156.16 1.44 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -55.46 114.5 1.86 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.39 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -79.25 100.68 1.8 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.817 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.68 101.5 12.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.582 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.6 tp -53.64 136.07 39.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' HE1' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m-85 -46.59 -39.95 12.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.582 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -56.31 -17.67 8.42 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.913 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 97.13 27.7 9.18 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.486 HG21 ' N ' ' A' ' 82' ' ' ARG . 1.7 m -111.77 142.42 44.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' N ' HG21 ' A' ' 81' ' ' THR . 4.1 ttm180 -79.93 94.33 5.85 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.955 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.395 ' CZ2' ' OD2' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.51 -58.34 7.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.886 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 173.14 20.41 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 104.38 0.52 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.94 HG23 ' HB1' ' A' ' 38' ' ' ALA . 9.9 p -79.44 150.92 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' N ' HG21 ' A' ' 86' ' ' VAL . 4.3 m-20 -107.21 98.09 7.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.445 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -53.24 -23.84 9.77 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.2 p -85.44 1.41 48.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.532 HG21 ' O ' ' A' ' 90' ' ' THR . 1.4 m -112.7 -26.93 8.37 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.03 179.69 6.1 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.0 128.44 41.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.884 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 36.7 m -104.41 153.29 21.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.079 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -147.25 147.05 30.03 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.981 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.095 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.9 t -110.92 160.04 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.27 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.24 166.37 37.39 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.345 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.01 123.82 35.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.978 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.082 ' N ' ' H ' ' A' ' 33' ' ' ASP . 14.2 m -107.65 144.18 35.08 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.901 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.6 OUTLIER -102.56 -160.75 0.8 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.979 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.63 -47.78 65.76 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.98 -24.42 66.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.72 53.78 1.76 Allowed Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.555 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.57 169.81 16.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.989 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.201 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.41 179.16 45.92 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.463 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.32 164.19 36.37 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.318 3.345 . . . . 0.0 109.601 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.529 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.61 126.92 1.14 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.976 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -42.93 154.69 0.17 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.906 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.9 t -120.84 103.79 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.64 126.54 35.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.079 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.6 mt -103.24 159.07 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.735 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -146.95 123.22 10.91 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.522 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 39.7 m-85 -95.36 125.57 40.07 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.98 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.175 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -65.92 120.85 72.52 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.685 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.3 Cg_endo -72.34 -178.13 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.288 3.325 . . . . 0.0 109.6 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.905 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.97 108.95 21.76 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 1.278 ' N ' ' OE2' ' A' ' 106' ' ' GLU . . . -124.29 146.78 48.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.587 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.85 114.62 28.89 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.98 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.951 HG23 HG21 ' A' ' 108' ' ' VAL . 41.4 t -109.82 147.74 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.942 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.43 176.01 1.38 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.913 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.942 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.1 Cg_endo -72.39 117.36 5.1 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.323 3.349 . . . . 0.0 109.615 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 1.044 ' HB2' HG22 ' A' ' 110' ' ' ILE . 14.5 p -113.38 48.52 1.04 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.981 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.717 ' HA ' ' O ' ' A' ' 111' ' ' SER . 5.9 m -128.99 105.83 8.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.872 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.705 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 93.49 28.04 12.12 Favored Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.73 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -105.01 129.25 53.5 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -104.45 170.39 7.92 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.564 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 7.4 p-10 -44.59 141.29 2.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.65 -22.87 32.84 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 89.6 m -79.39 149.6 31.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.423 HG12 ' O ' ' A' ' 18' ' ' VAL . 13.8 p -122.34 121.72 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.662 ' CG2' ' CG1' ' A' ' 69' ' ' VAL . 12.2 t -85.44 153.15 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.744 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.89 143.2 34.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.952 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.745 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -140.58 111.5 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.2 117.71 25.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.672 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -83.59 145.5 22.89 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.793 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -144.36 113.38 6.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 95.63 17.97 34.24 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.672 ' CD2' ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.87 170.78 9.8 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.772 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.6 mt-30 -51.78 119.58 4.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.521 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.33 130.28 39.83 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.64 7.34 87.23 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.517 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.83 137.27 34.13 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.703 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -81.47 152.41 27.36 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.741 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 36.8 m-85 -138.08 141.08 40.27 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.913 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.144 ' CB ' ' O ' ' A' ' 98' ' ' SER . 7.8 m-20 -106.01 113.45 26.99 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.309 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.0 147.46 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.919 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.1 168.16 41.1 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.742 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 22.7 tt0 -112.13 113.2 25.33 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.163 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 25.9 m -114.2 141.99 46.82 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.579 ' HB1' HG23 ' A' ' 86' ' ' VAL . . . -121.96 129.08 52.21 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.56 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.19 128.58 36.43 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.906 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.342 HG22 ' CD1' ' A' ' 83' ' ' TRP . 11.7 m -109.78 -43.91 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.664 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -141.08 160.12 40.76 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.5 m -55.55 113.49 1.46 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.94 8.06 87.98 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.308 HG13 ' NE1' ' A' ' 83' ' ' TRP . 58.8 t -130.34 108.99 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.973 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.796 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -118.22 144.23 45.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.102 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.64 143.63 33.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.163 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 15.5 m -110.24 152.71 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.688 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 42.6 t30 -111.86 108.02 55.94 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.73 9.12 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.355 3.37 . . . . 0.0 109.573 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.48 -11.23 35.2 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.852 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -129.82 19.62 5.56 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.77 107.76 16.39 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.0 t -101.46 173.36 6.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.9 p -146.06 149.39 33.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.89 159.72 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 63.6 m -127.74 136.68 51.86 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.38 142.44 46.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 40.6 p30 -80.86 -172.45 3.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -22.02 66.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -80.87 4.05 20.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.636 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 60.44 31.29 73.83 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 t -128.13 133.76 49.02 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.68 164.65 18.68 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.27 129.96 17.05 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.602 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -156.57 164.61 37.99 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.861 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.602 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -125.25 118.23 25.56 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.973 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.679 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.68 156.2 16.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -112.36 132.73 54.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.662 ' CG1' ' CG2' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.34 128.06 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.99 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.692 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.07 164.04 13.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.999 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.467 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 ptt180 -91.88 -9.47 43.13 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 12.8 t -174.8 144.37 0.81 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.742 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 13.3 p90 -175.83 157.63 1.99 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 117.06 3.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.102 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.32 100.56 1.92 Allowed Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.989 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.26 100.28 10.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.796 ' HA ' ' O ' ' A' ' 45' ' ' LEU . 1.7 tp -54.42 136.7 43.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.859 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.1 m-85 -46.25 -39.93 10.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.793 ' HB3' HD23 ' A' ' 77' ' ' LEU . 7.6 t0 -56.84 -17.36 9.07 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 96.38 28.2 9.3 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.427 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.2 m -112.31 140.08 47.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.6 ptt-85 -79.72 94.53 5.76 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.342 ' CD1' HG22 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.25 -55.78 24.99 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.59 172.86 19.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.35 107.09 1.01 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.579 HG23 ' HB1' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -83.7 152.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.962 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -109.5 99.6 8.79 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.58 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.2 m -53.27 -25.06 13.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 30.4 p -84.04 1.25 44.79 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -118.32 -27.98 5.88 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.911 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.55 177.4 6.24 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.07 125.3 41.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.284 ' O ' HG13 ' A' ' 110' ' ' ILE . 38.7 m -104.53 153.05 21.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.023 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.4 OUTLIER -151.17 146.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.929 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.679 ' CG1' HD13 ' A' ' 67' ' ' LEU . 21.5 t -105.84 153.48 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.943 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.232 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -170.2 165.97 39.22 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.309 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.32 131.76 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.144 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 7.6 t -112.29 150.91 30.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.703 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -112.6 -164.25 0.9 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.948 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.41 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.92 -48.51 68.44 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.8 -23.76 66.1 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.7 53.2 1.99 Allowed Glycine 0 C--N 1.336 0.55 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.772 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.94 171.89 13.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.977 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.741 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.27 176.43 46.64 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.685 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.1 Cg_endo -72.38 165.17 33.43 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.349 3.366 . . . . 0.0 109.622 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.278 ' OE2' ' N ' ' A' ' 5' ' ' ALA . 0.2 OUTLIER -38.08 136.51 0.6 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.988 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.98 149.0 6.06 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.951 HG21 HG23 ' A' ' 7' ' ' VAL . 11.9 t -123.84 105.93 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.471 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.57 147.96 23.0 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.284 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.09 159.76 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.717 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -142.28 111.98 6.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.953 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 66.2 m-85 -87.15 110.71 20.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.408 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -107.27 120.61 47.18 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.517 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.34 -178.29 3.22 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 124.357 3.371 . . . . 0.0 109.616 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.081 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -97.46 110.26 22.85 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.963 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.5 156.53 40.6 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -114.96 117.15 29.83 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.822 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 58.5 t -114.5 144.21 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.695 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.2 165.82 40.02 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.921 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.695 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.34 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 124.318 3.345 . . . . 0.0 109.617 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.812 ' OG ' HG13 ' A' ' 69' ' ' VAL . 47.7 t -127.84 17.57 6.79 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 1.026 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.1 p -92.2 111.78 23.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.967 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 89.43 25.6 27.79 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.731 HD12 ' HA ' ' A' ' 10' ' ' SER . 1.0 OUTLIER -108.52 139.48 43.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.989 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.6 m -67.47 144.69 55.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB3' ' H ' ' A' ' 71' ' ' ARG . 17.9 p-10 -48.1 147.49 2.14 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -18.97 45.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.6 m -60.99 130.53 46.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.46 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 9.3 p -92.87 115.05 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.651 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 3.6 m -100.58 159.33 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.943 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.822 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.6 146.1 39.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.82 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -138.5 114.52 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.8 116.31 23.47 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.944 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.639 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.21 145.96 22.57 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.081 ' O ' HG23 ' A' ' 4' ' ' THR . . . -142.23 115.83 9.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.73 16.02 29.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.661 ' CD1' ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.92 168.6 11.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.468 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.7 mt-30 -52.03 119.24 4.11 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.469 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.37 132.06 44.29 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.89 7.78 84.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.706 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 141.89 30.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.543 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.46 150.86 24.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.024 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 40.3 m-85 -138.29 141.73 39.82 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.18 ' OD2' ' HB2' ' A' ' 98' ' ' SER . 0.9 OUTLIER -105.85 115.54 30.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.413 ' CG2' ' HG ' ' A' ' 97' ' ' LEU . 1.8 t -96.64 136.46 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.874 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.66 153.51 24.53 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.856 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 17.2 tt0 -94.46 119.68 33.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.844 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.724 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.3 m -107.04 159.26 16.43 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.738 ' HB2' HG21 ' A' ' 86' ' ' VAL . . . -147.16 130.08 16.25 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.543 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -69.96 125.92 28.16 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.185 ' CG1' HG11 ' A' ' 86' ' ' VAL . 4.0 m -113.74 -39.56 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.609 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -146.65 -179.59 6.88 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.95 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.8 m -64.69 111.58 2.82 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.56 8.52 63.26 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.686 HG22 ' CH2' ' A' ' 83' ' ' TRP . 40.1 t -110.02 104.0 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.807 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 mt -106.86 155.94 19.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.372 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -134.27 126.7 30.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.141 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -107.84 158.83 16.99 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.482 ' OD1' ' HB1' ' A' ' 50' ' ' ALA . 8.5 t30 -118.83 113.96 35.78 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -72.43 -1.45 10.23 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.317 3.345 . . . . 0.0 109.577 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -11.48 40.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -131.63 26.58 4.71 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.667 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.34 122.07 41.97 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.983 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -104.65 -175.32 2.76 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.0 p -146.72 154.37 41.34 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.527 HG23 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.89 156.18 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.527 ' N ' HG23 ' A' ' 55' ' ' VAL . 41.7 m -125.97 121.68 33.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.76 150.18 20.45 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 p30 -97.02 -168.02 1.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.13 -25.37 68.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.983 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -83.37 3.75 30.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.661 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 62.25 31.23 78.4 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.3 t -126.22 142.85 51.36 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.402 ' HB2' HG22 ' A' ' 55' ' ' VAL . . . -133.98 159.81 39.61 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.21 124.96 22.42 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.618 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -144.62 178.43 7.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.866 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.618 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.3 OUTLIER -129.46 122.32 29.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.949 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.116 ' CD1' HG22 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.09 149.19 28.79 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.925 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.531 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -111.37 143.0 42.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.812 HG13 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -109.55 125.93 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.967 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.796 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -115.08 153.08 31.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.986 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.467 ' H ' ' HB3' ' A' ' 15' ' ' ASP . 10.0 ttp180 -74.03 -37.79 64.22 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 t -151.06 153.25 34.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.856 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.4 p90 -177.09 159.44 1.65 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.931 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.98 114.43 1.59 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.372 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -71.71 93.77 0.57 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 1.141 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.34 99.94 10.34 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.807 ' HA ' ' O ' ' A' ' 45' ' ' LEU . 3.4 tp -58.76 131.79 51.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.724 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 8.4 m-85 -47.06 -36.46 8.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.729 ' HB3' HD23 ' A' ' 77' ' ' LEU . 3.4 t0 -56.99 -17.51 10.08 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.15 27.29 8.87 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.419 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.3 m -114.0 143.05 45.37 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.77 94.71 9.83 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.609 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 34.8 t-105 -63.41 -58.46 6.99 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.893 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 171.11 18.48 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.6 109.0 0.71 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.185 HG11 ' CG1' ' A' ' 40' ' ' VAL . 18.1 m -89.93 150.83 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -108.88 89.14 2.9 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.115 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 2.0 m -52.92 -24.48 9.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -79.27 -1.75 38.06 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.18 -28.36 6.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -118.64 -165.63 1.14 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 124.62 40.9 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.273 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -104.27 152.36 22.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.044 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 0.7 OUTLIER -168.12 147.67 4.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.944 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.116 HG22 ' CD1' ' A' ' 67' ' ' LEU . 4.9 t -99.4 164.92 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.941 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -171.67 160.01 31.73 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.413 ' HG ' ' CG2' ' A' ' 34' ' ' VAL . 4.5 mp -100.2 163.57 12.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.18 ' HB2' ' OD2' ' A' ' 33' ' ' ASP . 14.8 m -155.83 121.68 5.01 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.635 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 4.8 p-10 -113.88 -168.93 1.42 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -47.64 -26.76 1.61 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.7 -25.94 14.52 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.912 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 92.01 21.15 33.98 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 1.024 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.64 -149.42 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' HD2' ' A' ' 3' ' ' PRO . . . 141.4 151.82 5.62 Favored Glycine 0 C--N 1.336 0.556 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.517 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.6 Cg_endo -72.37 161.69 43.63 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.302 3.335 . . . . 0.0 109.609 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.408 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 10.3 mt-10 -32.06 120.26 0.28 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -32.94 149.8 0.01 OUTLIER Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.044 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 2.6 t -108.26 103.33 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.52 126.72 31.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.273 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 7.0 pt -141.81 177.82 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 1.026 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -171.65 177.82 3.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.115 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -130.3 115.21 16.62 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.967 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.3 p30 . . . . . 0 N--CA 1.45 -0.469 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.097 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -147.34 119.81 4.75 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.601 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.5 Cg_endo -72.46 -178.59 3.44 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.301 3.334 . . . . 0.0 109.57 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.218 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.0 21.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.83 ' H ' ' CD ' ' A' ' 106' ' ' GLU . . . -122.53 151.05 41.75 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.952 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.7 p -116.49 116.27 27.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.77 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -106.82 148.92 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 1.026 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -65.69 179.39 0.45 Allowed Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.917 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 1.026 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.8 Cg_endo -72.36 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.315 3.343 . . . . 0.0 109.648 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.792 ' HB2' HG23 ' A' ' 110' ' ' ILE . 3.8 p -112.42 35.87 3.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -119.8 106.75 12.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.836 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.714 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.58 30.89 8.66 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.754 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -101.42 131.52 47.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.97 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -99.75 163.84 12.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -46.95 140.07 5.08 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.35 -22.22 36.91 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 37.0 m -72.05 149.53 44.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.459 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 7.6 p -126.7 117.12 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.636 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.0 m -84.33 165.27 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.77 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.6 135.18 54.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.456 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 9.8 p -124.3 120.46 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.29 117.5 23.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.533 ' HA3' HD22 ' A' ' 26' ' ' LEU . . . -93.49 140.14 14.92 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.724 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.5 116.38 10.92 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.99 20.53 18.26 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.968 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.52 -177.28 5.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.98 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.492 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 25.9 mt-30 -69.29 122.23 18.46 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.43 130.04 39.75 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.1 8.09 86.85 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.668 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.48 137.13 34.96 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.975 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 1.005 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.56 150.62 25.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.121 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.9 m-85 -136.81 146.84 46.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.891 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.113 ' H ' ' N ' ' A' ' 98' ' ' SER . 4.4 m-20 -111.96 113.85 26.41 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.535 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.5 t -99.98 143.23 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.871 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.33 165.34 38.73 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.782 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.28 113.07 25.29 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 62.6 m -111.13 145.76 38.03 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.921 ' HB2' HG22 ' A' ' 86' ' ' VAL . . . -123.23 128.29 49.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.75 120.63 13.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.951 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.307 HG12 ' NE1' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -99.35 -44.14 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.53 ' OD1' ' C ' ' A' ' 40' ' ' VAL . 0.2 OUTLIER -136.83 175.5 9.56 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.948 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.1 t -60.8 112.67 2.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.03 8.14 72.96 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.613 ' O ' HG21 ' A' ' 40' ' ' VAL . 3.2 t -124.17 110.89 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.506 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -126.01 138.69 53.75 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.971 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.157 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -93.09 156.04 17.12 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 37.1 m -117.12 150.63 38.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.683 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -114.11 107.11 52.39 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.31 -0.84 9.25 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.327 3.351 . . . . 0.0 109.627 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.456 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -12.11 41.38 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.521 ' OD1' HG21 ' A' ' 68' ' ' THR . 92.9 m-20 -131.46 26.14 4.78 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -97.23 120.03 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 32.2 t -113.84 -177.38 3.12 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.0 p -147.08 156.61 43.14 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.94 157.59 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 55' ' ' VAL . 48.3 m -125.35 134.08 52.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.57 140.73 48.26 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -83.82 -170.88 3.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.75 -26.14 68.55 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.2 -4.91 44.37 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.67 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.93 31.61 69.83 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.964 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.3 p -124.11 133.77 53.52 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -147.46 122.38 10.02 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -123.0 144.28 49.37 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.553 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -141.0 178.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.553 ' N ' HG21 ' A' ' 65' ' ' THR . 0.3 OUTLIER -108.32 116.56 32.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.301 ' CG ' HG22 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -108.46 123.6 49.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.95 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.521 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -91.4 137.48 32.33 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.516 HG22 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -112.31 126.54 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.497 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -114.36 173.38 6.48 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.962 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.499 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 10.6 ptt85 -100.99 -7.97 22.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.539 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.4 p -169.73 147.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.782 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.6 p90 -177.65 160.58 1.58 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.13 115.58 2.52 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.157 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -78.32 94.03 1.24 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.744 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.2 m-85 -83.85 99.58 10.42 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.805 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.4 tp -53.73 134.66 41.96 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.494 ' N ' HD11 ' A' ' 77' ' ' LEU . 3.6 p90 -46.26 -38.84 9.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.805 ' HB3' HD23 ' A' ' 77' ' ' LEU . 4.4 t70 -56.77 -17.26 8.47 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.29 27.99 8.88 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.412 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 1.2 m -112.59 139.73 47.93 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -82.12 93.28 7.0 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.307 ' NE1' HG12 ' A' ' 40' ' ' VAL . 6.8 t-105 -63.38 -57.57 9.9 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.77 169.91 17.86 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -60.92 104.68 0.38 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.977 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.921 HG22 ' HB2' ' A' ' 38' ' ' ALA . 6.2 p -81.61 149.27 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.497 ' N ' HG23 ' A' ' 86' ' ' VAL . 68.8 m-20 -105.93 98.33 8.03 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.514 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.6 m -51.76 -25.41 7.46 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 21.1 p -80.55 2.55 25.01 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.961 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.424 ' O ' HG22 ' A' ' 90' ' ' THR . 21.8 m -112.93 -27.2 8.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.59 -178.49 5.09 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.64 127.21 42.41 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.317 ' O ' HG13 ' A' ' 110' ' ' ILE . 82.4 m -103.17 153.0 20.79 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.097 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -147.34 146.18 29.59 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.301 HG22 ' CG ' ' A' ' 67' ' ' LEU . 3.3 t -100.6 163.15 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.329 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.13 158.61 24.36 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.535 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.66 127.56 37.22 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.996 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.113 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.0 m -117.03 158.27 24.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 1.005 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 1.0 OUTLIER -110.79 -157.36 0.61 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.986 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.91 -48.15 77.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.56 -25.93 61.54 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.78 47.3 2.31 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.62 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.34 154.7 29.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.121 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -165.09 171.98 40.61 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.983 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.601 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.36 171.88 16.09 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.294 3.329 . . . . 0.0 109.647 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.218 ' OE1' ' HA ' ' A' ' 4' ' ' THR . 6.5 pt-20 -36.49 153.44 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.72 153.97 52.96 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.991 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.972 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.5 t -128.07 109.92 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.992 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.706 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.7 151.33 19.72 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.923 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.317 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -120.63 164.87 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 t -154.82 120.39 5.09 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.516 ' HE2' HG22 ' A' ' 69' ' ' VAL . 46.4 m-85 -97.01 127.06 42.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.947 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.043 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -86.87 124.54 68.84 Favored Pre-proline 0 N--CA 1.45 -0.474 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.361 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.38 -174.19 1.35 Allowed 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.316 3.344 . . . . 0.0 109.545 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.795 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.5 m -93.95 108.51 20.31 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.746 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.65 143.59 51.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.63 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -98.29 111.98 24.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.795 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 24.2 t -109.51 143.98 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.932 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.0 175.19 1.86 Allowed Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.921 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.932 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.33 118.41 5.59 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.34 3.36 . . . . 0.0 109.598 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.718 ' HA ' HD11 ' A' ' 13' ' ' LEU . 25.0 p -116.77 46.04 1.72 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.3 p -124.8 106.04 9.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.9 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.701 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 92.72 28.08 13.16 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.718 HD11 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -103.99 129.75 51.61 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.967 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -103.8 170.99 7.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.762 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -45.91 142.32 2.67 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.984 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.13 -22.97 34.88 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.5 m -77.36 148.2 35.7 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.4 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 7.5 p -124.19 123.08 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 20.9 m -91.05 166.88 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.795 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.4 138.49 54.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.994 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.574 HG12 HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -132.73 117.81 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.746 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.86 116.22 21.21 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.56 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -82.0 144.41 23.83 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.795 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.79 106.26 4.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.505 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 104.19 22.09 8.98 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.066 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.64 -165.0 1.22 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -80.43 124.19 28.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.503 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 129.74 38.64 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.57 7.94 85.79 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.657 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.74 143.89 25.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.876 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -91.44 150.11 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.997 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.5 m-85 -138.29 146.41 42.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.27 ' CB ' ' HG ' ' A' ' 98' ' ' SER . 12.2 m-20 -112.48 113.86 26.25 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.519 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.27 152.58 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.792 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . 179.95 173.63 45.11 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.324 -1.111 . . . . 0.0 110.324 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.908 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 47.8 tt0 -106.23 119.68 39.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.0 m -109.14 162.58 14.13 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.305 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -148.73 136.26 20.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.892 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.03 123.69 19.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.89 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.022 HG23 ' HB3' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -102.2 -41.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.634 ' HB2' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -150.45 179.21 8.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.944 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -65.85 109.36 2.46 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.29 10.34 86.1 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.543 HG22 ' CE2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -130.87 131.7 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.405 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 1.8 pp -133.71 162.35 32.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.329 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -129.02 144.96 51.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.678 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.44 158.86 17.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.848 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -120.18 118.58 31.3 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.424 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.7 Cg_endo -72.37 1.64 5.92 Favored 'Trans proline' 0 N--CA 1.446 -1.278 0 C-N-CA 124.326 3.351 . . . . 0.0 109.606 179.884 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.29 -20.65 31.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.868 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.412 ' HB3' HG23 ' A' ' 68' ' ' THR . 91.7 m-20 -129.78 30.56 4.86 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.66 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -94.88 117.96 30.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.993 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.5 t -114.01 176.99 4.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.4 p -147.13 155.56 42.26 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' N ' ' A' ' 56' ' ' THR . 3.2 p -167.1 162.36 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.508 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.8 m -127.9 128.69 45.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.94 152.05 28.67 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.41 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.1 p30 -94.13 -170.75 2.37 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.52 69.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -76.02 -7.57 54.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.503 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.91 8.69 87.28 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.0 p -99.06 139.79 34.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.66 156.01 32.62 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -136.76 121.92 19.12 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.56 HG22 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -158.57 153.57 25.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.56 ' N ' HG22 ' A' ' 65' ' ' THR . 1.5 m -114.48 130.61 56.74 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.315 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -107.72 154.25 21.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.507 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -113.76 140.5 48.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.96 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.549 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.25 129.78 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.99 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.854 ' H ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.18 164.88 13.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -88.06 -25.01 23.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.572 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -162.11 147.58 13.0 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.932 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.908 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.2 p90 -176.57 156.01 1.44 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -55.86 121.18 8.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.329 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -82.46 96.86 1.88 Allowed Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.678 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.99 99.96 10.74 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.779 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.1 tp -57.46 129.3 41.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.995 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.622 ' N ' HD11 ' A' ' 77' ' ' LEU . 17.9 p90 -47.67 -34.51 8.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.779 ' HB3' HD23 ' A' ' 77' ' ' LEU . 2.7 t0 -57.68 -16.36 10.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.14 8.49 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.464 ' HB ' HD22 ' A' ' 77' ' ' LEU . 1.3 m -118.16 150.62 39.08 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.97 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.4 mtp180 -93.85 97.53 10.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.543 ' CE2' HG22 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.9 -55.6 21.44 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.947 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.81 176.47 22.19 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.9 113.42 4.37 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.986 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.305 HG12 ' CB ' ' A' ' 38' ' ' ALA . 3.6 t -89.15 152.96 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -117.65 93.13 4.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.161 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 57.6 m -52.92 -26.59 15.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 36.7 p -78.33 -0.23 28.1 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.589 ' O ' HG23 ' A' ' 90' ' ' THR . 1.1 m -117.63 -28.04 6.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.984 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.47 -173.56 2.94 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.13 124.21 47.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.812 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 65.9 m -105.25 152.52 22.78 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.103 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -144.21 145.5 32.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.315 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.2 t -107.82 156.04 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.303 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.46 174.34 46.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.519 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -128.08 142.61 51.16 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.27 ' HG ' ' CB ' ' A' ' 33' ' ' ASP . 97.3 p -118.77 152.63 35.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.876 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -114.06 -165.6 1.02 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.974 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -54.32 -49.34 69.92 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.13 -25.24 58.26 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 98.71 45.29 2.31 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.708 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.63 167.64 10.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.959 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.997 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.03 -171.3 39.71 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.361 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.34 152.51 55.37 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.322 3.348 . . . . 0.0 109.599 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.124 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -35.26 121.13 0.56 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.55 143.91 0.09 OUTLIER Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.971 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.103 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -114.3 105.49 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.05 130.48 34.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.096 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.8 mt -103.79 164.08 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.907 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.99 121.52 10.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.161 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 18.0 m-85 -90.56 113.15 25.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.51 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.637 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -142.92 139.41 16.88 Favored Pre-proline 0 N--CA 1.448 -0.53 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.391 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.0 Cg_endo -72.42 -174.7 1.51 Allowed 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 124.319 3.346 . . . . 0.0 109.623 179.927 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.771 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.8 108.97 21.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.695 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.22 140.1 52.81 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.939 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.599 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -98.7 114.11 26.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.742 HG21 HG22 ' A' ' 108' ' ' VAL . 38.2 t -111.25 149.17 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.938 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.19 175.7 1.43 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.909 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.938 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.9 Cg_endo -72.35 119.2 5.99 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.312 3.341 . . . . 0.0 109.635 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.928 ' CB ' HG22 ' A' ' 110' ' ' ILE . 51.7 p -113.17 47.9 1.08 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.541 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.2 p -125.21 106.85 10.19 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.87 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.672 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.63 26.15 23.51 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.947 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.707 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -100.95 131.58 46.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.415 ' OG ' ' OD1' ' A' ' 15' ' ' ASP . 17.7 t -118.04 177.06 4.93 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.645 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 5.2 p-10 -45.41 139.26 3.76 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.66 34.73 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.9 m -85.98 150.58 24.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -126.26 123.79 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.686 HG12 HG23 ' A' ' 69' ' ' VAL . 18.5 m -87.19 162.31 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.95 143.87 44.47 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.7 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -138.84 112.06 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.981 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.695 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.9 115.66 22.33 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.531 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -83.31 140.78 20.12 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.771 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -138.72 106.68 5.69 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.445 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 100.03 26.16 8.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.111 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.12 -169.27 2.5 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.521 HE21 ' HH ' ' A' ' 32' ' ' TYR . 33.4 mt-30 -80.14 123.47 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.685 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.39 130.12 40.53 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.68 8.74 84.6 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.678 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.8 134.4 38.8 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.795 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.84 151.76 23.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.506 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 40.9 m-85 -137.26 148.65 46.58 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.145 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -112.11 116.27 30.23 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.923 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.481 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.78 140.47 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.948 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.852 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -163.3 157.82 30.05 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.833 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.6 tt0 -106.53 116.38 31.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.441 ' SG ' HD12 ' A' ' 45' ' ' LEU . 1.6 m -102.96 165.21 11.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.906 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -151.91 142.94 23.15 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.95 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 0.5 OUTLIER -64.98 122.13 16.28 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.76 HG13 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -101.68 -55.23 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.939 ' OD2' ' CH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -131.86 168.62 17.53 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -50.07 110.88 0.44 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.87 8.31 63.8 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.517 HG12 ' CE2' ' A' ' 83' ' ' TRP . 62.1 t -119.62 125.14 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.442 HD11 ' N ' ' A' ' 46' ' ' ALA . 1.6 pp -125.85 162.05 26.03 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.379 ' HB3' ' C ' ' A' ' 75' ' ' GLY . . . -130.96 161.49 31.81 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.898 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.892 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -115.65 156.07 26.53 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.745 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 23.0 t30 -116.71 110.79 41.87 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -72.43 -0.89 9.4 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.356 3.371 . . . . 0.0 109.546 179.956 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.601 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.97 -11.58 43.93 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.601 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 3.5 m-20 -133.39 28.87 4.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.884 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.643 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -101.9 118.17 36.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 40.9 t -107.86 -176.39 3.05 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 96.9 p -146.25 152.65 39.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.892 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.7 p -166.59 155.57 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 74.0 m -126.41 126.94 44.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.924 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -56.43 146.68 23.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.3 p30 -88.16 -170.25 2.89 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.91 -25.85 67.82 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -84.58 5.23 28.63 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.685 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 65.27 8.78 38.99 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -98.35 134.42 41.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.39 166.23 14.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.5 p -150.03 124.5 9.64 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.574 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -159.36 151.87 21.39 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.901 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.574 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -111.16 132.79 54.01 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.952 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.126 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -109.8 119.17 38.52 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.895 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.574 ' N ' HD11 ' A' ' 67' ' ' LEU . 1.8 t -70.04 143.55 52.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.686 HG23 HG12 ' A' ' 19' ' ' VAL . 1.3 t -104.23 131.51 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.833 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -119.84 153.07 36.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.97 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 ptt85 -85.66 -22.77 27.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 t -166.79 152.96 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.745 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.5 p90 -175.4 167.24 3.33 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.921 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.38 125.02 22.46 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.915 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.379 ' C ' ' HB3' ' A' ' 46' ' ' ALA . . . -77.79 90.92 1.07 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.55 10.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.999 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.714 HD11 ' N ' ' A' ' 78' ' ' PHE . 1.6 tp -54.47 141.64 30.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.714 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.05 -42.13 18.05 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.63 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -57.52 -17.1 12.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.978 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.55 29.1 9.65 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.2 m -110.17 122.08 46.79 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.38 92.27 0.08 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.517 ' CE2' HG12 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.56 -58.34 7.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.93 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.03 170.28 21.15 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.63 139.36 53.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.906 HG22 ' CB ' ' A' ' 38' ' ' ALA . 2.7 p -126.34 140.55 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.52 ' N ' HG23 ' A' ' 86' ' ' VAL . 0.5 OUTLIER -93.48 94.97 8.97 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.964 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.98 -21.07 10.62 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.5 p -89.27 1.98 54.96 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.48 HG21 ' O ' ' A' ' 90' ' ' THR . 7.3 m -114.09 -27.38 7.7 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.95 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -123.26 -177.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.61 128.45 37.44 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.937 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.078 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 1.5 m -105.0 152.62 22.49 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.054 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.2 pt20 -152.89 147.32 25.85 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.126 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.6 t -114.17 158.16 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.957 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.262 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 163.71 33.06 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.481 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.07 124.16 36.36 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.988 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.145 ' N ' ' H ' ' A' ' 33' ' ' ASP . 11.5 m -113.52 156.68 23.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.795 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.19 -161.17 0.74 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.31 -48.62 69.74 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.68 -26.07 66.85 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.889 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.12 42.53 3.24 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.523 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.68 157.98 24.54 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.506 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.4 177.53 45.74 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.391 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.0 Cg_endo -72.41 154.86 55.88 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.317 3.345 . . . . 0.0 109.581 179.96 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.637 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -36.96 119.34 0.65 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.941 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.13 155.92 0.01 OUTLIER Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.855 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.1 t -119.23 107.59 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 118.19 25.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.054 HG13 ' HA ' ' A' ' 94' ' ' GLN . 8.5 mt -98.25 159.12 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.75 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -144.1 123.48 13.09 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.078 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 5.4 m-85 -92.02 127.26 37.42 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.892 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.7 p30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.96 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.345 ' HB3' ' CB ' ' A' ' 106' ' ' GLU . . . -101.11 114.1 65.8 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.565 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.39 -178.25 3.21 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.297 3.331 . . . . 0.0 109.584 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.121 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -100.23 111.87 24.16 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.936 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.741 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.5 160.53 29.29 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.8 p -124.75 119.08 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.806 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -116.73 154.84 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.933 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.22 174.9 1.74 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.954 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.933 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.4 Cg_endo -72.4 118.58 5.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.305 3.337 . . . . 0.0 109.593 179.889 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 1.231 ' OG ' HG22 ' A' ' 110' ' ' ILE . 11.9 p -116.02 48.76 1.19 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.651 ' HA ' ' O ' ' A' ' 111' ' ' SER . 18.8 p -126.43 104.71 8.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.606 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 89.79 29.05 16.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.726 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -94.85 133.41 38.6 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.986 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.4 t -96.61 158.32 15.49 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.998 ' OD1' ' HG3' ' A' ' 70' ' ' ARG . 25.5 t70 -45.1 142.51 1.9 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.26 -23.13 34.21 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 91.7 m -71.59 150.94 44.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.404 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 7.5 p -125.27 122.78 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.89 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 32.7 m -91.07 167.3 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.806 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -116.56 152.92 33.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.63 115.52 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.741 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -127.77 114.36 17.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.621 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -84.48 144.7 21.6 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.121 ' O ' HG23 ' A' ' 4' ' ' THR . . . -140.48 114.58 9.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.69 19.04 25.98 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.701 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.28 175.67 7.03 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -180.0 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 1.11 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 34.4 mt-30 -59.6 121.93 12.81 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.13 130.81 40.5 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.68 7.83 85.99 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.536 HG22 ' CZ ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -93.67 141.21 28.74 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.972 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 1.191 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.88 151.24 23.5 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.867 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.0 m-85 -135.77 146.81 48.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.437 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -109.79 114.89 28.84 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.951 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.522 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.9 140.24 22.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.772 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.78 168.98 39.91 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.219 -1.152 . . . . 0.0 110.219 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.96 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 45.3 tt0 -114.31 128.74 56.5 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 28.3 m -130.19 143.1 50.59 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.937 ' HB2' HG23 ' A' ' 86' ' ' VAL . . . -121.78 130.62 53.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.894 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.491 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.48 129.05 38.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.947 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.779 ' CG1' HG12 ' A' ' 86' ' ' VAL . 0.0 OUTLIER -111.12 -41.84 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.92 163.26 35.68 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 95.1 m -54.74 120.08 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.25 6.81 62.05 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.918 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 1.5 t -125.91 115.45 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.978 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.776 HD21 ' HE2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -125.08 143.62 50.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.97 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.152 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.39 142.93 34.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.198 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.0 m -112.14 163.71 14.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.513 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.2 t30 -126.82 110.73 22.3 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.43 0.58 7.25 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.299 3.332 . . . . 0.0 109.571 179.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.465 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.12 -12.67 43.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.7 p30 -129.24 28.85 5.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.41 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 0.1 OUTLIER -86.39 105.62 16.85 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.2 t -104.31 173.26 6.38 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.0 p -145.52 155.56 43.16 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 56' ' ' THR . 7.0 p -167.26 157.35 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 179.963 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.461 ' N ' HG23 ' A' ' 55' ' ' VAL . 89.8 m -128.1 137.0 51.95 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.16 137.29 41.23 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -76.82 -174.71 3.16 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.69 -19.11 61.99 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -84.6 7.51 19.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.987 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.649 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 56.87 32.06 61.77 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 t -129.31 133.52 47.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.25 164.37 19.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.67 126.35 11.02 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.504 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -158.64 154.19 26.07 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.87 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.504 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -105.39 133.35 50.29 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.951 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.438 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -115.25 119.84 37.68 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.893 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.645 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -72.07 133.82 45.47 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.882 HG21 ' HZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -108.17 123.9 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.998 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.998 ' HG3' ' OD1' ' A' ' 15' ' ' ASP . 0.5 OUTLIER -113.25 140.7 47.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.956 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.6 ptt180 -76.49 -7.71 55.68 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 77.3 p -167.29 146.6 5.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.96 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 7.2 p90 -177.19 164.98 2.26 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.02 115.07 3.45 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.956 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.152 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.47 98.31 1.25 Allowed Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.887 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 101.49 11.41 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.981 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.725 HD12 ' N ' ' A' ' 78' ' ' PHE . 2.2 tp -57.32 137.3 56.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.776 ' HE2' HD21 ' A' ' 45' ' ' LEU . 13.4 m-85 -47.23 -40.14 15.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.713 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.3 t0 -56.45 -17.06 6.96 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.65 28.11 9.88 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.4 ' HB ' HD22 ' A' ' 77' ' ' LEU . 28.3 m -112.3 143.44 43.39 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -81.17 94.48 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.918 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.7 t-105 -63.08 -48.97 76.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.13 173.56 13.68 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.39 106.91 1.49 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.937 HG23 ' HB2' ' A' ' 38' ' ' ALA . 26.8 m -87.66 151.86 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -101.97 92.33 4.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -53.55 -24.66 14.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.968 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 8.3 t -84.26 1.73 43.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.5 m -115.14 -27.49 7.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.45 -171.53 2.24 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.6 131.22 42.04 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.613 ' HB2' ' HB ' ' A' ' 110' ' ' ILE . 1.9 m -102.81 167.77 9.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.177 ' HG3' ' O ' ' A' ' 108' ' ' VAL . 11.2 tt0 -169.78 126.29 0.86 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.438 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 67.3 t -112.91 159.23 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.989 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.998 ' C ' HG13 ' A' ' 34' ' ' VAL . . . -179.17 -179.79 48.77 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.942 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.522 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.64 144.37 51.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.281 ' OG ' ' HB3' ' A' ' 33' ' ' ASP . 94.0 p -129.62 147.08 51.38 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 1.191 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -105.27 -163.41 0.95 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.987 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.86 -48.21 69.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.937 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.23 -21.04 66.29 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.76 53.2 2.62 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.909 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 1.11 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.14 162.53 27.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.98 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.867 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -171.94 -179.52 42.94 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.565 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 156.85 54.3 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.357 3.371 . . . . 0.0 109.593 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.345 ' CB ' ' HB3' ' A' ' 2' ' ' ALA . 10.8 pt-20 -35.69 120.84 0.6 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.9 148.2 0.04 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.177 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 72.0 t -124.4 118.95 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -98.14 150.47 21.43 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.231 HG22 ' OG ' ' A' ' 10' ' ' SER . 16.9 mt -126.09 163.49 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.651 ' O ' ' HA ' ' A' ' 11' ' ' SER . 13.5 t -152.75 134.61 14.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.882 ' HZ ' HG21 ' A' ' 69' ' ' VAL . 9.6 m-85 -102.5 125.52 49.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 31.0 m-80 . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.991 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.63 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -130.52 132.07 23.75 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.354 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.7 Cg_endo -72.35 -174.12 1.33 Allowed 'Trans proline' 0 N--CA 1.448 -1.201 0 C-N-CA 124.323 3.349 . . . . 0.0 109.609 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.792 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -96.47 107.12 19.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.66 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.39 147.53 48.18 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.987 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.528 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -102.26 111.57 23.9 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.924 ' CG2' HG22 ' A' ' 108' ' ' VAL . 38.6 t -107.28 148.04 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.89 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -73.24 176.74 2.39 Favored Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.93 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.89 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.6 Cg_endo -72.43 116.28 4.65 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.332 3.354 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 1.009 ' HB2' HG21 ' A' ' 110' ' ' ILE . 91.6 p -111.51 47.38 1.03 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.518 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.1 p -127.1 107.06 9.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.63 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.72 26.12 23.39 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.921 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.696 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -97.96 131.64 44.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.995 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.1 m -111.21 173.98 6.08 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 1.5 t0 -47.87 144.0 3.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.489 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 99.41 -23.6 35.57 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.953 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.7 m -74.33 151.17 39.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.453 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 7.8 p -125.31 117.41 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.949 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.62 ' HA ' HG23 ' A' ' 8' ' ' THR . 55.1 t -83.99 163.46 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.82 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tppt? -124.01 133.4 53.68 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.649 ' CG1' HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -135.53 110.39 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.973 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.66 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.6 119.24 33.2 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.569 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -82.76 140.68 20.44 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.751 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.4 108.8 6.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.93 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 101.99 24.37 8.6 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.053 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.66 -163.59 1.03 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.819 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -85.5 126.56 33.94 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.536 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.25 131.57 41.32 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.936 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.89 84.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.627 HG21 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.52 138.2 31.71 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.666 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -88.49 145.17 25.9 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.934 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -133.61 146.03 50.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.237 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -110.72 117.37 33.28 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.906 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.356 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.32 145.56 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.99 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.95 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.25 171.57 41.99 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.817 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -118.14 112.01 19.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.969 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.6 m -105.05 172.4 6.81 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.029 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -155.09 138.17 15.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.905 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.509 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.93 127.18 30.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.912 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.905 HG23 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -108.27 -51.85 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.027 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -143.01 165.14 28.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.946 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.1 t -51.46 112.15 0.7 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.08 9.15 75.87 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.966 HG12 ' CD1' ' A' ' 83' ' ' TRP . 4.5 t -129.06 114.37 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.647 ' C ' ' CD1' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -118.22 162.84 17.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.352 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -123.64 138.63 54.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.983 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 58.3 m -109.49 148.46 31.16 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.71 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.8 t-20 -107.04 107.17 60.08 Favored Pre-proline 0 N--CA 1.45 -0.469 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.456 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.7 Cg_endo -72.47 0.35 7.61 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.344 . . . . 0.0 109.564 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.445 ' N ' ' OD1' ' A' ' 48' ' ' ASN . . . -89.02 -9.54 50.92 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.9 p30 -131.72 27.16 4.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 104.98 13.9 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.991 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 29.8 t -98.32 172.29 7.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.34 154.68 41.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.504 HG22 ' N ' ' A' ' 56' ' ' THR . 6.0 p -166.7 158.31 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.954 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.504 ' N ' HG22 ' A' ' 55' ' ' VAL . 13.7 m -127.05 130.16 49.42 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.967 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.38 43.74 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.2 p30 -92.24 -171.59 2.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.27 -23.92 66.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.421 ' N ' ' OD1' ' A' ' 60' ' ' ASN . 1.8 m-20 -85.19 9.74 14.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 58.58 14.28 20.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -104.51 133.91 48.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.934 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.45 162.21 19.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -146.09 127.45 14.92 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.498 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -163.9 150.03 11.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.877 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.498 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -109.25 142.5 40.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.945 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.105 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -113.85 123.27 49.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.702 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.4 t -70.08 124.54 24.35 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.546 HG21 HG21 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -85.09 125.2 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.802 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.0 OUTLIER -117.08 144.76 44.3 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.412 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -87.16 -13.43 44.08 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 51.9 p -166.99 149.7 6.35 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.952 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.817 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.1 p90 -177.03 152.42 0.9 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.5 121.68 8.21 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.352 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -78.7 93.13 1.25 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.887 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 99.85 10.84 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.981 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.766 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.1 tp -57.1 130.8 47.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.532 ' N ' HD13 ' A' ' 77' ' ' LEU . 24.1 p90 -47.35 -35.75 8.55 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.766 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.68 -16.62 11.35 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.47 26.35 10.09 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 29.9 m -112.9 145.77 40.13 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -86.56 95.6 9.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.027 ' HZ2' ' CB ' ' A' ' 41' ' ' ASP . 1.0 OUTLIER -62.98 -53.84 47.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.939 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.7 173.21 14.32 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.13 125.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.029 HG11 ' HB3' ' A' ' 38' ' ' ALA . 54.5 t -100.05 148.63 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.47 93.25 4.14 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.412 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.5 m -52.86 -26.01 13.38 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.0 p -81.75 1.4 34.66 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.433 ' O ' HG23 ' A' ' 90' ' ' THR . 2.0 m -116.89 -27.18 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.98 -176.92 4.16 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.915 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.79 124.73 45.37 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.001 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 73.2 m -104.62 154.88 19.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.029 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -143.39 149.75 38.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.92 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.105 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 5.4 t -117.85 154.25 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.238 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.95 173.54 46.08 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.356 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.45 146.32 50.14 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.988 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.237 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 4.7 m -127.09 151.49 48.56 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.666 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -109.53 -165.62 1.03 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.984 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.48 -49.33 77.98 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.964 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.476 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . . . -68.64 -25.33 64.78 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.41 41.82 3.34 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.476 ' OD1' ' HB2' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -115.94 164.04 15.0 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.934 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.57 -177.49 42.01 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.354 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.44 156.25 54.54 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.251 3.301 . . . . 0.0 109.57 179.903 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.63 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 3.3 pt-20 -37.36 119.87 0.74 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.49 151.93 0.02 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.924 HG22 ' CG2' ' A' ' 7' ' ' VAL . 3.6 t -124.01 104.44 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.42 128.83 34.83 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.029 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.4 mt -102.03 160.77 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.931 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.744 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -144.52 120.89 10.95 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.946 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.46 123.43 40.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.458 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . -140.66 123.57 9.94 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.534 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.34 -178.64 3.42 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 124.356 3.371 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.191 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.2 m -101.91 109.52 21.28 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.961 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.91 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.71 141.9 51.58 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -104.75 117.76 34.87 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.992 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.777 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -115.92 151.73 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.951 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.642 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.4 OUTLIER -74.48 163.54 67.54 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.937 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.612 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.0 Cg_endo -72.41 120.09 6.53 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.267 3.312 . . . . 0.0 109.595 179.918 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.983 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -120.07 16.7 12.46 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.975 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 1.101 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.2 p -98.91 115.15 28.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.94 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.644 ' N ' ' H ' ' A' ' 113' ' ' ASN . . . 104.24 -0.13 44.0 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.983 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 1.3 pp -114.09 142.48 46.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.996 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.8 p -107.54 -167.76 1.3 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.669 ' CG ' HH11 ' A' ' 70' ' ' ARG . 7.2 t70 -42.15 153.67 0.06 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.98 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.75 -23.1 34.23 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.978 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.557 HG22 HD22 ' A' ' 13' ' ' LEU . 26.1 m -80.26 141.42 35.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.485 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 11.2 p -119.46 109.84 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.696 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 1.8 p -83.67 161.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.987 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.777 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.73 150.79 39.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.449 ' CG1' HG12 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -143.62 109.35 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.978 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.91 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.14 116.95 25.11 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.678 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -83.64 144.74 22.38 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.984 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.717 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.04 109.55 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.45 17.82 23.05 Favored Glycine 0 C--N 1.336 0.56 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.99 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.717 HD22 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.01 175.15 7.29 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.991 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.489 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 37.6 mt-30 -58.35 121.37 10.65 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.468 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.65 129.16 37.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.99 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.35 8.22 87.61 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.933 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.651 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.5 143.49 26.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.961 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.665 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.35 151.45 23.09 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.96 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.795 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.3 m-85 -138.9 139.35 38.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.911 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.141 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 6.3 m-20 -105.47 113.73 27.48 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.312 HG23 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.98 147.57 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.938 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.863 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.72 166.13 38.26 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 1.01 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 2.2 tt0 -108.26 123.56 48.96 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.963 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.2 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.7 m -117.57 143.86 45.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.959 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.549 ' HB3' HG23 ' A' ' 86' ' ' VAL . . . -124.07 137.61 54.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.52 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -65.61 127.94 33.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.607 HG12 ' CZ3' ' A' ' 83' ' ' TRP . 1.2 t -107.43 -55.14 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.473 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.62 167.62 17.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.962 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -50.81 112.11 0.65 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.72 8.09 66.96 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.999 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.537 HG11 ' NE1' ' A' ' 83' ' ' TRP . 11.6 t -122.74 112.89 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.988 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.639 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -121.97 131.98 54.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.984 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.047 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -89.31 153.77 20.62 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.942 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.2 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.8 m -110.81 156.87 20.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.825 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.6 t30 -114.9 106.24 52.03 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.37 -0.09 8.2 Favored 'Trans proline' 0 N--CA 1.448 -1.178 0 C-N-CA 124.319 3.346 . . . . 0.0 109.603 179.91 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.487 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -89.15 -11.61 43.36 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.7 p30 -130.25 27.26 5.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.23 106.76 15.28 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 t -101.09 171.79 7.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.896 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 p -146.88 154.26 41.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.437 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.77 161.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.928 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.437 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 19.9 m -128.03 135.8 50.37 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.63 135.19 39.16 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.917 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.0 p30 -76.02 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.914 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.5 -19.75 62.42 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -83.28 6.8 18.42 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.689 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 57.94 32.11 65.89 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.9 t -130.92 134.53 46.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.966 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.35 165.5 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -144.94 130.25 18.67 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.988 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.61 HG22 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.61 169.79 20.73 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.88 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.61 ' N ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -128.87 117.52 21.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.092 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.36 157.95 15.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.959 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.534 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -118.67 136.93 53.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.947 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.603 HG13 ' OG ' ' A' ' 10' ' ' SER . 0.5 OUTLIER -103.23 126.69 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.669 HH11 ' CG ' ' A' ' 15' ' ' ASP . 0.1 OUTLIER -113.73 142.68 45.74 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.959 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -62.81 -35.13 78.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 83.7 p -154.55 157.05 37.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.876 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 1.01 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.2 p90 -177.17 155.83 1.19 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' CG ' ' A' ' 74' ' ' GLU . 0.5 OUTLIER -53.49 109.93 0.5 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.935 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.047 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -70.1 103.0 1.07 Allowed Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.96 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.992 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.19 100.21 10.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.987 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.723 HD12 ' N ' ' A' ' 78' ' ' PHE . 3.3 tp -57.87 137.98 56.15 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.723 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.34 -40.36 17.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.566 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -57.32 -17.13 10.78 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.978 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.53 28.56 9.52 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.993 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 5.4 m -112.45 148.43 34.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.985 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -83.94 94.21 8.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.607 ' CZ3' HG12 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -64.24 -40.18 95.48 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.92 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.33 169.7 12.47 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.31 106.12 0.49 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.942 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.624 ' CG1' HG22 ' A' ' 40' ' ' VAL . 27.6 m -85.35 154.34 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.64 91.72 4.32 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.775 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.28 -20.65 7.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.977 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.518 ' HA ' ' CB ' ' A' ' 112' ' ' PHE . 76.0 p -90.59 2.82 55.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.971 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.552 ' O ' HG22 ' A' ' 90' ' ' THR . 15.6 m -112.61 -27.26 8.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.95 -178.77 4.28 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.28 129.19 35.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.434 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 3.8 m -105.04 155.24 19.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.313 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.6 tt0 -154.02 131.75 11.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 -179.939 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.092 ' CG1' HD12 ' A' ' 67' ' ' LEU . 6.5 t -94.09 163.67 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.989 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.244 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.69 165.0 33.84 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.312 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.41 132.2 45.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.986 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.141 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 32.9 m -111.66 153.01 27.01 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.904 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.665 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.03 -162.47 0.8 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.995 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.9 -48.45 65.98 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.24 -24.15 65.78 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.78 54.09 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -133.97 171.47 14.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.795 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.51 173.77 45.45 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.534 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.42 168.23 24.86 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 124.258 3.306 . . . . 0.0 109.571 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.458 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 9.1 pt-20 -39.54 125.63 1.77 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.945 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.3 161.22 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.914 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.313 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 50.0 t -119.13 102.4 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.91 132.35 36.04 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.232 ' CD1' ' HB2' ' A' ' 93' ' ' CYS . 16.1 pt -136.85 -175.3 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 1.101 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -177.27 153.17 0.92 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.968 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.434 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.1 m-85 -107.17 119.28 38.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.945 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.644 ' H ' ' N ' ' A' ' 12' ' ' GLY . 7.3 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.074 ' HB3' ' CA ' ' A' ' 106' ' ' GLU . . . -86.36 116.93 67.69 Favored Pre-proline 0 N--CA 1.448 -0.54 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.914 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.594 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 85.0 Cg_endo -72.37 -178.73 3.49 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.36 3.373 . . . . 0.0 109.608 179.925 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.973 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.2 m -100.9 108.74 20.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.644 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -120.16 145.2 47.18 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.957 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -108.66 115.29 29.82 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.976 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.715 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.33 153.57 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.993 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.851 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.18 175.09 1.95 Allowed Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.958 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.851 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.5 Cg_endo -72.43 117.45 5.14 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.292 3.328 . . . . 0.0 109.607 179.869 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 1.033 ' HB3' HG22 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -115.16 47.35 1.3 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.943 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.491 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -123.71 105.81 10.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.676 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 90.45 28.51 16.66 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.742 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -99.43 134.79 41.8 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.83 163.77 12.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 15' ' ' ASP . 3.5 t0 -45.94 142.91 2.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 103.44 -22.75 35.1 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.6 m -73.3 144.81 46.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 11.0 p -111.74 115.08 48.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.978 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.69 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.6 m -84.21 158.51 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.715 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.53 144.39 42.93 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.979 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.42 HG21 ' C ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -145.36 110.74 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.985 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.644 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.78 122.41 37.37 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.956 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.683 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -84.51 146.79 22.73 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.947 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.1 109.37 4.69 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.72 16.83 27.67 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.952 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.683 ' CD2' ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.43 176.06 6.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.945 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.504 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 31.7 mt-30 -56.5 120.82 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -180.0 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.446 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.73 130.66 41.02 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.28 7.34 84.78 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.558 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.26 140.39 29.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.964 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 1.227 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.8 147.86 27.34 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.112 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 27.4 m-85 -135.75 131.92 36.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.932 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.351 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.45 112.58 24.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.962 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.501 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.77 144.31 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.987 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.983 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.68 161.09 33.92 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.903 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 34.2 tt0 -104.03 119.18 38.39 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.208 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 85.7 m -117.08 143.54 45.67 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.731 ' HB1' HG12 ' A' ' 86' ' ' VAL . . . -123.29 139.25 54.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.544 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.98 125.29 24.43 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.407 ' CG1' ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -105.03 -44.09 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.991 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.543 ' OD1' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -142.36 169.41 17.63 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.4 m -50.99 112.41 0.71 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.997 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.63 7.47 61.33 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.411 HG11 HG13 ' A' ' 40' ' ' VAL . 2.3 t -120.8 118.7 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -128.99 134.91 48.34 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.986 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.148 ' HB2' ' C ' ' A' ' 75' ' ' GLY . . . -91.55 157.61 16.91 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.208 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 69.1 m -117.61 156.04 28.82 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.519 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.0 t30 -122.07 109.28 33.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.442 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.44 0.26 7.73 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.278 3.319 . . . . 0.0 109.576 179.936 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.475 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -85.44 -14.96 44.55 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.878 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 5.9 p30 -129.09 19.53 5.93 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.951 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.689 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -82.07 117.94 22.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.983 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 m -107.11 178.1 4.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.973 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 p -145.23 152.69 40.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.851 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.468 HG21 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.02 156.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.468 ' N ' HG21 ' A' ' 55' ' ' VAL . 22.0 m -127.92 133.05 49.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.959 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.75 134.49 46.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.936 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 37.5 p30 -75.05 -174.46 2.27 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.909 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.54 -25.23 67.93 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.975 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.32 -4.6 42.99 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 72.07 31.08 64.52 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.997 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.1 p -129.2 139.62 51.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.957 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.37 163.43 26.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.69 127.06 15.85 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.543 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -150.62 159.43 44.51 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.855 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.543 ' N ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -119.5 115.08 23.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.932 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.317 ' CD1' HG12 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.78 157.55 16.01 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.925 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.667 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -111.93 136.22 51.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.975 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.67 ' CG1' ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.95 129.16 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.99 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.769 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.38 164.3 15.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.994 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.2 -15.37 29.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.983 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -164.49 143.28 7.12 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.903 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -170.7 159.52 6.6 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -54.59 120.3 6.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.901 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.148 ' C ' ' HB2' ' A' ' 46' ' ' ALA . . . -79.94 92.28 1.35 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 179.986 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.19 100.14 10.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.966 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.747 HD21 ' HB3' ' A' ' 79' ' ' ASP . 1.6 tp -55.14 144.25 24.66 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.991 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.738 ' N ' HD11 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.35 -43.43 23.05 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.747 ' HB3' HD21 ' A' ' 77' ' ' LEU . 8.7 t0 -58.05 -17.02 14.97 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.958 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.2 28.56 10.6 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.999 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.2 m -107.66 119.22 38.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.83 91.43 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.407 ' CE2' ' CG1' ' A' ' 40' ' ' VAL . 29.0 t90 -62.7 -58.55 7.08 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.901 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.48 166.91 17.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.992 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.06 108.82 0.73 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.955 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.84 HG21 HG23 ' A' ' 40' ' ' VAL . 15.7 t -81.95 147.35 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.998 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -105.28 94.44 5.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.988 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -52.56 -24.99 9.23 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.6 p -79.3 -3.64 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 -26.87 7.36 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.4 -178.11 3.9 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.13 138.6 33.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.959 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.656 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -102.47 161.23 13.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.974 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.206 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.4 tt0 -168.39 127.19 1.16 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.317 HG12 ' CD1' ' A' ' 67' ' ' LEU . 2.5 t -97.04 164.56 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.967 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -175.75 167.99 40.09 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.501 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.82 128.5 38.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.981 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.351 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 19.8 m -116.84 142.19 47.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.913 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 1.227 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -98.33 -157.8 0.62 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.87 -48.22 69.45 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.903 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.77 -25.89 64.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.955 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.8 48.46 2.11 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.602 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -120.62 162.94 18.8 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.999 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.112 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.58 176.71 44.04 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.984 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.594 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.46 165.12 33.6 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.319 3.346 . . . . 0.0 109.601 179.935 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.074 ' CA ' ' HB3' ' A' ' 2' ' ' ALA . 5.2 pt-20 -38.24 135.91 0.69 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.961 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.61 147.56 3.93 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.967 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.206 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 13.0 t -127.42 104.15 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.985 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.641 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -88.71 157.16 18.62 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.033 HG22 ' HB3' ' A' ' 10' ' ' SER . 22.4 mt -127.97 168.31 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.491 ' O ' ' HA ' ' A' ' 11' ' ' SER . 21.1 t -153.97 137.26 15.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.954 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.656 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -102.09 124.94 48.56 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.51 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 30.3 m-80 . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.97 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.656 ' HB3' ' CG ' ' A' ' 106' ' ' GLU . . . -90.69 123.16 65.87 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.931 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.424 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -175.23 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.306 3.337 . . . . 0.0 109.61 179.924 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.912 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.72 108.21 20.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.722 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 146.52 49.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.43 110.33 22.31 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.973 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.682 ' CG2' HG23 ' A' ' 108' ' ' VAL . 14.3 t -105.62 146.1 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.927 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.17 175.24 2.2 Favored Pre-proline 0 N--CA 1.448 -0.528 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.945 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.927 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.42 116.54 4.75 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 124.323 3.349 . . . . 0.0 109.593 179.918 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.908 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 56.6 p -113.33 46.66 1.23 Allowed 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.957 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 111' ' ' SER . 61.9 p -126.34 105.2 8.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.907 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.624 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 92.79 26.84 15.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.723 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -98.13 132.34 43.74 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.965 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -104.15 169.41 8.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 15' ' ' ASP . 15.9 p30 -46.02 141.43 3.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.993 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.19 -22.95 34.84 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.991 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.407 HG22 HD13 ' A' ' 13' ' ' LEU . 24.6 m -79.63 152.32 30.08 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.991 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 1.2 t -124.92 125.66 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.998 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.678 HG21 ' O ' ' A' ' 67' ' ' LEU . 4.6 m -89.37 118.22 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -69.24 148.37 49.91 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.605 HG11 HG21 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.81 105.27 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.997 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.722 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.25 117.1 28.2 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.963 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.657 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -84.29 141.2 19.69 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.912 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.27 108.64 6.88 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.928 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' C ' HD22 ' A' ' 26' ' ' LEU . . . 101.67 23.88 9.1 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.976 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.295 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.34 -171.79 3.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.983 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.494 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 29.1 mt-30 -76.31 124.29 27.28 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.989 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.54 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.66 130.33 40.31 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.48 8.22 83.7 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.958 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.692 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -95.04 136.48 35.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.96 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.771 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.88 151.31 23.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.999 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.916 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 48.4 m-85 -138.12 144.17 40.71 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.052 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.0 m-20 -104.64 116.63 32.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.956 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.445 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.05 142.29 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.874 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.5 170.78 42.87 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.968 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.6 tt0 -114.42 116.3 28.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.934 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.169 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 64.2 m -114.6 143.2 45.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.664 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -122.9 131.45 53.74 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.914 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.84 123.72 20.53 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.935 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.059 ' HB ' ' CE3' ' A' ' 83' ' ' TRP . 14.2 m -103.58 -43.98 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.578 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -136.8 176.18 8.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.991 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.16 112.08 1.77 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.982 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.98 8.29 64.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.182 HG12 ' CE2' ' A' ' 83' ' ' TRP . 61.6 t -122.79 108.0 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 180.0 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.52 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -121.47 139.52 53.37 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.978 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.349 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -93.83 157.93 15.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.169 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.3 m -118.74 152.26 36.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.843 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.3 t-20 -110.93 107.47 57.79 Favored Pre-proline 0 N--CA 1.449 -0.492 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.37 -0.02 8.09 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.322 3.348 . . . . 0.0 109.591 179.891 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.436 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.78 -11.11 43.13 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.783 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.477 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.6 p30 -131.1 27.05 4.87 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.901 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.97 106.18 15.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.977 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.6 t -104.19 173.23 6.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.943 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 p -145.51 156.75 43.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.7 p -166.29 157.83 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.915 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 15.7 m -127.76 126.98 42.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.49 153.0 24.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.5 p30 -93.78 -171.63 2.64 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.885 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.22 67.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -83.17 5.24 23.4 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.54 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 64.59 9.24 37.03 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.975 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.5 t -101.22 134.41 44.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.985 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.56 163.48 17.91 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.4 p -147.78 130.72 16.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.972 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.555 HG22 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.49 164.19 17.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.968 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.555 ' N ' HG22 ' A' ' 65' ' ' THR . 0.8 OUTLIER -120.46 132.09 55.06 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.921 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.161 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.61 122.44 47.46 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.912 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.404 ' H ' HG23 ' A' ' 68' ' ' THR . 3.7 t -77.96 130.95 37.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.899 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.553 HG23 ' HZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -106.45 129.87 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.967 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.751 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.43 155.26 23.45 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.932 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -83.02 -13.67 55.45 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.978 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.544 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 13.9 m -167.24 147.4 5.41 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.968 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.6 p90 -177.31 157.36 1.32 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.949 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -56.56 117.61 4.03 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.942 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.349 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -78.14 97.26 1.39 Allowed Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.996 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.806 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.36 10.64 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.986 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.742 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.2 tp -54.5 141.74 30.04 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.74 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.22 -42.85 20.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.742 ' HB3' HD23 ' A' ' 77' ' ' LEU . 5.9 t0 -56.78 -16.8 7.21 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.69 27.98 10.82 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.931 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.405 ' HB ' HD22 ' A' ' 77' ' ' LEU . 2.6 m -108.19 130.82 55.12 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 6.9 ptt180 -72.24 92.95 1.42 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.578 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 0.6 OUTLIER -61.67 -54.96 35.73 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.893 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.5 174.19 21.37 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.07 113.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.664 HG23 ' CB ' ' A' ' 38' ' ' ALA . 1.1 m -91.36 152.4 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 1.5 m-20 -115.7 102.97 10.22 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.975 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.537 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 23.0 m -52.82 -27.46 18.27 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.3 p -79.56 -3.51 47.28 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.994 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.69 -27.78 6.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.27 -178.4 4.2 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.56 122.97 44.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.879 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.573 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 89.7 m -104.03 151.73 22.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.984 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.4 OUTLIER -152.24 146.81 25.71 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.951 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.161 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -110.21 159.05 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.983 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.243 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.07 169.6 41.49 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.445 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.8 129.42 46.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.958 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.052 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 5.8 m -110.26 152.35 26.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.961 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.771 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -114.37 -169.35 1.51 Allowed 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.943 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.65 -48.91 77.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.24 -24.29 66.57 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.928 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.02 53.5 1.89 Allowed Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.955 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.727 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -132.79 172.69 12.24 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.982 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.916 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.24 179.27 48.59 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.966 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.424 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 160.01 47.92 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.313 3.342 . . . . 0.0 109.586 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.656 ' CG ' ' HB3' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -36.82 122.2 0.8 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.38 155.38 0.03 OUTLIER Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.974 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.894 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.6 t -127.51 111.59 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.981 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -92.98 129.8 38.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.984 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.5 mt -103.74 156.16 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.609 ' O ' ' HA ' ' A' ' 11' ' ' SER . 11.7 t -145.25 129.7 17.86 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.91 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.553 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -96.23 126.59 41.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.947 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.49 ' CB ' ' CA ' ' A' ' 106' ' ' GLU . . . -102.01 124.55 39.71 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.96 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.574 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.41 -177.19 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.349 3.366 . . . . 0.0 109.584 179.949 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.833 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -95.42 108.63 20.85 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.926 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.826 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.91 145.26 51.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.577 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.49 111.98 24.86 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.836 HG22 HG23 ' A' ' 108' ' ' VAL . 26.2 t -106.96 149.21 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.993 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.53 178.32 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.938 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.993 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.37 117.75 5.28 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 C-N-CA 124.279 3.32 . . . . 0.0 109.569 179.942 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.687 ' HA ' HD12 ' A' ' 13' ' ' LEU . 17.2 p -114.13 45.16 1.54 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 111' ' ' SER . 92.5 p -127.78 106.38 9.09 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.873 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.589 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.59 24.5 20.86 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.76 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -94.1 130.11 40.39 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 45.8 t -98.49 168.27 10.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.93 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.63 141.15 17.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.4 -23.72 34.23 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 21.1 m -72.27 152.69 42.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.987 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.9 p -126.77 131.19 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.724 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 3.0 m -97.95 169.7 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.73 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.83 150.34 38.53 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.975 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.714 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -144.32 109.4 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.978 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.826 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.53 114.86 23.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.48 ' HA3' ' CD2' ' A' ' 26' ' ' LEU . . . -82.55 146.8 24.91 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.833 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.01 110.92 4.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.864 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.39 13.46 30.58 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.99 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.691 HD13 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.59 165.98 13.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.979 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.52 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.5 mt-30 -46.41 119.71 2.51 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.984 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.735 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.26 131.08 41.54 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.47 8.46 80.55 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.592 HG23 ' N ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -93.78 148.32 22.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.951 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.592 ' N ' HG23 ' A' ' 30' ' ' THR . . . -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.01 ' CB ' HD22 ' A' ' 97' ' ' LEU . 35.1 m-85 -138.26 151.75 47.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.907 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.419 ' CA ' ' H ' ' A' ' 98' ' ' SER . 35.0 m-20 -120.23 117.4 27.77 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -98.58 141.39 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.793 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -161.99 155.44 26.71 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.894 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 40.7 tt0 -105.65 115.7 30.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' SG ' HD12 ' A' ' 45' ' ' LEU . 1.3 m -102.96 166.66 10.32 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.097 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -153.33 134.0 13.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.956 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.592 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.2 122.55 17.36 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.91 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.514 ' HB ' ' CD1' ' A' ' 83' ' ' TRP . 2.5 m -102.9 -42.82 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.992 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.448 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -138.47 166.16 25.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m -50.79 111.77 0.6 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.35 8.92 63.35 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.97 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.413 HG13 ' CE2' ' A' ' 83' ' ' TRP . 75.0 t -120.3 119.35 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.46 HD12 ' SG ' ' A' ' 37' ' ' CYS . 1.9 pp -124.5 162.75 23.32 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.301 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -132.54 155.42 48.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.92 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.1 m -113.46 155.23 25.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.485 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 16.3 t30 -116.11 112.41 42.11 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.38 0.13 7.88 Favored 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 124.31 3.34 . . . . 0.0 109.65 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.478 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -90.03 -16.52 29.61 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.915 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.473 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.0 p30 -127.16 28.33 5.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.93 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -102.1 118.67 37.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.7 t -107.41 -177.27 3.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.932 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -147.65 154.58 40.81 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.412 ' CG2' ' N ' ' A' ' 56' ' ' THR . 6.7 p -167.31 161.9 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.977 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.412 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 20.7 m -126.34 130.19 50.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.58 145.55 55.48 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.977 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 51.6 p30 -83.7 -172.29 4.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.934 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.09 -27.57 69.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.66 -10.06 59.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.735 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.62 31.79 48.77 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.969 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.3 p -127.36 136.32 51.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.991 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.95 170.2 10.86 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.53 123.97 9.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.598 HG22 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -151.94 160.26 43.55 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.907 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.598 ' N ' HG22 ' A' ' 65' ' ' THR . 0.2 OUTLIER -114.43 129.68 56.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.913 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.069 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -107.26 118.01 35.58 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.901 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.656 ' N ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -67.66 120.46 14.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.987 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.491 HG22 HG11 ' A' ' 19' ' ' VAL . 0.6 OUTLIER -76.47 123.94 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.975 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.628 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 26.9 mmt180 -115.57 157.03 24.71 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.475 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 4.1 ptt180 -107.08 -10.73 15.82 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.99 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -177.05 146.93 0.53 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.927 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.894 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -176.69 171.52 2.25 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.878 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 118.36 7.28 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.301 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 94.07 1.35 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -84.44 100.63 11.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.74 HD12 ' N ' ' A' ' 78' ' ' PHE . 2.2 tp -54.45 145.41 18.42 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.74 ' N ' HD12 ' A' ' 77' ' ' LEU . 10.8 m-85 -47.2 -43.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.565 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -58.73 -16.52 17.03 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.965 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.12 28.25 12.15 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.43 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.2 m -106.38 122.67 46.74 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 ttm180 -61.71 90.96 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.956 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.514 ' CD1' ' HB ' ' A' ' 40' ' ' VAL . 42.8 t-105 -62.35 -58.4 7.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.53 163.2 12.09 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.994 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.56 105.73 0.47 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.951 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.097 HG22 ' CB ' ' A' ' 38' ' ' ALA . 3.4 p -80.21 148.89 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.488 ' N ' HG23 ' A' ' 86' ' ' VAL . 11.4 m-20 -110.47 98.74 7.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 17.8 m -51.91 -27.53 13.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.2 p -79.57 1.21 26.85 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.982 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.564 HG21 ' O ' ' A' ' 90' ' ' THR . 2.4 m -116.99 -26.68 6.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.81 -175.31 3.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.58 125.65 48.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.252 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.2 m -103.83 152.69 21.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.992 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.129 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -150.89 144.17 24.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.967 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.069 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 7.1 t -103.96 163.56 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.33 168.41 40.52 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.991 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.193 ' HG ' ' CG2' ' A' ' 34' ' ' VAL . 5.6 mp -99.5 162.16 13.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.419 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 13.0 m -154.16 118.48 4.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.451 ' OD1' ' N ' ' A' ' 102' ' ' GLY . 42.7 p-10 -113.54 -167.9 1.27 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.998 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.16 -19.89 2.23 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.946 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.45 -23.51 13.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.888 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.451 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 85.34 22.0 52.79 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.773 ' ND2' ' HD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -60.11 -151.83 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.974 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 143.47 153.38 5.86 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.953 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.574 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.41 165.4 32.79 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.247 3.298 . . . . 0.0 109.607 179.964 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.49 ' CA ' ' CB ' ' A' ' 2' ' ' ALA . 8.2 pt-20 -33.55 124.45 0.42 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.762 ' N ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.34 133.99 0.98 Allowed Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.129 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.6 104.03 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.952 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.456 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.58 144.97 26.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.252 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.11 159.47 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.917 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -144.2 115.05 7.79 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.587 ' CZ ' ' HB2' ' A' ' 93' ' ' CYS . 30.5 m-85 -100.06 126.21 46.25 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.934 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.947 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.577 ' HB2' ' CA ' ' A' ' 106' ' ' GLU . . . -114.98 126.3 28.01 Favored Pre-proline 0 N--CA 1.45 -0.467 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.484 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.39 -175.37 1.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.328 3.352 . . . . 0.0 109.605 179.907 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.21 HG23 ' O ' ' A' ' 24' ' ' ALA . 6.4 t -99.67 116.15 31.11 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.771 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.9 154.64 49.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.48 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -115.76 117.09 29.27 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -114.03 143.77 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.731 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.63 166.68 24.3 Favored Pre-proline 0 N--CA 1.448 -0.539 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.938 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.731 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.37 118.13 5.46 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.331 3.354 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.747 ' HA ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.45 9.43 7.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.961 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.742 ' HA ' ' O ' ' A' ' 111' ' ' SER . 50.0 p -88.51 106.72 18.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.882 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 1.005 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 101.94 17.98 19.15 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.888 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.747 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -108.12 133.24 52.67 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -87.77 174.54 8.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.913 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 27.8 t70 -46.71 153.33 0.4 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.53 -22.62 36.37 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.965 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.61 HG22 ' N ' ' A' ' 18' ' ' VAL . 18.9 m -71.94 148.0 46.43 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.61 ' N ' HG22 ' A' ' 17' ' ' THR . 7.7 p -118.76 129.6 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.979 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.614 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.8 OUTLIER -104.51 150.54 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.969 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.779 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.1 147.86 28.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.976 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.737 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -142.71 108.63 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.771 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.36 114.75 20.58 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.706 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.17 143.13 20.16 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.954 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.21 ' O ' HG23 ' A' ' 4' ' ' THR . . . -139.29 109.52 6.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.463 ' C ' HD22 ' A' ' 26' ' ' LEU . . . 101.15 24.22 9.14 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.364 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.47 -169.35 2.52 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.671 ' NE2' ' HH ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -81.03 125.25 29.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.3 131.29 43.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.992 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.94 8.15 77.43 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.763 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.63 132.14 42.56 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.972 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.402 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -86.25 150.67 24.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.856 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 51.6 m-85 -135.03 141.73 46.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.074 ' HB2' ' O ' ' A' ' 98' ' ' SER . 2.2 m-20 -100.69 113.96 27.27 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.958 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.258 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -101.26 151.55 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.977 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.726 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -175.89 172.77 45.76 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.957 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.849 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 41.4 tt0 -108.18 107.12 17.61 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.942 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 60.7 m -106.73 142.43 36.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.646 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -122.49 137.38 54.9 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.875 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.569 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.41 124.73 22.55 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.889 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.562 HG11 ' N ' ' A' ' 41' ' ' ASP . 1.2 t -105.27 -46.76 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.525 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.82 167.09 21.82 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.417 ' O ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -51.14 112.19 0.69 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.954 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.57 7.94 65.94 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.99 HG13 ' CZ3' ' A' ' 83' ' ' TRP . 2.0 t -122.38 117.58 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.983 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.533 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -127.35 136.3 51.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.979 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.291 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -92.34 151.76 20.11 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.97 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.6 m -110.77 146.75 35.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.974 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.751 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.1 p-10 -116.73 115.38 39.24 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.531 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.3 Cg_endo -72.4 -0.54 8.87 Favored 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.317 3.345 . . . . 0.0 109.6 179.868 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.03 -25.4 55.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.89 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -124.8 27.74 6.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -83.33 117.32 22.92 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.966 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 m -110.92 -178.24 3.42 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.8 p -144.86 155.07 43.27 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.875 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 56' ' ' THR . 7.6 p -166.91 151.66 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.472 ' N ' HG22 ' A' ' 55' ' ' VAL . 9.1 m -127.57 133.17 49.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.958 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 143.83 53.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.966 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 43.7 p30 -86.27 -172.03 3.85 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.36 -25.98 68.2 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.925 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -80.16 -7.77 59.1 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.05 30.59 57.13 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.927 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.3 p -122.57 133.01 54.56 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.4 162.66 18.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.981 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.2 p -149.5 129.03 13.07 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.971 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.585 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.91 157.57 31.67 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.868 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.585 ' N ' HG21 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.61 125.04 52.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.211 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -98.83 157.39 16.33 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.916 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -106.41 140.29 39.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.965 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.508 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -99.01 125.37 52.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.913 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -118.99 136.23 54.21 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.954 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.441 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -61.51 -34.49 75.6 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.441 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 62.5 p -156.58 162.4 39.9 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.849 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.9 p90 -177.71 165.62 2.08 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.961 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.8 116.55 8.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.911 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.291 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -76.66 94.73 1.08 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.95 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.868 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.69 99.76 10.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.979 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.747 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.1 tp -56.8 131.13 48.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.677 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 9.5 m-85 -47.83 -35.63 10.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.989 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.747 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.54 -16.91 11.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.948 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.96 27.51 8.84 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.988 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.582 HG22 ' N ' ' A' ' 82' ' ' ARG . 21.7 m -115.79 148.81 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.978 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.582 ' N ' HG22 ' A' ' 81' ' ' THR . 4.5 tmm_? -90.75 96.89 10.86 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 32.9 t-105 -63.44 -58.05 8.31 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 172.93 21.64 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.991 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.75 104.81 2.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.646 HG21 ' CB ' ' A' ' 38' ' ' ALA . 7.1 m -78.76 152.34 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.999 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.422 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.0 OUTLIER -115.75 92.91 4.05 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.971 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.141 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 32.7 m -51.6 -27.06 10.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.964 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -79.61 0.81 28.56 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.994 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.422 ' N ' ' O ' ' A' ' 87' ' ' ASP . 1.3 m -118.63 -27.97 5.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.899 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.46 180.0 5.7 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.827 ' HB3' ' OG ' ' A' ' 111' ' ' SER . . . -97.43 125.32 42.0 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.434 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 82.2 m -104.52 168.88 8.8 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.984 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.141 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -154.66 146.45 23.39 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.957 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.211 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.8 t -101.19 164.77 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.258 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.84 168.62 39.07 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.107 ' CB ' HG23 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.16 125.24 30.75 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.821 -0.436 . . . . 0.0 109.821 -179.95 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.074 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 56.6 m -100.75 154.07 18.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.895 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.44 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.1 OUTLIER -116.48 -164.29 0.96 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.44 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -61.77 -49.04 77.96 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.14 -24.4 61.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.922 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.22 53.58 1.46 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.995 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.52 178.28 6.86 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.856 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -179.7 -178.04 48.22 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.41 165.59 32.24 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.295 3.33 . . . . 0.0 109.61 179.928 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.577 ' CA ' ' HB2' ' A' ' 2' ' ' ALA . 3.8 pt-20 -38.3 121.84 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.82 153.87 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.141 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.9 t -114.1 102.33 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.51 128.51 34.35 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.434 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -139.28 -177.36 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.827 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 0.5 OUTLIER -172.21 174.66 3.91 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.915 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.141 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.3 m-85 -123.28 114.47 20.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.967 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 1.005 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 21.2 m-80 . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.973 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.502 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.076 ' HB2' ' HA ' ' A' ' 106' ' ' GLU . . . -126.95 116.12 22.11 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.524 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.44 -178.57 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.306 3.337 . . . . 0.0 109.59 179.945 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.999 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.18 109.11 21.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.942 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.808 ' CB ' ' HA2' ' A' ' 23' ' ' GLY . . . -122.92 150.73 42.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.661 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -113.82 119.64 38.02 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.999 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.897 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -114.79 143.87 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.961 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.776 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.12 167.36 17.98 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.985 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.776 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.34 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.349 3.366 . . . . 0.0 109.579 179.89 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.964 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.9 OUTLIER -122.06 13.96 10.58 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.99 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.864 ' HA ' ' O ' ' A' ' 111' ' ' SER . 53.3 p -98.95 114.61 27.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.877 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.668 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.03 1.59 41.95 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.964 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -114.39 142.01 46.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.972 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.9 m -104.98 -170.26 1.73 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.952 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.772 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 2.3 t0 -42.88 153.54 0.08 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.73 -24.63 31.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.568 HG22 ' CD2' ' A' ' 13' ' ' LEU . 3.7 m -96.21 148.81 22.33 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.413 ' N ' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -123.05 146.32 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.996 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.578 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.3 OUTLIER -110.87 119.94 60.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.96 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.897 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -78.55 127.43 32.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.587 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.2 OUTLIER -113.17 114.63 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.983 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' CA ' ' A' ' 5' ' ' ALA . . . -127.17 123.49 36.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.98 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.808 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -90.59 153.48 22.63 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.957 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.999 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.6 108.18 3.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.14 17.35 27.54 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.991 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.844 ' HG ' ' HB2' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -89.47 176.45 6.9 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.969 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.492 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 23.2 mt-30 -58.54 121.71 11.61 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.3 131.21 42.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.995 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.86 7.58 83.9 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.569 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -93.13 141.04 28.85 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.475 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.69 151.16 24.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.971 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.64 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 29.8 m-85 -138.54 134.86 34.43 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.884 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.169 ' CB ' ' O ' ' A' ' 98' ' ' SER . 8.3 m-20 -100.29 113.54 26.32 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.94 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.293 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.19 143.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.723 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -164.96 164.45 37.06 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.96 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.902 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 10.9 tt0 -110.87 117.08 32.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.931 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 98.5 m -108.01 166.31 10.82 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.978 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.747 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -151.98 135.14 15.83 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.933 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.471 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.75 129.94 41.65 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.955 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -108.93 -39.01 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -150.4 155.8 40.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.986 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -51.51 112.9 0.83 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.969 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.99 9.86 84.74 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.98 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.622 HG23 ' CH2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -139.04 130.05 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.417 ' HA ' HG21 ' A' ' 40' ' ' VAL . 1.9 pp -132.18 163.85 27.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.103 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -125.48 153.8 43.01 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.973 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.857 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 15.1 m -115.92 153.2 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.834 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 39.6 t30 -111.02 107.05 57.74 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 85.3 Cg_endo -72.3 -1.21 9.8 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.34 3.36 . . . . 0.0 109.631 179.849 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.15 -8.8 50.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.854 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -130.06 27.78 5.1 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.455 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.07 110.94 17.07 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.982 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.28 174.06 6.04 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.924 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 72.7 p -145.14 154.67 42.69 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG22 ' N ' ' A' ' 56' ' ' THR . 4.8 p -166.53 155.62 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.512 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.4 m -128.05 136.67 51.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -77.38 135.4 38.33 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.993 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.1 p30 -77.8 -173.18 2.94 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.893 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.17 -27.93 69.31 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.871 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -74.53 -6.94 51.3 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.992 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.701 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.99 32.23 56.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 93.4 p -128.48 141.11 51.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.982 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.45 ' HB3' HG21 ' A' ' 55' ' ' VAL . . . -130.11 164.8 23.62 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.997 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.06 134.29 19.44 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.587 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -155.13 176.99 11.84 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.587 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.3 OUTLIER -133.41 117.66 17.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.95 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.081 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.48 156.1 16.48 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.508 ' HG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -111.53 128.38 56.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.457 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -97.13 123.11 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.772 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -115.05 144.48 43.57 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.44 ' HG3' ' N ' ' A' ' 72' ' ' SER . 15.4 ptt85 -65.85 -32.18 73.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.44 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 16.4 p -155.65 158.06 37.7 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.902 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.7 p90 -176.79 155.24 1.25 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -53.71 108.87 0.39 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.103 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -67.05 94.54 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.99 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.857 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -82.53 98.89 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.751 HD12 ' N ' ' A' ' 78' ' ' PHE . 1.4 tp -54.66 144.81 20.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.751 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.2 -43.53 21.59 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.97 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.682 ' HB3' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -58.46 -16.7 16.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.7 28.1 11.78 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.3 m -106.97 120.68 42.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.414 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -64.25 91.42 0.07 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.622 ' CH2' HG23 ' A' ' 44' ' ' VAL . 3.9 t-105 -62.68 -58.52 7.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.915 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.78 163.39 12.92 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.36 104.59 0.18 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.747 HG21 ' CB ' ' A' ' 38' ' ' ALA . 12.6 p -79.2 151.67 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.515 ' N ' HG22 ' A' ' 86' ' ' VAL . 4.0 m-20 -105.71 95.01 5.51 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.972 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.153 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.94 -22.14 14.03 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.942 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 49.1 p -88.97 2.1 54.45 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.962 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.6 m -110.11 -24.92 10.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -137.93 174.9 10.08 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.979 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.79 127.27 35.61 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.951 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.393 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -104.56 163.86 12.17 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.984 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.041 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -151.42 142.27 22.91 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.917 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.081 ' CG1' HD12 ' A' ' 67' ' ' LEU . 16.5 t -97.92 164.6 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 180.0 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.293 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.33 163.84 32.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.976 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.006 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.62 131.63 49.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.993 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.169 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 42.5 m -112.28 141.02 46.49 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.52 -164.14 1.02 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.04 -49.03 71.75 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.946 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.2 65.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.937 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.28 1.98 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.941 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.4 177.08 7.76 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.19 174.25 46.59 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.989 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.524 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.4 170.44 19.27 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.304 3.336 . . . . 0.0 109.623 179.944 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.076 ' HA ' ' HB2' ' A' ' 2' ' ' ALA . 9.7 pt-20 -41.2 126.69 2.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.963 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.6 160.82 0.01 OUTLIER Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.032 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.3 t -120.9 103.11 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.969 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.98 133.81 34.67 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.955 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.041 HG12 ' HA ' ' A' ' 94' ' ' GLN . 31.8 pt -136.93 -169.93 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.916 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.864 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -178.28 158.74 1.18 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.393 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.3 m-85 -111.37 119.19 38.0 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.932 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.668 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.8 p30 . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.955 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.576 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -117.63 114.97 37.64 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.893 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.413 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.4 -178.15 3.15 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.331 3.354 . . . . 0.0 109.603 179.904 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.861 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.2 m -101.14 110.7 22.75 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.816 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.65 142.11 51.67 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.914 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.538 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.98 116.07 31.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.96 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.795 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.7 OUTLIER -114.69 149.76 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.963 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.672 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.24 165.35 40.04 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.672 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.42 119.62 6.24 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.333 3.356 . . . . 0.0 109.579 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.963 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -123.87 16.16 9.36 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 1.263 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.6 p -105.3 113.79 27.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.885 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.975 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.86 6.78 37.08 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.963 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -114.52 136.72 52.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.5 m -81.12 171.21 15.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.925 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.444 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 3.3 p-10 -45.24 154.31 0.17 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.979 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.87 -24.01 33.84 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.985 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.603 ' OG1' ' HB2' ' A' ' 13' ' ' LEU . 94.3 m -68.37 131.88 46.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.981 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.422 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 10.4 p -102.08 119.32 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.668 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -99.17 161.14 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.795 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -119.74 148.7 43.09 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.997 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.7 107.18 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.994 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.816 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -117.21 116.42 27.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.633 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -83.66 146.73 23.58 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.992 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.861 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.83 110.01 4.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.938 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.5 15.75 31.27 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.974 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.628 ' H ' ' CD1' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -90.19 172.16 9.0 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.993 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.485 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.0 mt-30 -54.34 120.36 6.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.964 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.526 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.11 131.27 41.87 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.967 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 6.88 84.59 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.999 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.485 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -93.02 144.2 25.49 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -86.1 151.38 23.73 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.52 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.8 m-85 -138.66 144.4 39.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.199 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -112.51 113.11 25.12 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.935 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.214 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -98.96 152.04 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.927 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -178.57 159.71 25.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.979 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 1.028 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 12.4 tt0 -98.77 118.55 35.76 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.942 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.483 ' SG ' HD12 ' A' ' 45' ' ' LEU . 1.8 m -108.28 165.55 11.42 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.982 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.86 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.71 122.66 7.58 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.632 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.68 122.09 16.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.839 HG23 ' CD1' ' A' ' 83' ' ' TRP . 16.7 m -101.32 -44.58 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.973 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.521 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -135.64 168.06 19.97 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.966 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.595 ' O ' ' CG2' ' A' ' 42' ' ' THR . 3.9 t -54.04 112.97 1.06 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.986 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.66 8.56 63.62 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.984 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.471 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.7 t -120.86 109.07 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.483 HD12 ' SG ' ' A' ' 37' ' ' CYS . 1.5 pp -119.83 162.36 19.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.131 ' HB3' ' C ' ' A' ' 75' ' ' GLY . . . -129.4 151.91 49.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.936 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.006 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -117.38 157.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.499 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 17.6 t30 -116.24 112.95 41.49 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -72.35 -0.51 8.79 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.31 3.34 . . . . 0.0 109.61 179.884 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.497 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -12.72 36.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.849 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.466 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 16.5 p30 -132.94 27.01 4.27 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.928 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.11 117.35 32.29 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.993 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.9 t -106.61 177.91 4.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.962 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.4 p -146.5 151.49 37.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.447 ' CG2' ' N ' ' A' ' 56' ' ' THR . 4.6 p -166.77 162.58 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.943 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 97.5 m -127.8 134.82 49.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.951 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.99 143.4 50.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.949 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 42.9 p30 -81.74 -172.73 4.04 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.95 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.1 -25.54 68.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.904 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.68 -7.26 53.88 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.624 ' O ' ' CD1' ' A' ' 26' ' ' LEU . . . 74.13 31.07 60.04 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.0 p -127.13 143.8 51.18 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.971 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.01 166.36 21.18 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.983 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -147.5 125.78 12.27 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.95 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.58 ' CG2' ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.24 173.04 12.92 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.938 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.58 ' N ' ' CG2' ' A' ' 65' ' ' THR . 0.4 OUTLIER -131.13 111.22 11.78 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.944 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.242 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.12 156.55 16.33 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.685 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -119.2 139.97 50.97 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.924 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.627 ' C ' ' CD ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -109.57 133.37 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.796 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -119.83 162.19 19.54 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.444 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 5.8 ptt180 -82.56 -18.14 42.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 p -165.12 151.22 9.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.922 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 1.028 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.1 p90 -175.99 154.94 1.53 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.897 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.45 124.81 14.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.989 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.131 ' C ' ' HB3' ' A' ' 46' ' ' ALA . . . -83.03 92.11 1.62 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 1.006 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.52 100.51 11.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.974 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.742 HD11 ' N ' ' A' ' 78' ' ' PHE . 2.6 tp -58.15 140.96 51.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.967 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.742 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.28 -42.01 19.95 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.935 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.564 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -57.41 -16.66 9.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.965 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.55 28.43 10.43 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.99 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.425 ' HB ' HD22 ' A' ' 77' ' ' LEU . 2.0 m -108.73 128.09 54.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.67 91.59 1.12 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.471 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.14 -58.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.869 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.06 167.59 16.39 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.975 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -59.36 115.16 3.06 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.86 HG11 ' CB ' ' A' ' 38' ' ' ALA . 59.9 t -88.29 146.57 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 180.0 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.82 91.67 4.26 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.949 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.759 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -52.52 -22.63 5.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.997 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.91 2.6 48.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.981 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.566 ' O ' HG23 ' A' ' 90' ' ' THR . 3.3 m -115.82 -27.81 6.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.47 169.39 16.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.91 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.92 126.02 35.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.938 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.598 ' HB2' HD12 ' A' ' 110' ' ' ILE . 12.4 m -104.14 159.77 15.41 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 -179.923 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.055 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -145.45 143.1 29.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.969 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.242 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.7 t -97.34 157.73 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.214 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.55 171.05 43.27 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.997 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.214 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.33 151.31 51.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.199 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 82.8 p -127.96 151.41 49.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.5 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -112.77 -163.46 0.85 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.96 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.43 -48.6 69.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.935 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.24 65.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.952 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.8 53.39 1.8 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.998 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.424 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.11 168.36 18.11 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 179.971 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.52 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.85 178.95 42.51 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.933 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.413 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.36 161.98 42.82 Favored 'Trans proline' 0 N--CA 1.447 -1.24 0 C-N-CA 124.34 3.36 . . . . 0.0 109.627 179.966 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.576 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -40.61 123.72 1.9 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.972 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.54 151.82 0.02 OUTLIER Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.01 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.2 t -119.21 104.24 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.66 138.71 36.4 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.982 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.055 HG12 ' HA ' ' A' ' 94' ' ' GLN . 25.8 pt -137.75 -172.34 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 1.263 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -179.23 163.69 1.31 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.942 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.759 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 2.3 m-85 -117.76 116.81 27.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.937 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.975 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 46.4 m-80 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.973 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.449 ' HB3' ' HG2' ' A' ' 106' ' ' GLU . . . -140.87 120.38 8.47 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.477 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.39 -174.61 1.48 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.322 3.348 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.174 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.1 t -97.99 110.68 23.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.952 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.84 146.92 50.46 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.953 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.473 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -109.26 112.44 24.59 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.784 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -109.07 145.38 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.993 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.777 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.28 168.65 12.85 Favored Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.777 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.39 117.14 4.99 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.296 3.331 . . . . 0.0 109.571 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.704 ' HA ' HD11 ' A' ' 13' ' ' LEU . 0.3 OUTLIER -127.05 17.18 7.25 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.975 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.461 ' HA ' ' O ' ' A' ' 111' ' ' SER . 39.2 p -94.6 112.72 24.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.9 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 1.029 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 87.98 28.75 22.49 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.942 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.741 HD21 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.18 137.33 46.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.976 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.4 t -76.2 150.24 37.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.964 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 2.3 p30 -44.43 153.02 0.17 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.5 -24.72 30.85 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 17.7 m -63.69 150.29 44.71 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.982 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.512 HG11 ' O ' ' A' ' 18' ' ' VAL . 14.7 p -112.46 121.8 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.612 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 2.2 p -97.42 153.52 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.996 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.784 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -107.28 150.45 26.66 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.973 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.741 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -148.63 107.64 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.998 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.952 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.05 114.96 23.33 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.988 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.644 ' HA2' ' HB3' ' A' ' 5' ' ' ALA . . . -85.2 139.95 17.98 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.952 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.174 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -135.89 110.22 8.44 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.922 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 103.29 21.19 10.17 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.966 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.308 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.4 -168.39 2.19 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.838 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -79.59 121.66 25.54 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.962 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.511 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.61 135.9 47.15 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.97 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.38 6.71 58.78 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.958 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.845 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.92 138.87 33.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.968 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.473 ' N ' HG23 ' A' ' 30' ' ' THR . . . -86.29 150.72 24.15 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.508 ' HB3' ' CD2' ' A' ' 97' ' ' LEU . 39.2 m-85 -136.44 155.79 49.52 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.409 ' O ' ' CA ' ' A' ' 97' ' ' LEU . 2.6 m-20 -121.89 114.18 20.67 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.244 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -95.02 144.7 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.983 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.01 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.07 166.92 34.76 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.954 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.696 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -121.63 106.98 11.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.929 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.3 m -105.21 172.78 6.61 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.961 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.915 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -146.37 127.34 14.55 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.932 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.77 117.83 8.07 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.92 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.59 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 3.6 m -98.22 -42.92 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.972 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -135.67 177.31 7.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.995 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 t -60.36 111.76 1.68 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.99 8.17 63.85 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.763 HG12 ' CD1' ' A' ' 83' ' ' TRP . 22.0 t -120.73 113.31 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.468 HD23 ' CD2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -128.51 140.61 51.72 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.991 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.187 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 138.65 34.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.956 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.929 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 82.1 m -106.37 140.62 39.0 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.971 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.613 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.8 t30 -100.31 111.49 62.58 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.1 Cg_endo -72.39 0.28 7.67 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.524 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -86.56 -14.94 41.45 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.854 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.52 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.9 p30 -123.21 29.69 6.61 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.447 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -82.66 106.02 14.17 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.987 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.6 m -100.32 179.02 4.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.5 p -145.71 158.52 43.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.915 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.662 ' CG1' HD21 ' A' ' 97' ' ' LEU . 7.2 p -169.11 156.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.973 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.509 ' N ' HG22 ' A' ' 55' ' ' VAL . 7.0 m -127.97 137.63 52.32 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.69 139.73 35.99 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.984 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.2 p30 -82.86 -165.85 1.17 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.927 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.89 -28.67 69.07 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.3 m-20 -83.1 6.35 19.4 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.986 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.93 22.04 59.63 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -109.21 130.92 55.48 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.446 ' HB1' HG21 ' A' ' 55' ' ' VAL . . . -121.41 167.31 12.94 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.84 131.61 16.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.905 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.638 HG22 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.79 157.71 32.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.638 ' N ' HG22 ' A' ' 65' ' ' THR . 0.2 OUTLIER -116.5 125.66 52.25 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.048 ' CD1' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -97.53 155.95 16.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.919 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.523 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -97.36 123.11 41.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.961 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.536 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -77.49 129.36 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.999 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.707 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -123.58 147.26 47.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.931 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -92.71 -20.2 21.04 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.994 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 53.4 p -172.99 153.18 2.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.922 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.707 ' CE2' ' HB2' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -178.02 179.08 0.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.949 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -68.56 117.83 10.8 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.187 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -79.6 89.13 1.23 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.956 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.781 ' HB3' ' O ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -83.47 103.33 12.73 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.796 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.8 tp -58.34 130.99 49.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.86 -35.36 10.23 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.796 ' HB3' HD23 ' A' ' 77' ' ' LEU . 5.4 t0 -57.26 -17.28 11.02 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.24 28.39 8.14 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.939 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.432 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.1 m -117.74 145.86 44.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.31 97.21 8.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.59 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 21.9 t90 -64.25 -57.65 8.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.879 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.98 160.27 8.6 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.61 105.18 0.14 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.977 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.915 HG12 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -82.35 154.03 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -120.13 96.78 5.3 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.998 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.11 ' HB3' ' CD1' ' A' ' 112' ' ' PHE . 24.9 m -52.76 -25.6 11.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.9 p -79.68 1.45 26.34 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.32 -177.08 4.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.77 126.67 47.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.239 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 18.6 m -104.43 164.14 11.95 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.964 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.231 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -154.79 149.57 26.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.973 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.048 ' CG1' ' CD1' ' A' ' 67' ' ' LEU . 6.8 t -104.05 165.85 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.244 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 170.63 43.78 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.94 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.508 ' CD2' ' HB3' ' A' ' 32' ' ' TYR . 4.8 mp -99.81 162.87 12.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.168 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -152.48 109.99 3.59 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.896 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.594 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 1.7 p-10 -104.75 -157.96 0.64 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.28 -43.94 64.71 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.981 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.45 -26.01 26.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.937 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.95 52.86 2.33 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.959 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.594 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -109.17 -174.32 2.48 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -179.99 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 172.57 179.24 43.24 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.993 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.477 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.36 160.29 47.32 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.366 3.377 . . . . 0.0 109.567 179.91 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -32.96 128.51 0.26 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.479 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.0 130.94 0.29 Allowed Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.231 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 41.6 t -99.29 101.55 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.482 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -80.04 140.47 36.52 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.938 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.1 pt -147.06 -172.23 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.569 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.4 OUTLIER -173.82 176.17 2.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.948 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.11 ' CD1' ' HB3' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -150.64 105.77 3.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 1.029 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.7 p30 . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 . . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.565 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -127.64 140.37 37.88 Favored Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.935 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.48 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.8 Cg_endo -72.39 -175.63 1.87 Allowed 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.275 3.317 . . . . 0.0 109.637 179.934 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.976 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.47 109.15 21.95 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.77 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.58 137.75 54.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.685 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -106.11 112.57 25.66 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.981 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.598 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -106.39 155.98 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.988 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.984 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.08 177.29 0.91 Allowed Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.923 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.984 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.5 Cg_endo -72.4 117.22 5.03 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.311 3.34 . . . . 0.0 109.573 179.909 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.868 ' HB2' HG22 ' A' ' 110' ' ' ILE . 13.4 p -112.73 44.69 1.44 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -124.73 106.3 9.97 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.885 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.653 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 88.39 31.9 12.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.969 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.733 ' N ' ' CD2' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -97.58 133.0 42.72 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 55.7 m -96.71 162.87 13.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -49.83 146.37 4.58 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.994 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.92 -22.51 35.81 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.965 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.9 m -63.3 147.62 50.56 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -112.2 122.7 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.495 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 3.6 m -96.93 161.24 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.598 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 151.16 32.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.975 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.719 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -150.11 109.96 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.959 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.77 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.14 116.49 22.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.999 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.682 ' HA2' ' HA ' ' A' ' 5' ' ' ALA . . . -94.29 141.1 15.37 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.959 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.976 ' O ' HG23 ' A' ' 4' ' ' THR . . . -133.12 118.0 18.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.887 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.445 ' C ' HD21 ' A' ' 26' ' ' LEU . . . 100.31 24.37 9.61 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.209 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.32 -173.67 4.49 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.972 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.869 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -80.67 120.76 25.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.993 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.78 136.74 57.24 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.955 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.25 7.95 58.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.991 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.692 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -85.6 148.22 26.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 1.009 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -100.81 134.68 43.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.061 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 37.4 m-85 -127.29 147.59 50.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.048 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.8 m-20 -116.86 114.05 23.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.997 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.268 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -96.61 152.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.965 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.099 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -177.66 164.98 34.37 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.963 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.804 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 1.7 tt0 -112.34 118.38 35.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.937 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 93' ' ' CYS . 90.8 m -108.23 173.5 6.29 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.983 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.064 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -152.62 123.97 7.67 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.917 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.617 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.57 124.0 21.18 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.907 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.056 HG23 ' CD2' ' A' ' 83' ' ' TRP . 15.2 m -103.93 -43.85 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.538 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -142.93 169.61 17.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 19.5 m -56.74 113.43 1.64 Allowed 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.952 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.78 4.83 62.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.997 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.49 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 15.5 t -122.19 105.07 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.975 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.541 HD11 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -117.3 162.73 17.43 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.136 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -122.54 140.7 52.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.68 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 23.4 m -109.3 150.8 27.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 1.059 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -108.41 105.75 57.32 Favored Pre-proline 0 N--CA 1.45 -0.453 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.988 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.456 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.0 Cg_endo -72.4 -1.23 9.89 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.309 3.339 . . . . 0.0 109.638 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.469 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -91.41 -12.97 33.22 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.888 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD2' ' HB3' ' A' ' 36' ' ' GLN . 29.6 p30 -127.27 18.77 6.99 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.46 ' CD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -83.5 103.51 12.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.981 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.1 t -93.43 177.57 5.99 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.905 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.3 p -147.04 155.24 42.06 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.6 p -167.36 155.97 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.971 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 73.5 m -122.87 130.32 52.72 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.948 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 125.28 24.52 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.915 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -71.39 -170.37 0.5 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 -23.67 66.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -85.38 6.97 24.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.985 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 61.15 14.08 38.04 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.99 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.3 t -102.52 131.83 48.98 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.942 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.81 124.0 38.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.97 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.7 p -110.78 134.05 52.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.988 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.564 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -158.39 152.6 24.13 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.897 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.564 ' N ' HG21 ' A' ' 65' ' ' THR . 0.3 OUTLIER -113.17 131.29 55.92 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.956 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.311 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.93 157.46 17.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.447 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 4.6 t -105.18 127.51 52.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.647 ' C ' ' HD2' ' A' ' 70' ' ' ARG . 1.7 t -84.34 126.23 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.664 ' HB2' ' OE1' ' A' ' 36' ' ' GLN . 1.2 mpt_? -119.76 145.9 46.15 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.55 ' HB2' HG21 ' A' ' 89' ' ' THR . 0.0 OUTLIER -89.83 -8.07 52.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.938 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.569 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 90.3 p -178.02 149.96 0.59 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 1.059 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 3.8 p90 -176.77 154.58 1.19 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.921 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -49.55 114.37 1.03 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.136 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -71.89 92.76 0.55 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.68 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -83.81 99.34 10.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.953 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.753 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.6 tp -59.09 129.03 40.17 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.628 ' N ' HD11 ' A' ' 77' ' ' LEU . 32.4 p90 -47.56 -34.7 8.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.939 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.753 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.7 -16.72 11.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.982 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.08 28.11 8.91 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.42 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 3.4 m -116.93 150.88 37.79 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.933 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -87.04 97.67 10.85 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.902 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.538 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 76.7 t-105 -65.28 -56.41 12.88 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.76 166.46 11.6 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.991 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.19 108.14 0.38 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.944 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.064 HG11 ' HB3' ' A' ' 38' ' ' ALA . 69.3 t -82.25 147.85 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.971 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -114.46 93.7 4.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.949 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.485 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.0 m -52.74 -26.04 12.94 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.55 HG21 ' HB2' ' A' ' 71' ' ' ARG . 78.7 p -80.19 0.14 33.7 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.54 -27.48 6.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.77 -177.98 4.6 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.967 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.21 124.45 46.92 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.908 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.932 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 60.5 m -103.6 153.61 20.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.999 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -142.85 145.12 32.84 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.964 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.311 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.2 t -102.73 160.33 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.268 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.63 166.72 37.25 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.132 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.64 128.59 37.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.974 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.048 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.8 m -115.36 160.97 19.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.936 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 1.009 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -115.45 -157.44 0.64 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.982 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.11 -47.84 81.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.39 -25.78 59.7 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.874 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.64 50.11 1.87 Allowed Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.976 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.52 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -119.46 158.32 26.48 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 1.061 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.48 176.35 43.46 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.988 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.48 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 171.04 17.79 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.317 3.345 . . . . 0.0 109.616 179.922 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.565 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 2.0 mt-10 -40.71 133.68 1.99 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.985 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.06 155.97 0.74 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.964 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 93.1 t -122.74 105.18 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.981 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.484 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -87.16 138.4 31.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.962 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.999 ' CG1' ' HA ' ' A' ' 94' ' ' GLN . 2.3 mt -117.68 157.94 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.984 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 10' ' ' SER . 3.1 t -149.34 127.82 12.29 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.894 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 -100.64 127.92 46.87 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.937 . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.481 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -52.88 118.6 13.91 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.921 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.638 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.42 -174.48 1.45 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.304 3.336 . . . . 0.0 109.614 179.949 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.351 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.5 t -98.72 111.7 23.99 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.987 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.63 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.42 152.31 47.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.972 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -109.8 113.32 25.98 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.83 HG22 HG21 ' A' ' 108' ' ' VAL . 40.3 t -110.47 147.28 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.942 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.945 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.77 175.47 1.68 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.952 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.945 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.36 116.59 4.77 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 124.346 3.364 . . . . 0.0 109.617 179.902 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.811 ' HB2' HG23 ' A' ' 110' ' ' ILE . 6.5 p -111.12 43.71 1.42 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.937 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.0 p -124.28 105.16 9.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.892 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.758 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 95.02 30.51 8.27 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.758 HD21 ' C ' ' A' ' 12' ' ' GLY . 0.4 OUTLIER -110.93 129.72 55.8 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -112.88 177.01 4.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -44.67 138.66 3.28 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.984 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.01 -23.1 31.7 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.938 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.5 m -88.67 152.15 22.0 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 p -129.33 134.22 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.994 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.491 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 17.9 m -95.27 166.13 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.989 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.806 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.57 143.64 44.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.679 HG12 ' CG2' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -139.32 104.52 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.919 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.63 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.1 115.29 23.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.934 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -83.03 143.93 22.42 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.949 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.351 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -139.83 107.21 5.53 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.853 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.481 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 103.72 20.02 11.33 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.945 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.269 ' CD1' ' HB3' ' A' ' 105' ' ' PRO . 0.2 OUTLIER -88.87 -172.29 3.64 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.975 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.577 HE22 ' CG ' ' A' ' 103' ' ' ASN . 31.0 mt-30 -71.87 121.47 19.08 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.932 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.977 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.14 133.67 44.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.0 8.48 73.78 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.989 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.643 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.11 138.25 33.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.955 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.791 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.58 151.58 24.43 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.972 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.7 m-85 -137.63 149.68 46.81 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.927 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.155 ' CB ' ' H ' ' A' ' 98' ' ' SER . 3.7 m-20 -113.25 114.18 26.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.991 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.296 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -100.42 145.32 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.124 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.01 169.37 41.34 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.925 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.716 HE22 ' H ' ' A' ' 70' ' ' ARG . 40.8 tt0 -113.74 106.07 14.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.974 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -108.4 146.27 33.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.95 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.964 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -125.97 137.87 53.71 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.629 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.4 119.67 11.42 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.965 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.351 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.6 m -100.56 -42.81 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.046 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -132.65 165.07 25.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.985 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 32.4 m -51.2 111.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.907 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.03 69.06 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.953 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.52 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 10.7 t -122.01 117.96 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.57 HD11 ' HB2' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -129.15 138.24 51.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.984 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.588 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -101.44 152.11 21.13 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.951 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.974 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.0 m -106.79 148.57 28.32 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.994 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.933 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -111.37 117.13 49.95 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.974 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.462 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.6 Cg_endo -72.44 1.06 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.287 3.325 . . . . 0.0 109.621 179.908 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.51 -20.51 36.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.898 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.745 ' OD1' HG21 ' A' ' 68' ' ' THR . 98.3 m-20 -129.72 30.97 4.82 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.913 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.703 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.58 117.52 30.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.1 t -116.26 -178.96 3.53 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.946 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.6 p -146.46 154.52 41.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.874 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.504 HG22 ' N ' ' A' ' 56' ' ' THR . 5.3 p -166.18 158.9 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.998 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.504 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.6 m -127.11 133.16 50.44 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.952 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.26 153.59 42.14 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.975 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -89.63 -171.84 3.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.926 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.0 67.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.911 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.05 -16.83 61.03 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.961 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 88.24 6.35 74.84 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.975 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.01 140.03 32.95 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.941 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.61 163.32 17.52 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.976 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.15 122.92 9.27 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.542 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -157.8 162.73 38.46 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.542 ' N ' HG21 ' A' ' 65' ' ' THR . 0.9 OUTLIER -118.37 129.85 55.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.912 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -106.77 124.45 49.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.913 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.745 HG21 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.6 141.43 41.08 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.962 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.471 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -102.67 131.65 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.994 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.716 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -119.13 157.3 28.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 -87.08 -20.66 26.81 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.8 t -168.77 151.71 5.18 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.9 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.933 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 1.7 p90 -173.7 159.54 3.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.94 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -61.01 114.96 3.37 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.943 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.588 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -73.43 94.6 0.74 Allowed Glycine 0 C--N 1.336 0.558 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 180.0 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -82.12 99.37 9.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.779 HD23 ' HB3' ' A' ' 79' ' ' ASP . 2.8 tp -54.61 132.58 45.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.982 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD13 ' A' ' 77' ' ' LEU . 5.9 m-85 -46.59 -37.29 7.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.953 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.779 ' HB3' HD23 ' A' ' 77' ' ' LEU . 6.8 t0 -56.98 -16.96 7.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.99 27.59 9.34 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.431 ' HB ' ' CD2' ' A' ' 77' ' ' LEU . 2.0 m -113.55 140.9 47.77 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.37 95.9 7.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.351 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 38.1 t-105 -63.0 -57.8 9.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.912 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.04 172.9 19.24 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.959 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.47 109.69 2.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.958 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.964 HG23 ' CB ' ' A' ' 38' ' ' ALA . 3.3 p -90.72 142.13 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.516 ' N ' HG21 ' A' ' 86' ' ' VAL . 3.2 m-20 -98.21 99.48 10.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.36 -22.32 7.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.0 p -87.31 1.58 52.83 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.922 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -112.83 -26.37 8.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.01 -178.94 5.26 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.954 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.04 128.35 42.86 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.301 ' O ' HG13 ' A' ' 110' ' ' ILE . 34.0 m -104.74 155.06 19.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.956 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -147.58 145.61 29.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.984 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.3 t -109.2 156.76 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.981 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.296 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -174.5 172.38 45.35 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.093 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -129.62 128.72 43.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.155 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 36.5 m -118.26 140.07 50.36 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.917 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.791 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 4.4 p-10 -111.81 -162.71 0.81 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.996 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.08 79.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.459 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -66.48 -24.37 66.41 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.926 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 83.02 35.29 18.86 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.957 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.577 ' CG ' HE22 ' A' ' 27' ' ' GLN . 0.3 OUTLIER -108.45 -173.7 2.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.943 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.819 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 167.84 164.75 24.07 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.638 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.39 162.81 40.46 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.242 3.295 . . . . 0.0 109.576 179.954 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.481 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.9 OUTLIER -36.05 126.58 0.74 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.479 ' N ' ' HB1' ' A' ' 2' ' ' ALA . . . -41.78 147.97 0.44 Allowed Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.83 HG21 HG22 ' A' ' 7' ' ' VAL . 9.0 t -122.15 106.74 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -91.36 150.48 21.26 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.954 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.301 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -118.45 161.87 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.944 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.534 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -145.22 111.78 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.954 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 113' ' ' ASN . 6.9 m-85 -87.93 101.91 14.2 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.924 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.584 ' CG ' ' O ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.938 -0.394 . . . . 0.0 109.938 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 041 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.383 ' CB ' ' O ' ' A' ' 106' ' ' GLU . . . -134.02 145.51 56.03 Favored Pre-proline 0 N--CA 1.449 -0.503 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.054 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.1 Cg_endo -72.38 -175.21 1.69 Allowed 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 124.272 3.314 . . . . 0.0 109.632 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.92 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.71 109.89 21.96 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.946 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.846 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.5 137.64 54.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.995 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.557 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -99.08 114.07 26.6 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.97 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.828 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.2 m -108.09 153.72 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.997 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.965 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.59 176.56 1.21 Allowed Pre-proline 0 N--CA 1.449 -0.476 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.965 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.3 Cg_endo -72.38 117.79 5.3 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 124.352 3.368 . . . . 0.0 109.553 179.925 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.722 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.9 p -114.69 45.7 1.52 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.7 p -123.75 105.39 9.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.87 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.68 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 91.63 29.84 11.45 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.948 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.722 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -101.43 132.22 47.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.948 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 51.1 m -104.7 166.56 10.31 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.9 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -44.98 140.04 2.84 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.998 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.47 35.71 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.976 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 28.3 m -76.53 148.83 36.86 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.986 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.8 p -122.38 127.22 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.595 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 16.1 m -93.76 170.31 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.62 148.3 41.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.999 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.724 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -143.75 108.18 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.997 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.846 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.83 115.13 21.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.445 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.81 143.13 19.67 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.958 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.92 ' O ' HG22 ' A' ' 4' ' ' THR . . . -137.6 111.97 8.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.949 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 102.77 24.59 8.06 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.027 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -91.12 -163.96 1.11 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.993 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.417 ' O ' ' HB ' ' A' ' 30' ' ' THR . 34.4 mt-30 -88.27 127.12 35.46 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.428 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.18 133.77 42.75 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.78 8.68 82.33 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.973 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.733 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -96.89 137.64 35.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.939 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.643 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.94 152.33 22.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.03 ' CD1' ' HD2' ' A' ' 105' ' ' PRO . 45.3 m-85 -139.29 149.34 44.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.91 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.077 ' CB ' ' H ' ' A' ' 98' ' ' SER . 14.7 m-20 -112.21 115.03 28.15 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.187 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.34 146.06 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.999 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.881 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.56 170.79 42.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.92 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.1 tt0 -117.46 122.99 45.27 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.92 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m -125.85 148.31 49.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.048 ' HB2' HG11 ' A' ' 86' ' ' VAL . . . -123.1 134.88 54.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.89 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.659 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.0 OUTLIER -65.31 123.5 19.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.909 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.098 ' CG2' ' CE2' ' A' ' 83' ' ' TRP . 32.3 m -103.84 -42.0 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.976 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.18 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -132.01 -178.67 5.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.963 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 33.1 m -69.67 113.45 6.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.948 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.91 10.01 80.17 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.638 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.23 125.48 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.964 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.618 HD11 ' HB2' ' A' ' 37' ' ' CYS . 1.5 pt? -133.62 140.92 47.39 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.959 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.445 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -94.72 144.15 25.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 23.2 m -105.51 159.89 15.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.739 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 21.8 t30 -118.67 111.57 37.64 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.989 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.44 0.55 7.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.307 3.338 . . . . 0.0 109.591 179.881 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.431 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -11.98 41.77 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.911 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.504 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.2 p30 -129.49 27.59 5.27 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.34 107.09 16.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.4 t -105.02 174.96 5.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.91 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.5 p -146.67 158.36 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.881 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.3 p -167.82 158.52 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.935 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 28.0 m -128.13 125.06 38.4 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.93 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.51 152.89 13.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -180.0 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.7 p30 -95.28 -169.47 1.98 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.951 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.65 -24.87 67.84 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.913 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -81.04 -7.26 59.52 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.973 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.428 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.43 13.28 83.55 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.978 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.8 p -105.02 139.69 39.32 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.867 -0.419 . . . . 0.0 109.867 179.951 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.54 162.27 20.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.972 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 p -150.14 122.19 8.26 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.921 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.537 HG23 ' CG1' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -151.24 153.25 34.52 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.903 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.532 ' N ' HG21 ' A' ' 65' ' ' THR . 0.5 OUTLIER -107.95 120.69 43.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.946 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.324 HD12 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -99.69 156.02 17.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.547 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -111.71 128.16 56.0 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.658 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -100.23 129.64 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.966 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.92 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -113.68 155.52 25.4 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.961 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 1.3 ppt_? -89.72 -12.77 38.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.992 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -166.06 142.39 5.06 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.92 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.739 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 10.8 p90 -178.0 158.05 1.2 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.895 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.19 124.9 21.69 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.911 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.445 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -83.18 103.97 2.54 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.915 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.732 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.57 102.03 12.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.761 HD21 ' HB3' ' A' ' 79' ' ' ASP . 3.9 tp -56.61 131.6 49.34 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.968 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.526 ' HD2' HD22 ' A' ' 45' ' ' LEU . 26.2 p90 -47.44 -36.6 10.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.761 ' HB3' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.39 -16.48 9.24 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.953 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.41 27.57 9.8 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.523 HG21 ' N ' ' A' ' 82' ' ' ARG . 1.4 m -115.11 150.3 36.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.971 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.523 ' N ' HG21 ' A' ' 81' ' ' THR . 5.4 mtm180 -85.36 98.0 10.3 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.956 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.638 ' CH2' HG21 ' A' ' 44' ' ' VAL . 22.8 t-105 -63.92 -51.33 64.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 179.896 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 139.03 179.73 17.69 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.969 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.86 134.26 56.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.927 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.048 HG11 ' HB2' ' A' ' 38' ' ' ALA . 6.5 t -114.62 150.08 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.2 94.43 4.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.926 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -53.37 -25.31 14.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 180.0 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.4 p -83.92 2.14 40.09 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.95 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.621 ' O ' HG23 ' A' ' 90' ' ' THR . 2.9 m -114.44 -27.85 7.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.942 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.33 179.88 5.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.937 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 126.32 41.93 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.907 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.339 ' C ' HG13 ' A' ' 110' ' ' ILE . 9.0 m -104.39 153.98 20.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.961 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.069 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -149.62 148.23 29.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.95 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.324 ' CG1' HD12 ' A' ' 67' ' ' LEU . 17.9 t -96.76 163.55 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.96 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.187 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.41 158.34 27.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.064 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -141.53 137.61 32.14 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.972 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.077 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -129.13 153.48 47.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.912 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.643 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -98.11 -166.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.996 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -59.28 -49.99 75.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.978 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.29 -24.82 64.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.926 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.415 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 100.65 41.71 2.65 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.417 ' ND2' ' CG ' ' A' ' 99' ' ' ASP . 0.5 OUTLIER -121.4 178.03 4.96 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.27 -176.0 20.81 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.98 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.054 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.46 134.03 21.8 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.298 3.332 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.383 ' O ' ' CB ' ' A' ' 2' ' ' ALA . 0.5 OUTLIER -136.04 144.3 45.17 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.992 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.39 59.46 0.19 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.979 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.001 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 36.4 t -133.54 100.74 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.37 153.75 18.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.969 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.339 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -121.91 161.36 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -148.65 117.05 6.51 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.961 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.039 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 45.3 m-85 -94.72 128.12 41.19 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.931 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.964 . . . . . . . . 0 0 . 1 . 042 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 042 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 106' ' ' GLU . . . -112.05 123.81 33.61 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.97 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.38 -177.35 2.67 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.331 3.354 . . . . 0.0 109.59 179.906 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.812 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.31 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.96 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.733 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.28 144.57 49.33 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.988 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.773 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -111.33 108.41 18.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.974 HG21 HG22 ' A' ' 108' ' ' VAL . 1.7 t -99.64 151.05 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.978 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -66.7 177.82 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.979 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.978 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 115.82 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.304 3.336 . . . . 0.0 109.628 179.89 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.789 ' HA ' HD12 ' A' ' 13' ' ' LEU . 30.0 p -118.32 38.84 3.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.968 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 111' ' ' SER . 11.5 p -117.86 104.78 11.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.901 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.937 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 95.22 26.58 12.07 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.961 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.789 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -98.2 129.76 44.95 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.958 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -91.87 161.9 14.65 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -45.33 142.03 2.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.957 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.24 33.14 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.988 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 34.4 m -76.48 150.71 36.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.99 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.8 124.41 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.995 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.541 ' HA ' HG22 ' A' ' 8' ' ' THR . 18.5 m -96.15 133.95 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.991 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.497 ' H ' ' HB ' ' A' ' 8' ' ' THR . 0.0 OUTLIER -79.2 154.47 29.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.69 ' HA ' HG23 ' A' ' 7' ' ' VAL . 4.2 p -140.95 103.13 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.773 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -109.51 121.33 44.96 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.94 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.624 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -101.7 139.62 14.49 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.812 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -134.37 127.07 30.91 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.992 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.03 24.18 23.24 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.883 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -91.29 -167.24 1.75 Allowed 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.488 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.0 mt-30 -84.93 125.18 32.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.991 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.76 130.74 41.18 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.54 8.22 83.81 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.954 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.731 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -95.4 132.16 40.75 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.899 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -79.64 150.63 30.91 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.934 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.599 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 31.5 m-85 -137.9 148.77 45.63 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.909 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.157 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.9 m-20 -113.89 116.29 29.06 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.917 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.349 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.12 145.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.995 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.038 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.69 169.57 41.3 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.978 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.883 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 29.1 tt0 -111.22 120.72 43.22 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.945 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -110.33 162.7 14.38 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.953 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.172 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -150.81 125.16 9.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.959 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.9 125.86 26.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.988 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.976 HG23 ' CG ' ' A' ' 83' ' ' TRP . 2.6 m -111.69 -35.62 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.154 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.2 -178.55 5.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.967 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 79.0 m -77.19 111.83 13.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.28 10.51 85.94 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.683 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -128.78 114.84 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -108.14 162.85 13.68 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.986 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.227 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -129.39 127.38 40.89 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.944 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.725 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.95 154.25 21.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.719 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.9 t30 -116.29 113.96 40.95 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.972 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.34 -0.11 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.33 3.353 . . . . 0.0 109.598 179.891 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.507 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -90.55 -16.1 29.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.836 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.3 p30 -125.96 25.63 6.75 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.915 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -91.22 106.25 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.967 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.2 t -99.66 -179.88 4.33 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.916 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.4 p -146.84 157.34 43.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.901 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -166.69 160.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.914 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 55' ' ' VAL . 12.0 m -127.52 141.08 51.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.36 134.51 36.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.4 p30 -78.6 -171.84 2.68 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.933 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.26 -26.14 68.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.947 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -77.77 -3.97 44.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.678 ' O ' HD13 ' A' ' 26' ' ' LEU . . . 69.53 31.26 70.87 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.999 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.6 p -123.14 133.7 54.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.963 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -139.22 124.57 19.17 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.983 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.97 143.04 46.72 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.949 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.487 HG21 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.48 166.23 33.35 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.487 ' N ' HG21 ' A' ' 65' ' ' THR . 0.6 OUTLIER -105.79 124.61 49.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.201 ' CG ' HG21 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.82 118.59 35.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.981 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.581 ' OG1' ' CZ ' ' A' ' 70' ' ' ARG . 3.1 t -80.88 132.34 35.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.938 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.567 HG22 ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -107.78 130.52 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.656 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.5 mpt_? -115.78 146.25 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.98 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.724 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.7 OUTLIER -70.86 -4.39 24.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.957 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 31.7 p -178.79 153.25 0.65 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.9 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.883 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 6.4 p90 -176.87 162.31 2.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.955 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -56.15 126.45 26.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.227 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -83.07 88.64 1.5 Allowed Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.933 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.725 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.87 100.85 11.25 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.996 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.779 HD21 ' HB3' ' A' ' 79' ' ' ASP . 4.3 tp -63.46 130.55 44.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.541 ' N ' HD11 ' A' ' 77' ' ' LEU . 26.9 p90 -47.48 -36.04 9.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.986 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.779 ' HB3' HD21 ' A' ' 77' ' ' LEU . 1.4 t70 -57.37 -16.63 9.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.994 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.0 27.36 9.51 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.994 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.641 HG22 ' N ' ' A' ' 82' ' ' ARG . 2.6 m -113.61 144.99 41.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.641 ' N ' HG22 ' A' ' 81' ' ' THR . 0.3 OUTLIER -88.87 94.24 9.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.683 ' CZ2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.41 -57.75 9.29 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.78 164.28 10.5 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.992 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -56.0 127.5 30.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.934 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.172 HG22 ' CB ' ' A' ' 38' ' ' ALA . 0.8 OUTLIER -107.79 154.95 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.993 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.56 108.7 16.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.957 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.831 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 35.1 m -54.25 -26.48 29.07 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.976 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.6 p -82.02 -0.97 46.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.965 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.613 HG21 ' O ' ' A' ' 90' ' ' THR . 1.1 m -116.4 -27.36 6.81 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.932 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.88 -178.31 4.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.69 124.24 40.62 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.16 ' C ' HG13 ' A' ' 110' ' ' ILE . 94.9 m -104.47 152.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.956 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.052 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -156.42 146.04 20.86 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.949 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.201 HG21 ' CG ' ' A' ' 67' ' ' LEU . 9.2 t -96.53 162.57 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.236 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 160.49 31.33 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.599 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -138.84 141.8 38.65 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.972 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.157 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -134.02 157.8 45.17 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.929 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.899 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.89 -164.16 1.02 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.448 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.13 -49.68 76.13 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.8 -24.78 61.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.902 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.85 41.13 2.95 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.57 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -117.68 176.69 5.06 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.948 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.4 -175.75 20.76 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 179.975 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.97 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.39 133.89 21.67 Favored 'Trans proline' 0 N--CA 1.447 -1.247 0 C-N-CA 124.338 3.359 . . . . 0.0 109.568 179.908 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.803 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 3.7 tt0 -137.26 147.49 45.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.96 58.11 0.23 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.946 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.037 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.4 t -130.88 101.38 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.41 143.36 28.94 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.16 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -110.79 169.27 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.92 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -161.4 127.64 3.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.943 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.831 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 11.2 m-85 -99.1 116.84 32.25 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.893 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.937 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 3.4 p30 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 043 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.15 ' HB3' ' O ' ' A' ' 106' ' ' GLU . . . -87.72 147.33 41.11 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.943 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.162 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.41 -175.3 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.297 3.331 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.723 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -100.55 108.68 20.68 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.92 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.868 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.98 136.87 54.38 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.932 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.625 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -98.53 112.27 24.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.969 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.823 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -106.2 153.42 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.997 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.95 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.73 176.93 1.1 Allowed Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.92 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.95 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.9 Cg_endo -72.35 115.9 4.5 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.323 3.349 . . . . 0.0 109.59 179.881 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.969 ' HB2' HG21 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -112.95 41.23 2.12 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.956 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.532 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -119.04 105.43 11.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.876 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 1.081 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 93.2 28.24 12.08 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.99 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.745 HD13 ' HA ' ' A' ' 10' ' ' SER . 0.6 OUTLIER -103.24 130.16 50.4 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.976 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -106.16 174.52 5.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.944 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -48.65 139.97 8.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.935 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.66 -23.59 32.26 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.999 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 58.3 m -80.17 151.92 29.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.973 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.1 p -127.11 130.2 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.979 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.783 ' CG2' ' O ' ' A' ' 67' ' ' LEU . 15.4 m -95.87 170.66 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.995 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.823 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.59 148.8 40.58 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.735 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -143.3 106.09 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.971 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.868 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.04 115.76 24.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.482 ' HA2' ' CB ' ' A' ' 5' ' ' ALA . . . -85.35 142.12 19.42 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.723 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.91 112.53 9.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.964 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 101.53 25.7 8.04 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -180.0 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.068 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -91.26 -163.8 1.09 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -89.25 125.21 34.99 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.423 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.97 133.86 44.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.66 8.57 84.4 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.691 HG23 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -98.83 134.57 41.52 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.995 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.931 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.47 152.24 25.05 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.535 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 38.0 m-85 -138.51 145.25 40.53 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.928 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -110.15 122.45 47.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.924 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.228 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.2 t -102.19 150.17 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.997 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.98 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.88 146.66 9.2 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.943 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.806 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 14.4 tt0 -92.58 115.86 28.48 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -103.13 163.78 12.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.951 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 1.17 ' CB ' HG12 ' A' ' 86' ' ' VAL . . . -149.16 131.42 15.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.96 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.542 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.0 OUTLIER -67.32 124.57 23.51 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.987 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.715 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.3 m -111.39 -41.64 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.974 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.532 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -146.1 -178.8 6.32 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.964 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.647 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.3 t -65.1 111.6 2.98 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.986 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 7.92 62.73 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.988 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.625 ' O ' HG23 ' A' ' 40' ' ' VAL . 45.9 t -111.02 105.2 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.694 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.3 mt -107.98 153.29 23.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.483 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -128.15 128.63 45.18 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.966 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -106.87 154.81 20.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.479 ' OD1' ' HB1' ' A' ' 50' ' ' ALA . 13.7 t30 -116.15 112.53 41.94 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -179.982 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -72.33 -0.35 8.55 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.308 3.338 . . . . 0.0 109.616 179.839 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.479 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -91.83 -12.26 34.2 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.832 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.455 ' HB2' ' CG2' ' A' ' 68' ' ' THR . 23.6 p30 -130.82 27.34 4.93 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.63 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -103.35 116.14 31.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.977 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 54' ' ' SER . 30.2 t -100.56 -173.22 2.35 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.984 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.442 ' N ' ' OG ' ' A' ' 53' ' ' SER . 4.7 p -147.14 154.08 40.67 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.85 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -167.06 154.44 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 58.7 m -123.8 122.73 38.8 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.954 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -52.79 149.75 5.95 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -92.27 -171.44 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.955 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.27 -25.06 67.64 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -81.35 -5.0 57.39 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 72.58 23.66 77.53 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 82.4 p -114.42 138.06 51.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.996 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.61 163.02 19.63 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.997 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -150.94 120.0 6.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.86 158.08 43.9 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.892 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.614 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -110.4 126.35 54.19 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.985 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.119 ' CG ' HG22 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -107.58 118.24 36.2 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.965 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.637 ' N ' HD11 ' A' ' 67' ' ' LEU . 4.7 t -69.0 149.73 48.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.922 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.522 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -106.46 123.93 61.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.967 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.522 ' HD2' ' O ' ' A' ' 69' ' ' VAL . 1.5 mpt_? -116.58 137.09 52.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.971 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.477 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 26.0 ptt180 -75.26 -18.34 60.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HB2' ' OD1' ' A' ' 87' ' ' ASP . 9.7 t -163.82 151.57 12.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.911 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.806 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -177.8 155.7 1.04 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.885 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -55.93 122.63 12.01 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.931 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.483 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.54 89.46 1.03 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.966 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.45 10.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.989 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.745 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.6 tp -54.25 141.74 28.56 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.728 ' N ' HD13 ' A' ' 77' ' ' LEU . 4.0 m-85 -47.1 -42.37 18.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.978 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.745 ' HB3' HD23 ' A' ' 77' ' ' LEU . 12.2 t0 -57.05 -17.06 8.71 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.959 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.82 28.16 9.71 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.934 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 3.0 m -108.78 131.16 55.23 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttt180 -72.94 91.62 1.56 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.944 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.532 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 0.5 OUTLIER -61.96 -57.0 13.37 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.884 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.41 170.2 21.31 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 179.982 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.47 142.22 33.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 1.17 HG12 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -117.91 154.11 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.973 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.512 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 10.0 m-20 -128.73 95.0 3.99 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.965 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 1.219 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 99.1 m -54.31 -25.63 24.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.977 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -80.45 1.87 27.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.978 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -113.83 -27.39 7.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.969 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.07 -170.55 2.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.983 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.89 126.52 42.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.92 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.354 ' C ' HG13 ' A' ' 110' ' ' ILE . 11.9 m -104.68 152.84 22.01 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.084 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.8 148.09 31.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.92 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.119 HG22 ' CG ' ' A' ' 67' ' ' LEU . 24.1 t -99.72 164.86 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.952 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.013 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.81 158.03 24.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.535 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -134.9 152.9 52.14 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.974 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER -141.32 158.47 43.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.903 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.931 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -105.28 -163.13 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.967 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.51 -49.34 77.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.941 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.79 -25.44 61.16 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.947 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.07 42.38 2.43 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.95 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.634 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -119.51 176.12 5.51 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.963 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.19 -173.22 22.81 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.994 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.162 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.38 133.35 20.72 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.345 3.363 . . . . 0.0 109.641 179.92 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.15 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 2.3 tt0 -136.1 145.74 46.24 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 57.36 0.23 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.964 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.02 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 25.5 t -131.58 100.94 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.978 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.646 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -97.57 155.22 17.06 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.996 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.354 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -124.29 163.49 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.949 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.532 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -153.61 122.47 6.41 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.959 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.219 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 10.0 m-85 -87.6 116.32 25.65 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 179.902 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 1.081 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 4.4 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.966 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 044 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.874 ' HA ' ' HG3' ' A' ' 106' ' ' GLU . . . -103.51 108.95 60.95 Favored Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.084 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -174.05 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.347 3.365 . . . . 0.0 109.579 179.964 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.648 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.03 109.48 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.939 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.781 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.73 141.74 49.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.937 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.576 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -96.72 111.44 23.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 1.048 HG21 HG22 ' A' ' 108' ' ' VAL . 21.9 t -107.66 148.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.973 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -68.48 177.63 1.04 Allowed Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.973 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.38 117.97 5.38 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 124.32 3.346 . . . . 0.0 109.607 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.983 ' HB2' HG22 ' A' ' 110' ' ' ILE . 9.3 p -115.11 44.58 1.78 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.957 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.4 m -122.91 105.11 9.71 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.88 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.637 ' C ' HD21 ' A' ' 13' ' ' LEU . . . 91.88 28.1 14.8 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.716 HD12 ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -97.69 132.69 43.1 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.8 m -107.19 172.93 6.55 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.956 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.65 140.05 15.15 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.39 -22.99 35.67 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.3 m -74.59 153.11 39.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.408 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 7.1 p -129.96 126.1 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.606 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 26.3 m -94.57 176.65 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.98 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.823 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.35 149.28 45.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.944 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.628 HG12 HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -145.11 108.03 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.781 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.27 116.78 23.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.456 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -84.39 144.34 21.48 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.648 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -140.67 112.6 7.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.933 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.574 ' N ' HD21 ' A' ' 26' ' ' LEU . . . 105.22 21.75 8.69 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.957 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -91.29 -163.91 1.1 Allowed 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -89.94 126.43 35.73 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.496 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -69.61 141.59 53.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.978 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.69 7.72 59.03 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.96 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.753 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.57 143.05 26.73 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.548 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.22 148.84 21.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.984 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.007 ' OH ' ' NE2' ' A' ' 27' ' ' GLN . 49.4 m-85 -137.85 148.55 45.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.175 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.7 m-20 -112.38 114.57 27.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.964 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.044 HG23 ' HB3' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -96.18 146.43 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.978 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.887 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.5 167.88 40.97 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.953 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.813 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 8.2 tt0 -115.97 113.38 23.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 1.047 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -114.3 149.05 36.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.971 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.497 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -124.66 134.91 52.72 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.928 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.663 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 120.56 13.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.95 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.507 HG22 ' CD1' ' A' ' 83' ' ' TRP . 24.8 m -101.07 -44.95 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.982 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.865 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.6 OUTLIER -133.36 172.36 12.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 t -56.47 111.44 0.99 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.92 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.88 7.53 62.21 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.003 HG11 ' NE1' ' A' ' 83' ' ' TRP . 21.6 t -120.68 111.08 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.951 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.6 HD11 ' HB2' ' A' ' 37' ' ' CYS . 1.1 pt? -123.43 140.97 52.47 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.297 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.33 146.03 26.09 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.047 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 12.1 m -106.48 153.97 21.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.752 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.0 t30 -114.52 109.82 47.92 Favored Pre-proline 0 N--CA 1.45 -0.468 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.4 -0.35 8.58 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.293 3.328 . . . . 0.0 109.585 179.914 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.458 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . . . -88.65 -16.57 32.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.876 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 13.7 p30 -128.24 28.44 5.49 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.878 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.47 118.95 36.29 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.97 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -111.43 -172.84 2.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.965 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -146.7 157.66 43.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.888 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' N ' ' A' ' 56' ' ' THR . 4.5 p -166.75 159.53 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.436 ' N ' HG22 ' A' ' 55' ' ' VAL . 14.0 m -127.1 137.5 53.02 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.985 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.83 131.44 39.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -73.75 -173.43 1.51 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.26 -20.42 62.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -85.98 10.09 15.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 56.79 26.78 54.77 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.946 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 t -121.21 133.54 55.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.44 156.75 32.06 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.989 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -139.02 133.69 32.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.597 HG21 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.93 170.34 19.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.942 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.597 ' N ' HG21 ' A' ' 65' ' ' THR . 0.7 OUTLIER -121.01 138.39 54.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.939 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.074 ' HG ' HG23 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -115.77 118.81 34.07 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.943 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.719 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -71.1 135.89 47.93 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.552 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -92.67 125.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.971 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.719 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 1.1 mpt_? -117.8 140.63 49.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.416 ' O ' ' OG ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -82.72 -15.84 50.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.472 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 58.4 m -167.33 152.13 7.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.979 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.813 ' HE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -176.55 161.86 2.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.929 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.54 110.58 1.74 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.94 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.297 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -69.97 94.21 0.44 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.958 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.867 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.5 m-85 -82.88 98.78 9.36 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.956 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.79 HD23 ' HB2' ' A' ' 79' ' ' ASP . 3.6 tp -55.49 142.28 33.62 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.982 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.735 ' N ' HD11 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.67 -42.91 25.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.79 ' HB2' HD23 ' A' ' 77' ' ' LEU . 4.0 m-20 -57.75 -16.76 12.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.78 27.73 12.25 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.985 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.9 m -106.08 134.07 49.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.97 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.48 91.64 0.78 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.507 ' CD1' HG22 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.76 -48.82 77.51 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.878 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.63 167.13 10.94 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -65.43 103.59 0.85 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.963 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.575 HG13 HG12 ' A' ' 40' ' ' VAL . 3.4 m -78.61 151.81 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.981 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 90' ' ' THR . 5.8 m-20 -110.48 93.85 4.71 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.78 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 13.7 m -51.29 -26.26 7.09 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.7 p -81.06 0.79 34.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 -179.999 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 ' N ' ' O ' ' A' ' 87' ' ' ASP . 1.3 m -117.3 -27.62 6.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.51 -179.9 5.43 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.34 123.77 40.1 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.308 ' C ' HG13 ' A' ' 110' ' ' ILE . 89.1 m -104.59 155.66 18.65 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -180.0 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.043 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 1.2 pt20 -144.56 147.49 33.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.944 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.074 HG23 ' HG ' ' A' ' 67' ' ' LEU . 14.2 t -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.944 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.08 160.05 28.71 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.044 ' HB3' HG23 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -128.35 155.29 44.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.954 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.175 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -143.45 144.23 31.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.898 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.548 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -90.97 -161.78 0.85 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.457 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.69 -49.29 78.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.13 -24.79 62.34 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.93 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.83 42.5 2.45 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.994 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.438 ' ND2' ' CG ' ' A' ' 99' ' ' ASP . 0.5 OUTLIER -121.07 177.16 5.24 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.99 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.92 -173.65 22.28 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.084 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.35 133.85 21.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.364 3.376 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.874 ' HG3' ' HA ' ' A' ' 2' ' ' ALA . 1.8 pt-20 -139.8 161.53 37.34 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.79 51.71 0.6 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.925 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.048 HG22 HG21 ' A' ' 7' ' ' VAL . 4.0 t -126.44 101.82 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.996 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.09 146.83 24.32 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.955 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.308 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -115.78 159.71 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.907 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -151.0 126.73 10.25 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.909 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.78 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 8.3 m-85 -101.48 124.93 47.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.932 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.566 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 49.2 m-80 . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.961 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 045 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.651 ' C ' ' HB3' ' A' ' 106' ' ' GLU . . . -133.34 123.61 17.76 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.932 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.386 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.38 -174.13 1.34 Allowed 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.286 3.324 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.162 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.4 t -95.93 109.73 22.05 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.827 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.99 145.7 50.89 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.444 ' OG1' ' HB1' ' A' ' 22' ' ' ALA . 1.3 p -103.9 113.37 26.85 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 38.5 t -110.66 148.53 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.996 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.15 175.94 1.59 Allowed Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.945 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.952 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 120.95 7.07 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.351 3.367 . . . . 0.0 109.63 179.851 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.772 ' OG ' HG21 ' A' ' 110' ' ' ILE . 30.8 p -120.83 52.48 1.18 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.599 ' HA ' ' O ' ' A' ' 111' ' ' SER . 62.0 p -137.81 106.14 5.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.9 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.68 8.47 40.01 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.9 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.759 ' CD2' ' HA ' ' A' ' 10' ' ' SER . 3.5 pp -114.68 143.08 45.61 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -122.47 -166.99 1.49 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.936 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.943 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 42.7 t0 -43.32 151.73 0.15 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.969 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 92.02 -23.38 26.86 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.998 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.628 HG21 ' N ' ' A' ' 18' ' ' VAL . 3.7 m -85.08 146.05 27.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.628 ' N ' HG21 ' A' ' 17' ' ' THR . 14.8 p -116.21 129.52 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.688 HG11 HG23 ' A' ' 69' ' ' VAL . 6.0 m -99.75 159.4 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.751 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 145.42 41.37 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.969 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.659 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -142.06 110.16 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.989 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.827 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.89 112.91 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.979 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.517 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -84.92 144.77 21.25 Favored Glycine 0 C--N 1.334 0.468 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.162 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -142.86 110.13 5.68 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.955 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.575 ' N ' HD22 ' A' ' 26' ' ' LEU . . . 107.89 14.92 15.95 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.044 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -91.04 165.94 13.26 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.549 ' N ' ' HH ' ' A' ' 32' ' ' TYR . 34.9 mt-30 -48.99 121.26 4.58 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.96 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.608 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.69 134.93 45.28 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.945 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 8.2 76.32 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.981 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.837 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -97.7 137.41 36.63 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.995 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.12 151.97 24.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.998 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.546 ' CB ' HD23 ' A' ' 97' ' ' LEU . 73.0 m-85 -135.77 158.2 44.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.925 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.451 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 17.1 m-20 -119.71 117.93 29.55 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.948 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.212 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.42 138.13 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.958 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 1.165 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -158.91 162.88 32.91 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.839 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 1.8 tt0 -115.13 121.62 43.59 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.915 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 93' ' ' CYS . 66.9 m -108.59 172.7 6.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.976 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.842 ' CB ' HG13 ' A' ' 86' ' ' VAL . . . -152.84 124.34 7.71 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.943 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.598 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 124.25 21.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.947 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.677 ' CG1' HG23 ' A' ' 86' ' ' VAL . 12.1 m -104.43 -43.7 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.952 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.702 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.88 164.13 30.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.6 m -53.33 114.06 1.36 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.944 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.6 7.92 70.4 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.5 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 15.0 t -126.44 105.76 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.953 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.84 162.65 17.76 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.197 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.18 146.96 49.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.822 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.4 m -108.35 155.95 19.96 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.828 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 33.6 t30 -114.59 105.64 53.3 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.443 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.287 3.325 . . . . 0.0 109.609 179.885 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.5 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -88.44 -12.94 41.67 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.878 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.9 p30 -126.71 28.51 5.87 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.72 104.57 13.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.997 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.1 t -101.65 177.26 4.96 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.923 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 p -146.44 153.08 40.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.852 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.532 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -167.37 153.04 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.532 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.1 m -122.58 139.62 53.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.947 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.0 142.86 32.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.917 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -80.02 -170.73 2.59 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -22.08 66.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.961 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.92 4.75 21.36 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.608 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.32 31.01 72.44 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.921 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.8 t -125.05 132.28 53.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.94 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.12 164.07 17.43 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.979 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -146.74 135.64 22.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.627 HG22 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.05 165.35 17.93 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.913 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.627 ' N ' HG22 ' A' ' 65' ' ' THR . 0.4 OUTLIER -122.34 126.06 47.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.939 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.125 HD11 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.83 155.34 16.82 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.441 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 5.0 t -103.7 119.29 38.62 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.946 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.688 HG23 HG11 ' A' ' 19' ' ' VAL . 2.1 t -84.35 128.4 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.943 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.6 OUTLIER -119.1 156.82 29.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HB2' HG23 ' A' ' 89' ' ' THR . 0.2 OUTLIER -90.93 -24.98 20.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.923 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.408 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -156.47 148.35 22.94 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.946 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.839 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.8 p90 -174.41 153.42 1.91 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.935 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -54.29 115.13 1.92 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.197 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.49 100.64 0.83 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.986 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.822 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -83.41 99.95 10.39 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.988 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.776 HD23 ' HB3' ' A' ' 79' ' ' ASP . 4.2 tp -58.61 130.94 49.25 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.539 ' N ' HD12 ' A' ' 77' ' ' LEU . 14.1 p90 -47.65 -35.75 9.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.776 ' HB3' HD23 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.96 -16.35 12.06 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.19 27.68 9.88 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.986 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.511 HG22 ' N ' ' A' ' 82' ' ' ARG . 2.3 m -115.36 151.65 34.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.511 ' N ' HG22 ' A' ' 81' ' ' THR . 0.0 OUTLIER -89.45 97.86 11.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.5 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.43 -55.9 20.57 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.883 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.56 172.67 17.09 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.26 108.25 0.45 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.978 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.842 HG13 ' CB ' ' A' ' 38' ' ' ALA . 86.4 t -86.05 147.43 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.485 ' N ' HG11 ' A' ' 86' ' ' VAL . 48.1 m-20 -108.09 90.87 3.43 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.963 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.428 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -53.06 -25.24 12.03 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.443 HG23 ' HB2' ' A' ' 71' ' ' ARG . 61.0 p -78.01 -3.33 41.5 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.78 -26.07 7.54 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.46 -179.89 4.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.962 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.26 136.97 36.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.899 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.463 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.69 166.05 10.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.998 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.335 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -169.52 127.9 0.96 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.911 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.165 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 3.9 t -92.41 164.28 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.212 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -170.22 164.83 38.16 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.546 HD23 ' CB ' ' A' ' 32' ' ' TYR . 4.3 mp -100.33 160.93 13.94 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.451 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 14.6 m -155.0 117.44 4.26 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.591 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 3.2 p-10 -112.11 -158.15 0.64 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.958 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.13 -39.49 59.99 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -26.89 19.6 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.77 53.52 2.23 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.591 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -106.68 -174.7 2.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.994 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.431 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 171.01 175.58 39.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.386 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.9 Cg_endo -72.33 160.63 46.54 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.32 3.347 . . . . 0.0 109.581 179.948 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.281 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -33.84 126.63 0.42 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.991 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.462 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.76 135.75 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.335 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 25.3 t -119.05 102.88 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.956 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.93 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.7 158.22 19.48 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.969 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.887 HG13 ' HA ' ' A' ' 94' ' ' GLN . 35.2 mt -125.98 162.49 29.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.986 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.599 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -141.07 121.39 13.95 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.903 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.463 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 2.9 m-85 -97.72 122.21 40.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.943 . . . . . . . . 0 0 . 1 . 046 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 . . . . . . . . . 0 0 . 1 . 046 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 1.231 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -145.03 130.56 9.41 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.91 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.561 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.4 Cg_endo -72.38 -174.3 1.39 Allowed 'Trans proline' 0 N--CA 1.446 -1.272 0 C-N-CA 124.337 3.358 . . . . 0.0 109.634 179.886 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.282 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.6 t -95.97 111.42 23.43 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.957 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.789 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.57 140.13 50.45 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.508 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -102.25 111.27 23.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.985 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.22 155.05 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.981 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.969 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.43 177.02 1.02 Allowed Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.929 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.969 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.2 Cg_endo -72.39 117.86 5.33 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.316 3.344 . . . . 0.0 109.605 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.711 ' OG ' HG22 ' A' ' 110' ' ' ILE . 22.6 p -114.31 41.39 2.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.963 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 111' ' ' SER . 60.4 p -123.41 105.97 10.26 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.928 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.639 ' C ' HD22 ' A' ' 13' ' ' LEU . . . 93.68 26.38 15.29 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.976 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.744 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -97.93 132.49 43.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.958 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.2 m -90.79 151.8 21.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.938 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -44.09 137.84 3.19 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.93 -20.9 37.43 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.984 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 90.9 m -64.78 147.46 53.13 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.995 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.472 ' CG1' ' O ' ' A' ' 18' ' ' VAL . 9.7 p -110.58 117.78 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.972 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 67' ' ' LEU . 14.8 m -95.48 164.75 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.615 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.16 153.33 29.75 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.947 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.681 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -149.39 113.48 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.982 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.789 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.25 114.5 21.47 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.555 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.28 147.69 23.61 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.282 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -147.48 109.85 4.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.933 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.562 ' N ' HD23 ' A' ' 26' ' ' LEU . . . 107.67 14.0 18.86 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.025 ' CD2' ' HB2' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -90.49 165.8 13.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' N ' ' HH ' ' A' ' 32' ' ' TYR . 35.5 mt-30 -50.91 118.99 3.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.852 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.05 134.99 46.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.971 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.25 8.73 80.05 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.916 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.739 HG21 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 142.69 29.41 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.975 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.574 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.03 153.21 22.3 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.055 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 59.2 m-85 -138.29 150.88 47.07 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.919 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.509 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.2 m-20 -116.87 114.86 24.47 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.492 ' CG2' ' HG ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.52 139.94 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.956 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.76 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.92 156.92 28.17 Favored Glycine 0 C--N 1.335 0.489 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.702 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 52.8 tt0 -96.33 113.54 25.14 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.3 m -102.17 159.5 15.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 -179.977 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.781 ' HB1' HG22 ' A' ' 86' ' ' VAL . . . -149.2 141.45 24.07 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.905 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.549 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.2 t90 -63.6 121.65 14.42 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -109.53 -36.37 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 1.016 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -155.24 -175.81 5.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 7.2 t -73.56 110.55 7.93 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.88 12.75 83.71 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 1.636 HG21 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -128.9 121.15 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.985 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -113.78 162.2 16.59 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.989 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.463 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -132.14 130.91 41.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.758 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.65 155.23 20.39 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.751 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.2 p-10 -118.69 120.1 31.98 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.955 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.34 1.66 5.88 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.298 3.332 . . . . 0.0 109.627 179.879 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.33 -24.79 29.63 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.874 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -123.39 30.98 6.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.932 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.14 117.71 34.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 -179.973 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.2 t -110.86 -177.95 3.35 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.7 p -148.46 153.79 38.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.437 ' CG2' ' N ' ' A' ' 56' ' ' THR . 3.1 p -167.63 161.65 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.901 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.437 ' N ' ' CG2' ' A' ' 55' ' ' VAL . 52.4 m -126.53 131.76 51.51 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 153.19 44.25 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 -179.999 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.3 p-10 -90.38 -166.42 1.58 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.937 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -30.23 71.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.885 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.39 -9.55 58.7 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.852 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.48 15.99 80.82 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.983 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.5 p -104.57 138.3 41.13 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.951 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.96 166.65 13.54 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 m -150.92 117.34 5.7 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.568 HG22 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -146.83 157.9 43.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.948 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.568 ' N ' HG22 ' A' ' 65' ' ' THR . 0.2 OUTLIER -110.76 125.22 53.31 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.899 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.298 ' CD1' HG22 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -104.65 155.3 18.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.967 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.431 ' H ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -116.74 142.81 46.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -110.48 125.13 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.623 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -110.14 159.91 16.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.976 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.67 -29.39 59.05 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 69.6 p -165.28 156.96 14.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.751 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 3.1 p90 -175.28 167.35 3.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -63.97 118.82 9.0 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.947 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.463 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -75.01 85.3 0.79 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.758 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.05 98.63 9.39 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 79' ' ' ASP . 1.8 tp -54.71 134.7 47.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.546 ' N ' HD13 ' A' ' 77' ' ' LEU . 27.2 p90 -45.63 -38.43 6.65 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.999 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.744 ' HB3' HD23 ' A' ' 77' ' ' LEU . 1.3 t70 -57.66 -17.14 13.12 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.943 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 95.88 28.7 9.18 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.988 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 2.9 m -112.65 115.91 29.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.948 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -66.03 93.36 0.2 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.636 ' CE2' HG21 ' A' ' 44' ' ' VAL . 2.3 t-105 -63.44 -57.98 8.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.925 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.35 171.38 19.88 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.967 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.48 140.67 56.02 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.781 HG22 ' HB1' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.61 151.6 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.524 ' N ' HG21 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -110.56 100.78 9.53 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.977 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.899 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 23.8 m -53.5 -26.0 18.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.979 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -82.5 -1.7 51.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.979 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.579 ' O ' HG23 ' A' ' 90' ' ' THR . 2.2 m -115.48 -27.99 6.98 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.919 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.515 ' HB3' ' HB3' ' A' ' 39' ' ' TRP . . . -125.4 -175.15 3.24 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.39 124.57 41.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.899 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.194 ' O ' HG13 ' A' ' 110' ' ' ILE . 1.7 m -104.66 153.65 20.97 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.141 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -158.5 144.92 17.22 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.959 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.298 HG22 ' CD1' ' A' ' 67' ' ' LEU . 25.4 t -101.41 162.38 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.257 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.81 164.25 35.63 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.492 ' HG ' ' CG2' ' A' ' 34' ' ' VAL . 4.5 mp -101.72 160.95 14.02 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -180.0 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.509 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 3.3 p -153.47 119.48 5.39 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.574 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 13.4 p-10 -115.11 -167.11 1.19 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -50.74 -21.15 1.49 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.875 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.18 -24.59 13.14 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.931 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 85.69 22.52 49.92 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 1.055 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.8 -151.17 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.987 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.06 153.73 6.11 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.975 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.561 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.4 Cg_endo -72.44 161.49 44.1 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.316 3.344 . . . . 0.0 109.6 179.985 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 1.231 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -32.75 123.91 0.35 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.936 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.896 ' H ' ' HB3' ' A' ' 2' ' ' ALA . . . -36.03 134.93 0.6 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.141 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.77 102.45 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.471 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -85.58 141.1 30.08 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.194 HG13 ' O ' ' A' ' 93' ' ' CYS . 1.0 OUTLIER -109.48 167.39 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.949 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -150.52 123.49 8.74 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.962 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 19.7 m-85 -99.6 126.19 45.55 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.903 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.993 . . . . . . . . 0 0 . 1 . 047 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.516 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 047 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.879 ' HB3' ' HG3' ' A' ' 106' ' ' GLU . . . -68.9 115.56 32.49 Favored Pre-proline 0 N--CA 1.449 -0.496 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.952 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 1.21 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.4 -177.83 2.96 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.266 3.311 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 1.142 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.8 114.45 28.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.98 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.892 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.37 131.85 50.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.712 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.03 112.07 23.81 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.975 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.827 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -113.08 149.69 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.926 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.995 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.14 179.87 0.65 Allowed Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.923 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.995 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.6 Cg_endo -72.42 121.0 7.09 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.321 3.348 . . . . 0.0 109.538 179.947 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.743 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -110.48 3.73 19.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.986 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 1.398 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 66.1 m -110.36 126.11 53.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.901 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.445 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 103.71 5.29 45.13 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.937 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.835 HD13 HG23 ' A' ' 69' ' ' VAL . 2.1 pp -114.32 146.58 40.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 88.4 p -99.0 171.5 8.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -45.37 151.82 0.34 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 179.969 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.79 -22.36 34.2 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.968 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.437 HG22 HD23 ' A' ' 13' ' ' LEU . 59.0 m -69.31 138.53 53.88 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.993 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -104.11 132.42 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.634 ' HA ' HG23 ' A' ' 8' ' ' THR . 21.5 t -104.12 168.41 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.979 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.827 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.78 134.87 53.57 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.945 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 2.2 p -128.08 104.86 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.892 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -111.39 115.23 28.91 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.692 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.61 145.62 21.99 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 1.142 ' O ' HG22 ' A' ' 4' ' ' THR . . . -146.2 112.27 5.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.15 26.18 8.48 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.961 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 1.152 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.83 -165.81 1.44 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.953 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.924 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 2.7 mp0 -94.35 124.83 38.61 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.1 137.45 57.98 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.4 8.66 63.01 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.304 -1.119 . . . . 0.0 110.304 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.789 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -91.69 142.71 27.31 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.993 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.761 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.13 150.5 21.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.983 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 1.102 ' CG ' ' HD2' ' A' ' 105' ' ' PRO . 56.9 m-85 -139.3 144.51 38.35 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.908 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 1.341 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.2 m-20 -105.57 114.76 29.13 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 1.29 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.47 150.88 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.983 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.755 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.87 168.4 38.56 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.98 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.884 ' CD ' ' HE2' ' A' ' 73' ' ' PHE . 11.6 tt0 -111.29 120.96 43.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 88.9 m -109.95 169.1 8.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.974 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.974 ' CB ' HG22 ' A' ' 86' ' ' VAL . . . -153.68 125.13 7.56 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.481 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.57 129.85 41.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.903 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 1.639 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.4 m -109.33 -37.81 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.408 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -146.82 163.69 35.23 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.958 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -53.19 114.89 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.56 1.93 62.63 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.582 ' O ' HG22 ' A' ' 40' ' ' VAL . 15.9 t -121.02 119.64 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.631 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 pp -126.75 162.22 26.32 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 1.261 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -124.24 139.67 53.7 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 1.031 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 24.1 m -109.18 151.83 25.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.523 ' ND2' ' OD2' ' A' ' 51' ' ' ASP . 16.9 t30 -112.77 110.74 51.9 Favored Pre-proline 0 N--CA 1.448 -0.552 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.977 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 124.341 3.361 . . . . 0.0 109.596 179.936 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.421 ' N ' ' OD1' ' A' ' 48' ' ' ASN . . . -90.05 -20.54 23.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.909 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.581 ' HB3' ' NH1' ' A' ' 70' ' ' ARG . 8.5 p30 -119.38 19.93 12.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.671 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -92.35 113.57 25.87 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.7 t -108.0 -174.28 2.48 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -146.28 155.9 42.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.915 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 p -166.88 158.13 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.941 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 86.5 m -127.78 129.42 46.99 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 135.57 55.62 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 p30 -76.66 -175.19 3.27 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.941 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.66 -19.96 64.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -87.34 10.3 17.73 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.813 ' O ' HD11 ' A' ' 26' ' ' LEU . . . 56.87 30.35 59.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.6 t -124.82 135.98 53.42 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.964 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.35 164.63 19.97 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.0 m -152.41 119.48 5.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.983 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.569 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.17 164.14 34.07 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.865 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.569 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -106.68 133.74 50.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.943 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 1.401 ' CG ' HG21 ' A' ' 95' ' ' VAL . 0.3 OUTLIER -119.59 120.2 36.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.916 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -83.97 145.04 28.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.989 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.835 HG23 HD13 ' A' ' 13' ' ' LEU . 0.2 OUTLIER -121.51 134.56 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.659 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.92 174.94 5.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.988 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.62 ' HG2' ' CG2' ' A' ' 89' ' ' THR . 6.5 mtt180 -98.68 -12.19 21.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.948 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 20.3 p -173.68 145.95 1.24 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.884 ' HE2' ' CD ' ' A' ' 36' ' ' GLN . 1.2 p90 -171.6 163.25 6.61 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.922 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.14 118.02 3.99 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.943 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 1.261 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -78.74 96.08 1.4 Allowed Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 1.031 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.14 100.64 11.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.772 HD23 ' HB3' ' A' ' 79' ' ' ASP . 3.6 tp -56.21 130.64 45.19 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.972 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.624 ' N ' HD13 ' A' ' 77' ' ' LEU . 3.1 p90 -47.42 -35.36 8.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.998 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.772 ' HB3' HD23 ' A' ' 77' ' ' LEU . 6.1 t0 -57.49 -17.55 14.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.4 27.92 8.34 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.638 HG21 ' N ' ' A' ' 82' ' ' ARG . 18.5 m -116.88 148.09 41.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.96 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.638 ' N ' HG21 ' A' ' 81' ' ' THR . 2.3 mtm180 -85.46 96.34 9.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.97 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 1.639 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 72.6 t90 -64.35 -58.05 7.6 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.859 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.42 170.79 16.65 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.987 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.52 0.4 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.974 HG22 ' CB ' ' A' ' 38' ' ' ALA . 2.5 p -86.3 143.1 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.981 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.72 96.43 8.6 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.954 ' O ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -55.35 -20.01 10.52 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.947 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.62 ' CG2' ' HG2' ' A' ' 71' ' ' ARG . 33.5 p -88.94 1.4 55.5 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 m -114.16 -27.44 7.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.978 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.31 179.42 4.91 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.975 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.45 123.14 41.2 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.907 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 1.559 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -104.71 157.71 17.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 1.121 ' N ' HG13 ' A' ' 110' ' ' ILE . 1.3 pt20 -156.19 144.67 20.02 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.975 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.401 HG21 ' CG ' ' A' ' 67' ' ' LEU . 11.9 t -93.58 156.98 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 1.23 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -172.54 165.91 38.51 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.294 -1.123 . . . . 0.0 110.294 179.997 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 1.29 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -136.52 143.44 43.74 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 1.341 ' N ' ' H ' ' A' ' 33' ' ' ASP . 3.5 m -133.52 147.59 51.62 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.95 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.761 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -93.49 -167.01 1.62 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.974 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.08 -50.13 74.53 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -68.76 -24.66 64.47 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.928 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.98 40.53 2.84 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.98 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.414 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -121.89 -178.62 3.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.985 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.64 -174.95 20.8 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.958 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 1.21 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.8 Cg_endo -72.43 134.55 22.77 Favored 'Trans proline' 0 N--CA 1.446 -1.271 0 C-N-CA 124.318 3.345 . . . . 0.0 109.612 179.935 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.879 ' HG3' ' HB3' ' A' ' 2' ' ' ALA . 3.1 pt-20 -137.99 141.54 40.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.904 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 136.27 57.67 0.06 OUTLIER Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.967 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 1.093 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.0 t -134.27 102.73 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.992 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.596 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -96.94 153.6 17.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.944 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 1.559 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.0 OUTLIER -117.94 163.76 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.89 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 1.398 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -162.24 131.0 4.21 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.973 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 1.032 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -108.35 120.07 41.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.445 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.1 t-20 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.605 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.686 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.32 -178.76 3.49 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.298 3.332 . . . . 0.0 109.635 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.201 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.08 113.64 26.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 1.033 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.96 136.11 51.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.55 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.54 115.41 29.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.765 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -113.71 147.39 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.856 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.32 167.43 21.82 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.38 118.52 5.64 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.294 3.329 . . . . 0.0 109.631 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.595 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.59 13.86 7.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 111' ' ' SER . 47.3 p -89.86 115.08 26.92 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.036 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 90.11 20.59 41.89 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.027 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -106.98 134.12 50.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.52 173.21 9.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -45.05 152.2 0.27 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.19 -23.6 32.69 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.666 HG21 HD12 ' A' ' 13' ' ' LEU . 3.0 m -66.5 150.41 49.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.91 122.59 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -105.35 119.35 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.765 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -79.78 149.85 30.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.69 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -142.37 109.7 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.033 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.62 116.96 26.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.911 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -85.32 144.93 21.0 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.201 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -144.81 110.07 5.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.39 15.07 24.22 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.036 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.22 166.09 13.56 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.46 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.5 mt-30 -50.2 121.64 5.81 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.514 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.57 131.35 41.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 7.67 85.21 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.485 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.85 146.21 23.81 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.64 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.25 151.39 22.16 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.65 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.2 m-85 -138.39 147.48 43.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -114.02 113.21 24.47 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.279 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -96.88 147.71 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.78 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.03 163.23 36.61 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.906 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.3 tt0 -106.25 112.4 25.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.4 m -113.53 146.51 39.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.144 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.42 128.97 50.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.593 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.51 120.94 13.79 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.31 HG21 ' CD1' ' A' ' 83' ' ' TRP . 2.7 m -101.2 -43.45 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.966 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -139.23 179.21 6.66 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 47.1 m -62.38 112.75 2.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.33 7.43 63.71 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.578 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 81.2 t -122.33 109.19 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -125.0 137.26 54.25 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.367 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -87.61 156.21 19.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.9 m -121.72 151.27 40.7 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.668 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 32.9 t30 -119.2 111.63 36.69 Favored Pre-proline 0 N--CA 1.448 -0.542 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.44 -0.65 9.05 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.289 3.326 . . . . 0.0 109.578 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.516 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.04 -13.67 43.74 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.588 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.8 m-20 -130.37 27.56 5.04 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.684 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -96.7 115.82 28.08 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.4 t -109.23 -177.76 3.38 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.3 p -147.37 153.91 40.24 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.546 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.59 162.85 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.546 ' N ' HG22 ' A' ' 55' ' ' VAL . 16.6 m -128.11 138.8 52.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.91 36.22 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 42.2 p30 -80.61 -173.26 4.04 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.94 -24.92 68.1 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -74.93 -8.49 56.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.033 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.9 31.61 59.86 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -128.26 139.33 52.5 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.85 167.75 16.9 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 84.1 p -150.49 127.01 10.8 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.552 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.71 163.31 38.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.864 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.552 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -112.7 130.73 55.95 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.944 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.54 125.43 51.81 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.62 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -81.52 129.45 34.67 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.536 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -90.69 128.22 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.536 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.4 OUTLIER -119.42 141.81 48.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.987 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -69.88 -34.19 73.22 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 51.5 p -164.63 159.85 19.44 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.906 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -178.03 172.24 1.64 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -62.72 119.37 9.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.367 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.86 91.63 1.21 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.914 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.5 99.65 10.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.4 132.27 52.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.7 m-85 -46.95 -37.05 8.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.7 t0 -57.6 -16.89 11.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.72 27.97 9.25 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.1 m -113.81 147.48 38.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -86.34 94.37 9.34 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.578 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -64.06 -57.93 8.17 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.4 164.33 11.36 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 108.97 0.66 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.144 HG11 ' CB ' ' A' ' 38' ' ' ALA . 5.7 t -85.55 152.0 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -115.19 93.74 4.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.959 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 4.9 m -53.9 -24.86 17.5 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.7 p -81.73 2.26 30.66 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -115.92 -27.18 7.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.12 -178.91 5.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.3 126.3 43.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.278 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 28.9 m -105.2 171.54 7.27 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.169 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.1 OUTLIER -154.05 147.39 24.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.93 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.944 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 8.8 t -103.87 165.28 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.279 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.79 166.32 35.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.106 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.14 133.04 43.81 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 13.5 m -116.11 145.2 43.23 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.64 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -99.93 -158.04 0.65 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.62 -48.66 76.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.603 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.49 -25.46 62.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 43.34 2.89 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.603 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.6 p30 -114.05 161.49 17.65 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.65 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -168.75 170.46 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.686 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.37 166.04 30.94 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.373 3.382 . . . . 0.0 109.577 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.605 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 mt-10 -36.62 118.1 0.54 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.92 156.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.169 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 5.6 t -106.15 102.16 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.15 116.99 20.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.278 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.3 pt -129.95 -177.5 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.634 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -169.55 173.95 6.15 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.959 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 8.2 m-85 -129.42 110.32 11.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.036 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 1.7 p-10 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.32 ' CB ' ' CG ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.457 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.654 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.0 Cg_endo -72.4 -177.78 2.93 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.292 3.328 . . . . 0.0 109.566 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.844 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.1 110.34 22.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.91 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.13 135.77 50.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -97.95 113.02 24.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.789 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -109.58 154.57 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.918 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.11 174.4 2.44 Favored Pre-proline 0 N--CA 1.45 -0.463 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.941 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.129 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.8 Cg_endo -72.39 119.44 6.13 Favored 'Trans proline' 0 N--CA 1.447 -1.233 0 C-N-CA 124.334 3.356 . . . . 0.0 109.569 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.946 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.1 p -111.4 48.34 0.95 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -129.39 106.01 8.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.17 31.37 9.81 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.129 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -104.44 131.48 51.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -108.79 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -48.66 142.08 6.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.435 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 101.34 -22.58 38.48 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.56 HG21 ' HB3' ' A' ' 13' ' ' LEU . 15.6 m -77.69 151.21 34.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.7 p -119.67 132.37 69.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.727 HG13 HG22 ' A' ' 8' ' ' THR . 20.9 t -95.66 155.38 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.789 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.02 144.49 42.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.7 110.9 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.98 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.91 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.54 116.5 25.51 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.795 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.08 146.6 24.1 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.844 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.85 110.8 4.34 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 101.57 14.63 29.38 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.088 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.87 179.32 6.01 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.754 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 68.4 mt-30 -60.87 121.38 12.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.512 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 132.24 42.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.31 8.12 79.16 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.96 143.33 26.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.695 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.69 151.19 23.62 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.046 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 42.2 m-85 -137.97 140.35 40.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.294 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.7 m-20 -104.47 115.12 29.81 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.288 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -101.02 139.84 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.937 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -160.67 169.78 36.46 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.097 HE22 ' HB2' ' A' ' 70' ' ' ARG . 14.7 tt0 -120.31 114.06 21.3 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.5 m -106.13 171.16 7.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -156.82 133.08 9.82 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.506 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.83 129.58 40.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.945 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.438 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 3.7 m -110.81 -37.47 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.698 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -147.95 165.69 29.93 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.942 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -53.13 113.82 1.25 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.1 4.66 60.1 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.026 ' CG2' ' CH2' ' A' ' 83' ' ' TRP . 98.8 t -121.58 120.53 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.729 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.65 163.57 21.73 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.535 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -127.03 143.74 51.21 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.7 m -110.35 150.47 28.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.692 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.5 t30 -110.26 106.56 58.12 Favored Pre-proline 0 N--CA 1.449 -0.495 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.9 Cg_endo -72.32 0.39 7.46 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.319 3.346 . . . . 0.0 109.591 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -87.98 -12.5 44.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 11.2 p30 -127.58 27.56 5.78 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.403 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.92 104.8 11.68 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.1 t -99.29 170.54 8.58 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.49 152.6 40.03 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 56' ' ' THR . 6.4 p -165.94 159.7 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.2 m -128.23 137.11 51.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.68 146.98 39.79 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.6 p30 -83.93 -175.02 5.61 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -24.6 67.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.36 -7.57 55.28 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.088 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.14 32.04 58.88 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.1 p -127.94 135.78 50.43 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.76 167.9 12.45 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.1 121.91 9.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.581 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -162.33 148.04 12.84 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.931 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.5 137.37 48.29 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.003 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -106.04 119.1 38.34 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.909 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.659 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -60.84 127.2 30.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.694 HG23 HG21 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -87.58 124.33 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 1.097 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.7 OUTLIER -115.74 143.68 45.04 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.518 ' HG3' HG23 ' A' ' 89' ' ' THR . 43.1 ttp180 -86.73 -16.45 36.4 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.5 t -171.47 145.11 2.03 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.908 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 2.0 p90 -169.62 163.93 10.18 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.37 124.78 20.68 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.535 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -81.04 91.54 1.43 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.22 100.67 10.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -57.3 136.69 56.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.665 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.54 -39.98 17.71 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.681 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -56.74 -17.14 7.97 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.955 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.94 28.1 9.69 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 15.7 m -112.38 147.36 36.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.69 93.82 6.85 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.438 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 11.5 t-105 -65.42 -48.29 73.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.57 165.08 10.16 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.79 133.66 54.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.183 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -111.67 143.8 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -109.84 104.07 12.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.481 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 26.3 m -51.81 -26.85 10.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.518 HG23 ' HG3' ' A' ' 71' ' ' ARG . 75.9 p -80.51 -2.26 45.27 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.71 -27.45 6.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.05 179.94 5.59 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.97 125.68 43.01 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.016 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 87.1 m -104.34 152.56 22.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.041 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.7 pt20 -150.57 152.72 34.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.003 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 10.3 t -117.51 159.78 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.46 166.51 37.52 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.288 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.74 131.19 51.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.294 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 3.2 m -111.73 153.09 27.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.695 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.5 -163.33 0.85 Allowed 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.43 -48.18 65.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.26 -24.45 66.58 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.6 53.77 1.77 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.754 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.26 170.92 14.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.046 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.4 46.72 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.654 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.42 162.8 40.47 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.328 3.352 . . . . 0.0 109.573 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.32 ' CG ' ' CB ' ' A' ' 2' ' ' ALA . 7.4 mt-10 -37.68 120.19 0.8 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.02 158.27 0.01 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.897 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.6 t -121.58 104.13 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.89 120.28 28.01 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.041 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.2 mt -98.61 159.09 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.0 OUTLIER -145.27 116.97 8.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.902 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -93.81 127.56 39.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.378 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.604 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.8 Cg_endo -72.47 -178.45 3.36 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.285 3.323 . . . . 0.0 109.592 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.859 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.92 111.04 23.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.769 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.09 157.84 36.98 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.6 p -121.86 119.59 32.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.81 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 22.5 t -114.82 146.34 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.732 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.1 165.78 35.12 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.716 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.0 Cg_endo -72.41 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.347 3.365 . . . . 0.0 109.546 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.88 12.35 7.26 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.996 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.71 ' HA ' ' O ' ' A' ' 111' ' ' SER . 42.2 m -87.78 110.58 20.58 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.085 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.33 14.31 42.07 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.985 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -105.56 132.79 51.28 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m -91.83 -179.97 5.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -44.54 152.68 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.84 -23.29 33.56 Favored Glycine 0 C--N 1.335 0.528 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.628 HG21 HD12 ' A' ' 13' ' ' LEU . 26.1 m -69.38 148.76 49.2 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.4 p -125.47 115.86 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.732 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.4 p -91.86 153.77 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.81 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.27 147.93 31.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.747 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.37 106.4 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.717 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.56 116.96 23.29 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.061 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.72 150.32 25.28 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.859 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -147.73 109.62 4.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.43 15.94 33.48 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.065 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.19 172.89 8.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.517 ' HB2' HG21 ' A' ' 30' ' ' THR . 0.1 OUTLIER -53.27 120.65 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.493 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.7 131.16 42.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.68 82.69 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.517 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.19 143.48 26.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.59 147.18 25.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.656 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 34.0 m-85 -134.48 134.05 41.07 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.077 ' HB2' ' O ' ' A' ' 98' ' ' SER . 1.7 m-20 -98.66 114.12 26.47 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.26 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.71 145.19 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.955 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.2 166.47 39.25 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.76 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.19 108.83 18.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.41 146.93 38.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.419 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -123.58 143.51 50.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.564 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.35 124.39 21.62 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.2 t -104.04 -49.26 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.27 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -135.43 169.65 17.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.956 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.412 ' H ' HG22 ' A' ' 42' ' ' THR . 0.6 OUTLIER -51.45 112.23 0.71 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.35 8.62 66.48 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.991 HG11 ' HE1' ' A' ' 83' ' ' TRP . 2.4 t -121.98 123.19 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -132.08 133.79 44.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.81 147.77 22.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.3 m -105.62 152.12 23.51 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.768 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -111.07 110.15 56.75 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 81.9 Cg_endo -72.43 -0.07 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 124.311 3.341 . . . . 0.0 109.616 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.29 -9.45 52.83 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.405 ' CB ' HG23 ' A' ' 68' ' ' THR . 82.4 m-20 -133.83 26.8 3.97 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.435 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.07 107.24 12.7 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.1 m -101.48 176.21 5.31 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.0 p -144.93 153.97 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.591 HG22 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.69 155.18 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.1 m -128.0 141.72 51.44 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.99 141.28 33.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 p30 -82.66 -173.18 4.48 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.71 -26.45 68.05 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -76.09 -9.17 58.41 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.065 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.23 32.28 52.57 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 80.9 p -127.79 135.83 50.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.591 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -122.95 164.38 18.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -145.64 136.19 24.19 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.739 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.88 174.62 10.39 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.739 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -138.95 122.96 17.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.891 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.089 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.04 156.43 16.33 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -103.78 133.37 48.89 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.954 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.473 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -93.47 127.18 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.628 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.4 OUTLIER -117.66 141.99 47.75 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -32.58 73.24 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 78.2 p -157.9 158.97 36.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.768 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 2.1 p90 -177.14 161.8 1.91 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.17 112.35 2.62 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.72 96.75 0.68 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.834 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.1 m-85 -83.23 99.41 9.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -57.18 131.68 50.7 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.674 ' N ' HD12 ' A' ' 77' ' ' LEU . 38.0 p90 -47.52 -36.11 9.88 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 3.3 t0 -57.67 -16.25 10.17 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.78 9.5 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.9 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -115.55 147.97 40.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -87.64 96.43 10.42 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.27 ' HZ2' ' CG ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.63 -55.16 25.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.63 170.89 16.15 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -66.12 103.83 1.04 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 73' ' ' PHE . 35.5 m -80.18 154.15 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -112.7 92.62 4.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.944 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.7 m -53.07 -24.63 10.41 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -82.32 2.07 33.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.38 -27.28 6.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.71 178.98 6.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.612 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.2 126.23 43.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.376 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 7.2 m -104.82 173.68 6.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 1.1 pt20 -153.61 147.12 24.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.089 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.7 t -104.97 165.32 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.26 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.29 166.38 36.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.003 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.83 132.9 46.63 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.077 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 3.7 t -113.48 150.89 32.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.455 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -110.48 -163.63 0.87 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.74 -48.43 71.92 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.65 -24.37 65.44 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.9 53.75 1.74 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.46 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -133.41 169.53 16.81 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.992 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.517 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.03 171.42 43.43 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.604 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.34 170.71 18.57 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.322 3.348 . . . . 0.0 109.597 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.378 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.67 121.6 0.9 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.98 163.87 0.01 OUTLIER Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.06 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 23.2 t -120.53 103.18 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.2 120.39 26.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.376 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -129.1 -178.76 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.71 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -168.33 171.14 9.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.0 m-85 -122.4 115.11 21.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.085 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 2.8 p-10 . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.252 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.584 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.4 -178.3 3.24 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 124.339 3.36 . . . . 0.0 109.633 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.305 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 5.1 t -99.69 116.12 31.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.78 153.76 48.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -110.66 112.16 23.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.901 HG22 ' CG1' ' A' ' 21' ' ' VAL . 95.2 t -107.47 145.93 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -66.79 176.42 1.11 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.9 Cg_endo -72.41 117.46 5.14 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.293 3.329 . . . . 0.0 109.612 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.594 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 32.4 p -112.58 47.07 1.12 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 51.4 p -126.36 106.73 9.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.72 14.72 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.73 131.77 47.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.983 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -111.41 174.57 5.8 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -48.05 140.3 7.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.08 -22.79 35.54 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.469 HG21 HD13 ' A' ' 13' ' ' LEU . 96.6 m -79.81 151.42 30.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.8 p -128.26 123.43 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.4 m -88.28 171.45 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.821 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.49 146.86 47.0 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.901 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -144.44 106.25 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.677 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.67 116.66 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.87 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.92 148.32 25.67 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.305 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -148.15 118.61 7.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.86 16.1 46.4 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.019 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -88.68 -174.15 4.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.516 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -70.3 120.7 16.36 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.931 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.02 136.02 53.21 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.02 7.82 60.21 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.721 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -82.95 146.71 28.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.868 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -96.07 134.96 38.48 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.813 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 38.6 m-85 -126.42 149.17 49.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.026 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -116.79 113.95 23.27 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.223 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -97.05 143.92 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.703 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.21 161.66 34.8 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.832 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 37.6 tt0 -110.85 118.44 36.13 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.1 m -115.95 148.37 40.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.109 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.27 140.39 52.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.517 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.26 127.42 31.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.94 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.813 HG12 ' CG1' ' A' ' 44' ' ' VAL . 1.1 t -108.7 -39.34 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.436 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 1.5 t0 -151.84 -178.53 6.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.1 m -70.41 111.47 6.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.51 10.01 86.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.333 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -136.99 124.52 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.572 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -133.1 137.23 46.27 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.357 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.53 155.77 21.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 67.7 m -120.77 156.91 30.85 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.676 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t30 -121.5 109.21 34.82 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.43 0.64 7.17 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.313 3.342 . . . . 0.0 109.592 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.489 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.63 -16.37 32.61 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 14.6 p30 -127.26 28.15 5.77 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.92 118.3 35.37 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.5 t -113.41 -177.77 3.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 94.9 p -146.49 157.36 43.74 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.485 HG22 ' N ' ' A' ' 56' ' ' THR . 4.9 p -167.68 159.4 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.485 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.8 m -128.06 137.45 52.17 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.9 136.02 41.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 17.1 p30 -73.62 -175.28 1.97 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -24.74 68.02 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -75.17 -7.25 53.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.019 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.15 32.09 58.78 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.3 p -129.89 135.83 48.82 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.92 164.06 18.22 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -147.73 127.96 13.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.86 170.0 23.08 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.936 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -126.86 136.76 52.78 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.965 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -111.71 120.37 41.81 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.968 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.622 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -70.88 117.67 12.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.516 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -75.14 128.43 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.622 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -116.77 147.14 42.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.978 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.451 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.3 OUTLIER -90.21 -15.68 30.92 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 52.2 p -178.81 154.89 0.75 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.832 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -177.94 179.75 0.83 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -66.89 123.11 19.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.357 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.7 91.93 1.31 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.886 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.75 100.62 11.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -55.38 140.27 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.688 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.58 -41.49 21.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.57 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -57.19 -17.44 11.26 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.54 28.36 9.71 Favored Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.1 m -110.89 145.23 38.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.0 93.21 3.79 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.436 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 54.7 t-105 -64.18 -58.12 7.53 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.87 155.86 7.3 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -54.95 109.99 0.6 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.109 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.9 t -86.43 151.65 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.77 96.16 6.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.069 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.5 OUTLIER -54.07 -23.91 15.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.5 p -84.6 0.5 49.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -113.72 -27.38 7.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.82 177.94 7.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.54 128.33 44.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.223 ' O ' HG13 ' A' ' 110' ' ' ILE . 58.0 m -104.84 157.17 17.39 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.03 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -141.21 145.8 36.1 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.889 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 20.4 t -108.94 157.47 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.223 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.74 172.41 45.36 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.975 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.57 130.96 46.36 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.026 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 40.2 m -111.04 145.02 39.24 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.868 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -106.86 -163.58 0.92 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.73 -49.13 69.56 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.18 -24.11 65.83 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.26 53.34 1.88 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.8 174.81 9.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.813 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -177.82 179.34 48.37 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.584 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.37 165.78 31.66 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.347 3.364 . . . . 0.0 109.577 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.252 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.8 pt-20 -37.0 133.88 0.58 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.77 149.63 5.36 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.965 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -121.85 110.54 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.17 139.46 30.57 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.223 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.6 OUTLIER -109.93 160.09 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -143.22 112.53 6.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.069 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 23.1 m-85 -93.68 124.4 37.65 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.943 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.035 ' HB1' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.5 Cg_endo -72.42 -178.19 3.18 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.293 3.328 . . . . 0.0 109.635 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.367 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 5.2 t -102.31 115.74 31.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.4 146.96 52.05 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.615 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.65 115.72 31.02 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.832 HG13 ' O ' ' A' ' 20' ' ' LYS . 35.9 t -111.92 148.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.41 176.2 1.31 Allowed Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.083 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.34 117.28 5.06 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.325 3.35 . . . . 0.0 109.626 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.051 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.3 p -110.17 49.23 0.86 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 111' ' ' SER . 94.3 p -127.37 106.09 8.97 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.044 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.47 27.26 18.2 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.083 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -103.34 131.38 50.46 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.982 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -118.97 -179.35 3.79 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -46.19 138.89 5.0 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.58 -23.17 33.61 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.514 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.1 m -87.51 150.95 23.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 18' ' ' VAL . 13.0 p -131.63 121.54 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' O ' ' A' ' 67' ' ' LEU . 23.7 m -80.74 167.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.832 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.37 145.54 43.14 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.567 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.87 112.82 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.08 114.8 20.18 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.882 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -81.93 147.9 26.72 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.315 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.8 115.49 5.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.22 15.39 51.49 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.35 -179.79 5.92 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.827 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 70.3 mt-30 -59.01 120.8 9.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.92 132.05 42.07 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.87 7.64 75.94 Favored Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.51 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -92.86 139.46 30.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.595 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.06 150.45 24.86 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.878 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 26.7 m-85 -135.58 143.81 45.84 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.258 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -105.83 114.59 28.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -100.18 139.6 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.909 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.7 164.59 37.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.87 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 20.9 tt0 -109.75 105.33 14.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 61.5 m -106.32 142.79 35.42 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.548 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.72 130.09 52.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.624 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.69 121.33 14.73 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.554 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 6.0 m -101.78 -43.05 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.479 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -138.17 169.95 16.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.0 m -55.03 112.56 1.08 Allowed 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.72 9.05 64.84 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.604 HG12 HG23 ' A' ' 40' ' ' VAL . 77.0 t -123.49 105.42 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.673 HD21 ' HD2' ' A' ' 78' ' ' PHE . 0.8 OUTLIER -121.3 138.35 54.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.463 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.42 158.13 16.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 52.2 m -118.59 148.13 43.0 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.92 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.3 t30 -110.61 106.19 57.64 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -72.42 -1.27 9.96 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.356 3.37 . . . . 0.0 109.567 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.527 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.17 -11.09 42.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.755 ' HB3' HG23 ' A' ' 68' ' ' THR . 6.1 m-20 -133.35 27.41 4.11 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.663 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.6 118.87 36.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -112.07 -176.1 2.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -144.84 153.02 41.17 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.421 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.64 156.27 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.421 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.3 m -126.45 141.0 52.04 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.26 138.33 37.74 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.0 p30 -73.57 -174.34 1.69 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.45 -25.04 68.09 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -75.23 -8.06 55.57 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.34 58.5 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 71.5 p -127.08 133.23 50.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.79 166.47 14.29 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.89 131.76 15.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.612 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.0 166.19 17.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.612 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -122.33 132.63 54.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.13 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.24 118.23 36.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.755 HG23 ' HB3' ' A' ' 51' ' ' ASP . 2.0 t -68.94 143.19 54.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.522 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -107.0 131.4 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.968 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.567 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -118.98 152.04 37.1 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.531 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -87.15 -10.63 52.25 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -174.04 149.43 1.47 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.92 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 5.7 p90 -176.72 158.91 1.75 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -58.75 112.53 1.66 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.463 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.66 94.54 0.67 Allowed Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.826 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -82.71 98.81 9.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.979 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.93 132.68 47.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.673 ' HD2' HD21 ' A' ' 45' ' ' LEU . 19.0 p90 -46.81 -37.43 8.66 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.602 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.3 t0 -56.69 -17.13 7.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.45 28.04 8.76 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.97 143.12 45.66 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.38 96.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.554 ' CD1' ' CG1' ' A' ' 40' ' ' VAL . 3.3 t-105 -63.35 -58.95 5.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.29 171.31 21.1 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -64.78 104.39 0.83 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -79.75 149.99 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -110.56 97.44 6.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.85 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 9.0 m -52.82 -25.4 11.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 53.0 p -82.57 -0.17 45.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -119.04 -28.41 5.51 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.1 179.72 5.28 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 125.23 44.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.1 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 61.3 m -104.17 152.95 21.52 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -144.47 147.36 33.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.13 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -110.64 159.9 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.85 167.74 39.29 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.177 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.04 125.25 43.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.258 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 15.8 m -112.8 143.98 43.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.595 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -101.85 -160.23 0.78 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.983 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.71 -47.94 61.32 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.73 -20.08 65.89 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.5 53.51 2.59 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.296 -1.121 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.827 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.64 167.75 19.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.878 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.97 176.53 46.44 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.34 170.2 19.8 Favored 'Trans proline' 0 N--CA 1.448 -1.2 0 C-N-CA 124.294 3.33 . . . . 0.0 109.618 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.367 ' OE2' ' CA ' ' A' ' 4' ' ' THR . 3.3 pm0 -40.96 120.02 1.25 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.46 162.81 0.01 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.849 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 34.8 t -128.57 104.44 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.74 30.18 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.1 ' HB ' ' O ' ' A' ' 93' ' ' CYS . 5.2 mt -99.5 153.58 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.664 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -138.31 123.05 18.73 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.85 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 6.1 m-85 -92.69 127.44 38.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.919 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.606 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.34 -177.78 2.91 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.312 3.341 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.9 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.46 109.59 22.32 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.767 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 146.63 50.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.2 p -110.22 121.01 44.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.872 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 41.2 t -113.88 143.64 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.682 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.74 166.11 30.18 Favored Pre-proline 0 N--CA 1.449 -0.475 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.693 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.41 117.16 5.0 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.29 3.327 . . . . 0.0 109.629 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.732 ' HB2' HG22 ' A' ' 19' ' ' VAL . 0.6 OUTLIER -129.29 11.78 5.94 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.693 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.6 m -92.34 108.72 20.17 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.087 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 97.17 24.08 13.45 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.087 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.24 133.78 51.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 t -67.36 154.39 41.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 1.3 p-10 -46.07 147.58 1.01 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.02 -18.69 51.55 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.832 HG21 HD12 ' A' ' 13' ' ' LEU . 30.6 m -61.91 145.36 53.09 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 p -110.26 134.69 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.732 HG22 ' HB2' ' A' ' 10' ' ' SER . 10.5 t -107.03 152.72 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.872 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.03 109.84 15.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -103.18 121.12 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.767 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -128.41 117.01 20.64 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.02 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.55 147.41 23.1 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.9 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.46 111.11 5.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.56 16.53 31.37 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.1 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.27 173.43 8.4 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.53 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 78.1 mt-30 -53.66 121.38 7.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.406 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.31 129.55 38.66 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.98 8.67 85.07 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.547 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.1 141.7 28.24 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 1.196 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.88 150.78 23.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.234 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 52.6 m-85 -136.19 143.35 44.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.227 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.73 114.7 29.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.935 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.513 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.03 141.87 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.029 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.52 161.99 35.79 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.1 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 10.8 tt0 -94.69 117.96 30.97 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.673 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.5 m -107.25 158.12 17.37 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.975 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -147.22 134.6 20.73 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.535 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -68.36 125.32 26.06 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.482 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.4 m -114.64 -36.05 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.535 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -150.17 -179.96 7.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -64.12 110.37 2.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 69.76 8.84 61.32 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.535 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 61.0 t -110.19 105.2 18.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.682 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.5 mt -105.82 156.61 18.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.485 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -135.11 129.35 33.78 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.915 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.52 156.01 19.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.702 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.6 p-10 -116.23 121.76 33.14 Favored Pre-proline 0 N--CA 1.449 -0.523 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.8 Cg_endo -72.37 1.98 5.56 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.26 3.307 . . . . 0.0 109.608 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.702 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -85.63 -20.87 28.82 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.505 ' CB ' HG23 ' A' ' 68' ' ' THR . 85.2 m-20 -128.47 28.78 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.59 117.1 29.6 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.3 t -109.99 -176.86 3.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.37 153.8 41.61 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.434 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -166.47 153.71 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.8 m -126.59 132.89 51.19 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.61 149.79 48.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -88.98 -168.38 2.17 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.29 -27.94 68.98 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -75.16 -9.32 58.44 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.737 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.2 31.51 51.9 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.0 p -127.97 141.24 51.58 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.434 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -131.15 164.68 24.98 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -143.35 139.62 30.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.694 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -167.56 172.1 9.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.694 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -124.88 129.03 49.58 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.942 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.267 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -112.56 119.57 38.62 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.505 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -79.59 141.45 36.56 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.509 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -112.02 132.81 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.509 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.3 OUTLIER -119.11 155.68 31.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 ptt180 -74.67 -34.58 62.72 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -151.15 149.34 29.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.1 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.5 p90 -177.13 163.66 2.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.479 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.4 OUTLIER -61.25 125.1 22.55 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.485 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.93 95.56 2.11 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.915 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -84.46 103.71 13.84 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.951 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.5 tp -53.91 135.01 42.94 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 8.3 m-85 -45.71 -38.68 7.16 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.661 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.6 t0 -57.26 -17.02 9.89 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.92 28.91 8.97 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.951 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -114.41 112.43 23.02 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 96.44 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.482 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 50.6 t-105 -62.41 -53.63 52.03 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 143.45 -179.66 20.74 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.17 140.79 43.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.975 HG11 ' CB ' ' A' ' 38' ' ' ALA . 4.8 t -127.7 152.6 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.26 90.4 3.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.209 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 30.6 m -54.15 -25.57 23.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.8 p -76.9 -0.64 24.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.48 -27.21 7.62 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.68 -164.2 1.28 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.4 125.49 43.58 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.228 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.1 OUTLIER -103.89 152.5 21.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.035 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -159.42 147.56 17.56 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.267 ' CG2' HD12 ' A' ' 67' ' ' LEU . 6.8 t -105.62 165.32 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.29 164.68 34.67 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.513 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.6 133.16 47.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.227 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 67.7 m -112.1 150.31 30.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 1.196 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -109.92 -161.31 0.75 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.08 -48.68 70.15 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.09 -24.13 64.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.74 52.47 1.8 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.618 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.57 171.87 12.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.234 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.37 175.24 44.34 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.606 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.34 169.55 21.37 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.377 3.385 . . . . 0.0 109.59 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.019 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -38.49 126.09 1.4 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.959 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.84 160.31 0.01 OUTLIER Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.021 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 89.1 t -123.08 102.69 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.97 134.54 33.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.228 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -140.53 -173.73 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.693 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.7 t -176.48 178.51 1.3 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.209 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.8 m-85 -130.75 113.15 13.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.883 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 42.5 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.562 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.4 Cg_endo -72.35 -175.28 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.355 3.37 . . . . 0.0 109.626 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.963 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.32 109.37 21.89 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.982 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.2 146.02 50.85 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -110.18 114.35 27.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.828 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.03 152.39 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.71 HG22 HG13 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -75.5 163.96 64.03 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.75 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.0 Cg_endo -72.36 118.16 5.47 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.337 3.358 . . . . 0.0 109.621 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.598 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.9 OUTLIER -128.59 14.29 6.5 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 1.076 ' HA ' ' O ' ' A' ' 111' ' ' SER . 68.9 p -95.73 109.2 21.53 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.146 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 95.59 26.07 12.53 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.12 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.48 140.94 41.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 t -71.45 156.31 39.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.54 ' HB3' ' HD2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.73 151.96 0.79 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.63 -16.1 59.96 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.805 HG21 HD12 ' A' ' 13' ' ' LEU . 15.2 m -62.34 138.56 58.46 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 p -99.69 146.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.71 HG13 HG22 ' A' ' 8' ' ' THR . 1.5 t -125.32 156.64 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.79 150.21 40.19 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.449 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.77 105.67 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.982 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.17 117.07 30.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.926 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -83.63 143.47 21.63 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.963 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.49 106.76 5.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.909 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 22.96 8.56 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.535 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.66 -167.03 1.75 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.406 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 74.3 mt-30 -85.57 125.56 33.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.483 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.29 134.4 44.19 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.37 8.16 83.39 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.589 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -96.3 139.44 32.43 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.508 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -90.65 150.96 21.47 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.965 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 54.0 m-85 -136.95 147.33 46.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.138 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.7 m-20 -110.97 112.85 24.98 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.27 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -102.26 151.03 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.953 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -178.1 176.67 48.14 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.208 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 5.0 tt0 -117.25 121.6 41.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.6 m -120.42 144.81 47.74 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.741 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 142.31 51.02 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.608 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.02 124.29 21.7 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.937 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.515 ' CB ' ' CD1' ' A' ' 83' ' ' TRP . 3.3 m -106.68 -38.37 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.107 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.49 -178.35 5.07 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.5 m -70.98 112.08 6.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.12 10.21 81.07 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.304 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 1.8 m -130.94 124.92 57.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.615 HD23 ' H ' ' A' ' 45' ' ' LEU . 1.6 pt? -127.76 147.04 50.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.41 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -102.22 150.65 23.08 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.7 m -106.27 160.33 15.44 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.742 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 26.8 t30 -119.24 109.96 38.29 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.35 0.01 8.03 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.33 3.353 . . . . 0.0 109.627 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.467 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -89.44 -13.08 38.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.688 ' HB3' HG23 ' A' ' 68' ' ' THR . 19.0 m-20 -134.73 27.71 3.62 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.628 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.43 115.17 27.0 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.4 t -106.53 178.34 4.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 p -147.18 156.32 42.87 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.5 HG22 ' N ' ' A' ' 56' ' ' THR . 2.3 p -167.35 161.93 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.5 ' N ' HG22 ' A' ' 55' ' ' VAL . 24.4 m -128.28 131.87 48.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 152.4 44.28 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -91.44 -170.8 2.73 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.43 -26.14 68.34 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -76.38 -6.06 49.95 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 75.27 9.42 84.25 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 85.9 p -101.64 140.16 36.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.43 164.11 17.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -150.38 121.86 7.94 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.698 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.38 172.19 15.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.698 ' N ' HG23 ' A' ' 65' ' ' THR . 1.1 m -128.24 120.23 26.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.307 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.2 OUTLIER -105.64 133.43 50.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.688 HG23 ' HB3' ' A' ' 51' ' ' ASP . 5.5 t -97.62 149.13 22.58 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.636 HG23 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -114.67 131.48 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.557 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.58 159.04 20.89 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.54 ' HD2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -80.3 -23.32 40.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.949 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.489 ' N ' ' HG2' ' A' ' 71' ' ' ARG . 53.9 p -160.72 156.72 25.81 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.208 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 2.5 p90 -178.12 158.82 1.24 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -60.58 109.43 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.41 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -64.27 98.77 0.28 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.804 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 98.78 10.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.995 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.2 tp -54.66 132.46 45.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.621 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.9 m-85 -47.0 -37.24 8.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.592 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.8 t0 -57.57 -16.65 10.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.84 28.99 8.94 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.995 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -117.3 152.2 35.38 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.94 99.54 8.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.515 ' CD1' ' CB ' ' A' ' 40' ' ' VAL . 15.0 t-105 -68.74 -50.49 50.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.5 163.72 9.62 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.99 104.7 0.21 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.741 HG11 ' HB3' ' A' ' 38' ' ' ALA . 14.4 p -85.83 149.71 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.77 97.24 7.9 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.854 ' SG ' ' HZ ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.8 -20.63 9.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.7 p -92.76 2.4 56.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.7 m -106.1 -24.35 12.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.52 179.01 6.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -90.97 125.5 35.8 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.246 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.3 m -104.48 162.98 12.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.036 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.3 OUTLIER -153.56 147.92 25.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.307 ' CG2' HD12 ' A' ' 67' ' ' LEU . 15.8 t -101.71 161.21 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.264 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.96 166.0 35.33 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.27 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.41 128.92 43.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 180.0 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.138 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 26.8 m -108.74 151.65 25.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.508 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -113.19 -162.41 0.8 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.58 -48.49 77.19 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.17 -24.37 62.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.22 53.77 1.69 Allowed Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.88 172.26 11.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.965 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.58 -179.21 46.89 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.463 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 81.7 Cg_endo -72.42 160.29 47.19 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.357 3.372 . . . . 0.0 109.549 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.127 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 2.8 tt0 -35.45 123.7 0.64 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -34.67 151.14 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.004 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 90.1 t -117.28 102.31 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 137.15 34.8 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.246 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 2.8 pt -143.0 179.71 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . 1.076 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -177.99 178.54 0.93 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.963 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 1.2 m-85 -126.21 116.1 20.78 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.146 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 1.8 p-10 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.449 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.475 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.594 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.37 -178.24 3.2 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.356 3.371 . . . . 0.0 109.609 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.257 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 6.8 t -100.17 116.95 33.38 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.78 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.37 135.36 47.15 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.95 113.11 24.69 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.624 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.96 155.03 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.969 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.939 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.09 175.42 1.79 Allowed Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.056 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.39 118.94 5.84 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 124.299 3.333 . . . . 0.0 109.602 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.007 ' HB2' HG23 ' A' ' 110' ' ' ILE . 20.6 p -110.74 48.48 0.91 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 55.5 p -127.06 105.99 8.97 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.137 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.12 31.93 9.36 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.289 -1.125 . . . . 0.0 110.289 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.137 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -110.18 129.19 55.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.89 175.84 5.27 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -44.92 139.74 2.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.93 -22.47 35.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.673 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.3 m -81.19 150.64 28.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.7 p -121.03 120.45 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 1.7 p -87.62 154.87 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.624 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.7 147.14 31.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.712 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.23 110.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.99 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.78 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.24 115.83 23.06 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.822 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.21 148.86 25.76 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.257 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.35 114.83 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.36 13.62 44.42 Favored Glycine 0 C--N 1.335 0.485 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.46 172.6 8.6 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.526 HE22 ' CG ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.95 119.84 5.12 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.51 132.84 43.33 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.77 7.84 75.88 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.524 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.56 141.56 28.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.42 150.16 25.5 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.486 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 30.1 m-85 -135.73 141.79 44.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.266 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.77 118.07 35.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -104.83 145.32 13.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.853 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.99 169.2 41.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.769 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 40.6 tt0 -112.01 108.96 18.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.2 m -111.74 144.63 40.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.799 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.83 130.41 52.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.583 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.18 122.83 17.98 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.443 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 9.7 m -102.94 -42.87 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.7 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -139.0 179.64 6.38 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.4 m -63.63 112.35 2.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.44 8.38 66.37 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 59.3 t -123.83 106.44 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -121.42 137.84 54.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.404 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -89.4 153.34 20.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m -115.04 151.86 33.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.671 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.4 t30 -117.72 109.54 41.44 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.33 -1.07 9.61 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.315 3.343 . . . . 0.0 109.602 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.589 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -84.68 -11.1 56.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.589 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.5 OUTLIER -131.79 26.25 4.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.71 104.38 13.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.7 t -101.33 176.32 5.28 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.51 150.04 35.73 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -166.96 153.63 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 67.9 m -123.49 132.7 54.0 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 141.63 53.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -77.53 -174.65 3.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.91 -24.83 68.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -76.29 -6.9 53.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.17 58.72 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.2 p -127.09 137.78 53.07 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.26 165.21 16.56 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 p -147.91 120.22 8.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.416 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -157.42 148.08 21.2 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -111.32 129.81 55.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.581 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -98.47 157.27 16.32 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.589 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.7 t -101.01 119.29 38.53 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.533 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -80.31 127.18 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.639 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.6 OUTLIER -118.7 152.47 36.07 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.486 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -91.59 -12.68 33.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.941 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 5.1 t -169.2 151.35 4.63 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.769 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.1 p90 -177.16 155.43 1.15 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.25 115.92 2.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.404 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.83 91.63 0.6 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.801 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -82.79 99.23 9.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.1 tp -55.54 134.55 50.9 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.76 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.4 m-85 -46.36 -38.68 9.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.602 ' HB2' HD21 ' A' ' 77' ' ' LEU . 2.5 t0 -56.99 -17.48 9.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.77 28.37 8.9 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -113.62 142.86 45.48 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.7 mtm180 -80.88 94.97 6.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.443 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 71.4 t-105 -64.28 -58.61 6.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.67 167.54 16.66 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.81 108.6 1.22 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.799 HG11 ' CB ' ' A' ' 38' ' ' ALA . 38.7 t -81.76 143.96 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.17 93.6 4.62 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.486 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 58.4 m -52.04 -26.07 10.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 77.9 p -79.85 -2.43 43.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.48 -27.76 6.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.07 -176.63 3.93 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.92 125.74 45.95 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.915 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 69.8 m -103.5 152.98 21.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.087 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -143.17 148.53 36.68 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.581 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.9 t -112.01 161.4 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.07 171.46 43.92 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.034 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.57 135.56 48.03 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.266 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 72.6 p -115.71 154.95 28.63 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.426 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -115.12 -167.07 1.18 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.974 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.03 -48.75 75.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.87 66.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.59 1.93 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.526 ' CG ' HE22 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.62 169.16 17.04 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.486 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.82 176.82 46.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.594 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 81.8 Cg_endo -72.41 161.84 43.16 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.332 3.355 . . . . 0.0 109.555 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.449 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.9 pt-20 -38.37 122.82 1.12 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -37.49 157.52 0.01 OUTLIER Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.828 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.8 t -124.66 104.59 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.01 138.29 32.55 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.087 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.8 mt -116.68 156.09 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -138.22 112.67 8.78 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.592 ' CE1' ' HB2' ' A' ' 93' ' ' CYS . 5.7 m-85 -87.3 101.11 13.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.588 ' CG ' ' C ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.562 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.657 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.3 Cg_endo -72.42 -175.39 1.77 Allowed 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.302 3.335 . . . . 0.0 109.615 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.224 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.82 22.51 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.44 148.95 49.56 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.4 p -113.23 117.75 32.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.94 HG13 ' O ' ' A' ' 20' ' ' LYS . 48.3 t -113.58 145.92 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.822 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.56 166.67 28.6 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.727 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.39 117.55 5.18 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.332 3.355 . . . . 0.0 109.58 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.619 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -127.55 13.08 6.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.862 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.6 p -92.56 106.51 18.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.115 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.57 22.66 11.0 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.115 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.81 140.49 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.68 173.19 8.74 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 19.4 p-10 -44.78 152.39 0.23 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.35 -22.09 40.67 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.754 HG21 HD12 ' A' ' 13' ' ' LEU . 22.9 m -63.46 150.46 43.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.28 114.1 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.822 ' HA ' HG22 ' A' ' 8' ' ' THR . 1.4 m -97.56 119.08 45.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.94 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.57 146.07 36.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.786 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -131.51 102.88 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.752 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -113.17 116.23 29.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.838 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -87.76 144.08 18.69 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.895 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.93 107.92 6.71 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.883 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 99.31 25.88 9.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.57 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.15 -175.77 5.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.755 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 72.0 mt-30 -74.32 122.28 22.65 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.439 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.96 130.87 42.04 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.48 9.23 81.71 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.533 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -97.43 139.95 32.6 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 1.143 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.69 151.99 22.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.289 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 33.3 m-85 -137.44 149.69 47.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.175 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.5 m-20 -111.84 113.82 26.39 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.36 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -101.01 142.48 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.961 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.69 164.36 37.98 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.958 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 11.8 tt0 -106.65 111.54 24.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 81.2 m -111.16 151.31 28.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.658 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -129.72 126.16 37.6 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.19 119.06 10.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.378 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 7.0 m -100.97 -42.71 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.501 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -139.47 165.53 26.98 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.2 OUTLIER -51.36 112.78 0.8 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.27 8.24 65.26 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.643 HG12 HG23 ' A' ' 40' ' ' VAL . 71.7 t -123.28 105.04 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.609 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -122.85 137.41 54.94 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.496 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.28 157.32 18.26 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 41.7 m -121.22 151.83 39.53 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.787 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -114.67 105.74 53.06 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -72.42 -0.91 9.42 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.296 3.331 . . . . 0.0 109.584 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.99 -11.77 40.63 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 65.0 m-20 -132.69 26.42 4.36 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.668 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.86 120.83 37.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.3 t -113.4 -174.68 2.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.35 157.2 43.76 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.83 156.95 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.5 m -127.63 127.24 43.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -59.95 146.31 42.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -87.35 -171.98 3.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.16 -28.38 69.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -76.49 -11.0 59.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 83.03 1.22 90.63 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.2 p -94.19 136.73 34.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.59 163.62 18.62 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.91 130.04 13.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.752 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -156.24 174.64 15.1 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.752 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -124.76 126.68 46.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.954 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.935 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.16 119.45 38.99 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -80.7 137.52 36.3 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.584 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.74 128.31 63.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.525 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -117.41 141.7 48.02 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -42.79 87.01 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.631 ' OG ' HG22 ' A' ' 85' ' ' THR . 11.5 t -147.01 156.74 43.28 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.958 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.0 p90 -177.02 157.93 1.48 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.03 111.54 0.86 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.496 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.5 99.05 1.3 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.746 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -84.46 99.51 10.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.923 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.7 tp -54.4 131.34 42.04 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.662 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.3 p90 -47.55 -36.29 10.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.578 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.0 t0 -57.3 -17.24 11.18 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.91 28.5 8.23 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.923 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.61 145.07 43.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -85.16 95.53 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.378 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 0.8 OUTLIER -64.87 -56.92 10.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.914 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.52 168.78 12.8 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.631 HG22 ' OG ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -58.28 104.7 0.22 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 38' ' ' ALA . 33.7 m -83.09 154.12 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -117.81 93.32 4.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.513 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 75.9 m -50.3 -29.32 9.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.752 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 5.5 t -73.5 -1.67 19.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.47 -27.48 7.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.36 -164.21 1.33 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.62 123.35 47.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.189 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -103.89 160.15 15.04 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.066 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -160.45 147.7 15.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.935 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -106.51 165.42 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.282 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.24 164.05 33.11 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.36 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.79 131.11 42.65 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.175 ' N ' ' H ' ' A' ' 33' ' ' ASP . 23.9 m -113.83 151.29 32.31 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 1.143 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -108.67 -158.09 0.64 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.436 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.54 -47.92 65.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.12 -25.05 64.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.3 53.99 1.65 Allowed Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.755 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.45 166.86 20.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.289 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.1 174.67 43.59 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.657 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.37 167.49 26.81 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.333 3.356 . . . . 0.0 109.603 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.562 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 1.4 pm0 -38.37 124.83 1.29 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.96 156.79 0.01 OUTLIER Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.964 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.1 t -118.38 103.29 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.62 135.99 34.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.189 HG13 ' C ' ' A' ' 93' ' ' CYS . 2.9 pt -145.03 -176.55 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.862 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -176.7 177.88 1.31 Allowed 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.513 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.8 m-85 -127.73 113.75 16.41 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.98 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 2.2 p-10 . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.201 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.576 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.39 -178.6 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.339 3.359 . . . . 0.0 109.591 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.905 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.66 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.753 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -124.14 157.92 33.54 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.579 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -126.31 129.41 48.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.944 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -119.41 148.59 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.72 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.64 165.76 33.01 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.72 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.35 117.2 5.02 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.286 3.324 . . . . 0.0 109.63 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.827 ' OG ' HG12 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -129.7 14.1 5.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 111' ' ' SER . 71.0 m -86.56 105.94 17.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.972 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.27 17.72 26.16 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.1 mt -106.79 133.17 51.86 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -87.28 -179.74 6.47 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.778 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 4.2 t0 -45.05 152.39 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.92 38.24 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.564 HG21 HD12 ' A' ' 13' ' ' LEU . 51.6 m -64.73 150.97 46.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -125.58 119.31 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.862 HG13 HG12 ' A' ' 69' ' ' VAL . 2.4 m -95.5 116.31 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.944 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -86.27 115.24 23.69 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.563 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -102.47 119.37 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -130.66 118.4 20.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.962 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.1 148.68 19.88 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.905 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.03 110.87 5.42 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.11 16.48 27.75 Favored Glycine 0 C--N 1.335 0.497 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.11 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.73 170.55 10.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.53 ' HB2' HG21 ' A' ' 30' ' ' THR . 7.2 mp0 -52.08 118.92 3.82 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.494 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.78 130.62 41.55 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.05 7.64 86.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.53 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -94.94 145.74 24.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.0 151.4 22.31 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.962 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 39.1 m-85 -138.76 140.57 38.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.28 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.2 m-20 -104.41 114.19 28.25 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.267 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.7 146.45 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.051 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.45 166.88 40.05 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.04 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 8.9 tt0 -111.73 118.91 36.9 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -123.84 147.91 47.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.916 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.27 135.5 54.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.588 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.9 121.32 14.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.525 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 10.6 m -102.15 -43.42 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.794 ' CG ' ' HH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.58 165.52 25.34 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.664 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.2 t -51.7 111.96 0.68 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.87 9.18 70.19 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.497 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.3 t -123.96 113.69 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.75 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.54 139.14 53.44 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.973 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -96.92 144.34 26.94 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 66.3 m -107.0 158.3 17.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.603 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -115.65 111.46 43.69 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.52 7.28 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.326 3.351 . . . . 0.0 109.603 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.501 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.37 -10.81 45.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 7.1 p30 -131.54 28.23 4.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.86 104.63 12.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.96 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.6 t -100.88 174.35 6.07 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.1 p -145.95 156.13 43.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.51 HG22 ' HB1' ' A' ' 63' ' ' ALA . 4.4 p -166.49 159.43 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.47 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.8 m -127.25 139.54 52.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.95 141.02 36.41 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.0 p30 -82.3 -172.24 3.88 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.2 -27.88 69.29 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -75.1 -7.27 53.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.11 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.89 30.9 58.75 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 77.9 p -125.29 136.12 53.19 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.51 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -123.26 157.44 33.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.71 126.46 23.87 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.443 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -150.21 161.67 41.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -125.57 108.53 11.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.388 HD22 ' CG2' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -95.6 157.88 15.7 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.415 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.1 OUTLIER -107.49 140.17 40.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.862 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.88 123.28 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.778 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -109.91 157.94 18.72 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.498 ' HD2' HG21 ' A' ' 89' ' ' THR . 5.8 mtm180 -87.63 -13.06 43.7 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.5 m -163.41 145.47 9.76 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.04 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 5.5 p90 -177.42 150.69 0.71 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -53.4 113.48 1.17 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.7 101.47 1.42 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.821 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.33 100.67 10.8 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -54.53 131.23 42.35 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.652 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.49 -36.04 9.64 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.597 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.2 t0 -57.77 -16.56 11.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.49 27.39 9.89 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.62 152.85 32.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.15 98.68 10.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 75.0 t-105 -65.61 -43.53 89.31 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.41 175.54 14.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.46 107.75 0.62 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.916 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.4 t -80.02 152.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -120.36 95.84 4.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.941 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.3 m -54.11 -22.93 12.23 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.498 HG21 ' HD2' ' A' ' 71' ' ' ARG . 70.2 p -84.75 2.13 43.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -112.41 -23.36 10.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.05 179.29 7.3 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.32 130.94 40.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.368 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 11.1 m -104.47 164.89 11.43 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.057 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.91 151.41 25.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.388 ' CG2' HD22 ' A' ' 67' ' ' LEU . 2.7 t -106.09 165.61 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.267 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.79 162.08 30.28 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.009 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -124.68 128.94 49.59 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.28 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 27.6 m -112.73 141.56 46.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -103.15 -162.03 0.88 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.996 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.83 -48.16 67.0 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.51 -24.67 66.43 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.61 53.69 1.92 Allowed Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.81 173.43 11.18 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.7 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -175.64 169.12 41.79 Favored Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.576 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.39 171.85 16.16 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.314 3.342 . . . . 0.0 109.595 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.201 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.8 OUTLIER -36.45 133.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.21 160.73 2.44 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.884 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 6.6 t -116.25 103.58 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.09 127.9 35.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.368 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -138.2 179.21 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -163.68 175.52 10.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.031 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.0 m-85 -131.01 114.85 15.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.971 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 10.7 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.698 ' HB3' ' CD ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.402 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.4 -174.51 1.45 Allowed 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 124.295 3.33 . . . . 0.0 109.619 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.73 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.28 108.83 21.38 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 140.42 52.39 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -102.06 112.45 25.11 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.732 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.74 154.86 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.942 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 174.41 2.52 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.127 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.36 118.4 5.58 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 111' ' ' SER . 30.3 p -112.36 46.9 1.12 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.8 p -127.4 106.19 9.03 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.989 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.81 27.67 16.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.127 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.65 131.99 45.28 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -107.54 168.4 9.27 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -44.67 141.17 2.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.85 -22.32 37.41 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.489 HG21 HD13 ' A' ' 13' ' ' LEU . 31.4 m -76.86 150.35 36.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.8 p -126.53 117.27 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.299 HG22 ' O ' ' A' ' 67' ' ' LEU . 13.3 m -83.73 164.12 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.732 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.75 152.25 36.51 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.1 111.51 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.49 116.37 26.54 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.712 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.84 143.25 23.16 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.73 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.0 105.54 4.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.902 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.22 23.05 8.28 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.201 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.81 -164.98 1.22 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.489 ' CD ' ' HH ' ' A' ' 32' ' ' TYR . 6.2 mp0 -85.6 123.77 31.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.62 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.12 134.57 45.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.86 7.57 75.73 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -94.82 138.97 31.92 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.956 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.523 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.4 150.76 22.38 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.251 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -137.17 146.42 44.93 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.258 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.2 m-20 -107.47 112.15 24.79 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.345 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -101.84 150.19 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.923 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -179.38 174.54 46.36 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.265 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.7 tt0 -114.96 113.25 23.89 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.1 m -118.02 145.62 44.65 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.222 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.73 135.98 54.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.582 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.45 124.8 22.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.427 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.1 m -107.15 -42.25 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.325 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -138.29 129.91 27.9 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.633 ' O ' HG23 ' A' ' 42' ' ' THR . 9.5 t -38.04 112.01 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.434 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 93.03 8.98 61.22 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.473 ' CG2' ' HE1' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -151.8 130.44 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.696 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.7 pt? -133.02 142.88 49.05 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.57 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.4 144.65 25.14 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 6.1 m -106.69 156.55 18.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.931 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.4 t-20 -112.97 109.1 52.71 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.4 8.65 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.31 3.34 . . . . 0.0 109.628 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.542 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -94.09 -9.32 37.0 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.912 ' HB3' HG23 ' A' ' 68' ' ' THR . 7.9 m-20 -133.58 15.17 4.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.648 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -85.09 117.11 23.86 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.7 t -112.13 -178.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -145.72 156.14 43.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 56' ' ' THR . 5.1 p -166.99 157.74 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 55' ' ' VAL . 35.0 m -127.66 132.89 49.65 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 153.39 39.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -92.98 -172.04 2.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.82 -29.15 69.3 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -75.22 -9.11 58.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.62 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.88 7.19 88.72 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 99.3 p -99.22 138.94 35.61 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.27 163.91 17.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.1 p -149.38 127.77 12.21 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.608 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -164.51 152.9 12.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -109.24 125.0 51.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.346 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.44 122.15 45.39 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.912 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.1 t -77.94 142.36 38.41 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 1.001 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -114.95 131.16 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.991 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.869 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.5 OUTLIER -113.74 156.84 23.08 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.981 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.26 -13.49 49.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 92.1 p -168.98 144.3 3.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.265 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 14.2 p90 -176.53 158.11 1.73 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -59.22 122.35 13.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.57 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.48 104.32 2.61 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.592 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.4 m-85 -84.82 101.31 12.17 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.89 HD21 ' OD2' ' A' ' 79' ' ' ASP . 6.0 tp -54.33 138.78 38.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.771 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.46 -41.85 21.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.89 ' OD2' HD21 ' A' ' 77' ' ' LEU . 44.1 m-20 -56.85 -17.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.42 26.08 12.73 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.78 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.63 149.17 29.31 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.7 mtt180 -78.7 95.21 5.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.473 ' HE1' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -62.85 -39.49 94.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 126.5 170.26 12.91 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.226 -1.149 . . . . 0.0 110.226 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.92 130.95 43.31 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.222 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.0 t -109.13 154.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -125.53 98.0 5.41 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.721 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 9.9 m -53.13 -27.2 19.64 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.5 p -80.12 0.99 29.78 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.97 -27.59 6.51 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.2 -177.72 4.58 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.34 124.37 45.74 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.828 ' O ' HG13 ' A' ' 110' ' ' ILE . 60.2 m -103.92 153.27 20.99 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.047 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -146.52 146.98 30.7 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.921 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.346 ' CG2' HD12 ' A' ' 67' ' ' LEU . 4.0 t -107.48 159.58 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.345 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.25 171.96 44.78 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.195 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.97 122.12 25.05 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.258 ' N ' ' H ' ' A' ' 33' ' ' ASP . 6.7 m -102.95 154.79 18.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.523 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -114.75 -160.93 0.75 Allowed 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.467 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.8 -49.04 79.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.538 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -74.14 -26.02 60.08 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 98.6 49.21 1.7 Allowed Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.538 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.2 p30 -120.5 167.48 12.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.251 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.66 -176.85 45.16 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.402 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.41 159.6 48.89 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.32 3.347 . . . . 0.0 109.577 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.361 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -37.32 125.44 1.01 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.94 147.64 0.09 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.047 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -115.89 104.51 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.65 138.09 32.38 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.039 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.4 mt -113.61 159.09 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -143.52 119.12 10.4 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.721 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 40.1 m-85 -95.14 123.42 38.63 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.6 m120 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.939 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.678 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.525 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.1 Cg_endo -72.41 -175.48 1.81 Allowed 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 124.336 3.357 . . . . 0.0 109.628 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.364 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -100.03 117.92 35.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.986 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -133.52 150.63 51.68 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.1 114.24 25.81 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.708 ' HB ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -111.08 149.75 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.748 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.9 167.36 24.76 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.748 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.3 Cg_endo -72.38 119.31 6.06 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.295 3.33 . . . . 0.0 109.586 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.574 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -125.38 13.71 8.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.1 p -92.33 114.95 27.63 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.105 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.03 22.58 32.34 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.105 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.39 139.16 43.5 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 179.963 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 59.1 m -97.27 169.57 9.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -44.71 151.2 0.3 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.81 -24.35 31.4 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.569 HG21 ' CD1' ' A' ' 13' ' ' LEU . 2.4 m -78.51 144.23 35.86 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.99 146.05 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.7 OUTLIER -117.2 157.61 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.708 ' O ' ' HB ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -113.1 151.1 31.2 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.753 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -146.16 105.37 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.841 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.21 115.46 26.03 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.986 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.26 143.34 21.03 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.364 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.56 110.66 6.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.885 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 98.81 23.83 11.4 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.608 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.75 -169.77 2.73 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -81.83 122.78 28.15 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.31 131.74 43.88 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.95 7.83 81.92 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.539 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.31 140.48 30.14 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.925 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -90.59 151.61 21.24 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.497 ' CB ' ' CD1' ' A' ' 97' ' ' LEU . 43.2 m-85 -138.0 154.58 49.32 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.525 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 11.1 m-20 -118.5 112.46 19.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.486 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -97.62 149.61 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.994 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.99 167.01 38.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.837 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 15.5 tt0 -107.72 129.34 55.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.0 m -125.88 165.5 18.6 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.226 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -142.51 123.93 14.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.634 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.97 117.63 7.9 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.737 HG12 HG22 ' A' ' 86' ' ' VAL . 5.5 m -99.53 -42.52 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.23 -179.49 5.82 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.4 m -63.38 111.52 2.33 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.18 8.46 65.32 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.574 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 62.4 t -121.97 106.96 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.694 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.84 136.47 54.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.45 157.79 20.37 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.3 m -126.24 156.63 39.97 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.601 HD21 ' HB3' ' A' ' 50' ' ' ALA . 30.5 t30 -123.91 111.94 28.9 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.4 -0.68 9.07 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.308 3.339 . . . . 0.0 109.604 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.601 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.55 -13.32 43.25 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.468 ' CB ' HG23 ' A' ' 68' ' ' THR . 9.0 p30 -130.09 27.9 5.08 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.56 117.72 33.63 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.8 t -111.36 -178.24 3.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.0 p -147.78 155.42 41.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 3.0 p -167.52 160.42 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 37.6 m -127.15 129.91 48.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.83 150.86 40.57 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -90.5 -171.08 2.94 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.62 -28.85 69.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -75.53 -7.94 55.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.5 10.05 86.48 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.2 p -102.03 137.68 39.99 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.35 165.04 15.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 p -150.1 125.18 9.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.573 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.96 164.4 38.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.949 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.573 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -120.39 126.17 49.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.899 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -103.74 118.69 37.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.68 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -68.44 116.78 9.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.58 HG23 HG11 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -73.32 122.83 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.68 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -118.02 133.01 56.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -67.85 -40.8 83.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.469 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 19.5 m -155.96 159.37 39.17 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.837 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -177.35 177.78 1.15 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -64.9 121.89 15.69 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.52 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.6 87.21 1.32 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.784 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.29 100.18 10.46 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.958 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.15 144.13 20.62 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.721 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.16 -43.67 21.27 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.572 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 10.3 t0 -57.76 -17.16 13.88 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.24 29.09 9.89 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.918 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.61 121.18 44.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.432 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.1 ptt180 -62.81 91.07 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.574 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.9 t-105 -63.13 -58.37 7.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.15 157.0 8.15 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -54.52 110.13 0.59 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.226 HG11 ' CB ' ' A' ' 38' ' ' ALA . 16.8 t -88.49 154.54 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.469 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 27.4 m-20 -118.85 94.55 4.49 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.184 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 93.5 m -52.0 -28.82 18.26 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.85 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 2.1 t -76.18 -1.24 25.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -115.24 -27.16 7.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.74 -166.2 1.6 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.52 123.39 46.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.15 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 0.8 OUTLIER -104.47 156.29 18.07 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.032 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.12 154.87 42.29 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.899 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 6.4 t -122.11 160.79 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.213 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.28 171.83 42.81 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.525 ' HA ' ' C ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -127.66 124.79 38.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.302 ' N ' ' O ' ' A' ' 33' ' ' ASP . 59.6 p -99.47 152.62 19.79 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.925 ' HB2' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -115.14 -164.24 0.93 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.9 -48.89 77.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -70.73 -24.86 62.71 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 95.6 53.81 1.51 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.831 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.13 175.9 8.71 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.669 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 179.31 -173.91 45.86 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.211 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.33 157.58 53.13 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.357 3.371 . . . . 0.0 109.611 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.678 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.01 124.71 1.18 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.64 140.13 0.3 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.997 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.3 t -101.47 113.99 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.84 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -87.27 126.08 34.61 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.032 HG12 ' HA ' ' A' ' 94' ' ' GLN . 13.1 pt -135.07 -172.94 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.54 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -175.74 178.27 1.57 Allowed 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.184 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.1 m-85 -140.75 109.35 5.94 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 3.8 p-10 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.521 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.566 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.7 Cg_endo -72.34 -177.73 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.263 0 C-N-CA 124.353 3.369 . . . . 0.0 109.619 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.88 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.4 m -98.51 109.51 22.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.27 163.67 22.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.482 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.1 p -129.55 115.63 17.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.924 ' CG2' HG23 ' A' ' 21' ' ' VAL . 3.3 t -111.07 149.53 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.871 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.66 171.17 7.6 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.871 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.33 117.18 5.01 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.366 3.377 . . . . 0.0 109.589 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.32 13.21 7.12 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.531 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.8 p -91.08 108.39 19.84 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.983 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.81 16.04 29.69 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.8 OUTLIER -103.81 140.46 37.62 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 p -95.67 173.28 7.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -47.04 153.77 0.41 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.38 -24.28 28.1 Favored Glycine 0 C--N 1.335 0.493 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 HD12 ' A' ' 13' ' ' LEU . 3.6 m -71.36 149.66 45.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.4 p -120.49 132.74 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.564 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.6 OUTLIER -111.51 153.51 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.847 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.32 152.87 23.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.924 HG23 ' CG2' ' A' ' 7' ' ' VAL . 1.1 p -145.04 109.42 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.871 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.23 114.44 21.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.018 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.65 146.39 22.37 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.88 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.94 113.25 7.26 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.49 14.97 31.03 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.22 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.99 165.89 13.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.598 ' CD ' ' OH ' ' A' ' 32' ' ' TYR . 2.6 mp0 -49.61 119.83 3.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.25 134.81 44.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.89 8.06 67.63 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.532 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -95.6 145.74 25.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.04 151.03 23.06 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.466 ' CE1' ' ND2' ' A' ' 103' ' ' ASN . 35.3 m-85 -137.96 159.16 42.77 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.248 ' OD2' ' HB3' ' A' ' 98' ' ' SER . 3.3 t0 -124.0 115.04 20.57 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.212 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -96.56 142.26 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.861 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.42 164.67 34.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.716 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.2 tt0 -116.19 111.34 20.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 59.4 m -107.82 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.062 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.63 123.86 9.53 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.64 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.95 117.45 7.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.598 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 5.6 m -98.2 -43.26 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.415 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -135.46 177.83 7.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.8 m -61.34 112.01 1.99 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.3 8.54 66.05 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 59.1 t -121.53 111.14 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -126.26 139.61 53.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.512 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.57 144.36 25.66 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.5 m -110.19 146.9 34.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.714 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 29.2 t30 -107.47 107.74 60.77 Favored Pre-proline 0 N--CA 1.449 -0.488 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.2 Cg_endo -72.34 0.61 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 124.368 3.378 . . . . 0.0 109.599 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.05 -14.1 39.82 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.492 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.7 p30 -126.04 28.24 6.13 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.43 105.49 14.42 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.1 t -103.14 178.27 4.6 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.8 p -147.06 156.86 43.36 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.616 ' CG1' HD21 ' A' ' 97' ' ' LEU . 7.1 p -167.88 160.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 26.9 m -126.96 138.32 53.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.8 143.6 34.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.4 p30 -80.25 -171.05 2.8 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.13 -26.11 68.39 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -10.07 59.13 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.22 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.11 31.18 53.6 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -127.61 137.27 52.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.46 168.32 13.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.6 128.51 11.75 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.531 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -154.09 162.32 41.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.531 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -115.82 119.73 36.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.21 HD13 ' CG2' ' A' ' 95' ' ' VAL . 1.0 OUTLIER -97.57 133.94 41.45 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.73 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -79.75 134.56 36.38 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG23 HG11 ' A' ' 19' ' ' VAL . 1.1 t -94.29 124.1 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.73 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.7 OUTLIER -117.2 142.95 46.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.92 -26.74 36.54 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -155.42 149.85 26.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.949 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.716 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -173.77 157.88 3.16 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.28 117.51 4.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.512 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.26 93.3 1.09 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.788 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -84.14 99.86 10.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.02 130.39 45.87 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.16 -35.63 7.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.78 -16.57 11.73 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.68 28.38 8.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -116.23 147.78 41.1 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -84.73 96.02 9.12 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.598 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 68.7 t90 -64.97 -58.82 5.13 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.75 163.87 10.93 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.17 106.42 0.23 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.062 HG11 ' CB ' ' A' ' 38' ' ' ALA . 20.2 t -80.77 152.46 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.68 93.99 4.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.266 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 12.1 m -53.13 -26.57 17.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.726 ' HA ' ' HB3' ' A' ' 112' ' ' PHE . 7.3 t -82.37 0.1 43.46 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.0 m -114.3 -27.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.93 3.63 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.69 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -99.57 126.0 45.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.957 ' CB ' HD11 ' A' ' 110' ' ' ILE . 92.4 m -104.2 172.01 7.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.041 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 1.2 tt0 -160.93 151.5 18.14 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.21 ' CG2' HD13 ' A' ' 67' ' ' LEU . 3.0 t -108.65 167.1 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.212 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.36 166.65 37.29 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.375 HD23 ' CB ' ' A' ' 32' ' ' TYR . 6.0 mp -102.16 161.82 13.39 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.248 ' HB3' ' OD2' ' A' ' 33' ' ' ASP . 46.7 t -150.86 121.07 7.25 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.494 ' OD1' ' OD1' ' A' ' 103' ' ' ASN . 0.8 OUTLIER -115.86 -170.9 1.88 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -46.0 -39.65 9.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.96 -25.33 26.12 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 91.16 22.61 31.94 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 1.466 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 23.6 p-10 -59.11 -150.27 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.2 150.62 5.49 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.566 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 166.0 31.03 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.307 3.338 . . . . 0.0 109.578 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.521 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 6.6 pt-20 -34.34 124.3 0.5 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.21 135.32 1.48 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.041 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 3.4 t -90.05 107.43 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.91 127.83 34.12 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.038 HG12 ' CA ' ' A' ' 94' ' ' GLN . 4.0 pt -141.5 -173.77 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.69 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.6 OUTLIER -174.75 163.4 3.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.266 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 6.6 m-85 -125.88 112.16 15.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.689 ' OD1' ' HA2' ' A' ' 12' ' ' GLY . 1.1 m-20 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.648 ' HB3' ' CG ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.525 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.39 -177.2 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.317 3.344 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.756 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.78 109.59 22.33 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.735 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.08 140.3 52.03 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -100.5 111.48 23.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 108' ' ' VAL . 21.8 t -105.84 150.29 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.96 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.5 175.7 1.51 Allowed Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.068 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.7 Cg_endo -72.4 118.59 5.67 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.318 3.346 . . . . 0.0 109.586 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.001 ' HB2' HG23 ' A' ' 110' ' ' ILE . 54.5 p -113.0 47.52 1.11 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.0 p -126.56 107.38 10.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.028 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 27.0 20.62 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.068 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -102.01 132.49 47.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 82.0 p -109.88 169.28 8.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -45.04 140.72 2.57 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.67 38.31 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.434 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -77.05 141.87 40.11 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.707 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.9 p -113.78 108.95 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.291 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.4 m -77.13 164.07 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.843 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.1 149.72 38.52 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.918 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -146.56 115.41 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.86 116.96 23.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.872 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.18 147.94 23.9 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.756 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.61 111.81 4.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.66 14.44 34.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.64 173.64 8.19 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.519 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.5 mt-30 -56.37 119.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.08 131.23 41.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.13 7.82 84.75 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.519 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.83 141.37 28.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.999 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.698 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.46 150.35 25.35 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.283 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 25.4 m-85 -136.38 140.81 43.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.41 ' N ' ' N ' ' A' ' 98' ' ' SER . 2.5 m-20 -103.11 116.91 33.4 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.562 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -107.12 145.63 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.966 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.886 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.54 161.73 31.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.953 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 18.9 tt0 -101.97 120.61 40.69 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.482 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.5 m -109.99 169.0 9.01 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.088 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.73 124.91 8.71 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.611 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.64 124.03 20.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.792 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 15.4 m -103.73 -44.07 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.863 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -138.52 165.23 27.39 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.5 m -51.88 112.6 0.81 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.24 8.21 65.05 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 97.3 t -122.32 107.47 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.709 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.71 162.38 18.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.507 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.11 156.59 41.5 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.859 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -118.47 155.49 30.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.67 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 19.8 t30 -112.86 113.58 49.79 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.38 0.03 8.02 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.343 3.362 . . . . 0.0 109.612 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.98 -9.51 45.73 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.2 p30 -134.16 27.72 3.82 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.42 107.29 17.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -103.49 171.38 7.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.2 p -145.27 153.54 41.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -166.6 158.23 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' VAL . 85.7 m -127.52 135.53 50.49 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.45 139.97 48.02 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.2 p30 -77.6 -174.75 3.54 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.8 -25.08 68.06 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -75.99 -8.04 56.04 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.942 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 75.3 32.18 55.96 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -129.87 137.62 50.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.6 167.39 14.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -150.56 125.43 9.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.462 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -159.84 158.26 30.68 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.462 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -111.17 133.46 53.51 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.291 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -110.3 120.16 41.54 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.638 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -79.26 129.86 34.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.78 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.88 137.02 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.874 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -120.31 165.62 14.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.5 -14.12 33.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.2 m -164.51 144.49 7.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.953 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.4 p90 -176.3 154.24 1.32 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.496 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.9 OUTLIER -57.3 124.26 18.26 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.507 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -84.75 98.08 2.18 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.859 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.2 101.75 12.1 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.862 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -57.81 131.62 50.88 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.679 ' N ' HD12 ' A' ' 77' ' ' LEU . 29.6 p90 -47.64 -35.76 9.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.656 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -58.01 -16.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.22 28.46 9.18 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.862 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.0 m -115.66 146.69 41.6 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.0 96.58 8.91 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.863 ' HZ2' ' HB2' ' A' ' 41' ' ' ASP . 5.2 t-105 -63.45 -42.69 98.66 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 128.43 176.55 14.49 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.53 135.55 54.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.088 HG11 ' CB ' ' A' ' 38' ' ' ALA . 1.6 t -114.82 154.93 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -127.81 101.34 6.31 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.907 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 48.9 m -53.35 -28.04 26.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -79.04 -2.45 40.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.19 -27.59 6.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.92 -176.12 3.76 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.0 123.38 45.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.704 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 72.3 m -104.35 152.24 22.5 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.025 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -145.05 148.81 34.12 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.138 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.5 t -114.31 148.2 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.405 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.74 173.87 46.41 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.562 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.7 OUTLIER -125.66 159.88 31.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.41 ' N ' ' N ' ' A' ' 33' ' ' ASP . 2.9 m -139.64 156.95 46.55 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.698 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.11 -165.45 1.0 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -55.79 -49.18 73.89 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.638 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.0 -25.37 62.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.69 39.55 3.37 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.638 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 3.8 p30 -113.57 154.32 27.34 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.283 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -161.86 -173.1 30.11 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.525 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.41 158.41 51.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.332 3.354 . . . . 0.0 109.557 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.648 ' CG ' ' HB3' ' A' ' 2' ' ' ALA . 2.4 mt-10 -38.64 117.26 0.63 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.09 153.2 0.01 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 7' ' ' VAL . 11.0 t -127.05 106.71 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.444 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -82.69 133.89 35.15 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.025 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.5 mt -102.76 163.87 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.722 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -145.73 123.34 11.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.907 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.7 m-85 -95.32 127.36 41.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.968 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.585 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.638 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.37 -174.1 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.327 3.351 . . . . 0.0 109.591 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.49 110.75 23.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.878 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.72 139.16 52.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.551 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -99.71 112.48 24.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.778 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.51 152.89 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.929 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.48 174.06 2.87 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.099 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.9 Cg_endo -72.38 118.74 5.74 Favored 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 124.321 3.348 . . . . 0.0 109.618 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.81 ' HB2' HG23 ' A' ' 110' ' ' ILE . 92.0 p -111.94 49.08 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -127.54 106.41 9.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.002 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.44 27.5 20.0 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.099 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.67 132.22 46.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.6 m -109.22 172.27 6.95 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 1.023 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 7.6 t70 -46.6 141.53 3.71 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.2 -22.5 36.3 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.49 HG21 HD13 ' A' ' 13' ' ' LEU . 29.1 m -76.58 149.75 36.58 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.64 ' O ' HG13 ' A' ' 18' ' ' VAL . 11.7 p -121.5 114.66 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.903 HG23 HG12 ' A' ' 69' ' ' VAL . 11.6 t -81.03 153.19 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.778 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.82 147.18 33.76 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.499 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.3 111.15 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.878 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.87 117.13 27.32 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.804 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.08 144.77 24.0 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.9 102.29 3.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.912 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 109.04 17.64 10.01 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.258 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -90.23 171.36 9.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.988 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.832 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 75.4 mt-30 -56.9 121.82 10.8 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.59 131.75 42.04 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.0 7.77 86.72 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.427 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -96.12 136.59 36.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.984 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -82.64 152.25 25.96 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.875 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.4 m-85 -136.57 146.05 45.68 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.278 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -107.47 113.55 26.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.984 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.4 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.09 144.53 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.994 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.57 169.7 42.53 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.105 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 11.9 tt0 -106.4 105.31 15.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -105.71 141.14 37.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.997 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.78 138.57 54.59 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.563 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.93 124.44 22.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.918 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.12 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -103.66 -51.32 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.953 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -132.72 168.29 18.58 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.94 112.49 0.72 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.47 7.96 65.52 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.671 HG11 ' HE1' ' A' ' 83' ' ' TRP . 86.3 t -121.8 120.97 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.578 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -130.26 134.5 47.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.979 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.468 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.42 153.53 18.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 98.6 m -112.64 145.51 40.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.917 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -108.88 114.18 58.72 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.36 -0.24 8.41 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 124.332 3.355 . . . . 0.0 109.584 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.4 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -81.33 -12.67 58.96 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.724 ' HB2' HD22 ' A' ' 48' ' ' ASN . 96.2 m-20 -136.66 29.78 2.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD1' ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -84.36 108.36 17.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.8 t -107.0 173.41 6.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 p -145.59 154.45 42.17 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' N ' ' A' ' 56' ' ' THR . 6.8 p -167.06 156.82 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.436 ' N ' HG22 ' A' ' 55' ' ' VAL . 36.3 m -126.84 135.62 51.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.14 154.1 42.62 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -92.86 -169.42 2.17 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.57 -28.34 69.81 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.72 -7.56 54.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.648 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.11 14.96 81.76 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -107.83 137.68 45.41 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.92 165.45 15.19 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 p -149.94 128.12 12.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.67 160.85 20.39 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.899 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -117.65 127.41 53.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.103 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.2 120.19 40.93 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.905 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.64 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -76.42 134.99 39.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.903 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.9 135.28 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 1.023 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -116.71 162.47 17.62 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -87.98 -19.51 27.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 28.5 t -163.05 146.73 10.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.105 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.7 p90 -177.04 152.75 0.93 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -57.66 118.96 5.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.468 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.64 98.98 1.83 Allowed Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.792 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.13 100.96 10.86 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.925 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.5 tp -54.78 131.79 44.62 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.672 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.8 m-85 -47.43 -36.48 9.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.575 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.13 -16.66 8.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.27 27.72 9.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.925 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -115.89 149.93 37.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.56 98.04 11.54 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.12 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -63.94 -43.71 95.06 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.946 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 135.69 -179.65 17.55 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.44 126.16 26.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.997 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.1 t -101.45 154.02 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 11.7 m-20 -127.45 96.79 4.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.782 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 54.4 m -53.23 -27.81 24.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -78.32 1.28 22.34 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.14 -27.53 6.06 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.16 -173.28 3.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.8 124.72 48.86 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.87 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 97.6 m -104.36 152.52 22.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.07 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -146.39 148.43 32.31 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.103 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.7 t -110.3 160.06 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.397 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 168.8 41.07 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.4 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.12 128.38 44.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.278 ' N ' ' H ' ' A' ' 33' ' ' ASP . 22.2 m -114.72 148.3 38.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.984 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -107.13 -157.97 0.64 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.49 -47.26 64.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.02 -23.97 64.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.01 53.88 1.98 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.832 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.21 165.96 20.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.875 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.62 46.71 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.638 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.38 162.44 41.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.346 3.364 . . . . 0.0 109.59 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.585 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 1.5 tt0 -37.59 120.83 0.84 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.66 153.54 0.02 OUTLIER Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.935 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.8 t -118.3 104.18 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.62 124.05 32.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.07 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.9 mt -101.31 157.0 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.65 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -141.94 125.36 16.64 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.782 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 9.5 m-85 -96.6 124.28 40.54 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.4 m120 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.39 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.465 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.485 ' CB ' HD22 ' A' ' 26' ' ' LEU . 81.4 Cg_endo -72.4 -174.31 1.39 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.268 3.312 . . . . 0.0 109.616 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.805 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.66 108.27 19.75 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.879 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.57 146.24 47.17 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -113.24 118.17 33.92 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.829 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -114.13 155.15 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.993 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.645 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -71.54 162.19 74.32 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.639 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 121.98 7.93 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.322 3.348 . . . . 0.0 109.606 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.659 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.2 OUTLIER -126.93 15.84 7.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.6 111.73 22.23 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.078 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.3 22.58 31.7 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.078 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -109.11 144.12 37.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 75.5 m -94.29 166.03 12.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 1.128 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 11.5 t0 -46.15 153.34 0.33 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 100.02 -24.27 32.78 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.438 HG21 HD12 ' A' ' 13' ' ' LEU . 24.5 m -69.17 132.62 46.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.3 p -106.43 111.33 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.645 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 6.4 m -90.37 166.08 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.829 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.04 149.1 44.82 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.454 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -136.41 104.88 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.879 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.8 117.83 31.84 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.746 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -88.03 143.82 18.37 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.805 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -135.01 108.09 7.65 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.921 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.69 25.69 7.98 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.485 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.89 179.69 6.14 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 180.0 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.425 ' HB2' HG21 ' A' ' 30' ' ' THR . 18.9 mt-30 -76.83 123.74 26.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.476 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.11 137.46 54.96 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.78 7.28 65.25 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.644 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.16 145.12 24.65 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.2 149.11 22.01 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.535 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 39.8 m-85 -138.05 136.83 37.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.109 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -99.61 114.75 27.99 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.114 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.99 143.19 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.897 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.66 162.14 35.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.936 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -101.01 117.78 35.7 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.436 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.9 m -108.65 164.57 12.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.771 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -150.47 139.44 20.98 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.527 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -64.67 124.55 22.21 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.228 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -106.4 -53.93 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.617 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -138.1 167.03 22.66 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -51.02 111.58 0.58 Allowed 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.59 8.15 66.51 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.602 ' CG1' ' CZ3' ' A' ' 83' ' ' TRP . 13.8 t -124.21 118.91 55.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.69 HD12 ' N ' ' A' ' 46' ' ' ALA . 2.0 pp -121.93 163.3 19.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.369 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.51 146.19 50.59 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.768 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.15 159.13 17.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.985 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.902 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.2 t30 -113.04 112.74 49.81 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.39 -0.82 9.28 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.339 3.36 . . . . 0.0 109.592 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.95 -7.92 50.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.449 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 32.9 m-20 -133.82 26.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.406 ' HD1' ' HA ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -84.25 106.12 15.62 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.8 t -104.73 176.38 5.18 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.7 p -146.09 158.45 43.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.449 HG22 ' N ' ' A' ' 56' ' ' THR . 5.5 p -166.98 158.3 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.449 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.5 m -128.37 127.35 42.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.61 141.57 58.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.5 p30 -85.22 -171.57 3.7 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.53 -23.52 67.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -83.67 1.0 44.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 70.44 2.35 41.83 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 t -95.12 136.08 35.88 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.45 161.99 21.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -147.51 129.59 15.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.715 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -151.7 174.24 13.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.888 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.715 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -130.96 114.64 15.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.613 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -98.38 156.89 16.52 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.984 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.601 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -116.64 134.67 54.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.649 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -101.03 131.06 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 1.128 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -115.74 147.92 40.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 ptt180 -74.48 -25.15 59.2 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.5 t -159.94 150.01 18.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.936 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.6 p90 -177.34 156.03 1.17 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.23 119.83 7.58 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.369 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.32 100.39 1.39 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.768 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.35 100.04 10.41 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 1.074 HD21 ' OD2' ' A' ' 79' ' ' ASP . 4.3 tp -55.05 137.12 47.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.69 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.62 -40.99 13.93 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 1.074 ' OD2' HD21 ' A' ' 77' ' ' LEU . 1.5 m-20 -57.09 -17.0 8.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.98 26.87 10.84 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -109.51 148.63 30.89 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.76 95.73 8.52 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.617 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 33.3 t-105 -62.8 -56.43 17.55 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.04 170.72 19.0 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.53 107.44 0.8 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.771 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.8 t -83.41 152.33 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.77 93.71 4.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.268 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -55.03 -22.27 15.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.526 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 25.7 p -85.93 2.24 46.86 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -110.98 -26.57 9.2 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.54 179.22 6.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.664 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -94.06 129.45 40.59 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.045 ' HB2' HD11 ' A' ' 110' ' ' ILE . 59.1 m -104.86 173.07 6.46 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.378 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -158.67 142.55 15.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.951 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.613 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.4 t -98.21 164.13 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.114 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.93 161.25 26.87 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.076 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -126.55 135.71 51.63 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.109 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 52.4 p -106.99 158.79 16.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.466 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.0 OUTLIER -112.46 -167.53 1.2 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.466 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -53.8 -49.83 67.45 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.629 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -74.52 -25.4 59.31 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.4 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 104.67 39.44 2.37 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.629 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 5.8 p30 -122.92 -175.34 3.14 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.535 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 162.14 -161.88 33.79 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.389 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.91 52.44 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.382 3.388 . . . . 0.0 109.553 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.39 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.0 pt-20 -42.84 145.23 0.48 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.76 164.5 1.75 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.378 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 37.3 t -116.84 102.69 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.448 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -75.88 132.48 40.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.045 HD11 ' HB2' ' A' ' 93' ' ' CYS . 6.2 pt -142.41 -174.36 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.664 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.1 OUTLIER -171.02 176.1 4.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.268 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 4.6 m-85 -132.55 114.29 14.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.002 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.4 m120 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.645 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.38 -177.7 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 124.314 3.343 . . . . 0.0 109.635 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.785 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.77 109.69 22.41 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.783 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.46 133.52 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.632 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -96.51 115.85 28.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.556 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.29 155.95 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.95 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 175.61 1.77 Allowed Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.051 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.37 117.4 5.11 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.32 3.346 . . . . 0.0 109.58 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.805 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 1.6 p -110.73 48.57 0.91 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 79.9 p -126.97 105.88 8.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.096 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.32 29.27 11.43 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.096 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.43 130.29 55.24 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.951 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.19 177.36 4.67 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -45.83 139.39 4.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.07 -22.77 34.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.679 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.2 m -83.13 150.56 26.19 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.503 ' O ' HG13 ' A' ' 18' ' ' VAL . 13.9 p -121.49 123.96 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.53 HG23 ' HB3' ' A' ' 67' ' ' LEU . 6.8 m -90.44 158.44 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.38 149.08 30.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.711 HG12 ' O ' ' A' ' 65' ' ' THR . 0.3 OUTLIER -145.09 113.38 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.65 117.19 22.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.834 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.06 147.75 23.89 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.785 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.36 111.32 4.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.17 15.61 30.04 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.059 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.6 177.05 6.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 29.7 mt-30 -59.61 121.5 11.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.22 129.8 39.3 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.08 7.04 86.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.52 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.23 141.5 28.51 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.965 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.92 149.85 23.83 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.779 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.6 m-85 -136.43 138.09 41.14 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.002 ' HB3' ' O ' ' A' ' 98' ' ' SER . 1.5 t0 -99.99 113.84 26.7 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.242 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.04 144.72 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.739 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.84 171.05 42.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.929 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 33.8 tt0 -117.64 108.77 15.84 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.76 147.66 37.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.288 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.33 142.87 50.04 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.503 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.98 124.97 23.45 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.898 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.443 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -104.89 -44.25 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.332 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -149.05 134.8 18.81 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 41' ' ' ASP . 1.5 m -38.18 110.92 0.14 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.459 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 94.46 8.3 59.87 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.173 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.7 OUTLIER -151.59 129.26 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.636 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -133.96 132.95 40.78 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.425 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -84.27 144.69 28.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 2.6 m -106.44 152.92 23.0 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 41.4 t-20 -111.64 107.4 56.64 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.1 Cg_endo -72.4 -0.05 8.16 Favored 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 124.308 3.338 . . . . 0.0 109.599 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.17 -10.44 49.89 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.697 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.3 OUTLIER -131.71 27.56 4.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.501 ' HD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -80.5 104.6 11.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -100.11 175.35 5.77 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.3 p -143.94 153.39 42.22 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.426 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -167.98 152.24 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.7 m -127.47 134.71 49.81 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -71.4 141.63 50.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 45.2 p30 -81.57 -173.33 4.34 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -27.21 68.71 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -8.61 57.13 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.059 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.81 31.87 52.05 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.1 p -127.93 139.67 52.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.426 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -123.35 165.81 16.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.71 122.89 8.91 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.711 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -158.73 152.22 22.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.75 127.95 56.23 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.486 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -97.78 156.4 16.59 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.956 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.8 t -102.67 120.96 41.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.511 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 1.0 OUTLIER -83.22 127.79 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.861 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.8 OUTLIER -117.14 155.81 28.7 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -94.21 -18.26 21.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.551 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 3.6 m -164.19 144.75 8.22 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.929 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.7 p90 -172.24 153.64 3.09 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -57.98 111.67 1.25 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.425 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.67 101.76 0.89 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.749 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.37 99.68 10.2 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.3 tp -55.44 141.14 37.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.718 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.3 m-85 -46.54 -42.9 16.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.746 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.33 -16.89 9.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.82 27.69 12.27 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.3 m -109.23 144.72 36.97 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -76.89 94.77 3.97 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.443 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 31.5 t-105 -63.19 -57.2 11.3 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.52 163.79 12.51 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.1 104.67 0.33 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.288 HG11 ' CB ' ' A' ' 38' ' ' ALA . 67.9 t -76.64 150.45 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.427 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 4.2 m-20 -117.19 93.91 4.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.002 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 30.8 m -52.16 -27.22 13.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.6 p -80.01 0.36 32.01 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.6 m -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.73 -175.1 3.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.65 126.48 47.15 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.903 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.2 m -104.55 154.37 20.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.027 ' HA ' HG13 ' A' ' 110' ' ' ILE . 2.1 pt20 -142.55 150.05 39.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.486 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.4 t -110.62 164.04 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.242 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.66 166.31 36.01 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.96 121.03 27.15 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.002 ' O ' ' HB3' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -103.52 150.96 23.41 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -109.81 -159.93 0.7 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.973 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.27 -48.87 79.07 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.501 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -75.53 -25.71 57.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.86 42.24 2.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.501 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 3.2 p30 -111.68 166.27 11.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.774 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.99 -177.64 44.24 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.06 54.0 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.3 3.333 . . . . 0.0 109.6 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.132 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 1.9 mt-10 -35.39 125.89 0.62 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.06 151.88 0.02 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.904 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -124.39 104.68 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -84.63 146.06 27.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.027 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.8 mt -121.05 157.37 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.54 115.76 11.77 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.002 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 11.6 m-85 -86.56 114.27 23.15 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 2.8 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.48 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.481 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.6 Cg_endo -72.4 -178.26 3.22 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 124.303 3.336 . . . . 0.0 109.581 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.839 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.62 111.33 23.68 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.69 159.58 33.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.434 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.5 p -124.29 121.28 34.57 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.83 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 55.5 t -116.87 146.39 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.773 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.96 167.75 18.72 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.773 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 118.65 5.7 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.357 3.372 . . . . 0.0 109.576 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -129.71 9.93 5.51 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.965 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . 1.045 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.2 p -85.66 106.44 16.94 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.431 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 102.25 14.52 28.1 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.964 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -106.04 136.07 46.38 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.969 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -92.31 176.63 6.41 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.64 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 11.0 t70 -44.79 153.12 0.19 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.82 -23.34 34.68 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.681 HG21 HD12 ' A' ' 13' ' ' LEU . 10.4 m -72.58 142.97 48.42 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.6 p -118.9 121.04 65.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.814 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -100.59 154.31 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.2 151.0 26.51 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.757 HG23 ' CG2' ' A' ' 7' ' ' VAL . 0.9 OUTLIER -141.95 109.19 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.46 115.43 22.21 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.025 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -86.62 146.36 20.7 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.839 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.2 112.12 6.86 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.49 17.75 25.56 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.125 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.48 167.61 12.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.637 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 52.3 mt-30 -52.22 121.21 6.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.515 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.23 130.69 40.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.35 7.12 86.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.483 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.95 139.12 31.78 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.522 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.42 152.55 23.95 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.69 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 33.5 m-85 -136.71 139.82 42.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.245 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.72 113.8 27.59 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.258 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -102.68 149.66 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.835 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.4 172.32 43.99 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.847 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 36.8 tt0 -113.5 110.91 21.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.7 m -108.94 147.12 32.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.864 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -125.95 131.58 52.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.61 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.25 120.52 12.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.919 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.973 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.7 m -100.35 -43.23 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.508 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -136.85 166.1 24.41 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.951 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.679 ' O ' HG23 ' A' ' 42' ' ' THR . 15.3 t -51.14 111.74 0.61 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.12 8.52 65.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.0 t -122.09 109.41 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.457 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.89 141.17 52.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.956 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.432 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -100.28 155.13 17.95 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.9 m -111.04 149.61 30.5 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.697 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -117.1 115.66 38.22 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HA ' ' HB2' ' A' ' 52' ' ' PHE . 83.2 Cg_endo -72.37 1.02 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.345 . . . . 0.0 109.629 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -81.28 -14.25 57.6 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CG ' HG23 ' A' ' 68' ' ' THR . 95.1 m-20 -132.86 29.58 4.11 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.405 ' HB2' ' HA ' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -84.53 109.77 18.18 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.5 t -105.7 174.1 6.03 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -146.35 149.78 34.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.412 HG22 ' N ' ' A' ' 56' ' ' THR . 6.1 p -166.22 155.51 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.1 m -126.05 133.02 51.84 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.17 138.73 47.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.7 p30 -77.44 -174.06 3.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -17.39 58.58 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -85.16 5.66 29.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.937 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 59.12 32.37 71.2 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.6 t -130.44 137.09 49.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.52 167.49 17.03 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 53.1 p -150.83 128.04 11.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.728 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.52 172.91 13.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.853 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.728 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -126.09 122.78 36.75 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.896 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -100.43 143.45 30.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.926 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.626 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -100.45 143.99 29.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 t -103.35 129.33 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.64 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -119.42 143.91 47.22 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.02 -32.05 68.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 33.2 t -158.09 158.96 35.71 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.847 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -177.0 163.93 2.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.26 120.93 13.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.432 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.11 93.2 0.96 Allowed Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 1.006 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 100.07 10.48 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.1 tp -54.5 137.47 42.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.816 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 3.0 m-85 -46.6 -40.77 13.49 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.564 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 7.7 t0 -56.89 -17.39 9.31 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.56 27.94 9.39 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.33 139.87 45.08 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -78.25 92.5 4.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.973 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 13.6 t90 -62.49 -57.92 9.48 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.07 166.06 13.41 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.95 128.83 38.83 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.864 HG11 ' HB3' ' A' ' 38' ' ' ALA . 13.7 p -113.15 147.51 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -99.3 95.19 6.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.74 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -54.88 -20.71 9.39 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.9 p -91.24 1.78 56.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 m -108.71 -27.01 10.04 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.4 176.64 8.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.439 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -89.59 126.72 35.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.24 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -104.98 172.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.953 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.68 147.81 22.1 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.896 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 29.6 t -104.86 163.49 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.258 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.55 167.98 37.72 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.164 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -133.02 138.75 46.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.245 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 22.8 m -121.73 145.55 47.91 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -103.19 -158.56 0.67 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -70.55 -47.75 58.83 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.95 -24.39 66.06 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.2 53.62 1.85 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.637 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.04 165.26 23.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.516 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.01 171.46 42.96 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.481 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 166.2 30.46 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.344 3.363 . . . . 0.0 109.604 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.48 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 11.2 pt-20 -37.87 120.24 0.82 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.83 158.78 0.01 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.899 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.6 t -115.03 103.56 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.08 124.03 30.67 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.24 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.6 pt -134.49 -174.87 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . 1.045 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -170.83 175.94 4.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.2 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.8 m-85 -124.46 115.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.431 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 36.1 m-80 . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.593 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.586 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.37 -174.46 1.43 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.29 3.327 . . . . 0.0 109.642 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.29 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 5.8 t -100.94 115.24 29.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.916 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -129.73 165.18 22.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.429 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.3 p -125.99 122.2 35.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.856 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -118.7 145.78 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.762 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -70.29 163.03 65.88 Favored Pre-proline 0 N--CA 1.448 -0.538 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.681 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.42 119.27 6.03 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.284 3.323 . . . . 0.0 109.595 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.682 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 2.2 t -126.95 14.03 7.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.813 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.0 p -88.95 105.83 18.02 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.088 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.17 21.59 13.22 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.088 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.87 139.51 44.87 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -85.96 169.2 13.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -44.42 152.29 0.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.53 -22.54 40.38 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 HD12 ' A' ' 13' ' ' LEU . 35.9 m -64.17 140.63 58.89 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.82 110.95 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.762 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER -93.29 118.61 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.856 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.6 146.38 36.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -135.19 110.5 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.676 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.56 115.01 22.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.916 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.21 143.35 20.25 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.232 ' O ' HG22 ' A' ' 4' ' ' THR . . . -136.8 110.38 8.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.9 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.18 24.15 9.9 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.586 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.6 -175.04 4.8 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.995 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.523 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 62.6 mt-30 -74.2 124.5 26.49 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.505 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.48 128.01 34.28 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.65 87.02 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.713 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.84 134.3 40.33 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.48 152.15 23.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.952 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 66.6 m-85 -137.05 156.15 48.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.037 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -114.62 115.26 26.87 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.942 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.087 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 1.4 t -98.77 143.11 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.775 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.7 163.58 37.3 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.922 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -106.38 115.55 30.4 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 93.9 m -107.45 168.23 9.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.91 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -153.71 126.7 8.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.604 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.39 122.82 18.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.619 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 11.6 m -103.92 -43.44 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.654 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -142.48 171.94 13.37 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.1 m -56.75 112.55 1.33 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 5.11 56.59 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.776 HG12 ' CD1' ' A' ' 83' ' ' TRP . 24.0 t -118.63 107.05 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.877 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.2 pp -117.08 162.85 17.15 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.529 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -125.26 146.12 49.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 51.1 m -115.53 152.36 33.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.7 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -112.64 107.15 55.17 Favored Pre-proline 0 N--CA 1.449 -0.5 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -72.46 -0.31 8.57 Favored 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.317 3.345 . . . . 0.0 109.554 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.646 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.65 -12.04 40.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 69.8 m-20 -131.82 24.88 4.67 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.664 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -95.51 117.86 31.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.9 t -110.77 -171.76 1.9 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.78 156.45 43.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 p -166.4 152.79 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 54.6 m -126.19 132.06 51.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.47 150.8 48.41 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.4 p30 -90.93 -169.11 2.25 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.25 -27.84 68.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -76.27 -10.57 59.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.58 9.33 86.97 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -100.64 137.61 38.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.11 161.67 21.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.88 130.38 13.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.718 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.23 173.26 15.31 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.883 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.718 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -121.36 133.35 55.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.903 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.932 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -117.59 119.4 34.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -78.72 141.08 38.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.948 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.671 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -113.78 130.24 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.986 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.667 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -114.78 154.75 27.99 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -76.25 -22.1 55.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 87.7 p -161.42 151.84 17.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.922 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -176.98 160.4 1.8 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.49 113.11 2.49 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.529 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -74.63 95.97 0.91 Allowed Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.693 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 99.9 10.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.937 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -53.56 144.51 17.18 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.846 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.61 -43.93 26.2 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.937 ' OD2' HD21 ' A' ' 77' ' ' LEU . 12.0 m-20 -58.08 -16.5 13.25 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.45 27.51 13.05 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.808 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -105.18 125.99 51.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.523 ' HB3' ' CZ ' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -64.53 91.69 0.08 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.619 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 87.2 t90 -62.02 -39.29 91.76 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 132.15 174.73 13.72 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.16 105.05 1.29 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.149 HG22 ' CG1' ' A' ' 40' ' ' VAL . 42.8 t -80.73 146.42 7.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -105.08 92.96 4.44 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.055 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -53.49 -21.26 5.96 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.2 p -89.18 3.14 52.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -112.92 -27.64 8.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.84 174.63 10.4 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.534 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -91.4 127.66 36.92 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.4 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 33.2 m -105.41 167.23 9.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.075 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -155.29 140.58 17.63 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.932 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -92.7 164.93 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.087 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.46 160.93 27.24 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.03 127.09 42.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.037 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 26.4 m -106.44 151.02 25.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.41 -161.45 0.75 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.998 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.86 -48.65 65.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.23 -24.17 65.8 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.12 53.82 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -135.18 172.17 13.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.952 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.02 178.45 45.0 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.494 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.39 164.06 36.75 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.265 3.31 . . . . 0.0 109.577 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.593 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 13.2 pt-20 -38.12 124.05 1.16 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.434 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.29 152.6 0.01 OUTLIER Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.029 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.8 t -111.8 103.26 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.33 130.59 35.6 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.4 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.0 pt -143.84 177.31 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.813 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -173.49 176.31 2.83 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.055 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 1.7 m-85 -128.09 120.0 26.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.699 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 27.5 m-80 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.374 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.458 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.456 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.44 -177.53 2.8 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.296 3.33 . . . . 0.0 109.595 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.189 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.17 109.06 21.88 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.883 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 139.66 53.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.65 117.75 34.87 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.852 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -113.17 155.27 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.955 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.83 176.65 1.22 Allowed Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.111 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.1 Cg_endo -72.39 117.71 5.26 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.305 3.337 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.663 ' HB2' HG23 ' A' ' 110' ' ' ILE . 24.0 p -113.29 43.56 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 60.7 p -123.58 106.79 10.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.75 28.39 14.24 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.111 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.08 133.5 45.51 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 m -104.61 165.0 11.35 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.689 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -44.75 139.13 3.11 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.28 -22.33 34.96 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 27.8 m -76.07 141.89 41.9 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 67' ' ' LEU . 10.4 p -113.28 128.86 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 8' ' ' THR . 2.7 t -96.23 164.36 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.852 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.21 144.85 41.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.662 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -139.58 113.21 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.883 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.46 114.62 19.06 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.81 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -88.74 140.96 16.22 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.189 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.31 116.76 10.73 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.18 19.35 21.55 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.81 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -88.35 173.76 8.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.495 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 27.0 mt-30 -64.35 120.74 12.78 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.13 136.95 56.67 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.09 8.19 61.14 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.722 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -86.1 146.58 26.55 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.892 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.97 138.22 33.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.045 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 32.7 m-85 -131.32 146.75 52.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.254 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -117.12 116.49 27.4 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.376 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.45 153.67 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.001 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.72 163.66 30.8 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.096 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.6 tt0 -103.1 120.33 40.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.1 m -108.25 164.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.74 -0.466 . . . . 0.0 109.74 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -152.0 131.08 12.65 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.496 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -66.29 128.75 37.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.923 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.53 ' CB ' ' NE1' ' A' ' 83' ' ' TRP . 3.3 m -117.07 -38.1 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.255 ' OD1' ' HH2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -146.68 178.78 8.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' HG23 ' A' ' 42' ' ' THR . 4.7 t -64.48 110.95 2.47 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 8.3 63.51 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.981 HG11 ' CE3' ' A' ' 83' ' ' TRP . 84.9 t -111.7 104.88 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.638 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.0 OUTLIER -104.33 154.81 19.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.934 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.595 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.16 129.01 44.56 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.836 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.72 157.43 18.12 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.753 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.1 t30 -115.67 114.56 42.13 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -72.46 -1.26 9.96 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.318 3.345 . . . . 0.0 109.611 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -91.19 -11.39 38.46 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 68' ' ' THR . 21.0 p30 -133.84 25.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.642 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -97.84 116.17 29.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 t -103.53 178.57 4.52 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.2 p -146.38 153.11 40.12 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.547 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.91 157.37 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 60.3 m -125.32 127.48 46.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.415 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -59.55 124.72 20.97 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.3 p30 -69.95 -170.3 0.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -23.73 66.46 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.25 2.12 29.33 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.807 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 65.54 32.45 83.35 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 32.7 t -127.65 145.03 51.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -143.85 124.66 14.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -108.72 133.68 52.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.412 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -148.94 155.65 41.15 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.412 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -111.24 120.43 42.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.615 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.79 159.36 15.85 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.803 -0.444 . . . . 0.0 109.803 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.614 HG23 ' HB2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -124.91 133.05 53.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.26 130.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.689 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -110.78 168.37 9.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 29.7 ptt180 -96.53 -8.34 32.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.8 t -176.54 146.15 0.59 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.096 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 10.3 p90 -176.77 166.72 2.58 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -62.13 127.29 30.68 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.595 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.15 93.41 1.7 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.836 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.58 100.59 11.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.942 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -57.19 130.67 47.18 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.655 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m-85 -47.67 -35.76 10.05 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.569 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.81 -16.88 12.88 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.55 27.5 9.08 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.942 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.26 150.18 36.6 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.45 97.19 10.93 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.53 ' NE1' ' CB ' ' A' ' 40' ' ' VAL . 15.2 t-105 -66.64 -56.88 8.63 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.5 168.25 13.41 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.45 142.88 31.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.832 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -127.13 154.64 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.981 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.418 ' N ' ' CG2' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -113.81 100.97 8.85 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.573 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.9 OUTLIER -53.78 -26.33 23.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -83.71 0.69 46.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 m -117.74 -27.85 6.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.23 175.64 7.28 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.95 123.04 40.56 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.195 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.9 m -104.47 152.62 22.12 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.988 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -143.77 143.39 31.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.615 HG13 ' CD1' ' A' ' 67' ' ' LEU . 3.4 t -101.95 151.57 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.372 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.72 171.57 43.78 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.376 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -128.27 146.05 50.87 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.254 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 5.9 m -123.18 153.25 40.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.892 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.59 -163.98 0.89 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.29 -49.28 78.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.603 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.37 -25.76 62.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 97.75 46.52 2.27 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.603 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.8 p30 -119.27 166.82 12.52 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.045 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.84 -176.53 41.5 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.456 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.47 162.45 41.41 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.306 3.337 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.374 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.85 127.45 1.58 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -43.75 144.54 1.72 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.986 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -120.87 110.94 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.85 142.84 27.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.195 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.9 OUTLIER -108.13 168.59 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.73 120.44 7.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 39.5 m-85 -97.99 121.89 40.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.948 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.061 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.484 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.1 Cg_endo -72.42 -177.53 2.79 Favored 'Trans proline' 0 N--CA 1.448 -1.205 0 C-N-CA 124.328 3.352 . . . . 0.0 109.537 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.834 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -97.47 109.83 22.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.792 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.8 133.59 50.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.561 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.35 114.64 26.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.681 HG11 ' CG2' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.3 155.87 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.993 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.925 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.79 174.61 2.15 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.073 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.7 Cg_endo -72.43 118.12 5.45 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.346 3.364 . . . . 0.0 109.538 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.9 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -117.05 46.79 1.6 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.631 ' HA ' ' O ' ' A' ' 111' ' ' SER . 96.6 p -124.85 105.33 9.17 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.866 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.944 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.5 15.48 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.073 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.06 133.43 41.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.996 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.6 p -99.83 163.26 12.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.506 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.01 140.96 4.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.24 36.43 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 27.9 m -71.38 150.22 45.24 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.606 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.9 p -121.13 118.29 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.754 HG22 ' O ' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -86.8 169.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.997 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.74 153.05 37.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -146.58 113.17 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.792 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.05 115.9 22.62 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.837 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.99 143.89 21.57 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.719 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.08 112.98 6.38 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.87 19.09 23.09 Favored Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.028 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.81 -176.55 4.72 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.938 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.455 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 76.9 mt-30 -70.91 124.83 25.26 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.69 127.59 33.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.32 7.26 88.71 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -88.65 143.67 26.78 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.862 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -91.3 141.93 28.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.98 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 33.5 m-85 -131.53 146.22 52.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.257 ' CB ' ' H ' ' A' ' 98' ' ' SER . 13.8 m-20 -111.97 113.13 25.25 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.379 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -95.8 144.36 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.925 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.17 163.77 36.1 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.981 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 19.3 tt0 -107.41 108.04 19.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -107.83 142.19 38.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.859 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.48 139.18 54.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.558 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.11 124.86 22.73 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.337 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -105.26 -49.67 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.598 ' N ' HG12 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -135.64 167.67 20.68 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -50.28 112.45 0.68 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.0 63.01 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.474 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 93.5 t -122.22 116.46 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.536 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -125.97 135.47 51.88 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.407 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -90.14 159.39 16.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 28.8 m -116.12 151.92 34.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.778 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.5 t30 -112.03 106.12 56.32 Favored Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.3 Cg_endo -72.44 -1.12 9.75 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 124.3 3.333 . . . . 0.0 109.599 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.41 -10.43 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 79.3 m-20 -135.61 27.04 3.38 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.51 121.22 38.1 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.8 t -115.4 -173.37 2.32 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.3 p -145.95 156.99 43.88 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.861 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 6.2 p -167.19 157.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.6 m -128.61 136.59 50.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.24 130.63 38.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.936 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p30 -72.13 -177.84 2.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.31 -16.22 43.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -86.12 7.56 24.35 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.028 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.01 32.64 62.84 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.1 t -131.89 135.38 46.61 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.91 166.64 16.53 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.7 m -151.15 128.0 10.97 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -155.46 169.85 23.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.89 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -118.69 133.28 55.97 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.203 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -115.69 118.99 34.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.936 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.632 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -77.64 137.04 38.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.973 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.731 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.09 125.85 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.42 ' N ' ' HD3' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -109.76 168.48 9.38 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.98 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.506 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -97.04 -15.73 20.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.993 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 47.8 t -167.37 146.45 5.04 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.981 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.7 p90 -176.92 151.8 0.88 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.7 OUTLIER -53.12 116.43 2.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.921 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.407 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.08 102.99 1.74 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.982 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -84.01 100.6 11.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.9 tp -54.24 132.89 44.41 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.987 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.966 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.5 m-85 -46.94 -37.16 8.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.581 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -57.51 -16.93 11.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.8 27.63 9.46 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.29 151.3 34.81 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.506 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.7 ptp180 -85.9 98.5 10.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.337 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -64.52 -58.03 7.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.883 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 174.42 23.29 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.13 110.73 1.94 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.859 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -85.93 154.39 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 11.4 m-20 -122.02 95.14 4.54 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.73 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 35.9 m -53.61 -26.69 22.98 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -80.0 -1.51 40.01 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -114.65 -27.67 7.4 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.53 -173.94 3.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.883 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.55 125.48 48.21 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.854 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 93.1 m -104.2 152.66 21.9 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.028 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -143.94 150.52 38.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.944 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.203 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 2.4 t -112.41 160.29 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.379 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.28 169.96 42.36 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.315 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.88 128.03 44.44 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.257 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 56.8 m -107.23 151.22 25.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.862 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.29 -163.24 0.84 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.985 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.426 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -64.97 -48.85 72.55 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.22 -24.12 63.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.88 53.37 1.79 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.511 ' OD1' ' HE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -130.49 172.62 11.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.98 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -177.85 -179.16 47.85 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.4 157.99 52.2 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.324 3.349 . . . . 0.0 109.573 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.095 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.8 pt-20 -36.02 123.13 0.72 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.72 149.86 0.03 OUTLIER Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.977 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.1 t -117.6 104.97 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.73 135.42 33.76 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.028 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.2 mt -111.79 167.12 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.631 ' O ' ' HA ' ' A' ' 11' ' ' SER . 4.7 t -153.11 128.48 9.89 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.73 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 26.6 m-85 -102.02 125.4 48.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.509 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.0 m120 . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.307 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.48 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.38 -177.79 2.93 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.328 3.352 . . . . 0.0 109.592 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.223 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.83 111.93 24.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.12 160.58 30.75 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -120.37 113.46 20.39 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 21' ' ' VAL . 0.5 OUTLIER -105.16 148.27 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.98 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.97 177.81 0.93 Allowed Pre-proline 0 N--CA 1.448 -0.533 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.959 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.114 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.4 115.99 4.54 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.342 3.361 . . . . 0.0 109.61 179.888 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.658 ' CB ' HG23 ' A' ' 110' ' ' ILE . 27.9 p -113.4 40.9 2.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.501 ' HA ' ' O ' ' A' ' 111' ' ' SER . 30.9 p -120.31 106.22 11.67 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.024 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.29 30.4 10.95 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.114 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.33 132.21 47.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -104.69 169.54 8.4 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.926 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -48.54 140.06 8.52 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.01 -22.54 36.5 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 46.2 m -75.14 147.04 40.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.506 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.5 p -120.62 124.96 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.13 HG22 ' O ' ' A' ' 67' ' ' LEU . 2.6 m -90.68 168.06 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.754 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -117.32 152.48 34.82 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.966 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.1 114.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.989 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.77 114.59 18.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.91 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.86 148.5 24.7 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.223 ' O ' HG22 ' A' ' 4' ' ' THR . . . -145.6 112.64 6.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.51 14.74 31.64 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.968 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.94 169.01 11.58 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.784 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 70.8 mt-30 -50.39 120.09 4.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.599 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.71 131.63 41.82 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.32 8.28 83.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.49 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.82 139.94 30.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.977 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.907 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.22 151.73 25.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.769 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.0 m-85 -137.47 144.61 42.36 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.333 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.0 m-20 -106.0 115.22 29.86 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.465 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.16 143.16 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.955 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.86 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.94 172.5 43.28 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.064 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 9.7 tt0 -116.61 117.41 29.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 94.1 m -109.44 167.84 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.151 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.6 126.11 9.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.595 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -66.35 124.97 24.17 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.669 HG21 ' CD1' ' A' ' 83' ' ' TRP . 12.2 m -105.12 -44.05 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.537 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -143.3 163.56 32.64 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.468 ' O ' HG23 ' A' ' 42' ' ' THR . 2.9 t -51.91 113.48 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.21 8.35 69.81 Favored Glycine 0 C--N 1.336 0.553 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.629 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 17.0 t -126.27 106.11 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.917 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -116.17 162.91 16.75 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.978 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.564 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.37 138.66 53.58 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.8 m -109.33 150.28 28.24 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.638 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 24.5 t30 -108.77 109.06 61.2 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.39 -0.13 8.26 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.296 3.33 . . . . 0.0 109.563 179.899 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.09 -13.44 41.39 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.474 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.4 p30 -127.73 27.06 5.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.6 105.19 14.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.9 t -100.94 173.21 6.59 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.58 153.03 40.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.27 156.44 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.428 ' N ' HG22 ' A' ' 55' ' ' VAL . 58.2 m -126.6 138.35 53.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.99 149.02 37.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.0 p30 -85.37 -173.47 4.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.64 -22.86 66.75 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -77.53 -7.69 56.67 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.968 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.79 31.86 59.81 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.8 p -127.36 139.0 53.15 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.04 166.0 17.77 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 14.8 p -150.48 127.8 11.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.436 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -162.97 156.93 20.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.861 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.436 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -109.35 134.74 51.45 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.943 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.53 119.21 37.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.667 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -74.87 128.33 35.32 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.885 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -102.91 128.14 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.998 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.468 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -114.57 149.94 35.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 ppt_? -78.33 -16.55 57.6 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.55 ' HB3' ' OD1' ' A' ' 87' ' ' ASP . 7.9 p -161.71 148.66 14.27 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.064 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 5.8 p90 -178.09 148.73 0.52 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.11 115.04 1.67 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.564 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.34 94.99 0.94 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.896 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.54 10.57 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.7 tp -54.22 139.29 36.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.51 -41.58 21.26 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.561 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 2.0 t70 -56.33 -17.0 6.45 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.76 27.93 9.96 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.1 m -110.1 141.61 42.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.7 94.2 5.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.669 ' CD1' HG21 ' A' ' 40' ' ' VAL . 7.6 t-105 -62.43 -57.11 12.44 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 168.82 17.39 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.63 108.59 0.75 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.151 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -79.07 153.96 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.55 ' OD1' ' HB3' ' A' ' 72' ' ' SER . 14.8 m-20 -129.97 97.4 4.46 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.541 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 96.6 m -53.0 -28.04 22.04 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 50.5 p -78.12 -0.53 28.54 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -118.88 -28.04 5.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.68 -173.18 3.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.42 125.28 49.09 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.898 ' O ' HG13 ' A' ' 110' ' ' ILE . 56.6 m -103.93 159.81 15.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -155.36 144.79 21.1 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -109.9 157.83 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.298 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.51 168.56 40.24 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.465 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.47 139.73 53.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.333 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 85.8 p -122.57 149.03 44.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.907 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -107.6 -161.6 0.79 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -68.56 -47.98 65.43 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.72 -23.71 66.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.68 52.42 2.13 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.784 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.67 165.79 21.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.95 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.07 177.59 44.7 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.933 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.48 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 161.15 45.13 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.372 3.381 . . . . 0.0 109.568 179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.307 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 4.6 pt-20 -36.63 128.92 0.81 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -46.98 150.38 2.08 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.866 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.4 t -126.03 115.05 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.538 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.15 143.91 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.06 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.1 mt -109.18 168.51 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.3 t -155.0 121.23 5.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.707 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 10.7 m-85 -94.8 129.76 41.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.972 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.647 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.512 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.482 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.37 -174.7 1.5 Allowed 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.291 3.327 . . . . 0.0 109.595 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.752 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.15 108.55 21.27 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.952 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.2 144.65 49.81 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.524 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -105.81 112.7 25.87 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.999 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.85 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.31 152.84 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.982 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.905 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.34 175.02 2.04 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.92 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.145 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.3 Cg_endo -72.39 118.01 5.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.298 3.332 . . . . 0.0 109.562 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.969 ' HB2' HG23 ' A' ' 110' ' ' ILE . 81.1 p -111.49 46.26 1.13 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.66 ' HA ' ' O ' ' A' ' 111' ' ' SER . 4.3 m -127.98 105.05 8.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.874 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.014 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.39 28.31 11.76 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.145 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -100.37 132.1 45.93 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -106.79 170.81 7.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -46.4 142.45 3.02 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.75 -23.41 33.96 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 52.0 m -77.86 151.8 33.7 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.6 p -128.26 116.26 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 67' ' ' LEU . 3.1 p -78.7 152.14 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.85 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.03 143.48 36.68 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.997 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.529 ' CG1' HG21 ' A' ' 108' ' ' VAL . 0.1 OUTLIER -140.76 106.99 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.966 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.7 117.12 28.93 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.672 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.79 139.77 20.32 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.43 108.33 7.12 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.927 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.45 25.95 8.45 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.237 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.7 -171.9 3.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.566 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 63.1 mt-30 -82.54 124.91 30.55 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.38 139.7 49.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.92 8.29 68.34 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.703 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.62 146.22 23.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.987 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.92 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.54 149.05 23.15 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.207 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 56.4 m-85 -136.95 145.06 43.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.867 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.145 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -110.54 113.76 26.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.995 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.301 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.07 140.07 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.956 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -162.37 164.44 35.58 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.699 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.5 tt0 -114.58 108.16 16.46 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.792 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.0 OUTLIER -110.83 146.32 36.65 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.987 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.754 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -122.81 138.28 54.69 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.605 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.52 123.2 19.04 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.959 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.741 HG21 ' CD1' ' A' ' 83' ' ' TRP . 0.0 OUTLIER -103.05 -44.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.395 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 1.1 m-20 -133.44 -179.28 5.42 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 m -69.03 111.12 4.82 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.66 85.97 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.035 HG21 ' HE1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -130.78 125.52 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.954 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.2 pt? -134.09 141.48 47.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.07 147.22 24.25 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.823 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 35.9 m -107.11 150.3 26.71 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.652 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.3 t30 -111.46 109.02 56.36 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -72.45 -0.65 9.06 Favored 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.315 3.343 . . . . 0.0 109.608 179.909 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.75 -11.87 43.79 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.576 ' CB ' HG23 ' A' ' 68' ' ' THR . 56.1 m-20 -132.71 28.64 4.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.666 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.92 119.3 38.01 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.994 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 t -113.4 -179.17 3.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.96 158.13 43.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' N ' ' A' ' 56' ' ' THR . 3.4 p -166.45 161.91 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.528 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.8 m -127.98 126.21 40.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.31 146.32 40.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.927 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 47.3 p30 -87.43 -173.44 4.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.52 -25.43 67.28 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -82.21 4.37 23.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 66.3 6.12 31.84 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.5 t -96.9 134.25 40.48 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.0 164.96 15.94 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -148.48 127.9 13.1 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.688 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -160.02 155.27 25.07 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.88 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.401 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.56 125.4 52.93 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.938 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.095 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -105.35 123.33 47.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.975 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.585 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -78.06 136.08 37.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.939 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.434 ' O ' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -112.6 124.99 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.979 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.435 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.97 173.46 6.32 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 27.5 ptt180 -99.41 -9.67 23.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 97.2 p -168.05 145.69 4.29 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.699 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 1.9 p90 -176.6 156.16 1.44 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -55.46 114.5 1.86 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 100.68 1.8 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.889 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -84.68 101.5 12.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -53.64 136.07 39.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.667 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.59 -39.95 12.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.702 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -56.31 -17.67 8.42 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.913 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.13 27.7 9.18 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.7 m -111.77 142.42 44.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -79.93 94.33 5.85 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.395 ' CZ2' ' OD2' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.51 -58.34 7.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.886 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 173.14 20.41 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 104.38 0.52 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 38' ' ' ALA . 9.9 p -79.44 150.92 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -107.21 98.09 7.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -53.24 -23.84 9.77 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.2 p -85.44 1.41 48.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -112.7 -26.93 8.37 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.03 179.69 6.1 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.0 128.44 41.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.885 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 36.7 m -104.41 153.29 21.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.081 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -147.25 147.05 30.03 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.981 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.095 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.9 t -110.92 160.04 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.27 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.24 166.37 37.39 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.301 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.01 123.82 35.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.978 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.145 ' N ' ' H ' ' A' ' 33' ' ' ASP . 14.2 m -107.65 144.18 35.08 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.92 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.6 OUTLIER -102.56 -160.75 0.8 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.979 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.63 -47.78 65.76 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.98 -24.42 66.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.72 53.78 1.76 Allowed Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.566 ' ND2' ' OE1' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -134.57 169.81 16.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.989 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.207 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.41 179.16 45.92 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.482 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.32 164.19 36.37 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.318 3.345 . . . . 0.0 109.601 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.647 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.61 126.92 1.14 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.976 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -42.93 154.69 0.17 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.89 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.9 t -120.84 103.79 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.64 126.54 35.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.081 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.6 mt -103.24 159.07 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.735 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -146.95 123.22 10.91 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.522 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 39.7 m-85 -95.36 125.57 40.07 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.9 m120 . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.98 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.26 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.647 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.3 Cg_endo -72.34 -178.13 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.288 3.325 . . . . 0.0 109.6 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.905 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.97 108.95 21.76 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 1.278 ' N ' ' OE2' ' A' ' 106' ' ' GLU . . . -124.29 146.78 48.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.587 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.85 114.62 28.89 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.98 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.786 HG13 ' O ' ' A' ' 20' ' ' LYS . 41.4 t -109.82 147.74 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.946 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.43 176.01 1.38 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.913 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.061 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.39 117.36 5.1 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.323 3.349 . . . . 0.0 109.615 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.917 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 14.5 p -113.38 48.52 1.04 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.981 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 111' ' ' SER . 5.9 m -128.99 105.83 8.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.872 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.49 28.04 12.12 Favored Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.069 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -105.01 129.25 53.5 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -104.45 170.39 7.92 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.564 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 7.4 p-10 -44.59 141.29 2.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.65 -22.87 32.84 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -79.39 149.6 31.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.538 ' O ' HG13 ' A' ' 18' ' ' VAL . 13.8 p -122.34 121.72 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.063 HG23 HG12 ' A' ' 69' ' ' VAL . 12.2 t -85.44 153.15 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.786 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.89 143.2 34.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.952 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.657 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -140.58 111.5 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.703 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.2 117.71 25.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.008 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.59 145.5 22.89 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.793 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -144.36 113.38 6.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 95.63 17.97 34.24 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.971 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.008 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.87 170.78 9.8 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.615 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 69.4 mt-30 -51.78 119.58 4.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.519 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.33 130.28 39.83 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.64 7.34 87.23 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.482 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.83 137.27 34.13 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.703 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -81.47 152.41 27.36 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.741 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 36.8 m-85 -138.08 141.08 40.27 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.913 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.18 ' CB ' ' H ' ' A' ' 98' ' ' SER . 7.8 m-20 -106.01 113.45 26.99 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.268 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.0 147.46 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.919 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.1 168.16 41.1 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.878 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.9 tt0 -112.13 113.2 25.33 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 25.9 m -114.2 141.99 46.82 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.706 ' O ' HD12 ' A' ' 45' ' ' LEU . . . -121.96 129.08 52.21 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.56 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.19 128.58 36.43 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.906 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.286 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.7 m -109.78 -43.91 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.664 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -141.08 160.12 40.76 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.5 m -55.55 113.49 1.46 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.94 8.06 87.98 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.149 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.8 t -130.34 108.99 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.973 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.822 HD11 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -118.22 144.23 45.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.366 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -105.64 143.63 33.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 15.5 m -110.24 152.71 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.685 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 42.6 t30 -111.86 108.02 55.94 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.73 9.12 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.355 3.37 . . . . 0.0 109.573 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.448 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -92.48 -11.23 35.2 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.852 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -129.82 19.62 5.56 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.77 107.76 16.39 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.0 t -101.46 173.36 6.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.9 p -146.06 149.39 33.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.89 159.72 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 55' ' ' VAL . 63.6 m -127.74 136.68 51.86 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.38 142.44 46.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 40.6 p30 -80.86 -172.45 3.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -22.02 66.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -80.87 4.05 20.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 60.44 31.29 73.83 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 t -128.13 133.76 49.02 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.68 164.65 18.68 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.27 129.96 17.05 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -156.57 164.61 37.99 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.861 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -125.25 118.23 25.56 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.973 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.552 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.68 156.2 16.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.501 ' N ' HD23 ' A' ' 67' ' ' LEU . 0.3 OUTLIER -112.36 132.73 54.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 1.063 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.34 128.06 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.99 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.471 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 0.4 OUTLIER -111.07 164.04 13.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.999 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 ptt180 -91.88 -9.47 43.13 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 12.8 t -174.8 144.37 0.81 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.902 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.878 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 13.3 p90 -175.83 157.63 1.99 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 117.06 3.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.366 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.32 100.56 1.92 Allowed Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.985 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.26 100.28 10.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.7 tp -54.42 136.7 43.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.859 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.1 m-85 -46.25 -39.93 10.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.568 ' HB2' HD21 ' A' ' 77' ' ' LEU . 7.6 t0 -56.84 -17.36 9.07 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.38 28.2 9.3 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.31 140.08 47.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.6 ptt-85 -79.72 94.53 5.76 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.286 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.25 -55.78 24.99 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.59 172.86 19.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.35 107.09 1.01 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -83.7 152.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.962 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -109.5 99.6 8.79 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.58 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.2 m -53.27 -25.06 13.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 30.4 p -84.04 1.25 44.79 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -118.32 -27.98 5.88 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.911 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.55 177.4 6.24 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.07 125.3 41.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.262 ' O ' HG13 ' A' ' 110' ' ' ILE . 38.7 m -104.53 153.05 21.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.013 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.4 OUTLIER -151.17 146.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.929 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.552 HG13 ' CD1' ' A' ' 67' ' ' LEU . 21.5 t -105.84 153.48 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.943 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.232 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -170.2 165.97 39.22 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.268 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.32 131.76 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.18 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 7.6 t -112.29 150.91 30.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.703 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -112.6 -164.25 0.9 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.948 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.41 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.92 -48.51 68.44 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.8 -23.76 66.1 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.7 53.2 1.99 Allowed Glycine 0 C--N 1.336 0.55 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.615 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.94 171.89 13.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.977 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.741 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.27 176.43 46.64 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.647 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.1 Cg_endo -72.38 165.17 33.43 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.349 3.366 . . . . 0.0 109.622 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.278 ' OE2' ' N ' ' A' ' 5' ' ' ALA . 0.2 OUTLIER -38.08 136.51 0.6 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.988 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.98 149.0 6.06 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.918 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 11.9 t -123.84 105.93 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.485 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.57 147.96 23.0 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.262 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.09 159.76 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.714 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -142.28 111.98 6.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.953 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 66.2 m-85 -87.15 110.71 20.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.478 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.545 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.34 -178.29 3.22 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 124.357 3.371 . . . . 0.0 109.616 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.111 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -97.46 110.26 22.85 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.963 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.843 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.5 156.53 40.6 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -114.96 117.15 29.83 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.111 HG22 ' CG1' ' A' ' 21' ' ' VAL . 58.5 t -114.5 144.21 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.697 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.2 165.82 40.02 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.921 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.697 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.34 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 124.318 3.345 . . . . 0.0 109.617 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.77 ' OG ' HG11 ' A' ' 69' ' ' VAL . 47.7 t -127.84 17.57 6.79 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' SER . . . . . 1.025 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.1 p -92.2 111.78 23.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.067 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.43 25.6 27.79 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.067 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -108.52 139.48 43.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.989 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.6 m -67.47 144.69 55.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.476 ' HB3' ' H ' ' A' ' 71' ' ' ARG . 17.9 p-10 -48.1 147.49 2.14 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -18.97 45.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.6 m -60.99 130.53 46.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.3 p -92.87 115.05 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.6 m -100.58 159.33 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.943 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.6 146.1 39.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.111 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -138.5 114.52 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.843 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.8 116.31 23.47 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.944 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.997 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.21 145.96 22.57 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.111 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -142.23 115.83 9.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.73 16.02 29.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.997 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -89.92 168.6 11.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.522 ' HB2' HG21 ' A' ' 30' ' ' THR . 82.5 mt-30 -52.03 119.24 4.11 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.477 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.37 132.06 44.29 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.89 7.78 84.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.522 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -98.01 141.89 30.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.46 150.86 24.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.891 ' HD1' ' OD1' ' A' ' 103' ' ' ASN . 40.3 m-85 -138.29 141.73 39.82 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.17 ' OD2' ' HB2' ' A' ' 98' ' ' SER . 0.9 OUTLIER -105.85 115.54 30.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.567 HG22 ' CG ' ' A' ' 97' ' ' LEU . 1.8 t -96.64 136.46 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.874 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.66 153.51 24.53 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.994 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.4 tt0 -94.46 119.68 33.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.844 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.724 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.3 m -107.04 159.26 16.43 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.715 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -147.16 130.08 16.25 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.543 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -69.96 125.92 28.16 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.174 ' CG1' HG12 ' A' ' 86' ' ' VAL . 4.0 m -113.74 -39.56 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.61 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -146.65 -179.59 6.88 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.95 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.8 m -64.69 111.58 2.82 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.955 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.56 8.52 63.26 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.596 HG21 ' CH2' ' A' ' 83' ' ' TRP . 40.1 t -110.02 104.0 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.799 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 mt -106.86 155.94 19.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.526 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -134.27 126.7 30.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.144 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -107.84 158.83 16.99 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.561 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.5 t30 -118.83 113.96 35.78 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -72.43 -1.45 10.23 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.317 3.345 . . . . 0.0 109.577 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.561 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -11.48 40.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -131.63 26.58 4.71 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.667 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.34 122.07 41.97 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.983 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -104.65 -175.32 2.76 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.0 p -146.72 154.37 41.34 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.89 156.18 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.424 ' N ' HG22 ' A' ' 55' ' ' VAL . 41.7 m -125.97 121.68 33.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.76 150.18 20.45 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 p30 -97.02 -168.02 1.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.13 -25.37 68.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.983 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -83.37 3.75 30.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.894 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 62.25 31.23 78.4 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.3 t -126.22 142.85 51.36 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -133.98 159.81 39.61 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.21 124.96 22.42 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.782 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -144.62 178.43 7.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.866 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.782 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -129.46 122.32 29.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.949 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.018 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -108.09 149.19 28.79 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.925 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.832 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -111.37 143.0 42.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.77 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -109.55 125.93 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.967 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.524 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -115.08 153.08 31.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.986 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.476 ' H ' ' HB3' ' A' ' 15' ' ' ASP . 10.0 ttp180 -74.03 -37.79 64.22 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 t -151.06 153.25 34.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.994 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 5.4 p90 -177.09 159.44 1.65 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.931 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.98 114.43 1.59 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.526 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.71 93.77 0.57 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 1.144 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.34 99.94 10.34 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.904 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.4 tp -58.76 131.79 51.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.724 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 8.4 m-85 -47.06 -36.46 8.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.592 ' HB2' HD21 ' A' ' 77' ' ' LEU . 3.4 t0 -56.99 -17.51 10.08 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.15 27.29 8.87 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.904 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.0 143.05 45.37 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.77 94.71 9.83 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.61 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 34.8 t-105 -63.41 -58.46 6.99 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.893 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 171.11 18.48 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.6 109.0 0.71 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.174 HG12 ' CG1' ' A' ' 40' ' ' VAL . 18.1 m -89.93 150.83 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -108.88 89.14 2.9 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.11 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 2.0 m -52.92 -24.48 9.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -79.27 -1.75 38.06 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.18 -28.36 6.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -118.64 -165.63 1.14 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 124.62 40.9 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.273 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -104.27 152.36 22.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.044 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 0.7 OUTLIER -168.12 147.67 4.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.944 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.009 HG21 HD12 ' A' ' 67' ' ' LEU . 4.9 t -99.4 164.92 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.95 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -171.67 160.01 31.73 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.567 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -100.2 163.57 12.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.17 ' HB2' ' OD2' ' A' ' 33' ' ' ASP . 14.8 m -155.83 121.68 5.01 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.588 ' HB3' ' HA ' ' A' ' 32' ' ' TYR . 4.8 p-10 -113.88 -168.93 1.42 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -47.64 -26.76 1.61 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.7 -25.94 14.52 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.912 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 92.01 21.15 33.98 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.891 ' OD1' ' HD1' ' A' ' 32' ' ' TYR . 19.8 p-10 -59.64 -149.42 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.493 ' O ' ' HD2' ' A' ' 3' ' ' PRO . . . 141.4 151.82 5.62 Favored Glycine 0 C--N 1.336 0.556 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.545 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.6 Cg_endo -72.37 161.69 43.63 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.302 3.335 . . . . 0.0 109.609 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.478 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.3 mt-10 -32.06 120.26 0.28 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -32.94 149.8 0.01 OUTLIER Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.044 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 2.6 t -108.26 103.33 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.52 126.72 31.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.273 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 7.0 pt -141.81 177.82 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 111' ' ' SER . . . . . 1.025 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -171.65 177.82 3.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.11 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -130.3 115.21 16.62 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.969 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 1.6 p-10 . . . . . 0 N--CA 1.45 -0.469 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.908 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.139 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.625 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.5 Cg_endo -72.46 -178.59 3.44 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.301 3.334 . . . . 0.0 109.57 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.223 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.0 21.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.82 ' H ' ' CD ' ' A' ' 106' ' ' GLU . . . -122.53 151.05 41.75 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.952 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.648 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.7 p -116.49 116.27 27.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -106.82 148.92 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 8' ' ' THR . . . . . 1.031 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -65.69 179.39 0.45 Allowed Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.917 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.128 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.36 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.315 3.343 . . . . 0.0 109.648 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.543 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 3.8 p -112.42 35.87 3.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -119.8 106.75 12.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.836 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.026 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.58 30.89 8.66 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.128 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.42 131.52 47.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.97 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -99.75 163.84 12.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -46.95 140.07 5.08 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.35 -22.22 36.91 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 37.0 m -72.05 149.53 44.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.619 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.6 p -126.7 117.12 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.0 m -84.33 165.27 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.779 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.6 135.18 54.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.595 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.8 p -124.3 120.46 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.648 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -126.29 117.5 23.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.864 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -93.49 140.14 14.92 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.724 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.5 116.38 10.92 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.99 20.53 18.26 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.023 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.52 -177.28 5.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.98 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 25.9 mt-30 -69.29 122.23 18.46 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.43 130.04 39.75 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.1 8.09 86.85 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.512 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.48 137.13 34.96 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.975 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 1.017 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.56 150.62 25.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.124 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.9 m-85 -136.81 146.84 46.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.891 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.174 ' H ' ' N ' ' A' ' 98' ' ' SER . 4.4 m-20 -111.96 113.85 26.41 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.478 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.98 143.23 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.88 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.33 165.34 38.73 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.782 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.28 113.07 25.29 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 62.6 m -111.13 145.76 38.03 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.538 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -123.23 128.29 49.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.75 120.63 13.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.951 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.497 HG11 ' CD1' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -99.35 -44.14 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.53 ' OD1' ' C ' ' A' ' 40' ' ' VAL . 0.2 OUTLIER -136.83 175.5 9.56 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.948 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.567 ' O ' HG23 ' A' ' 42' ' ' THR . 6.1 t -60.8 112.67 2.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.03 8.14 72.96 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.47 ' O ' HG23 ' A' ' 40' ' ' VAL . 3.2 t -124.17 110.89 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.531 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.01 138.69 53.75 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.971 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.373 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.09 156.04 17.12 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 37.1 m -117.12 150.63 38.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.693 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -114.11 107.11 52.39 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.31 -0.84 9.25 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.327 3.351 . . . . 0.0 109.627 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.639 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -12.11 41.38 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 68' ' ' THR . 92.9 m-20 -131.46 26.14 4.78 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -97.23 120.03 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 32.2 t -113.84 -177.38 3.12 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.0 p -147.08 156.61 43.14 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.474 HG22 ' HB1' ' A' ' 63' ' ' ALA . 5.9 p -166.94 157.59 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 48.3 m -125.35 134.08 52.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.838 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -72.57 140.73 48.26 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -83.82 -170.88 3.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.75 -26.14 68.55 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.2 -4.91 44.37 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.023 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.93 31.61 69.83 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.964 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.3 p -124.11 133.77 53.52 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.838 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -147.46 122.38 10.02 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -123.0 144.28 49.37 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.757 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -141.0 178.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.757 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -108.32 116.56 32.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.053 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -108.46 123.6 49.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.95 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.697 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -91.4 137.48 32.33 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -112.31 126.54 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.471 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -114.36 173.38 6.48 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.962 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 10.6 ptt85 -100.99 -7.97 22.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.548 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.4 p -169.73 147.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.782 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.6 p90 -177.65 160.58 1.58 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.13 115.58 2.52 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.373 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.32 94.03 1.24 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.741 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.2 m-85 -83.85 99.58 10.42 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.927 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -53.73 134.66 41.96 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.684 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.6 p90 -46.26 -38.84 9.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.556 ' CB ' HD21 ' A' ' 77' ' ' LEU . 4.4 t70 -56.77 -17.26 8.47 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.29 27.99 8.88 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.927 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.59 139.73 47.93 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -82.12 93.28 7.0 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.497 ' CD1' HG11 ' A' ' 40' ' ' VAL . 6.8 t-105 -63.38 -57.57 9.9 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.77 169.91 17.86 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -60.92 104.68 0.38 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 73' ' ' PHE . 6.2 p -81.61 149.27 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -105.93 98.33 8.03 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.517 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.6 m -51.76 -25.41 7.46 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 21.1 p -80.55 2.55 25.01 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.961 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 21.8 m -112.93 -27.2 8.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.59 -178.49 5.09 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.64 127.21 42.41 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.316 ' O ' HG13 ' A' ' 110' ' ' ILE . 82.4 m -103.17 153.0 20.79 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.086 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -147.34 146.18 29.59 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.053 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.3 t -100.6 163.15 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.331 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.13 158.61 24.36 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.478 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.66 127.56 37.22 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.996 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.174 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.0 m -117.03 158.27 24.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 1.017 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 1.0 OUTLIER -110.79 -157.36 0.61 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.986 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.91 -48.15 77.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.549 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -72.56 -25.93 61.54 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.78 47.3 2.31 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.62 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 2.1 p30 -116.34 154.7 29.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.124 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -165.09 171.98 40.61 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.625 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.36 171.88 16.09 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.294 3.329 . . . . 0.0 109.647 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.223 ' OE1' ' HA ' ' A' ' 4' ' ' THR . 6.5 pt-20 -36.49 153.44 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.72 153.97 52.96 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.991 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.959 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.5 t -128.07 109.92 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.992 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.716 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.7 151.33 19.72 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.923 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.316 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -120.63 164.87 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 t -154.82 120.39 5.09 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.512 ' HE2' HG23 ' A' ' 69' ' ' VAL . 46.4 m-85 -97.01 127.06 42.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.947 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.045 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.383 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.38 -174.19 1.35 Allowed 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.316 3.344 . . . . 0.0 109.545 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.795 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.5 m -93.95 108.51 20.31 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.761 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.65 143.59 51.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.733 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -98.29 111.98 24.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.036 HG21 ' CG2' ' A' ' 108' ' ' VAL . 24.2 t -109.51 143.98 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.934 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.0 175.19 1.86 Allowed Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.921 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.005 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.1 Cg_endo -72.33 118.41 5.59 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.34 3.36 . . . . 0.0 109.598 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.715 ' HB2' HG23 ' A' ' 110' ' ' ILE . 25.0 p -116.77 46.04 1.72 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.3 p -124.8 106.04 9.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.9 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.061 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.72 28.08 13.16 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.061 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -103.99 129.75 51.61 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.967 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -103.8 170.99 7.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.762 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -45.91 142.32 2.67 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.984 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.13 -22.97 34.88 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.479 HG21 ' HB3' ' A' ' 13' ' ' LEU . 29.5 m -77.36 148.2 35.7 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.539 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -124.19 123.08 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.569 ' HA ' HG21 ' A' ' 8' ' ' THR . 20.9 m -91.05 166.88 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.805 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.4 138.49 54.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.994 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.857 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -132.73 117.81 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.761 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.86 116.22 21.21 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.727 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.0 144.41 23.83 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.795 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.79 106.26 4.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.89 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.19 22.09 8.98 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.64 -165.0 1.22 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -80.43 124.19 28.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.499 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 129.74 38.64 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.57 7.94 85.79 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.509 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.74 143.89 25.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.876 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -91.44 150.11 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.0 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.5 m-85 -138.29 146.41 42.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.221 ' CA ' ' H ' ' A' ' 98' ' ' SER . 12.2 m-20 -112.48 113.86 26.25 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.484 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.27 152.58 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.802 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . 179.95 173.63 45.11 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.324 -1.111 . . . . 0.0 110.324 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.058 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 8.3 tt0 -106.23 119.68 39.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.432 ' HB3' HD13 ' A' ' 45' ' ' LEU . 11.0 m -109.14 162.58 14.13 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.301 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -148.73 136.26 20.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.892 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.03 123.69 19.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.89 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.017 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -102.2 -41.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.638 ' HB2' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -150.45 179.21 8.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.944 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -65.85 109.36 2.46 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.29 10.34 86.1 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.59 HG21 ' CE2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -130.87 131.7 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.8 pp -133.71 162.35 32.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.559 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.02 144.96 51.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.44 158.86 17.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.862 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -120.18 118.58 31.3 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.458 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.7 Cg_endo -72.37 1.64 5.92 Favored 'Trans proline' 0 N--CA 1.446 -1.278 0 C-N-CA 124.326 3.351 . . . . 0.0 109.606 179.884 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.29 -20.65 31.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.868 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.429 ' CB ' HG23 ' A' ' 68' ' ' THR . 91.7 m-20 -129.78 30.56 4.86 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.66 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -94.88 117.96 30.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.993 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.5 t -114.01 176.99 4.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.4 p -147.13 155.56 42.26 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.536 HG22 ' N ' ' A' ' 56' ' ' THR . 3.2 p -167.1 162.36 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.536 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.8 m -127.9 128.69 45.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.94 152.05 28.67 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.41 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.1 p30 -94.13 -170.75 2.37 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.52 69.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -76.02 -7.57 54.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.91 8.69 87.28 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.0 p -99.06 139.79 34.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.66 156.01 32.62 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -136.76 121.92 19.12 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.592 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.57 153.57 25.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 m -114.48 130.61 56.74 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.905 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.394 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -107.72 154.25 21.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.792 ' H ' HD13 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -113.76 140.5 48.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.96 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.435 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -110.25 129.78 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.99 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.762 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -114.18 164.88 13.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -88.06 -25.01 23.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -162.11 147.58 13.0 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.932 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.058 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.2 p90 -176.57 156.01 1.44 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -55.86 121.18 8.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.559 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -82.46 96.86 1.88 Allowed Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.99 99.96 10.74 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.46 129.3 41.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.995 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.606 ' N ' HD12 ' A' ' 77' ' ' LEU . 17.9 p90 -47.67 -34.51 8.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.617 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.68 -16.36 10.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.14 8.49 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -118.16 150.62 39.08 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.4 mtp180 -93.85 97.53 10.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.59 ' CE2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.9 -55.6 21.44 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.947 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.81 176.47 22.19 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.9 113.42 4.37 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.986 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.301 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.6 t -89.15 152.96 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -117.65 93.13 4.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.164 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 57.6 m -52.92 -26.59 15.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 36.7 p -78.33 -0.23 28.1 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -117.63 -28.04 6.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.47 -173.56 2.94 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.13 124.21 47.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.86 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.812 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 65.9 m -105.25 152.52 22.78 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.103 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -144.21 145.5 32.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.394 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -107.82 156.04 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.303 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.46 174.34 46.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.484 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -128.08 142.61 51.16 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.221 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 97.3 p -118.77 152.63 35.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.876 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -114.06 -165.6 1.02 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.974 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -54.32 -49.34 69.92 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.539 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -75.13 -25.24 58.26 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 98.71 45.29 2.31 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.708 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 3.3 p30 -116.63 167.64 10.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.0 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.03 -171.3 39.71 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.383 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.34 152.51 55.37 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.322 3.348 . . . . 0.0 109.599 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.126 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -35.26 121.13 0.56 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.55 143.91 0.09 OUTLIER Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.971 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.083 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -114.3 105.49 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.05 130.48 34.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.103 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.8 mt -103.79 164.08 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.907 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.99 121.52 10.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.164 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 18.0 m-85 -90.56 113.15 25.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.496 ' CB ' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.639 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.415 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.0 Cg_endo -72.42 -174.7 1.51 Allowed 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 124.319 3.346 . . . . 0.0 109.623 179.927 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.771 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.8 108.97 21.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.22 140.1 52.81 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.939 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.599 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -98.7 114.11 26.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.916 HG21 ' CG2' ' A' ' 108' ' ' VAL . 38.2 t -111.25 149.17 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.94 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.19 175.7 1.43 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.909 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.074 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.9 Cg_endo -72.35 119.2 5.99 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.312 3.341 . . . . 0.0 109.635 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.046 ' CB ' HG23 ' A' ' 110' ' ' ILE . 51.7 p -113.17 47.9 1.08 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.2 p -125.21 106.85 10.19 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.87 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.991 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.63 26.15 23.51 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.947 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.074 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.95 131.58 46.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 t -118.04 177.06 4.93 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.645 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 5.2 p-10 -45.41 139.26 3.76 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.66 34.73 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 62.9 m -85.98 150.58 24.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.508 ' O ' HG13 ' A' ' 18' ' ' VAL . 12.9 p -126.26 123.79 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.084 HG22 ' O ' ' A' ' 67' ' ' LEU . 18.5 m -87.19 162.31 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.905 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.95 143.87 44.47 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.736 HG23 HG22 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -138.84 112.06 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.981 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.709 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.9 115.66 22.33 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.31 140.78 20.12 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.771 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -138.72 106.68 5.69 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.888 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.03 26.16 8.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.22 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.12 -169.27 2.5 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.516 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.4 mt-30 -80.14 123.47 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.39 130.12 40.53 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.68 8.74 84.6 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.523 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.8 134.4 38.8 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.809 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.84 151.76 23.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.515 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 40.9 m-85 -137.26 148.65 46.58 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.209 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -112.11 116.27 30.23 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.923 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.368 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.78 140.47 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.948 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.856 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -163.3 157.82 30.05 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.791 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.6 tt0 -106.53 116.38 31.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.502 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.6 m -102.96 165.21 11.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.58 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -151.91 142.94 23.15 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.948 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 0.5 OUTLIER -64.98 122.13 16.28 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.843 HG11 ' CD2' ' A' ' 83' ' ' TRP . 1.1 t -101.68 -55.23 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.939 ' OD2' ' CH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -131.86 168.62 17.53 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -50.07 110.88 0.44 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.87 8.31 63.8 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.503 HG11 ' CE2' ' A' ' 83' ' ' TRP . 62.1 t -119.62 125.14 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.6 pp -125.85 162.05 26.03 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -130.96 161.49 31.81 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.898 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.888 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -115.65 156.07 26.53 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.752 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 23.0 t30 -116.71 110.79 41.87 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -72.43 -0.89 9.4 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.356 3.371 . . . . 0.0 109.546 179.956 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.601 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.97 -11.58 43.93 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.811 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.5 m-20 -133.39 28.87 4.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.884 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.643 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -101.9 118.17 36.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 40.9 t -107.86 -176.39 3.05 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 96.9 p -146.25 152.65 39.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.892 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.59 155.57 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 55' ' ' VAL . 74.0 m -126.41 126.94 44.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.924 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -56.43 146.68 23.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.3 p30 -88.16 -170.25 2.89 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.91 -25.85 67.82 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -84.58 5.23 28.63 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 65.27 8.78 38.99 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -98.35 134.42 41.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.986 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.39 166.23 14.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.5 p -150.03 124.5 9.64 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.701 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -159.36 151.87 21.39 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.901 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.16 132.79 54.01 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.127 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -109.8 119.17 38.52 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.895 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.811 HG23 ' HB3' ' A' ' 51' ' ' ASP . 1.8 t -70.04 143.55 52.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.544 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.3 t -104.23 131.51 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.791 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -119.84 153.07 36.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.97 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 ptt85 -85.66 -22.77 27.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 t -166.79 152.96 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.936 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.752 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.5 p90 -175.4 167.24 3.33 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.921 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.38 125.02 22.46 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.915 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.52 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.79 90.92 1.07 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.888 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.55 10.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.999 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.948 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.47 141.64 30.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.693 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.05 -42.13 18.05 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.628 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -57.52 -17.1 12.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.978 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 29.1 9.65 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.948 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.17 122.08 46.79 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.38 92.27 0.08 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.503 ' CE2' HG11 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.56 -58.34 7.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.93 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.03 170.28 21.15 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.63 139.36 53.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 73' ' ' PHE . 2.7 p -126.34 140.55 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -93.48 94.97 8.97 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.98 -21.07 10.62 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.5 p -89.27 1.98 54.96 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 m -114.09 -27.38 7.7 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -123.26 -177.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.61 128.45 37.44 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.937 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.078 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 1.5 m -105.0 152.62 22.49 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.2 pt20 -152.89 147.32 25.85 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.127 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.6 t -114.17 158.16 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.957 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.265 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.43 163.71 33.06 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.368 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.07 124.16 36.36 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.988 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.209 ' N ' ' H ' ' A' ' 33' ' ' ASP . 11.5 m -113.52 156.68 23.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.809 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.19 -161.17 0.74 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.31 -48.62 69.74 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -66.68 -26.07 66.85 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.889 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.12 42.53 3.24 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.7 p30 -116.68 157.98 24.54 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -180.0 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.515 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.4 177.53 45.74 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.415 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.0 Cg_endo -72.41 154.86 55.88 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.317 3.345 . . . . 0.0 109.581 179.96 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.639 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -36.96 119.34 0.65 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.941 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.13 155.92 0.01 OUTLIER Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.916 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.1 t -119.23 107.59 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 118.19 25.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.046 HG23 ' CB ' ' A' ' 10' ' ' SER . 8.5 mt -98.25 159.12 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.75 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -144.1 123.48 13.09 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.078 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 5.4 m-85 -92.02 127.26 37.42 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.426 ' H ' ' H ' ' A' ' 12' ' ' GLY . 3.7 p-10 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.322 ' HB1' ' CB ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.567 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.39 -178.25 3.21 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.297 3.331 . . . . 0.0 109.584 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.111 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -100.23 111.87 24.16 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.936 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.754 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.5 160.53 29.29 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.8 p -124.75 119.08 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.815 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -116.73 154.84 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.936 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.22 174.9 1.74 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.954 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.4 Cg_endo -72.4 118.58 5.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.305 3.337 . . . . 0.0 109.593 179.889 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.289 ' OG ' HG23 ' A' ' 110' ' ' ILE . 11.9 p -116.02 48.76 1.19 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.646 ' HA ' ' O ' ' A' ' 111' ' ' SER . 18.8 p -126.43 104.71 8.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.91 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.79 29.05 16.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -94.85 133.41 38.6 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.986 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.4 t -96.61 158.32 15.49 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.997 ' OD1' ' HG3' ' A' ' 70' ' ' ARG . 25.5 t70 -45.1 142.51 1.9 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.426 ' H ' ' NH1' ' A' ' 70' ' ' ARG . . . 103.26 -23.13 34.21 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 91.7 m -71.59 150.94 44.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -125.27 122.78 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.264 HG22 ' O ' ' A' ' 67' ' ' LEU . 32.7 m -91.07 167.3 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.815 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -116.56 152.92 33.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.63 115.52 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -127.77 114.36 17.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.983 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.48 144.7 21.6 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.111 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.48 114.58 9.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.69 19.04 25.98 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.016 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.28 175.67 7.03 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -180.0 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.958 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 71.9 mt-30 -59.6 121.93 12.81 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.13 130.81 40.5 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.68 7.83 85.99 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.461 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.67 141.21 28.74 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.972 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 1.205 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.88 151.24 23.5 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.867 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.0 m-85 -135.77 146.81 48.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.433 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -109.79 114.89 28.84 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.951 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.516 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.9 140.24 22.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.782 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.78 168.98 39.91 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.219 -1.152 . . . . 0.0 110.219 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.11 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 13.3 tt0 -114.31 128.74 56.5 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 28.3 m -130.19 143.1 50.59 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.88 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -121.78 130.62 53.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.894 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.491 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.48 129.05 38.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.947 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.953 HG23 HG12 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -111.12 -41.84 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.92 163.26 35.68 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 95.1 m -54.74 120.08 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.25 6.81 62.05 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.975 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 1.5 t -125.91 115.45 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.978 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.814 HD23 ' HE2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -125.08 143.62 50.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.97 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.272 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.39 142.93 34.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.0 m -112.14 163.71 14.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.2 t30 -126.82 110.73 22.3 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.43 0.58 7.25 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.299 3.332 . . . . 0.0 109.571 179.927 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.507 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.12 -12.67 43.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.7 p30 -129.24 28.85 5.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 0.1 OUTLIER -86.39 105.62 16.85 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.2 t -104.31 173.26 6.38 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.0 p -145.52 155.56 43.16 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 7.0 p -167.26 157.35 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 179.963 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.8 m -128.1 137.0 51.95 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.16 137.29 41.23 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -76.82 -174.71 3.16 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.69 -19.11 61.99 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -84.6 7.51 19.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.987 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.016 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 32.06 61.77 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 t -129.31 133.52 47.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.25 164.37 19.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.67 126.35 11.02 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -158.64 154.19 26.07 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.39 133.35 50.29 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.438 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -115.25 119.84 37.68 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.893 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.645 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -72.07 133.82 45.47 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.89 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.17 123.9 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.998 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.997 ' HG3' ' OD1' ' A' ' 15' ' ' ASP . 0.5 OUTLIER -113.25 140.7 47.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.956 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.6 ptt180 -76.49 -7.71 55.68 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 77.3 p -167.29 146.6 5.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.11 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 7.2 p90 -177.19 164.98 2.26 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.02 115.07 3.45 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.272 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.47 98.31 1.25 Allowed Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 101.49 11.41 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.981 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -57.32 137.3 56.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.814 ' HE2' HD23 ' A' ' 45' ' ' LEU . 13.4 m-85 -47.23 -40.14 15.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.606 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t0 -56.45 -17.06 6.96 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.65 28.11 9.88 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 28.3 m -112.3 143.44 43.39 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -81.17 94.48 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.975 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.7 t-105 -63.08 -48.97 76.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.13 173.56 13.68 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.39 106.91 1.49 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' HB3' ' A' ' 38' ' ' ALA . 26.8 m -87.66 151.86 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -101.97 92.33 4.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -53.55 -24.66 14.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.968 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 8.3 t -84.26 1.73 43.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.5 m -115.14 -27.49 7.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.45 -171.53 2.24 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.6 131.22 42.04 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.609 ' HB2' ' HB ' ' A' ' 110' ' ' ILE . 1.9 m -102.81 167.77 9.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.191 ' HG3' ' O ' ' A' ' 108' ' ' VAL . 11.2 tt0 -169.78 126.29 0.86 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.438 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 67.3 t -112.91 159.23 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.989 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.821 ' C ' HG13 ' A' ' 34' ' ' VAL . . . -179.17 -179.79 48.77 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.942 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.516 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.64 144.37 51.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.274 ' OG ' ' HB3' ' A' ' 33' ' ' ASP . 94.0 p -129.62 147.08 51.38 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 1.205 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -105.27 -163.41 0.95 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.987 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.86 -48.21 69.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.937 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.23 -21.04 66.29 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.76 53.2 2.62 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.909 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.958 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.14 162.53 27.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.98 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.867 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -171.94 -179.52 42.94 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.567 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 156.85 54.3 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.357 3.371 . . . . 0.0 109.593 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.322 ' CB ' ' HB1' ' A' ' 2' ' ' ALA . 10.8 pt-20 -35.69 120.84 0.6 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.9 148.2 0.04 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.191 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 72.0 t -124.4 118.95 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -98.14 150.47 21.43 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.289 HG23 ' OG ' ' A' ' 10' ' ' SER . 16.9 mt -126.09 163.49 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.646 ' O ' ' HA ' ' A' ' 11' ' ' SER . 13.5 t -152.75 134.61 14.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.872 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -102.5 125.52 49.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.8 m120 . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.991 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.619 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.347 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.7 Cg_endo -72.35 -174.12 1.33 Allowed 'Trans proline' 0 N--CA 1.448 -1.201 0 C-N-CA 124.323 3.349 . . . . 0.0 109.609 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.79 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -96.47 107.12 19.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.673 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.39 147.53 48.18 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.987 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.528 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -102.26 111.57 23.9 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.025 HG22 HG12 ' A' ' 21' ' ' VAL . 38.6 t -107.28 148.04 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.894 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -73.24 176.74 2.39 Favored Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.93 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.11 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.6 Cg_endo -72.43 116.28 4.65 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.332 3.354 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.02 ' HB2' HG23 ' A' ' 110' ' ' ILE . 91.6 p -111.51 47.38 1.03 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.1 p -127.1 107.06 9.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.96 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.72 26.12 23.39 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.921 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.11 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.96 131.64 44.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.995 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.1 m -111.21 173.98 6.08 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 1.5 t0 -47.87 144.0 3.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.489 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 99.41 -23.6 35.57 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.483 HG21 ' HB3' ' A' ' 13' ' ' LEU . 82.7 m -74.33 151.17 39.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.8 p -125.31 117.41 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.949 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.693 HG13 HG22 ' A' ' 8' ' ' THR . 55.1 t -83.99 163.46 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tppt? -124.01 133.4 53.68 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -135.53 110.39 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.973 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.673 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.6 119.24 33.2 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.762 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.76 140.68 20.44 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.751 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.4 108.8 6.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.93 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.922 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.99 24.37 8.6 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.187 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.66 -163.59 1.03 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.434 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 4.4 mp0 -85.5 126.56 33.94 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.537 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.25 131.57 41.32 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.936 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.89 84.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.59 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.52 138.2 31.71 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.666 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -88.49 145.17 25.9 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.936 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -133.61 146.03 50.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.218 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -110.72 117.37 33.28 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.906 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.316 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.32 145.56 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.99 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.957 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.25 171.57 41.99 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.817 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -118.14 112.01 19.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.969 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.6 m -105.05 172.4 6.81 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.996 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -155.09 138.17 15.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.905 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.509 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.93 127.18 30.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.912 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.912 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -108.27 -51.85 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.027 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -143.01 165.14 28.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.946 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.624 ' O ' HG23 ' A' ' 42' ' ' THR . 10.1 t -51.46 112.15 0.7 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.08 9.15 75.87 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.773 HG12 ' CD1' ' A' ' 83' ' ' TRP . 4.5 t -129.06 114.37 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.933 HD12 ' N ' ' A' ' 46' ' ' ALA . 0.9 OUTLIER -118.22 162.84 17.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -123.64 138.63 54.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.983 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 58.3 m -109.49 148.46 31.16 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.716 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.8 t-20 -107.04 107.17 60.08 Favored Pre-proline 0 N--CA 1.45 -0.469 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.7 Cg_endo -72.47 0.35 7.61 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.344 . . . . 0.0 109.564 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.02 -9.54 50.92 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.9 p30 -131.72 27.16 4.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 104.98 13.9 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.991 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 29.8 t -98.32 172.29 7.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.945 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.34 154.68 41.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' THR . 6.0 p -166.7 158.31 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.954 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' VAL . 13.7 m -127.05 130.16 49.42 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.38 43.74 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.2 p30 -92.24 -171.59 2.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.27 -23.92 66.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.421 ' N ' ' OD1' ' A' ' 60' ' ' ASN . 1.8 m-20 -85.19 9.74 14.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 58.58 14.28 20.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -104.51 133.91 48.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.934 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.45 162.21 19.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -146.09 127.45 14.92 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.577 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -163.9 150.03 11.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.877 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.25 142.5 40.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.105 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -113.85 123.27 49.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.702 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.4 t -70.08 124.54 24.35 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.555 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -85.09 125.2 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.0 OUTLIER -117.08 144.76 44.3 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.427 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -87.16 -13.43 44.08 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 51.9 p -166.99 149.7 6.35 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.952 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.817 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.1 p90 -177.03 152.42 0.9 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.5 121.68 8.21 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.7 93.13 1.25 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 99.85 10.84 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.981 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.1 130.8 47.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.685 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.35 -35.75 8.55 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.54 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.68 -16.62 11.35 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.47 26.35 10.09 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 29.9 m -112.9 145.77 40.13 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.947 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -86.56 95.6 9.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.027 ' HZ2' ' CB ' ' A' ' 41' ' ' ASP . 1.0 OUTLIER -62.98 -53.84 47.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.939 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.7 173.21 14.32 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.13 125.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.996 HG11 ' CB ' ' A' ' 38' ' ' ALA . 54.5 t -100.05 148.63 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.47 93.25 4.14 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.427 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.5 m -52.86 -26.01 13.38 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.0 p -81.75 1.4 34.66 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -116.89 -27.18 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.916 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.98 -176.92 4.16 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.915 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.79 124.73 45.37 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.001 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 73.2 m -104.62 154.88 19.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -143.39 149.75 38.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.92 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.105 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 5.4 t -117.85 154.25 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.24 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.95 173.54 46.08 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.316 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.45 146.32 50.14 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.988 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.218 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 4.7 m -127.09 151.49 48.56 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.666 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -109.53 -165.62 1.03 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.984 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.48 -49.33 77.98 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.964 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -68.64 -25.33 64.78 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.41 41.82 3.34 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.9 p30 -115.94 164.04 15.0 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.936 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.57 -177.49 42.01 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.347 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.44 156.25 54.54 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.251 3.301 . . . . 0.0 109.57 179.903 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.619 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 3.3 pt-20 -37.36 119.87 0.74 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.49 151.93 0.02 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.941 ' CG2' HG21 ' A' ' 7' ' ' VAL . 3.6 t -124.01 104.44 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.42 128.83 34.83 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.033 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.4 mt -102.03 160.77 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.931 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.744 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -144.52 120.89 10.95 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.946 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.46 123.43 40.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.4 m120 . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.547 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 . . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.34 -178.64 3.42 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 124.356 3.371 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.188 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.2 m -101.91 109.52 21.28 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.961 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.922 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.71 141.9 51.58 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -104.75 117.76 34.87 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.992 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.787 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -115.92 151.73 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.951 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.647 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.4 OUTLIER -74.48 163.54 67.54 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.937 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.628 ' O ' HD21 ' A' ' 13' ' ' LEU . 83.0 Cg_endo -72.41 120.09 6.53 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.267 3.312 . . . . 0.0 109.595 179.918 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.987 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -120.07 16.7 12.46 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.975 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 11' ' ' SER . . . . . 1.106 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.2 p -98.91 115.15 28.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.94 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.654 ' N ' ' H ' ' A' ' 113' ' ' ASN . . . 104.24 -0.13 44.0 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.059 HD22 HG21 ' A' ' 17' ' ' THR . 1.3 pp -114.09 142.48 46.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.996 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.8 p -107.54 -167.76 1.3 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.919 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.677 ' CG ' HH11 ' A' ' 70' ' ' ARG . 7.2 t70 -42.15 153.67 0.06 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.98 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.75 -23.1 34.23 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.978 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' THR . . . . . 1.059 HG21 HD22 ' A' ' 13' ' ' LEU . 26.1 m -80.26 141.42 35.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 18' ' ' VAL . 11.2 p -119.46 109.84 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.932 HG13 ' HB3' ' A' ' 67' ' ' LEU . 1.8 p -83.67 161.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.987 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.787 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.73 150.79 39.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.62 109.35 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.978 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.922 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.14 116.95 25.11 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.016 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.64 144.74 22.38 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.984 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.717 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.04 109.55 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.45 17.82 23.05 Favored Glycine 0 C--N 1.336 0.56 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.99 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.016 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.01 175.15 7.29 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.991 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 74.1 mt-30 -58.35 121.37 10.65 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.461 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.65 129.16 37.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.99 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.35 8.22 87.61 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.933 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.513 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.5 143.49 26.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.961 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.667 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -87.35 151.45 23.09 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.96 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.795 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.3 m-85 -138.9 139.35 38.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.911 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.192 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.3 m-20 -105.47 113.73 27.48 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.27 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.98 147.57 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.938 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.863 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.72 166.13 38.26 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.01 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 2.2 tt0 -108.26 123.56 48.96 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.963 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.7 m -117.57 143.86 45.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.959 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.557 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.07 137.61 54.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.52 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -65.61 127.94 33.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.625 HG13 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -107.43 -55.14 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.465 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.62 167.62 17.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.962 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.417 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -50.81 112.11 0.65 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.944 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.72 8.09 66.96 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.999 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.516 HG11 ' HE1' ' A' ' 83' ' ' TRP . 11.6 t -122.74 112.89 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.988 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.647 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -121.97 131.98 54.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.984 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.341 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.31 153.77 20.62 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.942 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.8 m -110.81 156.87 20.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.825 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.6 t30 -114.9 106.24 52.03 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.465 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.37 -0.09 8.2 Favored 'Trans proline' 0 N--CA 1.448 -1.178 0 C-N-CA 124.319 3.346 . . . . 0.0 109.603 179.91 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.15 -11.61 43.36 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.7 p30 -130.25 27.26 5.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.23 106.76 15.28 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 t -101.09 171.79 7.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.896 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 p -146.88 154.26 41.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.514 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.77 161.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.928 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.514 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.9 m -128.03 135.8 50.37 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.63 135.19 39.16 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.917 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.0 p30 -76.02 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.914 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.5 -19.75 62.42 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -83.28 6.8 18.42 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.006 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.94 32.11 65.89 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.9 t -130.92 134.53 46.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.966 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.35 165.5 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -144.94 130.25 18.67 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.988 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.656 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.61 169.79 20.73 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.88 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.656 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -128.87 117.52 21.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.423 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.36 157.95 15.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.959 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.534 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -118.67 136.93 53.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.947 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.527 HG21 ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -103.23 126.69 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.677 HH11 ' CG ' ' A' ' 15' ' ' ASP . 0.1 OUTLIER -113.73 142.68 45.74 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.959 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -62.81 -35.13 78.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 83.7 p -154.55 157.05 37.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.876 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.01 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.2 p90 -177.17 155.83 1.19 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' CG ' ' A' ' 74' ' ' GLU . 0.5 OUTLIER -53.49 109.93 0.5 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.935 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.341 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.1 103.0 1.07 Allowed Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.96 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.984 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.19 100.21 10.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.987 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.878 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.3 tp -57.87 137.98 56.15 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.682 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.34 -40.36 17.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.704 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -57.32 -17.13 10.78 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.978 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 28.56 9.52 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.878 ' HB ' HD23 ' A' ' 77' ' ' LEU . 5.4 m -112.45 148.43 34.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -83.94 94.21 8.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.625 ' CE3' HG13 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -64.24 -40.18 95.48 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.92 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.33 169.7 12.47 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.31 106.12 0.49 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.942 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 40' ' ' VAL . 27.6 m -85.35 154.34 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.64 91.72 4.32 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.774 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.28 -20.65 7.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.977 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.611 HG22 ' HD2' ' A' ' 112' ' ' PHE . 76.0 p -90.59 2.82 55.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.971 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.6 m -112.61 -27.26 8.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.95 -178.77 4.28 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.28 129.19 35.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.434 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 3.8 m -105.04 155.24 19.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.313 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -154.02 131.75 11.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 -179.939 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.423 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.5 t -94.09 163.67 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.989 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.231 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.69 165.0 33.84 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.27 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.41 132.2 45.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.986 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.192 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 32.9 m -111.66 153.01 27.01 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.904 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.667 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.03 -162.47 0.8 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.995 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.9 -48.45 65.98 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.24 -24.15 65.78 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.78 54.09 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -133.97 171.47 14.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.795 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.51 173.77 45.45 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.42 168.23 24.86 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 124.258 3.306 . . . . 0.0 109.571 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.547 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.1 pt-20 -39.54 125.63 1.77 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.945 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.3 161.22 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.914 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.313 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 50.0 t -119.13 102.4 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.91 132.35 36.04 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CD1' ' HB2' ' A' ' 93' ' ' CYS . 16.1 pt -136.85 -175.3 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 111' ' ' SER . . . . . 1.106 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -177.27 153.17 0.92 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.968 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.434 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.1 m-85 -107.17 119.28 38.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.945 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.654 ' H ' ' N ' ' A' ' 12' ' ' GLY . 4.4 p-10 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.189 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 85.0 Cg_endo -72.37 -178.73 3.49 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.36 3.373 . . . . 0.0 109.608 179.925 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.97 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.2 m -100.9 108.74 20.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.657 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -120.16 145.2 47.18 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.957 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -108.66 115.29 29.82 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.976 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.726 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.33 153.57 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.993 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.853 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.18 175.09 1.95 Allowed Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.958 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.063 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.43 117.45 5.14 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.292 3.328 . . . . 0.0 109.607 179.869 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.032 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -115.16 47.35 1.3 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.943 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.49 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -123.71 105.81 10.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.977 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.45 28.51 16.66 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.972 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.063 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.43 134.79 41.8 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.83 163.77 12.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 15' ' ' ASP . 3.5 t0 -45.94 142.91 2.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 103.44 -22.75 35.1 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.47 HG21 HD13 ' A' ' 13' ' ' LEU . 90.6 m -73.3 144.81 46.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.977 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 18' ' ' VAL . 11.0 p -111.74 115.08 48.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.978 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.082 HG13 HG12 ' A' ' 69' ' ' VAL . 5.6 m -84.21 158.51 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.726 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.53 144.39 42.93 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.979 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -145.36 110.74 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.985 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.657 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.78 122.41 37.37 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.956 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.063 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.51 146.79 22.73 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.947 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.1 109.37 4.69 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.72 16.83 27.67 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.952 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.063 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.43 176.06 6.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.945 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.509 ' HB2' HG21 ' A' ' 30' ' ' THR . 31.7 mt-30 -56.5 120.82 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -180.0 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.448 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.73 130.66 41.02 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.28 7.34 84.78 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.509 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.26 140.39 29.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.964 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 1.238 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.8 147.86 27.34 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.109 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 27.4 m-85 -135.75 131.92 36.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.932 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.351 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.45 112.58 24.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.962 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.458 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.77 144.31 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.987 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.983 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.68 161.09 33.92 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.903 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 34.2 tt0 -104.03 119.18 38.39 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 85.7 m -117.08 143.54 45.67 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.464 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.29 139.25 54.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.544 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.98 125.29 24.43 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.427 HG13 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -105.03 -44.09 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.991 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.543 ' OD1' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -142.36 169.41 17.63 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.4 m -50.99 112.41 0.71 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.997 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.63 7.47 61.33 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 40' ' ' VAL . 2.3 t -120.8 118.7 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.564 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -128.99 134.91 48.34 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.986 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.38 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.55 157.61 16.91 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 69.1 m -117.61 156.04 28.82 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.551 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.0 t30 -122.07 109.28 33.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.48 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.44 0.26 7.73 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.278 3.319 . . . . 0.0 109.576 179.936 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -85.44 -14.96 44.55 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.878 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 5.9 p30 -129.09 19.53 5.93 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.951 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.689 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -82.07 117.94 22.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.983 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 m -107.11 178.1 4.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.973 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 p -145.23 152.69 40.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.851 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.487 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -167.02 156.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.0 m -127.92 133.05 49.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.959 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.75 134.49 46.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.936 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 37.5 p30 -75.05 -174.46 2.27 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.909 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.54 -25.23 67.93 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.975 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.32 -4.6 42.99 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.912 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 72.07 31.08 64.52 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.997 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.1 p -129.2 139.62 51.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.957 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.37 163.43 26.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.964 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.69 127.06 15.85 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.416 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -150.62 159.43 44.51 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.855 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.416 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -119.5 115.08 23.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.932 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.641 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.78 157.55 16.01 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.925 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.667 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -111.93 136.22 51.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.975 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 1.082 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.95 129.16 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.99 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.78 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.38 164.3 15.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.994 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.2 -15.37 29.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.983 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -164.49 143.28 7.12 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.903 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -170.7 159.52 6.6 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -54.59 120.3 6.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.901 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.38 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.94 92.28 1.35 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 179.986 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.926 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.19 100.14 10.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.966 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -55.14 144.25 24.66 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.991 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.755 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.35 -43.43 23.05 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.579 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 8.7 t0 -58.05 -17.02 14.97 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.958 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.2 28.56 10.6 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.999 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -107.66 119.22 38.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.83 91.43 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.427 ' CE2' HG13 ' A' ' 40' ' ' VAL . 29.0 t90 -62.7 -58.55 7.08 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.901 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.48 166.91 17.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.992 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.06 108.82 0.73 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.955 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.605 HG22 HG23 ' A' ' 40' ' ' VAL . 15.7 t -81.95 147.35 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.998 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -105.28 94.44 5.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.988 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -52.56 -24.99 9.23 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.6 p -79.3 -3.64 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 -26.87 7.36 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.4 -178.11 3.9 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.13 138.6 33.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.959 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.656 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -102.47 161.23 13.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.974 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.206 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.4 tt0 -168.39 127.19 1.16 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.641 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.5 t -97.04 164.56 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.967 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -175.75 167.99 40.09 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.458 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.82 128.5 38.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.981 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.351 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 19.8 m -116.84 142.19 47.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.913 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 1.238 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -98.33 -157.8 0.62 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.87 -48.22 69.45 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.903 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.597 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -69.77 -25.89 64.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.955 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.8 48.46 2.11 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.602 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 2.3 p30 -120.62 162.94 18.8 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.109 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.58 176.71 44.04 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.984 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.608 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.46 165.12 33.6 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.319 3.346 . . . . 0.0 109.601 179.935 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.189 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 pt-20 -38.24 135.91 0.69 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.961 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.61 147.56 3.93 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.967 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.206 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 13.0 t -127.42 104.15 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.985 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.629 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -88.71 157.16 18.62 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.032 HG23 ' HB3' ' A' ' 10' ' ' SER . 22.4 mt -127.97 168.31 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.501 ' N ' HG22 ' A' ' 110' ' ' ILE . 21.1 t -153.97 137.26 15.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.954 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.656 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -102.09 124.94 48.56 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.553 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 30.3 m-80 . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.97 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.586 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.427 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -175.23 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.306 3.337 . . . . 0.0 109.61 179.924 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.897 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.72 108.21 20.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.736 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 146.52 49.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.43 110.33 22.31 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.973 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.902 HG21 ' CG2' ' A' ' 108' ' ' VAL . 14.3 t -105.62 146.1 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.93 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.17 175.24 2.2 Favored Pre-proline 0 N--CA 1.448 -0.528 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.945 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.119 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.8 Cg_endo -72.42 116.54 4.75 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 124.323 3.349 . . . . 0.0 109.593 179.918 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.973 ' HB2' HG23 ' A' ' 110' ' ' ILE . 56.6 p -113.33 46.66 1.23 Allowed 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.957 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 111' ' ' SER . 61.9 p -126.34 105.2 8.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.907 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.971 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.79 26.84 15.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.119 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -98.13 132.34 43.74 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.965 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -104.15 169.41 8.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 15' ' ' ASP . 15.9 p30 -46.02 141.43 3.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.993 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.19 -22.95 34.84 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.991 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 24.6 m -79.63 152.32 30.08 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.991 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -124.92 125.66 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.998 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.6 m -89.37 118.22 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.796 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -69.24 148.37 49.91 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.637 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.81 105.27 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.997 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.736 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.25 117.1 28.2 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.963 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.696 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.29 141.2 19.69 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.897 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.27 108.64 6.88 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.928 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.917 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.67 23.88 9.1 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.976 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.401 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.34 -171.79 3.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.983 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.493 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 72.7 mt-30 -76.31 124.29 27.28 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.989 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.66 130.33 40.31 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.48 8.22 83.7 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.958 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.552 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -95.04 136.48 35.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.96 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.771 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.88 151.31 23.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.999 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.919 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 48.4 m-85 -138.12 144.17 40.71 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.048 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.0 m-20 -104.64 116.63 32.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.956 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.418 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.05 142.29 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.882 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.5 170.78 42.87 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.118 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.0 tt0 -114.42 116.3 28.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.934 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 64.2 m -114.6 143.2 45.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.826 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.9 131.45 53.74 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.914 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.84 123.72 20.53 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.935 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.058 ' HB ' ' CE3' ' A' ' 83' ' ' TRP . 14.2 m -103.58 -43.98 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.575 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -136.8 176.18 8.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.991 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.16 112.08 1.77 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.982 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.98 8.29 64.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.304 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 61.6 t -122.79 108.0 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 180.0 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.561 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -121.47 139.52 53.37 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.978 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.475 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.83 157.93 15.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.3 m -118.74 152.26 36.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.3 t-20 -110.93 107.47 57.79 Favored Pre-proline 0 N--CA 1.449 -0.492 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.37 -0.02 8.09 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.322 3.348 . . . . 0.0 109.591 179.891 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.568 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.78 -11.11 43.13 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.783 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.502 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.6 p30 -131.1 27.05 4.87 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.901 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.97 106.18 15.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.977 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.6 t -104.19 173.23 6.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.943 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 p -145.51 156.75 43.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.443 HG22 ' N ' ' A' ' 56' ' ' THR . 4.7 p -166.29 157.83 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.443 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.7 m -127.76 126.98 42.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.49 153.0 24.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.5 p30 -93.78 -171.63 2.64 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.885 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.22 67.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -83.17 5.24 23.4 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.539 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 64.59 9.24 37.03 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.975 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.5 t -101.22 134.41 44.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.985 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.56 163.48 17.91 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.4 p -147.78 130.72 16.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.972 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.49 164.19 17.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.968 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -120.46 132.09 55.06 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.921 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.161 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.61 122.44 47.46 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.912 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.59 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.7 t -77.96 130.95 37.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.899 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.586 HG11 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.45 129.87 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.967 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.537 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 0.4 OUTLIER -111.43 155.26 23.45 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.932 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -83.02 -13.67 55.45 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.978 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.533 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 13.9 m -167.24 147.4 5.41 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.118 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.6 p90 -177.31 157.36 1.32 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.949 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.406 ' O ' ' HG3' ' A' ' 74' ' ' GLU . 14.8 pt-20 -56.56 117.61 4.03 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.475 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.14 97.26 1.39 Allowed Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.996 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.807 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.36 10.64 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.986 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.879 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -54.5 141.74 30.04 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.724 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.22 -42.85 20.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.574 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.9 t0 -56.78 -16.8 7.21 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.69 27.98 10.82 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.879 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -108.19 130.82 55.12 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 6.9 ptt180 -72.24 92.95 1.42 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.575 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 0.6 OUTLIER -61.67 -54.96 35.73 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.893 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.5 174.19 21.37 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.07 113.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' A' ' 38' ' ' ALA . 1.1 m -91.36 152.4 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.533 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 1.5 m-20 -115.7 102.97 10.22 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.975 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.537 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 23.0 m -52.82 -27.46 18.27 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.3 p -79.56 -3.51 47.28 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.994 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.69 -27.78 6.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.27 -178.4 4.2 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.56 122.97 44.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.879 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.573 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 89.7 m -104.03 151.73 22.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.986 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.4 OUTLIER -152.24 146.81 25.71 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.951 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.161 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -110.21 159.05 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.983 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.243 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.07 169.6 41.49 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.418 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.8 129.42 46.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.958 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.048 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 5.8 m -110.26 152.35 26.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.961 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.771 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -114.37 -169.35 1.51 Allowed 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.943 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.65 -48.91 77.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.24 -24.29 66.57 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.928 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.02 53.5 1.89 Allowed Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.955 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.727 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -132.79 172.69 12.24 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.982 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.919 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.24 179.27 48.59 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.966 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.427 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 160.01 47.92 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.313 3.342 . . . . 0.0 109.586 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.586 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -36.82 122.2 0.8 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.38 155.38 0.03 OUTLIER Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.974 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.902 ' CG2' HG21 ' A' ' 7' ' ' VAL . 8.6 t -127.51 111.59 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.981 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.411 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -92.98 129.8 38.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.986 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.5 mt -103.74 156.16 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.605 ' O ' ' HA ' ' A' ' 11' ' ' SER . 11.7 t -145.25 129.7 17.86 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.91 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.547 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -96.23 126.59 41.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.947 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.293 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.517 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 . . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.583 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.41 -177.19 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.349 3.366 . . . . 0.0 109.584 179.949 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.833 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -95.42 108.63 20.85 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.926 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.91 145.26 51.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.645 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.1 p -104.49 111.98 24.86 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.871 HG13 ' O ' ' A' ' 20' ' ' LYS . 26.2 t -106.96 149.21 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.996 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.53 178.32 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.938 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.121 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.6 Cg_endo -72.37 117.75 5.28 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 C-N-CA 124.279 3.32 . . . . 0.0 109.569 179.942 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.564 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 17.2 p -114.13 45.16 1.54 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 92.5 p -127.78 106.38 9.09 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.873 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.903 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.59 24.5 20.86 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.121 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -94.1 130.11 40.39 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 45.8 t -98.49 168.27 10.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.93 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.63 141.15 17.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.4 -23.72 34.23 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.458 HG21 ' HB3' ' A' ' 13' ' ' LEU . 21.1 m -72.27 152.69 42.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.987 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.9 p -126.77 131.19 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.0 m -97.95 169.7 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.871 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.83 150.34 38.53 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.975 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.847 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -144.32 109.4 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.978 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.838 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.53 114.86 23.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.55 146.8 24.91 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.833 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.01 110.92 4.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.864 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.39 13.46 30.58 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.99 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.993 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.59 165.98 13.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.979 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.525 ' HB2' HG21 ' A' ' 30' ' ' THR . 84.1 mt-30 -46.41 119.71 2.51 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.984 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.744 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.26 131.08 41.54 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.47 8.46 80.55 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.525 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.78 148.32 22.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.951 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.408 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.938 ' HB3' ' CB ' ' A' ' 97' ' ' LEU . 35.1 m-85 -138.26 151.75 47.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.907 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.406 ' CA ' ' H ' ' A' ' 98' ' ' SER . 35.0 m-20 -120.23 117.4 27.77 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.281 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -98.58 141.39 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.803 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -161.99 155.44 26.71 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.894 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 40.7 tt0 -105.65 115.7 30.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.449 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.3 m -102.96 166.66 10.32 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.025 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -153.33 134.0 13.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.956 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.592 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.2 122.55 17.36 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.91 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.514 ' HB ' ' CD1' ' A' ' 83' ' ' TRP . 2.5 m -102.9 -42.82 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.992 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.457 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -138.47 166.16 25.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m -50.79 111.77 0.6 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.35 8.92 63.35 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.97 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.52 HG11 ' CH2' ' A' ' 83' ' ' TRP . 75.0 t -120.3 119.35 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.5 162.75 23.32 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.515 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -132.54 155.42 48.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.926 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.1 m -113.46 155.23 25.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.521 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.3 t30 -116.11 112.41 42.11 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.38 0.13 7.88 Favored 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 124.31 3.34 . . . . 0.0 109.65 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.521 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.03 -16.52 29.61 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.915 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.473 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.0 p30 -127.16 28.33 5.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.93 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -102.1 118.67 37.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.7 t -107.41 -177.27 3.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.932 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -147.65 154.58 40.81 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.522 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -167.31 161.9 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.977 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.522 ' N ' HG22 ' A' ' 55' ' ' VAL . 20.7 m -126.34 130.19 50.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.58 145.55 55.48 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.977 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 51.6 p30 -83.7 -172.29 4.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.934 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.09 -27.57 69.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.66 -10.06 59.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.993 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.62 31.79 48.77 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.969 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.3 p -127.36 136.32 51.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.991 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.95 170.2 10.86 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.53 123.97 9.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.499 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -151.94 160.26 43.55 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.907 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.488 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -114.43 129.68 56.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.913 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.069 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -107.26 118.01 35.58 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.901 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.578 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -67.66 120.46 14.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.987 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.534 ' O ' HG12 ' A' ' 69' ' ' VAL . 0.6 OUTLIER -76.47 123.94 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.975 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.635 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 26.9 mmt180 -115.57 157.03 24.71 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.494 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 4.1 ptt180 -107.08 -10.73 15.82 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.99 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -177.05 146.93 0.53 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.927 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.894 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -176.69 171.52 2.25 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.878 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 118.36 7.28 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.515 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 94.07 1.35 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.996 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -84.44 100.63 11.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.848 HD12 ' H ' ' A' ' 78' ' ' PHE . 2.2 tp -54.45 145.41 18.42 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.848 ' H ' HD12 ' A' ' 77' ' ' LEU . 10.8 m-85 -47.2 -43.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.591 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -58.73 -16.52 17.03 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.965 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.12 28.25 12.15 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.826 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.2 m -106.38 122.67 46.74 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 ttm180 -61.71 90.96 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.956 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.52 ' CH2' HG11 ' A' ' 44' ' ' VAL . 42.8 t-105 -62.35 -58.4 7.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.53 163.2 12.09 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.994 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.56 105.73 0.47 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.951 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.025 HG21 ' HB1' ' A' ' 38' ' ' ALA . 3.4 p -80.21 148.89 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -110.47 98.74 7.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 17.8 m -51.91 -27.53 13.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.2 p -79.57 1.21 26.85 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.982 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.4 m -116.99 -26.68 6.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.933 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.81 -175.31 3.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.58 125.65 48.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.247 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.2 m -103.83 152.69 21.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.992 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -150.89 144.17 24.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.967 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.069 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 7.1 t -103.96 163.56 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.252 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.33 168.41 40.52 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.991 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.281 ' CG ' HG22 ' A' ' 34' ' ' VAL . 5.6 mp -99.5 162.16 13.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.406 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 13.0 m -154.16 118.48 4.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.451 ' OD1' ' N ' ' A' ' 102' ' ' GLY . 42.7 p-10 -113.54 -167.9 1.27 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.998 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.16 -19.89 2.23 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.946 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.45 -23.51 13.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.888 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.451 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 85.34 22.0 52.79 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.645 ' OD1' ' HD1' ' A' ' 32' ' ' TYR . 18.4 p-10 -60.11 -151.83 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 143.47 153.38 5.86 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.953 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.583 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.41 165.4 32.79 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.247 3.298 . . . . 0.0 109.607 179.964 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.293 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.2 pt-20 -33.55 124.45 0.42 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.542 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.34 133.99 0.98 Allowed Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.6 104.03 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.952 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.463 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.58 144.97 26.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.247 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.11 159.47 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.917 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.46 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -144.2 115.05 7.79 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 93' ' ' CYS . 30.5 m-85 -100.06 126.21 46.25 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.934 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.947 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.526 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.2 Cg_endo -72.39 -175.37 1.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.328 3.352 . . . . 0.0 109.605 179.907 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.291 HG22 ' O ' ' A' ' 24' ' ' ALA . 6.4 t -99.67 116.15 31.11 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.885 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -131.9 154.64 49.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.498 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -115.76 117.09 29.27 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.048 HG13 ' O ' ' A' ' 20' ' ' LYS . 84.8 t -114.03 143.77 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.736 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.63 166.68 24.3 Favored Pre-proline 0 N--CA 1.448 -0.539 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.938 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.736 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.37 118.13 5.46 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.331 3.354 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.615 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.45 9.43 7.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.961 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.747 ' HA ' ' O ' ' A' ' 111' ' ' SER . 50.0 p -88.51 106.72 18.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.882 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.071 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 101.94 17.98 19.15 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.888 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.071 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -108.12 133.24 52.67 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -87.77 174.54 8.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.913 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 27.8 t70 -46.71 153.33 0.4 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.53 -22.62 36.37 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.965 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.651 HG21 HD12 ' A' ' 13' ' ' LEU . 18.9 m -71.94 148.0 46.43 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.76 129.6 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.979 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.677 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -104.51 150.54 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.969 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 1.048 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.1 147.86 28.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.976 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.809 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -142.71 108.63 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.36 114.75 20.58 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.885 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.17 143.13 20.16 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.954 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.291 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.29 109.52 6.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.901 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.15 24.22 9.14 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.526 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.47 -169.35 2.52 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.531 ' HB2' HG21 ' A' ' 30' ' ' THR . 3.6 mp0 -81.03 125.25 29.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.991 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.3 131.29 43.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.992 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.94 8.15 77.43 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.599 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.63 132.14 42.56 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.972 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.42 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -86.25 150.67 24.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.856 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 51.6 m-85 -135.03 141.73 46.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.056 ' HB2' ' O ' ' A' ' 98' ' ' SER . 2.2 m-20 -100.69 113.96 27.27 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.958 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -101.26 151.55 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.977 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.726 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -175.89 172.77 45.76 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.957 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.849 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 41.4 tt0 -108.18 107.12 17.61 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.942 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 60.7 m -106.73 142.43 36.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.49 137.38 54.9 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.875 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.569 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.41 124.73 22.55 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.889 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.535 HG12 ' N ' ' A' ' 41' ' ' ASP . 1.2 t -105.27 -46.76 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.517 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.82 167.09 21.82 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -51.14 112.19 0.69 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.954 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.57 7.94 65.94 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.893 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 2.0 t -122.38 117.58 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.983 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.532 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -127.35 136.3 51.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.979 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.494 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.34 151.76 20.11 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.97 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.6 m -110.77 146.75 35.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.974 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.762 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.1 p-10 -116.73 115.38 39.24 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.567 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.3 Cg_endo -72.4 -0.54 8.87 Favored 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.317 3.345 . . . . 0.0 109.6 179.868 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.719 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -76.03 -25.4 55.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.89 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.472 ' CB ' HG23 ' A' ' 68' ' ' THR . 89.6 m-20 -124.8 27.74 6.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.948 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -83.33 117.32 22.92 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.966 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 m -110.92 -178.24 3.42 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.8 p -144.86 155.07 43.27 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.875 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.594 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.6 p -166.91 151.66 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 m -127.57 133.17 49.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 143.83 53.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.966 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 43.7 p30 -86.27 -172.03 3.85 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.36 -25.98 68.2 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.925 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -80.16 -7.77 59.1 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.05 30.59 57.13 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.927 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.3 p -122.57 133.01 54.56 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.594 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -119.4 162.66 18.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.981 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.2 p -149.5 129.03 13.07 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.971 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.442 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.91 157.57 31.67 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.868 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.442 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.61 125.04 52.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.452 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -98.83 157.39 16.33 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.916 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -106.41 140.29 39.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.965 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.597 HG23 HG11 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -99.01 125.37 52.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.913 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -118.99 136.23 54.21 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.954 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -61.51 -34.49 75.6 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.443 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 62.5 p -156.58 162.4 39.9 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.849 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.9 p90 -177.71 165.62 2.08 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.961 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.8 116.55 8.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.911 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.494 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.66 94.73 1.08 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.95 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.868 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.69 99.76 10.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.979 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -56.8 131.13 48.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.677 ' N ' HD12 ' A' ' 77' ' ' LEU . 9.5 m-85 -47.83 -35.63 10.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.989 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.54 -16.91 11.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.948 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.96 27.51 8.84 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.988 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 21.7 m -115.79 148.81 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.978 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -90.75 96.89 10.86 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.517 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 32.9 t-105 -63.44 -58.05 8.31 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 172.93 21.64 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.991 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.75 104.81 2.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.726 HG21 ' HB3' ' A' ' 38' ' ' ALA . 7.1 m -78.76 152.34 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.999 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.75 92.91 4.05 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.971 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.137 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 32.7 m -51.6 -27.06 10.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.964 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -79.61 0.81 28.56 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.994 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -118.63 -27.97 5.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.46 180.0 5.7 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.669 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -97.43 125.32 42.0 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.434 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 82.2 m -104.52 168.88 8.8 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.984 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -154.66 146.45 23.39 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.957 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.452 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.8 t -101.19 164.77 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.84 168.62 39.07 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.045 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.16 125.24 30.75 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.821 -0.436 . . . . 0.0 109.821 -179.95 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.056 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 56.6 m -100.75 154.07 18.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.895 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.44 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.1 OUTLIER -116.48 -164.29 0.96 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.44 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -61.77 -49.04 77.96 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.14 -24.4 61.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.922 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.22 53.58 1.46 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.995 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.52 178.28 6.86 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.856 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -179.7 -178.04 48.22 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.41 165.59 32.24 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.295 3.33 . . . . 0.0 109.61 179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.591 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 3.8 pt-20 -38.3 121.84 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.82 153.87 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.9 t -114.1 102.33 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.51 128.51 34.35 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.434 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -139.28 -177.36 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.747 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -172.21 174.66 3.91 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.915 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.137 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.3 m-85 -123.28 114.47 20.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.967 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.009 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 21.2 m-80 . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.973 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.341 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 . . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.44 -178.57 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.306 3.337 . . . . 0.0 109.59 179.945 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.999 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.18 109.11 21.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.942 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.884 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -122.92 150.73 42.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.661 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -113.82 119.64 38.02 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.999 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.903 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -114.79 143.87 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.961 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.779 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.12 167.36 17.98 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.985 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.779 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.34 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.349 3.366 . . . . 0.0 109.579 179.89 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.0 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -122.06 13.96 10.58 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.99 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.867 ' HA ' ' O ' ' A' ' 111' ' ' SER . 53.3 p -98.95 114.61 27.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.877 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.72 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.03 1.59 41.95 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.0 HD21 ' CA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -114.39 142.01 46.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.972 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.9 m -104.98 -170.26 1.73 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.952 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.772 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 2.3 t0 -42.88 153.54 0.08 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.73 -24.63 31.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.972 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -96.21 148.81 22.33 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 68' ' ' THR . 0.0 OUTLIER -123.05 146.32 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.996 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.736 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.3 OUTLIER -110.87 119.94 60.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.96 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.903 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -78.55 127.43 32.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.734 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.2 OUTLIER -113.17 114.63 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.983 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' CA ' ' A' ' 5' ' ' ALA . . . -127.17 123.49 36.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.98 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.033 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.59 153.48 22.63 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.957 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.999 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.6 108.18 3.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.14 17.35 27.54 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.991 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.116 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.47 176.45 6.9 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.969 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 64.7 mt-30 -58.54 121.71 11.61 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.3 131.21 42.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.995 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.86 7.58 83.9 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.5 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -93.13 141.04 28.85 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.475 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.69 151.16 24.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.971 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.63 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 29.8 m-85 -138.54 134.86 34.43 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.884 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.169 ' CB ' ' O ' ' A' ' 98' ' ' SER . 8.3 m-20 -100.29 113.54 26.32 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.94 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.305 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.19 143.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.723 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -164.96 164.45 37.06 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.96 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.902 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 10.9 tt0 -110.87 117.08 32.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.931 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.499 ' HB3' HD13 ' A' ' 45' ' ' LEU . 98.5 m -108.01 166.31 10.82 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.978 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.754 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -151.98 135.14 15.83 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.933 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.471 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.75 129.94 41.65 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.955 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.684 HG23 ' CG2' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -108.93 -39.01 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.053 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -150.4 155.8 40.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.986 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -51.51 112.9 0.83 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.969 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.99 9.86 84.74 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.98 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.622 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -139.04 130.05 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.605 ' HA ' HG22 ' A' ' 40' ' ' VAL . 1.9 pp -132.18 163.85 27.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.321 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -125.48 153.8 43.01 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.973 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.853 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 15.1 m -115.92 153.2 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.833 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 39.6 t30 -111.02 107.05 57.74 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 85.3 Cg_endo -72.3 -1.21 9.8 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.34 3.36 . . . . 0.0 109.631 179.849 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.15 -8.8 50.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.854 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -130.06 27.78 5.1 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.447 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.07 110.94 17.07 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.982 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.28 174.06 6.04 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.924 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 72.7 p -145.14 154.67 42.69 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 4.8 p -166.53 155.62 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.4 m -128.05 136.67 51.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -77.38 135.4 38.33 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.1 p30 -77.8 -173.18 2.94 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.893 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.17 -27.93 69.31 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.871 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -74.53 -6.94 51.3 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.992 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.116 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.99 32.23 56.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 93.4 p -128.48 141.11 51.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.982 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.11 164.8 23.62 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.997 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.06 134.29 19.44 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.763 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -155.13 176.99 11.84 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.763 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -133.41 117.66 17.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.95 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.332 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.48 156.1 16.48 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' HG12 ' A' ' 18' ' ' VAL . 0.5 OUTLIER -111.53 128.38 56.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.526 HG21 ' OG ' ' A' ' 10' ' ' SER . 1.2 t -97.13 123.11 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.772 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -115.05 144.48 43.57 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.445 ' HG3' ' N ' ' A' ' 72' ' ' SER . 15.4 ptt85 -65.85 -32.18 73.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.445 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 16.4 p -155.65 158.06 37.7 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.902 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.7 p90 -176.79 155.24 1.25 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -53.71 108.87 0.39 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.321 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -67.05 94.54 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.99 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.853 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -82.53 98.89 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.938 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.4 tp -54.66 144.81 20.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.763 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.2 -43.53 21.59 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.97 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.587 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -58.46 -16.7 16.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.7 28.1 11.78 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.938 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -106.97 120.68 42.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.414 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -64.25 91.42 0.07 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.622 ' CH2' HG21 ' A' ' 44' ' ' VAL . 3.9 t-105 -62.68 -58.52 7.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.915 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.78 163.39 12.92 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.36 104.59 0.18 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.754 HG11 ' HB3' ' A' ' 38' ' ' ALA . 12.6 p -79.2 151.67 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -105.71 95.01 5.51 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.155 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.94 -22.14 14.03 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.942 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 49.1 p -88.97 2.1 54.45 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.962 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.6 m -110.11 -24.92 10.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -137.93 174.9 10.08 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.979 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.79 127.27 35.61 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.951 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.393 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -104.56 163.86 12.17 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.984 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.019 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -151.42 142.27 22.91 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.917 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.332 ' CG1' HD13 ' A' ' 67' ' ' LEU . 16.5 t -97.92 164.6 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 180.0 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.305 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.33 163.84 32.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.976 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.08 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.62 131.63 49.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.993 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.169 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 42.5 m -112.28 141.02 46.49 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.52 -164.14 1.02 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.04 -49.03 71.75 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.946 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.2 65.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.937 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.28 1.98 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.941 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.4 177.08 7.76 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.19 174.25 46.59 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.989 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.535 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.4 170.44 19.27 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.304 3.336 . . . . 0.0 109.623 179.944 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.341 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.7 pt-20 -41.2 126.69 2.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.963 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.6 160.82 0.01 OUTLIER Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.011 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.3 t -120.9 103.11 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.969 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.98 133.81 34.67 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.955 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.048 HD11 ' HB2' ' A' ' 93' ' ' CYS . 31.8 pt -136.93 -169.93 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.916 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.867 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -178.28 158.74 1.18 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.393 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.3 m-85 -111.37 119.19 38.0 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.932 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.72 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 2.4 p-10 . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.955 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.568 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.439 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.4 -178.15 3.15 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.331 3.354 . . . . 0.0 109.603 179.904 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.861 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.2 m -101.14 110.7 22.75 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.65 142.11 51.67 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.914 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.98 116.07 31.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.96 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.804 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.7 OUTLIER -114.69 149.76 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.963 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.677 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.24 165.35 40.04 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.677 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.42 119.62 6.24 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.333 3.356 . . . . 0.0 109.579 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.051 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.7 OUTLIER -123.87 16.16 9.36 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 11' ' ' SER . . . . . 1.272 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.6 p -105.3 113.79 27.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.885 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.001 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.86 6.78 37.08 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.112 HD22 HG21 ' A' ' 17' ' ' THR . 0.4 OUTLIER -114.52 136.72 52.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.5 m -81.12 171.21 15.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.925 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.447 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 3.3 p-10 -45.24 154.31 0.17 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.979 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.87 -24.01 33.84 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.985 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 17' ' ' THR . . . . . 1.112 HG21 HD22 ' A' ' 13' ' ' LEU . 94.3 m -68.37 131.88 46.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.981 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.589 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.4 p -102.08 119.32 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -99.17 161.14 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.804 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -119.74 148.7 43.09 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.997 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.7 107.18 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.994 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -117.21 116.42 27.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.66 146.73 23.58 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.992 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.861 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.83 110.01 4.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.938 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.5 15.75 31.27 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.974 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.0 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.19 172.16 9.0 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.993 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 72.4 mt-30 -54.34 120.36 6.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.964 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.11 131.27 41.87 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.967 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 6.88 84.59 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.999 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.508 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -93.02 144.2 25.49 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -86.1 151.38 23.73 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.519 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.8 m-85 -138.66 144.4 39.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.199 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -112.51 113.11 25.12 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.935 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.228 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -98.96 152.04 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.927 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -178.57 159.71 25.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.979 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.028 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 12.4 tt0 -98.77 118.55 35.76 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.942 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.415 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.8 m -108.28 165.55 11.42 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.982 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 86' ' ' VAL . . . -151.71 122.66 7.58 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.632 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.68 122.09 16.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.823 HG21 ' CD1' ' A' ' 83' ' ' TRP . 16.7 m -101.32 -44.58 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.973 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.521 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -135.64 168.06 19.97 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.966 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.68 ' O ' HG23 ' A' ' 42' ' ' THR . 3.9 t -54.04 112.97 1.06 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.986 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.66 8.56 63.62 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.984 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.454 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.7 t -120.86 109.07 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.5 pp -119.83 162.36 19.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.4 151.91 49.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.936 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.012 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -117.38 157.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 17.6 t30 -116.24 112.95 41.49 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -72.35 -0.51 8.79 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.31 3.34 . . . . 0.0 109.61 179.884 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -12.72 36.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.849 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.466 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 16.5 p30 -132.94 27.01 4.27 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.928 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.11 117.35 32.29 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.993 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.9 t -106.61 177.91 4.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.962 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.4 p -146.5 151.49 37.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.532 HG22 ' N ' ' A' ' 56' ' ' THR . 4.6 p -166.77 162.58 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.943 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.532 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.5 m -127.8 134.82 49.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.951 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.99 143.4 50.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.949 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 42.9 p30 -81.74 -172.73 4.04 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.95 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.1 -25.54 68.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.904 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.68 -7.26 53.88 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.891 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.13 31.07 60.04 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.0 p -127.13 143.8 51.18 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.971 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.01 166.36 21.18 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.983 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -147.5 125.78 12.27 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.95 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.725 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.24 173.04 12.92 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.938 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.725 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -131.13 111.22 11.78 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.944 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.497 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.12 156.55 16.33 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.685 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -119.2 139.97 50.97 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.924 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.648 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.57 133.37 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -119.83 162.19 19.54 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.447 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 5.8 ptt180 -82.56 -18.14 42.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 p -165.12 151.22 9.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.922 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.028 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.1 p90 -175.99 154.94 1.53 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.897 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.45 124.81 14.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.989 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.03 92.11 1.62 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 1.012 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.52 100.51 11.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.974 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.902 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -58.15 140.96 51.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.967 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.726 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.28 -42.01 19.95 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.935 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.72 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -57.41 -16.66 9.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.965 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 28.43 10.43 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.902 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -108.73 128.09 54.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.67 91.59 1.12 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.454 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.14 -58.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.869 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.06 167.59 16.39 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.975 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -59.36 115.16 3.06 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 38' ' ' ALA . 59.9 t -88.29 146.57 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 180.0 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.82 91.67 4.26 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.949 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.759 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -52.52 -22.63 5.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.997 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.91 2.6 48.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.981 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 m -115.82 -27.81 6.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.961 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.47 169.39 16.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.91 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.92 126.02 35.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.938 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.438 ' HB2' HD11 ' A' ' 110' ' ' ILE . 12.4 m -104.14 159.77 15.41 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 -179.923 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -145.45 143.1 29.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.969 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.497 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.7 t -97.34 157.73 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.228 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.55 171.05 43.27 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.997 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.18 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.33 151.31 51.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.199 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 82.8 p -127.96 151.41 49.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.5 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -112.77 -163.46 0.85 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.96 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.43 -48.6 69.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.935 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.24 65.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.952 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.8 53.39 1.8 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.998 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -132.11 168.36 18.11 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.519 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.85 178.95 42.51 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.933 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.439 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.36 161.98 42.82 Favored 'Trans proline' 0 N--CA 1.447 -1.24 0 C-N-CA 124.34 3.36 . . . . 0.0 109.627 179.966 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.568 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -40.61 123.72 1.9 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.972 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.54 151.82 0.02 OUTLIER Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.991 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.2 t -119.21 104.24 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.66 138.71 36.4 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.982 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.042 HG12 ' HA ' ' A' ' 94' ' ' GLN . 25.8 pt -137.75 -172.34 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 111' ' ' SER . . . . . 1.272 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -179.23 163.69 1.31 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.942 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.759 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 2.3 m-85 -117.76 116.81 27.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.937 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.001 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 22.2 m120 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.973 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.425 ' C ' ' H ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.508 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.3 Cg_endo -72.39 -174.61 1.48 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.322 3.348 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.229 HG22 ' O ' ' A' ' 24' ' ' ALA . 4.1 t -97.99 110.68 23.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.964 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.84 146.92 50.46 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.953 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.473 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -109.26 112.44 24.59 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.794 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -109.07 145.38 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.993 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.782 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.28 168.65 12.85 Favored Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.782 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.39 117.14 4.99 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.296 3.331 . . . . 0.0 109.571 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.591 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -127.05 17.18 7.25 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.975 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 39.2 p -94.6 112.72 24.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.9 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.121 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 87.98 28.75 22.49 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.942 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.121 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.18 137.33 46.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.976 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.4 t -76.2 150.24 37.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.964 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 2.3 p30 -44.43 153.02 0.17 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.5 -24.72 30.85 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.437 HG21 HD12 ' A' ' 13' ' ' LEU . 17.7 m -63.69 150.29 44.71 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.982 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 18' ' ' VAL . 14.7 p -112.46 121.8 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.617 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 2.2 p -97.42 153.52 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.996 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.794 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -107.28 150.45 26.66 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.973 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.741 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -148.63 107.64 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.998 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.964 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.05 114.96 23.33 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.988 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.825 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.2 139.95 17.98 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.952 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.229 ' O ' HG22 ' A' ' 4' ' ' THR . . . -135.89 110.22 8.44 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.922 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.898 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.29 21.19 10.17 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.966 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.508 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.4 -168.39 2.19 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.934 ' CD ' ' HH ' ' A' ' 32' ' ' TYR . 4.1 mp0 -79.59 121.66 25.54 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.962 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.507 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.61 135.9 47.15 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.97 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.38 6.71 58.78 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.958 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.585 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.92 138.87 33.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.968 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -86.29 150.72 24.15 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.919 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.496 ' HB3' ' CD2' ' A' ' 97' ' ' LEU . 39.2 m-85 -136.44 155.79 49.52 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.409 ' O ' ' CA ' ' A' ' 97' ' ' LEU . 2.6 m-20 -121.89 114.18 20.67 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.253 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -95.02 144.7 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.983 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.022 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.07 166.92 34.76 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.954 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.696 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -121.63 106.98 11.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.767 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.3 m -105.21 172.78 6.61 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.961 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.966 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -146.37 127.34 14.55 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.932 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.77 117.83 8.07 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.92 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.591 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 3.6 m -98.22 -42.92 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.972 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -135.67 177.31 7.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.995 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 t -60.36 111.76 1.68 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.99 8.17 63.85 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.565 HG12 ' CD1' ' A' ' 83' ' ' TRP . 22.0 t -120.73 113.31 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.674 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -128.51 140.61 51.72 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.991 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.34 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.93 138.65 34.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.956 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.77 ' O ' ' HB3' ' A' ' 76' ' ' PHE . 82.1 m -106.37 140.62 39.0 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.971 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.62 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.8 t30 -100.31 111.49 62.58 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.442 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.1 Cg_endo -72.39 0.28 7.67 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -86.56 -14.94 41.45 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.854 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.52 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.9 p30 -123.21 29.69 6.61 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.442 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -82.66 106.02 14.17 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.987 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.6 m -100.32 179.02 4.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.5 p -145.71 158.52 43.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.915 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.747 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.2 p -169.11 156.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.973 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.425 ' N ' HG22 ' A' ' 55' ' ' VAL . 7.0 m -127.97 137.63 52.32 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -80.69 139.73 35.99 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.984 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.2 p30 -82.86 -165.85 1.17 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.927 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.89 -28.67 69.07 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.3 m-20 -83.1 6.35 19.4 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.986 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.93 22.04 59.63 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -109.21 130.92 55.48 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.747 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.41 167.31 12.94 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.84 131.61 16.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.905 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.628 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -158.79 157.71 32.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.447 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -116.5 125.66 52.25 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.19 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -97.53 155.95 16.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.919 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.523 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -97.36 123.11 41.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.961 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.549 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -77.49 129.36 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.999 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.711 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -123.58 147.26 47.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.931 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -92.71 -20.2 21.04 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.994 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 53.4 p -172.99 153.18 2.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.922 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.711 ' CE2' ' HB2' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -178.02 179.08 0.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.949 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -68.56 117.83 10.8 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.34 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.6 89.13 1.23 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.956 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.77 ' HB3' ' O ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -83.47 103.33 12.73 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -58.34 130.99 49.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.86 -35.36 10.23 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.618 ' CB ' HD21 ' A' ' 77' ' ' LEU . 5.4 t0 -57.26 -17.28 11.02 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.24 28.39 8.14 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.939 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.1 m -117.74 145.86 44.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.31 97.21 8.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.591 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 21.9 t90 -64.25 -57.65 8.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.879 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.98 160.27 8.6 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.61 105.18 0.14 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.977 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.966 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -82.35 154.03 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -120.13 96.78 5.3 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.998 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.105 ' HB3' ' CD1' ' A' ' 112' ' ' PHE . 24.9 m -52.76 -25.6 11.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.9 p -79.68 1.45 26.34 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.32 -177.08 4.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.77 126.67 47.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.239 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 18.6 m -104.43 164.14 11.95 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.964 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.216 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -154.79 149.57 26.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.973 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.19 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.8 t -104.05 165.85 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.253 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 170.63 43.78 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.94 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.496 ' CD2' ' HB3' ' A' ' 32' ' ' TYR . 4.8 mp -99.81 162.87 12.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.168 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -152.48 109.99 3.59 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.896 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.442 ' OD1' ' OD1' ' A' ' 103' ' ' ASN . 1.7 p-10 -104.75 -157.96 0.64 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.28 -43.94 64.71 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.981 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.45 -26.01 26.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.937 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.95 52.86 2.33 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.959 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.442 ' OD1' ' OD1' ' A' ' 99' ' ' ASP . 1.3 p30 -109.17 -174.32 2.48 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 172.57 179.24 43.24 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.993 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.475 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.36 160.29 47.32 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.366 3.377 . . . . 0.0 109.567 179.91 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -32.96 128.51 0.26 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.479 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.0 130.94 0.29 Allowed Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.216 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 41.6 t -99.29 101.55 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -80.04 140.47 36.52 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.938 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.1 pt -147.06 -172.23 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.569 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.4 OUTLIER -173.82 176.17 2.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.948 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.105 ' CD1' ' HB3' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -150.64 105.77 3.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.074 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 1.8 p-10 . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.522 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.8 Cg_endo -72.39 -175.63 1.87 Allowed 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.275 3.317 . . . . 0.0 109.637 179.934 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.971 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.47 109.15 21.95 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.782 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.58 137.75 54.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.685 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -106.11 112.57 25.66 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.981 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.611 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -106.39 155.98 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.988 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.987 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.08 177.29 0.91 Allowed Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.923 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.157 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.4 117.22 5.03 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.311 3.34 . . . . 0.0 109.573 179.909 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.783 ' HB2' HG23 ' A' ' 110' ' ' ILE . 13.4 p -112.73 44.69 1.44 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -124.73 106.3 9.97 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.885 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.943 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 88.39 31.9 12.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.969 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.157 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.58 133.0 42.72 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 55.7 m -96.71 162.87 13.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -49.83 146.37 4.58 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.994 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.92 -22.51 35.81 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.965 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.441 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.9 m -63.3 147.62 50.56 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.983 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.545 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -112.2 122.7 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.556 ' HA ' HG21 ' A' ' 8' ' ' THR . 3.6 m -96.93 161.24 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.611 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 151.16 32.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.975 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.719 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -150.11 109.96 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.959 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.782 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.14 116.49 22.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.999 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.665 ' HA2' ' HA ' ' A' ' 5' ' ' ALA . . . -94.29 141.1 15.37 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.959 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.971 ' O ' HG22 ' A' ' 4' ' ' THR . . . -133.12 118.0 18.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.887 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.87 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.31 24.37 9.61 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.345 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.32 -173.67 4.49 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.972 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.708 ' OE1' ' OH ' ' A' ' 32' ' ' TYR . 13.2 mp0 -80.67 120.76 25.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.993 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.78 136.74 57.24 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.955 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.25 7.95 58.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.991 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.692 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -85.6 148.22 26.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 1.028 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -100.81 134.68 43.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.047 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 37.4 m-85 -127.29 147.59 50.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.104 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.8 m-20 -116.86 114.05 23.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.997 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.268 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -96.61 152.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.965 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.108 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -177.66 164.98 34.37 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.963 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.804 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 1.7 tt0 -112.34 118.38 35.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.937 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.562 ' HB3' HD13 ' A' ' 45' ' ' LEU . 90.8 m -108.23 173.5 6.29 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.983 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -152.62 123.97 7.67 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.917 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.617 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.57 124.0 21.18 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.907 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.12 HG21 ' CD2' ' A' ' 83' ' ' TRP . 15.2 m -103.93 -43.85 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.528 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -142.93 169.61 17.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 19.5 m -56.74 113.43 1.64 Allowed 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.952 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.78 4.83 62.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.997 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.644 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 15.5 t -122.19 105.07 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.975 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.641 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -117.3 162.73 17.43 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.546 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -122.54 140.7 52.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.928 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.681 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 23.4 m -109.3 150.8 27.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 1.057 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -108.41 105.75 57.32 Favored Pre-proline 0 N--CA 1.45 -0.453 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.988 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.471 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.0 Cg_endo -72.4 -1.23 9.89 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.309 3.339 . . . . 0.0 109.638 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.41 -12.97 33.22 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.888 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CB ' HG23 ' A' ' 68' ' ' THR . 29.6 p30 -127.27 18.77 6.99 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.46 ' CD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -83.5 103.51 12.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.981 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.1 t -93.43 177.57 5.99 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.905 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.3 p -147.04 155.24 42.06 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.42 HG22 ' N ' ' A' ' 56' ' ' THR . 7.6 p -167.36 155.97 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.971 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.42 ' N ' HG22 ' A' ' 55' ' ' VAL . 73.5 m -122.87 130.32 52.72 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.948 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 125.28 24.52 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.915 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -71.39 -170.37 0.5 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 -23.67 66.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -85.38 6.97 24.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.985 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 61.15 14.08 38.04 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.99 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.3 t -102.52 131.83 48.98 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.942 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.81 124.0 38.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.97 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.7 p -110.78 134.05 52.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.988 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.554 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.39 152.6 24.13 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.897 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.17 131.29 55.92 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.956 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.555 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.93 157.46 17.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.447 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 4.6 t -105.18 127.51 52.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.649 ' C ' ' HD2' ' A' ' 70' ' ' ARG . 1.7 t -84.34 126.23 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.66 ' HB2' ' OE1' ' A' ' 36' ' ' GLN . 1.2 mpt_? -119.76 145.9 46.15 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HD3' ' N ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -89.83 -8.07 52.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.938 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 90.3 p -178.02 149.96 0.59 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.057 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 3.8 p90 -176.77 154.58 1.19 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.921 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -49.55 114.37 1.03 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.546 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.89 92.76 0.55 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.681 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -83.81 99.34 10.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.953 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.6 tp -59.09 129.03 40.17 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.622 ' N ' HD12 ' A' ' 77' ' ' LEU . 32.4 p90 -47.56 -34.7 8.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.939 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.576 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.7 -16.72 11.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.982 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.08 28.11 8.91 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.4 m -116.93 150.88 37.79 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.933 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -87.04 97.67 10.85 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.902 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.644 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 76.7 t-105 -65.28 -56.41 12.88 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.928 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.76 166.46 11.6 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.991 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.19 108.14 0.38 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.944 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.183 HG11 ' CB ' ' A' ' 38' ' ' ALA . 69.3 t -82.25 147.85 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.971 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -114.46 93.7 4.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.949 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.499 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.0 m -52.74 -26.04 12.94 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 71' ' ' ARG . 78.7 p -80.19 0.14 33.7 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.54 -27.48 6.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.77 -177.98 4.6 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.967 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.21 124.45 46.92 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.908 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.934 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 60.5 m -103.6 153.61 20.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.996 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -142.85 145.12 32.84 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.964 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.555 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.2 t -102.73 160.33 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.268 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.63 166.72 37.25 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.097 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.64 128.59 37.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.974 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.104 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.8 m -115.36 160.97 19.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.936 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 1.028 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -115.45 -157.44 0.64 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.982 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.11 -47.84 81.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.524 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -74.39 -25.78 59.7 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.874 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.64 50.11 1.87 Allowed Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.976 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.524 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.0 p30 -119.46 158.32 26.48 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 1.047 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.48 176.35 43.46 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.988 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.522 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 171.04 17.79 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.317 3.345 . . . . 0.0 109.616 179.922 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.513 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 2.0 mt-10 -40.71 133.68 1.99 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.06 155.97 0.74 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.947 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 93.1 t -122.74 105.18 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.981 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -87.16 138.4 31.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.962 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.996 ' CG1' ' HA ' ' A' ' 94' ' ' GLN . 2.3 mt -117.68 157.94 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.984 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 10' ' ' SER . 3.1 t -149.34 127.82 12.29 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.894 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 -100.64 127.92 46.87 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.937 . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.489 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.627 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.42 -174.48 1.45 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.304 3.336 . . . . 0.0 109.614 179.949 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.351 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.5 t -98.72 111.7 23.99 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.987 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.643 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.42 152.31 47.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.972 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -109.8 113.32 25.98 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 20' ' ' LYS . 40.3 t -110.47 147.28 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.942 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.949 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.77 175.47 1.68 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.952 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.058 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.4 Cg_endo -72.36 116.59 4.77 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 124.346 3.364 . . . . 0.0 109.617 179.902 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.638 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 6.5 p -111.12 43.71 1.42 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.937 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.0 p -124.28 105.16 9.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.892 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.189 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.02 30.51 8.27 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.189 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.4 OUTLIER -110.93 129.72 55.8 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -112.88 177.01 4.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -44.67 138.66 3.28 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.984 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.01 -23.1 31.7 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.938 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.632 HG21 ' HB3' ' A' ' 13' ' ' LEU . 30.5 m -88.67 152.15 22.0 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.971 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 p -129.33 134.22 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.994 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.715 HG22 ' O ' ' A' ' 67' ' ' LEU . 17.9 m -95.27 166.13 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.989 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.862 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.57 143.64 44.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -139.32 104.52 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.919 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.643 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.1 115.29 23.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.934 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.742 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.03 143.93 22.42 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.949 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.351 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -139.83 107.21 5.53 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.853 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 20.02 11.33 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.945 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.306 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.87 -172.29 3.64 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.975 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.521 ' HB2' HG21 ' A' ' 30' ' ' THR . 84.5 mt-30 -71.87 121.47 19.08 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.932 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.977 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.14 133.67 44.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.0 8.48 73.78 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.989 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.521 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.11 138.25 33.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.955 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.8 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.58 151.58 24.43 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.961 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.7 m-85 -137.63 149.68 46.81 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.927 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.175 ' CB ' ' H ' ' A' ' 98' ' ' SER . 3.7 m-20 -113.25 114.18 26.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.991 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.296 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -100.42 145.32 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.131 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.01 169.37 41.34 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.925 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.695 HE22 ' H ' ' A' ' 70' ' ' ARG . 40.8 tt0 -113.74 106.07 14.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -108.4 146.27 33.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.95 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.711 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -125.97 137.87 53.71 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.629 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.4 119.67 11.42 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.965 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.351 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.6 m -100.56 -42.81 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -132.65 165.07 25.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.985 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 44' ' ' VAL . 32.4 m -51.2 111.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.907 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.03 69.06 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.953 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.519 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 10.7 t -122.01 117.96 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.667 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -129.15 138.24 51.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.984 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.43 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -101.44 152.11 21.13 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.951 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.0 m -106.79 148.57 28.32 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.994 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.948 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -111.37 117.13 49.95 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.974 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.6 Cg_endo -72.44 1.06 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.287 3.325 . . . . 0.0 109.621 179.908 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.455 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -82.51 -20.51 36.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.898 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.784 ' CB ' HG23 ' A' ' 68' ' ' THR . 98.3 m-20 -129.72 30.97 4.82 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.913 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.703 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.58 117.52 30.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.1 t -116.26 -178.96 3.53 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.946 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.6 p -146.46 154.52 41.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.874 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.476 HG22 ' N ' ' A' ' 56' ' ' THR . 5.3 p -166.18 158.9 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.998 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.6 m -127.11 133.16 50.44 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.952 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.26 153.59 42.14 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.975 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -89.63 -171.84 3.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.926 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.0 67.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.911 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.05 -16.83 61.03 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.961 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 88.24 6.35 74.84 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.975 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.01 140.03 32.95 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.941 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.61 163.32 17.52 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.976 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.15 122.92 9.27 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.549 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -157.8 162.73 38.46 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.524 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -118.37 129.85 55.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.912 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -106.77 124.45 49.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.913 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.784 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.6 141.43 41.08 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.962 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.487 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -102.67 131.65 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.994 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.695 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -119.13 157.3 28.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 -87.08 -20.66 26.81 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.8 t -168.77 151.71 5.18 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.9 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.948 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 1.7 p90 -173.7 159.54 3.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.94 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -61.01 114.96 3.37 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.943 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.43 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -73.43 94.6 0.74 Allowed Glycine 0 C--N 1.336 0.558 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 180.0 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.821 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -82.12 99.37 9.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.955 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.61 132.58 45.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.982 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.655 ' N ' HD12 ' A' ' 77' ' ' LEU . 5.9 m-85 -46.59 -37.29 7.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.953 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.8 t0 -56.98 -16.96 7.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.99 27.59 9.34 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.955 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -113.55 140.9 47.77 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.37 95.9 7.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.351 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 38.1 t-105 -63.0 -57.8 9.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.912 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.04 172.9 19.24 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.959 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.47 109.69 2.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.958 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.711 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.3 p -90.72 142.13 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -98.21 99.48 10.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.983 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.36 -22.32 7.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.0 p -87.31 1.58 52.83 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.922 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -112.83 -26.37 8.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.01 -178.94 5.26 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.954 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.04 128.35 42.86 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.303 ' O ' HG13 ' A' ' 110' ' ' ILE . 34.0 m -104.74 155.06 19.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.951 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -147.58 145.61 29.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.984 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.3 t -109.2 156.76 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.981 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.296 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -174.5 172.38 45.35 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.057 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -129.62 128.72 43.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.175 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 36.5 m -118.26 140.07 50.36 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.917 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.8 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 4.4 p-10 -111.81 -162.71 0.81 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.996 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.08 79.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.931 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -66.48 -24.37 66.41 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.926 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 83.02 35.29 18.86 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.957 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.931 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 1.9 p30 -108.45 -173.7 2.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.943 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.809 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 167.84 164.75 24.07 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.627 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.39 162.81 40.46 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.242 3.295 . . . . 0.0 109.576 179.954 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.489 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.9 OUTLIER -36.05 126.58 0.74 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -41.78 147.97 0.44 Allowed Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.783 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.0 t -122.15 106.74 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -91.36 150.48 21.26 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.954 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.303 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -118.45 161.87 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.944 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.534 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -145.22 111.78 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.954 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 113' ' ' ASN . 6.9 m-85 -87.93 101.91 14.2 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.924 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.584 ' CG ' ' O ' ' A' ' 112' ' ' PHE . 0.7 OUTLIER . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.938 -0.394 . . . . 0.0 109.938 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.383 ' CB ' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.503 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 . . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.198 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.1 Cg_endo -72.38 -175.21 1.69 Allowed 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 124.272 3.314 . . . . 0.0 109.632 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.921 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.71 109.89 21.96 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.946 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.5 137.64 54.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.995 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.582 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -99.08 114.07 26.6 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.97 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.84 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.2 m -108.09 153.72 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.997 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.967 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.59 176.56 1.21 Allowed Pre-proline 0 N--CA 1.449 -0.476 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.077 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.38 117.79 5.3 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 124.352 3.368 . . . . 0.0 109.553 179.925 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 111' ' ' SER . 1.9 p -114.69 45.7 1.52 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.7 p -123.75 105.39 9.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.87 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.029 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.63 29.84 11.45 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.948 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.077 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.43 132.22 47.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.948 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 51.1 m -104.7 166.56 10.31 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.9 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -44.98 140.04 2.84 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.998 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.47 35.71 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.976 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 28.3 m -76.53 148.83 36.86 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.986 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.485 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.8 p -122.38 127.22 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 69' ' ' VAL . 16.1 m -93.76 170.31 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.84 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.62 148.3 41.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.999 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.724 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -143.75 108.18 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.997 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.859 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.83 115.13 21.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.81 143.13 19.67 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.958 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.921 ' O ' HG22 ' A' ' 4' ' ' THR . . . -137.6 111.97 8.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.949 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.932 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 102.77 24.59 8.06 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -91.12 -163.96 1.11 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.993 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.417 ' O ' ' HB ' ' A' ' 30' ' ' THR . 34.4 mt-30 -88.27 127.12 35.46 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.18 133.77 42.75 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.78 8.68 82.33 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.973 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.678 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -96.89 137.64 35.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.939 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.661 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.94 152.33 22.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.034 ' CD1' ' HD2' ' A' ' 105' ' ' PRO . 45.3 m-85 -139.29 149.34 44.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.91 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.105 ' CB ' ' H ' ' A' ' 98' ' ' SER . 14.7 m-20 -112.21 115.03 28.15 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.189 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.34 146.06 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.999 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.889 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.56 170.79 42.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.708 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 5.5 tt0 -117.46 122.99 45.27 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.92 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m -125.85 148.31 49.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.124 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 134.88 54.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.89 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.659 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.0 OUTLIER -65.31 123.5 19.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.909 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.17 HG21 ' CD2' ' A' ' 83' ' ' TRP . 32.3 m -103.84 -42.0 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.976 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.17 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -132.01 -178.67 5.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.963 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 33.1 m -69.67 113.45 6.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.948 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.91 10.01 80.17 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.641 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.23 125.48 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.964 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.736 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.5 pt? -133.62 140.92 47.39 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.959 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.72 144.15 25.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 23.2 m -105.51 159.89 15.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.741 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 21.8 t30 -118.67 111.57 37.64 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.989 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.44 0.55 7.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.307 3.338 . . . . 0.0 109.591 179.881 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -11.98 41.77 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.911 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.504 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.2 p30 -129.49 27.59 5.27 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.34 107.09 16.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.4 t -105.02 174.96 5.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.91 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.5 p -146.67 158.36 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.881 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.468 HG22 ' N ' ' A' ' 56' ' ' THR . 7.3 p -167.82 158.52 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.935 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.468 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.0 m -128.13 125.06 38.4 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.93 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.51 152.89 13.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -180.0 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.7 p30 -95.28 -169.47 1.98 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.951 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.65 -24.87 67.84 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.913 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -81.04 -7.26 59.52 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.973 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.43 13.28 83.55 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.978 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.8 p -105.02 139.69 39.32 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.867 -0.419 . . . . 0.0 109.867 179.951 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.54 162.27 20.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.972 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 p -150.14 122.19 8.26 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.921 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.539 HG22 HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -151.24 153.25 34.52 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.903 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -107.95 120.69 43.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.946 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.523 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -99.69 156.02 17.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.547 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -111.71 128.16 56.0 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -100.23 129.64 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.966 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.559 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -113.68 155.52 25.4 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.961 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.402 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 ppt_? -89.72 -12.77 38.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.544 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -166.06 142.39 5.06 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.92 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.741 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 10.8 p90 -178.0 158.05 1.2 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.895 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.19 124.9 21.69 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.911 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.513 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.18 103.97 2.54 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.915 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.726 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.57 102.03 12.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.958 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -56.61 131.6 49.34 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.968 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.659 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.2 p90 -47.44 -36.6 10.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.563 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.39 -16.48 9.24 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.953 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.41 27.57 9.8 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.958 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.4 m -115.11 150.3 36.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.971 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.4 mtm180 -85.36 98.0 10.3 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.956 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.641 ' CH2' HG21 ' A' ' 44' ' ' VAL . 22.8 t-105 -63.92 -51.33 64.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 179.896 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 139.03 179.73 17.69 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.969 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.86 134.26 56.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.927 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.124 HG11 ' HB3' ' A' ' 38' ' ' ALA . 6.5 t -114.62 150.08 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.2 94.43 4.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.926 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -53.37 -25.31 14.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 180.0 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.4 p -83.92 2.14 40.09 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.95 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -114.44 -27.85 7.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.942 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.33 179.88 5.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.937 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 126.32 41.93 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.907 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.327 ' C ' HG13 ' A' ' 110' ' ' ILE . 9.0 m -104.39 153.98 20.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.961 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.058 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -149.62 148.23 29.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.95 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.523 ' CG1' HD13 ' A' ' 67' ' ' LEU . 17.9 t -96.76 163.55 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.96 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.189 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.41 158.34 27.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.009 HD21 ' CG ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -141.53 137.61 32.14 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.972 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.105 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -129.13 153.48 47.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.912 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.661 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -98.11 -166.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.996 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -59.28 -49.99 75.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.978 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.639 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -69.29 -24.82 64.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.926 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.415 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 100.65 41.71 2.65 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.639 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 5.3 p30 -121.4 178.03 4.96 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.27 -176.0 20.81 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.98 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.04 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.46 134.03 21.8 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.298 3.332 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.383 ' O ' ' CB ' ' A' ' 2' ' ' ALA . 0.5 OUTLIER -136.04 144.3 45.17 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.992 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.39 59.46 0.19 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.979 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.99 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 36.4 t -133.54 100.74 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.617 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.37 153.75 18.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.969 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.327 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -121.91 161.36 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -148.65 117.05 6.51 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.961 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.039 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 45.3 m-85 -94.72 128.12 41.19 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.931 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.964 . . . . . . . . 0 0 . 1 . 042 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.847 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.938 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.38 -177.35 2.67 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.331 3.354 . . . . 0.0 109.59 179.906 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.812 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.31 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.96 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.746 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.28 144.57 49.33 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.988 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.773 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -111.33 108.41 18.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.754 ' CG2' HG23 ' A' ' 21' ' ' VAL . 1.7 t -99.64 151.05 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.983 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -66.7 177.82 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.979 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.048 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.4 Cg_endo -72.4 115.82 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.304 3.336 . . . . 0.0 109.628 179.89 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.588 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 30.0 p -118.32 38.84 3.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.968 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 111' ' ' SER . 11.5 p -117.86 104.78 11.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.901 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.996 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.22 26.58 12.07 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.961 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.048 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -98.2 129.76 44.95 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.958 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -91.87 161.9 14.65 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -45.33 142.03 2.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.957 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.24 33.14 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.988 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD13 ' A' ' 13' ' ' LEU . 34.4 m -76.48 150.71 36.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.99 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.8 124.41 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.995 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.547 HG11 ' CB ' ' A' ' 10' ' ' SER . 18.5 m -96.15 133.95 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.991 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.662 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -79.2 154.47 29.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.801 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.2 p -140.95 103.13 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.773 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -109.51 121.33 44.96 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.94 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.741 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -101.7 139.62 14.49 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.812 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -134.37 127.07 30.91 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.992 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.03 24.18 23.24 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.001 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -91.29 -167.24 1.75 Allowed 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.488 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.0 mt-30 -84.93 125.18 32.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.991 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.76 130.74 41.18 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.54 8.22 83.81 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.954 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.546 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -95.4 132.16 40.75 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.916 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -79.64 150.63 30.91 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.934 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.605 ' CB ' HD12 ' A' ' 97' ' ' LEU . 31.5 m-85 -137.9 148.77 45.63 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.909 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.194 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.9 m-20 -113.89 116.29 29.06 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.917 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.245 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.12 145.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.995 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.038 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.69 169.57 41.3 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.978 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.033 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 10.6 tt0 -111.22 120.72 43.22 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.945 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.549 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -110.33 162.7 14.38 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.953 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.172 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -150.81 125.16 9.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.959 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.9 125.86 26.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.988 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.81 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.6 m -111.69 -35.62 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.173 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.2 -178.55 5.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.967 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 79.0 m -77.19 111.83 13.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.976 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.28 10.51 85.94 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.668 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -128.78 114.84 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.551 HD23 ' C ' ' A' ' 38' ' ' ALA . 0.5 OUTLIER -108.14 162.85 13.68 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.986 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.39 127.38 40.89 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.944 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.733 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.95 154.25 21.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.728 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.9 t30 -116.29 113.96 40.95 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.972 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.34 -0.11 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.33 3.353 . . . . 0.0 109.598 179.891 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.55 -16.1 29.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.836 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.578 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.3 p30 -125.96 25.63 6.75 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.915 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -91.22 106.25 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.967 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.2 t -99.66 -179.88 4.33 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.916 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.4 p -146.84 157.34 43.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.901 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -166.69 160.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.914 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.508 ' N ' HG22 ' A' ' 55' ' ' VAL . 12.0 m -127.52 141.08 51.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.572 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -79.36 134.51 36.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.4 p30 -78.6 -171.84 2.68 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.933 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.26 -26.14 68.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.947 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -77.77 -3.97 44.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.001 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.53 31.26 70.87 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.999 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.6 p -123.14 133.7 54.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.963 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -139.22 124.57 19.17 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.983 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.97 143.04 46.72 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.949 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.48 166.23 33.35 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -105.79 124.61 49.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.029 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.82 118.59 35.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.981 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.641 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.1 t -80.88 132.34 35.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.938 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.555 HG23 ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -107.78 130.52 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.598 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 1.5 mpt_? -115.78 146.25 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.98 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.715 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.7 OUTLIER -70.86 -4.39 24.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.957 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 31.7 p -178.79 153.25 0.65 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.9 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.033 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 6.4 p90 -176.87 162.31 2.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.955 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -56.15 126.45 26.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.07 88.64 1.5 Allowed Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.933 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.733 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.87 100.85 11.25 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.996 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.3 tp -63.46 130.55 44.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.9 p90 -47.48 -36.04 9.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.986 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.539 ' H ' ' CD1' ' A' ' 77' ' ' LEU . 1.4 t70 -57.37 -16.63 9.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.994 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.0 27.36 9.51 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.994 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -113.61 144.99 41.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.87 94.24 9.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.966 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.668 ' CZ2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.41 -57.75 9.29 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.78 164.28 10.5 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.992 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -56.0 127.5 30.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.934 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.172 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.8 OUTLIER -107.79 154.95 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.993 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.56 108.7 16.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.957 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.84 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 35.1 m -54.25 -26.48 29.07 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.976 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.6 p -82.02 -0.97 46.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.965 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -116.4 -27.36 6.81 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.932 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.88 -178.31 4.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.69 124.24 40.62 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.15 ' C ' HG13 ' A' ' 110' ' ' ILE . 94.9 m -104.47 152.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.956 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.044 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -156.42 146.04 20.86 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.949 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.029 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 9.2 t -96.53 162.57 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.245 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 160.49 31.33 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.605 HD12 ' CB ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -138.84 141.8 38.65 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.972 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.194 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -134.02 157.8 45.17 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.929 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.916 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.89 -164.16 1.02 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.448 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.13 -49.68 76.13 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.576 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.8 -24.78 61.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.902 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.85 41.13 2.95 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 6.1 p30 -117.68 176.69 5.06 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.4 -175.75 20.76 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 179.975 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.985 ' HG2' HD21 ' A' ' 97' ' ' LEU . 83.2 Cg_endo -72.39 133.89 21.67 Favored 'Trans proline' 0 N--CA 1.447 -1.247 0 C-N-CA 124.338 3.359 . . . . 0.0 109.568 179.908 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.847 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 3.7 tt0 -137.26 147.49 45.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.96 58.11 0.23 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.946 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.025 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.4 t -130.88 101.38 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.41 143.36 28.94 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.15 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -110.79 169.27 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.92 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.451 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -161.4 127.64 3.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.943 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.84 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 11.2 m-85 -99.1 116.84 32.25 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.893 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.956 ' O ' ' HA2' ' A' ' 12' ' ' GLY . 3.4 p30 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.135 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.218 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.5 Cg_endo -72.41 -175.3 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.297 3.331 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.723 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -100.55 108.68 20.68 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.92 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.881 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.98 136.87 54.38 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.932 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.625 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -98.53 112.27 24.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.969 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.834 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -106.2 153.42 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.997 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.953 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.73 176.93 1.1 Allowed Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.92 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.096 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.9 Cg_endo -72.35 115.9 4.5 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.323 3.349 . . . . 0.0 109.59 179.881 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -112.95 41.23 2.12 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.956 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.529 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -119.04 105.43 11.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.876 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.081 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 93.2 28.24 12.08 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.99 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.096 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -103.24 130.16 50.4 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.976 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -106.16 174.52 5.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.944 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -48.65 139.97 8.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.935 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.66 -23.59 32.26 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.999 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.448 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.3 m -80.17 151.92 29.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.973 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.1 p -127.11 130.2 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.979 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 1.02 HG22 ' O ' ' A' ' 67' ' ' LEU . 15.4 m -95.87 170.66 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.995 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.834 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.59 148.8 40.58 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.735 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -143.3 106.09 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.971 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.881 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.04 115.76 24.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.798 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.35 142.12 19.42 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.723 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.91 112.53 9.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.964 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.947 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.53 25.7 8.04 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -180.0 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.218 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -91.26 -163.8 1.09 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -89.25 125.21 34.99 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.97 133.86 44.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.66 8.57 84.4 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.606 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -98.83 134.57 41.52 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.995 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.953 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.47 152.24 25.05 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.546 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 38.0 m-85 -138.51 145.25 40.53 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.928 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -110.15 122.45 47.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.924 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.116 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.2 t -102.19 150.17 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.997 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.996 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.88 146.66 9.2 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.943 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.806 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 14.4 tt0 -92.58 115.86 28.48 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.598 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -103.13 163.78 12.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.951 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 1.198 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.16 131.42 15.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.96 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.542 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.0 OUTLIER -67.32 124.57 23.51 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.987 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.3 m -111.39 -41.64 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.974 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.533 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -146.1 -178.8 6.32 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.964 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.673 ' O ' HG23 ' A' ' 42' ' ' THR . 1.3 t -65.1 111.6 2.98 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.986 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 7.92 62.73 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.988 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.571 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 45.9 t -111.02 105.2 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.69 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.3 mt -107.98 153.29 23.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.483 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -128.15 128.63 45.18 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.966 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -106.87 154.81 20.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.538 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.7 t30 -116.15 112.53 41.94 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -179.982 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -72.33 -0.35 8.55 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.308 3.338 . . . . 0.0 109.616 179.839 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.538 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.83 -12.26 34.2 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.832 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' A' ' 68' ' ' THR . 23.6 p30 -130.82 27.34 4.93 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.63 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -103.35 116.14 31.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.977 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 54' ' ' SER . 30.2 t -100.56 -173.22 2.35 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.984 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.442 ' N ' ' OG ' ' A' ' 53' ' ' SER . 4.7 p -147.14 154.08 40.67 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.85 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -167.06 154.44 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 58.7 m -123.8 122.73 38.8 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.954 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -52.79 149.75 5.95 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -92.27 -171.44 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.955 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.27 -25.06 67.64 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -81.35 -5.0 57.39 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.415 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 72.58 23.66 77.53 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 82.4 p -114.42 138.06 51.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.996 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.61 163.02 19.63 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.997 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -150.94 120.0 6.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.512 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -148.86 158.08 43.9 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.892 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.45 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -110.4 126.35 54.19 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.985 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.02 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -107.58 118.24 36.2 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.965 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.677 ' N ' HD13 ' A' ' 67' ' ' LEU . 4.7 t -69.0 149.73 48.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.922 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.531 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -106.46 123.93 61.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.967 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.531 ' HD2' ' O ' ' A' ' 69' ' ' VAL . 1.5 mpt_? -116.58 137.09 52.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.971 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.47 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 26.0 ptt180 -75.26 -18.34 60.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 9.7 t -163.82 151.57 12.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.911 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.806 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -177.8 155.7 1.04 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.885 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -55.93 122.63 12.01 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.931 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.483 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.54 89.46 1.03 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.966 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.45 10.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.989 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.855 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.25 141.74 28.56 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.711 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.0 m-85 -47.1 -42.37 18.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.978 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.573 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 12.2 t0 -57.05 -17.06 8.71 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.959 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.82 28.16 9.71 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.934 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.855 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.0 m -108.78 131.16 55.23 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttt180 -72.94 91.62 1.56 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.944 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.533 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 0.5 OUTLIER -61.96 -57.0 13.37 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.884 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.41 170.2 21.31 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 179.982 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.47 142.22 33.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.198 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -117.91 154.11 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.973 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.507 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 10.0 m-20 -128.73 95.0 3.99 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.965 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 1.226 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 99.1 m -54.31 -25.63 24.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.977 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -80.45 1.87 27.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.978 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -113.83 -27.39 7.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.969 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.07 -170.55 2.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.983 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.89 126.52 42.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.92 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.344 ' C ' HG13 ' A' ' 110' ' ' ILE . 11.9 m -104.68 152.84 22.01 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.073 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.8 148.09 31.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.92 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.837 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 24.1 t -99.72 164.86 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.952 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.026 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.81 158.03 24.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.546 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -134.9 152.9 52.14 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.974 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER -141.32 158.47 43.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.903 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.953 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -105.28 -163.13 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.967 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.51 -49.34 77.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.941 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.582 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -72.79 -25.44 61.16 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.947 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.07 42.38 2.43 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.95 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.634 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 5.0 p30 -119.51 176.12 5.51 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.19 -173.22 22.81 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.994 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.126 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.38 133.35 20.72 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.345 3.363 . . . . 0.0 109.641 179.92 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.135 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 2.3 tt0 -136.1 145.74 46.24 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 57.36 0.23 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.964 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.006 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 25.5 t -131.58 100.94 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.978 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.655 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -97.57 155.22 17.06 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.996 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.344 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -124.29 163.49 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.949 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.529 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -153.61 122.47 6.41 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.959 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.226 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 10.0 m-85 -87.6 116.32 25.65 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 179.902 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 1.081 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 4.4 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.966 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.893 ' HA ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.165 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.42 -174.05 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.347 3.365 . . . . 0.0 109.579 179.964 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.648 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.03 109.48 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.939 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.795 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.73 141.74 49.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.937 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -96.72 111.44 23.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.915 HG21 HG22 ' A' ' 108' ' ' VAL . 21.9 t -107.66 148.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.978 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -68.48 177.63 1.04 Allowed Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.103 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.38 117.97 5.38 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 124.32 3.346 . . . . 0.0 109.607 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 111' ' ' SER . 9.3 p -115.11 44.58 1.78 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.957 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.4 m -122.91 105.11 9.71 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.88 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.955 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.88 28.1 14.8 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.103 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.69 132.69 43.1 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.8 m -107.19 172.93 6.55 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.956 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.65 140.05 15.15 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.39 -22.99 35.67 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.496 HG21 HD13 ' A' ' 13' ' ' LEU . 86.3 m -74.59 153.11 39.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.506 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.1 p -129.96 126.1 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.894 HG22 ' O ' ' A' ' 67' ' ' LEU . 26.3 m -94.57 176.65 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.98 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.833 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.35 149.28 45.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.944 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.619 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -145.11 108.03 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.795 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.27 116.78 23.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.961 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.933 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.39 144.34 21.48 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.648 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -140.67 112.6 7.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.933 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 105.22 21.75 8.69 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.165 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -91.29 -163.91 1.1 Allowed 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.843 ' OE1' ' OH ' ' A' ' 32' ' ' TYR . 12.0 mp0 -89.94 126.43 35.73 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.485 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -69.61 141.59 53.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.978 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.69 7.72 59.03 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.96 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.753 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.57 143.05 26.73 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.564 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.22 148.84 21.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.984 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.843 ' OH ' ' OE1' ' A' ' 27' ' ' GLN . 49.4 m-85 -137.85 148.55 45.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.2 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.7 m-20 -112.38 114.57 27.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.964 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.074 HG22 ' HB3' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -96.18 146.43 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.978 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.887 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.5 167.88 40.97 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.953 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.812 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 8.2 tt0 -115.97 113.38 23.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -114.3 149.05 36.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.971 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.66 134.91 52.72 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.928 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.663 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 120.56 13.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.95 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.433 HG21 ' CD1' ' A' ' 83' ' ' TRP . 24.8 m -101.07 -44.95 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.982 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.865 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.6 OUTLIER -133.36 172.36 12.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 42' ' ' THR . 1.6 t -56.47 111.44 0.99 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.92 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.88 7.53 62.21 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.789 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 21.6 t -120.68 111.08 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.951 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.705 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.1 pt? -123.43 140.97 52.47 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.516 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -98.33 146.03 26.09 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 12.1 m -106.48 153.97 21.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.757 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.0 t30 -114.52 109.82 47.92 Favored Pre-proline 0 N--CA 1.45 -0.468 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.4 -0.35 8.58 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.293 3.328 . . . . 0.0 109.585 179.914 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.53 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.65 -16.57 32.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.876 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 13.7 p30 -128.24 28.44 5.49 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.878 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.47 118.95 36.29 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.97 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -111.43 -172.84 2.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.965 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -146.7 157.66 43.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.888 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 56' ' ' THR . 4.5 p -166.75 159.53 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.466 ' N ' HG22 ' A' ' 55' ' ' VAL . 14.0 m -127.1 137.5 53.02 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.985 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.83 131.44 39.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -73.75 -173.43 1.51 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.26 -20.42 62.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -85.98 10.09 15.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.485 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 56.79 26.78 54.77 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.946 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 t -121.21 133.54 55.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.439 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.44 156.75 32.06 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -139.02 133.69 32.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.663 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.93 170.34 19.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.942 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.663 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -121.01 138.39 54.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.939 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.894 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -115.77 118.81 34.07 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.943 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.719 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -71.1 135.89 47.93 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.565 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -92.67 125.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.971 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.719 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 1.1 mpt_? -117.8 140.63 49.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.416 ' O ' ' OG ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -82.72 -15.84 50.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 58.4 m -167.33 152.13 7.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.979 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.812 ' HE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -176.55 161.86 2.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.929 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.403 ' HG3' ' CD2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -62.54 110.58 1.74 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.94 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.516 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.97 94.21 0.44 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.958 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.867 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.5 m-85 -82.88 98.78 9.36 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.956 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 1.114 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -55.49 142.28 33.62 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.982 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.745 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.67 -42.91 25.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 1.114 ' OD2' HD21 ' A' ' 77' ' ' LEU . 4.0 m-20 -57.75 -16.76 12.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.78 27.73 12.25 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.836 ' HB ' HD23 ' A' ' 77' ' ' LEU . 4.9 m -106.08 134.07 49.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.97 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.48 91.64 0.78 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.433 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.76 -48.82 77.51 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.878 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.63 167.13 10.94 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -65.43 103.59 0.85 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.963 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.4 m -78.61 151.81 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.981 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -110.48 93.85 4.71 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.788 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 13.7 m -51.29 -26.26 7.09 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.7 p -81.06 0.79 34.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 -179.999 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -117.3 -27.62 6.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.51 -179.9 5.43 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.34 123.77 40.1 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.295 ' C ' HG13 ' A' ' 110' ' ' ILE . 89.1 m -104.59 155.66 18.65 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -180.0 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.034 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 1.2 pt20 -144.56 147.49 33.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.944 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.795 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 14.2 t -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.952 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.08 160.05 28.71 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.074 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -128.35 155.29 44.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.954 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.2 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -143.45 144.23 31.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.898 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.564 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -90.97 -161.78 0.85 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.457 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.69 -49.29 78.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.586 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.13 -24.79 62.34 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.93 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.83 42.5 2.45 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.994 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.586 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 5.7 p30 -121.07 177.16 5.24 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.92 -173.65 22.28 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.069 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.35 133.85 21.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.364 3.376 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.893 ' HG3' ' HA ' ' A' ' 2' ' ' ALA . 1.8 pt-20 -139.8 161.53 37.34 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.79 51.71 0.6 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.925 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.98 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.0 t -126.44 101.82 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.996 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.09 146.83 24.32 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.955 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.295 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -115.78 159.71 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.907 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -151.0 126.73 10.25 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.909 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.788 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 8.3 m-85 -101.48 124.93 47.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.932 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.616 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 49.2 m-80 . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.961 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.633 ' C ' ' HB3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.406 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.38 -174.13 1.34 Allowed 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.286 3.324 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.162 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.4 t -95.93 109.73 22.05 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.839 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.99 145.7 50.89 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.511 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -103.9 113.37 26.85 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.884 HG13 ' O ' ' A' ' 20' ' ' LYS . 38.5 t -110.66 148.53 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.996 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.15 175.94 1.59 Allowed Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.945 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.956 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 120.95 7.07 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.351 3.367 . . . . 0.0 109.63 179.851 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.085 ' HA ' HD21 ' A' ' 13' ' ' LEU . 30.8 p -120.83 52.48 1.18 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 62.0 p -137.81 106.14 5.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.9 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.68 8.47 40.01 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.9 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.146 ' O ' HD12 ' A' ' 13' ' ' LEU . 3.5 pp -114.68 143.08 45.61 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -122.47 -166.99 1.49 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.936 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.943 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 42.7 t0 -43.32 151.73 0.15 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.969 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 92.02 -23.38 26.86 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.998 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.778 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -85.08 146.05 27.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 18' ' ' VAL . 14.8 p -116.21 129.52 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.638 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 6.0 m -99.75 159.4 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.884 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 145.42 41.37 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.969 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.592 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -142.06 110.16 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.989 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.839 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.89 112.91 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.979 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.904 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.92 144.77 21.25 Favored Glycine 0 C--N 1.334 0.468 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.162 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -142.86 110.13 5.68 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.955 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.879 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.89 14.92 15.95 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.234 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -91.04 165.94 13.26 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.463 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.9 mt-30 -48.99 121.26 4.58 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.96 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.608 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.69 134.93 45.28 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.945 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 8.2 76.32 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.981 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.751 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -97.7 137.41 36.63 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.995 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.12 151.97 24.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.998 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.57 ' CB ' HD23 ' A' ' 97' ' ' LEU . 73.0 m-85 -135.77 158.2 44.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.925 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.45 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 17.1 m-20 -119.71 117.93 29.55 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.948 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.42 138.13 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.958 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 1.173 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -158.91 162.88 32.91 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.839 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 1.8 tt0 -115.13 121.62 43.59 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.915 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.567 ' HB3' HD13 ' A' ' 45' ' ' LEU . 66.9 m -108.59 172.7 6.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.976 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.833 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -152.84 124.34 7.71 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.943 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.598 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 124.25 21.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.947 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.641 ' CG1' HG22 ' A' ' 86' ' ' VAL . 12.1 m -104.43 -43.7 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.952 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.701 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.88 164.13 30.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.6 m -53.33 114.06 1.36 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.944 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.6 7.92 70.4 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.511 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 15.0 t -126.44 105.76 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.953 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.763 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.84 162.65 17.76 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.495 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.18 146.96 49.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.817 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.4 m -108.35 155.95 19.96 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.826 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 33.6 t30 -114.59 105.64 53.3 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.287 3.325 . . . . 0.0 109.609 179.885 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.44 -12.94 41.67 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.878 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.9 p30 -126.71 28.51 5.87 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.72 104.57 13.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.997 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.1 t -101.65 177.26 4.96 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.923 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 p -146.44 153.08 40.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.852 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -167.37 153.04 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.966 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.1 m -122.58 139.62 53.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.0 142.86 32.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.917 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -80.02 -170.73 2.59 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -22.08 66.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.961 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.92 4.75 21.36 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.608 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.32 31.01 72.44 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.921 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.8 t -125.05 132.28 53.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.94 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.12 164.07 17.43 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.979 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -146.74 135.64 22.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.593 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.05 165.35 17.93 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.913 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.593 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -122.34 126.06 47.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.939 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.206 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.83 155.34 16.82 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 68' ' ' THR . 5.0 t -103.7 119.29 38.62 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.946 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.813 HG11 ' CD1' ' A' ' 13' ' ' LEU . 2.1 t -84.35 128.4 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.943 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.6 OUTLIER -119.1 156.82 29.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.412 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -90.93 -24.98 20.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.923 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.412 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -156.47 148.35 22.94 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.946 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.839 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.8 p90 -174.41 153.42 1.91 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.935 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.501 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -54.29 115.13 1.92 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.495 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.49 100.64 0.83 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.986 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.817 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -83.41 99.95 10.39 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.988 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.952 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -58.61 130.94 49.25 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 14.1 p90 -47.65 -35.75 9.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.553 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.96 -16.35 12.06 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.19 27.68 9.88 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.986 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.952 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.3 m -115.36 151.65 34.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.419 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -89.45 97.86 11.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.511 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.43 -55.9 20.57 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.883 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.56 172.67 17.09 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.26 108.25 0.45 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.978 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.833 HG11 ' HB3' ' A' ' 38' ' ' ALA . 86.4 t -86.05 147.43 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 48.1 m-20 -108.09 90.87 3.43 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.963 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.429 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -53.06 -25.24 12.03 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 61.0 p -78.01 -3.33 41.5 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.78 -26.07 7.54 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.46 -179.89 4.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.962 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.26 136.97 36.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.899 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.463 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.69 166.05 10.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.998 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.335 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -169.52 127.9 0.96 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.911 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.206 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.9 t -92.41 164.28 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -170.22 164.83 38.16 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.57 HD23 ' CB ' ' A' ' 32' ' ' TYR . 4.3 mp -100.33 160.93 13.94 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.45 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 14.6 m -155.0 117.44 4.26 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.437 ' OD1' ' OD1' ' A' ' 103' ' ' ASN . 3.2 p-10 -112.11 -158.15 0.64 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.958 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.13 -39.49 59.99 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -26.89 19.6 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.77 53.52 2.23 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.437 ' OD1' ' OD1' ' A' ' 99' ' ' ASP . 0.9 OUTLIER -106.68 -174.7 2.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.994 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.422 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 171.01 175.58 39.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.406 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.9 Cg_endo -72.33 160.63 46.54 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.32 3.347 . . . . 0.0 109.581 179.948 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.271 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -33.84 126.63 0.42 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.991 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.462 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.76 135.75 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.335 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 25.3 t -119.05 102.88 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.956 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.908 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.7 158.22 19.48 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.969 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.87 HG13 ' HA ' ' A' ' 94' ' ' GLN . 35.2 mt -125.98 162.49 29.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.986 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.598 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -141.07 121.39 13.95 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.903 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.463 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 2.9 m-85 -97.72 122.21 40.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.2 m120 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.943 . . . . . . . . 0 0 . 1 . 046 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 1.292 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.565 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.4 Cg_endo -72.38 -174.3 1.39 Allowed 'Trans proline' 0 N--CA 1.446 -1.272 0 C-N-CA 124.337 3.358 . . . . 0.0 109.634 179.886 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.282 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.6 t -95.97 111.42 23.43 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.957 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.801 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.57 140.13 50.45 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -102.25 111.27 23.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.985 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.652 HG11 HG21 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -108.22 155.05 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.981 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.972 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.43 177.02 1.02 Allowed Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.929 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 1.136 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.39 117.86 5.33 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.316 3.344 . . . . 0.0 109.605 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.494 ' OG ' HG23 ' A' ' 110' ' ' ILE . 22.6 p -114.31 41.39 2.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.963 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 111' ' ' SER . 60.4 p -123.41 105.97 10.26 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.928 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.957 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.68 26.38 15.29 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.976 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.136 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.93 132.49 43.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.958 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.2 m -90.79 151.8 21.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.938 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -44.09 137.84 3.19 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.93 -20.9 37.43 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.984 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.435 HG21 HD13 ' A' ' 13' ' ' LEU . 90.9 m -64.78 147.46 53.13 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.995 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.7 p -110.58 117.78 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.972 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 67' ' ' LEU . 14.8 m -95.48 164.75 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.627 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.16 153.33 29.75 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.947 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.681 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -149.39 113.48 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.982 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.801 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.25 114.5 21.47 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.766 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.28 147.69 23.61 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.282 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -147.48 109.85 4.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.933 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.886 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.67 14.0 18.86 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.193 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -90.49 165.8 13.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 76.8 mt-30 -50.91 118.99 3.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.855 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.05 134.99 46.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.971 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.25 8.73 80.05 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.916 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.643 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 142.69 29.41 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.975 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.583 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.03 153.21 22.3 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.975 ' HB3' ' HB3' ' A' ' 97' ' ' LEU . 59.2 m-85 -138.29 150.88 47.07 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.919 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.493 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.2 m-20 -116.87 114.86 24.47 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.591 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.52 139.94 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.956 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.76 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.92 156.92 28.17 Favored Glycine 0 C--N 1.335 0.489 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.702 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 52.8 tt0 -96.33 113.54 25.14 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.3 m -102.17 159.5 15.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.992 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -149.2 141.45 24.07 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.905 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.549 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.2 t90 -63.6 121.65 14.42 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.718 HG12 ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -109.53 -36.37 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -155.24 -175.81 5.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.601 ' O ' HG23 ' A' ' 42' ' ' THR . 7.2 t -73.56 110.55 7.93 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.88 12.75 83.71 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.649 HG21 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -128.9 121.15 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.985 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -113.78 162.2 16.59 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.989 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.471 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -132.14 130.91 41.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.76 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.65 155.23 20.39 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.759 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.2 p-10 -118.69 120.1 31.98 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.955 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.422 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.5 Cg_endo -72.34 1.66 5.88 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.298 3.332 . . . . 0.0 109.627 179.879 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.736 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.33 -24.79 29.63 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.874 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.51 ' CB ' HG23 ' A' ' 68' ' ' THR . 94.4 m-20 -123.39 30.98 6.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.14 117.71 34.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 -179.973 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.2 t -110.86 -177.95 3.35 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.7 p -148.46 153.79 38.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 56' ' ' THR . 3.1 p -167.63 161.65 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.901 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.4 m -126.53 131.76 51.51 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 153.19 44.25 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 -179.999 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.3 p-10 -90.38 -166.42 1.58 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.937 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -30.23 71.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.885 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.39 -9.55 58.7 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.855 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.48 15.99 80.82 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.983 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.5 p -104.57 138.3 41.13 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.951 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.96 166.65 13.54 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 m -150.92 117.34 5.7 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.83 157.9 43.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.948 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.439 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -110.76 125.22 53.31 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.899 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.235 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -104.65 155.3 18.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.967 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.775 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -116.74 142.81 46.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -110.48 125.13 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.991 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.604 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -110.14 159.91 16.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.976 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.67 -29.39 59.05 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 69.6 p -165.28 156.96 14.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.759 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 3.1 p90 -175.28 167.35 3.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -63.97 118.82 9.0 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.947 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.471 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -75.01 85.3 0.79 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.76 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.05 98.63 9.39 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.8 tp -54.71 134.7 47.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 27.2 p90 -45.63 -38.43 6.65 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.999 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.587 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t70 -57.66 -17.14 13.12 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.943 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.88 28.7 9.18 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.9 m -112.65 115.91 29.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.948 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -66.03 93.36 0.2 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.649 ' CE2' HG21 ' A' ' 44' ' ' VAL . 2.3 t-105 -63.44 -57.98 8.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.925 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.35 171.38 19.88 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.967 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.48 140.67 56.02 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.992 HG21 ' HB1' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.61 151.6 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.56 100.78 9.53 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.899 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 23.8 m -53.5 -26.0 18.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.979 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -82.5 -1.7 51.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.979 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.48 -27.99 6.98 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.919 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -125.4 -175.15 3.24 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.39 124.57 41.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.899 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.185 ' O ' HG13 ' A' ' 110' ' ' ILE . 1.7 m -104.66 153.65 20.97 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.133 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -158.5 144.92 17.22 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.959 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.235 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 25.4 t -101.41 162.38 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.81 164.25 35.63 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.591 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -101.72 160.95 14.02 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -180.0 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.493 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 3.3 p -153.47 119.48 5.39 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.583 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 13.4 p-10 -115.11 -167.11 1.19 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -50.74 -21.15 1.49 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.875 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.18 -24.59 13.14 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.931 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 85.69 22.52 49.92 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.905 ' OD1' ' CD1' ' A' ' 32' ' ' TYR . 16.7 p-10 -59.8 -151.17 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.987 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.06 153.73 6.11 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.975 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.565 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.4 Cg_endo -72.44 161.49 44.1 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.316 3.344 . . . . 0.0 109.6 179.985 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 1.292 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -32.75 123.91 0.35 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.936 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.776 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -36.03 134.93 0.6 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.133 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.77 102.45 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.482 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -85.58 141.1 30.08 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.185 HG13 ' O ' ' A' ' 93' ' ' CYS . 1.0 OUTLIER -109.48 167.39 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.949 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -150.52 123.49 8.74 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.962 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 19.7 m-85 -99.6 126.19 45.55 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.903 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.993 . . . . . . . . 0 0 . 1 . 047 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.806 ' CB ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 . . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 1.187 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.4 -177.83 2.96 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.266 3.311 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.14 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.8 114.45 28.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.98 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.907 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.37 131.85 50.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.712 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.03 112.07 23.81 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.975 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.948 HG11 HG22 ' A' ' 108' ' ' VAL . 1.3 m -113.08 149.69 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.926 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.999 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.14 179.87 0.65 Allowed Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.923 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.999 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.6 Cg_endo -72.42 121.0 7.09 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.321 3.348 . . . . 0.0 109.538 179.947 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 10' ' ' SER . . . . . 1.016 ' HA ' HD21 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -110.48 3.73 19.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.986 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 11' ' ' SER . . . . . 1.398 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 66.1 m -110.36 126.11 53.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.901 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.489 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 103.71 5.29 45.13 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.937 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.016 HD21 ' HA ' ' A' ' 10' ' ' SER . 2.1 pp -114.32 146.58 40.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 88.4 p -99.0 171.5 8.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -45.37 151.82 0.34 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 179.969 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.79 -22.36 34.2 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.968 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 ' CB ' ' A' ' 13' ' ' LEU . 59.0 m -69.31 138.53 53.88 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.993 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.5 p -104.11 132.42 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.996 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.86 HG23 HG12 ' A' ' 69' ' ' VAL . 21.5 t -104.12 168.41 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.979 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.836 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.78 134.87 53.57 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.945 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.796 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.2 p -128.08 104.86 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.907 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -111.39 115.23 28.91 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.705 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.61 145.62 21.99 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.14 ' O ' HG22 ' A' ' 4' ' ' THR . . . -146.2 112.27 5.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.15 26.18 8.48 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.961 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 1.125 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.83 -165.81 1.44 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.953 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.788 ' OE1' ' OH ' ' A' ' 32' ' ' TYR . 16.9 mp0 -94.35 124.83 38.61 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.1 137.45 57.98 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.4 8.66 63.01 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.304 -1.119 . . . . 0.0 110.304 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.789 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -91.69 142.71 27.31 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.993 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.774 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.13 150.5 21.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.983 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 1.102 ' CG ' ' HD2' ' A' ' 105' ' ' PRO . 56.9 m-85 -139.3 144.51 38.35 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.908 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 1.408 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.2 m-20 -105.57 114.76 29.13 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.23 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.47 150.88 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.983 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.755 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.87 168.4 38.56 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.98 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 1.003 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.6 tt0 -111.29 120.96 43.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.536 ' HB3' HD13 ' A' ' 45' ' ' LEU . 88.9 m -109.95 169.1 8.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.863 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -153.68 125.13 7.56 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.481 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.57 129.85 41.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.903 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 1.638 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.4 m -109.33 -37.81 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.407 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -146.82 163.69 35.23 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.958 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.416 ' H ' HG22 ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.19 114.89 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.965 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.56 1.93 62.63 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.989 HG12 HG23 ' A' ' 40' ' ' VAL . 15.9 t -121.02 119.64 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.742 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -126.75 162.22 26.32 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.484 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -124.24 139.67 53.7 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 1.033 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 24.1 m -109.18 151.83 25.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.562 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.9 t30 -112.77 110.74 51.9 Favored Pre-proline 0 N--CA 1.448 -0.552 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.977 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 124.341 3.361 . . . . 0.0 109.596 179.936 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.562 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.05 -20.54 23.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.909 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.688 ' OD2' ' NE2' ' A' ' 36' ' ' GLN . 8.5 p30 -119.38 19.93 12.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.671 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -92.35 113.57 25.87 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.7 t -108.0 -174.28 2.48 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -146.28 155.9 42.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.915 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 56' ' ' THR . 5.7 p -166.88 158.13 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.941 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.456 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.5 m -127.78 129.42 46.99 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 135.57 55.62 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 p30 -76.66 -175.19 3.27 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.941 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.66 -19.96 64.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -87.34 10.3 17.73 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.074 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 30.35 59.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.6 t -124.82 135.98 53.42 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.964 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.35 164.63 19.97 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.0 m -152.41 119.48 5.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.983 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.17 164.14 34.07 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.865 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.554 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -106.68 133.74 50.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.943 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.184 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -119.59 120.2 36.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.916 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.616 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -83.97 145.04 28.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.989 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.86 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -121.51 134.56 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.859 ' HG2' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.92 174.94 5.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.988 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HG2' ' CG2' ' A' ' 89' ' ' THR . 6.5 mtt180 -98.68 -12.19 21.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.948 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 20.3 p -173.68 145.95 1.24 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 1.003 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 1.2 p90 -171.6 163.25 6.61 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.922 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.14 118.02 3.99 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.943 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.484 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.74 96.08 1.4 Allowed Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 1.033 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.14 100.64 11.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.875 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -56.21 130.64 45.19 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.972 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.619 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.1 p90 -47.42 -35.36 8.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.998 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.61 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.1 t0 -57.49 -17.55 14.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.4 27.92 8.34 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.875 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.5 m -116.88 148.09 41.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.96 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -85.46 96.34 9.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.97 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 1.638 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 72.6 t90 -64.35 -58.05 7.6 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.859 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.42 170.79 16.65 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.987 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.52 0.4 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.863 HG21 ' CB ' ' A' ' 38' ' ' ALA . 2.5 p -86.3 143.1 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.981 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.72 96.43 8.6 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.954 ' O ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -55.35 -20.01 10.52 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.947 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.604 ' CG2' ' HG2' ' A' ' 71' ' ' ARG . 33.5 p -88.94 1.4 55.5 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 m -114.16 -27.44 7.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.978 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.31 179.42 4.91 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.975 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.45 123.14 41.2 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.907 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 1.56 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -104.71 157.71 17.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 1.121 ' N ' HG13 ' A' ' 110' ' ' ILE . 1.3 pt20 -156.19 144.67 20.02 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.975 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.184 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 11.9 t -93.58 156.98 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 1.23 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -172.54 165.91 38.51 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.294 -1.123 . . . . 0.0 110.294 179.997 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.164 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -136.52 143.44 43.74 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 98' ' ' SER . . . . . 1.408 ' N ' ' H ' ' A' ' 33' ' ' ASP . 3.5 m -133.52 147.59 51.62 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.95 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 99' ' ' ASP . . . . . 0.774 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -93.49 -167.01 1.62 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.974 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.08 -50.13 74.53 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.642 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -68.76 -24.66 64.47 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.98 40.53 2.84 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.98 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.642 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 6.6 p30 -121.89 -178.62 3.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.64 -174.95 20.8 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.958 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 1.187 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.8 Cg_endo -72.43 134.55 22.77 Favored 'Trans proline' 0 N--CA 1.446 -1.271 0 C-N-CA 124.318 3.345 . . . . 0.0 109.612 179.935 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.806 ' HG3' ' CB ' ' A' ' 2' ' ' ALA . 3.1 pt-20 -137.99 141.54 40.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.904 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 136.27 57.67 0.06 OUTLIER Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.967 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 1.077 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.0 t -134.27 102.73 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.992 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -96.94 153.6 17.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.944 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.56 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.0 OUTLIER -117.94 163.76 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.89 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 111' ' ' SER . . . . . 1.398 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -162.24 131.0 4.21 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.973 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 1.032 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -108.35 120.07 41.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 113' ' ' ASN . . . . . 0.489 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.1 t-20 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.463 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.605 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -99.31 129.64 28.81 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.686 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.32 -178.76 3.49 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.298 3.332 . . . . 0.0 109.635 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.201 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.08 113.64 26.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 1.033 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.96 136.11 51.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.55 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.54 115.41 29.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.765 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -113.71 147.39 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.856 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.32 167.43 21.82 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.38 118.52 5.64 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.294 3.329 . . . . 0.0 109.631 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.595 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.59 13.86 7.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 111' ' ' SER . 47.3 p -89.86 115.08 26.92 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.036 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 90.11 20.59 41.89 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.027 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -106.98 134.12 50.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.52 173.21 9.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -45.05 152.2 0.27 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.19 -23.6 32.69 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.666 HG21 HD12 ' A' ' 13' ' ' LEU . 3.0 m -66.5 150.41 49.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.91 122.59 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -105.35 119.35 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.765 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -79.78 149.85 30.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.69 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -142.37 109.7 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.033 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.62 116.96 26.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.911 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -85.32 144.93 21.0 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.201 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -144.81 110.07 5.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.39 15.07 24.22 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.036 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.22 166.09 13.56 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.46 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.5 mt-30 -50.2 121.64 5.81 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.514 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.57 131.35 41.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 7.67 85.21 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.485 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.85 146.21 23.81 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.64 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.25 151.39 22.16 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.65 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.2 m-85 -138.39 147.48 43.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -114.02 113.21 24.47 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.279 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -96.88 147.71 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.78 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.03 163.23 36.61 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.906 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.3 tt0 -106.25 112.4 25.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.4 m -113.53 146.51 39.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.144 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.42 128.97 50.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.593 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.51 120.94 13.79 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.31 HG21 ' CD1' ' A' ' 83' ' ' TRP . 2.7 m -101.2 -43.45 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.966 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -139.23 179.21 6.66 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 47.1 m -62.38 112.75 2.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.33 7.43 63.71 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.578 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 81.2 t -122.33 109.19 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -125.0 137.26 54.25 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.367 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -87.61 156.21 19.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.9 m -121.72 151.27 40.7 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.668 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 32.9 t30 -119.2 111.63 36.69 Favored Pre-proline 0 N--CA 1.448 -0.542 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.44 -0.65 9.05 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.289 3.326 . . . . 0.0 109.578 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.516 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.04 -13.67 43.74 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.588 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.8 m-20 -130.37 27.56 5.04 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.684 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -96.7 115.82 28.08 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.4 t -109.23 -177.76 3.38 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.3 p -147.37 153.91 40.24 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.546 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.59 162.85 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.546 ' N ' HG22 ' A' ' 55' ' ' VAL . 16.6 m -128.11 138.8 52.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.91 36.22 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 42.2 p30 -80.61 -173.26 4.04 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.94 -24.92 68.1 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -74.93 -8.49 56.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.033 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.9 31.61 59.86 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -128.26 139.33 52.5 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.85 167.75 16.9 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 84.1 p -150.49 127.01 10.8 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.552 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.71 163.31 38.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.864 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.552 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -112.7 130.73 55.95 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.944 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.54 125.43 51.81 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.62 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -81.52 129.45 34.67 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.536 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -90.69 128.22 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.536 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.4 OUTLIER -119.42 141.81 48.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.987 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -69.88 -34.19 73.22 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 51.5 p -164.63 159.85 19.44 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.906 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -178.03 172.24 1.64 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -62.72 119.37 9.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.367 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.86 91.63 1.21 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.914 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.5 99.65 10.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.4 132.27 52.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.7 m-85 -46.95 -37.05 8.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.7 t0 -57.6 -16.89 11.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.72 27.97 9.25 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.1 m -113.81 147.48 38.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -86.34 94.37 9.34 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.578 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -64.06 -57.93 8.17 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.4 164.33 11.36 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 108.97 0.66 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.144 HG11 ' CB ' ' A' ' 38' ' ' ALA . 5.7 t -85.55 152.0 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -115.19 93.74 4.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.959 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 4.9 m -53.9 -24.86 17.5 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.7 p -81.73 2.26 30.66 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -115.92 -27.18 7.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.12 -178.91 5.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.3 126.3 43.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.278 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 28.9 m -105.2 171.54 7.27 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.169 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.1 OUTLIER -154.05 147.39 24.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.93 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.944 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 8.8 t -103.87 165.28 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.279 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.79 166.32 35.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.106 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.14 133.04 43.81 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 13.5 m -116.11 145.2 43.23 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.64 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -99.93 -158.04 0.65 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.62 -48.66 76.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.603 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.49 -25.46 62.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 43.34 2.89 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.603 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.6 p30 -114.05 161.49 17.65 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.65 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -168.75 170.46 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.686 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.37 166.04 30.94 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.373 3.382 . . . . 0.0 109.577 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.605 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 mt-10 -36.62 118.1 0.54 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.92 156.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.169 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 5.6 t -106.15 102.16 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.15 116.99 20.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.278 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.3 pt -129.95 -177.5 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.634 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -169.55 173.95 6.15 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.959 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 8.2 m-85 -129.42 110.32 11.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.036 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 1.7 p-10 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.32 ' CB ' ' CG ' ' A' ' 106' ' ' GLU . . . -145.89 119.07 5.23 Favored Pre-proline 0 N--CA 1.45 -0.457 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.654 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.0 Cg_endo -72.4 -177.78 2.93 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.292 3.328 . . . . 0.0 109.566 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.844 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.1 110.34 22.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.91 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.13 135.77 50.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -97.95 113.02 24.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.789 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -109.58 154.57 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.918 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.11 174.4 2.44 Favored Pre-proline 0 N--CA 1.45 -0.463 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.941 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.129 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.8 Cg_endo -72.39 119.44 6.13 Favored 'Trans proline' 0 N--CA 1.447 -1.233 0 C-N-CA 124.334 3.356 . . . . 0.0 109.569 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.946 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.1 p -111.4 48.34 0.95 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -129.39 106.01 8.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.17 31.37 9.81 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.129 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -104.44 131.48 51.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -108.79 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -48.66 142.08 6.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.435 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 101.34 -22.58 38.48 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.56 HG21 ' HB3' ' A' ' 13' ' ' LEU . 15.6 m -77.69 151.21 34.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.7 p -119.67 132.37 69.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.727 HG13 HG22 ' A' ' 8' ' ' THR . 20.9 t -95.66 155.38 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.789 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.02 144.49 42.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.7 110.9 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.98 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.91 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.54 116.5 25.51 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.795 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.08 146.6 24.1 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.844 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.85 110.8 4.34 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 101.57 14.63 29.38 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.088 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.87 179.32 6.01 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.754 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 68.4 mt-30 -60.87 121.38 12.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.512 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 132.24 42.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.31 8.12 79.16 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.96 143.33 26.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.695 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.69 151.19 23.62 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.046 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 42.2 m-85 -137.97 140.35 40.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.294 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.7 m-20 -104.47 115.12 29.81 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.288 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -101.02 139.84 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.937 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -160.67 169.78 36.46 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.097 HE22 ' HB2' ' A' ' 70' ' ' ARG . 14.7 tt0 -120.31 114.06 21.3 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.5 m -106.13 171.16 7.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -156.82 133.08 9.82 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.506 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.83 129.58 40.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.945 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.438 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 3.7 m -110.81 -37.47 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.698 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -147.95 165.69 29.93 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.942 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -53.13 113.82 1.25 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.1 4.66 60.1 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.026 ' CG2' ' CH2' ' A' ' 83' ' ' TRP . 98.8 t -121.58 120.53 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.729 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.65 163.57 21.73 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.535 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -127.03 143.74 51.21 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.7 m -110.35 150.47 28.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.692 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.5 t30 -110.26 106.56 58.12 Favored Pre-proline 0 N--CA 1.449 -0.495 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.9 Cg_endo -72.32 0.39 7.46 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.319 3.346 . . . . 0.0 109.591 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -87.98 -12.5 44.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 11.2 p30 -127.58 27.56 5.78 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.403 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.92 104.8 11.68 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.1 t -99.29 170.54 8.58 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.49 152.6 40.03 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 56' ' ' THR . 6.4 p -165.94 159.7 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.2 m -128.23 137.11 51.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.68 146.98 39.79 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.6 p30 -83.93 -175.02 5.61 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -24.6 67.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.36 -7.57 55.28 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.088 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.14 32.04 58.88 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.1 p -127.94 135.78 50.43 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.76 167.9 12.45 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.1 121.91 9.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.581 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -162.33 148.04 12.84 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.931 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.5 137.37 48.29 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.003 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -106.04 119.1 38.34 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.909 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.659 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -60.84 127.2 30.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.694 HG23 HG21 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -87.58 124.33 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 1.097 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.7 OUTLIER -115.74 143.68 45.04 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.518 ' HG3' HG23 ' A' ' 89' ' ' THR . 43.1 ttp180 -86.73 -16.45 36.4 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.5 t -171.47 145.11 2.03 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.908 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 2.0 p90 -169.62 163.93 10.18 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.37 124.78 20.68 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.535 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -81.04 91.54 1.43 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.22 100.67 10.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -57.3 136.69 56.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.665 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.54 -39.98 17.71 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.681 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -56.74 -17.14 7.97 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.955 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.94 28.1 9.69 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 15.7 m -112.38 147.36 36.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.69 93.82 6.85 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.438 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 11.5 t-105 -65.42 -48.29 73.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.57 165.08 10.16 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.79 133.66 54.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.183 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -111.67 143.8 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -109.84 104.07 12.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.481 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 26.3 m -51.81 -26.85 10.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.518 HG23 ' HG3' ' A' ' 71' ' ' ARG . 75.9 p -80.51 -2.26 45.27 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.71 -27.45 6.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.05 179.94 5.59 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.97 125.68 43.01 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.016 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 87.1 m -104.34 152.56 22.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.041 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.7 pt20 -150.57 152.72 34.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.003 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 10.3 t -117.51 159.78 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.46 166.51 37.52 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.288 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.74 131.19 51.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.294 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 3.2 m -111.73 153.09 27.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.695 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.5 -163.33 0.85 Allowed 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.43 -48.18 65.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.26 -24.45 66.58 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.6 53.77 1.77 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.754 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.26 170.92 14.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.046 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.4 46.72 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.654 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.42 162.8 40.47 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.328 3.352 . . . . 0.0 109.573 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.32 ' CG ' ' CB ' ' A' ' 2' ' ' ALA . 7.4 mt-10 -37.68 120.19 0.8 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.02 158.27 0.01 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.897 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.6 t -121.58 104.13 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.89 120.28 28.01 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.041 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.2 mt -98.61 159.09 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.0 OUTLIER -145.27 116.97 8.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.902 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -93.81 127.56 39.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.378 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -59.63 117.24 21.0 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.604 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.8 Cg_endo -72.47 -178.45 3.36 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.285 3.323 . . . . 0.0 109.592 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.859 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.92 111.04 23.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.769 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.09 157.84 36.98 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.6 p -121.86 119.59 32.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.81 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 22.5 t -114.82 146.34 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.732 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.1 165.78 35.12 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.716 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.0 Cg_endo -72.41 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.347 3.365 . . . . 0.0 109.546 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.88 12.35 7.26 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.996 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.71 ' HA ' ' O ' ' A' ' 111' ' ' SER . 42.2 m -87.78 110.58 20.58 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.085 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.33 14.31 42.07 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.985 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -105.56 132.79 51.28 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m -91.83 -179.97 5.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -44.54 152.68 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.84 -23.29 33.56 Favored Glycine 0 C--N 1.335 0.528 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.628 HG21 HD12 ' A' ' 13' ' ' LEU . 26.1 m -69.38 148.76 49.2 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.4 p -125.47 115.86 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.732 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.4 p -91.86 153.77 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.81 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.27 147.93 31.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.747 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.37 106.4 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.717 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.56 116.96 23.29 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.061 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.72 150.32 25.28 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.859 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -147.73 109.62 4.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.43 15.94 33.48 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.065 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.19 172.89 8.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.517 ' HB2' HG21 ' A' ' 30' ' ' THR . 0.1 OUTLIER -53.27 120.65 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.493 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.7 131.16 42.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.68 82.69 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.517 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.19 143.48 26.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.59 147.18 25.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.656 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 34.0 m-85 -134.48 134.05 41.07 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.077 ' HB2' ' O ' ' A' ' 98' ' ' SER . 1.7 m-20 -98.66 114.12 26.47 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.26 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.71 145.19 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.955 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.2 166.47 39.25 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.76 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.19 108.83 18.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.41 146.93 38.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.419 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -123.58 143.51 50.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.564 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.35 124.39 21.62 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.2 t -104.04 -49.26 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.27 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -135.43 169.65 17.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.956 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.412 ' H ' HG22 ' A' ' 42' ' ' THR . 0.6 OUTLIER -51.45 112.23 0.71 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.35 8.62 66.48 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.991 HG11 ' HE1' ' A' ' 83' ' ' TRP . 2.4 t -121.98 123.19 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -132.08 133.79 44.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.81 147.77 22.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.3 m -105.62 152.12 23.51 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.768 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -111.07 110.15 56.75 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 81.9 Cg_endo -72.43 -0.07 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 124.311 3.341 . . . . 0.0 109.616 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.29 -9.45 52.83 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.405 ' CB ' HG23 ' A' ' 68' ' ' THR . 82.4 m-20 -133.83 26.8 3.97 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.435 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.07 107.24 12.7 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.1 m -101.48 176.21 5.31 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.0 p -144.93 153.97 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.591 HG22 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.69 155.18 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.1 m -128.0 141.72 51.44 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.99 141.28 33.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 p30 -82.66 -173.18 4.48 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.71 -26.45 68.05 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -76.09 -9.17 58.41 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.065 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.23 32.28 52.57 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 80.9 p -127.79 135.83 50.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.591 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -122.95 164.38 18.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -145.64 136.19 24.19 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.739 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.88 174.62 10.39 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.739 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -138.95 122.96 17.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.891 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.089 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.04 156.43 16.33 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -103.78 133.37 48.89 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.954 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.473 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -93.47 127.18 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.628 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.4 OUTLIER -117.66 141.99 47.75 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -32.58 73.24 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 78.2 p -157.9 158.97 36.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.768 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 2.1 p90 -177.14 161.8 1.91 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.17 112.35 2.62 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.72 96.75 0.68 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.834 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.1 m-85 -83.23 99.41 9.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -57.18 131.68 50.7 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.674 ' N ' HD12 ' A' ' 77' ' ' LEU . 38.0 p90 -47.52 -36.11 9.88 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 3.3 t0 -57.67 -16.25 10.17 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.78 9.5 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.9 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -115.55 147.97 40.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -87.64 96.43 10.42 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.27 ' HZ2' ' CG ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.63 -55.16 25.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.63 170.89 16.15 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -66.12 103.83 1.04 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 73' ' ' PHE . 35.5 m -80.18 154.15 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -112.7 92.62 4.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.944 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.7 m -53.07 -24.63 10.41 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -82.32 2.07 33.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.38 -27.28 6.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.71 178.98 6.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.612 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.2 126.23 43.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.376 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 7.2 m -104.82 173.68 6.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 1.1 pt20 -153.61 147.12 24.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.089 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.7 t -104.97 165.32 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.26 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.29 166.38 36.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.003 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.83 132.9 46.63 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.077 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 3.7 t -113.48 150.89 32.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.455 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -110.48 -163.63 0.87 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.74 -48.43 71.92 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.65 -24.37 65.44 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.9 53.75 1.74 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.46 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -133.41 169.53 16.81 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.992 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.517 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.03 171.42 43.43 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.604 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.34 170.71 18.57 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.322 3.348 . . . . 0.0 109.597 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.378 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.67 121.6 0.9 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.98 163.87 0.01 OUTLIER Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.06 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 23.2 t -120.53 103.18 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.2 120.39 26.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.376 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -129.1 -178.76 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.71 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -168.33 171.14 9.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.0 m-85 -122.4 115.11 21.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.085 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 2.8 p-10 . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.252 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -117.98 115.32 36.75 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.584 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.4 -178.3 3.24 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 124.339 3.36 . . . . 0.0 109.633 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.305 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 5.1 t -99.69 116.12 31.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.78 153.76 48.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -110.66 112.16 23.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.901 HG22 ' CG1' ' A' ' 21' ' ' VAL . 95.2 t -107.47 145.93 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -66.79 176.42 1.11 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.9 Cg_endo -72.41 117.46 5.14 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.293 3.329 . . . . 0.0 109.612 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.594 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 32.4 p -112.58 47.07 1.12 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 51.4 p -126.36 106.73 9.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.72 14.72 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.73 131.77 47.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.983 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -111.41 174.57 5.8 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -48.05 140.3 7.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.08 -22.79 35.54 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.469 HG21 HD13 ' A' ' 13' ' ' LEU . 96.6 m -79.81 151.42 30.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.55 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.8 p -128.26 123.43 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.4 m -88.28 171.45 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.821 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.49 146.86 47.0 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.901 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -144.44 106.25 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.677 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.67 116.66 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.87 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.92 148.32 25.67 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.305 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -148.15 118.61 7.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.86 16.1 46.4 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.019 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -88.68 -174.15 4.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.516 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -70.3 120.7 16.36 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.931 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.02 136.02 53.21 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.02 7.82 60.21 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.721 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -82.95 146.71 28.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.868 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -96.07 134.96 38.48 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.813 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 38.6 m-85 -126.42 149.17 49.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.026 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -116.79 113.95 23.27 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.223 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -97.05 143.92 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.703 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.21 161.66 34.8 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.832 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 37.6 tt0 -110.85 118.44 36.13 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.1 m -115.95 148.37 40.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.109 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.27 140.39 52.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.517 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.26 127.42 31.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.94 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.813 HG12 ' CG1' ' A' ' 44' ' ' VAL . 1.1 t -108.7 -39.34 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.436 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 1.5 t0 -151.84 -178.53 6.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.1 m -70.41 111.47 6.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.51 10.01 86.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.333 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -136.99 124.52 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.572 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -133.1 137.23 46.27 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.357 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.53 155.77 21.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 67.7 m -120.77 156.91 30.85 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.676 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t30 -121.5 109.21 34.82 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.43 0.64 7.17 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.313 3.342 . . . . 0.0 109.592 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.489 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.63 -16.37 32.61 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 14.6 p30 -127.26 28.15 5.77 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.92 118.3 35.37 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.5 t -113.41 -177.77 3.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 94.9 p -146.49 157.36 43.74 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.485 HG22 ' N ' ' A' ' 56' ' ' THR . 4.9 p -167.68 159.4 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.485 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.8 m -128.06 137.45 52.17 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.9 136.02 41.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 17.1 p30 -73.62 -175.28 1.97 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -24.74 68.02 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -75.17 -7.25 53.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.019 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.15 32.09 58.78 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.3 p -129.89 135.83 48.82 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.92 164.06 18.22 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -147.73 127.96 13.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.86 170.0 23.08 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.936 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -126.86 136.76 52.78 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.965 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -111.71 120.37 41.81 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.968 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.622 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -70.88 117.67 12.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.516 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -75.14 128.43 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.622 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -116.77 147.14 42.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.978 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.451 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.3 OUTLIER -90.21 -15.68 30.92 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 52.2 p -178.81 154.89 0.75 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.832 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -177.94 179.75 0.83 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -66.89 123.11 19.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.357 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.7 91.93 1.31 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.886 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.75 100.62 11.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -55.38 140.27 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.688 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.58 -41.49 21.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.57 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -57.19 -17.44 11.26 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.54 28.36 9.71 Favored Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.1 m -110.89 145.23 38.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.0 93.21 3.79 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.436 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 54.7 t-105 -64.18 -58.12 7.53 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.87 155.86 7.3 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -54.95 109.99 0.6 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.109 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.9 t -86.43 151.65 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.77 96.16 6.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.069 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.5 OUTLIER -54.07 -23.91 15.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.5 p -84.6 0.5 49.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -113.72 -27.38 7.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.82 177.94 7.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.54 128.33 44.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.223 ' O ' HG13 ' A' ' 110' ' ' ILE . 58.0 m -104.84 157.17 17.39 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.03 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -141.21 145.8 36.1 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.889 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 20.4 t -108.94 157.47 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.223 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.74 172.41 45.36 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.975 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.57 130.96 46.36 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.026 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 40.2 m -111.04 145.02 39.24 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.868 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -106.86 -163.58 0.92 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.73 -49.13 69.56 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.18 -24.11 65.83 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.26 53.34 1.88 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.8 174.81 9.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.813 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -177.82 179.34 48.37 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.584 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.37 165.78 31.66 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.347 3.364 . . . . 0.0 109.577 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.252 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.8 pt-20 -37.0 133.88 0.58 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.77 149.63 5.36 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.965 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -121.85 110.54 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.17 139.46 30.57 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.223 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.6 OUTLIER -109.93 160.09 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -143.22 112.53 6.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.069 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 23.1 m-85 -93.68 124.4 37.65 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.943 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.493 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.035 ' HB1' ' HA ' ' A' ' 106' ' ' GLU . . . -65.37 115.68 24.01 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.5 Cg_endo -72.42 -178.19 3.18 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.293 3.328 . . . . 0.0 109.635 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.367 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 5.2 t -102.31 115.74 31.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.4 146.96 52.05 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.615 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.65 115.72 31.02 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.832 HG13 ' O ' ' A' ' 20' ' ' LYS . 35.9 t -111.92 148.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.41 176.2 1.31 Allowed Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.083 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.34 117.28 5.06 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.325 3.35 . . . . 0.0 109.626 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.051 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.3 p -110.17 49.23 0.86 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 111' ' ' SER . 94.3 p -127.37 106.09 8.97 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.044 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.47 27.26 18.2 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.083 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -103.34 131.38 50.46 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.982 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -118.97 -179.35 3.79 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -46.19 138.89 5.0 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.58 -23.17 33.61 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.514 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.1 m -87.51 150.95 23.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 18' ' ' VAL . 13.0 p -131.63 121.54 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' O ' ' A' ' 67' ' ' LEU . 23.7 m -80.74 167.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.832 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.37 145.54 43.14 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.567 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.87 112.82 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.08 114.8 20.18 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.882 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -81.93 147.9 26.72 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.315 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.8 115.49 5.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.22 15.39 51.49 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.35 -179.79 5.92 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.827 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 70.3 mt-30 -59.01 120.8 9.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.92 132.05 42.07 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.87 7.64 75.94 Favored Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.51 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -92.86 139.46 30.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.595 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.06 150.45 24.86 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.878 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 26.7 m-85 -135.58 143.81 45.84 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.258 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -105.83 114.59 28.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -100.18 139.6 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.909 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.7 164.59 37.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.87 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 20.9 tt0 -109.75 105.33 14.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 61.5 m -106.32 142.79 35.42 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.548 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.72 130.09 52.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.624 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.69 121.33 14.73 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.554 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 6.0 m -101.78 -43.05 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.479 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -138.17 169.95 16.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.0 m -55.03 112.56 1.08 Allowed 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.72 9.05 64.84 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.604 HG12 HG23 ' A' ' 40' ' ' VAL . 77.0 t -123.49 105.42 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.673 HD21 ' HD2' ' A' ' 78' ' ' PHE . 0.8 OUTLIER -121.3 138.35 54.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.463 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.42 158.13 16.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 52.2 m -118.59 148.13 43.0 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.92 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.3 t30 -110.61 106.19 57.64 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -72.42 -1.27 9.96 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.356 3.37 . . . . 0.0 109.567 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.527 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.17 -11.09 42.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.755 ' HB3' HG23 ' A' ' 68' ' ' THR . 6.1 m-20 -133.35 27.41 4.11 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.663 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.6 118.87 36.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -112.07 -176.1 2.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -144.84 153.02 41.17 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.421 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.64 156.27 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.421 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.3 m -126.45 141.0 52.04 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.26 138.33 37.74 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.0 p30 -73.57 -174.34 1.69 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.45 -25.04 68.09 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -75.23 -8.06 55.57 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.34 58.5 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 71.5 p -127.08 133.23 50.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.79 166.47 14.29 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.89 131.76 15.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.612 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.0 166.19 17.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.612 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -122.33 132.63 54.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.13 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.24 118.23 36.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.755 HG23 ' HB3' ' A' ' 51' ' ' ASP . 2.0 t -68.94 143.19 54.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.522 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -107.0 131.4 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.968 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.567 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -118.98 152.04 37.1 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.531 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -87.15 -10.63 52.25 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -174.04 149.43 1.47 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.92 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 5.7 p90 -176.72 158.91 1.75 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -58.75 112.53 1.66 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.463 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.66 94.54 0.67 Allowed Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.826 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -82.71 98.81 9.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.979 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.93 132.68 47.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.673 ' HD2' HD21 ' A' ' 45' ' ' LEU . 19.0 p90 -46.81 -37.43 8.66 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.602 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.3 t0 -56.69 -17.13 7.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.45 28.04 8.76 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.97 143.12 45.66 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.38 96.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.554 ' CD1' ' CG1' ' A' ' 40' ' ' VAL . 3.3 t-105 -63.35 -58.95 5.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.29 171.31 21.1 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -64.78 104.39 0.83 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -79.75 149.99 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -110.56 97.44 6.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.85 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 9.0 m -52.82 -25.4 11.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 53.0 p -82.57 -0.17 45.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -119.04 -28.41 5.51 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.1 179.72 5.28 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 125.23 44.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.1 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 61.3 m -104.17 152.95 21.52 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -144.47 147.36 33.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.13 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -110.64 159.9 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.85 167.74 39.29 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.177 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.04 125.25 43.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.258 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 15.8 m -112.8 143.98 43.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.595 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -101.85 -160.23 0.78 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.983 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.71 -47.94 61.32 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.73 -20.08 65.89 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.5 53.51 2.59 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.296 -1.121 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.827 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.64 167.75 19.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.878 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.97 176.53 46.44 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.34 170.2 19.8 Favored 'Trans proline' 0 N--CA 1.448 -1.2 0 C-N-CA 124.294 3.33 . . . . 0.0 109.618 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.367 ' OE2' ' CA ' ' A' ' 4' ' ' THR . 3.3 pm0 -40.96 120.02 1.25 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.46 162.81 0.01 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.849 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 34.8 t -128.57 104.44 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.74 30.18 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.1 ' HB ' ' O ' ' A' ' 93' ' ' CYS . 5.2 mt -99.5 153.58 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.664 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -138.31 123.05 18.73 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.85 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 6.1 m-85 -92.69 127.44 38.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.919 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -100.26 118.38 61.39 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.606 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.34 -177.78 2.91 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.312 3.341 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.9 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.46 109.59 22.32 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.767 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 146.63 50.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.2 p -110.22 121.01 44.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.872 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 41.2 t -113.88 143.64 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.682 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.74 166.11 30.18 Favored Pre-proline 0 N--CA 1.449 -0.475 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.693 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.41 117.16 5.0 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.29 3.327 . . . . 0.0 109.629 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.732 ' HB2' HG22 ' A' ' 19' ' ' VAL . 0.6 OUTLIER -129.29 11.78 5.94 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.693 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.6 m -92.34 108.72 20.17 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.087 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 97.17 24.08 13.45 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.087 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.24 133.78 51.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 t -67.36 154.39 41.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 1.3 p-10 -46.07 147.58 1.01 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.02 -18.69 51.55 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.832 HG21 HD12 ' A' ' 13' ' ' LEU . 30.6 m -61.91 145.36 53.09 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 p -110.26 134.69 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.732 HG22 ' HB2' ' A' ' 10' ' ' SER . 10.5 t -107.03 152.72 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.872 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.03 109.84 15.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -103.18 121.12 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.767 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -128.41 117.01 20.64 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.02 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.55 147.41 23.1 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.9 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.46 111.11 5.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.56 16.53 31.37 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.1 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.27 173.43 8.4 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.53 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 78.1 mt-30 -53.66 121.38 7.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.406 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.31 129.55 38.66 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.98 8.67 85.07 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.547 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.1 141.7 28.24 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 1.196 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.88 150.78 23.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.234 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 52.6 m-85 -136.19 143.35 44.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.227 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.73 114.7 29.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.935 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.513 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.03 141.87 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.029 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.52 161.99 35.79 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.1 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 10.8 tt0 -94.69 117.96 30.97 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.673 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.5 m -107.25 158.12 17.37 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.975 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -147.22 134.6 20.73 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.535 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -68.36 125.32 26.06 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.482 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.4 m -114.64 -36.05 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.535 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -150.17 -179.96 7.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -64.12 110.37 2.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 69.76 8.84 61.32 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.535 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 61.0 t -110.19 105.2 18.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.682 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.5 mt -105.82 156.61 18.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.485 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -135.11 129.35 33.78 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.915 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.52 156.01 19.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.702 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.6 p-10 -116.23 121.76 33.14 Favored Pre-proline 0 N--CA 1.449 -0.523 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.8 Cg_endo -72.37 1.98 5.56 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.26 3.307 . . . . 0.0 109.608 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.702 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -85.63 -20.87 28.82 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.505 ' CB ' HG23 ' A' ' 68' ' ' THR . 85.2 m-20 -128.47 28.78 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.59 117.1 29.6 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.3 t -109.99 -176.86 3.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.37 153.8 41.61 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.434 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -166.47 153.71 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.8 m -126.59 132.89 51.19 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.61 149.79 48.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -88.98 -168.38 2.17 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.29 -27.94 68.98 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -75.16 -9.32 58.44 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.737 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.2 31.51 51.9 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.0 p -127.97 141.24 51.58 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.434 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -131.15 164.68 24.98 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -143.35 139.62 30.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.694 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -167.56 172.1 9.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.694 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -124.88 129.03 49.58 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.942 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.267 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -112.56 119.57 38.62 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.505 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -79.59 141.45 36.56 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.509 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -112.02 132.81 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.509 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.3 OUTLIER -119.11 155.68 31.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 ptt180 -74.67 -34.58 62.72 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -151.15 149.34 29.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.1 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.5 p90 -177.13 163.66 2.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.479 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.4 OUTLIER -61.25 125.1 22.55 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.485 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.93 95.56 2.11 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.915 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -84.46 103.71 13.84 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.951 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.5 tp -53.91 135.01 42.94 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 8.3 m-85 -45.71 -38.68 7.16 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.661 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.6 t0 -57.26 -17.02 9.89 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.92 28.91 8.97 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.951 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -114.41 112.43 23.02 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 96.44 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.482 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 50.6 t-105 -62.41 -53.63 52.03 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 143.45 -179.66 20.74 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.17 140.79 43.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.975 HG11 ' CB ' ' A' ' 38' ' ' ALA . 4.8 t -127.7 152.6 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.26 90.4 3.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.209 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 30.6 m -54.15 -25.57 23.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.8 p -76.9 -0.64 24.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.48 -27.21 7.62 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.68 -164.2 1.28 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.4 125.49 43.58 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.228 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.1 OUTLIER -103.89 152.5 21.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.035 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -159.42 147.56 17.56 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.267 ' CG2' HD12 ' A' ' 67' ' ' LEU . 6.8 t -105.62 165.32 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.29 164.68 34.67 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.513 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.6 133.16 47.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.227 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 67.7 m -112.1 150.31 30.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 1.196 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -109.92 -161.31 0.75 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.08 -48.68 70.15 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.09 -24.13 64.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.74 52.47 1.8 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.618 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.57 171.87 12.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.234 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.37 175.24 44.34 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.606 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.34 169.55 21.37 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.377 3.385 . . . . 0.0 109.59 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.019 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -38.49 126.09 1.4 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.959 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.84 160.31 0.01 OUTLIER Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.021 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 89.1 t -123.08 102.69 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.97 134.54 33.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.228 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -140.53 -173.73 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.693 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.7 t -176.48 178.51 1.3 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.209 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.8 m-85 -130.75 113.15 13.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.883 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 42.5 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.562 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -141.25 122.07 8.79 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.4 Cg_endo -72.35 -175.28 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.355 3.37 . . . . 0.0 109.626 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.963 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.32 109.37 21.89 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.982 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.2 146.02 50.85 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -110.18 114.35 27.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.828 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.03 152.39 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.71 HG22 HG13 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -75.5 163.96 64.03 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.75 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.0 Cg_endo -72.36 118.16 5.47 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.337 3.358 . . . . 0.0 109.621 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.598 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.9 OUTLIER -128.59 14.29 6.5 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.076 ' HA ' ' O ' ' A' ' 111' ' ' SER . 68.9 p -95.73 109.2 21.53 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.146 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 95.59 26.07 12.53 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.12 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.48 140.94 41.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 t -71.45 156.31 39.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.54 ' HB3' ' HD2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.73 151.96 0.79 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.63 -16.1 59.96 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.805 HG21 HD12 ' A' ' 13' ' ' LEU . 15.2 m -62.34 138.56 58.46 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 p -99.69 146.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.71 HG13 HG22 ' A' ' 8' ' ' THR . 1.5 t -125.32 156.64 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.79 150.21 40.19 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.449 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.77 105.67 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.982 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.17 117.07 30.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.926 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -83.63 143.47 21.63 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.963 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.49 106.76 5.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.909 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 22.96 8.56 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.535 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.66 -167.03 1.75 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.406 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 74.3 mt-30 -85.57 125.56 33.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.483 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.29 134.4 44.19 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.37 8.16 83.39 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.589 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -96.3 139.44 32.43 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.508 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -90.65 150.96 21.47 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.965 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 54.0 m-85 -136.95 147.33 46.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.138 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.7 m-20 -110.97 112.85 24.98 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.27 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -102.26 151.03 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.953 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -178.1 176.67 48.14 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.208 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 5.0 tt0 -117.25 121.6 41.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.6 m -120.42 144.81 47.74 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.741 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 142.31 51.02 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.608 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.02 124.29 21.7 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.937 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.515 ' CB ' ' CD1' ' A' ' 83' ' ' TRP . 3.3 m -106.68 -38.37 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.107 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.49 -178.35 5.07 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.5 m -70.98 112.08 6.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.12 10.21 81.07 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.304 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 1.8 m -130.94 124.92 57.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.615 HD23 ' H ' ' A' ' 45' ' ' LEU . 1.6 pt? -127.76 147.04 50.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.41 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -102.22 150.65 23.08 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.7 m -106.27 160.33 15.44 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.742 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 26.8 t30 -119.24 109.96 38.29 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.35 0.01 8.03 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.33 3.353 . . . . 0.0 109.627 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.467 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -89.44 -13.08 38.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.688 ' HB3' HG23 ' A' ' 68' ' ' THR . 19.0 m-20 -134.73 27.71 3.62 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.628 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.43 115.17 27.0 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.4 t -106.53 178.34 4.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 p -147.18 156.32 42.87 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.5 HG22 ' N ' ' A' ' 56' ' ' THR . 2.3 p -167.35 161.93 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.5 ' N ' HG22 ' A' ' 55' ' ' VAL . 24.4 m -128.28 131.87 48.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 152.4 44.28 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -91.44 -170.8 2.73 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.43 -26.14 68.34 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -76.38 -6.06 49.95 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 75.27 9.42 84.25 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 85.9 p -101.64 140.16 36.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.43 164.11 17.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -150.38 121.86 7.94 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.698 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.38 172.19 15.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.698 ' N ' HG23 ' A' ' 65' ' ' THR . 1.1 m -128.24 120.23 26.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.307 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.2 OUTLIER -105.64 133.43 50.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.688 HG23 ' HB3' ' A' ' 51' ' ' ASP . 5.5 t -97.62 149.13 22.58 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.636 HG23 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -114.67 131.48 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.557 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.58 159.04 20.89 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.54 ' HD2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -80.3 -23.32 40.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.949 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.489 ' N ' ' HG2' ' A' ' 71' ' ' ARG . 53.9 p -160.72 156.72 25.81 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.208 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 2.5 p90 -178.12 158.82 1.24 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -60.58 109.43 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.41 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -64.27 98.77 0.28 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.804 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 98.78 10.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.995 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.2 tp -54.66 132.46 45.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.621 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.9 m-85 -47.0 -37.24 8.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.592 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.8 t0 -57.57 -16.65 10.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.84 28.99 8.94 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.995 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -117.3 152.2 35.38 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.94 99.54 8.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.515 ' CD1' ' CB ' ' A' ' 40' ' ' VAL . 15.0 t-105 -68.74 -50.49 50.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.5 163.72 9.62 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.99 104.7 0.21 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.741 HG11 ' HB3' ' A' ' 38' ' ' ALA . 14.4 p -85.83 149.71 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.77 97.24 7.9 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.854 ' SG ' ' HZ ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.8 -20.63 9.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.7 p -92.76 2.4 56.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.7 m -106.1 -24.35 12.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.52 179.01 6.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -90.97 125.5 35.8 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.246 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.3 m -104.48 162.98 12.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.036 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.3 OUTLIER -153.56 147.92 25.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.307 ' CG2' HD12 ' A' ' 67' ' ' LEU . 15.8 t -101.71 161.21 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.264 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.96 166.0 35.33 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.27 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.41 128.92 43.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 180.0 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.138 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 26.8 m -108.74 151.65 25.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.508 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -113.19 -162.41 0.8 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.58 -48.49 77.19 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.17 -24.37 62.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.22 53.77 1.69 Allowed Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -129.88 172.26 11.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.965 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.58 -179.21 46.89 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.463 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 81.7 Cg_endo -72.42 160.29 47.19 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.357 3.372 . . . . 0.0 109.549 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.127 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 2.8 tt0 -35.45 123.7 0.64 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -34.67 151.14 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.004 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 90.1 t -117.28 102.31 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 137.15 34.8 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.246 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 2.8 pt -143.0 179.71 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . 1.076 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -177.99 178.54 0.93 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.963 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 1.2 m-85 -126.21 116.1 20.78 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.146 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 1.8 p-10 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.449 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -132.64 117.96 15.49 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.594 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.37 -178.24 3.2 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.356 3.371 . . . . 0.0 109.609 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.257 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 6.8 t -100.17 116.95 33.38 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.78 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.37 135.36 47.15 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.95 113.11 24.69 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.624 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.96 155.03 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.969 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.939 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.09 175.42 1.79 Allowed Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.056 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.39 118.94 5.84 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 124.299 3.333 . . . . 0.0 109.602 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.007 ' HB2' HG23 ' A' ' 110' ' ' ILE . 20.6 p -110.74 48.48 0.91 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 55.5 p -127.06 105.99 8.97 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.137 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.12 31.93 9.36 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.289 -1.125 . . . . 0.0 110.289 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.137 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -110.18 129.19 55.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.89 175.84 5.27 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -44.92 139.74 2.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.93 -22.47 35.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.673 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.3 m -81.19 150.64 28.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.7 p -121.03 120.45 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 1.7 p -87.62 154.87 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.624 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.7 147.14 31.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.712 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.23 110.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.99 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.78 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.24 115.83 23.06 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.822 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.21 148.86 25.76 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.257 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.35 114.83 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.36 13.62 44.42 Favored Glycine 0 C--N 1.335 0.485 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.46 172.6 8.6 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.526 HE22 ' CG ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.95 119.84 5.12 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.51 132.84 43.33 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.77 7.84 75.88 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.524 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.56 141.56 28.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.42 150.16 25.5 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.486 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 30.1 m-85 -135.73 141.79 44.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.266 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.77 118.07 35.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -104.83 145.32 13.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.853 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.99 169.2 41.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.769 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 40.6 tt0 -112.01 108.96 18.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.2 m -111.74 144.63 40.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.799 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.83 130.41 52.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.583 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.18 122.83 17.98 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.443 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 9.7 m -102.94 -42.87 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.7 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -139.0 179.64 6.38 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.4 m -63.63 112.35 2.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.44 8.38 66.37 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 59.3 t -123.83 106.44 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -121.42 137.84 54.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.404 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -89.4 153.34 20.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m -115.04 151.86 33.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.671 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.4 t30 -117.72 109.54 41.44 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.33 -1.07 9.61 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.315 3.343 . . . . 0.0 109.602 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.589 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -84.68 -11.1 56.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.589 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.5 OUTLIER -131.79 26.25 4.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.71 104.38 13.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.7 t -101.33 176.32 5.28 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.51 150.04 35.73 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -166.96 153.63 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 67.9 m -123.49 132.7 54.0 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 141.63 53.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -77.53 -174.65 3.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.91 -24.83 68.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -76.29 -6.9 53.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.17 58.72 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.2 p -127.09 137.78 53.07 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.26 165.21 16.56 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 p -147.91 120.22 8.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.416 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -157.42 148.08 21.2 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -111.32 129.81 55.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.581 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -98.47 157.27 16.32 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.589 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.7 t -101.01 119.29 38.53 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.533 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -80.31 127.18 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.639 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.6 OUTLIER -118.7 152.47 36.07 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.486 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -91.59 -12.68 33.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.941 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 5.1 t -169.2 151.35 4.63 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.769 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.1 p90 -177.16 155.43 1.15 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.25 115.92 2.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.404 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.83 91.63 0.6 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.801 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -82.79 99.23 9.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.1 tp -55.54 134.55 50.9 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.76 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.4 m-85 -46.36 -38.68 9.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.602 ' HB2' HD21 ' A' ' 77' ' ' LEU . 2.5 t0 -56.99 -17.48 9.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.77 28.37 8.9 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -113.62 142.86 45.48 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.7 mtm180 -80.88 94.97 6.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.443 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 71.4 t-105 -64.28 -58.61 6.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.67 167.54 16.66 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.81 108.6 1.22 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.799 HG11 ' CB ' ' A' ' 38' ' ' ALA . 38.7 t -81.76 143.96 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.17 93.6 4.62 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.486 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 58.4 m -52.04 -26.07 10.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 77.9 p -79.85 -2.43 43.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.48 -27.76 6.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.07 -176.63 3.93 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.92 125.74 45.95 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.915 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 69.8 m -103.5 152.98 21.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.087 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -143.17 148.53 36.68 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.581 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.9 t -112.01 161.4 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.07 171.46 43.92 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.034 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.57 135.56 48.03 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.266 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 72.6 p -115.71 154.95 28.63 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.426 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -115.12 -167.07 1.18 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.974 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.03 -48.75 75.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.87 66.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.59 1.93 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.526 ' CG ' HE22 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.62 169.16 17.04 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.486 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.82 176.82 46.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.594 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 81.8 Cg_endo -72.41 161.84 43.16 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.332 3.355 . . . . 0.0 109.555 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.449 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.9 pt-20 -38.37 122.82 1.12 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -37.49 157.52 0.01 OUTLIER Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.828 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.8 t -124.66 104.59 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.01 138.29 32.55 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.087 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.8 mt -116.68 156.09 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -138.22 112.67 8.78 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.592 ' CE1' ' HB2' ' A' ' 93' ' ' CYS . 5.7 m-85 -87.3 101.11 13.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.588 ' CG ' ' C ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.562 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -48.12 120.0 7.8 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.657 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.3 Cg_endo -72.42 -175.39 1.77 Allowed 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.302 3.335 . . . . 0.0 109.615 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.224 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.82 22.51 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.44 148.95 49.56 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.4 p -113.23 117.75 32.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.94 HG13 ' O ' ' A' ' 20' ' ' LYS . 48.3 t -113.58 145.92 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.822 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.56 166.67 28.6 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.727 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.39 117.55 5.18 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.332 3.355 . . . . 0.0 109.58 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.619 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -127.55 13.08 6.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.862 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.6 p -92.56 106.51 18.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.115 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.57 22.66 11.0 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.115 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.81 140.49 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.68 173.19 8.74 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 19.4 p-10 -44.78 152.39 0.23 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.35 -22.09 40.67 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.754 HG21 HD12 ' A' ' 13' ' ' LEU . 22.9 m -63.46 150.46 43.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.28 114.1 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.822 ' HA ' HG22 ' A' ' 8' ' ' THR . 1.4 m -97.56 119.08 45.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.94 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.57 146.07 36.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.786 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -131.51 102.88 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.752 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -113.17 116.23 29.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.838 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -87.76 144.08 18.69 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.895 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.93 107.92 6.71 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.883 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 99.31 25.88 9.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.57 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.15 -175.77 5.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.755 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 72.0 mt-30 -74.32 122.28 22.65 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.439 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.96 130.87 42.04 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.48 9.23 81.71 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.533 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -97.43 139.95 32.6 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 1.143 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.69 151.99 22.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.289 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 33.3 m-85 -137.44 149.69 47.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.175 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.5 m-20 -111.84 113.82 26.39 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.36 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -101.01 142.48 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.961 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.69 164.36 37.98 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.958 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 11.8 tt0 -106.65 111.54 24.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 81.2 m -111.16 151.31 28.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.658 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -129.72 126.16 37.6 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.19 119.06 10.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.378 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 7.0 m -100.97 -42.71 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.501 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -139.47 165.53 26.98 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.2 OUTLIER -51.36 112.78 0.8 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.27 8.24 65.26 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.643 HG12 HG23 ' A' ' 40' ' ' VAL . 71.7 t -123.28 105.04 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.609 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -122.85 137.41 54.94 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.496 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.28 157.32 18.26 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 41.7 m -121.22 151.83 39.53 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.787 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -114.67 105.74 53.06 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -72.42 -0.91 9.42 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.296 3.331 . . . . 0.0 109.584 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.99 -11.77 40.63 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 65.0 m-20 -132.69 26.42 4.36 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.668 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.86 120.83 37.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.3 t -113.4 -174.68 2.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.35 157.2 43.76 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.83 156.95 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.5 m -127.63 127.24 43.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -59.95 146.31 42.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -87.35 -171.98 3.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.16 -28.38 69.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -76.49 -11.0 59.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 83.03 1.22 90.63 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.2 p -94.19 136.73 34.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.59 163.62 18.62 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.91 130.04 13.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.752 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -156.24 174.64 15.1 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.752 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -124.76 126.68 46.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.954 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.935 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.16 119.45 38.99 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -80.7 137.52 36.3 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.584 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.74 128.31 63.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.525 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -117.41 141.7 48.02 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -42.79 87.01 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.631 ' OG ' HG22 ' A' ' 85' ' ' THR . 11.5 t -147.01 156.74 43.28 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.958 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.0 p90 -177.02 157.93 1.48 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.03 111.54 0.86 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.496 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.5 99.05 1.3 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.746 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -84.46 99.51 10.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.923 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.7 tp -54.4 131.34 42.04 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.662 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.3 p90 -47.55 -36.29 10.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.578 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.0 t0 -57.3 -17.24 11.18 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.91 28.5 8.23 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.923 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.61 145.07 43.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -85.16 95.53 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.378 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 0.8 OUTLIER -64.87 -56.92 10.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.914 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.52 168.78 12.8 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.631 HG22 ' OG ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -58.28 104.7 0.22 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 38' ' ' ALA . 33.7 m -83.09 154.12 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -117.81 93.32 4.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.513 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 75.9 m -50.3 -29.32 9.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.752 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 5.5 t -73.5 -1.67 19.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.47 -27.48 7.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.36 -164.21 1.33 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.62 123.35 47.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.189 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -103.89 160.15 15.04 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.066 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -160.45 147.7 15.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.935 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -106.51 165.42 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.282 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.24 164.05 33.11 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.36 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.79 131.11 42.65 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.175 ' N ' ' H ' ' A' ' 33' ' ' ASP . 23.9 m -113.83 151.29 32.31 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 1.143 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -108.67 -158.09 0.64 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.436 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.54 -47.92 65.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.12 -25.05 64.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.3 53.99 1.65 Allowed Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.755 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.45 166.86 20.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.289 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.1 174.67 43.59 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.657 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.37 167.49 26.81 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.333 3.356 . . . . 0.0 109.603 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.562 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 1.4 pm0 -38.37 124.83 1.29 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.96 156.79 0.01 OUTLIER Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.964 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.1 t -118.38 103.29 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.62 135.99 34.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.189 HG13 ' C ' ' A' ' 93' ' ' CYS . 2.9 pt -145.03 -176.55 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.862 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -176.7 177.88 1.31 Allowed 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.513 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.8 m-85 -127.73 113.75 16.41 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.98 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 2.2 p-10 . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.495 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.201 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -108.17 109.7 61.88 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.576 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.39 -178.6 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.339 3.359 . . . . 0.0 109.591 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.905 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.66 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.753 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -124.14 157.92 33.54 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.579 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -126.31 129.41 48.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.944 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -119.41 148.59 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.72 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.64 165.76 33.01 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.72 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.35 117.2 5.02 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.286 3.324 . . . . 0.0 109.63 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.827 ' OG ' HG12 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -129.7 14.1 5.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 111' ' ' SER . 71.0 m -86.56 105.94 17.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.972 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.27 17.72 26.16 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.1 mt -106.79 133.17 51.86 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -87.28 -179.74 6.47 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.778 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 4.2 t0 -45.05 152.39 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.92 38.24 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.564 HG21 HD12 ' A' ' 13' ' ' LEU . 51.6 m -64.73 150.97 46.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -125.58 119.31 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.862 HG13 HG12 ' A' ' 69' ' ' VAL . 2.4 m -95.5 116.31 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.944 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -86.27 115.24 23.69 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.563 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -102.47 119.37 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -130.66 118.4 20.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.962 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.1 148.68 19.88 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.905 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.03 110.87 5.42 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.11 16.48 27.75 Favored Glycine 0 C--N 1.335 0.497 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.11 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.73 170.55 10.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.53 ' HB2' HG21 ' A' ' 30' ' ' THR . 7.2 mp0 -52.08 118.92 3.82 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.494 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.78 130.62 41.55 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.05 7.64 86.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.53 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -94.94 145.74 24.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.0 151.4 22.31 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.962 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 39.1 m-85 -138.76 140.57 38.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.28 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.2 m-20 -104.41 114.19 28.25 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.267 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.7 146.45 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.051 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.45 166.88 40.05 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.04 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 8.9 tt0 -111.73 118.91 36.9 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -123.84 147.91 47.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.916 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.27 135.5 54.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.588 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.9 121.32 14.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.525 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 10.6 m -102.15 -43.42 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.794 ' CG ' ' HH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.58 165.52 25.34 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.664 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.2 t -51.7 111.96 0.68 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.87 9.18 70.19 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.497 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.3 t -123.96 113.69 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.75 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.54 139.14 53.44 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.973 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -96.92 144.34 26.94 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 66.3 m -107.0 158.3 17.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.603 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -115.65 111.46 43.69 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.52 7.28 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.326 3.351 . . . . 0.0 109.603 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.501 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.37 -10.81 45.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 7.1 p30 -131.54 28.23 4.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.86 104.63 12.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.96 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.6 t -100.88 174.35 6.07 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.1 p -145.95 156.13 43.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.51 HG22 ' HB1' ' A' ' 63' ' ' ALA . 4.4 p -166.49 159.43 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.47 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.8 m -127.25 139.54 52.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.95 141.02 36.41 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.0 p30 -82.3 -172.24 3.88 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.2 -27.88 69.29 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -75.1 -7.27 53.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.11 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.89 30.9 58.75 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 77.9 p -125.29 136.12 53.19 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.51 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -123.26 157.44 33.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.71 126.46 23.87 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.443 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -150.21 161.67 41.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -125.57 108.53 11.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.388 HD22 ' CG2' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -95.6 157.88 15.7 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.415 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.1 OUTLIER -107.49 140.17 40.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.862 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.88 123.28 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.778 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -109.91 157.94 18.72 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.498 ' HD2' HG21 ' A' ' 89' ' ' THR . 5.8 mtm180 -87.63 -13.06 43.7 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.5 m -163.41 145.47 9.76 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.04 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 5.5 p90 -177.42 150.69 0.71 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -53.4 113.48 1.17 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.7 101.47 1.42 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.821 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.33 100.67 10.8 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -54.53 131.23 42.35 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.652 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.49 -36.04 9.64 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.597 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.2 t0 -57.77 -16.56 11.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.49 27.39 9.89 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.62 152.85 32.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.15 98.68 10.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 75.0 t-105 -65.61 -43.53 89.31 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.41 175.54 14.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.46 107.75 0.62 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.916 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.4 t -80.02 152.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -120.36 95.84 4.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.941 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.3 m -54.11 -22.93 12.23 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.498 HG21 ' HD2' ' A' ' 71' ' ' ARG . 70.2 p -84.75 2.13 43.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -112.41 -23.36 10.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.05 179.29 7.3 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.32 130.94 40.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.368 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 11.1 m -104.47 164.89 11.43 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.057 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.91 151.41 25.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.388 ' CG2' HD22 ' A' ' 67' ' ' LEU . 2.7 t -106.09 165.61 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.267 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.79 162.08 30.28 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.009 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -124.68 128.94 49.59 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.28 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 27.6 m -112.73 141.56 46.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -103.15 -162.03 0.88 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.996 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.83 -48.16 67.0 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.51 -24.67 66.43 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.61 53.69 1.92 Allowed Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.81 173.43 11.18 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.7 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -175.64 169.12 41.79 Favored Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.576 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.39 171.85 16.16 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.314 3.342 . . . . 0.0 109.595 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.201 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.8 OUTLIER -36.45 133.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.21 160.73 2.44 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.884 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 6.6 t -116.25 103.58 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.09 127.9 35.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.368 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -138.2 179.21 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -163.68 175.52 10.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.031 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.0 m-85 -131.01 114.85 15.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.971 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 10.7 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.698 ' HB3' ' CD ' ' A' ' 106' ' ' GLU . . . -45.14 133.18 5.52 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.402 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.4 -174.51 1.45 Allowed 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 124.295 3.33 . . . . 0.0 109.619 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.73 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.28 108.83 21.38 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 140.42 52.39 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -102.06 112.45 25.11 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.732 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.74 154.86 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.942 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 174.41 2.52 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.127 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.36 118.4 5.58 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 111' ' ' SER . 30.3 p -112.36 46.9 1.12 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.8 p -127.4 106.19 9.03 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.989 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.81 27.67 16.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.127 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.65 131.99 45.28 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -107.54 168.4 9.27 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -44.67 141.17 2.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.85 -22.32 37.41 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.489 HG21 HD13 ' A' ' 13' ' ' LEU . 31.4 m -76.86 150.35 36.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.8 p -126.53 117.27 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.299 HG22 ' O ' ' A' ' 67' ' ' LEU . 13.3 m -83.73 164.12 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.732 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.75 152.25 36.51 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.1 111.51 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.49 116.37 26.54 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.712 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.84 143.25 23.16 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.73 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.0 105.54 4.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.902 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.22 23.05 8.28 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.201 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.81 -164.98 1.22 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.489 ' CD ' ' HH ' ' A' ' 32' ' ' TYR . 6.2 mp0 -85.6 123.77 31.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.62 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.12 134.57 45.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.86 7.57 75.73 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -94.82 138.97 31.92 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.956 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.523 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.4 150.76 22.38 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.251 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -137.17 146.42 44.93 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.258 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.2 m-20 -107.47 112.15 24.79 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.345 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -101.84 150.19 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.923 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -179.38 174.54 46.36 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.265 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.7 tt0 -114.96 113.25 23.89 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.1 m -118.02 145.62 44.65 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.222 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.73 135.98 54.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.582 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.45 124.8 22.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.427 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.1 m -107.15 -42.25 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.325 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -138.29 129.91 27.9 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.633 ' O ' HG23 ' A' ' 42' ' ' THR . 9.5 t -38.04 112.01 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.434 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 93.03 8.98 61.22 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.473 ' CG2' ' HE1' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -151.8 130.44 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.696 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.7 pt? -133.02 142.88 49.05 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.57 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.4 144.65 25.14 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 6.1 m -106.69 156.55 18.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.931 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.4 t-20 -112.97 109.1 52.71 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.4 8.65 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.31 3.34 . . . . 0.0 109.628 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.542 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -94.09 -9.32 37.0 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.912 ' HB3' HG23 ' A' ' 68' ' ' THR . 7.9 m-20 -133.58 15.17 4.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.648 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -85.09 117.11 23.86 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.7 t -112.13 -178.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -145.72 156.14 43.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 56' ' ' THR . 5.1 p -166.99 157.74 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 55' ' ' VAL . 35.0 m -127.66 132.89 49.65 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 153.39 39.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -92.98 -172.04 2.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.82 -29.15 69.3 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -75.22 -9.11 58.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.62 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.88 7.19 88.72 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 99.3 p -99.22 138.94 35.61 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.27 163.91 17.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.1 p -149.38 127.77 12.21 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.608 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -164.51 152.9 12.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -109.24 125.0 51.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.346 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.44 122.15 45.39 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.912 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.1 t -77.94 142.36 38.41 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 1.001 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -114.95 131.16 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.991 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.869 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.5 OUTLIER -113.74 156.84 23.08 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.981 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.26 -13.49 49.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 92.1 p -168.98 144.3 3.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.265 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 14.2 p90 -176.53 158.11 1.73 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -59.22 122.35 13.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.57 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.48 104.32 2.61 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.592 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.4 m-85 -84.82 101.31 12.17 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.89 HD21 ' OD2' ' A' ' 79' ' ' ASP . 6.0 tp -54.33 138.78 38.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.771 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.46 -41.85 21.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.89 ' OD2' HD21 ' A' ' 77' ' ' LEU . 44.1 m-20 -56.85 -17.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.42 26.08 12.73 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.78 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.63 149.17 29.31 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.7 mtt180 -78.7 95.21 5.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.473 ' HE1' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -62.85 -39.49 94.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 126.5 170.26 12.91 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.226 -1.149 . . . . 0.0 110.226 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.92 130.95 43.31 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.222 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.0 t -109.13 154.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -125.53 98.0 5.41 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.721 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 9.9 m -53.13 -27.2 19.64 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.5 p -80.12 0.99 29.78 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.97 -27.59 6.51 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.2 -177.72 4.58 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.34 124.37 45.74 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.828 ' O ' HG13 ' A' ' 110' ' ' ILE . 60.2 m -103.92 153.27 20.99 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.047 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -146.52 146.98 30.7 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.921 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.346 ' CG2' HD12 ' A' ' 67' ' ' LEU . 4.0 t -107.48 159.58 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.345 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.25 171.96 44.78 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.195 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.97 122.12 25.05 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.258 ' N ' ' H ' ' A' ' 33' ' ' ASP . 6.7 m -102.95 154.79 18.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.523 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -114.75 -160.93 0.75 Allowed 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.467 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.8 -49.04 79.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.538 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -74.14 -26.02 60.08 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 98.6 49.21 1.7 Allowed Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.538 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.2 p30 -120.5 167.48 12.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.251 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.66 -176.85 45.16 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.402 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.41 159.6 48.89 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.32 3.347 . . . . 0.0 109.577 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.361 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -37.32 125.44 1.01 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.94 147.64 0.09 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.047 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -115.89 104.51 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.65 138.09 32.38 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.039 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.4 mt -113.61 159.09 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -143.52 119.12 10.4 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.721 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 40.1 m-85 -95.14 123.42 38.63 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.6 m120 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.939 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.678 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -148.1 121.99 4.84 Favored Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.1 Cg_endo -72.41 -175.48 1.81 Allowed 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 124.336 3.357 . . . . 0.0 109.628 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.364 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -100.03 117.92 35.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.986 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -133.52 150.63 51.68 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.1 114.24 25.81 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.708 ' HB ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -111.08 149.75 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.748 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.9 167.36 24.76 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.748 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.3 Cg_endo -72.38 119.31 6.06 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.295 3.33 . . . . 0.0 109.586 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.574 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -125.38 13.71 8.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.1 p -92.33 114.95 27.63 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.105 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.03 22.58 32.34 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.105 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.39 139.16 43.5 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 179.963 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 59.1 m -97.27 169.57 9.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -44.71 151.2 0.3 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.81 -24.35 31.4 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.569 HG21 ' CD1' ' A' ' 13' ' ' LEU . 2.4 m -78.51 144.23 35.86 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.99 146.05 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.7 OUTLIER -117.2 157.61 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.708 ' O ' ' HB ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -113.1 151.1 31.2 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.753 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -146.16 105.37 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.841 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.21 115.46 26.03 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.986 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.26 143.34 21.03 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.364 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.56 110.66 6.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.885 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 98.81 23.83 11.4 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.608 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.75 -169.77 2.73 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -81.83 122.78 28.15 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.31 131.74 43.88 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.95 7.83 81.92 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.539 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.31 140.48 30.14 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.925 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -90.59 151.61 21.24 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.497 ' CB ' ' CD1' ' A' ' 97' ' ' LEU . 43.2 m-85 -138.0 154.58 49.32 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.525 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 11.1 m-20 -118.5 112.46 19.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.486 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -97.62 149.61 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.994 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.99 167.01 38.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.837 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 15.5 tt0 -107.72 129.34 55.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.0 m -125.88 165.5 18.6 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.226 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -142.51 123.93 14.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.634 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.97 117.63 7.9 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.737 HG12 HG22 ' A' ' 86' ' ' VAL . 5.5 m -99.53 -42.52 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.23 -179.49 5.82 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.4 m -63.38 111.52 2.33 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.18 8.46 65.32 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.574 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 62.4 t -121.97 106.96 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.694 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.84 136.47 54.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.45 157.79 20.37 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.3 m -126.24 156.63 39.97 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.601 HD21 ' HB3' ' A' ' 50' ' ' ALA . 30.5 t30 -123.91 111.94 28.9 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.4 -0.68 9.07 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.308 3.339 . . . . 0.0 109.604 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.601 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.55 -13.32 43.25 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.468 ' CB ' HG23 ' A' ' 68' ' ' THR . 9.0 p30 -130.09 27.9 5.08 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.56 117.72 33.63 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.8 t -111.36 -178.24 3.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.0 p -147.78 155.42 41.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 3.0 p -167.52 160.42 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 37.6 m -127.15 129.91 48.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.83 150.86 40.57 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -90.5 -171.08 2.94 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.62 -28.85 69.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -75.53 -7.94 55.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.5 10.05 86.48 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.2 p -102.03 137.68 39.99 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.35 165.04 15.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 p -150.1 125.18 9.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.573 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.96 164.4 38.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.949 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.573 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -120.39 126.17 49.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.899 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -103.74 118.69 37.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.68 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -68.44 116.78 9.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.58 HG23 HG11 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -73.32 122.83 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.68 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -118.02 133.01 56.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -67.85 -40.8 83.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.469 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 19.5 m -155.96 159.37 39.17 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.837 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -177.35 177.78 1.15 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -64.9 121.89 15.69 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.52 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.6 87.21 1.32 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.784 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.29 100.18 10.46 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.958 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.15 144.13 20.62 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.721 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.16 -43.67 21.27 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.572 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 10.3 t0 -57.76 -17.16 13.88 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.24 29.09 9.89 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.918 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.61 121.18 44.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.432 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.1 ptt180 -62.81 91.07 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.574 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.9 t-105 -63.13 -58.37 7.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.15 157.0 8.15 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -54.52 110.13 0.59 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.226 HG11 ' CB ' ' A' ' 38' ' ' ALA . 16.8 t -88.49 154.54 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.469 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 27.4 m-20 -118.85 94.55 4.49 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.184 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 93.5 m -52.0 -28.82 18.26 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.85 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 2.1 t -76.18 -1.24 25.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -115.24 -27.16 7.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.74 -166.2 1.6 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.52 123.39 46.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.15 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 0.8 OUTLIER -104.47 156.29 18.07 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.032 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.12 154.87 42.29 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.899 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 6.4 t -122.11 160.79 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.213 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.28 171.83 42.81 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.525 ' HA ' ' C ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -127.66 124.79 38.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.302 ' N ' ' O ' ' A' ' 33' ' ' ASP . 59.6 p -99.47 152.62 19.79 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.925 ' HB2' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -115.14 -164.24 0.93 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.9 -48.89 77.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -70.73 -24.86 62.71 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 95.6 53.81 1.51 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.831 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.13 175.9 8.71 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.669 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 179.31 -173.91 45.86 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.211 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.33 157.58 53.13 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.357 3.371 . . . . 0.0 109.611 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.678 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.01 124.71 1.18 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.64 140.13 0.3 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.997 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.3 t -101.47 113.99 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.84 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -87.27 126.08 34.61 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.032 HG12 ' HA ' ' A' ' 94' ' ' GLN . 13.1 pt -135.07 -172.94 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.54 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -175.74 178.27 1.57 Allowed 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.184 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.1 m-85 -140.75 109.35 5.94 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 3.8 p-10 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.521 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -79.04 119.15 76.19 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.566 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.7 Cg_endo -72.34 -177.73 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.263 0 C-N-CA 124.353 3.369 . . . . 0.0 109.619 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.88 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.4 m -98.51 109.51 22.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.27 163.67 22.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.482 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.1 p -129.55 115.63 17.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.924 ' CG2' HG23 ' A' ' 21' ' ' VAL . 3.3 t -111.07 149.53 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.871 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.66 171.17 7.6 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.871 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.33 117.18 5.01 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.366 3.377 . . . . 0.0 109.589 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.32 13.21 7.12 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.531 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.8 p -91.08 108.39 19.84 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.983 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.81 16.04 29.69 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.8 OUTLIER -103.81 140.46 37.62 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 p -95.67 173.28 7.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -47.04 153.77 0.41 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.38 -24.28 28.1 Favored Glycine 0 C--N 1.335 0.493 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 HD12 ' A' ' 13' ' ' LEU . 3.6 m -71.36 149.66 45.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.4 p -120.49 132.74 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.564 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.6 OUTLIER -111.51 153.51 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.847 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.32 152.87 23.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.924 HG23 ' CG2' ' A' ' 7' ' ' VAL . 1.1 p -145.04 109.42 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.871 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.23 114.44 21.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.018 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.65 146.39 22.37 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.88 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.94 113.25 7.26 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.49 14.97 31.03 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.22 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.99 165.89 13.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.598 ' CD ' ' OH ' ' A' ' 32' ' ' TYR . 2.6 mp0 -49.61 119.83 3.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.25 134.81 44.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.89 8.06 67.63 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.532 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -95.6 145.74 25.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.04 151.03 23.06 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.466 ' CE1' ' ND2' ' A' ' 103' ' ' ASN . 35.3 m-85 -137.96 159.16 42.77 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.248 ' OD2' ' HB3' ' A' ' 98' ' ' SER . 3.3 t0 -124.0 115.04 20.57 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.212 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -96.56 142.26 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.861 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.42 164.67 34.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.716 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.2 tt0 -116.19 111.34 20.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 59.4 m -107.82 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.062 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.63 123.86 9.53 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.64 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.95 117.45 7.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.598 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 5.6 m -98.2 -43.26 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.415 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -135.46 177.83 7.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.8 m -61.34 112.01 1.99 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.3 8.54 66.05 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 59.1 t -121.53 111.14 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -126.26 139.61 53.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.512 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.57 144.36 25.66 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.5 m -110.19 146.9 34.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.714 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 29.2 t30 -107.47 107.74 60.77 Favored Pre-proline 0 N--CA 1.449 -0.488 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.2 Cg_endo -72.34 0.61 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 124.368 3.378 . . . . 0.0 109.599 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.05 -14.1 39.82 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.492 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.7 p30 -126.04 28.24 6.13 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.43 105.49 14.42 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.1 t -103.14 178.27 4.6 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.8 p -147.06 156.86 43.36 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.616 ' CG1' HD21 ' A' ' 97' ' ' LEU . 7.1 p -167.88 160.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 26.9 m -126.96 138.32 53.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.8 143.6 34.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.4 p30 -80.25 -171.05 2.8 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.13 -26.11 68.39 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -10.07 59.13 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.22 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.11 31.18 53.6 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -127.61 137.27 52.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.46 168.32 13.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.6 128.51 11.75 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.531 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -154.09 162.32 41.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.531 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -115.82 119.73 36.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.21 HD13 ' CG2' ' A' ' 95' ' ' VAL . 1.0 OUTLIER -97.57 133.94 41.45 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.73 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -79.75 134.56 36.38 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG23 HG11 ' A' ' 19' ' ' VAL . 1.1 t -94.29 124.1 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.73 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.7 OUTLIER -117.2 142.95 46.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.92 -26.74 36.54 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -155.42 149.85 26.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.949 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.716 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -173.77 157.88 3.16 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.28 117.51 4.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.512 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.26 93.3 1.09 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.788 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -84.14 99.86 10.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.02 130.39 45.87 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.16 -35.63 7.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.78 -16.57 11.73 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.68 28.38 8.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -116.23 147.78 41.1 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -84.73 96.02 9.12 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.598 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 68.7 t90 -64.97 -58.82 5.13 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.75 163.87 10.93 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.17 106.42 0.23 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.062 HG11 ' CB ' ' A' ' 38' ' ' ALA . 20.2 t -80.77 152.46 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.68 93.99 4.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.266 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 12.1 m -53.13 -26.57 17.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.726 ' HA ' ' HB3' ' A' ' 112' ' ' PHE . 7.3 t -82.37 0.1 43.46 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.0 m -114.3 -27.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.93 3.63 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.69 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -99.57 126.0 45.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.957 ' CB ' HD11 ' A' ' 110' ' ' ILE . 92.4 m -104.2 172.01 7.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.041 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 1.2 tt0 -160.93 151.5 18.14 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.21 ' CG2' HD13 ' A' ' 67' ' ' LEU . 3.0 t -108.65 167.1 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.212 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.36 166.65 37.29 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.375 HD23 ' CB ' ' A' ' 32' ' ' TYR . 6.0 mp -102.16 161.82 13.39 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.248 ' HB3' ' OD2' ' A' ' 33' ' ' ASP . 46.7 t -150.86 121.07 7.25 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.494 ' OD1' ' OD1' ' A' ' 103' ' ' ASN . 0.8 OUTLIER -115.86 -170.9 1.88 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -46.0 -39.65 9.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.96 -25.33 26.12 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 91.16 22.61 31.94 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 1.466 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 23.6 p-10 -59.11 -150.27 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.2 150.62 5.49 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.566 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 166.0 31.03 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.307 3.338 . . . . 0.0 109.578 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.521 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 6.6 pt-20 -34.34 124.3 0.5 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.21 135.32 1.48 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.041 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 3.4 t -90.05 107.43 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.91 127.83 34.12 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.038 HG12 ' CA ' ' A' ' 94' ' ' GLN . 4.0 pt -141.5 -173.77 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.69 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.6 OUTLIER -174.75 163.4 3.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.266 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 6.6 m-85 -125.88 112.16 15.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.689 ' OD1' ' HA2' ' A' ' 12' ' ' GLY . 1.1 m-20 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.648 ' HB3' ' CG ' ' A' ' 106' ' ' GLU . . . -128.38 144.37 51.7 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.525 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.39 -177.2 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.317 3.344 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.756 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.78 109.59 22.33 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.735 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.08 140.3 52.03 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -100.5 111.48 23.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 108' ' ' VAL . 21.8 t -105.84 150.29 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.96 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.5 175.7 1.51 Allowed Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.068 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.7 Cg_endo -72.4 118.59 5.67 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.318 3.346 . . . . 0.0 109.586 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.001 ' HB2' HG23 ' A' ' 110' ' ' ILE . 54.5 p -113.0 47.52 1.11 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.0 p -126.56 107.38 10.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.028 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 27.0 20.62 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.068 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -102.01 132.49 47.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 82.0 p -109.88 169.28 8.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -45.04 140.72 2.57 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.67 38.31 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.434 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -77.05 141.87 40.11 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.707 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.9 p -113.78 108.95 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.291 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.4 m -77.13 164.07 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.843 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.1 149.72 38.52 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.918 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -146.56 115.41 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.86 116.96 23.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.872 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.18 147.94 23.9 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.756 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.61 111.81 4.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.66 14.44 34.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.64 173.64 8.19 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.519 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.5 mt-30 -56.37 119.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.08 131.23 41.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.13 7.82 84.75 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.519 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.83 141.37 28.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.999 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.698 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.46 150.35 25.35 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.283 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 25.4 m-85 -136.38 140.81 43.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.41 ' N ' ' N ' ' A' ' 98' ' ' SER . 2.5 m-20 -103.11 116.91 33.4 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.562 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -107.12 145.63 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.966 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.886 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.54 161.73 31.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.953 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 18.9 tt0 -101.97 120.61 40.69 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.482 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.5 m -109.99 169.0 9.01 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.088 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.73 124.91 8.71 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.611 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.64 124.03 20.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.792 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 15.4 m -103.73 -44.07 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.863 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -138.52 165.23 27.39 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.5 m -51.88 112.6 0.81 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.24 8.21 65.05 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 97.3 t -122.32 107.47 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.709 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.71 162.38 18.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.507 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.11 156.59 41.5 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.859 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -118.47 155.49 30.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.67 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 19.8 t30 -112.86 113.58 49.79 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.38 0.03 8.02 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.343 3.362 . . . . 0.0 109.612 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.98 -9.51 45.73 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.2 p30 -134.16 27.72 3.82 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.42 107.29 17.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -103.49 171.38 7.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.2 p -145.27 153.54 41.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -166.6 158.23 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' VAL . 85.7 m -127.52 135.53 50.49 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.45 139.97 48.02 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.2 p30 -77.6 -174.75 3.54 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.8 -25.08 68.06 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -75.99 -8.04 56.04 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.942 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 75.3 32.18 55.96 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -129.87 137.62 50.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.6 167.39 14.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -150.56 125.43 9.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.462 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -159.84 158.26 30.68 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.462 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -111.17 133.46 53.51 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.291 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -110.3 120.16 41.54 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.638 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -79.26 129.86 34.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.78 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.88 137.02 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.874 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -120.31 165.62 14.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.5 -14.12 33.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.2 m -164.51 144.49 7.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.953 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.4 p90 -176.3 154.24 1.32 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.496 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.9 OUTLIER -57.3 124.26 18.26 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.507 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -84.75 98.08 2.18 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.859 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.2 101.75 12.1 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.862 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -57.81 131.62 50.88 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.679 ' N ' HD12 ' A' ' 77' ' ' LEU . 29.6 p90 -47.64 -35.76 9.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.656 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -58.01 -16.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.22 28.46 9.18 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.862 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.0 m -115.66 146.69 41.6 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.0 96.58 8.91 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.863 ' HZ2' ' HB2' ' A' ' 41' ' ' ASP . 5.2 t-105 -63.45 -42.69 98.66 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 128.43 176.55 14.49 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.53 135.55 54.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.088 HG11 ' CB ' ' A' ' 38' ' ' ALA . 1.6 t -114.82 154.93 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -127.81 101.34 6.31 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.907 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 48.9 m -53.35 -28.04 26.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -79.04 -2.45 40.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.19 -27.59 6.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.92 -176.12 3.76 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.0 123.38 45.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.704 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 72.3 m -104.35 152.24 22.5 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.025 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -145.05 148.81 34.12 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.138 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.5 t -114.31 148.2 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.405 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.74 173.87 46.41 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.562 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.7 OUTLIER -125.66 159.88 31.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.41 ' N ' ' N ' ' A' ' 33' ' ' ASP . 2.9 m -139.64 156.95 46.55 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.698 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.11 -165.45 1.0 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -55.79 -49.18 73.89 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.638 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.0 -25.37 62.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.69 39.55 3.37 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.638 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 3.8 p30 -113.57 154.32 27.34 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.283 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -161.86 -173.1 30.11 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.525 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.41 158.41 51.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.332 3.354 . . . . 0.0 109.557 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.648 ' CG ' ' HB3' ' A' ' 2' ' ' ALA . 2.4 mt-10 -38.64 117.26 0.63 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.09 153.2 0.01 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 7' ' ' VAL . 11.0 t -127.05 106.71 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.444 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -82.69 133.89 35.15 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.025 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.5 mt -102.76 163.87 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.722 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -145.73 123.34 11.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.907 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.7 m-85 -95.32 127.36 41.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.968 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.585 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -98.86 125.57 41.69 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.638 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.37 -174.1 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.327 3.351 . . . . 0.0 109.591 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.49 110.75 23.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.878 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.72 139.16 52.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.551 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -99.71 112.48 24.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.778 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.51 152.89 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.929 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.48 174.06 2.87 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.099 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.9 Cg_endo -72.38 118.74 5.74 Favored 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 124.321 3.348 . . . . 0.0 109.618 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.81 ' HB2' HG23 ' A' ' 110' ' ' ILE . 92.0 p -111.94 49.08 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -127.54 106.41 9.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.002 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.44 27.5 20.0 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.099 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.67 132.22 46.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.6 m -109.22 172.27 6.95 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 1.023 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 7.6 t70 -46.6 141.53 3.71 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.2 -22.5 36.3 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.49 HG21 HD13 ' A' ' 13' ' ' LEU . 29.1 m -76.58 149.75 36.58 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.64 ' O ' HG13 ' A' ' 18' ' ' VAL . 11.7 p -121.5 114.66 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.903 HG23 HG12 ' A' ' 69' ' ' VAL . 11.6 t -81.03 153.19 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.778 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.82 147.18 33.76 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.499 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.3 111.15 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.878 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.87 117.13 27.32 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.804 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.08 144.77 24.0 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.9 102.29 3.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.912 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 109.04 17.64 10.01 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.258 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -90.23 171.36 9.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.988 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.832 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 75.4 mt-30 -56.9 121.82 10.8 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.59 131.75 42.04 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.0 7.77 86.72 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.427 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -96.12 136.59 36.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.984 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -82.64 152.25 25.96 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.875 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.4 m-85 -136.57 146.05 45.68 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.278 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -107.47 113.55 26.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.984 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.4 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.09 144.53 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.994 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.57 169.7 42.53 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.105 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 11.9 tt0 -106.4 105.31 15.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -105.71 141.14 37.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.997 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.78 138.57 54.59 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.563 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.93 124.44 22.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.918 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.12 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -103.66 -51.32 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.953 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -132.72 168.29 18.58 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.94 112.49 0.72 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.47 7.96 65.52 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.671 HG11 ' HE1' ' A' ' 83' ' ' TRP . 86.3 t -121.8 120.97 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.578 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -130.26 134.5 47.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.979 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.468 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.42 153.53 18.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 98.6 m -112.64 145.51 40.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.917 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -108.88 114.18 58.72 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.36 -0.24 8.41 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 124.332 3.355 . . . . 0.0 109.584 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.4 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -81.33 -12.67 58.96 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.724 ' HB2' HD22 ' A' ' 48' ' ' ASN . 96.2 m-20 -136.66 29.78 2.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD1' ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -84.36 108.36 17.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.8 t -107.0 173.41 6.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 p -145.59 154.45 42.17 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' N ' ' A' ' 56' ' ' THR . 6.8 p -167.06 156.82 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.436 ' N ' HG22 ' A' ' 55' ' ' VAL . 36.3 m -126.84 135.62 51.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.14 154.1 42.62 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -92.86 -169.42 2.17 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.57 -28.34 69.81 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.72 -7.56 54.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.648 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.11 14.96 81.76 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -107.83 137.68 45.41 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.92 165.45 15.19 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 p -149.94 128.12 12.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.67 160.85 20.39 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.899 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -117.65 127.41 53.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.103 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.2 120.19 40.93 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.905 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.64 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -76.42 134.99 39.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.903 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.9 135.28 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 1.023 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -116.71 162.47 17.62 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -87.98 -19.51 27.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 28.5 t -163.05 146.73 10.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.105 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.7 p90 -177.04 152.75 0.93 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -57.66 118.96 5.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.468 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.64 98.98 1.83 Allowed Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.792 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.13 100.96 10.86 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.925 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.5 tp -54.78 131.79 44.62 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.672 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.8 m-85 -47.43 -36.48 9.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.575 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.13 -16.66 8.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.27 27.72 9.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.925 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -115.89 149.93 37.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.56 98.04 11.54 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.12 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -63.94 -43.71 95.06 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.946 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 135.69 -179.65 17.55 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.44 126.16 26.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.997 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.1 t -101.45 154.02 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 11.7 m-20 -127.45 96.79 4.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.782 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 54.4 m -53.23 -27.81 24.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -78.32 1.28 22.34 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.14 -27.53 6.06 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.16 -173.28 3.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.8 124.72 48.86 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.87 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 97.6 m -104.36 152.52 22.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.07 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -146.39 148.43 32.31 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.103 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.7 t -110.3 160.06 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.397 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 168.8 41.07 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.4 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.12 128.38 44.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.278 ' N ' ' H ' ' A' ' 33' ' ' ASP . 22.2 m -114.72 148.3 38.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.984 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -107.13 -157.97 0.64 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.49 -47.26 64.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.02 -23.97 64.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.01 53.88 1.98 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.832 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.21 165.96 20.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.875 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.62 46.71 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.638 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.38 162.44 41.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.346 3.364 . . . . 0.0 109.59 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.585 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 1.5 tt0 -37.59 120.83 0.84 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.66 153.54 0.02 OUTLIER Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.935 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.8 t -118.3 104.18 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.62 124.05 32.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.07 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.9 mt -101.31 157.0 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.65 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -141.94 125.36 16.64 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.782 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 9.5 m-85 -96.6 124.28 40.54 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.4 m120 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.39 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -61.48 131.64 92.61 Favored Pre-proline 0 N--CA 1.45 -0.465 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.485 ' CB ' HD22 ' A' ' 26' ' ' LEU . 81.4 Cg_endo -72.4 -174.31 1.39 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.268 3.312 . . . . 0.0 109.616 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.805 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.66 108.27 19.75 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.879 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.57 146.24 47.17 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -113.24 118.17 33.92 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.829 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -114.13 155.15 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.993 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.645 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -71.54 162.19 74.32 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.639 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 121.98 7.93 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.322 3.348 . . . . 0.0 109.606 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.659 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.2 OUTLIER -126.93 15.84 7.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.6 111.73 22.23 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.078 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.3 22.58 31.7 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.078 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -109.11 144.12 37.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 75.5 m -94.29 166.03 12.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 1.128 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 11.5 t0 -46.15 153.34 0.33 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 100.02 -24.27 32.78 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.438 HG21 HD12 ' A' ' 13' ' ' LEU . 24.5 m -69.17 132.62 46.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.3 p -106.43 111.33 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.645 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 6.4 m -90.37 166.08 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.829 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.04 149.1 44.82 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.454 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -136.41 104.88 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.879 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.8 117.83 31.84 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.746 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -88.03 143.82 18.37 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.805 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -135.01 108.09 7.65 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.921 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.69 25.69 7.98 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.485 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.89 179.69 6.14 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 180.0 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.425 ' HB2' HG21 ' A' ' 30' ' ' THR . 18.9 mt-30 -76.83 123.74 26.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.476 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.11 137.46 54.96 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.78 7.28 65.25 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.644 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.16 145.12 24.65 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.2 149.11 22.01 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.535 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 39.8 m-85 -138.05 136.83 37.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.109 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -99.61 114.75 27.99 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.114 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.99 143.19 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.897 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.66 162.14 35.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.936 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -101.01 117.78 35.7 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.436 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.9 m -108.65 164.57 12.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.771 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -150.47 139.44 20.98 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.527 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -64.67 124.55 22.21 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.228 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -106.4 -53.93 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.617 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -138.1 167.03 22.66 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -51.02 111.58 0.58 Allowed 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.59 8.15 66.51 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.602 ' CG1' ' CZ3' ' A' ' 83' ' ' TRP . 13.8 t -124.21 118.91 55.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.69 HD12 ' N ' ' A' ' 46' ' ' ALA . 2.0 pp -121.93 163.3 19.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.369 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.51 146.19 50.59 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.768 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.15 159.13 17.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.985 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.902 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.2 t30 -113.04 112.74 49.81 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.39 -0.82 9.28 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.339 3.36 . . . . 0.0 109.592 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.95 -7.92 50.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.449 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 32.9 m-20 -133.82 26.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.406 ' HD1' ' HA ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -84.25 106.12 15.62 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.8 t -104.73 176.38 5.18 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.7 p -146.09 158.45 43.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.449 HG22 ' N ' ' A' ' 56' ' ' THR . 5.5 p -166.98 158.3 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.449 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.5 m -128.37 127.35 42.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.61 141.57 58.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.5 p30 -85.22 -171.57 3.7 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.53 -23.52 67.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -83.67 1.0 44.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 70.44 2.35 41.83 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 t -95.12 136.08 35.88 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.45 161.99 21.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -147.51 129.59 15.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.715 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -151.7 174.24 13.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.888 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.715 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -130.96 114.64 15.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.613 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -98.38 156.89 16.52 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.984 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.601 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -116.64 134.67 54.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.649 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -101.03 131.06 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 1.128 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -115.74 147.92 40.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 ptt180 -74.48 -25.15 59.2 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.5 t -159.94 150.01 18.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.936 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.6 p90 -177.34 156.03 1.17 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.23 119.83 7.58 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.369 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.32 100.39 1.39 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.768 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.35 100.04 10.41 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 1.074 HD21 ' OD2' ' A' ' 79' ' ' ASP . 4.3 tp -55.05 137.12 47.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.69 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.62 -40.99 13.93 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 1.074 ' OD2' HD21 ' A' ' 77' ' ' LEU . 1.5 m-20 -57.09 -17.0 8.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.98 26.87 10.84 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -109.51 148.63 30.89 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.76 95.73 8.52 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.617 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 33.3 t-105 -62.8 -56.43 17.55 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.04 170.72 19.0 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.53 107.44 0.8 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.771 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.8 t -83.41 152.33 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.77 93.71 4.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.268 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -55.03 -22.27 15.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.526 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 25.7 p -85.93 2.24 46.86 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -110.98 -26.57 9.2 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.54 179.22 6.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.664 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -94.06 129.45 40.59 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.045 ' HB2' HD11 ' A' ' 110' ' ' ILE . 59.1 m -104.86 173.07 6.46 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.378 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -158.67 142.55 15.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.951 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.613 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.4 t -98.21 164.13 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.114 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.93 161.25 26.87 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.076 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -126.55 135.71 51.63 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.109 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 52.4 p -106.99 158.79 16.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.466 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.0 OUTLIER -112.46 -167.53 1.2 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.466 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -53.8 -49.83 67.45 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.629 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -74.52 -25.4 59.31 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.4 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 104.67 39.44 2.37 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.629 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 5.8 p30 -122.92 -175.34 3.14 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.535 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 162.14 -161.88 33.79 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.389 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.91 52.44 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.382 3.388 . . . . 0.0 109.553 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.39 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.0 pt-20 -42.84 145.23 0.48 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.76 164.5 1.75 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.378 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 37.3 t -116.84 102.69 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.448 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -75.88 132.48 40.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.045 HD11 ' HB2' ' A' ' 93' ' ' CYS . 6.2 pt -142.41 -174.36 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.664 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.1 OUTLIER -171.02 176.1 4.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.268 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 4.6 m-85 -132.55 114.29 14.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.002 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.4 m120 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.645 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -126.28 131.31 23.9 Favored Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.38 -177.7 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 124.314 3.343 . . . . 0.0 109.635 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.785 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.77 109.69 22.41 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.783 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.46 133.52 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.632 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -96.51 115.85 28.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.556 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.29 155.95 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.95 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 175.61 1.77 Allowed Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.051 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.37 117.4 5.11 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.32 3.346 . . . . 0.0 109.58 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.805 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 1.6 p -110.73 48.57 0.91 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 79.9 p -126.97 105.88 8.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.096 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.32 29.27 11.43 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.096 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.43 130.29 55.24 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.951 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.19 177.36 4.67 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -45.83 139.39 4.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.07 -22.77 34.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.679 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.2 m -83.13 150.56 26.19 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.503 ' O ' HG13 ' A' ' 18' ' ' VAL . 13.9 p -121.49 123.96 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.53 HG23 ' HB3' ' A' ' 67' ' ' LEU . 6.8 m -90.44 158.44 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.38 149.08 30.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.711 HG12 ' O ' ' A' ' 65' ' ' THR . 0.3 OUTLIER -145.09 113.38 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.65 117.19 22.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.834 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.06 147.75 23.89 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.785 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.36 111.32 4.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.17 15.61 30.04 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.059 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.6 177.05 6.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 29.7 mt-30 -59.61 121.5 11.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.22 129.8 39.3 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.08 7.04 86.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.52 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.23 141.5 28.51 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.965 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.92 149.85 23.83 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.779 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.6 m-85 -136.43 138.09 41.14 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.002 ' HB3' ' O ' ' A' ' 98' ' ' SER . 1.5 t0 -99.99 113.84 26.7 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.242 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.04 144.72 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.739 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.84 171.05 42.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.929 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 33.8 tt0 -117.64 108.77 15.84 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.76 147.66 37.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.288 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.33 142.87 50.04 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.503 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.98 124.97 23.45 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.898 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.443 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -104.89 -44.25 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.332 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -149.05 134.8 18.81 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 41' ' ' ASP . 1.5 m -38.18 110.92 0.14 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.459 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 94.46 8.3 59.87 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.173 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.7 OUTLIER -151.59 129.26 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.636 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -133.96 132.95 40.78 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.425 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -84.27 144.69 28.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 2.6 m -106.44 152.92 23.0 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 41.4 t-20 -111.64 107.4 56.64 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.1 Cg_endo -72.4 -0.05 8.16 Favored 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 124.308 3.338 . . . . 0.0 109.599 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.17 -10.44 49.89 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.697 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.3 OUTLIER -131.71 27.56 4.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.501 ' HD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -80.5 104.6 11.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -100.11 175.35 5.77 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.3 p -143.94 153.39 42.22 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.426 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -167.98 152.24 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.7 m -127.47 134.71 49.81 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -71.4 141.63 50.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 45.2 p30 -81.57 -173.33 4.34 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -27.21 68.71 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -8.61 57.13 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.059 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.81 31.87 52.05 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.1 p -127.93 139.67 52.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.426 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -123.35 165.81 16.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.71 122.89 8.91 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.711 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -158.73 152.22 22.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.75 127.95 56.23 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.486 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -97.78 156.4 16.59 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.956 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.8 t -102.67 120.96 41.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.511 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 1.0 OUTLIER -83.22 127.79 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.861 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.8 OUTLIER -117.14 155.81 28.7 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -94.21 -18.26 21.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.551 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 3.6 m -164.19 144.75 8.22 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.929 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.7 p90 -172.24 153.64 3.09 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -57.98 111.67 1.25 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.425 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.67 101.76 0.89 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.749 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.37 99.68 10.2 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.3 tp -55.44 141.14 37.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.718 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.3 m-85 -46.54 -42.9 16.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.746 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.33 -16.89 9.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.82 27.69 12.27 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.3 m -109.23 144.72 36.97 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -76.89 94.77 3.97 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.443 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 31.5 t-105 -63.19 -57.2 11.3 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.52 163.79 12.51 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.1 104.67 0.33 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.288 HG11 ' CB ' ' A' ' 38' ' ' ALA . 67.9 t -76.64 150.45 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.427 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 4.2 m-20 -117.19 93.91 4.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.002 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 30.8 m -52.16 -27.22 13.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.6 p -80.01 0.36 32.01 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.6 m -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.73 -175.1 3.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.65 126.48 47.15 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.903 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.2 m -104.55 154.37 20.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.027 ' HA ' HG13 ' A' ' 110' ' ' ILE . 2.1 pt20 -142.55 150.05 39.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.486 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.4 t -110.62 164.04 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.242 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.66 166.31 36.01 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.96 121.03 27.15 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.002 ' O ' ' HB3' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -103.52 150.96 23.41 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -109.81 -159.93 0.7 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.973 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.27 -48.87 79.07 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.501 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -75.53 -25.71 57.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.86 42.24 2.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.501 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 3.2 p30 -111.68 166.27 11.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.774 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.99 -177.64 44.24 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.06 54.0 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.3 3.333 . . . . 0.0 109.6 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.132 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 1.9 mt-10 -35.39 125.89 0.62 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.06 151.88 0.02 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.904 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -124.39 104.68 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -84.63 146.06 27.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.027 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.8 mt -121.05 157.37 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.54 115.76 11.77 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.002 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 11.6 m-85 -86.56 114.27 23.15 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 2.8 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.48 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -87.1 122.94 70.85 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.481 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.6 Cg_endo -72.4 -178.26 3.22 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 124.303 3.336 . . . . 0.0 109.581 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.839 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.62 111.33 23.68 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.69 159.58 33.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.434 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.5 p -124.29 121.28 34.57 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.83 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 55.5 t -116.87 146.39 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.773 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.96 167.75 18.72 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.773 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 118.65 5.7 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.357 3.372 . . . . 0.0 109.576 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -129.71 9.93 5.51 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.965 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.045 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.2 p -85.66 106.44 16.94 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.431 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 102.25 14.52 28.1 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.964 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -106.04 136.07 46.38 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.969 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -92.31 176.63 6.41 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.64 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 11.0 t70 -44.79 153.12 0.19 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.82 -23.34 34.68 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.681 HG21 HD12 ' A' ' 13' ' ' LEU . 10.4 m -72.58 142.97 48.42 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.6 p -118.9 121.04 65.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.814 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -100.59 154.31 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.2 151.0 26.51 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.757 HG23 ' CG2' ' A' ' 7' ' ' VAL . 0.9 OUTLIER -141.95 109.19 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.46 115.43 22.21 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.025 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -86.62 146.36 20.7 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.839 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.2 112.12 6.86 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.49 17.75 25.56 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.125 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.48 167.61 12.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.637 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 52.3 mt-30 -52.22 121.21 6.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.515 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.23 130.69 40.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.35 7.12 86.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.483 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.95 139.12 31.78 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.522 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.42 152.55 23.95 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.69 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 33.5 m-85 -136.71 139.82 42.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.245 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.72 113.8 27.59 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.258 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -102.68 149.66 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.835 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.4 172.32 43.99 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.847 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 36.8 tt0 -113.5 110.91 21.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.7 m -108.94 147.12 32.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.864 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -125.95 131.58 52.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.61 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.25 120.52 12.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.919 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.973 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.7 m -100.35 -43.23 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.508 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -136.85 166.1 24.41 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.951 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.679 ' O ' HG23 ' A' ' 42' ' ' THR . 15.3 t -51.14 111.74 0.61 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.12 8.52 65.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.0 t -122.09 109.41 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.457 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.89 141.17 52.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.956 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.432 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -100.28 155.13 17.95 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.9 m -111.04 149.61 30.5 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.697 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -117.1 115.66 38.22 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HA ' ' HB2' ' A' ' 52' ' ' PHE . 83.2 Cg_endo -72.37 1.02 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.345 . . . . 0.0 109.629 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -81.28 -14.25 57.6 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CG ' HG23 ' A' ' 68' ' ' THR . 95.1 m-20 -132.86 29.58 4.11 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' HB2' ' HA ' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -84.53 109.77 18.18 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.5 t -105.7 174.1 6.03 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -146.35 149.78 34.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.412 HG22 ' N ' ' A' ' 56' ' ' THR . 6.1 p -166.22 155.51 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.1 m -126.05 133.02 51.84 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.17 138.73 47.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.7 p30 -77.44 -174.06 3.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -17.39 58.58 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -85.16 5.66 29.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.937 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 59.12 32.37 71.2 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.6 t -130.44 137.09 49.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.52 167.49 17.03 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 53.1 p -150.83 128.04 11.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.728 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.52 172.91 13.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.853 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.728 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -126.09 122.78 36.75 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.896 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -100.43 143.45 30.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.926 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.626 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -100.45 143.99 29.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 t -103.35 129.33 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.64 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -119.42 143.91 47.22 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.02 -32.05 68.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 33.2 t -158.09 158.96 35.71 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.847 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -177.0 163.93 2.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.26 120.93 13.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.432 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.11 93.2 0.96 Allowed Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 1.006 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 100.07 10.48 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.1 tp -54.5 137.47 42.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.816 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 3.0 m-85 -46.6 -40.77 13.49 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.564 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 7.7 t0 -56.89 -17.39 9.31 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.56 27.94 9.39 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.33 139.87 45.08 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -78.25 92.5 4.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.973 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 13.6 t90 -62.49 -57.92 9.48 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.07 166.06 13.41 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.95 128.83 38.83 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.864 HG11 ' HB3' ' A' ' 38' ' ' ALA . 13.7 p -113.15 147.51 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -99.3 95.19 6.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.74 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -54.88 -20.71 9.39 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.9 p -91.24 1.78 56.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 m -108.71 -27.01 10.04 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.4 176.64 8.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.439 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -89.59 126.72 35.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.24 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -104.98 172.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.953 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.68 147.81 22.1 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.896 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 29.6 t -104.86 163.49 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.258 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.55 167.98 37.72 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.164 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -133.02 138.75 46.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.245 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 22.8 m -121.73 145.55 47.91 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -103.19 -158.56 0.67 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -70.55 -47.75 58.83 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.95 -24.39 66.06 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.2 53.62 1.85 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.637 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.04 165.26 23.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.516 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.01 171.46 42.96 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.481 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 166.2 30.46 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.344 3.363 . . . . 0.0 109.604 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.48 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 11.2 pt-20 -37.87 120.24 0.82 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.83 158.78 0.01 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.899 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.6 t -115.03 103.56 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.08 124.03 30.67 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.24 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.6 pt -134.49 -174.87 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . 1.045 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -170.83 175.94 4.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.2 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.8 m-85 -124.46 115.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.431 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 36.1 m-80 . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.593 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -143.99 119.9 6.3 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.586 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.37 -174.46 1.43 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.29 3.327 . . . . 0.0 109.642 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.29 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 5.8 t -100.94 115.24 29.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.916 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -129.73 165.18 22.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.429 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.3 p -125.99 122.2 35.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.856 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -118.7 145.78 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.762 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -70.29 163.03 65.88 Favored Pre-proline 0 N--CA 1.448 -0.538 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.681 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.42 119.27 6.03 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.284 3.323 . . . . 0.0 109.595 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.682 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 2.2 t -126.95 14.03 7.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.813 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.0 p -88.95 105.83 18.02 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.088 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.17 21.59 13.22 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.088 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.87 139.51 44.87 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -85.96 169.2 13.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -44.42 152.29 0.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.53 -22.54 40.38 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 HD12 ' A' ' 13' ' ' LEU . 35.9 m -64.17 140.63 58.89 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.82 110.95 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.762 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER -93.29 118.61 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.856 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.6 146.38 36.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -135.19 110.5 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.676 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.56 115.01 22.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.916 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.21 143.35 20.25 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.232 ' O ' HG22 ' A' ' 4' ' ' THR . . . -136.8 110.38 8.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.9 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.18 24.15 9.9 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.586 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.6 -175.04 4.8 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.995 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.523 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 62.6 mt-30 -74.2 124.5 26.49 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.505 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.48 128.01 34.28 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.65 87.02 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.713 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.84 134.3 40.33 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.48 152.15 23.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.952 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 66.6 m-85 -137.05 156.15 48.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.037 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -114.62 115.26 26.87 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.942 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.087 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 1.4 t -98.77 143.11 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.775 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.7 163.58 37.3 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.922 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -106.38 115.55 30.4 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 93.9 m -107.45 168.23 9.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.91 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -153.71 126.7 8.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.604 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.39 122.82 18.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.619 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 11.6 m -103.92 -43.44 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.654 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -142.48 171.94 13.37 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.1 m -56.75 112.55 1.33 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 5.11 56.59 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.776 HG12 ' CD1' ' A' ' 83' ' ' TRP . 24.0 t -118.63 107.05 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.877 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.2 pp -117.08 162.85 17.15 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.529 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -125.26 146.12 49.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 51.1 m -115.53 152.36 33.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.7 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -112.64 107.15 55.17 Favored Pre-proline 0 N--CA 1.449 -0.5 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -72.46 -0.31 8.57 Favored 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.317 3.345 . . . . 0.0 109.554 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.646 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.65 -12.04 40.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 69.8 m-20 -131.82 24.88 4.67 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.664 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -95.51 117.86 31.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.9 t -110.77 -171.76 1.9 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.78 156.45 43.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 p -166.4 152.79 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 54.6 m -126.19 132.06 51.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.47 150.8 48.41 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.4 p30 -90.93 -169.11 2.25 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.25 -27.84 68.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -76.27 -10.57 59.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.58 9.33 86.97 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -100.64 137.61 38.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.11 161.67 21.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.88 130.38 13.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.718 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.23 173.26 15.31 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.883 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.718 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -121.36 133.35 55.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.903 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.932 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -117.59 119.4 34.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -78.72 141.08 38.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.948 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.671 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -113.78 130.24 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.986 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.667 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -114.78 154.75 27.99 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -76.25 -22.1 55.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 87.7 p -161.42 151.84 17.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.922 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -176.98 160.4 1.8 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.49 113.11 2.49 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.529 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -74.63 95.97 0.91 Allowed Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.693 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 99.9 10.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.937 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -53.56 144.51 17.18 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.846 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.61 -43.93 26.2 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.937 ' OD2' HD21 ' A' ' 77' ' ' LEU . 12.0 m-20 -58.08 -16.5 13.25 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.45 27.51 13.05 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.808 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -105.18 125.99 51.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.523 ' HB3' ' CZ ' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -64.53 91.69 0.08 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.619 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 87.2 t90 -62.02 -39.29 91.76 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 132.15 174.73 13.72 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.16 105.05 1.29 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.149 HG22 ' CG1' ' A' ' 40' ' ' VAL . 42.8 t -80.73 146.42 7.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -105.08 92.96 4.44 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.055 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -53.49 -21.26 5.96 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.2 p -89.18 3.14 52.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -112.92 -27.64 8.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.84 174.63 10.4 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.534 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -91.4 127.66 36.92 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.4 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 33.2 m -105.41 167.23 9.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.075 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -155.29 140.58 17.63 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.932 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -92.7 164.93 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.087 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.46 160.93 27.24 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.03 127.09 42.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.037 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 26.4 m -106.44 151.02 25.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.41 -161.45 0.75 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.998 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.86 -48.65 65.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.23 -24.17 65.8 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.12 53.82 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -135.18 172.17 13.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.952 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.02 178.45 45.0 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.494 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.39 164.06 36.75 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.265 3.31 . . . . 0.0 109.577 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.593 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 13.2 pt-20 -38.12 124.05 1.16 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.434 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.29 152.6 0.01 OUTLIER Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.029 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.8 t -111.8 103.26 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.33 130.59 35.6 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.4 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.0 pt -143.84 177.31 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.813 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -173.49 176.31 2.83 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.055 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 1.7 m-85 -128.09 120.0 26.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.699 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 27.5 m-80 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.374 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -141.41 124.57 9.77 Favored Pre-proline 0 N--CA 1.45 -0.458 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.456 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.44 -177.53 2.8 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.296 3.33 . . . . 0.0 109.595 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.189 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.17 109.06 21.88 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.883 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 139.66 53.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.65 117.75 34.87 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.852 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -113.17 155.27 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.955 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.83 176.65 1.22 Allowed Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.111 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.1 Cg_endo -72.39 117.71 5.26 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.305 3.337 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.663 ' HB2' HG23 ' A' ' 110' ' ' ILE . 24.0 p -113.29 43.56 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 60.7 p -123.58 106.79 10.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.75 28.39 14.24 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.111 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.08 133.5 45.51 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 m -104.61 165.0 11.35 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.689 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -44.75 139.13 3.11 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.28 -22.33 34.96 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 27.8 m -76.07 141.89 41.9 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 67' ' ' LEU . 10.4 p -113.28 128.86 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 8' ' ' THR . 2.7 t -96.23 164.36 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.852 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.21 144.85 41.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.662 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -139.58 113.21 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.883 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.46 114.62 19.06 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.81 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -88.74 140.96 16.22 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.189 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.31 116.76 10.73 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.18 19.35 21.55 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.81 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -88.35 173.76 8.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.495 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 27.0 mt-30 -64.35 120.74 12.78 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.13 136.95 56.67 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.09 8.19 61.14 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.722 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -86.1 146.58 26.55 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.892 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.97 138.22 33.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.045 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 32.7 m-85 -131.32 146.75 52.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.254 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -117.12 116.49 27.4 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.376 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.45 153.67 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.001 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.72 163.66 30.8 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.096 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.6 tt0 -103.1 120.33 40.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.1 m -108.25 164.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.74 -0.466 . . . . 0.0 109.74 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -152.0 131.08 12.65 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.496 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -66.29 128.75 37.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.923 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.53 ' CB ' ' NE1' ' A' ' 83' ' ' TRP . 3.3 m -117.07 -38.1 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.255 ' OD1' ' HH2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -146.68 178.78 8.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' HG23 ' A' ' 42' ' ' THR . 4.7 t -64.48 110.95 2.47 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 8.3 63.51 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.981 HG11 ' CE3' ' A' ' 83' ' ' TRP . 84.9 t -111.7 104.88 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.638 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.0 OUTLIER -104.33 154.81 19.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.934 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.595 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.16 129.01 44.56 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.836 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.72 157.43 18.12 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.753 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.1 t30 -115.67 114.56 42.13 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -72.46 -1.26 9.96 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.318 3.345 . . . . 0.0 109.611 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -91.19 -11.39 38.46 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 68' ' ' THR . 21.0 p30 -133.84 25.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.642 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -97.84 116.17 29.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 t -103.53 178.57 4.52 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.2 p -146.38 153.11 40.12 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.547 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.91 157.37 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 60.3 m -125.32 127.48 46.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.415 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -59.55 124.72 20.97 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.3 p30 -69.95 -170.3 0.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -23.73 66.46 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.25 2.12 29.33 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.807 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 65.54 32.45 83.35 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 32.7 t -127.65 145.03 51.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -143.85 124.66 14.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -108.72 133.68 52.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.412 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -148.94 155.65 41.15 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.412 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -111.24 120.43 42.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.615 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.79 159.36 15.85 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.803 -0.444 . . . . 0.0 109.803 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.614 HG23 ' HB2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -124.91 133.05 53.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.26 130.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.689 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -110.78 168.37 9.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 29.7 ptt180 -96.53 -8.34 32.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.8 t -176.54 146.15 0.59 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.096 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 10.3 p90 -176.77 166.72 2.58 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -62.13 127.29 30.68 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.595 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.15 93.41 1.7 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.836 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.58 100.59 11.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.942 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -57.19 130.67 47.18 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.655 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m-85 -47.67 -35.76 10.05 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.569 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.81 -16.88 12.88 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.55 27.5 9.08 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.942 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.26 150.18 36.6 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.45 97.19 10.93 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.53 ' NE1' ' CB ' ' A' ' 40' ' ' VAL . 15.2 t-105 -66.64 -56.88 8.63 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.5 168.25 13.41 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.45 142.88 31.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.832 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -127.13 154.64 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.981 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.418 ' N ' ' CG2' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -113.81 100.97 8.85 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.573 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.9 OUTLIER -53.78 -26.33 23.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -83.71 0.69 46.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 m -117.74 -27.85 6.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.23 175.64 7.28 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.95 123.04 40.56 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.195 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.9 m -104.47 152.62 22.12 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.988 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -143.77 143.39 31.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.615 HG13 ' CD1' ' A' ' 67' ' ' LEU . 3.4 t -101.95 151.57 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.372 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.72 171.57 43.78 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.376 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -128.27 146.05 50.87 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.254 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 5.9 m -123.18 153.25 40.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.892 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.59 -163.98 0.89 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.29 -49.28 78.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.603 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.37 -25.76 62.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 97.75 46.52 2.27 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.603 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.8 p30 -119.27 166.82 12.52 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.045 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.84 -176.53 41.5 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.456 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.47 162.45 41.41 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.306 3.337 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.374 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.85 127.45 1.58 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -43.75 144.54 1.72 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.986 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -120.87 110.94 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.85 142.84 27.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.195 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.9 OUTLIER -108.13 168.59 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.73 120.44 7.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 39.5 m-85 -97.99 121.89 40.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.948 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.061 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -136.57 109.33 9.42 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.484 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.1 Cg_endo -72.42 -177.53 2.79 Favored 'Trans proline' 0 N--CA 1.448 -1.205 0 C-N-CA 124.328 3.352 . . . . 0.0 109.537 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.834 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -97.47 109.83 22.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.792 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.8 133.59 50.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.561 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.35 114.64 26.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.681 HG11 ' CG2' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.3 155.87 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.993 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.925 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.79 174.61 2.15 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.073 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.7 Cg_endo -72.43 118.12 5.45 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.346 3.364 . . . . 0.0 109.538 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.9 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -117.05 46.79 1.6 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.631 ' HA ' ' O ' ' A' ' 111' ' ' SER . 96.6 p -124.85 105.33 9.17 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.866 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.944 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.5 15.48 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.073 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.06 133.43 41.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.996 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.6 p -99.83 163.26 12.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.506 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.01 140.96 4.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.24 36.43 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 27.9 m -71.38 150.22 45.24 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.606 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.9 p -121.13 118.29 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.754 HG22 ' O ' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -86.8 169.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.997 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.74 153.05 37.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -146.58 113.17 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.792 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.05 115.9 22.62 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.837 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.99 143.89 21.57 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.719 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.08 112.98 6.38 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.87 19.09 23.09 Favored Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.028 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.81 -176.55 4.72 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.938 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.455 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 76.9 mt-30 -70.91 124.83 25.26 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.69 127.59 33.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.32 7.26 88.71 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -88.65 143.67 26.78 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.862 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -91.3 141.93 28.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.98 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 33.5 m-85 -131.53 146.22 52.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.257 ' CB ' ' H ' ' A' ' 98' ' ' SER . 13.8 m-20 -111.97 113.13 25.25 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.379 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -95.8 144.36 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.925 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.17 163.77 36.1 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.981 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 19.3 tt0 -107.41 108.04 19.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -107.83 142.19 38.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.859 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.48 139.18 54.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.558 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.11 124.86 22.73 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.337 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -105.26 -49.67 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.598 ' N ' HG12 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -135.64 167.67 20.68 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -50.28 112.45 0.68 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.0 63.01 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.474 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 93.5 t -122.22 116.46 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.536 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -125.97 135.47 51.88 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.407 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -90.14 159.39 16.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 28.8 m -116.12 151.92 34.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.778 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.5 t30 -112.03 106.12 56.32 Favored Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.3 Cg_endo -72.44 -1.12 9.75 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 124.3 3.333 . . . . 0.0 109.599 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.41 -10.43 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 79.3 m-20 -135.61 27.04 3.38 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.51 121.22 38.1 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.8 t -115.4 -173.37 2.32 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.3 p -145.95 156.99 43.88 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.861 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 6.2 p -167.19 157.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.6 m -128.61 136.59 50.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.24 130.63 38.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.936 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p30 -72.13 -177.84 2.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.31 -16.22 43.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -86.12 7.56 24.35 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.028 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.01 32.64 62.84 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.1 t -131.89 135.38 46.61 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.91 166.64 16.53 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.7 m -151.15 128.0 10.97 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -155.46 169.85 23.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.89 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -118.69 133.28 55.97 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.203 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -115.69 118.99 34.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.936 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.632 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -77.64 137.04 38.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.973 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.731 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.09 125.85 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.42 ' N ' ' HD3' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -109.76 168.48 9.38 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.98 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.506 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -97.04 -15.73 20.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.993 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 47.8 t -167.37 146.45 5.04 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.981 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.7 p90 -176.92 151.8 0.88 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.7 OUTLIER -53.12 116.43 2.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.921 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.407 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.08 102.99 1.74 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.982 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -84.01 100.6 11.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.9 tp -54.24 132.89 44.41 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.987 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.966 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.5 m-85 -46.94 -37.16 8.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.581 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -57.51 -16.93 11.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.8 27.63 9.46 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.29 151.3 34.81 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.506 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.7 ptp180 -85.9 98.5 10.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.337 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -64.52 -58.03 7.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.883 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 174.42 23.29 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.13 110.73 1.94 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.859 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -85.93 154.39 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 11.4 m-20 -122.02 95.14 4.54 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.73 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 35.9 m -53.61 -26.69 22.98 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -80.0 -1.51 40.01 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -114.65 -27.67 7.4 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.53 -173.94 3.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.883 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.55 125.48 48.21 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.854 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 93.1 m -104.2 152.66 21.9 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.028 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -143.94 150.52 38.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.944 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.203 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 2.4 t -112.41 160.29 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.379 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.28 169.96 42.36 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.315 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.88 128.03 44.44 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.257 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 56.8 m -107.23 151.22 25.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.862 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.29 -163.24 0.84 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.985 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.426 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -64.97 -48.85 72.55 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.22 -24.12 63.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.88 53.37 1.79 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.511 ' OD1' ' HE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -130.49 172.62 11.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.98 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -177.85 -179.16 47.85 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.4 157.99 52.2 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.324 3.349 . . . . 0.0 109.573 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.095 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.8 pt-20 -36.02 123.13 0.72 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.72 149.86 0.03 OUTLIER Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.977 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.1 t -117.6 104.97 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.73 135.42 33.76 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.028 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.2 mt -111.79 167.12 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.631 ' O ' ' HA ' ' A' ' 11' ' ' SER . 4.7 t -153.11 128.48 9.89 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.73 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 26.6 m-85 -102.02 125.4 48.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.509 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.0 m120 . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.307 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -122.36 125.13 26.62 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.48 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.38 -177.79 2.93 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.328 3.352 . . . . 0.0 109.592 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.223 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.83 111.93 24.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.12 160.58 30.75 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -120.37 113.46 20.39 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 21' ' ' VAL . 0.5 OUTLIER -105.16 148.27 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.98 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.97 177.81 0.93 Allowed Pre-proline 0 N--CA 1.448 -0.533 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.959 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.114 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.4 115.99 4.54 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.342 3.361 . . . . 0.0 109.61 179.888 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.658 ' CB ' HG23 ' A' ' 110' ' ' ILE . 27.9 p -113.4 40.9 2.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.501 ' HA ' ' O ' ' A' ' 111' ' ' SER . 30.9 p -120.31 106.22 11.67 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.024 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.29 30.4 10.95 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.114 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.33 132.21 47.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -104.69 169.54 8.4 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.926 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -48.54 140.06 8.52 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.01 -22.54 36.5 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 46.2 m -75.14 147.04 40.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.506 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.5 p -120.62 124.96 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.13 HG22 ' O ' ' A' ' 67' ' ' LEU . 2.6 m -90.68 168.06 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.754 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -117.32 152.48 34.82 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.966 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.1 114.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.989 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.77 114.59 18.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.91 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.86 148.5 24.7 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.223 ' O ' HG22 ' A' ' 4' ' ' THR . . . -145.6 112.64 6.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.51 14.74 31.64 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.968 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.94 169.01 11.58 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.784 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 70.8 mt-30 -50.39 120.09 4.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.599 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.71 131.63 41.82 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.997 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.32 8.28 83.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.49 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.82 139.94 30.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.977 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.907 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.22 151.73 25.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.769 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.0 m-85 -137.47 144.61 42.36 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.333 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.0 m-20 -106.0 115.22 29.86 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.465 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.16 143.16 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.955 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.86 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.94 172.5 43.28 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.064 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 9.7 tt0 -116.61 117.41 29.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 94.1 m -109.44 167.84 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.151 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.6 126.11 9.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.595 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -66.35 124.97 24.17 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.669 HG21 ' CD1' ' A' ' 83' ' ' TRP . 12.2 m -105.12 -44.05 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.537 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -143.3 163.56 32.64 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.468 ' O ' HG23 ' A' ' 42' ' ' THR . 2.9 t -51.91 113.48 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.21 8.35 69.81 Favored Glycine 0 C--N 1.336 0.553 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.629 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 17.0 t -126.27 106.11 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.917 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -116.17 162.91 16.75 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.978 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.564 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.37 138.66 53.58 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.8 m -109.33 150.28 28.24 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.638 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 24.5 t30 -108.77 109.06 61.2 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.39 -0.13 8.26 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.296 3.33 . . . . 0.0 109.563 179.899 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.09 -13.44 41.39 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.474 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.4 p30 -127.73 27.06 5.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.6 105.19 14.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.9 t -100.94 173.21 6.59 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.58 153.03 40.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.27 156.44 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.428 ' N ' HG22 ' A' ' 55' ' ' VAL . 58.2 m -126.6 138.35 53.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.99 149.02 37.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.0 p30 -85.37 -173.47 4.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.64 -22.86 66.75 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -77.53 -7.69 56.67 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.968 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.79 31.86 59.81 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.8 p -127.36 139.0 53.15 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.04 166.0 17.77 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 14.8 p -150.48 127.8 11.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.436 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -162.97 156.93 20.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.861 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.436 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -109.35 134.74 51.45 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.943 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.53 119.21 37.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.667 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -74.87 128.33 35.32 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.885 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -102.91 128.14 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.998 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.468 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -114.57 149.94 35.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 ppt_? -78.33 -16.55 57.6 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.55 ' HB3' ' OD1' ' A' ' 87' ' ' ASP . 7.9 p -161.71 148.66 14.27 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.064 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 5.8 p90 -178.09 148.73 0.52 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.11 115.04 1.67 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.564 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.34 94.99 0.94 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.896 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.54 10.57 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.7 tp -54.22 139.29 36.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.51 -41.58 21.26 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.561 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 2.0 t70 -56.33 -17.0 6.45 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.76 27.93 9.96 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.1 m -110.1 141.61 42.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.7 94.2 5.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.669 ' CD1' HG21 ' A' ' 40' ' ' VAL . 7.6 t-105 -62.43 -57.11 12.44 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 168.82 17.39 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.63 108.59 0.75 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.151 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -79.07 153.96 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.55 ' OD1' ' HB3' ' A' ' 72' ' ' SER . 14.8 m-20 -129.97 97.4 4.46 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.541 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 96.6 m -53.0 -28.04 22.04 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 50.5 p -78.12 -0.53 28.54 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -118.88 -28.04 5.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.68 -173.18 3.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.42 125.28 49.09 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.898 ' O ' HG13 ' A' ' 110' ' ' ILE . 56.6 m -103.93 159.81 15.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -155.36 144.79 21.1 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -109.9 157.83 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.298 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.51 168.56 40.24 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.465 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.47 139.73 53.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.333 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 85.8 p -122.57 149.03 44.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.907 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -107.6 -161.6 0.79 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -68.56 -47.98 65.43 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.72 -23.71 66.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.68 52.42 2.13 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.784 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.67 165.79 21.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.95 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.07 177.59 44.7 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.933 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.48 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 161.15 45.13 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.372 3.381 . . . . 0.0 109.568 179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.307 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 4.6 pt-20 -36.63 128.92 0.81 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -46.98 150.38 2.08 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.866 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.4 t -126.03 115.05 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.538 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.15 143.91 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.06 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.1 mt -109.18 168.51 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.3 t -155.0 121.23 5.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.707 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 10.7 m-85 -94.8 129.76 41.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.972 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.647 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -92.04 127.22 50.35 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.482 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.37 -174.7 1.5 Allowed 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.291 3.327 . . . . 0.0 109.595 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.752 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.15 108.55 21.27 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.952 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.2 144.65 49.81 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.524 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -105.81 112.7 25.87 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.999 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.85 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.31 152.84 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.982 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.905 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.34 175.02 2.04 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.92 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.145 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.3 Cg_endo -72.39 118.01 5.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.298 3.332 . . . . 0.0 109.562 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.969 ' HB2' HG23 ' A' ' 110' ' ' ILE . 81.1 p -111.49 46.26 1.13 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.66 ' HA ' ' O ' ' A' ' 111' ' ' SER . 4.3 m -127.98 105.05 8.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.874 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.014 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.39 28.31 11.76 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.145 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -100.37 132.1 45.93 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -106.79 170.81 7.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -46.4 142.45 3.02 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.75 -23.41 33.96 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 52.0 m -77.86 151.8 33.7 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.6 p -128.26 116.26 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 67' ' ' LEU . 3.1 p -78.7 152.14 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.85 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.03 143.48 36.68 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.997 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.529 ' CG1' HG21 ' A' ' 108' ' ' VAL . 0.1 OUTLIER -140.76 106.99 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.966 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.7 117.12 28.93 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.672 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.79 139.77 20.32 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.43 108.33 7.12 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.927 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.45 25.95 8.45 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.237 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.7 -171.9 3.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.566 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 63.1 mt-30 -82.54 124.91 30.55 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.38 139.7 49.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.92 8.29 68.34 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.703 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.62 146.22 23.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.987 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.92 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.54 149.05 23.15 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.207 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 56.4 m-85 -136.95 145.06 43.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.867 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.145 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -110.54 113.76 26.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.995 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.301 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.07 140.07 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.956 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -162.37 164.44 35.58 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.699 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.5 tt0 -114.58 108.16 16.46 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.792 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.0 OUTLIER -110.83 146.32 36.65 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.987 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.754 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -122.81 138.28 54.69 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.605 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.52 123.2 19.04 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.959 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.741 HG21 ' CD1' ' A' ' 83' ' ' TRP . 0.0 OUTLIER -103.05 -44.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.395 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 1.1 m-20 -133.44 -179.28 5.42 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 m -69.03 111.12 4.82 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.66 85.97 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.035 HG21 ' HE1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -130.78 125.52 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.954 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.2 pt? -134.09 141.48 47.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.07 147.22 24.25 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.823 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 35.9 m -107.11 150.3 26.71 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.652 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.3 t30 -111.46 109.02 56.36 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -72.45 -0.65 9.06 Favored 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.315 3.343 . . . . 0.0 109.608 179.909 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.75 -11.87 43.79 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.576 ' CB ' HG23 ' A' ' 68' ' ' THR . 56.1 m-20 -132.71 28.64 4.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.666 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.92 119.3 38.01 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.994 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 t -113.4 -179.17 3.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.96 158.13 43.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' N ' ' A' ' 56' ' ' THR . 3.4 p -166.45 161.91 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.528 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.8 m -127.98 126.21 40.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.31 146.32 40.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.927 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 47.3 p30 -87.43 -173.44 4.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.52 -25.43 67.28 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -82.21 4.37 23.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 66.3 6.12 31.84 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.5 t -96.9 134.25 40.48 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.0 164.96 15.94 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -148.48 127.9 13.1 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.688 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -160.02 155.27 25.07 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.88 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.401 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.56 125.4 52.93 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.938 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.095 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -105.35 123.33 47.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.975 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.585 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -78.06 136.08 37.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.939 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.434 ' O ' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -112.6 124.99 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.979 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.435 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.97 173.46 6.32 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 27.5 ptt180 -99.41 -9.67 23.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 97.2 p -168.05 145.69 4.29 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.699 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 1.9 p90 -176.6 156.16 1.44 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -55.46 114.5 1.86 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 100.68 1.8 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.889 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -84.68 101.5 12.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -53.64 136.07 39.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.667 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.59 -39.95 12.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.702 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -56.31 -17.67 8.42 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.913 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.13 27.7 9.18 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.7 m -111.77 142.42 44.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -79.93 94.33 5.85 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.395 ' CZ2' ' OD2' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.51 -58.34 7.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.886 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 173.14 20.41 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 104.38 0.52 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 38' ' ' ALA . 9.9 p -79.44 150.92 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -107.21 98.09 7.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -53.24 -23.84 9.77 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.2 p -85.44 1.41 48.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -112.7 -26.93 8.37 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.03 179.69 6.1 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.0 128.44 41.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.885 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 36.7 m -104.41 153.29 21.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.081 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -147.25 147.05 30.03 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.981 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.095 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.9 t -110.92 160.04 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.27 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.24 166.37 37.39 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.301 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.01 123.82 35.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.978 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.145 ' N ' ' H ' ' A' ' 33' ' ' ASP . 14.2 m -107.65 144.18 35.08 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.92 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.6 OUTLIER -102.56 -160.75 0.8 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.979 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.63 -47.78 65.76 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.98 -24.42 66.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.72 53.78 1.76 Allowed Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.566 ' ND2' ' OE1' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -134.57 169.81 16.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.989 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.207 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.41 179.16 45.92 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.482 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.32 164.19 36.37 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.318 3.345 . . . . 0.0 109.601 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.647 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.61 126.92 1.14 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.976 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -42.93 154.69 0.17 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.89 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.9 t -120.84 103.79 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.64 126.54 35.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.081 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.6 mt -103.24 159.07 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.735 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -146.95 123.22 10.91 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.522 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 39.7 m-85 -95.36 125.57 40.07 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 13.9 m120 . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.98 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.26 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -65.92 120.85 72.52 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.647 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.3 Cg_endo -72.34 -178.13 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.288 3.325 . . . . 0.0 109.6 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.905 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.97 108.95 21.76 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 1.278 ' N ' ' OE2' ' A' ' 106' ' ' GLU . . . -124.29 146.78 48.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.587 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.85 114.62 28.89 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.98 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.786 HG13 ' O ' ' A' ' 20' ' ' LYS . 41.4 t -109.82 147.74 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.946 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.43 176.01 1.38 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.913 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.061 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.39 117.36 5.1 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.323 3.349 . . . . 0.0 109.615 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.917 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 14.5 p -113.38 48.52 1.04 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.981 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 111' ' ' SER . 5.9 m -128.99 105.83 8.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.872 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.49 28.04 12.12 Favored Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.069 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -105.01 129.25 53.5 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -104.45 170.39 7.92 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.564 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 7.4 p-10 -44.59 141.29 2.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.65 -22.87 32.84 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -79.39 149.6 31.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.538 ' O ' HG13 ' A' ' 18' ' ' VAL . 13.8 p -122.34 121.72 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.063 HG23 HG12 ' A' ' 69' ' ' VAL . 12.2 t -85.44 153.15 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.786 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.89 143.2 34.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.952 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.657 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -140.58 111.5 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.703 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.2 117.71 25.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.008 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.59 145.5 22.89 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.793 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -144.36 113.38 6.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 95.63 17.97 34.24 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.971 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.008 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.87 170.78 9.8 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.615 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 69.4 mt-30 -51.78 119.58 4.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.519 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.33 130.28 39.83 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.64 7.34 87.23 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.482 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.83 137.27 34.13 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.703 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -81.47 152.41 27.36 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.741 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 36.8 m-85 -138.08 141.08 40.27 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.913 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.18 ' CB ' ' H ' ' A' ' 98' ' ' SER . 7.8 m-20 -106.01 113.45 26.99 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.268 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.0 147.46 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.919 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.1 168.16 41.1 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.878 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.9 tt0 -112.13 113.2 25.33 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 25.9 m -114.2 141.99 46.82 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.706 ' O ' HD12 ' A' ' 45' ' ' LEU . . . -121.96 129.08 52.21 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.56 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.19 128.58 36.43 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.906 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.286 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.7 m -109.78 -43.91 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.664 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -141.08 160.12 40.76 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.5 m -55.55 113.49 1.46 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.94 8.06 87.98 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.149 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.8 t -130.34 108.99 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.973 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.822 HD11 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -118.22 144.23 45.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.366 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -105.64 143.63 33.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 15.5 m -110.24 152.71 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.685 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 42.6 t30 -111.86 108.02 55.94 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.73 9.12 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.355 3.37 . . . . 0.0 109.573 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.448 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -92.48 -11.23 35.2 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.852 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -129.82 19.62 5.56 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.77 107.76 16.39 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.0 t -101.46 173.36 6.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.9 p -146.06 149.39 33.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.89 159.72 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 55' ' ' VAL . 63.6 m -127.74 136.68 51.86 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.38 142.44 46.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 40.6 p30 -80.86 -172.45 3.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -22.02 66.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -80.87 4.05 20.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 60.44 31.29 73.83 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 t -128.13 133.76 49.02 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.68 164.65 18.68 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.27 129.96 17.05 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -156.57 164.61 37.99 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.861 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -125.25 118.23 25.56 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.973 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.552 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.68 156.2 16.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.501 ' N ' HD23 ' A' ' 67' ' ' LEU . 0.3 OUTLIER -112.36 132.73 54.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 1.063 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.34 128.06 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.99 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.471 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 0.4 OUTLIER -111.07 164.04 13.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.999 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 ptt180 -91.88 -9.47 43.13 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 12.8 t -174.8 144.37 0.81 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.902 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.878 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 13.3 p90 -175.83 157.63 1.99 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 117.06 3.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.366 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.32 100.56 1.92 Allowed Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.985 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.26 100.28 10.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.7 tp -54.42 136.7 43.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.859 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.1 m-85 -46.25 -39.93 10.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.568 ' HB2' HD21 ' A' ' 77' ' ' LEU . 7.6 t0 -56.84 -17.36 9.07 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.38 28.2 9.3 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.31 140.08 47.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.6 ptt-85 -79.72 94.53 5.76 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.286 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.25 -55.78 24.99 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.59 172.86 19.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.35 107.09 1.01 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -83.7 152.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.962 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -109.5 99.6 8.79 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.58 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.2 m -53.27 -25.06 13.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 30.4 p -84.04 1.25 44.79 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -118.32 -27.98 5.88 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.911 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.55 177.4 6.24 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.07 125.3 41.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.262 ' O ' HG13 ' A' ' 110' ' ' ILE . 38.7 m -104.53 153.05 21.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.013 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.4 OUTLIER -151.17 146.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.929 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.552 HG13 ' CD1' ' A' ' 67' ' ' LEU . 21.5 t -105.84 153.48 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.943 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.232 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -170.2 165.97 39.22 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.268 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.32 131.76 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.18 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 7.6 t -112.29 150.91 30.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.703 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -112.6 -164.25 0.9 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.948 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.41 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.92 -48.51 68.44 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.8 -23.76 66.1 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.7 53.2 1.99 Allowed Glycine 0 C--N 1.336 0.55 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.615 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.94 171.89 13.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.977 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.741 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.27 176.43 46.64 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.647 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.1 Cg_endo -72.38 165.17 33.43 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.349 3.366 . . . . 0.0 109.622 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.278 ' OE2' ' N ' ' A' ' 5' ' ' ALA . 0.2 OUTLIER -38.08 136.51 0.6 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.988 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.98 149.0 6.06 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.918 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 11.9 t -123.84 105.93 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.485 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.57 147.96 23.0 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.262 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.09 159.76 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.714 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -142.28 111.98 6.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.953 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 66.2 m-85 -87.15 110.71 20.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.478 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -107.27 120.61 47.18 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.545 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.34 -178.29 3.22 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 124.357 3.371 . . . . 0.0 109.616 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.111 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -97.46 110.26 22.85 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.963 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.843 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.5 156.53 40.6 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -114.96 117.15 29.83 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.111 HG22 ' CG1' ' A' ' 21' ' ' VAL . 58.5 t -114.5 144.21 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.697 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.2 165.82 40.02 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.921 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.697 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.34 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 124.318 3.345 . . . . 0.0 109.617 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.77 ' OG ' HG11 ' A' ' 69' ' ' VAL . 47.7 t -127.84 17.57 6.79 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.025 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.1 p -92.2 111.78 23.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.067 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.43 25.6 27.79 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.067 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -108.52 139.48 43.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.989 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.6 m -67.47 144.69 55.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.476 ' HB3' ' H ' ' A' ' 71' ' ' ARG . 17.9 p-10 -48.1 147.49 2.14 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -18.97 45.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.6 m -60.99 130.53 46.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.3 p -92.87 115.05 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.6 m -100.58 159.33 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.943 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.6 146.1 39.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.111 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -138.5 114.52 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.843 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.8 116.31 23.47 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.944 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.997 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.21 145.96 22.57 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.111 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -142.23 115.83 9.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.73 16.02 29.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.997 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -89.92 168.6 11.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.522 ' HB2' HG21 ' A' ' 30' ' ' THR . 82.5 mt-30 -52.03 119.24 4.11 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.477 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.37 132.06 44.29 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.89 7.78 84.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.522 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -98.01 141.89 30.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.46 150.86 24.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.891 ' HD1' ' OD1' ' A' ' 103' ' ' ASN . 40.3 m-85 -138.29 141.73 39.82 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.17 ' OD2' ' HB2' ' A' ' 98' ' ' SER . 0.9 OUTLIER -105.85 115.54 30.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.567 HG22 ' CG ' ' A' ' 97' ' ' LEU . 1.8 t -96.64 136.46 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.874 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.66 153.51 24.53 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.994 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.4 tt0 -94.46 119.68 33.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.844 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.724 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.3 m -107.04 159.26 16.43 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.715 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -147.16 130.08 16.25 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.543 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -69.96 125.92 28.16 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.174 ' CG1' HG12 ' A' ' 86' ' ' VAL . 4.0 m -113.74 -39.56 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.61 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -146.65 -179.59 6.88 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.95 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.8 m -64.69 111.58 2.82 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.955 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.56 8.52 63.26 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.596 HG21 ' CH2' ' A' ' 83' ' ' TRP . 40.1 t -110.02 104.0 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.799 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 mt -106.86 155.94 19.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.526 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -134.27 126.7 30.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.144 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -107.84 158.83 16.99 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.561 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.5 t30 -118.83 113.96 35.78 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -72.43 -1.45 10.23 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.317 3.345 . . . . 0.0 109.577 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.561 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -11.48 40.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -131.63 26.58 4.71 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.667 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.34 122.07 41.97 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.983 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -104.65 -175.32 2.76 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.0 p -146.72 154.37 41.34 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.89 156.18 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.424 ' N ' HG22 ' A' ' 55' ' ' VAL . 41.7 m -125.97 121.68 33.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.76 150.18 20.45 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 p30 -97.02 -168.02 1.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.13 -25.37 68.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.983 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -83.37 3.75 30.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.894 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 62.25 31.23 78.4 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.3 t -126.22 142.85 51.36 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -133.98 159.81 39.61 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.21 124.96 22.42 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.782 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -144.62 178.43 7.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.866 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.782 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -129.46 122.32 29.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.949 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.018 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -108.09 149.19 28.79 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.925 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.832 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -111.37 143.0 42.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.77 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -109.55 125.93 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.967 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.524 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -115.08 153.08 31.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.986 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.476 ' H ' ' HB3' ' A' ' 15' ' ' ASP . 10.0 ttp180 -74.03 -37.79 64.22 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 t -151.06 153.25 34.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.994 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 5.4 p90 -177.09 159.44 1.65 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.931 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.98 114.43 1.59 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.526 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.71 93.77 0.57 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 1.144 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.34 99.94 10.34 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.904 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.4 tp -58.76 131.79 51.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.724 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 8.4 m-85 -47.06 -36.46 8.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.592 ' HB2' HD21 ' A' ' 77' ' ' LEU . 3.4 t0 -56.99 -17.51 10.08 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.15 27.29 8.87 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.904 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.0 143.05 45.37 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.77 94.71 9.83 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.61 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 34.8 t-105 -63.41 -58.46 6.99 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.893 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 171.11 18.48 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.6 109.0 0.71 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.174 HG12 ' CG1' ' A' ' 40' ' ' VAL . 18.1 m -89.93 150.83 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -108.88 89.14 2.9 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.11 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 2.0 m -52.92 -24.48 9.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -79.27 -1.75 38.06 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.18 -28.36 6.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -118.64 -165.63 1.14 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 124.62 40.9 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.273 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -104.27 152.36 22.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.044 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 0.7 OUTLIER -168.12 147.67 4.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.944 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.009 HG21 HD12 ' A' ' 67' ' ' LEU . 4.9 t -99.4 164.92 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.95 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -171.67 160.01 31.73 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.567 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -100.2 163.57 12.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.17 ' HB2' ' OD2' ' A' ' 33' ' ' ASP . 14.8 m -155.83 121.68 5.01 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.588 ' HB3' ' HA ' ' A' ' 32' ' ' TYR . 4.8 p-10 -113.88 -168.93 1.42 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -47.64 -26.76 1.61 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.7 -25.94 14.52 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.912 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 92.01 21.15 33.98 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.891 ' OD1' ' HD1' ' A' ' 32' ' ' TYR . 19.8 p-10 -59.64 -149.42 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.493 ' O ' ' HD2' ' A' ' 3' ' ' PRO . . . 141.4 151.82 5.62 Favored Glycine 0 C--N 1.336 0.556 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.545 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.6 Cg_endo -72.37 161.69 43.63 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.302 3.335 . . . . 0.0 109.609 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.478 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.3 mt-10 -32.06 120.26 0.28 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -32.94 149.8 0.01 OUTLIER Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.044 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 2.6 t -108.26 103.33 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.52 126.72 31.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.273 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 7.0 pt -141.81 177.82 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 111' ' ' SER . . . . . 1.025 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -171.65 177.82 3.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.11 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -130.3 115.21 16.62 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.969 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 1.6 p-10 . . . . . 0 N--CA 1.45 -0.469 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.908 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.139 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -147.34 119.81 4.75 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.625 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.5 Cg_endo -72.46 -178.59 3.44 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.301 3.334 . . . . 0.0 109.57 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.223 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.0 21.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.82 ' H ' ' CD ' ' A' ' 106' ' ' GLU . . . -122.53 151.05 41.75 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.952 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.648 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.7 p -116.49 116.27 27.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -106.82 148.92 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 8' ' ' THR . . . . . 1.031 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -65.69 179.39 0.45 Allowed Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.917 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.128 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.36 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.315 3.343 . . . . 0.0 109.648 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.543 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 3.8 p -112.42 35.87 3.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -119.8 106.75 12.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.836 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.026 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.58 30.89 8.66 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.128 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.42 131.52 47.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.97 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -99.75 163.84 12.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -46.95 140.07 5.08 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.35 -22.22 36.91 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 37.0 m -72.05 149.53 44.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.619 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.6 p -126.7 117.12 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.0 m -84.33 165.27 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.779 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.6 135.18 54.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.595 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.8 p -124.3 120.46 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.648 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -126.29 117.5 23.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.864 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -93.49 140.14 14.92 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.724 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.5 116.38 10.92 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.99 20.53 18.26 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.023 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.52 -177.28 5.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.98 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 25.9 mt-30 -69.29 122.23 18.46 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.43 130.04 39.75 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.1 8.09 86.85 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.512 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.48 137.13 34.96 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.975 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 1.017 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.56 150.62 25.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.124 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.9 m-85 -136.81 146.84 46.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.891 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.174 ' H ' ' N ' ' A' ' 98' ' ' SER . 4.4 m-20 -111.96 113.85 26.41 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.478 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.98 143.23 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.88 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.33 165.34 38.73 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.782 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.28 113.07 25.29 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 62.6 m -111.13 145.76 38.03 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.538 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -123.23 128.29 49.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.75 120.63 13.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.951 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.497 HG11 ' CD1' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -99.35 -44.14 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.53 ' OD1' ' C ' ' A' ' 40' ' ' VAL . 0.2 OUTLIER -136.83 175.5 9.56 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.948 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.567 ' O ' HG23 ' A' ' 42' ' ' THR . 6.1 t -60.8 112.67 2.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.03 8.14 72.96 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.47 ' O ' HG23 ' A' ' 40' ' ' VAL . 3.2 t -124.17 110.89 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.531 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.01 138.69 53.75 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.971 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.373 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.09 156.04 17.12 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 37.1 m -117.12 150.63 38.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.693 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -114.11 107.11 52.39 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.31 -0.84 9.25 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.327 3.351 . . . . 0.0 109.627 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.639 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -12.11 41.38 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 68' ' ' THR . 92.9 m-20 -131.46 26.14 4.78 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -97.23 120.03 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 32.2 t -113.84 -177.38 3.12 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.0 p -147.08 156.61 43.14 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.474 HG22 ' HB1' ' A' ' 63' ' ' ALA . 5.9 p -166.94 157.59 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 48.3 m -125.35 134.08 52.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.838 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -72.57 140.73 48.26 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -83.82 -170.88 3.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.75 -26.14 68.55 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.2 -4.91 44.37 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.023 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.93 31.61 69.83 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.964 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.3 p -124.11 133.77 53.52 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.838 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -147.46 122.38 10.02 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -123.0 144.28 49.37 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.757 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -141.0 178.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.757 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -108.32 116.56 32.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.053 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -108.46 123.6 49.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.95 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.697 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -91.4 137.48 32.33 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -112.31 126.54 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.471 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -114.36 173.38 6.48 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.962 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 10.6 ptt85 -100.99 -7.97 22.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.548 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.4 p -169.73 147.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.782 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.6 p90 -177.65 160.58 1.58 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.13 115.58 2.52 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.373 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.32 94.03 1.24 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.741 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.2 m-85 -83.85 99.58 10.42 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.927 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -53.73 134.66 41.96 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.684 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.6 p90 -46.26 -38.84 9.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.556 ' CB ' HD21 ' A' ' 77' ' ' LEU . 4.4 t70 -56.77 -17.26 8.47 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.29 27.99 8.88 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.927 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.59 139.73 47.93 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -82.12 93.28 7.0 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.497 ' CD1' HG11 ' A' ' 40' ' ' VAL . 6.8 t-105 -63.38 -57.57 9.9 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.77 169.91 17.86 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -60.92 104.68 0.38 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 73' ' ' PHE . 6.2 p -81.61 149.27 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -105.93 98.33 8.03 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.517 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.6 m -51.76 -25.41 7.46 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 21.1 p -80.55 2.55 25.01 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.961 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 21.8 m -112.93 -27.2 8.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.59 -178.49 5.09 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.64 127.21 42.41 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.316 ' O ' HG13 ' A' ' 110' ' ' ILE . 82.4 m -103.17 153.0 20.79 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.086 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -147.34 146.18 29.59 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.053 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.3 t -100.6 163.15 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.331 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.13 158.61 24.36 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.478 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.66 127.56 37.22 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.996 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.174 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.0 m -117.03 158.27 24.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 1.017 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 1.0 OUTLIER -110.79 -157.36 0.61 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.986 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.91 -48.15 77.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.549 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -72.56 -25.93 61.54 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.78 47.3 2.31 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.62 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 2.1 p30 -116.34 154.7 29.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.124 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -165.09 171.98 40.61 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.983 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.625 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.36 171.88 16.09 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.294 3.329 . . . . 0.0 109.647 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.223 ' OE1' ' HA ' ' A' ' 4' ' ' THR . 6.5 pt-20 -36.49 153.44 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.72 153.97 52.96 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.991 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.959 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.5 t -128.07 109.92 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.992 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.716 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.7 151.33 19.72 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.923 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.316 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -120.63 164.87 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 t -154.82 120.39 5.09 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.512 ' HE2' HG23 ' A' ' 69' ' ' VAL . 46.4 m-85 -97.01 127.06 42.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.947 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.045 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -86.87 124.54 68.84 Favored Pre-proline 0 N--CA 1.45 -0.474 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.383 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.38 -174.19 1.35 Allowed 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.316 3.344 . . . . 0.0 109.545 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.795 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.5 m -93.95 108.51 20.31 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.761 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.65 143.59 51.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.733 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -98.29 111.98 24.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.036 HG21 ' CG2' ' A' ' 108' ' ' VAL . 24.2 t -109.51 143.98 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.934 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.0 175.19 1.86 Allowed Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.921 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.005 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.1 Cg_endo -72.33 118.41 5.59 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.34 3.36 . . . . 0.0 109.598 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.715 ' HB2' HG23 ' A' ' 110' ' ' ILE . 25.0 p -116.77 46.04 1.72 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.3 p -124.8 106.04 9.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.9 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.061 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.72 28.08 13.16 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.061 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -103.99 129.75 51.61 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.967 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -103.8 170.99 7.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.762 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -45.91 142.32 2.67 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.984 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.13 -22.97 34.88 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.479 HG21 ' HB3' ' A' ' 13' ' ' LEU . 29.5 m -77.36 148.2 35.7 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.539 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -124.19 123.08 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.569 ' HA ' HG21 ' A' ' 8' ' ' THR . 20.9 m -91.05 166.88 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.805 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.4 138.49 54.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.994 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.857 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -132.73 117.81 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.761 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.86 116.22 21.21 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.727 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.0 144.41 23.83 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.795 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.79 106.26 4.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.89 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.19 22.09 8.98 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.64 -165.0 1.22 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -80.43 124.19 28.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.499 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 129.74 38.64 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.57 7.94 85.79 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.509 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.74 143.89 25.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.876 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -91.44 150.11 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.0 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.5 m-85 -138.29 146.41 42.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.221 ' CA ' ' H ' ' A' ' 98' ' ' SER . 12.2 m-20 -112.48 113.86 26.25 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.484 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.27 152.58 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.802 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . 179.95 173.63 45.11 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.324 -1.111 . . . . 0.0 110.324 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.058 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 8.3 tt0 -106.23 119.68 39.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.432 ' HB3' HD13 ' A' ' 45' ' ' LEU . 11.0 m -109.14 162.58 14.13 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.301 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -148.73 136.26 20.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.892 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.03 123.69 19.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.89 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.017 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -102.2 -41.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.638 ' HB2' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -150.45 179.21 8.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.944 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -65.85 109.36 2.46 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.29 10.34 86.1 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.59 HG21 ' CE2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -130.87 131.7 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.8 pp -133.71 162.35 32.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.559 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.02 144.96 51.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.44 158.86 17.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.862 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -120.18 118.58 31.3 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.458 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.7 Cg_endo -72.37 1.64 5.92 Favored 'Trans proline' 0 N--CA 1.446 -1.278 0 C-N-CA 124.326 3.351 . . . . 0.0 109.606 179.884 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.29 -20.65 31.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.868 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' CB ' HG23 ' A' ' 68' ' ' THR . 91.7 m-20 -129.78 30.56 4.86 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.66 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -94.88 117.96 30.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.993 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.5 t -114.01 176.99 4.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.4 p -147.13 155.56 42.26 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.536 HG22 ' N ' ' A' ' 56' ' ' THR . 3.2 p -167.1 162.36 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.536 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.8 m -127.9 128.69 45.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.94 152.05 28.67 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.41 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.1 p30 -94.13 -170.75 2.37 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.52 69.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -76.02 -7.57 54.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.91 8.69 87.28 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.0 p -99.06 139.79 34.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.66 156.01 32.62 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -136.76 121.92 19.12 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.592 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.57 153.57 25.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 m -114.48 130.61 56.74 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.905 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.394 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -107.72 154.25 21.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.792 ' H ' HD13 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -113.76 140.5 48.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.96 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.435 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -110.25 129.78 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.99 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.762 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -114.18 164.88 13.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -88.06 -25.01 23.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -162.11 147.58 13.0 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.932 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.058 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.2 p90 -176.57 156.01 1.44 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -55.86 121.18 8.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.559 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -82.46 96.86 1.88 Allowed Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.99 99.96 10.74 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.46 129.3 41.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.995 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.606 ' N ' HD12 ' A' ' 77' ' ' LEU . 17.9 p90 -47.67 -34.51 8.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.617 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.68 -16.36 10.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.14 8.49 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -118.16 150.62 39.08 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.4 mtp180 -93.85 97.53 10.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.59 ' CE2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.9 -55.6 21.44 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.947 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.81 176.47 22.19 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.9 113.42 4.37 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.986 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.301 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.6 t -89.15 152.96 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -117.65 93.13 4.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.164 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 57.6 m -52.92 -26.59 15.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 36.7 p -78.33 -0.23 28.1 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -117.63 -28.04 6.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.47 -173.56 2.94 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.13 124.21 47.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.86 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.812 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 65.9 m -105.25 152.52 22.78 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.103 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -144.21 145.5 32.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.394 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -107.82 156.04 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.303 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.46 174.34 46.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.484 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -128.08 142.61 51.16 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.221 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 97.3 p -118.77 152.63 35.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.876 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -114.06 -165.6 1.02 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.974 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -54.32 -49.34 69.92 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.539 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -75.13 -25.24 58.26 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 98.71 45.29 2.31 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.708 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 3.3 p30 -116.63 167.64 10.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.0 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.03 -171.3 39.71 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.383 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.34 152.51 55.37 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.322 3.348 . . . . 0.0 109.599 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.126 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -35.26 121.13 0.56 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.55 143.91 0.09 OUTLIER Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.971 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.083 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -114.3 105.49 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.05 130.48 34.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.103 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.8 mt -103.79 164.08 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.907 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.99 121.52 10.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.164 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 18.0 m-85 -90.56 113.15 25.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.496 ' CB ' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.639 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -142.92 139.41 16.88 Favored Pre-proline 0 N--CA 1.448 -0.53 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.415 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.0 Cg_endo -72.42 -174.7 1.51 Allowed 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 124.319 3.346 . . . . 0.0 109.623 179.927 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.771 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.8 108.97 21.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.22 140.1 52.81 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.939 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.599 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -98.7 114.11 26.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.916 HG21 ' CG2' ' A' ' 108' ' ' VAL . 38.2 t -111.25 149.17 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.94 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.19 175.7 1.43 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.909 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.074 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.9 Cg_endo -72.35 119.2 5.99 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.312 3.341 . . . . 0.0 109.635 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.046 ' CB ' HG23 ' A' ' 110' ' ' ILE . 51.7 p -113.17 47.9 1.08 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.2 p -125.21 106.85 10.19 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.87 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.991 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.63 26.15 23.51 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.947 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.074 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.95 131.58 46.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 t -118.04 177.06 4.93 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.645 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 5.2 p-10 -45.41 139.26 3.76 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.66 34.73 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 62.9 m -85.98 150.58 24.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.508 ' O ' HG13 ' A' ' 18' ' ' VAL . 12.9 p -126.26 123.79 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.084 HG22 ' O ' ' A' ' 67' ' ' LEU . 18.5 m -87.19 162.31 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.905 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.95 143.87 44.47 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.736 HG23 HG22 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -138.84 112.06 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.981 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.709 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.9 115.66 22.33 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.31 140.78 20.12 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.771 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -138.72 106.68 5.69 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.888 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.03 26.16 8.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.22 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.12 -169.27 2.5 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.516 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.4 mt-30 -80.14 123.47 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.39 130.12 40.53 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.68 8.74 84.6 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.523 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.8 134.4 38.8 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.809 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.84 151.76 23.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.515 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 40.9 m-85 -137.26 148.65 46.58 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.209 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -112.11 116.27 30.23 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.923 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.368 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.78 140.47 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.948 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.856 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -163.3 157.82 30.05 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.791 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.6 tt0 -106.53 116.38 31.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.502 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.6 m -102.96 165.21 11.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.58 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -151.91 142.94 23.15 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.948 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 0.5 OUTLIER -64.98 122.13 16.28 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.843 HG11 ' CD2' ' A' ' 83' ' ' TRP . 1.1 t -101.68 -55.23 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.939 ' OD2' ' CH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -131.86 168.62 17.53 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -50.07 110.88 0.44 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.87 8.31 63.8 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.503 HG11 ' CE2' ' A' ' 83' ' ' TRP . 62.1 t -119.62 125.14 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.6 pp -125.85 162.05 26.03 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -130.96 161.49 31.81 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.898 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.888 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -115.65 156.07 26.53 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.752 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 23.0 t30 -116.71 110.79 41.87 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -72.43 -0.89 9.4 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.356 3.371 . . . . 0.0 109.546 179.956 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.601 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.97 -11.58 43.93 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.811 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.5 m-20 -133.39 28.87 4.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.884 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.643 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -101.9 118.17 36.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 40.9 t -107.86 -176.39 3.05 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 96.9 p -146.25 152.65 39.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.892 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.59 155.57 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 55' ' ' VAL . 74.0 m -126.41 126.94 44.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.924 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -56.43 146.68 23.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.3 p30 -88.16 -170.25 2.89 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.91 -25.85 67.82 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -84.58 5.23 28.63 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 65.27 8.78 38.99 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -98.35 134.42 41.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.986 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.39 166.23 14.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.5 p -150.03 124.5 9.64 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.701 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -159.36 151.87 21.39 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.901 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.16 132.79 54.01 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.127 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -109.8 119.17 38.52 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.895 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.811 HG23 ' HB3' ' A' ' 51' ' ' ASP . 1.8 t -70.04 143.55 52.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.544 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.3 t -104.23 131.51 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.791 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -119.84 153.07 36.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.97 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 ptt85 -85.66 -22.77 27.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 t -166.79 152.96 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.936 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.752 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.5 p90 -175.4 167.24 3.33 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.921 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.38 125.02 22.46 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.915 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.52 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.79 90.92 1.07 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.888 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.55 10.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.999 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.948 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.47 141.64 30.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.693 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.05 -42.13 18.05 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.628 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -57.52 -17.1 12.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.978 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 29.1 9.65 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.948 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.17 122.08 46.79 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.38 92.27 0.08 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.503 ' CE2' HG11 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.56 -58.34 7.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.93 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.03 170.28 21.15 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.63 139.36 53.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 73' ' ' PHE . 2.7 p -126.34 140.55 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -93.48 94.97 8.97 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.98 -21.07 10.62 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.5 p -89.27 1.98 54.96 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 m -114.09 -27.38 7.7 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -123.26 -177.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.61 128.45 37.44 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.937 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.078 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 1.5 m -105.0 152.62 22.49 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.2 pt20 -152.89 147.32 25.85 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.127 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.6 t -114.17 158.16 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.957 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.265 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.43 163.71 33.06 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.368 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.07 124.16 36.36 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.988 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.209 ' N ' ' H ' ' A' ' 33' ' ' ASP . 11.5 m -113.52 156.68 23.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.809 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.19 -161.17 0.74 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.31 -48.62 69.74 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -66.68 -26.07 66.85 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.889 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.12 42.53 3.24 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.7 p30 -116.68 157.98 24.54 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -180.0 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.515 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.4 177.53 45.74 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.415 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.0 Cg_endo -72.41 154.86 55.88 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.317 3.345 . . . . 0.0 109.581 179.96 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.639 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -36.96 119.34 0.65 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.941 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.13 155.92 0.01 OUTLIER Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.916 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.1 t -119.23 107.59 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 118.19 25.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.046 HG23 ' CB ' ' A' ' 10' ' ' SER . 8.5 mt -98.25 159.12 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.75 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -144.1 123.48 13.09 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.078 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 5.4 m-85 -92.02 127.26 37.42 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.426 ' H ' ' H ' ' A' ' 12' ' ' GLY . 3.7 p-10 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.322 ' HB1' ' CB ' ' A' ' 106' ' ' GLU . . . -101.11 114.1 65.8 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.567 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.39 -178.25 3.21 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.297 3.331 . . . . 0.0 109.584 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.111 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -100.23 111.87 24.16 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.936 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.754 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.5 160.53 29.29 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.8 p -124.75 119.08 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.815 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -116.73 154.84 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.936 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.22 174.9 1.74 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.954 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.4 Cg_endo -72.4 118.58 5.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.305 3.337 . . . . 0.0 109.593 179.889 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.289 ' OG ' HG23 ' A' ' 110' ' ' ILE . 11.9 p -116.02 48.76 1.19 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.646 ' HA ' ' O ' ' A' ' 111' ' ' SER . 18.8 p -126.43 104.71 8.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.91 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.79 29.05 16.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -94.85 133.41 38.6 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.986 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.4 t -96.61 158.32 15.49 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.997 ' OD1' ' HG3' ' A' ' 70' ' ' ARG . 25.5 t70 -45.1 142.51 1.9 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.426 ' H ' ' NH1' ' A' ' 70' ' ' ARG . . . 103.26 -23.13 34.21 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 91.7 m -71.59 150.94 44.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -125.27 122.78 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.264 HG22 ' O ' ' A' ' 67' ' ' LEU . 32.7 m -91.07 167.3 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.815 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -116.56 152.92 33.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.63 115.52 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -127.77 114.36 17.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.983 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.48 144.7 21.6 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.111 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.48 114.58 9.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.69 19.04 25.98 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.016 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.28 175.67 7.03 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -180.0 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.958 ' OE1' ' OD1' ' A' ' 103' ' ' ASN . 71.9 mt-30 -59.6 121.93 12.81 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.13 130.81 40.5 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.68 7.83 85.99 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.461 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.67 141.21 28.74 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.972 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 1.205 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.88 151.24 23.5 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.867 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.0 m-85 -135.77 146.81 48.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.433 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -109.79 114.89 28.84 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.951 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.516 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.9 140.24 22.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.782 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.78 168.98 39.91 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.219 -1.152 . . . . 0.0 110.219 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.11 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 13.3 tt0 -114.31 128.74 56.5 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 28.3 m -130.19 143.1 50.59 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.88 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -121.78 130.62 53.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.894 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.491 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.48 129.05 38.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.947 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.953 HG23 HG12 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -111.12 -41.84 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.92 163.26 35.68 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 95.1 m -54.74 120.08 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.25 6.81 62.05 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.975 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 1.5 t -125.91 115.45 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.978 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.814 HD23 ' HE2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -125.08 143.62 50.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.97 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.272 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.39 142.93 34.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.0 m -112.14 163.71 14.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.2 t30 -126.82 110.73 22.3 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.43 0.58 7.25 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.299 3.332 . . . . 0.0 109.571 179.927 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.507 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.12 -12.67 43.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.7 p30 -129.24 28.85 5.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 0.1 OUTLIER -86.39 105.62 16.85 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.2 t -104.31 173.26 6.38 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.0 p -145.52 155.56 43.16 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 7.0 p -167.26 157.35 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 179.963 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.8 m -128.1 137.0 51.95 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.16 137.29 41.23 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -76.82 -174.71 3.16 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.69 -19.11 61.99 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -84.6 7.51 19.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.987 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.016 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 32.06 61.77 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 t -129.31 133.52 47.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.25 164.37 19.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.67 126.35 11.02 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -158.64 154.19 26.07 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.39 133.35 50.29 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.438 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -115.25 119.84 37.68 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.893 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.645 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -72.07 133.82 45.47 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.89 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.17 123.9 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.998 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.997 ' HG3' ' OD1' ' A' ' 15' ' ' ASP . 0.5 OUTLIER -113.25 140.7 47.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.956 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.6 ptt180 -76.49 -7.71 55.68 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 77.3 p -167.29 146.6 5.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.11 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 7.2 p90 -177.19 164.98 2.26 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.02 115.07 3.45 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.272 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.47 98.31 1.25 Allowed Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 101.49 11.41 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.981 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -57.32 137.3 56.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.814 ' HE2' HD23 ' A' ' 45' ' ' LEU . 13.4 m-85 -47.23 -40.14 15.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.606 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t0 -56.45 -17.06 6.96 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.65 28.11 9.88 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 28.3 m -112.3 143.44 43.39 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -81.17 94.48 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.975 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.7 t-105 -63.08 -48.97 76.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.13 173.56 13.68 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.39 106.91 1.49 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' HB3' ' A' ' 38' ' ' ALA . 26.8 m -87.66 151.86 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -101.97 92.33 4.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -53.55 -24.66 14.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.968 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 8.3 t -84.26 1.73 43.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.5 m -115.14 -27.49 7.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.45 -171.53 2.24 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.6 131.22 42.04 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.609 ' HB2' ' HB ' ' A' ' 110' ' ' ILE . 1.9 m -102.81 167.77 9.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.191 ' HG3' ' O ' ' A' ' 108' ' ' VAL . 11.2 tt0 -169.78 126.29 0.86 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.438 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 67.3 t -112.91 159.23 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.989 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.821 ' C ' HG13 ' A' ' 34' ' ' VAL . . . -179.17 -179.79 48.77 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.942 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.516 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.64 144.37 51.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.274 ' OG ' ' HB3' ' A' ' 33' ' ' ASP . 94.0 p -129.62 147.08 51.38 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 1.205 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -105.27 -163.41 0.95 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.987 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.86 -48.21 69.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.937 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.23 -21.04 66.29 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.76 53.2 2.62 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.909 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.958 ' OD1' ' OE1' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.14 162.53 27.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.98 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.867 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -171.94 -179.52 42.94 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.567 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 156.85 54.3 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.357 3.371 . . . . 0.0 109.593 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.322 ' CB ' ' HB1' ' A' ' 2' ' ' ALA . 10.8 pt-20 -35.69 120.84 0.6 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.9 148.2 0.04 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.191 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 72.0 t -124.4 118.95 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -98.14 150.47 21.43 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.289 HG23 ' OG ' ' A' ' 10' ' ' SER . 16.9 mt -126.09 163.49 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.646 ' O ' ' HA ' ' A' ' 11' ' ' SER . 13.5 t -152.75 134.61 14.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.872 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -102.5 125.52 49.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.8 m120 . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.991 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.619 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -130.52 132.07 23.75 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.347 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.7 Cg_endo -72.35 -174.12 1.33 Allowed 'Trans proline' 0 N--CA 1.448 -1.201 0 C-N-CA 124.323 3.349 . . . . 0.0 109.609 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.79 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -96.47 107.12 19.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.673 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.39 147.53 48.18 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.987 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.528 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -102.26 111.57 23.9 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.025 HG22 HG12 ' A' ' 21' ' ' VAL . 38.6 t -107.28 148.04 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.894 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -73.24 176.74 2.39 Favored Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.93 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.11 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.6 Cg_endo -72.43 116.28 4.65 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.332 3.354 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.02 ' HB2' HG23 ' A' ' 110' ' ' ILE . 91.6 p -111.51 47.38 1.03 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.1 p -127.1 107.06 9.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.96 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.72 26.12 23.39 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.921 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.11 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.96 131.64 44.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.995 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.1 m -111.21 173.98 6.08 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 1.5 t0 -47.87 144.0 3.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.489 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 99.41 -23.6 35.57 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.483 HG21 ' HB3' ' A' ' 13' ' ' LEU . 82.7 m -74.33 151.17 39.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.8 p -125.31 117.41 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.949 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.693 HG13 HG22 ' A' ' 8' ' ' THR . 55.1 t -83.99 163.46 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tppt? -124.01 133.4 53.68 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -135.53 110.39 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.973 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.673 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.6 119.24 33.2 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.762 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.76 140.68 20.44 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.751 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.4 108.8 6.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.93 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.922 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.99 24.37 8.6 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.187 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.66 -163.59 1.03 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.434 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 4.4 mp0 -85.5 126.56 33.94 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.537 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.25 131.57 41.32 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.936 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.89 84.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.59 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.52 138.2 31.71 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.666 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -88.49 145.17 25.9 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.936 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -133.61 146.03 50.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.218 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -110.72 117.37 33.28 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.906 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.316 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.32 145.56 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.99 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.957 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.25 171.57 41.99 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.817 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -118.14 112.01 19.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.969 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.6 m -105.05 172.4 6.81 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.996 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -155.09 138.17 15.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.905 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.509 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.93 127.18 30.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.912 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.912 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -108.27 -51.85 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.027 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -143.01 165.14 28.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.946 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.624 ' O ' HG23 ' A' ' 42' ' ' THR . 10.1 t -51.46 112.15 0.7 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.08 9.15 75.87 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.773 HG12 ' CD1' ' A' ' 83' ' ' TRP . 4.5 t -129.06 114.37 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.933 HD12 ' N ' ' A' ' 46' ' ' ALA . 0.9 OUTLIER -118.22 162.84 17.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -123.64 138.63 54.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.983 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 58.3 m -109.49 148.46 31.16 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.716 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.8 t-20 -107.04 107.17 60.08 Favored Pre-proline 0 N--CA 1.45 -0.469 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.7 Cg_endo -72.47 0.35 7.61 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.344 . . . . 0.0 109.564 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.02 -9.54 50.92 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.9 p30 -131.72 27.16 4.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 104.98 13.9 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.991 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 29.8 t -98.32 172.29 7.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.945 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.34 154.68 41.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' THR . 6.0 p -166.7 158.31 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.954 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' VAL . 13.7 m -127.05 130.16 49.42 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.38 43.74 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.2 p30 -92.24 -171.59 2.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.27 -23.92 66.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.421 ' N ' ' OD1' ' A' ' 60' ' ' ASN . 1.8 m-20 -85.19 9.74 14.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 58.58 14.28 20.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -104.51 133.91 48.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.934 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.45 162.21 19.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -146.09 127.45 14.92 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.577 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -163.9 150.03 11.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.877 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.25 142.5 40.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.105 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -113.85 123.27 49.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.702 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.4 t -70.08 124.54 24.35 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.555 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -85.09 125.2 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.0 OUTLIER -117.08 144.76 44.3 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.427 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -87.16 -13.43 44.08 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 51.9 p -166.99 149.7 6.35 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.952 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.817 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.1 p90 -177.03 152.42 0.9 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.5 121.68 8.21 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.7 93.13 1.25 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 99.85 10.84 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.981 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.1 130.8 47.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.685 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.35 -35.75 8.55 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.54 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.68 -16.62 11.35 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.47 26.35 10.09 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 29.9 m -112.9 145.77 40.13 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.947 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -86.56 95.6 9.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.027 ' HZ2' ' CB ' ' A' ' 41' ' ' ASP . 1.0 OUTLIER -62.98 -53.84 47.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.939 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.7 173.21 14.32 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.13 125.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.996 HG11 ' CB ' ' A' ' 38' ' ' ALA . 54.5 t -100.05 148.63 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.47 93.25 4.14 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.427 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.5 m -52.86 -26.01 13.38 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.0 p -81.75 1.4 34.66 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -116.89 -27.18 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.916 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.98 -176.92 4.16 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.915 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.79 124.73 45.37 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.001 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 73.2 m -104.62 154.88 19.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -143.39 149.75 38.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.92 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.105 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 5.4 t -117.85 154.25 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.24 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.95 173.54 46.08 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.316 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.45 146.32 50.14 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.988 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.218 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 4.7 m -127.09 151.49 48.56 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.666 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -109.53 -165.62 1.03 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.984 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.48 -49.33 77.98 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.964 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -68.64 -25.33 64.78 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.41 41.82 3.34 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.9 p30 -115.94 164.04 15.0 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.936 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.57 -177.49 42.01 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.347 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.44 156.25 54.54 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.251 3.301 . . . . 0.0 109.57 179.903 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.619 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 3.3 pt-20 -37.36 119.87 0.74 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.49 151.93 0.02 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.941 ' CG2' HG21 ' A' ' 7' ' ' VAL . 3.6 t -124.01 104.44 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.42 128.83 34.83 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.033 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.4 mt -102.03 160.77 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.931 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.744 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -144.52 120.89 10.95 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.946 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.46 123.43 40.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.4 m120 . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.547 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -140.66 123.57 9.94 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.34 -178.64 3.42 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 124.356 3.371 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.188 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.2 m -101.91 109.52 21.28 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.961 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.922 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.71 141.9 51.58 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -104.75 117.76 34.87 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.992 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.787 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -115.92 151.73 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.951 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.647 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.4 OUTLIER -74.48 163.54 67.54 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.937 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.628 ' O ' HD21 ' A' ' 13' ' ' LEU . 83.0 Cg_endo -72.41 120.09 6.53 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.267 3.312 . . . . 0.0 109.595 179.918 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.987 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -120.07 16.7 12.46 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.975 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.106 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.2 p -98.91 115.15 28.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.94 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.654 ' N ' ' H ' ' A' ' 113' ' ' ASN . . . 104.24 -0.13 44.0 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.059 HD22 HG21 ' A' ' 17' ' ' THR . 1.3 pp -114.09 142.48 46.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.996 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.8 p -107.54 -167.76 1.3 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.919 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.677 ' CG ' HH11 ' A' ' 70' ' ' ARG . 7.2 t70 -42.15 153.67 0.06 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.98 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.75 -23.1 34.23 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.978 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' THR . . . . . 1.059 HG21 HD22 ' A' ' 13' ' ' LEU . 26.1 m -80.26 141.42 35.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 18' ' ' VAL . 11.2 p -119.46 109.84 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.932 HG13 ' HB3' ' A' ' 67' ' ' LEU . 1.8 p -83.67 161.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.987 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.787 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.73 150.79 39.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.62 109.35 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.978 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.922 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.14 116.95 25.11 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.016 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.64 144.74 22.38 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.984 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.717 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.04 109.55 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.45 17.82 23.05 Favored Glycine 0 C--N 1.336 0.56 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.99 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.016 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.01 175.15 7.29 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.991 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 74.1 mt-30 -58.35 121.37 10.65 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.461 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.65 129.16 37.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.99 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.35 8.22 87.61 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.933 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.513 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.5 143.49 26.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.961 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.667 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -87.35 151.45 23.09 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.96 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.795 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.3 m-85 -138.9 139.35 38.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.911 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.192 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.3 m-20 -105.47 113.73 27.48 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.27 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.98 147.57 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.938 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.863 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.72 166.13 38.26 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.01 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 2.2 tt0 -108.26 123.56 48.96 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.963 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.7 m -117.57 143.86 45.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.959 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.557 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.07 137.61 54.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.52 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -65.61 127.94 33.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.625 HG13 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -107.43 -55.14 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.465 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.62 167.62 17.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.962 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.417 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -50.81 112.11 0.65 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.944 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.72 8.09 66.96 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.999 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.516 HG11 ' HE1' ' A' ' 83' ' ' TRP . 11.6 t -122.74 112.89 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.988 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.647 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -121.97 131.98 54.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.984 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.341 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.31 153.77 20.62 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.942 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.8 m -110.81 156.87 20.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.825 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.6 t30 -114.9 106.24 52.03 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.465 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.37 -0.09 8.2 Favored 'Trans proline' 0 N--CA 1.448 -1.178 0 C-N-CA 124.319 3.346 . . . . 0.0 109.603 179.91 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.15 -11.61 43.36 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.7 p30 -130.25 27.26 5.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.23 106.76 15.28 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 t -101.09 171.79 7.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.896 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 p -146.88 154.26 41.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.514 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.77 161.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.928 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.514 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.9 m -128.03 135.8 50.37 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.63 135.19 39.16 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.917 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.0 p30 -76.02 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.914 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.5 -19.75 62.42 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -83.28 6.8 18.42 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.006 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.94 32.11 65.89 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.9 t -130.92 134.53 46.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.966 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.35 165.5 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -144.94 130.25 18.67 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.988 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.656 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.61 169.79 20.73 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.88 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.656 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -128.87 117.52 21.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.423 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.36 157.95 15.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.959 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.534 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -118.67 136.93 53.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.947 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.527 HG21 ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -103.23 126.69 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.677 HH11 ' CG ' ' A' ' 15' ' ' ASP . 0.1 OUTLIER -113.73 142.68 45.74 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.959 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -62.81 -35.13 78.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 83.7 p -154.55 157.05 37.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.876 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.01 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.2 p90 -177.17 155.83 1.19 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' CG ' ' A' ' 74' ' ' GLU . 0.5 OUTLIER -53.49 109.93 0.5 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.935 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.341 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.1 103.0 1.07 Allowed Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.96 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.984 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.19 100.21 10.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.987 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.878 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.3 tp -57.87 137.98 56.15 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.682 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.34 -40.36 17.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.704 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -57.32 -17.13 10.78 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.978 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 28.56 9.52 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.878 ' HB ' HD23 ' A' ' 77' ' ' LEU . 5.4 m -112.45 148.43 34.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -83.94 94.21 8.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.625 ' CE3' HG13 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -64.24 -40.18 95.48 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.92 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.33 169.7 12.47 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.31 106.12 0.49 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.942 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 40' ' ' VAL . 27.6 m -85.35 154.34 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.64 91.72 4.32 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.774 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.28 -20.65 7.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.977 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.611 HG22 ' HD2' ' A' ' 112' ' ' PHE . 76.0 p -90.59 2.82 55.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.971 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.6 m -112.61 -27.26 8.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.95 -178.77 4.28 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.28 129.19 35.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.434 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 3.8 m -105.04 155.24 19.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.313 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -154.02 131.75 11.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 -179.939 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.423 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.5 t -94.09 163.67 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.989 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.231 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.69 165.0 33.84 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.27 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.41 132.2 45.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.986 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.192 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 32.9 m -111.66 153.01 27.01 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.904 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.667 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.03 -162.47 0.8 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.995 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.9 -48.45 65.98 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.24 -24.15 65.78 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.78 54.09 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -133.97 171.47 14.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.795 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.51 173.77 45.45 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.42 168.23 24.86 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 124.258 3.306 . . . . 0.0 109.571 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.547 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.1 pt-20 -39.54 125.63 1.77 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.945 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.3 161.22 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.914 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.313 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 50.0 t -119.13 102.4 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.91 132.35 36.04 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CD1' ' HB2' ' A' ' 93' ' ' CYS . 16.1 pt -136.85 -175.3 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 111' ' ' SER . . . . . 1.106 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -177.27 153.17 0.92 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.968 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.434 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.1 m-85 -107.17 119.28 38.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.945 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.654 ' H ' ' N ' ' A' ' 12' ' ' GLY . 4.4 p-10 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.189 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -86.36 116.93 67.69 Favored Pre-proline 0 N--CA 1.448 -0.54 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.914 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 85.0 Cg_endo -72.37 -178.73 3.49 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.36 3.373 . . . . 0.0 109.608 179.925 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.97 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.2 m -100.9 108.74 20.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.657 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -120.16 145.2 47.18 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.957 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -108.66 115.29 29.82 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.976 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.726 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.33 153.57 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.993 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.853 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.18 175.09 1.95 Allowed Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.958 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.063 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.43 117.45 5.14 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.292 3.328 . . . . 0.0 109.607 179.869 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.032 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -115.16 47.35 1.3 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.943 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.49 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -123.71 105.81 10.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.977 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.45 28.51 16.66 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.972 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.063 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.43 134.79 41.8 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.83 163.77 12.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 15' ' ' ASP . 3.5 t0 -45.94 142.91 2.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 103.44 -22.75 35.1 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.47 HG21 HD13 ' A' ' 13' ' ' LEU . 90.6 m -73.3 144.81 46.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.977 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 18' ' ' VAL . 11.0 p -111.74 115.08 48.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.978 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.082 HG13 HG12 ' A' ' 69' ' ' VAL . 5.6 m -84.21 158.51 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.726 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.53 144.39 42.93 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.979 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -145.36 110.74 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.985 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.657 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.78 122.41 37.37 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.956 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.063 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.51 146.79 22.73 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.947 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.1 109.37 4.69 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.72 16.83 27.67 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.952 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.063 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.43 176.06 6.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.945 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.509 ' HB2' HG21 ' A' ' 30' ' ' THR . 31.7 mt-30 -56.5 120.82 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -180.0 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.448 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.73 130.66 41.02 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.28 7.34 84.78 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.509 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.26 140.39 29.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.964 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 1.238 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.8 147.86 27.34 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.109 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 27.4 m-85 -135.75 131.92 36.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.932 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.351 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.45 112.58 24.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.962 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.458 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.77 144.31 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.987 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.983 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.68 161.09 33.92 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.903 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 34.2 tt0 -104.03 119.18 38.39 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 85.7 m -117.08 143.54 45.67 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.464 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.29 139.25 54.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.544 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.98 125.29 24.43 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.427 HG13 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -105.03 -44.09 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.991 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.543 ' OD1' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -142.36 169.41 17.63 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.4 m -50.99 112.41 0.71 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.997 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.63 7.47 61.33 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 40' ' ' VAL . 2.3 t -120.8 118.7 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.564 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -128.99 134.91 48.34 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.986 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.38 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.55 157.61 16.91 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 69.1 m -117.61 156.04 28.82 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.551 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.0 t30 -122.07 109.28 33.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.48 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.44 0.26 7.73 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.278 3.319 . . . . 0.0 109.576 179.936 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -85.44 -14.96 44.55 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.878 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 5.9 p30 -129.09 19.53 5.93 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.951 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.689 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -82.07 117.94 22.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.983 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 m -107.11 178.1 4.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.973 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 p -145.23 152.69 40.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.851 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.487 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -167.02 156.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.0 m -127.92 133.05 49.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.959 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.75 134.49 46.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.936 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 37.5 p30 -75.05 -174.46 2.27 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.909 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.54 -25.23 67.93 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.975 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.32 -4.6 42.99 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.912 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 72.07 31.08 64.52 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.997 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.1 p -129.2 139.62 51.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.957 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.37 163.43 26.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.964 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.69 127.06 15.85 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.416 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -150.62 159.43 44.51 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.855 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.416 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -119.5 115.08 23.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.932 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.641 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.78 157.55 16.01 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.925 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.667 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -111.93 136.22 51.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.975 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 1.082 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.95 129.16 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.99 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.78 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.38 164.3 15.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.994 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.2 -15.37 29.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.983 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -164.49 143.28 7.12 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.903 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -170.7 159.52 6.6 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -54.59 120.3 6.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.901 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.38 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.94 92.28 1.35 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 179.986 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.926 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.19 100.14 10.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.966 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -55.14 144.25 24.66 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.991 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.755 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.35 -43.43 23.05 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.579 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 8.7 t0 -58.05 -17.02 14.97 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.958 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.2 28.56 10.6 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.999 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -107.66 119.22 38.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.83 91.43 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.427 ' CE2' HG13 ' A' ' 40' ' ' VAL . 29.0 t90 -62.7 -58.55 7.08 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.901 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.48 166.91 17.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.992 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.06 108.82 0.73 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.955 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.605 HG22 HG23 ' A' ' 40' ' ' VAL . 15.7 t -81.95 147.35 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.998 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -105.28 94.44 5.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.988 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -52.56 -24.99 9.23 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.6 p -79.3 -3.64 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 -26.87 7.36 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.4 -178.11 3.9 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.13 138.6 33.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.959 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.656 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -102.47 161.23 13.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.974 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.206 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.4 tt0 -168.39 127.19 1.16 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.641 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.5 t -97.04 164.56 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.967 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -175.75 167.99 40.09 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.458 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.82 128.5 38.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.981 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.351 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 19.8 m -116.84 142.19 47.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.913 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 1.238 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -98.33 -157.8 0.62 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.87 -48.22 69.45 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.903 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.597 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -69.77 -25.89 64.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.955 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.8 48.46 2.11 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.602 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 2.3 p30 -120.62 162.94 18.8 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.109 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.58 176.71 44.04 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.984 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.608 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.46 165.12 33.6 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.319 3.346 . . . . 0.0 109.601 179.935 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.189 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 pt-20 -38.24 135.91 0.69 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.961 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.61 147.56 3.93 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.967 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.206 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 13.0 t -127.42 104.15 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.985 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.629 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -88.71 157.16 18.62 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.032 HG23 ' HB3' ' A' ' 10' ' ' SER . 22.4 mt -127.97 168.31 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.501 ' N ' HG22 ' A' ' 110' ' ' ILE . 21.1 t -153.97 137.26 15.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.954 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.656 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -102.09 124.94 48.56 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.553 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 30.3 m-80 . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.97 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.586 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -90.69 123.16 65.87 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.931 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.427 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -175.23 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.306 3.337 . . . . 0.0 109.61 179.924 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.897 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.72 108.21 20.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.736 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 146.52 49.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.43 110.33 22.31 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.973 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.902 HG21 ' CG2' ' A' ' 108' ' ' VAL . 14.3 t -105.62 146.1 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.93 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.17 175.24 2.2 Favored Pre-proline 0 N--CA 1.448 -0.528 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.945 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.119 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.8 Cg_endo -72.42 116.54 4.75 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 124.323 3.349 . . . . 0.0 109.593 179.918 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.973 ' HB2' HG23 ' A' ' 110' ' ' ILE . 56.6 p -113.33 46.66 1.23 Allowed 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.957 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 111' ' ' SER . 61.9 p -126.34 105.2 8.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.907 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.971 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.79 26.84 15.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.119 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -98.13 132.34 43.74 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.965 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -104.15 169.41 8.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 15' ' ' ASP . 15.9 p30 -46.02 141.43 3.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.993 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.19 -22.95 34.84 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.991 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 24.6 m -79.63 152.32 30.08 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.991 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -124.92 125.66 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.998 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.6 m -89.37 118.22 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.796 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -69.24 148.37 49.91 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.637 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.81 105.27 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.997 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.736 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.25 117.1 28.2 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.963 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.696 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.29 141.2 19.69 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.897 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.27 108.64 6.88 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.928 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.917 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.67 23.88 9.1 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.976 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.401 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.34 -171.79 3.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.983 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.493 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 72.7 mt-30 -76.31 124.29 27.28 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.989 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.66 130.33 40.31 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.48 8.22 83.7 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.958 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.552 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -95.04 136.48 35.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.96 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.771 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.88 151.31 23.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.999 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.919 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 48.4 m-85 -138.12 144.17 40.71 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.048 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.0 m-20 -104.64 116.63 32.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.956 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.418 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.05 142.29 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.882 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.5 170.78 42.87 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.118 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 6.0 tt0 -114.42 116.3 28.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.934 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 64.2 m -114.6 143.2 45.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.826 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.9 131.45 53.74 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.914 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.84 123.72 20.53 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.935 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.058 ' HB ' ' CE3' ' A' ' 83' ' ' TRP . 14.2 m -103.58 -43.98 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.575 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -136.8 176.18 8.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.991 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.16 112.08 1.77 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.982 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.98 8.29 64.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.304 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 61.6 t -122.79 108.0 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 180.0 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.561 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -121.47 139.52 53.37 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.978 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.475 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.83 157.93 15.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.3 m -118.74 152.26 36.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.3 t-20 -110.93 107.47 57.79 Favored Pre-proline 0 N--CA 1.449 -0.492 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.37 -0.02 8.09 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.322 3.348 . . . . 0.0 109.591 179.891 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.568 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.78 -11.11 43.13 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.783 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.502 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.6 p30 -131.1 27.05 4.87 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.901 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.97 106.18 15.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.977 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.6 t -104.19 173.23 6.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.943 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 p -145.51 156.75 43.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.443 HG22 ' N ' ' A' ' 56' ' ' THR . 4.7 p -166.29 157.83 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.443 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.7 m -127.76 126.98 42.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.49 153.0 24.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.5 p30 -93.78 -171.63 2.64 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.885 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.22 67.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -83.17 5.24 23.4 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.539 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 64.59 9.24 37.03 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.975 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.5 t -101.22 134.41 44.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.985 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.56 163.48 17.91 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.4 p -147.78 130.72 16.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.972 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.49 164.19 17.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.968 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -120.46 132.09 55.06 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.921 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.161 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.61 122.44 47.46 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.912 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.59 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.7 t -77.96 130.95 37.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.899 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.586 HG11 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.45 129.87 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.967 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.537 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 0.4 OUTLIER -111.43 155.26 23.45 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.932 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -83.02 -13.67 55.45 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.978 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.533 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 13.9 m -167.24 147.4 5.41 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.118 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 8.6 p90 -177.31 157.36 1.32 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.949 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.406 ' O ' ' HG3' ' A' ' 74' ' ' GLU . 14.8 pt-20 -56.56 117.61 4.03 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.475 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.14 97.26 1.39 Allowed Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.996 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.807 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.36 10.64 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.986 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.879 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -54.5 141.74 30.04 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.724 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.22 -42.85 20.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.574 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.9 t0 -56.78 -16.8 7.21 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.69 27.98 10.82 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.879 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -108.19 130.82 55.12 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 6.9 ptt180 -72.24 92.95 1.42 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.575 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 0.6 OUTLIER -61.67 -54.96 35.73 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.893 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.5 174.19 21.37 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.07 113.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' A' ' 38' ' ' ALA . 1.1 m -91.36 152.4 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.533 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 1.5 m-20 -115.7 102.97 10.22 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.975 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.537 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 23.0 m -52.82 -27.46 18.27 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.3 p -79.56 -3.51 47.28 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.994 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.69 -27.78 6.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.27 -178.4 4.2 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.56 122.97 44.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.879 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.573 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 89.7 m -104.03 151.73 22.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.986 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.4 OUTLIER -152.24 146.81 25.71 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.951 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.161 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -110.21 159.05 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.983 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.243 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.07 169.6 41.49 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.418 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.8 129.42 46.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.958 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.048 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 5.8 m -110.26 152.35 26.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.961 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.771 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -114.37 -169.35 1.51 Allowed 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.943 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.65 -48.91 77.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.24 -24.29 66.57 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.928 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.02 53.5 1.89 Allowed Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.955 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.727 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -132.79 172.69 12.24 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.982 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.919 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.24 179.27 48.59 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.966 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.427 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 160.01 47.92 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.313 3.342 . . . . 0.0 109.586 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.586 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -36.82 122.2 0.8 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.38 155.38 0.03 OUTLIER Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.974 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.902 ' CG2' HG21 ' A' ' 7' ' ' VAL . 8.6 t -127.51 111.59 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.981 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.411 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -92.98 129.8 38.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.986 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.5 mt -103.74 156.16 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.605 ' O ' ' HA ' ' A' ' 11' ' ' SER . 11.7 t -145.25 129.7 17.86 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.91 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.547 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -96.23 126.59 41.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.947 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.293 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -102.01 124.55 39.71 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.96 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.583 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.41 -177.19 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.349 3.366 . . . . 0.0 109.584 179.949 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.833 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -95.42 108.63 20.85 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.926 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.91 145.26 51.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.645 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.1 p -104.49 111.98 24.86 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.871 HG13 ' O ' ' A' ' 20' ' ' LYS . 26.2 t -106.96 149.21 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.996 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.53 178.32 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.938 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.121 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.6 Cg_endo -72.37 117.75 5.28 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 C-N-CA 124.279 3.32 . . . . 0.0 109.569 179.942 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.564 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 17.2 p -114.13 45.16 1.54 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 92.5 p -127.78 106.38 9.09 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.873 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.903 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.59 24.5 20.86 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.121 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -94.1 130.11 40.39 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 45.8 t -98.49 168.27 10.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.93 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.63 141.15 17.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.4 -23.72 34.23 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.458 HG21 ' HB3' ' A' ' 13' ' ' LEU . 21.1 m -72.27 152.69 42.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.987 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.9 p -126.77 131.19 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.0 m -97.95 169.7 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.871 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.83 150.34 38.53 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.975 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.847 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -144.32 109.4 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.978 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.838 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.53 114.86 23.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.55 146.8 24.91 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.833 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.01 110.92 4.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.864 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.39 13.46 30.58 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.99 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.993 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.59 165.98 13.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.979 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.525 ' HB2' HG21 ' A' ' 30' ' ' THR . 84.1 mt-30 -46.41 119.71 2.51 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.984 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.744 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.26 131.08 41.54 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.47 8.46 80.55 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.525 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.78 148.32 22.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.951 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.408 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.938 ' HB3' ' CB ' ' A' ' 97' ' ' LEU . 35.1 m-85 -138.26 151.75 47.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.907 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.406 ' CA ' ' H ' ' A' ' 98' ' ' SER . 35.0 m-20 -120.23 117.4 27.77 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.281 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -98.58 141.39 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.803 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -161.99 155.44 26.71 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.894 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 40.7 tt0 -105.65 115.7 30.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.449 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.3 m -102.96 166.66 10.32 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.025 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -153.33 134.0 13.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.956 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.592 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.2 122.55 17.36 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.91 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.514 ' HB ' ' CD1' ' A' ' 83' ' ' TRP . 2.5 m -102.9 -42.82 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.992 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.457 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -138.47 166.16 25.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m -50.79 111.77 0.6 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.35 8.92 63.35 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.97 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.52 HG11 ' CH2' ' A' ' 83' ' ' TRP . 75.0 t -120.3 119.35 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.5 162.75 23.32 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.515 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -132.54 155.42 48.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.926 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.1 m -113.46 155.23 25.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.521 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.3 t30 -116.11 112.41 42.11 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.38 0.13 7.88 Favored 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 124.31 3.34 . . . . 0.0 109.65 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.521 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.03 -16.52 29.61 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.915 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.473 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.0 p30 -127.16 28.33 5.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.93 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -102.1 118.67 37.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.7 t -107.41 -177.27 3.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.932 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -147.65 154.58 40.81 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.522 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -167.31 161.9 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.977 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.522 ' N ' HG22 ' A' ' 55' ' ' VAL . 20.7 m -126.34 130.19 50.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.58 145.55 55.48 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.977 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 51.6 p30 -83.7 -172.29 4.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.934 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.09 -27.57 69.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.66 -10.06 59.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.993 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.62 31.79 48.77 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.969 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.3 p -127.36 136.32 51.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.991 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.95 170.2 10.86 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.53 123.97 9.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.499 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -151.94 160.26 43.55 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.907 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.488 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -114.43 129.68 56.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.913 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.069 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -107.26 118.01 35.58 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.901 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.578 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -67.66 120.46 14.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.987 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.534 ' O ' HG12 ' A' ' 69' ' ' VAL . 0.6 OUTLIER -76.47 123.94 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.975 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.635 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 26.9 mmt180 -115.57 157.03 24.71 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.494 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 4.1 ptt180 -107.08 -10.73 15.82 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.99 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -177.05 146.93 0.53 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.927 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.894 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -176.69 171.52 2.25 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.878 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 118.36 7.28 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.515 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 94.07 1.35 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.996 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -84.44 100.63 11.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.848 HD12 ' H ' ' A' ' 78' ' ' PHE . 2.2 tp -54.45 145.41 18.42 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.848 ' H ' HD12 ' A' ' 77' ' ' LEU . 10.8 m-85 -47.2 -43.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.591 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -58.73 -16.52 17.03 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.965 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.12 28.25 12.15 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.826 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.2 m -106.38 122.67 46.74 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 ttm180 -61.71 90.96 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.956 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.52 ' CH2' HG11 ' A' ' 44' ' ' VAL . 42.8 t-105 -62.35 -58.4 7.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.53 163.2 12.09 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.994 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.56 105.73 0.47 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.951 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.025 HG21 ' HB1' ' A' ' 38' ' ' ALA . 3.4 p -80.21 148.89 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -110.47 98.74 7.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 17.8 m -51.91 -27.53 13.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.2 p -79.57 1.21 26.85 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.982 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.4 m -116.99 -26.68 6.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.933 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.81 -175.31 3.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.58 125.65 48.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.247 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.2 m -103.83 152.69 21.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.992 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -150.89 144.17 24.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.967 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.069 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 7.1 t -103.96 163.56 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.252 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.33 168.41 40.52 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.991 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.281 ' CG ' HG22 ' A' ' 34' ' ' VAL . 5.6 mp -99.5 162.16 13.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.406 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 13.0 m -154.16 118.48 4.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.451 ' OD1' ' N ' ' A' ' 102' ' ' GLY . 42.7 p-10 -113.54 -167.9 1.27 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.998 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.16 -19.89 2.23 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.946 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.45 -23.51 13.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.888 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.451 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 85.34 22.0 52.79 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.645 ' OD1' ' HD1' ' A' ' 32' ' ' TYR . 18.4 p-10 -60.11 -151.83 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 143.47 153.38 5.86 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.953 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.583 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.41 165.4 32.79 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.247 3.298 . . . . 0.0 109.607 179.964 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.293 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.2 pt-20 -33.55 124.45 0.42 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.542 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.34 133.99 0.98 Allowed Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.6 104.03 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.952 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.463 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.58 144.97 26.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.247 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.11 159.47 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.917 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.46 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -144.2 115.05 7.79 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 93' ' ' CYS . 30.5 m-85 -100.06 126.21 46.25 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.934 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.947 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -114.98 126.3 28.01 Favored Pre-proline 0 N--CA 1.45 -0.467 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.526 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.2 Cg_endo -72.39 -175.37 1.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.328 3.352 . . . . 0.0 109.605 179.907 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.291 HG22 ' O ' ' A' ' 24' ' ' ALA . 6.4 t -99.67 116.15 31.11 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.885 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -131.9 154.64 49.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.498 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -115.76 117.09 29.27 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.048 HG13 ' O ' ' A' ' 20' ' ' LYS . 84.8 t -114.03 143.77 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.736 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.63 166.68 24.3 Favored Pre-proline 0 N--CA 1.448 -0.539 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.938 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.736 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.37 118.13 5.46 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.331 3.354 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.615 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.45 9.43 7.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.961 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.747 ' HA ' ' O ' ' A' ' 111' ' ' SER . 50.0 p -88.51 106.72 18.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.882 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.071 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 101.94 17.98 19.15 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.888 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.071 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -108.12 133.24 52.67 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -87.77 174.54 8.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.913 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 27.8 t70 -46.71 153.33 0.4 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.53 -22.62 36.37 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.965 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.651 HG21 HD12 ' A' ' 13' ' ' LEU . 18.9 m -71.94 148.0 46.43 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.76 129.6 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.979 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.677 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -104.51 150.54 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.969 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 1.048 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.1 147.86 28.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.976 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.809 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -142.71 108.63 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.36 114.75 20.58 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.885 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.17 143.13 20.16 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.954 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.291 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.29 109.52 6.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.901 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.15 24.22 9.14 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.526 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.47 -169.35 2.52 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.531 ' HB2' HG21 ' A' ' 30' ' ' THR . 3.6 mp0 -81.03 125.25 29.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.991 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.3 131.29 43.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.992 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.94 8.15 77.43 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.599 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.63 132.14 42.56 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.972 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.42 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -86.25 150.67 24.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.856 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 51.6 m-85 -135.03 141.73 46.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.056 ' HB2' ' O ' ' A' ' 98' ' ' SER . 2.2 m-20 -100.69 113.96 27.27 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.958 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -101.26 151.55 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.977 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.726 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -175.89 172.77 45.76 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.957 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.849 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 41.4 tt0 -108.18 107.12 17.61 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.942 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 60.7 m -106.73 142.43 36.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.49 137.38 54.9 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.875 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.569 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.41 124.73 22.55 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.889 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.535 HG12 ' N ' ' A' ' 41' ' ' ASP . 1.2 t -105.27 -46.76 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.517 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.82 167.09 21.82 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -51.14 112.19 0.69 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.954 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.57 7.94 65.94 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.893 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 2.0 t -122.38 117.58 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.983 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.532 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -127.35 136.3 51.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.979 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.494 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.34 151.76 20.11 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.97 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.6 m -110.77 146.75 35.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.974 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.762 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.1 p-10 -116.73 115.38 39.24 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.567 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.3 Cg_endo -72.4 -0.54 8.87 Favored 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.317 3.345 . . . . 0.0 109.6 179.868 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.719 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -76.03 -25.4 55.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.89 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.472 ' CB ' HG23 ' A' ' 68' ' ' THR . 89.6 m-20 -124.8 27.74 6.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.948 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -83.33 117.32 22.92 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.966 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 m -110.92 -178.24 3.42 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.8 p -144.86 155.07 43.27 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.875 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.594 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.6 p -166.91 151.66 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 m -127.57 133.17 49.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 143.83 53.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.966 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 43.7 p30 -86.27 -172.03 3.85 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.36 -25.98 68.2 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.925 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -80.16 -7.77 59.1 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.05 30.59 57.13 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.927 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.3 p -122.57 133.01 54.56 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.594 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -119.4 162.66 18.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.981 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.2 p -149.5 129.03 13.07 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.971 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.442 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.91 157.57 31.67 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.868 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.442 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.61 125.04 52.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.452 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -98.83 157.39 16.33 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.916 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -106.41 140.29 39.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.965 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.597 HG23 HG11 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -99.01 125.37 52.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.913 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -118.99 136.23 54.21 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.954 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -61.51 -34.49 75.6 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.443 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 62.5 p -156.58 162.4 39.9 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.849 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.9 p90 -177.71 165.62 2.08 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.961 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.8 116.55 8.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.911 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.494 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.66 94.73 1.08 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.95 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.868 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.69 99.76 10.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.979 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -56.8 131.13 48.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.677 ' N ' HD12 ' A' ' 77' ' ' LEU . 9.5 m-85 -47.83 -35.63 10.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.989 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.54 -16.91 11.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.948 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.96 27.51 8.84 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.988 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 21.7 m -115.79 148.81 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.978 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -90.75 96.89 10.86 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.517 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 32.9 t-105 -63.44 -58.05 8.31 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 172.93 21.64 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.991 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.75 104.81 2.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.726 HG21 ' HB3' ' A' ' 38' ' ' ALA . 7.1 m -78.76 152.34 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.999 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.75 92.91 4.05 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.971 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.137 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 32.7 m -51.6 -27.06 10.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.964 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -79.61 0.81 28.56 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.994 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -118.63 -27.97 5.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.46 180.0 5.7 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.669 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -97.43 125.32 42.0 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.434 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 82.2 m -104.52 168.88 8.8 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.984 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -154.66 146.45 23.39 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.957 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.452 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.8 t -101.19 164.77 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.84 168.62 39.07 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.045 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.16 125.24 30.75 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.821 -0.436 . . . . 0.0 109.821 -179.95 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.056 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 56.6 m -100.75 154.07 18.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.895 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.44 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.1 OUTLIER -116.48 -164.29 0.96 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.44 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -61.77 -49.04 77.96 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.14 -24.4 61.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.922 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.22 53.58 1.46 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.995 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.52 178.28 6.86 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.856 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -179.7 -178.04 48.22 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.41 165.59 32.24 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.295 3.33 . . . . 0.0 109.61 179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.591 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 3.8 pt-20 -38.3 121.84 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.82 153.87 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.9 t -114.1 102.33 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.51 128.51 34.35 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.434 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -139.28 -177.36 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.747 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -172.21 174.66 3.91 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.915 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.137 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.3 m-85 -123.28 114.47 20.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.967 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.009 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 21.2 m-80 . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.973 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.502 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.341 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -126.95 116.12 22.11 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.44 -178.57 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.306 3.337 . . . . 0.0 109.59 179.945 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.999 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.18 109.11 21.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.942 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.884 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -122.92 150.73 42.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.661 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -113.82 119.64 38.02 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.999 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.903 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -114.79 143.87 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.961 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.779 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.12 167.36 17.98 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.985 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.779 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.34 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.349 3.366 . . . . 0.0 109.579 179.89 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.0 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -122.06 13.96 10.58 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.99 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.867 ' HA ' ' O ' ' A' ' 111' ' ' SER . 53.3 p -98.95 114.61 27.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.877 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.72 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.03 1.59 41.95 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.0 HD21 ' CA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -114.39 142.01 46.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.972 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.9 m -104.98 -170.26 1.73 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.952 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.772 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 2.3 t0 -42.88 153.54 0.08 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.73 -24.63 31.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.972 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -96.21 148.81 22.33 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 68' ' ' THR . 0.0 OUTLIER -123.05 146.32 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.996 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.736 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.3 OUTLIER -110.87 119.94 60.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.96 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.903 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -78.55 127.43 32.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.734 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.2 OUTLIER -113.17 114.63 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.983 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' CA ' ' A' ' 5' ' ' ALA . . . -127.17 123.49 36.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.98 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.033 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.59 153.48 22.63 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.957 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.999 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.6 108.18 3.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.14 17.35 27.54 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.991 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.116 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.47 176.45 6.9 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.969 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 64.7 mt-30 -58.54 121.71 11.61 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.3 131.21 42.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.995 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.86 7.58 83.9 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.5 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -93.13 141.04 28.85 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.475 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.69 151.16 24.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.971 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.63 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 29.8 m-85 -138.54 134.86 34.43 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.884 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.169 ' CB ' ' O ' ' A' ' 98' ' ' SER . 8.3 m-20 -100.29 113.54 26.32 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.94 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.305 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.19 143.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.723 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -164.96 164.45 37.06 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.96 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.902 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 10.9 tt0 -110.87 117.08 32.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.931 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.499 ' HB3' HD13 ' A' ' 45' ' ' LEU . 98.5 m -108.01 166.31 10.82 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.978 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.754 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -151.98 135.14 15.83 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.933 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.471 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.75 129.94 41.65 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.955 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.684 HG23 ' CG2' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -108.93 -39.01 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.053 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -150.4 155.8 40.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.986 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -51.51 112.9 0.83 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.969 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.99 9.86 84.74 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.98 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.622 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -139.04 130.05 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.605 ' HA ' HG22 ' A' ' 40' ' ' VAL . 1.9 pp -132.18 163.85 27.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.321 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -125.48 153.8 43.01 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.973 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.853 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 15.1 m -115.92 153.2 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.833 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 39.6 t30 -111.02 107.05 57.74 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 85.3 Cg_endo -72.3 -1.21 9.8 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.34 3.36 . . . . 0.0 109.631 179.849 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.15 -8.8 50.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.854 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -130.06 27.78 5.1 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.447 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.07 110.94 17.07 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.982 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.28 174.06 6.04 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.924 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 72.7 p -145.14 154.67 42.69 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 4.8 p -166.53 155.62 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.4 m -128.05 136.67 51.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -77.38 135.4 38.33 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.1 p30 -77.8 -173.18 2.94 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.893 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.17 -27.93 69.31 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.871 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -74.53 -6.94 51.3 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.992 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.116 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.99 32.23 56.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 93.4 p -128.48 141.11 51.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.982 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.11 164.8 23.62 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.997 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.06 134.29 19.44 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.763 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -155.13 176.99 11.84 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.763 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -133.41 117.66 17.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.95 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.332 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.48 156.1 16.48 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' HG12 ' A' ' 18' ' ' VAL . 0.5 OUTLIER -111.53 128.38 56.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.526 HG21 ' OG ' ' A' ' 10' ' ' SER . 1.2 t -97.13 123.11 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.772 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -115.05 144.48 43.57 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.445 ' HG3' ' N ' ' A' ' 72' ' ' SER . 15.4 ptt85 -65.85 -32.18 73.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.445 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 16.4 p -155.65 158.06 37.7 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.902 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.7 p90 -176.79 155.24 1.25 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -53.71 108.87 0.39 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.321 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -67.05 94.54 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.99 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.853 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -82.53 98.89 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.938 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.4 tp -54.66 144.81 20.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.763 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.2 -43.53 21.59 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.97 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.587 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -58.46 -16.7 16.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.7 28.1 11.78 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.938 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -106.97 120.68 42.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.414 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -64.25 91.42 0.07 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.622 ' CH2' HG21 ' A' ' 44' ' ' VAL . 3.9 t-105 -62.68 -58.52 7.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.915 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.78 163.39 12.92 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.36 104.59 0.18 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.754 HG11 ' HB3' ' A' ' 38' ' ' ALA . 12.6 p -79.2 151.67 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -105.71 95.01 5.51 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.155 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.94 -22.14 14.03 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.942 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 49.1 p -88.97 2.1 54.45 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.962 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.6 m -110.11 -24.92 10.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -137.93 174.9 10.08 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.979 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.79 127.27 35.61 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.951 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.393 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -104.56 163.86 12.17 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.984 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.019 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -151.42 142.27 22.91 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.917 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.332 ' CG1' HD13 ' A' ' 67' ' ' LEU . 16.5 t -97.92 164.6 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 180.0 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.305 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.33 163.84 32.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.976 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.08 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.62 131.63 49.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.993 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.169 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 42.5 m -112.28 141.02 46.49 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.52 -164.14 1.02 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.04 -49.03 71.75 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.946 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.2 65.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.937 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.28 1.98 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.941 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -131.4 177.08 7.76 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.19 174.25 46.59 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.989 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.535 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.4 170.44 19.27 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.304 3.336 . . . . 0.0 109.623 179.944 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.341 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.7 pt-20 -41.2 126.69 2.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.963 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.6 160.82 0.01 OUTLIER Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.011 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.3 t -120.9 103.11 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.969 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.98 133.81 34.67 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.955 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.048 HD11 ' HB2' ' A' ' 93' ' ' CYS . 31.8 pt -136.93 -169.93 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.916 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.867 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -178.28 158.74 1.18 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.393 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.3 m-85 -111.37 119.19 38.0 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.932 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.72 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 2.4 p-10 . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.955 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.568 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -117.63 114.97 37.64 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.893 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.439 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.4 -178.15 3.15 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.331 3.354 . . . . 0.0 109.603 179.904 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.861 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.2 m -101.14 110.7 22.75 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.65 142.11 51.67 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.914 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.98 116.07 31.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.96 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.804 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.7 OUTLIER -114.69 149.76 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.963 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.677 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.24 165.35 40.04 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.677 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.42 119.62 6.24 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.333 3.356 . . . . 0.0 109.579 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.051 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.7 OUTLIER -123.87 16.16 9.36 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.272 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.6 p -105.3 113.79 27.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.885 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.001 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.86 6.78 37.08 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.112 HD22 HG21 ' A' ' 17' ' ' THR . 0.4 OUTLIER -114.52 136.72 52.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.5 m -81.12 171.21 15.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.925 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.447 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 3.3 p-10 -45.24 154.31 0.17 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.979 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.87 -24.01 33.84 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.985 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 17' ' ' THR . . . . . 1.112 HG21 HD22 ' A' ' 13' ' ' LEU . 94.3 m -68.37 131.88 46.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.981 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.589 ' O ' HG13 ' A' ' 18' ' ' VAL . 10.4 p -102.08 119.32 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -99.17 161.14 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.804 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -119.74 148.7 43.09 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.997 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.7 107.18 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.994 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -117.21 116.42 27.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.66 146.73 23.58 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.992 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.861 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.83 110.01 4.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.938 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.5 15.75 31.27 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.974 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.0 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.19 172.16 9.0 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.993 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 72.4 mt-30 -54.34 120.36 6.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.964 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.11 131.27 41.87 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.967 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 6.88 84.59 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.999 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.508 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -93.02 144.2 25.49 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -86.1 151.38 23.73 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.519 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.8 m-85 -138.66 144.4 39.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.199 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -112.51 113.11 25.12 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.935 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.228 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -98.96 152.04 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.927 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -178.57 159.71 25.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.979 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.028 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 12.4 tt0 -98.77 118.55 35.76 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.942 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.415 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.8 m -108.28 165.55 11.42 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.982 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 86' ' ' VAL . . . -151.71 122.66 7.58 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.632 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.68 122.09 16.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.823 HG21 ' CD1' ' A' ' 83' ' ' TRP . 16.7 m -101.32 -44.58 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.973 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.521 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -135.64 168.06 19.97 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.966 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.68 ' O ' HG23 ' A' ' 42' ' ' THR . 3.9 t -54.04 112.97 1.06 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.986 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.66 8.56 63.62 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.984 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.454 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.7 t -120.86 109.07 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.5 pp -119.83 162.36 19.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.4 151.91 49.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.936 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.012 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -117.38 157.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 17.6 t30 -116.24 112.95 41.49 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -72.35 -0.51 8.79 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.31 3.34 . . . . 0.0 109.61 179.884 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -12.72 36.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.849 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.466 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 16.5 p30 -132.94 27.01 4.27 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.928 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.11 117.35 32.29 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.993 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.9 t -106.61 177.91 4.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.962 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.4 p -146.5 151.49 37.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.532 HG22 ' N ' ' A' ' 56' ' ' THR . 4.6 p -166.77 162.58 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.943 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.532 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.5 m -127.8 134.82 49.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.951 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.99 143.4 50.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.949 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 42.9 p30 -81.74 -172.73 4.04 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.95 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.1 -25.54 68.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.904 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.68 -7.26 53.88 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.891 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.13 31.07 60.04 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.0 p -127.13 143.8 51.18 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.971 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.01 166.36 21.18 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.983 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -147.5 125.78 12.27 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.95 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.725 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.24 173.04 12.92 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.938 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.725 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -131.13 111.22 11.78 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.944 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.497 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.12 156.55 16.33 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.685 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -119.2 139.97 50.97 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.924 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.648 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.57 133.37 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -119.83 162.19 19.54 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.447 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 5.8 ptt180 -82.56 -18.14 42.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 p -165.12 151.22 9.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.922 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.028 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.1 p90 -175.99 154.94 1.53 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.897 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.45 124.81 14.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.989 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.03 92.11 1.62 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 1.012 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.52 100.51 11.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.974 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.902 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -58.15 140.96 51.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.967 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.726 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.28 -42.01 19.95 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.935 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.72 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -57.41 -16.66 9.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.965 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 28.43 10.43 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.902 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -108.73 128.09 54.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.67 91.59 1.12 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.454 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.14 -58.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.869 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.06 167.59 16.39 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.975 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -59.36 115.16 3.06 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 38' ' ' ALA . 59.9 t -88.29 146.57 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 180.0 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.82 91.67 4.26 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.949 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.759 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -52.52 -22.63 5.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.997 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.91 2.6 48.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.981 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 m -115.82 -27.81 6.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.961 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.47 169.39 16.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.91 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.92 126.02 35.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.938 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.438 ' HB2' HD11 ' A' ' 110' ' ' ILE . 12.4 m -104.14 159.77 15.41 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 -179.923 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -145.45 143.1 29.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.969 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.497 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.7 t -97.34 157.73 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.228 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.55 171.05 43.27 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.997 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.18 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.33 151.31 51.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.199 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 82.8 p -127.96 151.41 49.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.5 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -112.77 -163.46 0.85 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.96 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.43 -48.6 69.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.935 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.24 65.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.952 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.8 53.39 1.8 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.998 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -132.11 168.36 18.11 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.519 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.85 178.95 42.51 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.933 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.439 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.36 161.98 42.82 Favored 'Trans proline' 0 N--CA 1.447 -1.24 0 C-N-CA 124.34 3.36 . . . . 0.0 109.627 179.966 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.568 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -40.61 123.72 1.9 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.972 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.54 151.82 0.02 OUTLIER Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.991 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.2 t -119.21 104.24 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.66 138.71 36.4 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.982 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.042 HG12 ' HA ' ' A' ' 94' ' ' GLN . 25.8 pt -137.75 -172.34 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 111' ' ' SER . . . . . 1.272 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -179.23 163.69 1.31 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.942 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.759 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 2.3 m-85 -117.76 116.81 27.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.937 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.001 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 22.2 m120 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.973 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.425 ' C ' ' H ' ' A' ' 106' ' ' GLU . . . -140.87 120.38 8.47 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.508 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.3 Cg_endo -72.39 -174.61 1.48 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.322 3.348 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.229 HG22 ' O ' ' A' ' 24' ' ' ALA . 4.1 t -97.99 110.68 23.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.964 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.84 146.92 50.46 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.953 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.473 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -109.26 112.44 24.59 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.794 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -109.07 145.38 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.993 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.782 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.28 168.65 12.85 Favored Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.782 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.39 117.14 4.99 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.296 3.331 . . . . 0.0 109.571 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.591 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -127.05 17.18 7.25 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.975 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 39.2 p -94.6 112.72 24.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.9 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.121 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 87.98 28.75 22.49 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.942 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.121 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.18 137.33 46.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.976 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.4 t -76.2 150.24 37.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.964 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 2.3 p30 -44.43 153.02 0.17 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.5 -24.72 30.85 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.437 HG21 HD12 ' A' ' 13' ' ' LEU . 17.7 m -63.69 150.29 44.71 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.982 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 18' ' ' VAL . 14.7 p -112.46 121.8 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.617 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 2.2 p -97.42 153.52 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.996 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.794 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -107.28 150.45 26.66 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.973 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.741 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -148.63 107.64 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.998 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.964 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.05 114.96 23.33 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.988 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.825 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.2 139.95 17.98 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.952 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.229 ' O ' HG22 ' A' ' 4' ' ' THR . . . -135.89 110.22 8.44 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.922 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.898 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.29 21.19 10.17 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.966 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.508 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.4 -168.39 2.19 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.934 ' CD ' ' HH ' ' A' ' 32' ' ' TYR . 4.1 mp0 -79.59 121.66 25.54 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.962 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.507 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.61 135.9 47.15 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.97 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.38 6.71 58.78 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.958 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.585 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.92 138.87 33.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.968 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -86.29 150.72 24.15 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.919 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.496 ' HB3' ' CD2' ' A' ' 97' ' ' LEU . 39.2 m-85 -136.44 155.79 49.52 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.409 ' O ' ' CA ' ' A' ' 97' ' ' LEU . 2.6 m-20 -121.89 114.18 20.67 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.253 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -95.02 144.7 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.983 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.022 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.07 166.92 34.76 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.954 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.696 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -121.63 106.98 11.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.767 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.3 m -105.21 172.78 6.61 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.961 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.966 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -146.37 127.34 14.55 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.932 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.77 117.83 8.07 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.92 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.591 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 3.6 m -98.22 -42.92 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.972 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -135.67 177.31 7.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.995 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 t -60.36 111.76 1.68 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.99 8.17 63.85 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.565 HG12 ' CD1' ' A' ' 83' ' ' TRP . 22.0 t -120.73 113.31 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.674 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -128.51 140.61 51.72 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.991 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.34 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.93 138.65 34.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.956 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.77 ' O ' ' HB3' ' A' ' 76' ' ' PHE . 82.1 m -106.37 140.62 39.0 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.971 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.62 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.8 t30 -100.31 111.49 62.58 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.442 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.1 Cg_endo -72.39 0.28 7.67 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -86.56 -14.94 41.45 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.854 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.52 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.9 p30 -123.21 29.69 6.61 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.442 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -82.66 106.02 14.17 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.987 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.6 m -100.32 179.02 4.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.5 p -145.71 158.52 43.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.915 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.747 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.2 p -169.11 156.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.973 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.425 ' N ' HG22 ' A' ' 55' ' ' VAL . 7.0 m -127.97 137.63 52.32 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -80.69 139.73 35.99 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.984 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.2 p30 -82.86 -165.85 1.17 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.927 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.89 -28.67 69.07 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.3 m-20 -83.1 6.35 19.4 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.986 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.93 22.04 59.63 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -109.21 130.92 55.48 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.747 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.41 167.31 12.94 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.84 131.61 16.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.905 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.628 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -158.79 157.71 32.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.447 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -116.5 125.66 52.25 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.19 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -97.53 155.95 16.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.919 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.523 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -97.36 123.11 41.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.961 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.549 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -77.49 129.36 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.999 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.711 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -123.58 147.26 47.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.931 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -92.71 -20.2 21.04 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.994 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 53.4 p -172.99 153.18 2.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.922 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.711 ' CE2' ' HB2' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -178.02 179.08 0.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.949 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -68.56 117.83 10.8 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.34 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.6 89.13 1.23 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.956 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.77 ' HB3' ' O ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -83.47 103.33 12.73 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -58.34 130.99 49.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.86 -35.36 10.23 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.618 ' CB ' HD21 ' A' ' 77' ' ' LEU . 5.4 t0 -57.26 -17.28 11.02 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.24 28.39 8.14 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.939 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.1 m -117.74 145.86 44.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.31 97.21 8.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.591 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 21.9 t90 -64.25 -57.65 8.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.879 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.98 160.27 8.6 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.61 105.18 0.14 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.977 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.966 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -82.35 154.03 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -120.13 96.78 5.3 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.998 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.105 ' HB3' ' CD1' ' A' ' 112' ' ' PHE . 24.9 m -52.76 -25.6 11.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.9 p -79.68 1.45 26.34 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.32 -177.08 4.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.77 126.67 47.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.239 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 18.6 m -104.43 164.14 11.95 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.964 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.216 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -154.79 149.57 26.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.973 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.19 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.8 t -104.05 165.85 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.253 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 170.63 43.78 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.94 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.496 ' CD2' ' HB3' ' A' ' 32' ' ' TYR . 4.8 mp -99.81 162.87 12.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.168 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -152.48 109.99 3.59 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.896 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.442 ' OD1' ' OD1' ' A' ' 103' ' ' ASN . 1.7 p-10 -104.75 -157.96 0.64 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.28 -43.94 64.71 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.981 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.45 -26.01 26.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.937 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.95 52.86 2.33 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.959 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.442 ' OD1' ' OD1' ' A' ' 99' ' ' ASP . 1.3 p30 -109.17 -174.32 2.48 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 172.57 179.24 43.24 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.993 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.475 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.36 160.29 47.32 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.366 3.377 . . . . 0.0 109.567 179.91 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -32.96 128.51 0.26 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.479 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.0 130.94 0.29 Allowed Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.216 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 41.6 t -99.29 101.55 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.96 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -80.04 140.47 36.52 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.938 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.1 pt -147.06 -172.23 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.569 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.4 OUTLIER -173.82 176.17 2.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.948 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.105 ' CD1' ' HB3' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -150.64 105.77 3.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.074 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 1.8 p-10 . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 . . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -127.64 140.37 37.88 Favored Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.935 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.522 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.8 Cg_endo -72.39 -175.63 1.87 Allowed 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.275 3.317 . . . . 0.0 109.637 179.934 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.971 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.47 109.15 21.95 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.782 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.58 137.75 54.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.685 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -106.11 112.57 25.66 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.981 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.611 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -106.39 155.98 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.988 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.987 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.08 177.29 0.91 Allowed Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.923 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.157 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.4 117.22 5.03 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.311 3.34 . . . . 0.0 109.573 179.909 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.783 ' HB2' HG23 ' A' ' 110' ' ' ILE . 13.4 p -112.73 44.69 1.44 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -124.73 106.3 9.97 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.885 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.943 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 88.39 31.9 12.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.969 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.157 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.58 133.0 42.72 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 55.7 m -96.71 162.87 13.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -49.83 146.37 4.58 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.994 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.92 -22.51 35.81 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.965 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.441 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.9 m -63.3 147.62 50.56 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.983 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.545 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.5 p -112.2 122.7 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.556 ' HA ' HG21 ' A' ' 8' ' ' THR . 3.6 m -96.93 161.24 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.611 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 151.16 32.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.975 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.719 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -150.11 109.96 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.959 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.782 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.14 116.49 22.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.999 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.665 ' HA2' ' HA ' ' A' ' 5' ' ' ALA . . . -94.29 141.1 15.37 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.959 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.971 ' O ' HG22 ' A' ' 4' ' ' THR . . . -133.12 118.0 18.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.887 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.87 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.31 24.37 9.61 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.345 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.32 -173.67 4.49 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.972 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.708 ' OE1' ' OH ' ' A' ' 32' ' ' TYR . 13.2 mp0 -80.67 120.76 25.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.993 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.78 136.74 57.24 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.955 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.25 7.95 58.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.991 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.692 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -85.6 148.22 26.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 1.028 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -100.81 134.68 43.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.047 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 37.4 m-85 -127.29 147.59 50.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.104 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.8 m-20 -116.86 114.05 23.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.997 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.268 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -96.61 152.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.965 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.108 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -177.66 164.98 34.37 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.963 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.804 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 1.7 tt0 -112.34 118.38 35.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.937 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.562 ' HB3' HD13 ' A' ' 45' ' ' LEU . 90.8 m -108.23 173.5 6.29 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.983 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -152.62 123.97 7.67 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.917 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.617 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.57 124.0 21.18 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.907 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.12 HG21 ' CD2' ' A' ' 83' ' ' TRP . 15.2 m -103.93 -43.85 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.528 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -142.93 169.61 17.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 19.5 m -56.74 113.43 1.64 Allowed 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.952 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.78 4.83 62.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.997 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.644 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 15.5 t -122.19 105.07 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.975 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.641 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -117.3 162.73 17.43 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.546 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -122.54 140.7 52.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.928 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.681 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 23.4 m -109.3 150.8 27.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 1.057 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -108.41 105.75 57.32 Favored Pre-proline 0 N--CA 1.45 -0.453 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.988 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.471 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.0 Cg_endo -72.4 -1.23 9.89 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.309 3.339 . . . . 0.0 109.638 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.41 -12.97 33.22 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.888 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CB ' HG23 ' A' ' 68' ' ' THR . 29.6 p30 -127.27 18.77 6.99 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.46 ' CD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -83.5 103.51 12.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.981 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.1 t -93.43 177.57 5.99 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.905 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.3 p -147.04 155.24 42.06 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.42 HG22 ' N ' ' A' ' 56' ' ' THR . 7.6 p -167.36 155.97 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.971 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.42 ' N ' HG22 ' A' ' 55' ' ' VAL . 73.5 m -122.87 130.32 52.72 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.948 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 125.28 24.52 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.915 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -71.39 -170.37 0.5 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 -23.67 66.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -85.38 6.97 24.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.985 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 61.15 14.08 38.04 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.99 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.3 t -102.52 131.83 48.98 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.942 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.81 124.0 38.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.97 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.7 p -110.78 134.05 52.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.988 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.554 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.39 152.6 24.13 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.897 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.17 131.29 55.92 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.956 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.555 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.93 157.46 17.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.447 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 4.6 t -105.18 127.51 52.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.649 ' C ' ' HD2' ' A' ' 70' ' ' ARG . 1.7 t -84.34 126.23 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.66 ' HB2' ' OE1' ' A' ' 36' ' ' GLN . 1.2 mpt_? -119.76 145.9 46.15 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HD3' ' N ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -89.83 -8.07 52.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.938 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 90.3 p -178.02 149.96 0.59 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.057 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 3.8 p90 -176.77 154.58 1.19 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.921 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -49.55 114.37 1.03 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.546 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.89 92.76 0.55 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.681 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -83.81 99.34 10.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.953 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.6 tp -59.09 129.03 40.17 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.622 ' N ' HD12 ' A' ' 77' ' ' LEU . 32.4 p90 -47.56 -34.7 8.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.939 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.576 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.7 -16.72 11.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.982 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.08 28.11 8.91 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.4 m -116.93 150.88 37.79 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.933 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -87.04 97.67 10.85 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.902 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.644 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 76.7 t-105 -65.28 -56.41 12.88 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.928 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.76 166.46 11.6 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.991 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.19 108.14 0.38 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.944 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.183 HG11 ' CB ' ' A' ' 38' ' ' ALA . 69.3 t -82.25 147.85 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.971 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -114.46 93.7 4.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.949 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.499 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.0 m -52.74 -26.04 12.94 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 71' ' ' ARG . 78.7 p -80.19 0.14 33.7 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.54 -27.48 6.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.77 -177.98 4.6 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.967 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.21 124.45 46.92 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.908 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.934 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 60.5 m -103.6 153.61 20.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.996 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -142.85 145.12 32.84 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.964 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.555 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.2 t -102.73 160.33 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.268 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.63 166.72 37.25 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.097 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.64 128.59 37.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.974 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.104 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.8 m -115.36 160.97 19.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.936 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 1.028 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -115.45 -157.44 0.64 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.982 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.11 -47.84 81.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.524 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -74.39 -25.78 59.7 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.874 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.64 50.11 1.87 Allowed Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.976 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.524 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 2.0 p30 -119.46 158.32 26.48 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 1.047 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.48 176.35 43.46 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.988 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.522 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 171.04 17.79 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.317 3.345 . . . . 0.0 109.616 179.922 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.513 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 2.0 mt-10 -40.71 133.68 1.99 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.985 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.06 155.97 0.74 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.947 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 93.1 t -122.74 105.18 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.981 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -87.16 138.4 31.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.962 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.996 ' CG1' ' HA ' ' A' ' 94' ' ' GLN . 2.3 mt -117.68 157.94 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.984 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 10' ' ' SER . 3.1 t -149.34 127.82 12.29 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.894 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 -100.64 127.92 46.87 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.937 . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.489 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -52.88 118.6 13.91 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.921 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.627 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.42 -174.48 1.45 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.304 3.336 . . . . 0.0 109.614 179.949 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.351 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.5 t -98.72 111.7 23.99 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.987 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.643 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.42 152.31 47.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.972 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -109.8 113.32 25.98 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 20' ' ' LYS . 40.3 t -110.47 147.28 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.942 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.949 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.77 175.47 1.68 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.952 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.058 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.4 Cg_endo -72.36 116.59 4.77 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 124.346 3.364 . . . . 0.0 109.617 179.902 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.638 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 6.5 p -111.12 43.71 1.42 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.937 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.0 p -124.28 105.16 9.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.892 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.189 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.02 30.51 8.27 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.189 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.4 OUTLIER -110.93 129.72 55.8 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -112.88 177.01 4.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -44.67 138.66 3.28 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.984 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.01 -23.1 31.7 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.938 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.632 HG21 ' HB3' ' A' ' 13' ' ' LEU . 30.5 m -88.67 152.15 22.0 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.971 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 p -129.33 134.22 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.994 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.715 HG22 ' O ' ' A' ' 67' ' ' LEU . 17.9 m -95.27 166.13 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.989 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.862 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.57 143.64 44.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -139.32 104.52 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.919 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.643 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.1 115.29 23.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.934 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.742 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.03 143.93 22.42 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.949 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.351 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -139.83 107.21 5.53 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.853 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 20.02 11.33 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.945 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.306 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.87 -172.29 3.64 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.975 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.521 ' HB2' HG21 ' A' ' 30' ' ' THR . 84.5 mt-30 -71.87 121.47 19.08 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.932 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.977 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.14 133.67 44.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.0 8.48 73.78 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.989 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.521 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.11 138.25 33.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.955 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.8 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.58 151.58 24.43 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.961 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.7 m-85 -137.63 149.68 46.81 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.927 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.175 ' CB ' ' H ' ' A' ' 98' ' ' SER . 3.7 m-20 -113.25 114.18 26.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.991 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.296 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -100.42 145.32 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.131 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.01 169.37 41.34 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.925 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.695 HE22 ' H ' ' A' ' 70' ' ' ARG . 40.8 tt0 -113.74 106.07 14.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -108.4 146.27 33.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.95 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.711 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -125.97 137.87 53.71 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.629 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.4 119.67 11.42 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.965 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.351 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.6 m -100.56 -42.81 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -132.65 165.07 25.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.985 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 44' ' ' VAL . 32.4 m -51.2 111.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.907 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.03 69.06 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.953 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.519 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 10.7 t -122.01 117.96 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.667 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -129.15 138.24 51.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.984 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.43 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -101.44 152.11 21.13 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.951 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.0 m -106.79 148.57 28.32 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.994 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.948 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -111.37 117.13 49.95 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.974 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.6 Cg_endo -72.44 1.06 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.287 3.325 . . . . 0.0 109.621 179.908 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.455 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -82.51 -20.51 36.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.898 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.784 ' CB ' HG23 ' A' ' 68' ' ' THR . 98.3 m-20 -129.72 30.97 4.82 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.913 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.703 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.58 117.52 30.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.1 t -116.26 -178.96 3.53 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.946 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.6 p -146.46 154.52 41.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.874 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.476 HG22 ' N ' ' A' ' 56' ' ' THR . 5.3 p -166.18 158.9 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.998 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.6 m -127.11 133.16 50.44 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.952 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.26 153.59 42.14 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.975 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -89.63 -171.84 3.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.926 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.0 67.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.911 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.05 -16.83 61.03 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.961 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 88.24 6.35 74.84 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.975 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.01 140.03 32.95 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.941 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.61 163.32 17.52 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.976 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.15 122.92 9.27 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.549 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -157.8 162.73 38.46 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.524 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -118.37 129.85 55.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.912 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -106.77 124.45 49.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.913 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.784 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.6 141.43 41.08 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.962 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.487 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -102.67 131.65 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.994 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.695 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -119.13 157.3 28.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 -87.08 -20.66 26.81 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.8 t -168.77 151.71 5.18 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.9 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.948 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 1.7 p90 -173.7 159.54 3.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.94 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -61.01 114.96 3.37 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.943 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.43 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -73.43 94.6 0.74 Allowed Glycine 0 C--N 1.336 0.558 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 180.0 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.821 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -82.12 99.37 9.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.955 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.61 132.58 45.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.982 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.655 ' N ' HD12 ' A' ' 77' ' ' LEU . 5.9 m-85 -46.59 -37.29 7.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.953 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.8 t0 -56.98 -16.96 7.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.99 27.59 9.34 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.955 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -113.55 140.9 47.77 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.37 95.9 7.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.351 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 38.1 t-105 -63.0 -57.8 9.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.912 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.04 172.9 19.24 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.959 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.47 109.69 2.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.958 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.711 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.3 p -90.72 142.13 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -98.21 99.48 10.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.983 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.36 -22.32 7.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.0 p -87.31 1.58 52.83 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.922 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -112.83 -26.37 8.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.01 -178.94 5.26 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.954 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.04 128.35 42.86 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.303 ' O ' HG13 ' A' ' 110' ' ' ILE . 34.0 m -104.74 155.06 19.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.951 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -147.58 145.61 29.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.984 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.3 t -109.2 156.76 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.981 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.296 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -174.5 172.38 45.35 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.057 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -129.62 128.72 43.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.175 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 36.5 m -118.26 140.07 50.36 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.917 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.8 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 4.4 p-10 -111.81 -162.71 0.81 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.996 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.08 79.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.931 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -66.48 -24.37 66.41 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.926 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 83.02 35.29 18.86 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.957 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.931 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 1.9 p30 -108.45 -173.7 2.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.943 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.809 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 167.84 164.75 24.07 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.627 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.39 162.81 40.46 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.242 3.295 . . . . 0.0 109.576 179.954 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.489 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.9 OUTLIER -36.05 126.58 0.74 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -41.78 147.97 0.44 Allowed Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.783 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.0 t -122.15 106.74 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -91.36 150.48 21.26 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.954 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.303 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -118.45 161.87 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.944 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.534 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -145.22 111.78 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.954 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 113' ' ' ASN . 6.9 m-85 -87.93 101.91 14.2 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.924 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.584 ' CG ' ' O ' ' A' ' 112' ' ' PHE . 0.7 OUTLIER . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.938 -0.394 . . . . 0.0 109.938 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 041 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.383 ' CB ' ' O ' ' A' ' 106' ' ' GLU . . . -134.02 145.51 56.03 Favored Pre-proline 0 N--CA 1.449 -0.503 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.198 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.1 Cg_endo -72.38 -175.21 1.69 Allowed 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 124.272 3.314 . . . . 0.0 109.632 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.921 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.71 109.89 21.96 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.946 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.5 137.64 54.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.995 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.582 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -99.08 114.07 26.6 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.97 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.84 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.2 m -108.09 153.72 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.997 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.967 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.59 176.56 1.21 Allowed Pre-proline 0 N--CA 1.449 -0.476 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.077 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.38 117.79 5.3 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 124.352 3.368 . . . . 0.0 109.553 179.925 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 111' ' ' SER . 1.9 p -114.69 45.7 1.52 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.7 p -123.75 105.39 9.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.87 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.029 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.63 29.84 11.45 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.948 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.077 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.43 132.22 47.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.948 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 51.1 m -104.7 166.56 10.31 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.9 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -44.98 140.04 2.84 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.998 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.47 35.71 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.976 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 28.3 m -76.53 148.83 36.86 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.986 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.485 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.8 p -122.38 127.22 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 69' ' ' VAL . 16.1 m -93.76 170.31 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.84 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.62 148.3 41.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.999 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.724 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -143.75 108.18 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.997 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.859 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.83 115.13 21.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.81 143.13 19.67 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.958 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.921 ' O ' HG22 ' A' ' 4' ' ' THR . . . -137.6 111.97 8.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.949 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.932 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 102.77 24.59 8.06 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -91.12 -163.96 1.11 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.993 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.417 ' O ' ' HB ' ' A' ' 30' ' ' THR . 34.4 mt-30 -88.27 127.12 35.46 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.18 133.77 42.75 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.78 8.68 82.33 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.973 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.678 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -96.89 137.64 35.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.939 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.661 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.94 152.33 22.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.034 ' CD1' ' HD2' ' A' ' 105' ' ' PRO . 45.3 m-85 -139.29 149.34 44.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.91 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.105 ' CB ' ' H ' ' A' ' 98' ' ' SER . 14.7 m-20 -112.21 115.03 28.15 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.189 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.34 146.06 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.999 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.889 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.56 170.79 42.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.708 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 5.5 tt0 -117.46 122.99 45.27 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.92 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m -125.85 148.31 49.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.124 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 134.88 54.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.89 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.659 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.0 OUTLIER -65.31 123.5 19.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.909 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.17 HG21 ' CD2' ' A' ' 83' ' ' TRP . 32.3 m -103.84 -42.0 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.976 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.17 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -132.01 -178.67 5.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.963 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 33.1 m -69.67 113.45 6.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.948 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.91 10.01 80.17 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.641 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.23 125.48 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.964 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.736 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.5 pt? -133.62 140.92 47.39 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.959 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.72 144.15 25.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 23.2 m -105.51 159.89 15.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.741 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 21.8 t30 -118.67 111.57 37.64 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.989 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.44 0.55 7.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.307 3.338 . . . . 0.0 109.591 179.881 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -11.98 41.77 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.911 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.504 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.2 p30 -129.49 27.59 5.27 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.34 107.09 16.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.4 t -105.02 174.96 5.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.91 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.5 p -146.67 158.36 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.881 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.468 HG22 ' N ' ' A' ' 56' ' ' THR . 7.3 p -167.82 158.52 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.935 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.468 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.0 m -128.13 125.06 38.4 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.93 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.51 152.89 13.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -180.0 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.7 p30 -95.28 -169.47 1.98 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.951 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.65 -24.87 67.84 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.913 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -81.04 -7.26 59.52 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.973 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.43 13.28 83.55 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.978 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.8 p -105.02 139.69 39.32 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.867 -0.419 . . . . 0.0 109.867 179.951 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.54 162.27 20.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.972 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 p -150.14 122.19 8.26 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.921 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.539 HG22 HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -151.24 153.25 34.52 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.903 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -107.95 120.69 43.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.946 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.523 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -99.69 156.02 17.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.547 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -111.71 128.16 56.0 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -100.23 129.64 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.966 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.559 ' HB2' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -113.68 155.52 25.4 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.961 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.402 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 ppt_? -89.72 -12.77 38.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.544 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -166.06 142.39 5.06 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.92 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.741 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 10.8 p90 -178.0 158.05 1.2 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.895 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.19 124.9 21.69 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.911 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.513 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.18 103.97 2.54 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.915 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.726 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.57 102.03 12.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.958 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -56.61 131.6 49.34 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.968 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.659 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.2 p90 -47.44 -36.6 10.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.563 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.39 -16.48 9.24 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.953 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.41 27.57 9.8 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.958 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.4 m -115.11 150.3 36.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.971 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.4 mtm180 -85.36 98.0 10.3 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.956 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.641 ' CH2' HG21 ' A' ' 44' ' ' VAL . 22.8 t-105 -63.92 -51.33 64.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 179.896 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 139.03 179.73 17.69 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.969 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.86 134.26 56.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.927 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.124 HG11 ' HB3' ' A' ' 38' ' ' ALA . 6.5 t -114.62 150.08 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.2 94.43 4.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.926 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -53.37 -25.31 14.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 180.0 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.4 p -83.92 2.14 40.09 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.95 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -114.44 -27.85 7.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.942 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.33 179.88 5.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.937 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 126.32 41.93 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.907 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.327 ' C ' HG13 ' A' ' 110' ' ' ILE . 9.0 m -104.39 153.98 20.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.961 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.058 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -149.62 148.23 29.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.95 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.523 ' CG1' HD13 ' A' ' 67' ' ' LEU . 17.9 t -96.76 163.55 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.96 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.189 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.41 158.34 27.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.009 HD21 ' CG ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -141.53 137.61 32.14 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.972 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.105 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -129.13 153.48 47.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.912 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.661 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -98.11 -166.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.996 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -59.28 -49.99 75.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.978 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.639 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -69.29 -24.82 64.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.926 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.415 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 100.65 41.71 2.65 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.639 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 5.3 p30 -121.4 178.03 4.96 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.27 -176.0 20.81 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.98 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.04 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.46 134.03 21.8 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.298 3.332 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.383 ' O ' ' CB ' ' A' ' 2' ' ' ALA . 0.5 OUTLIER -136.04 144.3 45.17 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.992 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.39 59.46 0.19 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.979 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.99 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 36.4 t -133.54 100.74 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.617 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.37 153.75 18.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.969 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.327 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -121.91 161.36 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -148.65 117.05 6.51 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.961 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.039 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 45.3 m-85 -94.72 128.12 41.19 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.931 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.964 . . . . . . . . 0 0 . 1 . 042 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 042 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.847 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . -112.05 123.81 33.61 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.938 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.38 -177.35 2.67 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.331 3.354 . . . . 0.0 109.59 179.906 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.812 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.31 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.96 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.746 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.28 144.57 49.33 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.988 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.773 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -111.33 108.41 18.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.754 ' CG2' HG23 ' A' ' 21' ' ' VAL . 1.7 t -99.64 151.05 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.983 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -66.7 177.82 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.979 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.048 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.4 Cg_endo -72.4 115.82 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.304 3.336 . . . . 0.0 109.628 179.89 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.588 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 30.0 p -118.32 38.84 3.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.968 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 111' ' ' SER . 11.5 p -117.86 104.78 11.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.901 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.996 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.22 26.58 12.07 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.961 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.048 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -98.2 129.76 44.95 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.958 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -91.87 161.9 14.65 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -45.33 142.03 2.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.957 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.24 33.14 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.988 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD13 ' A' ' 13' ' ' LEU . 34.4 m -76.48 150.71 36.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.99 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.8 124.41 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.995 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.547 HG11 ' CB ' ' A' ' 10' ' ' SER . 18.5 m -96.15 133.95 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.991 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.662 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -79.2 154.47 29.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.801 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.2 p -140.95 103.13 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.773 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -109.51 121.33 44.96 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.94 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.741 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -101.7 139.62 14.49 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.812 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -134.37 127.07 30.91 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.992 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.03 24.18 23.24 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.001 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -91.29 -167.24 1.75 Allowed 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.488 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.0 mt-30 -84.93 125.18 32.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.991 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.76 130.74 41.18 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.54 8.22 83.81 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.954 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.546 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -95.4 132.16 40.75 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.916 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -79.64 150.63 30.91 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.934 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.605 ' CB ' HD12 ' A' ' 97' ' ' LEU . 31.5 m-85 -137.9 148.77 45.63 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.909 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.194 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.9 m-20 -113.89 116.29 29.06 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.917 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.245 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.12 145.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.995 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.038 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.69 169.57 41.3 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.978 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.033 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 10.6 tt0 -111.22 120.72 43.22 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.945 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.549 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -110.33 162.7 14.38 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.953 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.172 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -150.81 125.16 9.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.959 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.9 125.86 26.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.988 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.81 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.6 m -111.69 -35.62 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.173 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.2 -178.55 5.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.967 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 79.0 m -77.19 111.83 13.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.976 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.28 10.51 85.94 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.668 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -128.78 114.84 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.551 HD23 ' C ' ' A' ' 38' ' ' ALA . 0.5 OUTLIER -108.14 162.85 13.68 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.986 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.39 127.38 40.89 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.944 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.733 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.95 154.25 21.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.728 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.9 t30 -116.29 113.96 40.95 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.972 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.34 -0.11 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.33 3.353 . . . . 0.0 109.598 179.891 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.55 -16.1 29.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.836 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.578 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.3 p30 -125.96 25.63 6.75 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.915 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -91.22 106.25 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.967 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.2 t -99.66 -179.88 4.33 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.916 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.4 p -146.84 157.34 43.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.901 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -166.69 160.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.914 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.508 ' N ' HG22 ' A' ' 55' ' ' VAL . 12.0 m -127.52 141.08 51.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.572 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -79.36 134.51 36.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.4 p30 -78.6 -171.84 2.68 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.933 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.26 -26.14 68.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.947 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -77.77 -3.97 44.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.001 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.53 31.26 70.87 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.999 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.6 p -123.14 133.7 54.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.963 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -139.22 124.57 19.17 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.983 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.97 143.04 46.72 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.949 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.48 166.23 33.35 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -105.79 124.61 49.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.029 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.82 118.59 35.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.981 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.641 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.1 t -80.88 132.34 35.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.938 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.555 HG23 ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -107.78 130.52 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.598 ' O ' ' SG ' ' A' ' 88' ' ' CYS . 1.5 mpt_? -115.78 146.25 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.98 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.715 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.7 OUTLIER -70.86 -4.39 24.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.957 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 31.7 p -178.79 153.25 0.65 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.9 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.033 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 6.4 p90 -176.87 162.31 2.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.955 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -56.15 126.45 26.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.07 88.64 1.5 Allowed Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.933 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.733 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.87 100.85 11.25 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.996 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.3 tp -63.46 130.55 44.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.9 p90 -47.48 -36.04 9.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.986 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.539 ' H ' ' CD1' ' A' ' 77' ' ' LEU . 1.4 t70 -57.37 -16.63 9.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.994 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.0 27.36 9.51 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.994 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -113.61 144.99 41.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.87 94.24 9.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.966 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.668 ' CZ2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.41 -57.75 9.29 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.78 164.28 10.5 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.992 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -56.0 127.5 30.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.934 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.172 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.8 OUTLIER -107.79 154.95 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.993 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.56 108.7 16.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.957 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.84 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 35.1 m -54.25 -26.48 29.07 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.976 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.6 p -82.02 -0.97 46.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.965 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -116.4 -27.36 6.81 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.932 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.88 -178.31 4.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.69 124.24 40.62 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.15 ' C ' HG13 ' A' ' 110' ' ' ILE . 94.9 m -104.47 152.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.956 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.044 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -156.42 146.04 20.86 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.949 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.029 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 9.2 t -96.53 162.57 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.245 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 160.49 31.33 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.605 HD12 ' CB ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -138.84 141.8 38.65 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.972 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.194 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -134.02 157.8 45.17 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.929 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.916 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.89 -164.16 1.02 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.448 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.13 -49.68 76.13 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.576 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.8 -24.78 61.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.902 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.85 41.13 2.95 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 6.1 p30 -117.68 176.69 5.06 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.4 -175.75 20.76 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 179.975 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.985 ' HG2' HD21 ' A' ' 97' ' ' LEU . 83.2 Cg_endo -72.39 133.89 21.67 Favored 'Trans proline' 0 N--CA 1.447 -1.247 0 C-N-CA 124.338 3.359 . . . . 0.0 109.568 179.908 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.847 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 3.7 tt0 -137.26 147.49 45.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.96 58.11 0.23 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.946 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.025 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.4 t -130.88 101.38 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.41 143.36 28.94 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.15 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -110.79 169.27 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.92 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.451 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -161.4 127.64 3.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.943 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.84 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 11.2 m-85 -99.1 116.84 32.25 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.893 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.956 ' O ' ' HA2' ' A' ' 12' ' ' GLY . 3.4 p30 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 043 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.135 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . -87.72 147.33 41.11 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.943 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.218 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.5 Cg_endo -72.41 -175.3 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.297 3.331 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.723 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -100.55 108.68 20.68 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.92 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.881 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.98 136.87 54.38 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.932 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.625 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -98.53 112.27 24.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.969 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.834 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -106.2 153.42 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.997 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.953 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.73 176.93 1.1 Allowed Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.92 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.096 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.9 Cg_endo -72.35 115.9 4.5 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.323 3.349 . . . . 0.0 109.59 179.881 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -112.95 41.23 2.12 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.956 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.529 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -119.04 105.43 11.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.876 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.081 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 93.2 28.24 12.08 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.99 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.096 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -103.24 130.16 50.4 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.976 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -106.16 174.52 5.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.944 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -48.65 139.97 8.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.935 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.66 -23.59 32.26 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.999 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.448 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.3 m -80.17 151.92 29.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.973 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.1 p -127.11 130.2 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.979 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 1.02 HG22 ' O ' ' A' ' 67' ' ' LEU . 15.4 m -95.87 170.66 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.995 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.834 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.59 148.8 40.58 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.735 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -143.3 106.09 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.971 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.881 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.04 115.76 24.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.798 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.35 142.12 19.42 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.723 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.91 112.53 9.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.964 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.947 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.53 25.7 8.04 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -180.0 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.218 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -91.26 -163.8 1.09 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -89.25 125.21 34.99 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.97 133.86 44.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.66 8.57 84.4 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.606 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -98.83 134.57 41.52 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.995 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.953 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.47 152.24 25.05 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.546 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 38.0 m-85 -138.51 145.25 40.53 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.928 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -110.15 122.45 47.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.924 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.116 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.2 t -102.19 150.17 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.997 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.996 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.88 146.66 9.2 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.943 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.806 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 14.4 tt0 -92.58 115.86 28.48 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.598 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -103.13 163.78 12.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.951 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 1.198 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.16 131.42 15.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.96 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.542 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.0 OUTLIER -67.32 124.57 23.51 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.987 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.3 m -111.39 -41.64 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.974 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.533 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -146.1 -178.8 6.32 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.964 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.673 ' O ' HG23 ' A' ' 42' ' ' THR . 1.3 t -65.1 111.6 2.98 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.986 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 7.92 62.73 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.988 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.571 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 45.9 t -111.02 105.2 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.69 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.3 mt -107.98 153.29 23.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.483 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -128.15 128.63 45.18 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.966 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -106.87 154.81 20.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.538 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.7 t30 -116.15 112.53 41.94 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -179.982 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -72.33 -0.35 8.55 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.308 3.338 . . . . 0.0 109.616 179.839 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.538 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.83 -12.26 34.2 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.832 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' A' ' 68' ' ' THR . 23.6 p30 -130.82 27.34 4.93 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.63 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -103.35 116.14 31.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.977 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 54' ' ' SER . 30.2 t -100.56 -173.22 2.35 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.984 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.442 ' N ' ' OG ' ' A' ' 53' ' ' SER . 4.7 p -147.14 154.08 40.67 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.85 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -167.06 154.44 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 58.7 m -123.8 122.73 38.8 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.954 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -52.79 149.75 5.95 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -92.27 -171.44 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.955 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.27 -25.06 67.64 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -81.35 -5.0 57.39 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.415 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 72.58 23.66 77.53 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 82.4 p -114.42 138.06 51.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.996 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.61 163.02 19.63 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.997 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -150.94 120.0 6.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.512 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -148.86 158.08 43.9 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.892 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.45 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -110.4 126.35 54.19 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.985 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.02 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -107.58 118.24 36.2 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.965 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.677 ' N ' HD13 ' A' ' 67' ' ' LEU . 4.7 t -69.0 149.73 48.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.922 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.531 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -106.46 123.93 61.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.967 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.531 ' HD2' ' O ' ' A' ' 69' ' ' VAL . 1.5 mpt_? -116.58 137.09 52.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.971 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.47 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 26.0 ptt180 -75.26 -18.34 60.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 9.7 t -163.82 151.57 12.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.911 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.806 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -177.8 155.7 1.04 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.885 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -55.93 122.63 12.01 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.931 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.483 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.54 89.46 1.03 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.966 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.45 10.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.989 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.855 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.25 141.74 28.56 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.711 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.0 m-85 -47.1 -42.37 18.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.978 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.573 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 12.2 t0 -57.05 -17.06 8.71 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.959 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.82 28.16 9.71 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.934 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.855 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.0 m -108.78 131.16 55.23 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttt180 -72.94 91.62 1.56 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.944 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.533 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 0.5 OUTLIER -61.96 -57.0 13.37 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.884 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.41 170.2 21.31 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 179.982 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.47 142.22 33.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.198 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -117.91 154.11 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.973 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.507 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 10.0 m-20 -128.73 95.0 3.99 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.965 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 1.226 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 99.1 m -54.31 -25.63 24.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.977 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -80.45 1.87 27.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.978 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -113.83 -27.39 7.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.969 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.07 -170.55 2.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.983 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.89 126.52 42.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.92 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.344 ' C ' HG13 ' A' ' 110' ' ' ILE . 11.9 m -104.68 152.84 22.01 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.073 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.8 148.09 31.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.92 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.837 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 24.1 t -99.72 164.86 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.952 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.026 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.81 158.03 24.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.546 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -134.9 152.9 52.14 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.974 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER -141.32 158.47 43.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.903 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.953 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -105.28 -163.13 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.967 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.51 -49.34 77.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.941 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.582 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -72.79 -25.44 61.16 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.947 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.07 42.38 2.43 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.95 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.634 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 5.0 p30 -119.51 176.12 5.51 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.19 -173.22 22.81 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.994 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.126 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.38 133.35 20.72 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.345 3.363 . . . . 0.0 109.641 179.92 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.135 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 2.3 tt0 -136.1 145.74 46.24 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 57.36 0.23 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.964 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.006 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 25.5 t -131.58 100.94 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.978 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.655 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -97.57 155.22 17.06 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.996 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.344 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -124.29 163.49 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.949 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.529 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -153.61 122.47 6.41 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.959 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.226 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 10.0 m-85 -87.6 116.32 25.65 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 179.902 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 1.081 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 4.4 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.966 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 044 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.893 ' HA ' ' HG3' ' A' ' 106' ' ' GLU . . . -103.51 108.95 60.95 Favored Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.165 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.42 -174.05 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.347 3.365 . . . . 0.0 109.579 179.964 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.648 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.03 109.48 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.939 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.795 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.73 141.74 49.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.937 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -96.72 111.44 23.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.915 HG21 HG22 ' A' ' 108' ' ' VAL . 21.9 t -107.66 148.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.978 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -68.48 177.63 1.04 Allowed Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.103 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.38 117.97 5.38 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 124.32 3.346 . . . . 0.0 109.607 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 111' ' ' SER . 9.3 p -115.11 44.58 1.78 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.957 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.4 m -122.91 105.11 9.71 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.88 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.955 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.88 28.1 14.8 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.103 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.69 132.69 43.1 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.8 m -107.19 172.93 6.55 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.956 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.65 140.05 15.15 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.39 -22.99 35.67 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.496 HG21 HD13 ' A' ' 13' ' ' LEU . 86.3 m -74.59 153.11 39.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.506 ' O ' HG13 ' A' ' 18' ' ' VAL . 7.1 p -129.96 126.1 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.894 HG22 ' O ' ' A' ' 67' ' ' LEU . 26.3 m -94.57 176.65 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.98 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.833 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.35 149.28 45.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.944 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.619 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -145.11 108.03 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.795 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.27 116.78 23.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.961 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.933 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.39 144.34 21.48 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.648 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -140.67 112.6 7.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.933 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 105.22 21.75 8.69 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.165 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -91.29 -163.91 1.1 Allowed 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.843 ' OE1' ' OH ' ' A' ' 32' ' ' TYR . 12.0 mp0 -89.94 126.43 35.73 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.485 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -69.61 141.59 53.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.978 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.69 7.72 59.03 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.96 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.753 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.57 143.05 26.73 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.564 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.22 148.84 21.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.984 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.843 ' OH ' ' OE1' ' A' ' 27' ' ' GLN . 49.4 m-85 -137.85 148.55 45.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.2 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.7 m-20 -112.38 114.57 27.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.964 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.074 HG22 ' HB3' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -96.18 146.43 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.978 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.887 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.5 167.88 40.97 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.953 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.812 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 8.2 tt0 -115.97 113.38 23.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -114.3 149.05 36.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.971 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.66 134.91 52.72 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.928 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.663 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 120.56 13.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.95 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.433 HG21 ' CD1' ' A' ' 83' ' ' TRP . 24.8 m -101.07 -44.95 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.982 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.865 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.6 OUTLIER -133.36 172.36 12.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 42' ' ' THR . 1.6 t -56.47 111.44 0.99 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.92 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.88 7.53 62.21 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.789 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 21.6 t -120.68 111.08 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.951 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.705 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.1 pt? -123.43 140.97 52.47 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.516 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -98.33 146.03 26.09 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 12.1 m -106.48 153.97 21.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.757 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.0 t30 -114.52 109.82 47.92 Favored Pre-proline 0 N--CA 1.45 -0.468 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.4 -0.35 8.58 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.293 3.328 . . . . 0.0 109.585 179.914 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.53 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.65 -16.57 32.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.876 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 13.7 p30 -128.24 28.44 5.49 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.878 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.682 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.47 118.95 36.29 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.97 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -111.43 -172.84 2.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.965 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -146.7 157.66 43.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.888 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 56' ' ' THR . 4.5 p -166.75 159.53 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.466 ' N ' HG22 ' A' ' 55' ' ' VAL . 14.0 m -127.1 137.5 53.02 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.985 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.83 131.44 39.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -73.75 -173.43 1.51 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.26 -20.42 62.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -85.98 10.09 15.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.485 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 56.79 26.78 54.77 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.946 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 t -121.21 133.54 55.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.439 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.44 156.75 32.06 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -139.02 133.69 32.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.663 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.93 170.34 19.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.942 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.663 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -121.01 138.39 54.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.939 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.894 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -115.77 118.81 34.07 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.943 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.719 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -71.1 135.89 47.93 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.565 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -92.67 125.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.971 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.719 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 1.1 mpt_? -117.8 140.63 49.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.416 ' O ' ' OG ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -82.72 -15.84 50.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 58.4 m -167.33 152.13 7.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.979 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.812 ' HE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -176.55 161.86 2.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.929 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.403 ' HG3' ' CD2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -62.54 110.58 1.74 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.94 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.516 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.97 94.21 0.44 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.958 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.867 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.5 m-85 -82.88 98.78 9.36 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.956 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 1.114 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -55.49 142.28 33.62 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.982 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.745 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.67 -42.91 25.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 1.114 ' OD2' HD21 ' A' ' 77' ' ' LEU . 4.0 m-20 -57.75 -16.76 12.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.78 27.73 12.25 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.836 ' HB ' HD23 ' A' ' 77' ' ' LEU . 4.9 m -106.08 134.07 49.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.97 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.48 91.64 0.78 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.433 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.76 -48.82 77.51 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.878 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.63 167.13 10.94 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -65.43 103.59 0.85 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.963 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.4 m -78.61 151.81 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.981 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -110.48 93.85 4.71 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.788 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 13.7 m -51.29 -26.26 7.09 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.7 p -81.06 0.79 34.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 -179.999 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -117.3 -27.62 6.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.51 -179.9 5.43 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.34 123.77 40.1 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.295 ' C ' HG13 ' A' ' 110' ' ' ILE . 89.1 m -104.59 155.66 18.65 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -180.0 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.034 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 1.2 pt20 -144.56 147.49 33.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.944 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.795 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 14.2 t -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.952 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.08 160.05 28.71 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.074 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -128.35 155.29 44.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.954 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.2 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -143.45 144.23 31.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.898 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.564 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -90.97 -161.78 0.85 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.457 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.69 -49.29 78.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.586 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -71.13 -24.79 62.34 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.93 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.83 42.5 2.45 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.994 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.586 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 5.7 p30 -121.07 177.16 5.24 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.92 -173.65 22.28 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.069 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.35 133.85 21.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.364 3.376 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.893 ' HG3' ' HA ' ' A' ' 2' ' ' ALA . 1.8 pt-20 -139.8 161.53 37.34 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.79 51.71 0.6 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.925 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.98 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.0 t -126.44 101.82 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.996 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.09 146.83 24.32 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.955 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.295 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -115.78 159.71 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.907 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -151.0 126.73 10.25 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.909 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.788 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 8.3 m-85 -101.48 124.93 47.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.932 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.616 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 49.2 m-80 . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.961 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 045 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.633 ' C ' ' HB3' ' A' ' 106' ' ' GLU . . . -133.34 123.61 17.76 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.932 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.406 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.38 -174.13 1.34 Allowed 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.286 3.324 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.162 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.4 t -95.93 109.73 22.05 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.839 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.99 145.7 50.89 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.511 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -103.9 113.37 26.85 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.884 HG13 ' O ' ' A' ' 20' ' ' LYS . 38.5 t -110.66 148.53 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.996 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.15 175.94 1.59 Allowed Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.945 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.956 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 120.95 7.07 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.351 3.367 . . . . 0.0 109.63 179.851 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.085 ' HA ' HD21 ' A' ' 13' ' ' LEU . 30.8 p -120.83 52.48 1.18 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 62.0 p -137.81 106.14 5.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.9 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.68 8.47 40.01 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.9 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.146 ' O ' HD12 ' A' ' 13' ' ' LEU . 3.5 pp -114.68 143.08 45.61 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -122.47 -166.99 1.49 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.936 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.943 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 42.7 t0 -43.32 151.73 0.15 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.969 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 92.02 -23.38 26.86 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.998 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.778 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -85.08 146.05 27.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 18' ' ' VAL . 14.8 p -116.21 129.52 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.638 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 6.0 m -99.75 159.4 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.884 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 145.42 41.37 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.969 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.592 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -142.06 110.16 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.989 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.839 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.89 112.91 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.979 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.904 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.92 144.77 21.25 Favored Glycine 0 C--N 1.334 0.468 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.162 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -142.86 110.13 5.68 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.955 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.879 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.89 14.92 15.95 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.234 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -91.04 165.94 13.26 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.463 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.9 mt-30 -48.99 121.26 4.58 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.96 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.608 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.69 134.93 45.28 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.945 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 8.2 76.32 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.981 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.751 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -97.7 137.41 36.63 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.995 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.12 151.97 24.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.998 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.57 ' CB ' HD23 ' A' ' 97' ' ' LEU . 73.0 m-85 -135.77 158.2 44.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.925 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.45 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 17.1 m-20 -119.71 117.93 29.55 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.948 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.42 138.13 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.958 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 1.173 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -158.91 162.88 32.91 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.839 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 1.8 tt0 -115.13 121.62 43.59 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.915 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.567 ' HB3' HD13 ' A' ' 45' ' ' LEU . 66.9 m -108.59 172.7 6.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.976 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.833 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -152.84 124.34 7.71 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.943 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.598 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 124.25 21.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.947 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.641 ' CG1' HG22 ' A' ' 86' ' ' VAL . 12.1 m -104.43 -43.7 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.952 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.701 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.88 164.13 30.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.6 m -53.33 114.06 1.36 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.944 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.6 7.92 70.4 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.511 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 15.0 t -126.44 105.76 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.953 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.763 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.84 162.65 17.76 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.495 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.18 146.96 49.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.817 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.4 m -108.35 155.95 19.96 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.826 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 33.6 t30 -114.59 105.64 53.3 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.287 3.325 . . . . 0.0 109.609 179.885 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.44 -12.94 41.67 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.878 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.9 p30 -126.71 28.51 5.87 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.72 104.57 13.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.997 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.1 t -101.65 177.26 4.96 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.923 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 p -146.44 153.08 40.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.852 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -167.37 153.04 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.966 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.1 m -122.58 139.62 53.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.0 142.86 32.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.917 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -80.02 -170.73 2.59 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -22.08 66.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.961 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.92 4.75 21.36 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.608 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.32 31.01 72.44 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.921 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.8 t -125.05 132.28 53.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.94 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.12 164.07 17.43 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.979 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -146.74 135.64 22.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.593 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.05 165.35 17.93 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.913 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.593 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -122.34 126.06 47.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.939 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.206 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.83 155.34 16.82 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 68' ' ' THR . 5.0 t -103.7 119.29 38.62 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.946 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.813 HG11 ' CD1' ' A' ' 13' ' ' LEU . 2.1 t -84.35 128.4 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.943 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.6 OUTLIER -119.1 156.82 29.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.412 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -90.93 -24.98 20.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.923 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.412 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -156.47 148.35 22.94 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.946 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.839 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.8 p90 -174.41 153.42 1.91 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.935 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.501 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -54.29 115.13 1.92 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.495 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.49 100.64 0.83 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.986 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.817 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -83.41 99.95 10.39 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.988 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.952 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -58.61 130.94 49.25 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 14.1 p90 -47.65 -35.75 9.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.553 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.96 -16.35 12.06 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.19 27.68 9.88 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.986 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.952 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.3 m -115.36 151.65 34.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.419 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -89.45 97.86 11.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.511 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.43 -55.9 20.57 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.883 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.56 172.67 17.09 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.26 108.25 0.45 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.978 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.833 HG11 ' HB3' ' A' ' 38' ' ' ALA . 86.4 t -86.05 147.43 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 48.1 m-20 -108.09 90.87 3.43 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.963 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.429 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -53.06 -25.24 12.03 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 61.0 p -78.01 -3.33 41.5 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.78 -26.07 7.54 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.46 -179.89 4.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.962 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.26 136.97 36.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.899 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.463 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.69 166.05 10.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.998 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.335 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -169.52 127.9 0.96 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.911 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.206 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.9 t -92.41 164.28 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -170.22 164.83 38.16 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.57 HD23 ' CB ' ' A' ' 32' ' ' TYR . 4.3 mp -100.33 160.93 13.94 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.45 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 14.6 m -155.0 117.44 4.26 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.437 ' OD1' ' OD1' ' A' ' 103' ' ' ASN . 3.2 p-10 -112.11 -158.15 0.64 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.958 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.13 -39.49 59.99 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -26.89 19.6 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.77 53.52 2.23 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.437 ' OD1' ' OD1' ' A' ' 99' ' ' ASP . 0.9 OUTLIER -106.68 -174.7 2.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.994 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.422 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 171.01 175.58 39.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.406 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.9 Cg_endo -72.33 160.63 46.54 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.32 3.347 . . . . 0.0 109.581 179.948 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.271 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -33.84 126.63 0.42 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.991 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.462 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.76 135.75 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.335 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 25.3 t -119.05 102.88 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.956 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.908 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.7 158.22 19.48 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.969 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.87 HG13 ' HA ' ' A' ' 94' ' ' GLN . 35.2 mt -125.98 162.49 29.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.986 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.598 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -141.07 121.39 13.95 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.903 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.463 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 2.9 m-85 -97.72 122.21 40.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.2 m120 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.943 . . . . . . . . 0 0 . 1 . 046 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 . . . . . . . . . 0 0 . 1 . 046 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 1.292 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -145.03 130.56 9.41 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.91 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.565 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.4 Cg_endo -72.38 -174.3 1.39 Allowed 'Trans proline' 0 N--CA 1.446 -1.272 0 C-N-CA 124.337 3.358 . . . . 0.0 109.634 179.886 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.282 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.6 t -95.97 111.42 23.43 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.957 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.801 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.57 140.13 50.45 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -102.25 111.27 23.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.985 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.652 HG11 HG21 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -108.22 155.05 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.981 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.972 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.43 177.02 1.02 Allowed Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.929 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 1.136 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.39 117.86 5.33 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.316 3.344 . . . . 0.0 109.605 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.494 ' OG ' HG23 ' A' ' 110' ' ' ILE . 22.6 p -114.31 41.39 2.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.963 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 111' ' ' SER . 60.4 p -123.41 105.97 10.26 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.928 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.957 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.68 26.38 15.29 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.976 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.136 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.93 132.49 43.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.958 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.2 m -90.79 151.8 21.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.938 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -44.09 137.84 3.19 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.93 -20.9 37.43 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.984 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.435 HG21 HD13 ' A' ' 13' ' ' LEU . 90.9 m -64.78 147.46 53.13 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.995 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.7 p -110.58 117.78 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.972 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 67' ' ' LEU . 14.8 m -95.48 164.75 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.627 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.16 153.33 29.75 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.947 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.681 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -149.39 113.48 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.982 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.801 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.25 114.5 21.47 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.766 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.28 147.69 23.61 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.282 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -147.48 109.85 4.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.933 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.886 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.67 14.0 18.86 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.193 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -90.49 165.8 13.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 76.8 mt-30 -50.91 118.99 3.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.855 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.05 134.99 46.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.971 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.25 8.73 80.05 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.916 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.643 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 142.69 29.41 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.975 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.583 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.03 153.21 22.3 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.975 ' HB3' ' HB3' ' A' ' 97' ' ' LEU . 59.2 m-85 -138.29 150.88 47.07 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.919 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.493 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.2 m-20 -116.87 114.86 24.47 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.591 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.52 139.94 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.956 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.76 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.92 156.92 28.17 Favored Glycine 0 C--N 1.335 0.489 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.702 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 52.8 tt0 -96.33 113.54 25.14 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.3 m -102.17 159.5 15.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.992 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -149.2 141.45 24.07 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.905 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.549 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.2 t90 -63.6 121.65 14.42 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.718 HG12 ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -109.53 -36.37 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -155.24 -175.81 5.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.601 ' O ' HG23 ' A' ' 42' ' ' THR . 7.2 t -73.56 110.55 7.93 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.88 12.75 83.71 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.649 HG21 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -128.9 121.15 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.985 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -113.78 162.2 16.59 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.989 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.471 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -132.14 130.91 41.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.76 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.65 155.23 20.39 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.759 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.2 p-10 -118.69 120.1 31.98 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.955 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.422 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.5 Cg_endo -72.34 1.66 5.88 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.298 3.332 . . . . 0.0 109.627 179.879 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.736 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.33 -24.79 29.63 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.874 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.51 ' CB ' HG23 ' A' ' 68' ' ' THR . 94.4 m-20 -123.39 30.98 6.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.665 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.14 117.71 34.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 -179.973 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.2 t -110.86 -177.95 3.35 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.7 p -148.46 153.79 38.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 56' ' ' THR . 3.1 p -167.63 161.65 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.901 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.4 m -126.53 131.76 51.51 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 153.19 44.25 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 -179.999 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.3 p-10 -90.38 -166.42 1.58 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.937 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -30.23 71.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.885 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.39 -9.55 58.7 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.855 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.48 15.99 80.82 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.983 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.5 p -104.57 138.3 41.13 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.951 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.96 166.65 13.54 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 m -150.92 117.34 5.7 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.83 157.9 43.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.948 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.439 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -110.76 125.22 53.31 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.899 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.235 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -104.65 155.3 18.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.967 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.775 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -116.74 142.81 46.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -110.48 125.13 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.991 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.604 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -110.14 159.91 16.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.976 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.67 -29.39 59.05 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 69.6 p -165.28 156.96 14.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.759 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 3.1 p90 -175.28 167.35 3.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -63.97 118.82 9.0 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.947 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.471 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -75.01 85.3 0.79 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.76 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.05 98.63 9.39 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.8 tp -54.71 134.7 47.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 27.2 p90 -45.63 -38.43 6.65 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.999 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.587 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t70 -57.66 -17.14 13.12 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.943 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.88 28.7 9.18 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.9 m -112.65 115.91 29.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.948 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -66.03 93.36 0.2 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.649 ' CE2' HG21 ' A' ' 44' ' ' VAL . 2.3 t-105 -63.44 -57.98 8.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.925 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.35 171.38 19.88 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.967 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.48 140.67 56.02 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.992 HG21 ' HB1' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.61 151.6 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.56 100.78 9.53 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.899 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 23.8 m -53.5 -26.0 18.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.979 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -82.5 -1.7 51.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.979 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.48 -27.99 6.98 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.919 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -125.4 -175.15 3.24 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.39 124.57 41.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.899 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.185 ' O ' HG13 ' A' ' 110' ' ' ILE . 1.7 m -104.66 153.65 20.97 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.133 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -158.5 144.92 17.22 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.959 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.235 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 25.4 t -101.41 162.38 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.81 164.25 35.63 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.591 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -101.72 160.95 14.02 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -180.0 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.493 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 3.3 p -153.47 119.48 5.39 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.583 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 13.4 p-10 -115.11 -167.11 1.19 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -50.74 -21.15 1.49 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.875 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.18 -24.59 13.14 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.931 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 85.69 22.52 49.92 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.905 ' OD1' ' CD1' ' A' ' 32' ' ' TYR . 16.7 p-10 -59.8 -151.17 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.987 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.06 153.73 6.11 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.975 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.565 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.4 Cg_endo -72.44 161.49 44.1 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.316 3.344 . . . . 0.0 109.6 179.985 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 1.292 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -32.75 123.91 0.35 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.936 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.776 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -36.03 134.93 0.6 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.133 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.77 102.45 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.482 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -85.58 141.1 30.08 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.185 HG13 ' O ' ' A' ' 93' ' ' CYS . 1.0 OUTLIER -109.48 167.39 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.949 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -150.52 123.49 8.74 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.962 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 19.7 m-85 -99.6 126.19 45.55 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.903 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.993 . . . . . . . . 0 0 . 1 . 047 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.516 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 047 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.806 ' CB ' ' HG3' ' A' ' 106' ' ' GLU . . . -68.9 115.56 32.49 Favored Pre-proline 0 N--CA 1.449 -0.496 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.952 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 1.187 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.4 -177.83 2.96 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.266 3.311 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.14 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.8 114.45 28.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.98 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.907 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.37 131.85 50.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.712 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.03 112.07 23.81 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.975 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.948 HG11 HG22 ' A' ' 108' ' ' VAL . 1.3 m -113.08 149.69 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.926 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.999 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.14 179.87 0.65 Allowed Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.923 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.999 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.6 Cg_endo -72.42 121.0 7.09 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.321 3.348 . . . . 0.0 109.538 179.947 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 10' ' ' SER . . . . . 1.016 ' HA ' HD21 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -110.48 3.73 19.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.986 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 11' ' ' SER . . . . . 1.398 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 66.1 m -110.36 126.11 53.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.901 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.489 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 103.71 5.29 45.13 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.937 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.016 HD21 ' HA ' ' A' ' 10' ' ' SER . 2.1 pp -114.32 146.58 40.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 88.4 p -99.0 171.5 8.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -45.37 151.82 0.34 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 179.969 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.79 -22.36 34.2 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.968 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 ' CB ' ' A' ' 13' ' ' LEU . 59.0 m -69.31 138.53 53.88 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.993 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.5 p -104.11 132.42 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.996 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.86 HG23 HG12 ' A' ' 69' ' ' VAL . 21.5 t -104.12 168.41 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.979 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.836 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.78 134.87 53.57 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.945 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.796 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.2 p -128.08 104.86 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.907 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -111.39 115.23 28.91 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.705 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.61 145.62 21.99 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.14 ' O ' HG22 ' A' ' 4' ' ' THR . . . -146.2 112.27 5.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.15 26.18 8.48 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.961 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 1.125 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.83 -165.81 1.44 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.953 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.788 ' OE1' ' OH ' ' A' ' 32' ' ' TYR . 16.9 mp0 -94.35 124.83 38.61 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.1 137.45 57.98 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.4 8.66 63.01 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.304 -1.119 . . . . 0.0 110.304 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.789 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -91.69 142.71 27.31 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.993 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.774 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.13 150.5 21.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.983 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 1.102 ' CG ' ' HD2' ' A' ' 105' ' ' PRO . 56.9 m-85 -139.3 144.51 38.35 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.908 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 1.408 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.2 m-20 -105.57 114.76 29.13 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.23 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.47 150.88 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.983 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.755 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.87 168.4 38.56 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.98 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 1.003 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.6 tt0 -111.29 120.96 43.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.536 ' HB3' HD13 ' A' ' 45' ' ' LEU . 88.9 m -109.95 169.1 8.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.863 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -153.68 125.13 7.56 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.481 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.57 129.85 41.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.903 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 1.638 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.4 m -109.33 -37.81 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.407 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -146.82 163.69 35.23 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.958 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.416 ' H ' HG22 ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.19 114.89 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.965 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.56 1.93 62.63 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.989 HG12 HG23 ' A' ' 40' ' ' VAL . 15.9 t -121.02 119.64 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.742 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -126.75 162.22 26.32 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.484 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -124.24 139.67 53.7 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 1.033 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 24.1 m -109.18 151.83 25.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.562 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.9 t30 -112.77 110.74 51.9 Favored Pre-proline 0 N--CA 1.448 -0.552 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.977 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 124.341 3.361 . . . . 0.0 109.596 179.936 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.562 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.05 -20.54 23.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.909 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.688 ' OD2' ' NE2' ' A' ' 36' ' ' GLN . 8.5 p30 -119.38 19.93 12.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.671 ' CD1' ' C ' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -92.35 113.57 25.87 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.7 t -108.0 -174.28 2.48 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -146.28 155.9 42.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.915 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 56' ' ' THR . 5.7 p -166.88 158.13 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.941 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.456 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.5 m -127.78 129.42 46.99 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 135.57 55.62 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 p30 -76.66 -175.19 3.27 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.941 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.66 -19.96 64.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -87.34 10.3 17.73 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.074 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 30.35 59.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.6 t -124.82 135.98 53.42 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.964 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.35 164.63 19.97 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.0 m -152.41 119.48 5.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.983 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.17 164.14 34.07 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.865 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.554 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -106.68 133.74 50.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.943 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.184 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -119.59 120.2 36.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.916 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.616 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -83.97 145.04 28.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.989 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.86 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -121.51 134.56 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.859 ' HG2' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.92 174.94 5.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.988 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HG2' ' CG2' ' A' ' 89' ' ' THR . 6.5 mtt180 -98.68 -12.19 21.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.948 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 20.3 p -173.68 145.95 1.24 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 1.003 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 1.2 p90 -171.6 163.25 6.61 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.922 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.14 118.02 3.99 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.943 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.484 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.74 96.08 1.4 Allowed Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 1.033 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.14 100.64 11.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.875 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -56.21 130.64 45.19 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.972 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.619 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.1 p90 -47.42 -35.36 8.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.998 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.61 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.1 t0 -57.49 -17.55 14.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.4 27.92 8.34 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.875 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.5 m -116.88 148.09 41.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.96 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -85.46 96.34 9.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.97 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 1.638 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 72.6 t90 -64.35 -58.05 7.6 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.859 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.42 170.79 16.65 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.987 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.52 0.4 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.863 HG21 ' CB ' ' A' ' 38' ' ' ALA . 2.5 p -86.3 143.1 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.981 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.72 96.43 8.6 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.954 ' O ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -55.35 -20.01 10.52 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.947 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.604 ' CG2' ' HG2' ' A' ' 71' ' ' ARG . 33.5 p -88.94 1.4 55.5 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 m -114.16 -27.44 7.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.978 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.31 179.42 4.91 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.975 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.45 123.14 41.2 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.907 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 1.56 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -104.71 157.71 17.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 1.121 ' N ' HG13 ' A' ' 110' ' ' ILE . 1.3 pt20 -156.19 144.67 20.02 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.975 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.184 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 11.9 t -93.58 156.98 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 1.23 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -172.54 165.91 38.51 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.294 -1.123 . . . . 0.0 110.294 179.997 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.164 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -136.52 143.44 43.74 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 98' ' ' SER . . . . . 1.408 ' N ' ' H ' ' A' ' 33' ' ' ASP . 3.5 m -133.52 147.59 51.62 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.95 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.774 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -93.49 -167.01 1.62 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.974 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.08 -50.13 74.53 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.642 ' HB3' ' ND2' ' A' ' 103' ' ' ASN . . . -68.76 -24.66 64.47 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.98 40.53 2.84 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.98 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.642 ' ND2' ' HB3' ' A' ' 101' ' ' ALA . 6.6 p30 -121.89 -178.62 3.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.64 -174.95 20.8 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.958 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 1.187 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.8 Cg_endo -72.43 134.55 22.77 Favored 'Trans proline' 0 N--CA 1.446 -1.271 0 C-N-CA 124.318 3.345 . . . . 0.0 109.612 179.935 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.806 ' HG3' ' CB ' ' A' ' 2' ' ' ALA . 3.1 pt-20 -137.99 141.54 40.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.904 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 136.27 57.67 0.06 OUTLIER Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.967 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 1.077 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.0 t -134.27 102.73 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.992 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -96.94 153.6 17.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.944 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.56 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.0 OUTLIER -117.94 163.76 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.89 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 111' ' ' SER . . . . . 1.398 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -162.24 131.0 4.21 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.973 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 1.032 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -108.35 120.07 41.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.489 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.1 t-20 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.605 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.686 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.32 -178.76 3.49 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.298 3.332 . . . . 0.0 109.635 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.201 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.08 113.64 26.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 1.033 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.96 136.11 51.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.55 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.54 115.41 29.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.765 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -113.71 147.39 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.856 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.32 167.43 21.82 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.38 118.52 5.64 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.294 3.329 . . . . 0.0 109.631 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.595 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.59 13.86 7.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 111' ' ' SER . 47.3 p -89.86 115.08 26.92 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.036 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 90.11 20.59 41.89 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.027 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -106.98 134.12 50.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.52 173.21 9.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -45.05 152.2 0.27 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.19 -23.6 32.69 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.666 HG21 HD12 ' A' ' 13' ' ' LEU . 3.0 m -66.5 150.41 49.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.91 122.59 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -105.35 119.35 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.765 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -79.78 149.85 30.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.69 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -142.37 109.7 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.033 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.62 116.96 26.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.911 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -85.32 144.93 21.0 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.201 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -144.81 110.07 5.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.39 15.07 24.22 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.036 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.22 166.09 13.56 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.46 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.5 mt-30 -50.2 121.64 5.81 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.514 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.57 131.35 41.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 7.67 85.21 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.485 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.85 146.21 23.81 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.64 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.25 151.39 22.16 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.65 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.2 m-85 -138.39 147.48 43.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -114.02 113.21 24.47 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.279 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -96.88 147.71 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.78 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.03 163.23 36.61 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.906 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.3 tt0 -106.25 112.4 25.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.4 m -113.53 146.51 39.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.144 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.42 128.97 50.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.593 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.51 120.94 13.79 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.31 HG21 ' CD1' ' A' ' 83' ' ' TRP . 2.7 m -101.2 -43.45 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.966 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -139.23 179.21 6.66 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 47.1 m -62.38 112.75 2.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.33 7.43 63.71 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.578 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 81.2 t -122.33 109.19 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -125.0 137.26 54.25 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.367 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -87.61 156.21 19.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.9 m -121.72 151.27 40.7 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.668 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 32.9 t30 -119.2 111.63 36.69 Favored Pre-proline 0 N--CA 1.448 -0.542 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.44 -0.65 9.05 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.289 3.326 . . . . 0.0 109.578 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.516 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.04 -13.67 43.74 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.588 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.8 m-20 -130.37 27.56 5.04 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.684 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -96.7 115.82 28.08 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.4 t -109.23 -177.76 3.38 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.3 p -147.37 153.91 40.24 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.546 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.59 162.85 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.546 ' N ' HG22 ' A' ' 55' ' ' VAL . 16.6 m -128.11 138.8 52.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.91 36.22 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 42.2 p30 -80.61 -173.26 4.04 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.94 -24.92 68.1 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -74.93 -8.49 56.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.033 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.9 31.61 59.86 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -128.26 139.33 52.5 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.85 167.75 16.9 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 84.1 p -150.49 127.01 10.8 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.552 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.71 163.31 38.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.864 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.552 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -112.7 130.73 55.95 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.944 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.54 125.43 51.81 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.62 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -81.52 129.45 34.67 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.536 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -90.69 128.22 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.536 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.4 OUTLIER -119.42 141.81 48.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.987 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -69.88 -34.19 73.22 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 51.5 p -164.63 159.85 19.44 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.906 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -178.03 172.24 1.64 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -62.72 119.37 9.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.367 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.86 91.63 1.21 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.914 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.5 99.65 10.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.4 132.27 52.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.7 m-85 -46.95 -37.05 8.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.7 t0 -57.6 -16.89 11.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.72 27.97 9.25 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.1 m -113.81 147.48 38.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -86.34 94.37 9.34 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.578 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -64.06 -57.93 8.17 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.4 164.33 11.36 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 108.97 0.66 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.144 HG11 ' CB ' ' A' ' 38' ' ' ALA . 5.7 t -85.55 152.0 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -115.19 93.74 4.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.959 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 4.9 m -53.9 -24.86 17.5 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.7 p -81.73 2.26 30.66 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -115.92 -27.18 7.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.12 -178.91 5.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.3 126.3 43.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.278 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 28.9 m -105.2 171.54 7.27 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.169 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.1 OUTLIER -154.05 147.39 24.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.944 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 8.8 t -103.87 165.28 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.279 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.79 166.32 35.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.106 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.14 133.04 43.81 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 13.5 m -116.11 145.2 43.23 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.64 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -99.93 -158.04 0.65 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.62 -48.66 76.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.452 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.49 -25.46 62.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 43.34 2.89 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.453 HD21 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -114.05 161.49 17.65 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.65 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -168.75 170.46 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.686 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.37 166.04 30.94 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.373 3.382 . . . . 0.0 109.577 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.605 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 mt-10 -36.62 118.1 0.54 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.92 156.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.169 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 5.6 t -106.15 102.16 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.15 116.99 20.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.278 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.3 pt -129.95 -177.5 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.634 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -169.55 173.95 6.15 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.959 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 8.2 m-85 -129.42 110.32 11.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.036 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.9 p30 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.32 ' CB ' ' CG ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.457 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.654 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.0 Cg_endo -72.4 -177.78 2.93 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.292 3.328 . . . . 0.0 109.566 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.844 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.1 110.34 22.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.91 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.13 135.77 50.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -97.95 113.02 24.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.789 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -109.58 154.57 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.918 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.11 174.4 2.44 Favored Pre-proline 0 N--CA 1.45 -0.463 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.941 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.129 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.8 Cg_endo -72.39 119.44 6.13 Favored 'Trans proline' 0 N--CA 1.447 -1.233 0 C-N-CA 124.334 3.356 . . . . 0.0 109.569 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.946 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.1 p -111.4 48.34 0.95 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -129.39 106.01 8.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.17 31.37 9.81 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.129 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -104.44 131.48 51.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -108.79 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -48.66 142.08 6.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.435 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 101.34 -22.58 38.48 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.56 HG21 ' HB3' ' A' ' 13' ' ' LEU . 15.6 m -77.69 151.21 34.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.7 p -119.67 132.37 69.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.727 HG13 HG22 ' A' ' 8' ' ' THR . 20.9 t -95.66 155.38 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.789 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.02 144.49 42.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.7 110.9 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.91 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.54 116.5 25.51 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.795 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.08 146.6 24.1 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.844 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.85 110.8 4.34 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 101.57 14.63 29.38 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.088 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.87 179.32 6.01 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.898 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 25.1 mt-30 -60.87 121.38 12.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.512 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 132.24 42.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.31 8.12 79.16 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.96 143.33 26.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.695 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.69 151.19 23.62 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.046 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 42.2 m-85 -137.97 140.35 40.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.294 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.7 m-20 -104.47 115.12 29.81 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.288 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -101.02 139.84 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.937 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -160.67 169.78 36.46 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.843 HE22 ' H ' ' A' ' 70' ' ' ARG . 25.9 tt0 -120.31 114.06 21.3 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.5 m -106.13 171.16 7.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -156.82 133.08 9.82 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.506 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.83 129.58 40.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.945 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.438 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 3.7 m -110.81 -37.47 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.698 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -147.95 165.69 29.93 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -53.13 113.82 1.25 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.1 4.66 60.1 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.026 ' CG2' ' CH2' ' A' ' 83' ' ' TRP . 98.8 t -121.58 120.53 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.729 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.65 163.57 21.73 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.535 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -127.03 143.74 51.21 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.7 m -110.35 150.47 28.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.692 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.5 t30 -110.26 106.56 58.12 Favored Pre-proline 0 N--CA 1.449 -0.495 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.9 Cg_endo -72.32 0.39 7.46 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.319 3.346 . . . . 0.0 109.591 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -87.98 -12.5 44.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 11.2 p30 -127.58 27.56 5.78 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.403 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.92 104.8 11.68 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.1 t -99.29 170.54 8.58 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.49 152.6 40.03 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 56' ' ' THR . 6.4 p -165.94 159.7 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.2 m -128.23 137.11 51.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.68 146.98 39.79 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.6 p30 -83.93 -175.02 5.61 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -24.6 67.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.36 -7.57 55.28 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.088 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.14 32.04 58.88 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.1 p -127.94 135.78 50.43 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.76 167.9 12.45 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.1 121.91 9.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.581 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -162.33 148.04 12.84 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.931 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.5 137.37 48.29 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.003 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -106.04 119.1 38.34 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.909 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.659 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -60.84 127.2 30.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.694 HG23 HG21 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -87.58 124.33 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.843 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.7 OUTLIER -115.74 143.68 45.04 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.518 ' HG3' HG23 ' A' ' 89' ' ' THR . 43.1 ttp180 -86.73 -16.45 36.4 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.5 t -171.47 145.11 2.03 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.758 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.0 p90 -169.62 163.93 10.18 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.37 124.78 20.68 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.535 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -81.04 91.54 1.43 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.22 100.67 10.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -57.3 136.69 56.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.665 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.54 -39.98 17.71 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.681 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -56.74 -17.14 7.97 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.955 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.94 28.1 9.69 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 15.7 m -112.38 147.36 36.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.69 93.82 6.85 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.438 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 11.5 t-105 -65.42 -48.29 73.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.57 165.08 10.16 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.79 133.66 54.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.183 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -111.67 143.8 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -109.84 104.07 12.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.481 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 26.3 m -51.81 -26.85 10.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.518 HG23 ' HG3' ' A' ' 71' ' ' ARG . 75.9 p -80.51 -2.26 45.27 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.71 -27.45 6.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.05 179.94 5.59 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.97 125.68 43.01 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.016 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 87.1 m -104.34 152.56 22.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.041 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.7 pt20 -150.57 152.72 34.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.003 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 10.3 t -117.51 159.78 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.46 166.51 37.52 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.288 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.74 131.19 51.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.294 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 3.2 m -111.73 153.09 27.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.695 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.5 -163.33 0.85 Allowed 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.43 -48.18 65.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.26 -24.45 66.58 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.6 53.77 1.77 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.898 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.26 170.92 14.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.046 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.4 46.72 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.654 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.42 162.8 40.47 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.328 3.352 . . . . 0.0 109.573 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.32 ' CG ' ' CB ' ' A' ' 2' ' ' ALA . 7.4 mt-10 -37.68 120.19 0.8 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.02 158.27 0.01 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.897 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.6 t -121.58 104.13 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.89 120.28 28.01 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.041 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.2 mt -98.61 159.09 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.0 OUTLIER -145.27 116.97 8.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.902 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -93.81 127.56 39.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.378 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.604 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.8 Cg_endo -72.47 -178.45 3.36 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.285 3.323 . . . . 0.0 109.592 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.859 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.92 111.04 23.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.769 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.09 157.84 36.98 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.6 p -121.86 119.59 32.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.81 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 22.5 t -114.82 146.34 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.732 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.1 165.78 35.12 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.716 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.0 Cg_endo -72.41 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.347 3.365 . . . . 0.0 109.546 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.88 12.35 7.26 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.71 ' HA ' ' O ' ' A' ' 111' ' ' SER . 42.2 m -87.78 110.58 20.58 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.085 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.33 14.31 42.07 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.985 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -105.56 132.79 51.28 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m -91.83 -179.97 5.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -44.54 152.68 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.84 -23.29 33.56 Favored Glycine 0 C--N 1.335 0.528 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.628 HG21 HD12 ' A' ' 13' ' ' LEU . 26.1 m -69.38 148.76 49.2 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.4 p -125.47 115.86 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.732 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.4 p -91.86 153.77 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.81 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.27 147.93 31.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.747 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.37 106.4 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.717 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.56 116.96 23.29 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.061 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.72 150.32 25.28 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.859 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -147.73 109.62 4.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.43 15.94 33.48 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.065 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.19 172.89 8.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.517 ' HB2' HG21 ' A' ' 30' ' ' THR . 0.1 OUTLIER -53.27 120.65 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.493 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.7 131.16 42.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.68 82.69 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.517 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.19 143.48 26.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.59 147.18 25.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.656 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 34.0 m-85 -134.48 134.05 41.07 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.077 ' HB2' ' O ' ' A' ' 98' ' ' SER . 1.7 m-20 -98.66 114.12 26.47 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.26 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.71 145.19 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.955 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.2 166.47 39.25 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.76 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.19 108.83 18.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.41 146.93 38.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.419 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -123.58 143.51 50.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.564 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.35 124.39 21.62 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.2 t -104.04 -49.26 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.27 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -135.43 169.65 17.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.956 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.412 ' H ' HG22 ' A' ' 42' ' ' THR . 0.6 OUTLIER -51.45 112.23 0.71 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.35 8.62 66.48 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.991 HG11 ' HE1' ' A' ' 83' ' ' TRP . 2.4 t -121.98 123.19 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -132.08 133.79 44.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.81 147.77 22.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.3 m -105.62 152.12 23.51 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.768 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -111.07 110.15 56.75 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 81.9 Cg_endo -72.43 -0.07 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 124.311 3.341 . . . . 0.0 109.616 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.29 -9.45 52.83 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.405 ' CB ' HG23 ' A' ' 68' ' ' THR . 82.4 m-20 -133.83 26.8 3.97 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.435 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.07 107.24 12.7 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.1 m -101.48 176.21 5.31 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.0 p -144.93 153.97 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.591 HG22 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.69 155.18 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.1 m -128.0 141.72 51.44 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.99 141.28 33.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 p30 -82.66 -173.18 4.48 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.71 -26.45 68.05 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -76.09 -9.17 58.41 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.065 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.23 32.28 52.57 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 80.9 p -127.79 135.83 50.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.591 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -122.95 164.38 18.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -145.64 136.19 24.19 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.739 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.88 174.62 10.39 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.739 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -138.95 122.96 17.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.891 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.089 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.04 156.43 16.33 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -103.78 133.37 48.89 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.954 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.473 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -93.47 127.18 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.628 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.4 OUTLIER -117.66 141.99 47.75 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -32.58 73.24 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 78.2 p -157.9 158.97 36.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.768 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 2.1 p90 -177.14 161.8 1.91 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.17 112.35 2.62 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.72 96.75 0.68 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.834 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.1 m-85 -83.23 99.41 9.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -57.18 131.68 50.7 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.674 ' N ' HD12 ' A' ' 77' ' ' LEU . 38.0 p90 -47.52 -36.11 9.88 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 3.3 t0 -57.67 -16.25 10.17 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.78 9.5 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.9 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -115.55 147.97 40.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -87.64 96.43 10.42 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.27 ' HZ2' ' CG ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.63 -55.16 25.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.63 170.89 16.15 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -66.12 103.83 1.04 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 73' ' ' PHE . 35.5 m -80.18 154.15 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -112.7 92.62 4.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.944 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.7 m -53.07 -24.63 10.41 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -82.32 2.07 33.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.38 -27.28 6.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.71 178.98 6.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.612 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.2 126.23 43.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.376 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 7.2 m -104.82 173.68 6.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 1.1 pt20 -153.61 147.12 24.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.089 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.7 t -104.97 165.32 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.26 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.29 166.38 36.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.003 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.83 132.9 46.63 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.077 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 3.7 t -113.48 150.89 32.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.455 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -110.48 -163.63 0.87 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.74 -48.43 71.92 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.65 -24.37 65.44 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.9 53.75 1.74 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.46 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -133.41 169.53 16.81 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.992 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.517 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.03 171.42 43.43 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.604 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.34 170.71 18.57 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.322 3.348 . . . . 0.0 109.597 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.378 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.67 121.6 0.9 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.98 163.87 0.01 OUTLIER Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.06 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 23.2 t -120.53 103.18 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.2 120.39 26.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.376 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -129.1 -178.76 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.71 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -168.33 171.14 9.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.0 m-85 -122.4 115.11 21.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.085 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.252 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.584 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.4 -178.3 3.24 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 124.339 3.36 . . . . 0.0 109.633 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.305 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 5.1 t -99.69 116.12 31.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.78 153.76 48.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -110.66 112.16 23.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.901 HG22 ' CG1' ' A' ' 21' ' ' VAL . 95.2 t -107.47 145.93 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -66.79 176.42 1.11 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.9 Cg_endo -72.41 117.46 5.14 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.293 3.329 . . . . 0.0 109.612 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.594 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 32.4 p -112.58 47.07 1.12 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 51.4 p -126.36 106.73 9.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.72 14.72 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.73 131.77 47.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.983 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -111.41 174.57 5.8 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -48.05 140.3 7.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.08 -22.79 35.54 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.469 HG21 HD13 ' A' ' 13' ' ' LEU . 96.6 m -79.81 151.42 30.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.55 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.8 p -128.26 123.43 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.4 m -88.28 171.45 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.821 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.49 146.86 47.0 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.901 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -144.44 106.25 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.677 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.67 116.66 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.87 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.92 148.32 25.67 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.305 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -148.15 118.61 7.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.86 16.1 46.4 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.019 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -88.68 -174.15 4.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.516 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -70.3 120.7 16.36 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.931 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.02 136.02 53.21 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.02 7.82 60.21 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.721 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -82.95 146.71 28.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.868 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -96.07 134.96 38.48 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.813 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 38.6 m-85 -126.42 149.17 49.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.026 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -116.79 113.95 23.27 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.223 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -97.05 143.92 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.703 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.21 161.66 34.8 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.832 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 37.6 tt0 -110.85 118.44 36.13 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.1 m -115.95 148.37 40.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.109 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.27 140.39 52.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.517 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.26 127.42 31.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.813 HG12 ' CG1' ' A' ' 44' ' ' VAL . 1.1 t -108.7 -39.34 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.436 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 1.5 t0 -151.84 -178.53 6.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.1 m -70.41 111.47 6.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.51 10.01 86.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.333 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -136.99 124.52 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.572 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -133.1 137.23 46.27 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.357 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.53 155.77 21.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 67.7 m -120.77 156.91 30.85 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.676 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t30 -121.5 109.21 34.82 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.43 0.64 7.17 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.313 3.342 . . . . 0.0 109.592 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.489 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.63 -16.37 32.61 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 14.6 p30 -127.26 28.15 5.77 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.685 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.92 118.3 35.37 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.5 t -113.41 -177.77 3.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 94.9 p -146.49 157.36 43.74 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.485 HG22 ' N ' ' A' ' 56' ' ' THR . 4.9 p -167.68 159.4 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.485 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.8 m -128.06 137.45 52.17 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.9 136.02 41.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 17.1 p30 -73.62 -175.28 1.97 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -24.74 68.02 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -75.17 -7.25 53.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.019 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.15 32.09 58.78 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.3 p -129.89 135.83 48.82 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.92 164.06 18.22 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -147.73 127.96 13.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.86 170.0 23.08 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.936 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -126.86 136.76 52.78 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.965 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -111.71 120.37 41.81 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.968 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.622 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -70.88 117.67 12.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.516 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -75.14 128.43 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.622 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -116.77 147.14 42.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.978 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.451 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.3 OUTLIER -90.21 -15.68 30.92 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 52.2 p -178.81 154.89 0.75 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.832 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -177.94 179.75 0.83 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -66.89 123.11 19.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.357 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.7 91.93 1.31 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.886 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.75 100.62 11.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -55.38 140.27 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.688 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.58 -41.49 21.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.57 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -57.19 -17.44 11.26 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.54 28.36 9.71 Favored Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.1 m -110.89 145.23 38.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.0 93.21 3.79 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.436 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 54.7 t-105 -64.18 -58.12 7.53 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.87 155.86 7.3 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -54.95 109.99 0.6 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.109 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.9 t -86.43 151.65 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.77 96.16 6.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.069 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.5 OUTLIER -54.07 -23.91 15.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.5 p -84.6 0.5 49.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -113.72 -27.38 7.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.82 177.94 7.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.54 128.33 44.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.223 ' O ' HG13 ' A' ' 110' ' ' ILE . 58.0 m -104.84 157.17 17.39 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.03 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -141.21 145.8 36.1 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.889 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 20.4 t -108.94 157.47 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.223 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.74 172.41 45.36 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.975 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.57 130.96 46.36 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.026 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 40.2 m -111.04 145.02 39.24 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.868 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -106.86 -163.58 0.92 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.73 -49.13 69.56 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.18 -24.11 65.83 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.26 53.34 1.88 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.8 174.81 9.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.813 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -177.82 179.34 48.37 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.584 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.37 165.78 31.66 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.347 3.364 . . . . 0.0 109.577 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.252 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.8 pt-20 -37.0 133.88 0.58 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.77 149.63 5.36 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.965 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -121.85 110.54 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.17 139.46 30.57 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.223 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.6 OUTLIER -109.93 160.09 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -143.22 112.53 6.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.069 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 23.1 m-85 -93.68 124.4 37.65 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.943 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.035 ' HB1' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.5 Cg_endo -72.42 -178.19 3.18 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.293 3.328 . . . . 0.0 109.635 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.367 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 5.2 t -102.31 115.74 31.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.4 146.96 52.05 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.615 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.65 115.72 31.02 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.832 HG13 ' O ' ' A' ' 20' ' ' LYS . 35.9 t -111.92 148.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.41 176.2 1.31 Allowed Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.083 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.34 117.28 5.06 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.325 3.35 . . . . 0.0 109.626 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.051 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.3 p -110.17 49.23 0.86 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 111' ' ' SER . 94.3 p -127.37 106.09 8.97 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.044 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.47 27.26 18.2 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.083 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -103.34 131.38 50.46 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -118.97 -179.35 3.79 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -46.19 138.89 5.0 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.58 -23.17 33.61 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.514 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.1 m -87.51 150.95 23.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 18' ' ' VAL . 13.0 p -131.63 121.54 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' O ' ' A' ' 67' ' ' LEU . 23.7 m -80.74 167.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.832 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.37 145.54 43.14 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.567 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.87 112.82 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.08 114.8 20.18 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.882 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -81.93 147.9 26.72 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.315 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.8 115.49 5.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.22 15.39 51.49 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.35 -179.79 5.92 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.977 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 37.1 mt-30 -59.01 120.8 9.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.92 132.05 42.07 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.87 7.64 75.94 Favored Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.51 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -92.86 139.46 30.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.595 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.06 150.45 24.86 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.878 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 26.7 m-85 -135.58 143.81 45.84 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.258 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -105.83 114.59 28.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -100.18 139.6 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.909 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.7 164.59 37.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.87 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 20.9 tt0 -109.75 105.33 14.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 61.5 m -106.32 142.79 35.42 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.548 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.72 130.09 52.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.624 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.69 121.33 14.73 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.554 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 6.0 m -101.78 -43.05 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.479 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -138.17 169.95 16.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.0 m -55.03 112.56 1.08 Allowed 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.72 9.05 64.84 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.604 HG12 HG23 ' A' ' 40' ' ' VAL . 77.0 t -123.49 105.42 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.673 HD21 ' HD2' ' A' ' 78' ' ' PHE . 0.8 OUTLIER -121.3 138.35 54.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.463 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.42 158.13 16.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 52.2 m -118.59 148.13 43.0 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.92 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.3 t30 -110.61 106.19 57.64 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -72.42 -1.27 9.96 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.356 3.37 . . . . 0.0 109.567 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.527 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.17 -11.09 42.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.755 ' HB3' HG23 ' A' ' 68' ' ' THR . 6.1 m-20 -133.35 27.41 4.11 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.663 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.6 118.87 36.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -112.07 -176.1 2.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -144.84 153.02 41.17 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.421 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.64 156.27 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.421 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.3 m -126.45 141.0 52.04 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.26 138.33 37.74 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.0 p30 -73.57 -174.34 1.69 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.45 -25.04 68.09 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -75.23 -8.06 55.57 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.34 58.5 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 71.5 p -127.08 133.23 50.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.79 166.47 14.29 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.89 131.76 15.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.612 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.0 166.19 17.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.612 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -122.33 132.63 54.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.13 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.24 118.23 36.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.755 HG23 ' HB3' ' A' ' 51' ' ' ASP . 2.0 t -68.94 143.19 54.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.522 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -107.0 131.4 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.567 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -118.98 152.04 37.1 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.531 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -87.15 -10.63 52.25 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -174.04 149.43 1.47 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.92 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 5.7 p90 -176.72 158.91 1.75 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -58.75 112.53 1.66 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.463 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.66 94.54 0.67 Allowed Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.826 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -82.71 98.81 9.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.93 132.68 47.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.673 ' HD2' HD21 ' A' ' 45' ' ' LEU . 19.0 p90 -46.81 -37.43 8.66 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.602 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.3 t0 -56.69 -17.13 7.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.45 28.04 8.76 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.97 143.12 45.66 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.38 96.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.554 ' CD1' ' CG1' ' A' ' 40' ' ' VAL . 3.3 t-105 -63.35 -58.95 5.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.29 171.31 21.1 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -64.78 104.39 0.83 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -79.75 149.99 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -110.56 97.44 6.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.85 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 9.0 m -52.82 -25.4 11.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 53.0 p -82.57 -0.17 45.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -119.04 -28.41 5.51 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.1 179.72 5.28 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 125.23 44.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.1 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 61.3 m -104.17 152.95 21.52 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -144.47 147.36 33.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.13 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -110.64 159.9 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.85 167.74 39.29 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.177 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.04 125.25 43.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.258 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 15.8 m -112.8 143.98 43.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.595 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -101.85 -160.23 0.78 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.983 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.71 -47.94 61.32 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.73 -20.08 65.89 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.5 53.51 2.59 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.296 -1.121 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.977 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.64 167.75 19.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.878 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.97 176.53 46.44 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.34 170.2 19.8 Favored 'Trans proline' 0 N--CA 1.448 -1.2 0 C-N-CA 124.294 3.33 . . . . 0.0 109.618 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.367 ' OE2' ' CA ' ' A' ' 4' ' ' THR . 3.3 pm0 -40.96 120.02 1.25 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.46 162.81 0.01 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.849 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 34.8 t -128.57 104.44 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.74 30.18 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.1 ' HB ' ' O ' ' A' ' 93' ' ' CYS . 5.2 mt -99.5 153.58 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.664 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -138.31 123.05 18.73 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.85 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 6.1 m-85 -92.69 127.44 38.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.919 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.606 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.34 -177.78 2.91 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.312 3.341 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.9 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.46 109.59 22.32 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.767 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 146.63 50.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.2 p -110.22 121.01 44.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.872 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 41.2 t -113.88 143.64 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.682 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.74 166.11 30.18 Favored Pre-proline 0 N--CA 1.449 -0.475 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.693 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.41 117.16 5.0 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.29 3.327 . . . . 0.0 109.629 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.732 ' HB2' HG22 ' A' ' 19' ' ' VAL . 0.6 OUTLIER -129.29 11.78 5.94 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.693 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.6 m -92.34 108.72 20.17 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.087 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 97.17 24.08 13.45 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.087 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.24 133.78 51.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 t -67.36 154.39 41.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 1.3 p-10 -46.07 147.58 1.01 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.02 -18.69 51.55 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.832 HG21 HD12 ' A' ' 13' ' ' LEU . 30.6 m -61.91 145.36 53.09 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 p -110.26 134.69 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.732 HG22 ' HB2' ' A' ' 10' ' ' SER . 10.5 t -107.03 152.72 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.872 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.03 109.84 15.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -103.18 121.12 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.767 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -128.41 117.01 20.64 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.02 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.55 147.41 23.1 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.9 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.46 111.11 5.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.56 16.53 31.37 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.1 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.27 173.43 8.4 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.582 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.9 mt-30 -53.66 121.38 7.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.406 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.31 129.55 38.66 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.98 8.67 85.07 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.547 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.1 141.7 28.24 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 1.196 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.88 150.78 23.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.234 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 52.6 m-85 -136.19 143.35 44.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.227 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.73 114.7 29.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.513 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.03 141.87 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.029 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.52 161.99 35.79 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.95 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 54.9 tt0 -94.69 117.96 30.97 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.673 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.5 m -107.25 158.12 17.37 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.975 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -147.22 134.6 20.73 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.535 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -68.36 125.32 26.06 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.482 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.4 m -114.64 -36.05 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.535 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -150.17 -179.96 7.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -64.12 110.37 2.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 69.76 8.84 61.32 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.535 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 61.0 t -110.19 105.2 18.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.682 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.5 mt -105.82 156.61 18.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.485 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -135.11 129.35 33.78 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.915 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.52 156.01 19.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.702 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.6 p-10 -116.23 121.76 33.14 Favored Pre-proline 0 N--CA 1.449 -0.523 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.8 Cg_endo -72.37 1.98 5.56 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.26 3.307 . . . . 0.0 109.608 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.702 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -85.63 -20.87 28.82 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.505 ' CB ' HG23 ' A' ' 68' ' ' THR . 85.2 m-20 -128.47 28.78 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.59 117.1 29.6 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.3 t -109.99 -176.86 3.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.37 153.8 41.61 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.434 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -166.47 153.71 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.8 m -126.59 132.89 51.19 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.61 149.79 48.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -88.98 -168.38 2.17 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.29 -27.94 68.98 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -75.16 -9.32 58.44 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.737 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.2 31.51 51.9 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.0 p -127.97 141.24 51.58 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.434 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -131.15 164.68 24.98 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -143.35 139.62 30.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.694 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -167.56 172.1 9.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.694 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -124.88 129.03 49.58 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.942 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.267 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -112.56 119.57 38.62 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.505 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -79.59 141.45 36.56 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.593 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -112.02 132.81 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.927 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -119.11 155.68 31.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 ptt180 -74.67 -34.58 62.72 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -151.15 149.34 29.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.95 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.5 p90 -177.13 163.66 2.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.479 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.4 OUTLIER -61.25 125.1 22.55 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.485 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.93 95.56 2.11 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.915 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -84.46 103.71 13.84 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.951 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.5 tp -53.91 135.01 42.94 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 8.3 m-85 -45.71 -38.68 7.16 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.661 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.6 t0 -57.26 -17.02 9.89 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.92 28.91 8.97 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.951 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -114.41 112.43 23.02 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 96.44 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.482 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 50.6 t-105 -62.41 -53.63 52.03 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 143.45 -179.66 20.74 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.17 140.79 43.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.975 HG11 ' CB ' ' A' ' 38' ' ' ALA . 4.8 t -127.7 152.6 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.26 90.4 3.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.209 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 30.6 m -54.15 -25.57 23.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.8 p -76.9 -0.64 24.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.48 -27.21 7.62 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.68 -164.2 1.28 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.4 125.49 43.58 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.228 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.1 OUTLIER -103.89 152.5 21.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.035 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -159.42 147.56 17.56 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.267 ' CG2' HD12 ' A' ' 67' ' ' LEU . 6.8 t -105.62 165.32 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.29 164.68 34.67 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.513 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.6 133.16 47.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.227 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 67.7 m -112.1 150.31 30.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 1.196 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -109.92 -161.31 0.75 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.08 -48.68 70.15 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.09 -24.13 64.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.74 52.47 1.8 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.618 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.57 171.87 12.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.234 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.37 175.24 44.34 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.606 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.34 169.55 21.37 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.377 3.385 . . . . 0.0 109.59 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.019 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -38.49 126.09 1.4 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.959 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.84 160.31 0.01 OUTLIER Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.021 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 89.1 t -123.08 102.69 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.97 134.54 33.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.228 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -140.53 -173.73 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.693 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.7 t -176.48 178.51 1.3 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.209 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.8 m-85 -130.75 113.15 13.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.883 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 42.5 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.562 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.4 Cg_endo -72.35 -175.28 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.355 3.37 . . . . 0.0 109.626 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.963 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.32 109.37 21.89 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.982 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.2 146.02 50.85 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -110.18 114.35 27.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.828 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.03 152.39 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.71 HG22 HG13 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -75.5 163.96 64.03 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.75 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.0 Cg_endo -72.36 118.16 5.47 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.337 3.358 . . . . 0.0 109.621 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.598 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.9 OUTLIER -128.59 14.29 6.5 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 1.076 ' HA ' ' O ' ' A' ' 111' ' ' SER . 68.9 p -95.73 109.2 21.53 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.146 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 95.59 26.07 12.53 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.12 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.48 140.94 41.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 t -71.45 156.31 39.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.54 ' HB3' ' HD2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.73 151.96 0.79 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.63 -16.1 59.96 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.805 HG21 HD12 ' A' ' 13' ' ' LEU . 15.2 m -62.34 138.56 58.46 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 p -99.69 146.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.71 HG13 HG22 ' A' ' 8' ' ' THR . 1.5 t -125.32 156.64 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.79 150.21 40.19 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.449 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.77 105.67 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.982 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.17 117.07 30.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.926 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -83.63 143.47 21.63 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.963 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.49 106.76 5.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.909 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 22.96 8.56 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.535 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.66 -167.03 1.75 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.522 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 29.7 mt-30 -85.57 125.56 33.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.483 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.29 134.4 44.19 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.37 8.16 83.39 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.589 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -96.3 139.44 32.43 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.508 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -90.65 150.96 21.47 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.965 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 54.0 m-85 -136.95 147.33 46.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.138 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.7 m-20 -110.97 112.85 24.98 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.27 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -102.26 151.03 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.953 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -178.1 176.67 48.14 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 1.058 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 9.2 tt0 -117.25 121.6 41.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.6 m -120.42 144.81 47.74 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.741 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 142.31 51.02 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.608 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.02 124.29 21.7 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.937 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.515 ' CB ' ' CD1' ' A' ' 83' ' ' TRP . 3.3 m -106.68 -38.37 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.107 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.49 -178.35 5.07 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.5 m -70.98 112.08 6.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.12 10.21 81.07 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.304 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 1.8 m -130.94 124.92 57.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.615 ' H ' HD23 ' A' ' 45' ' ' LEU . 1.6 pt? -127.76 147.04 50.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.41 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -102.22 150.65 23.08 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.7 m -106.27 160.33 15.44 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.742 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 26.8 t30 -119.24 109.96 38.29 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.35 0.01 8.03 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.33 3.353 . . . . 0.0 109.627 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.467 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -89.44 -13.08 38.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.688 ' HB3' HG23 ' A' ' 68' ' ' THR . 19.0 m-20 -134.73 27.71 3.62 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.628 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.43 115.17 27.0 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.4 t -106.53 178.34 4.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 p -147.18 156.32 42.87 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.5 HG22 ' N ' ' A' ' 56' ' ' THR . 2.3 p -167.35 161.93 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.5 ' N ' HG22 ' A' ' 55' ' ' VAL . 24.4 m -128.28 131.87 48.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 152.4 44.28 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -91.44 -170.8 2.73 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.43 -26.14 68.34 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -76.38 -6.06 49.95 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 75.27 9.42 84.25 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 85.9 p -101.64 140.16 36.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.43 164.11 17.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -150.38 121.86 7.94 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.698 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.38 172.19 15.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.698 ' N ' HG23 ' A' ' 65' ' ' THR . 1.1 m -128.24 120.23 26.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.307 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.2 OUTLIER -105.64 133.43 50.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.688 HG23 ' HB3' ' A' ' 51' ' ' ASP . 5.5 t -97.62 149.13 22.58 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.636 HG23 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -114.67 131.48 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.851 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.58 159.04 20.89 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.54 ' HD2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -80.3 -23.32 40.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.949 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.489 ' N ' ' HG2' ' A' ' 71' ' ' ARG . 53.9 p -160.72 156.72 25.81 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 1.058 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.5 p90 -178.12 158.82 1.24 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -60.58 109.43 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.41 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -64.27 98.77 0.28 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.804 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 98.78 10.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.995 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.2 tp -54.66 132.46 45.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.621 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.9 m-85 -47.0 -37.24 8.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.592 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.8 t0 -57.57 -16.65 10.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.84 28.99 8.94 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.995 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -117.3 152.2 35.38 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.94 99.54 8.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.515 ' CD1' ' CB ' ' A' ' 40' ' ' VAL . 15.0 t-105 -68.74 -50.49 50.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.5 163.72 9.62 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.99 104.7 0.21 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.741 HG11 ' HB3' ' A' ' 38' ' ' ALA . 14.4 p -85.83 149.71 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.77 97.24 7.9 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.854 ' SG ' ' HZ ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.8 -20.63 9.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.7 p -92.76 2.4 56.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.7 m -106.1 -24.35 12.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.52 179.01 6.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -90.97 125.5 35.8 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.246 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.3 m -104.48 162.98 12.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.036 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.3 OUTLIER -153.56 147.92 25.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.307 ' CG2' HD12 ' A' ' 67' ' ' LEU . 15.8 t -101.71 161.21 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.264 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.96 166.0 35.33 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.27 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.41 128.92 43.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 180.0 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.138 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 26.8 m -108.74 151.65 25.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.508 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -113.19 -162.41 0.8 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.58 -48.49 77.19 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.17 -24.37 62.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.22 53.77 1.69 Allowed Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.522 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.88 172.26 11.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.965 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.58 -179.21 46.89 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.463 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 81.7 Cg_endo -72.42 160.29 47.19 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.357 3.372 . . . . 0.0 109.549 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.127 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 2.8 tt0 -35.45 123.7 0.64 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -34.67 151.14 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.004 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 90.1 t -117.28 102.31 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 137.15 34.8 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.246 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 2.8 pt -143.0 179.71 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 1.076 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -177.99 178.54 0.93 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.963 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 1.2 m-85 -126.21 116.1 20.78 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.146 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 6.3 p30 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.449 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.475 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.594 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.37 -178.24 3.2 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.356 3.371 . . . . 0.0 109.609 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.257 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 6.8 t -100.17 116.95 33.38 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.78 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.37 135.36 47.15 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.95 113.11 24.69 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.624 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.96 155.03 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.969 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.939 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.09 175.42 1.79 Allowed Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.056 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.39 118.94 5.84 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 124.299 3.333 . . . . 0.0 109.602 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.007 ' HB2' HG23 ' A' ' 110' ' ' ILE . 20.6 p -110.74 48.48 0.91 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 55.5 p -127.06 105.99 8.97 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.137 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.12 31.93 9.36 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.289 -1.125 . . . . 0.0 110.289 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.137 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -110.18 129.19 55.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.89 175.84 5.27 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -44.92 139.74 2.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.93 -22.47 35.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.673 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.3 m -81.19 150.64 28.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.527 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.7 p -121.03 120.45 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 1.7 p -87.62 154.87 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.624 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.7 147.14 31.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.712 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.23 110.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.99 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.78 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.24 115.83 23.06 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.822 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.21 148.86 25.76 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.257 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.35 114.83 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.36 13.62 44.42 Favored Glycine 0 C--N 1.335 0.485 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.46 172.6 8.6 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.526 HE22 ' CG ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.95 119.84 5.12 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.51 132.84 43.33 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.77 7.84 75.88 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.524 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.56 141.56 28.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.42 150.16 25.5 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.486 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 30.1 m-85 -135.73 141.79 44.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.266 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.77 118.07 35.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -104.83 145.32 13.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.853 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.99 169.2 41.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.769 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 40.6 tt0 -112.01 108.96 18.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.2 m -111.74 144.63 40.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.799 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.83 130.41 52.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.583 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.18 122.83 17.98 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.443 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 9.7 m -102.94 -42.87 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.7 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -139.0 179.64 6.38 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.4 m -63.63 112.35 2.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.44 8.38 66.37 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 59.3 t -123.83 106.44 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -121.42 137.84 54.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.404 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -89.4 153.34 20.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m -115.04 151.86 33.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.671 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.4 t30 -117.72 109.54 41.44 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.33 -1.07 9.61 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.315 3.343 . . . . 0.0 109.602 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.589 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -84.68 -11.1 56.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.589 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.5 OUTLIER -131.79 26.25 4.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.71 104.38 13.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.7 t -101.33 176.32 5.28 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.51 150.04 35.73 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -166.96 153.63 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 67.9 m -123.49 132.7 54.0 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 141.63 53.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -77.53 -174.65 3.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.91 -24.83 68.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -76.29 -6.9 53.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.17 58.72 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.2 p -127.09 137.78 53.07 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.26 165.21 16.56 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 p -147.91 120.22 8.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.416 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -157.42 148.08 21.2 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -111.32 129.81 55.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.581 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -98.47 157.27 16.32 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.589 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.7 t -101.01 119.29 38.53 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.533 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -80.31 127.18 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.639 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.6 OUTLIER -118.7 152.47 36.07 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.486 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -91.59 -12.68 33.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.941 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 5.1 t -169.2 151.35 4.63 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.769 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.1 p90 -177.16 155.43 1.15 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.25 115.92 2.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.404 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.83 91.63 0.6 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.801 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -82.79 99.23 9.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.1 tp -55.54 134.55 50.9 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.76 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.4 m-85 -46.36 -38.68 9.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.602 ' HB2' HD21 ' A' ' 77' ' ' LEU . 2.5 t0 -56.99 -17.48 9.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.77 28.37 8.9 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -113.62 142.86 45.48 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.7 mtm180 -80.88 94.97 6.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.443 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 71.4 t-105 -64.28 -58.61 6.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.67 167.54 16.66 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.81 108.6 1.22 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.799 HG11 ' CB ' ' A' ' 38' ' ' ALA . 38.7 t -81.76 143.96 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.17 93.6 4.62 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.486 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 58.4 m -52.04 -26.07 10.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 77.9 p -79.85 -2.43 43.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.48 -27.76 6.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.07 -176.63 3.93 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.92 125.74 45.95 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.915 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 69.8 m -103.5 152.98 21.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.087 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -143.17 148.53 36.68 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.581 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.9 t -112.01 161.4 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.07 171.46 43.92 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.034 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.57 135.56 48.03 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.266 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 72.6 p -115.71 154.95 28.63 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.426 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -115.12 -167.07 1.18 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.974 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.03 -48.75 75.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.87 66.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.59 1.93 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.526 ' CG ' HE22 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.62 169.16 17.04 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.486 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.82 176.82 46.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.594 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 81.8 Cg_endo -72.41 161.84 43.16 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.332 3.355 . . . . 0.0 109.555 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.449 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.9 pt-20 -38.37 122.82 1.12 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -37.49 157.52 0.01 OUTLIER Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.828 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.8 t -124.66 104.59 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.01 138.29 32.55 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.087 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.8 mt -116.68 156.09 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -138.22 112.67 8.78 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.592 ' CE1' ' HB2' ' A' ' 93' ' ' CYS . 5.7 m-85 -87.3 101.11 13.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.588 ' CG ' ' C ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.562 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.657 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.3 Cg_endo -72.42 -175.39 1.77 Allowed 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.302 3.335 . . . . 0.0 109.615 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.224 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.82 22.51 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.44 148.95 49.56 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.4 p -113.23 117.75 32.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.94 HG13 ' O ' ' A' ' 20' ' ' LYS . 48.3 t -113.58 145.92 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.822 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.56 166.67 28.6 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.727 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.39 117.55 5.18 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.332 3.355 . . . . 0.0 109.58 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.619 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -127.55 13.08 6.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.862 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.6 p -92.56 106.51 18.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.115 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.57 22.66 11.0 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.115 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.81 140.49 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.68 173.19 8.74 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 19.4 p-10 -44.78 152.39 0.23 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.35 -22.09 40.67 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.754 HG21 HD12 ' A' ' 13' ' ' LEU . 22.9 m -63.46 150.46 43.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.28 114.1 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.822 ' HA ' HG22 ' A' ' 8' ' ' THR . 1.4 m -97.56 119.08 45.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.94 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.57 146.07 36.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.786 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -131.51 102.88 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.752 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -113.17 116.23 29.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.838 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -87.76 144.08 18.69 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.895 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.93 107.92 6.71 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.883 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 99.31 25.88 9.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.57 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.15 -175.77 5.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.917 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 24.7 mt-30 -74.32 122.28 22.65 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.439 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.96 130.87 42.04 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.48 9.23 81.71 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.533 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -97.43 139.95 32.6 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 1.143 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.69 151.99 22.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.289 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 33.3 m-85 -137.44 149.69 47.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.175 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.5 m-20 -111.84 113.82 26.39 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.36 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -101.01 142.48 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.961 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.69 164.36 37.98 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.958 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 11.8 tt0 -106.65 111.54 24.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 81.2 m -111.16 151.31 28.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.658 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -129.72 126.16 37.6 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.19 119.06 10.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.378 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 7.0 m -100.97 -42.71 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.501 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -139.47 165.53 26.98 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.2 OUTLIER -51.36 112.78 0.8 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.27 8.24 65.26 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.643 HG12 HG23 ' A' ' 40' ' ' VAL . 71.7 t -123.28 105.04 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.609 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -122.85 137.41 54.94 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.496 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.28 157.32 18.26 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 41.7 m -121.22 151.83 39.53 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.787 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -114.67 105.74 53.06 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -72.42 -0.91 9.42 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.296 3.331 . . . . 0.0 109.584 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.99 -11.77 40.63 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 65.0 m-20 -132.69 26.42 4.36 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.668 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.86 120.83 37.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.3 t -113.4 -174.68 2.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.35 157.2 43.76 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.83 156.95 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.5 m -127.63 127.24 43.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -59.95 146.31 42.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -87.35 -171.98 3.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.16 -28.38 69.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -76.49 -11.0 59.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 83.03 1.22 90.63 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.2 p -94.19 136.73 34.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.59 163.62 18.62 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.91 130.04 13.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.752 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -156.24 174.64 15.1 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.752 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -124.76 126.68 46.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.954 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.935 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.16 119.45 38.99 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -80.7 137.52 36.3 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.584 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.74 128.31 63.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.525 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -117.41 141.7 48.02 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -42.79 87.01 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.631 ' OG ' HG22 ' A' ' 85' ' ' THR . 11.5 t -147.01 156.74 43.28 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.958 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.0 p90 -177.02 157.93 1.48 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.03 111.54 0.86 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.496 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.5 99.05 1.3 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.746 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -84.46 99.51 10.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.923 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.7 tp -54.4 131.34 42.04 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.662 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.3 p90 -47.55 -36.29 10.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.578 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.0 t0 -57.3 -17.24 11.18 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.91 28.5 8.23 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.923 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.61 145.07 43.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -85.16 95.53 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.378 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 0.8 OUTLIER -64.87 -56.92 10.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.914 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.52 168.78 12.8 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.631 HG22 ' OG ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -58.28 104.7 0.22 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 38' ' ' ALA . 33.7 m -83.09 154.12 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -117.81 93.32 4.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.513 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 75.9 m -50.3 -29.32 9.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.752 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 5.5 t -73.5 -1.67 19.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.47 -27.48 7.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.36 -164.21 1.33 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.62 123.35 47.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.189 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -103.89 160.15 15.04 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.066 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -160.45 147.7 15.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.935 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -106.51 165.42 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.282 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.24 164.05 33.11 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.36 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.79 131.11 42.65 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.175 ' N ' ' H ' ' A' ' 33' ' ' ASP . 23.9 m -113.83 151.29 32.31 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 1.143 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -108.67 -158.09 0.64 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.436 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.54 -47.92 65.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.12 -25.05 64.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.3 53.99 1.65 Allowed Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.917 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.45 166.86 20.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.289 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.1 174.67 43.59 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.657 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.37 167.49 26.81 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.333 3.356 . . . . 0.0 109.603 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.562 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 1.4 pm0 -38.37 124.83 1.29 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.96 156.79 0.01 OUTLIER Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.964 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.1 t -118.38 103.29 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.62 135.99 34.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.189 HG13 ' C ' ' A' ' 93' ' ' CYS . 2.9 pt -145.03 -176.55 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.862 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -176.7 177.88 1.31 Allowed 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.513 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.8 m-85 -127.73 113.75 16.41 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.98 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 6.6 p30 . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.201 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.576 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.39 -178.6 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.339 3.359 . . . . 0.0 109.591 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.905 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.66 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.753 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -124.14 157.92 33.54 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.579 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -126.31 129.41 48.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.944 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -119.41 148.59 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.72 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.64 165.76 33.01 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.72 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.35 117.2 5.02 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.286 3.324 . . . . 0.0 109.63 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.827 ' OG ' HG12 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -129.7 14.1 5.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 111' ' ' SER . 71.0 m -86.56 105.94 17.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.972 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.27 17.72 26.16 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.1 mt -106.79 133.17 51.86 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -87.28 -179.74 6.47 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.778 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 4.2 t0 -45.05 152.39 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.92 38.24 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.564 HG21 HD12 ' A' ' 13' ' ' LEU . 51.6 m -64.73 150.97 46.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -125.58 119.31 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.862 HG13 HG12 ' A' ' 69' ' ' VAL . 2.4 m -95.5 116.31 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.944 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -86.27 115.24 23.69 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.563 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -102.47 119.37 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -130.66 118.4 20.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.962 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.1 148.68 19.88 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.905 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.03 110.87 5.42 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.11 16.48 27.75 Favored Glycine 0 C--N 1.335 0.497 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.11 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.73 170.55 10.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.53 ' HB2' HG21 ' A' ' 30' ' ' THR . 1.6 mp0 -52.08 118.92 3.82 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.494 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.78 130.62 41.55 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.05 7.64 86.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.53 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -94.94 145.74 24.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.0 151.4 22.31 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.962 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 39.1 m-85 -138.76 140.57 38.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.28 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.2 m-20 -104.41 114.19 28.25 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.267 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.7 146.45 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.051 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.45 166.88 40.05 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.894 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.2 tt0 -111.73 118.91 36.9 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -123.84 147.91 47.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.916 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.27 135.5 54.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.588 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.9 121.32 14.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.525 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 10.6 m -102.15 -43.42 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.794 ' CG ' ' HH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.58 165.52 25.34 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.664 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.2 t -51.7 111.96 0.68 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.87 9.18 70.19 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.497 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.3 t -123.96 113.69 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.75 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.54 139.14 53.44 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -96.92 144.34 26.94 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 66.3 m -107.0 158.3 17.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.603 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -115.65 111.46 43.69 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.52 7.28 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.326 3.351 . . . . 0.0 109.603 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.501 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.37 -10.81 45.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 7.1 p30 -131.54 28.23 4.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.86 104.63 12.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.96 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.6 t -100.88 174.35 6.07 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.1 p -145.95 156.13 43.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.51 HG22 ' HB1' ' A' ' 63' ' ' ALA . 4.4 p -166.49 159.43 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.47 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.8 m -127.25 139.54 52.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.95 141.02 36.41 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.0 p30 -82.3 -172.24 3.88 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.2 -27.88 69.29 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -75.1 -7.27 53.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.11 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.89 30.9 58.75 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 77.9 p -125.29 136.12 53.19 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.51 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -123.26 157.44 33.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.71 126.46 23.87 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.443 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -150.21 161.67 41.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -125.57 108.53 11.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.388 HD22 ' CG2' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -95.6 157.88 15.7 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.415 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.1 OUTLIER -107.49 140.17 40.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.862 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.88 123.28 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.778 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -109.91 157.94 18.72 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.498 ' HD2' HG21 ' A' ' 89' ' ' THR . 5.8 mtm180 -87.63 -13.06 43.7 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.5 m -163.41 145.47 9.76 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.894 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.5 p90 -177.42 150.69 0.71 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -53.4 113.48 1.17 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.7 101.47 1.42 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.821 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.33 100.67 10.8 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -54.53 131.23 42.35 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.652 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.49 -36.04 9.64 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.597 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.2 t0 -57.77 -16.56 11.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.49 27.39 9.89 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.62 152.85 32.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.15 98.68 10.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 75.0 t-105 -65.61 -43.53 89.31 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.41 175.54 14.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.46 107.75 0.62 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.916 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.4 t -80.02 152.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -120.36 95.84 4.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.941 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.3 m -54.11 -22.93 12.23 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.498 HG21 ' HD2' ' A' ' 71' ' ' ARG . 70.2 p -84.75 2.13 43.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -112.41 -23.36 10.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.05 179.29 7.3 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.32 130.94 40.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.368 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 11.1 m -104.47 164.89 11.43 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.057 ' HA ' HG12 ' A' ' 110' ' ' ILE . 1.1 tt0 -156.91 151.41 25.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.388 ' CG2' HD22 ' A' ' 67' ' ' LEU . 2.7 t -106.09 165.61 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.267 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.79 162.08 30.28 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.009 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -124.68 128.94 49.59 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.28 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 27.6 m -112.73 141.56 46.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -103.15 -162.03 0.88 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.996 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.83 -48.16 67.0 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.51 -24.67 66.43 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.61 53.69 1.92 Allowed Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.81 173.43 11.18 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.7 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -175.64 169.12 41.79 Favored Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.576 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.39 171.85 16.16 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.314 3.342 . . . . 0.0 109.595 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.201 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.8 OUTLIER -36.45 133.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.21 160.73 2.44 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.884 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 6.6 t -116.25 103.58 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.09 127.9 35.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.368 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -138.2 179.21 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -163.68 175.52 10.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.031 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.0 m-85 -131.01 114.85 15.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.971 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 10.7 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.698 ' HB3' ' CD ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.402 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.4 -174.51 1.45 Allowed 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 124.295 3.33 . . . . 0.0 109.619 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.73 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.28 108.83 21.38 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 140.42 52.39 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -102.06 112.45 25.11 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.732 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.74 154.86 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.942 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 174.41 2.52 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.127 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.36 118.4 5.58 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 111' ' ' SER . 30.3 p -112.36 46.9 1.12 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.8 p -127.4 106.19 9.03 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.989 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.81 27.67 16.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.127 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.65 131.99 45.28 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -107.54 168.4 9.27 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -44.67 141.17 2.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.85 -22.32 37.41 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.489 HG21 HD13 ' A' ' 13' ' ' LEU . 31.4 m -76.86 150.35 36.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.615 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.8 p -126.53 117.27 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.299 HG22 ' O ' ' A' ' 67' ' ' LEU . 13.3 m -83.73 164.12 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.732 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.75 152.25 36.51 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.1 111.51 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.49 116.37 26.54 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.712 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.84 143.25 23.16 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.73 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.0 105.54 4.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.902 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.22 23.05 8.28 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.201 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.81 -164.98 1.22 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.587 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -85.6 123.77 31.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.62 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.12 134.57 45.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.86 7.57 75.73 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -94.82 138.97 31.92 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.956 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.523 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.4 150.76 22.38 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.251 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -137.17 146.42 44.93 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.258 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.2 m-20 -107.47 112.15 24.79 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.345 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -101.84 150.19 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.923 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -179.38 174.54 46.36 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 1.097 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 31.0 tt0 -114.96 113.25 23.89 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.1 m -118.02 145.62 44.65 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.222 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.73 135.98 54.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.582 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.45 124.8 22.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.427 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.1 m -107.15 -42.25 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.325 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -138.29 129.91 27.9 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.633 HG23 ' O ' ' A' ' 42' ' ' THR . 9.5 t -38.04 112.01 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.434 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 93.03 8.98 61.22 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.473 ' CG2' ' HE1' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -151.8 130.44 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.696 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.7 pt? -133.02 142.88 49.05 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.57 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.4 144.65 25.14 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 6.1 m -106.69 156.55 18.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.931 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.4 t-20 -112.97 109.1 52.71 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.4 8.65 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.31 3.34 . . . . 0.0 109.628 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.542 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -94.09 -9.32 37.0 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.912 ' HB3' HG23 ' A' ' 68' ' ' THR . 7.9 m-20 -133.58 15.17 4.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.648 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -85.09 117.11 23.86 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.7 t -112.13 -178.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -145.72 156.14 43.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 56' ' ' THR . 5.1 p -166.99 157.74 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 55' ' ' VAL . 35.0 m -127.66 132.89 49.65 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 153.39 39.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -92.98 -172.04 2.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.82 -29.15 69.3 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -75.22 -9.11 58.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.62 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.88 7.19 88.72 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 99.3 p -99.22 138.94 35.61 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.27 163.91 17.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.1 p -149.38 127.77 12.21 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.608 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -164.51 152.9 12.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -109.24 125.0 51.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.346 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.44 122.15 45.39 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.912 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.1 t -77.94 142.36 38.41 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 1.001 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -114.95 131.16 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.991 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 1.023 ' H ' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -113.74 156.84 23.08 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.981 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.26 -13.49 49.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 92.1 p -168.98 144.3 3.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 1.097 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 14.2 p90 -176.53 158.11 1.73 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -59.22 122.35 13.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.57 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.48 104.32 2.61 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.592 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.4 m-85 -84.82 101.31 12.17 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.89 HD21 ' OD2' ' A' ' 79' ' ' ASP . 6.0 tp -54.33 138.78 38.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.771 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.46 -41.85 21.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.89 ' OD2' HD21 ' A' ' 77' ' ' LEU . 44.1 m-20 -56.85 -17.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.42 26.08 12.73 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.78 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.63 149.17 29.31 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.7 mtt180 -78.7 95.21 5.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.473 ' HE1' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -62.85 -39.49 94.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 126.5 170.26 12.91 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.226 -1.149 . . . . 0.0 110.226 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.92 130.95 43.31 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.222 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.0 t -109.13 154.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -125.53 98.0 5.41 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.721 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 9.9 m -53.13 -27.2 19.64 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.5 p -80.12 0.99 29.78 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.97 -27.59 6.51 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.2 -177.72 4.58 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.34 124.37 45.74 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.828 ' O ' HG13 ' A' ' 110' ' ' ILE . 60.2 m -103.92 153.27 20.99 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.047 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -146.52 146.98 30.7 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.921 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.346 ' CG2' HD12 ' A' ' 67' ' ' LEU . 4.0 t -107.48 159.58 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.345 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.25 171.96 44.78 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.195 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.97 122.12 25.05 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.258 ' N ' ' H ' ' A' ' 33' ' ' ASP . 6.7 m -102.95 154.79 18.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.523 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -114.75 -160.93 0.75 Allowed 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.467 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.8 -49.04 79.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.14 -26.02 60.08 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 98.6 49.21 1.7 Allowed Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.447 HD21 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -120.5 167.48 12.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.251 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.66 -176.85 45.16 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.402 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.41 159.6 48.89 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.32 3.347 . . . . 0.0 109.577 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.361 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -37.32 125.44 1.01 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.94 147.64 0.09 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.047 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -115.89 104.51 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.65 138.09 32.38 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.039 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.4 mt -113.61 159.09 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -143.52 119.12 10.4 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.721 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 40.1 m-85 -95.14 123.42 38.63 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.939 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.678 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.525 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.1 Cg_endo -72.41 -175.48 1.81 Allowed 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 124.336 3.357 . . . . 0.0 109.628 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.364 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -100.03 117.92 35.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.986 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -133.52 150.63 51.68 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.1 114.24 25.81 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.708 ' HB ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -111.08 149.75 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.748 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.9 167.36 24.76 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.748 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.3 Cg_endo -72.38 119.31 6.06 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.295 3.33 . . . . 0.0 109.586 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.574 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -125.38 13.71 8.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.1 p -92.33 114.95 27.63 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.105 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.03 22.58 32.34 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.105 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.39 139.16 43.5 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 179.963 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 59.1 m -97.27 169.57 9.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -44.71 151.2 0.3 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.81 -24.35 31.4 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.569 HG21 ' CD1' ' A' ' 13' ' ' LEU . 2.4 m -78.51 144.23 35.86 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.99 146.05 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.7 OUTLIER -117.2 157.61 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.708 ' O ' ' HB ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -113.1 151.1 31.2 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.753 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -146.16 105.37 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.841 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.21 115.46 26.03 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.986 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.26 143.34 21.03 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.364 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.56 110.66 6.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.885 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 98.81 23.83 11.4 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.608 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.75 -169.77 2.73 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -81.83 122.78 28.15 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.31 131.74 43.88 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.95 7.83 81.92 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.539 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.31 140.48 30.14 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.925 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -90.59 151.61 21.24 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.497 ' CB ' ' CD1' ' A' ' 97' ' ' LEU . 43.2 m-85 -138.0 154.58 49.32 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.525 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 11.1 m-20 -118.5 112.46 19.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.486 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -97.62 149.61 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.994 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.99 167.01 38.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.837 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 15.5 tt0 -107.72 129.34 55.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.0 m -125.88 165.5 18.6 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.226 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -142.51 123.93 14.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.634 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.97 117.63 7.9 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.737 HG12 HG22 ' A' ' 86' ' ' VAL . 5.5 m -99.53 -42.52 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.23 -179.49 5.82 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.4 m -63.38 111.52 2.33 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.18 8.46 65.32 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.574 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 62.4 t -121.97 106.96 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.694 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.84 136.47 54.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.45 157.79 20.37 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.3 m -126.24 156.63 39.97 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.601 HD21 ' HB3' ' A' ' 50' ' ' ALA . 30.5 t30 -123.91 111.94 28.9 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.4 -0.68 9.07 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.308 3.339 . . . . 0.0 109.604 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.601 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.55 -13.32 43.25 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.468 ' CB ' HG23 ' A' ' 68' ' ' THR . 9.0 p30 -130.09 27.9 5.08 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.688 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.56 117.72 33.63 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.8 t -111.36 -178.24 3.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.0 p -147.78 155.42 41.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 3.0 p -167.52 160.42 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 37.6 m -127.15 129.91 48.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.83 150.86 40.57 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -90.5 -171.08 2.94 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.62 -28.85 69.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -75.53 -7.94 55.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.5 10.05 86.48 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.2 p -102.03 137.68 39.99 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.35 165.04 15.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 p -150.1 125.18 9.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.573 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.96 164.4 38.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.949 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.573 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -120.39 126.17 49.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.899 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -103.74 118.69 37.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.68 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -68.44 116.78 9.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.58 HG23 HG11 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -73.32 122.83 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.68 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -118.02 133.01 56.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -67.85 -40.8 83.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.469 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 19.5 m -155.96 159.37 39.17 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.837 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -177.35 177.78 1.15 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -64.9 121.89 15.69 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.52 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.6 87.21 1.32 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.784 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.29 100.18 10.46 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.958 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.15 144.13 20.62 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.721 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.16 -43.67 21.27 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.572 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 10.3 t0 -57.76 -17.16 13.88 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.24 29.09 9.89 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.918 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.61 121.18 44.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.432 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.1 ptt180 -62.81 91.07 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.574 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.9 t-105 -63.13 -58.37 7.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.15 157.0 8.15 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -54.52 110.13 0.59 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.226 HG11 ' CB ' ' A' ' 38' ' ' ALA . 16.8 t -88.49 154.54 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.469 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 27.4 m-20 -118.85 94.55 4.49 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.184 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 93.5 m -52.0 -28.82 18.26 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.85 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 2.1 t -76.18 -1.24 25.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -115.24 -27.16 7.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.74 -166.2 1.6 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.52 123.39 46.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.15 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 0.8 OUTLIER -104.47 156.29 18.07 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.032 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.12 154.87 42.29 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.899 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 6.4 t -122.11 160.79 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.213 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.28 171.83 42.81 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.525 ' HA ' ' C ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -127.66 124.79 38.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.302 ' N ' ' O ' ' A' ' 33' ' ' ASP . 59.6 p -99.47 152.62 19.79 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.925 ' HB2' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -115.14 -164.24 0.93 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.9 -48.89 77.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -70.73 -24.86 62.71 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 95.6 53.81 1.51 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.831 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.13 175.9 8.71 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.669 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 179.31 -173.91 45.86 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.211 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.33 157.58 53.13 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.357 3.371 . . . . 0.0 109.611 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.678 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.01 124.71 1.18 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.64 140.13 0.3 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.997 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.3 t -101.47 113.99 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.84 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -87.27 126.08 34.61 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.032 HG12 ' HA ' ' A' ' 94' ' ' GLN . 13.1 pt -135.07 -172.94 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.54 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -175.74 178.27 1.57 Allowed 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.184 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.1 m-85 -140.75 109.35 5.94 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 8.2 p30 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.521 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.566 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.7 Cg_endo -72.34 -177.73 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.263 0 C-N-CA 124.353 3.369 . . . . 0.0 109.619 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.88 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.4 m -98.51 109.51 22.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.27 163.67 22.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.482 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.1 p -129.55 115.63 17.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.924 ' CG2' HG23 ' A' ' 21' ' ' VAL . 3.3 t -111.07 149.53 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.871 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.66 171.17 7.6 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.871 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.33 117.18 5.01 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.366 3.377 . . . . 0.0 109.589 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.32 13.21 7.12 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.531 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.8 p -91.08 108.39 19.84 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.983 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.81 16.04 29.69 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.8 OUTLIER -103.81 140.46 37.62 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 p -95.67 173.28 7.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -47.04 153.77 0.41 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.38 -24.28 28.1 Favored Glycine 0 C--N 1.335 0.493 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 HD12 ' A' ' 13' ' ' LEU . 3.6 m -71.36 149.66 45.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.4 p -120.49 132.74 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.564 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.6 OUTLIER -111.51 153.51 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.847 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.32 152.87 23.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.924 HG23 ' CG2' ' A' ' 7' ' ' VAL . 1.1 p -145.04 109.42 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.871 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.23 114.44 21.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.018 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.65 146.39 22.37 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.88 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.94 113.25 7.26 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.49 14.97 31.03 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.22 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.99 165.89 13.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.598 ' CD ' ' OH ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -49.61 119.83 3.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.25 134.81 44.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.89 8.06 67.63 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.532 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -95.6 145.74 25.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.04 151.03 23.06 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.375 ' CB ' HD23 ' A' ' 97' ' ' LEU . 35.3 m-85 -137.96 159.16 42.77 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.248 ' OD2' ' HB3' ' A' ' 98' ' ' SER . 3.3 t0 -124.0 115.04 20.57 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.212 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -96.56 142.26 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.861 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.42 164.67 34.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.716 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.2 tt0 -116.19 111.34 20.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 59.4 m -107.82 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.062 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.63 123.86 9.53 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.64 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.95 117.45 7.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.598 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 5.6 m -98.2 -43.26 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.415 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -135.46 177.83 7.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.8 m -61.34 112.01 1.99 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.3 8.54 66.05 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 59.1 t -121.53 111.14 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -126.26 139.61 53.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.512 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.57 144.36 25.66 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.5 m -110.19 146.9 34.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.714 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 29.2 t30 -107.47 107.74 60.77 Favored Pre-proline 0 N--CA 1.449 -0.488 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.2 Cg_endo -72.34 0.61 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 124.368 3.378 . . . . 0.0 109.599 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.05 -14.1 39.82 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.492 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.7 p30 -126.04 28.24 6.13 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.43 105.49 14.42 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.1 t -103.14 178.27 4.6 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.8 p -147.06 156.86 43.36 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.616 ' CG1' HD21 ' A' ' 97' ' ' LEU . 7.1 p -167.88 160.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 26.9 m -126.96 138.32 53.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.8 143.6 34.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.4 p30 -80.25 -171.05 2.8 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.13 -26.11 68.39 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -10.07 59.13 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.22 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.11 31.18 53.6 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -127.61 137.27 52.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.46 168.32 13.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.6 128.51 11.75 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.531 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -154.09 162.32 41.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.531 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -115.82 119.73 36.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.21 HD13 ' CG2' ' A' ' 95' ' ' VAL . 1.0 OUTLIER -97.57 133.94 41.45 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.73 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -79.75 134.56 36.38 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG23 HG11 ' A' ' 19' ' ' VAL . 1.1 t -94.29 124.1 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.73 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.7 OUTLIER -117.2 142.95 46.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.92 -26.74 36.54 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -155.42 149.85 26.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.949 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.716 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -173.77 157.88 3.16 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.28 117.51 4.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.512 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.26 93.3 1.09 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.788 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -84.14 99.86 10.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.02 130.39 45.87 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.16 -35.63 7.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.78 -16.57 11.73 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.68 28.38 8.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -116.23 147.78 41.1 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -84.73 96.02 9.12 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.598 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 68.7 t90 -64.97 -58.82 5.13 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.75 163.87 10.93 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.17 106.42 0.23 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.062 HG11 ' CB ' ' A' ' 38' ' ' ALA . 20.2 t -80.77 152.46 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.68 93.99 4.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.266 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 12.1 m -53.13 -26.57 17.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.726 ' HA ' ' HB3' ' A' ' 112' ' ' PHE . 7.3 t -82.37 0.1 43.46 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.0 m -114.3 -27.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.93 3.63 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.69 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -99.57 126.0 45.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.957 ' CB ' HD11 ' A' ' 110' ' ' ILE . 92.4 m -104.2 172.01 7.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.041 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 1.2 tt0 -160.93 151.5 18.14 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.21 ' CG2' HD13 ' A' ' 67' ' ' LEU . 3.0 t -108.65 167.1 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.212 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.36 166.65 37.29 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.375 HD23 ' CB ' ' A' ' 32' ' ' TYR . 6.0 mp -102.16 161.82 13.39 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.248 ' HB3' ' OD2' ' A' ' 33' ' ' ASP . 46.7 t -150.86 121.07 7.25 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.645 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.8 OUTLIER -115.86 -170.9 1.88 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -46.0 -39.65 9.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.96 -25.33 26.12 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 91.16 22.61 31.94 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 1.35 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.11 -150.27 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.996 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.2 150.62 5.49 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.566 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 166.0 31.03 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.307 3.338 . . . . 0.0 109.578 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.521 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 6.6 pt-20 -34.34 124.3 0.5 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.21 135.32 1.48 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.041 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 3.4 t -90.05 107.43 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.91 127.83 34.12 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.038 HG12 ' CA ' ' A' ' 94' ' ' GLN . 4.0 pt -141.5 -173.77 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.69 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.6 OUTLIER -174.75 163.4 3.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.266 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 6.6 m-85 -125.88 112.16 15.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.919 HD22 ' HA2' ' A' ' 12' ' ' GLY . 0.8 OUTLIER . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.648 ' HB3' ' CG ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.525 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.39 -177.2 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.317 3.344 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.756 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.78 109.59 22.33 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.735 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.08 140.3 52.03 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -100.5 111.48 23.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 108' ' ' VAL . 21.8 t -105.84 150.29 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.96 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.5 175.7 1.51 Allowed Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.068 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.7 Cg_endo -72.4 118.59 5.67 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.318 3.346 . . . . 0.0 109.586 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.001 ' HB2' HG23 ' A' ' 110' ' ' ILE . 54.5 p -113.0 47.52 1.11 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.0 p -126.56 107.38 10.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.028 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 27.0 20.62 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.068 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -102.01 132.49 47.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 82.0 p -109.88 169.28 8.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -45.04 140.72 2.57 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.67 38.31 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.434 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -77.05 141.87 40.11 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.707 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.9 p -113.78 108.95 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.291 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.4 m -77.13 164.07 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.843 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.1 149.72 38.52 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.918 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -146.56 115.41 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.86 116.96 23.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.872 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.18 147.94 23.9 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.756 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.61 111.81 4.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.66 14.44 34.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.64 173.64 8.19 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.519 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.5 mt-30 -56.37 119.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.08 131.23 41.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.13 7.82 84.75 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.519 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.83 141.37 28.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.698 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.46 150.35 25.35 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.283 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 25.4 m-85 -136.38 140.81 43.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.41 ' N ' ' N ' ' A' ' 98' ' ' SER . 2.5 m-20 -103.11 116.91 33.4 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.562 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -107.12 145.63 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.886 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.54 161.73 31.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.953 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 18.9 tt0 -101.97 120.61 40.69 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.482 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.5 m -109.99 169.0 9.01 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.088 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.73 124.91 8.71 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.611 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.64 124.03 20.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.792 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 15.4 m -103.73 -44.07 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.863 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -138.52 165.23 27.39 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.5 m -51.88 112.6 0.81 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.24 8.21 65.05 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 97.3 t -122.32 107.47 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.709 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.71 162.38 18.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.507 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.11 156.59 41.5 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.859 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -118.47 155.49 30.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.67 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 19.8 t30 -112.86 113.58 49.79 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.38 0.03 8.02 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.343 3.362 . . . . 0.0 109.612 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.98 -9.51 45.73 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.2 p30 -134.16 27.72 3.82 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.42 107.29 17.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -103.49 171.38 7.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.2 p -145.27 153.54 41.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -166.6 158.23 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' VAL . 85.7 m -127.52 135.53 50.49 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.45 139.97 48.02 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.2 p30 -77.6 -174.75 3.54 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.8 -25.08 68.06 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -75.99 -8.04 56.04 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.942 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 75.3 32.18 55.96 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -129.87 137.62 50.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.6 167.39 14.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -150.56 125.43 9.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.462 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -159.84 158.26 30.68 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.462 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -111.17 133.46 53.51 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.291 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -110.3 120.16 41.54 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.638 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -79.26 129.86 34.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.78 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.88 137.02 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.874 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -120.31 165.62 14.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.5 -14.12 33.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.2 m -164.51 144.49 7.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.953 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.4 p90 -176.3 154.24 1.32 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.496 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.9 OUTLIER -57.3 124.26 18.26 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.507 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -84.75 98.08 2.18 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.859 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.2 101.75 12.1 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.862 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -57.81 131.62 50.88 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.679 ' N ' HD12 ' A' ' 77' ' ' LEU . 29.6 p90 -47.64 -35.76 9.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.656 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -58.01 -16.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.22 28.46 9.18 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.862 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.0 m -115.66 146.69 41.6 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.0 96.58 8.91 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.863 ' HZ2' ' HB2' ' A' ' 41' ' ' ASP . 5.2 t-105 -63.45 -42.69 98.66 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 128.43 176.55 14.49 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.53 135.55 54.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.088 HG11 ' CB ' ' A' ' 38' ' ' ALA . 1.6 t -114.82 154.93 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -127.81 101.34 6.31 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.907 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 48.9 m -53.35 -28.04 26.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -79.04 -2.45 40.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.19 -27.59 6.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.92 -176.12 3.76 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.0 123.38 45.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.704 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 72.3 m -104.35 152.24 22.5 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.025 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -145.05 148.81 34.12 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.138 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.5 t -114.31 148.2 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.405 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.74 173.87 46.41 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.562 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.7 OUTLIER -125.66 159.88 31.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.41 ' N ' ' N ' ' A' ' 33' ' ' ASP . 2.9 m -139.64 156.95 46.55 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.698 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.11 -165.45 1.0 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -55.79 -49.18 73.89 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.488 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.0 -25.37 62.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.69 39.55 3.37 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.589 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -113.57 154.32 27.34 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.283 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -161.86 -173.1 30.11 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.525 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.41 158.41 51.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.332 3.354 . . . . 0.0 109.557 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.648 ' CG ' ' HB3' ' A' ' 2' ' ' ALA . 2.4 mt-10 -38.64 117.26 0.63 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.09 153.2 0.01 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 7' ' ' VAL . 11.0 t -127.05 106.71 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.444 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -82.69 133.89 35.15 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.025 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.5 mt -102.76 163.87 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.722 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -145.73 123.34 11.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.907 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.7 m-85 -95.32 127.36 41.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.968 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.585 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.638 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.37 -174.1 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.327 3.351 . . . . 0.0 109.591 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.49 110.75 23.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.878 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.72 139.16 52.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.551 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -99.71 112.48 24.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.778 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.51 152.89 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.929 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.48 174.06 2.87 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.099 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.9 Cg_endo -72.38 118.74 5.74 Favored 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 124.321 3.348 . . . . 0.0 109.618 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.81 ' HB2' HG23 ' A' ' 110' ' ' ILE . 92.0 p -111.94 49.08 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -127.54 106.41 9.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.002 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.44 27.5 20.0 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.099 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.67 132.22 46.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.6 m -109.22 172.27 6.95 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 1.023 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 7.6 t70 -46.6 141.53 3.71 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.2 -22.5 36.3 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.49 HG21 HD13 ' A' ' 13' ' ' LEU . 29.1 m -76.58 149.75 36.58 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.64 HG13 ' O ' ' A' ' 18' ' ' VAL . 11.7 p -121.5 114.66 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.903 HG23 HG12 ' A' ' 69' ' ' VAL . 11.6 t -81.03 153.19 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.778 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.82 147.18 33.76 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.499 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.3 111.15 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.878 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.87 117.13 27.32 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.804 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.08 144.77 24.0 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.9 102.29 3.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.912 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 109.04 17.64 10.01 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.258 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -90.23 171.36 9.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.988 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.982 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 26.7 mt-30 -56.9 121.82 10.8 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.59 131.75 42.04 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.0 7.77 86.72 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.427 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -96.12 136.59 36.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.984 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -82.64 152.25 25.96 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.875 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.4 m-85 -136.57 146.05 45.68 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.278 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -107.47 113.55 26.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.984 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.4 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.09 144.53 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.994 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.57 169.7 42.53 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.957 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 38.5 tt0 -106.4 105.31 15.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -105.71 141.14 37.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.997 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.78 138.57 54.59 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.563 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.93 124.44 22.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.918 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.12 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -103.66 -51.32 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.953 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -132.72 168.29 18.58 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.94 112.49 0.72 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.47 7.96 65.52 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.671 HG11 ' HE1' ' A' ' 83' ' ' TRP . 86.3 t -121.8 120.97 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.578 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -130.26 134.5 47.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.979 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.468 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.42 153.53 18.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 98.6 m -112.64 145.51 40.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.917 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -108.88 114.18 58.72 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.36 -0.24 8.41 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 124.332 3.355 . . . . 0.0 109.584 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.762 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -81.33 -12.67 58.96 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.584 ' CG ' HG23 ' A' ' 68' ' ' THR . 96.2 m-20 -136.66 29.78 2.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD1' ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -84.36 108.36 17.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.8 t -107.0 173.41 6.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 p -145.59 154.45 42.17 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' N ' ' A' ' 56' ' ' THR . 6.8 p -167.06 156.82 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.436 ' N ' HG22 ' A' ' 55' ' ' VAL . 36.3 m -126.84 135.62 51.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.14 154.1 42.62 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -92.86 -169.42 2.17 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.57 -28.34 69.81 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.72 -7.56 54.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.648 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.11 14.96 81.76 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -107.83 137.68 45.41 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.92 165.45 15.19 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 p -149.94 128.12 12.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.67 160.85 20.39 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.899 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -117.65 127.41 53.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.103 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.2 120.19 40.93 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.905 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.64 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -76.42 134.99 39.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.903 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.9 135.28 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 1.023 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -116.71 162.47 17.62 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -87.98 -19.51 27.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 28.5 t -163.05 146.73 10.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.957 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.7 p90 -177.04 152.75 0.93 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -57.66 118.96 5.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.468 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.64 98.98 1.83 Allowed Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.792 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.13 100.96 10.86 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.925 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.5 tp -54.78 131.79 44.62 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.672 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.8 m-85 -47.43 -36.48 9.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.575 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.13 -16.66 8.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.27 27.72 9.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.925 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -115.89 149.93 37.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.56 98.04 11.54 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.12 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -63.94 -43.71 95.06 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.946 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 135.69 -179.65 17.55 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.44 126.16 26.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.997 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.1 t -101.45 154.02 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 11.7 m-20 -127.45 96.79 4.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.782 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 54.4 m -53.23 -27.81 24.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -78.32 1.28 22.34 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.14 -27.53 6.06 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.16 -173.28 3.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.8 124.72 48.86 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.87 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 97.6 m -104.36 152.52 22.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.07 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -146.39 148.43 32.31 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.103 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.7 t -110.3 160.06 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.397 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 168.8 41.07 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.4 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.12 128.38 44.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.278 ' N ' ' H ' ' A' ' 33' ' ' ASP . 22.2 m -114.72 148.3 38.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.984 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -107.13 -157.97 0.64 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.49 -47.26 64.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.02 -23.97 64.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.01 53.88 1.98 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.982 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.21 165.96 20.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.875 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.62 46.71 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.638 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.38 162.44 41.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.346 3.364 . . . . 0.0 109.59 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.585 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 1.5 tt0 -37.59 120.83 0.84 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.66 153.54 0.02 OUTLIER Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.935 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.8 t -118.3 104.18 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.62 124.05 32.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.07 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.9 mt -101.31 157.0 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.65 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -141.94 125.36 16.64 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.782 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 9.5 m-85 -96.6 124.28 40.54 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.39 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.465 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.485 ' CB ' HD22 ' A' ' 26' ' ' LEU . 81.4 Cg_endo -72.4 -174.31 1.39 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.268 3.312 . . . . 0.0 109.616 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.805 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.66 108.27 19.75 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.879 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.57 146.24 47.17 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -113.24 118.17 33.92 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.829 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -114.13 155.15 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.993 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.645 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -71.54 162.19 74.32 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.639 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 121.98 7.93 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.322 3.348 . . . . 0.0 109.606 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.659 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.2 OUTLIER -126.93 15.84 7.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.6 111.73 22.23 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.078 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.3 22.58 31.7 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.078 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -109.11 144.12 37.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 75.5 m -94.29 166.03 12.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 1.128 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 11.5 t0 -46.15 153.34 0.33 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 100.02 -24.27 32.78 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.438 HG21 HD12 ' A' ' 13' ' ' LEU . 24.5 m -69.17 132.62 46.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.3 p -106.43 111.33 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.645 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 6.4 m -90.37 166.08 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.829 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.04 149.1 44.82 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.454 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -136.41 104.88 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.879 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.8 117.83 31.84 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.746 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -88.03 143.82 18.37 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.805 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -135.01 108.09 7.65 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.921 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.69 25.69 7.98 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.485 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.89 179.69 6.14 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 180.0 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.425 ' HB2' HG21 ' A' ' 30' ' ' THR . 18.9 mt-30 -76.83 123.74 26.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.476 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.11 137.46 54.96 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.78 7.28 65.25 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.644 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.16 145.12 24.65 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.2 149.11 22.01 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.535 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 39.8 m-85 -138.05 136.83 37.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.109 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -99.61 114.75 27.99 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.114 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.99 143.19 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.897 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.66 162.14 35.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.936 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -101.01 117.78 35.7 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.436 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.9 m -108.65 164.57 12.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.771 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -150.47 139.44 20.98 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.527 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -64.67 124.55 22.21 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.228 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -106.4 -53.93 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.617 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -138.1 167.03 22.66 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -51.02 111.58 0.58 Allowed 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.59 8.15 66.51 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.602 ' CG1' ' CZ3' ' A' ' 83' ' ' TRP . 13.8 t -124.21 118.91 55.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.69 HD12 ' N ' ' A' ' 46' ' ' ALA . 2.0 pp -121.93 163.3 19.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.369 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.51 146.19 50.59 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.768 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.15 159.13 17.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.985 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.902 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.2 t30 -113.04 112.74 49.81 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.39 -0.82 9.28 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.339 3.36 . . . . 0.0 109.592 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.95 -7.92 50.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.449 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 32.9 m-20 -133.82 26.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.406 ' HD1' ' HA ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -84.25 106.12 15.62 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.8 t -104.73 176.38 5.18 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.7 p -146.09 158.45 43.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.449 HG22 ' N ' ' A' ' 56' ' ' THR . 5.5 p -166.98 158.3 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.449 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.5 m -128.37 127.35 42.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.61 141.57 58.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.5 p30 -85.22 -171.57 3.7 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.53 -23.52 67.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -83.67 1.0 44.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 70.44 2.35 41.83 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 t -95.12 136.08 35.88 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.45 161.99 21.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -147.51 129.59 15.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.715 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -151.7 174.24 13.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.888 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.715 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -130.96 114.64 15.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.613 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -98.38 156.89 16.52 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.601 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -116.64 134.67 54.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.649 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -101.03 131.06 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 1.128 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -115.74 147.92 40.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 ptt180 -74.48 -25.15 59.2 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.5 t -159.94 150.01 18.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.936 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.6 p90 -177.34 156.03 1.17 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.23 119.83 7.58 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.369 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.32 100.39 1.39 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.768 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.35 100.04 10.41 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 1.074 HD21 ' OD2' ' A' ' 79' ' ' ASP . 4.3 tp -55.05 137.12 47.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.69 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.62 -40.99 13.93 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 1.074 ' OD2' HD21 ' A' ' 77' ' ' LEU . 1.5 m-20 -57.09 -17.0 8.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.98 26.87 10.84 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -109.51 148.63 30.89 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.76 95.73 8.52 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.617 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 33.3 t-105 -62.8 -56.43 17.55 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.04 170.72 19.0 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.53 107.44 0.8 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.771 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.8 t -83.41 152.33 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.77 93.71 4.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.268 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -55.03 -22.27 15.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.526 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 25.7 p -85.93 2.24 46.86 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -110.98 -26.57 9.2 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.54 179.22 6.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.664 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -94.06 129.45 40.59 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.045 ' HB2' HD11 ' A' ' 110' ' ' ILE . 59.1 m -104.86 173.07 6.46 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.378 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -158.67 142.55 15.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.951 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.613 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.4 t -98.21 164.13 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.114 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.93 161.25 26.87 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.076 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -126.55 135.71 51.63 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.109 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 52.4 p -106.99 158.79 16.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.466 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.0 OUTLIER -112.46 -167.53 1.2 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.466 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -53.8 -49.83 67.45 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.489 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -74.52 -25.4 59.31 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.4 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 104.67 39.44 2.37 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.489 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -122.92 -175.34 3.14 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.535 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 162.14 -161.88 33.79 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.389 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.91 52.44 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.382 3.388 . . . . 0.0 109.553 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.39 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.0 pt-20 -42.84 145.23 0.48 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.76 164.5 1.75 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.378 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 37.3 t -116.84 102.69 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.448 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -75.88 132.48 40.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.045 HD11 ' HB2' ' A' ' 93' ' ' CYS . 6.2 pt -142.41 -174.36 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.664 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.1 OUTLIER -171.02 176.1 4.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.268 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 4.6 m-85 -132.55 114.29 14.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.002 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.4 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.645 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.38 -177.7 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 124.314 3.343 . . . . 0.0 109.635 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.785 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.77 109.69 22.41 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.783 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.46 133.52 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.632 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -96.51 115.85 28.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.556 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.29 155.95 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.95 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 175.61 1.77 Allowed Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.051 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.37 117.4 5.11 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.32 3.346 . . . . 0.0 109.58 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.805 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 1.6 p -110.73 48.57 0.91 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 79.9 p -126.97 105.88 8.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.096 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.32 29.27 11.43 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.096 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.43 130.29 55.24 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.951 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.19 177.36 4.67 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -45.83 139.39 4.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.07 -22.77 34.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.679 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.2 m -83.13 150.56 26.19 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.503 HG13 ' O ' ' A' ' 18' ' ' VAL . 13.9 p -121.49 123.96 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.53 HG23 ' HB3' ' A' ' 67' ' ' LEU . 6.8 m -90.44 158.44 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.38 149.08 30.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.711 HG12 ' O ' ' A' ' 65' ' ' THR . 0.3 OUTLIER -145.09 113.38 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.65 117.19 22.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.834 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.06 147.75 23.89 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.785 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.36 111.32 4.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.17 15.61 30.04 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.059 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.6 177.05 6.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 29.7 mt-30 -59.61 121.5 11.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.22 129.8 39.3 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.08 7.04 86.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.52 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.23 141.5 28.51 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.92 149.85 23.83 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.779 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.6 m-85 -136.43 138.09 41.14 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.002 ' HB3' ' O ' ' A' ' 98' ' ' SER . 1.5 t0 -99.99 113.84 26.7 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.242 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.04 144.72 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.739 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.84 171.05 42.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.929 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 33.8 tt0 -117.64 108.77 15.84 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.76 147.66 37.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.288 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.33 142.87 50.04 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.503 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.98 124.97 23.45 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.898 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.443 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -104.89 -44.25 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.332 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -149.05 134.8 18.81 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 41' ' ' ASP . 1.5 m -38.18 110.92 0.14 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.459 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 94.46 8.3 59.87 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.173 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.7 OUTLIER -151.59 129.26 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.636 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -133.96 132.95 40.78 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.425 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -84.27 144.69 28.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 2.6 m -106.44 152.92 23.0 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 41.4 t-20 -111.64 107.4 56.64 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.1 Cg_endo -72.4 -0.05 8.16 Favored 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 124.308 3.338 . . . . 0.0 109.599 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.17 -10.44 49.89 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.697 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.3 OUTLIER -131.71 27.56 4.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.501 ' HD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -80.5 104.6 11.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -100.11 175.35 5.77 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.3 p -143.94 153.39 42.22 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.426 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -167.98 152.24 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.7 m -127.47 134.71 49.81 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -71.4 141.63 50.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 45.2 p30 -81.57 -173.33 4.34 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -27.21 68.71 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -8.61 57.13 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.059 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.81 31.87 52.05 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.1 p -127.93 139.67 52.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.426 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -123.35 165.81 16.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.71 122.89 8.91 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.711 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -158.73 152.22 22.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.75 127.95 56.23 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.486 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -97.78 156.4 16.59 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.956 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.8 t -102.67 120.96 41.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.511 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 1.0 OUTLIER -83.22 127.79 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.861 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.8 OUTLIER -117.14 155.81 28.7 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -94.21 -18.26 21.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.551 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 3.6 m -164.19 144.75 8.22 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.929 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.7 p90 -172.24 153.64 3.09 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -57.98 111.67 1.25 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.425 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.67 101.76 0.89 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.749 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.37 99.68 10.2 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.3 tp -55.44 141.14 37.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.718 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.3 m-85 -46.54 -42.9 16.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.746 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.33 -16.89 9.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.82 27.69 12.27 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.3 m -109.23 144.72 36.97 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -76.89 94.77 3.97 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.443 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 31.5 t-105 -63.19 -57.2 11.3 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.52 163.79 12.51 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.1 104.67 0.33 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.288 HG11 ' CB ' ' A' ' 38' ' ' ALA . 67.9 t -76.64 150.45 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.427 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 4.2 m-20 -117.19 93.91 4.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.002 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 30.8 m -52.16 -27.22 13.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.6 p -80.01 0.36 32.01 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.6 m -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.73 -175.1 3.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.65 126.48 47.15 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.903 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.2 m -104.55 154.37 20.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.027 ' HA ' HG13 ' A' ' 110' ' ' ILE . 2.1 pt20 -142.55 150.05 39.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.486 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.4 t -110.62 164.04 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.242 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.66 166.31 36.01 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.96 121.03 27.15 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.002 ' O ' ' HB3' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -103.52 150.96 23.41 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -109.81 -159.93 0.7 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.973 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.27 -48.87 79.07 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.53 -25.71 57.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.86 42.24 2.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.454 HD21 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -111.68 166.27 11.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.774 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.99 -177.64 44.24 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.06 54.0 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.3 3.333 . . . . 0.0 109.6 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.132 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 1.9 mt-10 -35.39 125.89 0.62 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.06 151.88 0.02 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.904 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -124.39 104.68 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -84.63 146.06 27.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.027 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.8 mt -121.05 157.37 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.54 115.76 11.77 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.002 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 11.6 m-85 -86.56 114.27 23.15 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 2.8 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.48 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.524 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.481 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.6 Cg_endo -72.4 -178.26 3.22 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 124.303 3.336 . . . . 0.0 109.581 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.839 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.62 111.33 23.68 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.69 159.58 33.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.434 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.5 p -124.29 121.28 34.57 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.83 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 55.5 t -116.87 146.39 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.773 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.96 167.75 18.72 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.773 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 118.65 5.7 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.357 3.372 . . . . 0.0 109.576 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -129.71 9.93 5.51 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.965 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 1.045 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.2 p -85.66 106.44 16.94 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.431 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 102.25 14.52 28.1 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.964 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -106.04 136.07 46.38 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.969 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -92.31 176.63 6.41 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.64 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 11.0 t70 -44.79 153.12 0.19 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.82 -23.34 34.68 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.681 HG21 HD12 ' A' ' 13' ' ' LEU . 10.4 m -72.58 142.97 48.42 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.6 p -118.9 121.04 65.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.814 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -100.59 154.31 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.2 151.0 26.51 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.757 HG23 ' CG2' ' A' ' 7' ' ' VAL . 0.9 OUTLIER -141.95 109.19 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.46 115.43 22.21 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.025 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -86.62 146.36 20.7 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.839 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.2 112.12 6.86 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.49 17.75 25.56 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.125 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.48 167.61 12.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.786 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 18.2 mt-30 -52.22 121.21 6.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.515 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.23 130.69 40.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.35 7.12 86.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.483 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.95 139.12 31.78 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.522 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.42 152.55 23.95 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.69 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 33.5 m-85 -136.71 139.82 42.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.245 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.72 113.8 27.59 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.258 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -102.68 149.66 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.835 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.4 172.32 43.99 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.847 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 36.8 tt0 -113.5 110.91 21.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.7 m -108.94 147.12 32.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.864 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -125.95 131.58 52.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.61 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.25 120.52 12.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.919 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.973 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.7 m -100.35 -43.23 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.508 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -136.85 166.1 24.41 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.951 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.679 HG23 ' O ' ' A' ' 42' ' ' THR . 15.3 t -51.14 111.74 0.61 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.12 8.52 65.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.0 t -122.09 109.41 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.457 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.89 141.17 52.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.956 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.432 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -100.28 155.13 17.95 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.9 m -111.04 149.61 30.5 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.697 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -117.1 115.66 38.22 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HA ' ' HB2' ' A' ' 52' ' ' PHE . 83.2 Cg_endo -72.37 1.02 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.345 . . . . 0.0 109.629 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -81.28 -14.25 57.6 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CG ' HG23 ' A' ' 68' ' ' THR . 95.1 m-20 -132.86 29.58 4.11 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.405 ' HB2' ' HA ' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -84.53 109.77 18.18 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.5 t -105.7 174.1 6.03 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -146.35 149.78 34.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.412 HG22 ' N ' ' A' ' 56' ' ' THR . 6.1 p -166.22 155.51 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.1 m -126.05 133.02 51.84 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.17 138.73 47.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.7 p30 -77.44 -174.06 3.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -17.39 58.58 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -85.16 5.66 29.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.937 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 59.12 32.37 71.2 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.6 t -130.44 137.09 49.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.52 167.49 17.03 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 53.1 p -150.83 128.04 11.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.728 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.52 172.91 13.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.853 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.728 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -126.09 122.78 36.75 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.896 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -100.43 143.45 30.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.926 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.626 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -100.45 143.99 29.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 t -103.35 129.33 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.64 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -119.42 143.91 47.22 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.02 -32.05 68.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 33.2 t -158.09 158.96 35.71 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.847 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -177.0 163.93 2.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.26 120.93 13.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.432 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.11 93.2 0.96 Allowed Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 1.006 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 100.07 10.48 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.1 tp -54.5 137.47 42.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.816 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 3.0 m-85 -46.6 -40.77 13.49 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.564 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 7.7 t0 -56.89 -17.39 9.31 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.56 27.94 9.39 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.33 139.87 45.08 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -78.25 92.5 4.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.973 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 13.6 t90 -62.49 -57.92 9.48 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.07 166.06 13.41 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.95 128.83 38.83 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.864 HG11 ' HB3' ' A' ' 38' ' ' ALA . 13.7 p -113.15 147.51 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -99.3 95.19 6.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.74 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -54.88 -20.71 9.39 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.9 p -91.24 1.78 56.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 m -108.71 -27.01 10.04 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.4 176.64 8.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.439 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -89.59 126.72 35.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.24 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -104.98 172.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.953 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.68 147.81 22.1 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.896 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 29.6 t -104.86 163.49 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.258 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.55 167.98 37.72 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.164 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -133.02 138.75 46.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.245 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 22.8 m -121.73 145.55 47.91 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -103.19 -158.56 0.67 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -70.55 -47.75 58.83 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.95 -24.39 66.06 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.2 53.62 1.85 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.786 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.04 165.26 23.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.516 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.01 171.46 42.96 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.481 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 166.2 30.46 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.344 3.363 . . . . 0.0 109.604 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.48 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 11.2 pt-20 -37.87 120.24 0.82 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.83 158.78 0.01 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.899 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.6 t -115.03 103.56 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.08 124.03 30.67 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.24 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.6 pt -134.49 -174.87 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 1.045 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -170.83 175.94 4.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.2 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.8 m-85 -124.46 115.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.431 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 36.1 m-80 . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.593 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.586 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.37 -174.46 1.43 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.29 3.327 . . . . 0.0 109.642 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.29 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 5.8 t -100.94 115.24 29.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.916 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -129.73 165.18 22.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.429 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.3 p -125.99 122.2 35.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.856 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -118.7 145.78 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.762 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -70.29 163.03 65.88 Favored Pre-proline 0 N--CA 1.448 -0.538 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.681 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.42 119.27 6.03 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.284 3.323 . . . . 0.0 109.595 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.682 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 2.2 t -126.95 14.03 7.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.813 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.0 p -88.95 105.83 18.02 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.088 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.17 21.59 13.22 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.088 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.87 139.51 44.87 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -85.96 169.2 13.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -44.42 152.29 0.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.53 -22.54 40.38 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 HD12 ' A' ' 13' ' ' LEU . 35.9 m -64.17 140.63 58.89 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.82 110.95 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.762 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER -93.29 118.61 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.856 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.6 146.38 36.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -135.19 110.5 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.676 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.56 115.01 22.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.916 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.21 143.35 20.25 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.232 ' O ' HG22 ' A' ' 4' ' ' THR . . . -136.8 110.38 8.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.9 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.18 24.15 9.9 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.586 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.6 -175.04 4.8 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.995 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.523 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 25.3 mt-30 -74.2 124.5 26.49 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.505 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.48 128.01 34.28 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.65 87.02 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.713 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.84 134.3 40.33 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.48 152.15 23.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.952 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 66.6 m-85 -137.05 156.15 48.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.037 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -114.62 115.26 26.87 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.942 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.087 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 1.4 t -98.77 143.11 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.775 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.7 163.58 37.3 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.922 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -106.38 115.55 30.4 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 93.9 m -107.45 168.23 9.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.91 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -153.71 126.7 8.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.604 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.39 122.82 18.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.619 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 11.6 m -103.92 -43.44 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.654 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -142.48 171.94 13.37 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.1 m -56.75 112.55 1.33 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 5.11 56.59 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.776 HG12 ' CD1' ' A' ' 83' ' ' TRP . 24.0 t -118.63 107.05 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.877 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.2 pp -117.08 162.85 17.15 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.529 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -125.26 146.12 49.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 51.1 m -115.53 152.36 33.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.7 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -112.64 107.15 55.17 Favored Pre-proline 0 N--CA 1.449 -0.5 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -72.46 -0.31 8.57 Favored 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.317 3.345 . . . . 0.0 109.554 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.646 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.65 -12.04 40.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 69.8 m-20 -131.82 24.88 4.67 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.664 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -95.51 117.86 31.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.9 t -110.77 -171.76 1.9 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.78 156.45 43.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 p -166.4 152.79 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 54.6 m -126.19 132.06 51.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.47 150.8 48.41 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.4 p30 -90.93 -169.11 2.25 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.25 -27.84 68.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -76.27 -10.57 59.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.58 9.33 86.97 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -100.64 137.61 38.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.11 161.67 21.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.88 130.38 13.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.718 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.23 173.26 15.31 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.718 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -121.36 133.35 55.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.903 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.932 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -117.59 119.4 34.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -78.72 141.08 38.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.948 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.671 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -113.78 130.24 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.986 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.667 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -114.78 154.75 27.99 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -76.25 -22.1 55.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 87.7 p -161.42 151.84 17.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.922 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -176.98 160.4 1.8 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.49 113.11 2.49 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.529 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -74.63 95.97 0.91 Allowed Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.693 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 99.9 10.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.937 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -53.56 144.51 17.18 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.846 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.61 -43.93 26.2 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.937 ' OD2' HD21 ' A' ' 77' ' ' LEU . 12.0 m-20 -58.08 -16.5 13.25 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.45 27.51 13.05 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.808 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -105.18 125.99 51.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.523 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -64.53 91.69 0.08 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.619 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 87.2 t90 -62.02 -39.29 91.76 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 132.15 174.73 13.72 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.16 105.05 1.29 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.149 HG22 ' CG1' ' A' ' 40' ' ' VAL . 42.8 t -80.73 146.42 7.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -105.08 92.96 4.44 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.055 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -53.49 -21.26 5.96 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.2 p -89.18 3.14 52.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -112.92 -27.64 8.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.84 174.63 10.4 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.534 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -91.4 127.66 36.92 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.4 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 33.2 m -105.41 167.23 9.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.075 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -155.29 140.58 17.63 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.932 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -92.7 164.93 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.087 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.46 160.93 27.24 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.03 127.09 42.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.037 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 26.4 m -106.44 151.02 25.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.41 -161.45 0.75 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.998 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.86 -48.65 65.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.23 -24.17 65.8 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.12 53.82 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 172.17 13.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.952 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.02 178.45 45.0 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.494 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.39 164.06 36.75 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.265 3.31 . . . . 0.0 109.577 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.593 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 13.2 pt-20 -38.12 124.05 1.16 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.434 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.29 152.6 0.01 OUTLIER Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.029 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.8 t -111.8 103.26 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.33 130.59 35.6 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.4 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.0 pt -143.84 177.31 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.813 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -173.49 176.31 2.83 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.055 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 1.7 m-85 -128.09 120.0 26.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.699 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 27.5 m-80 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.374 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.458 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.456 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.44 -177.53 2.8 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.296 3.33 . . . . 0.0 109.595 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.189 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.17 109.06 21.88 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.883 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 139.66 53.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.65 117.75 34.87 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.852 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -113.17 155.27 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.955 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.83 176.65 1.22 Allowed Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.111 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.1 Cg_endo -72.39 117.71 5.26 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.305 3.337 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.663 ' HB2' HG23 ' A' ' 110' ' ' ILE . 24.0 p -113.29 43.56 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 60.7 p -123.58 106.79 10.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.75 28.39 14.24 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.111 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.08 133.5 45.51 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 m -104.61 165.0 11.35 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.689 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -44.75 139.13 3.11 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.28 -22.33 34.96 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 27.8 m -76.07 141.89 41.9 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 67' ' ' LEU . 10.4 p -113.28 128.86 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 8' ' ' THR . 2.7 t -96.23 164.36 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.852 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.21 144.85 41.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.662 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -139.58 113.21 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.883 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.46 114.62 19.06 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.81 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -88.74 140.96 16.22 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.189 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.31 116.76 10.73 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.18 19.35 21.55 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.81 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -88.35 173.76 8.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.495 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 27.0 mt-30 -64.35 120.74 12.78 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.13 136.95 56.67 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.09 8.19 61.14 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.722 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -86.1 146.58 26.55 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.892 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.97 138.22 33.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.045 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 32.7 m-85 -131.32 146.75 52.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.254 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -117.12 116.49 27.4 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.376 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.45 153.67 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.001 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.72 163.66 30.8 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.946 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 21.0 tt0 -103.1 120.33 40.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.1 m -108.25 164.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.74 -0.466 . . . . 0.0 109.74 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -152.0 131.08 12.65 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.496 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -66.29 128.75 37.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.923 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.53 ' CB ' ' NE1' ' A' ' 83' ' ' TRP . 3.3 m -117.07 -38.1 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.255 ' OD1' ' HH2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -146.68 178.78 8.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 42' ' ' THR . 4.7 t -64.48 110.95 2.47 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 8.3 63.51 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.981 HG11 ' CE3' ' A' ' 83' ' ' TRP . 84.9 t -111.7 104.88 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.638 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.0 OUTLIER -104.33 154.81 19.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.934 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.595 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.16 129.01 44.56 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.836 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.72 157.43 18.12 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.753 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.1 t30 -115.67 114.56 42.13 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -72.46 -1.26 9.96 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.318 3.345 . . . . 0.0 109.611 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -91.19 -11.39 38.46 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 68' ' ' THR . 21.0 p30 -133.84 25.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.642 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -97.84 116.17 29.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 t -103.53 178.57 4.52 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.2 p -146.38 153.11 40.12 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.547 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.91 157.37 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 60.3 m -125.32 127.48 46.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.415 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -59.55 124.72 20.97 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.3 p30 -69.95 -170.3 0.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -23.73 66.46 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.25 2.12 29.33 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.807 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 65.54 32.45 83.35 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 32.7 t -127.65 145.03 51.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -143.85 124.66 14.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -108.72 133.68 52.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.412 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -148.94 155.65 41.15 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.412 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -111.24 120.43 42.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.615 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.79 159.36 15.85 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.803 -0.444 . . . . 0.0 109.803 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.614 HG23 ' HB2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -124.91 133.05 53.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.26 130.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.713 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -110.78 168.37 9.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 29.7 ptt180 -96.53 -8.34 32.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.8 t -176.54 146.15 0.59 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.946 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.3 p90 -176.77 166.72 2.58 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -62.13 127.29 30.68 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.595 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.15 93.41 1.7 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.836 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.58 100.59 11.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.942 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -57.19 130.67 47.18 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.655 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m-85 -47.67 -35.76 10.05 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.569 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.81 -16.88 12.88 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.55 27.5 9.08 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.942 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.26 150.18 36.6 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.45 97.19 10.93 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.53 ' NE1' ' CB ' ' A' ' 40' ' ' VAL . 15.2 t-105 -66.64 -56.88 8.63 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.5 168.25 13.41 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.45 142.88 31.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.832 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -127.13 154.64 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.981 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.418 ' N ' ' CG2' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -113.81 100.97 8.85 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.573 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.9 OUTLIER -53.78 -26.33 23.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -83.71 0.69 46.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 m -117.74 -27.85 6.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.23 175.64 7.28 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.95 123.04 40.56 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.195 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.9 m -104.47 152.62 22.12 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.988 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -143.77 143.39 31.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.615 HG13 ' CD1' ' A' ' 67' ' ' LEU . 3.4 t -101.95 151.57 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.372 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.72 171.57 43.78 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.376 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -128.27 146.05 50.87 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.254 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 5.9 m -123.18 153.25 40.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.892 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.59 -163.98 0.89 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.29 -49.28 78.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.37 -25.76 62.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 97.75 46.52 2.27 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.453 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -119.27 166.82 12.52 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.045 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.84 -176.53 41.5 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.456 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.47 162.45 41.41 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.306 3.337 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.374 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.85 127.45 1.58 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -43.75 144.54 1.72 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.986 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -120.87 110.94 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.85 142.84 27.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.195 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.9 OUTLIER -108.13 168.59 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.73 120.44 7.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 39.5 m-85 -97.99 121.89 40.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.948 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.061 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.484 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.1 Cg_endo -72.42 -177.53 2.79 Favored 'Trans proline' 0 N--CA 1.448 -1.205 0 C-N-CA 124.328 3.352 . . . . 0.0 109.537 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.834 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -97.47 109.83 22.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.792 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.8 133.59 50.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.561 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.35 114.64 26.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.681 HG11 ' CG2' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.3 155.87 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.993 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.925 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.79 174.61 2.15 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.073 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.7 Cg_endo -72.43 118.12 5.45 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.346 3.364 . . . . 0.0 109.538 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.9 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -117.05 46.79 1.6 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.631 ' HA ' ' O ' ' A' ' 111' ' ' SER . 96.6 p -124.85 105.33 9.17 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.866 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.944 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.5 15.48 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.073 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.06 133.43 41.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.996 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.6 p -99.83 163.26 12.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.506 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.01 140.96 4.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.24 36.43 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 27.9 m -71.38 150.22 45.24 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 18' ' ' VAL . 9.9 p -121.13 118.29 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.754 HG22 ' O ' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -86.8 169.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.997 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.74 153.05 37.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -146.58 113.17 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.792 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.05 115.9 22.62 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.837 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.99 143.89 21.57 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.719 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.08 112.98 6.38 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.87 19.09 23.09 Favored Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.028 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.81 -176.55 4.72 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.938 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.455 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 22.7 mt-30 -70.91 124.83 25.26 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.69 127.59 33.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.32 7.26 88.71 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -88.65 143.67 26.78 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.862 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -91.3 141.93 28.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.98 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 33.5 m-85 -131.53 146.22 52.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.257 ' CB ' ' H ' ' A' ' 98' ' ' SER . 13.8 m-20 -111.97 113.13 25.25 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.379 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -95.8 144.36 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.925 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.17 163.77 36.1 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.981 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 19.3 tt0 -107.41 108.04 19.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -107.83 142.19 38.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.859 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.48 139.18 54.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.558 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.11 124.86 22.73 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.337 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -105.26 -49.67 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.598 ' N ' HG12 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -135.64 167.67 20.68 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -50.28 112.45 0.68 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.0 63.01 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.474 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 93.5 t -122.22 116.46 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.536 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -125.97 135.47 51.88 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.407 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -90.14 159.39 16.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 28.8 m -116.12 151.92 34.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.778 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.5 t30 -112.03 106.12 56.32 Favored Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.3 Cg_endo -72.44 -1.12 9.75 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 124.3 3.333 . . . . 0.0 109.599 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.41 -10.43 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 79.3 m-20 -135.61 27.04 3.38 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.665 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.51 121.22 38.1 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.8 t -115.4 -173.37 2.32 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.3 p -145.95 156.99 43.88 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.861 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 6.2 p -167.19 157.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.6 m -128.61 136.59 50.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.24 130.63 38.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p30 -72.13 -177.84 2.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.31 -16.22 43.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -86.12 7.56 24.35 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.028 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.01 32.64 62.84 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.1 t -131.89 135.38 46.61 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.91 166.64 16.53 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.7 m -151.15 128.0 10.97 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -155.46 169.85 23.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.89 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -118.69 133.28 55.97 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.203 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -115.69 118.99 34.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.936 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.632 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -77.64 137.04 38.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.973 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.731 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.09 125.85 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.42 ' N ' ' HD3' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -109.76 168.48 9.38 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.98 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.506 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -97.04 -15.73 20.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.993 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 47.8 t -167.37 146.45 5.04 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.981 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.7 p90 -176.92 151.8 0.88 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.7 OUTLIER -53.12 116.43 2.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.921 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.407 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.08 102.99 1.74 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.982 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -84.01 100.6 11.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.9 tp -54.24 132.89 44.41 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.987 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.966 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.5 m-85 -46.94 -37.16 8.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.581 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -57.51 -16.93 11.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.8 27.63 9.46 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.29 151.3 34.81 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.506 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.7 ptp180 -85.9 98.5 10.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.337 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -64.52 -58.03 7.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.883 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 174.42 23.29 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.13 110.73 1.94 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.859 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -85.93 154.39 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 11.4 m-20 -122.02 95.14 4.54 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.73 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 35.9 m -53.61 -26.69 22.98 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -80.0 -1.51 40.01 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -114.65 -27.67 7.4 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.53 -173.94 3.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.883 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.55 125.48 48.21 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.854 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 93.1 m -104.2 152.66 21.9 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.028 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -143.94 150.52 38.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.944 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.203 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 2.4 t -112.41 160.29 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.379 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.28 169.96 42.36 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.315 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.88 128.03 44.44 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.257 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 56.8 m -107.23 151.22 25.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.862 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.29 -163.24 0.84 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.985 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.426 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -64.97 -48.85 72.55 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.22 -24.12 63.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.88 53.37 1.79 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.511 ' OD1' ' HE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -130.49 172.62 11.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.98 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -177.85 -179.16 47.85 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.4 157.99 52.2 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.324 3.349 . . . . 0.0 109.573 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.095 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.8 pt-20 -36.02 123.13 0.72 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.72 149.86 0.03 OUTLIER Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.977 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.1 t -117.6 104.97 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.73 135.42 33.76 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.028 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.2 mt -111.79 167.12 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.631 ' O ' ' HA ' ' A' ' 11' ' ' SER . 4.7 t -153.11 128.48 9.89 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.73 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 26.6 m-85 -102.02 125.4 48.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.509 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 m-80 . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.307 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.48 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.38 -177.79 2.93 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.328 3.352 . . . . 0.0 109.592 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.223 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.83 111.93 24.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.12 160.58 30.75 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -120.37 113.46 20.39 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 21' ' ' VAL . 0.5 OUTLIER -105.16 148.27 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.98 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.97 177.81 0.93 Allowed Pre-proline 0 N--CA 1.448 -0.533 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.959 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.114 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.4 115.99 4.54 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.342 3.361 . . . . 0.0 109.61 179.888 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.658 ' CB ' HG23 ' A' ' 110' ' ' ILE . 27.9 p -113.4 40.9 2.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.501 ' HA ' ' O ' ' A' ' 111' ' ' SER . 30.9 p -120.31 106.22 11.67 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.024 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.29 30.4 10.95 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.114 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.33 132.21 47.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -104.69 169.54 8.4 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.926 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -48.54 140.06 8.52 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.01 -22.54 36.5 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 46.2 m -75.14 147.04 40.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.5 p -120.62 124.96 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.13 HG22 ' O ' ' A' ' 67' ' ' LEU . 2.6 m -90.68 168.06 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.754 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -117.32 152.48 34.82 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.966 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.1 114.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.989 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.77 114.59 18.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.91 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.86 148.5 24.7 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.223 ' O ' HG22 ' A' ' 4' ' ' THR . . . -145.6 112.64 6.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.51 14.74 31.64 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.968 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.94 169.01 11.58 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.934 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 28.1 mt-30 -50.39 120.09 4.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.599 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.71 131.63 41.82 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.32 8.28 83.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.49 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.82 139.94 30.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.977 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.907 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.22 151.73 25.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.769 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.0 m-85 -137.47 144.61 42.36 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.333 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.0 m-20 -106.0 115.22 29.86 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.465 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.16 143.16 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.955 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.86 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.94 172.5 43.28 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.909 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.8 tt0 -116.61 117.41 29.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 94.1 m -109.44 167.84 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.151 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.6 126.11 9.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.595 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -66.35 124.97 24.17 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.669 HG21 ' CD1' ' A' ' 83' ' ' TRP . 12.2 m -105.12 -44.05 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.537 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -143.3 163.56 32.64 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 42' ' ' THR . 2.9 t -51.91 113.48 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.21 8.35 69.81 Favored Glycine 0 C--N 1.336 0.553 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.629 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 17.0 t -126.27 106.11 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.917 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -116.17 162.91 16.75 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.564 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.37 138.66 53.58 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.8 m -109.33 150.28 28.24 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.638 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 24.5 t30 -108.77 109.06 61.2 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.39 -0.13 8.26 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.296 3.33 . . . . 0.0 109.563 179.899 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.09 -13.44 41.39 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.474 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.4 p30 -127.73 27.06 5.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.6 105.19 14.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.9 t -100.94 173.21 6.59 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.58 153.03 40.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.27 156.44 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.428 ' N ' HG22 ' A' ' 55' ' ' VAL . 58.2 m -126.6 138.35 53.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.99 149.02 37.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.0 p30 -85.37 -173.47 4.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.64 -22.86 66.75 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -77.53 -7.69 56.67 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.968 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.79 31.86 59.81 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.8 p -127.36 139.0 53.15 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.04 166.0 17.77 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 14.8 p -150.48 127.8 11.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.436 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -162.97 156.93 20.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.861 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.436 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -109.35 134.74 51.45 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.943 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.53 119.21 37.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.667 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -74.87 128.33 35.32 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.885 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -102.91 128.14 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.998 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.721 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.57 149.94 35.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 ppt_? -78.33 -16.55 57.6 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.55 ' HB3' ' OD1' ' A' ' 87' ' ' ASP . 7.9 p -161.71 148.66 14.27 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.909 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.8 p90 -178.09 148.73 0.52 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.11 115.04 1.67 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.564 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.34 94.99 0.94 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.896 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.54 10.57 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.7 tp -54.22 139.29 36.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.51 -41.58 21.26 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.561 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 2.0 t70 -56.33 -17.0 6.45 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.76 27.93 9.96 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.1 m -110.1 141.61 42.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.7 94.2 5.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.669 ' CD1' HG21 ' A' ' 40' ' ' VAL . 7.6 t-105 -62.43 -57.11 12.44 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 168.82 17.39 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.63 108.59 0.75 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.151 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -79.07 153.96 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.55 ' OD1' ' HB3' ' A' ' 72' ' ' SER . 14.8 m-20 -129.97 97.4 4.46 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.541 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 96.6 m -53.0 -28.04 22.04 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 50.5 p -78.12 -0.53 28.54 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -118.88 -28.04 5.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.68 -173.18 3.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.42 125.28 49.09 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.898 ' O ' HG13 ' A' ' 110' ' ' ILE . 56.6 m -103.93 159.81 15.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -155.36 144.79 21.1 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -109.9 157.83 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.298 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.51 168.56 40.24 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.465 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.47 139.73 53.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.333 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 85.8 p -122.57 149.03 44.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.907 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -107.6 -161.6 0.79 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -68.56 -47.98 65.43 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.72 -23.71 66.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.68 52.42 2.13 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.934 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.67 165.79 21.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.95 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.07 177.59 44.7 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.48 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 161.15 45.13 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.372 3.381 . . . . 0.0 109.568 179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.307 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 4.6 pt-20 -36.63 128.92 0.81 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -46.98 150.38 2.08 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.866 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.4 t -126.03 115.05 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.538 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.15 143.91 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.06 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.1 mt -109.18 168.51 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.3 t -155.0 121.23 5.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.707 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 10.7 m-85 -94.8 129.76 41.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.972 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.647 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.512 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.482 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.37 -174.7 1.5 Allowed 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.291 3.327 . . . . 0.0 109.595 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.752 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.15 108.55 21.27 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.952 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.2 144.65 49.81 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.524 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -105.81 112.7 25.87 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.999 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.85 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.31 152.84 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.982 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.905 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.34 175.02 2.04 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.92 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.145 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.3 Cg_endo -72.39 118.01 5.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.298 3.332 . . . . 0.0 109.562 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.969 ' HB2' HG23 ' A' ' 110' ' ' ILE . 81.1 p -111.49 46.26 1.13 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.66 ' HA ' ' O ' ' A' ' 111' ' ' SER . 4.3 m -127.98 105.05 8.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.874 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.014 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.39 28.31 11.76 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.145 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -100.37 132.1 45.93 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -106.79 170.81 7.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -46.4 142.45 3.02 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.75 -23.41 33.96 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 52.0 m -77.86 151.8 33.7 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.546 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.6 p -128.26 116.26 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 67' ' ' LEU . 3.1 p -78.7 152.14 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.85 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.03 143.48 36.68 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.997 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.529 ' CG1' HG21 ' A' ' 108' ' ' VAL . 0.1 OUTLIER -140.76 106.99 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.966 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.7 117.12 28.93 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.672 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.79 139.77 20.32 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.43 108.33 7.12 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.927 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.45 25.95 8.45 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.237 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.7 -171.9 3.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 19.5 mt-30 -82.54 124.91 30.55 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.38 139.7 49.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.92 8.29 68.34 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.703 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.62 146.22 23.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.987 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.92 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.54 149.05 23.15 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.207 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 56.4 m-85 -136.95 145.06 43.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.867 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.145 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -110.54 113.76 26.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.995 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.301 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.07 140.07 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.956 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -162.37 164.44 35.58 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.549 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 29.5 tt0 -114.58 108.16 16.46 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.792 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.0 OUTLIER -110.83 146.32 36.65 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.987 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.754 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -122.81 138.28 54.69 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.605 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.52 123.2 19.04 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.959 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.741 HG21 ' CD1' ' A' ' 83' ' ' TRP . 0.0 OUTLIER -103.05 -44.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.395 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 1.1 m-20 -133.44 -179.28 5.42 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 m -69.03 111.12 4.82 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.66 85.97 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.035 HG21 ' HE1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -130.78 125.52 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.954 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.2 pt? -134.09 141.48 47.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.07 147.22 24.25 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.823 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 35.9 m -107.11 150.3 26.71 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.652 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.3 t30 -111.46 109.02 56.36 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -72.45 -0.65 9.06 Favored 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.315 3.343 . . . . 0.0 109.608 179.909 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.75 -11.87 43.79 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.576 ' CB ' HG23 ' A' ' 68' ' ' THR . 56.1 m-20 -132.71 28.64 4.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.666 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.92 119.3 38.01 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.994 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 t -113.4 -179.17 3.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.96 158.13 43.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' N ' ' A' ' 56' ' ' THR . 3.4 p -166.45 161.91 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.528 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.8 m -127.98 126.21 40.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.31 146.32 40.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.927 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 47.3 p30 -87.43 -173.44 4.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.52 -25.43 67.28 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -82.21 4.37 23.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 66.3 6.12 31.84 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.5 t -96.9 134.25 40.48 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.0 164.96 15.94 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -148.48 127.9 13.1 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.688 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -160.02 155.27 25.07 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.88 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.401 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.56 125.4 52.93 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.938 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.095 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -105.35 123.33 47.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.975 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.585 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -78.06 136.08 37.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.939 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.434 ' O ' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -112.6 124.99 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.979 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.542 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.97 173.46 6.32 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 27.5 ptt180 -99.41 -9.67 23.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 97.2 p -168.05 145.69 4.29 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.698 ' O ' HG12 ' A' ' 86' ' ' VAL . 1.9 p90 -176.6 156.16 1.44 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -55.46 114.5 1.86 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 100.68 1.8 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.889 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -84.68 101.5 12.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -53.64 136.07 39.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.667 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.59 -39.95 12.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.702 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -56.31 -17.67 8.42 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.913 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.13 27.7 9.18 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.7 m -111.77 142.42 44.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -79.93 94.33 5.85 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.395 ' CZ2' ' OD2' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.51 -58.34 7.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.886 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 173.14 20.41 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 104.38 0.52 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 38' ' ' ALA . 9.9 p -79.44 150.92 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -107.21 98.09 7.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -53.24 -23.84 9.77 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.2 p -85.44 1.41 48.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -112.7 -26.93 8.37 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.03 179.69 6.1 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.0 128.44 41.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.885 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 36.7 m -104.41 153.29 21.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.081 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -147.25 147.05 30.03 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.981 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.095 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.9 t -110.92 160.04 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.27 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.24 166.37 37.39 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.301 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.01 123.82 35.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.978 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.145 ' N ' ' H ' ' A' ' 33' ' ' ASP . 14.2 m -107.65 144.18 35.08 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.92 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.6 OUTLIER -102.56 -160.75 0.8 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.979 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.63 -47.78 65.76 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.98 -24.42 66.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.72 53.78 1.76 Allowed Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.555 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.57 169.81 16.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.989 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.207 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.41 179.16 45.92 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.482 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.32 164.19 36.37 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.318 3.345 . . . . 0.0 109.601 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.647 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.61 126.92 1.14 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.976 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -42.93 154.69 0.17 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.89 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.9 t -120.84 103.79 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.64 126.54 35.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.081 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.6 mt -103.24 159.07 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.735 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -146.95 123.22 10.91 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.522 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 39.7 m-85 -95.36 125.57 40.07 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.98 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.26 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.647 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.3 Cg_endo -72.34 -178.13 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.288 3.325 . . . . 0.0 109.6 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.905 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.97 108.95 21.76 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 1.278 ' N ' ' OE2' ' A' ' 106' ' ' GLU . . . -124.29 146.78 48.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.587 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.85 114.62 28.89 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.98 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.786 HG13 ' O ' ' A' ' 20' ' ' LYS . 41.4 t -109.82 147.74 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.946 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.43 176.01 1.38 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.913 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.061 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.39 117.36 5.1 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.323 3.349 . . . . 0.0 109.615 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.917 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 14.5 p -113.38 48.52 1.04 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.981 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 111' ' ' SER . 5.9 m -128.99 105.83 8.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.872 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.49 28.04 12.12 Favored Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.069 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -105.01 129.25 53.5 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -104.45 170.39 7.92 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.564 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 7.4 p-10 -44.59 141.29 2.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.65 -22.87 32.84 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -79.39 149.6 31.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.538 HG13 ' O ' ' A' ' 18' ' ' VAL . 13.8 p -122.34 121.72 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.063 HG23 HG12 ' A' ' 69' ' ' VAL . 12.2 t -85.44 153.15 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.786 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.89 143.2 34.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.952 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.657 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -140.58 111.5 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.703 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.2 117.71 25.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.008 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.59 145.5 22.89 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.793 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -144.36 113.38 6.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 95.63 17.97 34.24 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.008 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.87 170.78 9.8 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.772 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.6 mt-30 -51.78 119.58 4.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.519 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.33 130.28 39.83 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.64 7.34 87.23 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.482 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.83 137.27 34.13 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.703 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -81.47 152.41 27.36 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.741 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 36.8 m-85 -138.08 141.08 40.27 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.913 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.18 ' CB ' ' H ' ' A' ' 98' ' ' SER . 7.8 m-20 -106.01 113.45 26.99 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.268 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.0 147.46 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.919 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.1 168.16 41.1 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.742 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 22.7 tt0 -112.13 113.2 25.33 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 25.9 m -114.2 141.99 46.82 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.706 ' O ' HD12 ' A' ' 45' ' ' LEU . . . -121.96 129.08 52.21 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.56 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.19 128.58 36.43 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.906 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.286 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.7 m -109.78 -43.91 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.664 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -141.08 160.12 40.76 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.5 m -55.55 113.49 1.46 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.94 8.06 87.98 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.149 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.8 t -130.34 108.99 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.973 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.822 HD11 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -118.22 144.23 45.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.366 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -105.64 143.63 33.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 15.5 m -110.24 152.71 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.685 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 42.6 t30 -111.86 108.02 55.94 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.73 9.12 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.355 3.37 . . . . 0.0 109.573 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.448 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -92.48 -11.23 35.2 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.852 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -129.82 19.62 5.56 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.77 107.76 16.39 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.0 t -101.46 173.36 6.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.9 p -146.06 149.39 33.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.89 159.72 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 55' ' ' VAL . 63.6 m -127.74 136.68 51.86 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.38 142.44 46.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 40.6 p30 -80.86 -172.45 3.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -22.02 66.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -80.87 4.05 20.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 60.44 31.29 73.83 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 t -128.13 133.76 49.02 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.68 164.65 18.68 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.27 129.96 17.05 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -156.57 164.61 37.99 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.861 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -125.25 118.23 25.56 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.973 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.552 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.68 156.2 16.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.501 ' N ' HD23 ' A' ' 67' ' ' LEU . 0.3 OUTLIER -112.36 132.73 54.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 1.063 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.34 128.06 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.99 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.7 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.07 164.04 13.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.999 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 ptt180 -91.88 -9.47 43.13 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 12.8 t -174.8 144.37 0.81 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.902 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.742 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 13.3 p90 -175.83 157.63 1.99 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 117.06 3.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.366 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.32 100.56 1.92 Allowed Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.985 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.26 100.28 10.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.7 tp -54.42 136.7 43.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.859 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.1 m-85 -46.25 -39.93 10.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.568 ' HB2' HD21 ' A' ' 77' ' ' LEU . 7.6 t0 -56.84 -17.36 9.07 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.38 28.2 9.3 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.31 140.08 47.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.6 ptt-85 -79.72 94.53 5.76 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.286 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.25 -55.78 24.99 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.59 172.86 19.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.35 107.09 1.01 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -83.7 152.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.962 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -109.5 99.6 8.79 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.58 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.2 m -53.27 -25.06 13.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 30.4 p -84.04 1.25 44.79 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -118.32 -27.98 5.88 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.911 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.55 177.4 6.24 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.07 125.3 41.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.262 ' O ' HG13 ' A' ' 110' ' ' ILE . 38.7 m -104.53 153.05 21.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.013 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.4 OUTLIER -151.17 146.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.929 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.552 HG13 ' CD1' ' A' ' 67' ' ' LEU . 21.5 t -105.84 153.48 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.943 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.232 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -170.2 165.97 39.22 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.268 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.32 131.76 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.18 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 7.6 t -112.29 150.91 30.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.703 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -112.6 -164.25 0.9 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.948 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.41 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.92 -48.51 68.44 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.8 -23.76 66.1 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.7 53.2 1.99 Allowed Glycine 0 C--N 1.336 0.55 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.772 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.94 171.89 13.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.977 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.741 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.27 176.43 46.64 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.647 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.1 Cg_endo -72.38 165.17 33.43 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.349 3.366 . . . . 0.0 109.622 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.278 ' OE2' ' N ' ' A' ' 5' ' ' ALA . 0.2 OUTLIER -38.08 136.51 0.6 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.988 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.98 149.0 6.06 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.918 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 11.9 t -123.84 105.93 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.485 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.57 147.96 23.0 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.262 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.09 159.76 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.714 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -142.28 111.98 6.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.953 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 66.2 m-85 -87.15 110.71 20.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.478 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.545 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.34 -178.29 3.22 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 124.357 3.371 . . . . 0.0 109.616 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.111 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -97.46 110.26 22.85 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.963 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.843 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.5 156.53 40.6 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -114.96 117.15 29.83 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.111 HG22 ' CG1' ' A' ' 21' ' ' VAL . 58.5 t -114.5 144.21 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.697 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.2 165.82 40.02 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.921 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.697 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.34 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 124.318 3.345 . . . . 0.0 109.617 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.77 ' OG ' HG11 ' A' ' 69' ' ' VAL . 47.7 t -127.84 17.57 6.79 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 1.025 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.1 p -92.2 111.78 23.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.067 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.43 25.6 27.79 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.067 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -108.52 139.48 43.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.989 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.6 m -67.47 144.69 55.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.476 ' HB3' ' H ' ' A' ' 71' ' ' ARG . 17.9 p-10 -48.1 147.49 2.14 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -18.97 45.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.6 m -60.99 130.53 46.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 18' ' ' VAL . 9.3 p -92.87 115.05 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.6 m -100.58 159.33 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.943 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.6 146.1 39.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.111 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -138.5 114.52 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.843 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.8 116.31 23.47 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.944 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.997 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.21 145.96 22.57 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.111 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -142.23 115.83 9.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.73 16.02 29.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.997 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -89.92 168.6 11.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.522 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.7 mt-30 -52.03 119.24 4.11 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.477 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.37 132.06 44.29 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.89 7.78 84.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.522 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -98.01 141.89 30.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.46 150.86 24.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.024 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 40.3 m-85 -138.29 141.73 39.82 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.17 ' OD2' ' HB2' ' A' ' 98' ' ' SER . 0.9 OUTLIER -105.85 115.54 30.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.567 HG22 ' CG ' ' A' ' 97' ' ' LEU . 1.8 t -96.64 136.46 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.874 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.66 153.51 24.53 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.856 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 17.2 tt0 -94.46 119.68 33.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.844 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.724 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.3 m -107.04 159.26 16.43 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.715 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -147.16 130.08 16.25 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.543 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -69.96 125.92 28.16 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.174 ' CG1' HG12 ' A' ' 86' ' ' VAL . 4.0 m -113.74 -39.56 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.61 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -146.65 -179.59 6.88 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.95 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.8 m -64.69 111.58 2.82 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.955 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.56 8.52 63.26 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.596 HG21 ' CH2' ' A' ' 83' ' ' TRP . 40.1 t -110.02 104.0 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.799 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 mt -106.86 155.94 19.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.526 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -134.27 126.7 30.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.144 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -107.84 158.83 16.99 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.561 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.5 t30 -118.83 113.96 35.78 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -72.43 -1.45 10.23 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.317 3.345 . . . . 0.0 109.577 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.561 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -11.48 40.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -131.63 26.58 4.71 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.667 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.34 122.07 41.97 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.983 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -104.65 -175.32 2.76 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.0 p -146.72 154.37 41.34 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.89 156.18 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.424 ' N ' HG22 ' A' ' 55' ' ' VAL . 41.7 m -125.97 121.68 33.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.76 150.18 20.45 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 p30 -97.02 -168.02 1.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.13 -25.37 68.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.983 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -83.37 3.75 30.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.894 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 62.25 31.23 78.4 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.3 t -126.22 142.85 51.36 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -133.98 159.81 39.61 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.21 124.96 22.42 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.782 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -144.62 178.43 7.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.866 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.782 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -129.46 122.32 29.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.949 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.018 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -108.09 149.19 28.79 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.925 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.832 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -111.37 143.0 42.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.77 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -109.55 125.93 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.967 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.809 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -115.08 153.08 31.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.986 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.476 ' H ' ' HB3' ' A' ' 15' ' ' ASP . 10.0 ttp180 -74.03 -37.79 64.22 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 t -151.06 153.25 34.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.856 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.4 p90 -177.09 159.44 1.65 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.931 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.98 114.43 1.59 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.526 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.71 93.77 0.57 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 1.144 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.34 99.94 10.34 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.904 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.4 tp -58.76 131.79 51.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.724 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 8.4 m-85 -47.06 -36.46 8.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.592 ' HB2' HD21 ' A' ' 77' ' ' LEU . 3.4 t0 -56.99 -17.51 10.08 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.15 27.29 8.87 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.904 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.0 143.05 45.37 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.77 94.71 9.83 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.61 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 34.8 t-105 -63.41 -58.46 6.99 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.893 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 171.11 18.48 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.6 109.0 0.71 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.174 HG12 ' CG1' ' A' ' 40' ' ' VAL . 18.1 m -89.93 150.83 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -108.88 89.14 2.9 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.11 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 2.0 m -52.92 -24.48 9.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -79.27 -1.75 38.06 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.18 -28.36 6.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -118.64 -165.63 1.14 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 124.62 40.9 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.273 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -104.27 152.36 22.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.044 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 0.7 OUTLIER -168.12 147.67 4.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.944 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.009 HG21 HD12 ' A' ' 67' ' ' LEU . 4.9 t -99.4 164.92 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.95 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -171.67 160.01 31.73 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.567 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -100.2 163.57 12.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.17 ' HB2' ' OD2' ' A' ' 33' ' ' ASP . 14.8 m -155.83 121.68 5.01 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.635 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 4.8 p-10 -113.88 -168.93 1.42 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -47.64 -26.76 1.61 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.7 -25.94 14.52 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.912 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 92.01 21.15 33.98 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 1.024 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.64 -149.42 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.493 ' O ' ' HD2' ' A' ' 3' ' ' PRO . . . 141.4 151.82 5.62 Favored Glycine 0 C--N 1.336 0.556 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.545 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.6 Cg_endo -72.37 161.69 43.63 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.302 3.335 . . . . 0.0 109.609 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.478 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.3 mt-10 -32.06 120.26 0.28 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -32.94 149.8 0.01 OUTLIER Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.044 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 2.6 t -108.26 103.33 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.52 126.72 31.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.273 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 7.0 pt -141.81 177.82 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 1.025 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -171.65 177.82 3.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.11 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -130.3 115.21 16.62 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.969 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.3 p30 . . . . . 0 N--CA 1.45 -0.469 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.908 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.139 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.625 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.5 Cg_endo -72.46 -178.59 3.44 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.301 3.334 . . . . 0.0 109.57 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.223 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.0 21.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.82 ' H ' ' CD ' ' A' ' 106' ' ' GLU . . . -122.53 151.05 41.75 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.952 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.648 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.7 p -116.49 116.27 27.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -106.82 148.92 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 1.031 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -65.69 179.39 0.45 Allowed Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.917 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.128 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.36 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.315 3.343 . . . . 0.0 109.648 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.543 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 3.8 p -112.42 35.87 3.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -119.8 106.75 12.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.836 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.026 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.58 30.89 8.66 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.128 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.42 131.52 47.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.97 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -99.75 163.84 12.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -46.95 140.07 5.08 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.35 -22.22 36.91 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 37.0 m -72.05 149.53 44.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.619 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.6 p -126.7 117.12 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.0 m -84.33 165.27 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.779 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.6 135.18 54.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 21' ' ' VAL . 9.8 p -124.3 120.46 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.648 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -126.29 117.5 23.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.864 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -93.49 140.14 14.92 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.724 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.5 116.38 10.92 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.99 20.53 18.26 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.023 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.52 -177.28 5.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.98 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 25.9 mt-30 -69.29 122.23 18.46 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.43 130.04 39.75 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.1 8.09 86.85 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.512 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.48 137.13 34.96 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.975 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 1.017 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.56 150.62 25.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.124 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.9 m-85 -136.81 146.84 46.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.891 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.174 ' H ' ' N ' ' A' ' 98' ' ' SER . 4.4 m-20 -111.96 113.85 26.41 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.478 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.98 143.23 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.88 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.33 165.34 38.73 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.782 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.28 113.07 25.29 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 62.6 m -111.13 145.76 38.03 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.538 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -123.23 128.29 49.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.75 120.63 13.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.951 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.497 HG11 ' CD1' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -99.35 -44.14 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.53 ' OD1' ' C ' ' A' ' 40' ' ' VAL . 0.2 OUTLIER -136.83 175.5 9.56 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.948 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.567 HG23 ' O ' ' A' ' 42' ' ' THR . 6.1 t -60.8 112.67 2.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.03 8.14 72.96 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.47 ' O ' HG23 ' A' ' 40' ' ' VAL . 3.2 t -124.17 110.89 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.531 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.01 138.69 53.75 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.971 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.373 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.09 156.04 17.12 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 37.1 m -117.12 150.63 38.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.693 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -114.11 107.11 52.39 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.31 -0.84 9.25 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.327 3.351 . . . . 0.0 109.627 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.639 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -12.11 41.38 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 68' ' ' THR . 92.9 m-20 -131.46 26.14 4.78 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.682 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -97.23 120.03 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 32.2 t -113.84 -177.38 3.12 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.0 p -147.08 156.61 43.14 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.474 HG22 ' HB1' ' A' ' 63' ' ' ALA . 5.9 p -166.94 157.59 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 48.3 m -125.35 134.08 52.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.838 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -72.57 140.73 48.26 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -83.82 -170.88 3.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.75 -26.14 68.55 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.2 -4.91 44.37 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.023 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.93 31.61 69.83 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.964 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.3 p -124.11 133.77 53.52 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.838 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -147.46 122.38 10.02 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -123.0 144.28 49.37 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.757 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -141.0 178.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.757 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -108.32 116.56 32.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.053 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -108.46 123.6 49.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.95 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.697 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -91.4 137.48 32.33 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -112.31 126.54 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.471 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -114.36 173.38 6.48 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.962 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 10.6 ptt85 -100.99 -7.97 22.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.548 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.4 p -169.73 147.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.782 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.6 p90 -177.65 160.58 1.58 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.13 115.58 2.52 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.373 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.32 94.03 1.24 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.741 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.2 m-85 -83.85 99.58 10.42 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.927 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -53.73 134.66 41.96 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.684 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.6 p90 -46.26 -38.84 9.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.556 ' CB ' HD21 ' A' ' 77' ' ' LEU . 4.4 t70 -56.77 -17.26 8.47 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.29 27.99 8.88 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.927 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.59 139.73 47.93 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -82.12 93.28 7.0 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.497 ' CD1' HG11 ' A' ' 40' ' ' VAL . 6.8 t-105 -63.38 -57.57 9.9 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.77 169.91 17.86 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -60.92 104.68 0.38 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 73' ' ' PHE . 6.2 p -81.61 149.27 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -105.93 98.33 8.03 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.517 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.6 m -51.76 -25.41 7.46 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 21.1 p -80.55 2.55 25.01 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.961 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 21.8 m -112.93 -27.2 8.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.59 -178.49 5.09 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.64 127.21 42.41 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.316 ' O ' HG13 ' A' ' 110' ' ' ILE . 82.4 m -103.17 153.0 20.79 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.086 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -147.34 146.18 29.59 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.053 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.3 t -100.6 163.15 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.331 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.13 158.61 24.36 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.478 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.66 127.56 37.22 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.996 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.174 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.0 m -117.03 158.27 24.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 1.017 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 1.0 OUTLIER -110.79 -157.36 0.61 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.986 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.91 -48.15 77.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.56 -25.93 61.54 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.78 47.3 2.31 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.62 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.34 154.7 29.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.124 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -165.09 171.98 40.61 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.625 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.36 171.88 16.09 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.294 3.329 . . . . 0.0 109.647 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.223 ' OE1' ' HA ' ' A' ' 4' ' ' THR . 6.5 pt-20 -36.49 153.44 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.72 153.97 52.96 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.991 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.959 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.5 t -128.07 109.92 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.992 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.716 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.7 151.33 19.72 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.923 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.316 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -120.63 164.87 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 t -154.82 120.39 5.09 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.512 ' HE2' HG23 ' A' ' 69' ' ' VAL . 46.4 m-85 -97.01 127.06 42.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.947 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.045 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.383 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.38 -174.19 1.35 Allowed 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.316 3.344 . . . . 0.0 109.545 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.795 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.5 m -93.95 108.51 20.31 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.761 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.65 143.59 51.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.733 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -98.29 111.98 24.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.036 HG21 ' CG2' ' A' ' 108' ' ' VAL . 24.2 t -109.51 143.98 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.934 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.0 175.19 1.86 Allowed Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.921 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.005 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.1 Cg_endo -72.33 118.41 5.59 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.34 3.36 . . . . 0.0 109.598 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.715 ' HB2' HG23 ' A' ' 110' ' ' ILE . 25.0 p -116.77 46.04 1.72 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.3 p -124.8 106.04 9.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.9 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.061 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.72 28.08 13.16 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.061 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -103.99 129.75 51.61 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.967 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -103.8 170.99 7.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.762 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -45.91 142.32 2.67 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.984 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.13 -22.97 34.88 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.479 HG21 ' HB3' ' A' ' 13' ' ' LEU . 29.5 m -77.36 148.2 35.7 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.5 p -124.19 123.08 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.569 ' HA ' HG21 ' A' ' 8' ' ' THR . 20.9 m -91.05 166.88 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.805 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.4 138.49 54.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.994 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.857 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -132.73 117.81 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.761 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.86 116.22 21.21 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.727 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.0 144.41 23.83 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.795 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.79 106.26 4.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.89 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.19 22.09 8.98 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.64 -165.0 1.22 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -80.43 124.19 28.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.499 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 129.74 38.64 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.57 7.94 85.79 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.509 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.74 143.89 25.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.876 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -91.44 150.11 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.0 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.5 m-85 -138.29 146.41 42.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.221 ' CA ' ' H ' ' A' ' 98' ' ' SER . 12.2 m-20 -112.48 113.86 26.25 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.484 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.27 152.58 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.802 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . 179.95 173.63 45.11 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.324 -1.111 . . . . 0.0 110.324 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.908 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 47.8 tt0 -106.23 119.68 39.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.432 ' HB3' HD13 ' A' ' 45' ' ' LEU . 11.0 m -109.14 162.58 14.13 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.301 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -148.73 136.26 20.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.892 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.03 123.69 19.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.89 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.017 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -102.2 -41.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.638 ' HB2' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -150.45 179.21 8.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.944 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -65.85 109.36 2.46 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.29 10.34 86.1 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.59 HG21 ' CE2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -130.87 131.7 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.8 pp -133.71 162.35 32.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.559 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.02 144.96 51.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.44 158.86 17.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.862 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -120.18 118.58 31.3 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.458 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.7 Cg_endo -72.37 1.64 5.92 Favored 'Trans proline' 0 N--CA 1.446 -1.278 0 C-N-CA 124.326 3.351 . . . . 0.0 109.606 179.884 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.29 -20.65 31.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.868 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.429 ' CB ' HG23 ' A' ' 68' ' ' THR . 91.7 m-20 -129.78 30.56 4.86 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.66 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -94.88 117.96 30.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.993 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.5 t -114.01 176.99 4.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.4 p -147.13 155.56 42.26 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.536 HG22 ' N ' ' A' ' 56' ' ' THR . 3.2 p -167.1 162.36 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.536 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.8 m -127.9 128.69 45.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.94 152.05 28.67 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.41 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.1 p30 -94.13 -170.75 2.37 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.52 69.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -76.02 -7.57 54.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.91 8.69 87.28 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.0 p -99.06 139.79 34.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.66 156.01 32.62 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -136.76 121.92 19.12 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.592 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.57 153.57 25.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 m -114.48 130.61 56.74 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.394 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -107.72 154.25 21.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.792 ' H ' HD13 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -113.76 140.5 48.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.96 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.559 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.25 129.78 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.99 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.886 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.18 164.88 13.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -88.06 -25.01 23.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -162.11 147.58 13.0 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.932 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.908 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.2 p90 -176.57 156.01 1.44 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -55.86 121.18 8.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.559 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -82.46 96.86 1.88 Allowed Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.99 99.96 10.74 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.46 129.3 41.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.995 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.606 ' N ' HD12 ' A' ' 77' ' ' LEU . 17.9 p90 -47.67 -34.51 8.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.617 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.68 -16.36 10.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.14 8.49 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -118.16 150.62 39.08 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.4 mtp180 -93.85 97.53 10.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.59 ' CE2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.9 -55.6 21.44 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.947 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.81 176.47 22.19 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.9 113.42 4.37 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.301 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.6 t -89.15 152.96 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -117.65 93.13 4.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.164 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 57.6 m -52.92 -26.59 15.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 36.7 p -78.33 -0.23 28.1 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -117.63 -28.04 6.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.47 -173.56 2.94 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.13 124.21 47.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.86 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.812 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 65.9 m -105.25 152.52 22.78 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.103 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -144.21 145.5 32.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.394 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -107.82 156.04 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.303 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.46 174.34 46.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.484 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -128.08 142.61 51.16 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.221 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 97.3 p -118.77 152.63 35.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.876 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -114.06 -165.6 1.02 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.974 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -54.32 -49.34 69.92 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.13 -25.24 58.26 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 98.71 45.29 2.31 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.708 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.63 167.64 10.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.959 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.0 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.03 -171.3 39.71 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.383 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.34 152.51 55.37 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.322 3.348 . . . . 0.0 109.599 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.126 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -35.26 121.13 0.56 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.55 143.91 0.09 OUTLIER Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.971 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.083 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -114.3 105.49 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.05 130.48 34.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.103 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.8 mt -103.79 164.08 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.907 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.99 121.52 10.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.164 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 18.0 m-85 -90.56 113.15 25.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.496 ' CB ' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.639 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.415 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.0 Cg_endo -72.42 -174.7 1.51 Allowed 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 124.319 3.346 . . . . 0.0 109.623 179.927 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.771 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.8 108.97 21.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.22 140.1 52.81 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.939 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.599 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -98.7 114.11 26.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.916 HG21 ' CG2' ' A' ' 108' ' ' VAL . 38.2 t -111.25 149.17 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.94 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.19 175.7 1.43 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.909 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.074 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.9 Cg_endo -72.35 119.2 5.99 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.312 3.341 . . . . 0.0 109.635 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.046 ' CB ' HG23 ' A' ' 110' ' ' ILE . 51.7 p -113.17 47.9 1.08 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.2 p -125.21 106.85 10.19 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.87 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.991 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.63 26.15 23.51 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.947 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.074 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.95 131.58 46.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 t -118.04 177.06 4.93 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.645 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 5.2 p-10 -45.41 139.26 3.76 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.66 34.73 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 62.9 m -85.98 150.58 24.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.508 HG13 ' O ' ' A' ' 18' ' ' VAL . 12.9 p -126.26 123.79 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.084 HG22 ' O ' ' A' ' 67' ' ' LEU . 18.5 m -87.19 162.31 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.905 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.95 143.87 44.47 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.736 HG23 HG22 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -138.84 112.06 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.981 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.709 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.9 115.66 22.33 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.31 140.78 20.12 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.771 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -138.72 106.68 5.69 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.888 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.03 26.16 8.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.22 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.12 -169.27 2.5 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.516 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.4 mt-30 -80.14 123.47 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.39 130.12 40.53 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.68 8.74 84.6 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.523 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.8 134.4 38.8 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.809 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.84 151.76 23.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.515 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 40.9 m-85 -137.26 148.65 46.58 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.209 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -112.11 116.27 30.23 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.923 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.368 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.78 140.47 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.948 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.856 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -163.3 157.82 30.05 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.791 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.6 tt0 -106.53 116.38 31.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.502 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.6 m -102.96 165.21 11.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.58 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -151.91 142.94 23.15 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.948 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 0.5 OUTLIER -64.98 122.13 16.28 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.843 HG11 ' CD2' ' A' ' 83' ' ' TRP . 1.1 t -101.68 -55.23 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.939 ' OD2' ' CH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -131.86 168.62 17.53 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -50.07 110.88 0.44 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.87 8.31 63.8 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.503 HG11 ' CE2' ' A' ' 83' ' ' TRP . 62.1 t -119.62 125.14 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.6 pp -125.85 162.05 26.03 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -130.96 161.49 31.81 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.898 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.888 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -115.65 156.07 26.53 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.752 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 23.0 t30 -116.71 110.79 41.87 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -72.43 -0.89 9.4 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.356 3.371 . . . . 0.0 109.546 179.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.601 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.97 -11.58 43.93 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.811 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.5 m-20 -133.39 28.87 4.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.884 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.643 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -101.9 118.17 36.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 40.9 t -107.86 -176.39 3.05 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 96.9 p -146.25 152.65 39.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.892 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.59 155.57 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 55' ' ' VAL . 74.0 m -126.41 126.94 44.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.924 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -56.43 146.68 23.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.3 p30 -88.16 -170.25 2.89 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.91 -25.85 67.82 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -84.58 5.23 28.63 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 65.27 8.78 38.99 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -98.35 134.42 41.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.986 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.39 166.23 14.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.5 p -150.03 124.5 9.64 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.701 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -159.36 151.87 21.39 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.901 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.16 132.79 54.01 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.127 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -109.8 119.17 38.52 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.895 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.811 HG23 ' HB3' ' A' ' 51' ' ' ASP . 1.8 t -70.04 143.55 52.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.544 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.3 t -104.23 131.51 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.791 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -119.84 153.07 36.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.97 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 ptt85 -85.66 -22.77 27.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 t -166.79 152.96 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.752 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.5 p90 -175.4 167.24 3.33 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.921 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.38 125.02 22.46 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.915 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.52 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.79 90.92 1.07 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.888 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.55 10.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.999 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.948 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.47 141.64 30.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.693 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.05 -42.13 18.05 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.628 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -57.52 -17.1 12.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.978 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 29.1 9.65 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.948 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.17 122.08 46.79 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.38 92.27 0.08 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.503 ' CE2' HG11 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.56 -58.34 7.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.93 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.03 170.28 21.15 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.63 139.36 53.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 73' ' ' PHE . 2.7 p -126.34 140.55 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -93.48 94.97 8.97 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.98 -21.07 10.62 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.5 p -89.27 1.98 54.96 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 m -114.09 -27.38 7.7 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -123.26 -177.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.61 128.45 37.44 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.937 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.078 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 1.5 m -105.0 152.62 22.49 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.2 pt20 -152.89 147.32 25.85 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.127 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.6 t -114.17 158.16 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.957 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.265 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.43 163.71 33.06 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.368 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.07 124.16 36.36 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.988 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.209 ' N ' ' H ' ' A' ' 33' ' ' ASP . 11.5 m -113.52 156.68 23.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.809 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.19 -161.17 0.74 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.31 -48.62 69.74 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.545 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -66.68 -26.07 66.85 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.889 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.12 42.53 3.24 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.545 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -116.68 157.98 24.54 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.515 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.4 177.53 45.74 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.415 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.0 Cg_endo -72.41 154.86 55.88 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.317 3.345 . . . . 0.0 109.581 179.96 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.639 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -36.96 119.34 0.65 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.941 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.13 155.92 0.01 OUTLIER Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.916 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.1 t -119.23 107.59 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 118.19 25.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.046 HG23 ' CB ' ' A' ' 10' ' ' SER . 8.5 mt -98.25 159.12 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.75 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -144.1 123.48 13.09 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.078 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 5.4 m-85 -92.02 127.26 37.42 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.426 ' H ' ' H ' ' A' ' 12' ' ' GLY . 8.7 p30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.322 ' HB1' ' CB ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.567 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.39 -178.25 3.21 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.297 3.331 . . . . 0.0 109.584 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.111 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -100.23 111.87 24.16 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.936 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.754 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.5 160.53 29.29 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.8 p -124.75 119.08 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.815 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -116.73 154.84 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.936 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.22 174.9 1.74 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.954 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.4 Cg_endo -72.4 118.58 5.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.305 3.337 . . . . 0.0 109.593 179.889 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.289 ' OG ' HG23 ' A' ' 110' ' ' ILE . 11.9 p -116.02 48.76 1.19 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.646 ' HA ' ' O ' ' A' ' 111' ' ' SER . 18.8 p -126.43 104.71 8.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.91 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.79 29.05 16.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -94.85 133.41 38.6 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.986 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.4 t -96.61 158.32 15.49 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.997 ' OD1' ' HG3' ' A' ' 70' ' ' ARG . 25.5 t70 -45.1 142.51 1.9 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.426 ' H ' ' NH1' ' A' ' 70' ' ' ARG . . . 103.26 -23.13 34.21 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 91.7 m -71.59 150.94 44.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.546 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.5 p -125.27 122.78 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.264 HG22 ' O ' ' A' ' 67' ' ' LEU . 32.7 m -91.07 167.3 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.815 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -116.56 152.92 33.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.63 115.52 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -127.77 114.36 17.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.983 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.48 144.7 21.6 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.111 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.48 114.58 9.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.69 19.04 25.98 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.016 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.28 175.67 7.03 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -180.0 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.11 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 34.4 mt-30 -59.6 121.93 12.81 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.13 130.81 40.5 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.68 7.83 85.99 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.461 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.67 141.21 28.74 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.972 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 1.205 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.88 151.24 23.5 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.867 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.0 m-85 -135.77 146.81 48.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.433 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -109.79 114.89 28.84 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.951 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.516 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.9 140.24 22.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.782 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.78 168.98 39.91 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.219 -1.152 . . . . 0.0 110.219 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.96 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 45.3 tt0 -114.31 128.74 56.5 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 28.3 m -130.19 143.1 50.59 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.88 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -121.78 130.62 53.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.894 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.491 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.48 129.05 38.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.947 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.953 HG23 HG12 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -111.12 -41.84 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.92 163.26 35.68 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 95.1 m -54.74 120.08 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.25 6.81 62.05 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.975 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 1.5 t -125.91 115.45 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.978 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.814 HD23 ' HE2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -125.08 143.62 50.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.97 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.272 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.39 142.93 34.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.0 m -112.14 163.71 14.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.2 t30 -126.82 110.73 22.3 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.43 0.58 7.25 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.299 3.332 . . . . 0.0 109.571 179.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.507 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.12 -12.67 43.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.7 p30 -129.24 28.85 5.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 0.1 OUTLIER -86.39 105.62 16.85 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.2 t -104.31 173.26 6.38 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.0 p -145.52 155.56 43.16 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 7.0 p -167.26 157.35 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 179.963 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.8 m -128.1 137.0 51.95 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.16 137.29 41.23 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -76.82 -174.71 3.16 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.69 -19.11 61.99 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -84.6 7.51 19.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.987 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.016 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 32.06 61.77 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 t -129.31 133.52 47.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.25 164.37 19.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.67 126.35 11.02 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -158.64 154.19 26.07 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.39 133.35 50.29 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.438 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -115.25 119.84 37.68 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.893 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.645 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -72.07 133.82 45.47 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.89 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.17 123.9 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.998 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.997 ' HG3' ' OD1' ' A' ' 15' ' ' ASP . 0.5 OUTLIER -113.25 140.7 47.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.956 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.6 ptt180 -76.49 -7.71 55.68 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 77.3 p -167.29 146.6 5.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.96 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 7.2 p90 -177.19 164.98 2.26 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.02 115.07 3.45 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.272 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.47 98.31 1.25 Allowed Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 101.49 11.41 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.981 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -57.32 137.3 56.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.814 ' HE2' HD23 ' A' ' 45' ' ' LEU . 13.4 m-85 -47.23 -40.14 15.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.606 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t0 -56.45 -17.06 6.96 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.65 28.11 9.88 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 28.3 m -112.3 143.44 43.39 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -81.17 94.48 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.975 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.7 t-105 -63.08 -48.97 76.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.13 173.56 13.68 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.39 106.91 1.49 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' HB3' ' A' ' 38' ' ' ALA . 26.8 m -87.66 151.86 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -101.97 92.33 4.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -53.55 -24.66 14.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 8.3 t -84.26 1.73 43.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.5 m -115.14 -27.49 7.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.45 -171.53 2.24 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.6 131.22 42.04 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.609 ' HB2' ' HB ' ' A' ' 110' ' ' ILE . 1.9 m -102.81 167.77 9.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.191 ' HG3' ' O ' ' A' ' 108' ' ' VAL . 11.2 tt0 -169.78 126.29 0.86 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.438 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 67.3 t -112.91 159.23 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.989 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.821 ' C ' HG13 ' A' ' 34' ' ' VAL . . . -179.17 -179.79 48.77 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.942 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.516 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.64 144.37 51.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.274 ' OG ' ' HB3' ' A' ' 33' ' ' ASP . 94.0 p -129.62 147.08 51.38 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 1.205 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -105.27 -163.41 0.95 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.987 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.86 -48.21 69.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.937 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.23 -21.04 66.29 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.76 53.2 2.62 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.909 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 1.11 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.14 162.53 27.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.98 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.867 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -171.94 -179.52 42.94 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.567 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 156.85 54.3 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.357 3.371 . . . . 0.0 109.593 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.322 ' CB ' ' HB1' ' A' ' 2' ' ' ALA . 10.8 pt-20 -35.69 120.84 0.6 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.9 148.2 0.04 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.191 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 72.0 t -124.4 118.95 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -98.14 150.47 21.43 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.289 HG23 ' OG ' ' A' ' 10' ' ' SER . 16.9 mt -126.09 163.49 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.646 ' O ' ' HA ' ' A' ' 11' ' ' SER . 13.5 t -152.75 134.61 14.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.872 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -102.5 125.52 49.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 31.0 m-80 . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.991 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.619 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.347 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.7 Cg_endo -72.35 -174.12 1.33 Allowed 'Trans proline' 0 N--CA 1.448 -1.201 0 C-N-CA 124.323 3.349 . . . . 0.0 109.609 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.79 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -96.47 107.12 19.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.673 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.39 147.53 48.18 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.987 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.528 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -102.26 111.57 23.9 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.025 HG22 HG12 ' A' ' 21' ' ' VAL . 38.6 t -107.28 148.04 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.894 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -73.24 176.74 2.39 Favored Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.93 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.11 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.6 Cg_endo -72.43 116.28 4.65 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.332 3.354 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.02 ' HB2' HG23 ' A' ' 110' ' ' ILE . 91.6 p -111.51 47.38 1.03 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.1 p -127.1 107.06 9.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.96 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.72 26.12 23.39 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.921 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.11 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.96 131.64 44.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.995 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.1 m -111.21 173.98 6.08 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 1.5 t0 -47.87 144.0 3.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.489 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 99.41 -23.6 35.57 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.953 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.483 HG21 ' HB3' ' A' ' 13' ' ' LEU . 82.7 m -74.33 151.17 39.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.8 p -125.31 117.41 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.949 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.693 HG13 HG22 ' A' ' 8' ' ' THR . 55.1 t -83.99 163.46 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tppt? -124.01 133.4 53.68 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -135.53 110.39 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.973 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.673 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.6 119.24 33.2 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.762 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.76 140.68 20.44 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.751 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.4 108.8 6.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.93 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.922 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.99 24.37 8.6 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.187 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.66 -163.59 1.03 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.434 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -85.5 126.56 33.94 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.537 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.25 131.57 41.32 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.89 84.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.59 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.52 138.2 31.71 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.666 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -88.49 145.17 25.9 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.936 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -133.61 146.03 50.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.218 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -110.72 117.37 33.28 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.906 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.316 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.32 145.56 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.99 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.957 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.25 171.57 41.99 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.817 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -118.14 112.01 19.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.969 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.6 m -105.05 172.4 6.81 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.996 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -155.09 138.17 15.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.905 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.509 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.93 127.18 30.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.912 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.912 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -108.27 -51.85 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.027 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -143.01 165.14 28.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.946 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.624 HG23 ' O ' ' A' ' 42' ' ' THR . 10.1 t -51.46 112.15 0.7 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.08 9.15 75.87 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.773 HG12 ' CD1' ' A' ' 83' ' ' TRP . 4.5 t -129.06 114.37 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.933 HD12 ' N ' ' A' ' 46' ' ' ALA . 0.9 OUTLIER -118.22 162.84 17.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -123.64 138.63 54.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.983 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 58.3 m -109.49 148.46 31.16 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.716 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.8 t-20 -107.04 107.17 60.08 Favored Pre-proline 0 N--CA 1.45 -0.469 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.7 Cg_endo -72.47 0.35 7.61 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.344 . . . . 0.0 109.564 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.02 -9.54 50.92 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.9 p30 -131.72 27.16 4.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 104.98 13.9 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.991 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 29.8 t -98.32 172.29 7.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.945 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.34 154.68 41.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' THR . 6.0 p -166.7 158.31 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.954 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' VAL . 13.7 m -127.05 130.16 49.42 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.38 43.74 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.2 p30 -92.24 -171.59 2.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.27 -23.92 66.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 60' ' ' ASN . 1.8 m-20 -85.19 9.74 14.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 58.58 14.28 20.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -104.51 133.91 48.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.934 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.45 162.21 19.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -146.09 127.45 14.92 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.577 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -163.9 150.03 11.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.877 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.25 142.5 40.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.105 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -113.85 123.27 49.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.702 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.4 t -70.08 124.54 24.35 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.555 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -85.09 125.2 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.0 OUTLIER -117.08 144.76 44.3 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.427 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -87.16 -13.43 44.08 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 51.9 p -166.99 149.7 6.35 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.952 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.817 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.1 p90 -177.03 152.42 0.9 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.5 121.68 8.21 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.7 93.13 1.25 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 99.85 10.84 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.981 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.1 130.8 47.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.685 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.35 -35.75 8.55 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.54 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.68 -16.62 11.35 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.47 26.35 10.09 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 29.9 m -112.9 145.77 40.13 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -86.56 95.6 9.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.027 ' HZ2' ' CB ' ' A' ' 41' ' ' ASP . 1.0 OUTLIER -62.98 -53.84 47.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.939 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.7 173.21 14.32 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.13 125.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.996 HG11 ' CB ' ' A' ' 38' ' ' ALA . 54.5 t -100.05 148.63 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.47 93.25 4.14 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.427 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.5 m -52.86 -26.01 13.38 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.0 p -81.75 1.4 34.66 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -116.89 -27.18 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.916 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.98 -176.92 4.16 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.915 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.79 124.73 45.37 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.001 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 73.2 m -104.62 154.88 19.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -143.39 149.75 38.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.92 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.105 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 5.4 t -117.85 154.25 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.24 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.95 173.54 46.08 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.316 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.45 146.32 50.14 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.988 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.218 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 4.7 m -127.09 151.49 48.56 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.666 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -109.53 -165.62 1.03 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.984 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.48 -49.33 77.98 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.964 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.551 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -68.64 -25.33 64.78 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.41 41.82 3.34 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.551 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -115.94 164.04 15.0 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.936 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.57 -177.49 42.01 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.347 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.44 156.25 54.54 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.251 3.301 . . . . 0.0 109.57 179.903 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.619 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 3.3 pt-20 -37.36 119.87 0.74 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.49 151.93 0.02 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.941 ' CG2' HG21 ' A' ' 7' ' ' VAL . 3.6 t -124.01 104.44 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.42 128.83 34.83 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.033 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.4 mt -102.03 160.77 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.931 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.744 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -144.52 120.89 10.95 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.946 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.46 123.43 40.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.547 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.34 -178.64 3.42 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 124.356 3.371 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.188 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.2 m -101.91 109.52 21.28 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.961 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.922 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.71 141.9 51.58 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -104.75 117.76 34.87 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.992 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.787 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -115.92 151.73 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.951 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.647 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.4 OUTLIER -74.48 163.54 67.54 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.937 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.628 ' O ' HD21 ' A' ' 13' ' ' LEU . 83.0 Cg_endo -72.41 120.09 6.53 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.267 3.312 . . . . 0.0 109.595 179.918 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.987 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -120.07 16.7 12.46 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.975 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 1.106 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.2 p -98.91 115.15 28.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.654 ' N ' ' H ' ' A' ' 113' ' ' ASN . . . 104.24 -0.13 44.0 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.059 HD22 HG21 ' A' ' 17' ' ' THR . 1.3 pp -114.09 142.48 46.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.996 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.8 p -107.54 -167.76 1.3 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.919 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.677 ' CG ' HH11 ' A' ' 70' ' ' ARG . 7.2 t70 -42.15 153.67 0.06 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.98 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.75 -23.1 34.23 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.978 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 1.059 HG21 HD22 ' A' ' 13' ' ' LEU . 26.1 m -80.26 141.42 35.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 18' ' ' VAL . 11.2 p -119.46 109.84 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.932 HG13 ' HB3' ' A' ' 67' ' ' LEU . 1.8 p -83.67 161.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.987 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.787 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.73 150.79 39.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.62 109.35 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.978 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.922 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.14 116.95 25.11 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.016 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.64 144.74 22.38 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.984 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.717 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.04 109.55 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.45 17.82 23.05 Favored Glycine 0 C--N 1.336 0.56 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.99 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.016 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.01 175.15 7.29 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.991 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 37.6 mt-30 -58.35 121.37 10.65 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.461 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.65 129.16 37.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.99 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.35 8.22 87.61 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.933 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.513 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.5 143.49 26.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.961 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.667 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -87.35 151.45 23.09 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.96 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.795 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.3 m-85 -138.9 139.35 38.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.911 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.192 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.3 m-20 -105.47 113.73 27.48 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.27 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.98 147.57 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.938 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.863 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.72 166.13 38.26 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 1.01 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 2.2 tt0 -108.26 123.56 48.96 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.963 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.7 m -117.57 143.86 45.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.959 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.557 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.07 137.61 54.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.52 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -65.61 127.94 33.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.625 HG13 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -107.43 -55.14 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.465 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.62 167.62 17.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.962 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.417 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -50.81 112.11 0.65 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.944 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.72 8.09 66.96 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.999 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.516 HG11 ' HE1' ' A' ' 83' ' ' TRP . 11.6 t -122.74 112.89 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.988 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.647 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -121.97 131.98 54.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.984 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.341 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.31 153.77 20.62 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.942 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.8 m -110.81 156.87 20.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.825 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.6 t30 -114.9 106.24 52.03 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.465 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.37 -0.09 8.2 Favored 'Trans proline' 0 N--CA 1.448 -1.178 0 C-N-CA 124.319 3.346 . . . . 0.0 109.603 179.91 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.15 -11.61 43.36 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.7 p30 -130.25 27.26 5.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.23 106.76 15.28 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 t -101.09 171.79 7.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.896 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 p -146.88 154.26 41.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.514 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.77 161.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.928 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.514 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.9 m -128.03 135.8 50.37 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.63 135.19 39.16 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.917 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.0 p30 -76.02 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.914 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.5 -19.75 62.42 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -83.28 6.8 18.42 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.006 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.94 32.11 65.89 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.9 t -130.92 134.53 46.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.966 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.35 165.5 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -144.94 130.25 18.67 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.988 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.656 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.61 169.79 20.73 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.88 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.656 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -128.87 117.52 21.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.423 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.36 157.95 15.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.959 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.534 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -118.67 136.93 53.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.947 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.527 HG21 ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -103.23 126.69 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.677 HH11 ' CG ' ' A' ' 15' ' ' ASP . 0.1 OUTLIER -113.73 142.68 45.74 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.959 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -62.81 -35.13 78.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 83.7 p -154.55 157.05 37.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.876 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 1.01 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.2 p90 -177.17 155.83 1.19 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' CG ' ' A' ' 74' ' ' GLU . 0.5 OUTLIER -53.49 109.93 0.5 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.935 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.341 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.1 103.0 1.07 Allowed Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.96 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.984 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.19 100.21 10.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.987 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.878 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.3 tp -57.87 137.98 56.15 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.682 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.34 -40.36 17.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.704 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -57.32 -17.13 10.78 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.978 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 28.56 9.52 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.878 ' HB ' HD23 ' A' ' 77' ' ' LEU . 5.4 m -112.45 148.43 34.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -83.94 94.21 8.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.625 ' CE3' HG13 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -64.24 -40.18 95.48 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.92 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.33 169.7 12.47 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.31 106.12 0.49 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.942 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 40' ' ' VAL . 27.6 m -85.35 154.34 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.64 91.72 4.32 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.774 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.28 -20.65 7.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.977 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.611 HG22 ' HD2' ' A' ' 112' ' ' PHE . 76.0 p -90.59 2.82 55.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.971 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.6 m -112.61 -27.26 8.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.95 -178.77 4.28 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.28 129.19 35.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.434 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 3.8 m -105.04 155.24 19.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.313 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.6 tt0 -154.02 131.75 11.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 -179.939 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.423 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.5 t -94.09 163.67 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.989 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.231 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.69 165.0 33.84 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.27 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.41 132.2 45.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.986 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.192 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 32.9 m -111.66 153.01 27.01 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.904 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.667 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.03 -162.47 0.8 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.995 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.9 -48.45 65.98 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.24 -24.15 65.78 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.78 54.09 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -133.97 171.47 14.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.795 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.51 173.77 45.45 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.42 168.23 24.86 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 124.258 3.306 . . . . 0.0 109.571 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.547 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.1 pt-20 -39.54 125.63 1.77 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.945 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.3 161.22 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.914 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.313 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 50.0 t -119.13 102.4 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.91 132.35 36.04 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CD1' ' HB2' ' A' ' 93' ' ' CYS . 16.1 pt -136.85 -175.3 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 1.106 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -177.27 153.17 0.92 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.968 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.434 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.1 m-85 -107.17 119.28 38.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.945 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.654 ' H ' ' N ' ' A' ' 12' ' ' GLY . 7.3 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.189 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 85.0 Cg_endo -72.37 -178.73 3.49 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.36 3.373 . . . . 0.0 109.608 179.925 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.97 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.2 m -100.9 108.74 20.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.657 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -120.16 145.2 47.18 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.957 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -108.66 115.29 29.82 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.976 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.726 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.33 153.57 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.993 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.853 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.18 175.09 1.95 Allowed Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.958 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.063 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.43 117.45 5.14 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.292 3.328 . . . . 0.0 109.607 179.869 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.032 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -115.16 47.35 1.3 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.943 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.49 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -123.71 105.81 10.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.977 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.45 28.51 16.66 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.063 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.43 134.79 41.8 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.83 163.77 12.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 15' ' ' ASP . 3.5 t0 -45.94 142.91 2.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 103.44 -22.75 35.1 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.47 HG21 HD13 ' A' ' 13' ' ' LEU . 90.6 m -73.3 144.81 46.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.977 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 18' ' ' VAL . 11.0 p -111.74 115.08 48.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.978 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.082 HG13 HG12 ' A' ' 69' ' ' VAL . 5.6 m -84.21 158.51 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.726 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.53 144.39 42.93 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.979 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -145.36 110.74 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.985 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.657 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.78 122.41 37.37 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.956 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.063 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.51 146.79 22.73 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.947 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.1 109.37 4.69 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.72 16.83 27.67 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.952 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.063 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.43 176.06 6.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.945 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.509 ' HB2' HG21 ' A' ' 30' ' ' THR . 31.7 mt-30 -56.5 120.82 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -180.0 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.448 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.73 130.66 41.02 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.28 7.34 84.78 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.509 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.26 140.39 29.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.964 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 1.238 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.8 147.86 27.34 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.109 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 27.4 m-85 -135.75 131.92 36.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.932 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.351 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.45 112.58 24.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.962 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.458 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.77 144.31 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.987 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.983 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.68 161.09 33.92 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.903 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 34.2 tt0 -104.03 119.18 38.39 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 85.7 m -117.08 143.54 45.67 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.464 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.29 139.25 54.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.544 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.98 125.29 24.43 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.427 HG13 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -105.03 -44.09 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.991 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.543 ' OD1' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -142.36 169.41 17.63 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.4 m -50.99 112.41 0.71 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.997 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.63 7.47 61.33 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 40' ' ' VAL . 2.3 t -120.8 118.7 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.564 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -128.99 134.91 48.34 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.986 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.38 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.55 157.61 16.91 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 69.1 m -117.61 156.04 28.82 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.551 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.0 t30 -122.07 109.28 33.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.48 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.44 0.26 7.73 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.278 3.319 . . . . 0.0 109.576 179.936 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -85.44 -14.96 44.55 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.878 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 5.9 p30 -129.09 19.53 5.93 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.951 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.689 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -82.07 117.94 22.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.983 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 m -107.11 178.1 4.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.973 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 p -145.23 152.69 40.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.851 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.487 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -167.02 156.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.0 m -127.92 133.05 49.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.959 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.75 134.49 46.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.936 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 37.5 p30 -75.05 -174.46 2.27 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.909 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.54 -25.23 67.93 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.975 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.32 -4.6 42.99 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.912 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 72.07 31.08 64.52 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.997 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.1 p -129.2 139.62 51.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.957 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.37 163.43 26.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.964 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.69 127.06 15.85 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.416 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -150.62 159.43 44.51 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.855 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.416 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -119.5 115.08 23.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.932 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.641 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.78 157.55 16.01 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.925 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.667 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -111.93 136.22 51.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.975 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 1.082 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.95 129.16 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.99 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.78 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.38 164.3 15.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.994 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.2 -15.37 29.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.983 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -164.49 143.28 7.12 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.903 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -170.7 159.52 6.6 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -54.59 120.3 6.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.901 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.38 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.94 92.28 1.35 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 179.986 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.926 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.19 100.14 10.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.966 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -55.14 144.25 24.66 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.991 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.755 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.35 -43.43 23.05 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.579 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 8.7 t0 -58.05 -17.02 14.97 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.958 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.2 28.56 10.6 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.999 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -107.66 119.22 38.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.83 91.43 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.427 ' CE2' HG13 ' A' ' 40' ' ' VAL . 29.0 t90 -62.7 -58.55 7.08 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.901 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.48 166.91 17.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.992 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.06 108.82 0.73 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.955 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.605 HG22 HG23 ' A' ' 40' ' ' VAL . 15.7 t -81.95 147.35 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.998 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -105.28 94.44 5.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.988 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -52.56 -24.99 9.23 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.6 p -79.3 -3.64 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 -26.87 7.36 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.4 -178.11 3.9 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.13 138.6 33.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.959 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.656 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -102.47 161.23 13.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.974 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.206 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.4 tt0 -168.39 127.19 1.16 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.641 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.5 t -97.04 164.56 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.967 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -175.75 167.99 40.09 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.458 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.82 128.5 38.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.981 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.351 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 19.8 m -116.84 142.19 47.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.913 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 1.238 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -98.33 -157.8 0.62 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.87 -48.22 69.45 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.903 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.462 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -69.77 -25.89 64.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.955 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.8 48.46 2.11 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.602 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -120.62 162.94 18.8 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.999 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.109 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.58 176.71 44.04 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.984 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.608 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.46 165.12 33.6 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.319 3.346 . . . . 0.0 109.601 179.935 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.189 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 pt-20 -38.24 135.91 0.69 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.961 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.61 147.56 3.93 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.967 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.206 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 13.0 t -127.42 104.15 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.985 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.629 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -88.71 157.16 18.62 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.032 HG23 ' HB3' ' A' ' 10' ' ' SER . 22.4 mt -127.97 168.31 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.501 ' N ' HG22 ' A' ' 110' ' ' ILE . 21.1 t -153.97 137.26 15.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.954 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.656 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -102.09 124.94 48.56 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.553 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 30.3 m-80 . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.97 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.586 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.427 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -175.23 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.306 3.337 . . . . 0.0 109.61 179.924 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.897 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.72 108.21 20.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.736 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 146.52 49.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.43 110.33 22.31 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.973 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.902 HG21 ' CG2' ' A' ' 108' ' ' VAL . 14.3 t -105.62 146.1 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.93 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.17 175.24 2.2 Favored Pre-proline 0 N--CA 1.448 -0.528 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.945 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.119 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.8 Cg_endo -72.42 116.54 4.75 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 124.323 3.349 . . . . 0.0 109.593 179.918 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.973 ' HB2' HG23 ' A' ' 110' ' ' ILE . 56.6 p -113.33 46.66 1.23 Allowed 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.957 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 111' ' ' SER . 61.9 p -126.34 105.2 8.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.907 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.971 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.79 26.84 15.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.119 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -98.13 132.34 43.74 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.965 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -104.15 169.41 8.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 15' ' ' ASP . 15.9 p30 -46.02 141.43 3.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.993 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.19 -22.95 34.84 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.991 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 24.6 m -79.63 152.32 30.08 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.991 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -124.92 125.66 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.998 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.6 m -89.37 118.22 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.796 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -69.24 148.37 49.91 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.637 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.81 105.27 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.997 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.736 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.25 117.1 28.2 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.963 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.696 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.29 141.2 19.69 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.897 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.27 108.64 6.88 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.928 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.917 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.67 23.88 9.1 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.976 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.401 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.34 -171.79 3.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.983 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.493 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 29.1 mt-30 -76.31 124.29 27.28 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.989 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.66 130.33 40.31 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.48 8.22 83.7 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.958 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.552 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -95.04 136.48 35.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.96 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.771 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.88 151.31 23.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.999 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.919 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 48.4 m-85 -138.12 144.17 40.71 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.048 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.0 m-20 -104.64 116.63 32.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.956 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.418 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.05 142.29 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.882 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.5 170.78 42.87 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.968 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.6 tt0 -114.42 116.3 28.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.934 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 64.2 m -114.6 143.2 45.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.826 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.9 131.45 53.74 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.914 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.84 123.72 20.53 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.935 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.058 ' HB ' ' CE3' ' A' ' 83' ' ' TRP . 14.2 m -103.58 -43.98 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.575 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -136.8 176.18 8.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.991 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.16 112.08 1.77 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.982 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.98 8.29 64.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.304 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 61.6 t -122.79 108.0 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 180.0 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.561 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -121.47 139.52 53.37 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.978 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.475 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.83 157.93 15.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.3 m -118.74 152.26 36.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.3 t-20 -110.93 107.47 57.79 Favored Pre-proline 0 N--CA 1.449 -0.492 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.37 -0.02 8.09 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.322 3.348 . . . . 0.0 109.591 179.891 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.568 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.78 -11.11 43.13 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.783 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.502 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.6 p30 -131.1 27.05 4.87 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.901 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.97 106.18 15.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.977 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.6 t -104.19 173.23 6.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.943 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 p -145.51 156.75 43.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.443 HG22 ' N ' ' A' ' 56' ' ' THR . 4.7 p -166.29 157.83 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.443 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.7 m -127.76 126.98 42.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.49 153.0 24.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.5 p30 -93.78 -171.63 2.64 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.885 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.22 67.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -83.17 5.24 23.4 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.539 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 64.59 9.24 37.03 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.975 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.5 t -101.22 134.41 44.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.985 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.56 163.48 17.91 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.4 p -147.78 130.72 16.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.972 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.49 164.19 17.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.968 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -120.46 132.09 55.06 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.921 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.161 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.61 122.44 47.46 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.912 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.59 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.7 t -77.96 130.95 37.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.899 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.586 HG11 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.45 129.87 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.967 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.746 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.43 155.26 23.45 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.932 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -83.02 -13.67 55.45 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.978 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.533 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 13.9 m -167.24 147.4 5.41 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.968 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.6 p90 -177.31 157.36 1.32 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.949 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.406 ' O ' ' HG3' ' A' ' 74' ' ' GLU . 14.8 pt-20 -56.56 117.61 4.03 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.475 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.14 97.26 1.39 Allowed Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.996 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.807 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.36 10.64 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.986 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.879 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -54.5 141.74 30.04 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.724 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.22 -42.85 20.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.574 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.9 t0 -56.78 -16.8 7.21 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.69 27.98 10.82 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.879 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -108.19 130.82 55.12 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 6.9 ptt180 -72.24 92.95 1.42 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.575 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 0.6 OUTLIER -61.67 -54.96 35.73 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.893 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.5 174.19 21.37 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.07 113.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' A' ' 38' ' ' ALA . 1.1 m -91.36 152.4 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.533 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 1.5 m-20 -115.7 102.97 10.22 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.975 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.537 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 23.0 m -52.82 -27.46 18.27 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.3 p -79.56 -3.51 47.28 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.994 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.69 -27.78 6.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.27 -178.4 4.2 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.56 122.97 44.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.879 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.573 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 89.7 m -104.03 151.73 22.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.986 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.4 OUTLIER -152.24 146.81 25.71 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.951 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.161 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -110.21 159.05 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.983 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.243 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.07 169.6 41.49 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.418 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.8 129.42 46.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.958 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.048 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 5.8 m -110.26 152.35 26.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.961 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.771 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -114.37 -169.35 1.51 Allowed 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.943 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.65 -48.91 77.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.24 -24.29 66.57 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.928 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.02 53.5 1.89 Allowed Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.955 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.727 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -132.79 172.69 12.24 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.982 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.919 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.24 179.27 48.59 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.966 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.427 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 160.01 47.92 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.313 3.342 . . . . 0.0 109.586 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.586 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -36.82 122.2 0.8 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.38 155.38 0.03 OUTLIER Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.974 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.902 ' CG2' HG21 ' A' ' 7' ' ' VAL . 8.6 t -127.51 111.59 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.981 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.411 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -92.98 129.8 38.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.986 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.5 mt -103.74 156.16 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.605 ' O ' ' HA ' ' A' ' 11' ' ' SER . 11.7 t -145.25 129.7 17.86 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.91 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.547 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -96.23 126.59 41.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.947 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.293 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.517 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.583 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.41 -177.19 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.349 3.366 . . . . 0.0 109.584 179.949 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.833 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -95.42 108.63 20.85 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.926 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.91 145.26 51.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.645 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.1 p -104.49 111.98 24.86 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.871 HG13 ' O ' ' A' ' 20' ' ' LYS . 26.2 t -106.96 149.21 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.996 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.53 178.32 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.938 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.121 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.6 Cg_endo -72.37 117.75 5.28 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 C-N-CA 124.279 3.32 . . . . 0.0 109.569 179.942 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.564 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 17.2 p -114.13 45.16 1.54 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 92.5 p -127.78 106.38 9.09 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.873 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.903 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.59 24.5 20.86 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.121 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -94.1 130.11 40.39 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 45.8 t -98.49 168.27 10.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.93 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.63 141.15 17.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.4 -23.72 34.23 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.458 HG21 ' HB3' ' A' ' 13' ' ' LEU . 21.1 m -72.27 152.69 42.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.987 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.424 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.9 p -126.77 131.19 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.0 m -97.95 169.7 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.871 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.83 150.34 38.53 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.975 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.847 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -144.32 109.4 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.978 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.838 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.53 114.86 23.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.55 146.8 24.91 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.833 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.01 110.92 4.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.864 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.39 13.46 30.58 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.99 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.993 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.59 165.98 13.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.979 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.525 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.5 mt-30 -46.41 119.71 2.51 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.984 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.744 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.26 131.08 41.54 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.47 8.46 80.55 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.525 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.78 148.32 22.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.951 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.408 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.938 ' HB3' ' CB ' ' A' ' 97' ' ' LEU . 35.1 m-85 -138.26 151.75 47.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.907 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.406 ' CA ' ' H ' ' A' ' 98' ' ' SER . 35.0 m-20 -120.23 117.4 27.77 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.281 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -98.58 141.39 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.803 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -161.99 155.44 26.71 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.894 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 40.7 tt0 -105.65 115.7 30.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.449 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.3 m -102.96 166.66 10.32 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.025 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -153.33 134.0 13.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.956 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.592 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.2 122.55 17.36 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.91 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.514 ' HB ' ' CD1' ' A' ' 83' ' ' TRP . 2.5 m -102.9 -42.82 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.992 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.457 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -138.47 166.16 25.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m -50.79 111.77 0.6 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.35 8.92 63.35 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.97 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.52 HG11 ' CH2' ' A' ' 83' ' ' TRP . 75.0 t -120.3 119.35 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.5 162.75 23.32 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.515 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -132.54 155.42 48.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.926 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.1 m -113.46 155.23 25.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.521 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.3 t30 -116.11 112.41 42.11 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.38 0.13 7.88 Favored 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 124.31 3.34 . . . . 0.0 109.65 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.521 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.03 -16.52 29.61 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.915 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.473 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.0 p30 -127.16 28.33 5.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.93 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -102.1 118.67 37.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.7 t -107.41 -177.27 3.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.932 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -147.65 154.58 40.81 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.522 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -167.31 161.9 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.977 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.522 ' N ' HG22 ' A' ' 55' ' ' VAL . 20.7 m -126.34 130.19 50.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.58 145.55 55.48 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.977 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 51.6 p30 -83.7 -172.29 4.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.934 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.09 -27.57 69.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.66 -10.06 59.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.993 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.62 31.79 48.77 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.969 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.3 p -127.36 136.32 51.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.991 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.95 170.2 10.86 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.53 123.97 9.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.499 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -151.94 160.26 43.55 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.907 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.488 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -114.43 129.68 56.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.913 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.069 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -107.26 118.01 35.58 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.901 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.578 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -67.66 120.46 14.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.987 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.534 HG12 ' O ' ' A' ' 69' ' ' VAL . 0.6 OUTLIER -76.47 123.94 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.975 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.635 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 26.9 mmt180 -115.57 157.03 24.71 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.494 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 4.1 ptt180 -107.08 -10.73 15.82 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.99 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -177.05 146.93 0.53 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.927 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.894 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -176.69 171.52 2.25 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.878 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 118.36 7.28 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.515 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 94.07 1.35 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.996 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -84.44 100.63 11.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.848 HD12 ' H ' ' A' ' 78' ' ' PHE . 2.2 tp -54.45 145.41 18.42 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.848 ' H ' HD12 ' A' ' 77' ' ' LEU . 10.8 m-85 -47.2 -43.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.591 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -58.73 -16.52 17.03 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.965 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.12 28.25 12.15 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.826 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.2 m -106.38 122.67 46.74 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 ttm180 -61.71 90.96 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.956 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.52 ' CH2' HG11 ' A' ' 44' ' ' VAL . 42.8 t-105 -62.35 -58.4 7.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.53 163.2 12.09 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.994 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.56 105.73 0.47 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.951 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.025 HG21 ' HB1' ' A' ' 38' ' ' ALA . 3.4 p -80.21 148.89 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -110.47 98.74 7.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 17.8 m -51.91 -27.53 13.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.2 p -79.57 1.21 26.85 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.982 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.4 m -116.99 -26.68 6.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.933 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.81 -175.31 3.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.58 125.65 48.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.247 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.2 m -103.83 152.69 21.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.992 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -150.89 144.17 24.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.967 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.069 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 7.1 t -103.96 163.56 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.252 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.33 168.41 40.52 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.991 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.281 ' CG ' HG22 ' A' ' 34' ' ' VAL . 5.6 mp -99.5 162.16 13.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.406 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 13.0 m -154.16 118.48 4.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.451 ' OD1' ' N ' ' A' ' 102' ' ' GLY . 42.7 p-10 -113.54 -167.9 1.27 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.998 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.16 -19.89 2.23 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.946 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.45 -23.51 13.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.888 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.451 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 85.34 22.0 52.79 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.773 ' ND2' ' HD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -60.11 -151.83 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.974 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 143.47 153.38 5.86 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.953 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.583 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.41 165.4 32.79 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.247 3.298 . . . . 0.0 109.607 179.964 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.293 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.2 pt-20 -33.55 124.45 0.42 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.542 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.34 133.99 0.98 Allowed Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.6 104.03 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.952 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.463 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.58 144.97 26.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.247 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.11 159.47 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.917 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.46 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -144.2 115.05 7.79 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 93' ' ' CYS . 30.5 m-85 -100.06 126.21 46.25 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.934 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.947 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.45 -0.467 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.526 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.2 Cg_endo -72.39 -175.37 1.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.328 3.352 . . . . 0.0 109.605 179.907 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.291 HG22 ' O ' ' A' ' 24' ' ' ALA . 6.4 t -99.67 116.15 31.11 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.885 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -131.9 154.64 49.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.498 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -115.76 117.09 29.27 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.048 HG13 ' O ' ' A' ' 20' ' ' LYS . 84.8 t -114.03 143.77 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.736 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.63 166.68 24.3 Favored Pre-proline 0 N--CA 1.448 -0.539 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.938 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.736 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.37 118.13 5.46 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.331 3.354 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.615 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.45 9.43 7.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.961 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.747 ' HA ' ' O ' ' A' ' 111' ' ' SER . 50.0 p -88.51 106.72 18.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.882 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.071 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 101.94 17.98 19.15 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.888 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.071 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -108.12 133.24 52.67 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -87.77 174.54 8.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.913 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 27.8 t70 -46.71 153.33 0.4 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.53 -22.62 36.37 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.965 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.651 HG21 HD12 ' A' ' 13' ' ' LEU . 18.9 m -71.94 148.0 46.43 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.76 129.6 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.979 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.677 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -104.51 150.54 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.969 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 1.048 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.1 147.86 28.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.976 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.809 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -142.71 108.63 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.36 114.75 20.58 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.885 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.17 143.13 20.16 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.954 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.291 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.29 109.52 6.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.901 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.15 24.22 9.14 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.526 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.47 -169.35 2.52 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.531 ' HB2' HG21 ' A' ' 30' ' ' THR . 0.1 OUTLIER -81.03 125.25 29.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.3 131.29 43.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.992 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.94 8.15 77.43 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.599 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.63 132.14 42.56 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.972 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.42 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -86.25 150.67 24.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.856 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 51.6 m-85 -135.03 141.73 46.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.056 ' HB2' ' O ' ' A' ' 98' ' ' SER . 2.2 m-20 -100.69 113.96 27.27 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.958 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -101.26 151.55 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.977 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.726 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -175.89 172.77 45.76 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.957 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.849 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 41.4 tt0 -108.18 107.12 17.61 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.942 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 60.7 m -106.73 142.43 36.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.49 137.38 54.9 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.875 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.569 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.41 124.73 22.55 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.889 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.535 HG12 ' N ' ' A' ' 41' ' ' ASP . 1.2 t -105.27 -46.76 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.517 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.82 167.09 21.82 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -51.14 112.19 0.69 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.954 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.57 7.94 65.94 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.893 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 2.0 t -122.38 117.58 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.983 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.532 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -127.35 136.3 51.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.979 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.494 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.34 151.76 20.11 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.97 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.6 m -110.77 146.75 35.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.974 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.762 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.1 p-10 -116.73 115.38 39.24 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.567 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.3 Cg_endo -72.4 -0.54 8.87 Favored 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.317 3.345 . . . . 0.0 109.6 179.868 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.719 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -76.03 -25.4 55.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.89 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.472 ' CB ' HG23 ' A' ' 68' ' ' THR . 89.6 m-20 -124.8 27.74 6.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.948 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.73 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -83.33 117.32 22.92 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.966 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 m -110.92 -178.24 3.42 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.8 p -144.86 155.07 43.27 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.875 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.594 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.6 p -166.91 151.66 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 m -127.57 133.17 49.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 143.83 53.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.966 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 43.7 p30 -86.27 -172.03 3.85 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.36 -25.98 68.2 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.925 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -80.16 -7.77 59.1 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.05 30.59 57.13 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.927 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.3 p -122.57 133.01 54.56 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.594 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -119.4 162.66 18.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.981 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.2 p -149.5 129.03 13.07 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.971 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.442 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.91 157.57 31.67 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.868 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.442 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.61 125.04 52.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.452 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -98.83 157.39 16.33 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.916 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -106.41 140.29 39.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.965 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.597 HG23 HG11 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -99.01 125.37 52.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.913 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -118.99 136.23 54.21 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.954 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -61.51 -34.49 75.6 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.443 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 62.5 p -156.58 162.4 39.9 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.849 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.9 p90 -177.71 165.62 2.08 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.961 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.8 116.55 8.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.911 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.494 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.66 94.73 1.08 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.95 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.868 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.69 99.76 10.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.979 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -56.8 131.13 48.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.677 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 9.5 m-85 -47.83 -35.63 10.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.989 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.54 -16.91 11.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.948 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.96 27.51 8.84 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.988 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 21.7 m -115.79 148.81 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.978 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -90.75 96.89 10.86 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.517 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 32.9 t-105 -63.44 -58.05 8.31 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 172.93 21.64 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.991 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.75 104.81 2.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.726 HG21 ' HB3' ' A' ' 38' ' ' ALA . 7.1 m -78.76 152.34 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.999 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.75 92.91 4.05 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.971 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.137 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 32.7 m -51.6 -27.06 10.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.964 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -79.61 0.81 28.56 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.994 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -118.63 -27.97 5.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.46 180.0 5.7 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.669 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -97.43 125.32 42.0 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.434 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 82.2 m -104.52 168.88 8.8 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.984 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -154.66 146.45 23.39 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.957 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.452 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.8 t -101.19 164.77 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.84 168.62 39.07 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.045 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.16 125.24 30.75 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.821 -0.436 . . . . 0.0 109.821 -179.95 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.056 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 56.6 m -100.75 154.07 18.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.895 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.44 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.1 OUTLIER -116.48 -164.29 0.96 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.44 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -61.77 -49.04 77.96 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.14 -24.4 61.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.922 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.22 53.58 1.46 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.995 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.52 178.28 6.86 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.856 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -179.7 -178.04 48.22 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.41 165.59 32.24 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.295 3.33 . . . . 0.0 109.61 179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.591 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 3.8 pt-20 -38.3 121.84 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.82 153.87 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.9 t -114.1 102.33 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.51 128.51 34.35 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.434 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -139.28 -177.36 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.747 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -172.21 174.66 3.91 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.915 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.137 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.3 m-85 -123.28 114.47 20.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.967 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.009 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 21.2 m-80 . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.973 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.341 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.44 -178.57 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.306 3.337 . . . . 0.0 109.59 179.945 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.999 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.18 109.11 21.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.942 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.884 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -122.92 150.73 42.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.661 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -113.82 119.64 38.02 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.999 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.903 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -114.79 143.87 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.961 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.779 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.12 167.36 17.98 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.985 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.779 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.34 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.349 3.366 . . . . 0.0 109.579 179.89 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.0 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -122.06 13.96 10.58 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.99 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.867 ' HA ' ' O ' ' A' ' 111' ' ' SER . 53.3 p -98.95 114.61 27.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.877 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.72 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.03 1.59 41.95 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.0 HD21 ' CA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -114.39 142.01 46.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.972 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.9 m -104.98 -170.26 1.73 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.952 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.772 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 2.3 t0 -42.88 153.54 0.08 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.73 -24.63 31.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.972 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -96.21 148.81 22.33 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 68' ' ' THR . 0.0 OUTLIER -123.05 146.32 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.996 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.736 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.3 OUTLIER -110.87 119.94 60.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.96 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.903 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -78.55 127.43 32.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.734 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.2 OUTLIER -113.17 114.63 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.983 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' CA ' ' A' ' 5' ' ' ALA . . . -127.17 123.49 36.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.98 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.033 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.59 153.48 22.63 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.957 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.999 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.6 108.18 3.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.14 17.35 27.54 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.991 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.116 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.47 176.45 6.9 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.969 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 23.2 mt-30 -58.54 121.71 11.61 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.3 131.21 42.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.995 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.86 7.58 83.9 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.5 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -93.13 141.04 28.85 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.475 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.69 151.16 24.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.971 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.63 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 29.8 m-85 -138.54 134.86 34.43 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.884 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.169 ' CB ' ' O ' ' A' ' 98' ' ' SER . 8.3 m-20 -100.29 113.54 26.32 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.94 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.305 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.19 143.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.723 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -164.96 164.45 37.06 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.96 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.902 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 10.9 tt0 -110.87 117.08 32.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.931 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.499 ' HB3' HD13 ' A' ' 45' ' ' LEU . 98.5 m -108.01 166.31 10.82 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.978 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.754 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -151.98 135.14 15.83 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.933 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.471 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.75 129.94 41.65 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.955 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.684 HG23 ' CG2' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -108.93 -39.01 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.053 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -150.4 155.8 40.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.986 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -51.51 112.9 0.83 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.99 9.86 84.74 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.98 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.622 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -139.04 130.05 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.605 ' HA ' HG22 ' A' ' 40' ' ' VAL . 1.9 pp -132.18 163.85 27.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.321 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -125.48 153.8 43.01 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.973 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.853 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 15.1 m -115.92 153.2 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.833 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 39.6 t30 -111.02 107.05 57.74 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 85.3 Cg_endo -72.3 -1.21 9.8 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.34 3.36 . . . . 0.0 109.631 179.849 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.15 -8.8 50.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.854 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -130.06 27.78 5.1 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.447 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.07 110.94 17.07 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.982 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.28 174.06 6.04 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.924 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 72.7 p -145.14 154.67 42.69 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 4.8 p -166.53 155.62 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.4 m -128.05 136.67 51.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -77.38 135.4 38.33 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.1 p30 -77.8 -173.18 2.94 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.893 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.17 -27.93 69.31 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.871 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -74.53 -6.94 51.3 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.992 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.116 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.99 32.23 56.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 93.4 p -128.48 141.11 51.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.982 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.11 164.8 23.62 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.997 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.06 134.29 19.44 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.763 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -155.13 176.99 11.84 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.763 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -133.41 117.66 17.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.95 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.332 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.48 156.1 16.48 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' HG12 ' A' ' 18' ' ' VAL . 0.5 OUTLIER -111.53 128.38 56.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.526 HG21 ' OG ' ' A' ' 10' ' ' SER . 1.2 t -97.13 123.11 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.772 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -115.05 144.48 43.57 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.445 ' HG3' ' N ' ' A' ' 72' ' ' SER . 15.4 ptt85 -65.85 -32.18 73.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.445 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 16.4 p -155.65 158.06 37.7 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.902 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.7 p90 -176.79 155.24 1.25 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -53.71 108.87 0.39 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.321 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -67.05 94.54 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.99 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.853 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -82.53 98.89 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.938 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.4 tp -54.66 144.81 20.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.763 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.2 -43.53 21.59 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.97 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.587 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -58.46 -16.7 16.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.7 28.1 11.78 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.938 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -106.97 120.68 42.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.414 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -64.25 91.42 0.07 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.622 ' CH2' HG21 ' A' ' 44' ' ' VAL . 3.9 t-105 -62.68 -58.52 7.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.915 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.78 163.39 12.92 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.36 104.59 0.18 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.754 HG11 ' HB3' ' A' ' 38' ' ' ALA . 12.6 p -79.2 151.67 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -105.71 95.01 5.51 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.155 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.94 -22.14 14.03 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.942 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 49.1 p -88.97 2.1 54.45 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.962 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.6 m -110.11 -24.92 10.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -137.93 174.9 10.08 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.979 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.79 127.27 35.61 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.951 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.393 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -104.56 163.86 12.17 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.984 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.019 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -151.42 142.27 22.91 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.917 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.332 ' CG1' HD13 ' A' ' 67' ' ' LEU . 16.5 t -97.92 164.6 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 180.0 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.305 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.33 163.84 32.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.976 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.08 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.62 131.63 49.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.993 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.169 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 42.5 m -112.28 141.02 46.49 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.52 -164.14 1.02 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.04 -49.03 71.75 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.946 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.2 65.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.937 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.28 1.98 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.941 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.4 177.08 7.76 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.19 174.25 46.59 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.989 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.535 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.4 170.44 19.27 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.304 3.336 . . . . 0.0 109.623 179.944 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.341 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.7 pt-20 -41.2 126.69 2.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.963 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.6 160.82 0.01 OUTLIER Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.011 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.3 t -120.9 103.11 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.969 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.98 133.81 34.67 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.955 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.048 HD11 ' HB2' ' A' ' 93' ' ' CYS . 31.8 pt -136.93 -169.93 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.916 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.867 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -178.28 158.74 1.18 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.393 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.3 m-85 -111.37 119.19 38.0 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.932 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.72 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.8 p30 . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.955 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.568 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.439 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.4 -178.15 3.15 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.331 3.354 . . . . 0.0 109.603 179.904 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.861 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.2 m -101.14 110.7 22.75 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.65 142.11 51.67 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.914 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.98 116.07 31.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.96 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.804 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.7 OUTLIER -114.69 149.76 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.963 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.677 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.24 165.35 40.04 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.677 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.42 119.62 6.24 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.333 3.356 . . . . 0.0 109.579 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.051 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.7 OUTLIER -123.87 16.16 9.36 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 1.272 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.6 p -105.3 113.79 27.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.885 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.001 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.86 6.78 37.08 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.112 HD22 HG21 ' A' ' 17' ' ' THR . 0.4 OUTLIER -114.52 136.72 52.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.5 m -81.12 171.21 15.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.925 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.447 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 3.3 p-10 -45.24 154.31 0.17 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.979 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.87 -24.01 33.84 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.985 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 1.112 HG21 HD22 ' A' ' 13' ' ' LEU . 94.3 m -68.37 131.88 46.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.981 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.4 p -102.08 119.32 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -99.17 161.14 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.804 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -119.74 148.7 43.09 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.997 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.7 107.18 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.994 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -117.21 116.42 27.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.66 146.73 23.58 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.992 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.861 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.83 110.01 4.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.938 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.5 15.75 31.27 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.974 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.0 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.19 172.16 9.0 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.993 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 24.0 mt-30 -54.34 120.36 6.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.964 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.11 131.27 41.87 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.967 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 6.88 84.59 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.999 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.508 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -93.02 144.2 25.49 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -86.1 151.38 23.73 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.519 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.8 m-85 -138.66 144.4 39.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.199 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -112.51 113.11 25.12 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.935 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.228 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -98.96 152.04 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.927 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -178.57 159.71 25.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.979 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 1.028 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 12.4 tt0 -98.77 118.55 35.76 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.942 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.415 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.8 m -108.28 165.55 11.42 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.982 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 86' ' ' VAL . . . -151.71 122.66 7.58 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.632 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.68 122.09 16.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.823 HG21 ' CD1' ' A' ' 83' ' ' TRP . 16.7 m -101.32 -44.58 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.973 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.521 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -135.64 168.06 19.97 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.966 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.68 HG23 ' O ' ' A' ' 42' ' ' THR . 3.9 t -54.04 112.97 1.06 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.986 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.66 8.56 63.62 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.984 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.454 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.7 t -120.86 109.07 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.5 pp -119.83 162.36 19.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.4 151.91 49.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.936 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.012 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -117.38 157.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 17.6 t30 -116.24 112.95 41.49 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -72.35 -0.51 8.79 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.31 3.34 . . . . 0.0 109.61 179.884 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -12.72 36.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.849 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.466 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 16.5 p30 -132.94 27.01 4.27 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.928 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.646 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.11 117.35 32.29 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.993 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.9 t -106.61 177.91 4.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.962 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.4 p -146.5 151.49 37.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.532 HG22 ' N ' ' A' ' 56' ' ' THR . 4.6 p -166.77 162.58 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.943 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.532 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.5 m -127.8 134.82 49.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.951 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.99 143.4 50.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.949 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 42.9 p30 -81.74 -172.73 4.04 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.95 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.1 -25.54 68.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.904 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.68 -7.26 53.88 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.891 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.13 31.07 60.04 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.0 p -127.13 143.8 51.18 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.971 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.01 166.36 21.18 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.983 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -147.5 125.78 12.27 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.95 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.725 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.24 173.04 12.92 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.938 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.725 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -131.13 111.22 11.78 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.944 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.497 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.12 156.55 16.33 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.685 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -119.2 139.97 50.97 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.924 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.648 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.57 133.37 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -119.83 162.19 19.54 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.447 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 5.8 ptt180 -82.56 -18.14 42.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 p -165.12 151.22 9.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.922 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 1.028 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.1 p90 -175.99 154.94 1.53 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.897 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.45 124.81 14.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.989 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.03 92.11 1.62 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 1.012 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.52 100.51 11.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.974 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.902 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -58.15 140.96 51.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.967 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.726 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.28 -42.01 19.95 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.935 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.72 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -57.41 -16.66 9.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.965 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 28.43 10.43 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.902 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -108.73 128.09 54.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.67 91.59 1.12 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.454 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.14 -58.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.869 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.06 167.59 16.39 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.975 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -59.36 115.16 3.06 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 38' ' ' ALA . 59.9 t -88.29 146.57 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 180.0 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.82 91.67 4.26 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.949 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.759 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -52.52 -22.63 5.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.997 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.91 2.6 48.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.981 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 m -115.82 -27.81 6.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.961 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.47 169.39 16.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.91 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.92 126.02 35.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.938 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.438 ' HB2' HD11 ' A' ' 110' ' ' ILE . 12.4 m -104.14 159.77 15.41 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 -179.923 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -145.45 143.1 29.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.969 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.497 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.7 t -97.34 157.73 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.228 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.55 171.05 43.27 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.997 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.18 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.33 151.31 51.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.199 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 82.8 p -127.96 151.41 49.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.5 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -112.77 -163.46 0.85 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.96 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.43 -48.6 69.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.935 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.24 65.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.952 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.8 53.39 1.8 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.998 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.424 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.11 168.36 18.11 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 179.971 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.519 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.85 178.95 42.51 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.933 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.439 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.36 161.98 42.82 Favored 'Trans proline' 0 N--CA 1.447 -1.24 0 C-N-CA 124.34 3.36 . . . . 0.0 109.627 179.966 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.568 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -40.61 123.72 1.9 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.972 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.54 151.82 0.02 OUTLIER Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.991 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.2 t -119.21 104.24 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.66 138.71 36.4 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.982 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.042 HG12 ' HA ' ' A' ' 94' ' ' GLN . 25.8 pt -137.75 -172.34 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 1.272 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -179.23 163.69 1.31 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.942 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.759 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 2.3 m-85 -117.76 116.81 27.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.937 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.001 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 46.4 m-80 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.973 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.425 ' C ' ' H ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.508 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.3 Cg_endo -72.39 -174.61 1.48 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.322 3.348 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.229 HG22 ' O ' ' A' ' 24' ' ' ALA . 4.1 t -97.99 110.68 23.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.964 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.84 146.92 50.46 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.953 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.473 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -109.26 112.44 24.59 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.794 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -109.07 145.38 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.993 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.782 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.28 168.65 12.85 Favored Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.782 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.39 117.14 4.99 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.296 3.331 . . . . 0.0 109.571 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.591 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -127.05 17.18 7.25 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.975 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 39.2 p -94.6 112.72 24.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.9 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.121 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 87.98 28.75 22.49 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.942 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.121 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.18 137.33 46.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.976 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.4 t -76.2 150.24 37.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.964 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 2.3 p30 -44.43 153.02 0.17 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.5 -24.72 30.85 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.437 HG21 HD12 ' A' ' 13' ' ' LEU . 17.7 m -63.69 150.29 44.71 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.982 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 18' ' ' VAL . 14.7 p -112.46 121.8 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.617 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 2.2 p -97.42 153.52 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.996 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.794 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -107.28 150.45 26.66 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.973 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.741 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -148.63 107.64 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.998 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.964 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.05 114.96 23.33 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.988 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.825 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.2 139.95 17.98 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.952 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.229 ' O ' HG22 ' A' ' 4' ' ' THR . . . -135.89 110.22 8.44 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.922 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.898 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.29 21.19 10.17 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.966 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.508 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.4 -168.39 2.19 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.838 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -79.59 121.66 25.54 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.962 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.507 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.61 135.9 47.15 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.97 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.38 6.71 58.78 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.958 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.585 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.92 138.87 33.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.968 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -86.29 150.72 24.15 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.919 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.496 ' HB3' ' CD2' ' A' ' 97' ' ' LEU . 39.2 m-85 -136.44 155.79 49.52 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.409 ' O ' ' CA ' ' A' ' 97' ' ' LEU . 2.6 m-20 -121.89 114.18 20.67 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.253 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -95.02 144.7 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.983 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.022 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.07 166.92 34.76 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.954 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.696 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -121.63 106.98 11.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.767 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.3 m -105.21 172.78 6.61 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.961 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.966 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -146.37 127.34 14.55 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.932 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.77 117.83 8.07 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.92 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.591 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 3.6 m -98.22 -42.92 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.972 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -135.67 177.31 7.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.995 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 t -60.36 111.76 1.68 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.99 8.17 63.85 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.565 HG12 ' CD1' ' A' ' 83' ' ' TRP . 22.0 t -120.73 113.31 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.674 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -128.51 140.61 51.72 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.991 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.34 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.93 138.65 34.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.956 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.77 ' O ' ' HB3' ' A' ' 76' ' ' PHE . 82.1 m -106.37 140.62 39.0 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.971 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.62 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.8 t30 -100.31 111.49 62.58 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.442 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.1 Cg_endo -72.39 0.28 7.67 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -86.56 -14.94 41.45 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.854 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.52 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.9 p30 -123.21 29.69 6.61 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.442 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -82.66 106.02 14.17 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.987 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.6 m -100.32 179.02 4.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.5 p -145.71 158.52 43.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.915 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.747 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.2 p -169.11 156.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.973 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.425 ' N ' HG22 ' A' ' 55' ' ' VAL . 7.0 m -127.97 137.63 52.32 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -80.69 139.73 35.99 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.984 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.2 p30 -82.86 -165.85 1.17 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.927 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.89 -28.67 69.07 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.3 m-20 -83.1 6.35 19.4 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.986 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.93 22.04 59.63 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -109.21 130.92 55.48 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.747 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.41 167.31 12.94 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.84 131.61 16.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.905 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.628 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -158.79 157.71 32.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.447 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -116.5 125.66 52.25 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.19 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -97.53 155.95 16.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.919 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.523 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -97.36 123.11 41.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.961 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.549 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -77.49 129.36 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.999 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.711 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -123.58 147.26 47.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.931 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -92.71 -20.2 21.04 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.994 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 53.4 p -172.99 153.18 2.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.922 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.711 ' CE2' ' HB2' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -178.02 179.08 0.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.949 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -68.56 117.83 10.8 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.34 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.6 89.13 1.23 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.956 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.77 ' HB3' ' O ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -83.47 103.33 12.73 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -58.34 130.99 49.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.86 -35.36 10.23 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.618 ' CB ' HD21 ' A' ' 77' ' ' LEU . 5.4 t0 -57.26 -17.28 11.02 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.24 28.39 8.14 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.939 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.1 m -117.74 145.86 44.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.31 97.21 8.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.591 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 21.9 t90 -64.25 -57.65 8.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.879 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.98 160.27 8.6 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.61 105.18 0.14 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.977 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.966 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -82.35 154.03 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -120.13 96.78 5.3 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.998 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.105 ' HB3' ' CD1' ' A' ' 112' ' ' PHE . 24.9 m -52.76 -25.6 11.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.9 p -79.68 1.45 26.34 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.32 -177.08 4.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.77 126.67 47.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.239 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 18.6 m -104.43 164.14 11.95 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.964 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.216 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -154.79 149.57 26.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.973 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.19 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.8 t -104.05 165.85 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.253 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 170.63 43.78 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.94 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.496 ' CD2' ' HB3' ' A' ' 32' ' ' TYR . 4.8 mp -99.81 162.87 12.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.168 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -152.48 109.99 3.59 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.896 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.594 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 1.7 p-10 -104.75 -157.96 0.64 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.28 -43.94 64.71 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.981 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.45 -26.01 26.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.937 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.95 52.86 2.33 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.959 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.594 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -109.17 -174.32 2.48 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -179.99 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 172.57 179.24 43.24 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.993 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.475 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.36 160.29 47.32 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.366 3.377 . . . . 0.0 109.567 179.91 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -32.96 128.51 0.26 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.479 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.0 130.94 0.29 Allowed Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.216 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 41.6 t -99.29 101.55 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -80.04 140.47 36.52 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.938 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.1 pt -147.06 -172.23 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.569 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.4 OUTLIER -173.82 176.17 2.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.948 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.105 ' CD1' ' HB3' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -150.64 105.77 3.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.074 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.7 p30 . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.522 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.8 Cg_endo -72.39 -175.63 1.87 Allowed 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.275 3.317 . . . . 0.0 109.637 179.934 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.971 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.47 109.15 21.95 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.782 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.58 137.75 54.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.685 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -106.11 112.57 25.66 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.981 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.611 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -106.39 155.98 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.988 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.987 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.08 177.29 0.91 Allowed Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.923 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.157 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.4 117.22 5.03 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.311 3.34 . . . . 0.0 109.573 179.909 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.783 ' HB2' HG23 ' A' ' 110' ' ' ILE . 13.4 p -112.73 44.69 1.44 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -124.73 106.3 9.97 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.885 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.943 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 88.39 31.9 12.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.969 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.157 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.58 133.0 42.72 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 55.7 m -96.71 162.87 13.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -49.83 146.37 4.58 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.994 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.92 -22.51 35.81 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.965 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.441 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.9 m -63.3 147.62 50.56 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.983 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.545 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.5 p -112.2 122.7 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.556 ' HA ' HG21 ' A' ' 8' ' ' THR . 3.6 m -96.93 161.24 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.611 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 151.16 32.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.975 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.719 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -150.11 109.96 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.959 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.782 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.14 116.49 22.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.999 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.665 ' HA2' ' HA ' ' A' ' 5' ' ' ALA . . . -94.29 141.1 15.37 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.959 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.971 ' O ' HG22 ' A' ' 4' ' ' THR . . . -133.12 118.0 18.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.887 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.87 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.31 24.37 9.61 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.345 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.32 -173.67 4.49 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.972 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.869 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -80.67 120.76 25.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.993 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.78 136.74 57.24 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.955 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.25 7.95 58.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.991 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.692 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -85.6 148.22 26.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 1.028 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -100.81 134.68 43.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.047 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 37.4 m-85 -127.29 147.59 50.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.104 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.8 m-20 -116.86 114.05 23.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.997 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.268 ' HA ' ' C ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -96.61 152.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.965 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.108 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -177.66 164.98 34.37 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.963 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.804 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 1.7 tt0 -112.34 118.38 35.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.937 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.562 ' HB3' HD13 ' A' ' 45' ' ' LEU . 90.8 m -108.23 173.5 6.29 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.983 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -152.62 123.97 7.67 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.917 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.617 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.57 124.0 21.18 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.907 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.12 HG21 ' CD2' ' A' ' 83' ' ' TRP . 15.2 m -103.93 -43.85 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.528 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -142.93 169.61 17.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 19.5 m -56.74 113.43 1.64 Allowed 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.952 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.78 4.83 62.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.997 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.644 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 15.5 t -122.19 105.07 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.975 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.641 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -117.3 162.73 17.43 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.546 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -122.54 140.7 52.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.681 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 23.4 m -109.3 150.8 27.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 1.057 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -108.41 105.75 57.32 Favored Pre-proline 0 N--CA 1.45 -0.453 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.988 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.471 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.0 Cg_endo -72.4 -1.23 9.89 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.309 3.339 . . . . 0.0 109.638 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.41 -12.97 33.22 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.888 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CB ' HG23 ' A' ' 68' ' ' THR . 29.6 p30 -127.27 18.77 6.99 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.46 ' CD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -83.5 103.51 12.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.981 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.1 t -93.43 177.57 5.99 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.905 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.3 p -147.04 155.24 42.06 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.42 HG22 ' N ' ' A' ' 56' ' ' THR . 7.6 p -167.36 155.97 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.971 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.42 ' N ' HG22 ' A' ' 55' ' ' VAL . 73.5 m -122.87 130.32 52.72 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.948 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 125.28 24.52 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.915 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -71.39 -170.37 0.5 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 -23.67 66.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -85.38 6.97 24.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.985 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 61.15 14.08 38.04 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.99 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.3 t -102.52 131.83 48.98 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.942 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.81 124.0 38.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.97 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.7 p -110.78 134.05 52.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.988 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.554 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.39 152.6 24.13 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.897 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.17 131.29 55.92 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.956 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.555 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.93 157.46 17.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.447 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 4.6 t -105.18 127.51 52.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.649 ' C ' ' HD2' ' A' ' 70' ' ' ARG . 1.7 t -84.34 126.23 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.66 ' HB2' ' OE1' ' A' ' 36' ' ' GLN . 1.2 mpt_? -119.76 145.9 46.15 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HD3' ' N ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -89.83 -8.07 52.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.938 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 90.3 p -178.02 149.96 0.59 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 1.057 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 3.8 p90 -176.77 154.58 1.19 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.921 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -49.55 114.37 1.03 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.546 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.89 92.76 0.55 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.681 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -83.81 99.34 10.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.953 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.6 tp -59.09 129.03 40.17 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.622 ' N ' HD12 ' A' ' 77' ' ' LEU . 32.4 p90 -47.56 -34.7 8.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.939 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.576 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.7 -16.72 11.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.982 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.08 28.11 8.91 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.4 m -116.93 150.88 37.79 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.933 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -87.04 97.67 10.85 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.902 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.644 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 76.7 t-105 -65.28 -56.41 12.88 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.76 166.46 11.6 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.991 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.19 108.14 0.38 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.944 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.183 HG11 ' CB ' ' A' ' 38' ' ' ALA . 69.3 t -82.25 147.85 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.971 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -114.46 93.7 4.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.949 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.499 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.0 m -52.74 -26.04 12.94 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 71' ' ' ARG . 78.7 p -80.19 0.14 33.7 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.54 -27.48 6.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.77 -177.98 4.6 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.967 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.21 124.45 46.92 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.908 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.934 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 60.5 m -103.6 153.61 20.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.996 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -142.85 145.12 32.84 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.964 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.555 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.2 t -102.73 160.33 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.268 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.63 166.72 37.25 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.097 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.64 128.59 37.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.974 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.104 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.8 m -115.36 160.97 19.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.936 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 1.028 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -115.45 -157.44 0.64 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.982 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.11 -47.84 81.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.39 -25.78 59.7 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.874 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.64 50.11 1.87 Allowed Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.976 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.521 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -119.46 158.32 26.48 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 1.047 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.48 176.35 43.46 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.988 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.522 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 171.04 17.79 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.317 3.345 . . . . 0.0 109.616 179.922 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.513 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 2.0 mt-10 -40.71 133.68 1.99 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.06 155.97 0.74 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.947 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 93.1 t -122.74 105.18 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.981 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -87.16 138.4 31.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.962 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.996 ' CG1' ' HA ' ' A' ' 94' ' ' GLN . 2.3 mt -117.68 157.94 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.984 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 10' ' ' SER . 3.1 t -149.34 127.82 12.29 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.894 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 -100.64 127.92 46.87 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.937 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.489 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.627 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.42 -174.48 1.45 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.304 3.336 . . . . 0.0 109.614 179.949 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.351 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.5 t -98.72 111.7 23.99 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.987 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.643 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.42 152.31 47.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.972 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -109.8 113.32 25.98 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 20' ' ' LYS . 40.3 t -110.47 147.28 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.942 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.949 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.77 175.47 1.68 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.952 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.058 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.4 Cg_endo -72.36 116.59 4.77 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 124.346 3.364 . . . . 0.0 109.617 179.902 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.638 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 6.5 p -111.12 43.71 1.42 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.937 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.0 p -124.28 105.16 9.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.892 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.189 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.02 30.51 8.27 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.189 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.4 OUTLIER -110.93 129.72 55.8 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -112.88 177.01 4.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -44.67 138.66 3.28 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.984 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.01 -23.1 31.7 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.938 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.632 HG21 ' HB3' ' A' ' 13' ' ' LEU . 30.5 m -88.67 152.15 22.0 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.971 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 p -129.33 134.22 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.994 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.715 HG22 ' O ' ' A' ' 67' ' ' LEU . 17.9 m -95.27 166.13 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.989 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.862 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.57 143.64 44.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -139.32 104.52 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.919 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.643 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.1 115.29 23.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.934 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.742 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.03 143.93 22.42 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.949 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.351 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -139.83 107.21 5.53 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.853 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 20.02 11.33 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.945 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.306 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.87 -172.29 3.64 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.975 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.587 HE22 ' CG ' ' A' ' 103' ' ' ASN . 31.0 mt-30 -71.87 121.47 19.08 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.932 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.977 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.14 133.67 44.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.0 8.48 73.78 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.989 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.521 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.11 138.25 33.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.955 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.8 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.58 151.58 24.43 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.961 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.7 m-85 -137.63 149.68 46.81 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.927 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.175 ' CB ' ' H ' ' A' ' 98' ' ' SER . 3.7 m-20 -113.25 114.18 26.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.991 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.296 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -100.42 145.32 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.131 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.01 169.37 41.34 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.925 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.695 HE22 ' H ' ' A' ' 70' ' ' ARG . 40.8 tt0 -113.74 106.07 14.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -108.4 146.27 33.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.95 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.711 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -125.97 137.87 53.71 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.629 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.4 119.67 11.42 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.965 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.351 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.6 m -100.56 -42.81 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -132.65 165.07 25.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.985 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 44' ' ' VAL . 32.4 m -51.2 111.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.907 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.03 69.06 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.953 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.519 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 10.7 t -122.01 117.96 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.667 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -129.15 138.24 51.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.984 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.43 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -101.44 152.11 21.13 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.951 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.0 m -106.79 148.57 28.32 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.994 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.948 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -111.37 117.13 49.95 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.974 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.6 Cg_endo -72.44 1.06 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.287 3.325 . . . . 0.0 109.621 179.908 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.786 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -82.51 -20.51 36.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.898 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.784 ' CB ' HG23 ' A' ' 68' ' ' THR . 98.3 m-20 -129.72 30.97 4.82 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.913 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.703 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.58 117.52 30.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.1 t -116.26 -178.96 3.53 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.946 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.6 p -146.46 154.52 41.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.874 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.476 HG22 ' N ' ' A' ' 56' ' ' THR . 5.3 p -166.18 158.9 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.998 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.6 m -127.11 133.16 50.44 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.952 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.26 153.59 42.14 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.975 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -89.63 -171.84 3.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.926 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.0 67.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.911 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.05 -16.83 61.03 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.961 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 88.24 6.35 74.84 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.975 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.01 140.03 32.95 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.941 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.61 163.32 17.52 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.976 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.15 122.92 9.27 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.549 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -157.8 162.73 38.46 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.524 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -118.37 129.85 55.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.912 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -106.77 124.45 49.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.913 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.784 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.6 141.43 41.08 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.962 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.487 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -102.67 131.65 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.994 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.695 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -119.13 157.3 28.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 -87.08 -20.66 26.81 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.8 t -168.77 151.71 5.18 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.9 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.948 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 1.7 p90 -173.7 159.54 3.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.94 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -61.01 114.96 3.37 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.943 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.43 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -73.43 94.6 0.74 Allowed Glycine 0 C--N 1.336 0.558 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 180.0 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.821 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -82.12 99.37 9.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.955 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.61 132.58 45.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.982 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.655 ' N ' HD12 ' A' ' 77' ' ' LEU . 5.9 m-85 -46.59 -37.29 7.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.953 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.8 t0 -56.98 -16.96 7.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.99 27.59 9.34 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.955 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -113.55 140.9 47.77 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.37 95.9 7.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.351 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 38.1 t-105 -63.0 -57.8 9.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.912 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.04 172.9 19.24 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.959 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.47 109.69 2.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.958 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.711 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.3 p -90.72 142.13 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -98.21 99.48 10.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.983 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.36 -22.32 7.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.0 p -87.31 1.58 52.83 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.922 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -112.83 -26.37 8.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.01 -178.94 5.26 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.954 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.04 128.35 42.86 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.303 ' O ' HG13 ' A' ' 110' ' ' ILE . 34.0 m -104.74 155.06 19.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.951 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -147.58 145.61 29.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.984 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.3 t -109.2 156.76 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.981 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.296 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -174.5 172.38 45.35 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.057 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -129.62 128.72 43.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.175 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 36.5 m -118.26 140.07 50.36 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.917 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.8 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 4.4 p-10 -111.81 -162.71 0.81 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.996 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.08 79.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.781 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -66.48 -24.37 66.41 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.926 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 83.02 35.29 18.86 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.957 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.781 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.3 OUTLIER -108.45 -173.7 2.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.943 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.809 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 167.84 164.75 24.07 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.627 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.39 162.81 40.46 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.242 3.295 . . . . 0.0 109.576 179.954 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.489 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.9 OUTLIER -36.05 126.58 0.74 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -41.78 147.97 0.44 Allowed Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.783 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.0 t -122.15 106.74 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -91.36 150.48 21.26 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.954 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.303 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -118.45 161.87 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.944 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.534 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -145.22 111.78 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.954 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 113' ' ' ASN . 6.9 m-85 -87.93 101.91 14.2 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.924 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.584 ' CG ' ' O ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.938 -0.394 . . . . 0.0 109.938 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.383 ' CB ' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.503 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 . . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.198 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.1 Cg_endo -72.38 -175.21 1.69 Allowed 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 124.272 3.314 . . . . 0.0 109.632 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.921 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.71 109.89 21.96 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.946 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.5 137.64 54.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.995 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.582 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -99.08 114.07 26.6 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.97 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.84 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.2 m -108.09 153.72 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.997 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.967 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.59 176.56 1.21 Allowed Pre-proline 0 N--CA 1.449 -0.476 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.077 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.38 117.79 5.3 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 124.352 3.368 . . . . 0.0 109.553 179.925 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 111' ' ' SER . 1.9 p -114.69 45.7 1.52 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.7 p -123.75 105.39 9.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.87 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.029 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.63 29.84 11.45 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.948 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.077 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.43 132.22 47.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.948 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 51.1 m -104.7 166.56 10.31 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.9 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -44.98 140.04 2.84 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.998 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.47 35.71 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.976 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 28.3 m -76.53 148.83 36.86 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.986 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.8 p -122.38 127.22 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 69' ' ' VAL . 16.1 m -93.76 170.31 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.84 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.62 148.3 41.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.999 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.724 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -143.75 108.18 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.997 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.859 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.83 115.13 21.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.81 143.13 19.67 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.958 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.921 ' O ' HG22 ' A' ' 4' ' ' THR . . . -137.6 111.97 8.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.949 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.932 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 102.77 24.59 8.06 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -91.12 -163.96 1.11 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.993 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.417 ' O ' ' HB ' ' A' ' 30' ' ' THR . 34.4 mt-30 -88.27 127.12 35.46 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.18 133.77 42.75 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.78 8.68 82.33 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.973 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.678 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -96.89 137.64 35.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.939 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.661 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.94 152.33 22.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.034 ' CD1' ' HD2' ' A' ' 105' ' ' PRO . 45.3 m-85 -139.29 149.34 44.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.91 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.105 ' CB ' ' H ' ' A' ' 98' ' ' SER . 14.7 m-20 -112.21 115.03 28.15 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.189 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.34 146.06 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.999 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.889 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.56 170.79 42.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.885 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.1 tt0 -117.46 122.99 45.27 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.92 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m -125.85 148.31 49.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.124 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 134.88 54.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.89 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.659 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.0 OUTLIER -65.31 123.5 19.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.909 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.17 HG21 ' CD2' ' A' ' 83' ' ' TRP . 32.3 m -103.84 -42.0 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.976 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.17 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -132.01 -178.67 5.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.963 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 33.1 m -69.67 113.45 6.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.948 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.91 10.01 80.17 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.641 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.23 125.48 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.964 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.736 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.5 pt? -133.62 140.92 47.39 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.959 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.72 144.15 25.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 23.2 m -105.51 159.89 15.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.741 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 21.8 t30 -118.67 111.57 37.64 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.989 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.44 0.55 7.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.307 3.338 . . . . 0.0 109.591 179.881 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -11.98 41.77 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.911 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.504 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.2 p30 -129.49 27.59 5.27 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.34 107.09 16.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.4 t -105.02 174.96 5.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.91 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.5 p -146.67 158.36 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.881 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.468 HG22 ' N ' ' A' ' 56' ' ' THR . 7.3 p -167.82 158.52 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.935 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.468 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.0 m -128.13 125.06 38.4 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.93 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.51 152.89 13.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -180.0 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.7 p30 -95.28 -169.47 1.98 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.951 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.65 -24.87 67.84 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.913 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -81.04 -7.26 59.52 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.973 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.43 13.28 83.55 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.978 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.8 p -105.02 139.69 39.32 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.867 -0.419 . . . . 0.0 109.867 179.951 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.54 162.27 20.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.972 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 p -150.14 122.19 8.26 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.921 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.539 HG22 HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -151.24 153.25 34.52 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.903 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -107.95 120.69 43.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.946 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.523 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -99.69 156.02 17.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.547 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -111.71 128.16 56.0 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -100.23 129.64 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.966 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.885 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -113.68 155.52 25.4 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.961 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.402 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 ppt_? -89.72 -12.77 38.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.544 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -166.06 142.39 5.06 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.92 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.741 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 10.8 p90 -178.0 158.05 1.2 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.895 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.19 124.9 21.69 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.911 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.513 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.18 103.97 2.54 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.915 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.726 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.57 102.03 12.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.958 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -56.61 131.6 49.34 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.968 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.659 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.2 p90 -47.44 -36.6 10.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.563 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.39 -16.48 9.24 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.953 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.41 27.57 9.8 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.958 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.4 m -115.11 150.3 36.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.971 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.4 mtm180 -85.36 98.0 10.3 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.956 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.641 ' CH2' HG21 ' A' ' 44' ' ' VAL . 22.8 t-105 -63.92 -51.33 64.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 179.896 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 139.03 179.73 17.69 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.969 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.86 134.26 56.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.927 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.124 HG11 ' HB3' ' A' ' 38' ' ' ALA . 6.5 t -114.62 150.08 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.2 94.43 4.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.926 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -53.37 -25.31 14.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 180.0 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.4 p -83.92 2.14 40.09 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.95 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -114.44 -27.85 7.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.942 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.33 179.88 5.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.937 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 126.32 41.93 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.907 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.327 ' C ' HG13 ' A' ' 110' ' ' ILE . 9.0 m -104.39 153.98 20.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.961 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.058 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -149.62 148.23 29.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.95 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.523 ' CG1' HD13 ' A' ' 67' ' ' LEU . 17.9 t -96.76 163.55 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.96 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.189 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.41 158.34 27.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.009 HD21 ' CG ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -141.53 137.61 32.14 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.972 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.105 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -129.13 153.48 47.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.912 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.661 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -98.11 -166.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.996 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -59.28 -49.99 75.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.978 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.49 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -69.29 -24.82 64.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.926 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.415 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 100.65 41.71 2.65 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.49 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -121.4 178.03 4.96 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.27 -176.0 20.81 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.98 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.04 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.46 134.03 21.8 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.298 3.332 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.383 ' O ' ' CB ' ' A' ' 2' ' ' ALA . 0.5 OUTLIER -136.04 144.3 45.17 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.992 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.39 59.46 0.19 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.979 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.99 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 36.4 t -133.54 100.74 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.617 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.37 153.75 18.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.969 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.327 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -121.91 161.36 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -148.65 117.05 6.51 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.961 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.039 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 45.3 m-85 -94.72 128.12 41.19 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.931 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.964 . . . . . . . . 0 0 . 1 . 042 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.847 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.938 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.38 -177.35 2.67 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.331 3.354 . . . . 0.0 109.59 179.906 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.812 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.31 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.96 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.746 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.28 144.57 49.33 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.988 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.773 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -111.33 108.41 18.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.754 ' CG2' HG23 ' A' ' 21' ' ' VAL . 1.7 t -99.64 151.05 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.983 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -66.7 177.82 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.979 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.048 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.4 Cg_endo -72.4 115.82 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.304 3.336 . . . . 0.0 109.628 179.89 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.588 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 30.0 p -118.32 38.84 3.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.968 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 111' ' ' SER . 11.5 p -117.86 104.78 11.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.901 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.996 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.22 26.58 12.07 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.961 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.048 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -98.2 129.76 44.95 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.958 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -91.87 161.9 14.65 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -45.33 142.03 2.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.957 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.24 33.14 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.988 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD13 ' A' ' 13' ' ' LEU . 34.4 m -76.48 150.71 36.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.99 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.8 124.41 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.995 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.547 HG11 ' CB ' ' A' ' 10' ' ' SER . 18.5 m -96.15 133.95 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.991 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.662 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -79.2 154.47 29.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.801 HG13 ' O ' ' A' ' 21' ' ' VAL . 4.2 p -140.95 103.13 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.773 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -109.51 121.33 44.96 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.94 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.741 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -101.7 139.62 14.49 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.812 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -134.37 127.07 30.91 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.992 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.03 24.18 23.24 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.001 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -91.29 -167.24 1.75 Allowed 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.488 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.0 mt-30 -84.93 125.18 32.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.991 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.76 130.74 41.18 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.54 8.22 83.81 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.954 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.546 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -95.4 132.16 40.75 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.916 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -79.64 150.63 30.91 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.934 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.605 ' CB ' HD12 ' A' ' 97' ' ' LEU . 31.5 m-85 -137.9 148.77 45.63 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.909 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.194 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.9 m-20 -113.89 116.29 29.06 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.917 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.245 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.12 145.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.995 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.038 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.69 169.57 41.3 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.978 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.883 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 29.1 tt0 -111.22 120.72 43.22 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.945 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.549 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -110.33 162.7 14.38 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.953 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.172 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -150.81 125.16 9.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.959 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.9 125.86 26.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.988 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.81 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.6 m -111.69 -35.62 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.173 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.2 -178.55 5.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.967 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 79.0 m -77.19 111.83 13.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.28 10.51 85.94 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.668 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -128.78 114.84 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.551 HD23 ' C ' ' A' ' 38' ' ' ALA . 0.5 OUTLIER -108.14 162.85 13.68 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.986 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.39 127.38 40.89 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.944 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.733 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.95 154.25 21.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.728 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.9 t30 -116.29 113.96 40.95 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.972 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.34 -0.11 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.33 3.353 . . . . 0.0 109.598 179.891 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.55 -16.1 29.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.836 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.578 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.3 p30 -125.96 25.63 6.75 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.915 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -91.22 106.25 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.967 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.2 t -99.66 -179.88 4.33 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.916 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.4 p -146.84 157.34 43.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.901 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -166.69 160.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.914 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.508 ' N ' HG22 ' A' ' 55' ' ' VAL . 12.0 m -127.52 141.08 51.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.572 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -79.36 134.51 36.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.4 p30 -78.6 -171.84 2.68 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.933 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.26 -26.14 68.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.947 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -77.77 -3.97 44.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.001 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.53 31.26 70.87 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.999 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.6 p -123.14 133.7 54.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.963 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -139.22 124.57 19.17 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.983 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.97 143.04 46.72 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.949 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.48 166.23 33.35 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -105.79 124.61 49.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.029 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.82 118.59 35.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.981 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.641 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.1 t -80.88 132.34 35.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.938 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.555 HG23 ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -107.78 130.52 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.635 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.5 mpt_? -115.78 146.25 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.98 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.715 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.7 OUTLIER -70.86 -4.39 24.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.957 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 31.7 p -178.79 153.25 0.65 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.9 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.883 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 6.4 p90 -176.87 162.31 2.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.955 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -56.15 126.45 26.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.07 88.64 1.5 Allowed Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.933 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.733 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.87 100.85 11.25 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.996 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.3 tp -63.46 130.55 44.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.9 p90 -47.48 -36.04 9.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.986 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.539 ' H ' ' CD1' ' A' ' 77' ' ' LEU . 1.4 t70 -57.37 -16.63 9.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.994 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.0 27.36 9.51 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.994 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -113.61 144.99 41.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.87 94.24 9.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.966 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.668 ' CZ2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.41 -57.75 9.29 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.78 164.28 10.5 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.992 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -56.0 127.5 30.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.934 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.172 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.8 OUTLIER -107.79 154.95 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.993 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.56 108.7 16.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.957 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.84 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 35.1 m -54.25 -26.48 29.07 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.976 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.6 p -82.02 -0.97 46.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.965 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -116.4 -27.36 6.81 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.932 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.88 -178.31 4.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.69 124.24 40.62 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.15 ' C ' HG13 ' A' ' 110' ' ' ILE . 94.9 m -104.47 152.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.956 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.044 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -156.42 146.04 20.86 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.949 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.029 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 9.2 t -96.53 162.57 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.245 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 160.49 31.33 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.605 HD12 ' CB ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -138.84 141.8 38.65 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.972 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.194 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -134.02 157.8 45.17 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.929 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.916 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.89 -164.16 1.02 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.448 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.13 -49.68 76.13 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.426 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.8 -24.78 61.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.902 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.85 41.13 2.95 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.57 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -117.68 176.69 5.06 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.948 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.4 -175.75 20.76 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 179.975 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.985 ' HG2' HD21 ' A' ' 97' ' ' LEU . 83.2 Cg_endo -72.39 133.89 21.67 Favored 'Trans proline' 0 N--CA 1.447 -1.247 0 C-N-CA 124.338 3.359 . . . . 0.0 109.568 179.908 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.847 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 3.7 tt0 -137.26 147.49 45.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.96 58.11 0.23 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.946 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.025 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.4 t -130.88 101.38 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.41 143.36 28.94 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.15 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -110.79 169.27 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.92 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.451 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -161.4 127.64 3.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.943 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.84 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 11.2 m-85 -99.1 116.84 32.25 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.893 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.956 ' O ' ' HA2' ' A' ' 12' ' ' GLY . 3.4 p30 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.135 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.218 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.5 Cg_endo -72.41 -175.3 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.297 3.331 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.723 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -100.55 108.68 20.68 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.92 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.881 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.98 136.87 54.38 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.932 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.625 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -98.53 112.27 24.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.969 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.834 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -106.2 153.42 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.997 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.953 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.73 176.93 1.1 Allowed Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.92 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.096 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.9 Cg_endo -72.35 115.9 4.5 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.323 3.349 . . . . 0.0 109.59 179.881 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -112.95 41.23 2.12 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.956 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.529 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -119.04 105.43 11.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.876 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.081 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 93.2 28.24 12.08 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.99 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.096 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -103.24 130.16 50.4 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.976 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -106.16 174.52 5.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.944 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -48.65 139.97 8.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.935 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.66 -23.59 32.26 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.999 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.448 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.3 m -80.17 151.92 29.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.973 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.1 p -127.11 130.2 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.979 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 1.02 HG22 ' O ' ' A' ' 67' ' ' LEU . 15.4 m -95.87 170.66 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.995 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.834 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.59 148.8 40.58 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.735 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -143.3 106.09 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.971 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.881 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.04 115.76 24.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.798 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.35 142.12 19.42 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.723 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.91 112.53 9.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.964 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.947 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.53 25.7 8.04 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -180.0 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.218 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -91.26 -163.8 1.09 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -89.25 125.21 34.99 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.97 133.86 44.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.66 8.57 84.4 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.606 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -98.83 134.57 41.52 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.995 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.953 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.47 152.24 25.05 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.546 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 38.0 m-85 -138.51 145.25 40.53 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.928 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -110.15 122.45 47.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.924 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.116 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.2 t -102.19 150.17 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.997 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.996 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.88 146.66 9.2 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.943 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.806 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 14.4 tt0 -92.58 115.86 28.48 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.598 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -103.13 163.78 12.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.951 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 1.198 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.16 131.42 15.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.96 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.542 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.0 OUTLIER -67.32 124.57 23.51 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.987 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.3 m -111.39 -41.64 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.974 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.533 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -146.1 -178.8 6.32 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.964 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.673 HG23 ' O ' ' A' ' 42' ' ' THR . 1.3 t -65.1 111.6 2.98 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.986 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 7.92 62.73 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.988 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.571 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 45.9 t -111.02 105.2 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.69 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.3 mt -107.98 153.29 23.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.483 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -128.15 128.63 45.18 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.966 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -106.87 154.81 20.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.538 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.7 t30 -116.15 112.53 41.94 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -179.982 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -72.33 -0.35 8.55 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.308 3.338 . . . . 0.0 109.616 179.839 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.538 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.83 -12.26 34.2 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.832 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' A' ' 68' ' ' THR . 23.6 p30 -130.82 27.34 4.93 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.63 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -103.35 116.14 31.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.977 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 54' ' ' SER . 30.2 t -100.56 -173.22 2.35 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.984 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.442 ' N ' ' OG ' ' A' ' 53' ' ' SER . 4.7 p -147.14 154.08 40.67 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.85 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -167.06 154.44 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 58.7 m -123.8 122.73 38.8 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.954 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -52.79 149.75 5.95 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -92.27 -171.44 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.955 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.27 -25.06 67.64 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -81.35 -5.0 57.39 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.415 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 72.58 23.66 77.53 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 82.4 p -114.42 138.06 51.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.996 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.61 163.02 19.63 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.997 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -150.94 120.0 6.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.512 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -148.86 158.08 43.9 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.892 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.45 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -110.4 126.35 54.19 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.985 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.02 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -107.58 118.24 36.2 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.965 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.677 ' N ' HD13 ' A' ' 67' ' ' LEU . 4.7 t -69.0 149.73 48.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.922 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.531 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -106.46 123.93 61.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.967 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.531 ' HD2' ' O ' ' A' ' 69' ' ' VAL . 1.5 mpt_? -116.58 137.09 52.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.971 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.47 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 26.0 ptt180 -75.26 -18.34 60.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.507 ' HB2' ' OD1' ' A' ' 87' ' ' ASP . 9.7 t -163.82 151.57 12.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.911 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.806 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -177.8 155.7 1.04 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.885 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -55.93 122.63 12.01 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.931 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.483 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.54 89.46 1.03 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.966 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.45 10.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.989 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.855 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.25 141.74 28.56 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.711 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.0 m-85 -47.1 -42.37 18.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.978 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.573 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 12.2 t0 -57.05 -17.06 8.71 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.959 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.82 28.16 9.71 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.934 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.855 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.0 m -108.78 131.16 55.23 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttt180 -72.94 91.62 1.56 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.944 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.533 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 0.5 OUTLIER -61.96 -57.0 13.37 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.884 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.41 170.2 21.31 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 179.982 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.47 142.22 33.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.198 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -117.91 154.11 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.973 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.507 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 10.0 m-20 -128.73 95.0 3.99 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.965 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 1.226 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 99.1 m -54.31 -25.63 24.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.977 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -80.45 1.87 27.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.978 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -113.83 -27.39 7.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.969 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.07 -170.55 2.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.983 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.89 126.52 42.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.92 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.344 ' C ' HG13 ' A' ' 110' ' ' ILE . 11.9 m -104.68 152.84 22.01 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.073 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.8 148.09 31.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.92 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.837 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 24.1 t -99.72 164.86 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.952 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.026 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.81 158.03 24.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.546 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -134.9 152.9 52.14 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.974 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER -141.32 158.47 43.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.903 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.953 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -105.28 -163.13 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.967 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.51 -49.34 77.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.941 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.441 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -72.79 -25.44 61.16 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.947 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.07 42.38 2.43 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.95 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.634 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -119.51 176.12 5.51 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.963 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.19 -173.22 22.81 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.994 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.126 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.38 133.35 20.72 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.345 3.363 . . . . 0.0 109.641 179.92 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.135 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 2.3 tt0 -136.1 145.74 46.24 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 57.36 0.23 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.964 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.006 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 25.5 t -131.58 100.94 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.978 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.655 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -97.57 155.22 17.06 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.996 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.344 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -124.29 163.49 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.949 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.529 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -153.61 122.47 6.41 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.959 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.226 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 10.0 m-85 -87.6 116.32 25.65 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 179.902 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 1.081 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 4.4 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.966 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.893 ' HA ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.165 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.42 -174.05 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.347 3.365 . . . . 0.0 109.579 179.964 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.648 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.03 109.48 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.939 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.795 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.73 141.74 49.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.937 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -96.72 111.44 23.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.915 HG21 HG22 ' A' ' 108' ' ' VAL . 21.9 t -107.66 148.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.978 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -68.48 177.63 1.04 Allowed Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.103 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.38 117.97 5.38 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 124.32 3.346 . . . . 0.0 109.607 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 111' ' ' SER . 9.3 p -115.11 44.58 1.78 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.957 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.4 m -122.91 105.11 9.71 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.88 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.955 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.88 28.1 14.8 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.103 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.69 132.69 43.1 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.8 m -107.19 172.93 6.55 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.956 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.65 140.05 15.15 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.39 -22.99 35.67 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.496 HG21 HD13 ' A' ' 13' ' ' LEU . 86.3 m -74.59 153.11 39.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.1 p -129.96 126.1 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.894 HG22 ' O ' ' A' ' 67' ' ' LEU . 26.3 m -94.57 176.65 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.98 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.833 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.35 149.28 45.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.944 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.619 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -145.11 108.03 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.795 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.27 116.78 23.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.933 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.39 144.34 21.48 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.648 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -140.67 112.6 7.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.933 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 105.22 21.75 8.69 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.165 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -91.29 -163.91 1.1 Allowed 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -89.94 126.43 35.73 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.485 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -69.61 141.59 53.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.978 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.69 7.72 59.03 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.96 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.753 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.57 143.05 26.73 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.564 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.22 148.84 21.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.984 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.007 ' OH ' ' NE2' ' A' ' 27' ' ' GLN . 49.4 m-85 -137.85 148.55 45.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.2 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.7 m-20 -112.38 114.57 27.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.964 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.074 HG22 ' HB3' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -96.18 146.43 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.978 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.887 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.5 167.88 40.97 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.953 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.812 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 8.2 tt0 -115.97 113.38 23.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -114.3 149.05 36.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.971 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.66 134.91 52.72 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.928 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.663 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 120.56 13.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.95 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.433 HG21 ' CD1' ' A' ' 83' ' ' TRP . 24.8 m -101.07 -44.95 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.982 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.865 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.6 OUTLIER -133.36 172.36 12.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 42' ' ' THR . 1.6 t -56.47 111.44 0.99 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.92 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.88 7.53 62.21 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.789 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 21.6 t -120.68 111.08 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.951 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.705 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.1 pt? -123.43 140.97 52.47 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.516 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -98.33 146.03 26.09 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 12.1 m -106.48 153.97 21.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.757 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.0 t30 -114.52 109.82 47.92 Favored Pre-proline 0 N--CA 1.45 -0.468 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.4 -0.35 8.58 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.293 3.328 . . . . 0.0 109.585 179.914 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.53 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.65 -16.57 32.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.876 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 13.7 p30 -128.24 28.44 5.49 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.878 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.682 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.47 118.95 36.29 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.97 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -111.43 -172.84 2.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.965 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -146.7 157.66 43.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.888 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 56' ' ' THR . 4.5 p -166.75 159.53 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.466 ' N ' HG22 ' A' ' 55' ' ' VAL . 14.0 m -127.1 137.5 53.02 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.985 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.83 131.44 39.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -73.75 -173.43 1.51 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.26 -20.42 62.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -85.98 10.09 15.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.485 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 56.79 26.78 54.77 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.946 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 t -121.21 133.54 55.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.439 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.44 156.75 32.06 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -139.02 133.69 32.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.663 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.93 170.34 19.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.942 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.663 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -121.01 138.39 54.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.939 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.894 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -115.77 118.81 34.07 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.943 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.719 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -71.1 135.89 47.93 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.565 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -92.67 125.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.971 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.719 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 1.1 mpt_? -117.8 140.63 49.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.416 ' O ' ' OG ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -82.72 -15.84 50.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 58.4 m -167.33 152.13 7.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.979 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.812 ' HE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -176.55 161.86 2.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.929 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.403 ' HG3' ' CD2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -62.54 110.58 1.74 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.94 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.516 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.97 94.21 0.44 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.958 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.867 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.5 m-85 -82.88 98.78 9.36 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.956 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 1.114 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -55.49 142.28 33.62 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.982 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.745 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.67 -42.91 25.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 1.114 ' OD2' HD21 ' A' ' 77' ' ' LEU . 4.0 m-20 -57.75 -16.76 12.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.78 27.73 12.25 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.836 ' HB ' HD23 ' A' ' 77' ' ' LEU . 4.9 m -106.08 134.07 49.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.97 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.48 91.64 0.78 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.433 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.76 -48.82 77.51 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.878 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.63 167.13 10.94 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -65.43 103.59 0.85 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.963 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.4 m -78.61 151.81 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.981 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -110.48 93.85 4.71 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.788 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 13.7 m -51.29 -26.26 7.09 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.7 p -81.06 0.79 34.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 -179.999 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -117.3 -27.62 6.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.51 -179.9 5.43 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.34 123.77 40.1 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.295 ' C ' HG13 ' A' ' 110' ' ' ILE . 89.1 m -104.59 155.66 18.65 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -180.0 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.034 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 1.2 pt20 -144.56 147.49 33.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.944 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.795 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 14.2 t -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.952 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.08 160.05 28.71 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.074 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -128.35 155.29 44.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.954 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.2 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -143.45 144.23 31.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.898 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.564 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -90.97 -161.78 0.85 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.457 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.69 -49.29 78.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.449 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.13 -24.79 62.34 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.93 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.83 42.5 2.45 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.994 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.449 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -121.07 177.16 5.24 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.99 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.92 -173.65 22.28 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.069 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.35 133.85 21.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.364 3.376 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.893 ' HG3' ' HA ' ' A' ' 2' ' ' ALA . 1.8 pt-20 -139.8 161.53 37.34 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.79 51.71 0.6 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.925 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.98 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.0 t -126.44 101.82 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.996 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.09 146.83 24.32 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.955 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.295 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -115.78 159.71 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.907 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -151.0 126.73 10.25 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.909 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.788 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 8.3 m-85 -101.48 124.93 47.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.932 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.616 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 49.2 m-80 . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.961 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.633 ' C ' ' HB3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.406 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.38 -174.13 1.34 Allowed 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.286 3.324 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.162 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.4 t -95.93 109.73 22.05 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.839 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.99 145.7 50.89 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.511 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -103.9 113.37 26.85 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.884 HG13 ' O ' ' A' ' 20' ' ' LYS . 38.5 t -110.66 148.53 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.996 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.15 175.94 1.59 Allowed Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.945 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.956 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 120.95 7.07 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.351 3.367 . . . . 0.0 109.63 179.851 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.085 ' HA ' HD21 ' A' ' 13' ' ' LEU . 30.8 p -120.83 52.48 1.18 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 62.0 p -137.81 106.14 5.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.9 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.68 8.47 40.01 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.9 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.146 ' O ' HD12 ' A' ' 13' ' ' LEU . 3.5 pp -114.68 143.08 45.61 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -122.47 -166.99 1.49 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.936 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.943 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 42.7 t0 -43.32 151.73 0.15 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.969 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 92.02 -23.38 26.86 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.998 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.778 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -85.08 146.05 27.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 18' ' ' VAL . 14.8 p -116.21 129.52 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.638 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 6.0 m -99.75 159.4 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.884 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 145.42 41.37 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.969 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.592 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -142.06 110.16 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.989 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.839 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.89 112.91 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.979 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.904 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.92 144.77 21.25 Favored Glycine 0 C--N 1.334 0.468 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.162 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -142.86 110.13 5.68 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.955 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.879 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.89 14.92 15.95 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.234 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -91.04 165.94 13.26 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.463 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.9 mt-30 -48.99 121.26 4.58 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.96 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.608 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.69 134.93 45.28 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.945 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 8.2 76.32 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.981 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.751 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -97.7 137.41 36.63 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.995 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.12 151.97 24.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.998 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.57 ' CB ' HD23 ' A' ' 97' ' ' LEU . 73.0 m-85 -135.77 158.2 44.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.925 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.45 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 17.1 m-20 -119.71 117.93 29.55 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.948 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.42 138.13 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.958 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 1.173 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -158.91 162.88 32.91 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.839 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 1.8 tt0 -115.13 121.62 43.59 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.915 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.567 ' HB3' HD13 ' A' ' 45' ' ' LEU . 66.9 m -108.59 172.7 6.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.976 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.833 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -152.84 124.34 7.71 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.943 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.598 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 124.25 21.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.947 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.641 ' CG1' HG22 ' A' ' 86' ' ' VAL . 12.1 m -104.43 -43.7 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.952 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.701 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.88 164.13 30.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.6 m -53.33 114.06 1.36 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.944 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.6 7.92 70.4 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.511 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 15.0 t -126.44 105.76 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.953 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.763 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.84 162.65 17.76 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.495 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.18 146.96 49.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.817 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.4 m -108.35 155.95 19.96 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.826 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 33.6 t30 -114.59 105.64 53.3 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.287 3.325 . . . . 0.0 109.609 179.885 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.44 -12.94 41.67 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.878 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.9 p30 -126.71 28.51 5.87 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.72 104.57 13.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.997 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.1 t -101.65 177.26 4.96 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.923 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 p -146.44 153.08 40.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.852 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -167.37 153.04 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.966 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.1 m -122.58 139.62 53.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.0 142.86 32.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.917 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -80.02 -170.73 2.59 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -22.08 66.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.961 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.92 4.75 21.36 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.608 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.32 31.01 72.44 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.921 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.8 t -125.05 132.28 53.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.94 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.12 164.07 17.43 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.979 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -146.74 135.64 22.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.593 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.05 165.35 17.93 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.913 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.593 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -122.34 126.06 47.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.939 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.206 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.83 155.34 16.82 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 68' ' ' THR . 5.0 t -103.7 119.29 38.62 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.946 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.813 HG11 ' CD1' ' A' ' 13' ' ' LEU . 2.1 t -84.35 128.4 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.943 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.6 OUTLIER -119.1 156.82 29.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.412 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -90.93 -24.98 20.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.923 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.412 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -156.47 148.35 22.94 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.946 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.839 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.8 p90 -174.41 153.42 1.91 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.935 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.501 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -54.29 115.13 1.92 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.495 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.49 100.64 0.83 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.986 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.817 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -83.41 99.95 10.39 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.988 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.952 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -58.61 130.94 49.25 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 14.1 p90 -47.65 -35.75 9.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.553 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.96 -16.35 12.06 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.19 27.68 9.88 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.986 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.952 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.3 m -115.36 151.65 34.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.419 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -89.45 97.86 11.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.511 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.43 -55.9 20.57 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.883 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.56 172.67 17.09 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.26 108.25 0.45 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.978 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.833 HG11 ' HB3' ' A' ' 38' ' ' ALA . 86.4 t -86.05 147.43 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 48.1 m-20 -108.09 90.87 3.43 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.963 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.429 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -53.06 -25.24 12.03 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 61.0 p -78.01 -3.33 41.5 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.78 -26.07 7.54 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.46 -179.89 4.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.962 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.26 136.97 36.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.899 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.463 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.69 166.05 10.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.998 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.335 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -169.52 127.9 0.96 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.911 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.206 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.9 t -92.41 164.28 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -170.22 164.83 38.16 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.57 HD23 ' CB ' ' A' ' 32' ' ' TYR . 4.3 mp -100.33 160.93 13.94 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.45 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 14.6 m -155.0 117.44 4.26 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.591 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 3.2 p-10 -112.11 -158.15 0.64 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.958 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.13 -39.49 59.99 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -26.89 19.6 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.77 53.52 2.23 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.591 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -106.68 -174.7 2.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.994 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.422 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 171.01 175.58 39.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.406 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.9 Cg_endo -72.33 160.63 46.54 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.32 3.347 . . . . 0.0 109.581 179.948 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.271 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -33.84 126.63 0.42 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.991 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.462 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.76 135.75 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.335 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 25.3 t -119.05 102.88 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.956 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.908 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.7 158.22 19.48 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.969 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.87 HG13 ' HA ' ' A' ' 94' ' ' GLN . 35.2 mt -125.98 162.49 29.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.986 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.598 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -141.07 121.39 13.95 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.903 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.463 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 2.9 m-85 -97.72 122.21 40.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.943 . . . . . . . . 0 0 . 1 . 046 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 1.292 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.565 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.4 Cg_endo -72.38 -174.3 1.39 Allowed 'Trans proline' 0 N--CA 1.446 -1.272 0 C-N-CA 124.337 3.358 . . . . 0.0 109.634 179.886 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.282 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.6 t -95.97 111.42 23.43 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.957 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.801 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.57 140.13 50.45 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -102.25 111.27 23.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.985 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.652 HG11 HG21 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -108.22 155.05 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.981 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.972 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.43 177.02 1.02 Allowed Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.929 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 1.136 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.39 117.86 5.33 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.316 3.344 . . . . 0.0 109.605 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.494 ' OG ' HG23 ' A' ' 110' ' ' ILE . 22.6 p -114.31 41.39 2.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.963 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 111' ' ' SER . 60.4 p -123.41 105.97 10.26 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.928 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.957 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.68 26.38 15.29 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.976 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.136 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.93 132.49 43.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.958 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.2 m -90.79 151.8 21.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.938 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -44.09 137.84 3.19 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.93 -20.9 37.43 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.984 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.435 HG21 HD13 ' A' ' 13' ' ' LEU . 90.9 m -64.78 147.46 53.13 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.995 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.615 HG13 ' O ' ' A' ' 18' ' ' VAL . 9.7 p -110.58 117.78 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.972 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 67' ' ' LEU . 14.8 m -95.48 164.75 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.627 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.16 153.33 29.75 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.947 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.681 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -149.39 113.48 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.982 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.801 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.25 114.5 21.47 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.766 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.28 147.69 23.61 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.282 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -147.48 109.85 4.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.933 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.886 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.67 14.0 18.86 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.193 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -90.49 165.8 13.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 35.5 mt-30 -50.91 118.99 3.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.855 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.05 134.99 46.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.971 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.25 8.73 80.05 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.916 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.643 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 142.69 29.41 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.975 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.583 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.03 153.21 22.3 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.055 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 59.2 m-85 -138.29 150.88 47.07 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.919 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.493 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.2 m-20 -116.87 114.86 24.47 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.591 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.52 139.94 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.956 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.76 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.92 156.92 28.17 Favored Glycine 0 C--N 1.335 0.489 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.702 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 52.8 tt0 -96.33 113.54 25.14 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.3 m -102.17 159.5 15.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.992 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -149.2 141.45 24.07 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.905 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.549 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.2 t90 -63.6 121.65 14.42 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.718 HG12 ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -109.53 -36.37 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -155.24 -175.81 5.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.601 HG23 ' O ' ' A' ' 42' ' ' THR . 7.2 t -73.56 110.55 7.93 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.88 12.75 83.71 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.649 HG21 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -128.9 121.15 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.985 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -113.78 162.2 16.59 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.989 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.471 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -132.14 130.91 41.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.76 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.65 155.23 20.39 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.759 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.2 p-10 -118.69 120.1 31.98 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.955 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.422 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.5 Cg_endo -72.34 1.66 5.88 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.298 3.332 . . . . 0.0 109.627 179.879 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.736 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.33 -24.79 29.63 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.874 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.51 ' CB ' HG23 ' A' ' 68' ' ' THR . 94.4 m-20 -123.39 30.98 6.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.665 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.14 117.71 34.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 -179.973 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.2 t -110.86 -177.95 3.35 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.7 p -148.46 153.79 38.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 56' ' ' THR . 3.1 p -167.63 161.65 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.901 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.4 m -126.53 131.76 51.51 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 153.19 44.25 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 -179.999 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.3 p-10 -90.38 -166.42 1.58 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.937 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -30.23 71.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.885 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.39 -9.55 58.7 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.855 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.48 15.99 80.82 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.983 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.5 p -104.57 138.3 41.13 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.951 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.96 166.65 13.54 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 m -150.92 117.34 5.7 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.83 157.9 43.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.948 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.439 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -110.76 125.22 53.31 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.899 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.235 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -104.65 155.3 18.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.967 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.775 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -116.74 142.81 46.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -110.48 125.13 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.991 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.604 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -110.14 159.91 16.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.976 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.67 -29.39 59.05 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 69.6 p -165.28 156.96 14.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.759 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 3.1 p90 -175.28 167.35 3.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -63.97 118.82 9.0 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.947 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.471 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -75.01 85.3 0.79 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.76 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.05 98.63 9.39 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.8 tp -54.71 134.7 47.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 27.2 p90 -45.63 -38.43 6.65 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.999 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.587 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t70 -57.66 -17.14 13.12 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.943 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.88 28.7 9.18 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.9 m -112.65 115.91 29.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.948 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -66.03 93.36 0.2 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.649 ' CE2' HG21 ' A' ' 44' ' ' VAL . 2.3 t-105 -63.44 -57.98 8.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.925 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.35 171.38 19.88 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.967 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.48 140.67 56.02 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.992 HG21 ' HB1' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.61 151.6 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.56 100.78 9.53 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.899 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 23.8 m -53.5 -26.0 18.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.979 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -82.5 -1.7 51.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.979 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.48 -27.99 6.98 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.919 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -125.4 -175.15 3.24 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.39 124.57 41.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.899 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.185 ' O ' HG13 ' A' ' 110' ' ' ILE . 1.7 m -104.66 153.65 20.97 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.133 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -158.5 144.92 17.22 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.959 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.235 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 25.4 t -101.41 162.38 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.81 164.25 35.63 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.591 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -101.72 160.95 14.02 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -180.0 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.493 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 3.3 p -153.47 119.48 5.39 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.583 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 13.4 p-10 -115.11 -167.11 1.19 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -50.74 -21.15 1.49 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.875 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.18 -24.59 13.14 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.931 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 85.69 22.52 49.92 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 1.055 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.8 -151.17 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.987 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.06 153.73 6.11 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.975 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.565 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.4 Cg_endo -72.44 161.49 44.1 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.316 3.344 . . . . 0.0 109.6 179.985 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 1.292 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -32.75 123.91 0.35 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.936 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.776 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -36.03 134.93 0.6 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.133 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.77 102.45 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.482 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -85.58 141.1 30.08 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.185 HG13 ' O ' ' A' ' 93' ' ' CYS . 1.0 OUTLIER -109.48 167.39 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.949 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -150.52 123.49 8.74 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.962 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 19.7 m-85 -99.6 126.19 45.55 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.903 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.993 . . . . . . . . 0 0 . 1 . 047 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.806 ' CB ' ' HG3' ' A' ' 106' ' ' GLU . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 . . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 1.187 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.4 -177.83 2.96 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.266 3.311 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.14 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.8 114.45 28.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.98 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.907 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.37 131.85 50.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.712 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.03 112.07 23.81 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.975 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.948 HG11 HG22 ' A' ' 108' ' ' VAL . 1.3 m -113.08 149.69 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.926 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.999 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.14 179.87 0.65 Allowed Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.923 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.999 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.6 Cg_endo -72.42 121.0 7.09 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.321 3.348 . . . . 0.0 109.538 179.947 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 1.016 ' HA ' HD21 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -110.48 3.73 19.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.986 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 1.398 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 66.1 m -110.36 126.11 53.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.901 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.489 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 103.71 5.29 45.13 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.937 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.016 HD21 ' HA ' ' A' ' 10' ' ' SER . 2.1 pp -114.32 146.58 40.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 88.4 p -99.0 171.5 8.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -45.37 151.82 0.34 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 179.969 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.79 -22.36 34.2 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.968 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 ' CB ' ' A' ' 13' ' ' LEU . 59.0 m -69.31 138.53 53.88 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.993 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.5 p -104.11 132.42 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.996 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.86 HG23 HG12 ' A' ' 69' ' ' VAL . 21.5 t -104.12 168.41 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.979 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.836 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.78 134.87 53.57 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.945 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 21' ' ' VAL . 2.2 p -128.08 104.86 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.907 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -111.39 115.23 28.91 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.705 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.61 145.62 21.99 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.14 ' O ' HG22 ' A' ' 4' ' ' THR . . . -146.2 112.27 5.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.15 26.18 8.48 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.961 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 1.125 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.83 -165.81 1.44 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.953 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.924 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 2.7 mp0 -94.35 124.83 38.61 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.1 137.45 57.98 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.4 8.66 63.01 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.304 -1.119 . . . . 0.0 110.304 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.789 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -91.69 142.71 27.31 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.993 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.774 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.13 150.5 21.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.983 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 1.102 ' CG ' ' HD2' ' A' ' 105' ' ' PRO . 56.9 m-85 -139.3 144.51 38.35 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.908 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 1.408 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.2 m-20 -105.57 114.76 29.13 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.23 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.47 150.88 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.983 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.755 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.87 168.4 38.56 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.98 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.884 ' CD ' ' HE2' ' A' ' 73' ' ' PHE . 11.6 tt0 -111.29 120.96 43.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.536 ' HB3' HD13 ' A' ' 45' ' ' LEU . 88.9 m -109.95 169.1 8.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.863 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -153.68 125.13 7.56 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.481 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.57 129.85 41.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.903 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 1.638 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.4 m -109.33 -37.81 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.407 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -146.82 163.69 35.23 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.958 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.416 ' H ' HG22 ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.19 114.89 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.965 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.56 1.93 62.63 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.989 HG12 HG23 ' A' ' 40' ' ' VAL . 15.9 t -121.02 119.64 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.742 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -126.75 162.22 26.32 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.484 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -124.24 139.67 53.7 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 1.033 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 24.1 m -109.18 151.83 25.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.562 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.9 t30 -112.77 110.74 51.9 Favored Pre-proline 0 N--CA 1.448 -0.552 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.977 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 124.341 3.361 . . . . 0.0 109.596 179.936 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.562 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.05 -20.54 23.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.909 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.577 ' HB3' ' NH1' ' A' ' 70' ' ' ARG . 8.5 p30 -119.38 19.93 12.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.671 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -92.35 113.57 25.87 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.7 t -108.0 -174.28 2.48 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -146.28 155.9 42.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.915 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 56' ' ' THR . 5.7 p -166.88 158.13 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.941 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.456 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.5 m -127.78 129.42 46.99 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 135.57 55.62 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 p30 -76.66 -175.19 3.27 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.941 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.66 -19.96 64.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -87.34 10.3 17.73 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.074 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 30.35 59.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.6 t -124.82 135.98 53.42 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.964 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.35 164.63 19.97 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.0 m -152.41 119.48 5.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.983 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.17 164.14 34.07 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.865 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.554 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -106.68 133.74 50.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.943 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.184 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -119.59 120.2 36.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.916 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.616 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -83.97 145.04 28.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.989 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.86 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -121.51 134.56 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.677 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.92 174.94 5.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.988 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HG2' ' CG2' ' A' ' 89' ' ' THR . 6.5 mtt180 -98.68 -12.19 21.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.948 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 20.3 p -173.68 145.95 1.24 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.884 ' HE2' ' CD ' ' A' ' 36' ' ' GLN . 1.2 p90 -171.6 163.25 6.61 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.922 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.14 118.02 3.99 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.943 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.484 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.74 96.08 1.4 Allowed Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 1.033 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.14 100.64 11.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.875 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -56.21 130.64 45.19 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.972 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.619 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.1 p90 -47.42 -35.36 8.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.998 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.61 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.1 t0 -57.49 -17.55 14.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.4 27.92 8.34 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.875 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.5 m -116.88 148.09 41.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.96 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -85.46 96.34 9.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.97 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 1.638 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 72.6 t90 -64.35 -58.05 7.6 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.859 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.42 170.79 16.65 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.987 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.52 0.4 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.863 HG21 ' CB ' ' A' ' 38' ' ' ALA . 2.5 p -86.3 143.1 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.981 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.72 96.43 8.6 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.954 ' O ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -55.35 -20.01 10.52 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.947 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.604 ' CG2' ' HG2' ' A' ' 71' ' ' ARG . 33.5 p -88.94 1.4 55.5 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 m -114.16 -27.44 7.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.978 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.31 179.42 4.91 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.975 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.45 123.14 41.2 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.907 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 1.56 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -104.71 157.71 17.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 1.121 ' N ' HG13 ' A' ' 110' ' ' ILE . 1.3 pt20 -156.19 144.67 20.02 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.975 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.184 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 11.9 t -93.58 156.98 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 1.23 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -172.54 165.91 38.51 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.294 -1.123 . . . . 0.0 110.294 179.997 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.164 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -136.52 143.44 43.74 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 1.408 ' N ' ' H ' ' A' ' 33' ' ' ASP . 3.5 m -133.52 147.59 51.62 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.95 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . 0.774 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -93.49 -167.01 1.62 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.974 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.08 -50.13 74.53 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.498 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -68.76 -24.66 64.47 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.98 40.53 2.84 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.98 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.498 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -121.89 -178.62 3.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.985 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.64 -174.95 20.8 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.958 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 1.187 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.8 Cg_endo -72.43 134.55 22.77 Favored 'Trans proline' 0 N--CA 1.446 -1.271 0 C-N-CA 124.318 3.345 . . . . 0.0 109.612 179.935 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.806 ' HG3' ' CB ' ' A' ' 2' ' ' ALA . 3.1 pt-20 -137.99 141.54 40.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.904 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 136.27 57.67 0.06 OUTLIER Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.967 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 1.077 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.0 t -134.27 102.73 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.992 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -96.94 153.6 17.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.944 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.56 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.0 OUTLIER -117.94 163.76 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.89 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 1.398 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -162.24 131.0 4.21 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.973 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 1.032 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -108.35 120.07 41.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . 0.489 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.1 t-20 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.463 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.605 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -99.31 129.64 28.81 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.686 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.32 -178.76 3.49 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.298 3.332 . . . . 0.0 109.635 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.201 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.08 113.64 26.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 1.033 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.96 136.11 51.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.55 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -99.54 115.41 29.29 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.765 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -113.71 147.39 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.856 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.32 167.43 21.82 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.38 118.52 5.64 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.294 3.329 . . . . 0.0 109.631 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.595 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.59 13.86 7.55 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 111' ' ' SER . 47.3 p -89.86 115.08 26.92 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.036 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 90.11 20.59 41.89 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.027 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -106.98 134.12 50.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -87.52 173.21 9.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -45.05 152.2 0.27 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.19 -23.6 32.69 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.666 HG21 HD12 ' A' ' 13' ' ' LEU . 3.0 m -66.5 150.41 49.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.91 122.59 68.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.915 HG13 ' O ' ' A' ' 67' ' ' LEU . 0.3 OUTLIER -105.35 119.35 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.765 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -79.78 149.85 30.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.69 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -142.37 109.7 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.033 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.62 116.96 26.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.911 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -85.32 144.93 21.0 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.201 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -144.81 110.07 5.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.39 15.07 24.22 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.036 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.22 166.09 13.56 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.46 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 24.5 mt-30 -50.2 121.64 5.81 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.514 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.57 131.35 41.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 7.67 85.21 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.485 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.85 146.21 23.81 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.64 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.25 151.39 22.16 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.65 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.2 m-85 -138.39 147.48 43.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -114.02 113.21 24.47 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.279 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.5 OUTLIER -96.88 147.71 6.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.78 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.03 163.23 36.61 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.906 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 2.3 tt0 -106.25 112.4 25.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.4 m -113.53 146.51 39.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.144 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.42 128.97 50.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.593 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.51 120.94 13.79 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.889 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.31 HG21 ' CD1' ' A' ' 83' ' ' TRP . 2.7 m -101.2 -43.45 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.966 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -139.23 179.21 6.66 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 47.1 m -62.38 112.75 2.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.33 7.43 63.71 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.578 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 81.2 t -122.33 109.19 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -125.0 137.26 54.25 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.367 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -87.61 156.21 19.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.9 m -121.72 151.27 40.7 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.668 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 32.9 t30 -119.2 111.63 36.69 Favored Pre-proline 0 N--CA 1.448 -0.542 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.44 -0.65 9.05 Favored 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.289 3.326 . . . . 0.0 109.578 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.516 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.04 -13.67 43.74 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.588 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.8 m-20 -130.37 27.56 5.04 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.684 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -96.7 115.82 28.08 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.4 t -109.23 -177.76 3.38 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 4.3 p -147.37 153.91 40.24 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.546 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.59 162.85 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.546 ' N ' HG22 ' A' ' 55' ' ' VAL . 16.6 m -128.11 138.8 52.67 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.91 36.22 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 42.2 p30 -80.61 -173.26 4.04 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.94 -24.92 68.1 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -74.93 -8.49 56.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.033 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.9 31.61 59.86 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -128.26 139.33 52.5 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.85 167.75 16.9 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 84.1 p -150.49 127.01 10.8 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.552 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.71 163.31 38.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.864 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.552 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -112.7 130.73 55.95 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.944 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -108.54 125.43 51.81 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.62 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -81.52 129.45 34.67 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.536 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.2 t -90.69 128.22 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.536 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.4 OUTLIER -119.42 141.81 48.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.987 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -69.88 -34.19 73.22 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 51.5 p -164.63 159.85 19.44 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.906 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -178.03 172.24 1.64 Allowed 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -62.72 119.37 9.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.367 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.86 91.63 1.21 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.914 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.5 99.65 10.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.4 132.27 52.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.7 m-85 -46.95 -37.05 8.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.7 t0 -57.6 -16.89 11.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.72 27.97 9.25 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.1 m -113.81 147.48 38.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -86.34 94.37 9.34 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.578 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -64.06 -57.93 8.17 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.4 164.33 11.36 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.01 108.97 0.66 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.144 HG11 ' CB ' ' A' ' 38' ' ' ALA . 5.7 t -85.55 152.0 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -115.19 93.74 4.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.959 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 4.9 m -53.9 -24.86 17.5 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.7 p -81.73 2.26 30.66 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -115.92 -27.18 7.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.12 -178.91 5.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.3 126.3 43.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.278 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 28.9 m -105.2 171.54 7.27 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.169 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.1 OUTLIER -154.05 147.39 24.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.944 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 8.8 t -103.87 165.28 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.279 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.79 166.32 35.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.106 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.14 133.04 43.81 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 13.5 m -116.11 145.2 43.23 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.64 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -99.93 -158.04 0.65 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.62 -48.66 76.4 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.452 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.49 -25.46 62.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.85 43.34 2.89 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.453 HD21 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -114.05 161.49 17.65 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.65 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -168.75 170.46 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.686 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.37 166.04 30.94 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.373 3.382 . . . . 0.0 109.577 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.605 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 mt-10 -36.62 118.1 0.54 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.92 156.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.169 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 5.6 t -106.15 102.16 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.15 116.99 20.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.278 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.3 pt -129.95 -177.5 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.634 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -169.55 173.95 6.15 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.959 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 8.2 m-85 -129.42 110.32 11.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.036 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.9 p30 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.32 ' CB ' ' CG ' ' A' ' 106' ' ' GLU . . . -145.89 119.07 5.23 Favored Pre-proline 0 N--CA 1.45 -0.457 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.654 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.0 Cg_endo -72.4 -177.78 2.93 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.292 3.328 . . . . 0.0 109.566 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.844 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.1 110.34 22.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.91 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.13 135.77 50.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -97.95 113.02 24.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.789 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -109.58 154.57 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.918 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.11 174.4 2.44 Favored Pre-proline 0 N--CA 1.45 -0.463 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.941 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.129 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.8 Cg_endo -72.39 119.44 6.13 Favored 'Trans proline' 0 N--CA 1.447 -1.233 0 C-N-CA 124.334 3.356 . . . . 0.0 109.569 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.946 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.1 p -111.4 48.34 0.95 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.6 m -129.39 106.01 8.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.17 31.37 9.81 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.129 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -104.44 131.48 51.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -108.79 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 0.3 OUTLIER -48.66 142.08 6.47 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.435 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 101.34 -22.58 38.48 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.56 HG21 ' HB3' ' A' ' 13' ' ' LEU . 15.6 m -77.69 151.21 34.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.7 p -119.67 132.37 69.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.727 HG13 HG22 ' A' ' 8' ' ' THR . 20.9 t -95.66 155.38 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.789 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.02 144.49 42.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.696 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.7 110.9 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.91 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.54 116.5 25.51 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.795 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.08 146.6 24.1 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.844 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.85 110.8 4.34 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 101.57 14.63 29.38 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.088 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.87 179.32 6.01 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.898 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 25.1 mt-30 -60.87 121.38 12.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.512 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 132.24 42.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.31 8.12 79.16 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.96 143.33 26.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.695 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.69 151.19 23.62 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.046 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 42.2 m-85 -137.97 140.35 40.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.294 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.7 m-20 -104.47 115.12 29.81 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.288 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -101.02 139.84 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.937 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -160.67 169.78 36.46 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.843 HE22 ' H ' ' A' ' 70' ' ' ARG . 25.9 tt0 -120.31 114.06 21.3 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.5 m -106.13 171.16 7.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -156.82 133.08 9.82 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.506 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.83 129.58 40.3 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.945 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.438 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 3.7 m -110.81 -37.47 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.698 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -147.95 165.69 29.93 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -53.13 113.82 1.25 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.1 4.66 60.1 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.026 ' CG2' ' CH2' ' A' ' 83' ' ' TRP . 98.8 t -121.58 120.53 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.729 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.65 163.57 21.73 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.535 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -127.03 143.74 51.21 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.275 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.7 m -110.35 150.47 28.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.692 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.5 t30 -110.26 106.56 58.12 Favored Pre-proline 0 N--CA 1.449 -0.495 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.403 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.9 Cg_endo -72.32 0.39 7.46 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.319 3.346 . . . . 0.0 109.591 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -87.98 -12.5 44.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 11.2 p30 -127.58 27.56 5.78 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.403 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.92 104.8 11.68 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.1 t -99.29 170.54 8.58 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.49 152.6 40.03 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 56' ' ' THR . 6.4 p -165.94 159.7 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.2 m -128.23 137.11 51.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.68 146.98 39.79 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.6 p30 -83.93 -175.02 5.61 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -24.6 67.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.36 -7.57 55.28 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.088 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.14 32.04 58.88 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.1 p -127.94 135.78 50.43 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.76 167.9 12.45 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.1 121.91 9.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.581 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -162.33 148.04 12.84 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.931 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.5 137.37 48.29 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.003 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -106.04 119.1 38.34 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.909 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.659 ' N ' HD13 ' A' ' 67' ' ' LEU . 5.2 t -60.84 127.2 30.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.694 HG23 HG21 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -87.58 124.33 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.843 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.7 OUTLIER -115.74 143.68 45.04 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.518 ' HG3' HG23 ' A' ' 89' ' ' THR . 43.1 ttp180 -86.73 -16.45 36.4 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.5 t -171.47 145.11 2.03 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.758 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.0 p90 -169.62 163.93 10.18 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.37 124.78 20.68 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.535 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -81.04 91.54 1.43 Allowed Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.92 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.22 100.67 10.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -57.3 136.69 56.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.665 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.54 -39.98 17.71 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.681 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -56.74 -17.14 7.97 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.955 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.94 28.1 9.69 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 15.7 m -112.38 147.36 36.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.69 93.82 6.85 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.438 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 11.5 t-105 -65.42 -48.29 73.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.57 165.08 10.16 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.79 133.66 54.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.183 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -111.67 143.8 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -109.84 104.07 12.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.481 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 26.3 m -51.81 -26.85 10.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.518 HG23 ' HG3' ' A' ' 71' ' ' ARG . 75.9 p -80.51 -2.26 45.27 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.71 -27.45 6.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.05 179.94 5.59 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.97 125.68 43.01 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.016 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 87.1 m -104.34 152.56 22.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.041 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.7 pt20 -150.57 152.72 34.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.003 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 10.3 t -117.51 159.78 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.46 166.51 37.52 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.288 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.74 131.19 51.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.294 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 3.2 m -111.73 153.09 27.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.695 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.5 -163.33 0.85 Allowed 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.43 -48.18 65.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.26 -24.45 66.58 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.6 53.77 1.77 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.898 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.26 170.92 14.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.046 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.4 46.72 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.654 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.42 162.8 40.47 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.328 3.352 . . . . 0.0 109.573 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.32 ' CG ' ' CB ' ' A' ' 2' ' ' ALA . 7.4 mt-10 -37.68 120.19 0.8 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.02 158.27 0.01 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.897 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.6 t -121.58 104.13 14.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.89 120.28 28.01 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.041 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.2 mt -98.61 159.09 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.0 OUTLIER -145.27 116.97 8.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.902 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -93.81 127.56 39.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.518 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.378 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -59.63 117.24 21.0 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.604 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 81.8 Cg_endo -72.47 -178.45 3.36 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.285 3.323 . . . . 0.0 109.592 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.859 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.92 111.04 23.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.769 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.09 157.84 36.98 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.506 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.6 p -121.86 119.59 32.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.81 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 22.5 t -114.82 146.34 19.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.732 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.1 165.78 35.12 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.716 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.0 Cg_endo -72.41 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.347 3.365 . . . . 0.0 109.546 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.88 12.35 7.26 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.71 ' HA ' ' O ' ' A' ' 111' ' ' SER . 42.2 m -87.78 110.58 20.58 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.085 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 97.33 14.31 42.07 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.985 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -105.56 132.79 51.28 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m -91.83 -179.97 5.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -44.54 152.68 0.2 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.84 -23.29 33.56 Favored Glycine 0 C--N 1.335 0.528 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.628 HG21 HD12 ' A' ' 13' ' ' LEU . 26.1 m -69.38 148.76 49.2 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.4 p -125.47 115.86 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.732 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.4 p -91.86 153.77 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.81 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.27 147.93 31.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.747 HG13 ' CG2' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.37 106.4 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.717 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.56 116.96 23.29 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.061 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.72 150.32 25.28 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.859 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -147.73 109.62 4.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.43 15.94 33.48 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.065 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.19 172.89 8.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.517 ' HB2' HG21 ' A' ' 30' ' ' THR . 0.1 OUTLIER -53.27 120.65 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.493 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.7 131.16 42.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.68 82.69 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.517 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -92.19 143.48 26.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.59 147.18 25.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.656 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 34.0 m-85 -134.48 134.05 41.07 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.077 ' HB2' ' O ' ' A' ' 98' ' ' SER . 1.7 m-20 -98.66 114.12 26.47 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.26 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.71 145.19 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.955 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.2 166.47 39.25 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.76 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.19 108.83 18.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.41 146.93 38.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.419 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -123.58 143.51 50.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.564 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.35 124.39 21.62 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.2 t -104.04 -49.26 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.27 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -135.43 169.65 17.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.956 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.412 ' H ' HG22 ' A' ' 42' ' ' THR . 0.6 OUTLIER -51.45 112.23 0.71 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.35 8.62 66.48 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.991 HG11 ' HE1' ' A' ' 83' ' ' TRP . 2.4 t -121.98 123.19 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -132.08 133.79 44.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.81 147.77 22.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.919 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.3 m -105.62 152.12 23.51 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.768 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -111.07 110.15 56.75 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 81.9 Cg_endo -72.43 -0.07 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.255 0 C-N-CA 124.311 3.341 . . . . 0.0 109.616 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.29 -9.45 52.83 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.405 ' CB ' HG23 ' A' ' 68' ' ' THR . 82.4 m-20 -133.83 26.8 3.97 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.435 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -80.07 107.24 12.7 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.1 m -101.48 176.21 5.31 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.0 p -144.93 153.97 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.591 HG22 ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.69 155.18 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.1 m -128.0 141.72 51.44 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.99 141.28 33.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 p30 -82.66 -173.18 4.48 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.71 -26.45 68.05 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -76.09 -9.17 58.41 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.065 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.23 32.28 52.57 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 80.9 p -127.79 135.83 50.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.591 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -122.95 164.38 18.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -145.64 136.19 24.19 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.739 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.88 174.62 10.39 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.739 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -138.95 122.96 17.88 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.891 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.089 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.04 156.43 16.33 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -103.78 133.37 48.89 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.954 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.473 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -93.47 127.18 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.628 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.4 OUTLIER -117.66 141.99 47.75 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -32.58 73.24 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 78.2 p -157.9 158.97 36.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.768 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 2.1 p90 -177.14 161.8 1.91 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.17 112.35 2.62 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.72 96.75 0.68 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.834 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 1.1 m-85 -83.23 99.41 9.95 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.9 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -57.18 131.68 50.7 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.674 ' N ' HD12 ' A' ' 77' ' ' LEU . 38.0 p90 -47.52 -36.11 9.88 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 3.3 t0 -57.67 -16.25 10.17 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.58 27.78 9.5 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.9 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -115.55 147.97 40.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -87.64 96.43 10.42 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.27 ' HZ2' ' CG ' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.63 -55.16 25.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.63 170.89 16.15 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.3 m -66.12 103.83 1.04 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 73' ' ' PHE . 35.5 m -80.18 154.15 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -112.7 92.62 4.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.944 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 1.7 m -53.07 -24.63 10.41 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -82.32 2.07 33.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.38 -27.28 6.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.71 178.98 6.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.612 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -98.2 126.23 43.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.376 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 7.2 m -104.82 173.68 6.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 1.1 pt20 -153.61 147.12 24.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.089 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.7 t -104.97 165.32 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.26 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.29 166.38 36.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.003 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.83 132.9 46.63 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.077 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 3.7 t -113.48 150.89 32.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.455 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.3 OUTLIER -110.48 -163.63 0.87 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -65.74 -48.43 71.92 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.65 -24.37 65.44 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.9 53.75 1.74 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.46 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -133.41 169.53 16.81 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.992 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.517 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.03 171.42 43.43 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.604 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.34 170.71 18.57 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.322 3.348 . . . . 0.0 109.597 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.378 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.67 121.6 0.9 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.98 163.87 0.01 OUTLIER Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.06 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 23.2 t -120.53 103.18 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.2 120.39 26.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.376 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -129.1 -178.76 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.71 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -168.33 171.14 9.44 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.0 m-85 -122.4 115.11 21.7 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.085 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.6 p30 . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.252 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -117.98 115.32 36.75 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.584 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.4 -178.3 3.24 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 124.339 3.36 . . . . 0.0 109.633 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.305 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 5.1 t -99.69 116.12 31.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.78 153.76 48.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -110.66 112.16 23.86 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.901 HG22 ' CG1' ' A' ' 21' ' ' VAL . 95.2 t -107.47 145.93 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -66.79 176.42 1.11 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.9 Cg_endo -72.41 117.46 5.14 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.293 3.329 . . . . 0.0 109.612 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.594 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 32.4 p -112.58 47.07 1.12 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 51.4 p -126.36 106.73 9.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.72 14.72 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.73 131.77 47.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.983 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -111.41 174.57 5.8 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -48.05 140.3 7.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.08 -22.79 35.54 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.469 HG21 HD13 ' A' ' 13' ' ' LEU . 96.6 m -79.81 151.42 30.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.55 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.8 p -128.26 123.43 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.965 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.4 m -88.28 171.45 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.821 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.49 146.86 47.0 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.901 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -144.44 106.25 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.677 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.67 116.66 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.87 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.92 148.32 25.67 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.305 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -148.15 118.61 7.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.86 16.1 46.4 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.019 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -88.68 -174.15 4.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.516 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.2 OUTLIER -70.3 120.7 16.36 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.931 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.02 136.02 53.21 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.02 7.82 60.21 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.721 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -82.95 146.71 28.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.868 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -96.07 134.96 38.48 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.813 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 38.6 m-85 -126.42 149.17 49.44 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.026 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -116.79 113.95 23.27 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.223 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -97.05 143.92 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.936 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.703 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.21 161.66 34.8 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.832 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 37.6 tt0 -110.85 118.44 36.13 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.1 m -115.95 148.37 40.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.109 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.27 140.39 52.68 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.517 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.26 127.42 31.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.813 HG12 ' CG1' ' A' ' 44' ' ' VAL . 1.1 t -108.7 -39.34 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.436 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 1.5 t0 -151.84 -178.53 6.79 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.1 m -70.41 111.47 6.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.51 10.01 86.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.333 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -136.99 124.52 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.572 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -133.1 137.23 46.27 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.357 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.53 155.77 21.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.14 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 67.7 m -120.77 156.91 30.85 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.676 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t30 -121.5 109.21 34.82 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.43 0.64 7.17 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.313 3.342 . . . . 0.0 109.592 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.489 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.63 -16.37 32.61 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 14.6 p30 -127.26 28.15 5.77 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.685 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.92 118.3 35.37 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.5 t -113.41 -177.77 3.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 94.9 p -146.49 157.36 43.74 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.485 HG22 ' N ' ' A' ' 56' ' ' THR . 4.9 p -167.68 159.4 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.485 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.8 m -128.06 137.45 52.17 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -74.9 136.02 41.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 17.1 p30 -73.62 -175.28 1.97 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -24.74 68.02 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -75.17 -7.25 53.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.019 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.15 32.09 58.78 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.3 p -129.89 135.83 48.82 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.92 164.06 18.22 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -147.73 127.96 13.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.86 170.0 23.08 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.936 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -126.86 136.76 52.78 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.965 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -111.71 120.37 41.81 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.968 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.622 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -70.88 117.67 12.68 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.516 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -75.14 128.43 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.622 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -116.77 147.14 42.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.978 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.451 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.3 OUTLIER -90.21 -15.68 30.92 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 52.2 p -178.81 154.89 0.75 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.832 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -177.94 179.75 0.83 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -66.89 123.11 19.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.357 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.7 91.93 1.31 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.886 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.75 100.62 11.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -55.38 140.27 40.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.688 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.58 -41.49 21.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.57 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -57.19 -17.44 11.26 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.54 28.36 9.71 Favored Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.1 m -110.89 145.23 38.66 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.0 93.21 3.79 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.436 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 54.7 t-105 -64.18 -58.12 7.53 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.87 155.86 7.3 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -54.95 109.99 0.6 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.973 -0.381 . . . . 0.0 109.973 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.109 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.9 t -86.43 151.65 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.77 96.16 6.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.069 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.5 OUTLIER -54.07 -23.91 15.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.5 p -84.6 0.5 49.87 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -113.72 -27.38 7.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.82 177.94 7.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.54 128.33 44.83 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.223 ' O ' HG13 ' A' ' 110' ' ' ILE . 58.0 m -104.84 157.17 17.39 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.03 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -141.21 145.8 36.1 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.889 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 20.4 t -108.94 157.47 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.223 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.74 172.41 45.36 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.975 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.57 130.96 46.36 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.026 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 40.2 m -111.04 145.02 39.24 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.868 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -106.86 -163.58 0.92 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.73 -49.13 69.56 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.18 -24.11 65.83 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.26 53.34 1.88 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.8 174.81 9.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.813 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -177.82 179.34 48.37 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.584 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.37 165.78 31.66 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.347 3.364 . . . . 0.0 109.577 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.252 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.8 pt-20 -37.0 133.88 0.58 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.77 149.63 5.36 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.965 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -121.85 110.54 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.17 139.46 30.57 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.223 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.6 OUTLIER -109.93 160.09 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -143.22 112.53 6.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.069 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 23.1 m-85 -93.68 124.4 37.65 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.5 m-80 . . . . . 0 N--CA 1.449 -0.504 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.943 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.493 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.035 ' HB1' ' HA ' ' A' ' 106' ' ' GLU . . . -65.37 115.68 24.01 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.5 Cg_endo -72.42 -178.19 3.18 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.293 3.328 . . . . 0.0 109.635 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.367 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 5.2 t -102.31 115.74 31.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.4 146.96 52.05 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.615 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.65 115.72 31.02 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.832 HG13 ' O ' ' A' ' 20' ' ' LYS . 35.9 t -111.92 148.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.952 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.41 176.2 1.31 Allowed Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.962 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.083 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.34 117.28 5.06 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.325 3.35 . . . . 0.0 109.626 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.051 ' HB2' HG23 ' A' ' 110' ' ' ILE . 96.3 p -110.17 49.23 0.86 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 111' ' ' SER . 94.3 p -127.37 106.09 8.97 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.044 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.47 27.26 18.2 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.083 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -103.34 131.38 50.46 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -118.97 -179.35 3.79 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -46.19 138.89 5.0 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.58 -23.17 33.61 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.514 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.1 m -87.51 150.95 23.4 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 18' ' ' VAL . 13.0 p -131.63 121.54 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.844 HG22 ' O ' ' A' ' 67' ' ' LEU . 23.7 m -80.74 167.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.832 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.37 145.54 43.14 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.567 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -139.87 112.82 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.08 114.8 20.18 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.882 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -81.93 147.9 26.72 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.315 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.8 115.49 5.21 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.22 15.39 51.49 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.35 -179.79 5.92 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.977 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 37.1 mt-30 -59.01 120.8 9.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.92 132.05 42.07 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.87 7.64 75.94 Favored Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.51 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -92.86 139.46 30.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.595 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.06 150.45 24.86 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.878 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 26.7 m-85 -135.58 143.81 45.84 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.258 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -105.83 114.59 28.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.8 OUTLIER -100.18 139.6 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.909 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.7 164.59 37.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.87 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 20.9 tt0 -109.75 105.33 14.52 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 61.5 m -106.32 142.79 35.42 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.548 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.72 130.09 52.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.624 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.69 121.33 14.73 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.554 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 6.0 m -101.78 -43.05 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.479 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.1 OUTLIER -138.17 169.95 16.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.0 m -55.03 112.56 1.08 Allowed 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.72 9.05 64.84 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.604 HG12 HG23 ' A' ' 40' ' ' VAL . 77.0 t -123.49 105.42 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.673 HD21 ' HD2' ' A' ' 78' ' ' PHE . 0.8 OUTLIER -121.3 138.35 54.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.463 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.42 158.13 16.22 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.093 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 52.2 m -118.59 148.13 43.0 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.92 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.3 t30 -110.61 106.19 57.64 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -72.42 -1.27 9.96 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.356 3.37 . . . . 0.0 109.567 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.527 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -90.17 -11.09 42.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.755 ' HB3' HG23 ' A' ' 68' ' ' THR . 6.1 m-20 -133.35 27.41 4.11 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.663 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.6 118.87 36.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -112.07 -176.1 2.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -144.84 153.02 41.17 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.421 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.64 156.27 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.421 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.3 m -126.45 141.0 52.04 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.26 138.33 37.74 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.0 p30 -73.57 -174.34 1.69 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.45 -25.04 68.09 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.0 t30 -75.23 -8.06 55.57 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.34 58.5 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 71.5 p -127.08 133.23 50.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.79 166.47 14.29 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.89 131.76 15.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.612 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.0 166.19 17.48 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.612 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -122.33 132.63 54.49 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.13 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.24 118.23 36.17 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.755 HG23 ' HB3' ' A' ' 51' ' ' ASP . 2.0 t -68.94 143.19 54.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.522 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -107.0 131.4 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.567 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -118.98 152.04 37.1 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.531 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -87.15 -10.63 52.25 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -174.04 149.43 1.47 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.92 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 5.7 p90 -176.72 158.91 1.75 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -58.75 112.53 1.66 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.463 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.66 94.54 0.67 Allowed Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.826 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -82.71 98.81 9.26 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.93 132.68 47.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.673 ' HD2' HD21 ' A' ' 45' ' ' LEU . 19.0 p90 -46.81 -37.43 8.66 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.602 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.3 t0 -56.69 -17.13 7.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.45 28.04 8.76 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.97 143.12 45.66 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -85.38 96.05 9.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.554 ' CD1' ' CG1' ' A' ' 40' ' ' VAL . 3.3 t-105 -63.35 -58.95 5.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.29 171.31 21.1 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -64.78 104.39 0.83 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -79.75 149.99 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -110.56 97.44 6.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.85 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 9.0 m -52.82 -25.4 11.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 53.0 p -82.57 -0.17 45.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -119.04 -28.41 5.51 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.1 179.72 5.28 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.14 125.23 44.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.1 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 61.3 m -104.17 152.95 21.52 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -144.47 147.36 33.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.13 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -110.64 159.9 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.85 167.74 39.29 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.177 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.04 125.25 43.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.258 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 15.8 m -112.8 143.98 43.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.595 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.7 OUTLIER -101.85 -160.23 0.78 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.983 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.71 -47.94 61.32 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.73 -20.08 65.89 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.5 53.51 2.59 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.296 -1.121 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.977 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.64 167.75 19.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.878 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.97 176.53 46.44 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.34 170.2 19.8 Favored 'Trans proline' 0 N--CA 1.448 -1.2 0 C-N-CA 124.294 3.33 . . . . 0.0 109.618 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.367 ' OE2' ' CA ' ' A' ' 4' ' ' THR . 3.3 pm0 -40.96 120.02 1.25 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -40.46 162.81 0.01 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.849 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 34.8 t -128.57 104.44 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.74 30.18 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.1 ' HB ' ' O ' ' A' ' 93' ' ' CYS . 5.2 mt -99.5 153.58 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.664 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -138.31 123.05 18.73 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.954 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.85 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 6.1 m-85 -92.69 127.44 38.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.6 p30 . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.919 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -100.26 118.38 61.39 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.606 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.34 -177.78 2.91 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.312 3.341 . . . . 0.0 109.617 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.9 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.46 109.59 22.32 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.767 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 146.63 50.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.2 p -110.22 121.01 44.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.872 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 41.2 t -113.88 143.64 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.682 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.74 166.11 30.18 Favored Pre-proline 0 N--CA 1.449 -0.475 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.693 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.41 117.16 5.0 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.29 3.327 . . . . 0.0 109.629 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.732 ' HB2' HG22 ' A' ' 19' ' ' VAL . 0.6 OUTLIER -129.29 11.78 5.94 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.693 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.6 m -92.34 108.72 20.17 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.087 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 97.17 24.08 13.45 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.087 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.24 133.78 51.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.8 t -67.36 154.39 41.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 1.3 p-10 -46.07 147.58 1.01 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.02 -18.69 51.55 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.832 HG21 HD12 ' A' ' 13' ' ' LEU . 30.6 m -61.91 145.36 53.09 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 p -110.26 134.69 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.732 HG22 ' HB2' ' A' ' 10' ' ' SER . 10.5 t -107.03 152.72 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.872 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.03 109.84 15.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.854 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -103.18 121.12 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.767 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -128.41 117.01 20.64 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.02 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.55 147.41 23.1 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.9 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.46 111.11 5.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.56 16.53 31.37 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.1 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -89.27 173.43 8.4 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.582 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.9 mt-30 -53.66 121.38 7.69 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.406 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.31 129.55 38.66 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.98 8.67 85.07 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.547 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -94.1 141.7 28.24 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 1.196 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.88 150.78 23.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.234 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 52.6 m-85 -136.19 143.35 44.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.227 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.73 114.7 29.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.513 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.03 141.87 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.029 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.52 161.99 35.79 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.95 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 54.9 tt0 -94.69 117.96 30.97 Favored 'General case' 0 N--CA 1.45 -0.447 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.673 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.5 m -107.25 158.12 17.37 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.975 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -147.22 134.6 20.73 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.535 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -68.36 125.32 26.06 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.482 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.4 m -114.64 -36.05 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.535 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -150.17 -179.96 7.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -64.12 110.37 2.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 69.76 8.84 61.32 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.535 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 61.0 t -110.19 105.2 18.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.682 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.5 mt -105.82 156.61 18.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.485 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -135.11 129.35 33.78 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.915 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.52 156.01 19.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.702 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.6 p-10 -116.23 121.76 33.14 Favored Pre-proline 0 N--CA 1.449 -0.523 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.448 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.8 Cg_endo -72.37 1.98 5.56 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 124.26 3.307 . . . . 0.0 109.608 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.702 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -85.63 -20.87 28.82 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.505 ' CB ' HG23 ' A' ' 68' ' ' THR . 85.2 m-20 -128.47 28.78 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.59 117.1 29.6 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.3 t -109.99 -176.86 3.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.37 153.8 41.61 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.434 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.5 p -166.47 153.71 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 32.8 m -126.59 132.89 51.19 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.61 149.79 48.74 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -88.98 -168.38 2.17 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.29 -27.94 68.98 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -75.16 -9.32 58.44 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.737 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.2 31.51 51.9 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.0 p -127.97 141.24 51.58 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.434 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -131.15 164.68 24.98 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -143.35 139.62 30.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.694 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -167.56 172.1 9.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.694 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -124.88 129.03 49.58 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.942 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.267 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -112.56 119.57 38.62 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.505 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -79.59 141.45 36.56 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.593 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -112.02 132.81 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.927 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -119.11 155.68 31.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.6 ptt180 -74.67 -34.58 62.72 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -151.15 149.34 29.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.95 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.5 p90 -177.13 163.66 2.13 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.479 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.4 OUTLIER -61.25 125.1 22.55 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.485 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.93 95.56 2.11 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.915 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -84.46 103.71 13.84 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.951 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.5 tp -53.91 135.01 42.94 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 8.3 m-85 -45.71 -38.68 7.16 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.661 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.6 t0 -57.26 -17.02 9.89 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.92 28.91 8.97 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.951 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -114.41 112.43 23.02 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 96.44 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.482 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 50.6 t-105 -62.41 -53.63 52.03 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 143.45 -179.66 20.74 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.17 140.79 43.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.975 HG11 ' CB ' ' A' ' 38' ' ' ALA . 4.8 t -127.7 152.6 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.455 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.26 90.4 3.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.209 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 30.6 m -54.15 -25.57 23.14 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.8 p -76.9 -0.64 24.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -114.48 -27.21 7.62 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.68 -164.2 1.28 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.4 125.49 43.58 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.228 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.1 OUTLIER -103.89 152.5 21.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.035 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -159.42 147.56 17.56 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.958 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.267 ' CG2' HD12 ' A' ' 67' ' ' LEU . 6.8 t -105.62 165.32 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.265 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.29 164.68 34.67 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.513 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.6 133.16 47.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.947 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.227 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 67.7 m -112.1 150.31 30.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 1.196 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -109.92 -161.31 0.75 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.08 -48.68 70.15 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.09 -24.13 64.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.74 52.47 1.8 Allowed Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.618 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.57 171.87 12.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.234 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.37 175.24 44.34 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.606 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.34 169.55 21.37 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.377 3.385 . . . . 0.0 109.59 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.019 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -38.49 126.09 1.4 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 -179.959 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.84 160.31 0.01 OUTLIER Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.021 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 89.1 t -123.08 102.69 11.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.97 134.54 33.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.228 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -140.53 -173.73 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.693 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.7 t -176.48 178.51 1.3 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.209 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.8 m-85 -130.75 113.15 13.77 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.883 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 42.5 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.562 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -141.25 122.07 8.79 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.4 Cg_endo -72.35 -175.28 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.355 3.37 . . . . 0.0 109.626 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.963 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.32 109.37 21.89 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.982 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.2 146.02 50.85 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -110.18 114.35 27.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.828 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.03 152.39 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.71 HG22 HG13 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -75.5 163.96 64.03 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.75 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.0 Cg_endo -72.36 118.16 5.47 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.337 3.358 . . . . 0.0 109.621 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.598 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.9 OUTLIER -128.59 14.29 6.5 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.076 ' HA ' ' O ' ' A' ' 111' ' ' SER . 68.9 p -95.73 109.2 21.53 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.146 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 95.59 26.07 12.53 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.12 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.48 140.94 41.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.7 t -71.45 156.31 39.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.54 ' HB3' ' HD2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.73 151.96 0.79 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 91.63 -16.1 59.96 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.805 HG21 HD12 ' A' ' 13' ' ' LEU . 15.2 m -62.34 138.56 58.46 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 p -99.69 146.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.71 HG13 HG22 ' A' ' 8' ' ' THR . 1.5 t -125.32 156.64 34.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.79 150.21 40.19 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.449 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.77 105.67 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.982 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.17 117.07 30.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.926 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -83.63 143.47 21.63 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.963 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.49 106.76 5.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.909 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 22.96 8.56 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.535 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.66 -167.03 1.75 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.522 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 29.7 mt-30 -85.57 125.56 33.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.483 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.29 134.4 44.19 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.37 8.16 83.39 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.589 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -96.3 139.44 32.43 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.948 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.508 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -90.65 150.96 21.47 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.965 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 54.0 m-85 -136.95 147.33 46.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.138 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.7 m-20 -110.97 112.85 24.98 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.27 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -102.26 151.03 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.953 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -178.1 176.67 48.14 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 1.058 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 9.2 tt0 -117.25 121.6 41.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.6 m -120.42 144.81 47.74 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.741 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 142.31 51.02 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.608 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.02 124.29 21.7 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.937 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.515 ' CB ' ' CD1' ' A' ' 83' ' ' TRP . 3.3 m -106.68 -38.37 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.107 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -135.49 -178.35 5.07 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.5 m -70.98 112.08 6.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.12 10.21 81.07 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.304 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 1.8 m -130.94 124.92 57.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.615 ' H ' HD23 ' A' ' 45' ' ' LEU . 1.6 pt? -127.76 147.04 50.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.41 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -102.22 150.65 23.08 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.011 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.7 m -106.27 160.33 15.44 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.742 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 26.8 t30 -119.24 109.96 38.29 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.35 0.01 8.03 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.33 3.353 . . . . 0.0 109.627 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.467 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -89.44 -13.08 38.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.688 ' HB3' HG23 ' A' ' 68' ' ' THR . 19.0 m-20 -134.73 27.71 3.62 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.628 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.43 115.17 27.0 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.4 t -106.53 178.34 4.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 p -147.18 156.32 42.87 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.5 HG22 ' N ' ' A' ' 56' ' ' THR . 2.3 p -167.35 161.93 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.5 ' N ' HG22 ' A' ' 55' ' ' VAL . 24.4 m -128.28 131.87 48.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.67 152.4 44.28 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -91.44 -170.8 2.73 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.43 -26.14 68.34 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -76.38 -6.06 49.95 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 75.27 9.42 84.25 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 85.9 p -101.64 140.16 36.3 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.43 164.11 17.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -150.38 121.86 7.94 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.698 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.38 172.19 15.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.698 ' N ' HG23 ' A' ' 65' ' ' THR . 1.1 m -128.24 120.23 26.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.307 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.2 OUTLIER -105.64 133.43 50.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.688 HG23 ' HB3' ' A' ' 51' ' ' ASP . 5.5 t -97.62 149.13 22.58 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.636 HG23 ' HE2' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -114.67 131.48 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.851 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.58 159.04 20.89 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.54 ' HD2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -80.3 -23.32 40.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.949 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.489 ' N ' ' HG2' ' A' ' 71' ' ' ARG . 53.9 p -160.72 156.72 25.81 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 1.058 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.5 p90 -178.12 158.82 1.24 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -60.58 109.43 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.41 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -64.27 98.77 0.28 Allowed Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.804 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 98.78 10.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.995 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.2 tp -54.66 132.46 45.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.621 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.9 m-85 -47.0 -37.24 8.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.592 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.8 t0 -57.57 -16.65 10.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.84 28.99 8.94 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.995 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -117.3 152.2 35.38 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.94 99.54 8.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.515 ' CD1' ' CB ' ' A' ' 40' ' ' VAL . 15.0 t-105 -68.74 -50.49 50.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.5 163.72 9.62 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.99 104.7 0.21 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.741 HG11 ' HB3' ' A' ' 38' ' ' ALA . 14.4 p -85.83 149.71 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.77 97.24 7.9 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.854 ' SG ' ' HZ ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.8 -20.63 9.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.7 p -92.76 2.4 56.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.7 m -106.1 -24.35 12.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.52 179.01 6.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -90.97 125.5 35.8 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.246 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.3 m -104.48 162.98 12.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.036 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.3 OUTLIER -153.56 147.92 25.94 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.307 ' CG2' HD12 ' A' ' 67' ' ' LEU . 15.8 t -101.71 161.21 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.264 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.96 166.0 35.33 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.27 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.41 128.92 43.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 180.0 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.138 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 26.8 m -108.74 151.65 25.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.508 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -113.19 -162.41 0.8 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.58 -48.49 77.19 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.17 -24.37 62.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.22 53.77 1.69 Allowed Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.522 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.88 172.26 11.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.965 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.58 -179.21 46.89 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.463 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 81.7 Cg_endo -72.42 160.29 47.19 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.357 3.372 . . . . 0.0 109.549 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.127 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 2.8 tt0 -35.45 123.7 0.64 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -34.67 151.14 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.004 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 90.1 t -117.28 102.31 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.4 137.15 34.8 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.246 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 2.8 pt -143.0 179.71 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 1.076 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -177.99 178.54 0.93 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.963 ' HE1' ' SG ' ' A' ' 93' ' ' CYS . 1.2 m-85 -126.21 116.1 20.78 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.146 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 6.3 p30 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.449 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -132.64 117.96 15.49 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.594 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.3 Cg_endo -72.37 -178.24 3.2 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.356 3.371 . . . . 0.0 109.609 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.257 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 6.8 t -100.17 116.95 33.38 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.78 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -131.37 135.36 47.15 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.618 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.95 113.11 24.69 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.624 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.96 155.03 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.969 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.939 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.09 175.42 1.79 Allowed Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.056 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.2 Cg_endo -72.39 118.94 5.84 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 124.299 3.333 . . . . 0.0 109.602 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.007 ' HB2' HG23 ' A' ' 110' ' ' ILE . 20.6 p -110.74 48.48 0.91 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 55.5 p -127.06 105.99 8.97 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.137 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.12 31.93 9.36 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.289 -1.125 . . . . 0.0 110.289 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.137 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -110.18 129.19 55.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.967 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.89 175.84 5.27 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -44.92 139.74 2.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.93 -22.47 35.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.673 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.3 m -81.19 150.64 28.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.527 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.7 p -121.03 120.45 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 1.7 p -87.62 154.87 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.624 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.7 147.14 31.14 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.712 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -144.23 110.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.99 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.78 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.24 115.83 23.06 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.822 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.21 148.86 25.76 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.257 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -150.35 114.83 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.36 13.62 44.42 Favored Glycine 0 C--N 1.335 0.485 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.047 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.46 172.6 8.6 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.965 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.526 HE22 ' CG ' ' A' ' 103' ' ' ASN . 0.0 OUTLIER -52.95 119.84 5.12 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.51 132.84 43.33 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.77 7.84 75.88 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.524 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.56 141.56 28.46 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.42 150.16 25.5 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.486 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 30.1 m-85 -135.73 141.79 44.92 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.266 ' HB2' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.77 118.07 35.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -104.83 145.32 13.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.853 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.99 169.2 41.24 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.769 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 40.6 tt0 -112.01 108.96 18.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.2 m -111.74 144.63 40.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.799 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.83 130.41 52.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.583 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.18 122.83 17.98 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.443 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 9.7 m -102.94 -42.87 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.7 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -139.0 179.64 6.38 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.4 m -63.63 112.35 2.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.44 8.38 66.37 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.537 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 59.3 t -123.83 106.44 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.9 OUTLIER -121.42 137.84 54.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.929 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.404 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -89.4 153.34 20.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m -115.04 151.86 33.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.671 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.4 t30 -117.72 109.54 41.44 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.33 -1.07 9.61 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.315 3.343 . . . . 0.0 109.602 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.589 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -84.68 -11.1 56.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.589 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.5 OUTLIER -131.79 26.25 4.67 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.939 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.71 104.38 13.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.7 t -101.33 176.32 5.28 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.1 p -145.51 150.04 35.73 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -166.96 153.63 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 67.9 m -123.49 132.7 54.0 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 141.63 53.88 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -77.53 -174.65 3.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.91 -24.83 68.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -76.29 -6.9 53.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.047 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.73 31.17 58.72 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.2 p -127.09 137.78 53.07 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -122.26 165.21 16.56 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 p -147.91 120.22 8.4 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.416 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -157.42 148.08 21.2 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -111.32 129.81 55.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.581 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -98.47 157.27 16.32 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.589 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.7 t -101.01 119.29 38.53 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.533 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -80.31 127.18 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.994 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.639 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.6 OUTLIER -118.7 152.47 36.07 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.486 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -91.59 -12.68 33.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.941 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 5.1 t -169.2 151.35 4.63 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.769 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.1 p90 -177.16 155.43 1.15 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.25 115.92 2.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.404 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -72.83 91.63 0.6 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.801 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -82.79 99.23 9.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.1 tp -55.54 134.55 50.9 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.76 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.4 m-85 -46.36 -38.68 9.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.602 ' HB2' HD21 ' A' ' 77' ' ' LEU . 2.5 t0 -56.99 -17.48 9.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.77 28.37 8.9 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -113.62 142.86 45.48 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.7 mtm180 -80.88 94.97 6.58 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.443 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 71.4 t-105 -64.28 -58.61 6.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.67 167.54 16.66 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.81 108.6 1.22 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.799 HG11 ' CB ' ' A' ' 38' ' ' ALA . 38.7 t -81.76 143.96 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.17 93.6 4.62 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.486 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 58.4 m -52.04 -26.07 10.01 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 77.9 p -79.85 -2.43 43.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.48 -27.76 6.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.07 -176.63 3.93 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.92 125.74 45.95 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.915 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 69.8 m -103.5 152.98 21.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.087 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.3 OUTLIER -143.17 148.53 36.68 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.581 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.9 t -112.01 161.4 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.07 171.46 43.92 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.034 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.57 135.56 48.03 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.266 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 72.6 p -115.71 154.95 28.63 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.426 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -115.12 -167.07 1.18 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.974 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -64.03 -48.75 75.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.87 66.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.59 1.93 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.526 ' CG ' HE22 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.62 169.16 17.04 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -180.0 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.486 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.82 176.82 46.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.594 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 81.8 Cg_endo -72.41 161.84 43.16 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.332 3.355 . . . . 0.0 109.555 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.449 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.9 pt-20 -38.37 122.82 1.12 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -37.49 157.52 0.01 OUTLIER Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.828 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 6.8 t -124.66 104.59 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.01 138.29 32.55 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.087 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.8 mt -116.68 156.09 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -138.22 112.67 8.78 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.592 ' CE1' ' HB2' ' A' ' 93' ' ' CYS . 5.7 m-85 -87.3 101.11 13.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.588 ' CG ' ' C ' ' A' ' 112' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.562 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -48.12 120.0 7.8 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.657 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.3 Cg_endo -72.42 -175.39 1.77 Allowed 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.302 3.335 . . . . 0.0 109.615 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.224 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.82 22.51 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -126.44 148.95 49.56 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.4 p -113.23 117.75 32.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.94 HG13 ' O ' ' A' ' 20' ' ' LYS . 48.3 t -113.58 145.92 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.822 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -69.56 166.67 28.6 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.946 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.727 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.4 Cg_endo -72.39 117.55 5.18 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 124.332 3.355 . . . . 0.0 109.58 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.619 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.8 OUTLIER -127.55 13.08 6.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.862 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.6 p -92.56 106.51 18.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.115 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.57 22.66 11.0 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.115 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.81 140.49 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -88.68 173.19 8.74 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 19.4 p-10 -44.78 152.39 0.23 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.35 -22.09 40.67 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.754 HG21 HD12 ' A' ' 13' ' ' LEU . 22.9 m -63.46 150.46 43.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.28 114.1 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.822 ' HA ' HG22 ' A' ' 8' ' ' THR . 1.4 m -97.56 119.08 45.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.94 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.57 146.07 36.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.786 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -131.51 102.88 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.752 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -113.17 116.23 29.5 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.838 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -87.76 144.08 18.69 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.895 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.93 107.92 6.71 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.883 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 99.31 25.88 9.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.57 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.15 -175.77 5.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.917 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 24.7 mt-30 -74.32 122.28 22.65 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.439 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.96 130.87 42.04 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.48 9.23 81.71 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.533 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -97.43 139.95 32.6 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 1.143 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -87.69 151.99 22.5 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.289 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 33.3 m-85 -137.44 149.69 47.05 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.175 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.5 m-20 -111.84 113.82 26.39 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.36 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.9 OUTLIER -101.01 142.48 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.961 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.69 164.36 37.98 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.958 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 11.8 tt0 -106.65 111.54 24.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 81.2 m -111.16 151.31 28.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.658 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -129.72 126.16 37.6 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.19 119.06 10.16 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.378 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 7.0 m -100.97 -42.71 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.501 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -139.47 165.53 26.98 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.2 OUTLIER -51.36 112.78 0.8 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.27 8.24 65.26 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.643 HG12 HG23 ' A' ' 40' ' ' VAL . 71.7 t -123.28 105.04 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.609 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -122.85 137.41 54.94 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.969 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.496 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.28 157.32 18.26 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.143 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 41.7 m -121.22 151.83 39.53 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.787 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 12.9 t30 -114.67 105.74 53.06 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -72.42 -0.91 9.42 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.296 3.331 . . . . 0.0 109.584 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.99 -11.77 40.63 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 65.0 m-20 -132.69 26.42 4.36 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.668 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.86 120.83 37.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.3 t -113.4 -174.68 2.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.35 157.2 43.76 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG22 ' N ' ' A' ' 56' ' ' THR . 5.9 p -166.83 156.95 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.5 m -127.63 127.24 43.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -59.95 146.31 42.88 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -87.35 -171.98 3.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.16 -28.38 69.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -76.49 -11.0 59.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 83.03 1.22 90.63 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.2 p -94.19 136.73 34.16 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.59 163.62 18.62 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.91 130.04 13.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.752 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -156.24 174.64 15.1 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.752 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -124.76 126.68 46.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.954 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.935 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.16 119.45 38.99 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -80.7 137.52 36.3 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.584 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.74 128.31 63.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.525 ' HD3' ' C ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -117.41 141.7 48.02 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -58.22 -42.79 87.01 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.631 ' OG ' HG22 ' A' ' 85' ' ' THR . 11.5 t -147.01 156.74 43.28 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.958 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.0 p90 -177.02 157.93 1.48 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.03 111.54 0.86 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.496 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.5 99.05 1.3 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.746 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -84.46 99.51 10.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.98 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.923 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.7 tp -54.4 131.34 42.04 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.662 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.3 p90 -47.55 -36.29 10.27 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.578 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.0 t0 -57.3 -17.24 11.18 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.91 28.5 8.23 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.923 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.61 145.07 43.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.963 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.0 ttp180 -85.16 95.53 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.378 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 0.8 OUTLIER -64.87 -56.92 10.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.914 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.52 168.78 12.8 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.631 HG22 ' OG ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -58.28 104.7 0.22 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 38' ' ' ALA . 33.7 m -83.09 154.12 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -117.81 93.32 4.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.513 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 75.9 m -50.3 -29.32 9.49 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.752 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 5.5 t -73.5 -1.67 19.5 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.47 -27.48 7.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.36 -164.21 1.33 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.62 123.35 47.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.189 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -103.89 160.15 15.04 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.066 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -160.45 147.7 15.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.935 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -106.51 165.42 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.282 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.24 164.05 33.11 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.36 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.79 131.11 42.65 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.175 ' N ' ' H ' ' A' ' 33' ' ' ASP . 23.9 m -113.83 151.29 32.31 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 1.143 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -108.67 -158.09 0.64 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.436 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.54 -47.92 65.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.12 -25.05 64.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.3 53.99 1.65 Allowed Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.917 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.45 166.86 20.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.289 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.1 174.67 43.59 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.657 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.5 Cg_endo -72.37 167.49 26.81 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.333 3.356 . . . . 0.0 109.603 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.562 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 1.4 pm0 -38.37 124.83 1.29 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -36.96 156.79 0.01 OUTLIER Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.964 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.1 t -118.38 103.29 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.62 135.99 34.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.189 HG13 ' C ' ' A' ' 93' ' ' CYS . 2.9 pt -145.03 -176.55 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.862 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -176.7 177.88 1.31 Allowed 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.513 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.8 m-85 -127.73 113.75 16.41 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.98 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 6.6 p30 . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.495 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.201 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -108.17 109.7 61.88 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.576 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.39 -178.6 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.339 3.359 . . . . 0.0 109.591 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.905 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.66 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.753 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -124.14 157.92 33.54 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.579 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -126.31 129.41 48.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.944 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -119.41 148.59 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.72 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.64 165.76 33.01 Favored Pre-proline 0 N--CA 1.449 -0.504 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.72 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.8 Cg_endo -72.35 117.2 5.02 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.286 3.324 . . . . 0.0 109.63 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.827 ' OG ' HG12 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -129.7 14.1 5.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 111' ' ' SER . 71.0 m -86.56 105.94 17.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.972 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.27 17.72 26.16 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.1 mt -106.79 133.17 51.86 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.4 m -87.28 -179.74 6.47 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.778 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 4.2 t0 -45.05 152.39 0.25 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 97.51 -22.92 38.24 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.564 HG21 HD12 ' A' ' 13' ' ' LEU . 51.6 m -64.73 150.97 46.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -125.58 119.31 54.7 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.862 HG13 HG12 ' A' ' 69' ' ' VAL . 2.4 m -95.5 116.31 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.944 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -86.27 115.24 23.69 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.563 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -102.47 119.37 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -130.66 118.4 20.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.962 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.1 148.68 19.88 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.905 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.03 110.87 5.42 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.11 16.48 27.75 Favored Glycine 0 C--N 1.335 0.497 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.11 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.73 170.55 10.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.53 ' HB2' HG21 ' A' ' 30' ' ' THR . 1.6 mp0 -52.08 118.92 3.82 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.494 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.78 130.62 41.55 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.05 7.64 86.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.53 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -94.94 145.74 24.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -89.0 151.4 22.31 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.962 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 39.1 m-85 -138.76 140.57 38.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.28 ' CB ' ' H ' ' A' ' 98' ' ' SER . 26.2 m-20 -104.41 114.19 28.25 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.267 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.7 146.45 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.051 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.45 166.88 40.05 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.894 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.2 tt0 -111.73 118.91 36.9 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -123.84 147.91 47.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.916 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.27 135.5 54.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.588 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.9 121.32 14.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.525 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 10.6 m -102.15 -43.42 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.794 ' CG ' ' HH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.58 165.52 25.34 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.664 ' O ' ' CG2' ' A' ' 42' ' ' THR . 1.2 t -51.7 111.96 0.68 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.87 9.18 70.19 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.497 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.3 t -123.96 113.69 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.75 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.54 139.14 53.44 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -96.92 144.34 26.94 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.859 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 66.3 m -107.0 158.3 17.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.603 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -115.65 111.46 43.69 Favored Pre-proline 0 N--CA 1.449 -0.522 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.9 Cg_endo -72.32 0.52 7.28 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.326 3.351 . . . . 0.0 109.603 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.501 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.37 -10.81 45.22 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 7.1 p30 -131.54 28.23 4.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.86 104.63 12.37 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.96 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.6 t -100.88 174.35 6.07 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.1 p -145.95 156.13 43.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.51 HG22 ' HB1' ' A' ' 63' ' ' ALA . 4.4 p -166.49 159.43 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.47 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.8 m -127.25 139.54 52.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.95 141.02 36.41 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.0 p30 -82.3 -172.24 3.88 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.2 -27.88 69.29 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -75.1 -7.27 53.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.11 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.89 30.9 58.75 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 77.9 p -125.29 136.12 53.19 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.51 ' HB1' HG22 ' A' ' 55' ' ' VAL . . . -123.26 157.44 33.14 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.71 126.46 23.87 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.443 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -150.21 161.67 41.96 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -125.57 108.53 11.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.388 HD22 ' CG2' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -95.6 157.88 15.7 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.415 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.1 OUTLIER -107.49 140.17 40.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.862 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.88 123.28 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.778 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -109.91 157.94 18.72 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.498 ' HD2' HG21 ' A' ' 89' ' ' THR . 5.8 mtm180 -87.63 -13.06 43.7 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.5 m -163.41 145.47 9.76 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.894 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.5 p90 -177.42 150.69 0.71 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -53.4 113.48 1.17 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.7 101.47 1.42 Allowed Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.821 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.33 100.67 10.8 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.949 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -54.53 131.23 42.35 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.652 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.49 -36.04 9.64 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.597 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.2 t0 -57.77 -16.56 11.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.49 27.39 9.89 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.949 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.62 152.85 32.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.15 98.68 10.6 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.525 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 75.0 t-105 -65.61 -43.53 89.31 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.41 175.54 14.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.46 107.75 0.62 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.916 HG11 ' HB3' ' A' ' 38' ' ' ALA . 2.4 t -80.02 152.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -120.36 95.84 4.9 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.941 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.3 m -54.11 -22.93 12.23 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.498 HG21 ' HD2' ' A' ' 71' ' ' ARG . 70.2 p -84.75 2.13 43.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -112.41 -23.36 10.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -144.05 179.29 7.3 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -94.32 130.94 40.42 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.368 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 11.1 m -104.47 164.89 11.43 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.057 ' HA ' HG12 ' A' ' 110' ' ' ILE . 1.1 tt0 -156.91 151.41 25.46 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.388 ' CG2' HD22 ' A' ' 67' ' ' LEU . 2.7 t -106.09 165.61 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.267 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.79 162.08 30.28 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.009 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -124.68 128.94 49.59 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.28 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 27.6 m -112.73 141.56 46.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.425 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -103.15 -162.03 0.88 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.996 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.83 -48.16 67.0 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.51 -24.67 66.43 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.61 53.69 1.92 Allowed Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.81 173.43 11.18 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.7 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -175.64 169.12 41.79 Favored Glycine 0 N--CA 1.448 -0.511 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.576 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.39 171.85 16.16 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.314 3.342 . . . . 0.0 109.595 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.201 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.8 OUTLIER -36.45 133.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.21 160.73 2.44 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.884 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 6.6 t -116.25 103.58 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.09 127.9 35.41 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.368 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 6.0 pt -138.2 179.21 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -163.68 175.52 10.5 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.031 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.0 m-85 -131.01 114.85 15.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.971 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 10.7 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.698 ' HB3' ' CD ' ' A' ' 106' ' ' GLU . . . -45.14 133.18 5.52 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.402 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.4 -174.51 1.45 Allowed 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 124.295 3.33 . . . . 0.0 109.619 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.73 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.28 108.83 21.38 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.77 140.42 52.39 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -102.06 112.45 25.11 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.732 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -108.74 154.86 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.942 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 174.41 2.52 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.127 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.36 118.4 5.58 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 111' ' ' SER . 30.3 p -112.36 46.9 1.12 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.8 p -127.4 106.19 9.03 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.989 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.81 27.67 16.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.127 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.65 131.99 45.28 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.992 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.6 m -107.54 168.4 9.27 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -44.67 141.17 2.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.85 -22.32 37.41 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.489 HG21 HD13 ' A' ' 13' ' ' LEU . 31.4 m -76.86 150.35 36.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.615 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.8 p -126.53 117.27 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.299 HG22 ' O ' ' A' ' 67' ' ' LEU . 13.3 m -83.73 164.12 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.732 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.75 152.25 36.51 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.1 111.51 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.49 116.37 26.54 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.712 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.84 143.25 23.16 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.73 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.0 105.54 4.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.902 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.22 23.05 8.28 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.201 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.81 -164.98 1.22 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.587 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -85.6 123.77 31.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.62 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.12 134.57 45.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.86 7.57 75.73 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.516 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -94.82 138.97 31.92 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.956 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.523 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.4 150.76 22.38 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.251 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -137.17 146.42 44.93 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.258 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.2 m-20 -107.47 112.15 24.79 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.345 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.4 OUTLIER -101.84 150.19 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.923 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -179.38 174.54 46.36 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 1.097 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 31.0 tt0 -114.96 113.25 23.89 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.1 m -118.02 145.62 44.65 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.222 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.73 135.98 54.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.582 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.45 124.8 22.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.427 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.1 m -107.15 -42.25 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.325 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -138.29 129.91 27.9 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.633 HG23 ' O ' ' A' ' 42' ' ' THR . 9.5 t -38.04 112.01 0.2 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.434 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 93.03 8.98 61.22 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.473 ' CG2' ' HE1' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -151.8 130.44 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.696 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.7 pt? -133.02 142.88 49.05 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.57 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.4 144.65 25.14 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.086 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 6.1 m -106.69 156.55 18.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.931 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 48.4 t-20 -112.97 109.1 52.71 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.4 8.65 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.31 3.34 . . . . 0.0 109.628 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.542 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -94.09 -9.32 37.0 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.912 ' HB3' HG23 ' A' ' 68' ' ' THR . 7.9 m-20 -133.58 15.17 4.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.648 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -85.09 117.11 23.86 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 7.7 t -112.13 -178.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -145.72 156.14 43.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.453 HG22 ' N ' ' A' ' 56' ' ' THR . 5.1 p -166.99 157.74 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.453 ' N ' HG22 ' A' ' 55' ' ' VAL . 35.0 m -127.66 132.89 49.65 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 153.39 39.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -92.98 -172.04 2.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.82 -29.15 69.3 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -75.22 -9.11 58.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.62 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.88 7.19 88.72 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 99.3 p -99.22 138.94 35.61 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.27 163.91 17.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.1 p -149.38 127.77 12.21 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.608 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -164.51 152.9 12.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -109.24 125.0 51.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.346 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.44 122.15 45.39 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.912 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.1 t -77.94 142.36 38.41 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 1.001 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -114.95 131.16 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.991 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 1.023 ' H ' ' NE2' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -113.74 156.84 23.08 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.981 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.26 -13.49 49.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 92.1 p -168.98 144.3 3.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 1.097 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 14.2 p90 -176.53 158.11 1.73 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -59.22 122.35 13.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.57 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.48 104.32 2.61 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.592 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.4 m-85 -84.82 101.31 12.17 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.89 HD21 ' OD2' ' A' ' 79' ' ' ASP . 6.0 tp -54.33 138.78 38.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.771 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.46 -41.85 21.35 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.89 ' OD2' HD21 ' A' ' 77' ' ' LEU . 44.1 m-20 -56.85 -17.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.42 26.08 12.73 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.78 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.63 149.17 29.31 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.7 mtt180 -78.7 95.21 5.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.473 ' HE1' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -62.85 -39.49 94.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 126.5 170.26 12.91 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.226 -1.149 . . . . 0.0 110.226 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.92 130.95 43.31 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.222 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.0 t -109.13 154.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -125.53 98.0 5.41 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.721 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 9.9 m -53.13 -27.2 19.64 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.5 p -80.12 0.99 29.78 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.97 -27.59 6.51 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.2 -177.72 4.58 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.34 124.37 45.74 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.828 ' O ' HG13 ' A' ' 110' ' ' ILE . 60.2 m -103.92 153.27 20.99 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.047 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -146.52 146.98 30.7 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.921 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.346 ' CG2' HD12 ' A' ' 67' ' ' LEU . 4.0 t -107.48 159.58 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.345 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.25 171.96 44.78 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.195 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.97 122.12 25.05 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.258 ' N ' ' H ' ' A' ' 33' ' ' ASP . 6.7 m -102.95 154.79 18.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.523 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -114.75 -160.93 0.75 Allowed 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.467 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.8 -49.04 79.09 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.14 -26.02 60.08 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 98.6 49.21 1.7 Allowed Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.447 HD21 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -120.5 167.48 12.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.954 -0.388 . . . . 0.0 109.954 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.251 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.66 -176.85 45.16 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.402 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.41 159.6 48.89 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.32 3.347 . . . . 0.0 109.577 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.361 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -37.32 125.44 1.01 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.99 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.94 147.64 0.09 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.047 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -115.89 104.51 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.65 138.09 32.38 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.039 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.4 mt -113.61 159.09 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -143.52 119.12 10.4 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.721 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 40.1 m-85 -95.14 123.42 38.63 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.939 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.678 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -148.1 121.99 4.84 Favored Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.1 Cg_endo -72.41 -175.48 1.81 Allowed 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 124.336 3.357 . . . . 0.0 109.628 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.364 HG22 ' O ' ' A' ' 24' ' ' ALA . 8.9 t -100.03 117.92 35.32 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.986 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -133.52 150.63 51.68 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.549 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.1 114.24 25.81 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.708 ' HB ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -111.08 149.75 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.748 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.9 167.36 24.76 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.748 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.3 Cg_endo -72.38 119.31 6.06 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.295 3.33 . . . . 0.0 109.586 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.574 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -125.38 13.71 8.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 81.1 p -92.33 114.95 27.63 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.105 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.03 22.58 32.34 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.105 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.39 139.16 43.5 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 179.963 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 59.1 m -97.27 169.57 9.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -44.71 151.2 0.3 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 96.81 -24.35 31.4 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.569 HG21 ' CD1' ' A' ' 13' ' ' LEU . 2.4 m -78.51 144.23 35.86 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.99 146.05 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.7 OUTLIER -117.2 157.61 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.708 ' O ' ' HB ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -113.1 151.1 31.2 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.753 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -146.16 105.37 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.841 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.21 115.46 26.03 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.986 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.26 143.34 21.03 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.364 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.56 110.66 6.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.885 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 98.81 23.83 11.4 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.608 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.75 -169.77 2.73 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 0.1 OUTLIER -81.83 122.78 28.15 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.31 131.74 43.88 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.95 7.83 81.92 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.539 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.31 140.48 30.14 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.925 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -90.59 151.61 21.24 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.497 ' CB ' ' CD1' ' A' ' 97' ' ' LEU . 43.2 m-85 -138.0 154.58 49.32 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.525 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 11.1 m-20 -118.5 112.46 19.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.486 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -97.62 149.61 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.994 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.74 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.99 167.01 38.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.837 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 15.5 tt0 -107.72 129.34 55.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 73.0 m -125.88 165.5 18.6 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.226 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -142.51 123.93 14.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.634 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.97 117.63 7.9 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.737 HG12 HG22 ' A' ' 86' ' ' VAL . 5.5 m -99.53 -42.52 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -138.23 -179.49 5.82 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.4 m -63.38 111.52 2.33 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.18 8.46 65.32 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.574 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 62.4 t -121.97 106.96 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.694 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.84 136.47 54.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -85.45 157.79 20.37 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.192 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 32.3 m -126.24 156.63 39.97 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.601 HD21 ' HB3' ' A' ' 50' ' ' ALA . 30.5 t30 -123.91 111.94 28.9 Favored Pre-proline 0 N--CA 1.45 -0.475 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.4 -0.68 9.07 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.308 3.339 . . . . 0.0 109.604 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.601 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -87.55 -13.32 43.25 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.468 ' CB ' HG23 ' A' ' 68' ' ' THR . 9.0 p30 -130.09 27.9 5.08 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.688 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.56 117.72 33.63 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.8 t -111.36 -178.24 3.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.0 p -147.78 155.42 41.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.496 HG22 ' N ' ' A' ' 56' ' ' THR . 3.0 p -167.52 160.42 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.496 ' N ' HG22 ' A' ' 55' ' ' VAL . 37.6 m -127.15 129.91 48.79 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.83 150.86 40.57 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.0 p30 -90.5 -171.08 2.94 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.62 -28.85 69.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 22.6 t30 -75.53 -7.94 55.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 77.5 10.05 86.48 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.2 p -102.03 137.68 39.99 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.35 165.04 15.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 p -150.1 125.18 9.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.573 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.96 164.4 38.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.949 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.573 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -120.39 126.17 49.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.899 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -103.74 118.69 37.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.68 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -68.44 116.78 9.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.58 HG23 HG11 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -73.32 122.83 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.68 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.1 OUTLIER -118.02 133.01 56.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -67.85 -40.8 83.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.469 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 19.5 m -155.96 159.37 39.17 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.837 ' CE2' ' NE2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -177.35 177.78 1.15 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -64.9 121.89 15.69 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.52 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.6 87.21 1.32 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.784 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.29 100.18 10.46 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.958 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.918 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.15 144.13 20.62 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.721 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.16 -43.67 21.27 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.572 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 10.3 t0 -57.76 -17.16 13.88 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 94.24 29.09 9.89 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.918 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -108.61 121.18 44.46 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.432 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.1 ptt180 -62.81 91.07 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.574 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.9 t-105 -63.13 -58.37 7.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.15 157.0 8.15 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.5 m -54.52 110.13 0.59 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.226 HG11 ' CB ' ' A' ' 38' ' ' ALA . 16.8 t -88.49 154.54 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.469 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 27.4 m-20 -118.85 94.55 4.49 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.184 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 93.5 m -52.0 -28.82 18.26 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.85 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 2.1 t -76.18 -1.24 25.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -115.24 -27.16 7.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.74 -166.2 1.6 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.52 123.39 46.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.15 ' HB2' ' CE1' ' A' ' 112' ' ' PHE . 0.8 OUTLIER -104.47 156.29 18.07 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.032 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.12 154.87 42.29 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.899 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 6.4 t -122.11 160.79 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.213 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.28 171.83 42.81 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.525 ' HA ' ' C ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -127.66 124.79 38.81 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.302 ' N ' ' O ' ' A' ' 33' ' ' ASP . 59.6 p -99.47 152.62 19.79 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.925 ' HB2' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -115.14 -164.24 0.93 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.9 -48.89 77.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -70.73 -24.86 62.71 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 95.6 53.81 1.51 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.831 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -131.13 175.9 8.71 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.669 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 179.31 -173.91 45.86 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.211 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.33 157.58 53.13 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.357 3.371 . . . . 0.0 109.611 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.678 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.01 124.71 1.18 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.64 140.13 0.3 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.997 ' O ' ' HG2' ' A' ' 94' ' ' GLN . 2.3 t -101.47 113.99 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.84 ' HA ' ' HG2' ' A' ' 94' ' ' GLN . . . -87.27 126.08 34.61 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.032 HG12 ' HA ' ' A' ' 94' ' ' GLN . 13.1 pt -135.07 -172.94 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.54 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -175.74 178.27 1.57 Allowed 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.184 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.1 m-85 -140.75 109.35 5.94 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 112' ' ' PHE . 8.2 p30 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.521 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -79.04 119.15 76.19 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.566 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.7 Cg_endo -72.34 -177.73 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.263 0 C-N-CA 124.353 3.369 . . . . 0.0 109.619 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.88 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.4 m -98.51 109.51 22.26 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.27 163.67 22.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.482 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.1 p -129.55 115.63 17.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.924 ' CG2' HG23 ' A' ' 21' ' ' VAL . 3.3 t -111.07 149.53 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.871 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.66 171.17 7.6 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.871 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.0 Cg_endo -72.33 117.18 5.01 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.366 3.377 . . . . 0.0 109.589 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.32 13.21 7.12 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.531 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.8 p -91.08 108.39 19.84 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.983 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 99.81 16.04 29.69 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.8 OUTLIER -103.81 140.46 37.62 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.9 p -95.67 173.28 7.56 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -47.04 153.77 0.41 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.38 -24.28 28.1 Favored Glycine 0 C--N 1.335 0.493 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 HD12 ' A' ' 13' ' ' LEU . 3.6 m -71.36 149.66 45.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.4 p -120.49 132.74 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.564 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 0.6 OUTLIER -111.51 153.51 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.95 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.847 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.32 152.87 23.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.924 HG23 ' CG2' ' A' ' 7' ' ' VAL . 1.1 p -145.04 109.42 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.871 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -120.23 114.44 21.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.018 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.65 146.39 22.37 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.88 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.94 113.25 7.26 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.49 14.97 31.03 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.22 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.99 165.89 13.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.986 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.598 ' CD ' ' OH ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -49.61 119.83 3.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.25 134.81 44.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.89 8.06 67.63 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.532 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -95.6 145.74 25.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.04 151.03 23.06 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.375 ' CB ' HD23 ' A' ' 97' ' ' LEU . 35.3 m-85 -137.96 159.16 42.77 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.248 ' OD2' ' HB3' ' A' ' 98' ' ' SER . 3.3 t0 -124.0 115.04 20.57 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.212 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -96.56 142.26 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.861 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.42 164.67 34.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.716 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.2 tt0 -116.19 111.34 20.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 59.4 m -107.82 173.15 6.45 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.062 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.63 123.86 9.53 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.64 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.95 117.45 7.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.598 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 5.6 m -98.2 -43.26 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.415 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -135.46 177.83 7.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.8 m -61.34 112.01 1.99 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.3 8.54 66.05 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 59.1 t -121.53 111.14 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -126.26 139.61 53.19 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.512 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.57 144.36 25.66 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.191 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.5 m -110.19 146.9 34.76 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.714 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 29.2 t30 -107.47 107.74 60.77 Favored Pre-proline 0 N--CA 1.449 -0.488 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.2 Cg_endo -72.34 0.61 7.16 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 124.368 3.378 . . . . 0.0 109.599 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.05 -14.1 39.82 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.492 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.7 p30 -126.04 28.24 6.13 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.43 105.49 14.42 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.1 t -103.14 178.27 4.6 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.8 p -147.06 156.86 43.36 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.616 ' CG1' HD21 ' A' ' 97' ' ' LEU . 7.1 p -167.88 160.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.491 ' N ' HG22 ' A' ' 55' ' ' VAL . 26.9 m -126.96 138.32 53.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -79.8 143.6 34.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.4 p30 -80.25 -171.05 2.8 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.13 -26.11 68.39 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -10.07 59.13 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.22 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.11 31.18 53.6 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -127.61 137.27 52.51 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.46 168.32 13.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.6 128.51 11.75 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.531 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -154.09 162.32 41.28 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.531 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -115.82 119.73 36.94 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.21 HD13 ' CG2' ' A' ' 95' ' ' VAL . 1.0 OUTLIER -97.57 133.94 41.45 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.73 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -79.75 134.56 36.38 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG23 HG11 ' A' ' 19' ' ' VAL . 1.1 t -94.29 124.1 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.73 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 0.7 OUTLIER -117.2 142.95 46.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.92 -26.74 36.54 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -155.42 149.85 26.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.949 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.716 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -173.77 157.88 3.16 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.28 117.51 4.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.512 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.26 93.3 1.09 Allowed Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.788 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -84.14 99.86 10.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.953 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -57.02 130.39 45.87 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.5 p90 -47.16 -35.63 7.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.78 -16.57 11.73 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.68 28.38 8.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.953 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -116.23 147.78 41.1 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -84.73 96.02 9.12 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.598 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 68.7 t90 -64.97 -58.82 5.13 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 147.75 163.87 10.93 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.17 106.42 0.23 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.062 HG11 ' CB ' ' A' ' 38' ' ' ALA . 20.2 t -80.77 152.46 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.68 93.99 4.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.266 ' O ' ' HB2' ' A' ' 112' ' ' PHE . 12.1 m -53.13 -26.57 17.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.726 ' HA ' ' HB3' ' A' ' 112' ' ' PHE . 7.3 t -82.37 0.1 43.46 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.0 m -114.3 -27.0 7.76 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -133.3 -174.93 3.63 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.69 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -99.57 126.0 45.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.957 ' CB ' HD11 ' A' ' 110' ' ' ILE . 92.4 m -104.2 172.01 7.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.041 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 1.2 tt0 -160.93 151.5 18.14 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.21 ' CG2' HD13 ' A' ' 67' ' ' LEU . 3.0 t -108.65 167.1 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.212 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.36 166.65 37.29 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.375 HD23 ' CB ' ' A' ' 32' ' ' TYR . 6.0 mp -102.16 161.82 13.39 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.248 ' HB3' ' OD2' ' A' ' 33' ' ' ASP . 46.7 t -150.86 121.07 7.25 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.645 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 0.8 OUTLIER -115.86 -170.9 1.88 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -46.0 -39.65 9.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.96 -25.33 26.12 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 91.16 22.61 31.94 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 1.35 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.11 -150.27 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.996 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.2 150.62 5.49 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.566 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 166.0 31.03 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.307 3.338 . . . . 0.0 109.578 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.521 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 6.6 pt-20 -34.34 124.3 0.5 Allowed 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.21 135.32 1.48 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.041 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 3.4 t -90.05 107.43 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.91 127.83 34.12 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.038 HG12 ' CA ' ' A' ' 94' ' ' GLN . 4.0 pt -141.5 -173.77 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.69 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.6 OUTLIER -174.75 163.4 3.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.266 ' HB2' ' O ' ' A' ' 88' ' ' CYS . 6.6 m-85 -125.88 112.16 15.66 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.919 HD22 ' HA2' ' A' ' 12' ' ' GLY . 0.8 OUTLIER . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.479 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.648 ' HB3' ' CG ' ' A' ' 106' ' ' GLU . . . -128.38 144.37 51.7 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.525 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.39 -177.2 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.317 3.344 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.756 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.78 109.59 22.33 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.735 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.08 140.3 52.03 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -100.5 111.48 23.74 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 108' ' ' VAL . 21.8 t -105.84 150.29 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.96 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.5 175.7 1.51 Allowed Pre-proline 0 N--CA 1.448 -0.525 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.068 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.7 Cg_endo -72.4 118.59 5.67 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.318 3.346 . . . . 0.0 109.586 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.001 ' HB2' HG23 ' A' ' 110' ' ' ILE . 54.5 p -113.0 47.52 1.11 Allowed 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.0 p -126.56 107.38 10.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.028 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 27.0 20.62 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.068 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -102.01 132.49 47.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 82.0 p -109.88 169.28 8.82 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -45.04 140.72 2.57 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.67 38.31 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.434 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -77.05 141.87 40.11 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.707 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.9 p -113.78 108.95 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.291 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.4 m -77.13 164.07 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.843 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.1 149.72 38.52 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.918 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -146.56 115.41 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.86 116.96 23.08 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.872 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.18 147.94 23.9 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.756 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.61 111.81 4.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.66 14.44 34.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.64 173.64 8.19 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.519 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.5 mt-30 -56.37 119.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.08 131.23 41.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.13 7.82 84.75 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.519 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.83 141.37 28.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.698 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.46 150.35 25.35 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.283 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 25.4 m-85 -136.38 140.81 43.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.41 ' N ' ' N ' ' A' ' 98' ' ' SER . 2.5 m-20 -103.11 116.91 33.4 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.562 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -107.12 145.63 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.886 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -174.54 161.73 31.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.953 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 18.9 tt0 -101.97 120.61 40.69 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.482 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.5 m -109.99 169.0 9.01 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.088 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.73 124.91 8.71 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.611 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.64 124.03 20.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.958 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.792 ' CG1' ' CD1' ' A' ' 83' ' ' TRP . 15.4 m -103.73 -44.07 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.863 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -138.52 165.23 27.39 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.5 m -51.88 112.6 0.81 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.24 8.21 65.05 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 97.3 t -122.32 107.47 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.709 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.71 162.38 18.15 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.507 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.11 156.59 41.5 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.859 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -118.47 155.49 30.71 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.67 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 19.8 t30 -112.86 113.58 49.79 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.38 0.03 8.02 Favored 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 124.343 3.362 . . . . 0.0 109.612 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.98 -9.51 45.73 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 9.2 p30 -134.16 27.72 3.82 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -85.42 107.29 17.33 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -103.49 171.38 7.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.2 p -145.27 153.54 41.4 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -166.6 158.23 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' VAL . 85.7 m -127.52 135.53 50.49 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.45 139.97 48.02 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.2 p30 -77.6 -174.75 3.54 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.8 -25.08 68.06 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -75.99 -8.04 56.04 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.942 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 75.3 32.18 55.96 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -129.87 137.62 50.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.6 167.39 14.56 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -150.56 125.43 9.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.462 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -159.84 158.26 30.68 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.462 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -111.17 133.46 53.51 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.291 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.3 OUTLIER -110.3 120.16 41.54 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.638 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -79.26 129.86 34.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.78 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.88 137.02 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.874 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -120.31 165.62 14.61 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.5 -14.12 33.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.2 m -164.51 144.49 7.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.953 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.4 p90 -176.3 154.24 1.32 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.496 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.9 OUTLIER -57.3 124.26 18.26 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.507 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -84.75 98.08 2.18 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.859 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.2 101.75 12.1 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.979 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.862 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.0 tp -57.81 131.62 50.88 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.679 ' N ' HD12 ' A' ' 77' ' ' LEU . 29.6 p90 -47.64 -35.76 9.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.656 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -58.01 -16.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.963 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.22 28.46 9.18 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.862 ' HB ' HD23 ' A' ' 77' ' ' LEU . 22.0 m -115.66 146.69 41.6 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.0 96.58 8.91 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.863 ' HZ2' ' HB2' ' A' ' 41' ' ' ASP . 5.2 t-105 -63.45 -42.69 98.66 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 128.43 176.55 14.49 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.53 135.55 54.5 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.088 HG11 ' CB ' ' A' ' 38' ' ' ALA . 1.6 t -114.82 154.93 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.4 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -127.81 101.34 6.31 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.907 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 48.9 m -53.35 -28.04 26.78 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -79.04 -2.45 40.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -116.19 -27.59 6.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -128.92 -176.12 3.76 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.0 123.38 45.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.704 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 72.3 m -104.35 152.24 22.5 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.025 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -145.05 148.81 34.12 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.138 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.5 t -114.31 148.2 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.405 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.74 173.87 46.41 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.562 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.7 OUTLIER -125.66 159.88 31.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.41 ' N ' ' N ' ' A' ' 33' ' ' ASP . 2.9 m -139.64 156.95 46.55 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.698 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.11 -165.45 1.0 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -55.79 -49.18 73.89 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.488 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.0 -25.37 62.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.69 39.55 3.37 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.589 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -113.57 154.32 27.34 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.999 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.283 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -161.86 -173.1 30.11 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.525 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.41 158.41 51.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.332 3.354 . . . . 0.0 109.557 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.648 ' CG ' ' HB3' ' A' ' 2' ' ' ALA . 2.4 mt-10 -38.64 117.26 0.63 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.447 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.09 153.2 0.01 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.134 HG21 HG21 ' A' ' 7' ' ' VAL . 11.0 t -127.05 106.71 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.444 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -82.69 133.89 35.15 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.025 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.5 mt -102.76 163.87 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.722 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER -145.73 123.34 11.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.907 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 5.7 m-85 -95.32 127.36 41.3 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.968 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.585 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -98.86 125.57 41.69 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.638 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.37 -174.1 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.327 3.351 . . . . 0.0 109.591 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.765 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.49 110.75 23.07 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.878 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.72 139.16 52.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.551 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -99.71 112.48 24.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.778 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -110.51 152.89 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.929 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.48 174.06 2.87 Favored Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.099 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.9 Cg_endo -72.38 118.74 5.74 Favored 'Trans proline' 0 N--CA 1.448 -1.183 0 C-N-CA 124.321 3.348 . . . . 0.0 109.618 179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.81 ' HB2' HG23 ' A' ' 110' ' ' ILE . 92.0 p -111.94 49.08 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 48.5 p -127.54 106.41 9.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.002 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.44 27.5 20.0 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.099 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.67 132.22 46.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.6 m -109.22 172.27 6.95 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 1.023 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 7.6 t70 -46.6 141.53 3.71 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.2 -22.5 36.3 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.49 HG21 HD13 ' A' ' 13' ' ' LEU . 29.1 m -76.58 149.75 36.58 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.64 HG13 ' O ' ' A' ' 18' ' ' VAL . 11.7 p -121.5 114.66 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.903 HG23 HG12 ' A' ' 69' ' ' VAL . 11.6 t -81.03 153.19 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.778 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.82 147.18 33.76 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.499 HG12 HG12 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -147.3 111.15 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.878 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.87 117.13 27.32 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.804 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.08 144.77 24.0 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.765 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.9 102.29 3.87 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.912 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 109.04 17.64 10.01 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.258 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -90.23 171.36 9.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.988 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.982 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 26.7 mt-30 -56.9 121.82 10.8 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.59 131.75 42.04 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.0 7.77 86.72 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.427 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -96.12 136.59 36.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.984 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -82.64 152.25 25.96 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.875 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.4 m-85 -136.57 146.05 45.68 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.278 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -107.47 113.55 26.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.984 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.4 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.09 144.53 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.994 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.994 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -170.57 169.7 42.53 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.957 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 38.5 tt0 -106.4 105.31 15.28 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -105.71 141.14 37.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.997 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.78 138.57 54.59 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.563 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.93 124.44 22.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.918 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.12 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -103.66 -51.32 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.953 ' CG ' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -132.72 168.29 18.58 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.94 112.49 0.72 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.47 7.96 65.52 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.671 HG11 ' HE1' ' A' ' 83' ' ' TRP . 86.3 t -121.8 120.97 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.578 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -130.26 134.5 47.28 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.979 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.468 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.42 153.53 18.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.103 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 98.6 m -112.64 145.51 40.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.917 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -108.88 114.18 58.72 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.36 -0.24 8.41 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 124.332 3.355 . . . . 0.0 109.584 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.762 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -81.33 -12.67 58.96 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.584 ' CG ' HG23 ' A' ' 68' ' ' THR . 96.2 m-20 -136.66 29.78 2.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.406 ' CD1' ' HA3' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -84.36 108.36 17.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.8 t -107.0 173.41 6.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.9 p -145.59 154.45 42.17 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' N ' ' A' ' 56' ' ' THR . 6.8 p -167.06 156.82 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.436 ' N ' HG22 ' A' ' 55' ' ' VAL . 36.3 m -126.84 135.62 51.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.14 154.1 42.62 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -92.86 -169.42 2.17 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.57 -28.34 69.81 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -75.72 -7.56 54.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.648 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.11 14.96 81.76 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.7 p -107.83 137.68 45.41 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.92 165.45 15.19 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 p -149.94 128.12 12.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -164.67 160.85 20.39 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.899 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -117.65 127.41 53.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.103 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -105.2 120.19 40.93 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.905 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.64 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -76.42 134.99 39.43 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.941 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.903 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.9 135.28 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 1.023 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -116.71 162.47 17.62 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -87.98 -19.51 27.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 28.5 t -163.05 146.73 10.95 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.957 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.7 p90 -177.04 152.75 0.93 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -57.66 118.96 5.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.468 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.64 98.98 1.83 Allowed Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.792 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.13 100.96 10.86 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.957 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.925 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.5 tp -54.78 131.79 44.62 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.672 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.8 m-85 -47.43 -36.48 9.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.575 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.13 -16.66 8.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.27 27.72 9.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.925 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.6 m -115.89 149.93 37.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.56 98.04 11.54 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.12 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -63.94 -43.71 95.06 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.946 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 135.69 -179.65 17.55 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.44 126.16 26.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.997 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.1 t -101.45 154.02 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.483 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 11.7 m-20 -127.45 96.79 4.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.782 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 54.4 m -53.23 -27.81 24.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -78.32 1.28 22.34 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -118.14 -27.53 6.06 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.16 -173.28 3.11 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.8 124.72 48.86 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.87 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 97.6 m -104.36 152.52 22.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.07 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.1 pt20 -146.39 148.43 32.31 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.103 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.7 t -110.3 160.06 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.397 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.43 168.8 41.07 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.4 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.12 128.38 44.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.278 ' N ' ' H ' ' A' ' 33' ' ' ASP . 22.2 m -114.72 148.3 38.48 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.984 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -107.13 -157.97 0.64 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -69.49 -47.26 64.46 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.02 -23.97 64.14 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.01 53.88 1.98 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.982 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.21 165.96 20.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.875 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.37 176.62 46.71 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.638 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.7 Cg_endo -72.38 162.44 41.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.346 3.364 . . . . 0.0 109.59 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.585 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 1.5 tt0 -37.59 120.83 0.84 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.66 153.54 0.02 OUTLIER Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.935 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.8 t -118.3 104.18 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.62 124.05 32.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.07 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.9 mt -101.31 157.0 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.65 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -141.94 125.36 16.64 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.782 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 9.5 m-85 -96.6 124.28 40.54 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.1 m-80 . . . . . 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.39 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -61.48 131.64 92.61 Favored Pre-proline 0 N--CA 1.45 -0.465 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.485 ' CB ' HD22 ' A' ' 26' ' ' LEU . 81.4 Cg_endo -72.4 -174.31 1.39 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.268 3.312 . . . . 0.0 109.616 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.805 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.66 108.27 19.75 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.879 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.57 146.24 47.17 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -113.24 118.17 33.92 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.829 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -114.13 155.15 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.993 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.645 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -71.54 162.19 74.32 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.639 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.4 Cg_endo -72.4 121.98 7.93 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.322 3.348 . . . . 0.0 109.606 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.659 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.2 OUTLIER -126.93 15.84 7.39 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.6 111.73 22.23 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.078 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.3 22.58 31.7 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.078 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -109.11 144.12 37.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 75.5 m -94.29 166.03 12.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 1.128 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 11.5 t0 -46.15 153.34 0.33 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 100.02 -24.27 32.78 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.438 HG21 HD12 ' A' ' 13' ' ' LEU . 24.5 m -69.17 132.62 46.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.3 p -106.43 111.33 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.645 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 6.4 m -90.37 166.08 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.829 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.04 149.1 44.82 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.454 HG13 ' CG1' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -136.41 104.88 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.999 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.879 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -114.8 117.83 31.84 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.746 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -88.03 143.82 18.37 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.805 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -135.01 108.09 7.65 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.921 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.69 25.69 7.98 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.485 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.89 179.69 6.14 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 180.0 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.425 ' HB2' HG21 ' A' ' 30' ' ' THR . 18.9 mt-30 -76.83 123.74 26.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.476 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.11 137.46 54.96 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.78 7.28 65.25 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.644 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.16 145.12 24.65 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.2 149.11 22.01 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.535 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 39.8 m-85 -138.05 136.83 37.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.109 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -99.61 114.75 27.99 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.114 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -100.99 143.19 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.897 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.66 162.14 35.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.936 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -101.01 117.78 35.7 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.436 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.9 m -108.65 164.57 12.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.771 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -150.47 139.44 20.98 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.527 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.8 OUTLIER -64.67 124.55 22.21 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.228 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -106.4 -53.93 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.617 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -138.1 167.03 22.66 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -51.02 111.58 0.58 Allowed 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.59 8.15 66.51 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.602 ' CG1' ' CZ3' ' A' ' 83' ' ' TRP . 13.8 t -124.21 118.91 55.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.69 HD12 ' N ' ' A' ' 46' ' ' ALA . 2.0 pp -121.93 163.3 19.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.369 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -127.51 146.19 50.59 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.768 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.15 159.13 17.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.985 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.902 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.2 t30 -113.04 112.74 49.81 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -72.39 -0.82 9.28 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.339 3.36 . . . . 0.0 109.592 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.95 -7.92 50.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.449 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 32.9 m-20 -133.82 26.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.406 ' HD1' ' HA ' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -84.25 106.12 15.62 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 33.8 t -104.73 176.38 5.18 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.7 p -146.09 158.45 43.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.449 HG22 ' N ' ' A' ' 56' ' ' THR . 5.5 p -166.98 158.3 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.449 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.5 m -128.37 127.35 42.47 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -62.61 141.57 58.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.5 p30 -85.22 -171.57 3.7 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.53 -23.52 67.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -83.67 1.0 44.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.476 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 70.44 2.35 41.83 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 t -95.12 136.08 35.88 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.45 161.99 21.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -147.51 129.59 15.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.715 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -151.7 174.24 13.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.888 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.715 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -130.96 114.64 15.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.613 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -98.38 156.89 16.52 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.601 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -116.64 134.67 54.54 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.649 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -101.03 131.06 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 1.128 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -115.74 147.92 40.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.7 ptt180 -74.48 -25.15 59.2 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.5 t -159.94 150.01 18.45 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.936 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.6 p90 -177.34 156.03 1.17 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.23 119.83 7.58 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.369 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.32 100.39 1.39 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.768 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.6 OUTLIER -83.35 100.04 10.41 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 1.074 HD21 ' OD2' ' A' ' 79' ' ' ASP . 4.3 tp -55.05 137.12 47.15 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.69 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.62 -40.99 13.93 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 1.074 ' OD2' HD21 ' A' ' 77' ' ' LEU . 1.5 m-20 -57.09 -17.0 8.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.98 26.87 10.84 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -109.51 148.63 30.89 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.76 95.73 8.52 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.617 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 33.3 t-105 -62.8 -56.43 17.55 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.04 170.72 19.0 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -61.53 107.44 0.8 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.771 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.8 t -83.41 152.33 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.77 93.71 4.31 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.268 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -55.03 -22.27 15.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.526 ' HA ' ' HB2' ' A' ' 112' ' ' PHE . 25.7 p -85.93 2.24 46.86 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -110.98 -26.57 9.2 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.54 179.22 6.69 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.664 ' HA ' ' HA ' ' A' ' 111' ' ' SER . . . -94.06 129.45 40.59 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.045 ' HB2' HD11 ' A' ' 110' ' ' ILE . 59.1 m -104.86 173.07 6.46 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.378 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.5 OUTLIER -158.67 142.55 15.37 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.951 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.613 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.4 t -98.21 164.13 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.114 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.93 161.25 26.87 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.076 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -126.55 135.71 51.63 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.109 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 52.4 p -106.99 158.79 16.77 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.466 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.0 OUTLIER -112.46 -167.53 1.2 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.466 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -53.8 -49.83 67.45 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.489 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -74.52 -25.4 59.31 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.4 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 104.67 39.44 2.37 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.489 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -122.92 -175.34 3.14 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.535 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 162.14 -161.88 33.79 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.389 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.91 52.44 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.382 3.388 . . . . 0.0 109.553 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.39 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.0 pt-20 -42.84 145.23 0.48 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -52.76 164.5 1.75 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.378 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 37.3 t -116.84 102.69 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.448 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -75.88 132.48 40.35 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.045 HD11 ' HB2' ' A' ' 93' ' ' CYS . 6.2 pt -142.41 -174.36 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.664 ' HA ' ' HA ' ' A' ' 92' ' ' ALA . 0.1 OUTLIER -171.02 176.1 4.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.268 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 4.6 m-85 -132.55 114.29 14.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.002 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.4 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.645 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -126.28 131.31 23.9 Favored Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.587 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 84.2 Cg_endo -72.38 -177.7 2.88 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 124.314 3.343 . . . . 0.0 109.635 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.785 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.77 109.69 22.41 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.783 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.46 133.52 51.19 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.632 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -96.51 115.85 28.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.556 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.29 155.95 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.95 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.33 175.61 1.77 Allowed Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.051 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.37 117.4 5.11 Favored 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.32 3.346 . . . . 0.0 109.58 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.805 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 1.6 p -110.73 48.57 0.91 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 79.9 p -126.97 105.88 8.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.096 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.32 29.27 11.43 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.096 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -108.43 130.29 55.24 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.951 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.19 177.36 4.67 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -45.83 139.39 4.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.07 -22.77 34.06 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.679 HG21 ' HB3' ' A' ' 13' ' ' LEU . 17.2 m -83.13 150.56 26.19 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.503 HG13 ' O ' ' A' ' 18' ' ' VAL . 13.9 p -121.49 123.96 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.53 HG23 ' HB3' ' A' ' 67' ' ' LEU . 6.8 m -90.44 158.44 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.38 149.08 30.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.711 HG12 ' O ' ' A' ' 65' ' ' THR . 0.3 OUTLIER -145.09 113.38 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.65 117.19 22.98 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.834 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.06 147.75 23.89 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.785 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.36 111.32 4.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.17 15.61 30.04 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.059 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.6 177.05 6.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 29.7 mt-30 -59.61 121.5 11.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.22 129.8 39.3 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.08 7.04 86.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.52 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.23 141.5 28.51 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -87.92 149.85 23.83 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.779 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.6 m-85 -136.43 138.09 41.14 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.002 ' HB3' ' O ' ' A' ' 98' ' ' SER . 1.5 t0 -99.99 113.84 26.7 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.242 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.04 144.72 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.739 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.84 171.05 42.17 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.929 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 33.8 tt0 -117.64 108.77 15.84 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -113.76 147.66 37.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.288 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.33 142.87 50.04 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.503 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.98 124.97 23.45 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.898 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.443 ' CG2' ' CD1' ' A' ' 83' ' ' TRP . 1.2 t -104.89 -44.25 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.332 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -149.05 134.8 18.81 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 41' ' ' ASP . 1.5 m -38.18 110.92 0.14 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.459 ' C ' ' CG1' ' A' ' 44' ' ' VAL . . . 94.46 8.3 59.87 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.173 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.7 OUTLIER -151.59 129.26 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.636 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -133.96 132.95 40.78 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.987 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.425 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -84.27 144.69 28.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.068 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 2.6 m -106.44 152.92 23.0 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 41.4 t-20 -111.64 107.4 56.64 Favored Pre-proline 0 N--CA 1.449 -0.511 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.1 Cg_endo -72.4 -0.05 8.16 Favored 'Trans proline' 0 N--CA 1.447 -1.235 0 C-N-CA 124.308 3.338 . . . . 0.0 109.599 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.17 -10.44 49.89 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.697 ' OD1' ' C ' ' A' ' 50' ' ' ALA . 0.3 OUTLIER -131.71 27.56 4.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.501 ' HD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -80.5 104.6 11.15 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -100.11 175.35 5.77 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.3 p -143.94 153.39 42.22 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.426 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 8.6 p -167.98 152.24 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 39.7 m -127.47 134.71 49.81 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -71.4 141.63 50.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 45.2 p30 -81.57 -173.33 4.34 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.01 -27.21 68.71 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.32 -8.61 57.13 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.059 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 76.81 31.87 52.05 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 79.1 p -127.93 139.67 52.45 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.426 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -123.35 165.81 16.37 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.71 122.89 8.91 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.711 ' O ' HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -158.73 152.22 22.99 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.75 127.95 56.23 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.486 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -97.78 156.4 16.59 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.956 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 51' ' ' ASP . 4.8 t -102.67 120.96 41.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.511 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 1.0 OUTLIER -83.22 127.79 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.861 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.8 OUTLIER -117.14 155.81 28.7 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -94.21 -18.26 21.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.551 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 3.6 m -164.19 144.75 8.22 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.929 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.7 p90 -172.24 153.64 3.09 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -57.98 111.67 1.25 Allowed 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.425 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.67 101.76 0.89 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.749 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.37 99.68 10.2 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.3 tp -55.44 141.14 37.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.718 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.3 m-85 -46.54 -42.9 16.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.746 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -57.33 -16.89 9.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.82 27.69 12.27 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.3 m -109.23 144.72 36.97 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.6 ptt180 -76.89 94.77 3.97 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.443 ' CD1' ' CG2' ' A' ' 40' ' ' VAL . 31.5 t-105 -63.19 -57.2 11.3 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 155.52 163.79 12.51 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.1 104.67 0.33 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.288 HG11 ' CB ' ' A' ' 38' ' ' ALA . 67.9 t -76.64 150.45 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.427 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 4.2 m-20 -117.19 93.91 4.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.002 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 30.8 m -52.16 -27.22 13.62 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.6 p -80.01 0.36 32.01 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.6 m -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.73 -175.1 3.61 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.65 126.48 47.15 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.903 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.2 m -104.55 154.37 20.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.027 ' HA ' HG13 ' A' ' 110' ' ' ILE . 2.1 pt20 -142.55 150.05 39.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.486 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.4 t -110.62 164.04 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.242 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.66 166.31 36.01 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.96 121.03 27.15 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.002 ' O ' ' HB3' ' A' ' 33' ' ' ASP . 0.6 OUTLIER -103.52 150.96 23.41 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -109.81 -159.93 0.7 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.973 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.27 -48.87 79.07 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.53 -25.71 57.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.86 42.24 2.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.454 HD21 ' CG ' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -111.68 166.27 11.31 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.774 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.99 -177.64 44.24 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.587 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.36 157.06 54.0 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.3 3.333 . . . . 0.0 109.6 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.132 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 1.9 mt-10 -35.39 125.89 0.62 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.06 151.88 0.02 OUTLIER Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.904 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.9 t -124.39 104.68 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -84.63 146.06 27.68 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.027 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.8 mt -121.05 157.37 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.54 115.76 11.77 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.002 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 11.6 m-85 -86.56 114.27 23.15 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 2.8 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.48 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -87.1 122.94 70.85 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.481 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.6 Cg_endo -72.4 -178.26 3.22 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 124.303 3.336 . . . . 0.0 109.581 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.839 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.62 111.33 23.68 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.69 159.58 33.27 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.434 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.5 p -124.29 121.28 34.57 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.83 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 55.5 t -116.87 146.39 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.773 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.96 167.75 18.72 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.773 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 118.65 5.7 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.357 3.372 . . . . 0.0 109.576 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -129.71 9.93 5.51 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.965 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.045 ' HA ' ' O ' ' A' ' 111' ' ' SER . 79.2 p -85.66 106.44 16.94 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.431 ' CA ' ' H ' ' A' ' 113' ' ' ASN . . . 102.25 14.52 28.1 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.964 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -106.04 136.07 46.38 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.969 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -92.31 176.63 6.41 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.64 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 11.0 t70 -44.79 153.12 0.19 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.82 -23.34 34.68 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.681 HG21 HD12 ' A' ' 13' ' ' LEU . 10.4 m -72.58 142.97 48.42 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.6 p -118.9 121.04 65.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.814 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -100.59 154.31 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.2 151.0 26.51 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.757 HG23 ' CG2' ' A' ' 7' ' ' VAL . 0.9 OUTLIER -141.95 109.19 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.969 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.848 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.46 115.43 22.21 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.025 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -86.62 146.36 20.7 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.839 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -142.2 112.12 6.86 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.49 17.75 25.56 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.125 HD23 ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.48 167.61 12.46 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.786 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 18.2 mt-30 -52.22 121.21 6.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.515 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.23 130.69 40.77 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.35 7.12 86.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.483 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -94.95 139.12 31.78 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.522 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.42 152.55 23.95 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.69 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 33.5 m-85 -136.71 139.82 42.21 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.245 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -103.72 113.8 27.59 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.258 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -102.68 149.66 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.835 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.4 172.32 43.99 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.847 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 36.8 tt0 -113.5 110.91 21.03 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 58.7 m -108.94 147.12 32.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.864 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -125.95 131.58 52.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.61 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.25 120.52 12.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.919 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.973 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.7 m -100.35 -43.23 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.508 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -136.85 166.1 24.41 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.951 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.679 HG23 ' O ' ' A' ' 42' ' ' THR . 15.3 t -51.14 111.74 0.61 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.12 8.52 65.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 21.0 t -122.09 109.41 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.457 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -123.89 141.17 52.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.956 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.432 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -100.28 155.13 17.95 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.214 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 57.9 m -111.04 149.61 30.5 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.697 HD22 ' HB3' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -117.1 115.66 38.22 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.405 ' HA ' ' HB2' ' A' ' 52' ' ' PHE . 83.2 Cg_endo -72.37 1.02 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.345 . . . . 0.0 109.629 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -81.28 -14.25 57.6 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CG ' HG23 ' A' ' 68' ' ' THR . 95.1 m-20 -132.86 29.58 4.11 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' HB2' ' HA ' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -84.53 109.77 18.18 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 41.5 t -105.7 174.1 6.03 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -146.35 149.78 34.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.412 HG22 ' N ' ' A' ' 56' ' ' THR . 6.1 p -166.22 155.51 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.1 m -126.05 133.02 51.84 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.17 138.73 47.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.7 p30 -77.44 -174.06 3.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.3 -17.39 58.58 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -85.16 5.66 29.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.937 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 59.12 32.37 71.2 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.6 t -130.44 137.09 49.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -128.52 167.49 17.03 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 53.1 p -150.83 128.04 11.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.728 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -148.52 172.91 13.73 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.853 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.728 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -126.09 122.78 36.75 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.896 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -100.43 143.45 30.6 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.926 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.626 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -100.45 143.99 29.98 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.99 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 t -103.35 129.33 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.64 ' NH1' ' OD2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -119.42 143.91 47.22 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.02 -32.05 68.71 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 33.2 t -158.09 158.96 35.71 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.847 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -177.0 163.93 2.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -65.26 120.93 13.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.432 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.11 93.2 0.96 Allowed Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 1.006 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 100.07 10.48 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.1 tp -54.5 137.47 42.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.816 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 3.0 m-85 -46.6 -40.77 13.49 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.564 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 7.7 t0 -56.89 -17.39 9.31 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.56 27.94 9.39 Favored Glycine 0 C--N 1.335 0.504 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.33 139.87 45.08 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 mtm180 -78.25 92.5 4.5 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.973 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 13.6 t90 -62.49 -57.92 9.48 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.07 166.06 13.41 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.95 128.83 38.83 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.864 HG11 ' HB3' ' A' ' 38' ' ' ALA . 13.7 p -113.15 147.51 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -99.3 95.19 6.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.74 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -54.88 -20.71 9.39 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.9 p -91.24 1.78 56.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.8 m -108.71 -27.01 10.04 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.4 176.64 8.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.439 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -89.59 126.72 35.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.24 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -104.98 172.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.953 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -156.68 147.81 22.1 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.896 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 29.6 t -104.86 163.49 4.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.258 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . 179.55 167.98 37.72 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.164 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -133.02 138.75 46.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.245 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 22.8 m -121.73 145.55 47.91 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.9 OUTLIER -103.19 -158.56 0.67 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -70.55 -47.75 58.83 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.95 -24.39 66.06 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.2 53.62 1.85 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.786 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.04 165.26 23.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.516 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.01 171.46 42.96 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.481 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 166.2 30.46 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.344 3.363 . . . . 0.0 109.604 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.48 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 11.2 pt-20 -37.87 120.24 0.82 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -38.83 158.78 0.01 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.899 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.6 t -115.03 103.56 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.08 124.03 30.67 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.24 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 4.6 pt -134.49 -174.87 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 1.045 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -170.83 175.94 4.32 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.2 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.8 m-85 -124.46 115.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.431 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 36.1 m-80 . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.593 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -143.99 119.9 6.3 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.586 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.37 -174.46 1.43 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.29 3.327 . . . . 0.0 109.642 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.29 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 5.8 t -100.94 115.24 29.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.916 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -129.73 165.18 22.4 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.429 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.3 p -125.99 122.2 35.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.856 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 84.8 t -118.7 145.78 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.762 HG22 ' HA ' ' A' ' 19' ' ' VAL . 0.5 OUTLIER -70.29 163.03 65.88 Favored Pre-proline 0 N--CA 1.448 -0.538 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.681 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.42 119.27 6.03 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.284 3.323 . . . . 0.0 109.595 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.682 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 2.2 t -126.95 14.03 7.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.813 ' HA ' ' O ' ' A' ' 111' ' ' SER . 83.0 p -88.95 105.83 18.02 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.088 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 100.17 21.59 13.22 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.088 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -109.87 139.51 44.87 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -85.96 169.2 13.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -44.42 152.29 0.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.53 -22.54 40.38 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 HD12 ' A' ' 13' ' ' LEU . 35.9 m -64.17 140.63 58.89 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.82 110.95 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.762 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.9 OUTLIER -93.29 118.61 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.856 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -77.6 146.38 36.23 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -135.19 110.5 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.985 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.676 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.56 115.01 22.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.916 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.21 143.35 20.25 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.232 ' O ' HG22 ' A' ' 4' ' ' THR . . . -136.8 110.38 8.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.9 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.18 24.15 9.9 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.301 -1.12 . . . . 0.0 110.301 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.586 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.6 -175.04 4.8 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.995 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.523 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 25.3 mt-30 -74.2 124.5 26.49 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.505 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.48 128.01 34.28 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.27 8.65 87.02 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.713 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.84 134.3 40.33 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.973 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.48 152.15 23.42 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.952 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 66.6 m-85 -137.05 156.15 48.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.037 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -114.62 115.26 26.87 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.942 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.087 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 1.4 t -98.77 143.11 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.775 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.7 163.58 37.3 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.922 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -106.38 115.55 30.4 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 93.9 m -107.45 168.23 9.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.91 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -153.71 126.7 8.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.604 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.39 122.82 18.03 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.619 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 11.6 m -103.92 -43.44 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.654 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -142.48 171.94 13.37 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.1 m -56.75 112.55 1.33 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 5.11 56.59 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.776 HG12 ' CD1' ' A' ' 83' ' ' TRP . 24.0 t -118.63 107.05 20.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.877 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.2 pp -117.08 162.85 17.15 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.529 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -125.26 146.12 49.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.293 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 51.1 m -115.53 152.36 33.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.7 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -112.64 107.15 55.17 Favored Pre-proline 0 N--CA 1.449 -0.5 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -72.46 -0.31 8.57 Favored 'Trans proline' 0 N--CA 1.447 -1.242 0 C-N-CA 124.317 3.345 . . . . 0.0 109.554 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.646 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.65 -12.04 40.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.674 ' CB ' HG23 ' A' ' 68' ' ' THR . 69.8 m-20 -131.82 24.88 4.67 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.664 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -95.51 117.86 31.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.9 t -110.77 -171.76 1.9 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.78 156.45 43.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.6 p -166.4 152.79 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 54.6 m -126.19 132.06 51.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.47 150.8 48.41 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.4 p30 -90.93 -169.11 2.25 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.25 -27.84 68.74 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -76.27 -10.57 59.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 79.58 9.33 86.97 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -100.64 137.61 38.81 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.11 161.67 21.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.88 130.38 13.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.718 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.23 173.26 15.31 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.718 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -121.36 133.35 55.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.903 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.932 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -117.59 119.4 34.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.674 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -78.72 141.08 38.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.948 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.671 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -113.78 130.24 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.986 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.667 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -114.78 154.75 27.99 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -76.25 -22.1 55.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 87.7 p -161.42 151.84 17.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.922 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -176.98 160.4 1.8 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.49 113.11 2.49 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.529 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -74.63 95.97 0.91 Allowed Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.693 ' N ' ' H ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 99.9 10.34 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.937 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -53.56 144.51 17.18 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.846 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.61 -43.93 26.2 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.937 ' OD2' HD21 ' A' ' 77' ' ' LEU . 12.0 m-20 -58.08 -16.5 13.25 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.45 27.51 13.05 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.808 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -105.18 125.99 51.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.523 ' CZ ' ' HB3' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -64.53 91.69 0.08 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.964 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.619 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 87.2 t90 -62.02 -39.29 91.76 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 132.15 174.73 13.72 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.16 105.05 1.29 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.149 HG22 ' CG1' ' A' ' 40' ' ' VAL . 42.8 t -80.73 146.42 7.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -105.08 92.96 4.44 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.055 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -53.49 -21.26 5.96 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 28.2 p -89.18 3.14 52.91 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -112.92 -27.64 8.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -135.84 174.63 10.4 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.534 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -91.4 127.66 36.92 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.4 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 33.2 m -105.41 167.23 9.88 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.075 ' CA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -155.29 140.58 17.63 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.932 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -92.7 164.93 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.087 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.46 160.93 27.24 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.005 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.03 127.09 42.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.037 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 26.4 m -106.44 151.02 25.47 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.41 -161.45 0.75 Allowed 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.998 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.86 -48.65 65.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.23 -24.17 65.8 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 94.12 53.82 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 172.17 13.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.952 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.02 178.45 45.0 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.494 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.39 164.06 36.75 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.265 3.31 . . . . 0.0 109.577 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.593 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 13.2 pt-20 -38.12 124.05 1.16 Allowed 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.434 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.29 152.6 0.01 OUTLIER Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.029 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 72.8 t -111.8 103.26 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.33 130.59 35.6 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.4 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.0 pt -143.84 177.31 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.813 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -173.49 176.31 2.83 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.943 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.055 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 1.7 m-85 -128.09 120.0 26.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.699 ' H ' ' CA ' ' A' ' 12' ' ' GLY . 27.5 m-80 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.374 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -141.41 124.57 9.77 Favored Pre-proline 0 N--CA 1.45 -0.458 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.456 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.44 -177.53 2.8 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.296 3.33 . . . . 0.0 109.595 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.189 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.17 109.06 21.88 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.883 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 139.66 53.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -104.65 117.75 34.87 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.852 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -113.17 155.27 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.955 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.83 176.65 1.22 Allowed Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.111 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.1 Cg_endo -72.39 117.71 5.26 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 124.305 3.337 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.663 ' HB2' HG23 ' A' ' 110' ' ' ILE . 24.0 p -113.29 43.56 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 60.7 p -123.58 106.79 10.87 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.019 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.75 28.39 14.24 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.111 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.08 133.5 45.51 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 m -104.61 165.0 11.35 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.689 ' OD2' ' NH1' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -44.75 139.13 3.11 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.28 -22.33 34.96 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 27.8 m -76.07 141.89 41.9 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 67' ' ' LEU . 10.4 p -113.28 128.86 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 8' ' ' THR . 2.7 t -96.23 164.36 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.852 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.21 144.85 41.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.662 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -139.58 113.21 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.883 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.46 114.62 19.06 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.81 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -88.74 140.96 16.22 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.189 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.31 116.76 10.73 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.18 19.35 21.55 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.81 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -88.35 173.76 8.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.495 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 27.0 mt-30 -64.35 120.74 12.78 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.13 136.95 56.67 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.09 8.19 61.14 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.722 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -86.1 146.58 26.55 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.892 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.97 138.22 33.92 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.045 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 32.7 m-85 -131.32 146.75 52.42 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.254 ' CB ' ' H ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -117.12 116.49 27.4 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.376 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.45 153.67 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.001 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.72 163.66 30.8 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.946 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 21.0 tt0 -103.1 120.33 40.48 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.655 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.1 m -108.25 164.37 12.37 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.74 -0.466 . . . . 0.0 109.74 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -152.0 131.08 12.65 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.496 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -66.29 128.75 37.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.923 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.53 ' CB ' ' NE1' ' A' ' 83' ' ' TRP . 3.3 m -117.07 -38.1 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.255 ' OD1' ' HH2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -146.68 178.78 8.04 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 42' ' ' THR . 4.7 t -64.48 110.95 2.47 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 8.3 63.51 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.981 HG11 ' CE3' ' A' ' 83' ' ' TRP . 84.9 t -111.7 104.88 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.638 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.0 OUTLIER -104.33 154.81 19.36 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.934 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.595 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.16 129.01 44.56 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.836 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.72 157.43 18.12 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.753 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.1 t30 -115.67 114.56 42.13 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -72.46 -1.26 9.96 Favored 'Trans proline' 0 N--CA 1.446 -1.267 0 C-N-CA 124.318 3.345 . . . . 0.0 109.611 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -91.19 -11.39 38.46 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 68' ' ' THR . 21.0 p30 -133.84 25.89 3.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.642 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -97.84 116.17 29.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 t -103.53 178.57 4.52 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.2 p -146.38 153.11 40.12 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.547 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.91 157.37 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 60.3 m -125.32 127.48 46.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.415 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -59.55 124.72 20.97 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 45.3 p30 -69.95 -170.3 0.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.26 -23.73 66.46 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -81.25 2.12 29.33 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.807 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 65.54 32.45 83.35 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 32.7 t -127.65 145.03 51.02 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -143.85 124.66 14.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -108.72 133.68 52.47 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.412 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -148.94 155.65 41.15 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.412 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -111.24 120.43 42.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.615 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.79 159.36 15.85 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.803 -0.444 . . . . 0.0 109.803 179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.614 HG23 ' HB2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -124.91 133.05 53.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.26 130.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.713 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -110.78 168.37 9.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 29.7 ptt180 -96.53 -8.34 32.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 4.8 t -176.54 146.15 0.59 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.946 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 10.3 p90 -176.77 166.72 2.58 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -62.13 127.29 30.68 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.595 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.15 93.41 1.7 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.836 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.58 100.59 11.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.985 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.942 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -57.19 130.67 47.18 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.655 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 13.1 m-85 -47.67 -35.76 10.05 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.569 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.81 -16.88 12.88 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.55 27.5 9.08 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.942 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -115.26 150.18 36.6 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.45 97.19 10.93 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.53 ' NE1' ' CB ' ' A' ' 40' ' ' VAL . 15.2 t-105 -66.64 -56.88 8.63 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.5 168.25 13.41 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.45 142.88 31.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.832 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -127.13 154.64 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.981 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.418 ' N ' ' CG2' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -113.81 100.97 8.85 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.573 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.9 OUTLIER -53.78 -26.33 23.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -83.71 0.69 46.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 m -117.74 -27.85 6.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.23 175.64 7.28 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.95 123.04 40.56 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.195 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.9 m -104.47 152.62 22.12 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.988 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -143.77 143.39 31.35 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.615 HG13 ' CD1' ' A' ' 67' ' ' LEU . 3.4 t -101.95 151.57 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.372 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.72 171.57 43.78 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.376 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -128.27 146.05 50.87 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.254 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 5.9 m -123.18 153.25 40.31 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.892 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.59 -163.98 0.89 Allowed 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.29 -49.28 78.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.37 -25.76 62.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 97.75 46.52 2.27 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.453 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -119.27 166.82 12.52 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.045 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.84 -176.53 41.5 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.456 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.47 162.45 41.41 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.306 3.337 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.374 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -38.85 127.45 1.58 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -43.75 144.54 1.72 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.986 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.0 t -120.87 110.94 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.85 142.84 27.34 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.195 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.9 OUTLIER -108.13 168.59 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.73 120.44 7.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CE2' ' HB3' ' A' ' 88' ' ' CYS . 39.5 m-85 -97.99 121.89 40.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.948 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.061 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -136.57 109.33 9.42 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.484 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.1 Cg_endo -72.42 -177.53 2.79 Favored 'Trans proline' 0 N--CA 1.448 -1.205 0 C-N-CA 124.328 3.352 . . . . 0.0 109.537 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.834 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -97.47 109.83 22.51 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.792 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.8 133.59 50.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.561 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.35 114.64 26.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.681 HG11 ' CG2' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -109.3 155.87 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.993 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.925 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.79 174.61 2.15 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.073 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.7 Cg_endo -72.43 118.12 5.45 Favored 'Trans proline' 0 N--CA 1.447 -1.23 0 C-N-CA 124.346 3.364 . . . . 0.0 109.538 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.9 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -117.05 46.79 1.6 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.631 ' HA ' ' O ' ' A' ' 111' ' ' SER . 96.6 p -124.85 105.33 9.17 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.866 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.944 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.9 28.5 15.48 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.073 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.06 133.43 41.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.996 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.6 p -99.83 163.26 12.54 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.506 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 0.0 OUTLIER -47.01 140.96 4.45 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.24 36.43 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 27.9 m -71.38 150.22 45.24 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 18' ' ' VAL . 9.9 p -121.13 118.29 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.754 HG22 ' O ' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -86.8 169.33 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.997 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -120.74 153.05 37.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -146.58 113.17 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.792 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.05 115.9 22.62 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.837 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.99 143.89 21.57 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.719 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -145.08 112.98 6.38 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.87 19.09 23.09 Favored Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.028 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.81 -176.55 4.72 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.938 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.455 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 22.7 mt-30 -70.91 124.83 25.26 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.449 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.69 127.59 33.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.32 7.26 88.71 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -88.65 143.67 26.78 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.862 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -91.3 141.93 28.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.98 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 33.5 m-85 -131.53 146.22 52.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.257 ' CB ' ' H ' ' A' ' 98' ' ' SER . 13.8 m-20 -111.97 113.13 25.25 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.379 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -95.8 144.36 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.978 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.925 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.17 163.77 36.1 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.981 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 19.3 tt0 -107.41 108.04 19.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 65.9 m -107.83 142.19 38.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.859 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -122.48 139.18 54.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.558 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.11 124.86 22.73 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.337 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.1 t -105.26 -49.67 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.598 ' N ' HG12 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -135.64 167.67 20.68 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.2 t -50.28 112.45 0.68 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.83 8.0 63.01 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.474 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 93.5 t -122.22 116.46 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.536 ' CD1' ' HB3' ' A' ' 37' ' ' CYS . 0.5 OUTLIER -125.97 135.47 51.88 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.996 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.407 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -90.14 159.39 16.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.18 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 28.8 m -116.12 151.92 34.66 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.778 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.5 t30 -112.03 106.12 56.32 Favored Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.3 Cg_endo -72.44 -1.12 9.75 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 124.3 3.333 . . . . 0.0 109.599 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.624 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.41 -10.43 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.882 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ALA . 79.3 m-20 -135.61 27.04 3.38 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.665 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -96.51 121.22 38.1 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.8 t -115.4 -173.37 2.32 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.3 p -145.95 156.99 43.88 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.861 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 6.2 p -167.19 157.77 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 25.6 m -128.61 136.59 50.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.24 130.63 38.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.3 p30 -72.13 -177.84 2.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.31 -16.22 43.59 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -86.12 7.56 24.35 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.028 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.01 32.64 62.84 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.1 t -131.89 135.38 46.61 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.91 166.64 16.53 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.7 m -151.15 128.0 10.97 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.652 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -155.46 169.85 23.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.89 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.652 ' N ' HG23 ' A' ' 65' ' ' THR . 0.0 OUTLIER -118.69 133.28 55.97 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.203 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -115.69 118.99 34.6 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.936 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.632 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -77.64 137.04 38.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.973 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.731 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.09 125.85 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.73 -0.471 . . . . 0.0 109.73 -179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.42 ' N ' ' HD3' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -109.76 168.48 9.38 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.98 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.506 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -97.04 -15.73 20.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.993 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 47.8 t -167.37 146.45 5.04 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.981 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.7 p90 -176.92 151.8 0.88 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.7 OUTLIER -53.12 116.43 2.39 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.921 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.407 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.08 102.99 1.74 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.982 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -84.01 100.6 11.17 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.9 tp -54.24 132.89 44.41 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.987 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.966 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.5 m-85 -46.94 -37.16 8.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.581 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -57.51 -16.93 11.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.8 27.63 9.46 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.5 m -115.29 151.3 34.81 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.506 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 7.7 ptp180 -85.9 98.5 10.82 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.337 ' CE3' HG22 ' A' ' 40' ' ' VAL . 0.4 OUTLIER -64.52 -58.03 7.52 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.883 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 174.42 23.29 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.13 110.73 1.94 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.859 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -85.93 154.39 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 86' ' ' VAL . 11.4 m-20 -122.02 95.14 4.54 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.73 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 35.9 m -53.61 -26.69 22.98 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -80.0 -1.51 40.01 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.8 m -114.65 -27.67 7.4 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.53 -173.94 3.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.883 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.55 125.48 48.21 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.854 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 93.1 m -104.2 152.66 21.9 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.028 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -143.94 150.52 38.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.944 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.203 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 2.4 t -112.41 160.29 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.379 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -177.28 169.96 42.36 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.315 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.88 128.03 44.44 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.257 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 56.8 m -107.23 151.22 25.72 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.862 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.29 -163.24 0.84 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.985 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.426 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -64.97 -48.85 72.55 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.22 -24.12 63.98 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.88 53.37 1.79 Allowed Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.511 ' OD1' ' HE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -130.49 172.62 11.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.965 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.98 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -177.85 -179.16 47.85 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.4 157.99 52.2 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.324 3.349 . . . . 0.0 109.573 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.095 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 16.8 pt-20 -36.02 123.13 0.72 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.72 149.86 0.03 OUTLIER Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.977 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.1 t -117.6 104.97 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.73 135.42 33.76 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.028 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.2 mt -111.79 167.12 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.631 ' O ' ' HA ' ' A' ' 11' ' ' SER . 4.7 t -153.11 128.48 9.89 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.73 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 26.6 m-85 -102.02 125.4 48.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.509 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 m-80 . . . . . 0 N--CA 1.448 -0.54 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.307 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -122.36 125.13 26.62 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.48 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.38 -177.79 2.93 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 124.328 3.352 . . . . 0.0 109.592 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.223 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.83 111.93 24.35 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.756 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.12 160.58 30.75 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.543 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -120.37 113.46 20.39 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 21' ' ' VAL . 0.5 OUTLIER -105.16 148.27 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.98 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.97 177.81 0.93 Allowed Pre-proline 0 N--CA 1.448 -0.533 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.959 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.114 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.4 115.99 4.54 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.342 3.361 . . . . 0.0 109.61 179.888 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.658 ' CB ' HG23 ' A' ' 110' ' ' ILE . 27.9 p -113.4 40.9 2.26 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.501 ' HA ' ' O ' ' A' ' 111' ' ' SER . 30.9 p -120.31 106.22 11.67 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.024 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.29 30.4 10.95 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.114 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -101.33 132.21 47.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 15.8 m -104.69 169.54 8.4 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.926 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -48.54 140.06 8.52 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.01 -22.54 36.5 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 HD13 ' A' ' 13' ' ' LEU . 46.2 m -75.14 147.04 40.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.5 p -120.62 124.96 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.13 HG22 ' O ' ' A' ' 67' ' ' LEU . 2.6 m -90.68 168.06 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.754 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -117.32 152.48 34.82 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.966 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -150.1 114.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.989 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -126.77 114.59 18.16 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.91 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.86 148.5 24.7 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.223 ' O ' HG22 ' A' ' 4' ' ' THR . . . -145.6 112.64 6.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.51 14.74 31.64 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.968 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.94 169.01 11.58 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.934 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 28.1 mt-30 -50.39 120.09 4.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.599 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.71 131.63 41.82 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.32 8.28 83.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.49 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.82 139.94 30.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.977 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.907 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.22 151.73 25.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.769 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 46.0 m-85 -137.47 144.61 42.36 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.333 ' CA ' ' H ' ' A' ' 98' ' ' SER . 2.0 m-20 -106.0 115.22 29.86 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.465 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.16 143.16 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.955 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.86 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -168.94 172.5 43.28 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.909 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 16.8 tt0 -116.61 117.41 29.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 94.1 m -109.44 167.84 9.83 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.151 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -151.6 126.11 9.48 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.595 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -66.35 124.97 24.17 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.953 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.669 HG21 ' CD1' ' A' ' 83' ' ' TRP . 12.2 m -105.12 -44.05 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.537 ' HB2' ' HZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -143.3 163.56 32.64 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.951 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 42' ' ' THR . 2.9 t -51.91 113.48 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.21 8.35 69.81 Favored Glycine 0 C--N 1.336 0.553 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.629 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 17.0 t -126.27 106.11 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.917 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -116.17 162.91 16.75 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.859 -0.422 . . . . 0.0 109.859 179.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.564 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.37 138.66 53.58 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.228 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 55.8 m -109.33 150.28 28.24 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.638 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 24.5 t30 -108.77 109.06 61.2 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.39 -0.13 8.26 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.296 3.33 . . . . 0.0 109.563 179.899 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.567 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.09 -13.44 41.39 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.474 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.4 p30 -127.73 27.06 5.81 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.6 105.19 14.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.986 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.9 t -100.94 173.21 6.59 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -145.58 153.03 40.63 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.428 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -167.27 156.44 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.428 ' N ' HG22 ' A' ' 55' ' ' VAL . 58.2 m -126.6 138.35 53.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.99 149.02 37.69 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.0 p30 -85.37 -173.47 4.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.64 -22.86 66.75 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -77.53 -7.69 56.67 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.968 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 73.79 31.86 59.81 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.8 p -127.36 139.0 53.15 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.04 166.0 17.77 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 14.8 p -150.48 127.8 11.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.436 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -162.97 156.93 20.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.861 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.436 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -109.35 134.74 51.45 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.943 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.53 119.21 37.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.992 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.667 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.5 t -74.87 128.33 35.32 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.885 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -102.91 128.14 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.998 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.721 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.57 149.94 35.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.6 ppt_? -78.33 -16.55 57.6 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.55 ' HB3' ' OD1' ' A' ' 87' ' ' ASP . 7.9 p -161.71 148.66 14.27 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.909 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.8 p90 -178.09 148.73 0.52 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.11 115.04 1.67 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.564 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -75.34 94.99 0.94 Allowed Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.896 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.54 10.57 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.866 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.7 tp -54.22 139.29 36.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.8 m-85 -47.51 -41.58 21.26 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.561 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 2.0 t70 -56.33 -17.0 6.45 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.76 27.93 9.96 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.866 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.1 m -110.1 141.61 42.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.7 94.2 5.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.669 ' CD1' HG21 ' A' ' 40' ' ' VAL . 7.6 t-105 -62.43 -57.11 12.44 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.91 168.82 17.39 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.63 108.59 0.75 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.151 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -79.07 153.96 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.55 ' OD1' ' HB3' ' A' ' 72' ' ' SER . 14.8 m-20 -129.97 97.4 4.46 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.541 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 96.6 m -53.0 -28.04 22.04 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 50.5 p -78.12 -0.53 28.54 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -118.88 -28.04 5.65 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.68 -173.18 3.01 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.42 125.28 49.09 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.898 ' O ' HG13 ' A' ' 110' ' ' ILE . 56.6 m -103.93 159.81 15.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.06 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -155.36 144.79 21.1 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.4 t -109.9 157.83 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.298 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.51 168.56 40.24 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.465 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -125.47 139.73 53.38 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.333 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 85.8 p -122.57 149.03 44.51 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.907 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -107.6 -161.6 0.79 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -68.56 -47.98 65.43 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.72 -23.71 66.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.68 52.42 2.13 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.934 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.67 165.79 21.11 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.95 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.769 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.07 177.59 44.7 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.48 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.2 Cg_endo -72.37 161.15 45.13 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.372 3.381 . . . . 0.0 109.568 179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.307 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 4.6 pt-20 -36.63 128.92 0.81 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -46.98 150.38 2.08 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.866 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.4 t -126.03 115.05 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.538 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.15 143.91 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.06 HG13 ' HA ' ' A' ' 94' ' ' GLN . 1.1 mt -109.18 168.51 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.3 t -155.0 121.23 5.25 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.707 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 10.7 m-85 -94.8 129.76 41.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 9.7 p30 . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.972 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.647 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -92.04 127.22 50.35 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.482 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.37 -174.7 1.5 Allowed 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.291 3.327 . . . . 0.0 109.595 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.752 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -98.15 108.55 21.27 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.952 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.2 144.65 49.81 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.524 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -105.81 112.7 25.87 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.999 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.85 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -110.31 152.84 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.982 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.905 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.34 175.02 2.04 Favored Pre-proline 0 N--CA 1.449 -0.486 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.92 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.145 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.3 Cg_endo -72.39 118.01 5.4 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 124.298 3.332 . . . . 0.0 109.562 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.969 ' HB2' HG23 ' A' ' 110' ' ' ILE . 81.1 p -111.49 46.26 1.13 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.66 ' HA ' ' O ' ' A' ' 111' ' ' SER . 4.3 m -127.98 105.05 8.14 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.874 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.014 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.39 28.31 11.76 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.145 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -100.37 132.1 45.93 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.0 m -106.79 170.81 7.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -46.4 142.45 3.02 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.75 -23.41 33.96 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 52.0 m -77.86 151.8 33.7 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.546 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.6 p -128.26 116.26 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.941 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 67' ' ' LEU . 3.1 p -78.7 152.14 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.85 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.03 143.48 36.68 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.997 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.529 ' CG1' HG21 ' A' ' 108' ' ' VAL . 0.1 OUTLIER -140.76 106.99 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.966 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -116.7 117.12 28.93 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.672 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -81.79 139.77 20.32 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.43 108.33 7.12 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.927 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.45 25.95 8.45 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.237 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.7 -171.9 3.36 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 19.5 mt-30 -82.54 124.91 30.55 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.38 139.7 49.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.92 8.29 68.34 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.703 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -93.62 146.22 23.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.987 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.92 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.54 149.05 23.15 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.207 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 56.4 m-85 -136.95 145.06 43.77 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.867 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.145 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -110.54 113.76 26.64 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.995 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.301 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.07 140.07 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.956 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -162.37 164.44 35.58 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.549 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 29.5 tt0 -114.58 108.16 16.46 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.792 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.0 OUTLIER -110.83 146.32 36.65 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.987 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.754 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -122.81 138.28 54.69 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.605 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.52 123.2 19.04 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.959 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.741 HG21 ' CD1' ' A' ' 83' ' ' TRP . 0.0 OUTLIER -103.05 -44.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.993 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.395 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 1.1 m-20 -133.44 -179.28 5.42 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 m -69.03 111.12 4.82 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.905 -0.405 . . . . 0.0 109.905 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.66 85.97 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.035 HG21 ' HE1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -130.78 125.52 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.954 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.2 pt? -134.09 141.48 47.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.46 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.07 147.22 24.25 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.823 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 35.9 m -107.11 150.3 26.71 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.652 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.3 t30 -111.46 109.02 56.36 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -72.45 -0.65 9.06 Favored 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.315 3.343 . . . . 0.0 109.608 179.909 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.75 -11.87 43.79 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.576 ' CB ' HG23 ' A' ' 68' ' ' THR . 56.1 m-20 -132.71 28.64 4.24 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.946 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.666 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.92 119.3 38.01 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.994 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.6 t -113.4 -179.17 3.56 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -145.96 158.13 43.87 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.91 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' N ' ' A' ' 56' ' ' THR . 3.4 p -166.45 161.91 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.528 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.8 m -127.98 126.21 40.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -59.31 146.32 40.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.927 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 47.3 p30 -87.43 -173.44 4.37 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.52 -25.43 67.28 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -82.21 4.37 23.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 66.3 6.12 31.84 Favored Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.5 t -96.9 134.25 40.48 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.0 164.96 15.94 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -148.48 127.9 13.1 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.688 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -160.02 155.27 25.07 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.88 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.401 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.56 125.4 52.93 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.938 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.095 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -105.35 123.33 47.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.975 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.585 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -78.06 136.08 37.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.939 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.434 ' O ' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -112.6 124.99 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.979 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.542 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.97 173.46 6.32 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 27.5 ptt180 -99.41 -9.67 23.17 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.542 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 97.2 p -168.05 145.69 4.29 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.698 ' O ' HG12 ' A' ' 86' ' ' VAL . 1.9 p90 -176.6 156.16 1.44 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -55.46 114.5 1.86 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.46 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 100.68 1.8 Allowed Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.889 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -84.68 101.5 12.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.907 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -53.64 136.07 39.73 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.667 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.5 m-85 -46.59 -39.95 12.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.702 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.4 OUTLIER -56.31 -17.67 8.42 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.913 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.13 27.7 9.18 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.907 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.7 m -111.77 142.42 44.14 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -79.93 94.33 5.85 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.395 ' CZ2' ' OD2' ' A' ' 41' ' ' ASP . 0.0 OUTLIER -63.51 -58.34 7.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.886 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 173.14 20.41 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 104.38 0.52 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 38' ' ' ALA . 9.9 p -79.44 150.92 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.465 . . . . 0.0 109.743 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -107.21 98.09 7.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -53.24 -23.84 9.77 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 29.2 p -85.44 1.41 48.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.4 m -112.7 -26.93 8.37 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.03 179.69 6.1 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.0 128.44 41.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.885 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 36.7 m -104.41 153.29 21.28 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.081 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -147.25 147.05 30.03 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.981 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.095 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 2.9 t -110.92 160.04 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.27 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -176.24 166.37 37.39 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.301 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.01 123.82 35.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.978 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.145 ' N ' ' H ' ' A' ' 33' ' ' ASP . 14.2 m -107.65 144.18 35.08 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.927 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.92 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.6 OUTLIER -102.56 -160.75 0.8 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.979 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -68.63 -47.78 65.76 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.98 -24.42 66.04 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.72 53.78 1.76 Allowed Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.555 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -134.57 169.81 16.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.989 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.207 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.41 179.16 45.92 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.482 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.32 164.19 36.37 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.318 3.345 . . . . 0.0 109.601 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.647 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -37.61 126.92 1.14 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.976 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -42.93 154.69 0.17 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.89 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.9 t -120.84 103.79 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -88.64 126.54 35.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.081 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.6 mt -103.24 159.07 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.735 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.2 t -146.95 123.22 10.91 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.522 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 39.7 m-85 -95.36 125.57 40.07 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.98 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.26 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -65.92 120.85 72.52 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.647 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.3 Cg_endo -72.34 -178.13 3.12 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.288 3.325 . . . . 0.0 109.6 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.905 ' CA ' ' OE2' ' A' ' 106' ' ' GLU . 1.3 m -98.97 108.95 21.76 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 1.278 ' N ' ' OE2' ' A' ' 106' ' ' GLU . . . -124.29 146.78 48.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.587 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.85 114.62 28.89 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.98 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.786 HG13 ' O ' ' A' ' 20' ' ' LYS . 41.4 t -109.82 147.74 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.946 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.43 176.01 1.38 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.913 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.061 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.1 Cg_endo -72.39 117.36 5.1 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.323 3.349 . . . . 0.0 109.615 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.917 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 14.5 p -113.38 48.52 1.04 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.981 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 111' ' ' SER . 5.9 m -128.99 105.83 8.47 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.872 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.069 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.49 28.04 12.12 Favored Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.069 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -105.01 129.25 53.5 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.988 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -104.45 170.39 7.92 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.564 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 7.4 p-10 -44.59 141.29 2.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.65 -22.87 32.84 Favored Glycine 0 C--N 1.335 0.492 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.485 HG21 ' HB3' ' A' ' 13' ' ' LEU . 89.6 m -79.39 149.6 31.6 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.538 HG13 ' O ' ' A' ' 18' ' ' VAL . 13.8 p -122.34 121.72 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.063 HG23 HG12 ' A' ' 69' ' ' VAL . 12.2 t -85.44 153.15 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.786 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.89 143.2 34.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.952 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.657 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -140.58 111.5 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.703 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.2 117.71 25.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.008 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.59 145.5 22.89 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.793 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -144.36 113.38 6.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 95.63 17.97 34.24 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.008 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.87 170.78 9.8 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.772 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 32.6 mt-30 -51.78 119.58 4.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.519 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.33 130.28 39.83 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.64 7.34 87.23 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.482 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -94.83 137.27 34.13 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.703 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -81.47 152.41 27.36 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.741 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 36.8 m-85 -138.08 141.08 40.27 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.913 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.18 ' CB ' ' H ' ' A' ' 98' ' ' SER . 7.8 m-20 -106.01 113.45 26.99 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.268 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.0 147.46 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.992 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.919 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.1 168.16 41.1 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.742 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 22.7 tt0 -112.13 113.2 25.33 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 25.9 m -114.2 141.99 46.82 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.706 ' O ' HD12 ' A' ' 45' ' ' LEU . . . -121.96 129.08 52.21 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.56 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.19 128.58 36.43 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.906 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.286 HG21 ' CD1' ' A' ' 83' ' ' TRP . 11.7 m -109.78 -43.91 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.664 ' OD2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -141.08 160.12 40.76 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.994 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.5 m -55.55 113.49 1.46 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.94 8.06 87.98 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.149 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.8 t -130.34 108.99 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.973 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.822 HD11 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -118.22 144.23 45.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.963 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.366 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -105.64 143.63 33.52 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.066 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 15.5 m -110.24 152.71 25.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.685 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 42.6 t30 -111.86 108.02 55.94 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.36 -0.73 9.12 Favored 'Trans proline' 0 N--CA 1.448 -1.195 0 C-N-CA 124.355 3.37 . . . . 0.0 109.573 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.448 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -92.48 -11.23 35.2 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.852 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -129.82 19.62 5.56 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.77 107.76 16.39 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.0 t -101.46 173.36 6.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.9 p -146.06 149.39 33.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.89 159.72 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.483 ' N ' HG22 ' A' ' 55' ' ' VAL . 63.6 m -127.74 136.68 51.86 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -73.38 142.44 46.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 40.6 p30 -80.86 -172.45 3.69 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.18 -22.02 66.59 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -80.87 4.05 20.58 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 60.44 31.29 73.83 Favored Glycine 0 C--N 1.335 0.474 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 t -128.13 133.76 49.02 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.68 164.65 18.68 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.27 129.96 17.05 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.5 OUTLIER -156.57 164.61 37.99 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 179.861 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -125.25 118.23 25.56 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.973 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.552 ' CD1' HG13 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.68 156.2 16.65 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.501 ' N ' HD23 ' A' ' 67' ' ' LEU . 0.3 OUTLIER -112.36 132.73 54.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 1.063 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.34 128.06 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.99 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.7 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.07 164.04 13.24 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.999 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 ptt180 -91.88 -9.47 43.13 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 12.8 t -174.8 144.37 0.81 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.902 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.742 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 13.3 p90 -175.83 157.63 1.99 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 117.06 3.03 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.366 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -80.32 100.56 1.92 Allowed Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.985 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -83.26 100.28 10.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.7 tp -54.42 136.7 43.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.859 ' CE1' ' SG ' ' A' ' 47' ' ' CYS . 2.1 m-85 -46.25 -39.93 10.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.568 ' HB2' HD21 ' A' ' 77' ' ' LEU . 7.6 t0 -56.84 -17.36 9.07 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.38 28.2 9.3 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.31 140.08 47.33 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.6 ptt-85 -79.72 94.53 5.76 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.286 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.25 -55.78 24.99 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.919 -0.401 . . . . 0.0 109.919 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.59 172.86 19.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.35 107.09 1.01 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -83.7 152.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.962 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -109.5 99.6 8.79 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.58 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.2 m -53.27 -25.06 13.12 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 30.4 p -84.04 1.25 44.79 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.9 m -118.32 -27.98 5.88 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.911 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.55 177.4 6.24 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.07 125.3 41.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.262 ' O ' HG13 ' A' ' 110' ' ' ILE . 38.7 m -104.53 153.05 21.64 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.013 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.4 OUTLIER -151.17 146.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.929 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.552 HG13 ' CD1' ' A' ' 67' ' ' LEU . 21.5 t -105.84 153.48 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.943 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.232 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -170.2 165.97 39.22 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.268 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -129.32 131.76 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.18 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 7.6 t -112.29 150.91 30.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.955 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.703 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -112.6 -164.25 0.9 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.948 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.41 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.92 -48.51 68.44 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.8 -23.76 66.1 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.7 53.2 1.99 Allowed Glycine 0 C--N 1.336 0.55 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.772 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -131.94 171.89 13.02 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.977 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.741 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -174.27 176.43 46.64 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.647 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.1 Cg_endo -72.38 165.17 33.43 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.349 3.366 . . . . 0.0 109.622 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.278 ' OE2' ' N ' ' A' ' 5' ' ' ALA . 0.2 OUTLIER -38.08 136.51 0.6 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.988 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -49.98 149.0 6.06 Favored Glycine 0 C--N 1.335 0.513 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.918 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 11.9 t -123.84 105.93 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.485 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -90.57 147.96 23.0 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.262 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.09 159.76 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.714 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -142.28 111.98 6.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.953 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 66.2 m-85 -87.15 110.71 20.32 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.478 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -107.27 120.61 47.18 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.545 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.5 Cg_endo -72.34 -178.29 3.22 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 124.357 3.371 . . . . 0.0 109.616 179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.111 ' CG2' ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -97.46 110.26 22.85 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.963 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.843 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.5 156.53 40.6 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -114.96 117.15 29.83 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.111 HG22 ' CG1' ' A' ' 21' ' ' VAL . 58.5 t -114.5 144.21 22.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.697 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -70.2 165.82 40.02 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.921 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.697 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.7 Cg_endo -72.34 118.0 5.4 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 124.318 3.345 . . . . 0.0 109.617 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.77 ' OG ' HG11 ' A' ' 69' ' ' VAL . 47.7 t -127.84 17.57 6.79 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.025 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.1 p -92.2 111.78 23.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.067 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.43 25.6 27.79 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.067 HD23 ' C ' ' A' ' 12' ' ' GLY . 1.0 OUTLIER -108.52 139.48 43.22 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.989 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 13.6 m -67.47 144.69 55.58 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.476 ' HB3' ' H ' ' A' ' 71' ' ' ARG . 17.9 p-10 -48.1 147.49 2.14 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -18.97 45.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.6 m -60.99 130.53 46.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 18' ' ' VAL . 9.3 p -92.87 115.05 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.6 m -100.58 159.33 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.943 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.83 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.6 146.1 39.19 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.111 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -138.5 114.52 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.988 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.843 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.8 116.31 23.47 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.944 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.997 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.21 145.96 22.57 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.111 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -142.23 115.83 9.12 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.73 16.02 29.94 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.997 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -89.92 168.6 11.91 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.928 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.522 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.7 mt-30 -52.03 119.24 4.11 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.477 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.37 132.06 44.29 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.89 7.78 84.15 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.522 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -98.01 141.89 30.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.99 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.46 150.86 24.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.024 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 40.3 m-85 -138.29 141.73 39.82 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.17 ' OD2' ' HB2' ' A' ' 98' ' ' SER . 0.9 OUTLIER -105.85 115.54 30.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.977 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.567 HG22 ' CG ' ' A' ' 97' ' ' LEU . 1.8 t -96.64 136.46 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.874 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.66 153.51 24.53 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.856 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 17.2 tt0 -94.46 119.68 33.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.844 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.724 ' SG ' ' CE2' ' A' ' 78' ' ' PHE . 1.3 m -107.04 159.26 16.43 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.715 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -147.16 130.08 16.25 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.543 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -69.96 125.92 28.16 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.174 ' CG1' HG12 ' A' ' 86' ' ' VAL . 4.0 m -113.74 -39.56 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.61 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -146.65 -179.59 6.88 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.95 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.8 m -64.69 111.58 2.82 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.955 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.56 8.52 63.26 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.596 HG21 ' CH2' ' A' ' 83' ' ' TRP . 40.1 t -110.02 104.0 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.799 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.4 mt -106.86 155.94 19.21 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.526 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -134.27 126.7 30.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.144 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -107.84 158.83 16.99 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.971 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.561 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.5 t30 -118.83 113.96 35.78 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.7 Cg_endo -72.43 -1.45 10.23 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.317 3.345 . . . . 0.0 109.577 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.561 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -11.48 40.39 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -131.63 26.58 4.71 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.667 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.34 122.07 41.97 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.983 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -104.65 -175.32 2.76 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.0 p -146.72 154.37 41.34 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -166.89 156.18 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.424 ' N ' HG22 ' A' ' 55' ' ' VAL . 41.7 m -125.97 121.68 33.78 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.76 150.18 20.45 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 p30 -97.02 -168.02 1.64 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.13 -25.37 68.32 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.983 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -83.37 3.75 30.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.894 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 62.25 31.23 78.4 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.3 t -126.22 142.85 51.36 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -133.98 159.81 39.61 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -137.21 124.96 22.42 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.782 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -144.62 178.43 7.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.866 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.782 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -129.46 122.32 29.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.949 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.018 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -108.09 149.19 28.79 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.925 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.832 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -111.37 143.0 42.87 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.77 HG11 ' OG ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -109.55 125.93 66.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.967 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.809 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -115.08 153.08 31.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.986 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.476 ' H ' ' HB3' ' A' ' 15' ' ' ASP . 10.0 ttp180 -74.03 -37.79 64.22 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 t -151.06 153.25 34.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.856 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 5.4 p90 -177.09 159.44 1.65 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.931 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.98 114.43 1.59 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.944 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.526 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.71 93.77 0.57 Allowed Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 1.144 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.34 99.94 10.34 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.904 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.4 tp -58.76 131.79 51.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.724 ' CE2' ' SG ' ' A' ' 37' ' ' CYS . 8.4 m-85 -47.06 -36.46 8.1 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.592 ' HB2' HD21 ' A' ' 77' ' ' LEU . 3.4 t0 -56.99 -17.51 10.08 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.15 27.29 8.87 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.904 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -114.0 143.05 45.37 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.77 94.71 9.83 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.61 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 34.8 t-105 -63.41 -58.46 6.99 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.893 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.54 171.11 18.48 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.6 109.0 0.71 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.174 HG12 ' CG1' ' A' ' 40' ' ' VAL . 18.1 m -89.93 150.83 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 32.6 m-20 -108.88 89.14 2.9 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.11 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 2.0 m -52.92 -24.48 9.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -79.27 -1.75 38.06 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.18 -28.36 6.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -118.64 -165.63 1.14 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 124.62 40.9 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.273 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -104.27 152.36 22.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.991 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.044 ' CB ' ' O ' ' A' ' 108' ' ' VAL . 0.7 OUTLIER -168.12 147.67 4.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.944 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.009 HG21 HD12 ' A' ' 67' ' ' LEU . 4.9 t -99.4 164.92 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.95 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -171.67 160.01 31.73 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.567 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -100.2 163.57 12.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.17 ' HB2' ' OD2' ' A' ' 33' ' ' ASP . 14.8 m -155.83 121.68 5.01 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.635 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 4.8 p-10 -113.88 -168.93 1.42 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -47.64 -26.76 1.61 Allowed 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -98.7 -25.94 14.52 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.912 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 92.01 21.15 33.98 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 1.024 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.64 -149.42 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.999 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.493 ' O ' ' HD2' ' A' ' 3' ' ' PRO . . . 141.4 151.82 5.62 Favored Glycine 0 C--N 1.336 0.556 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.545 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.6 Cg_endo -72.37 161.69 43.63 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.302 3.335 . . . . 0.0 109.609 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.478 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 10.3 mt-10 -32.06 120.26 0.28 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.962 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -32.94 149.8 0.01 OUTLIER Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.044 ' O ' ' CB ' ' A' ' 94' ' ' GLN . 2.6 t -108.26 103.33 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.52 126.72 31.24 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.273 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 7.0 pt -141.81 177.82 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 1.025 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -171.65 177.82 3.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.941 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.11 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -130.3 115.21 16.62 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.931 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.969 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.3 p30 . . . . . 0 N--CA 1.45 -0.469 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.908 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.139 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -147.34 119.81 4.75 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.625 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.5 Cg_endo -72.46 -178.59 3.44 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.301 3.334 . . . . 0.0 109.57 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.223 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -98.57 109.0 21.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.82 ' H ' ' CD ' ' A' ' 106' ' ' GLU . . . -122.53 151.05 41.75 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.952 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.648 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.7 p -116.49 116.27 27.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -106.82 148.92 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.454 . . . . 0.0 109.776 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 1.031 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -65.69 179.39 0.45 Allowed Pre-proline 0 N--CA 1.449 -0.482 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.917 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.128 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.8 Cg_endo -72.36 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 124.315 3.343 . . . . 0.0 109.648 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.543 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 3.8 p -112.42 35.87 3.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -119.8 106.75 12.4 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.836 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.026 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.58 30.89 8.66 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.229 -1.149 . . . . 0.0 110.229 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.128 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.42 131.52 47.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.97 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.3 t -99.75 163.84 12.3 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -46.95 140.07 5.08 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.35 -22.22 36.91 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.484 HG21 HD13 ' A' ' 13' ' ' LEU . 37.0 m -72.05 149.53 44.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.619 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.6 p -126.7 117.12 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 67' ' ' LEU . 29.0 m -84.33 165.27 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.779 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.6 135.18 54.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 21' ' ' VAL . 9.8 p -124.3 120.46 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.648 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -126.29 117.5 23.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.864 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -93.49 140.14 14.92 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.994 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.724 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -139.5 116.38 10.92 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.99 20.53 18.26 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.023 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.52 -177.28 5.28 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.98 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 25.9 mt-30 -69.29 122.23 18.46 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.43 130.04 39.75 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.1 8.09 86.85 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.512 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.48 137.13 34.96 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.975 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 1.017 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.56 150.62 25.1 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.124 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.9 m-85 -136.81 146.84 46.15 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.891 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.174 ' H ' ' N ' ' A' ' 98' ' ' SER . 4.4 m-20 -111.96 113.85 26.41 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.478 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -99.98 143.23 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.88 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.33 165.34 38.73 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.782 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 15.2 tt0 -111.28 113.07 25.29 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 62.6 m -111.13 145.76 38.03 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.538 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -123.23 128.29 49.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.75 120.63 13.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.951 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.497 HG11 ' CD1' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -99.35 -44.14 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.53 ' OD1' ' C ' ' A' ' 40' ' ' VAL . 0.2 OUTLIER -136.83 175.5 9.56 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.948 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.567 HG23 ' O ' ' A' ' 42' ' ' THR . 6.1 t -60.8 112.67 2.12 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.03 8.14 72.96 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.47 ' O ' HG23 ' A' ' 40' ' ' VAL . 3.2 t -124.17 110.89 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.531 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -126.01 138.69 53.75 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.971 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.373 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -93.09 156.04 17.12 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.162 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 37.1 m -117.12 150.63 38.37 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.693 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 10.2 t30 -114.11 107.11 52.39 Favored Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.31 -0.84 9.25 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.327 3.351 . . . . 0.0 109.627 179.867 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.639 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -12.11 41.38 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 68' ' ' THR . 92.9 m-20 -131.46 26.14 4.78 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.682 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -97.23 120.03 36.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 32.2 t -113.84 -177.38 3.12 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 80.0 p -147.08 156.61 43.14 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.474 HG22 ' HB1' ' A' ' 63' ' ' ALA . 5.9 p -166.94 157.59 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 48.3 m -125.35 134.08 52.32 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.838 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -72.57 140.73 48.26 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 46.6 p30 -83.82 -170.88 3.29 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.75 -26.14 68.55 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.916 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.2 -4.91 44.37 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.968 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.023 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.93 31.61 69.83 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.239 -1.145 . . . . 0.0 110.239 179.964 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 83.3 p -124.11 133.77 53.52 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.838 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -147.46 122.38 10.02 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -123.0 144.28 49.37 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.757 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -141.0 178.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.757 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -108.32 116.56 32.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.053 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -108.46 123.6 49.13 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.95 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.697 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.2 OUTLIER -91.4 137.48 32.33 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.912 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -112.31 126.54 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.987 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.471 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.3 OUTLIER -114.36 173.38 6.48 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.962 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 10.6 ptt85 -100.99 -7.97 22.81 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.548 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 1.4 p -169.73 147.66 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.782 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.6 p90 -177.65 160.58 1.58 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.929 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.13 115.58 2.52 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.373 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.32 94.03 1.24 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.741 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.2 m-85 -83.85 99.58 10.42 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.927 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.4 tp -53.73 134.66 41.96 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.684 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.6 p90 -46.26 -38.84 9.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.556 ' CB ' HD21 ' A' ' 77' ' ' LEU . 4.4 t70 -56.77 -17.26 8.47 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.29 27.99 8.88 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.927 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -112.59 139.73 47.93 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -82.12 93.28 7.0 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.497 ' CD1' HG11 ' A' ' 40' ' ' VAL . 6.8 t-105 -63.38 -57.57 9.9 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 151.77 169.91 17.86 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -60.92 104.68 0.38 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 73' ' ' PHE . 6.2 p -81.61 149.27 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -105.93 98.33 8.03 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.517 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.6 m -51.76 -25.41 7.46 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 21.1 p -80.55 2.55 25.01 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.961 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 21.8 m -112.93 -27.2 8.17 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.912 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.59 -178.49 5.09 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.64 127.21 42.41 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.316 ' O ' HG13 ' A' ' 110' ' ' ILE . 82.4 m -103.17 153.0 20.79 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.086 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -147.34 146.18 29.59 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.053 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.3 t -100.6 163.15 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.331 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.13 158.61 24.36 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.478 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.66 127.56 37.22 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.996 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.174 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.0 m -117.03 158.27 24.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 1.017 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 1.0 OUTLIER -110.79 -157.36 0.61 Allowed 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.986 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.91 -48.15 77.74 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.56 -25.93 61.54 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.78 47.3 2.31 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.62 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.34 154.7 29.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.124 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -165.09 171.98 40.61 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.294 -1.122 . . . . 0.0 110.294 -179.983 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.625 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.3 Cg_endo -72.36 171.88 16.09 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.294 3.329 . . . . 0.0 109.647 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.223 ' OE1' ' HA ' ' A' ' 4' ' ' THR . 6.5 pt-20 -36.49 153.44 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -67.72 153.97 52.96 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.991 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.959 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 8.5 t -128.07 109.92 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.992 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.716 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -93.7 151.33 19.72 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.923 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.316 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -120.63 164.87 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.929 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 11.0 t -154.82 120.39 5.09 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.512 ' HE2' HG23 ' A' ' 69' ' ' VAL . 46.4 m-85 -97.01 127.06 42.61 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.947 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.045 ' O ' ' HG3' ' A' ' 106' ' ' GLU . . . -86.87 124.54 68.84 Favored Pre-proline 0 N--CA 1.45 -0.474 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.383 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.6 Cg_endo -72.38 -174.19 1.35 Allowed 'Trans proline' 0 N--CA 1.447 -1.209 0 C-N-CA 124.316 3.344 . . . . 0.0 109.545 179.961 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.795 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.5 m -93.95 108.51 20.31 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.761 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.65 143.59 51.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.733 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -98.29 111.98 24.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.036 HG21 ' CG2' ' A' ' 108' ' ' VAL . 24.2 t -109.51 143.98 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.934 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.0 175.19 1.86 Allowed Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.921 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.005 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.1 Cg_endo -72.33 118.41 5.59 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.34 3.36 . . . . 0.0 109.598 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.715 ' HB2' HG23 ' A' ' 110' ' ' ILE . 25.0 p -116.77 46.04 1.72 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.3 p -124.8 106.04 9.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.9 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.061 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.72 28.08 13.16 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.061 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.7 OUTLIER -103.99 129.75 51.61 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.967 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 m -103.8 170.99 7.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.762 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -45.91 142.32 2.67 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.984 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.13 -22.97 34.88 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.479 HG21 ' HB3' ' A' ' 13' ' ' LEU . 29.5 m -77.36 148.2 35.7 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.5 p -124.19 123.08 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.569 ' HA ' HG21 ' A' ' 8' ' ' THR . 20.9 m -91.05 166.88 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.805 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -122.4 138.49 54.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.994 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.857 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -132.73 117.81 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.761 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.86 116.22 21.21 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.727 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.0 144.41 23.83 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.795 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.79 106.26 4.42 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.89 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 104.19 22.09 8.98 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.64 -165.0 1.22 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 0.0 OUTLIER -80.43 124.19 28.69 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.499 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.4 129.74 38.64 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.57 7.94 85.79 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.509 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.74 143.89 25.85 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.999 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.876 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -91.44 150.11 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.0 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.5 m-85 -138.29 146.41 42.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.894 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.221 ' CA ' ' H ' ' A' ' 98' ' ' SER . 12.2 m-20 -112.48 113.86 26.25 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.484 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.27 152.58 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.802 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . 179.95 173.63 45.11 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.324 -1.111 . . . . 0.0 110.324 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.908 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 47.8 tt0 -106.23 119.68 39.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.432 ' HB3' HD13 ' A' ' 45' ' ' LEU . 11.0 m -109.14 162.58 14.13 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.301 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -148.73 136.26 20.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.892 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.03 123.69 19.66 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.89 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.017 HG21 ' HB3' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -102.2 -41.36 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.638 ' HB2' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -150.45 179.21 8.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.944 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.4 m -65.85 109.36 2.46 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.29 10.34 86.1 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.59 HG21 ' CE2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -130.87 131.7 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.67 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.8 pp -133.71 162.35 32.2 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.98 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.559 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.02 144.96 51.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.674 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -109.44 158.86 17.53 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.862 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -120.18 118.58 31.3 Favored Pre-proline 0 N--CA 1.449 -0.508 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.975 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.458 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.7 Cg_endo -72.37 1.64 5.92 Favored 'Trans proline' 0 N--CA 1.446 -1.278 0 C-N-CA 124.326 3.351 . . . . 0.0 109.606 179.884 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.29 -20.65 31.78 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.868 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' CB ' HG23 ' A' ' 68' ' ' THR . 91.7 m-20 -129.78 30.56 4.86 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.66 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -94.88 117.96 30.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.993 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 28.5 t -114.01 176.99 4.8 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.4 p -147.13 155.56 42.26 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.536 HG22 ' N ' ' A' ' 56' ' ' THR . 3.2 p -167.1 162.36 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.536 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.8 m -127.9 128.69 45.6 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.94 152.05 28.67 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.41 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.1 p30 -94.13 -170.75 2.37 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.29 -29.52 69.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -76.02 -7.57 54.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.91 8.69 87.28 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 92.0 p -99.06 139.79 34.18 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.66 156.01 32.62 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -136.76 121.92 19.12 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.592 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.57 153.57 25.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 m -114.48 130.61 56.74 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.394 HD12 ' CG2' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -107.72 154.25 21.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.923 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.792 ' H ' HD13 ' A' ' 67' ' ' LEU . 0.6 OUTLIER -113.76 140.5 48.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.96 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.559 ' HA ' ' NE2' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -110.25 129.78 64.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.99 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.886 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -114.18 164.88 13.27 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 13.1 ptt180 -88.06 -25.01 23.28 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -162.11 147.58 13.0 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.932 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.908 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.2 p90 -176.57 156.01 1.44 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -55.86 121.18 8.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.559 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -82.46 96.86 1.88 Allowed Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.674 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.99 99.96 10.74 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.958 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.926 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.46 129.3 41.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.995 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.606 ' N ' HD12 ' A' ' 77' ' ' LEU . 17.9 p90 -47.67 -34.51 8.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.617 ' CB ' HD21 ' A' ' 77' ' ' LEU . 2.7 t0 -57.68 -16.36 10.57 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.14 8.49 Favored Glycine 0 C--N 1.336 0.54 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.926 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -118.16 150.62 39.08 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.4 mtp180 -93.85 97.53 10.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.59 ' CE2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.9 -55.6 21.44 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.947 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.81 176.47 22.19 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.9 113.42 4.37 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.301 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.6 t -89.15 152.96 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -117.65 93.13 4.04 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.164 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 57.6 m -52.92 -26.59 15.46 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 36.7 p -78.33 -0.23 28.1 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -117.63 -28.04 6.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -127.47 -173.56 2.94 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.13 124.21 47.33 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.86 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.812 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 65.9 m -105.25 152.52 22.78 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.103 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -144.21 145.5 32.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.394 ' CG2' HD12 ' A' ' 67' ' ' LEU . 3.2 t -107.82 156.04 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.303 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.46 174.34 46.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.484 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -128.08 142.61 51.16 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.221 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 97.3 p -118.77 152.63 35.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.876 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -114.06 -165.6 1.02 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.974 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -54.32 -49.34 69.92 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -75.13 -25.24 58.26 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 98.71 45.29 2.31 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.708 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -116.63 167.64 10.9 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.959 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.0 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -176.03 -171.3 39.71 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.383 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.34 152.51 55.37 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.322 3.348 . . . . 0.0 109.599 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.126 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -35.26 121.13 0.56 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -179.989 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.55 143.91 0.09 OUTLIER Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.971 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.083 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -114.3 105.49 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -85.05 130.48 34.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.103 HG13 ' HA ' ' A' ' 94' ' ' GLN . 3.8 mt -103.79 164.08 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.907 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.99 121.52 10.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.963 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.164 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 18.0 m-85 -90.56 113.15 25.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.496 ' CB ' ' O ' ' A' ' 112' ' ' PHE . 3.5 p30 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.639 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -142.92 139.41 16.88 Favored Pre-proline 0 N--CA 1.448 -0.53 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.415 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.0 Cg_endo -72.42 -174.7 1.51 Allowed 'Trans proline' 0 N--CA 1.446 -1.291 0 C-N-CA 124.319 3.346 . . . . 0.0 109.623 179.927 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.771 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.8 108.97 21.8 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -126.22 140.1 52.81 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.939 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.599 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -98.7 114.11 26.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.916 HG21 ' CG2' ' A' ' 108' ' ' VAL . 38.2 t -111.25 149.17 14.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.94 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.19 175.7 1.43 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.909 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.074 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.9 Cg_endo -72.35 119.2 5.99 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.312 3.341 . . . . 0.0 109.635 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.046 ' CB ' HG23 ' A' ' 110' ' ' ILE . 51.7 p -113.17 47.9 1.08 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.535 ' HA ' ' O ' ' A' ' 111' ' ' SER . 65.2 p -125.21 106.85 10.19 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.87 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.991 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.63 26.15 23.51 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.947 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.074 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -100.95 131.58 46.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 t -118.04 177.06 4.93 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.645 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 5.2 p-10 -45.41 139.26 3.76 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.66 34.73 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 62.9 m -85.98 150.58 24.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.508 HG13 ' O ' ' A' ' 18' ' ' VAL . 12.9 p -126.26 123.79 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.084 HG22 ' O ' ' A' ' 67' ' ' LEU . 18.5 m -87.19 162.31 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.905 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.95 143.87 44.47 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.736 HG23 HG22 ' A' ' 7' ' ' VAL . 0.4 OUTLIER -138.84 112.06 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.981 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.709 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.9 115.66 22.33 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.539 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.31 140.78 20.12 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.771 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -138.72 106.68 5.69 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.888 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.03 26.16 8.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.22 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -88.12 -169.27 2.5 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.516 ' HB2' HG21 ' A' ' 30' ' ' THR . 33.4 mt-30 -80.14 123.47 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.39 130.12 40.53 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.68 8.74 84.6 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.523 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -95.8 134.4 38.8 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.809 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -85.84 151.76 23.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.515 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 40.9 m-85 -137.26 148.65 46.58 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.209 ' H ' ' N ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -112.11 116.27 30.23 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.923 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.368 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.78 140.47 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.948 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.856 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -163.3 157.82 30.05 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.791 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.6 tt0 -106.53 116.38 31.83 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.502 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.6 m -102.96 165.21 11.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.58 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -151.91 142.94 23.15 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.948 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 0.5 OUTLIER -64.98 122.13 16.28 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.943 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.843 HG11 ' CD2' ' A' ' 83' ' ' TRP . 1.1 t -101.68 -55.23 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.939 ' OD2' ' CH2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -131.86 168.62 17.53 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -50.07 110.88 0.44 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.87 8.31 63.8 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.503 HG11 ' CE2' ' A' ' 83' ' ' TRP . 62.1 t -119.62 125.14 74.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.6 pp -125.85 162.05 26.03 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.52 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -130.96 161.49 31.81 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.898 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.888 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -115.65 156.07 26.53 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.752 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 23.0 t30 -116.71 110.79 41.87 Favored Pre-proline 0 N--CA 1.449 -0.512 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_endo -72.43 -0.89 9.4 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.356 3.371 . . . . 0.0 109.546 179.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.601 ' C ' ' OD1' ' A' ' 51' ' ' ASP . . . -88.97 -11.58 43.93 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.811 ' HB3' HG23 ' A' ' 68' ' ' THR . 3.5 m-20 -133.39 28.87 4.0 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.884 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.643 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -101.9 118.17 36.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.997 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 40.9 t -107.86 -176.39 3.05 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 96.9 p -146.25 152.65 39.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.892 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 56' ' ' THR . 7.7 p -166.59 155.57 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 55' ' ' VAL . 74.0 m -126.41 126.94 44.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.924 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -56.43 146.68 23.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.3 p30 -88.16 -170.25 2.89 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.91 -25.85 67.82 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -84.58 5.23 28.63 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 65.27 8.78 38.99 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -98.35 134.42 41.38 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.986 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.39 166.23 14.4 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 12.5 p -150.03 124.5 9.64 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.941 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.701 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -159.36 151.87 21.39 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.901 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.16 132.79 54.01 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.952 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.127 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -109.8 119.17 38.52 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.895 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.811 HG23 ' HB3' ' A' ' 51' ' ' ASP . 1.8 t -70.04 143.55 52.48 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.544 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 1.3 t -104.23 131.51 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.791 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.2 OUTLIER -119.84 153.07 36.34 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.97 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 6.7 ptt85 -85.66 -22.77 27.74 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.6 t -166.79 152.96 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.752 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 1.5 p90 -175.4 167.24 3.33 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.921 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.38 125.02 22.46 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.915 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.52 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -77.79 90.92 1.07 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.888 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.55 10.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.999 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.948 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.47 141.64 30.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.693 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.05 -42.13 18.05 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.994 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.628 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -57.52 -17.1 12.03 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.978 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 29.1 9.65 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.948 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -110.17 122.08 46.79 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -64.38 92.27 0.08 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.503 ' CE2' HG11 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.56 -58.34 7.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.93 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.03 170.28 21.15 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.63 139.36 53.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 73' ' ' PHE . 2.7 p -126.34 140.55 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -93.48 94.97 8.97 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.98 -21.07 10.62 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.947 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.5 p -89.27 1.98 54.96 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.3 m -114.09 -27.38 7.7 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -123.26 -177.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.61 128.45 37.44 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.937 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.078 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 1.5 m -105.0 152.62 22.49 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG13 ' A' ' 110' ' ' ILE . 1.2 pt20 -152.89 147.32 25.85 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.127 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.6 t -114.17 158.16 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.957 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.265 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.43 163.71 33.06 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.368 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -128.07 124.16 36.36 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.988 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.209 ' N ' ' H ' ' A' ' 33' ' ' ASP . 11.5 m -113.52 156.68 23.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.809 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -110.19 -161.17 0.74 Allowed 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.31 -48.62 69.74 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.545 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -66.68 -26.07 66.85 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.889 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.12 42.53 3.24 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.545 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -116.68 157.98 24.54 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.515 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -173.4 177.53 45.74 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.984 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.415 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.0 Cg_endo -72.41 154.86 55.88 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.317 3.345 . . . . 0.0 109.581 179.96 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.639 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -36.96 119.34 0.65 Allowed 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.941 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -37.13 155.92 0.01 OUTLIER Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.916 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.1 t -119.23 107.59 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 118.19 25.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.046 HG23 ' CB ' ' A' ' 10' ' ' SER . 8.5 mt -98.25 159.12 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.75 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -144.1 123.48 13.09 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.078 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 5.4 m-85 -92.02 127.26 37.42 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.426 ' H ' ' H ' ' A' ' 12' ' ' GLY . 8.7 p30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.322 ' HB1' ' CB ' ' A' ' 106' ' ' GLU . . . -101.11 114.1 65.8 Favored Pre-proline 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.567 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.2 Cg_endo -72.39 -178.25 3.21 Favored 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 124.297 3.331 . . . . 0.0 109.584 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.111 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -100.23 111.87 24.16 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.936 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.754 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.5 160.53 29.29 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . 2.8 p -124.75 119.08 27.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.815 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -116.73 154.84 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.936 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.22 174.9 1.74 Allowed Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.954 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.1 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.4 Cg_endo -72.4 118.58 5.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.305 3.337 . . . . 0.0 109.593 179.889 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.289 ' OG ' HG23 ' A' ' 110' ' ' ILE . 11.9 p -116.02 48.76 1.19 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.646 ' HA ' ' O ' ' A' ' 111' ' ' SER . 18.8 p -126.43 104.71 8.3 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.91 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 89.79 29.05 16.84 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.1 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -94.85 133.41 38.6 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.986 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.4 t -96.61 158.32 15.49 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.997 ' OD1' ' HG3' ' A' ' 70' ' ' ARG . 25.5 t70 -45.1 142.51 1.9 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.426 ' H ' ' NH1' ' A' ' 70' ' ' ARG . . . 103.26 -23.13 34.21 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 91.7 m -71.59 150.94 44.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.546 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.5 p -125.27 122.78 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.264 HG22 ' O ' ' A' ' 67' ' ' LEU . 32.7 m -91.07 167.3 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.815 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -116.56 152.92 33.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.992 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.655 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.63 115.52 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.754 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -127.77 114.36 17.17 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.983 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.48 144.7 21.6 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.111 ' O ' HG22 ' A' ' 4' ' ' THR . . . -140.48 114.58 9.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 97.69 19.04 25.98 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.016 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -90.28 175.67 7.03 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -180.0 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.11 ' NE2' ' OD1' ' A' ' 103' ' ' ASN . 34.4 mt-30 -59.6 121.93 12.81 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.13 130.81 40.5 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.68 7.83 85.99 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.461 ' HB ' ' CB ' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.67 141.21 28.74 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.972 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 1.205 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.88 151.24 23.5 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.989 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.867 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.0 m-85 -135.77 146.81 48.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.433 ' C ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -109.79 114.89 28.84 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.951 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.516 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.9 140.24 22.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.982 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.782 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -165.78 168.98 39.91 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.219 -1.152 . . . . 0.0 110.219 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.96 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 45.3 tt0 -114.31 128.74 56.5 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 28.3 m -130.19 143.1 50.59 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.88 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -121.78 130.62 53.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.894 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.491 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.6 OUTLIER -64.48 129.05 38.39 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.947 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.953 HG23 HG12 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -111.12 -41.84 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.92 163.26 35.68 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 95.1 m -54.74 120.08 6.26 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.921 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.25 6.81 62.05 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.975 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 1.5 t -125.91 115.45 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.458 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.978 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.814 HD23 ' HE2' ' A' ' 78' ' ' PHE . 1.0 OUTLIER -125.08 143.62 50.83 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.97 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.272 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -105.39 142.93 34.29 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.135 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.0 m -112.14 163.71 14.01 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 25.2 t30 -126.82 110.73 22.3 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.43 0.58 7.25 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.299 3.332 . . . . 0.0 109.571 179.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.507 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.12 -12.67 43.4 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.483 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.7 p30 -129.24 28.85 5.21 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 0.1 OUTLIER -86.39 105.62 16.85 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.2 t -104.31 173.26 6.38 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.0 p -145.52 155.56 43.16 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.447 HG22 ' N ' ' A' ' 56' ' ' THR . 7.0 p -167.26 157.35 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 179.963 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.447 ' N ' HG22 ' A' ' 55' ' ' VAL . 89.8 m -128.1 137.0 51.95 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.16 137.29 41.23 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -76.82 -174.71 3.16 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.69 -19.11 61.99 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -84.6 7.51 19.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.987 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.016 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 32.06 61.77 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 t -129.31 133.52 47.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -124.25 164.37 19.7 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.67 126.35 11.02 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -158.64 154.19 26.07 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.39 133.35 50.29 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.438 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.6 OUTLIER -115.25 119.84 37.68 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.893 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.645 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -72.07 133.82 45.47 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.89 ' CG1' HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -108.17 123.9 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.998 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.997 ' HG3' ' OD1' ' A' ' 15' ' ' ASP . 0.5 OUTLIER -113.25 140.7 47.75 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.956 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 3.6 ptt180 -76.49 -7.71 55.68 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 77.3 p -167.29 146.6 5.15 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.96 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 7.2 p90 -177.19 164.98 2.26 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.02 115.07 3.45 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.272 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.47 98.31 1.25 Allowed Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.43 101.49 11.41 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.981 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.884 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -57.32 137.3 56.22 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.814 ' HE2' HD23 ' A' ' 45' ' ' LEU . 13.4 m-85 -47.23 -40.14 15.74 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.606 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t0 -56.45 -17.06 6.96 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.65 28.11 9.88 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.884 ' HB ' HD23 ' A' ' 77' ' ' LEU . 28.3 m -112.3 143.44 43.39 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -81.17 94.48 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.975 ' CZ2' HG11 ' A' ' 44' ' ' VAL . 4.7 t-105 -63.08 -48.97 76.34 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 141.13 173.56 13.68 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.39 106.91 1.49 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' HB3' ' A' ' 38' ' ' ALA . 26.8 m -87.66 151.86 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -101.97 92.33 4.74 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -53.55 -24.66 14.16 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.968 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 8.3 t -84.26 1.73 43.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.5 m -115.14 -27.49 7.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.45 -171.53 2.24 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -95.6 131.22 42.04 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.609 ' HB2' ' HB ' ' A' ' 110' ' ' ILE . 1.9 m -102.81 167.77 9.66 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.191 ' HG3' ' O ' ' A' ' 108' ' ' VAL . 11.2 tt0 -169.78 126.29 0.86 Allowed 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.438 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 67.3 t -112.91 159.23 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.989 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.821 ' C ' HG13 ' A' ' 34' ' ' VAL . . . -179.17 -179.79 48.77 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.942 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.516 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.64 144.37 51.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.274 ' OG ' ' HB3' ' A' ' 33' ' ' ASP . 94.0 p -129.62 147.08 51.38 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 1.205 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -105.27 -163.41 0.95 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.987 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.86 -48.21 69.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.937 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.23 -21.04 66.29 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 88.76 53.2 2.62 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.909 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 1.11 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -129.14 162.53 27.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.98 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.867 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -171.94 -179.52 42.94 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.567 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 156.85 54.3 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.357 3.371 . . . . 0.0 109.593 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.322 ' CB ' ' HB1' ' A' ' 2' ' ' ALA . 10.8 pt-20 -35.69 120.84 0.6 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.9 148.2 0.04 OUTLIER Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.951 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.191 ' O ' ' HG3' ' A' ' 94' ' ' GLN . 72.0 t -124.4 118.95 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.996 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -98.14 150.47 21.43 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.289 HG23 ' OG ' ' A' ' 10' ' ' SER . 16.9 mt -126.09 163.49 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.646 ' O ' ' HA ' ' A' ' 11' ' ' SER . 13.5 t -152.75 134.61 14.71 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.872 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -102.5 125.52 49.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 31.0 m-80 . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 179.991 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.619 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -130.52 132.07 23.75 Favored Pre-proline 0 N--CA 1.449 -0.506 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.347 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.7 Cg_endo -72.35 -174.12 1.33 Allowed 'Trans proline' 0 N--CA 1.448 -1.201 0 C-N-CA 124.323 3.349 . . . . 0.0 109.609 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.79 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.3 m -96.47 107.12 19.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.673 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -124.39 147.53 48.18 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.987 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.528 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -102.26 111.57 23.9 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.025 HG22 HG12 ' A' ' 21' ' ' VAL . 38.6 t -107.28 148.04 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.894 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -73.24 176.74 2.39 Favored Pre-proline 0 N--CA 1.449 -0.507 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.93 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.11 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.6 Cg_endo -72.43 116.28 4.65 Favored 'Trans proline' 0 N--CA 1.447 -1.217 0 C-N-CA 124.332 3.354 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.02 ' HB2' HG23 ' A' ' 110' ' ' ILE . 91.6 p -111.51 47.38 1.03 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.1 p -127.1 107.06 9.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.96 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.72 26.12 23.39 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.921 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.11 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.96 131.64 44.23 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.995 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.1 m -111.21 173.98 6.08 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 16' ' ' GLY . 1.5 t0 -47.87 144.0 3.76 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.489 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 99.41 -23.6 35.57 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.953 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.483 HG21 ' HB3' ' A' ' 13' ' ' LEU . 82.7 m -74.33 151.17 39.84 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.8 p -125.31 117.41 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.949 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.693 HG13 HG22 ' A' ' 8' ' ' THR . 55.1 t -83.99 163.46 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.828 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tppt? -124.01 133.4 53.68 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -135.53 110.39 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 179.973 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.673 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.6 119.24 33.2 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.984 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.762 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -82.76 140.68 20.44 Favored Glycine 0 C--N 1.335 0.515 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.751 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.4 108.8 6.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.93 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.922 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.99 24.37 8.6 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.187 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.66 -163.59 1.03 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.434 ' HB2' ' CB ' ' A' ' 30' ' ' THR . 0.1 OUTLIER -85.5 126.56 33.94 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.952 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.537 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.25 131.57 41.32 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.89 84.81 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.59 HG21 ' CZ ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -92.52 138.2 31.71 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.666 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -88.49 145.17 25.9 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.936 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 41.3 m-85 -133.61 146.03 50.56 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.218 ' CA ' ' H ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -110.72 117.37 33.28 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.906 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.316 ' CG2' ' HB3' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.32 145.56 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.99 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.957 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -167.25 171.57 41.99 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.817 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 24.7 tt0 -118.14 112.01 19.61 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.969 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 82.6 m -105.05 172.4 6.81 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.996 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -155.09 138.17 15.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.905 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.509 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -64.93 127.18 30.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.912 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.912 HG22 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -108.27 -51.85 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.027 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -143.01 165.14 28.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.946 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.624 HG23 ' O ' ' A' ' 42' ' ' THR . 10.1 t -51.46 112.15 0.7 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.08 9.15 75.87 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.773 HG12 ' CD1' ' A' ' 83' ' ' TRP . 4.5 t -129.06 114.37 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.933 HD12 ' N ' ' A' ' 46' ' ' ALA . 0.9 OUTLIER -118.22 162.84 17.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -123.64 138.63 54.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.983 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.222 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 58.3 m -109.49 148.46 31.16 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.716 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 30.8 t-20 -107.04 107.17 60.08 Favored Pre-proline 0 N--CA 1.45 -0.469 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 82.7 Cg_endo -72.47 0.35 7.61 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.317 3.344 . . . . 0.0 109.564 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.02 -9.54 50.92 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.867 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 10.9 p30 -131.72 27.16 4.66 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 104.98 13.9 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.991 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 29.8 t -98.32 172.29 7.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.945 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.6 p -146.34 154.68 41.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.464 HG22 ' N ' ' A' ' 56' ' ' THR . 6.0 p -166.7 158.31 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.954 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.464 ' N ' HG22 ' A' ' 55' ' ' VAL . 13.7 m -127.05 130.16 49.42 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.38 43.74 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.2 p30 -92.24 -171.59 2.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.27 -23.92 66.02 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 60' ' ' ASN . 1.8 m-20 -85.19 9.74 14.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.537 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 58.58 14.28 20.73 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -104.51 133.91 48.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.934 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.45 162.21 19.92 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 p -146.09 127.45 14.92 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.577 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -163.9 150.03 11.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.877 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.25 142.5 40.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.105 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -113.85 123.27 49.39 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.702 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 2.4 t -70.08 124.54 24.35 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.875 -0.416 . . . . 0.0 109.875 179.983 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.555 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -85.09 125.2 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.985 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.0 OUTLIER -117.08 144.76 44.3 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.427 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -87.16 -13.43 44.08 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 51.9 p -166.99 149.7 6.35 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.952 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.817 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 3.1 p90 -177.03 152.42 0.9 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.95 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.5 121.68 8.21 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.7 93.13 1.25 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.892 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.26 99.85 10.84 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.981 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -57.1 130.8 47.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.685 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.35 -35.75 8.55 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.54 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.68 -16.62 11.35 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.47 26.35 10.09 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 29.9 m -112.9 145.77 40.13 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -86.56 95.6 9.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.434 . . . . 0.0 109.83 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.027 ' HZ2' ' CB ' ' A' ' 41' ' ' ASP . 1.0 OUTLIER -62.98 -53.84 47.75 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.939 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 142.7 173.21 14.32 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.13 125.57 21.12 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.996 HG11 ' CB ' ' A' ' 38' ' ' ALA . 54.5 t -100.05 148.63 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -116.47 93.25 4.14 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.427 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.5 m -52.86 -26.01 13.38 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.0 p -81.75 1.4 34.66 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.0 m -116.89 -27.18 6.66 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.916 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.98 -176.92 4.16 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.915 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -99.79 124.73 45.37 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.001 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 73.2 m -104.62 154.88 19.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.033 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.9 OUTLIER -143.39 149.75 38.12 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.92 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.105 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 5.4 t -117.85 154.25 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.24 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.95 173.54 46.08 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.316 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -126.45 146.32 50.14 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.988 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.218 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 4.7 m -127.09 151.49 48.56 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.666 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -109.53 -165.62 1.03 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.984 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.421 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.48 -49.33 77.98 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.964 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.551 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -68.64 -25.33 64.78 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 97.41 41.82 3.34 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.551 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -115.94 164.04 15.0 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.975 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.936 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.57 -177.49 42.01 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.347 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.44 156.25 54.54 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.251 3.301 . . . . 0.0 109.57 179.903 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.619 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 3.3 pt-20 -37.36 119.87 0.74 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.49 151.93 0.02 OUTLIER Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.941 ' CG2' HG21 ' A' ' 7' ' ' VAL . 3.6 t -124.01 104.44 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.42 128.83 34.83 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.033 HG13 ' HA ' ' A' ' 94' ' ' GLN . 6.4 mt -102.03 160.77 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.931 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.744 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -144.52 120.89 10.95 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.946 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.46 123.43 40.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.475 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.547 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -140.66 123.57 9.94 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.573 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.34 -178.64 3.42 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 124.356 3.371 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.188 ' HA ' ' OE2' ' A' ' 106' ' ' GLU . 1.2 m -101.91 109.52 21.28 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -179.961 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.922 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.71 141.9 51.58 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -104.75 117.76 34.87 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.992 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.787 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.0 OUTLIER -115.92 151.73 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.951 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.647 ' CG2' ' HA ' ' A' ' 19' ' ' VAL . 0.4 OUTLIER -74.48 163.54 67.54 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.937 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.628 ' O ' HD21 ' A' ' 13' ' ' LEU . 83.0 Cg_endo -72.41 120.09 6.53 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.267 3.312 . . . . 0.0 109.595 179.918 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.987 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -120.07 16.7 12.46 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.975 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.106 ' HA ' ' O ' ' A' ' 111' ' ' SER . 78.2 p -98.91 115.15 28.23 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.654 ' N ' ' H ' ' A' ' 113' ' ' ASN . . . 104.24 -0.13 44.0 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.059 HD22 HG21 ' A' ' 17' ' ' THR . 1.3 pp -114.09 142.48 46.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.996 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.8 p -107.54 -167.76 1.3 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.919 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.677 ' CG ' HH11 ' A' ' 70' ' ' ARG . 7.2 t70 -42.15 153.67 0.06 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.98 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.75 -23.1 34.23 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.978 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 1.059 HG21 HD22 ' A' ' 13' ' ' LEU . 26.1 m -80.26 141.42 35.57 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 18' ' ' VAL . 11.2 p -119.46 109.84 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.932 HG13 ' HB3' ' A' ' 67' ' ' LEU . 1.8 p -83.67 161.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.987 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.787 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -118.73 150.79 39.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.972 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.62 109.35 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.978 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.922 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.14 116.95 25.11 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.016 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.64 144.74 22.38 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.984 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.717 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -143.04 109.55 5.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -179.979 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.45 17.82 23.05 Favored Glycine 0 C--N 1.336 0.56 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.99 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.016 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.01 175.15 7.29 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.991 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.49 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 37.6 mt-30 -58.35 121.37 10.65 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.461 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.65 129.16 37.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.99 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.35 8.22 87.61 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.933 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.513 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -94.5 143.49 26.37 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.961 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.667 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -87.35 151.45 23.09 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.96 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.795 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 39.3 m-85 -138.9 139.35 38.02 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.911 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.192 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.3 m-20 -105.47 113.73 27.48 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.27 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.98 147.57 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.938 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.863 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -173.72 166.13 38.26 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.982 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 1.01 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 2.2 tt0 -108.26 123.56 48.96 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.963 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 72.7 m -117.57 143.86 45.69 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.959 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.557 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.07 137.61 54.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.52 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.5 OUTLIER -65.61 127.94 33.91 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.906 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.625 HG13 ' CE3' ' A' ' 83' ' ' TRP . 1.2 t -107.43 -55.14 5.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.465 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.62 167.62 17.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.962 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.417 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -50.81 112.11 0.65 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.944 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.72 8.09 66.96 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.999 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.516 HG11 ' HE1' ' A' ' 83' ' ' TRP . 11.6 t -122.74 112.89 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.988 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.647 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.4 OUTLIER -121.97 131.98 54.29 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.984 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.341 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -89.31 153.77 20.62 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.942 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.197 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 14.8 m -110.81 156.87 20.48 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.825 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.6 t30 -114.9 106.24 52.03 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.965 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.465 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.8 Cg_endo -72.37 -0.09 8.2 Favored 'Trans proline' 0 N--CA 1.448 -1.178 0 C-N-CA 124.319 3.346 . . . . 0.0 109.603 179.91 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.15 -11.61 43.36 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.7 p30 -130.25 27.26 5.09 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.23 106.76 15.28 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 t -101.09 171.79 7.41 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.896 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.5 p -146.88 154.26 41.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.941 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.514 HG22 ' N ' ' A' ' 56' ' ' THR . 3.5 p -166.77 161.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.928 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.514 ' N ' HG22 ' A' ' 55' ' ' VAL . 19.9 m -128.03 135.8 50.37 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.966 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.63 135.19 39.16 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.917 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.0 p30 -76.02 -175.35 3.04 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.914 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.5 -19.75 62.42 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -83.28 6.8 18.42 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.006 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 57.94 32.11 65.89 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.9 t -130.92 134.53 46.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.966 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.35 165.5 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -144.94 130.25 18.67 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.988 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.656 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -150.61 169.79 20.73 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.88 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.656 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -128.87 117.52 21.16 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.423 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.36 157.95 15.72 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.959 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.534 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -118.67 136.93 53.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.947 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.527 HG21 ' CD1' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -103.23 126.69 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.991 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.677 HH11 ' CG ' ' A' ' 15' ' ' ASP . 0.1 OUTLIER -113.73 142.68 45.74 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.959 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -62.81 -35.13 78.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.992 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 83.7 p -154.55 157.05 37.71 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.876 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 1.01 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.2 p90 -177.17 155.83 1.19 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' CG ' ' A' ' 74' ' ' GLU . 0.5 OUTLIER -53.49 109.93 0.5 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.935 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.341 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.1 103.0 1.07 Allowed Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.281 -1.127 . . . . 0.0 110.281 179.96 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.984 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -83.19 100.21 10.43 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.987 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.878 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.3 tp -57.87 137.98 56.15 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.682 ' N ' HD12 ' A' ' 77' ' ' LEU . 1.7 m-85 -47.34 -40.36 17.11 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.704 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -57.32 -17.13 10.78 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.978 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.53 28.56 9.52 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.993 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.878 ' HB ' HD23 ' A' ' 77' ' ' LEU . 5.4 m -112.45 148.43 34.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -83.94 94.21 8.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.625 ' CE3' HG13 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -64.24 -40.18 95.48 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.92 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 131.33 169.7 12.47 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -60.31 106.12 0.49 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.942 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.625 ' CG1' HG23 ' A' ' 40' ' ' VAL . 27.6 m -85.35 154.34 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -102.64 91.72 4.32 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.923 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.774 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.28 -20.65 7.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.977 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.611 HG22 ' HD2' ' A' ' 112' ' ' PHE . 76.0 p -90.59 2.82 55.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.971 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.6 m -112.61 -27.26 8.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.95 -178.77 4.28 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.28 129.19 35.87 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.434 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 3.8 m -105.04 155.24 19.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.313 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.6 tt0 -154.02 131.75 11.51 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 -179.939 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.423 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.5 t -94.09 163.67 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.989 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.231 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.69 165.0 33.84 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.27 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -130.41 132.2 45.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.986 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.192 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 32.9 m -111.66 153.01 27.01 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.904 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.667 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -113.03 -162.47 0.8 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.995 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -67.9 -48.45 65.98 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.941 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.24 -24.15 65.78 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.78 54.09 1.7 Allowed Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.951 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -133.97 171.47 14.14 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.795 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -172.51 173.77 45.45 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.573 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.3 Cg_endo -72.42 168.23 24.86 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 124.258 3.306 . . . . 0.0 109.571 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.547 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.1 pt-20 -39.54 125.63 1.77 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -179.945 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.3 161.22 0.01 OUTLIER Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.914 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.313 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 50.0 t -119.13 102.4 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -79.91 132.35 36.04 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.944 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CD1' ' HB2' ' A' ' 93' ' ' CYS . 16.1 pt -136.85 -175.3 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.985 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 1.106 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -177.27 153.17 0.92 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.968 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.434 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.1 m-85 -107.17 119.28 38.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.945 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.654 ' H ' ' N ' ' A' ' 12' ' ' GLY . 7.3 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.904 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.189 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -86.36 116.93 67.69 Favored Pre-proline 0 N--CA 1.448 -0.54 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.914 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.608 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 85.0 Cg_endo -72.37 -178.73 3.49 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 124.36 3.373 . . . . 0.0 109.608 179.925 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.97 ' HA ' ' OE1' ' A' ' 106' ' ' GLU . 1.2 m -100.9 108.74 20.58 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.657 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -120.16 145.2 47.18 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.957 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -108.66 115.29 29.82 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.976 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.726 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.9 OUTLIER -112.33 153.57 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.993 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.853 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.18 175.09 1.95 Allowed Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.958 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.063 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.43 117.45 5.14 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.292 3.328 . . . . 0.0 109.607 179.869 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.032 ' HB3' HG23 ' A' ' 110' ' ' ILE . 0.1 OUTLIER -115.16 47.35 1.3 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.943 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.49 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -123.71 105.81 10.0 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.977 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 90.45 28.51 16.66 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.274 -1.131 . . . . 0.0 110.274 179.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.063 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -99.43 134.79 41.8 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.83 163.77 12.02 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 15' ' ' ASP . 3.5 t0 -45.94 142.91 2.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 103.44 -22.75 35.1 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.972 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.47 HG21 HD13 ' A' ' 13' ' ' LEU . 90.6 m -73.3 144.81 46.45 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.977 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 18' ' ' VAL . 11.0 p -111.74 115.08 48.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.978 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.082 HG13 HG12 ' A' ' 69' ' ' VAL . 5.6 m -84.21 158.51 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.726 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.53 144.39 42.93 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.979 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -145.36 110.74 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.985 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.657 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.78 122.41 37.37 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.956 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.063 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -84.51 146.79 22.73 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.947 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.752 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.1 109.37 4.69 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.72 16.83 27.67 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.952 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.063 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.43 176.06 6.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.945 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.509 ' HB2' HG21 ' A' ' 30' ' ' THR . 31.7 mt-30 -56.5 120.82 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -180.0 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.448 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.73 130.66 41.02 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.976 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.28 7.34 84.78 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.509 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -92.26 140.39 29.66 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.964 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 1.238 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.8 147.86 27.34 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.109 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 27.4 m-85 -135.75 131.92 36.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.932 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.351 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.45 112.58 24.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.962 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.458 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.77 144.31 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.987 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.983 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.68 161.09 33.92 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.903 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 34.2 tt0 -104.03 119.18 38.39 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 85.7 m -117.08 143.54 45.67 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.464 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -123.29 139.25 54.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.544 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.3 OUTLIER -64.98 125.29 24.43 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.427 HG13 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -105.03 -44.09 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.991 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.543 ' OD1' ' HZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -142.36 169.41 17.63 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.952 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.4 m -50.99 112.41 0.71 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.997 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.63 7.47 61.33 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.964 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.402 HG12 HG12 ' A' ' 40' ' ' VAL . 2.3 t -120.8 118.7 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.564 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.6 OUTLIER -128.99 134.91 48.34 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.986 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.38 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -91.55 157.61 16.91 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.161 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 69.1 m -117.61 156.04 28.82 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.983 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.551 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.0 t30 -122.07 109.28 33.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.48 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 81.9 Cg_endo -72.44 0.26 7.73 Favored 'Trans proline' 0 N--CA 1.447 -1.232 0 C-N-CA 124.278 3.319 . . . . 0.0 109.576 179.936 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -85.44 -14.96 44.55 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.878 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 5.9 p30 -129.09 19.53 5.93 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.951 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.689 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -82.07 117.94 22.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.983 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 m -107.11 178.1 4.65 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.973 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 p -145.23 152.69 40.37 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.851 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.487 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.7 p -167.02 156.56 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 55' ' ' VAL . 22.0 m -127.92 133.05 49.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.959 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -71.75 134.49 46.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.936 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 37.5 p30 -75.05 -174.46 2.27 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.909 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.54 -25.23 67.93 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.975 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.32 -4.6 42.99 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.912 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 72.07 31.08 64.52 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.997 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.1 p -129.2 139.62 51.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 179.957 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.37 163.43 26.89 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.964 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.69 127.06 15.85 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.416 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -150.62 159.43 44.51 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.855 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.416 ' N ' HG23 ' A' ' 65' ' ' THR . 0.5 OUTLIER -119.5 115.08 23.3 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.932 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.641 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.78 157.55 16.01 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.925 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.667 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.6 OUTLIER -111.93 136.22 51.53 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.975 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 1.082 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -107.95 129.16 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.99 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.78 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.38 164.3 15.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 179.994 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.2 -15.37 29.41 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.983 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -164.49 143.28 7.12 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.923 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.903 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.5 p90 -170.7 159.52 6.6 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.947 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -54.59 120.3 6.5 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.901 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.38 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.94 92.28 1.35 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 179.986 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.926 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.19 100.14 10.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.966 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.929 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -55.14 144.25 24.66 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -179.991 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.755 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.35 -43.43 23.05 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.579 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 8.7 t0 -58.05 -17.02 14.97 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.958 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.2 28.56 10.6 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.284 -1.127 . . . . 0.0 110.284 179.999 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.929 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.2 m -107.66 119.22 38.83 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.979 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.83 91.43 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.952 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.427 ' CE2' HG13 ' A' ' 40' ' ' VAL . 29.0 t90 -62.7 -58.55 7.08 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.901 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 157.48 166.91 17.73 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.992 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.06 108.82 0.73 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.955 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.605 HG22 HG23 ' A' ' 40' ' ' VAL . 15.7 t -81.95 147.35 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.998 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -105.28 94.44 5.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.988 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -52.56 -24.99 9.23 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.973 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.6 p -79.3 -3.64 46.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 -26.87 7.36 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.4 -178.11 3.9 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.958 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.13 138.6 33.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.959 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.656 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -102.47 161.23 13.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.974 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.206 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 4.4 tt0 -168.39 127.19 1.16 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.942 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.641 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.5 t -97.04 164.56 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.967 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -175.75 167.99 40.09 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.99 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.458 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -131.82 128.5 38.85 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.981 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.351 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 19.8 m -116.84 142.19 47.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.913 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 1.238 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -98.33 -157.8 0.62 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.989 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.437 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.87 -48.22 69.45 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.903 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.462 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -69.77 -25.89 64.02 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.955 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.8 48.46 2.11 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.602 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -120.62 162.94 18.8 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -179.999 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.109 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -170.58 176.71 44.04 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.984 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.608 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.1 Cg_endo -72.46 165.12 33.6 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.319 3.346 . . . . 0.0 109.601 179.935 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.189 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 5.2 pt-20 -38.24 135.91 0.69 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.961 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.61 147.56 3.93 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.967 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.206 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 13.0 t -127.42 104.15 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.985 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.629 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -88.71 157.16 18.62 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.032 HG23 ' HB3' ' A' ' 10' ' ' SER . 22.4 mt -127.97 168.31 21.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.941 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.501 ' N ' HG22 ' A' ' 110' ' ' ILE . 21.1 t -153.97 137.26 15.73 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.954 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.656 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -102.09 124.94 48.56 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.553 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 30.3 m-80 . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.97 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.586 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -90.69 123.16 65.87 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.931 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.427 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.42 -175.23 1.7 Allowed 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.306 3.337 . . . . 0.0 109.61 179.924 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.897 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -96.72 108.21 20.8 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.736 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.26 146.52 49.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.652 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.43 110.33 22.31 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.973 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.902 HG21 ' CG2' ' A' ' 108' ' ' VAL . 14.3 t -105.62 146.1 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.93 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.17 175.24 2.2 Favored Pre-proline 0 N--CA 1.448 -0.528 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.945 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.119 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.8 Cg_endo -72.42 116.54 4.75 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 124.323 3.349 . . . . 0.0 109.593 179.918 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.973 ' HB2' HG23 ' A' ' 110' ' ' ILE . 56.6 p -113.33 46.66 1.23 Allowed 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.957 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 111' ' ' SER . 61.9 p -126.34 105.2 8.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.907 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.971 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 92.79 26.84 15.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.119 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -98.13 132.34 43.74 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.965 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -104.15 169.41 8.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.944 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' A' ' 15' ' ' ASP . 15.9 p30 -46.02 141.43 3.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.993 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.19 -22.95 34.84 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.991 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.502 HG21 HD13 ' A' ' 13' ' ' LEU . 24.6 m -79.63 152.32 30.08 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.991 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 18' ' ' VAL . 1.2 t -124.92 125.66 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.998 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.711 HG22 ' O ' ' A' ' 67' ' ' LEU . 4.6 m -89.37 118.22 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.796 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -69.24 148.37 49.91 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.637 HG12 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -146.81 105.27 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.997 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.736 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.25 117.1 28.2 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.963 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.696 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.29 141.2 19.69 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.897 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -137.27 108.64 6.88 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.928 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.917 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.67 23.88 9.1 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.976 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.401 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -89.34 -171.79 3.37 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.983 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.493 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 29.1 mt-30 -76.31 124.29 27.28 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.989 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.66 130.33 40.31 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.48 8.22 83.7 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.958 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.552 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -95.04 136.48 35.31 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.96 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.771 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.88 151.31 23.88 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.999 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.919 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 48.4 m-85 -138.12 144.17 40.71 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.851 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.048 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.0 m-20 -104.64 116.63 32.4 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.956 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.418 HG22 ' CB ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -104.05 142.29 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.975 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.882 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.5 170.78 42.87 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.958 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.968 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 5.6 tt0 -114.42 116.3 28.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.934 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 64.2 m -114.6 143.2 45.39 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.826 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.9 131.45 53.74 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.914 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.84 123.72 20.53 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.935 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.058 ' HB ' ' CE3' ' A' ' 83' ' ' TRP . 14.2 m -103.58 -43.98 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.575 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -136.8 176.18 8.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.991 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 30.9 p -60.16 112.08 1.77 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.982 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.98 8.29 64.09 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.304 HG11 ' CZ2' ' A' ' 83' ' ' TRP . 61.6 t -122.79 108.0 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 180.0 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.561 HD12 ' HB3' ' A' ' 37' ' ' CYS . 0.9 OUTLIER -121.47 139.52 53.37 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.978 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.475 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -93.83 157.93 15.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.137 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 35.3 m -118.74 152.26 36.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.997 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.846 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 36.3 t-20 -110.93 107.47 57.79 Favored Pre-proline 0 N--CA 1.449 -0.492 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.1 Cg_endo -72.37 -0.02 8.09 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.322 3.348 . . . . 0.0 109.591 179.891 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.568 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.78 -11.11 43.13 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.783 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.502 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.6 p30 -131.1 27.05 4.87 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.901 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.97 106.18 15.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.977 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 11.6 t -104.19 173.23 6.39 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.943 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 7.2 p -145.51 156.75 43.91 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.443 HG22 ' N ' ' A' ' 56' ' ' THR . 4.7 p -166.29 157.83 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.915 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.443 ' N ' HG22 ' A' ' 55' ' ' VAL . 15.7 m -127.76 126.98 42.8 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.944 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.49 153.0 24.37 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.5 p30 -93.78 -171.63 2.64 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.885 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.22 67.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -83.17 5.24 23.4 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.991 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.539 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 64.59 9.24 37.03 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.975 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.5 t -101.22 134.41 44.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.985 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.56 163.48 17.91 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.984 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.4 p -147.78 130.72 16.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.972 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.49 164.19 17.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.968 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.8 OUTLIER -120.46 132.09 55.06 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.921 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.161 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -109.61 122.44 47.46 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.912 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.59 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.7 t -77.96 130.95 37.16 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.899 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.586 HG11 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -106.45 129.87 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.967 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.746 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -111.43 155.26 23.45 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.932 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -83.02 -13.67 55.45 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.978 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.533 ' OG ' ' OD1' ' A' ' 87' ' ' ASP . 13.9 m -167.24 147.4 5.41 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.968 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 8.6 p90 -177.31 157.36 1.32 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.949 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.406 ' O ' ' HG3' ' A' ' 74' ' ' GLU . 14.8 pt-20 -56.56 117.61 4.03 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.942 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.475 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.14 97.26 1.39 Allowed Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.996 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.807 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.38 100.36 10.64 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.986 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.879 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.2 tp -54.5 141.74 30.04 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.724 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.22 -42.85 20.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.574 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 5.9 t0 -56.78 -16.8 7.21 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.974 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.69 27.98 10.82 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.879 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -108.19 130.82 55.12 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 6.9 ptt180 -72.24 92.95 1.42 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.575 ' CH2' ' HB2' ' A' ' 41' ' ' ASP . 0.6 OUTLIER -61.67 -54.96 35.73 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.893 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 150.5 174.19 21.37 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.259 -1.137 . . . . 0.0 110.259 -179.987 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.07 113.96 3.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.965 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' A' ' 38' ' ' ALA . 1.1 m -91.36 152.4 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.982 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.533 ' OD1' ' OG ' ' A' ' 72' ' ' SER . 1.5 m-20 -115.7 102.97 10.22 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.975 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.537 ' SG ' ' O ' ' A' ' 70' ' ' ARG . 23.0 m -52.82 -27.46 18.27 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.994 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.3 p -79.56 -3.51 47.28 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.994 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.69 -27.78 6.57 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.993 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.27 -178.4 4.2 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.959 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.56 122.97 44.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.879 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.573 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 89.7 m -104.03 151.73 22.88 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.973 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.986 ' HA ' HG13 ' A' ' 110' ' ' ILE . 0.4 OUTLIER -152.24 146.81 25.71 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.951 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.161 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 3.0 t -110.21 159.05 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.983 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.243 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -178.07 169.6 41.49 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.992 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.418 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -127.8 129.42 46.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.958 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.048 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 5.8 m -110.26 152.35 26.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.961 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.771 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -114.37 -169.35 1.51 Allowed 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.943 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.428 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -62.65 -48.91 77.31 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.24 -24.29 66.57 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.928 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.02 53.5 1.89 Allowed Glycine 0 C--N 1.335 0.512 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -179.955 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.727 ' ND2' ' CE1' ' A' ' 32' ' ' TYR . 0.0 OUTLIER -132.79 172.69 12.24 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.982 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.919 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.24 179.27 48.59 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.966 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.427 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.7 Cg_endo -72.4 160.01 47.92 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 124.313 3.342 . . . . 0.0 109.586 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.586 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -36.82 122.2 0.8 Allowed 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.993 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -39.38 155.38 0.03 OUTLIER Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.974 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.902 ' CG2' HG21 ' A' ' 7' ' ' VAL . 8.6 t -127.51 111.59 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.981 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.411 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -92.98 129.8 38.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.949 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.986 HG13 ' HA ' ' A' ' 94' ' ' GLN . 2.5 mt -103.74 156.16 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.605 ' O ' ' HA ' ' A' ' 11' ' ' SER . 11.7 t -145.25 129.7 17.86 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.91 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.547 ' HZ ' HG23 ' A' ' 69' ' ' VAL . 9.6 m-85 -96.23 126.59 41.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.947 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.952 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.468 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.293 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -102.01 124.55 39.71 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.96 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.583 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.8 Cg_endo -72.41 -177.19 2.58 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 124.349 3.366 . . . . 0.0 109.584 179.949 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.833 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -95.42 108.63 20.85 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.926 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -128.91 145.26 51.27 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.645 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.1 p -104.49 111.98 24.86 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.871 HG13 ' O ' ' A' ' 20' ' ' LYS . 26.2 t -106.96 149.21 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.952 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.996 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.53 178.32 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.938 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.121 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.6 Cg_endo -72.37 117.75 5.28 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 C-N-CA 124.279 3.32 . . . . 0.0 109.569 179.942 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.564 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 17.2 p -114.13 45.16 1.54 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.981 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 92.5 p -127.78 106.38 9.09 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.873 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.903 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.59 24.5 20.86 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.121 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -94.1 130.11 40.39 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 45.8 t -98.49 168.27 10.29 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.93 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.63 141.15 17.02 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.959 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.4 -23.72 34.23 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.458 HG21 ' HB3' ' A' ' 13' ' ' LEU . 21.1 m -72.27 152.69 42.0 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.987 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.424 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.9 p -126.77 131.19 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 67' ' ' LEU . 3.0 m -97.95 169.7 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.871 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.83 150.34 38.53 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.975 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.847 HG23 HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -144.32 109.4 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.978 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.838 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -118.53 114.86 23.47 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -82.55 146.8 24.91 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.833 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.01 110.92 4.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.864 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 102.39 13.46 30.58 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.99 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.993 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.59 165.98 13.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.979 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.525 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.5 mt-30 -46.41 119.71 2.51 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.984 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.744 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.26 131.08 41.54 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.936 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.47 8.46 80.55 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.918 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.525 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.7 OUTLIER -93.78 148.32 22.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.951 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.408 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.976 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.938 ' HB3' ' CB ' ' A' ' 97' ' ' LEU . 35.1 m-85 -138.26 151.75 47.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.907 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.406 ' CA ' ' H ' ' A' ' 98' ' ' SER . 35.0 m-20 -120.23 117.4 27.77 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.281 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -98.58 141.39 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.803 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -161.99 155.44 26.71 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 -179.986 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.894 ' NE2' ' HE2' ' A' ' 73' ' ' PHE . 40.7 tt0 -105.65 115.7 30.68 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.965 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.449 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.3 m -102.96 166.66 10.32 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.025 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -153.33 134.0 13.76 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.956 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.592 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -65.2 122.55 17.36 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.91 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.514 ' HB ' ' CD1' ' A' ' 83' ' ' TRP . 2.5 m -102.9 -42.82 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.992 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.457 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -138.47 166.16 25.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m -50.79 111.77 0.6 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.997 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.35 8.92 63.35 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.97 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.52 HG11 ' CH2' ' A' ' 83' ' ' TRP . 75.0 t -120.3 119.35 59.64 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -124.5 162.75 23.32 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.515 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -132.54 155.42 48.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.926 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.1 m -113.46 155.23 25.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.521 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.3 t30 -116.11 112.41 42.11 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -72.38 0.13 7.88 Favored 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 124.31 3.34 . . . . 0.0 109.65 179.844 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.521 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.03 -16.52 29.61 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.915 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.473 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 15.0 p30 -127.16 28.33 5.77 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.93 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -102.1 118.67 37.4 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.7 t -107.41 -177.27 3.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.932 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.7 p -147.65 154.58 40.81 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.522 HG22 ' N ' ' A' ' 56' ' ' THR . 6.7 p -167.31 161.9 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.977 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.522 ' N ' HG22 ' A' ' 55' ' ' VAL . 20.7 m -126.34 130.19 50.32 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.94 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.58 145.55 55.48 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.977 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 51.6 p30 -83.7 -172.29 4.07 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.934 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -64.09 -27.57 69.19 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.66 -10.06 59.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.976 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.993 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 77.62 31.79 48.77 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.969 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.3 p -127.36 136.32 51.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.991 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -123.95 170.2 10.86 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.6 m -150.53 123.97 9.0 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.946 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.499 HG21 HG21 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -151.94 160.26 43.55 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.907 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.488 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -114.43 129.68 56.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.913 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.069 ' HG ' ' CG2' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -107.26 118.01 35.58 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.901 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.578 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -67.66 120.46 14.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.987 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.534 HG12 ' O ' ' A' ' 69' ' ' VAL . 0.6 OUTLIER -76.47 123.94 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.975 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.635 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 26.9 mmt180 -115.57 157.03 24.71 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.494 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 4.1 ptt180 -107.08 -10.73 15.82 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.99 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -177.05 146.93 0.53 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.927 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.894 ' HE2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -176.69 171.52 2.25 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.878 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 118.36 7.28 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.515 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.25 94.07 1.35 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.996 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.3 OUTLIER -84.44 100.63 11.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.987 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.848 HD12 ' H ' ' A' ' 78' ' ' PHE . 2.2 tp -54.45 145.41 18.42 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.848 ' H ' HD12 ' A' ' 77' ' ' LEU . 10.8 m-85 -47.2 -43.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.591 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.2 OUTLIER -58.73 -16.52 17.03 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.965 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.12 28.25 12.15 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.826 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.2 m -106.38 122.67 46.74 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.1 ttm180 -61.71 90.96 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.956 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.52 ' CH2' HG11 ' A' ' 44' ' ' VAL . 42.8 t-105 -62.35 -58.4 7.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.933 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.53 163.2 12.09 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.994 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.56 105.73 0.47 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.951 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.025 HG21 ' HB1' ' A' ' 38' ' ' ALA . 3.4 p -80.21 148.89 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -110.47 98.74 7.88 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.965 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 17.8 m -51.91 -27.53 13.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.989 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.2 p -79.57 1.21 26.85 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.982 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.4 m -116.99 -26.68 6.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.933 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.81 -175.31 3.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.992 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.58 125.65 48.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.247 ' O ' HG13 ' A' ' 110' ' ' ILE . 62.2 m -103.83 152.69 21.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.992 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -150.89 144.17 24.83 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.967 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.069 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 7.1 t -103.96 163.56 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.252 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -176.33 168.41 40.52 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.266 -1.133 . . . . 0.0 110.266 179.991 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.281 ' CG ' HG22 ' A' ' 34' ' ' VAL . 5.6 mp -99.5 162.16 13.19 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.988 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.406 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 13.0 m -154.16 118.48 4.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.92 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.451 ' OD1' ' N ' ' A' ' 102' ' ' GLY . 42.7 p-10 -113.54 -167.9 1.27 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.998 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.16 -19.89 2.23 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.946 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -103.45 -23.51 13.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.888 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.451 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 85.34 22.0 52.79 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.957 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.773 ' ND2' ' HD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -60.11 -151.83 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.974 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 143.47 153.38 5.86 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.953 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.583 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.41 165.4 32.79 Favored 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 124.247 3.298 . . . . 0.0 109.607 179.964 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.293 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 8.2 pt-20 -33.55 124.45 0.42 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.542 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -37.34 133.99 0.98 Allowed Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.6 104.03 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.952 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.463 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.58 144.97 26.94 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.247 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -116.11 159.47 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.917 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.46 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -144.2 115.05 7.79 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.963 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.586 ' CZ ' ' HB2' ' A' ' 93' ' ' CYS . 30.5 m-85 -100.06 126.21 46.25 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.934 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.947 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.505 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -114.98 126.3 28.01 Favored Pre-proline 0 N--CA 1.45 -0.467 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.526 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.2 Cg_endo -72.39 -175.37 1.76 Allowed 'Trans proline' 0 N--CA 1.447 -1.237 0 C-N-CA 124.328 3.352 . . . . 0.0 109.605 179.907 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.291 HG22 ' O ' ' A' ' 24' ' ' ALA . 6.4 t -99.67 116.15 31.11 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.885 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -131.9 154.64 49.02 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.934 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.498 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -115.76 117.09 29.27 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.048 HG13 ' O ' ' A' ' 20' ' ' LYS . 84.8 t -114.03 143.77 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.736 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.63 166.68 24.3 Favored Pre-proline 0 N--CA 1.448 -0.539 0 N-CA-C 109.959 -0.385 . . . . 0.0 109.959 179.938 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.736 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.37 118.13 5.46 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.331 3.354 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.615 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.0 OUTLIER -126.45 9.43 7.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.961 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.747 ' HA ' ' O ' ' A' ' 111' ' ' SER . 50.0 p -88.51 106.72 18.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.882 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.071 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 101.94 17.98 19.15 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 179.888 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.071 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.6 OUTLIER -108.12 133.24 52.67 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -87.77 174.54 8.32 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.913 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 27.8 t70 -46.71 153.33 0.4 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.962 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 94.53 -22.62 36.37 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.965 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.651 HG21 HD12 ' A' ' 13' ' ' LEU . 18.9 m -71.94 148.0 46.43 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.76 129.6 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.979 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.677 HG22 ' HB3' ' A' ' 67' ' ' LEU . 0.8 OUTLIER -104.51 150.54 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.969 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 1.048 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.1 147.86 28.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.976 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.809 ' HA ' HG22 ' A' ' 7' ' ' VAL . 0.3 OUTLIER -142.71 108.63 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -123.36 114.75 20.58 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.885 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.17 143.13 20.16 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.954 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.291 ' O ' HG22 ' A' ' 4' ' ' THR . . . -139.29 109.52 6.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.901 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.15 24.22 9.14 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.526 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -88.47 -169.35 2.52 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.531 ' HB2' HG21 ' A' ' 30' ' ' THR . 0.1 OUTLIER -81.03 125.25 29.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.991 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.3 131.29 43.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.992 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.94 8.15 77.43 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.599 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -96.63 132.14 42.56 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.972 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.42 ' O ' ' HB2' ' A' ' 99' ' ' ASP . . . -86.25 150.67 24.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.856 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 51.6 m-85 -135.03 141.73 46.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.056 ' HB2' ' O ' ' A' ' 98' ' ' SER . 2.2 m-20 -100.69 113.96 27.27 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -179.958 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.247 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -101.26 151.55 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.977 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.726 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -175.89 172.77 45.76 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.957 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.849 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 41.4 tt0 -108.18 107.12 17.61 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.942 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 60.7 m -106.73 142.43 36.38 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.726 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -122.49 137.38 54.9 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.875 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.569 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.4 OUTLIER -64.41 124.73 22.55 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.889 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.535 HG12 ' N ' ' A' ' 41' ' ' ASP . 1.2 t -105.27 -46.76 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.517 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.3 OUTLIER -135.82 167.09 21.82 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.936 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' HG23 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -51.14 112.19 0.69 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.954 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.57 7.94 65.94 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.893 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 2.0 t -122.38 117.58 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.983 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.532 ' O ' ' HG ' ' A' ' 45' ' ' LEU . 0.6 OUTLIER -127.35 136.3 51.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.979 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.494 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -92.34 151.76 20.11 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.813 -0.439 . . . . 0.0 109.813 -179.97 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.174 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.6 m -110.77 146.75 35.81 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.974 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.762 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.1 p-10 -116.73 115.38 39.24 Favored Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.567 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.3 Cg_endo -72.4 -0.54 8.87 Favored 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.317 3.345 . . . . 0.0 109.6 179.868 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.719 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -76.03 -25.4 55.63 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.89 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.472 ' CB ' HG23 ' A' ' 68' ' ' THR . 89.6 m-20 -124.8 27.74 6.71 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.948 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.73 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -83.33 117.32 22.92 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.966 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 m -110.92 -178.24 3.42 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.8 p -144.86 155.07 43.27 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.875 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.594 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.6 p -166.91 151.66 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.966 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.1 m -127.57 133.17 49.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.958 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -69.5 143.83 53.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.966 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 43.7 p30 -86.27 -172.03 3.85 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.936 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.36 -25.98 68.2 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.925 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -80.16 -7.77 59.1 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.05 30.59 57.13 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.927 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.3 p -122.57 133.01 54.56 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.98 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.594 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -119.4 162.66 18.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.981 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.2 p -149.5 129.03 13.07 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.971 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.442 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -158.91 157.57 31.67 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.868 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.442 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -115.61 125.04 52.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.927 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.452 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -98.83 157.39 16.33 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.916 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.628 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -106.41 140.29 39.56 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.965 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.597 HG23 HG11 ' A' ' 19' ' ' VAL . 0.9 OUTLIER -99.01 125.37 52.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.994 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.913 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -118.99 136.23 54.21 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.954 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.443 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -61.51 -34.49 75.6 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.443 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 62.5 p -156.58 162.4 39.9 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.849 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 2.9 p90 -177.71 165.62 2.08 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.961 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.8 116.55 8.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.911 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.494 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -76.66 94.73 1.08 Allowed Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.95 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.868 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.69 99.76 10.44 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.979 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.858 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.1 tp -56.8 131.13 48.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.988 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.677 ' CE2' ' SG ' ' A' ' 47' ' ' CYS . 9.5 m-85 -47.83 -35.63 10.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 179.989 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.551 ' CB ' HD21 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -57.54 -16.91 11.32 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.948 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.96 27.51 8.84 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.988 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.858 ' HB ' HD23 ' A' ' 77' ' ' LEU . 21.7 m -115.79 148.81 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.978 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 4.5 tmm_? -90.75 96.89 10.86 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.84 -0.429 . . . . 0.0 109.84 -179.977 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.517 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 32.9 t-105 -63.44 -58.05 8.31 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 172.93 21.64 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.991 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.75 104.81 2.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.726 HG21 ' HB3' ' A' ' 38' ' ' ALA . 7.1 m -78.76 152.34 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.999 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.75 92.91 4.05 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.971 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.137 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 32.7 m -51.6 -27.06 10.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.964 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 81.7 p -79.61 0.81 28.56 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.994 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -118.63 -27.97 5.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.899 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.46 180.0 5.7 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.669 ' CB ' ' OG ' ' A' ' 111' ' ' SER . . . -97.43 125.32 42.0 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.927 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.434 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 82.2 m -104.52 168.88 8.8 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.984 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.12 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -154.66 146.45 23.39 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.957 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.452 ' CG1' HD13 ' A' ' 67' ' ' LEU . 4.8 t -101.19 164.77 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.247 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -179.84 168.62 39.07 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.045 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.16 125.24 30.75 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.821 -0.436 . . . . 0.0 109.821 -179.95 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.056 ' O ' ' HB2' ' A' ' 33' ' ' ASP . 56.6 m -100.75 154.07 18.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.895 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.44 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.1 OUTLIER -116.48 -164.29 0.96 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -179.986 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.44 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -61.77 -49.04 77.96 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.926 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -72.14 -24.4 61.45 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.922 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.22 53.58 1.46 Allowed Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.995 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.52 178.28 6.86 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.856 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -179.7 -178.04 48.22 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.99 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.484 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.41 165.59 32.24 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.295 3.33 . . . . 0.0 109.61 179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.591 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 3.8 pt-20 -38.3 121.84 1.02 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -35.82 153.87 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.941 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.12 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.9 t -114.1 102.33 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.938 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.51 128.51 34.35 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.434 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.6 pt -139.28 -177.36 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.747 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.5 OUTLIER -172.21 174.66 3.91 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.915 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.137 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 4.3 m-85 -123.28 114.47 20.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.967 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.009 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 21.2 m-80 . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.973 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.502 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.341 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -126.95 116.12 22.11 Favored Pre-proline 0 N--CA 1.449 -0.51 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.535 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.1 Cg_endo -72.44 -178.57 3.42 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.306 3.337 . . . . 0.0 109.59 179.945 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.999 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -99.18 109.11 21.83 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.942 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.884 ' HB2' ' HA2' ' A' ' 23' ' ' GLY . . . -122.92 150.73 42.55 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.959 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.661 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -113.82 119.64 38.02 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.999 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.903 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.5 OUTLIER -114.79 143.87 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.961 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.779 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.12 167.36 17.98 Favored Pre-proline 0 N--CA 1.448 -0.526 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.985 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.779 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 84.1 Cg_endo -72.34 115.14 4.21 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.349 3.366 . . . . 0.0 109.579 179.89 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.0 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -122.06 13.96 10.58 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.99 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.867 ' HA ' ' O ' ' A' ' 111' ' ' SER . 53.3 p -98.95 114.61 27.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.877 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.72 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.03 1.59 41.95 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.0 HD21 ' CA ' ' A' ' 10' ' ' SER . 0.7 OUTLIER -114.39 142.01 46.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.972 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.9 m -104.98 -170.26 1.73 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.952 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.772 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 2.3 t0 -42.88 153.54 0.08 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.73 -24.63 31.32 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.998 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.972 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -96.21 148.81 22.33 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' A' ' 68' ' ' THR . 0.0 OUTLIER -123.05 146.32 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.996 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.736 ' HA ' HG22 ' A' ' 8' ' ' THR . 0.3 OUTLIER -110.87 119.94 60.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.96 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.903 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -78.55 127.43 32.14 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.734 ' HA ' HG23 ' A' ' 7' ' ' VAL . 0.2 OUTLIER -113.17 114.63 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.983 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.738 ' O ' ' CA ' ' A' ' 5' ' ' ALA . . . -127.17 123.49 36.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.98 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.033 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -90.59 153.48 22.63 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.957 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.999 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -149.6 108.18 3.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.929 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.14 17.35 27.54 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.991 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.116 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -89.47 176.45 6.9 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.969 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 23.2 mt-30 -58.54 121.71 11.61 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.3 131.21 42.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.995 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.86 7.58 83.9 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.96 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.5 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.5 OUTLIER -93.13 141.04 28.85 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.995 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.475 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -85.69 151.16 24.08 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.971 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.63 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 29.8 m-85 -138.54 134.86 34.43 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.884 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.169 ' CB ' ' O ' ' A' ' 98' ' ' SER . 8.3 m-20 -100.29 113.54 26.32 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.94 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.305 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.19 143.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.723 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -164.96 164.45 37.06 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.96 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.902 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 10.9 tt0 -110.87 117.08 32.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.931 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.499 ' HB3' HD13 ' A' ' 45' ' ' LEU . 98.5 m -108.01 166.31 10.82 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.978 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.754 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -151.98 135.14 15.83 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.933 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.471 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.75 129.94 41.65 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.955 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.684 HG23 ' CG2' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -108.93 -39.01 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.053 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.1 OUTLIER -150.4 155.8 40.28 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.986 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -51.51 112.9 0.83 Allowed 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.969 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 81.99 9.86 84.74 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.98 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.622 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -139.04 130.05 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.994 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.605 ' HA ' HG22 ' A' ' 40' ' ' VAL . 1.9 pp -132.18 163.85 27.63 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.321 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -125.48 153.8 43.01 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.973 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.853 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 15.1 m -115.92 153.2 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.833 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 39.6 t30 -111.02 107.05 57.74 Favored Pre-proline 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 85.3 Cg_endo -72.3 -1.21 9.8 Favored 'Trans proline' 0 N--CA 1.447 -1.216 0 C-N-CA 124.34 3.36 . . . . 0.0 109.631 179.849 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.15 -8.8 50.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.854 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -130.06 27.78 5.1 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.447 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -81.07 110.94 17.07 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.982 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.28 174.06 6.04 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.924 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 72.7 p -145.14 154.67 42.69 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.733 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 4.8 p -166.53 155.62 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.931 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 55' ' ' VAL . 18.4 m -128.05 136.67 51.55 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.966 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -77.38 135.4 38.33 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.1 p30 -77.8 -173.18 2.94 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.893 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.17 -27.93 69.31 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.871 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -74.53 -6.94 51.3 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.992 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.116 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.99 32.23 56.94 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 93.4 p -128.48 141.11 51.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.982 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.733 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -130.11 164.8 23.62 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.997 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.06 134.29 19.44 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.763 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -155.13 176.99 11.84 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.763 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -133.41 117.66 17.49 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.95 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.332 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.48 156.1 16.48 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.925 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' HG12 ' A' ' 18' ' ' VAL . 0.5 OUTLIER -111.53 128.38 56.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.526 HG21 ' OG ' ' A' ' 10' ' ' SER . 1.2 t -97.13 123.11 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.968 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.772 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -115.05 144.48 43.57 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.964 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.445 ' HG3' ' N ' ' A' ' 72' ' ' SER . 15.4 ptt85 -65.85 -32.18 73.55 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.445 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 16.4 p -155.65 158.06 37.7 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 179.923 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.902 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.7 p90 -176.79 155.24 1.25 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -53.71 108.87 0.39 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.975 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.321 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -67.05 94.54 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.99 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.853 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.1 m-85 -82.53 98.89 9.18 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.938 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.4 tp -54.66 144.81 20.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.763 ' H ' HD12 ' A' ' 77' ' ' LEU . 1.4 m-85 -47.2 -43.53 21.59 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.97 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.587 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -58.46 -16.7 16.26 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 77' ' ' LEU . . . 93.7 28.1 11.78 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.993 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.938 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.3 m -106.97 120.68 42.71 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 -179.974 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.414 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -64.25 91.42 0.07 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.622 ' CH2' HG21 ' A' ' 44' ' ' VAL . 3.9 t-105 -62.68 -58.52 7.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.915 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 158.78 163.39 12.92 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.36 104.59 0.18 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.998 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.754 HG11 ' HB3' ' A' ' 38' ' ' ALA . 12.6 p -79.2 151.67 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.962 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -105.71 95.01 5.51 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.155 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -54.94 -22.14 14.03 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.942 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 49.1 p -88.97 2.1 54.45 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.962 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.6 m -110.11 -24.92 10.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.947 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -137.93 174.9 10.08 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.979 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -88.79 127.27 35.61 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 -179.951 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.393 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -104.56 163.86 12.17 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.984 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.019 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -151.42 142.27 22.91 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.917 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.332 ' CG1' HD13 ' A' ' 67' ' ' LEU . 16.5 t -97.92 164.6 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 180.0 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.305 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.33 163.84 32.7 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.976 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.08 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -127.62 131.63 49.87 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.993 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.169 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 42.5 m -112.28 141.02 46.49 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.52 -164.14 1.02 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.974 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.425 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -65.04 -49.03 71.75 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.946 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.2 65.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.937 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 92.67 53.28 1.98 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.941 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -131.4 177.08 7.76 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -178.19 174.25 46.59 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.989 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.535 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.8 Cg_endo -72.4 170.44 19.27 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 124.304 3.336 . . . . 0.0 109.623 179.944 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.341 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 9.7 pt-20 -41.2 126.69 2.72 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.963 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' A' ' 106' ' ' GLU . . . -39.6 160.82 0.01 OUTLIER Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.991 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.011 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 3.3 t -120.9 103.11 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.969 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -83.98 133.81 34.67 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.955 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.048 HD11 ' HB2' ' A' ' 93' ' ' CYS . 31.8 pt -136.93 -169.93 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.916 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.867 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -178.28 158.74 1.18 Allowed 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.93 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.393 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 3.3 m-85 -111.37 119.19 38.0 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.932 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.72 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 9.8 p30 . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.955 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.497 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.568 ' CB ' ' HG2' ' A' ' 106' ' ' GLU . . . -117.63 114.97 37.64 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.893 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.439 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.0 Cg_endo -72.4 -178.15 3.15 Favored 'Trans proline' 0 N--CA 1.447 -1.239 0 C-N-CA 124.331 3.354 . . . . 0.0 109.603 179.904 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.861 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.2 m -101.14 110.7 22.75 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.829 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -125.65 142.11 51.67 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.914 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.98 116.07 31.31 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.96 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.804 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.7 OUTLIER -114.69 149.76 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.963 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.677 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.24 165.35 40.04 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.677 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.5 Cg_endo -72.42 119.62 6.24 Favored 'Trans proline' 0 N--CA 1.447 -1.259 0 C-N-CA 124.333 3.356 . . . . 0.0 109.579 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.051 ' CA ' HD21 ' A' ' 13' ' ' LEU . 0.7 OUTLIER -123.87 16.16 9.36 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.976 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.272 ' HA ' ' O ' ' A' ' 111' ' ' SER . 19.6 p -105.3 113.79 27.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.885 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.001 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 105.86 6.78 37.08 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.112 HD22 HG21 ' A' ' 17' ' ' THR . 0.4 OUTLIER -114.52 136.72 52.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.999 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.5 m -81.12 171.21 15.2 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.925 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.447 ' HB3' ' HG2' ' A' ' 71' ' ' ARG . 3.3 p-10 -45.24 154.31 0.17 Allowed 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.979 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 99.87 -24.01 33.84 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.985 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 1.112 HG21 HD22 ' A' ' 13' ' ' LEU . 94.3 m -68.37 131.88 46.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.981 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 18' ' ' VAL . 10.4 p -102.08 119.32 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.675 ' HA ' ' CG2' ' A' ' 8' ' ' THR . 1.4 m -99.17 161.14 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.804 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -119.74 148.7 43.09 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.997 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.7 107.18 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.994 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.829 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -117.21 116.42 27.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.932 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -83.66 146.73 23.58 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.286 -1.126 . . . . 0.0 110.286 -179.992 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.861 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -146.83 110.01 4.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.938 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.5 15.75 31.27 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.974 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.0 HD21 ' HA3' ' A' ' 23' ' ' GLY . 0.0 OUTLIER -90.19 172.16 9.0 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 -179.993 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.508 ' HB2' HG21 ' A' ' 30' ' ' THR . 24.0 mt-30 -54.34 120.36 6.45 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.964 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.11 131.27 41.87 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.967 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.37 6.88 84.59 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.999 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.508 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -93.02 144.2 25.49 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.5 ' O ' ' CB ' ' A' ' 99' ' ' ASP . . . -86.1 151.38 23.73 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.519 ' CD1' ' HA2' ' A' ' 104' ' ' GLY . 24.8 m-85 -138.66 144.4 39.62 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.931 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.199 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.9 OUTLIER -112.51 113.11 25.12 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.935 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.228 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -98.96 152.04 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.986 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.927 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -178.57 159.71 25.13 Favored Glycine 0 C--N 1.335 0.518 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 179.979 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 1.028 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 12.4 tt0 -98.77 118.55 35.76 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.832 -0.432 . . . . 0.0 109.832 -179.942 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.415 ' HB3' HD13 ' A' ' 45' ' ' LEU . 1.8 m -108.28 165.55 11.42 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.982 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 86' ' ' VAL . . . -151.71 122.66 7.58 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.946 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.632 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.68 122.09 16.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.823 HG21 ' CD1' ' A' ' 83' ' ' TRP . 16.7 m -101.32 -44.58 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.973 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.521 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.3 OUTLIER -135.64 168.06 19.97 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.966 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.68 HG23 ' O ' ' A' ' 42' ' ' THR . 3.9 t -54.04 112.97 1.06 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.986 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.66 8.56 63.62 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.984 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.454 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 58.7 t -120.86 109.07 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.5 pp -119.83 162.36 19.24 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.451 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -129.4 151.91 49.52 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.936 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.012 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -117.38 157.46 26.13 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.996 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.51 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 17.6 t30 -116.24 112.95 41.49 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.981 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -72.35 -0.51 8.79 Favored 'Trans proline' 0 N--CA 1.447 -1.241 0 C-N-CA 124.31 3.34 . . . . 0.0 109.61 179.884 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.508 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.39 -12.72 36.7 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.849 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.466 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 16.5 p30 -132.94 27.01 4.27 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.928 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.646 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -98.11 117.35 32.29 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.993 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 22.9 t -106.61 177.91 4.72 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.962 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.4 p -146.5 151.49 37.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.532 HG22 ' N ' ' A' ' 56' ' ' THR . 4.6 p -166.77 162.58 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.943 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.532 ' N ' HG22 ' A' ' 55' ' ' VAL . 97.5 m -127.8 134.82 49.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.951 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -70.99 143.4 50.82 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.949 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 42.9 p30 -81.74 -172.73 4.04 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.95 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -63.1 -25.54 68.41 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.904 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.68 -7.26 53.88 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -179.994 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.891 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 74.13 31.07 60.04 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.0 p -127.13 143.8 51.18 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.971 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -131.01 166.36 21.18 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.983 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -147.5 125.78 12.27 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.95 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.725 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.24 173.04 12.92 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.938 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.725 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -131.13 111.22 11.78 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.944 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.497 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -97.12 156.55 16.33 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.975 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.685 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.5 OUTLIER -119.2 139.97 50.97 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.924 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.648 HG12 ' CG1' ' A' ' 19' ' ' VAL . 0.2 OUTLIER -109.57 133.37 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.786 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -119.83 162.19 19.54 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.985 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.447 ' HG2' ' HB3' ' A' ' 15' ' ' ASP . 5.8 ptt180 -82.56 -18.14 42.44 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.968 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 33.9 p -165.12 151.22 9.98 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.922 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 1.028 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.1 p90 -175.99 154.94 1.53 Allowed 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.897 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.45 124.81 14.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.989 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.451 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.03 92.11 1.62 Allowed Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 1.012 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.52 100.51 11.42 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.974 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.902 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.6 tp -58.15 140.96 51.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.967 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.726 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.3 m-85 -47.28 -42.01 19.95 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.935 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.72 ' HB2' HD21 ' A' ' 77' ' ' LEU . 0.3 OUTLIER -57.41 -16.66 9.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.965 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 94.55 28.43 10.43 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 179.99 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.902 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -108.73 128.09 54.56 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.67 91.59 1.12 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.976 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.454 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.14 -58.77 6.56 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.869 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 154.06 167.59 16.39 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -179.975 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -59.36 115.16 3.06 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.969 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 38' ' ' ALA . 59.9 t -88.29 146.57 6.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 180.0 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.82 91.67 4.26 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.949 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.759 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -52.52 -22.63 5.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.997 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.91 2.6 48.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.981 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.3 m -115.82 -27.81 6.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.961 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -132.47 169.39 16.63 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.91 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.92 126.02 35.57 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.938 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.438 ' HB2' HD11 ' A' ' 110' ' ' ILE . 12.4 m -104.14 159.77 15.41 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 -179.923 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.042 ' HA ' HG12 ' A' ' 110' ' ' ILE . 0.7 OUTLIER -145.45 143.1 29.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.969 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.497 ' CG1' HD13 ' A' ' 67' ' ' LEU . 2.7 t -97.34 157.73 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.228 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -178.55 171.05 43.27 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 179.997 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.18 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -131.33 151.31 51.64 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.978 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.199 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 82.8 p -127.96 151.41 49.15 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.934 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.5 ' CB ' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -112.77 -163.46 0.85 Allowed 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.96 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -66.43 -48.6 69.48 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.935 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.16 -24.24 65.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.952 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 93.8 53.39 1.8 Allowed Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.998 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.424 ' OD1' ' NE2' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -132.11 168.36 18.11 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 179.971 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.519 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . -169.85 178.95 42.51 Favored Glycine 0 C--N 1.335 0.511 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.933 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.439 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.3 Cg_endo -72.36 161.98 42.82 Favored 'Trans proline' 0 N--CA 1.447 -1.24 0 C-N-CA 124.34 3.36 . . . . 0.0 109.627 179.966 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.568 ' HG2' ' CB ' ' A' ' 2' ' ' ALA . 0.1 OUTLIER -40.61 123.72 1.9 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.972 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -36.54 151.82 0.02 OUTLIER Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.991 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.2 t -119.21 104.24 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.991 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -80.66 138.71 36.4 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.982 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.042 HG12 ' HA ' ' A' ' 94' ' ' GLN . 25.8 pt -137.75 -172.34 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.976 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 1.272 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -179.23 163.69 1.31 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.942 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.759 ' CZ ' ' SG ' ' A' ' 88' ' ' CYS . 2.3 m-85 -117.76 116.81 27.76 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.937 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.001 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 46.4 m-80 . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.973 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.425 ' C ' ' H ' ' A' ' 106' ' ' GLU . . . -140.87 120.38 8.47 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.508 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.3 Cg_endo -72.39 -174.61 1.48 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 124.322 3.348 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.229 HG22 ' O ' ' A' ' 24' ' ' ALA . 4.1 t -97.99 110.68 23.21 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.964 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.84 146.92 50.46 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.953 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.473 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.4 p -109.26 112.44 24.59 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.794 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -109.07 145.38 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.993 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.782 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.28 168.65 12.85 Favored Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.782 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 82.7 Cg_endo -72.39 117.14 4.99 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.296 3.331 . . . . 0.0 109.571 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.591 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 0.3 OUTLIER -127.05 17.18 7.25 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.975 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 111' ' ' SER . 39.2 p -94.6 112.72 24.47 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.9 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.121 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 87.98 28.75 22.49 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.942 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.121 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.9 OUTLIER -108.18 137.33 46.35 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.976 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.4 t -76.2 150.24 37.12 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.964 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 15' ' ' ASP . 2.3 p30 -44.43 153.02 0.17 Allowed 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.99 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 98.5 -24.72 30.85 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.437 HG21 HD12 ' A' ' 13' ' ' LEU . 17.7 m -63.69 150.29 44.71 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.982 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 18' ' ' VAL . 14.7 p -112.46 121.8 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.967 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.617 ' CG1' ' HB3' ' A' ' 67' ' ' LEU . 2.2 p -97.42 153.52 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.996 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.794 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -107.28 150.45 26.66 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.973 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.741 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -148.63 107.64 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.998 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.964 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.05 114.96 23.33 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.988 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.825 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -85.2 139.95 17.98 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.952 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.229 ' O ' HG22 ' A' ' 4' ' ' THR . . . -135.89 110.22 8.44 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.922 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.898 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.29 21.19 10.17 Favored Glycine 0 C--N 1.335 0.523 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.966 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.508 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.4 -168.39 2.19 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.838 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -79.59 121.66 25.54 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.962 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.507 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -71.61 135.9 47.15 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.97 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.38 6.71 58.78 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.958 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.585 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -96.92 138.87 33.79 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.968 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -86.29 150.72 24.15 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.919 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.496 ' HB3' ' CD2' ' A' ' 97' ' ' LEU . 39.2 m-85 -136.44 155.79 49.52 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.409 ' O ' ' CA ' ' A' ' 97' ' ' LEU . 2.6 m-20 -121.89 114.18 20.67 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.253 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -95.02 144.7 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.983 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.022 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -159.07 166.92 34.76 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.954 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.696 ' NE2' ' CE2' ' A' ' 73' ' ' PHE . 7.9 tt0 -121.63 106.98 11.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.767 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.3 m -105.21 172.78 6.61 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.961 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.966 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -146.37 127.34 14.55 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.932 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.77 117.83 8.07 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.92 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.591 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 3.6 m -98.22 -42.92 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.972 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -135.67 177.31 7.93 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.995 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.1 t -60.36 111.76 1.68 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.99 8.17 63.85 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.565 HG12 ' CD1' ' A' ' 83' ' ' TRP . 22.0 t -120.73 113.31 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.993 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.674 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.0 OUTLIER -128.51 140.61 51.72 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.991 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.34 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -97.93 138.65 34.94 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.956 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.77 ' O ' ' HB3' ' A' ' 76' ' ' PHE . 82.1 m -106.37 140.62 39.0 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.971 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.62 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 14.8 t30 -100.31 111.49 62.58 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.442 ' HA ' ' CD2' ' A' ' 52' ' ' PHE . 83.1 Cg_endo -72.39 0.28 7.67 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.355 3.37 . . . . 0.0 109.6 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -86.56 -14.94 41.45 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.854 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.52 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 4.9 p30 -123.21 29.69 6.61 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.919 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.442 ' CD2' ' HA ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -82.66 106.02 14.17 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.987 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.6 m -100.32 179.02 4.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.899 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.5 p -145.71 158.52 43.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.915 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.747 ' CG2' ' HB1' ' A' ' 63' ' ' ALA . 7.2 p -169.11 156.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.973 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.425 ' N ' HG22 ' A' ' 55' ' ' VAL . 7.0 m -127.97 137.63 52.32 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.922 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.654 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -80.69 139.73 35.99 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.984 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.2 p30 -82.86 -165.85 1.17 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.927 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.89 -28.67 69.07 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.936 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.3 m-20 -83.1 6.35 19.4 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 -179.986 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.93 22.04 59.63 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.966 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.6 t -109.21 130.92 55.48 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.747 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.41 167.31 12.94 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -148.84 131.61 16.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.905 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.628 HG21 HG21 ' A' ' 34' ' ' VAL . 0.4 OUTLIER -158.79 157.71 32.15 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.447 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -116.5 125.66 52.25 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.19 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -97.53 155.95 16.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.919 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.523 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -97.36 123.11 41.08 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.961 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.549 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -77.49 129.36 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.999 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.711 ' HB2' ' CE2' ' A' ' 73' ' ' PHE . 0.1 OUTLIER -123.58 147.26 47.48 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.931 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -92.71 -20.2 21.04 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.994 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 53.4 p -172.99 153.18 2.51 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.922 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.711 ' CE2' ' HB2' ' A' ' 70' ' ' ARG . 0.2 OUTLIER -178.02 179.08 0.87 Allowed 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.949 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -68.56 117.83 10.8 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.97 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.34 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -79.6 89.13 1.23 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.956 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.77 ' HB3' ' O ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -83.47 103.33 12.73 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.986 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.8 tp -58.34 130.99 49.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.625 ' N ' HD12 ' A' ' 77' ' ' LEU . 24.1 p90 -47.86 -35.36 10.23 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.618 ' CB ' HD21 ' A' ' 77' ' ' LEU . 5.4 t0 -57.26 -17.28 11.02 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.24 28.39 8.14 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.939 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.1 m -117.74 145.86 44.17 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.31 97.21 8.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.973 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.591 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 21.9 t90 -64.25 -57.65 8.84 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 179.879 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 145.98 160.27 8.6 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -179.997 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.61 105.18 0.14 Allowed 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.977 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.966 HG11 ' CB ' ' A' ' 38' ' ' ALA . 3.0 t -82.35 154.03 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -120.13 96.78 5.3 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.998 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.105 ' HB3' ' CD1' ' A' ' 112' ' ' PHE . 24.9 m -52.76 -25.6 11.73 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.9 p -79.68 1.45 26.34 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -117.1 -27.66 6.44 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.32 -177.08 4.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.974 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.77 126.67 47.35 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.96 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.239 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 18.6 m -104.43 164.14 11.95 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.964 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.216 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.2 OUTLIER -154.79 149.57 26.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.973 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.19 ' CG1' HD13 ' A' ' 67' ' ' LEU . 6.8 t -104.05 165.85 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.991 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.253 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 170.63 43.78 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.94 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.496 ' CD2' ' HB3' ' A' ' 32' ' ' TYR . 4.8 mp -99.81 162.87 12.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.168 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -152.48 109.99 3.59 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.896 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.594 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 1.7 p-10 -104.75 -157.96 0.64 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.28 -43.94 64.71 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.981 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -85.45 -26.01 26.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.937 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.95 52.86 2.33 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.959 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.594 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -109.17 -174.32 2.48 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -179.99 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 172.57 179.24 43.24 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.993 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.475 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.5 Cg_endo -72.36 160.29 47.32 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.366 3.377 . . . . 0.0 109.567 179.91 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -32.96 128.51 0.26 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.974 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.479 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.0 130.94 0.29 Allowed Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.216 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 41.6 t -99.29 101.55 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -80.04 140.47 36.52 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.938 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.239 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 3.1 pt -147.06 -172.23 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.939 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.569 ' C ' ' CD1' ' A' ' 112' ' ' PHE . 0.4 OUTLIER -173.82 176.17 2.71 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.948 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.105 ' CD1' ' HB3' ' A' ' 88' ' ' CYS . 0.2 OUTLIER -150.64 105.77 3.34 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.941 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.074 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 3.7 p30 . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.99 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.528 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -127.64 140.37 37.88 Favored Pre-proline 0 N--CA 1.448 -0.527 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.935 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.522 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 83.8 Cg_endo -72.39 -175.63 1.87 Allowed 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 124.275 3.317 . . . . 0.0 109.637 179.934 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.971 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -98.47 109.15 21.95 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.782 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.58 137.75 54.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.685 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -106.11 112.57 25.66 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.981 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.611 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -106.39 155.98 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.988 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.987 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.08 177.29 0.91 Allowed Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.923 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.157 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.5 Cg_endo -72.4 117.22 5.03 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.311 3.34 . . . . 0.0 109.573 179.909 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.783 ' HB2' HG23 ' A' ' 110' ' ' ILE . 13.4 p -112.73 44.69 1.44 Allowed 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.964 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 m -124.73 106.3 9.97 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.885 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.943 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 88.39 31.9 12.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.969 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.157 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.58 133.0 42.72 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 55.7 m -96.71 162.87 13.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.976 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -49.83 146.37 4.58 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.994 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 93.92 -22.51 35.81 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.965 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.441 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.9 m -63.3 147.62 50.56 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.983 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.545 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.5 p -112.2 122.7 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.556 ' HA ' HG21 ' A' ' 8' ' ' THR . 3.6 m -96.93 161.24 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.611 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 151.16 32.25 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.975 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.719 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.4 OUTLIER -150.11 109.96 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.959 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.782 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -125.14 116.49 22.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.999 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.665 ' HA2' ' HA ' ' A' ' 5' ' ' ALA . . . -94.29 141.1 15.37 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.959 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.971 ' O ' HG22 ' A' ' 4' ' ' THR . . . -133.12 118.0 18.19 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.887 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.87 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 100.31 24.37 9.61 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.345 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.4 OUTLIER -87.32 -173.67 4.49 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.972 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.869 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -80.67 120.76 25.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.993 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.78 136.74 57.24 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.955 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.25 7.95 58.09 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.991 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.692 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -85.6 148.22 26.03 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 1.028 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -100.81 134.68 43.42 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.047 ' CE1' ' HA2' ' A' ' 104' ' ' GLY . 37.4 m-85 -127.29 147.59 50.24 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.104 ' H ' ' N ' ' A' ' 98' ' ' SER . 1.8 m-20 -116.86 114.05 23.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.997 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.268 ' HA ' ' C ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -96.61 152.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.965 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.108 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -177.66 164.98 34.37 Favored Glycine 0 C--N 1.336 0.544 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.963 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.804 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 1.7 tt0 -112.34 118.38 35.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.937 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.562 ' HB3' HD13 ' A' ' 45' ' ' LEU . 90.8 m -108.23 173.5 6.29 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.983 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.183 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -152.62 123.97 7.67 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.917 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.617 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.57 124.0 21.18 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.907 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.12 HG21 ' CD2' ' A' ' 83' ' ' TRP . 15.2 m -103.93 -43.85 8.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.528 ' HB2' ' CH2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -142.93 169.61 17.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.961 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 19.5 m -56.74 113.43 1.64 Allowed 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.952 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.78 4.83 62.89 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 179.997 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.644 HG11 ' CZ3' ' A' ' 83' ' ' TRP . 15.5 t -122.19 105.07 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.975 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.641 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.9 pp -117.3 162.73 17.43 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.961 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.546 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -122.54 140.7 52.48 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.681 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 23.4 m -109.3 150.8 27.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 1.057 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 22.2 t30 -108.41 105.75 57.32 Favored Pre-proline 0 N--CA 1.45 -0.453 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 -179.988 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.471 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.0 Cg_endo -72.4 -1.23 9.89 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 124.309 3.339 . . . . 0.0 109.638 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.596 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.41 -12.97 33.22 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.888 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.443 ' CB ' HG23 ' A' ' 68' ' ' THR . 29.6 p30 -127.27 18.77 6.99 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.46 ' CD1' ' O ' ' A' ' 34' ' ' VAL . 0.1 OUTLIER -83.5 103.51 12.91 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.981 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 47.1 t -93.43 177.57 5.99 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.905 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.3 p -147.04 155.24 42.06 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.913 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.42 HG22 ' N ' ' A' ' 56' ' ' THR . 7.6 p -167.36 155.97 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.971 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.42 ' N ' HG22 ' A' ' 55' ' ' VAL . 73.5 m -122.87 130.32 52.72 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.948 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 125.28 24.52 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.915 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -71.39 -170.37 0.5 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 -23.67 66.51 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -85.38 6.97 24.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.985 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 61.15 14.08 38.04 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.99 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.3 t -102.52 131.83 48.98 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.942 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -126.81 124.0 38.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.97 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.7 p -110.78 134.05 52.82 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.988 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.554 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -158.39 152.6 24.13 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.897 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.17 131.29 55.92 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.956 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.555 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -104.93 157.46 17.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.969 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.447 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 4.6 t -105.18 127.51 52.95 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.952 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.649 ' C ' ' HD2' ' A' ' 70' ' ' ARG . 1.7 t -84.34 126.23 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.66 ' HB2' ' OE1' ' A' ' 36' ' ' GLN . 1.2 mpt_? -119.76 145.9 46.15 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.517 ' HD3' ' N ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -89.83 -8.07 52.88 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.938 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 90.3 p -178.02 149.96 0.59 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.949 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 1.057 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 3.8 p90 -176.77 154.58 1.19 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.921 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -49.55 114.37 1.03 Allowed 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.546 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -71.89 92.76 0.55 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.998 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.681 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -83.81 99.34 10.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.953 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.6 tp -59.09 129.03 40.17 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.622 ' N ' HD12 ' A' ' 77' ' ' LEU . 32.4 p90 -47.56 -34.7 8.03 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.939 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.576 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.7 -16.72 11.74 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.982 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.08 28.11 8.91 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -179.972 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.4 m -116.93 150.88 37.79 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.933 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -87.04 97.67 10.85 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.902 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.644 ' CZ3' HG11 ' A' ' 44' ' ' VAL . 76.7 t-105 -65.28 -56.41 12.88 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.76 166.46 11.6 Favored Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.991 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -55.19 108.14 0.38 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.944 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.183 HG11 ' CB ' ' A' ' 38' ' ' ALA . 69.3 t -82.25 147.85 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.971 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -114.46 93.7 4.46 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.949 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.499 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.0 m -52.74 -26.04 12.94 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.989 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 71' ' ' ARG . 78.7 p -80.19 0.14 33.7 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -116.54 -27.48 6.72 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.989 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.77 -177.98 4.6 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.967 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.21 124.45 46.92 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.908 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.934 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 60.5 m -103.6 153.61 20.42 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.991 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.996 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.5 OUTLIER -142.85 145.12 32.84 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -179.964 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.555 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.2 t -102.73 160.33 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.268 ' C ' ' HA ' ' A' ' 34' ' ' VAL . . . -177.63 166.72 37.25 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.956 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.097 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -132.64 128.59 37.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.974 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.104 ' N ' ' H ' ' A' ' 33' ' ' ASP . 9.8 m -115.36 160.97 19.17 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.936 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 1.028 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.8 OUTLIER -115.45 -157.44 0.64 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.982 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -63.11 -47.84 81.12 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.946 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.39 -25.78 59.7 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.874 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 96.64 50.11 1.87 Allowed Glycine 0 C--N 1.336 0.539 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 -179.976 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.521 ' O ' ' HD1' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -119.46 158.32 26.48 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.998 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 1.047 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . -169.48 176.35 43.46 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.988 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.522 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 84.0 Cg_endo -72.35 171.04 17.79 Favored 'Trans proline' 0 N--CA 1.447 -1.213 0 C-N-CA 124.317 3.345 . . . . 0.0 109.616 179.922 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.513 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 2.0 mt-10 -40.71 133.68 1.99 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.985 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -47.06 155.97 0.74 Allowed Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 -179.983 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.947 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 93.1 t -122.74 105.18 15.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.981 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.495 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -87.16 138.4 31.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.962 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.996 ' CG1' ' HA ' ' A' ' 94' ' ' GLN . 2.3 mt -117.68 157.94 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.984 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 10' ' ' SER . 3.1 t -149.34 127.82 12.29 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.894 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 -100.64 127.92 46.87 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.996 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.937 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.508 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.489 ' CB ' ' HA ' ' A' ' 106' ' ' GLU . . . -52.88 118.6 13.91 Favored Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.921 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.627 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 82.9 Cg_endo -72.42 -174.48 1.45 Allowed 'Trans proline' 0 N--CA 1.447 -1.244 0 C-N-CA 124.304 3.336 . . . . 0.0 109.614 179.949 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.351 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 4.5 t -98.72 111.7 23.99 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.987 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.643 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.42 152.31 47.69 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.972 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -109.8 113.32 25.98 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 20' ' ' LYS . 40.3 t -110.47 147.28 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.942 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.949 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -67.77 175.47 1.68 Allowed Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.952 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.058 ' O ' HD11 ' A' ' 13' ' ' LEU . 84.4 Cg_endo -72.36 116.59 4.77 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 124.346 3.364 . . . . 0.0 109.617 179.902 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.638 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 6.5 p -111.12 43.71 1.42 Allowed 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.937 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.0 p -124.28 105.16 9.25 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.892 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.189 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.02 30.51 8.27 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.189 HD23 ' C ' ' A' ' 12' ' ' GLY . 0.4 OUTLIER -110.93 129.72 55.8 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.2 m -112.88 177.01 4.77 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 39.5 t0 -44.67 138.66 3.28 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.984 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.01 -23.1 31.7 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -179.938 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.632 HG21 ' HB3' ' A' ' 13' ' ' LEU . 30.5 m -88.67 152.15 22.0 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 -179.971 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 p -129.33 134.22 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.994 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.715 HG22 ' O ' ' A' ' 67' ' ' LEU . 17.9 m -95.27 166.13 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.989 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.862 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.57 143.64 44.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -139.32 104.52 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -179.919 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.643 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.1 115.29 23.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.934 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.742 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -83.03 143.93 22.42 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.949 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.351 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -139.83 107.21 5.53 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -179.853 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 103.72 20.02 11.33 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.945 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.306 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -88.87 -172.29 3.64 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.975 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.587 HE22 ' CG ' ' A' ' 103' ' ' ASN . 31.0 mt-30 -71.87 121.47 19.08 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.932 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.977 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -73.14 133.67 44.18 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.966 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.0 8.48 73.78 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.989 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.521 HG21 ' HB2' ' A' ' 27' ' ' GLN . 0.6 OUTLIER -95.11 138.25 33.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.955 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.8 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -84.58 151.58 24.43 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.961 ' C ' ' HB2' ' A' ' 97' ' ' LEU . 41.7 m-85 -137.63 149.68 46.81 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.927 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.175 ' CB ' ' H ' ' A' ' 98' ' ' SER . 3.7 m-20 -113.25 114.18 26.35 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.991 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.296 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER -100.42 145.32 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.131 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -168.01 169.37 41.34 Favored Glycine 0 C--N 1.335 0.52 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.925 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.695 HE22 ' H ' ' A' ' 70' ' ' ARG . 40.8 tt0 -113.74 106.07 14.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -108.4 146.27 33.3 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 179.95 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.711 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -125.97 137.87 53.71 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.629 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.4 119.67 11.42 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.965 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.351 ' HB ' ' NE1' ' A' ' 83' ' ' TRP . 2.6 m -100.56 -42.81 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.2 OUTLIER -132.65 165.07 25.3 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.985 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 44' ' ' VAL . 32.4 m -51.2 111.25 0.54 Allowed 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.907 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.03 69.06 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.953 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.519 ' HB ' ' CB ' ' A' ' 41' ' ' ASP . 10.7 t -122.01 117.96 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 -179.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.667 HD12 ' HB2' ' A' ' 37' ' ' CYS . 0.8 OUTLIER -129.15 138.24 51.66 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.984 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.43 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -101.44 152.11 21.13 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.951 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.787 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 59.0 m -106.79 148.57 28.32 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -179.994 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.948 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -111.37 117.13 49.95 Favored Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.974 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 82.6 Cg_endo -72.44 1.06 6.58 Favored 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 124.287 3.325 . . . . 0.0 109.621 179.908 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.786 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -82.51 -20.51 36.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.898 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.784 ' CB ' HG23 ' A' ' 68' ' ' THR . 98.3 m-20 -129.72 30.97 4.82 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.913 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.703 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -94.58 117.52 30.25 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.999 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 30.1 t -116.26 -178.96 3.53 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.946 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.6 p -146.46 154.52 41.67 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.874 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.476 HG22 ' N ' ' A' ' 56' ' ' THR . 5.3 p -166.18 158.9 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.998 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.476 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.6 m -127.11 133.16 50.44 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.952 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.26 153.59 42.14 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.975 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -89.63 -171.84 3.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.926 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.0 67.8 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.911 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.05 -16.83 61.03 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.961 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 88.24 6.35 74.84 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.975 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.01 140.03 32.95 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.941 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -119.61 163.32 17.52 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.976 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -149.15 122.92 9.27 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.549 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -157.8 162.73 38.46 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.907 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.524 ' N ' HG23 ' A' ' 65' ' ' THR . 0.9 OUTLIER -118.37 129.85 55.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.912 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.158 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -106.77 124.45 49.64 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.913 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.784 HG23 ' CB ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -76.6 141.43 41.08 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.962 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.487 ' C ' ' HD3' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -102.67 131.65 50.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.994 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.695 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.1 OUTLIER -119.13 157.3 28.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 -87.08 -20.66 26.81 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.992 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 11.8 t -168.77 151.71 5.18 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.9 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.948 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 1.7 p90 -173.7 159.54 3.53 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.94 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -61.01 114.96 3.37 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.943 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.43 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -73.43 94.6 0.74 Allowed Glycine 0 C--N 1.336 0.558 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 180.0 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.821 ' N ' ' HB1' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -82.12 99.37 9.18 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.955 HD23 ' HB ' ' A' ' 81' ' ' THR . 2.8 tp -54.61 132.58 45.51 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -179.982 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.655 ' N ' HD12 ' A' ' 77' ' ' LEU . 5.9 m-85 -46.59 -37.29 7.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 179.953 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.596 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.8 t0 -56.98 -16.96 7.99 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.973 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.99 27.59 9.34 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.291 -1.124 . . . . 0.0 110.291 -179.971 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.955 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.0 m -113.55 140.9 47.77 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.37 95.9 7.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.351 ' NE1' ' HB ' ' A' ' 40' ' ' VAL . 38.1 t-105 -63.0 -57.8 9.47 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.912 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 149.04 172.9 19.24 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 -179.959 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.47 109.69 2.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.958 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.711 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.3 p -90.72 142.13 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -98.21 99.48 10.71 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.983 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.36 -22.32 7.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.983 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 24.0 p -87.31 1.58 52.83 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.922 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -112.83 -26.37 8.59 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -134.01 -178.94 5.26 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.954 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.04 128.35 42.86 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.917 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.303 ' O ' HG13 ' A' ' 110' ' ' ILE . 34.0 m -104.74 155.06 19.22 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.983 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.951 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.7 OUTLIER -147.58 145.61 29.09 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.984 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.158 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 4.3 t -109.2 156.76 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.981 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.296 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -174.5 172.38 45.35 Favored Glycine 0 C--N 1.336 0.545 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.999 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.057 ' HB3' ' CG2' ' A' ' 34' ' ' VAL . 0.8 OUTLIER -129.62 128.72 43.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.96 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.175 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 36.5 m -118.26 140.07 50.36 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.917 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.8 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 4.4 p-10 -111.81 -162.71 0.81 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.996 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.08 79.4 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.897 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.781 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -66.48 -24.37 66.41 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.926 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 83.02 35.29 18.86 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.957 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.781 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.3 OUTLIER -108.45 -173.7 2.34 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.943 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.809 ' HA2' ' CE1' ' A' ' 32' ' ' TYR . . . 167.84 164.75 24.07 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.964 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.627 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.39 162.81 40.46 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.242 3.295 . . . . 0.0 109.576 179.954 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.489 ' HA ' ' CB ' ' A' ' 2' ' ' ALA . 0.9 OUTLIER -36.05 126.58 0.74 Allowed 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.978 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -41.78 147.97 0.44 Allowed Glycine 0 C--N 1.335 0.51 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.96 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.783 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.0 t -122.15 106.74 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.965 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -91.36 150.48 21.26 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.954 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.303 HG13 ' O ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -118.45 161.87 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.944 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.534 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -145.22 111.78 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.954 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.584 ' O ' ' CG ' ' A' ' 113' ' ' ASN . 6.9 m-85 -87.93 101.91 14.2 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.924 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.584 ' CG ' ' O ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER . . . . . 0 N--CA 1.449 -0.511 0 N-CA-C 109.938 -0.394 . . . . 0.0 109.938 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 041 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.383 ' CB ' ' O ' ' A' ' 106' ' ' GLU . . . -134.02 145.51 56.03 Favored Pre-proline 0 N--CA 1.449 -0.503 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.198 ' CB ' HD22 ' A' ' 26' ' ' LEU . 84.1 Cg_endo -72.38 -175.21 1.69 Allowed 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 124.272 3.314 . . . . 0.0 109.632 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.921 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -100.71 109.89 21.96 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.946 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -121.5 137.64 54.64 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.995 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.582 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.1 p -99.08 114.07 26.6 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.97 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.84 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.2 m -108.09 153.72 9.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.997 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.967 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.59 176.56 1.21 Allowed Pre-proline 0 N--CA 1.449 -0.476 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.929 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.077 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.3 Cg_endo -72.38 117.79 5.3 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 124.352 3.368 . . . . 0.0 109.553 179.925 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 111' ' ' SER . 1.9 p -114.69 45.7 1.52 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.7 p -123.75 105.39 9.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.87 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.029 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.63 29.84 11.45 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.948 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.077 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.7 OUTLIER -101.43 132.22 47.13 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.948 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 51.1 m -104.7 166.56 10.31 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.9 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -44.98 140.04 2.84 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.998 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.59 -22.47 35.71 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.976 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.462 HG21 HD13 ' A' ' 13' ' ' LEU . 28.3 m -76.53 148.83 36.86 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.986 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 18' ' ' VAL . 8.8 p -122.38 127.22 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.992 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 69' ' ' VAL . 16.1 m -93.76 170.31 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.84 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.62 148.3 41.09 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.999 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.724 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -143.75 108.18 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.997 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.859 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -122.83 115.13 21.48 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.976 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.856 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.81 143.13 19.67 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.958 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.921 ' O ' HG22 ' A' ' 4' ' ' THR . . . -137.6 111.97 8.62 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.949 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.932 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 102.77 24.59 8.06 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.198 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -91.12 -163.96 1.11 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.993 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.417 ' O ' ' HB ' ' A' ' 30' ' ' THR . 34.4 mt-30 -88.27 127.12 35.46 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.418 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -74.18 133.77 42.75 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.96 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.78 8.68 82.33 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.973 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.678 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -96.89 137.64 35.67 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.939 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.661 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.94 152.33 22.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.034 ' CD1' ' HD2' ' A' ' 105' ' ' PRO . 45.3 m-85 -139.29 149.34 44.15 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.91 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.105 ' CB ' ' H ' ' A' ' 98' ' ' SER . 14.7 m-20 -112.21 115.03 28.15 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.952 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.189 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.34 146.06 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.999 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.889 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -169.56 170.79 42.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.885 HE22 ' H ' ' A' ' 70' ' ' ARG . 16.1 tt0 -117.46 122.99 45.27 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 -179.92 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 1.5 m -125.85 148.31 49.2 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.955 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.124 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -123.1 134.88 54.21 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.89 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.659 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.0 OUTLIER -65.31 123.5 19.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 179.909 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.17 HG21 ' CD2' ' A' ' 83' ' ' TRP . 32.3 m -103.84 -42.0 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.976 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.17 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -132.01 -178.67 5.0 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.963 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 33.1 m -69.67 113.45 6.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.948 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 73.91 10.01 80.17 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.641 HG21 ' CH2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -129.23 125.48 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.964 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.736 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.5 pt? -133.62 140.92 47.39 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.959 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.513 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -94.72 144.15 25.86 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.058 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 23.2 m -105.51 159.89 15.59 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.981 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.741 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 21.8 t30 -118.67 111.57 37.64 Favored Pre-proline 0 N--CA 1.449 -0.48 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.989 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 83.2 Cg_endo -72.44 0.55 7.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 124.307 3.338 . . . . 0.0 109.591 179.881 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -89.35 -11.98 41.77 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.911 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.504 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 6.2 p30 -129.49 27.59 5.27 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.945 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.34 107.09 16.43 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.969 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.4 t -105.02 174.96 5.66 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 179.91 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 60.5 p -146.67 158.36 43.89 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.881 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.468 HG22 ' N ' ' A' ' 56' ' ' THR . 7.3 p -167.82 158.52 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.935 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.468 ' N ' HG22 ' A' ' 55' ' ' VAL . 28.0 m -128.13 125.06 38.4 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.93 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -57.51 152.89 13.89 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -180.0 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 58.7 p30 -95.28 -169.47 1.98 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.951 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.65 -24.87 67.84 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.913 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -81.04 -7.26 59.52 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.973 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 76.43 13.28 83.55 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.978 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.8 p -105.02 139.69 39.32 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.867 -0.419 . . . . 0.0 109.867 179.951 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.54 162.27 20.86 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 -179.972 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 p -150.14 122.19 8.26 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.921 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.539 HG22 HG12 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -151.24 153.25 34.52 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.903 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -107.95 120.69 43.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.946 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.523 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.4 OUTLIER -99.69 156.02 17.31 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.547 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -111.71 128.16 56.0 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.783 HG12 HG13 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -100.23 129.64 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.966 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.885 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.4 OUTLIER -113.68 155.52 25.4 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.961 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.402 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 ppt_? -89.72 -12.77 38.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.544 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -166.06 142.39 5.06 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.92 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.741 ' CD1' ' HB2' ' A' ' 48' ' ' ASN . 10.8 p90 -178.0 158.05 1.2 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.895 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -60.19 124.9 21.69 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.911 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.513 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.18 103.97 2.54 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.915 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.726 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -84.57 102.03 12.57 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.958 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.9 tp -56.61 131.6 49.34 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.968 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.659 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.2 p90 -47.44 -36.6 10.21 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.996 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.563 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.5 OUTLIER -57.39 -16.48 9.24 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.953 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.41 27.57 9.8 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.958 ' HB ' HD23 ' A' ' 77' ' ' LEU . 1.4 m -115.11 150.3 36.21 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -179.971 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 5.4 mtm180 -85.36 98.0 10.3 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.956 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.641 ' CH2' HG21 ' A' ' 44' ' ' VAL . 22.8 t-105 -63.92 -51.33 64.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 179.896 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 139.03 179.73 17.69 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.969 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.86 134.26 56.74 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.927 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.124 HG11 ' HB3' ' A' ' 38' ' ' ALA . 6.5 t -114.62 150.08 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.987 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.2 94.43 4.8 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.926 ' SG ' ' CZ ' ' A' ' 112' ' ' PHE . 1.1 m -53.37 -25.31 14.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 180.0 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 75.4 p -83.92 2.14 40.09 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.95 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.9 m -114.44 -27.85 7.41 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.942 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -130.33 179.88 5.65 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.937 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.87 126.32 41.93 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.907 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.327 ' C ' HG13 ' A' ' 110' ' ' ILE . 9.0 m -104.39 153.98 20.41 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.961 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.058 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.8 OUTLIER -149.62 148.23 29.06 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.95 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.523 ' CG1' HD13 ' A' ' 67' ' ' LEU . 17.9 t -96.76 163.55 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.96 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.189 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.41 158.34 27.68 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.97 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.009 HD21 ' CG ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -141.53 137.61 32.14 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.972 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.105 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -129.13 153.48 47.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.912 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.661 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -98.11 -166.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.996 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -59.28 -49.99 75.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.978 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.49 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -69.29 -24.82 64.0 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.926 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.415 ' N ' ' OD1' ' A' ' 99' ' ' ASP . . . 100.65 41.71 2.65 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.992 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.49 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -121.4 178.03 4.96 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.981 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.27 -176.0 20.81 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 179.98 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.04 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 83.0 Cg_endo -72.46 134.03 21.8 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 124.298 3.332 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.383 ' O ' ' CB ' ' A' ' 2' ' ' ALA . 0.5 OUTLIER -136.04 144.3 45.17 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.992 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.39 59.46 0.19 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.979 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.99 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 36.4 t -133.54 100.74 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.617 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.37 153.75 18.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.969 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.327 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -121.91 161.36 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.957 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.495 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.1 OUTLIER -148.65 117.05 6.51 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.961 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.039 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 45.3 m-85 -94.72 128.12 41.19 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.931 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 N--CA 1.449 -0.514 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.964 . . . . . . . . 0 0 . 1 . 042 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 042 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.847 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . -112.05 123.81 33.61 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.938 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 83.9 Cg_endo -72.38 -177.35 2.67 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 124.331 3.354 . . . . 0.0 109.59 179.906 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.812 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -97.31 109.48 22.23 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.96 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.746 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -123.28 144.57 49.33 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.988 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.773 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -111.33 108.41 18.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.754 ' CG2' HG23 ' A' ' 21' ' ' VAL . 1.7 t -99.64 151.05 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.996 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.983 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -66.7 177.82 0.77 Allowed Pre-proline 0 N--CA 1.449 -0.509 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.979 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.048 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.4 Cg_endo -72.4 115.82 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 124.304 3.336 . . . . 0.0 109.628 179.89 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.588 ' HA ' ' CD1' ' A' ' 13' ' ' LEU . 30.0 p -118.32 38.84 3.59 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 -179.968 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 111' ' ' SER . 11.5 p -117.86 104.78 11.26 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.901 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.996 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 95.22 26.58 12.07 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.961 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.048 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -98.2 129.76 44.95 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.958 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -91.87 161.9 14.65 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.908 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 p-10 -45.33 142.03 2.3 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.957 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.24 33.14 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.988 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD13 ' A' ' 13' ' ' LEU . 34.4 m -76.48 150.71 36.63 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -179.99 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.8 124.41 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.995 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.547 HG11 ' CB ' ' A' ' 10' ' ' SER . 18.5 m -96.15 133.95 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.991 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.662 ' O ' HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -79.2 154.47 29.22 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.801 HG13 ' O ' ' A' ' 21' ' ' VAL . 4.2 p -140.95 103.13 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.938 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.773 ' O ' ' N ' ' A' ' 6' ' ' THR . . . -109.51 121.33 44.96 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.94 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.741 ' HA3' HD21 ' A' ' 26' ' ' LEU . . . -101.7 139.62 14.49 Favored Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.812 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -134.37 127.07 30.91 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.992 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.03 24.18 23.24 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -179.967 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.001 HD12 ' O ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -91.29 -167.24 1.75 Allowed 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.983 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.488 ' CB ' ' HB ' ' A' ' 30' ' ' THR . 34.0 mt-30 -84.93 125.18 32.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.991 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.76 130.74 41.18 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.54 8.22 83.81 Favored Glycine 0 C--N 1.336 0.538 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.954 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.546 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -95.4 132.16 40.75 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.916 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -79.64 150.63 30.91 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.934 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.605 ' CB ' HD12 ' A' ' 97' ' ' LEU . 31.5 m-85 -137.9 148.77 45.63 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.909 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.194 ' CB ' ' H ' ' A' ' 98' ' ' SER . 2.9 m-20 -113.89 116.29 29.06 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.917 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.245 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -102.12 145.98 10.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.995 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.038 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -167.69 169.57 41.3 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.978 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.883 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 29.1 tt0 -111.22 120.72 43.22 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.945 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.549 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -110.33 162.7 14.38 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.953 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.172 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -150.81 125.16 9.46 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.959 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.554 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.2 OUTLIER -64.9 125.86 26.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.988 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.81 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.6 m -111.69 -35.62 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 179.962 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.173 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.2 -178.55 5.78 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.967 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 79.0 m -77.19 111.83 13.22 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 79.28 10.51 85.94 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.668 HG21 ' CZ2' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -128.78 114.84 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.972 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.551 HD23 ' C ' ' A' ' 38' ' ' ALA . 0.5 OUTLIER -108.14 162.85 13.68 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.986 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.591 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -129.39 127.38 40.89 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.944 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.733 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.95 154.25 21.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.728 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 13.9 t30 -116.29 113.96 40.95 Favored Pre-proline 0 N--CA 1.449 -0.519 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.972 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.34 -0.11 8.2 Favored 'Trans proline' 0 N--CA 1.447 -1.229 0 C-N-CA 124.33 3.353 . . . . 0.0 109.598 179.891 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' HD21 ' A' ' 48' ' ' ASN . . . -90.55 -16.1 29.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.836 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.578 ' CB ' HG23 ' A' ' 68' ' ' THR . 12.3 p30 -125.96 25.63 6.75 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.915 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -91.22 106.25 18.38 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.967 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.2 t -99.66 -179.88 4.33 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.916 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.4 p -146.84 157.34 43.64 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.901 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' N ' ' A' ' 56' ' ' THR . 7.2 p -166.69 160.64 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.914 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.508 ' N ' HG22 ' A' ' 55' ' ' VAL . 12.0 m -127.52 141.08 51.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.572 ' HA ' ' HB2' ' A' ' 63' ' ' ALA . . . -79.36 134.51 36.59 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.4 p30 -78.6 -171.84 2.68 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.933 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.26 -26.14 68.22 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.947 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -77.77 -3.97 44.02 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.964 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.001 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 69.53 31.26 70.87 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.999 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.6 p -123.14 133.7 54.25 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.963 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 57' ' ' ALA . . . -139.22 124.57 19.17 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.983 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.97 143.04 46.72 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.949 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 66' ' ' SER . 0.4 OUTLIER -153.48 166.23 33.35 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.935 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.572 ' N ' HG23 ' A' ' 65' ' ' THR . 0.6 OUTLIER -105.79 124.61 49.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.029 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -111.82 118.59 35.98 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.981 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.641 ' N ' HD13 ' A' ' 67' ' ' LEU . 3.1 t -80.88 132.34 35.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.938 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.555 HG23 ' CZ ' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -107.78 130.52 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.966 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.635 ' H ' HE22 ' A' ' 36' ' ' GLN . 1.5 mpt_? -115.78 146.25 42.1 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.98 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.715 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.7 OUTLIER -70.86 -4.39 24.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.957 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 31.7 p -178.79 153.25 0.65 Allowed 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.9 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.883 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 6.4 p90 -176.87 162.31 2.09 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.955 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -56.15 126.45 26.14 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.591 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -83.07 88.64 1.5 Allowed Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 179.933 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.733 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.1 OUTLIER -83.87 100.85 11.25 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.996 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.931 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.3 tp -63.46 130.55 44.89 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.692 ' N ' HD12 ' A' ' 77' ' ' LEU . 26.9 p90 -47.48 -36.04 9.58 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.986 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.539 ' H ' ' CD1' ' A' ' 77' ' ' LEU . 1.4 t70 -57.37 -16.63 9.52 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.994 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.0 27.36 9.51 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 -179.994 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.931 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.6 m -113.61 144.99 41.96 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.946 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -88.87 94.24 9.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.966 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.668 ' CZ2' HG21 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.41 -57.75 9.29 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 179.946 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 144.78 164.28 10.5 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 -179.992 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -56.0 127.5 30.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.934 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.172 HG21 ' CB ' ' A' ' 38' ' ' ALA . 0.8 OUTLIER -107.79 154.95 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.993 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.56 108.7 16.29 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 -179.957 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.84 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 35.1 m -54.25 -26.48 29.07 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.976 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.6 p -82.02 -0.97 46.71 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.965 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.1 m -116.4 -27.36 6.81 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.932 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -131.88 -178.31 4.83 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.977 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.69 124.24 40.62 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.941 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.15 ' C ' HG13 ' A' ' 110' ' ' ILE . 94.9 m -104.47 152.86 21.84 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.956 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.044 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.6 OUTLIER -156.42 146.04 20.86 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.949 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.029 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 9.2 t -96.53 162.57 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -179.984 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.245 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -172.99 160.49 31.33 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.605 HD12 ' CB ' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -138.84 141.8 38.65 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.972 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.194 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 0.5 OUTLIER -134.02 157.8 45.17 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.929 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.916 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -104.89 -164.16 1.02 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.964 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.448 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.13 -49.68 76.13 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.972 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.426 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.8 -24.78 61.79 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.902 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 99.85 41.13 2.95 Favored Glycine 0 C--N 1.335 0.516 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.57 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -117.68 176.69 5.06 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.948 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 136.4 -175.75 20.76 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.256 -1.138 . . . . 0.0 110.256 179.975 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.985 ' HG2' HD21 ' A' ' 97' ' ' LEU . 83.2 Cg_endo -72.39 133.89 21.67 Favored 'Trans proline' 0 N--CA 1.447 -1.247 0 C-N-CA 124.338 3.359 . . . . 0.0 109.568 179.908 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.847 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 3.7 tt0 -137.26 147.49 45.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.948 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.96 58.11 0.23 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.946 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.025 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 9.4 t -130.88 101.38 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.992 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -98.41 143.36 28.94 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.919 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.15 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.2 OUTLIER -110.79 169.27 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.92 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.451 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -161.4 127.64 3.83 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.943 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.84 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 11.2 m-85 -99.1 116.84 32.25 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.893 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.956 ' O ' ' HA2' ' A' ' 12' ' ' GLY . 3.4 p30 . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 043 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.135 ' HB1' ' O ' ' A' ' 106' ' ' GLU . . . -87.72 147.33 41.11 Favored Pre-proline 0 N--CA 1.449 -0.489 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.943 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.218 ' CB ' HD22 ' A' ' 26' ' ' LEU . 83.5 Cg_endo -72.41 -175.3 1.73 Allowed 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 124.297 3.331 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.723 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -100.55 108.68 20.68 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.92 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.881 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.98 136.87 54.38 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.932 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.625 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -98.53 112.27 24.36 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.969 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.834 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 m -106.2 153.42 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.997 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.953 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.73 176.93 1.1 Allowed Pre-proline 0 N--CA 1.449 -0.502 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.92 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.096 ' O ' HD11 ' A' ' 13' ' ' LEU . 81.9 Cg_endo -72.35 115.9 4.5 Favored 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.323 3.349 . . . . 0.0 109.59 179.881 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HB2' ' CG2' ' A' ' 110' ' ' ILE . 0.2 OUTLIER -112.95 41.23 2.12 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.956 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.529 ' HA ' ' O ' ' A' ' 111' ' ' SER . 89.6 p -119.04 105.43 11.42 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.876 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.081 ' CA ' ' O ' ' A' ' 113' ' ' ASN . . . 93.2 28.24 12.08 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 179.99 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.096 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -103.24 130.16 50.4 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.976 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -106.16 174.52 5.85 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.944 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -48.65 139.97 8.85 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.935 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.66 -23.59 32.26 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.999 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.448 HG21 ' HB3' ' A' ' 13' ' ' LEU . 58.3 m -80.17 151.92 29.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.973 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 18' ' ' VAL . 9.1 p -127.11 130.2 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.979 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 1.02 HG22 ' O ' ' A' ' 67' ' ' LEU . 15.4 m -95.87 170.66 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.995 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.834 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -116.59 148.8 40.58 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.735 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.5 OUTLIER -143.3 106.09 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.971 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.881 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -119.04 115.76 24.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.798 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -85.35 142.12 19.42 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.723 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -136.91 112.53 9.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.784 -0.451 . . . . 0.0 109.784 -179.964 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.947 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 101.53 25.7 8.04 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 -180.0 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.218 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.3 OUTLIER -91.26 -163.8 1.09 Allowed 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.993 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -89.25 125.21 34.99 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.97 133.86 44.48 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.956 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.66 8.57 84.4 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.606 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -98.83 134.57 41.52 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.995 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.953 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -83.47 152.24 25.05 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.546 ' HB3' ' CD1' ' A' ' 97' ' ' LEU . 38.0 m-85 -138.51 145.25 40.53 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.928 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.148 ' CB ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -110.15 122.45 47.65 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.924 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.116 HG22 ' CB ' ' A' ' 97' ' ' LEU . 1.2 t -102.19 150.17 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.997 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.996 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -172.88 146.66 9.2 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.943 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.806 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 14.4 tt0 -92.58 115.86 28.48 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.598 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.0 OUTLIER -103.13 163.78 12.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.951 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 1.198 ' CB ' HG11 ' A' ' 86' ' ' VAL . . . -149.16 131.42 15.53 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.96 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.542 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.0 OUTLIER -67.32 124.57 23.51 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.987 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' CG ' ' A' ' 83' ' ' TRP . 2.3 m -111.39 -41.64 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 109.708 -0.478 . . . . 0.0 109.708 -179.974 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.533 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -146.1 -178.8 6.32 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.964 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.673 HG23 ' O ' ' A' ' 42' ' ' THR . 1.3 t -65.1 111.6 2.98 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.986 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.79 7.92 62.73 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -179.988 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.571 ' O ' ' CG2' ' A' ' 40' ' ' VAL . 45.9 t -111.02 105.2 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.749 -0.464 . . . . 0.0 109.749 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.69 ' O ' ' HA ' ' A' ' 77' ' ' LEU . 1.3 mt -107.98 153.29 23.3 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.963 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.483 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -128.15 128.63 45.18 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.966 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -106.87 154.81 20.49 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.538 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.7 t30 -116.15 112.53 41.94 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -179.982 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -72.33 -0.35 8.55 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 124.308 3.338 . . . . 0.0 109.616 179.839 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.538 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -91.83 -12.26 34.2 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.832 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' A' ' 68' ' ' THR . 23.6 p30 -130.82 27.34 4.93 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.63 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.1 OUTLIER -103.35 116.14 31.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.977 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 54' ' ' SER . 30.2 t -100.56 -173.22 2.35 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.984 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.442 ' N ' ' OG ' ' A' ' 53' ' ' SER . 4.7 p -147.14 154.08 40.67 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.85 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -167.06 154.44 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 179.949 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 58.7 m -123.8 122.73 38.8 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.954 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -52.79 149.75 5.95 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.933 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 56.8 p30 -92.27 -171.44 2.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 -179.955 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.27 -25.06 67.64 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -81.35 -5.0 57.39 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.415 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 72.58 23.66 77.53 Favored Glycine 0 C--N 1.336 0.537 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 82.4 p -114.42 138.06 51.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.996 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.61 163.02 19.63 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.997 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -150.94 120.0 6.71 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.974 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.512 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -148.86 158.08 43.9 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.892 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.45 ' N ' HG23 ' A' ' 65' ' ' THR . 0.3 OUTLIER -110.4 126.35 54.19 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.985 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.02 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.7 OUTLIER -107.58 118.24 36.2 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.965 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.677 ' N ' HD13 ' A' ' 67' ' ' LEU . 4.7 t -69.0 149.73 48.48 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.922 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.531 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -106.46 123.93 61.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.967 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.531 ' HD2' ' O ' ' A' ' 69' ' ' VAL . 1.5 mpt_? -116.58 137.09 52.44 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.971 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.47 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 26.0 ptt180 -75.26 -18.34 60.11 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.969 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.507 ' HB2' ' OD1' ' A' ' 87' ' ' ASP . 9.7 t -163.82 151.57 12.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.911 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.806 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 4.3 p90 -177.8 155.7 1.04 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.885 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -55.93 122.63 12.01 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.931 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.483 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -77.54 89.46 1.03 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 179.96 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.966 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -83.08 100.45 10.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.989 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.855 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.6 tp -54.25 141.74 28.56 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.711 ' N ' HD12 ' A' ' 77' ' ' LEU . 4.0 m-85 -47.1 -42.37 18.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.978 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.573 ' N ' ' HG ' ' A' ' 77' ' ' LEU . 12.2 t0 -57.05 -17.06 8.71 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.959 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.82 28.16 9.71 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.934 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.855 ' HB ' HD23 ' A' ' 77' ' ' LEU . 3.0 m -108.78 131.16 55.23 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.97 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.5 ttt180 -72.94 91.62 1.56 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.944 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.533 ' CZ2' ' HB2' ' A' ' 41' ' ' ASP . 0.5 OUTLIER -61.96 -57.0 13.37 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.884 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 156.41 170.2 21.31 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 110.226 -1.15 . . . . 0.0 110.226 179.982 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -55.47 142.22 33.73 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.962 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.198 HG11 ' CB ' ' A' ' 38' ' ' ALA . 2.5 t -117.91 154.11 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.973 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.507 ' OD1' ' HB2' ' A' ' 72' ' ' SER . 10.0 m-20 -128.73 95.0 3.99 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.965 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 1.226 ' HB3' ' CE1' ' A' ' 112' ' ' PHE . 99.1 m -54.31 -25.63 24.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.977 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 76.4 p -80.45 1.87 27.47 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.978 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m -113.83 -27.39 7.79 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.969 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -138.07 -170.55 2.82 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.983 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.89 126.52 42.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.92 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.344 ' C ' HG13 ' A' ' 110' ' ' ILE . 11.9 m -104.68 152.84 22.01 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.968 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.073 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 0.9 OUTLIER -146.8 148.09 31.55 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.92 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.837 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 24.1 t -99.72 164.86 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.952 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.026 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.81 158.03 24.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.546 ' CD1' ' HB3' ' A' ' 32' ' ' TYR . 0.9 OUTLIER -134.9 152.9 52.14 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.974 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.148 ' O ' ' CB ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER -141.32 158.47 43.84 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.903 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.953 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -105.28 -163.13 0.92 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.967 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.51 -49.34 77.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.941 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.441 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -72.79 -25.44 61.16 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.947 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 101.07 42.38 2.43 Favored Glycine 0 C--N 1.335 0.502 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 -179.95 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.634 ' O ' ' CD1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -119.51 176.12 5.51 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.963 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 139.19 -173.22 22.81 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.994 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.126 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.9 Cg_endo -72.38 133.35 20.72 Favored 'Trans proline' 0 N--CA 1.447 -1.223 0 C-N-CA 124.345 3.363 . . . . 0.0 109.641 179.92 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.135 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 2.3 tt0 -136.1 145.74 46.24 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.966 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 57.36 0.23 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.964 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.006 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 25.5 t -131.58 100.94 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.978 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.655 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -97.57 155.22 17.06 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.996 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.344 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -124.29 163.49 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.949 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.529 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -153.61 122.47 6.41 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.959 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.226 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 10.0 m-85 -87.6 116.32 25.65 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 179.902 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 1.081 ' O ' ' CA ' ' A' ' 12' ' ' GLY . 4.4 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.966 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 044 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.893 ' HA ' ' HG3' ' A' ' 106' ' ' GLU . . . -103.51 108.95 60.95 Favored Pre-proline 0 N--CA 1.449 -0.484 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.165 ' CB ' HD22 ' A' ' 26' ' ' LEU . 82.8 Cg_endo -72.42 -174.05 1.32 Allowed 'Trans proline' 0 N--CA 1.447 -1.252 0 C-N-CA 124.347 3.365 . . . . 0.0 109.579 179.964 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.648 ' O ' ' N ' ' A' ' 24' ' ' ALA . 1.3 m -101.03 109.48 21.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.939 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.795 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -119.73 141.74 49.15 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.937 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.2 p -96.72 111.44 23.6 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.915 HG21 HG22 ' A' ' 108' ' ' VAL . 21.9 t -107.66 148.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.978 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -68.48 177.63 1.04 Allowed Pre-proline 0 N--CA 1.449 -0.518 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.99 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.103 ' O ' HD11 ' A' ' 13' ' ' LEU . 83.7 Cg_endo -72.38 117.97 5.38 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 124.32 3.346 . . . . 0.0 109.607 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 111' ' ' SER . 9.3 p -115.11 44.58 1.78 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.957 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.4 m -122.91 105.11 9.71 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.88 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.955 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 91.88 28.1 14.8 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.103 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.69 132.69 43.1 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.873 -0.418 . . . . 0.0 109.873 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.8 m -107.19 172.93 6.55 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.956 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -50.65 140.05 15.15 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.39 -22.99 35.67 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.99 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.496 HG21 HD13 ' A' ' 13' ' ' LEU . 86.3 m -74.59 153.11 39.15 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.983 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 18' ' ' VAL . 7.1 p -129.96 126.1 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.894 HG22 ' O ' ' A' ' 67' ' ' LEU . 26.3 m -94.57 176.65 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.98 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.833 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.35 149.28 45.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.944 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.619 ' CG1' HG22 ' A' ' 7' ' ' VAL . 0.1 OUTLIER -145.11 108.03 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.795 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -124.27 116.78 23.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.933 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.39 144.34 21.48 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.648 ' N ' ' O ' ' A' ' 4' ' ' THR . . . -140.67 112.6 7.66 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.933 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.899 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 105.22 21.75 8.69 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.165 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -91.29 -163.91 1.1 Allowed 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 1.8 mp0 -89.94 126.43 35.73 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.485 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -69.61 141.59 53.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.978 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.69 7.72 59.03 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.96 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.753 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -92.57 143.05 26.73 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.995 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.564 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -95.22 148.84 21.97 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.984 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.007 ' OH ' ' NE2' ' A' ' 27' ' ' GLN . 49.4 m-85 -137.85 148.55 45.51 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.2 ' CB ' ' H ' ' A' ' 98' ' ' SER . 6.7 m-20 -112.38 114.57 27.36 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.964 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.074 HG22 ' HB3' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -96.18 146.43 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.978 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.887 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -170.5 167.88 40.97 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.953 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.812 ' OE1' ' HE2' ' A' ' 73' ' ' PHE . 8.2 tt0 -115.97 113.38 23.18 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -114.3 149.05 36.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.971 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 86' ' ' VAL . . . -124.66 134.91 52.72 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.928 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.663 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 120.56 13.14 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.95 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.433 HG21 ' CD1' ' A' ' 83' ' ' TRP . 24.8 m -101.07 -44.95 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 -179.982 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.865 ' CB ' ' HZ2' ' A' ' 83' ' ' TRP . 0.6 OUTLIER -133.36 172.36 12.81 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.941 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 42' ' ' THR . 1.6 t -56.47 111.44 0.99 Allowed 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.92 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 70.88 7.53 62.21 Favored Glycine 0 C--N 1.336 0.534 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 179.962 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.789 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 21.6 t -120.68 111.08 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.951 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.705 HD12 ' HB2' ' A' ' 37' ' ' CYS . 1.1 pt? -123.43 140.97 52.47 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.96 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.516 ' HB1' ' C ' ' A' ' 75' ' ' GLY . . . -98.33 146.03 26.09 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.02 ' SG ' ' SG ' ' A' ' 37' ' ' CYS . 12.1 m -106.48 153.97 21.52 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.757 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 27.0 t30 -114.52 109.82 47.92 Favored Pre-proline 0 N--CA 1.45 -0.468 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -72.4 -0.35 8.58 Favored 'Trans proline' 0 N--CA 1.448 -1.203 0 C-N-CA 124.293 3.328 . . . . 0.0 109.585 179.914 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.53 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.65 -16.57 32.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.876 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 13.7 p30 -128.24 28.44 5.49 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.878 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.682 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -98.47 118.95 36.29 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.97 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 38.0 t -111.43 -172.84 2.11 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.965 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.9 p -146.7 157.66 43.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.888 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 56' ' ' THR . 4.5 p -166.75 159.53 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.466 ' N ' HG22 ' A' ' 55' ' ' VAL . 14.0 m -127.1 137.5 53.02 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.985 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.83 131.44 39.74 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 50.9 p30 -73.75 -173.43 1.51 Allowed 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.94 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.26 -20.42 62.83 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.913 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -85.98 10.09 15.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 179.952 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.485 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 56.79 26.78 54.77 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.946 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.3 t -121.21 133.54 55.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.439 ' HB1' ' CG2' ' A' ' 55' ' ' VAL . . . -121.44 156.75 32.06 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -139.02 133.69 32.02 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.93 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.663 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -161.93 170.34 19.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.942 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.663 ' N ' HG23 ' A' ' 65' ' ' THR . 0.7 OUTLIER -121.01 138.39 54.19 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.939 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.894 ' O ' HG22 ' A' ' 19' ' ' VAL . 0.5 OUTLIER -115.77 118.81 34.07 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.943 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.719 ' OG1' ' NE ' ' A' ' 70' ' ' ARG . 0.0 OUTLIER -71.1 135.89 47.93 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.972 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.565 ' O ' ' HD2' ' A' ' 70' ' ' ARG . 0.9 OUTLIER -92.67 125.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.971 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.719 ' NE ' ' OG1' ' A' ' 68' ' ' THR . 1.1 mpt_? -117.8 140.63 49.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.943 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.416 ' O ' ' OG ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -82.72 -15.84 50.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.997 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 58.4 m -167.33 152.13 7.08 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.979 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.812 ' HE2' ' OE1' ' A' ' 36' ' ' GLN . 1.4 p90 -176.55 161.86 2.2 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.929 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.403 ' HG3' ' CD2' ' A' ' 76' ' ' PHE . 0.1 OUTLIER -62.54 110.58 1.74 Allowed 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.94 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.516 ' C ' ' HB1' ' A' ' 46' ' ' ALA . . . -69.97 94.21 0.44 Allowed Glycine 0 C--N 1.336 0.532 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.958 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.867 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 1.5 m-85 -82.88 98.78 9.36 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.956 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 1.114 HD21 ' OD2' ' A' ' 79' ' ' ASP . 3.6 tp -55.49 142.28 33.62 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.982 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.745 ' N ' HD12 ' A' ' 77' ' ' LEU . 2.0 m-85 -47.67 -42.91 25.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 1.114 ' OD2' HD21 ' A' ' 77' ' ' LEU . 4.0 m-20 -57.75 -16.76 12.17 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 93.78 27.73 12.25 Favored Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.836 ' HB ' HD23 ' A' ' 77' ' ' LEU . 4.9 m -106.08 134.07 49.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.97 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.48 91.64 0.78 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.433 ' CD1' HG21 ' A' ' 40' ' ' VAL . 0.0 OUTLIER -62.76 -48.82 77.51 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.878 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 140.63 167.13 10.94 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.985 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 1.2 m -65.43 103.59 0.85 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.963 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 38' ' ' ALA . 3.4 m -78.61 151.81 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.981 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -110.48 93.85 4.71 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.987 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.788 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 13.7 m -51.29 -26.26 7.09 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.99 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 5.7 p -81.06 0.79 34.38 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 -179.999 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 m -117.3 -27.62 6.37 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.922 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -129.51 -179.9 5.43 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.98 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.34 123.77 40.1 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.948 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.295 ' C ' HG13 ' A' ' 110' ' ' ILE . 89.1 m -104.59 155.66 18.65 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -180.0 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.034 ' HA ' ' CG1' ' A' ' 110' ' ' ILE . 1.2 pt20 -144.56 147.49 33.26 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 -179.944 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.795 ' CG2' ' HG ' ' A' ' 67' ' ' LEU . 14.2 t -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.961 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.952 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -175.08 160.05 28.71 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.989 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.074 ' HB3' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -128.35 155.29 44.91 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.954 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.2 ' H ' ' CB ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER -143.45 144.23 31.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.898 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.564 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.4 OUTLIER -90.97 -161.78 0.85 Allowed 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 -179.945 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.457 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -60.69 -49.29 78.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.925 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.449 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -71.13 -24.79 62.34 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.93 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.83 42.5 2.45 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.994 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.449 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -121.07 177.16 5.24 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 -179.99 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 137.92 -173.65 22.28 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.069 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.4 Cg_endo -72.35 133.85 21.66 Favored 'Trans proline' 0 N--CA 1.447 -1.227 0 C-N-CA 124.364 3.376 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.893 ' HG3' ' HA ' ' A' ' 2' ' ' ALA . 1.8 pt-20 -139.8 161.53 37.34 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.79 51.71 0.6 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.925 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.98 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 4.0 t -126.44 101.82 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.996 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -96.09 146.83 24.32 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.955 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.295 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.1 OUTLIER -115.78 159.71 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.907 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.776 ' O ' ' O ' ' A' ' 10' ' ' SER . 0.3 OUTLIER -151.0 126.73 10.25 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.909 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.788 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 8.3 m-85 -101.48 124.93 47.95 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.932 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.616 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 49.2 m-80 . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.961 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 045 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.633 ' C ' ' HB3' ' A' ' 106' ' ' GLU . . . -133.34 123.61 17.76 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.932 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.406 ' CD ' ' HA ' ' A' ' 105' ' ' PRO . 82.4 Cg_endo -72.38 -174.13 1.34 Allowed 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 124.286 3.324 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.162 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.4 t -95.93 109.73 22.05 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.839 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.99 145.7 50.89 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.511 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -103.9 113.37 26.85 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.884 HG13 ' O ' ' A' ' 20' ' ' LYS . 38.5 t -110.66 148.53 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.996 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.956 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -68.15 175.94 1.59 Allowed Pre-proline 0 N--CA 1.449 -0.517 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.945 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.956 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 83.6 Cg_endo -72.38 120.95 7.07 Favored 'Trans proline' 0 N--CA 1.447 -1.246 0 C-N-CA 124.351 3.367 . . . . 0.0 109.63 179.851 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.085 ' HA ' HD21 ' A' ' 13' ' ' LEU . 30.8 p -120.83 52.48 1.18 Allowed 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 111' ' ' SER . 62.0 p -137.81 106.14 5.79 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 179.9 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.68 8.47 40.01 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 179.9 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.146 ' O ' HD12 ' A' ' 13' ' ' LEU . 3.5 pp -114.68 143.08 45.61 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.983 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -122.47 -166.99 1.49 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.936 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.943 ' OD1' ' NH1' ' A' ' 70' ' ' ARG . 42.7 t0 -43.32 151.73 0.15 Allowed 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.969 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' ' OD1' ' A' ' 15' ' ' ASP . . . 92.02 -23.38 26.86 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.998 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.778 HG21 HD22 ' A' ' 13' ' ' LEU . 3.7 m -85.08 146.05 27.35 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 18' ' ' VAL . 14.8 p -116.21 129.52 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.966 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.638 ' CG2' ' HB3' ' A' ' 67' ' ' LEU . 6.0 m -99.75 159.4 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.884 ' O ' HG13 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.7 145.42 41.37 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 179.969 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.592 HG13 HG22 ' A' ' 7' ' ' VAL . 0.0 OUTLIER -142.06 110.16 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.989 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.839 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.89 112.91 18.9 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.979 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.904 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.92 144.77 21.25 Favored Glycine 0 C--N 1.334 0.468 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.982 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.162 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -142.86 110.13 5.68 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.955 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.879 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.89 14.92 15.95 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.234 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -91.04 165.94 13.26 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.984 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.463 ' HB2' HG21 ' A' ' 30' ' ' THR . 34.9 mt-30 -48.99 121.26 4.58 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.96 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.608 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.69 134.93 45.28 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.945 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 8.2 76.32 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.981 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.751 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -97.7 137.41 36.63 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.995 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -84.12 151.97 24.59 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.998 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.57 ' CB ' HD23 ' A' ' 97' ' ' LEU . 73.0 m-85 -135.77 158.2 44.99 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.925 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.45 ' HB2' ' CA ' ' A' ' 98' ' ' SER . 17.1 m-20 -119.71 117.93 29.55 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.948 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.21 ' HA ' ' O ' ' A' ' 96' ' ' GLY . 0.1 OUTLIER -100.42 138.13 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.958 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 1.173 ' O ' ' HA ' ' A' ' 95' ' ' VAL . . . -158.91 162.88 32.91 Favored Glycine 0 C--N 1.335 0.514 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.97 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.839 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 1.8 tt0 -115.13 121.62 43.59 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.915 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.567 ' HB3' HD13 ' A' ' 45' ' ' LEU . 66.9 m -108.59 172.7 6.69 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.976 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.833 ' HB3' HG11 ' A' ' 86' ' ' VAL . . . -152.84 124.34 7.71 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 -179.943 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.598 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -65.58 124.25 21.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.947 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.641 ' CG1' HG22 ' A' ' 86' ' ' VAL . 12.1 m -104.43 -43.7 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.952 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.701 ' HB2' ' CZ2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -142.88 164.13 30.92 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.968 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.6 m -53.33 114.06 1.36 Allowed 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.944 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 72.6 7.92 70.4 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.511 ' CG1' ' HE1' ' A' ' 83' ' ' TRP . 15.0 t -126.44 105.76 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -179.953 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.763 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -117.84 162.65 17.76 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.942 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.495 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -126.18 146.96 49.75 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.817 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.4 m -108.35 155.95 19.96 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.992 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.826 ' HB2' ' CD1' ' A' ' 73' ' ' PHE . 33.6 t30 -114.59 105.64 53.3 Favored Pre-proline 0 N--CA 1.449 -0.525 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 48' ' ' ASN . 84.3 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 124.287 3.325 . . . . 0.0 109.609 179.885 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -88.44 -12.94 41.67 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.878 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.417 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 12.9 p30 -126.71 28.51 5.87 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.936 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.72 104.57 13.93 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.997 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.1 t -101.65 177.26 4.96 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.923 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 p -146.44 153.08 40.04 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.852 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.2 p -167.37 153.04 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.966 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.1 m -122.58 139.62 53.71 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.947 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -81.0 142.86 32.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.917 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -80.02 -170.73 2.59 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -22.08 66.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.961 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -81.92 4.75 21.36 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.998 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.608 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 60.32 31.01 72.44 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.921 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.8 t -125.05 132.28 53.23 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.94 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -121.12 164.07 17.43 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.979 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -146.74 135.64 22.35 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.593 HG23 ' N ' ' A' ' 66' ' ' SER . 0.6 OUTLIER -166.05 165.35 17.93 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.913 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.593 ' N ' HG23 ' A' ' 65' ' ' THR . 0.4 OUTLIER -122.34 126.06 47.25 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.939 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.206 HD13 ' CG1' ' A' ' 95' ' ' VAL . 0.5 OUTLIER -96.83 155.34 16.82 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 68' ' ' THR . 5.0 t -103.7 119.29 38.62 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.946 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.813 HG11 ' CD1' ' A' ' 13' ' ' LEU . 2.1 t -84.35 128.4 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.943 ' NH1' ' OD1' ' A' ' 15' ' ' ASP . 0.6 OUTLIER -119.1 156.82 29.05 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.412 ' HG3' ' N ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -90.93 -24.98 20.01 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.923 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.412 ' N ' ' HG3' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -156.47 148.35 22.94 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.946 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.839 ' CE2' ' OE1' ' A' ' 36' ' ' GLN . 1.8 p90 -174.41 153.42 1.91 Allowed 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.935 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.501 ' HG2' ' O ' ' A' ' 74' ' ' GLU . 0.6 OUTLIER -54.29 115.13 1.92 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.953 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.495 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -70.49 100.64 0.83 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.986 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.817 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -83.41 99.95 10.39 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.988 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.952 HD23 ' HB ' ' A' ' 81' ' ' THR . 4.2 tp -58.61 130.94 49.25 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.678 ' N ' HD12 ' A' ' 77' ' ' LEU . 14.1 p90 -47.65 -35.75 9.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.553 ' CB ' HD21 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -57.96 -16.35 12.06 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.19 27.68 9.88 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.986 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.952 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.3 m -115.36 151.65 34.26 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.419 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -89.45 97.86 11.44 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 -179.967 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.511 ' HE1' ' CG1' ' A' ' 44' ' ' VAL . 0.0 OUTLIER -63.43 -55.9 20.57 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 179.883 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 146.56 172.67 17.09 Favored Glycine 0 C--N 1.335 0.5 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.26 108.25 0.45 Allowed 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.978 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.833 HG11 ' HB3' ' A' ' 38' ' ' ALA . 86.4 t -86.05 147.43 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 -179.984 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 48.1 m-20 -108.09 90.87 3.43 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.963 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.429 ' HB3' ' CE2' ' A' ' 112' ' ' PHE . 0.1 OUTLIER -53.06 -25.24 12.03 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.945 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 61.0 p -78.01 -3.33 41.5 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.97 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -115.78 -26.07 7.54 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -123.46 -179.89 4.5 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.962 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -96.26 136.97 36.01 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.899 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.463 ' SG ' ' CE1' ' A' ' 112' ' ' PHE . 0.2 OUTLIER -102.69 166.05 10.72 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.998 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.335 ' CG ' ' O ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -169.52 127.9 0.96 Allowed 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -179.911 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.206 ' CG1' HD13 ' A' ' 67' ' ' LEU . 3.9 t -92.41 164.28 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 -179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.21 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -170.22 164.83 38.16 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.57 HD23 ' CB ' ' A' ' 32' ' ' TYR . 4.3 mp -100.33 160.93 13.94 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.45 ' CA ' ' HB2' ' A' ' 33' ' ' ASP . 14.6 m -155.0 117.44 4.26 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.591 ' OD1' ' ND2' ' A' ' 103' ' ' ASN . 3.2 p-10 -112.11 -158.15 0.64 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.958 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -52.13 -39.49 59.99 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 -179.921 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -90.46 -26.89 19.6 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 -179.901 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 90.77 53.52 2.23 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.247 -1.141 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.591 ' ND2' ' OD1' ' A' ' 99' ' ' ASP . 0.2 OUTLIER -106.68 -174.7 2.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.994 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.422 ' HA2' ' CD1' ' A' ' 32' ' ' TYR . . . 171.01 175.58 39.64 Favored Glycine 0 C--N 1.336 0.549 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 179.975 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.406 ' HA ' ' CD ' ' A' ' 3' ' ' PRO . 82.9 Cg_endo -72.33 160.63 46.54 Favored 'Trans proline' 0 N--CA 1.447 -1.225 0 C-N-CA 124.32 3.347 . . . . 0.0 109.581 179.948 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.271 ' HG2' ' O ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -33.84 126.63 0.42 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.991 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.462 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . -33.76 135.75 0.25 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.993 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.335 ' O ' ' CG ' ' A' ' 94' ' ' GLN . 25.3 t -119.05 102.88 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.956 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.908 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -86.7 158.22 19.48 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 -179.969 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.87 HG13 ' HA ' ' A' ' 94' ' ' GLN . 35.2 mt -125.98 162.49 29.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.986 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.598 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -141.07 121.39 13.95 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.903 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.463 ' CE1' ' SG ' ' A' ' 93' ' ' CYS . 2.9 m-85 -97.72 122.21 40.54 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 . . . . . 0 N--CA 1.45 -0.466 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.943 . . . . . . . . 0 0 . 1 . 046 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 . . . . . . . . . 0 0 . 1 . 046 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 1.292 ' HB1' ' CA ' ' A' ' 106' ' ' GLU . . . -145.03 130.56 9.41 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -179.91 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.565 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 84.4 Cg_endo -72.38 -174.3 1.39 Allowed 'Trans proline' 0 N--CA 1.446 -1.272 0 C-N-CA 124.337 3.358 . . . . 0.0 109.634 179.886 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.282 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 3.6 t -95.97 111.42 23.43 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.957 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.801 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -130.57 140.13 50.45 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.94 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -102.25 111.27 23.48 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.985 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.652 HG11 HG21 ' A' ' 108' ' ' VAL . 0.9 OUTLIER -108.22 155.05 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.981 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.972 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.6 OUTLIER -67.43 177.02 1.02 Allowed Pre-proline 0 N--CA 1.449 -0.497 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.929 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 1.136 ' O ' HD11 ' A' ' 13' ' ' LEU . 82.2 Cg_endo -72.39 117.86 5.33 Favored 'Trans proline' 0 N--CA 1.447 -1.254 0 C-N-CA 124.316 3.344 . . . . 0.0 109.605 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.494 ' OG ' HG23 ' A' ' 110' ' ' ILE . 22.6 p -114.31 41.39 2.3 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -179.963 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 111' ' ' SER . 60.4 p -123.41 105.97 10.26 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.928 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.957 ' C ' HD23 ' A' ' 13' ' ' LEU . . . 93.68 26.38 15.29 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.976 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.136 HD11 ' O ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -97.93 132.49 43.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.958 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.2 m -90.79 151.8 21.04 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.938 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -44.09 137.84 3.19 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.93 -20.9 37.43 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.984 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.435 HG21 HD13 ' A' ' 13' ' ' LEU . 90.9 m -64.78 147.46 53.13 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.995 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.615 HG13 ' O ' ' A' ' 18' ' ' VAL . 9.7 p -110.58 117.78 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.972 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 67' ' ' LEU . 14.8 m -95.48 164.75 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.627 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -114.16 153.33 29.75 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.947 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.681 ' CG1' ' O ' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -149.39 113.48 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.982 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.801 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -121.25 114.5 21.47 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.819 -0.438 . . . . 0.0 109.819 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.766 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -84.28 147.69 23.61 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.249 -1.14 . . . . 0.0 110.249 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.282 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -147.48 109.85 4.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.933 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.886 ' C ' HD23 ' A' ' 26' ' ' LEU . . . 107.67 14.0 18.86 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -179.982 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.193 HD22 ' CB ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -90.49 165.8 13.59 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.5 ' HB2' HG21 ' A' ' 30' ' ' THR . 35.5 mt-30 -50.91 118.99 3.52 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.968 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.855 ' HA ' ' HA2' ' A' ' 61' ' ' GLY . . . -72.05 134.99 46.17 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.971 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.25 8.73 80.05 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.341 -1.104 . . . . 0.0 110.341 -179.916 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.643 HG22 ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -98.01 142.69 29.41 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.975 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.583 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -86.03 153.21 22.3 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.929 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.055 ' CD1' ' ND2' ' A' ' 103' ' ' ASN . 59.2 m-85 -138.29 150.88 47.07 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.919 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.493 ' CA ' ' H ' ' A' ' 98' ' ' SER . 17.2 m-20 -116.87 114.86 24.47 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.591 HG22 ' CG ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.52 139.94 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -179.956 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.76 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . -159.92 156.92 28.17 Favored Glycine 0 C--N 1.335 0.489 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.702 ' OE1' ' CE2' ' A' ' 73' ' ' PHE . 52.8 tt0 -96.33 113.54 25.14 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -179.97 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.517 ' HB3' HD22 ' A' ' 45' ' ' LEU . 1.3 m -102.17 159.5 15.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.992 ' HB1' HG21 ' A' ' 86' ' ' VAL . . . -149.2 141.45 24.07 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.905 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.549 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 1.2 t90 -63.6 121.65 14.42 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.718 HG12 ' CG2' ' A' ' 44' ' ' VAL . 0.9 OUTLIER -109.53 -36.37 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 1.043 ' HB2' ' HE1' ' A' ' 83' ' ' TRP . 0.9 OUTLIER -155.24 -175.81 5.62 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.995 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.601 HG23 ' O ' ' A' ' 42' ' ' THR . 7.2 t -73.56 110.55 7.93 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.991 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.88 12.75 83.71 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.649 HG21 ' CE2' ' A' ' 83' ' ' TRP . 1.0 OUTLIER -128.9 121.15 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.985 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 38' ' ' ALA . 0.7 OUTLIER -113.78 162.2 16.59 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.989 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.471 ' CB ' ' HA3' ' A' ' 75' ' ' GLY . . . -132.14 130.91 41.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.973 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.76 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 1.2 m -107.65 155.23 20.39 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 -179.958 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.759 ' HB3' ' CD1' ' A' ' 73' ' ' PHE . 1.2 p-10 -118.69 120.1 31.98 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.955 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.422 ' HA ' ' HB3' ' A' ' 52' ' ' PHE . 83.5 Cg_endo -72.34 1.66 5.88 Favored 'Trans proline' 0 N--CA 1.447 -1.221 0 C-N-CA 124.298 3.332 . . . . 0.0 109.627 179.879 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.736 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -84.33 -24.79 29.63 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 -179.874 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.51 ' CB ' HG23 ' A' ' 68' ' ' THR . 94.4 m-20 -123.39 30.98 6.09 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.665 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -99.14 117.71 34.23 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 -179.973 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 34.2 t -110.86 -177.95 3.35 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 179.997 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.7 p -148.46 153.79 38.98 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.934 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 56' ' ' THR . 3.1 p -167.63 161.65 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.901 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 55' ' ' VAL . 52.4 m -126.53 131.76 51.51 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.09 153.19 44.25 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 -179.999 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 52.3 p-10 -90.38 -166.42 1.58 Allowed 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.937 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.7 -30.23 71.25 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.885 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.39 -9.55 58.7 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.855 ' HA2' ' HA ' ' A' ' 28' ' ' ALA . . . 77.48 15.99 80.82 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.983 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 78.5 p -104.57 138.3 41.13 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 179.951 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -120.96 166.65 13.54 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.987 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 m -150.92 117.34 5.7 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.944 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG21 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.83 157.9 43.78 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.948 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.439 ' N ' HG23 ' A' ' 65' ' ' THR . 0.2 OUTLIER -110.76 125.22 53.31 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.899 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.235 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -104.65 155.3 18.98 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.967 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.775 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.5 OUTLIER -116.74 142.81 46.43 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.976 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 69' ' ' VAL . 0.2 OUTLIER -110.48 125.13 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.991 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.604 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -110.14 159.91 16.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.976 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.67 -29.39 59.05 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -179.932 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 69.6 p -165.28 156.96 14.85 Favored 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.951 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.759 ' CD1' ' HB3' ' A' ' 48' ' ' ASN . 3.1 p90 -175.28 167.35 3.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.906 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -63.97 118.82 9.0 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.947 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.471 ' HA3' ' CB ' ' A' ' 46' ' ' ALA . . . -75.01 85.3 0.79 Allowed Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.76 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -83.05 98.63 9.39 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 -179.988 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.887 HD23 ' HB ' ' A' ' 81' ' ' THR . 1.8 tp -54.71 134.7 47.47 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.986 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.687 ' N ' HD12 ' A' ' 77' ' ' LEU . 27.2 p90 -45.63 -38.43 6.65 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.999 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.587 ' HB2' HD21 ' A' ' 77' ' ' LEU . 1.3 t70 -57.66 -17.14 13.12 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.943 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 95.88 28.7 9.18 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 179.988 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.887 ' HB ' HD23 ' A' ' 77' ' ' LEU . 2.9 m -112.65 115.91 29.32 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.948 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -66.03 93.36 0.2 Allowed 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.649 ' CE2' HG21 ' A' ' 44' ' ' VAL . 2.3 t-105 -63.44 -57.98 8.51 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.925 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.35 171.38 19.88 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -179.967 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -59.48 140.67 56.02 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.987 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.992 HG21 ' HB1' ' A' ' 38' ' ' ALA . 0.2 OUTLIER -126.61 151.6 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.965 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.56 100.78 9.53 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.899 ' HB3' ' CZ ' ' A' ' 112' ' ' PHE . 23.8 m -53.5 -26.0 18.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.979 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -82.5 -1.7 51.2 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 179.979 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.2 m -115.48 -27.99 6.98 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.919 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' A' ' 39' ' ' TRP . . . -125.4 -175.15 3.24 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.39 124.57 41.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.899 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.185 ' O ' HG13 ' A' ' 110' ' ' ILE . 1.7 m -104.66 153.65 20.97 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.985 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.133 ' HB2' ' O ' ' A' ' 108' ' ' VAL . 0.8 OUTLIER -158.5 144.92 17.22 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.959 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.235 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 25.4 t -101.41 162.38 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.986 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.25 ' O ' ' HA ' ' A' ' 34' ' ' VAL . . . -173.81 164.25 35.63 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.991 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.591 ' CG ' HG22 ' A' ' 34' ' ' VAL . 4.5 mp -101.72 160.95 14.02 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -180.0 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.493 ' H ' ' CA ' ' A' ' 33' ' ' ASP . 3.3 p -153.47 119.48 5.39 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.583 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 13.4 p-10 -115.11 -167.11 1.19 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.998 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -50.74 -21.15 1.49 Allowed 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -179.875 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -104.18 -24.59 13.14 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -179.931 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 103' ' ' ASN . . . 85.69 22.52 49.92 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.266 -1.134 . . . . 0.0 110.266 179.999 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 1.055 ' ND2' ' CD1' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -59.8 -151.17 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.987 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 140.06 153.73 6.11 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.975 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.565 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 82.4 Cg_endo -72.44 161.49 44.1 Favored 'Trans proline' 0 N--CA 1.447 -1.249 0 C-N-CA 124.316 3.344 . . . . 0.0 109.6 179.985 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 1.292 ' CA ' ' HB1' ' A' ' 2' ' ' ALA . 0.0 OUTLIER -32.75 123.91 0.35 Allowed 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 -179.936 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.776 ' H ' ' HB2' ' A' ' 2' ' ' ALA . . . -36.03 134.93 0.6 Allowed Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.923 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.133 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 2.2 t -108.77 102.45 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.996 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.482 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -85.58 141.1 30.08 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.935 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.185 HG13 ' O ' ' A' ' 93' ' ' CYS . 1.0 OUTLIER -109.48 167.39 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 179.949 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -150.52 123.49 8.74 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.962 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CZ ' ' HB3' ' A' ' 88' ' ' CYS . 19.7 m-85 -99.6 126.19 45.55 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.903 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 N--CA 1.449 -0.51 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.993 . . . . . . . . 0 0 . 1 . 047 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.516 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 047 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.806 ' CB ' ' HG3' ' A' ' 106' ' ' GLU . . . -68.9 115.56 32.49 Favored Pre-proline 0 N--CA 1.449 -0.496 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.952 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 1.187 ' CG ' ' HA ' ' A' ' 105' ' ' PRO . 81.9 Cg_endo -72.4 -177.83 2.96 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 124.266 3.311 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.14 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -101.8 114.45 28.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.98 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.907 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -127.37 131.85 50.28 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.712 ' N ' ' O ' ' A' ' 22' ' ' ALA . 1.3 p -95.03 112.07 23.81 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.975 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.948 HG11 HG22 ' A' ' 108' ' ' VAL . 1.3 m -113.08 149.69 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.926 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.999 ' OG1' ' HD2' ' A' ' 9' ' ' PRO . 0.5 OUTLIER -69.14 179.87 0.65 Allowed Pre-proline 0 N--CA 1.449 -0.499 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.923 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.999 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 81.6 Cg_endo -72.42 121.0 7.09 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 124.321 3.348 . . . . 0.0 109.538 179.947 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 1.016 ' HA ' HD21 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -110.48 3.73 19.86 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -179.986 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 1.398 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 66.1 m -110.36 126.11 53.9 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.901 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.489 ' HA2' ' H ' ' A' ' 113' ' ' ASN . . . 103.71 5.29 45.13 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.937 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.016 HD21 ' HA ' ' A' ' 10' ' ' SER . 2.1 pp -114.32 146.58 40.32 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 88.4 p -99.0 171.5 8.0 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -45.37 151.82 0.34 Allowed 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 109.759 -0.459 . . . . 0.0 109.759 179.969 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 92.79 -22.36 34.2 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.968 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.552 HG21 ' CB ' ' A' ' 13' ' ' LEU . 59.0 m -69.31 138.53 53.88 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.993 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.412 ' O ' HG13 ' A' ' 18' ' ' VAL . 8.5 p -104.11 132.42 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.996 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.86 HG23 HG12 ' A' ' 69' ' ' VAL . 21.5 t -104.12 168.41 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.979 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.836 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -123.78 134.87 53.57 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 179.945 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 21' ' ' VAL . 2.2 p -128.08 104.86 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.907 ' O ' ' HA ' ' A' ' 5' ' ' ALA . . . -111.39 115.23 28.91 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.705 ' HA2' ' HB2' ' A' ' 5' ' ' ALA . . . -84.61 145.62 21.99 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.14 ' O ' HG22 ' A' ' 4' ' ' THR . . . -146.2 112.27 5.74 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.15 26.18 8.48 Favored Glycine 0 C--N 1.335 0.522 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.961 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 1.125 ' CD2' ' HB3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -90.83 -165.81 1.44 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.953 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.924 ' NE2' ' OH ' ' A' ' 32' ' ' TYR . 2.7 mp0 -94.35 124.83 38.61 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.973 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.1 137.45 57.98 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.977 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.4 8.66 63.01 Favored Glycine 0 C--N 1.336 0.546 0 N-CA-C 110.304 -1.119 . . . . 0.0 110.304 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.789 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -91.69 142.71 27.31 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.993 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.774 ' O ' ' HB3' ' A' ' 99' ' ' ASP . . . -98.13 150.5 21.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.983 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 1.102 ' CG ' ' HD2' ' A' ' 105' ' ' PRO . 56.9 m-85 -139.3 144.51 38.35 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -179.908 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 1.408 ' H ' ' N ' ' A' ' 98' ' ' SER . 3.2 m-20 -105.57 114.76 29.13 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.23 ' CA ' ' O ' ' A' ' 96' ' ' GLY . 0.2 OUTLIER -99.47 150.88 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 179.983 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.755 ' N ' ' O ' ' A' ' 96' ' ' GLY . . . 179.87 168.4 38.56 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.98 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.884 ' CD ' ' HE2' ' A' ' 73' ' ' PHE . 11.6 tt0 -111.29 120.96 43.99 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.536 ' HB3' HD13 ' A' ' 45' ' ' LEU . 88.9 m -109.95 169.1 8.94 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.863 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -153.68 125.13 7.56 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.925 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.481 ' C ' ' CD1' ' A' ' 39' ' ' TRP . 0.1 OUTLIER -64.57 129.85 41.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.903 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 1.638 ' HB ' ' CE2' ' A' ' 83' ' ' TRP . 2.4 m -109.33 -37.81 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.407 ' CB ' ' HB ' ' A' ' 44' ' ' VAL . 0.4 OUTLIER -146.82 163.69 35.23 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.958 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.416 ' H ' HG22 ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.19 114.89 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 179.965 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 74.56 1.93 62.63 Favored Glycine 0 C--N 1.336 0.542 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -179.965 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.989 HG12 HG23 ' A' ' 40' ' ' VAL . 15.9 t -121.02 119.64 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 179.991 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.742 HD12 ' N ' ' A' ' 46' ' ' ALA . 1.4 pp -126.75 162.22 26.32 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.484 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -124.24 139.67 53.7 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.827 -0.434 . . . . 0.0 109.827 -179.985 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 1.033 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 24.1 m -109.18 151.83 25.96 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.974 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.562 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 16.9 t30 -112.77 110.74 51.9 Favored Pre-proline 0 N--CA 1.448 -0.552 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 -179.977 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -72.39 0.49 7.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 124.341 3.361 . . . . 0.0 109.596 179.936 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.562 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -90.05 -20.54 23.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 -179.909 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.577 ' HB3' ' NH1' ' A' ' 70' ' ' ARG . 8.5 p30 -119.38 19.93 12.63 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.942 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.671 ' C ' ' CD1' ' A' ' 52' ' ' PHE . 0.0 OUTLIER -92.35 113.57 25.87 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 46.7 t -108.0 -174.28 2.48 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.905 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 6.0 p -146.28 155.9 42.98 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.915 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 56' ' ' THR . 5.7 p -166.88 158.13 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.941 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.456 ' N ' HG22 ' A' ' 55' ' ' VAL . 86.5 m -127.78 129.42 46.99 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.954 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 135.57 55.62 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 p30 -76.66 -175.19 3.27 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.941 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.66 -19.96 64.35 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.911 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -87.34 10.3 17.73 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.074 ' O ' HD12 ' A' ' 26' ' ' LEU . . . 56.87 30.35 59.89 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.6 t -124.82 135.98 53.42 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 179.964 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -125.35 164.63 19.97 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.994 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.0 m -152.41 119.48 5.85 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.983 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 66' ' ' SER . 0.3 OUTLIER -147.17 164.14 34.07 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.865 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.554 ' N ' HG23 ' A' ' 65' ' ' THR . 0.1 OUTLIER -106.68 133.74 50.89 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.943 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.184 ' HG ' ' CG1' ' A' ' 95' ' ' VAL . 0.3 OUTLIER -119.59 120.2 36.01 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.916 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.616 ' N ' HD13 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -83.97 145.04 28.76 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.989 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.86 HG12 HG23 ' A' ' 19' ' ' VAL . 0.2 OUTLIER -121.51 134.56 64.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.677 ' H ' HE22 ' A' ' 36' ' ' GLN . 0.0 OUTLIER -117.92 174.94 5.9 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.988 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HG2' ' CG2' ' A' ' 89' ' ' THR . 6.5 mtt180 -98.68 -12.19 21.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.948 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 86' ' ' VAL . 20.3 p -173.68 145.95 1.24 Allowed 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.884 ' HE2' ' CD ' ' A' ' 36' ' ' GLN . 1.2 p90 -171.6 163.25 6.61 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.922 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.14 118.02 3.99 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.943 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.484 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -78.74 96.08 1.4 Allowed Glycine 0 C--N 1.336 0.528 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 1.033 ' HB2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -84.14 100.64 11.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.875 HD23 ' HB ' ' A' ' 81' ' ' THR . 3.6 tp -56.21 130.64 45.19 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.972 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.619 ' N ' HD12 ' A' ' 77' ' ' LEU . 3.1 p90 -47.42 -35.36 8.33 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.998 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.61 ' CB ' HD21 ' A' ' 77' ' ' LEU . 6.1 t0 -57.49 -17.55 14.07 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -179.962 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.4 27.92 8.34 Favored Glycine 0 CA--C 1.522 0.51 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -179.987 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.875 ' HB ' HD23 ' A' ' 77' ' ' LEU . 18.5 m -116.88 148.09 41.6 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.96 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -85.46 96.34 9.56 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 -179.97 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 1.638 ' CE2' ' HB ' ' A' ' 40' ' ' VAL . 72.6 t90 -64.35 -58.05 7.6 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.859 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 148.42 170.79 16.65 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.987 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.58 106.52 0.4 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.966 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.863 HG21 ' CB ' ' A' ' 38' ' ' ALA . 2.5 p -86.3 143.1 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 179.981 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.72 96.43 8.6 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.996 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.954 ' O ' ' CE1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -55.35 -20.01 10.52 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.947 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.604 ' CG2' ' HG2' ' A' ' 71' ' ' ARG . 33.5 p -88.94 1.4 55.5 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 179.976 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 m -114.16 -27.44 7.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.978 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -124.31 179.42 4.91 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.975 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -97.45 123.14 41.2 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.907 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 1.56 ' C ' HG13 ' A' ' 110' ' ' ILE . 0.0 OUTLIER -104.71 157.71 17.0 Favored 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 1.121 ' N ' HG13 ' A' ' 110' ' ' ILE . 1.3 pt20 -156.19 144.67 20.02 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 -179.975 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.184 ' CG1' ' HG ' ' A' ' 67' ' ' LEU . 11.9 t -93.58 156.98 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 1.23 ' O ' ' CA ' ' A' ' 34' ' ' VAL . . . -172.54 165.91 38.51 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.294 -1.123 . . . . 0.0 110.294 179.997 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.164 ' CB ' HG22 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -136.52 143.44 43.74 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.994 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 1.408 ' N ' ' H ' ' A' ' 33' ' ' ASP . 3.5 m -133.52 147.59 51.62 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.95 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.774 ' HB3' ' O ' ' A' ' 31' ' ' ALA . 0.1 OUTLIER -93.49 -167.01 1.62 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.974 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.434 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -58.08 -50.13 74.53 Favored 'General case' 0 N--CA 1.45 -0.472 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -179.965 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.498 ' HB3' ' OD1' ' A' ' 103' ' ' ASN . . . -68.76 -24.66 64.47 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 100.98 40.53 2.84 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.98 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.498 ' OD1' ' HB3' ' A' ' 101' ' ' ALA . 0.5 OUTLIER -121.89 -178.62 3.89 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -179.985 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 134.64 -174.95 20.8 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 179.958 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 1.187 ' HA ' ' CG ' ' A' ' 3' ' ' PRO . 83.8 Cg_endo -72.43 134.55 22.77 Favored 'Trans proline' 0 N--CA 1.446 -1.271 0 C-N-CA 124.318 3.345 . . . . 0.0 109.612 179.935 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.806 ' HG3' ' CB ' ' A' ' 2' ' ' ALA . 3.1 pt-20 -137.99 141.54 40.46 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.904 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 136.27 57.67 0.06 OUTLIER Glycine 0 C--N 1.335 0.496 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.967 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 1.077 ' O ' ' HB2' ' A' ' 94' ' ' GLN . 54.0 t -134.27 102.73 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.992 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HB2' ' A' ' 94' ' ' GLN . . . -96.94 153.6 17.8 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 -179.944 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.56 HG13 ' C ' ' A' ' 93' ' ' CYS . 0.0 OUTLIER -117.94 163.76 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.89 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 1.398 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -162.24 131.0 4.21 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.973 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 1.032 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 4.6 m-85 -108.35 120.07 41.31 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.965 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.489 ' H ' ' HA2' ' A' ' 12' ' ' GLY . 14.1 t-20 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -179.985 . . . . . . . . 1 1 . 1 stop_ save_